PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mizutani, A; Furukawa, T; Adachi, Y; Ikehara, S; Taketani, S				Mizutani, A; Furukawa, T; Adachi, Y; Ikehara, S; Taketani, S			A zinc-finger protein, PLAGL2, induces the expression of a proapoptotic protein Nip3, leading to cellular apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; TRANSCRIPTIONAL ACTIVATION; PLEOMORPHIC ADENOMAS; GENE-EXPRESSION; SOLID TUMORS; CELLS; IDENTIFICATION; REGION; ENHANCER; PROMOTER	Pleomorphic adenomas gene-like 2 (PLAGL2) protein containing seven C,H, zinc finger motifs exhibits DNA binding and transcriptional activation activity and is expressed in response to hypoxia or iron deficiency. To identify the target genes of PLAGL2, we transfected mouse PLAGL2 cDNA into Balb/c3T3 fibroblasts and neuroblastoma Neuro2a cells. Both cells were induced to undergo apoptosis by the expression of PLAGL2 as judged by assays of TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling), DNA fragmentation, propidium iodide staining, and the binding of annexin V to the cell surface. The treatment of the cells with an iron chelator, desferrioxamine, resulted in the induction of apoptosis with a concomitant accumulation of PLAGL2 in the nucleus. The expression of PLAGL2 in Balb/c3T3 cells led to the mRNA expression of a proapoptotic factor, Nip3, which can dimerize with Bcl-2. Nip3 mRNA was also induced in desferrioxamine-treated cells. Furthermore, the Nip3 promoter containing a hypoxia-responsive element was activated by PLAGL2, independent of hypoxia-inducible factor-1 (HIF-1). The transfection of antisense oligonucleotide to mouse Nip3 mRNA into PLAGL2-expressing cells led to a decrease in apoptotic cells compared with sense oligonucleotide-transfected cells. Despite the activation of DNA-HIF-1 binding activity under hypoxic conditions, neither an accumulation of HIF-1alpha nor the activation of HIF-1 was observed following the expression of P]PLAGL2. These results indicate that PLAGL2 is located downstream of HIF-1 and suggest that PLAGL2 functions as a tumor suppressor in association with HIF-1.	Kyoto Inst Technol, Dept Biotechnol, Sakyo Ku, Kyoto 6068585, Japan; Fukui Med Univ, Biomed Imaging Res Ctr, Matsuoka, Fukui 9101193, Japan; Kansai Med Univ, Dept Pathol 1, Osaka 5708506, Japan	Kyoto Institute of Technology; University of Fukui; Kansai Medical University	Taketani, S (corresponding author), Kyoto Inst Technol, Dept Biotechnol, Sakyo Ku, Kyoto 6068585, Japan.	taketani@ipc.kit.ac.jp						Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Blagosklonny MV, 1998, J BIOL CHEM, V273, P11995, DOI 10.1074/jbc.273.20.11995; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Chen G, 1999, J BIOL CHEM, V274, P7, DOI 10.1074/jbc.274.1.7; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Furukawa T, 2001, ONCOGENE, V20, P4718, DOI 10.1038/sj.onc.1204647; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, NAT GENET, V15, P170, DOI 10.1038/ng0297-170; Kas K, 1997, GENOMICS, V43, P349, DOI 10.1006/geno.1997.4819; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; MIYASHITA T, 1995, CELL, V80, P293; Mohri T, 1999, EXP CELL RES, V253, P533, DOI 10.1006/excr.1999.4720; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6417; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Takahashi S, 1998, BLOOD, V92, P3436, DOI 10.1182/blood.V92.9.3436.421k13_3436_3444; Taketani S, 1998, J BIOL CHEM, V273, P31388, DOI 10.1074/jbc.273.47.31388; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Zhang YM, 1997, GENE CHROMOSOME CANC, V18, P310, DOI 10.1002/(SICI)1098-2264(199704)18:4<310::AID-GCC10>3.0.CO;2-K; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9	37	67	72	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15851	15858		10.1074/jbc.M111431200	http://dx.doi.org/10.1074/jbc.M111431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11832486	hybrid			2022-12-25	WOS:000175510400086
J	Takahashi, N; Tsutsumi, S; Tsuchiya, T; Stillman, B; Mizushima, T				Takahashi, N; Tsutsumi, S; Tsuchiya, T; Stillman, B; Mizushima, T			Functions of sensor 1 and sensor 2 regions of Saccharomyces cerevisiae Cdc6p in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; CYCLIN-DEPENDENT KINASES; MINICHROMOSOME MAINTENANCE PROTEIN; PRE-REPLICATIVE COMPLEXES; DNA HELICASE ACTIVITY; ESCHERICHIA-COLI; BUDDING YEAST; MCM PROTEINS; S-PHASE; CRYSTAL-STRUCTURE	Cdc6p is a key regulator of the cell cycle in eukaryotes and is a member of the AAA(+) (ATPases associated with a variety of cellular activities) family of proteins. In this family of proteins, the sensor I and sensor 2 regions are important for their function and ATPase activity. Here, site-directed mutagenesis has been used to examine the role of these regions of Saccharomyces cerevisiae Cdc6p in controlling the cell cycle progression and initiation of DNA replication. Two important amino acid residues (Asn(263) in sensor 1 and Arg(332) in sensor 2) were identified as key residues for Cdc6p function in vivo. Cells expressing mutant Cdc6p (N263A or R332E) grew slowly and accumulated in the S phase. In cells expressing mutant Cdc6p, loading of the minichromosome maintenance (MCM) complex of proteins was decreased, suggesting that the slow progression of S phase in these cells was due to inefficient MCM loading on chromatin. Purified wild type Cdc6p but not mutant Cdc6p (N263A and R332E) caused the structural modification of origin recognition complex proteins. These results are consistent with the idea that Cdc6p uses its ATPase activity to change the conformation of origin recognition complex, and then together they recruit the MCM complex.	Okayama Univ, Fac Pharmaceut Sci, Okayama 7008530, Japan; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Japan Sci & Technol Corp, PRESTO, Okayama 7008530, Japan	Okayama University; Cold Spring Harbor Laboratory; Japan Science & Technology Agency (JST)	Mizushima, T (corresponding author), Okayama Univ, Fac Pharmaceut Sci, 1-1-1 Tsushima Naka, Okayama 7008530, Japan.	mizushima@pharm.okayama-u.ac.jp		Stillman, Bruce/0000-0002-9453-4091	NIGMS NIH HHS [GM45306, R01 GM045436] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045436] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Bielinsky AK, 2001, J CELL SCI, V114, P643; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; Calzada A, 2001, NATURE, V412, P355, DOI 10.1038/35085610; CARLE GF, 1984, NUCLEIC ACIDS RES, V12, P5647, DOI 10.1093/nar/12.14.5647; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Desdouets C, 1998, EMBO J, V17, P4139, DOI 10.1093/emboj/17.14.4139; Detweiler CS, 1997, J CELL SCI, V110, P753; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; Donaldson AD, 1999, CURR OPIN GENET DEV, V9, P62, DOI 10.1016/S0959-437X(99)80009-4; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; HENNESSY KM, 1991, GENE DEV, V5, P958, DOI 10.1101/gad.5.6.958; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; Klemm RD, 1997, CELL, V88, P493, DOI 10.1016/S0092-8674(00)81889-9; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Leatherwood J, 1998, CURR OPIN CELL BIOL, V10, P742, DOI 10.1016/S0955-0674(98)80117-8; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lin S, 1997, MOL CELL BIOL, V17, P5473, DOI 10.1128/MCB.17.9.5473; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Mizushima T, 2000, GENE DEV, V14, P1631; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; MuziFalconi M, 1996, P NATL ACAD SCI USA, V93, P1566, DOI 10.1073/pnas.93.4.1566; Neuwald AF, 1999, GENOME RES, V9, P27; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Nishitani H, 1997, Prog Cell Cycle Res, V3, P135; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Perkins G, 1998, MOL CELL, V2, P23, DOI 10.1016/S1097-2765(00)80110-0; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Schepers A, 2001, J MOL BIOL, V308, P597, DOI 10.1006/jmbi.2001.4637; SCHWARTZ DC, 1984, CELL, V37, P67, DOI 10.1016/0092-8674(84)90301-5; Seong IS, 2000, FEBS LETT, V477, P224, DOI 10.1016/S0014-5793(00)01808-1; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stillman B, 1996, SCIENCE, V274, P1659, DOI 10.1126/science.274.5293.1659; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Tugal T, 1998, J BIOL CHEM, V273, P32421, DOI 10.1074/jbc.273.49.32421; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Weinreich M, 1999, P NATL ACAD SCI USA, V96, P441, DOI 10.1073/pnas.96.2.441; Weinreich M, 2001, P NATL ACAD SCI USA, V98, P11211, DOI 10.1073/pnas.201387198; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	65	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16033	16040		10.1074/jbc.M108615200	http://dx.doi.org/10.1074/jbc.M108615200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11827963	Green Accepted, hybrid			2022-12-25	WOS:000175510400109
J	Lakkaraju, A; Rahman, YE; Dubinsky, JM				Lakkaraju, A; Rahman, YE; Dubinsky, JM			Low-density lipoprotein receptor-related protein mediates the endocytosis of anionic liposomes in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLE ENDOCYTOSIS; NMR SOLUTION STRUCTURE; GENE FAMILY; PLASMA-MEMBRANE; HIPPOCAMPAL; CELLS; CHOLESTEROL; CLATHRIN; TRAFFICKING; CALCIUM	We have recently demonstrated that anionic liposomes efficiently introduce foreign DNA into postmitotic neurons and other cell types (Lakkaraju, A., Dubinsky, J. M., Low, W. C., and Rahman, Y.-E. (2001) J. Biol. Chem. 276, 32000-32007). To investigate the mechanism of liposome uptake, we followed the internalization of anionic liposome-encapsulated Cy3-labeled oligonucleotides (A-L-Cy3ONs) by hippocampal neurons using confocal microscopy. Uptake of AL-Cy3ONs was widespread and time- and temperature-dependent, indicative of receptor-mediated endocytosis. The low-density lipoprotein receptor-related protein (LRP) was crucial for anionic liposome endocytosis because the receptor-associated protein or an anti-LRP antibody inhibited internalization, and fibroblasts lacking LRP did not internalize AL-Cy3ONs. Using selective endocytosis inhibitors, we found that liposome endocytosis and intracellular transport required clathrin, dynamin, an intact cytoskeletal network, and phosphatidylinositol 3-kinase activity. Cy3ONs did not significantly colocalize with recycling endosomal/ lysosomal markers and entered neuronal nuclei within 1-3 h of incubation. Approximately 50% of the internalized liposomal phospholipids were recycled back to the cell surface, in keeping with the fluidity of their acyl chains. Liposome endocytosis did not require heparan sulfate proteoglycans or cause calcium influx into neurons. Thus, constitutive endocytosis of anionic liposomes by LRP utilizes only one component, in contrast to the more involved heparan sulfate proteoglycan-LRP pathway implicated in the pathogenesis of Alzheimer's disease.	Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmaceut, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Dubinsky, JM (corresponding author), Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA.	dubin001@tc.umn.edu			NINDS NIH HHS [NS39414] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039414] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Barres BA, 2001, SCIENCE, V294, P1296, DOI 10.1126/science.1066724; Beattie EC, 2000, J NEUROSCI, V20, P7325; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Brustovetsky N, 2000, J NEUROSCI, V20, P103, DOI 10.1523/JNEUROSCI.20-01-00103.2000; BU GJ, 1994, J BIOL CHEM, V269, P18521; BU GJ, 1994, J BIOL CHEM, V269, P29874; Bu GJ, 1998, J BIOL CHEM, V273, P13359, DOI 10.1074/jbc.273.21.13359; Cavalli V, 2001, MOL CELL, V7, P421, DOI 10.1016/S1097-2765(01)00189-7; Dietschy JM, 2001, CURR OPIN LIPIDOL, V12, P105, DOI 10.1097/00041433-200104000-00003; Dolmer K, 2000, J BIOL CHEM, V275, P3264, DOI 10.1074/jbc.275.5.3264; DUBINSKY JM, 1993, J NEUROSCI, V13, P623; Fire E, 1997, J BIOL CHEM, V272, P29538, DOI 10.1074/jbc.272.47.29538; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; Geddes JW, 1997, NEUROBIOL AGING, V18, P305, DOI 10.1016/S0197-4580(97)80312-0; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hemar A, 1997, J NEUROSCI, V17, P9026; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Huang W, 1999, J BIOL CHEM, V274, P14130, DOI 10.1074/jbc.274.20.14130; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; JUNKER M, 1993, BIOCHEMISTRY-US, V32, P9968, DOI 10.1021/bi00089a012; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Ko KWS, 1998, J BIOL CHEM, V273, P27779, DOI 10.1074/jbc.273.43.27779; Ko KWS, 2001, BIOCHEMISTRY-US, V40, P752, DOI 10.1021/bi001797+; KOK JW, 1990, EUR J CELL BIOL, V53, P173; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Lakkaraju A, 2001, J BIOL CHEM, V276, P32000, DOI 10.1074/jbc.M100138200; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Maples CJ, 1997, J BIOL CHEM, V272, P6741, DOI 10.1074/jbc.272.10.6741; Martys JL, 1996, J BIOL CHEM, V271, P10953, DOI 10.1074/jbc.271.18.10953; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOESTRUP SK, 1992, CELL TISSUE RES, V269, P375, DOI 10.1007/BF00353892; Mukherjee S, 1999, J CELL BIOL, V144, P1271, DOI 10.1083/jcb.144.6.1271; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; Narita M, 1997, J NEUROCHEM, V68, P587; OKA JA, 1989, J BIOL CHEM, V264, P12016; Prekeris R, 1999, J NEUROSCI, V19, P10324; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; Shpetner H, 1996, J CELL BIOL, V132, P595, DOI 10.1083/jcb.132.4.595; Wells K, 1995, NEUROCHEM RES, V20, P1329, DOI 10.1007/BF00992508; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Willnow TE, 1999, J MOL MED-JMM, V77, P306, DOI 10.1007/s001090050356; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	48	29	29	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15085	15092		10.1074/jbc.M111764200	http://dx.doi.org/10.1074/jbc.M111764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11830589	hybrid			2022-12-25	WOS:000175203000093
J	Barnouin, K; Dubuisson, ML; Child, ES; de Mattos, SF; Glassford, J; Medema, RH; Mann, DJ; Lam, EWF				Barnouin, K; Dubuisson, ML; Child, ES; de Mattos, SF; Glassford, J; Medema, RH; Mann, DJ; Lam, EWF			H2O2 induces a transient multi-phase cell cycle arrest in mouse fibroblasts through modulating cyclin D and p21(Cip1) expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; ABL TYROSINE KINASE; DNA-DAMAGE; OXIDATIVE STRESS; DEPENDENT KINASES; GROWTH ARREST; RETINOBLASTOMA PROTEIN; OXYGEN RADICALS; CDK INHIBITORS; G(1) CYCLIN	To defend against the potential damages induced by reactive oxygen species, proliferating cells enter a transient cell cycle arrest. We treated mouse fibroblasts with H2O2 and found that sublethal doses of H2O2 induced a transient multi-phase cell cycle arrest at the G, S, and G. phases but not the M phase. Western blot analysis demonstrated that this transient cell cycle arrest is associated with the down-regulation of cyclins D1 and D3 and up-regulation of the CKI p21(Cip1) expression. We also demonstrate that the induction in p21(Cip1) expression by H2O2 is at least partially mediated at the transcriptional level and can occur in the absence of p53 function. Further immunoprecipitation kinase and immunodepletion assays indicated that in response to H2O2 treatment, the down-regulation of cyclin Ds expression are associated with repression of cyclin D-CDK4, whereas the accumulation of P21(Cip1) is responsible for the inhibition of cyclin E and A-CDK2 activity and associated with the down-regulation of cyclin B-CDC2 activity. These data could account for the cell cycle arrest at the G(1), S, and G(2) phases following H2O2 stimulation. Deletion of p21(Cip1), restoration of cyclin D expression, or overexpression of cyclin E alone is insufficient to effectively overcome the cell cycle arrest caused by sublethal doses of H2O2. By contrast, overexpression of the human Herpesvirus 8 K cyclin, which can mimic the function of cyclin D and E, is enough to override this transient cell cycle arrest. On the basis of our findings, we propose a model in which moderate levels of H2O2 induce a transient multi-phase cell cycle arrest at least partially through up-regulation of P21(Cip1) and down-regulation of cyclin D expression.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, CRC Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Ludwig Inst Canc Res, St Marys, London W2 1PG, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Ludwig Inst Canc Res, London W1 7BS, England; Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AY, England; Netherlands Canc Inst, Dept Mol Biol H8, NL-1066 CX Amsterdam, Netherlands; Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, CRC Labs, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, St Marys, Sect Virol & Cell Biol, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research; University of London; University College London; Ludwig Institute for Cancer Research; Imperial College London; Netherlands Cancer Institute; Imperial College London; Imperial College London	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Hammersmith Hosp, CRC Labs, Du Cane Rd, London W12 0NN, England.	eric.lam@ic.ac.uk	Medema, Rene H/E-2981-2013; Lam, Eric W-F/AAW-8566-2020; Medema, Rene H/G-5415-2011; de Mattos, Silvia Fernández/K-5153-2014	Lam, Eric W-F/0000-0003-1274-3576; de Mattos, Silvia Fernández/0000-0003-4144-3687; Medema, Rene/0000-0002-6754-0381				AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Ando T, 2001, J BIOL CHEM, V276, P42971, DOI 10.1074/jbc.M106460200; Barnouin K, 1999, ONCOGENE, V18, P6388, DOI 10.1038/sj.onc.1203162; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Boulaire J, 2000, PATHOL BIOL, V48, P190; BRECHOT C, 1993, CURR OPIN GENET DEV, V3, P11, DOI 10.1016/S0959-437X(05)80335-1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; CERUTTI PA, 1994, LANCET, V344, P862, DOI 10.1016/S0140-6736(94)92832-0; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Chen QM, 2000, BIOCHEM J, V347, P543, DOI 10.1042/0264-6021:3470543; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; CROSS CE, 1987, ANN INTERN MED, V107, P526, DOI 10.7326/0003-4819-107-4-526; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; Davies KJA, 2000, IUBMB LIFE, V50, P279, DOI 10.1080/15216540051081010; Deininger MWN, 2001, CANCER RES, V61, P8005; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DOREE M, 1994, FASEB J, V8, P1114, DOI 10.1096/fasebj.8.14.7958616; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Finkel T, 2000, FEBS LETT, V476, P52, DOI 10.1016/S0014-5793(00)01669-0; Finkel T, 1998, CURR OPIN CELL BIOL, V10, P248, DOI 10.1016/S0955-0674(98)80147-6; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Gudas JM, 1999, MOL CELL BIOL, V19, P612; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lin JY, 1996, MOL CELL BIOL, V16, P1786; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Pestell KE, 2000, ONCOGENE, V19, P6607, DOI 10.1038/sj.onc.1204084; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2, P1; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smits VAJ, 2000, J BIOL CHEM, V275, P30638, DOI 10.1074/jbc.M005437200; Smits VAJ, 2001, BBA-GENE STRUCT EXPR, V1519, P1, DOI 10.1016/S0167-4781(01)00204-4; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Storz G, 1999, CURR OPIN MICROBIOL, V2, P188, DOI 10.1016/S1369-5274(99)80033-2; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Walworth NC, 2001, CURR OPIN GENET DEV, V11, P78, DOI 10.1016/S0959-437X(00)00160-X; Wang G, 1999, ONCOGENE, V18, P5204, DOI 10.1038/sj.onc.1202912; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	61	133	137	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13761	13770		10.1074/jbc.M111123200	http://dx.doi.org/10.1074/jbc.M111123200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827966	hybrid			2022-12-25	WOS:000175096000056
J	Giblin, JP; Cui, Y; Clapp, LH; Tinker, A				Giblin, JP; Cui, Y; Clapp, LH; Tinker, A			Assembly limits the pharmacological complexity of ATP-sensitive potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY SULFONYLUREA RECEPTOR; PANCREATIC BETA-CELLS; K+ CHANNELS; INSULIN-SECRETION; SKELETAL-MUSCLE; KIR6.2 SUBUNIT; CARDIAC-MUSCLE; SMOOTH-MUSCLE; STOICHIOMETRY; EXPRESSION	ATP-sensitive potassium channels (K(ATP) channels) are formed from an octameric complex of an inwardly rectifying K(+) channel (Kir6.1, Kir6.2) and a sulfonylurea receptor (SUR1, SUR2A, and SUR2B). In this study we have attempted to address the question of whether SUR heteromultimers can form using a combination of biochemical and electrophysiological approaches. We have constructed monoclonal stable lines in HEK293 cells coexpressing Kir6.2 with SUR1 and SUR2A. Using coimmunoprecipitation analysis with SUR isotype-specific antibodies two biochemical populations are distinguished, one containing SUR1 and the other SUR2A. It is not possible to detect immune complexes containing both SUR1 and SUR2A. Functional studies were undertaken and whole cell membrane currents were studied using the patch clamp. Concentrations of sulfonylureas and potassium channel openers were determined that selectively inhibited or activated SUR1/Kir6.2 and SUR2A/Kir6.2. In the cell line expressing SUR1/SUR2A-Kir6.2 we were unable to demonstrate a population of channels with unique pharmacological properties. Thus we conclude from these studies that heteromultimeric channel complexes containing both SUR1 and SUR2A are not formed, suggesting an incompatibility between different SUR subtypes. This incompatibility limits the pharmacological complexity of K(ATP) channels that may be observed in native tissues.	UCL, Rayne Inst, Dept Med, Ctr Clin Pharmacol, London WC1E 6JJ, England	University of London; King's College London; University College London	Tinker, A (corresponding author), UCL, Rayne Inst, Dept Med, Ctr Clin Pharmacol, Rm F2,4th Floor,5 Univ St, London WC1E 6JJ, England.	a.tinker@ucl.ac.uk	Clapp, Lucie/B-1088-2008; Clapp, Lucie/L-4199-2019	Clapp, Lucie/0000-0001-7802-4481; Clapp, Lucie/0000-0001-7802-4481				Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; Babenko AP, 1998, ANNU REV PHYSIOL, V60, P667, DOI 10.1146/annurev.physiol.60.1.667; Brady PA, 1998, CIRC RES, V82, P272; Brady PA, 1996, AM J PHYSIOL-HEART C, V271, pH2710, DOI 10.1152/ajpheart.1996.271.6.H2710; Buckner SA, 2000, EUR J PHARMACOL, V400, P287, DOI 10.1016/S0014-2999(00)00388-5; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Cui Y, 2001, P NATL ACAD SCI USA, V98, P729, DOI 10.1073/pnas.011370498; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; FINDLAY I, 1993, J PHARMACOL EXP THER, V266, P456; Giblin JP, 1999, J BIOL CHEM, V274, P22652, DOI 10.1074/jbc.274.32.22652; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Gross I, 1999, MOL PHARMACOL, V56, P1370, DOI 10.1124/mol.56.6.1370; Grover GJ, 2000, J MOL CELL CARDIOL, V32, P677, DOI 10.1006/jmcc.2000.1111; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hu H, 1999, MOL PHARMACOL, V55, P1000, DOI 10.1124/mol.55.6.1000; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1997, JPN J PHYSIOL, V47, P11, DOI 10.2170/jjphysiol.47.11; Isomoto S, 1997, J CARDIOVASC ELECTR, V8, P1431, DOI 10.1111/j.1540-8167.1997.tb01040.x; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Karschin C, 1997, FEBS LETT, V401, P59, DOI 10.1016/S0014-5793(96)01438-X; Liss B, 1999, EMBO J, V18, P833, DOI 10.1093/emboj/18.4.833; Liu YG, 2001, MOL PHARMACOL, V59, P225, DOI 10.1124/mol.59.2.225; Matsuoka T, 2000, CIRC RES, V87, P873, DOI 10.1161/01.RES.87.10.873; Mikhailov MV, 2000, J BIOL CHEM, V275, P3360, DOI 10.1074/jbc.275.5.3360; Nelson DA, 1996, BIOCHEMISTRY-US, V35, P14793, DOI 10.1021/bi960777y; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; Quayle JM, 1997, PHYSIOL REV, V77, P1165, DOI 10.1152/physrev.1997.77.4.1165; Repunte VP, 1999, EMBO J, V18, P3317, DOI 10.1093/emboj/18.12.3317; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; Sakura H, 1999, J PHYSIOL-LONDON, V521, P337, DOI 10.1111/j.1469-7793.1999.00337.x; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shyng SL, 1997, J GEN PHYSIOL, V110, P141, DOI 10.1085/jgp.110.2.141; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1998, CURR OPIN NEUROBIOL, V8, P316, DOI 10.1016/S0959-4388(98)80055-X; Tucker SJ, 1998, EMBO J, V17, P3290, DOI 10.1093/emboj/17.12.3290; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; VENKATESH N, 1991, CIRC RES, V69, P623, DOI 10.1161/01.RES.69.3.623; VIRAG L, 1993, MOL CELL BIOCHEM, V119, P209, DOI 10.1007/BF00926873; Wulfsen I, 2000, J NEUROENDOCRINOL, V12, P263; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yamada M, 1997, J PHYSIOL-LONDON, V499, P715, DOI 10.1113/jphysiol.1997.sp021963; Yellon DM, 2000, CIRC RES, V87, P543, DOI 10.1161/01.RES.87.7.543; Yokoshiki H, 1999, PFLUG ARCH EUR J PHY, V437, P400, DOI 10.1007/s004240050794; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	54	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13717	13723		10.1074/jbc.M112209200	http://dx.doi.org/10.1074/jbc.M112209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825905	hybrid			2022-12-25	WOS:000175096000050
J	Goldberg-Cohen, I; Furneauxb, H; Levy, AP				Goldberg-Cohen, I; Furneauxb, H; Levy, AP			A 40-bp RNA element that mediates stabilization of vascular endothelial growth factor mRNA by HuR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; BINDING PROTEIN HUR; 3'-UNTRANSLATED REGION; FACTOR GENE; HYPOXIA; STABILITY; IDENTIFICATION; ANGIOGENESIS; MODULATION; EXPRESSION	VEGF is a critical mediator of hypoxia-induced angiogenesis in numerous physiological and pathophysiological conditions. The hypoxic induction of VEGF is due in large part to an increase in the stability of its mRNA. We recently demonstrated that the stabilization of VEGF mRNA by hypoxia is dependent upon the RNA-binding protein HuR. This report describes the identification of a 40-bp functional HuR binding site in the VEGF mRNA 3'-untranslated region. This element can confer HuR-mediated stabilization of a heterologous gene in vitro and in vivo. Furthermore, the element is sufficient to confer an increase in the hypoxic induction of a heterologous gene. Deletion of the HuR binding site within this 40-bp element as mapped by RNase T1 and lead footprinting uncouples a stabilizing sequence from a destabilizing sequence, thus providing a novel RNA-protein regulatory model that might be exploited to manipulate VEGF expression and hypoxia-induced angiogenesis.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel; Univ Connecticut, Ctr Hlth, Dept Physiol, Farmington, CT 06032 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Connecticut	Levy, AP (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, POB 9649, IL-31096 Haifa, Israel.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058510] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL58510] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Boast K, 1999, HUM GENE THER, V10, P2197, DOI 10.1089/10430349950017185; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; Haeussler J, 2000, BIOCHEM BIOPH RES CO, V267, P726, DOI 10.1006/bbrc.1999.2019; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; Koshikawa N, 2000, CANCER RES, V60, P2936; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Ma WJ, 1996, J BIOL CHEM, V271, P8144, DOI 10.1074/jbc.271.14.8144; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Modlich U, 2000, GENE THER, V7, P896, DOI 10.1038/sj.gt.3301177; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Oku T, 1998, CANCER RES, V58, P4185; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Ruan Hangjun, 1999, Neoplasia (New York), V1, P431, DOI 10.1038/sj.neo.7900059; SABRI MN, 1991, AM HEART J, V121, P876, DOI 10.1016/0002-8703(91)90202-S; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Sokolowski M, 1999, J VIROL, V73, P1080, DOI 10.1128/JVI.73.2.1080-1091.1999; STEIN I, 1995, MOL CELL BIOL, V15, P5362; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; White FC, 1995, GROWTH FACTORS, V12, P289, DOI 10.3109/08977199509028967; Zhao ZQ, 2000, NUCLEIC ACIDS RES, V28, P2695, DOI 10.1093/nar/28.14.2695	32	103	117	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13635	13640		10.1074/jbc.M108703200	http://dx.doi.org/10.1074/jbc.M108703200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834731	hybrid			2022-12-25	WOS:000175096000040
J	Hellman, J; Roberts, JD; Tehan, MM; Allaire, JE; Warren, HS				Hellman, J; Roberts, JD; Tehan, MM; Allaire, JE; Warren, HS			Bacterial peptidoglycan-associated lipoprotein is released into the bloodstream in gram-negative sepsis and causes inflammation and death in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; TOLL-LIKE RECEPTOR-2; BORRELIA-BURGDORFERI LIPOPROTEINS; OUTER-MEMBRANE PROTEINS; MULTIPLE ORGAN FAILURE; NF-KAPPA-B; NITRIC-OXIDE; NUCLEOTIDE-SEQUENCE; LIPOTEICHOIC ACID; CELL ACTIVATION	Gram-negative bacterial sepsis commonly causes organ dysfunction and death in humans. Although circulating bacterial toxins trigger inflammation in sepsis, little is known about the composition of bacterial products released into the blood during sepsis or the contribution of various bacterial components to the pathogenesis of sepsis. We have shown that diverse Gram-negative bacteria release bacterial peptidoglycan-associated lipoprotein (PAL) into serum. The present studies explored release of PAL into the blood during sepsis and tested the hypothesis that PAL contributes to bacterial virulence and inflammation in Gram-negative sepsis. Released PAL was detected in the blood of 94% of mice following cecal ligation and puncture. Picomolar to nanomolar levels of PAL stimulated macrophages and splenocytes from lipopolysaccharide-hyporesponsive (C3H/HeJ) mice. Injection of PAL into C3H/HeJ mice stimulated production of serum cytokines and increased pulmonary and myocardial expression of inflammatory markers. PAL caused death in sensitized C3H/HeJ mice. Mutant Escherichia coli bacteria with reduced levels of PAL or truncated PAL were less virulent than wild-type bacteria, as indicated by higher survival rates and lower circulating levels of interleukin 6 and bacteria in a model of peritonitis in lipopolysaccharide-responsive mice. The studies suggest that PAL may be an important bacterial mediator of Gram-negative sepsis.	Massachusetts Gen Hosp, Dept Anaesthesia & Crit Care, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Dept Med, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Hellman, J (corresponding author), Massachusetts Gen Hosp, Dept Anaesthesia & Crit Care, 149 13th St, Charlestown, MA 02129 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL004237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059694] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL004237, HL-04237, K08 HL004237-02] Funding Source: Medline; NIAID NIH HHS [AI01722] Funding Source: Medline; NIGMS NIH HHS [GM59694] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; BEUTLER B, 1985, SCIENCE, V229, P869, DOI 10.1126/science.3895437; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BRAUDE I, 1973, J INFECT DIS, V128, P157; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; CDC, 1990, JAMA-J AM MED ASSOC, V263, P937; CHAN YL, 1984, J BIOL CHEM, V259, P224; CHEDID L, 1968, J IMMUNOL, V100, P292; CHEN R, 1987, EUR J BIOCHEM, V163, P73, DOI 10.1111/j.1432-1033.1987.tb10738.x; CHEN YHU, 1980, INFECT IMMUN, V28, P178, DOI 10.1128/IAI.28.1.178-184.1980; Clavel T, 1998, MOL MICROBIOL, V29, P359, DOI 10.1046/j.1365-2958.1998.00945.x; COLIGAN J, 2001, CURRENT PROTOCOLS IM; DEICH RA, 1990, INFECT IMMUN, V58, P3388, DOI 10.1128/IAI.58.10.3388-3393.1990; DEKIMPE SJ, 1995, P NATL ACAD SCI USA, V92, P10359, DOI 10.1073/pnas.92.22.10359; DIJKSTRA J, 1988, J LEUKOCYTE BIOL, V43, P436, DOI 10.1002/jlb.43.5.436; DUSTIN ML, 1986, J IMMUNOL, V137, P245; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; Ebong S, 1999, INFECT IMMUN, V67, P6603; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; GALANOS C, 1993, IMMUNOBIOLOGY, V187, P346, DOI 10.1016/S0171-2985(11)80349-9; GALDIERO F, 1993, INFECT IMMUN, V61, P155, DOI 10.1128/IAI.61.1.155-161.1993; GLAUSER MP, 1991, LANCET, V338, P732, DOI 10.1016/0140-6736(91)91452-Z; GOODMAN GW, 1979, INFECT IMMUN, V24, P685, DOI 10.1128/IAI.24.3.685-696.1979; Greisman SE, 1997, J ENDOTOXIN RES, V4, P123, DOI 10.1177/096805199700400206; Hellman J, 2001, J ENDOTOXIN RES, V7, P69, DOI 10.1177/09680519010070010101; Hellman J, 1997, J INFECT DIS, V176, P1260, DOI 10.1086/514121; Hellman J, 2000, J INFECT DIS, V181, P1034, DOI 10.1086/315302; Hellman J, 2000, INFECT IMMUN, V68, P2566, DOI 10.1128/IAI.68.5.2566-2572.2000; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HEUMANN D, 1991, J INFECT DIS, V163, P762, DOI 10.1093/infdis/163.4.762; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310, DOI 10.1152/ajplung.1999.277.2.L310; Kengatharan KM, 1998, J EXP MED, V188, P305, DOI 10.1084/jem.188.2.305; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; LAZZARONI JC, 1992, MOL MICROBIOL, V6, P735, DOI 10.1111/j.1365-2958.1992.tb01523.x; LAZZARONI JC, 1989, MOL GEN GENET, V218, P460, DOI 10.1007/BF00332410; LUDWIG B, 1991, INFECT IMMUN, V59, P2515, DOI 10.1128/IAI.59.8.2515-2521.1991; MARTIN MA, 1992, CLIN INFECT DIS, V14, P1213, DOI 10.1093/clinids/14.6.1213; Means TK, 1999, J IMMUNOL, V163, P6748; Means TK, 2001, J IMMUNOL, V166, P4074, DOI 10.4049/jimmunol.166.6.4074; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; MIZUNO T, 1981, J BIOCHEM, V89, P1039; MIZUNO T, 1979, J BIOCHEM-TOKYO, V86, P991, DOI 10.1093/oxfordjournals.jbchem.a132631; MIZUNO T, 1991, J BIOCHEM-TOKYO, V89, P1051; MIZUSHIMA S, 1984, MOL CELL BIOCHEM, V60, P5; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; NIKAIDO H, 1994, METHOD ENZYMOL, V235, P225; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; NOVITSKY TJ, 1985, J CLIN MICROBIOL, V20, P211; Parratt JR, 1998, J ANTIMICROB CHEMOTH, V41, P31, DOI 10.1093/jac/41.suppl_1.31; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REED L. J., 1938, AMER JOUR HYG, V27, P493; RENKEMA TEJ, 1991, EUR RESPIR J, V4, P1237; Roberts JD, 2000, CIRC RES, V87, P140, DOI 10.1161/01.RES.87.2.140; RodriguezHerva JJ, 1996, J BACTERIOL, V178, P1699, DOI 10.1128/jb.178.6.1699-1706.1996; Salkowski CA, 1998, INFECT IMMUN, V66, P3569, DOI 10.1128/IAI.66.8.3569-3578.1998; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; Vianney A, 1996, J BACTERIOL, V178, P4031, DOI 10.1128/jb.178.14.4031-4038.1996; WICHTERMAN KA, 1980, J SURG RES, V29, P189, DOI 10.1016/0022-4804(80)90037-2; Zhang HW, 1997, J IMMUNOL, V159, P4868; ZIEGLER EJ, 1982, NEW ENGL J MED, V307, P1225, DOI 10.1056/NEJM198211113072001	67	76	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14274	14280		10.1074/jbc.M109696200	http://dx.doi.org/10.1074/jbc.M109696200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830585	hybrid			2022-12-25	WOS:000175096000119
J	Pommier, Y; Kohlhagen, G; Laco, GS; Kroth, H; Sayer, JM; Jerina, DM				Pommier, Y; Kohlhagen, G; Laco, GS; Kroth, H; Sayer, JM; Jerina, DM			Different effects on human topoisomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUTION CONFORMATION; DNA DUPLEX; ANTICANCER DRUG; OPPOSITE DT; CAMPTOTHECIN; COMPLEXES; BASE; INHIBITORS; MECHANISM; SEQUENCE	Topoisomerase I (top1) relieves supercoiling in DNA by forming transient covalent cleavage complexes. These cleavage complexes can accumulate in the presence of damaged DNA or anticancer drugs that either intercalate or lie in the minor groove. Recently we reported that covalent diol epoxide (DE) adducts of benzo[a]pyrene (BaP) at the exocyclic amino group of G(+1) block cleavage at a preferred cleavage site (similar toCTT-G(+1)G(+2)Asimilar to) and cause accumulation of cleavage products at remote sites. In the present study, we nave found that the 10S G(+2) adduct of Bal? DE, which lies toward the scissile bond in the minor groove, blocks normal cleavage, whereas the 10R isomer, which orients away from this bond, allows normal cleavage but blocks religation. In contrast to BaP, the pair of benzo[c] phenanthrene (BcPh) DE adducts at G(+2), which intercalate from the minor groove either between G(+1)/G(+2) or between G(+2)/A, allow normal cleavage but block religation. Both intercalated BcPh DE adducts at G(+1) suppress normal cleavage, as do both groove bound BaP DE adducts at this position. These studies demonstrate that these DE adducts provide a novel set of tools to study DNA topoisomerases and emphasize the importance of contacts between the minor groove and top1's catalytic site.	NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Pommier, Y (corresponding author), NCI, Mol Pharmacol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 5068, Bethesda, MD 20892 USA.			Kroth, Heiko/0000-0002-6936-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1985, BIOACTIVATION FOREIG; BONVEN BJ, 1985, CELL, V41, P541, DOI 10.1016/S0092-8674(85)80027-1; Buterin T, 2000, CANCER RES, V60, P1849; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHEN AY, 1993, P NATL ACAD SCI USA, V90, P8131, DOI 10.1073/pnas.90.17.8131; CHEN AY, 1994, ANN REV PHARM TOXICO, V94, P194; CHENG SC, 1989, CHEM RES TOXICOL, V2, P334, DOI 10.1021/tx00011a011; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; DELOSSANTOS C, 1992, BIOCHEMISTRY-US, V31, P5246; Dipple A, 1999, INT J ONCOL, V14, P103; Fan Y, 1998, J MED CHEM, V41, P2216, DOI 10.1021/jm9605445; HSIANG YH, 1988, CANCER RES, V48, P1722; Kerrigan JE, 2001, BIOCHEMISTRY-US, V40, P9792, DOI 10.1021/bi010913l; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Laco GS, 2002, BIOCHEMISTRY-US, V41, P1428, DOI 10.1021/bi011774a; Lin CH, 2001, J MOL BIOL, V306, P1059, DOI 10.1006/jmbi.2001.4425; MOORE PD, 1977, DRUG METABOLISM CONC, P127; POMMIER Y, 1995, MUTAT RES-DNA REPAIR, V337, P135, DOI 10.1016/0921-8777(95)00019-G; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; Pommier Y, 1998, BBA-GENE STRUCT EXPR, V1400, P83, DOI 10.1016/S0167-4781(98)00129-8; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 2001, ADV CANCER RES, V80, P189, DOI 10.1016/S0065-230X(01)80016-6; Pradhan P, 2001, BIOCHEMISTRY-US, V40, P5870, DOI 10.1021/bi002896q; Redinbo Matthew R., 1999, Current Opinion in Structural Biology, V9, P29, DOI 10.1016/S0959-440X(99)80005-0; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; Sambrook J., 2002, MOL CLONING LAB MANU; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Sim SP, 1997, BIOCHEMISTRY-US, V36, P13285, DOI 10.1021/bi971261x; Takebayashi Y, 1999, P NATL ACAD SCI USA, V96, P7196, DOI 10.1073/pnas.96.13.7196; Volk DE, 2000, BIOCHEMISTRY-US, V39, P14040, DOI 10.1021/bi001669l; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YEH HJC, 1995, BIOCHEMISTRY-US, V34, P13570, DOI 10.1021/bi00041a037; Zegar IS, 1998, BIOCHEMISTRY-US, V37, P16516, DOI 10.1021/bi9817616	38	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13666	13672		10.1074/jbc.M200209200	http://dx.doi.org/10.1074/jbc.M200209200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832494	hybrid			2022-12-25	WOS:000175096000044
J	Vogel, LK; Sahkri, S; Sjostrom, H; Noren, O; Spiess, M				Vogel, LK; Sahkri, S; Sjostrom, H; Noren, O; Spiess, M			Secretion of antithrombin is converted from nonpolarized to apical by exchanging its amino terminus for that of apically secreted family members	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORTICOSTEROID-BINDING GLOBULIN; POLARIZED MDCK CELLS; CANINE KIDNEY-CELLS; INFLUENZA-VIRUS HEMAGGLUTININ; HUMAN AMINOPEPTIDASE-N; EPITHELIAL-CELLS; SORTING SIGNAL; TRANSMEMBRANE DOMAIN; CYTOPLASMIC TAIL; MEMBRANE-PROTEIN	The three members of the serpin family, corticosteroid binding globulin, alpha1-antitrypsin, and C1 inhibitor are secreted apically from Madin-Darby canine kidney (MDCK) cells, whereas two homologous family members, antithrombin and plasminogen activator inhibitor-1, are secreted in a nonpolarized fashion. cDNAs coding for chimeras composed of complementary portions of an apically targeted serpin and a nonsorted serpin were generated, expressed in MDCK cells, and the ratio between apical and basolateral secretion was analyzed. These experiments identified an amino-terminal sequence of corticosteroid binding globulin (residues 1-19) that is sufficient to direct a chimera with antithrombin mainly to the apical side. A deletion/mutagenesis analysis showed that no individual amino acid is absolutely required for the apical. targeting ability of amino acids 1-30 of corticosteroid binding globulin. The corresponding amino-terminal sequences of alpha1-antitrypsin and C1 inhibitor were also sufficient to confer apical sorting. Based on our results we suggest that the apical. targeting ability is encoded in the conformation of the protein.	Univ Copenhagen, Panum Inst, Biochem Lab C, Dept Med Biochem & Genet, DK-2200 Copenhagen N, Denmark; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Copenhagen; University of Basel	Vogel, LK (corresponding author), Univ Copenhagen, Panum Inst, Biochem Lab C, Dept Med Biochem & Genet, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark.			Vogel, Lotte K./0000-0001-9920-0982; Spiess, Martin/0000-0001-7139-0550				AVVAKUMOV GV, 1995, J STEROID BIOCHEM, V53, P515, DOI 10.1016/0960-0760(95)00099-L; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; Cescato R, 2000, J NEUROCHEM, V74, P1131; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; CORBEIL D, 1992, J BIOL CHEM, V267, P2798; Dunbar LA, 2000, J CELL BIOL, V148, P769, DOI 10.1083/jcb.148.4.769; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; GILARDI P, 1990, FEBS LETT, V267, P60, DOI 10.1016/0014-5793(90)80287-S; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; HAMMOND GL, 1987, P NATL ACAD SCI USA, V84, P5153, DOI 10.1073/pnas.84.15.5153; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; Kuhn U, 2000, BIOCHEM BIOPH RES CO, V270, P631, DOI 10.1006/bbrc.2000.2469; KUNDU A, 1994, J VIROL, V68, P1812, DOI 10.1128/JVI.68.3.1812-1818.1994; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Larsen JE, 1999, FEBS LETT, V451, P19, DOI 10.1016/S0014-5793(99)00526-8; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P3248, DOI 10.1073/pnas.070049497; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; Marzolo MP, 1997, P NATL ACAD SCI USA, V94, P1834, DOI 10.1073/pnas.94.5.1834; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MUSTO NA, 1993, EXP CELL RES, V209, P271, DOI 10.1006/excr.1993.1311; ROBINSON PA, 1985, J ENDOCRINOL, V104, P269, DOI 10.1677/joe.0.1040269; Rodionov DG, 2000, J BIOL CHEM, V275, P8279, DOI 10.1074/jbc.275.12.8279; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SHEFFIELD WP, 1992, BLOOD, V79, P2330; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sun AQ, 1998, AM J PHYSIOL-GASTR L, V275, pG1045, DOI 10.1152/ajpgi.1998.275.5.G1045; Sun AQ, 2001, J BIOL CHEM, V276, P6825, DOI 10.1074/jbc.M008797200; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VOGEL LK, 1995, J BIOL CHEM, V270, P22933, DOI 10.1074/jbc.270.39.22933; Vogel LK, 2000, FEBS LETT, V473, P297, DOI 10.1016/S0014-5793(00)01548-9; VOGEL LK, 1992, J BIOL CHEM, V267, P2794; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; VOGEL LK, 1993, FEBS LETT, V330, P293, DOI 10.1016/0014-5793(93)80891-W; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; WESSELS HP, 1989, J BIOL CHEM, V264, P17; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929	42	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13883	13888		10.1074/jbc.M107997200	http://dx.doi.org/10.1074/jbc.M107997200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11839735	hybrid			2022-12-25	WOS:000175096000071
J	Kawashima, H; Atarashi, K; Hirose, M; Hirose, J; Yamada, S; Sugahara, K; Miyasaka, M				Kawashima, H; Atarashi, K; Hirose, M; Hirose, J; Yamada, S; Sugahara, K; Miyasaka, M			Oversulfated chondroitin/dermatan sulfates containing GlcA beta 1/IdoA alpha 1-3GalNAc(4,6-O-disulfate) interact with L- and P-selectin and chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY GRANULES; DERMATAN SULFATE; KINETIC-ANALYSIS; CELL-ADHESION; PROTEOGLYCAN; HEPARIN; BINDING; VERSICAN; LIGAND; CD44	We previously reported that versican, a large chondroitin/dermatan sulfate (CS/DS) proteoglycan, interacts through its CS/DS chains with adhesion molecules L- and P-selectin and CD44, as well as chemokines. Here, we have characterized these interactions further. Using a metabolic inhibitor of sulfation, sodium chlorate, we show that the interactions of the CS/DS chains of versican with L- and P-selectin and chemokines are sulfation-dependent but the interaction with CD44 is sulfation-independent. Consistently, versican's binding to L- and P-selectin and chemokines is specifically inhibited by oversulfated CS/DS chains containing G1cAbeta1-3GalNAc(4,6-O-disulfate) or IdoAalpha1-3GalNAc(4,6-O-disulfate), but its binding to CD44 is inhibited by all the CS/DS chains, including low-sulfated and unsulfated ones. Affinity and kinetic analyses using surface plasmon resonance revealed that the oversulfated CS/DS chains containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) bind directly to selectins and chemokines with high affinity (K-d 21.1 to 293 nm). In addition, a tetrasaccharide fragment of repeating GlcAbeta1-3GalNAc(4,6-O-disulfate) units directly interacts with L- and P-selectin and chemokines and oversulfated CS/DS chains containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) inhibit chemokine-induced Ca2+ mobilization. Taken together, our results show that oversulfated CS/DS chains containing GlcAbeta1/IdoAalpha1-3GalNAc(4,6-O-disulfate) are recognized by L- and P-selectin and chemokines, and imply that these chains are important in selectin- and/or chemokine-mediated cellular responses.	Osaka Univ, Lab Mol & Cellular Recognit, Grad Sch Med, Suita, Osaka 5650871, Japan; Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Osaka University; Kobe Pharmaceutical University	Kawashima, H (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA.	hkawashima@burnham.org	Miyasaka, Masayuki/AAM-6343-2020; まゆみ, 廣瀬/AAK-5735-2020	Atarashi, Kazuyuki/0000-0002-4166-7114				ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Fujimoto T, 2001, INT IMMUNOL, V13, P359, DOI 10.1093/intimm/13.3.359; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; IMAI Y, 1993, NATURE, V361, P555; KATZ HR, 1986, J BIOL CHEM, V261, P3393; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; MCGEE MP, 1995, J BIOL CHEM, V270, P26109, DOI 10.1074/jbc.270.44.26109; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NAGASAWA K, 1986, CARBOHYD RES, V158, P183, DOI 10.1016/0008-6215(86)84016-2; NAGASAWA K, 1984, CARBOHYD RES, V131, P301, DOI 10.1016/0008-6215(84)85252-0; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; NELSON RM, 1993, BLOOD, V82, P3253; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; OHHASHI Y, 1984, BIOCHEM J, V217, P199, DOI 10.1042/bj2170199; Petersen F, 1999, J BIOL CHEM, V274, P12376, DOI 10.1074/jbc.274.18.12376; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; SUZUKI S, 1968, J BIOL CHEM, V243, P1543; TOYAMASORIMACHI N, 1995, J BIOL CHEM, V270, P7437, DOI 10.1074/jbc.270.13.7437; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; UHLINHANSEN L, 1989, J BIOL CHEM, V264, P14916; YAOITA E, 1990, J BIOL CHEM, V265, P522; ZAKO M, 1995, J BIOL CHEM, V270, P3914, DOI 10.1074/jbc.270.8.3914; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	40	210	214	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12921	12930		10.1074/jbc.M200396200	http://dx.doi.org/10.1074/jbc.M200396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821431	hybrid			2022-12-25	WOS:000175036300057
J	Satomura, T; Kawakami, R; Sakuruba, H; Ohshima, T				Satomura, T; Kawakami, R; Sakuruba, H; Ohshima, T			Dye-linked D-proline dehydrogenase from hyperthermophilic archaeon Pyrobaculum islandicum is a novel FAD-dependent amino acid dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURIFICATION; OPERON; ENZYME; SULFUR	The activity of dye-linked D-proline dehydrogenase was found in the crude extract of a hyperthermophilic archacon, Pyrobaculum islandicum JCM 9189. The dye-linked D-proline dehydrogenase was a membrane associated enzyme and was solubilized from the membrane fractions by treatment with Tween 20. The solubilized enzyme was purified 34-fold in the presence of 0.1% Tween 20 by four sequential chromatographies. The enzyme has a molecular mass of about 145 kDa and consisted of homotetrameric subunits with a molecular mass of about 42 kDa. The N-terminal amino acid sequence of the subunit was MKVAIVGGGIIGLFTAYHL-RQQGADVVI. The enzyme retained its full activity both after incubation at 80 degreesC for 10 min and after incubation in the range of pH 4.0-10.0 at 50 degreesC for 10 min. The enzyme-catalyzed dehydrogenation of several D-amino acids was carried out using 2,6-dichloroindophenol as an electron acceptor, and D-proline was the most preferred substrate among the D-amino acids. The Michaelis constants for D-proline and 2,6-dichloroindophenol were determined to be 4.2 and 0.14 mM, respectively. Delta(1)-Pyrroline-2-carboxylate was identified as the reaction product from D-proline by thin layer chromatography. The prosthetic group of the enzyme was identified to be FAD by high-performance liquid chromatography. The gene encoding the enzyme was cloned and expressed in Escherichia coli. The nucleotide sequence of the dye-linked D-proline dehydrogenase gene was determined and encoded a peptide of 363 amino acids with a calculated molecular weight of 40,341. The amino acid sequence of the Pb. islandicum enzyme showed the highest similarity (38%) with that of the probable oxidoreductase in Sulfolobus solfataricus, but low similarity with those Of D-alanine dehydrogenases from the mesophiles so far reported. This shows that the membrane-bound D-proline dehydrogenase from Pb. islandicum is a novel FAD-dependent amino acid dehydrogenase.	Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, Tokushima 7708506, Japan	Tokushima University	Ohshima, T (corresponding author), Univ Tokushima, Fac Engn, Dept Biol Sci & Technol, 2-1 Minamijosanjimacho, Tokushima 7708506, Japan.							Frew J. E., 1987, ANAL CHEM, V59, P933; Hayashi T, 2001, DNA RES, V8, P11, DOI 10.1093/dnares/8.1.11; HUBER R, 1987, ARCH MICROBIOL, V149, P95, DOI 10.1007/BF00425072; Janes BK, 1998, J BACTERIOL, V180, P563, DOI 10.1128/JB.180.3.563-570.1998; JONES H, 1983, FEBS LETT, V151, P189, DOI 10.1016/0014-5793(83)80066-0; KANAMOTO T, 2000, DNA RES, V7, P331; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kujo C, 1998, APPL ENVIRON MICROB, V64, P2152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOBOCKA M, 1994, J BACTERIOL, V176, P1500, DOI 10.1128/jb.176.5.1500-1510.1994; MA K, 1994, J BACTERIOL, V176, P6509, DOI 10.1128/JB.176.21.6509-6517.1994; MAGOR AM, 1987, BIOCHIMIE, V69, P63, DOI 10.1016/0300-9084(87)90272-0; MEISTER A, 1954, J BIOL CHEM, V206, P577; Nagata Y, 1999, BBA-PROTEIN STRUCT M, V1435, P160, DOI 10.1016/S0167-4838(99)00208-3; OHSHIMA T, 1993, EUR J BIOCHEM, V214, P37, DOI 10.1111/j.1432-1033.1993.tb17893.x; OLSIEWSKI PJ, 1980, J BIOL CHEM, V255, P4487; Sakuraba H, 2001, APPL ENVIRON MICROB, V67, P1470, DOI 10.1128/AEM.67.4.1470-1475.2001; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sazuka T, 1996, DNA Res, V3, P225, DOI 10.1093/dnares/3.4.225; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Stover CK, 2000, NATURE, V406, P959, DOI 10.1038/35023079; TSUKADA K, 1966, J BIOL CHEM, V241, P4522; WILD J, 1974, MOL GEN GENET, V128, P131, DOI 10.1007/BF02654486; Willie A, 1995, BIOCHEMISTRY-US, V34, P16703, DOI 10.1021/bi00051a019	24	34	39	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12861	12867		10.1074/jbc.M112272200	http://dx.doi.org/10.1074/jbc.M112272200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823469	hybrid			2022-12-25	WOS:000175036300049
J	Vannelli, TA; Dykman, A; de Montellano, PRO				Vannelli, TA; Dykman, A; de Montellano, PRO			The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS; CATALASE-PEROXIDASE; THIOBENZAMIDE; OXIDATION; HEPATOTOXICITY; CHEMOTHERAPY; PURIFICATION; RESISTANCE; MICROSOMES; NITRILES	Ethionamide (ETA), a prodrug that must undergo metabolic activation to exert its cytotoxic effects, is a second line drug against tuberculosis, a disease that infects more than a third of the world's population. It has been proposed, on the basis of genetic experiments, that ETA is activated in Mycobacterium tuberculosis by the protein encoded by the gene Rv3854c (DeBarber, A. E., Mdluli, K., Bosnian, M., Bekker, L.-G., and Barry, C. E., 1111 (2000) Proc. Natl. Acad. Sci. U. S. A 97, 9677-96829; Baulard, A. R., Betts, J. C., Engohang-Ndong, J., Quan, S., McAdam, R. A., Brennan, P. J., Locht, C., and Besra, G. S. (2000) J. Biol. Chem. 275, 28326-28331). We report here the expression, purification, and characterization of the protein encoded by this gene. Our results establish that the enzyme (EtaA) is an FAD-containing enzyme that oxidizes ETA to the corresponding S-oxide. The S-oxide, which has a similar biological activity as ETA, is further oxidized by EtaA to 2-ethyl-4-amidopyridine, presumably via the unstable doubly oxidized sulfinic acid intermediate. This flavoenzyme also oxidizes thiacetazone, thiobenzamide, and isothionicotinamide and thus is probably responsible, as suggested by the observation of crossover resistance, for the oxidative activation of other thioamide antitubercular drugs.	Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, S-926, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu		Vannelli, Tommaso/0000-0002-0610-392X	NIGMS NIH HHS [GM 56531] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM056531] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; Baulard AR, 2000, J BIOL CHEM, V275, P28326; Bose DS, 2000, SYNTHETIC COMMUN, V30, P3047, DOI 10.1080/00397910008087453; CACCHI S, 1980, SYNTHESIS-STUTTGART, P243; CASHMAN JR, 1981, BIOCHEM BIOPH RES CO, V98, P147, DOI 10.1016/0006-291X(81)91881-7; CASHMAN JR, 1983, CHEM-BIOL INTERACT, V45, P341, DOI 10.1016/0009-2797(83)90080-7; CASHMAN JR, 1982, J ORG CHEM, V47, P4645, DOI 10.1021/jo00145a008; Crofton J., 1997, GUIDELINES MANAGEMEN; DeBarber AE, 2000, P NATL ACAD SCI USA, V97, P9677, DOI 10.1073/pnas.97.17.9677; DOERGE DR, 1984, MOL PHARMACOL, V26, P348; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Farmer P, 1998, INT J TUBERC LUNG D, V2, P869; GRUNERT M, 1967, ARZNEI-FORSCHUNG, V17, P411; HANZLIK RP, 1980, TOXICOL APPL PHARM, V55, P260, DOI 10.1016/0041-008X(80)90088-5; HANZLIK RP, 1983, DRUG METAB DISPOS, V11, P201; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; JENNER PJ, 1984, J ANTIMICROB CHEMOTH, V13, P267, DOI 10.1093/jac/13.3.267; Johnsson K, 1997, J BIOL CHEM, V272, P2834, DOI 10.1074/jbc.272.5.2834; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JOHNSTON JP, 1967, J PHARM PHARMACOL, V19, P1, DOI 10.1111/j.2042-7158.1967.tb07986.x; MCMANUS ME, 1987, DRUG METAB DISPOS, V15, P256; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; PREMA K, 1976, J INDIAN I SCI, V58, P16; PUTTER J, 1972, ARZNEI-FORSCHUNG, V22, P1027; RIST N, 1959, AM REV TUBERC PULM, V79, P1; Rozwarski DA, 1998, SCIENCE, V279, P98, DOI 10.1126/science.279.5347.98; TYNES RE, 1983, BIOCHEM PHARMACOL, V32, P3419, DOI 10.1016/0006-2952(83)90371-4; van der Werf MJ, 2000, BIOCHEM J, V347, P693, DOI 10.1042/0264-6021:3470693; Wilson W, 1999, P NATL ACAD SCI USA, V96, P12833, DOI 10.1073/pnas.96.22.12833	31	172	185	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12824	12829		10.1074/jbc.M110751200	http://dx.doi.org/10.1074/jbc.M110751200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823459	hybrid			2022-12-25	WOS:000175036300044
J	Giovannardi, S; Forlani, G; Balestrini, M; Bossi, E; Tonini, R; Sturani, E; Peres, A; Zippel, R				Giovannardi, S; Forlani, G; Balestrini, M; Bossi, E; Tonini, R; Sturani, E; Peres, A; Zippel, R			Modulation of the inward rectifier potassium channel IRK1 by the Ras signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; K+ CHANNELS; RECEPTOR; PHOSPHORYLATION; ENDOCYTOSIS; SUPPRESSION; INCREASES; CURRENTS; KINASES; CELLS	In this study, we investigated the role of Ras and the mitogen-activated protein kinase (MAPK) pathway in the modulation of the inward rectifier potassium channel IRK1. We show that although expression of IRK1 in HEK 293 cells leads to the appearance of a potassium current with strong inward rectifying properties, coexpression of the constitutively active form of Ras (Ras-L61) results in a significant reduction of the mean current density without altering the biophysical properties of the channel. The inhibitory effect of Ras-L61 is not due to a decreased expression of IRK1 since Northern analysis indicates that IRK1 mRNA level is not affected by Ras-L61 co-expression. Moreover, the inhibition can be relieved by treatment with the mitogen-activated protein kinase/ERK kinase (MEK) inhibitor PD98059. Confocal microscopy analysis of cells transfected with the fusion construct green fluorescent protein-IRK1 shows that the channel is mainly localized at the plasma membrane. Coexpression of Ras-L61 delocalizes fluorescence to the cytoplasm, whereas treatment with PD98059 partially restores the membrane localization. In conclusion, our data indicate that the Ras-MAPK pathway modulates IRK1 current by affecting the subcellular localization of the channel. This suggests a role for Ras signaling in regulating the intracellular trafficking of this channel.	Univ Milan, Dept Gen Physiol & Biochem, I-20133 Milan, Italy; Univ Insubria, Dept Struct & Functional Biol, I-21100 Varese, Italy	University of Milan; University of Insubria	Zippel, R (corresponding author), Univ Milan, Dept Gen Physiol & Biochem, Via Celoria 26, I-20133 Milan, Italy.	renata.zippel@unimi.it	Bossi, Elena/F-4730-2012; Tonini, Raffaella/J-2960-2012	Bossi, Elena/0000-0002-9549-2153; TONINI, Raffaella/0000-0003-1652-4709; FORLANI, GRETA/0000-0003-1987-7761				Arcangeli A, 1997, EUR J NEUROSCI, V9, P2596, DOI 10.1111/j.1460-9568.1997.tb01689.x; AUSUBEL FM, 1999, CURRENT PROTOCOLS S, V1; Bianchi L, 1998, CANCER RES, V58, P815; Brock P, 1999, CYTOMETRY, V35, P353, DOI 10.1002/(SICI)1097-0320(19990401)35:4<353::AID-CYTO8>3.0.CO;2-M; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DZWOKAI M, 2001, SCIENCE, V291, P316; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fitzgerald EM, 1997, EUR J NEUROSCI, V9, P1252, DOI 10.1111/j.1460-9568.1997.tb01480.x; HAHNEL C, 1992, EUR J NEUROSCI, V4, P361, DOI 10.1111/j.1460-9568.1992.tb00883.x; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hida H, 1998, J NEUROSCI, V18, P8712; Hilborn MD, 1998, J NEUROSCI, V18, P590; Johns DC, 1999, J NEUROSCI, V19, P1691; Jones SVP, 1996, MOL PHARMACOL, V49, P662; JONES SVP, 2000, SOC NEUR ABSTR, V26; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Sakmann B., 1995, SINGLE CHANNEL RECOR; Tong YH, 2001, J GEN PHYSIOL, V117, P103, DOI 10.1085/jgp.117.2.103; Tonini R, 1999, EUR J NEUROSCI, V11, P959, DOI 10.1046/j.1460-9568.1999.00504.x; Wischmeyer E, 1998, J BIOL CHEM, V273, P34063, DOI 10.1074/jbc.273.51.34063; Wischmeyer E, 1996, P NATL ACAD SCI USA, V93, P5819, DOI 10.1073/pnas.93.12.5819; WOOD LS, 1995, GENE, V163, P313, DOI 10.1016/0378-1119(95)00244-Z	26	28	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12158	12163		10.1074/jbc.M110466200	http://dx.doi.org/10.1074/jbc.M110466200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809752	hybrid			2022-12-25	WOS:000174846400073
J	Hernandez, MP; Chadli, A; Toft, DO				Hernandez, MP; Chadli, A; Toft, DO			HSP40 binding is the first step in the HSP90 chaperoning pathway for the progesterone receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DNAJ-LIKE PROTEINS; MOLECULAR CHAPERONE; GLUCOCORTICOID-RECEPTOR; STEROID-RECEPTORS; SIGNAL-TRANSDUCTION; HSP70 CHAPERONES; CO-CHAPERONE; ATP BINDING; J-DOMAIN	The progesterone receptor (PR) can be isolated in its native conformation able to bind hormone, yet its ligand-binding domain rapidly loses its activity at elevated temperature. However, an in vitro chaperoning system consisting of five proteins (HSP40, HSP70, HOP, HSP90, and p23) with ATP is capable of restoring this function. The first step of this chaperoning mechanism is usually thought to be the binding of HSP70 to PR. Our findings here show that the binding of HSP40 to PR is, instead, the first step. HSP40 binding occurred rapidly and was not dependent on ATP or other proteins. The stoichiometry of HSP40 to native PR in these complexes was similar to1:1. HSP40 bound specifically and with a high affinity to native PR (K-d = 77 nM). The binding of HSP40 to PR was sustained and did not interact in the highly dynamic fashion that has been observed previously for HSP90 in this system. The HSP40(.)PR complex could be isolated as a functional unit that could, after the addition of the other chaperones, progress to a PR complex capable of hormone binding. These results indicate that HSP40 initiates the entry of PR into the HSP90 pathway.	Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	toft.david@mayo.edu			NIDDK NIH HHS [DK59284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CAPLAN AJ, 1995, J BIOL CHEM, V270, P5251, DOI 10.1074/jbc.270.10.5251; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; CYR DM, 1994, J BIOL CHEM, V269, P9798; Dey B, 1996, MOL BIOL CELL, V7, P91, DOI 10.1091/mbc.7.1.91; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; Johnson JL, 2000, MOL CELL BIOL, V20, P3027, DOI 10.1128/MCB.20.9.3027-3036.2000; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; KIMURA Y, 1995, SCIENCE, V268, P1362, DOI 10.1126/science.7761857; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Ungewickell E, 1997, J BIOL CHEM, V272, P19594, DOI 10.1074/jbc.272.31.19594; WICKNER S, 1991, NATURE, V350, P165, DOI 10.1038/350165a0	58	112	116	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11873	11881		10.1074/jbc.M111445200	http://dx.doi.org/10.1074/jbc.M111445200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809754	hybrid			2022-12-25	WOS:000174846400036
J	Kido, K; Doerks, A; Lochelt, M; Flugel, RM				Kido, K; Doerks, A; Lochelt, M; Flugel, RM			Identification and functional characterization of an intragenic DNA binding site for the spumaretroviral trans-activator in the human p57(Kip2) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; VIRUS INTERNAL PROMOTER; FOAMY VIRUS; TAX PROTEIN; DISTINCT; CELLS; TRANSACTIVATOR; DIFFERENTIATION; TRANSFORMATION; TRANSCRIPTION	Expression of the human cyclin-dependent protein kinase inhibitor p57(Kip2) gene was previously shown to be specifically and strongly activated by the retroviral trans-activator Bel1 of human foamy virus by means of expression profiling, Northern, and Western blot analysis. Here we report that Bel1-mediated trans-activation was conferred by a Bel1 response element (BRE) located in the second exon of p57(Kip2). The intragenic Kip2-BRE was capable of trans-activating the luciferase reporter gene upon cotransfection with Bel1. In electrophoretic mobility shift assays using 293T nuclear extracts or a purified glutathione S-transferase (GST)(.)Bel1 fusion protein, we identified the 55-nucleotide-long Kip2-BRE site that mainly consists of three direct repeats of 14-mers partially homologous to a functionally active ERE in the viral internal promoter. The specificity of the transactivator-DNA binding was shown by using mutated and shortened Kip2-BRE oligodeoxynucleotides in competition experiments with the authentic viral internal promoter and by Bel1-specific antibody that led to a supershift of the nuclear protein(.)Kip2-BRE and GST(.)Bel1(.)Kip2-BRE complex. The data indicate that bel1 can directly bind to BRE sites. The cellular Kip2-BRE can be used to predict those human genes that are directly or indirectly activated by the Bel1 trans-activator.	Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Div Retroviral Gene Express, Res Program Appl Tumor Virol, D-69009 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Flugel, RM (corresponding author), Deutsch Krebsforschungszentrum, Forschungsschwerpunkt Angew Tumorvirol, Div Retroviral Gene Express, Res Program Appl Tumor Virol, INF 242, D-69009 Heidelberg, Germany.							Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; BLAIR WS, 1994, J VIROL, V68, P3803, DOI 10.1128/JVI.68.6.3803-3808.1994; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COFFIN JM, 1997, RETROVIRUSES, P225; ENGEMANN S, 2000, NUCLEIC ACIDS RES, V18, P2691; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; Goodman RH, 2000, GENE DEV, V14, P1553; HE FL, 1993, J VIROL, V67, P1896, DOI 10.1128/JVI.67.4.1896-1904.1993; He FL, 1996, J VIROL, V70, P3902, DOI 10.1128/JVI.70.6.3902-3908.1996; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Kang YB, 1998, J VIROL, V72, P504, DOI 10.1128/JVI.72.1.504-511.1998; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Liu Y, 1999, GENE DEV, V13, P1692, DOI 10.1101/gad.13.13.1692; LOCHELT M, 1993, NUCLEIC ACIDS RES, V21, P4226; LOCHELT M, 1993, P NATL ACAD SCI USA, V90, P7317, DOI 10.1073/pnas.90.15.7317; LOCHELT M, 1995, RETROVIRIDAE, V4, P239; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Reik W, 2000, NATURE, V405, P408, DOI 10.1038/35013178; Sambrook J., 2002, MOL CLONING LAB MANU; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scoggin KES, 2001, MOL CELL BIOL, V21, P5520, DOI 10.1128/MCB.21.16.5520-5530.2001; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; Svaren J, 2000, J BIOL CHEM, V275, P38524, DOI 10.1074/jbc.M005220200; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; VENKATESH LK, 1993, J VIROL, V67, P161, DOI 10.1128/JVI.67.1.161-169.1993; Wagner A, 2000, J VIROL, V74, P4441, DOI 10.1128/JVI.74.10.4441-4447.2000; Winkler I, 1997, J VIROL, V71, P6727, DOI 10.1128/JVI.71.9.6727-6741.1997; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yu SF, 1996, SCIENCE, V271, P1579, DOI 10.1126/science.271.5255.1579; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0; Zou JX, 1996, P NATL ACAD SCI USA, V93, P326, DOI 10.1073/pnas.93.1.326	35	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12032	12039		10.1074/jbc.M108747200	http://dx.doi.org/10.1074/jbc.M108747200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815601	hybrid			2022-12-25	WOS:000174846400057
J	Makinen, MW; Brady, MJ				Makinen, MW; Brady, MJ			Structural origins of the insulin-mimetic activity of bis(acetylacetonato)oxovanadium(IV)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RESONANCE; INHIBITOR GLYCOPROTEIN NEPHROCALCIN; VANADYL SULFATE; BINDING-SITES; HUMAN SEROTRANSFERRIN; MOLECULAR-STRUCTURE; IN-VIVO; COMPLEXES; ENDOR; BIS(MALTOLATO)OXOVANADIUM(IV)	We have investigated the interaction of bis(acetylacetonato)oxovanadium(IV) (VO(acac)(2)) with bovine serum albumin (BSA) by EPR and angle-selected electron nuclear double resonance, correlating results with assays of glucose uptake by 3T3-L1 adipocytes. EPR spectra of VO(acac)2 showed no broadening in the presence of BSA, however, electron nuclear double resonance titrations of VO(acac)2 in the presence of BSA were indicative of adduct formation of VO(acac)2 with albumin of 1:1 stoichiometry. The influence of VO(acac)2 on uptake of 2-deOXY-D- [1-C-14] glucose by serum-starved 3T3-LI adipocytes was measured in the presence and absence of BSA. Glucose uptake was stimulated 9-fold in the presence of 0.5 nM VO(acac)(2), 17-fold in the presence of 0.5 midi VO(acac)2 Plus I mm BSA, and 22-fold in the presence of 100 nM insulin. BSA had no influence on glucose uptake, on the action of insulin, or on glucose uptake in the presence Of VOSO4. The maximum insulin-mimetic effect of VO(acac), was observed at VO(acac)2:BSA ratios less than or equal to 1.0. Similar results were obtained also with bis(maltolato)oxovanadium(M. These results suggest that the enhanced insulin-mimetic action of organic chelates of VO2+ may be dependent on adduct formation with BSA and possibly other serum transport proteins.	Univ Chicago, Dept Biochem & Mol Biol, Cummings Life Sci Ctr, Chicago, IL 60637 USA; Univ Chicago, Albert Merritt Billings Hosp, Endocrinol Sect, Dept Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Makinen, MW (corresponding author), Univ Chicago, Dept Biochem & Mol Biol, Cummings Life Sci Ctr, 920 E 58Th St, Chicago, IL 60637 USA.	makinen@uchicago.edu			NIDDK NIH HHS [DK20959] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANESE NF, 1978, J PHYS CHEM-US, V82, P910, DOI 10.1021/j100497a014; Amin SS, 2000, INORG CHEM, V39, P406, DOI 10.1021/ic9905897; BAILEY S, 1988, BIOCHEMISTRY-US, V27, P5804, DOI 10.1021/bi00415a061; Bates R.G., 1973, J ELECTROCHEM SOC, V120, p263C, DOI [10.1149/1.2403829, DOI 10.1149/1.2403829]; Boden G, 1996, METABOLISM, V45, P1130, DOI 10.1016/S0026-0495(96)90013-X; Brady MJ, 1999, J BIOL CHEM, V274, P27497, DOI 10.1074/jbc.274.39.27497; CANNON JC, 1975, BIOCHEMISTRY-US, V14, P4573, DOI 10.1021/bi00692a003; Chasteen N.D., 1981, BIOL MAGN RESON, V3, P53; CHASTEEN ND, 1977, COORDIN CHEM REV, V22, P1; CHASTEEN ND, 1986, BIOCHIM BIOPHYS ACTA, V884, P84, DOI 10.1016/0304-4165(86)90230-8; CHASTEEN ND, 1976, J PHYS CHEM-US, V80, P867, DOI 10.1021/j100549a021; CHASTEEN ND, 1977, BIOCHEMISTRY-US, V16, P363, DOI 10.1021/bi00622a004; COHEN N, 1995, J CLIN INVEST, V95, P2501, DOI 10.1172/JCI117951; CRANS DC, 1998, ACS SYM SER, V711, P82; Goldfine AB, 1995, MOL CELL BIOCHEM, V153, P217, DOI 10.1007/BF01075941; GOLDFINE AB, 1995, J CLIN ENDOCR METAB, V80, P3311, DOI 10.1210/jc.80.11.3311; Hanson GR, 1996, INORG CHEM, V35, P6507, DOI 10.1021/ic960490p; Hollender D, 2001, J INORG BIOCHEM, V86, P267; JAKOBY MG, 1995, BIOCHEMISTRY-US, V34, P8780, DOI 10.1021/bi00027a029; Jensen TC, 2000, J BIOL CHEM, V275, P40148, DOI 10.1074/jbc.M004902200; JIANG FS, 1995, INORG CHEM, V34, P1736, DOI 10.1021/ic00111a021; Li JP, 1996, BIOCHEMISTRY-US, V35, P8314, DOI 10.1021/bi960209i; MAKINEN MW, 1995, MET IONS BIOL SYST, V31, P89; MCNEILL JH, 1992, J MED CHEM, V35, P1489, DOI 10.1021/jm00086a020; Mustafi D, 1996, BIOCHEMISTRY-US, V35, P14703, DOI 10.1021/bi961200j; MUSTAFI D, 1994, P NATL ACAD SCI USA, V91, P11323, DOI 10.1073/pnas.91.24.11323; Mustafi D, 2000, CELL MOL BIOL, V46, P1345; MUSTAFI D, 1988, INORG CHEM, V27, P3360, DOI 10.1021/ic00292a020; Mustafi D, 1999, J PHYS CHEM A, V103, P11279, DOI 10.1021/jp991287t; MUSTAFI D, 2000, CELL MOL BIOL, V114, P6219; Reul BA, 1999, BRIT J PHARMACOL, V126, P467, DOI 10.1038/sj.bjp.0702311; RIST GH, 1970, J CHEM PHYS, V52, P4633, DOI 10.1063/1.1673696; SAKURAI H, 1987, INORG CHIM A-BIOINOR, V138, P149, DOI 10.1016/S0020-1693(00)81199-8; WOJTCZAK A, 1993, J BIOL CHEM, V268, P6202; WOJTCZAK A, 1992, J BIOL CHEM, V267, P353; YUEN VG, 1995, CAN J PHYSIOL PHARM, V73, P55, DOI 10.1139/y95-008	36	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12215	12220		10.1074/jbc.M110798200	http://dx.doi.org/10.1074/jbc.M110798200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815612	hybrid			2022-12-25	WOS:000174846400080
J	Caldwell, MC; Hough, C; Furer, S; Linehan, WM; Morin, PJ; Gorospe, M				Caldwell, MC; Hough, C; Furer, S; Linehan, WM; Morin, PJ; Gorospe, M			Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNF alpha cytotoxicity	ONCOGENE			English	Article						VHL; SAGE; renal cell carcinoma; gene expression; TNF alpha	ENDOTHELIAL GROWTH-FACTOR; HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR PROTEIN; NECROSIS-FACTOR-ALPHA; APOPTOSIS; ELONGATION; PRODUCT; ARREST; DEATH	We have used serial analysis of gene expression (SAGE) to investigate the influence of the von Hippel-Lindau (VHL) gene on global gene expression profiles. SAGE libraries were prepared from renal cell carcinoma (RCC) lines that either lack (parental) or express wild-type VHL (wtVHL). Comparison of these libraries revealed some differentially expressed genes (Glut-1, for example) that were known to be influenced by VHL, but the majority of genes had not previously been reported to be affected by the cell's VHL status. The identification of several genes involved in TNFalpha-mediated events prompted us to compare the sensitivity of cells with different VHL status in TNFalpha cytotoxicity assays. Strikingly, VHL-deficient cells were much more resistant to the toxic influence of TNFalpha. We propose that VHL-dependent sensitization of RCC cells to TNFalpha-mediated killing may contribute to VHL's growth suppressive function.	NIA, GRC, IRP,NIH, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gorospe, M (corresponding author), NIA, GRC, IRP,NIH, Cellular & Mol Biol Lab, Box 12,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.				NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; CHU KT, 1995, P NATL ACAD SCI USA, V92, P11894, DOI 10.1073/pnas.92.25.11894; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FAJARDO LF, 1992, AM J PATHOL, V140, P539; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hough CD, 2000, CANCER RES, V60, P6281; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Moutet M, 1998, FREE RADICAL BIO MED, V25, P270, DOI 10.1016/S0891-5849(98)00038-0; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; OHH M, 2000, J BIOL CHEM, V275, P25733; Rae FK, 2000, INT J CANCER, V88, P726, DOI 10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H; SATO K, 1994, TOHOKU J EXP MED, V173, P355, DOI 10.1620/tjem.173.355; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Spyridopoulos I, 1997, J MOL CELL CARDIOL, V29, P1321, DOI 10.1006/jmcc.1996.0365; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WIZIGMANNVOOS S, 1995, CANCER RES, V55, P1358; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012	26	33	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					929	936		10.1038/sj.onc.1205140	http://dx.doi.org/10.1038/sj.onc.1205140			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840338				2022-12-25	WOS:000173427100008
J	Grant, SL; Hammacher, A; Douglas, AM; Goss, GA; Mansfield, RK; Heath, JK; Begley, CG				Grant, SL; Hammacher, A; Douglas, AM; Goss, GA; Mansfield, RK; Heath, JK; Begley, CG			An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells	ONCOGENE			English	Article						breast cancer; oncostatin M; epidermal growth factor; ErbB; gp130; receptors	EPIDERMAL GROWTH-FACTOR; LEUKEMIA INHIBITORY FACTOR; ONCOSTATIN-M RECEPTOR; SIGNAL-TRANSDUCTION; ESTROGEN-RECEPTOR; TYROSINE KINASES; GENE-EXPRESSION; CARCINOMA-CELLS; DIFFERENTIATION; INTERLEUKIN-6	Oncostatin M (OSM), an interleukin-6 type cytokine, acts via the gp130 signaling receptor to inhibit proliferation and induce differentiation of breast cancer cells. EGF, a mitogen for breast cells, signals via EGFR/ErbB tyrosine kinase receptors which are implicated in breast cancer pathogenesis. Here we show paradoxically that EGF enhanced the OSM-induced inhibition of proliferation and induction of cellular differentiation in both estrogen receptor positive and negative breast cancer cells. This functional synergism was also seen with heregulin but not SCF, PDGF or IGF-1, indicating that it was specific to EGF-related growth factors. Immunoprecipitation experiments revealed that gp130 was constitutively associated with ErbB-2 and ErbB-3. There was a similar association between the OSMRbeta and ErbB-2. Furthermore, EGF unexpectedly induced tyrosine phosphorylation of gp130. We show that OSM induced phosphorylation of STAT3. Both OSM and EGF activated the p42/44 MAP kinases, but while the MEK inhibitor, PD98059, ablated the OSM-induced inhibition, it only partially ablated the inhibitory effects of OSM plus EGF. Thus, we have demonstrated that the receptors and signalling pathways of two apparently unrelated growth factors were intimately linked, resulting in an unexpected biological effect. This provides a new mechanism for generating signalling diversity and has potential clinical implications in breast cancer.	Rotary Bone Marrow Res Labs, Parkville, Vic 3050, Australia; Cooperat Res Ctr Cellular Growth Factors, Parkville, Vic 3050, Australia; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Melbourne Tumour Biol Branch, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; Univ Birmingham, Sch Biochem, Growth Factors Grp, Canc Res Campaign, Birmingham B15 2TT, W Midlands, England; Univ Western Australia, TVW Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA, Australia; Western Australian Inst Med Res, Perth, WA, Australia	Walter & Eliza Hall Institute; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Birmingham; Telethon Kids Institute; University of Western Australia; University of Western Australia	Grant, SL (corresponding author), Inst Child Htlh Res, Subiaco, WA 6008, Australia.	suzieg@ichr.uwa.edu.au						Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Auguste P, 1997, J BIOL CHEM, V272, P15760, DOI 10.1074/jbc.272.25.15760; Baselga J, 2000, SEMIN ONCOL, V27, P20; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; DAVIDSON NE, 1987, MOL ENDOCRINOL, V1, P216, DOI 10.1210/mend-1-3-216; De Leon DD, 1992, GROWTH FACTORS, V6, P327, DOI 10.3109/08977199209021544; DICKSON RB, 1988, BREAST CANCER CELLUL, P119; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; FIDDES RJ, 1995, CELL GROWTH DIFFER, V6, P1567; FITZPATRICK SL, 1984, CANCER RES, V44, P3448; FITZPATRICK SL, 1984, CANCER RES, V44, P3442; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GULLICK WJ, 1991, BRIT MED BULL, V47, P87, DOI 10.1093/oxfordjournals.bmb.a072464; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Halfter H, 1999, Mol Cell Biol Res Commun, V1, P109, DOI 10.1006/mcbr.1999.0117; Hammacher A, 1998, J BIOL CHEM, V273, P22701, DOI 10.1074/jbc.273.35.22701; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; Hoffmann M, 1998, CANCER IMMUNOL IMMUN, V47, P167, DOI 10.1007/s002620050517; Horn D, 1990, GROWTH FACTORS, V2, P157, DOI 10.3109/08977199009071502; Klapper LN, 2000, ADV CANCER RES, V77, P25; KOGA M, 1987, BIOCHEM BIOPH RES CO, V146, P739, DOI 10.1016/0006-291X(87)90591-2; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; METCALF D, 1988, LEUKEMIA, V2, P216; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; Murakami-Mori K, 1999, BIOCHEM BIOPH RES CO, V264, P676, DOI 10.1006/bbrc.1999.1574; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; OSBORNE CK, 1980, CANCER RES, V40, P2361; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; RAO KVS, 1987, CANCER RES, V47, P5888; ROSE TM, 1994, CYTOKINE, V6, P48, DOI 10.1016/1043-4666(94)90007-8; SARUP JC, 1988, CANCER RES, V48, P5071; SEYMOUR L, 1994, BREAST CANCER RES TR, V32, P229, DOI 10.1007/BF00665774; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Taga T, 1996, J NEUROCHEM, V67, P1; Taylor ML, 2000, HEMATOL ONCOL CLIN N, V14, P517, DOI 10.1016/S0889-8588(05)70294-X; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang YP, 1999, HEPATOLOGY, V30, P682, DOI 10.1002/hep.510300318; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	50	45	48	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					460	474		10.1038/sj.onc.1205100	http://dx.doi.org/10.1038/sj.onc.1205100			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821958				2022-12-25	WOS:000173311200014
J	Aguilar-Lemarroy, A; Gariglio, P; Whitaker, NJ; Eichhorst, ST; zur Hausen, H; Krammer, PH; Rosl, F				Aguilar-Lemarroy, A; Gariglio, P; Whitaker, NJ; Eichhorst, ST; zur Hausen, H; Krammer, PH; Rosl, F			Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis	ONCOGENE			English	Article						CD95; cervical cancer; myc; p53; HPV; proteasome inhibitor	PROGRAMMED CELL-DEATH; RETINOBLASTOMA GENE-PRODUCT; FAS-MEDIATED APOPTOSIS; IN-VIVO; EPITHELIAL-CELLS; CANCER-CELLS; PROTEASOME INHIBITORS; MONOCLONAL-ANTIBODY; SIGNALING COMPLEX; MOLECULAR-CLONING	To understand the function of the individual oncogenes of HPV16 in modulating the cellular response to apoptogenic signals, we used human keratinocytes immortalized with either E6, E7 or E6/E7 oncoproteins as model system. Applying CD95 antibodies or recombinant CD95 ligand, only the E7-immortalized cells underwent extensive apoptosis. In contrast, E6- and E6/E7-expressing keratinocytes were resistant. Dominance of E6 correlated with significant down-regulation of p53, c-Myc, p21 and Bcl-2. CD95 was found to be reduced in resistant HPV-positive cells, while there were no quantitative differences in expression levels of FADD, FLICE/caspase-8 or caspase-3. Notably, in contrast to primary human keratinocytes, all immortalized cells showed a general reduction of c-FLIP, an inhibitory protein which normally prevents unscheduled CD95-induced apoptosis. E6- and E6/E7-positive keratinocytes, however, can be sensitized to CD95 apoptosis by blocking proteasome-mediated proteolysis. CD95-resistant HPV-positive cells underwent apoptosis within 3-5 h upon co-incubation with MG132 and agonistic antibodies or CD95 ligand, which was preceded by a strong re-expression of p53 and c-Myc, but not of other half-life controlled proteins such as Bax or I kappaB alpha. Blockage of proteasomal activity alone did not result in apoptosis, although the same set of pro-apoptotic proteins was up-regulated. Performing similar experiments with cervical carcinoma cells expressing mutated p53 (C33a) or with P53-'null' lung carcinoma cells (H1299), no CD95 cell killing occurred eventhough c-Myc was strong induced. These data indicate that the reduced bioavailability of p53 is a key-regulatory event in perturbation of CD95 signaling in HPV16 immortalized keratinocytes.	Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, D-69120 Heidelberg, Germany; Inst Politecn Nacl, CINVESTAV, Dept Mol Biol & Genet, Mexico City, DF, Mexico; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia; Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Tumorimmunol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico; University of New South Wales Sydney; Helmholtz Association; German Cancer Research Center (DKFZ)	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Forsch Schwerpunkt Angew Tumorvirol, Abt Tumorvirus Immunol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	F.Roesl@DKFZ.de	Aguilar-Lemarroy, Adriana/Y-7001-2018	Aguilar-Lemarroy, Adriana/0000-0001-9288-4824				BARBOSA MS, 1989, ONCOGENE, V4, P1529; BEHRMANN I, 1994, EUR J IMMUNOL, V24, P3057, DOI 10.1002/eji.1830241221; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Boyer SN, 1996, CANCER RES, V56, P4620; BRISTOW RG, 1994, ONCOGENE, V9, P1527; Brown J, 1997, J CELL BIOCHEM, V66, P245, DOI 10.1002/(SICI)1097-4644(19970801)66:2<245::AID-JCB11>3.0.CO;2-G; Butz K, 1996, INT J CANCER, V68, P506, DOI 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2; Chaturvedi V, 1999, J BIOL CHEM, V274, P23358, DOI 10.1074/jbc.274.33.23358; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DHEIN J, 1992, J IMMUNOL, V149, P3166; DOORBAR J, 1990, VIROLOGY, V178, P254, DOI 10.1016/0042-6822(90)90401-C; Drexler HCA, 1997, P NATL ACAD SCI USA, V94, P855, DOI 10.1073/pnas.94.3.855; Duerksen-Hughes PJ, 1999, VIROLOGY, V264, P55, DOI 10.1006/viro.1999.9977; EL DW, 1993, CELL, V75, P817; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; Fukazawa T, 1999, ONCOGENE, V18, P2189, DOI 10.1038/sj.onc.1202561; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; Griffiths DJ, 1997, J VIROL, V71, P2866, DOI 10.1128/JVI.71.4.2866-2872.1997; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; Hengstermann A, 1998, ONCOGENE, V17, P2933, DOI 10.1038/sj.onc.1202282; IFTNER T, 1992, J VIROL, V66, P4639, DOI 10.1128/JVI.66.8.4639-4646.1992; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; Kim CY, 1997, CANCER RES, V57, P4200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; LANGONE JJ, 1982, J IMMUNOL METHODS, V51, P3, DOI 10.1016/0022-1759(82)90376-3; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Leverkus M, 2000, CANCER RES, V60, P553; Li BY, 2000, P NATL ACAD SCI USA, V97, P3850, DOI 10.1073/pnas.070047997; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIANG XH, 1993, ONCOGENE, V8, P2645; Maki CG, 1996, CANCER RES, V56, P2649; MARTIN SJ, 1990, J IMMUNOL, V145, P1859; Meriin AB, 1998, J BIOL CHEM, V273, P6373, DOI 10.1074/jbc.273.11.6373; MITSUDOMI T, 1992, ONCOGENE, V7, P171; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nair P, 1999, Pathol Oncol Res, V5, P95, DOI 10.1053/paor.1999.0161; NATOLI G, 1995, ONCOGENE, V11, P1157; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; OEHM A, 1992, J BIOL CHEM, V267, P10709; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Pim D, 1999, ONCOGENE, V18, P7403, DOI 10.1038/sj.onc.1203134; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Rolfe M, 1997, J MOL MED-JMM, V75, P5, DOI 10.1007/s001090050081; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1994, P NATL ACAD SCI USA, V91, P8797, DOI 10.1073/pnas.91.19.8797; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; SCHULZEOSTHOFF K, 1994, EMBO J, V13, P4587, DOI 10.1002/j.1460-2075.1994.tb06780.x; Seewaldt VL, 2001, CANCER RES, V61, P616; Sheets EE, 1996, GYNECOL ONCOL, V63, P94, DOI 10.1006/gyno.1996.0285; Stoppler H, 1998, ONCOGENE, V17, P1207, DOI 10.1038/sj.onc.1202053; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; von Reyher U, 1998, CANCER RES, V58, P526; Winoto A, 1997, CURR OPIN IMMUNOL, V9, P365, DOI 10.1016/S0952-7915(97)80083-0; XU C, 1995, P NATL ACAD SCI USA, V92, P7829, DOI 10.1073/pnas.92.17.7829; YEE C, 1985, AM J PATHOL, V119, P361; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690	85	55	55	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					165	175		10.1038/sj.onc.1204979	http://dx.doi.org/10.1038/sj.onc.1204979			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803460				2022-12-25	WOS:000173026200001
J	Bowe, DB; Kenney, NJ; Adereth, Y; Maroulakou, IG				Bowe, DB; Kenney, NJ; Adereth, Y; Maroulakou, IG			Suppression of Neu-induced mammary tumor growth in cyclin D1 deficient mice is compensated for by cyclin E	ONCOGENE			English	Article						Neu; mice; mammary gland; cyclin E; cyclin D1	NEGATIVE BREAST-CANCER; TRANSGENIC MICE; POINT MUTATION; ONCOGENIC ACTIVATION; GLAND HYPERPLASIA; SIGNALING PATHWAY; INDUCTION; RAS; EXPRESSION; OVEREXPRESSION	Amplification and/or overexpression of the receptor tyrosine kinase HER2/Neu and the cell cycle regulatory gene cyclin D1 are frequently associated with human breast cancer. We studied the functional significance of cyclin D1 in Neu-induced mammary oncogenesis by developing mice overexpressing either wild-type or mutant Neu in a cyclin D1 deficient background. The absence of cyclin D1 suppresses mammary tumor formation induced by the wild-type or activated mutant form of Neu, which promote multi- and single-step progression of tumorigenesis, respectively. These data indicate that cyclin D1 is preferentially required for Neu-mediated signal transduction pathways in mammary oncogenesis. Significantly, 35% of mutant Neu/cyclin D1(-/-) mice regained mammary tumor potential due to compensation by cyclin E. Thus, shared targets of cyclins D1 and E are important in modulating Neu function in mammary tumorigenesis. Our results imply that the combinatorial inhibition of cyclins D1 and E might be useful in the treatment of malignancies induced by Neu.	Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Charleston, SC 29425 USA; Med Univ S Carolina, Hollings Canc Ctr, Dept Med, Charleston, SC 29425 USA; Hampton Univ, Dept Biol Sci, Hampton, VA 23668 USA	Medical University of South Carolina; Medical University of South Carolina; Hampton University	Maroulakou, IG (corresponding author), Med Univ S Carolina, Hollings Canc Ctr, Lab Canc Genom, Room 337,86 Jonathan Lucas St, Charleston, SC 29425 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BRISCOE WT, 1993, BREAST CANCER RES TR, V28, P45, DOI 10.1007/BF00666355; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; GrayBablin J, 1996, P NATL ACAD SCI USA, V93, P15215, DOI 10.1073/pnas.93.26.15215; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; JANES PW, 1994, ONCOGENE, V9, P3601; KEYOMARSI K, 1994, CANCER RES, V54, P380; Kurebayashi  J, 2001, Breast Cancer, V8, P45, DOI 10.1007/BF02967477; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRESS MF, 1993, CANCER RES, V53, P4960; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINER DB, 1989, ONCOGENE, V4, P1175; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	35	55	55	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					291	298		10.1038/sj/onc/1205025	http://dx.doi.org/10.1038/sj/onc/1205025			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803472				2022-12-25	WOS:000173026200013
J	Cho, JH; Park, IY; Kim, HS; Lee, WT; Kim, MS; Kim, SC				Cho, JH; Park, IY; Kim, HS; Lee, WT; Kim, MS; Kim, SC			Cathepsin D produces antimicrobial peptide parasin I from histone H2A in the skin mucosa of fish	FASEB JOURNAL			English	Article						innate immunity; metalloprotease; Parasilurus asotus; teleost	MONOCLONAL-ANTIBODIES; PROCATHEPSIN-D; RAINBOW-TROUT; PROTEINS; CATFISH; ANTIBIOTICS; INHIBITORS; IMMUNITY; SEQUENCE; DEFENSE	Parasin I is a potent 19-residue antimicrobial peptide isolated from the skin mucus of wounded catfish (Parasilurus asotus). Here we describe the mechanism of parasin I production from histone H2A in catfish skin mucosa on epidermal injury. Cathepsin D is found to exist in the mucus as an inactive proenzyme (procathepsin D), and a metalloprotease, induced on injury, cleaves procathepsin D to generate active cathepsin D. This activated form of cathepsin D then cleaves the Ser(19)-Arg(20) bond of histone H2A to produce parasin I. Immunohistochemical analysis reveals that unacetylated histone H2A, a precursor of parasin I, and procathepsin D are present in the cytoplasm of epithelial mucous cells and that parasin I is produced on the mucosal surface on epidermal injury. Western blot analysis shows that parasin I is also present in the skin mucus of other fish species. Furthermore, parasin I shows good antimicrobial activity against fish-specific bacterial pathogens. Taken together, these results indicate that cathepsin D and a metalloprotease participate in the production of parasin I from histone H2A and that parasin I contributes to the innate host defense of the fish against invading microorganisms.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Yonsei Univ, Coll Med, Dept Anat, Seoul 120752, South Korea; Korea Inst Energy Res, Biomass Team, Taejon 305343, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Yonsei University; Yonsei University Health System; Korea Institute of Energy Research (KIER)	Kim, SC (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Kusong Dong Yusong Gu, Taejon 305701, South Korea.	sckim@mail.kaist.ac.kr	Kim, Sun/GSN-4867-2022; Kim, Sun Chang/C-2026-2011	Lee, Won Taek/0000-0001-7348-9562				Alexander John B., 1992, Annual Review of Fish Diseases, V2, P249, DOI 10.1016/0959-8030(92)90066-7; ALHASSAN JM, 1990, INT J TISSUE REACT, V12, P121; BLY JE, 1991, VET IMMUNOL IMMUNOP, V28, P365, DOI 10.1016/0165-2427(91)90127-X; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brooks S, 1997, GENE, V201, P45, DOI 10.1016/S0378-1119(97)00426-5; Brun NT, 2000, J INVERTEBR PATHOL, V75, P163, DOI 10.1006/jipa.1999.4917; Capasso C, 1999, BBA-PROTEIN STRUCT M, V1431, P64, DOI 10.1016/S0167-4838(99)00039-4; Cole AM, 1997, J BIOL CHEM, V272, P12008, DOI 10.1074/jbc.272.18.12008; CONNER GE, 1998, HDB PROTEOLYTIC ENZY, P828; CONNOR W, 1984, J MOL EVOL, V20, P236, DOI 10.1007/BF02104730; Ellis A. E., 1982, MICROBIAL DISEASES F, P1; ERICKSON AH, 1989, J CELL BIOCHEM, V40, P31, DOI 10.1002/jcb.240400104; GALLO RL, 1994, P NATL ACAD SCI USA, V91, P11035, DOI 10.1073/pnas.91.23.11035; Garcia M, 1996, STEM CELLS, V14, P642, DOI 10.1002/stem.140642; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; HARVIMA RJ, 1988, BIOCHEM J, V250, P859, DOI 10.1042/bj2500859; HIEMSTRA PS, 1993, INFECT IMMUN, V61, P3038, DOI 10.1128/IAI.61.7.3038-3046.1993; HIRSCH JG, 1958, J EXP MED, V108, P925, DOI 10.1084/jem.108.6.925; Huang HJ, 1997, J LEUKOCYTE BIOL, V61, P624, DOI 10.1002/jlb.61.5.624; HUNTER K, 1999, PEDIATR RES, V45, P785; Kim HS, 2000, J IMMUNOL, V165, P3268, DOI 10.4049/jimmunol.165.6.3268; LARSEN LB, 1993, FEBS LETT, V319, P54, DOI 10.1016/0014-5793(93)80036-T; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lemaitre C, 1996, EUR J BIOCHEM, V240, P143, DOI 10.1111/j.1432-1033.1996.0143h.x; MONESTIER M, 1993, MOL IMMUNOL, V30, P1069, DOI 10.1016/0161-5890(93)90153-3; Monestier M, 2000, J BIOL CHEM, V275, P13558, DOI 10.1074/jbc.275.18.13558; MURPHY CJ, 1993, J CELL PHYSIOL, V155, P408, DOI 10.1002/jcp.1041550223; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Park IY, 1998, FEBS LETT, V437, P258, DOI 10.1016/S0014-5793(98)01238-1; Patrzykat A, 2001, ANTIMICROB AGENTS CH, V45, P1337, DOI 10.1128/AAC.45.5.1337-1342.2001; PILLAI S, 1986, J BIOL CHEM, V261, P4919; Riggio M, 2000, GENE, V260, P67, DOI 10.1016/S0378-1119(00)00469-8; Rose FRAJ, 1998, INFECT IMMUN, V66, P3255, DOI 10.1128/IAI.66.7.3255-3263.1998; SAMAREL AM, 1989, AM J PHYSIOL, V257, pC1069, DOI 10.1152/ajpcell.1989.257.6.C1069; Schiltz RL, 1999, J BIOL CHEM, V274, P1189, DOI 10.1074/jbc.274.3.1189; Skin Suzuki Y, 1995, ATLAS FISH HISTOLOGY, P8; VETVICKA V, 1993, BIOCHEM MOL BIOL INT, V30, P921; Westley BR, 1996, EUR J CANCER, V32A, P15, DOI 10.1016/0959-8049(95)00530-7; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yano Tomoki, 1996, Fish Physiology, V15, P105; YEOMAN LC, 1972, J BIOL CHEM, V247, P6018; ZUHLSDORF M, 1983, BIOCHEM J, V213, P733	45	136	145	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					429	+		10.1096/fj.01-0736fje	http://dx.doi.org/10.1096/fj.01-0736fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821259				2022-12-25	WOS:000173656600015
J	Huang, DS; Cheung, AT; Parsons, JT; Bryer-Ash, M				Huang, DS; Cheung, AT; Parsons, JT; Bryer-Ash, M			Focal adhesion kinase (FAK) regulates insulin-stimulated glycogen synthesis in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED GLUCOSE-TRANSPORT; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SYNTHASE KINASE-3; RECEPTOR SUBSTRATE-1; DIFFERENTIAL REGULATION; 3T3-L1 ADIPOCYTES; SKELETAL-MUSCLE; POTENTIAL ROLE; CELL-ADHESION	Experimental data support a role for FAK, an important component of the integrin signaling pathway, in insulin action. To test the hypothesis that FAK plays a regulatory role in hepatic insulin action, we overexpressed wild type (WT), a kinase inactive (KR), or a COOH-terminal focal adhesion targeting (FAT) sequence-truncated mutant of FAK in HepG2 hepatoma cells. In control untransfected (NON) and vector (CMV2)- and WT-transfected cells, insulin stimulated an expected 54 +/- 13, 37 +/- 4, and 47 +/- 12 increase in [U-C-14]glucose incorporation into glycogen, respectively. This was entirely abolished in the presence of either KR (-1 +/- 7%) or FAT mutants (0 +/- 8%, n = 5, p < 0.05 for KR or FAT versus other groups), and this was associated with a significant attenuation of incremental insulin-stimulated glycogen synthase (GS) activity. Insulin-stimulated serine phosphorylation of Akt/protein kinase B was significantly impaired in mutant-transfected cells. Moreover, the ability of insulin to inactivate GS kinase-3 beta (GSK-3 beta), the regulatory enzyme immediately upstream of GS, by serine phosphorylation (308 +/- 16, 321 +/- 41, and 458 +/- 34 optical densitometric units (odu) in NON, CMV2, and WT, respectively, p < 0.02 for WT versus CMV2) was attenuated in the presence of either FAT (205 +/- 14, p < 0.01) or KR (189 +/- 4, p < 0.005) mutants. FAK co-immunoprecipitated with GSK-3beta, but only in cells overexpressing the KR (374 +/- 254 odu) and FAT (555 +/- 308) mutants was this association stimulated by insulin compared with NON (-209 +/- 92), CMV2 (-47 +/- 70), and WT (-39 +/- 31 odu). This suggests that FAK and GSK-3beta form both a constitutive association and a transient complex upon insulin stimulation, the dissociation of which requires normal function and localization of FAK. We conclude that FAK regulates the activity of Akt/protein kinase B and GSK-3beta and the association of GSK-3beta with FAK to influence insulin-stimulated glycogen synthesis in hepatocytes. Insulin action may be subject to regulation by the integrin signaling pathway, ensuring that these growth and differentiation-promoting pathways act in a coordinated and/or complementary manner.	Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Gonda Goldschmied Diabet Ctr, Los Angeles, CA 90095 USA; W Los Angeles Vet Adm Med Ctr, Res Serv, Los Angeles, CA 90095 USA; Univ Tennessee, Hlth Sci Ctr, Memphis, TN 38103 USA; Vet Adm Med Ctr, Res Serv, Memphis, TN 38103 USA; Univ Virginia, Charlottesville, VA 22908 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center; University of Virginia	Bryer-Ash, M (corresponding author), Univ Calif Los Angeles, Sch Med, Div Endocrinol Diabet & Hypertens, Gonda Goldschmied Diabet Ctr, 900 Vet Ave,Warren Hall 24-130, Los Angeles, CA 90095 USA.	mbryerash@mednet.ucla.edu			NCRR NIH HHS [RR00211] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AGIUS L, 1990, BIOCHEM J, V266, P91, DOI 10.1042/bj2660091; AKIYAMA SK, 1994, J BIOL CHEM, V269, P15961; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BACKER JM, 1992, J BIOL CHEM, V267, P1367; Baron V, 1998, J BIOL CHEM, V273, P7162, DOI 10.1074/jbc.273.12.7162; Bogdanovic E, 2001, DIABETES, V50, pA267; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; Cary LA, 1996, J CELL SCI, V109, P1787; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHEN HC, 1994, J BIOL CHEM, V269, P31229; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Cheung AT, 2000, DIABETES, V49, P810, DOI 10.2337/diabetes.49.5.810; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Disatnik MH, 1999, J BIOL CHEM, V274, P32486, DOI 10.1074/jbc.274.45.32486; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; GOODE N, 1992, J BIOL CHEM, V267, P16878; Guilherme A, 1998, J BIOL CHEM, V273, P22899, DOI 10.1074/jbc.273.36.22899; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; Halse R, 1999, J BIOL CHEM, V274, P776, DOI 10.1074/jbc.274.2.776; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Hungerford JE, 1996, J CELL BIOL, V135, P1383, DOI 10.1083/jcb.135.5.1383; Ilic D, 1997, J CELL SCI, V110, P401; ILLC D, 1995, NATURE, V377, P539; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KNIGHT JB, 1995, J BIOL CHEM, V270, P10199, DOI 10.1074/jbc.270.17.10199; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kurowski TG, 1999, DIABETES, V48, P658, DOI 10.2337/diabetes.48.3.658; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lavoie L, 1999, J BIOL CHEM, V274, P28279, DOI 10.1074/jbc.274.40.28279; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; Lebrun P, 1998, J BIOL CHEM, V273, P32244, DOI 10.1074/jbc.273.48.32244; Lebrun P, 2000, J BIOL CHEM, V275, P38371, DOI 10.1074/jbc.M006162200; Lee HS, 2000, J BONE MINER RES, V15, P1501, DOI 10.1359/jbmr.2000.15.8.1501; Lin YS, 2001, AM J PHYSIOL-ENDOC M, V281, pE8, DOI 10.1152/ajpendo.2001.281.1.E8; LUKASHEV ME, 1994, J BIOL CHEM, V269, P18311; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Noe V, 1999, BIOCHEM SOC SYMP, V65, P43; OKADA T, 1994, J BIOL CHEM, V269, P3568; Proud CG, 1997, BIOCHEM J, V328, P329; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Ridyard MS, 2001, CELL BIOL INT, V25, P215, DOI 10.1006/cbir.2000.0634; ROBINSON LJ, 1993, J BIOL CHEM, V268, P26422; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; SMITH RL, 1985, J BIOL CHEM, V260, P273; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Sung CK, 1998, J RECEPT SIGNAL TR R, V18, P243, DOI 10.3109/10799899809047746; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; VanderZon GCM, 1996, BIOCHEMISTRY-US, V35, P10377, DOI 10.1021/bi960350r; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang QH, 1998, MOL BIOL CELL, V9, P3057, DOI 10.1091/mbc.9.11.3057; WOODGETT JR, 1994, SEMIN CANCER BIOL, V5, P269; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	69	38	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18151	18160		10.1074/jbc.M104252200	http://dx.doi.org/10.1074/jbc.M104252200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11809746	hybrid			2022-12-25	WOS:000175685100097
J	Bannikov, GA; Karelina, TV; Collier, IE; Marmer, BL; Goldberg, GI				Bannikov, GA; Karelina, TV; Collier, IE; Marmer, BL; Goldberg, GI			Substrate binding of gelatinase B induces its enzymatic activity in the presence of intact propeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKIN FIBROBLAST PROCOLLAGENASE; IV COLLAGENASE; TISSUE INHIBITOR; MATRIX METALLOPROTEINASES; HUMAN PLACENTA; CDNA CLONING; EXPRESSION; ACTIVATION; MATRIX-METALLOPROTEINASE-9; TIMP-2	Expression of gelatinase B (matrix metalloprotease 9) in human placenta is developmentally regulated, presumably to fulfill a proteolytic function. Here we demonstrate that gelatinolytic activity in situ, in tissue sections of term placenta, is co-localized with gelatinase B. Judging by molecular mass, however, all the enzyme extracted from this tissue was found in a proform. To address this apparent incongruity, we examined the activity of gelatinase B bound to either gelatin- or type IV collagen-coated surfaces. Surprisingly, we found that upon binding, the purified proenzyme acquired activity against both the fluorogenic peptide (7-methoxycoumarin-4-yl) -acetic acid (MCA) -Pro-Leu-Gly-Leu-3- (2,4-dinitrophenyl)-L-2,3-diaminopropionyl-Ala-Arg-NH2 and gelatin substrates, whereas its propeptide remained intact. These results suggest that although activation of all known matrix metalloproteases in vitro is accomplished by proteolytic processing of the propeptide, other mechanisms, such as binding to a ligand or to a substrate, may lead to a disengagement of the propeptide from the active center of the enzyme, causing its activation.	Washington Univ, Sch Med, Dept Med, Div Dermatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Goldberg, GI (corresponding author), Washington Univ, Sch Med, Dept Med, Div Dermatol, 660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@medicine.wustl.edu			NIAMS NIH HHS [R01 AR40618, R01 AR39472] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040618, R01AR039472] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahrens D, 1996, ARTHRITIS RHEUM, V39, P1576, DOI 10.1002/art.1780390919; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Alexander CM, 1996, DEVELOPMENT, V122, P1723; ALLAN JA, 1994, ANN NY ACAD SCI, V732, P365, DOI 10.1111/j.1749-6632.1994.tb24754.x; Aoudjit F, 1999, INT J CANCER, V82, P743, DOI 10.1002/(SICI)1097-0215(19990827)82:5<743::AID-IJC19>3.0.CO;2-6; BEHRENDTSEN O, 1992, DEVELOPMENT, V114, P447; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; CARMICHAEL DF, 1986, P NATL ACAD SCI USA, V83, P2407, DOI 10.1073/pnas.83.8.2407; Chiquet M, 1999, MATRIX BIOL, V18, P417, DOI 10.1016/S0945-053X(99)00039-6; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Collier IE, 2001, BIOPHYS J, V81, P2370, DOI 10.1016/S0006-3495(01)75883-3; Damsky CH, 1997, KIDNEY INT, V51, P1427, DOI 10.1038/ki.1997.195; DECLERCK YA, 1991, J BIOL CHEM, V266, P3893; DECLERCK YA, 1989, J BIOL CHEM, V264, P17445; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GIJBELS K, 1993, J NEUROSCI RES, V36, P432, DOI 10.1002/jnr.490360409; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Grant G A, 1992, Matrix Suppl, V1, P217; GRANT GA, 1987, J BIOL CHEM, V262, P5886; Hurskainen T, 1996, J HISTOCHEM CYTOCHEM, V44, P1379, DOI 10.1177/44.12.8985130; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Maj JG, 1997, PLACENTA, V18, P683, DOI 10.1016/S0143-4004(97)90010-2; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Morgunova E, 1999, SCIENCE, V284, P1667, DOI 10.1126/science.284.5420.1667; Nagase H, 1997, BIOL CHEM, V378, P151; Niu R, 2000, LIFE SCI, V66, P1127, DOI 10.1016/S0024-3205(00)00416-1; Norrby K, 1997, APMIS, V105, P417, DOI 10.1111/j.1699-0463.1997.tb00590.x; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Olson MW, 1998, J BIOL CHEM, V273, P10672, DOI 10.1074/jbc.273.17.10672; POLETTE M, 1994, LAB INVEST, V71, P838; REPONEN P, 1995, DEV DYNAM, V202, P388, DOI 10.1002/aja.1002020408; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; Sehgal G, 1998, AM J PATHOL, V152, P591; SHIMONOVITZ S, 1994, AM J OBSTET GYNECOL, V171, P832, DOI 10.1016/0002-9378(94)90107-4; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1990, J BIOL CHEM, V265, P13933; STRICKLIN GP, 1983, BIOCHEMISTRY-US, V22, P61, DOI 10.1021/bi00270a009; Trojanowska M, 1998, J MOL MED, V76, P266, DOI 10.1007/s001090050216; Tschesche H, 1992, Matrix Suppl, V1, P245; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, BIOL EXTRAC, P115; WELGUS HG, 1985, COLLAGEN REL RES, V5, P167; WELGUS HG, 1979, J BIOL CHEM, V254, P1938; Werb Z, 1998, ANN NY ACAD SCI, V857, P110, DOI 10.1111/j.1749-6632.1998.tb10111.x; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; ZHI L, 2000, CELL, V102, P647	54	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16022	16027		10.1074/jbc.M110931200	http://dx.doi.org/10.1074/jbc.M110931200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839746	hybrid			2022-12-25	WOS:000175510400107
J	Asagoshi, K; Terato, H; Ohyama, Y; Ide, H				Asagoshi, K; Terato, H; Ohyama, Y; Ide, H			Effects of a guanine-derived formamidopyrimidine lesion on DNA replication - Translesion DNA synthesis, nucleotide insertion, and extension kinetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRADIENT GEL-ELECTROPHORESIS; THYMINE GLYCOL LESIONS; ESCHERICHIA-COLI; ALPHA-DEOXYADENOSINE; ABASIC SITES; STRUCTURAL-ANALYSIS; IONIZING-RADIATION; SEQUENCE CONTEXTS; MAMMALIAN-CELLS; ENDONUCLEASE-IV	2,6-Diamino-4-hydroxy-5-formamidopyrimidine derived from guanine (FapyG) is a major DNA lesion formed by reactive oxygen species. In this study, a defined oligonucleotide template containing a 5-N-methylated analog of FapyG (mFapyG) was prepared, and its effect on DNA replication was quantitatively assessed in vitro. The results were further compared with those obtained for 7,8-dihydro-8-oxoguanine and an apurinic/apyrimidinic site embedded in the same sequence context. mFapyG constituted a fairly strong but not absolute block to DNA synthesis catalyzed by Escherichia coli DNA polymerase I Klenow fragment with and without an associated 3'-5' exonuclease activity, thereby permitting translesion synthesis with a limited efficiency. The efficiency of translesion synthesis was G > 7,8-dihydro-8-oxoguanine > mFapyG > apurinic/apyrimidinic site. Analysis of the nucleotide insertion (f(ins) = V-max/K-m for insertion) and extension (f(ext) = V-max/K-m for extension) efficiencies for mFapyG revealed that the extension step constituted a major kinetic barrier to DNA synthesis. When mFapyG was bypassed, dCMP, a cognate nucleotide, was preferentially inserted opposite the lesion (dCMP (relative f(ins) = 1) >> dTMP (2.4 x 10(-4)) approximate to dAMP (8.1 x 10(-5)) > dGMP (4.5 x 10(-7))), and the primer terminus containing a mFapyG:C pair was most efficiently extended (mFapyG:C (relative f(ext) = 1) > mFapyG:T (4.6 x 10(-3)) >> mFapyG:A and mFapyG:G (extension not observed)). Thus, mFapyG is a potentially lethal but not premutagenic lesion.	Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan	Hiroshima University	Ide, H (corresponding author), Hiroshima Univ, Grad Sch Sci, Dept Math & Life Sci, Higashihiroshima 7398526, Japan.			Terato, Hiroaki/0000-0002-7070-5263				AMES BN, 1983, SCIENCE, V221, P1256, DOI 10.1126/science.6351251; Asagoshi K, 2000, BIOCHEMISTRY-US, V39, P11389, DOI 10.1021/bi000422l; Asagoshi K, 2000, J BIOL CHEM, V275, P24781, DOI 10.1074/jbc.M000576200; Asagoshi K, 2000, J BIOL CHEM, V275, P4956, DOI 10.1074/jbc.275.7.4956; BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; BOITEUX S, 1982, BIOCHEMISTRY-US, V21, P6746, DOI 10.1021/bi00269a020; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; CAI H, 1993, J BIOL CHEM, V268, P23567; CHENG KC, 1992, J BIOL CHEM, V267, P166; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Creighton S, 1995, METHOD ENZYMOL, V262, P232; DIZDAROGLU M, 1991, ARCH BIOCHEM BIOPHYS, V285, P388, DOI 10.1016/0003-9861(91)90378-V; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; EVANS J, 1993, MUTAT RES, V299, P147, DOI 10.1016/0165-1218(93)90092-R; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Graziewicz MA, 2000, FREE RADICAL BIO MED, V28, P75, DOI 10.1016/S0891-5849(99)00208-7; Greenberg MM, 2001, BIOCHEMISTRY-US, V40, P15856, DOI 10.1021/bi011490q; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Haraguchi K, 2001, J AM CHEM SOC, V123, P8636, DOI 10.1021/ja0160952; HAYES RC, 1988, J MOL BIOL, V201, P239, DOI 10.1016/0022-2836(88)90135-0; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; IDE H, 1995, NUCLEIC ACIDS RES, V23, P123, DOI 10.1093/nar/23.1.123; IDE H, 1991, J BIOL CHEM, V266, P1469; IDE H, 1995, BIOCHEMISTRY-US, V34, P6947, DOI 10.1021/bi00021a006; IDE H, 1993, BIOCHEM MOL BIOL INT, V31, P485; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; IDE H, 1994, BIOCHEMISTRY-US, V33, P7127, DOI 10.1021/bi00189a016; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; Iwai S, 2001, CHEM-EUR J, V7, P4343, DOI 10.1002/1521-3765(20011015)7:20<4343::AID-CHEM4343>3.0.CO;2-H; KAMIYA H, 1995, CARCINOGENESIS, V16, P883, DOI 10.1093/carcin/16.4.883; KE SH, 1993, NUCLEIC ACIDS RES, V21, P5137, DOI 10.1093/nar/21.22.5137; Ke SH, 1996, NUCLEIC ACIDS RES, V24, P707, DOI 10.1093/nar/24.4.707; KE SH, 1995, BIOCHEMISTRY-US, V34, P4593, DOI 10.1021/bi00014a012; Kool ET, 2001, ANNU REV BIOPH BIOM, V30, P1, DOI 10.1146/annurev.biophys.30.1.1; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; Lowe LG, 1996, BIOCHEMISTRY-US, V35, P9840, DOI 10.1021/bi960485x; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; NISHIGAKI K, 1992, J BIOCHEM-TOKYO, V111, P151, DOI 10.1093/oxfordjournals.jbchem.a123729; NISHIGAKI K, 1992, J BIOCHEM-TOKYO, V111, P144, DOI 10.1093/oxfordjournals.jbchem.a123728; OCONNOR TR, 1988, NUCLEIC ACIDS RES, V16, P5879, DOI 10.1093/nar/16.13.5879; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; Pham P, 2001, P NATL ACAD SCI USA, V98, P8350, DOI 10.1073/pnas.111007198; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; SCHAAPER RM, 1990, CARCINOGENESIS, V11, P1087, DOI 10.1093/carcin/11.7.1087; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; SHIBUTANI S, 1993, J BIOL CHEM, V268, P11703; SHIBUTANI S, 1993, CHEM RES TOXICOL, V6, P625, DOI 10.1021/tx00035a006; Shimizu H, 1997, NUCLEIC ACIDS RES, V25, P597, DOI 10.1093/nar/25.3.597; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; TUDEK B, 1992, NUCLEIC ACIDS RES, V20, P3079, DOI 10.1093/nar/20.12.3079; Tudek B, 1999, ACTA BIOCHIM POL, V46, P785, DOI 10.18388/abp.1999_4151; Von Sonntag C, 1987, CHEM BASIS RAD BIOL; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WOOD ML, 1992, NUCLEIC ACIDS RES, V20, P6023, DOI 10.1093/nar/20.22.6023	61	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14589	14597		10.1074/jbc.M200316200	http://dx.doi.org/10.1074/jbc.M200316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839760	hybrid			2022-12-25	WOS:000175203000032
J	Guo, M; Mathieu, PA; Linebaugh, B; Sloane, BF; Reiners, JJ				Guo, M; Mathieu, PA; Linebaugh, B; Sloane, BF; Reiners, JJ			Phorbol ester activation of a proteolytic cascade capable of activating latent transforming growth factor-beta - A process initiated by the exocytosis of cathepsin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; UROKINASE PLASMINOGEN-ACTIVATOR; REGULATES CA2+-DEPENDENT EXOCYTOSIS; LYSOSOMAL-ENZYME SECRETION; TGF-BETA; EPITHELIAL-CELLS; CYTOSOLIC PH; FACTOR-ALPHA; IN-VIVO; PRO-UPA	12-O-Tetradecanoylphorbol-13-acetate (TPA) suppresses the proliferation of the human breast epithelial cell line MCF10A-Neo by initiating proteolytic processes that activate latent transforming growth factor (TGF)-)-beta in the serum used to supplement culture medium. Within 1 h of treatment, cultures accumulated an extracellular activity capable of cleaving a substrate for urokinase-type plasminogen activator (uPA) and tissue plasminogen activator (tPA). This activity was inhibited by plasminogen activator inhibitor-1 or antibodies to uPA but not tPA. Pro-uPA activation was preceded by dramatic changes in lysosome trafficking and the extracellular appearance of cathepsin B and beta-hexosaminidase but not cathepsins D or L. Co-treatment of cultures with the cathepsin B inhibitors CA-074 or Z-FA-FMK suppressed the cytostatic effects of TPA and activation of pro-uPA. In the absence of TPA, exogenously added cathepsin B activated pro-uPA and suppressed MCF10A-Neo proliferation. The cytostatic effects of both TPA and cathepsin B were suppressed in cells cultured in medium depleted of plasminogen/ plasmin or supplemented with neutralizing TGF-beta antibody. Pretreatment with cycloheximide did not suppress the exocytosis of cathepsin B or the activation of pro-uPA. Hence, TPA activates signaling processes that trigger the exocytosis of a subpopulation of lysosomes/endosomes containing cathepsin B. Subsequently, extracellular cathepsin B initiates a proteolytic cascade involving uPA, plasminogen, and plasmin that activates serum-derived latent TGF-beta.	Wayne State Univ, Inst Environm Hlth Sci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Reiners, JJ (corresponding author), Wayne State Univ, Inst Environm Hlth Sci, 2727 2nd Ave,Rm 4000, Detroit, MI 48201 USA.	john.reiners.jr@wayne.edu	Sloane, Bonnie F/A-1050-2009		NATIONAL CANCER INSTITUTE [R01CA056586, R01CA034469] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NCI NIH HHS [CA34469, CA56586] Funding Source: Medline; NIEHS NIH HHS [P30 ES06639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adam PJ, 2000, CYTOKINE, V12, P348, DOI 10.1006/cyto.1999.0559; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; BASOLO F, 1992, INT J CANCER, V51, P634, DOI 10.1002/ijc.2910510421; BIGBEE WL, 1978, ANAL BIOCHEM, V88, P114, DOI 10.1016/0003-2697(78)90403-7; BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BROMME D, 1987, BIOCHEM J, V245, P381; Burgin J, 1999, CELL MOL LIFE SCI, V55, P135, DOI 10.1007/s000180050278; BUTTLE DJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P377, DOI 10.1016/0003-9861(92)90290-D; CECH P, 1986, THROMB RES, V42, P383, DOI 10.1016/0049-3848(86)90267-7; CECH P, 1987, THROMB RES, V45, P827, DOI 10.1016/0049-3848(87)90092-2; Chu TM, 1998, BIOCHEM BIOPH RES CO, V253, P128, DOI 10.1006/bbrc.1998.9760; Clark DA, 1998, INT J BIOCHEM CELL B, V30, P293, DOI 10.1016/S1357-2725(97)00128-3; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Dano K, 1999, APMIS, V107, P120, DOI 10.1111/j.1699-0463.1999.tb01534.x; Davis GE, 2001, J CELL SCI, V114, P917; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; FISCHER SM, 1989, CANCER RES, V49, P6693; Garbett EA, 1999, J CLIN PATHOL-MOL PA, V52, P140, DOI 10.1136/mp.52.3.140; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; Gorska AE, 1998, CELL GROWTH DIFFER, V9, P229; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Gulnik SV, 1997, FEBS LETT, V413, P379, DOI 10.1016/S0014-5793(97)00886-7; Guo M, 2000, CARCINOGENESIS, V21, P1303, DOI 10.1093/carcin/21.7.1303; Guo M, 2001, BIOCHEM PHARMACOL, V62, P1449, DOI 10.1016/S0006-2952(01)00801-2; Hackel CG, 2000, CANCER-AM CANCER SOC, V89, P995; HANSEN SK, 1992, EMBO J, V11, P205, DOI 10.1002/j.1460-2075.1992.tb05043.x; HATTON MWC, 1975, BIOCHIM BIOPHYS ACTA, V386, P451, DOI 10.1016/0005-2795(75)90288-3; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Herbert JM, 1997, FEBS LETT, V413, P401, DOI 10.1016/S0014-5793(97)00915-0; HONN KV, 1994, EXP CELL RES, V214, P120, DOI 10.1006/excr.1994.1240; Hu B, 2000, MATRIX BIOL, V19, P657, DOI 10.1016/S0945-053X(00)00114-1; Inuzuka K, 2000, J SURG RES, V93, P211, DOI 10.1006/jsre.2000.5952; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kazes I, 1998, KIDNEY INT, V54, P1976, DOI 10.1046/j.1523-1755.1998.00216.x; Kessel D, 2000, PHOTOCHEM PHOTOBIOL, V71, P196, DOI 10.1562/0031-8655(2000)071<0196:DOTART>2.0.CO;2; KOBAYASHI H, 1993, BIOCHIM BIOPHYS ACTA, V1178, P55, DOI 10.1016/0167-4889(93)90109-3; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; KULKARNI AB, 1995, AM J PATHOL, V146, P264; Kulkarni AB, 1997, RES IMMUNOL, V148, P453, DOI 10.1016/S0923-2494(97)82669-7; LADROR US, 1994, J BIOL CHEM, V269, P18422; Li J, 1999, J BIOL CHEM, V274, P4213, DOI 10.1074/jbc.274.7.4213; Lijnen HR, 1998, THROMB HAEMOSTASIS, V79, P1171; Lim YT, 1996, J CELL PHYSIOL, V167, P333, DOI 10.1002/(SICI)1097-4652(199605)167:2<333::AID-JCP18>3.0.CO;2-8; Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x; LYONS RM, 1988, J CELL BIOL, V106, P1659, DOI 10.1083/jcb.106.5.1659; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Martinez I, 2000, J CELL BIOL, V148, P1141, DOI 10.1083/jcb.148.6.1141; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matrat M, 1998, J TOXICOL ENV HEAL A, V55, P359; MOIN K, 1992, BIOCHEM J, V285, P427, DOI 10.1042/bj2850427; MOIN K, 1994, PROTEASES INVOLVES C, P51; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; OURSLER MJ, 1993, ENDOCRINOLOGY, V133, P2187, DOI 10.1210/en.133.5.2187; Pepper Michael S., 1997, Cytokine and Growth Factor Reviews, V8, P21, DOI 10.1016/S1359-6101(96)00048-2; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Prud'homme GJ, 2000, J AUTOIMMUN, V14, P23, DOI 10.1006/jaut.1999.0339; RASNICK D, 1985, ANAL BIOCHEM, V149, P461, DOI 10.1016/0003-2697(85)90598-6; REN WP, 1996, MAMMARY TUMOR CELL C, P325; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; Rice RL, 1998, INT J CANCER, V77, P271, DOI 10.1002/(SICI)1097-0215(19980717)77:2<271::AID-IJC17>3.0.CO;2-E; Rodriguez A, 1999, J BIOL CHEM, V274, P16754, DOI 10.1074/jbc.274.24.16754; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Sameni Mansoureh, 1995, Pathol Oncol Res, V1, P43; Sanford LP, 1997, DEVELOPMENT, V124, P2659; SCHMITT M, 1991, BIOMED BIOCHIM ACTA, V50, P731; SCHOLLER A, 1994, MOL PHARMACOL, V45, P944; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SOULE HD, 1990, CANCER RES, V50, P6075; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Sundler R, 1997, ACTA PHYSIOL SCAND, V161, P553, DOI 10.1046/j.1365-201X.1997.00262.x; Tang DG, 1997, ADV EXP MED BIOL, V400, P349; TAPPER H, 1995, J LEUKOCYTE BIOL, V58, P485, DOI 10.1002/jlb.58.4.485; TAPPER H, 1990, BIOCHEM J, V272, P407, DOI 10.1042/bj2720407; Ulbricht B, 1996, EXP CELL RES, V226, P255, DOI 10.1006/excr.1996.0226; Ulbricht B, 1997, EUR J CELL BIOL, V74, P294; WALKER B, 1984, THROMB RES, V34, P103, DOI 10.1016/0049-3848(84)90066-5; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439	84	75	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14829	14837		10.1074/jbc.M108180200	http://dx.doi.org/10.1074/jbc.M108180200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11815600	hybrid			2022-12-25	WOS:000175203000062
J	Kamaraju, AK; Bertolotto, C; Chebath, J; Revell, M				Kamaraju, AK; Bertolotto, C; Chebath, J; Revell, M			Pax3 down-regulation and shut-off of melanogenesis in melanoma B16/F10.9 by interleukin-6 receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GENE; NECROSIS-FACTOR-ALPHA; WAARDENBURG-SYNDROME; NEURAL CREST; CELL-DIFFERENTIATION; HIRSCHSPRUNG-DISEASE; STIMULATING HORMONE; MALIGNANT-MELANOMA; DNA-BINDING; IN-VITRO	The microphthalmia-associated transcription factor (Mitf) is essential for melanocytic lineage development and for expression of melanogenic enzymes, such as tyrosinase. Interleukin-6 receptor/interleukin-6 chimera (IL6RIL6) induces in B16/F10.9 melanoma cells a loss of melanogenesis preceded by a sharp decrease in Mitf mRNA and gene promoter activity. In the Mitf promoter, the main cis-acting element mediating the IL6RIL6 effect is shown to be the binding site of Pax3, a paired homeodomain factor regulating among other things the development of melanocytes. Pax3 protein and mRNA levels decline steadily after IL6RIL6 treatment, and overexpression of an ectopic Pax3 cDNA suppresses the Mitf promoter inhibition. Loss of the synergism between Pax3 and Sox10, a high mobility group domain costimulatory factor, seems to be critical in the rapid decrease in Mitf gene expression. The Pax3 down-regulation in IL6RIL6-induced F10.9 cell is linked to growth arrest and transdifferentiation to a glial cell phenotype. IL6RIL6 stimulates the interleukin-6 family cytokine receptor gp130, leading to the rapid phosphorylation of Stat3 on tyrosine 705. This phosphorylation is required for Pax3 down-regulation and Mitf promoter silencing since these are inhibited in F10.9 cells overexpressing the Stat3 DN-mutant Y705F.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Fac Med Nice, INSERM, U385, F-06000 Nice, France	Weizmann Institute of Science; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Revell, M (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	michel.revel@weizmann.ac.il	Bertolotto-Ballotti, Corine/O-2155-2016	Chebath, Judith/0000-0002-8151-7428				Abdel-Malek Z, 1999, ANN NY ACAD SCI, V885, P117; AKIRA S, 1992, CHEM IMMUNOL, V51, P299; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Banerjee SS, 2000, HISTOPATHOLOGY, V36, P387; Barber TD, 1999, GENE, V237, P311, DOI 10.1016/S0378-1119(99)00339-X; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1998, J CELL BIOL, V142, P827, DOI 10.1083/jcb.142.3.827; Bondurand N, 2000, HUM MOL GENET, V9, P1907, DOI 10.1093/hmg/9.13.1907; BOSMAN C, 1995, TUMORI, V81, P208, DOI 10.1177/030089169508100312; Busca R, 1998, MOL BIOL CELL, V9, P1367, DOI 10.1091/mbc.9.6.1367; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; Chebath J, 1997, EUR CYTOKINE NETW, V8, P359; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; Dupin E, 2000, P NATL ACAD SCI USA, V97, P7882, DOI 10.1073/pnas.97.14.7882; Englaro W, 1998, J BIOL CHEM, V273, P9966, DOI 10.1074/jbc.273.16.9966; EPSTEIN DJ, 1991, CELL, V67, P767, DOI 10.1016/0092-8674(91)90071-6; Faruqi TR, 2001, P NATL ACAD SCI USA, V98, P9014, DOI 10.1073/pnas.161281298; Fischer M, 1997, NAT BIOTECHNOL, V15, P142, DOI 10.1038/nbt0297-142; FRIEDMANN PS, 1987, J CELL PHYSIOL, V133, P88, DOI 10.1002/jcp.1041330111; Fuse N, 1996, BIOCHEM BIOPH RES CO, V219, P702, DOI 10.1006/bbrc.1996.0298; Galibert MD, 1999, J BIOL CHEM, V274, P26894, DOI 10.1074/jbc.274.38.26894; Goding CR, 2000, GENE DEV, V14, P1712; Haggiag S, 2001, J NEUROSCI RES, V64, P564, DOI 10.1002/jnr.1108; HARA H, 1994, J INVEST DERMATOL, V102, P495, DOI 10.1111/1523-1747.ep12373136; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Herbarth B, 1998, P NATL ACAD SCI USA, V95, P5161, DOI 10.1073/pnas.95.9.5161; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Hornyak TJ, 2001, MECH DEVELOP, V101, P47, DOI 10.1016/S0925-4773(00)00569-4; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Jacquemin P, 2001, BIOCHEM BIOPH RES CO, V285, P1200, DOI 10.1006/bbrc.2001.5294; Kelsall SR, 1997, BIOCHEM BIOPH RES CO, V236, P173, DOI 10.1006/bbrc.1997.6925; KIOUSSI C, 1995, NEURON, V15, P553, DOI 10.1016/0896-6273(95)90144-2; Kollet O, 1999, BLOOD, V94, P923, DOI 10.1182/blood.V94.3.923.415k08_923_931; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; KUMAR A, 2000, EUR CYTOKINE NETW, V11, P197; Le Douarin NM, 1999, NEURAL CREST, V2; Lee M, 2000, J BIOL CHEM, V275, P37978, DOI 10.1074/jbc.M003816200; Martinez-Esparza M, 1998, EUR J BIOCHEM, V255, P139, DOI 10.1046/j.1432-1327.1998.2550139.x; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Nakashima K, 1999, J NEUROSCI, V19, P5429; Nataf V, 2000, PIGM CELL RES, V13, P172, DOI 10.1034/j.1600-0749.2000.130309.x; Oh JW, 1997, ONCOGENE, V15, P569, DOI 10.1038/sj.onc.1201213; Opdecamp K, 1997, DEVELOPMENT, V124, P2377; Pingault V, 1998, NAT GENET, V18, P171, DOI 10.1038/ng0298-171; PORGADOR A, 1989, J IMMUNOGENET, V16, P291; Potterf SB, 2000, HUM GENET, V107, P1, DOI 10.1007/s004390050001; PRESTON SF, 1987, P NATL ACAD SCI USA, V84, P5247, DOI 10.1073/pnas.84.15.5247; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; Read AP, 1997, J MED GENET, V34, P656, DOI 10.1136/jmg.34.8.656; Reed JA, 1999, AM J PATHOL, V155, P549, DOI 10.1016/S0002-9440(10)65150-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298; Scholl FA, 2001, CANCER RES, V61, P823; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Scott GA, 1998, J INVEST DERMATOL, V111, P243, DOI 10.1046/j.1523-1747.1998.00276.x; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; SWOPE VB, 1991, J INVEST DERMATOL, V96, P180, DOI 10.1111/1523-1747.ep12460991; Tachibana M, 1997, PIGM CELL RES, V10, P25, DOI 10.1111/j.1600-0749.1997.tb00462.x; Tachibana M, 1999, PIGM CELL RES, V12, P344, DOI 10.1111/j.1600-0749.1999.tb00518.x; TAKAHASHI H, 1992, J INVEST DERMATOL, V98, P481, DOI 10.1111/1523-1747.ep12499862; Takeda K, 2000, J BIOL CHEM, V275, P14013, DOI 10.1074/jbc.C000113200; Verastegui C, 2000, J BIOL CHEM, V275, P30757, DOI 10.1074/jbc.C000445200; Watanabe A, 1998, NAT GENET, V18, P283, DOI 10.1038/ng0398-283; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yasumoto K, 1997, J BIOL CHEM, V272, P503; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	75	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15132	15141		10.1074/jbc.M200004200	http://dx.doi.org/10.1074/jbc.M200004200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11830592	hybrid			2022-12-25	WOS:000175203000099
J	Langmann, T; Porsch-Ozcurumez, M; Heimerl, S; Probst, M; Moehle, C; Taher, M; Borsukova, H; Kielar, D; Kaminski, WE; Dittrich-Wengenroth, E; Schmitz, G				Langmann, T; Porsch-Ozcurumez, M; Heimerl, S; Probst, M; Moehle, C; Taher, M; Borsukova, H; Kielar, D; Kaminski, WE; Dittrich-Wengenroth, E; Schmitz, G			Identification of sterol-independent regulatory elements in the human ATP-binding cassette transporter A1 promoter - Role of Sp1/3, E-box binding factors, and an oncostatin M-responsive element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MESSENGER-RNA EXPRESSION; NUCLEAR FACTOR-I; HUMAN ABCA1 GENE; TANGIER-DISEASE; TRANSCRIPTION FACTORS; CHOLESTEROL EFFLUX; MOLECULAR-CLONING; LDL RECEPTOR; MUTATIONS	The ATP-binding cassette transporter A1 (ABCA1) shows a differentiation-, cAMP-, and sterol-dependent up-regulation in human monocytes. As part of an ongoing study, we investigated the proximal promoter regions that are highly conserved between the human and murine ABCA1 genes. Using reporter gene assays, we show here that a TATA box 24 by upstream of the transcription initiation site is essential for promoter activity in RAW 264.7 and HepG2 cells, whereas further enhancement of transcriptional activity is mediated by the -175 by promoter region. Gel shift assays revealed in vitro binding of Sp1 to a -91 GnC motif as well as binding of Sp1 and Spa to a -157 GnC promoter region. In co-transfection experiments using Drosophila S2 cells, we demonstrate that Spa competes with Sp1 for binding to the -157 GnC motif and acts as a repressor. On the other hand, overexpression of Sp1 increased ABCA1 mRNA expression in HeLa cells and enhanced cellular cholesterol and phospholipid efflux in RAW 246.7 macrophages. We also show here that the conserved E-box at position -140 binds upstream stimulatory factors 1 and 2 and hepatic nuclear factor la and that mutagenesis of the E-box enhanced constitutive ABCA1 expression in RAW 264.7 cells, implying a role for this element in silencing ABCA1 expression. Besides the functional importance for basal gene expression, we have identified that the core promoter region (-175 to +224) is also responsible for the induction of ABCA1 by the cytokine oncostatin M, resulting in a rapid increase in ABCA1 mRNA levels in HepG2 cells. Interestingly, this oncostatin M-induced expression is not dependent on the currently known sequence motifs in the ABCA1 promoter. In conclusion, a functional complex of cis-elements within the proximal human ABCA1 promoter associated with the transcription factors Sp1/3, upstream stimulatory factors 1 and 2, and hepatic nuclear factor la has been characterized, which allows a subtle tissue-specific regulation of ABCA1 gene expression.	Univ Regensburg, Inst Clin Chem, D-93042 Regensburg, Germany; Bayer AG, Pharma Res Ctr, D-42096 Wuppertal, Germany	University of Regensburg; Bayer AG	Schmitz, G (corresponding author), Univ Klinikum Regensburg, Inst Klin Chem & Blutbank, Franz Josef Strauss Allee 11, D-93042 Regensburg, Germany.	gerd.schmitz@klinik.uni-regensburg.de	Özcürümez, Mustafa K./GRS-4840-2022; Özcürümez, Mustafa/AAQ-3250-2021; Langmann, Thomas/HHZ-9814-2022	Özcürümez, Mustafa K./0000-0002-4360-5005; Özcürümez, Mustafa/0000-0002-4360-5005; Langmann, Thomas/0000-0001-6826-529X; Schmitz, Gerd/0000-0002-1325-1007				ASSMAN G, 1989, METABOLIC BASE INHER; BHAKDI S, 1995, J EXP MED, V182, P1959, DOI 10.1084/jem.182.6.1959; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BROOKS AR, 1992, MOL CELL BIOL, V12, P1134, DOI 10.1128/MCB.12.3.1134; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Cavelier LB, 2001, J BIOL CHEM, V276, P18046, DOI 10.1074/jbc.M100565200; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; Costet P, 2000, J BIOL CHEM, V275, P28240; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; GROVE RI, 1991, J LIPID RES, V32, P1889; Hegele RA, 2000, ARTERIOSCL THROM VAS, V20, P217, DOI 10.1161/01.ATV.20.1.217; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Hirai H, 1999, INT J BIOCHEM CELL B, V31, P1367, DOI 10.1016/S1357-2725(99)00064-3; Ihn H, 1997, J BIOL CHEM, V272, P24666, DOI 10.1074/jbc.272.39.24666; Kielar D, 2001, CLIN CHEM, V47, P2089; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Langmann T, 1999, J LIPID RES, V40, P870; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liu JW, 1997, ARTERIOSCL THROM VAS, V17, P2948, DOI 10.1161/01.ATV.17.11.2948; Liu JW, 1997, J LIPID RES, V38, P2035; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Navasa M, 1998, J LIPID RES, V39, P1220; OCHOA A, 1993, BIOCHIM BIOPHYS ACTA, V1210, P41, DOI 10.1016/0005-2760(93)90047-D; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Porsch-Ozcurumez M, 2001, J BIOL CHEM, V276, P12427, DOI 10.1074/jbc.M100218200; Qiu Y, 2001, GENOMICS, V73, P66, DOI 10.1006/geno.2000.6467; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Santamarina-Fojo S, 2000, P NATL ACAD SCI USA, V97, P7987, DOI 10.1073/pnas.97.14.7987; Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; Schwartz K, 2000, BIOCHEM BIOPH RES CO, V274, P794, DOI 10.1006/bbrc.2000.3243; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; WADE DP, 1994, J BIOL CHEM, V269, P19757; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; ZHANG DE, 1994, J BIOL CHEM, V269, P11425	47	53	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14443	14450		10.1074/jbc.M110270200	http://dx.doi.org/10.1074/jbc.M110270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839742	hybrid			2022-12-25	WOS:000175203000014
J	DiDonato, M; Zhang, JY; Que, L; Sarkar, B				DiDonato, M; Zhang, JY; Que, L; Sarkar, B			Zinc binding to the NH2-terminal domain of the Wilson disease copper-transporting ATPase - Implications for in vivo metal ion-mediated regulation of ATPase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; N-TERMINAL DOMAIN; FINE-STRUCTURE SPECTROSCOPY; MENKES-DISEASE; ABINITIO CALCULATIONS; PROTEIN STRUCTURES; PHASE FUNCTIONS; CANDIDATE GENE; SITES; TRAFFICKING	Mutations in the Wilson disease copper transporting, P-type ATPase lead to the accumulation of toxic levels of copper in the liver, brain, and kidney causing extensive tissue damage and eventual death. The NH2-terminal domain (similar to70 kDa), which contains six copies of the heavy metal-associated repeat GMT/HCXXC, is also able to bind zinc. We have used circular dichroism (CD) and x-ray absorption spectroscopy (XAS) to characterize zinc binding to the NH2-terminal metal-binding domain. These studies have revealed that zinc is able to bind to this domain with a stoichiometry of 6:1, and upon binding, induces conformational changes in the NH2-terminal domain. These conformational changes are completely different from those previously observed for copper binding to the domain and lead to an overall loss of secondary structure in the domain. The XAS spectra indicate that zinc is ligated primarily by nitrogen atoms and therefore has low affinity for the heavy metal-associated repeats where copper has been shown to bind. The differences between zinc and copper binding may serve as the basis for the metal-ion mediated regulation of the ATPase in vivo.	Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Met Biocatalyis, Minneapolis, MN 55455 USA; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Dept Biol Struct & Biochem, Toronto, ON M5G 1X8, Canada	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Que, L (corresponding author), Univ Minnesota, Dept Chem, 207 Pleasant St SE, Minneapolis, MN 55455 USA.			DiDonato, Michael/0000-0002-9074-7284	NCRR NIH HHS [RR-08630] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Bunker G., 1991, XRAY ABSORPTION FINE, P751; CHELLY J, 1993, NAT GENET, V5, P317, DOI 10.1038/ng1293-317; Clark-Baldwin K, 1998, J AM CHEM SOC, V120, P8401, DOI 10.1021/ja980580o; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 1997, BBA-MOL BASIS DIS, V1360, P3, DOI 10.1016/S0925-4439(96)00064-6; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Goodyer ID, 1999, HUM MOL GENET, V8, P1473, DOI 10.1093/hmg/8.8.1473; Hou ZJ, 2001, J BIOL CHEM, V276, P40858, DOI 10.1074/jbc.M107455200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; Jensen PY, 1998, J INHERIT METAB DIS, V21, P195, DOI 10.1023/A:1005331130245; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14225, DOI 10.1073/pnas.94.26.14225; Karlin S, 1997, P NATL ACAD SCI USA, V94, P14231, DOI 10.1073/pnas.94.26.14231; Leon O, 2000, BIOL RES, V33, P21; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MCKALE AG, 1988, J AM CHEM SOC, V110, P3763, DOI 10.1021/ja00220a008; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; Mercer JFB, 2001, TRENDS MOL MED, V7, P64, DOI 10.1016/S1471-4914(01)01920-7; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Ralle M, 1998, J AM CHEM SOC, V120, P13525, DOI 10.1021/ja982990i; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; RIGGSGELASCO PJ, 1995, COORDIN CHEM REV, V144, P245, DOI 10.1016/0010-8545(95)01144-E; Roelofsen H, 2000, GASTROENTEROLOGY, V119, P782, DOI 10.1053/gast.2000.17834; SCARROW RC, 1994, BIOCHEMISTRY-US, V33, P15023, DOI 10.1021/bi00254a011; SCARROW RC, 1987, J AM CHEM SOC, V109, P7857, DOI 10.1021/ja00259a039; Schaefer M, 1999, AM J PHYSIOL-GASTR L, V276, pG639, DOI 10.1152/ajpgi.1999.276.3.G639; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; STERN EA, 1993, PHYS REV B, V48, P9825, DOI 10.1103/PhysRevB.48.9825; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; Teo B.K., 1981, EXAFS SPECTROSCOPY, P13; TEO BK, 1979, J AM CHEM SOC, V101, P2815, DOI 10.1021/ja00505a003; TEO BK, 1983, J AM CHEM SOC, V105, P3751, DOI 10.1021/ja00350a001; Vanderwerf SM, 2001, J BIOL CHEM, V276, P36289, DOI 10.1074/jbc.M102055200; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WINGFIELD PT, 1996, CURRENT PROTOCOLS PR	42	21	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13409	13414		10.1074/jbc.M111649200	http://dx.doi.org/10.1074/jbc.M111649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11823463	hybrid			2022-12-25	WOS:000175096000010
J	Andreasen, EA; Tanguay, RL; Peterson, RE; Heideman, W				Andreasen, EA; Tanguay, RL; Peterson, RE; Heideman, W			Identification of a critical amino acid in the aryl hydrocarbon receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROUT ONCORHYNCHUS-MYKISS; DIBENZO-P-DIOXIN; PHOTOACTIVE YELLOW PROTEIN; LIFE STAGE MORTALITY; AH RECEPTOR; BIPHENYL CONGENERS; DNA-BINDING; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN-INDUCED DEGRADATION; FUNCTIONAL-CHARACTERIZATION; DISTINCT FUNCTIONS	Two aryl hydrocarbon receptors (rtAHR2alpha and rtAHR2beta) have been identified in the rainbow trout (Oncorhynchus mykiss). These receptors share 98% amino acid identity, yet their functional properties differ. Both rtAHR2alpha and rtAHR2beta bind 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), dimerize with rainbow trout ARNTb (rtARNTb), and recognize dioxin response elements in vitro. However, in a transient transfection assay the two proteins show differential ability to recognize enhancers, produce transactivation, and respond to TCDD. To identify the sequence differences that confer the functional differences between rtAHR2alpha and rtAHR2beta we constructed chimeric rtAHRs, in which segments of one receptor form was replaced with the corresponding part from the other isoform. This approach progressively narrowed the region being examined to a single residue, corresponding to position 111 in rtAHR2beta. Altering this residue in rtAHR2beta from the lysine to glutamate found in rtAHR2alpha produced an rtAHR2beta with the properties of rtAHR2alpha. All other known AHRs resemble rtAHR2alpha and carry glutamate at this position, located at the N terminus of the PAS-A domain. We tested the effect of altering this glutamate in the human and zebrafish AHRs to lysine. This lysine substitution produced AHRs with transactivation properties that were similar to rtAHR2beta. These results identify a critical residue in AHR proteins that has an important impact on transactivation, enhancer site recognition, and regulation by ligand.	Univ Wisconsin, Sch Pharm, Madison, WI 53705 USA; Univ Wisconsin, Mol & Environm Toxicol Program, Madison, WI 53705 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Heideman, W (corresponding author), Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010820, P30ES009090] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 09090, ES 10820] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abnet CC, 1999, J BIOL CHEM, V274, P15159, DOI 10.1074/jbc.274.21.15159; Abnet CC, 1999, TOXICOL APPL PHARM, V159, P41, DOI 10.1006/taap.1999.8719; Bacsi SG, 1996, J BIOL CHEM, V271, P8843, DOI 10.1074/jbc.271.15.8843; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; Berg P, 2001, J BIOL CHEM, V276, P43231, DOI 10.1074/jbc.M105261200; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; CHEN HS, 1994, J BIOL CHEM, V269, P27554; COUMAILLEAU P, 1995, J BIOL CHEM, V270, P25291, DOI 10.1074/jbc.270.42.25291; Denison MS, 1998, B ENVIRON CONTAM TOX, V61, P557, DOI 10.1007/PL00002973; Elonen GE, 1998, ENVIRON TOXICOL CHEM, V17, P472, DOI 10.1002/etc.5620170319; EMA M, 1994, J BIOL CHEM, V269, P27337; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Garrison PM, 1996, FUND APPL TOXICOL, V30, P194, DOI 10.1006/faat.1996.0056; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; JAIN S, 1994, J BIOL CHEM, V269, P31518; Jones LC, 2001, J BIOL CHEM, V276, P25037, DOI 10.1074/jbc.M102910200; Karchner SI, 1999, J BIOL CHEM, V274, P33814, DOI 10.1074/jbc.274.47.33814; Korkalainen M, 2000, BIOCHEM BIOPH RES CO, V273, P272, DOI 10.1006/bbrc.2000.2931; Korkalainen M, 2001, BIOCHEM BIOPH RES CO, V285, P1121, DOI 10.1006/bbrc.2001.5317; Kumar MB, 2001, J BIOL CHEM, V276, P42302, DOI 10.1074/jbc.M104798200; Levine SL, 2000, MOL PHARMACOL, V58, P1517, DOI 10.1124/mol.58.6.1517; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Ma Q, 2000, J BIOL CHEM, V275, P12676, DOI 10.1074/jbc.275.17.12676; Ma Q, 1997, J BIOL CHEM, V272, P8878; MA Q, 1995, J BIOL CHEM, V270, P1267; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Pollenz RS, 2000, MOL CELL BIOL, V20, P6095, DOI 10.1128/MCB.20.16.6095-6104.2000; Pollenz RS, 1996, J BIOL CHEM, V271, P30886, DOI 10.1074/jbc.271.48.30886; Pollenz RS, 1996, MOL PHARMACOL, V49, P391; Powell WH, 1999, ARCH BIOCHEM BIOPHYS, V361, P156, DOI 10.1006/abbi.1998.0992; Puga A, 2000, J BIOL CHEM, V275, P2943, DOI 10.1074/jbc.275.4.2943; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Roy NK, 1997, ARCH BIOCHEM BIOPHYS, V344, P373, DOI 10.1006/abbi.1997.0238; Schmidt JV, 1996, ANNU REV CELL DEV BI, V12, P55, DOI 10.1146/annurev.cellbio.12.1.55; Sun WM, 1997, J BIOL CHEM, V272, P31845, DOI 10.1074/jbc.272.50.31845; Tanguay RL, 2000, BBA-GENE STRUCT EXPR, V1494, P117, DOI 10.1016/S0167-4781(00)00225-6; Tanguay RL, 1999, BBA-GENE STRUCT EXPR, V1444, P35, DOI 10.1016/S0167-4781(98)00252-8; WALKER MK, 1991, AQUAT TOXICOL, V21, P219, DOI 10.1016/0166-445X(91)90074-J; WHITELAW ML, 1994, MOL CELL BIOL, V14, P8343, DOI 10.1128/MCB.14.12.8343; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Zabel EW, 1996, ENVIRON TOXICOL CHEM, V15, P2310, DOI 10.1002/etc.5620151229; ZABEL EW, 1995, AQUAT TOXICOL, V31, P315, DOI 10.1016/0166-445X(94)00075-2	48	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13210	13218		10.1074/jbc.M200073200	http://dx.doi.org/10.1074/jbc.M200073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823471	hybrid			2022-12-25	WOS:000175036300091
J	Chaturvedi, LS; Koul, S; Sekhon, A; Bhandari, A; Menon, M; Koul, HK				Chaturvedi, LS; Koul, S; Sekhon, A; Bhandari, A; Menon, M; Koul, HK			Oxalate selectively activates p38 mitogen-activated protein kinase and c-Jun N-terminal kinase signal transduction pathways in renal epithelial cells.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; CALCIUM-OXALATE; LLC-PK1 CELLS; GENE-EXPRESSION; IN-VITRO; TUBULAR CELLS; GROWTH-FACTOR; PC12 CELLS; STRESS; PHOSPHORYLATION	Oxalate, a metabolic end product, is an important factor in the pathogenesis of renal stone disease. Oxalate exposure to renal epithelial cells results in re-initiation of the DNA synthesis, altered gene expression, and apoptosis, but the signaling pathways involved in these diverse effects have not been evaluated. The effects of oxalate on mitogen- and stress-activated protein kinase signaling pathways were studied in LLC-PK1 cells. Exposure to oxalate (1 mm) rapidly stimulated robust phosphorylation and activation of p38 MAPK. Oxalate exposure also induced modest activation of JNK, as monitored by phosphorylation of c-Jun. In contrast, oxalate exposure had no effect on phosphorylation and enzyme activity of p42/44 MAPK. We also show that specific inhibition of p38 MAPK by 4(4-(fluorophenyl)2-(4-methylsulfonylphenyl)-5-(4-pyridyl)imidazole (SB203580) or by overexpression of a kinase-dead dominant negative mutant of p38 MAPK abolishes oxalate induced re-initiation of DNA synthesis in LLC-PK1 cells. The inhibition is dose-dependent and correlates with in situ activity of native p38 ALA-P kinase, determined as MAPK-activated protein kinase-2 activity in cell extracts. Thus, this study not only provides the first demonstration of selective activation of p38 MAPK and JNK signaling pathways by oxalate but also suggests that p38 MAPK activity is essential for the effects of oxalate on re-initiation of DNA synthesis.	Henry Ford Hlth Sci Ctr, Biochem & Mol Biol Lab, Vattikuti Urol Inst, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Koul, HK (corresponding author), Henry Ford Hlth Sci Ctr, Biochem & Mol Biol Lab, Vattikuti Urol Inst, 1 Ford Pl,Ste 2D-33, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054084] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK-54084] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baliga R, 1998, KIDNEY INT, V53, P394, DOI 10.1046/j.1523-1755.1998.00767.x; Beitner-Johnson D, 1998, J BIOL CHEM, V273, P19834, DOI 10.1074/jbc.273.31.19834; BLINK B, 2001, MOL MED, V7, P755; Bonventre JV, 1998, CURR OPIN NEPHROL HY, V7, P425, DOI 10.1097/00041552-199807000-00013; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANTIELLO HF, 1987, AM J PHYSIOL, V252, pF590, DOI 10.1152/ajprenal.1987.252.4.F590; Carter S, 1998, ONCOGENE, V16, P2787, DOI 10.1038/sj.onc.1201802; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Cheng Y, 2000, J BIOL CHEM, V275, P23326, DOI 10.1074/jbc.M001837200; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; COOPER JA, 1994, CURR BIOL, V4, P1118, DOI 10.1016/S0960-9822(00)00251-7; Crawley JB, 1997, J BIOL CHEM, V272, P15023, DOI 10.1074/jbc.272.23.15023; Craxton A, 1998, J IMMUNOL, V161, P3225; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOZA YN, 1995, FEBS LETT, V364, P223, DOI 10.1016/0014-5793(95)00346-B; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Force T, 1996, CIRC RES, V78, P947, DOI 10.1161/01.RES.78.6.947; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Guillonneau X, 1998, J BIOL CHEM, V273, P22367, DOI 10.1074/jbc.273.35.22367; HACKETT RL, 1988, SCANNING MICROSCOPY, V2, P241; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Harada S, 1996, J BIOL CHEM, V271, P30222, DOI 10.1074/jbc.271.47.30222; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hu YH, 1997, J BIOL CHEM, V272, P9113; HUGHSON MD, 1986, ARCH PATHOL LAB MED, V110, P592; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Khan SR, 1999, J AM SOC NEPHROL, V10, pS457; KNIGHT TF, 1979, KIDNEY INT, V16, P572, DOI 10.1038/ki.1979.167; KOUL H, 1994, AM J PHYSIOL, V266, pF266, DOI 10.1152/ajprenal.1994.266.2.F266; Koul H, 1996, KIDNEY INT, V50, P1525, DOI 10.1038/ki.1996.467; KOUL H, 1994, BIOCHEM BIOPH RES CO, V205, P1632, DOI 10.1006/bbrc.1994.2854; Koul H, 1996, ITAL J MINER ELECT M, V10, P67; Koul HK, 1999, J AM SOC NEPHROL, V10, pS417; Koul S, 2002, KIDNEY INT, V61, P525, DOI 10.1046/j.1523-1755.2002.00163.x; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; Kuo SM, 1996, J BIOL CHEM, V271, P15491, DOI 10.1074/jbc.271.26.15491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; MENON M, 1992, J CLIN ENDOCR METAB, V74, P703, DOI 10.1210/jc.74.4.703; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; Morita N, 2001, J PHARMACOL EXP THER, V298, P1179; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; RADI MJ, 1989, ARCH PATHOL LAB MED, V113, P1367; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Saldeen J, 2001, BIOCHEM PHARMACOL, V61, P1561, DOI 10.1016/S0006-2952(01)00605-0; Scheid C, 1996, J UROLOGY, V155, P1112, DOI 10.1016/S0022-5347(01)66402-4; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Sodhi CP, 2000, KIDNEY INT, V58, P691, DOI 10.1046/j.1523-1755.2000.00215.x; STEINMASSL D, 1995, IN VITRO CELL DEV-AN, V31, P94; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Takakura Y, 1995, PHARMACEUT RES, V12, P1968, DOI 10.1023/A:1016256325921; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; TRUONG LD, 1992, MODERN PATHOL, V5, P146; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	73	51	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13321	13330		10.1074/jbc.M108203200	http://dx.doi.org/10.1074/jbc.M108203200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823457	hybrid			2022-12-25	WOS:000175036300103
J	Hauck, CR; Hsia, DA; Ilic, D; Schlaepfer, DD				Hauck, CR; Hsia, DA; Ilic, D; Schlaepfer, DD			v-Src SH3-enhanced interaction with focal adhesion kinase at beta(1) integrin-containing invadopodia promotes cell invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ROUS-SARCOMA VIRUS; SH3 DOMAIN; C-SRC; FIBRONECTIN; PHOSPHORYLATION; TRANSFORMATION; P130(CAS); SEQUENCE; BINDING	In viral Src (v-Src)-transformed cells, focal adhesion kinase (FAK) associates with v-Src by combined v-Src SH2 and gain-of-function v-Src SH3 domain binding to FAK. Here we assess the significance of the Arg-95 to Trp gain-of-function mutation in the v-Src SH3 domain through comparisons of Src-/- fibroblasts transformed with either Prague C v-Src or a point mutant (v-Src-RT) containing a normal (Arg-95) SH3 domain. Both v-Src isoforms exhibited equivalent kinase activity, enhanced Src-/- cell motility, and stimulated cell growth in both low serum and soft agar. The stability of a v-Src(.)FAK signaling complex and FAK phosphorylation at Tyr-861 and Tyr-925 were reduced in v-Src-RT- compared with v-Src-transformed cells. v-Src but not v-Src-RT promoted Src-/- cell invasion through a reconstituted Matrigel basement membrane barrier and v-Src co-localized. with FAK and,6, integrin at invadopodia. In contrast, v-Src-RT exhibited a partial perinuclear and focal contact distribution in Src-/- cells. Adenovirus-mediated FAK overexpression promoted v-Src-RT recruitment to invadopodia, the formation of a v-Src-RT(.)FAK signaling complex, and reversed the v-Src-RT invasion deficit. Adenovirus-mediated inhibition of FAK blocked v-Src-stimulated cell invasion. These studies establish that gain-of-function v-Src SH3 targeting interactions with FAK at beta(1) integrin-containing invadopodia act to stabilize a v-Src(.)FAK signaling complex promoting cell invasion.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	Scripps Research Institute; University of California System; University of California San Francisco	Schlaepfer, DD (corresponding author), Scripps Res Inst, Dept Immunol, IMM26,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	dschlaep@scripps.edu		ILIC, DUSKO/0000-0003-1647-0026				Cance WG, 2000, CLIN CANCER RES, V6, P2417; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; Fincham VJ, 2000, MOL CELL BIOL, V20, P6518, DOI 10.1128/MCB.20.17.6518-6536.2000; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; Hauck CR, 2001, J BIOL CHEM, V276, P17653, DOI 10.1074/jbc.M009329200; Hauck CR, 2001, CANCER RES, V61, P7079; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ilic D, 2001, AM J PATHOL, V159, P93, DOI 10.1016/S0002-9440(10)61677-X; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; LERNER TL, 1984, J VIROL, V49, P549, DOI 10.1128/JVI.49.2.549-556.1984; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MUELLER SC, 1991, J CELL SCI, V99, P213; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Sakai T, 2001, P NATL ACAD SCI USA, V98, P3808, DOI 10.1073/pnas.240456398; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; Zhao J H, 2000, Prog Mol Subcell Biol, V25, P37	27	90	93	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12487	12490		10.1074/jbc.C100760200	http://dx.doi.org/10.1074/jbc.C100760200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11839732	hybrid			2022-12-25	WOS:000175036300001
J	Liu, J; Wang, SL; Hoxie, JA; LaBranche, CC; Lu, M				Liu, J; Wang, SL; Hoxie, JA; LaBranche, CC; Lu, M			Mutations that destabilize the gp41 core are determinants for stabilizing the simian immunodeficiency virus-CPmac envelope glycoprotein complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HIV-1 TRANSMEMBRANE GLYCOPROTEIN; HUMAN MONOCLONAL-ANTIBODY; VIRAL MEMBRANE-FUSION; TYPE-1 GP41; INFLUENZA HEMAGGLUTININ; SIV GP41; CRYSTAL-STRUCTURE; LEUCINE ZIPPER; COILED-COIL; HELICAL INTERACTIONS	The human and simian immunodeficiency viruses (HIV and SIV) envelope glycoprotein consists of a trimer of two noncovalently and weakly associated subunits, gp120 and gp41. Upon binding of gp120 to cellular receptors, this labile native envelope complex undergoes conformational changes, resulting in a stable trimer-of-hairpins structure in gp41. Formation of the hairpin structure is thought to mediate membrane fusion by placing the viral and cellular membranes in close proximity. An in vitro-derived variant of SIVmac251, denoted CPmac, has acquired an unusually stable virion-associated gp120-gp41 complex. This unique phenotype is conferred by five amino acid substitutions in the gp41 ectodomain. Here we characterize the structural and physicochemical properties of the N40(L6)C38 model of the CPmac gp41 core. The 1.7-Angstrom resolution crystal structure of N40(L6)C38 is very similar to the six-helix bundle structure present in the parent SIVmac251 gp41. In both structures, three N40 peptides form a central three-stranded coiled coil, and three C38 peptides pack in an antiparallel orientation into hydrophobic grooves on the coiled-coil surface. Thermal unfolding studies show that the CPmac mutations destabilize the SIVmac251 six-helix bundle by 15 kJ/mol. Our results suggest that the formation of the gp41 trimer-of-hairpins structure is thermodynamically coupled to the conformational stability of the native envelope glycoprotein and raise the intriguing possibility that introduction of mutations to destabilize the six-helix bundle may lead to the stabilization of the trimeric gp120-gp41 complex. This study suggests a potential strategy for the production of stably folded envelope protein immunogens for HIV vaccine development.	Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA	Cornell University; University of Pennsylvania; Duke University	Lu, M (corresponding author), Cornell Univ, Weill Med Coll, Dept Biochem, 1300 York Ave, New York, NY 10021 USA.	mlu@mail.med.cornell.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050504, R56AI042382, R01AI049784, R21AI042382, R01AI042382] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 42382, AI 49784, AI 50504] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Baker KA, 1999, MOL CELL, V3, P309, DOI 10.1016/S1097-2765(00)80458-X; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BERMAN PW, 1988, J VIROL, V62, P3135, DOI 10.1128/JVI.62.9.3135-3142.1988; Binley JM, 2000, J VIROL, V74, P627, DOI 10.1128/JVI.74.2.627-643.2000; BLACKLOW SC, 1995, BIOCHEMISTRY-US, V34, P14955, DOI 10.1021/bi00046a001; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUUGER AT, 1992, XPLOR VERSIO 3 1 SYS; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; BURTON DR, 1994, SCIENCE, V266, P1024, DOI 10.1126/science.7973652; BURTON DR, 1997, AIDS SA, V11, P587; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; CANTOR C, 1980, BIOPHYSICAL CHEM 3, P1131; CAO J, 1993, J VIROL, V67, P2747, DOI 10.1128/JVI.67.5.2747-2755.1993; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAMBERS P, 1990, J GEN VIROL, V71, P3075, DOI 10.1099/0022-1317-71-12-3075; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHEN CH, 1995, J VIROL, V69, P3771, DOI 10.1128/JVI.69.6.3771-3777.1995; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DELWART EL, 1990, AIDS RES HUM RETROV, V6, P703, DOI 10.1089/aid.1990.6.703; Doering DS, 1996, BIOCHEMISTRY-US, V35, P12677, DOI 10.1021/bi9615699; DUBAY JW, 1992, J VIROL, V66, P4748, DOI 10.1128/JVI.66.8.4748-4756.1992; EARL PL, 1994, J VIROL, V68, P3015, DOI 10.1128/JVI.68.5.3015-3026.1994; Earl PL, 1997, J VIROL, V71, P2674, DOI 10.1128/JVI.71.4.2674-2684.1997; EARL PL, 1990, P NATL ACAD SCI USA, V87, P648, DOI 10.1073/pnas.87.2.648; Eckert DM, 1999, CELL, V99, P103, DOI 10.1016/S0092-8674(00)80066-5; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Edinger AL, 1999, J VIROL, V73, P4062, DOI 10.1128/JVI.73.5.4062-4073.1999; Farzan M, 1998, J VIROL, V72, P7620, DOI 10.1128/JVI.72.9.7620-7625.1998; Ferrer M, 1999, NAT STRUCT BIOL, V6, P953; Fouts TR, 1997, J VIROL, V71, P2779, DOI 10.1128/JVI.71.4.2779-2785.1997; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; GALLAHER WR, 1989, AIDS RES HUM RETROV, V5, P431, DOI 10.1089/aid.1989.5.431; GELDERBLOM HR, 1985, LANCET, V2, P1016; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; HUGHSON FM, 1997, CURR BIOL, V7, P565; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; Jelesarov I, 2001, J MOL BIOL, V307, P637, DOI 10.1006/jmbi.2001.4469; Ji H, 2000, BIOCHEMISTRY-US, V39, P676, DOI 10.1021/bi991893e; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LABRANCHE CC, 1994, J VIROL, V68, P5509, DOI 10.1128/JVI.68.9.5509-5522.1994; LABRANCHE CC, 1995, J VIROL, V69, P5217, DOI 10.1128/JVI.69.9.5217-5227.1995; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Liu J, 2001, BIOCHEMISTRY-US, V40, P2797, DOI 10.1021/bi0024759; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Lu M, 1999, J VIROL, V73, P4433, DOI 10.1128/JVI.73.5.4433-4438.1999; LUCIW PA, 1996, FIELDS VIROLOGY; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; MOORE JP, 1995, AIDS, V9, P117; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; MUSTER T, 1994, J VIROL, V68, P4031, DOI 10.1128/JVI.68.6.4031-4034.1994; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parker CE, 2001, J VIROL, V75, P10906, DOI 10.1128/JVI.75.22.10906-10911.2001; Parren PWHI, 1997, NAT MED, V3, P366, DOI 10.1038/nm0497-366d; PARREN PWHI, 1999, J ACQ IMMUN DEF SYND, V13, pS137; Poignard P, 1996, J EXP MED, V183, P473, DOI 10.1084/jem.183.2.473; Richardson TM, 1996, J VIROL, V70, P753, DOI 10.1128/JVI.70.2.753-762.1996; Rimsky LT, 1998, J VIROL, V72, P986, DOI 10.1128/JVI.72.2.986-993.1998; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; ROBEN P, 1994, J VIROL, V68, P4821, DOI 10.1128/JVI.68.8.4821-4828.1994; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; SATTENTAU QJ, 1995, VIROLOGY, V206, P713, DOI 10.1016/S0042-6822(95)80094-8; SATTENTAU QJ, 1995, J EXP MED, V182, P185, DOI 10.1084/jem.182.1.185; Shu W, 2000, BIOCHEMISTRY-US, V39, P1634, DOI 10.1021/bi9921687; Skehel JJ, 1998, CELL, V95, P871, DOI 10.1016/S0092-8674(00)81710-9; Sodroski JG, 1999, CELL, V99, P243, DOI 10.1016/S0092-8674(00)81655-4; Stamatatos L, 2000, AIDS RES HUM RETROV, V16, P981, DOI 10.1089/08892220050058407; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; Sugiura W, 1999, VIROLOGY, V254, P257, DOI 10.1006/viro.1998.9549; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Trkola A, 1996, J VIROL, V70, P1100, DOI 10.1128/JVI.70.2.1100-1108.1996; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; VanCott TC, 1997, J VIROL, V71, P4319, DOI 10.1128/JVI.71.6.4319-4330.1997; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Weng YK, 1998, J VIROL, V72, P9676, DOI 10.1128/JVI.72.12.9676-9682.1998; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Yang XZ, 2000, J VIROL, V74, P4746, DOI 10.1128/JVI.74.10.4746-4754.2000; Yang XZ, 2001, J VIROL, V75, P1165, DOI 10.1128/JVI.75.3.1165-1171.2001; Yang XZ, 2000, J VIROL, V74, P5716, DOI 10.1128/JVI.74.12.5716-5725.2000; Yang ZN, 1999, J STRUCT BIOL, V126, P131, DOI 10.1006/jsbi.1999.4116; Zwick MB, 2001, J VIROL, V75, P10892, DOI 10.1128/JVI.75.22.10892-10905.2001	106	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12891	12900		10.1074/jbc.M110315200	http://dx.doi.org/10.1074/jbc.M110315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11830586	hybrid			2022-12-25	WOS:000175036300053
J	Sunnarborg, SW; Hinkle, CL; Stevenson, M; Russell, WE; Raska, CS; Peschon, JJ; Castner, BJ; Gerhart, MJ; Paxton, RJ; Black, RA; Lee, DC				Sunnarborg, SW; Hinkle, CL; Stevenson, M; Russell, WE; Raska, CS; Peschon, JJ; Castner, BJ; Gerhart, MJ; Paxton, RJ; Black, RA; Lee, DC			Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-ALPHA; CELL-SURFACE; EGF RECEPTOR; ECTODOMAIN CLEAVAGE; HUMAN AMPHIREGULIN; MICE LACKING; PRECURSOR; BINDING; MUTATION; METALLOPROTEINASE	We previously implicated tumor necrosis factor-alpha converting enzyme (TACE/ADAM17) in the processing of the integral membrane precursor to soluble transforming growth factor-alpha (TGF-alpha), pro-TGF-alpha. Here we examined TGF-alpha processing in a physiologically relevant cell model, primary keratinocytes, showing that cells lacking TACE activity shed dramatically less TGF-alpha as compared with wild-type cultures and that TGF-alpha cleavage was partially restored by infection of TACE-deficient cells with TACE-encoding adenovirus. Moreover, cotransfection of TACE-deficient fibroblasts with proTGF-alpha and TACE cDNAs increased shedding of mature TGF-alpha with concomitant conversion of cell-associated pro-TGF-alpha to a processed form. Purified TACE accurately cleaved pro-TGF-alpha in vitro at the N-terminal site and also cleaved a soluble form of pro-TGF-alpha containing only the ectodomain at the C-terminal site. In vitro, TACE accurately cleaved peptides corresponding to cleavage sites of several epidermal growth factor (EGF) family members, and transfection of TACE into TACE-deficient cells increased the shedding of amphiregulin and heparin-binding EGF (HB-EGF) proteins. Consistent with the hypothesis that TACE regulates EGF receptor (EGYR) ligand availability in vivo, mice heterozygous for Tace and homozygous for an impaired EGFR allele (wa-2) were born with open eyes significantly more often than Tace(+/+)Egfr(wa-2/wa-2) counterparts. Collectively, these data support a broad role for TACE in the regulated shedding of EGFR ligands.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Lineberger Comprehen Canc Ctr, Chapel Hill, NC 27599 USA; Immunex Corp, Seattle, WA 98101 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37232 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Immunex Corporation; Vanderbilt University; Vanderbilt University	Lee, DC (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, CB 7260, Chapel Hill, NC 27599 USA.	dclee@med.unc.edu	, Proteomics Core UNC/AFQ-7201-2022; Russell, William/A-7307-2009		NCI NIH HHS [CA 71341, CA 85410, CA43793] Funding Source: Medline; NIDDK NIH HHS [DK53804] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043793, R01CA085410, T32CA071341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053804, R01DK053804] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANKLESARIA P, 1990, P NATL ACAD SCI USA, V87, P3289, DOI 10.1073/pnas.87.9.3289; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; Brown CL, 1998, J BIOL CHEM, V273, P17258, DOI 10.1074/jbc.273.27.17258; Brown CL, 2001, J BIOL CHEM, V276, P29538, DOI 10.1074/jbc.M102114200; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; Dempsey PJ, 1997, J CELL BIOL, V138, P747, DOI 10.1083/jcb.138.4.747; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; Gechtman Z, 1999, J BIOL CHEM, V274, P28828, DOI 10.1074/jbc.274.40.28828; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; Iwamoto R, 1999, J BIOL CHEM, V274, P25906, DOI 10.1074/jbc.274.36.25906; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; LEE DC, 1995, PHARMACOL REV, V47, P51; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MARQUARDT H, 1984, SCIENCE, V223, P1079, DOI 10.1126/science.6320373; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Merlos-Suarez A, 2001, J BIOL CHEM, V276, P48510, DOI 10.1074/jbc.M103488200; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; NAKAMURA T, 1987, FEBS LETT, V224, P311, DOI 10.1016/0014-5793(87)80475-1; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qu CK, 1999, P NATL ACAD SCI USA, V96, P8528, DOI 10.1073/pnas.96.15.8528; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Rifkin DB, 1999, APMIS, V107, P80, DOI 10.1111/j.1699-0463.1999.tb01529.x; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Tada H, 1999, J CELL BIOCHEM, V72, P423, DOI 10.1002/(SICI)1097-4644(19990301)72:3<423::AID-JCB11>3.3.CO;2-G; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Toyoda H, 1997, BIOCHEM J, V326, P69, DOI 10.1042/bj3260069; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Wang DZM, 1997, GENE DEV, V11, P309, DOI 10.1101/gad.11.3.309; WATANABE T, 1994, J BIOL CHEM, V269, P9966; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	63	344	354	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12838	12845		10.1074/jbc.M112050200	http://dx.doi.org/10.1074/jbc.M112050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823465	hybrid			2022-12-25	WOS:000175036300046
J	Yang, WY; Rogers, PA; Ding, HG				Yang, WY; Rogers, PA; Ding, HG			Repair of nitric oxide-modified ferredoxin [2Fe-2S] cluster by cysteine desulfurase (IscS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-S CLUSTER; IRON-SULFUR PROTEINS; DIHYDROXY-ACID DEHYDRATASE; ESCHERICHIA-COLI; AZOTOBACTER-VINELANDII; ACTIVATED MACROPHAGES; GENE-CLUSTER; NIFS GENE; COMPLEXES; MITOCHONDRIA	Iron-sulfur proteins are among the sensitive targets of the nitric oxide cytotoxicity. When Escherichia coli cells are exposed to nitric oxide, iron-sulfur clusters are modified forming protein-bound dinitrosyl iron complexes. Such modified protein dinitrosyl iron complexes are stable in vitro but are efficiently repaired in aerobically growing E. coli cells even without any new protein synthesis. Here we show that cysteine desulfurase encoded by the gene iscS of E. coli can directly convert the ferredoxin dinitrosyl iron complex to the ferredoxin [2Fe-2S] cluster in the presence of L-cysteine in vitro. A reassembly of the [2Fe-2S] cluster in the ferredoxin dinitrosyl iron complex does not require any addition of iron or other protein components. Furthermore, a complete removal of the dinitrosyl iron complex from ferredoxin prevents reassembly of the [2Fe-2S] cluster in the protein. The results suggest that cysteine desulfurase (IscS) together with L-cysteine can efficiently repair the nitric oxide-modified ferredoxin [2Fe-2S] cluster and that the iron center in the dinitrosyl iron complex may be recycled for the reassembly of iron-sulfur clusters in proteins.	Louisiana State Univ, Dept Sci Biol, Baton Rouge, LA 70803 USA	Louisiana State University System; Louisiana State University	Ding, HG (corresponding author), Louisiana State Univ, Dept Sci Biol, 202 Life Sci Bldg, Baton Rouge, LA 70803 USA.		Ding, Huangen/AAJ-8550-2020	Ding, Huangen/0000-0002-4815-7336				Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; Beinert H, 1999, CURR OPIN CHEM BIOL, V3, P152, DOI 10.1016/S1367-5931(99)80027-1; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Ding HG, 2000, P NATL ACAD SCI USA, V97, P5146, DOI 10.1073/pnas.97.10.5146; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; FLINT DH, 1993, J BIOL CHEM, V268, P25547; Flint DH, 1996, J BIOL CHEM, V271, P16068; Foster HW, 1999, J AM CHEM SOC, V121, P4093; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; Jensen LT, 2000, MOL CELL BIOL, V20, P3918, DOI 10.1128/MCB.20.11.3918-3927.2000; Johnson MK, 1998, CURR OPIN CHEM BIOL, V2, P173, DOI 10.1016/S1367-5931(98)80058-6; Jung YS, 1999, J BIOL CHEM, V274, P32402, DOI 10.1074/jbc.274.45.32402; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; Keyer K, 1996, P NATL ACAD SCI USA, V93, P13635, DOI 10.1073/pnas.93.24.13635; Kim R, 2001, J BIOL CHEM, V276, P17524, DOI 10.1074/jbc.M010695200; KREDICH NM, 1996, ESCHERICHIA COLI SAL, P514; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; Land T, 1998, MOL CELL, V2, P807, DOI 10.1016/S1097-2765(00)80295-6; Lange H, 2000, P NATL ACAD SCI USA, V97, P1050, DOI 10.1073/pnas.97.3.1050; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nakai Y, 2001, J BIOL CHEM, V276, P8314, DOI 10.1074/jbc.M007878200; NUNOSHIBA T, 1993, P NATL ACAD SCI USA, V90, P9993, DOI 10.1073/pnas.90.21.9993; Oliveira L, 1999, J BIOL CHEM, V274, P516, DOI 10.1074/jbc.274.1.516; Rogers PA, 2001, J BIOL CHEM, V276, P30980, DOI 10.1074/jbc.M101037200; Rouault T, 1997, CURR TOP CELL REGUL, V35, P1, DOI 10.1016/S0070-2137(97)80001-5; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Sellers VM, 1996, BIOCHEMISTRY-US, V35, P2699, DOI 10.1021/bi952631p; Skovran E, 2000, J BACTERIOL, V182, P3896, DOI 10.1128/JB.182.14.3896-3903.2000; Smith AD, 2001, J AM CHEM SOC, V123, P11103, DOI 10.1021/ja016757n; TA DT, 1992, J BIOL CHEM, V267, P11120; Takahashi Y, 1999, J BIOCHEM, V126, P917, DOI 10.1093/oxfordjournals.jbchem.a022535; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Tong WH, 2000, EMBO J, V19, P5692, DOI 10.1093/emboj/19.21.5692; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Welter R, 1996, ARCH BIOCHEM BIOPHYS, V331, P9, DOI 10.1006/abbi.1996.0276; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	47	88	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12868	12873		10.1074/jbc.M109485200	http://dx.doi.org/10.1074/jbc.M109485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11825893	hybrid			2022-12-25	WOS:000175036300050
J	Gotoh, T; Oyadomari, S; Mori, K; Mori, M				Gotoh, T; Oyadomari, S; Mori, K; Mori, M			Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-Y CBF; PROTEIN; ELEMENT; EXPRESSION; BINDING; GENE; IDENTIFICATION; PROTEOLYSIS; INDUCTION; ACTIVATOR	Excess nitric oxide (NO) induces apoptosis in some cell types including macrophages; however, the cascade of NO-mediated apoptosis is not fully understood. We investigated the initial steps of NO-mediated apoptosis in mouse macrophage-like RAW 264.7 cells. When cells were treated with bacterial lipopolysaccharide (LPS) plus interferon-gamma (IFN-gamma), NO-mediated apoptosis occurred. Under these conditions, p53 accumulation was not observed, indicating that DNA damage is not the main trigger of NO-mediated apoptosis. On the other hand, mRNA and protein for CHOP, a transcription factor known to be induced by endoplasmic reticulum (ER) stress, were induced. The CHOP induction by LPS/IFN-gamma treatment preceded cytochrome c release from mitochondria. In addition, p90ATF6, an ER membrane-bound transcription factor involved in ER stress response, was cleaved to its active soluble form p50ATF6, which was transported to nucleus and bound to the ER stress response element of the CHOP gene. In the luciferase reporter assay, both the CHOP-bindiug element of the Rous sarcoma virus long terminal repeat and ER stress response element of the CHOP gene were activated by LPS/IFN-gamma treatment. When RAW 264.7 cells or COS-7 cells were transfected with expression plasmids for CHOP, p90ATF6, or p50ATF6, cell death was observed. In addition, apoptosis induced by p50ATF6 was prevented by a CHOP dominant negative form as well as by an ATF6 dominant negative form, and LPS/IFN-gamma-induced apoptosis was prevented by the CHOP dominant negative form. Peritoneal macrophages from CHOP knockout mice showed resistance to NO-induced apoptosis. These results indicate that the ER stress pathway involving ATF6 and CHOP plays a key role in NO-mediated apoptosis in macrophages.	Kumamoto Univ, Sch Med, Dept Mol Genet, Kumamoto 8600811, Japan; Kyoto Univ, Grad Sch Biostudies, Kyoto 6068304, Japan	Kumamoto University; Kyoto University	Mori, K (corresponding author), Kumamoto Univ, Sch Med, Dept Mol Genet, Honjo 2-2-1, Kumamoto 8600811, Japan.	tomomi@gpo.kumamoto-u.ac.jp	Oyadomari, Seiichi/GZA-7157-2022; Oyadomari, Seiichi/GZA-7072-2022; Mori, Kazutoshi/K-6106-2015					Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gotoh T, 2001, CELL DEATH DIFFER, V8, P357, DOI 10.1038/sj.cdd.4400829; GOTOH T, 1994, J BIOCHEM-TOKYO, V115, P778, DOI 10.1093/oxfordjournals.jbchem.a124409; Gotoh T, 1999, J CELL BIOL, V144, P427, DOI 10.1083/jcb.144.3.427; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawahara K, 2001, FEBS LETT, V506, P135, DOI 10.1016/S0014-5793(01)02898-8; Kroncke KD, 1997, NITRIC OXIDE-BIOL CH, V1, P107, DOI 10.1006/niox.1997.0118; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Matsumoto M, 1996, FEBS LETT, V395, P143, DOI 10.1016/0014-5793(96)01016-2; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Messmer UK, 1996, BIOCHEM J, V319, P299, DOI 10.1042/bj3190299; MIYAZAKI J, 1989, GENE, V79, P269; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Salimuddin, 1999, AM J PHYSIOL-ENDOC M, V277, pE110, DOI 10.1152/ajpendo.1999.277.1.E110; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Urano F, 2000, J CELL SCI, V113, P3697; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	35	209	228	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12343	12350	PII 10.1074/jbc.M107988200	10.1074/jbc.M107988200	http://dx.doi.org/10.1074/jbc.M107988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805088	hybrid			2022-12-25	WOS:000174846400097
J	Hirohata, S; Wang, LW; Miyagi, M; Yan, L; Seldin, MF; Keene, DR; Crabb, JW; Apte, SS				Hirohata, S; Wang, LW; Miyagi, M; Yan, L; Seldin, MF; Keene, DR; Crabb, JW; Apte, SS			Punctin, a novel ADAMTS-like molecule, ADAMTSL-1, in extracellular matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; HUMAN GELATINASE-A; CELL-ADHESION; TNF-ALPHA; TS FAMILY; PROTEIN; DOMAIN; FIBRONECTIN; BINDING; IDENTIFICATION	Punctin (ADAMTSL-1) is a secreted molecule resembling members of the ADAMTS family of proteases. Punctin lacks the pro-metalloprotease and the disintegrin-like domain typical of this family but contains other ADAMTS domains in precise order including four thrombospondin type I repeats. Punctin is the product of a distinct gene on human chromosome 9p21-22 and mouse chromosome 4 that is expressed in adult skeletal muscle. His-tagged punctin expressed in stably transfected High-Five(TM) insect cells was purified to apparent homogeneity by Ni-chromatography of conditioned medium. The NH2 terminus is not blocked and has the sequence EEDRD and so forth as determined by Edman degradation, demonstrating signal peptidase processing. Recombinant epitope-tagged punctin has a calculated mass of 59,991 Da but exhibits major molecular species of 61970 +/- 6 Da and 62131 +/- 5 Da as measured by liquid chromatography electrospray mass spectrometry. Punctin is a glycoprotein based on carbohydrate staining and liquid chromatography electrospray mass spectrometry glycopeptide analysis. Glycosylation occurs at a single N-linked site as demonstrated by altered electrophoretic migration of punctin expressed in the presence of tunicamycin A. Punctin contains disulfide bonds based on antibody accessibility and electrophoretic migration under reducing versus nonreducing conditions. Rotary shadowing demonstrates that punctin is hatchet-shaped having a globular region attached to a short stem. In transfected COS-1 cells, punctin is deposited in the cell substratum in a punctate fashion and is excluded from focal contacts. Punctin is the first member of a novel family of ADAMTS-like proteins that may have important functions in the extracellular matrix.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Orthopaed Surg, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA; Univ Calif Davis, Rowe Program Genet, Dept Biol Chem, Davis, CA 95616 USA; Univ Calif Davis, Rowe Program Genet, Dept Med, Davis, CA 95616 USA; Shriners Hosp Children, Portland, OR 97201 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of California System; University of California Davis; University of California System; University of California Davis	Apte, SS (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn, 9500 Euclid Ave ND20, Cleveland, OH 44195 USA.			Apte, Suneel/0000-0001-8441-1226	NEI NIH HHS [EY06603] Funding Source: Medline; NHGRI NIH HHS [HGO0734] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000734] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bornstein P, 2000, MATRIX BIOL, V19, P557, DOI 10.1016/S0945-053X(00)00104-9; BORNSTEIN P, 1994, METHOD ENZYMOL, V245, P62; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Colige A, 1999, AM J HUM GENET, V65, P308, DOI 10.1086/302504; Crabb JW, 1998, J BIOL CHEM, V273, P20712, DOI 10.1074/jbc.273.33.20712; CRABB JW, 1997, CURRENT PROTOCOLS PR; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Georgiadis KE, 1999, GENOMICS, V62, P312, DOI 10.1006/geno.1999.6014; HAYMAN EG, 1982, J CELL BIOL, V94, P28, DOI 10.1083/jcb.94.1.28; HAYMAN EG, 1985, EXP CELL RES, V160, P245, DOI 10.1016/0014-4827(85)90173-9; Holden P, 2001, J BIOL CHEM, V276, P6046, DOI 10.1074/jbc.M009507200; Hulmes DJS, 1997, MATRIX BIOL, V16, P41, DOI 10.1016/S0945-053X(97)90115-3; Hurskainen TL, 1999, J BIOL CHEM, V274, P25555, DOI 10.1074/jbc.274.36.25555; Isogai Z, 1996, CANCER RES, V56, P3902; Kapron JT, 1997, PROTEIN SCI, V6, P2120; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kramerova IA, 2000, DEVELOPMENT, V127, P5475; Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556; Kuno K, 1998, J BIOL CHEM, V273, P13912, DOI 10.1074/jbc.273.22.13912; Kuno K, 1999, J BIOL CHEM, V274, P18821, DOI 10.1074/jbc.274.26.18821; MADDOX BK, 1989, J BIOL CHEM, V264, P21381; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nardi JB, 1999, INSECT BIOCHEM MOLEC, V29, P883, DOI 10.1016/S0965-1748(99)00064-8; OHJI M, 1994, INVEST OPHTH VIS SCI, V35, P479; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Overall CM, 1999, J BIOL CHEM, V274, P4421, DOI 10.1074/jbc.274.7.4421; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SINGER II, 1987, EXP CELL RES, V173, P558, DOI 10.1016/0014-4827(87)90295-3; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; Solomon KA, 1999, J IMMUNOL, V163, P4105; STASKUS PW, 1991, J BIOL CHEM, V266, P449; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; TAKAHARA K, 1994, J BIOL CHEM, V269, P26280; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WATSON ML, 1994, METH MOL G, V5, P369; YAMAGATA M, 1993, J CELL SCI, V106, P55; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zolkiewska A, 1999, EXP CELL RES, V252, P423, DOI 10.1006/excr.1999.4632	43	67	72	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12182	12189		10.1074/jbc.M109665200	http://dx.doi.org/10.1074/jbc.M109665200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805097	hybrid			2022-12-25	WOS:000174846400076
J	Lang, R; Gomes, AV; Zhao, JJ; Housmans, PR; Miller, T; Potter, JD				Lang, R; Gomes, AV; Zhao, JJ; Housmans, PR; Miller, T; Potter, JD			Functional analysis of a troponin I (R145G) mutation associated with familial hypertrophic cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIAC-MUSCLE CONTRACTION; PROTEIN-C GENE; INHIBITORY REGION; T MUTATIONS; INTRACELLULAR CA2+; ALTERED REGULATION; CALCIUM-BINDING; MYOSIN; TROPOMYOSIN; PHOSPHORYLATION	Familial hypertrophic cardiomyopathy has been associated with several mutations in the gene encoding human cardiac troponin I (HCTnI). A missense mutation in the inhibitory region of TnI replaces an arginine residue at position 145 with a glycine and cosegregates with the disease. Results from several assays indicate that the inhibitory function of HCTnI(R145G) is significantly reduced. When HCTnI(R145G) was incorporated into whole troponin, Tn(R145G) (HCTnT.HCTnIR(145G).HCTnC), only partial inhibition of the actin-tropomyosin-myosin ATPase activity was observed in the absence of Ca2+ compared with wild type Tn (HCTnT.HCTnI-HCTnC). Maximal activation of actin-tropomyosin-myosin ATPase in the presence of Ca2+ was also decreased in Tn(R145G) when compared with Tn. Using skinned cardiac muscle fibers, we determined that in comparison with the wild type complex 1) the complex containing HCTnI(R145G) only inhibited 84% of Ca2+-unregulated force, 2) the recovery of Ca2+-activated force was decreased, and 3) there was a significant increase in the Ca2+ sensitivity of force development. Computer modeling of troponin C and I variables predicts that the primary defect in TnI caused by these mutations would lead to diastolic dysfunction. These results suggest that severe diastolic dysfunction and somewhat decreased contractility would be prominent clinical features and that hypertrophy could arise as a compensatory mechanism.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA	University of Miami; Mayo Clinic	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, POB 016189 R-189, Miami, FL 33101 USA.	jdpotter@miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042325, R01HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42325] Funding Source: Medline; NIGMS NIH HHS [GM36365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMOUR KL, 1993, GENE, V131, P287, DOI 10.1016/0378-1119(93)90308-P; Bhavsar PK, 1996, GENOMICS, V35, P11, DOI 10.1006/geno.1996.0317; BLINKS JR, 1986, CIRCULATION, V73, P85; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CHEN YH, 1971, BIOCHEM BIOPH RES CO, V44, P1285, DOI 10.1016/S0006-291X(71)80225-5; Deng Y, 2001, BIOCHEMISTRY-US, V40, P14593, DOI 10.1021/bi0115232; Elliott K, 2000, J BIOL CHEM, V275, P22069, DOI 10.1074/jbc.M002502200; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Fiske CH, 1925, J BIOL CHEM, V66, P375; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HATAKENAKA M, 1992, EUR J BIOCHEM, V205, P985, DOI 10.1111/j.1432-1033.1992.tb16865.x; Hernandez OM, 2001, J APPL PHYSIOL, V90, P1125, DOI 10.1152/jappl.2001.90.3.1125; Hoffmann B, 2001, Hum Mutat, V17, P524, DOI 10.1002/humu.1143; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC541, DOI 10.1152/ajpcell.1987.253.4.C541; Housmans PR, 2000, ANESTHESIOLOGY, V93, P189, DOI 10.1097/00000542-200007000-00030; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; James J, 2000, CIRC RES, V87, P805, DOI 10.1161/01.RES.87.9.805; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; Knollmann BC, 2001, TRENDS CARDIOVAS MED, V11, P206, DOI 10.1016/S1050-1738(01)00115-3; Kokado H, 2000, CIRCULATION, V102, P663, DOI 10.1161/01.CIR.102.6.663; LANDESBERG A, 1994, AM J PHYSIOL, V266, pH1260, DOI 10.1152/ajpheart.1994.266.3.H1260; Marian AJ, 1998, J CARDIOVASC ELECTR, V9, P88, DOI 10.1111/j.1540-8167.1998.tb00871.x; Mikane T, 1997, AM J PHYSIOL-HEART C, V273, pH2891, DOI 10.1152/ajpheart.1997.273.6.H2891; Miller T, 2001, J BIOL CHEM, V276, P3743, DOI 10.1074/jbc.M006746200; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Morner S, 2000, J MOL CELL CARDIOL, V32, P521, DOI 10.1006/jmcc.1999.1099; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POTTER JD, 1982, METHOD ENZYMOL, V85, P241; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; SHENG ZL, 1992, J BIOL CHEM, V267, P25407; Szczesna D, 1999, J BIOL CHEM, V274, P29536, DOI 10.1074/jbc.274.41.29536; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; Takahashi-Yanaga F, 2000, J BIOCHEM-TOKYO, V127, P355, DOI 10.1093/oxfordjournals.jbchem.a022615; TALBOT JA, 1981, J BIOL CHEM, V256, P2374; TALBOT JA, 1981, J BIOL CHEM, V256, P2798; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Van Eyk Jennifer E., 1993, Methods (Orlando), V5, P264, DOI 10.1006/meth.1993.1033; VANEYK JE, 1988, J BIOL CHEM, V263, P1726; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; YUE DT, 1986, J GEN PHYSIOL, V87, P223, DOI 10.1085/jgp.87.2.223; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031	46	66	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11670	11678		10.1074/jbc.M108912200	http://dx.doi.org/10.1074/jbc.M108912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801593	hybrid			2022-12-25	WOS:000174846400009
J	Meier, A; Livingstone-Zatchej, M; Thoma, F				Meier, A; Livingstone-Zatchej, M; Thoma, F			Repair of active and silenced rDNA in yeast - The contributions of photolyase and transcription-coupled nucleotide excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CYCLOBUTANE PYRIMIDINE DIMER; MODULATES DNA-REPAIR; SACCHAROMYCES-CEREVISIAE; NONTRANSCRIBED STRAND; CHROMATIN TRANSITIONS; RIBOSOMAL GENES; THYMINE DIMER; IN-VIVO; DAMAGE	DNA repair by photolyase (photoreactivation) and nucleotide excision repair (NER) are the major pathways to remove UV-induced cyclobutane-pyrimidine dimers (CPDs). The nucleolus is a nuclear subcompartment containing the ribosomal RNA genes (rDNA) of which a fraction is transcribed by RNA polymerase I (RNAP-I), and the rest is silenced. Here yeast was used to investigate how photoreactivation and NER contribute to repair of active and inactive rDNA. Cells were irradiated with UV light and exposed to different repair conditions. Nuclei were isolated, and the active genes were separated from the inactive genes by restriction endonuclease digestion. CPDs were measured in total rDNA, in both fractions, and in the GAL10 gene. Repair in rDNA was as efficient as in GAL10 indicating that both pathways have unrestricted access to the nucleolus. Photoreactivation was much faster than NER and therefore was the predominant repair pathway. Active genes were faster repaired by photolyase than were silenced genes providing evidence for an open chromatin structure during repair. The transcribed strands of active genes, but not of inactive genes, were slightly faster repaired by NER providing evidence for transcription-coupled repair by RNAP-I. There was no pronounced inhibition of photoreactivation by RNAP-I in the transcribed strand, which is in contrast to genes transcribed by RNAP-II and suggests different stabilities of RNAP-I and RNAP-II stalled at CPDs.	ETH Honggerberg, Inst Zellbiol, Dept Biol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thoma, F (corresponding author), ETH Honggerberg, Inst Zellbiol, Dept Biol, CH-8093 Zurich, Switzerland.							Aboussekhra A, 1998, GENE DEV, V12, P411, DOI 10.1101/gad.12.3.411; Aboussekhra A, 1999, EMBO J, V18, P433, DOI 10.1093/emboj/18.2.433; Balajee AS, 1999, NUCLEIC ACIDS RES, V27, P2511, DOI 10.1093/nar/27.12.2511; Carmo-Fonseca M, 2000, NAT CELL BIOL, V2, pE107, DOI 10.1038/35014078; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; Cavalli G, 1996, EMBO J, V15, P590, DOI 10.1002/j.1460-2075.1996.tb00391.x; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; DAMMANN R, 1995, MOL CELL BIOL, V15, P5294; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; Dammann R, 1997, MOL CELL BIOL, V17, P219, DOI 10.1128/MCB.17.1.219; DONAHUE BA, 1994, P NATL ACAD SCI USA, V91, P8502, DOI 10.1073/pnas.91.18.8502; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Fritz LK, 1996, J BIOL CHEM, V271, P12972, DOI 10.1074/jbc.271.22.12972; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hara R, 1999, J BIOL CHEM, V274, P24779, DOI 10.1074/jbc.274.35.24779; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Leger-Silvestre I, 1999, CHROMOSOMA, V108, P103, DOI 10.1007/s004120050357; LivingstoneZatchej M, 1997, NUCLEIC ACIDS RES, V25, P3795, DOI 10.1093/nar/25.19.3795; Lucchini R, 1998, TRANSCRIPTION RIBOSO, P255; Meijer M, 1999, BIOESSAYS, V21, P596, DOI 10.1002/(SICI)1521-1878(199907)21:7<596::AID-BIES8>3.0.CO;2-5; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Moggs JG, 1999, BIOCHIMIE, V81, P45, DOI 10.1016/S0300-9084(99)80037-6; Muller M, 2000, MOL CELL, V5, P767, DOI 10.1016/S1097-2765(00)80317-2; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; Sancar GB, 2000, MUTAT RES-FUND MOL M, V451, P25, DOI 10.1016/S0027-5107(00)00038-5; Selby CP, 1997, NUCLEIC ACIDS RES, V25, P787, DOI 10.1093/nar/25.4.787; Sherman F, 1986, LAB COURSE MANUAL ME; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; Smerdon MJ, 1999, PROG NUCLEIC ACID RE, V62, P227; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1591, DOI 10.1093/carcin/14.8.1591; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Suter B, 2000, NUCLEIC ACIDS RES, V28, P2060, DOI 10.1093/nar/28.10.2060; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Suter B, 1999, METHOD ENZYMOL, V304, P447; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Tornaletti S, 1999, BIOCHIMIE, V81, P139, DOI 10.1016/S0300-9084(99)80046-7; Tornaletti S, 1999, J BIOL CHEM, V274, P24124, DOI 10.1074/jbc.274.34.24124; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; VANGOOL AJ, 1994, EMBO J, V13, P5361, DOI 10.1002/j.1460-2075.1994.tb06871.x; Verhage RA, 1996, NUCLEIC ACIDS RES, V24, P1020, DOI 10.1093/nar/24.6.1020; VOS JMH, 1991, MOL CELL BIOL, V11, P2245, DOI 10.1128/MCB.11.4.2245; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; YASUI A, 1994, EMBO J, V13, P6143, DOI 10.1002/j.1460-2075.1994.tb06961.x	52	33	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11845	11852		10.1074/jbc.M110941200	http://dx.doi.org/10.1074/jbc.M110941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805105	hybrid			2022-12-25	WOS:000174846400032
J	Schwartz, Z; Sylvia, VL; Larsson, D; Nemere, I; Casasola, D; Dean, DD; Boyan, BD				Schwartz, Z; Sylvia, VL; Larsson, D; Nemere, I; Casasola, D; Dean, DD; Boyan, BD			1 alpha 25(OH)(2)D-3 regulates chondrocyte matrix vesicle protein kinase C (PKQ) directly via G-protein-dependent mechanisms and indirectly via incorporation of PKC during matrix vesicle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-D METABOLITES; GROWTH-PLATE CHONDROCYTES; CARTILAGE CELLS-INVITRO; RESTING ZONE; MEMBRANE-RECEPTOR; ARACHIDONIC-ACID; PHOSPHOLIPASE-D; ALKALINE-PHOSPHATASE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; NONGENOMIC REGULATION	Matrix vesicles are extracellular organelles involved in mineral formation that are regulated by 1alpha,25 (OH)(2)D-3. Prior studies have shown that protein kinase C (PKC) activity is involved in mediating the effects of 1alpha,25(OH),D, in both matrix vesicles and plasma membranes. Here, we examined the regulation of matrix vesicle PKC by 1alpha,25(OH)(2)D-3 during biogenesis and after deposition in the matrix. When growth zone costochondral chondrocytes were treated for 9 min with 1alpha,25 (OH)(2)D-3, PCKzeta in matrix vesicles was inhibited, while PKCalpha in plasma membranes was increased. In contrast, after treatment for 12 or 24 h, PKCzeta in matrix vesicles was increased, while PKCa in plasma membranes was unchanged. The effect of 1alpha,25(OH)(2)D-3 was stereospecific and metabolite-specific. Monensin blocked the increase in matrix vesicle PKC after 24 h, suggesting the secosteroid-regulated packaging of PKC. In addition, the 1alpha,25(OH)(2)D-3 membrane vitamin D receptor (1,25-mVDR) was involved, since a specific antibody blocked the 1alpha,25(OH)(2)D-3-dependent changes in PKC after both long and short treatment times. In contrast, antibodies to annexin II had no effect, and there was no evidence for the presence of the nuclear VDR on Western blots. To investigate the signaling pathways involved in regulating matrix vesicle PKC activity after biosynthesis, matrix vesicles were isolated and then treated for 9 min with 1alpha,25(OH)(2)D-3 in the presence and absence of specific inhibitors. Inhibition of phosphatidylinositol-phospholipase C, phospholipase D, or G(i)/G(s). had no effect. However, inhibition of G(q) blocked the effect of 1alpha,25(OH)(2)D-3. The rapid effect of 1alpha,25(OH)(2)D-3 also involved the 1,25-mVDR. Moreover, arachidonic acid was found to stimulate PKC when added directly to isolated matrix vesicles. These results indicate that matrix vesicle PKC is regulated by 1alpha,25(OH)(2)D-3 at three levels: 1) during matrix vesicle biogenesis; 2) through direct action on the membrane; and 3) through production of other factors such as arachidonic acid.	Univ Texas, Hlth Sci Ctr, Dept Orthopaed, San Antonio, TX 78229 USA; Hebrew Univ Jerusalem, IL-91120 Jerusalem, Israel; Utah State Univ, Logan, UT 84322 USA	University of Texas System; University of Texas Health San Antonio; Hebrew University of Jerusalem; Utah System of Higher Education; Utah State University	Boyan, BD (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Orthopaed, MSC 7774,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Nemere, Ilka/A-7077-2008	Dean, David/0000-0002-4512-9065	NIDCR NIH HHS [DE-05937, DE-08603] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005937, R01DE008603] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Baran DT, 2000, J CELL BIOCHEM, V78, P34, DOI 10.1002/(SICI)1097-4644(20000701)78:1<34::AID-JCB4>3.3.CO;2-Q; Boyan B. D., 1997, Vitamin D., P395; BOYAN BD, 1988, ENDOCRINOLOGY, V122, P2851, DOI 10.1210/endo-122-6-2851; BOYAN BD, 1988, BONE, V9, P185, DOI 10.1016/8756-3282(88)90008-7; Boyan BD, 1999, STEROIDS, V64, P129, DOI 10.1016/S0039-128X(98)00099-3; BOYAN BD, 1994, J BIOL CHEM, V269, P28374; Boyan BD, 1998, J CELL PHYSIOL, V176, P516, DOI 10.1002/(SICI)1097-4652(199809)176:3<516::AID-JCP8>3.3.CO;2-I; BOYAN BD, 1984, CALCIFIED TISSUE INT, V36, P332, DOI 10.1007/BF02405339; BOYAN BD, 2002, IN PRESS DISORDERS B; BOYAN BD, IN PRESS CRIT REV OR; BOYAN BD, 2002, IN PRESS STEROIDS; CARRASCOMARIN E, 1994, EUR J IMMUNOL, V24, P2031, DOI 10.1002/eji.1830240915; de Boland AR, 1998, J CELL BIOCHEM, V69, P470, DOI 10.1002/(SICI)1097-4644(19980615)69:4<470::AID-JCB8>3.0.CO;2-K; Dean DD, 1996, CALCIFIED TISSUE INT, V59, P109, DOI 10.1007/s002239900096; DEAN DD, 1992, CALCIFIED TISSUE INT, V50, P342, DOI 10.1007/BF00301632; DEBOLAND AR, 1994, CELL SIGNAL, V6, P717, DOI 10.1016/0898-6568(94)00042-5; DUGGAN J, 2001, J DENT RES, V80, P44; EINHORN TA, 1989, J ORTHOPAED RES, V7, P792, DOI 10.1002/jor.1100070604; Facchinetti MM, 1999, CELL SIGNAL, V11, P39, DOI 10.1016/S0898-6568(98)00029-1; Facchinetti MM, 1998, J LIPID RES, V39, P197; Kirsch T, 2000, J BIOL CHEM, V275, P35577, DOI 10.1074/jbc.M005648200; KOCHS G, 1993, EUR J BIOCHEM, V216, P597, DOI 10.1111/j.1432-1033.1993.tb18179.x; LEACH RJ, 1995, J BONE MINER RES, V10, P1614; LOPEZRUIZ MP, 1992, ENDOCRINOLOGY, V130, P1122, DOI 10.1210/en.130.3.1122; Maeda S, 2001, J BONE MINER RES, V16, P1281, DOI 10.1359/jbmr.2001.16.7.1281; MOLLINEDO F, 1994, J IMMUNOL, V153, P2457; MORELLI S, 1993, BIOCHEM J, V289, P675, DOI 10.1042/bj2890675; Nemere I, 1998, J BONE MINER RES, V13, P1353, DOI 10.1359/jbmr.1998.13.9.1353; NEMERE I, 1994, J BIOL CHEM, V269, P23750; Nemere I, 2000, AM J PHYSIOL-ENDOC M, V278, pE1104, DOI 10.1152/ajpendo.2000.278.6.E1104; NEMERE I, 1996, J BONE MINER RES, V11, pS312; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NORMAN AW, 1992, BIOCHEM BIOPH RES CO, V189, P1450, DOI 10.1016/0006-291X(92)90237-F; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Pedrozo HA, 1999, J BONE MINER RES, V14, P856, DOI 10.1359/jbmr.1999.14.6.856; Pedrozo HA, 1999, CALCIFIED TISSUE INT, V64, P50, DOI 10.1007/s002239900578; PERESS NS, 1974, CALC TISS RES, V14, P275, DOI 10.1007/BF02060301; Racz A, 1999, J BIOL CHEM, V274, P19352, DOI 10.1074/jbc.274.27.19352; Schmitz JP, 1996, J CELL PHYSIOL, V168, P570, DOI 10.1002/(SICI)1097-4652(199609)168:3<570::AID-JCP9>3.3.CO;2-S; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V123, P2878, DOI 10.1210/endo-123-6-2878; Schwartz Z, 1998, ENDOCRINOLOGY, V139, P1825, DOI 10.1210/en.139.4.1825; SCHWARTZ Z, 1990, BIOCHIM BIOPHYS ACTA, V1027, P278, DOI 10.1016/0005-2736(90)90319-J; SCHWARTZ Z, 1988, ENDOCRINOLOGY, V122, P2191, DOI 10.1210/endo-122-5-2191; SCHWARTZ Z, 1992, ENDOCRINOLOGY, V130, P2495, DOI 10.1210/en.130.5.2495; Schwartz Z, 2001, J BIOMED MATER RES, V56, P417, DOI 10.1002/1097-4636(20010905)56:3<417::AID-JBM1111>3.0.CO;2-K; Schwartz Z, 2001, STEROIDS, V66, P683, DOI 10.1016/S0039-128X(01)00100-3; SCHWARTZ Z, 1988, J BIOL CHEM, V263, P6023; SHAH BH, 1995, P NATL ACAD SCI USA, V92, P1886, DOI 10.1073/pnas.92.6.1886; SIMBOLICAMPBELL M, 1994, J BIOL CHEM, V269, P3257; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SWAIN LD, 1992, BONE MINER, V17, P192, DOI 10.1016/0169-6009(92)90735-V; SWAIN LD, 1993, BONE, V14, P609, DOI 10.1016/8756-3282(93)90082-L; Sylvia VL, 1998, J BONE MINER RES, V13, P559, DOI 10.1359/jbmr.1998.13.4.559; SYLVIA VL, 1993, J CELL PHYSIOL, V157, P271, DOI 10.1002/jcp.1041570209; Sylvia VL, 1996, J CELL PHYSIOL, V167, P380, DOI 10.1002/(SICI)1097-4652(199606)167:3<380::AID-JCP2>3.0.CO;2-L; Sylvia VL, 2001, J STEROID BIOCHEM, V78, P261, DOI 10.1016/S0960-0760(01)00099-1; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	59	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11828	11837		10.1074/jbc.M110398200	http://dx.doi.org/10.1074/jbc.M110398200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805100	hybrid			2022-12-25	WOS:000174846400030
J	Frade, R; Balbo, M; Barel, M				Frade, R; Balbo, M; Barel, M			RB18A regulates p53-dependent apoptosis	ONCOGENE			English	Article						RB18A; TRAP220; DRIP205; PBP; p53-dependent apoptosis; co-transcriptional factor	NUCLEAR RECEPTORS; PROTEIN; P53; INTERACTS; TRAP220; SUBUNIT; GENE	We previously demonstrated that RB18A, a member of TRAP220/DRIP205/PBP family, in vivo acted as a cofactor of transcription by differently regulating p53wt transactivating activity on physiological promoters. Using p53-negative cells transfected with different constructs, we herein demonstrated that RB18A down-regulated p53wt-dependent apoptosis. This biological regulation was due to a specific diminution of p53wt protein level, as level of p91mut and GAPDH proteins was not modified. This p53wt diminution was dependent on proteasome activity, as inhibited by MG-132 inhibitor. This specific p53wt degradation was correlated with an increase in expression of MDM2, which promoted p53wt degradation into proteasome. RB18A up-regulated MDM2 expression by activating MDM2 promoter, even in absence of p53wt. Altogether, these data emphasized that RB18A could regulate p53wt function not only by direct interaction between both proteins, but also by up-regulating promoter activity of MDM2, a p53-regulating partner.	Hop St Antoine, Ctr INSERM, INSERM,U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Frade, R (corresponding author), Hop St Antoine, Ctr INSERM, INSERM,U354, Immunochim Regulat Cellulaires & Interact Virales, F-75012 Paris, France.	frade354@easynet.fr	BAREL, Monique/K-3772-2017	BAREL, Monique/0000-0001-8171-7027				Atkins GB, 1999, MOL ENDOCRINOL, V13, P1550, DOI 10.1210/me.13.9.1550; BAREL M, 1989, P NATL ACAD SCI USA, V86, P10054, DOI 10.1073/pnas.86.24.10054; Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Drane P, 1997, ONCOGENE, V15, P3013, DOI 10.1038/sj.onc.1201492; Frade R, 2000, CANCER RES, V60, P6585; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ito M, 1999, MOL CELL, V3, P361, DOI 10.1016/S1097-2765(00)80463-3; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P14584; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	19	15	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					861	866		10.1038/sj.onc.1205177	http://dx.doi.org/10.1038/sj.onc.1205177			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840331				2022-12-25	WOS:000173427100001
J	Cheresh, P; Harrison, T; Fujioka, H; Haldar, K				Cheresh, P; Harrison, T; Fujioka, H; Haldar, K			Targeting the malarial plastid via the parasitophorous vacuole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASEXUAL BLOOD STAGES; PLASMODIUM-FALCIPARUM; TOXOPLASMA-GONDII; BREFELDIN-A; APICOMPLEXAN PARASITES; SECRETORY PATHWAY; PROTEIN; CHLOROPLASTS; APICOPLAST; ORGANELLE	The malarial "apicoplast" derived from an algal plastid, has stimulated interest for its novel evolutionary biology and potential as a drug target. An endoplasmic reticulum-type signal sequence followed by a plastid targeting sequence are required to target proteins to the apicoplast but the pathway by which proteins are transported to the organelle is unknown. By stage regulating the expression of transgenes we show that early (0-12 h) in the parasite's development in red cells, newly synthesized green fluorescent protein that contains the plastid targeting sequence (plastid targeting sequence-green fluorescent protein (PTS-GFP)) is recruited into the parasite's secretory pathway. PTS-GFP in 0-12-h parasites is found released into the parasitophorous vacuole (PV) and in apposition with the Golgi. However, import into the apicoplast and processing to GFP does not occur until 18-36 h in development. In intermediate, 18-h parasites PTS-GFP resides in the PV. Quantitative exit of PTS-GFP from the PV and its conversion to GFP is seen at 36 h. The data suggest that: (i) import into the apicoplast is stage regulated and (ii) the PTS can signal endomembrane targeting from the PV to the apicoplast.	Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Dept Immunol Microbiol, Chicago, IL 60611 USA; Case Western Reserve Univ, Inst Pathol, Cleveland, OH 44106 USA	Northwestern University; Northwestern University; Case Western Reserve University	Haldar, K (corresponding author), Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA.		Haldar, Kasturi/C-6685-2014		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI026670, R01AI026670] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL69630] Funding Source: Medline; NIAID NIH HHS [AI26670] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINSON CT, 1990, BLOOD CELLS, V16, P351; Bannister LH, 2000, PARASITOL TODAY, V16, P427, DOI 10.1016/S0169-4758(00)01755-5; Bruce BD, 2000, TRENDS CELL BIOL, V10, P440, DOI 10.1016/S0962-8924(00)01833-X; CRARY JL, 1992, MOL BIOCHEM PARASIT, V53, P185, DOI 10.1016/0166-6851(92)90020-K; DeRocher A, 2000, J CELL SCI, V113, P3969; Fichera ME, 1997, NATURE, V390, P407, DOI 10.1038/37132; GIBBS SP, 1981, INT REV CYTOL, V72, P49, DOI DOI 10.1016/S0074-7696(08)61194-8; HALDAR K, 1985, J BIOL CHEM, V260, P4969; Haldar K, 2001, CURR OPIN HEMATOL, V8, P92, DOI 10.1097/00062752-200103000-00006; He CY, 2001, J BIOL CHEM, V276, P28436, DOI 10.1074/jbc.M102000200; He CY, 2001, EMBO J, V20, P330, DOI 10.1093/emboj/20.3.330; Hiraoka Y, 1991, Semin Cell Biol, V2, P153; Hopkins J, 1999, PROTIST, V150, P283, DOI 10.1016/S1434-4610(99)70030-1; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; Kadekoppala M, 2000, INFECT IMMUN, V68, P2328, DOI 10.1128/IAI.68.4.2328-2332.2000; Kadekoppala M, 2001, MOL BIOCHEM PARASIT, V112, P211, DOI 10.1016/S0166-6851(00)00368-6; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; LAUER SA, 1995, P NATL ACAD SCI USA, V92, P9181, DOI 10.1073/pnas.92.20.9181; Lauer SA, 2001, MOL BIOCHEM PARASIT, V115, P275, DOI 10.1016/S0166-6851(01)00281-X; Marechal E, 2001, TRENDS PLANT SCI, V6, P200, DOI 10.1016/S1360-1385(01)01921-5; McConkey GA, 1997, J BIOL CHEM, V272, P2046, DOI 10.1074/jbc.272.4.2046; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; OSAFUNE T, 1991, EXP CELL RES, V193, P320, DOI 10.1016/0014-4827(91)90103-2; Palmer JD, 1996, P NATL ACAD SCI USA, V93, P7432, DOI 10.1073/pnas.93.15.7432; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; Samuel BU, 2001, J BIOL CHEM, V276, P29319, DOI 10.1074/jbc.M101268200; Schwartzbach SD, 1998, PLANT MOL BIOL, V38, P247, DOI 10.1023/A:1006029919283; Striepen B, 2000, J CELL BIOL, V151, P1423, DOI 10.1083/jcb.151.7.1423; Sulli C, 1996, PLANT CELL, V8, P43; SULLI C, 1995, J BIOL CHEM, V270, P13084, DOI 10.1074/jbc.270.22.13084; Sullivan M, 2000, MOL BIOCHEM PARASIT, V109, P17, DOI 10.1016/S0166-6851(00)00226-7; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; VANDERJAGT DL, 1982, J PARASITOL, V68, P1068, DOI 10.2307/3281093; VanWye J, 1996, MOL BIOCHEM PARASIT, V83, P107, DOI 10.1016/S0166-6851(96)02759-4; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1997, MICROBIOL MOL BIOL R, V61, P1; Wiser MF, 1997, P NATL ACAD SCI USA, V94, P9108, DOI 10.1073/pnas.94.17.9108	41	34	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16265	16277		10.1074/jbc.M109331200	http://dx.doi.org/10.1074/jbc.M109331200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11815606	hybrid			2022-12-25	WOS:000175510400137
J	Ackerman, SJ; Liu, L; Kwatia, MA; Savage, MP; Leonidas, DD; Swaminathan, GJ; Acharya, KR				Ackerman, SJ; Liu, L; Kwatia, MA; Savage, MP; Leonidas, DD; Swaminathan, GJ; Acharya, KR			Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EOSINOPHIL LYSOPHOSPHOLIPASE; MAJOR BASIC-PROTEIN; CARBOXYL ESTER LIPASE; MYELOID CELL-LINE; F-MET PEPTIDE; HUMAN BASOPHILS; ULTRASTRUCTURAL-LOCALIZATION; MAMMALIAN LYSOPHOSPHOLIPASES; ANIMAL LECTINS; CDNA CLONING	Charcot-Leyden crystal (CLC) protein, initially reported to possess weak lysophospholipase activity, is still considered to be the eosinophil's lysophospholipase, but it shows no sequence similarities to any known lysophospholipases. In contrast, CLC protein has moderate sequence similarity, conserved genomic organization, and near structural identity to members of the galectin superfamily, and it has been designated galectin-10. To definitively determine whether or not CLC protein is a lysophospholipase, we reassessed its enzymatic activity in peripheral blood eosinophils and an eosinophil myelocyte cell line (AML14.3D10). Antibody affinity chromatography was used to fully deplete CLC protein from eosinophil lysates. The CLC-depleted lysates retained their full lysophospholipase activity, and this activity could be blocked by sulfhydryl group-reactive inhibitors, N-ethylmaleimide and p-chloromereuribenzenesulfonate, previously reported to inhibit the eosinophil enzyme. In contrast, the affinity-purified CLC protein lacked significant lysophospholipase activity. X-ray crystallographic structures of CLC protein in complex with the inhibitors showed that p-chloromercuribenzenesulfonate bound CLC protein via disulfide bonds with Cys(29) and with Cys(57) near the carbohydrate recognition domain (CRD), whereas N-ethylmaleimide bound to the galectin-10 CRD via ring stacking interactions with Trp(72), in a manner highly analogous to mannose binding to this CRD. Antibodies to rat pancreatic lysophospholipase identified a protein in eosinophil and AML14.3D10 cell lysates, comparable in size with human pancreatic lysophospholipase, which co-purifies in small quantities with CLC protein. Ligand blotting of human and murine eosinophil lysates with CLC protein as probe showed that it binds proteins also recognized by antibodies to pancreatic lysophospholipase. Our results definitively show that CLC protein is not one of the eosinophil's lysophospholipases but that it does interact with eosinophil lysophospholipases and known inhibitors of this lipolytic activity.	Univ Illinois, Coll Med W A312, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Bath	Ackerman, SJ (corresponding author), Univ Illinois, Coll Med W A312, Dept Biochem & Mol Biol, MC536,1819 W Polk St, Chicago, IL 60612 USA.	sackerma@uic.edu	Leonidas, Demetres/AAE-9296-2021; Leonidas, Demetres/F-7228-2013	Leonidas, Demetres/0000-0002-3874-2523; Leonidas, Demetres/0000-0002-3874-2523; Acharya, K. Ravi/0000-0002-3009-4058	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR013987] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025230] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR13987] Funding Source: Medline; NIAID NIH HHS [R01-AI25230] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ackerman SJ, 2000, RESP MED, V94, P1135, DOI 10.1053/rmed.2000.0913; ACKERMAN SJ, 1980, J IMMUNOL, V125, P2118; ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; ACKERMAN SJ, 1982, J EXP MED, V155, P1597, DOI 10.1084/jem.155.6.1597; ACKERMAN SJ, 1981, J IMMUNOL, V127, P1093; Ackerman Steven J., 1993, P33; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Baumann MA, 1998, STEM CELLS, V16, P16, DOI 10.1002/stem.160016; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Charot J.M., 1853, CR SOC BIOL, V5, P44; Chen SCA, 2000, BIOCHEM J, V347, P431, DOI 10.1042/0264-6021:3470431; Dvorak AM, 1997, INT ARCH ALLERGY IMM, V113, P465, DOI 10.1159/000237624; DVORAK AM, 1989, LAB INVEST, V60, P557; Dvorak AM, 1997, CLIN EXP ALLERGY, V27, P452; DVORAK AM, 1988, BLOOD, V72, P150; Dyer KD, 1997, GENOMICS, V40, P217, DOI 10.1006/geno.1996.4590; Dyer KD, 1996, LIFE SCI, V58, P2073, DOI 10.1016/0024-3205(96)00201-9; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GARSETTI DE, 1993, J LIPID MEDIATOR, V6, P223; GOLIGHTLY LM, 1992, J LEUKOCYTE BIOL, V51, P386, DOI 10.1002/jlb.51.4.386; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HOLTSBERG FW, 1995, BIOCHEM J, V309, P141, DOI 10.1042/bj3090141; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KASARI C, 1996, DOWN SYNDROME Q, V1, P1; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee NA, 1997, J IMMUNOL, V158, P1332; Leffler H, 1997, TRENDS GLYCOSCI GLYC, V9, P9, DOI 10.4052/tigg.9.9; Leonidas DD, 1998, BIOCHEMISTRY-US, V37, P13930, DOI 10.1021/bi981056x; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LIDBERG U, 1992, GENOMICS, V13, P630, DOI 10.1016/0888-7543(92)90134-E; Longhi S, 1996, PROTEINS, V26, P442, DOI [10.1002/(SICI)1097-0134(199612)26:4<442::AID-PROT5>3.3.CO;2-H, 10.1002/(SICI)1097-0134(199612)26:4&lt;442::AID-PROT5&gt;3.0.CO;2-D]; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Nakajima T, 2001, BLOOD, V98, P1127, DOI 10.1182/blood.V98.4.1127; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAUL CC, 1994, J LEUKOCYTE BIOL, V56, P74, DOI 10.1002/jlb.56.1.74; Paul CC, 1997, AM J HEMATOL, V56, P79, DOI 10.1002/(SICI)1096-8652(199710)56:2<79::AID-AJH2>3.0.CO;2-Y; PAUL CC, 1995, BLOOD, V86, P3737, DOI 10.1182/blood.V86.10.3737.bloodjournal86103737; PAUL CC, 1993, BLOOD, V81, P1193; Plager DA, 1999, J BIOL CHEM, V274, P14464, DOI 10.1074/jbc.274.20.14464; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REUE K, 1991, J LIPID RES, V32, P267; ROLINK H, 2000, THESIS U MARBURG MAR; Savage MP, 1997, GLYCOBIOLOGY, V7, P106; SHE HS, 1994, BIOCHEM J, V298, P23, DOI 10.1042/bj2980023; Swaminathan GJ, 1999, BIOCHEMISTRY-US, V38, P13837, DOI 10.1021/bi990756e; Wang AJ, 1999, BBA-MOL CELL BIOL L, V1437, P157, DOI 10.1016/S1388-1981(99)00012-8; Wang AJ, 1999, BBA-MOL CELL BIOL L, V1439, P1, DOI 10.1016/S1388-1981(99)00063-3; Wang AJ, 1997, J BIOL CHEM, V272, P22030, DOI 10.1074/jbc.272.35.22030; Wang AJ, 1997, J BIOL CHEM, V272, P12723, DOI 10.1074/jbc.272.19.12723; WELLER PF, 1982, J IMMUNOL, V128, P1346; WELLER PF, 1984, J BIOL CHEM, V259, P5100; WELLER PF, 1988, METHOD ENZYMOL, V163, P31; WELLER PF, 1980, P NATL ACAD SCI-BIOL, V77, P7440, DOI 10.1073/pnas.77.12.7440; WELLER PF, 1981, T ASSOC AM PHYSICIAN, V94, P165; WELLER PF, 1980, EOSINOPHIL HLTH DISE, P115; ZHOU Z, 1992, J LEUKOCYTE BIOL, V52, P588, DOI 10.1002/jlb.52.6.588; Zimmermann N, 2000, J IMMUNOL, V164, P1055, DOI 10.4049/jimmunol.164.2.1055	61	86	96	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14859	14868		10.1074/jbc.M200221200	http://dx.doi.org/10.1074/jbc.M200221200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11834744	hybrid			2022-12-25	WOS:000175203000066
J	Robinson, FL; Whitehurst, AW; Raman, M; Cobb, MH				Robinson, FL; Whitehurst, AW; Raman, M; Cobb, MH			Identification of novel point mutations in ERK2 that selectively disrupt binding to MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE KINASE; NERVE GROWTH-FACTOR; MAP KINASE; CRYSTAL-STRUCTURE; DOCKING SITE; C-JUN; ACTIVATION; PHOSPHORYLATION; CELLS; SEQUENCE	Extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) are essential components of pathways through which signals received at membrane receptors are converted into specific changes in protein function and gene expression. As with other members of the mitogen-activated protein (MAP) kinase family, ERK1 and ERK2 are activated by phosphorylations catalyzed by dual-specificity protein kinases known as MAP/ERK kinases (MEKs). MEKs exhibit stringent specificity for individual MA-P kinases. Indeed, MEK1 and MEK2 are the only known activators of ERK1 and ERK2. ERK2-MEK1/2 complexes can be detected in vitro and in vivo. The biochemical nature of such complexes and their role in MAP kinase signaling are under investigation. This report describes the use of a yeast two-hybrid screen to identify point mutations in ERK2 that impair its interaction with MEK1/2, yet do not alter its interactions with other proteins. ERK2 residues identified in this screen are on the surface of the C-terminal domain of the kinase, either within or immediately preceding a-helix G, or within the MAP kinase insert. Some mutations identified in this manner impaired the two-hybrid interaction of ERK2 with both MEK1 and MEK2, whereas others had a predominant effect on the interaction with either MEK1 or MEK2. Mutant ERK2 proteins displayed reduced activation in REK293 cells following epidermal growth factor treatment, consistent with their impaired interaction with MEK1/2. However, ERK2 proteins containing MEK-specific mutations retained kinase activity, and were similar to wild type ERK2 in their activation following overexpression of constitutively active MEK1. Unlike wild type ERK2, proteins containing MEK-specific point mutations were constitutively localized in the nucleus, even in the presence of overexpressed MEK1. These data suggest an essential role for the MAP kinase insert and residues within or just preceding a-helix G in the interaction of ERK2 with MEK1/2.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	mcobb@mednet.swmed.edu		raman, malavika/0000-0002-4773-8673; Cobb, Melanie/0000-0003-0833-5473	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034128, R37DK034128] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34128] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; AHN NG, 1992, J NEUROCHEM, V59, P147, DOI 10.1111/j.1471-4159.1992.tb08885.x; Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRILL JA, 1994, MOL BIOL CELL, V5, P297, DOI 10.1091/mbc.5.3.297; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAI TN, 1995, ONCOGENE, V10, P849; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; Eblen ST, 2001, MOL CELL BIOL, V21, P249, DOI 10.1128/MCB.21.1.249-259.2001; English JM, 1998, J BIOL CHEM, V273, P3854, DOI 10.1074/jbc.273.7.3854; Enslen H, 2000, EMBO J, V19, P1301, DOI 10.1093/emboj/19.6.1301; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; GOTOH Y, 1990, EUR J BIOCHEM, V193, P671, DOI 10.1111/j.1432-1033.1990.tb19385.x; Harlow E., 1988, ANTIBODIES LAB MANUA; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Holland PM, 1999, CURR BIOL, V9, pR329, DOI 10.1016/S0960-9822(99)80205-X; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Kaur KJ, 2001, METHOD ENZYMOL, V332, P270; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; Pawson T, 2000, GENE DEV, V14, P1027; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; ROBBINS DJ, 1992, MOL BIOL CELL, V3, P299, DOI 10.1091/mbc.3.3.299; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, J BIOL CHEM, V271, P29734, DOI 10.1074/jbc.271.47.29734; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SEGER R, 1992, J BIOL CHEM, V267, P14373; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Wolf I, 2001, J BIOL CHEM, V276, P24490, DOI 10.1074/jbc.M103352200; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; XU SC, 1995, P NATL ACAD SCI USA, V92, P6808, DOI 10.1073/pnas.92.15.6808; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	54	72	73	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14844	14852		10.1074/jbc.M107776200	http://dx.doi.org/10.1074/jbc.M107776200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11823456	hybrid			2022-12-25	WOS:000175203000064
J	Suzuki, T; Nakamoto, T; Ogawa, S; Seo, S; Matsumura, T; Tachibana, K; Morimoto, C; Hirai, H				Suzuki, T; Nakamoto, T; Ogawa, S; Seo, S; Matsumura, T; Tachibana, K; Morimoto, C; Hirai, H			MICAL, a novel CasL interacting molecule, associates with vimentin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; SRC HOMOLOGY-3 DOMAINS; EXCHANGE FACTOR C3G; INTERMEDIATE FILAMENTS; TYROSINE PHOSPHORYLATION; LACKING VIMENTIN; DOCKING PROTEIN; DIRECT BINDING; SIGNALING PATHWAY; ANTIGEN RECEPTOR	CasL/HEF1 belongs to the p130(Cas) family. It is tyrosine-phosphorylated following beta(1) integrin and/or T cell receptor stimulation and is thus considered to be important for immunological reactions. CasL has several structural motifs such as an SH3 domain and a substrate domain and interacts with many molecules through these motifs. To obtain more insights on the CasL-mediated signal transduction, we sought proteins that interact with the CasL SH3 domain by far Western screening, and we identified a novel human molecule, MICAL (a Molecule Interacting with CasL). MICAL is a protein of 118 kDa and is expressed in the thymus, lung, spleen, kidney, testis, and hematopoietic cells. MICAL has a calponin homology domain, a LIM domain, a putative leucine zipper motif, and a proline-rich PPKPP sequence. MICAL associates with CasL through this PPKPP sequence. MICAL is a cytoplasmic protein and colocalizes with CasL at the perinuclear area. Through the COOH-terminal region, MICAL also associates with vimentin that is a major component of intermediate filaments. Immunostaining revealed that MICAL localizes along with vimentin intermediate filaments. These results suggest that MICAL may be a cytoskeletal regulator that connects CasL to intermediate filaments.	Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, Tokyo 1138655, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Lab Gene Funct Anal, Tsukuba, Ibaraki 3058568, Japan; Univ Tokyo, Inst Med Sci, Dept Clin Immunol, Minato Ku, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, AIDS Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo; University of Tokyo	Hirai, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	hhirai-tky@umin.ac.jp						Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Colucci-Guyon E, 1999, GLIA, V25, P33, DOI 10.1002/(SICI)1098-1136(19990101)25:1<33::AID-GLIA4>3.0.CO;2-J; Correia I, 1999, J CELL BIOL, V146, P831, DOI 10.1083/jcb.146.4.831; Eckes B, 2000, J CELL SCI, V113, P2455; EN R, 1993, SCIENCE, V259, P1157; FOISNER R, 1991, P NATL ACAD SCI USA, V88, P3812, DOI 10.1073/pnas.88.9.3812; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Galou M, 1997, BIOL CELL, V89, P85, DOI 10.1016/S0248-4900(99)80068-9; Garton AJ, 1997, ONCOGENE, V15, P877, DOI 10.1038/sj.onc.1201279; Gimona M, 1998, J CELL SCI, V111, P1813; Henrion D, 1997, J CLIN INVEST, V100, P2909, DOI 10.1172/JCI119840; HIROKAWA N, 1988, J NEUROSCI, V8, P2769; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ishino M, 1995, ONCOGENE, V11, P2331; Kamiguchi K, 1999, J IMMUNOL, V163, P563; Kanda H, 1997, EUR J IMMUNOL, V27, P2113, DOI 10.1002/eji.1830270840; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Law SF, 1996, MOL CELL BIOL, V16, P3327; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Mabuchi K, 1997, J BIOL CHEM, V272, P22662, DOI 10.1074/jbc.272.36.22662; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Nagase T, 1998, DNA Res, V5, P277, DOI 10.1093/dnares/5.5.277; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; Nakamoto T, 1997, MOL CELL BIOL, V17, P3884, DOI 10.1128/MCB.17.7.3884; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; NOJIMA Y, 1992, J EXP MED, V175, P1045, DOI 10.1084/jem.175.4.1045; Ohashi Y, 1999, J IMMUNOL, V163, P3727; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rezniczek GA, 1998, J CELL BIOL, V141, P209, DOI 10.1083/jcb.141.1.209; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sattler M, 1997, J BIOL CHEM, V272, P14320, DOI 10.1074/jbc.272.22.14320; Sin WC, 1998, MOL CELL BIOL, V18, P6325, DOI 10.1128/MCB.18.11.6325; Smit L, 1996, J BIOL CHEM, V271, P8564, DOI 10.1074/jbc.271.15.8564; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Terzi F, 1997, J CLIN INVEST, V100, P1520, DOI 10.1172/JCI119675; UENO H, 1995, J BIOL CHEM, V270, P20135, DOI 10.1074/jbc.270.34.20135; Wu AL, 1999, MOL CELL, V4, P619, DOI 10.1016/S1097-2765(00)80212-9; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	53	103	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14933	14941		10.1074/jbc.M111842200	http://dx.doi.org/10.1074/jbc.M111842200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11827972	hybrid			2022-12-25	WOS:000175203000075
J	Anwar, A; Siegel, D; Kepa, JK; Ross, D				Anwar, A; Siegel, D; Kepa, JK; Ross, D			Interaction of the molecular chaperone Hsp70 with human NAD(P)H : quinone oxidoreductase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DT-DIAPHORASE; HUMAN LUNG; POLYMORPHISM; NAD(P)H; REDUCTASE; NQO1; CONFORMATIONS; PREVALENCE; TOXICITY; PROTEINS	NAD(P)H:quinone oxidoreduetase 1 (EC 1.6.99.2; DT-Diaphorase, NQO1) is predominantly a cytosolic flavoenzyme that catalyzes a two-electron reduction. Using human tumor cell lines devoid of NQO1 enzymatic activity, we have previously identified a single nucleotide polymorphism (NQO1*2 allele) in the human NQO1 gene. This mutation has been characterized as a genetic polymorphism (NQO1*2), which leads to greatly diminished levels of protein due to rapid degradation of the NQO1*2 protein by the ubiquitin proteasomal pathway (UPP). In an attempt to decipher the mechanism responsible for the differential stability of wild-type NQO1*1 and mutant NQO1*2 proteins, we have investigated the interactions of these proteins with molecular chaperones of the Hsp family. Using co-immunoprecipitation studies (co-IPs), no association was observed between Hsp90 and either wildtype NQO1*1 or mutant NQO1*2 proteins. Hsp70, however, was found to associate with NQO1*1 dprotein in cells when co-IPs were performed with an anti-NQO1 antibody followed by immunoblotting with an anti-Hsp70 antibody or vice versa. Hsp40 could also be detected in the immunoprecipitated protein complex. Experiments were also performed using either the NQO1*1 or NQO1*2 coding regions in an in vitro transcription/translation system employing rabbit reticulocyte lysates (RRLs). Consistent with the cellular data, co-IP experiments in RRLs demonstrated an association of Hsp70 with wild-type NQO1*1 protein but not with NQO1*2 protein. To further elucidate the role of the association of Hsp70 with the NQO1*1 protein, site-directed mutagenesis was used to modify a proposed Hsp70 binding site near the N terminus of the NQO1 protein. We generated a plasmid containing an NQO1*1 coding region with a mutated Hsp70 binding site (isoleucine to aspartic acid at position 8, NQO1*1/I8D). In contrast to the NQO1*1 protein translated in RRLs, the NQO1*1/I8D protein did not associate with Hsp70, as demonstrated by co-IP, was catalytically inactive, and was degraded by the UPP. These data suggest that the association of Hsp70 with NQO1*1 may play an important role in the stability and functionality of the NQO1 protein.	Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Ross, D (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmaceut Sci, Sch Pharm, 4200 E 9th Ave,Box C-238, Denver, CO 80262 USA.			Ross, David/0000-0002-8307-5942	NATIONAL CANCER INSTITUTE [R01CA051210] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASBER G, 2001, P NATL ACAD SCI USA, V98, P1188; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Bercovich B, 1997, J BIOL CHEM, V272, P9002; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; CUI KY, 1995, P NATL ACAD SCI USA, V92, P1043, DOI 10.1073/pnas.92.4.1043; Faig M, 2000, P NATL ACAD SCI USA, V97, P3177, DOI 10.1073/pnas.050585797; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Fung KL, 1996, J BIOL CHEM, V271, P21559, DOI 10.1074/jbc.271.35.21559; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Kelsey KT, 1997, BRIT J CANCER, V76, P852, DOI 10.1038/bjc.1997.474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Larson RA, 1999, BLOOD, V94, P803, DOI 10.1182/blood.V94.2.803.414k44_803_807; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Marin A, 1997, BRIT J CANCER, V76, P923, DOI 10.1038/bjc.1997.485; Moran JL, 1999, P NATL ACAD SCI USA, V96, P8150, DOI 10.1073/pnas.96.14.8150; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SCHLAGER JJ, 1990, INT J CANCER, V45, P403, DOI 10.1002/ijc.2910450304; SHARKIS DH, 1989, BIOCHEM BIOPH RES CO, V161, P434, DOI 10.1016/0006-291X(89)92617-X; SIEGEL D, 1992, BIOCHEMISTRY-US, V31, P7879, DOI 10.1021/bi00149a019; Siegel D, 1998, CLIN CANCER RES, V4, P2065; Siegel D, 1999, PHARMACOGENETICS, V9, P113, DOI 10.1097/00008571-199902000-00015; Siegel D, 2001, MOL PHARMACOL, V59, P263, DOI 10.1124/mol.59.2.263; Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5; Smith MT, 2001, BLOOD, V97, P1422, DOI 10.1182/blood.V97.5.1422; Traver RD, 1997, BRIT J CANCER, V75, P69, DOI 10.1038/bjc.1997.11; Wiemels JL, 1999, CANCER RES, V59, P4095; Winski SL, 1998, CLIN CANCER RES, V4, P3083; Wu KB, 1998, PATHOPHYSIOLOGY OF LIPID PEROXIDES AND RELATED FREE RADICALS, P135	34	49	52	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14060	14067		10.1074/jbc.M111576200	http://dx.doi.org/10.1074/jbc.M111576200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821413	hybrid			2022-12-25	WOS:000175096000093
J	Bolognesi, A; Polito, L; Lubelli, C; Barbieri, L; Parente, A; Stirpe, F				Bolognesi, A; Polito, L; Lubelli, C; Barbieri, L; Parente, A; Stirpe, F			Ribosome-inactivating and adenine polynucleotide glycosylase activities in Mirabilis jalapa L. tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE GLYCOSIDASE ACTIVITY; RNA N-GLYCOSIDASES; ANTIVIRAL PROTEIN; ESCHERICHIA-COLI; IMMUNOTOXINS; DNA; PURIFICATION; EXPRESSION; APOPTOSIS; INDUCTION	Several tissues of Mirabilis jalapa L. (Nyctaginaceae) were assayed for inhibition of translation by a rabbit reticulocyte lysate (as a signal of ribosome-inactivating activity) and for adenine DNA glycosylase activity, activities that are both due to the presence of a class of enzymes called ribosome-inactivating proteins (RIPs), currently classified as rRNA N-glycosylases (EC 3.2.2.22). These activities were highest in seed; intermediate in flower bud, immature seed, sepal + gynoecium, leaf, and root; and very low in all other tissues. By cation-exchange chromatography, four protein peaks with inhibitory activity on cell-free translation were identified in extracts from seeds, and two proteins were isolated from. peaks 1 and 4, all of which have the properties of single-chain type 1 RIP. One is Mirabilis antiviral protein (MAP), so far purified only from roots. The second is a new protein that we propose to call MAP-4. The distribution of MAP and MAP-4 in several tissues was determined with a novel experimental approach based on liquid chromatography/mass spectrometry. The direct enzymatic activity of ALAP on several substrates is described here for the first time. ALAP depurinated not only rRNA in intact ribosomes, thus inhibiting protein synthesis, but also other polynucleotides such as poly(A), DNA, and tobacco mosaic virus RNA. Autologous DNA was depurinated more extensively than other polynucleotides. Therefore, the enzymatic activity of this protein may be better described as adenine polynucleotide glycosylase activity rather than rRNA N-glycosylase activity. Finally, MAP does not cross-react immunologically with other commonly utilized RIP's.	Univ Bologna, Dipartimento Patol Sperimentale, I-40126 Bologna, Italy; Seconda Univ Napoli, Dipartimento Sci Vita, I-81100 Caserta, Italy	University of Bologna; Universita della Campania Vanvitelli	Bolognesi, A (corresponding author), Univ Bologna, Dipartimento Patol Sperimentale, Via Giacomo 14, I-40126 Bologna, Italy.		Bolognesi, Andrea/Q-6526-2017; Polito, Letizia/H-2877-2019	Polito, Letizia/0000-0001-8051-4981; Bolognesi, Andrea/0000-0001-7497-4586				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BARBIERI L, 1987, J CHROMATOGR, V408, P235, DOI 10.1016/S0021-9673(01)81806-9; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; Barbieri L, 2001, METH MOL B, V166, P71; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; Bergamaschi G, 1996, BRIT J HAEMATOL, V93, P789, DOI 10.1046/j.1365-2141.1996.d01-1730.x; Bolognesi A, 1997, PLANTA, V203, P422, DOI 10.1007/s004250050209; Bolognesi A, 1996, INT J CANCER, V68, P349, DOI 10.1002/(SICI)1097-0215(19961104)68:3<349::AID-IJC13>3.0.CO;2-3; BOLOGNESI A, 1995, EUR J BIOCHEM, V228, P935, DOI 10.1111/j.1432-1033.1995.tb20343.x; Carnicelli D, 1997, J EXP BOT, V48, P1519, DOI 10.1093/jexbot/48.313.1519; Di Cola A, 1999, J EXP BOT, V50, P573, DOI 10.1093/jexbot/50.334.573; Di Maro A, 2001, J MASS SPECTROM, V36, P38; Endo Y, 1988, IMMUNOTOXINS, P75; FERRERAS JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P31, DOI 10.1016/0167-4781(93)90034-B; Girbes T, 1996, NATURE, V379, P777, DOI 10.1038/379777b0; HABUKA N, 1989, J BIOL CHEM, V264, P6629; HARLEY SM, 1984, PLANT SCI LETT, V36, P1, DOI 10.1016/0304-4211(84)90268-2; IKEDA T, 1987, PLANT CELL REP, V6, P216, DOI 10.1007/BF00268483; IRVIN JD, 1994, ANTIVIRAL PROTEINS H, P65; KATAOKA J, 1991, J BIOL CHEM, V266, P8426; Kreitman RJ, 1998, ADV DRUG DELIVER REV, V31, P53, DOI 10.1016/S0169-409X(97)00094-X; KUBO S, 1990, Annals of the Phytopathological Society of Japan, V56, P481, DOI 10.3186/jjphytopath.56.481; MCCANN WP, 1985, ANTIMICROB AGENTS CH, V28, P265, DOI 10.1128/AAC.28.2.265; MCCANN WP, 1983, ANAL CHEM, V55, P1455; Nielsen K, 2001, ANNU REV PLANT PHYS, V52, P785, DOI 10.1146/annurev.arplant.52.1.785; PARENTE A, 1993, BIOCHIM BIOPHYS ACTA, V1216, P43, DOI 10.1016/0167-4781(93)90035-C; Peumans WJ, 2001, FASEB J, V15, P1493, DOI 10.1096/fj.00-0751rev; Pincus SH, 1996, ANTIVIR RES, V33, P1, DOI 10.1016/S0166-3542(96)00995-3; REINBOTHE S, 1994, P NATL ACAD SCI USA, V91, P7012, DOI 10.1073/pnas.91.15.7012; Song SK, 2000, PLANT MOL BIOL, V43, P439, DOI 10.1023/A:1006444322626; Stirpe F, 1996, FEBS LETT, V382, P309, DOI 10.1016/0014-5793(96)00188-3; TAKANAMI Y, 1990, Annals of the Phytopathological Society of Japan, V56, P488, DOI 10.3186/jjphytopath.56.488; Vivanco JM, 1999, PLANT PHYSIOL, V119, P1447, DOI 10.1104/pp.119.4.1447; WONG RNS, 1992, BIOCHEM INT, V28, P585; ZAMBONI M, 1989, BIOCHEM J, V259, P639, DOI 10.1042/bj2590639	36	53	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13709	13716		10.1074/jbc.M111514200	http://dx.doi.org/10.1074/jbc.M111514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825901	hybrid			2022-12-25	WOS:000175096000049
J	Higashino, K; Yokota, Y; Ono, T; Kamitani, S; Arita, H; Hanasaki, K				Higashino, K; Yokota, Y; Ono, T; Kamitani, S; Arita, H; Hanasaki, K			Identification of a soluble form phospholipase A(2) receptor as a circulating endogenous inhibitor for secretory phosphoipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC-TYPE PHOSPHOLIPASE-A2; SURFACTANT PROTEIN-A; SMOOTH-MUSCLE CELLS; ACUTE LUNG INJURY; ARACHIDONIC-ACID; GROUP-IIA; TRIMERESURUS-FLAVOVIRIDIS; TISSUE DISTRIBUTION; MOLECULAR-CLONING; ENDOTOXIC-SHOCK	Venomous snakes have various types of phospholipase A(2) inhibitory proteins (PLIs) in their circulatory system to protect them from attack by their own phospholipase A(2)s (PLA(2)s). Here we show the first evidence for the existence of circulating PLI against secretory PLA(2)s (sPLA(2)s) in mammals. In mouse serum, we detected specific binding activities of group IB and X sPLA(2)s, which was in contrast with the absence of binding activities in serum prepared from mice deficient in PLA(2) receptor (PLA(2)R), a type I transmembrane glycoprotein related to the C-type animal lectin family. Western blot analysis after partial purification with group IB sPLA(2) affinity column confirmed the identity of serum sPLA(2)-binding protein as a soluble form of PLA(2)R (sPLA(2)R) that retained all of the extracellular domains of the membrane-bound receptor. Both purified sPLA(2)R and the recombinant soluble receptor having all of the extracellular portions blocked the biological functions of group X sPLA(2), including its potent enzymatic activity and its binding to the membrane-bound receptor. Protease inhibitor tests with PLA(2)R-overexpressing Chinese hamster ovary cells suggested that sPLA(2)R is produced by cleavage of the membrane-bound receptor by metalloproteinases. Thus, sPLA(2)R is the first example of circulating PLI that acts as an endogenous inhibitor for enzymatic activities and receptor-mediated functions of sPLA(2)s in mice.	Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, Osaka 5530002, Japan	Shionogi & Company Limited	Hanasaki, K (corresponding author), Shionogi & Co Ltd, Shionogi Res Labs, Fukushima Ku, 12-4 Sagisu,5 Chome, Osaka 5530002, Japan.			Kamitani, Shigeki/0000-0002-1268-4652				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Arbibe L, 1998, J CLIN INVEST, V102, P1152, DOI 10.1172/JCI3236; ARITA H, 1989, PROG LIPID RES, V28, P273, DOI 10.1016/0163-7827(89)90002-7; ARITA H, 1991, J BIOL CHEM, V266, P19139; Barlaam B, 1999, J MED CHEM, V42, P4890, DOI 10.1021/jm990377j; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375, DOI 10.1074/jbc.271.27.16375; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISHER AB, 1994, BBA-LIPID LIPID MET, V1211, P256, DOI 10.1016/0005-2760(94)90148-1; FUNK JL, 1995, ENDOCRINOLOGY, V136, P3412, DOI 10.1210/en.136.8.3412; Furue S, 1999, AM J RESP CRIT CARE, V160, P1292, DOI 10.1164/ajrccm.160.4.9812042; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; HANASAKI K, 1992, J BIOL CHEM, V267, P6414; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; HANASAKI K, 1992, BIOCHIM BIOPHYS ACTA, V1127, P233, DOI 10.1016/0005-2760(92)90226-L; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HIGASHINO K, 1994, EUR J BIOCHEM, V225, P375, DOI 10.1111/j.1432-1033.1994.00375.x; INOUE S, 1991, J BIOL CHEM, V266, P1001; ISHIZAKI J, 1994, J BIOL CHEM, V269, P5897; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Jolly-Tornetta C, 2000, BIOCHEMISTRY-US, V39, P15282, DOI 10.1021/bi001723y; KANEMASA T, 1992, BIOCHIM BIOPHYS ACTA, V1125, P210, DOI 10.1016/0005-2760(92)90047-Y; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; KISHINO J, 1995, J BIOCHEM-TOKYO, V117, P420, DOI 10.1093/jb/117.2.420; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; NAKAJIMA M, 1992, FEBS LETT, V309, P261, DOI 10.1016/0014-5793(92)80785-F; NICOLAS JP, 1995, J BIOL CHEM, V270, P28869, DOI 10.1074/jbc.270.48.28869; NISHIJIMA J, 1983, J BIOCHEM, V94, P137, DOI 10.1093/oxfordjournals.jbchem.a134322; OHARA O, 1995, PROG LIPID RES, V34, P117, DOI 10.1016/0163-7827(94)00009-B; Okumura K, 1999, BBA-MOL CELL BIOL L, V1441, P51, DOI 10.1016/S1388-1981(99)00141-9; Pagenstecher A, 2000, AM J PATHOL, V157, P197, DOI 10.1016/S0002-9440(10)64531-2; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; POMARES LM, 1998, J BIOL CHEM, V273, P23376; Rasmussen HS, 1997, PHARMACOL THERAPEUT, V75, P69, DOI 10.1016/S0163-7258(97)00023-5; Saiga A, 2001, BBA-MOL CELL BIOL L, V1530, P67, DOI 10.1016/S1388-1981(00)00167-0; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; TOJO H, 1993, J LIPID RES, V34, P837; VADAS P, 1992, LIFE SCI, V50, P807, DOI 10.1016/0024-3205(92)90186-S; VADAS P, 1986, LAB INVEST, V55, P391; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; Yokota Y, 2000, ARCH BIOCHEM BIOPHYS, V379, P7, DOI 10.1006/abbi.2000.1849; Yokota Y, 2000, FEBS LETT, V478, P187, DOI 10.1016/S0014-5793(00)01848-2	55	29	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13583	13588		10.1074/jbc.M108752200	http://dx.doi.org/10.1074/jbc.M108752200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830583	hybrid			2022-12-25	WOS:000175096000033
J	Kerkela, R; Pikkarainen, S; Majalahti-Palviainen, T; Tokola, H; Ruskoaho, H				Kerkela, R; Pikkarainen, S; Majalahti-Palviainen, T; Tokola, H; Ruskoaho, H			Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcription factor-mediated regulation of B-type natriuretic peptide gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; HEART TUBE FORMATION; SMOOTH-MUSCLE CELLS; HEAVY-CHAIN GENE; CARDIOMYOCYTE HYPERTROPHY; VENTRAL MORPHOGENESIS; CARDIAC-HYPERTROPHY; POTENTIAL ROLE; C-JUN; EXPRESSION	The expression of cardiac hormones, atrial natriuretic peptide and B-type natriuretic peptide, is induced by cardiac wall stretch and responds to various hypertrophic agonists such as endothelin-1. In cardiac myocytes, endothelin-1 induces GATA-4 binding to the B-type natriuretic peptide gene, but the signaling pathways involved in endothelin-1-induced GATA-4 activation are unknown. Mitogen-activated protein kinase pathways are stimulated in response to various extracellular stimuli, and they modulate the function of several transcription activators. Here we show that inhibition of p38 kinase with SB203580 inhibited endothelin-l-induced GATA.4 binding to B-type natriuretic peptide gene and serine phosphorylation of GATA-4. Inhibition of extracellular signal-regulated protein kinase with MEK1 inhibitor PD98059 reduced basal and p38-induced GATA-4 binding activity, but it had no significant effect on endothelin-1-induced GATA-4 binding activity. Overexpression of p38 kinase pathway, but not extracellular signal-regulated kinase or c-Jun N-terminal protein kinase, activated GATA-4 binding to B-type natriuretic peptide gene and induced rat B-type natriuretic peptide promoter activity via proximal GATA binding sites. In conclusion, these findings demonstrate that activation of p38 kinase is necessary for hypertrophic agonist-induced GATA-4 binding to B-type natriuretic peptide gene and sufficient for GATA-dependent B-type natriuretic peptide gene expression.	Oulu Univ, Dept Pharmacol & Toxicol, Oulu 90014, Finland; Oulu Univ, Dept Physiol, Bioctr Oulu, Oulu 90014, Finland	University of Oulu; University of Oulu	Ruskoaho, H (corresponding author), Oulu Univ, Dept Pharmacol & Toxicol, POB 5000, Oulu 90014, Finland.	heikki.ruskoaho@oulu.fi						ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BOGOYEVITCH MA, 1993, FEBS LETT, V317, P271, DOI 10.1016/0014-5793(93)81291-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bueno OF, 2001, CIRC RES, V88, P88, DOI 10.1161/01.RES.88.1.88; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Carter KB, 2000, J BIOL CHEM, V275, P27858; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; CHIEN KR, 1991, FASEB J, V5, P3037, DOI 10.1096/fasebj.5.15.1835945; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; CLERK A, 1994, J BIOL CHEM, V269, P32848; Clerk A, 1998, J CELL BIOL, V142, P523, DOI 10.1083/jcb.142.2.523; CROSSLEY M, 1994, J BIOL CHEM, V269, P16589; DUFF JL, 1993, J BIOL CHEM, V268, P26037; Durocher D, 1997, EMBO J, V16, P5687, DOI 10.1093/emboj/16.18.5687; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Haneda M, 1999, EUR J PHARMACOL, V365, P1, DOI 10.1016/S0014-2999(98)00857-7; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hautala N, 2001, CIRCULATION, V103, P730; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; KINNUNEN P, 1993, ENDOCRINOLOGY, V132, P1961, DOI 10.1210/en.132.5.1961; KRAMER BK, 1991, CIRC RES, V68, P269, DOI 10.1161/01.RES.68.1.269; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANG CC, 1992, CLIN SCI, V83, P519, DOI 10.1042/cs0830519; LANG RE, 1985, NATURE, V314, P264, DOI 10.1038/314264a0; Levin ER, 1998, NEW ENGL J MED, V339, P321; Liang FQ, 2000, HYPERTENSION, V35, P188, DOI 10.1161/01.HYP.35.1.188; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Lorell BH, 2000, CIRCULATION, V102, P470; Lu JR, 1999, MOL CELL BIOL, V19, P4495; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MINAMINO N, 1988, BIOCHEM BIOPH RES CO, V155, P740, DOI 10.1016/S0006-291X(88)80557-6; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Morin S, 2000, EMBO J, V19, P2046, DOI 10.1093/emboj/19.9.2046; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; NAKAO K, 1992, J HYPERTENS, V10, P907; Nemoto S, 1998, MOL CELL BIOL, V18, P3518, DOI 10.1128/MCB.18.6.3518; ORKIN SH, 1995, CURR OPIN CELL BIOL, V7, P870, DOI 10.1016/0955-0674(95)80072-7; RUSKOAHO H, 1992, PHARMACOL REV, V44, P479; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scimeca JC, 1997, ONCOGENE, V15, P717, DOI 10.1038/sj.onc.1201231; Sugden PH, 1997, CELL SIGNAL, V9, P337, DOI 10.1016/S0898-6568(96)00191-X; Sugden PH, 1999, CIRC RES, V84, P633, DOI 10.1161/01.RES.84.6.633; Svensson EC, 1999, P NATL ACAD SCI USA, V96, P956, DOI 10.1073/pnas.96.3.956; Swynghedauw B, 1999, PHYSIOL REV, V79, P215, DOI 10.1152/physrev.1999.79.1.215; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Thorburn J, 1997, EMBO J, V16, P1888, DOI 10.1093/emboj/16.8.1888; THUERAUF DJ, 1994, J BIOL CHEM, V269, P17772; Thuerauf DJ, 1998, J BIOL CHEM, V273, P20636, DOI 10.1074/jbc.273.32.20636; TOKOLA H, 1994, EUR J PHARM-MOLEC PH, V267, P195, DOI 10.1016/0922-4106(94)90171-6; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zechner D, 1997, J CELL BIOL, V139, P115, DOI 10.1083/jcb.139.1.115	69	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13752	13760		10.1074/jbc.M105736200	http://dx.doi.org/10.1074/jbc.M105736200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827958	hybrid			2022-12-25	WOS:000175096000055
J	Magnusson, U; Chaudhuri, BN; Ko, J; Park, C; Jones, TA; Mowbray, SL				Magnusson, U; Chaudhuri, BN; Ko, J; Park, C; Jones, TA; Mowbray, SL			Hinge-bending motion of D-allose-binding protein from Escherichia coli - Three open conformations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-STRUCTURE; TRANSPORT; RECEPTOR; GLUCOSE/GALACTOSE; MECHANISMS; PARAMETERS; DATABASES; PROGRAM; MODELS; PHASES	Conformational changes of periplasmic binding proteins are essential for their function in chemotaxis and transport. The allose-binding protein from Escherichia coli is, like other receptors in its family, composed of two alpha/beta domains joined by a three-stranded hinge. In the previously determined structure of the closed, ligand-bound form (Chaudhuri, B. N., Ko, J., Park, C., Jones, T. A., and Mowbray, S. L. (1999) J. Mol. Biol. 286, 1519-1531), the ligand-binding site is buried between the two domains. We report here the structures of three distinct open, ligand-free forms of this receptor, one solved at 3.1-Angstrom resolution and two others at 1.7-Angstrom resolution. Together, these allow a description of the conformational changes associated with ligand binding. A few large, coupled torsional changes in the hinge strands are sufficient to generate the overall bending motion, with only minor disruption of the individual domains. Integral water molecules appear to act as structural "ball bearings" in this process. The conformational changes of the related ribose-binding protein follow a distinct pattern. The observed differences between the two proteins can be interpreted in the context of changes in sequence and in crystal packing and provide new insights into the nature of hinge bending motion in this class of periplasmic binding proteins.	Swedish Univ Agr Sci, Dept Biol Mol, BMC, SE-75124 Uppsala, Sweden; Uppsala Univ, Dept Cell & Mol Biol, BMC, SE-75124 Uppsala, Sweden; Korea Adv Inst Sci & Technol, Dept Sci Biol, Natl Creat Res Initiat Ctr Behav Genet, Yusong Ku, Taejon 305701, South Korea	Swedish University of Agricultural Sciences; Uppsala University; Korea Advanced Institute of Science & Technology (KAIST)	Mowbray, SL (corresponding author), Swedish Univ Agr Sci, Dept Biol Mol, BMC, Box 590, SE-75124 Uppsala, Sweden.	mowbray@xray.bmc.uu.se	Park, Chankyu/C-1936-2011; Mowbray, Sherry L/D-2141-2013					AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; Bjorkman AJ, 1998, J MOL BIOL, V279, P651, DOI 10.1006/jmbi.1998.1785; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BOOS W, 1996, ESCHERICHIA COLI SAL, P1175; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; Chaudhuri BN, 1999, J MOL BIOL, V286, P1519, DOI 10.1006/jmbi.1999.2571; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Evenas J, 2001, J MOL BIOL, V309, P961, DOI 10.1006/jmbi.2001.4695; FABER HR, 1990, NATURE, V348, P263, DOI 10.1038/348263a0; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; GERSTEIN M, 1994, BIOCHEMISTRY-US, V33, P6739, DOI 10.1021/bi00188a001; GILLILAND GL, 1981, J MOL BIOL, V146, P341, DOI 10.1016/0022-2836(81)90392-2; Harris M, 2001, ACTA CRYSTALLOGR D, V57, P1201, DOI 10.1107/S0907444901007697; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kim CH, 1997, J BACTERIOL, V179, P7631, DOI 10.1128/jb.179.24.7631-7637.1997; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESK AM, 1984, J MOL BIOL, V174, P175, DOI 10.1016/0022-2836(84)90371-1; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; LUCK LA, 1991, BIOCHEMISTRY-US, V30, P4248, DOI 10.1021/bi00231a021; MCPHERSON AJ, 1982, PROPARATION ANAL PRO; Mowbray S L, 1990, Receptor, V1, P41; MOWBRAY SL, 1992, J MOL BIOL, V225, P155, DOI 10.1016/0022-2836(92)91033-L; Mowbray SL, 1999, ACTA CRYSTALLOGR D, V55, P1309, DOI 10.1107/S0907444999005211; Mowbray SL, 1999, J MOL BIOL, V294, P487, DOI 10.1006/jmbi.1999.3271; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NEWCOMER ME, 1981, J BIOL CHEM, V256, P3218; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; QUIOCHO FA, 1984, NATURE, V310, P381, DOI 10.1038/310381a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SCHUMACHER MA, 1995, CELL, V83, P147, DOI 10.1016/0092-8674(95)90243-0; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; Shilton BH, 1996, J MOL BIOL, V264, P350, DOI 10.1006/jmbi.1996.0645; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; VYAS NK, 1988, SCIENCE, V242, P1290, DOI 10.1126/science.3057628; VYAS NK, 1987, NATURE, V327, P635, DOI 10.1038/327635a0; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZOU JY, 1994, ACTA CRYSTALLOGR D, V50, P237, DOI 10.1107/S0907444993011321; ZOU JY, 1993, J MOL BIOL, V233, P739, DOI 10.1006/jmbi.1993.1549	53	59	59	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14077	14084		10.1074/jbc.M200514200	http://dx.doi.org/10.1074/jbc.M200514200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825912	hybrid			2022-12-25	WOS:000175096000095
J	Ryan, RM; Vandenberg, RJ				Ryan, RM; Vandenberg, RJ			Distinct conformational states mediate the transport and anion channel properties of the glutamate transporter EAAT-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTERS; SUBSTRATE-BINDING; REENTRANT LOOP; ION FLUXES; GLT-1; IDENTIFICATION; ACCESSIBILITY; CONDUCTANCE; EXPRESSION; REVEALS	Glutamate transport by the excitatory amino acid transporters (EAATs) is coupled to the co-transport of 3 Na+, 1 H+, and the counter-transport of 1 K+ ion. In addition to coupled ion fluxes, glutamate and Na+ binding to the transporter activates a thermodynamically uncoupled anion conductance through the transporter. In this study, we have distinguished between these two conductance states of the EAAT-1 transporter using a [2-(trimethylammonium)ethyl]methanethiosulfonate-modified V452C mutant transporter. Glutamate binds to the modified mutant transporter and activates the uncoupled anion conductance but is not transported. The selective alteration of the transport function without altering the anion channel function of the V452C mutant transporter suggests that the two functions are generated by distinct conformational states of the transporter.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia	University of Sydney	Vandenberg, RJ (corresponding author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.	robv@pharmacol.usyd.edu.au	Ryan, Renae/AAC-3540-2021; Vandenberg, Robert John/E-6018-2016	Ryan, Renae/0000-0002-8680-4610; Vandenberg, Robert John/0000-0003-1523-4814				AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BARISH ME, 1983, J PHYSIOL-LONDON, V342, P309, DOI 10.1113/jphysiol.1983.sp014852; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Billups B, 1996, J NEUROSCI, V16, P6722; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GRANT GB, 1995, J NEUROSCI, V15, P3852; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Mitrovic AD, 1998, J BIOL CHEM, V273, P14698, DOI 10.1074/jbc.273.24.14698; Mitrovic AD, 2001, J BIOL CHEM, V276, P26071, DOI 10.1074/jbc.M011318200; MOTULSKY H, 1999, ANAL DATA GRAPH PAD, P45; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; SARANTIS M, 1988, NATURE, V332, P451, DOI 10.1038/332451a0; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 1998, NEURON, V21, P1487, DOI 10.1016/S0896-6273(00)80666-2; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Shimamoto K, 1998, MOL PHARMACOL, V53, P195, DOI 10.1124/mol.53.2.195; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; VANDENBERG RJ, 1995, J BIOL CHEM, V270, P17668, DOI 10.1074/jbc.270.30.17668; Vandenberg RJ, 1997, MOL PHARMACOL, V51, P809, DOI 10.1124/mol.51.5.809; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2001, FEBS LETT, V503, P121, DOI 10.1016/S0014-5793(01)02715-6; Zarbiv R, 1998, J BIOL CHEM, V273, P14231, DOI 10.1074/jbc.273.23.14231; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0	36	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13494	13500		10.1074/jbc.M109970200	http://dx.doi.org/10.1074/jbc.M109970200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11815608	hybrid			2022-12-25	WOS:000175096000022
J	Tanida, I; Tanida-Miyake, E; Komatsu, M; Ueno, T; Kominami, E				Tanida, I; Tanida-Miyake, E; Komatsu, M; Ueno, T; Kominami, E			Human Apg3p/Aut1p homologue is an authentic E2 enzyme for multiple substrates, GATE-16, GABARAP, and MAP-LC3, and facilitates the conjugation of hApg12p to hApg5p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-ACTIVATING ENZYME; CELL BIOLOGY; AUTOPHAGY; YEAST; BINDING; SYSTEM; AUTOPHAGOCYTOSIS; APG7P/CVT2P; DISSECTION; INTERACTS	Autophagy is a process of bulk degradation of cytoplasmic components by the lysosome/vacuole and has a significant relationship to several neurodegenerative disorders and myopathies in mammals. One of APG gene products essential for autophagy in yeast, Apg3p, is a protein-conjugating enzyme for Apg8p lipidation (Ichimura, Y., Kirisako, T., Takao, T., Satomi, Y., Shimonishi, Y., Ishihara, N., Mizushima, N., Tanida, I., Kominami, E., Ohsumi, M., Noda, T., and Ohsumi, Y. (2000) Nature 408, 488-492). In this study, the cloning of a human Apg3p homologue (hApg3p) as an E2 enzyme essential for human Apg8p homologues (i.e. GATE-16, GABARAP, and MAP-LC3) is shown, and its unique characteristics are described. The predicted amino acid sequence of the isolated clone shows 34.1% identity and 48.1% similarity to yeast Apg3p. Site-directed mutagenesis revealed that Cys(264) of hApg3p is an authentic active-site cysteine residue essential for the formation of hApg3p-hApg8p homologue intermediates. Overexpression of hApg7p enhances the formation of a stable E2-substrate complex between hApg3p(C264S) and each of the hApg8p homologues, and MAP-LC3 is preferred as the substrate over the other two Apg8p homologues. These results indicate that hApg3p is an E2-like enzyme essential for three human Apg8p homologues. Co-immunoprecipitation of hApg7p with hApg3p indicates that hApg3p forms an E1.E2 complex with hApg7p as in the case of yeast Apg3p and Apg7p. Furthermore, hApg3p coimmunoprecipitates with hApg12p, and the overexpression of hApg3p facilitates the formation of the GFPhApg12p.hApg5p conjugate, suggesting that hApg3p cross-talks with the hApg12p conjugation system.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	kominami@med.juntendo.ac.jp	Kominami, Eiki/D-3802-2009; Tanida, Isei/C-8277-2009; Komatsu, Masaaki/B-8321-2011	Komatsu, Masaaki/0000-0001-7672-7722; Tanida, Isei/0000-0001-8999-3990				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Bennett MJ, 1999, J INHERIT METAB DIS, V22, P535, DOI 10.1023/A:1005564509027; GARDINER RM, 1993, J INHERIT METAB DIS, V16, P787, DOI 10.1007/BF00711910; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; Hunt RT, 1999, PHILOS T ROY SOC B, V354, P1580; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Komatsu M, 2001, J BIOL CHEM, V276, P9846, DOI 10.1074/jbc.M007737200; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MANN SS, 1994, J BIOL CHEM, V269, P11492; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Ohsumi Y, 1999, TRENDS CELL BIOL, V9, P162; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Saftig P, 2001, TRENDS MOL MED, V7, P37, DOI 10.1016/S1471-4914(00)01868-2; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Schlumpberger M, 1997, J BACTERIOL, V179, P1068, DOI 10.1128/jb.179.4.1068-1076.1997; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Wang HB, 2000, J NEUROCHEM, V75, P644, DOI 10.1046/j.1471-4159.2000.0750644.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264	36	217	235	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13739	13744		10.1074/jbc.M200385200	http://dx.doi.org/10.1074/jbc.M200385200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825910	hybrid			2022-12-25	WOS:000175096000053
J	Zhuang, MB; Oltean, DI; Gomez, I; Pullikuth, AK; Soberon, M; Bravo, A; Gill, SS				Zhuang, MB; Oltean, DI; Gomez, I; Pullikuth, AK; Soberon, M; Bravo, A; Gill, SS			Heliothis virescens and Manduca sexta lipid rafts are involved in Cry1A toxin binding to the midgut epithelium and subsequent pore formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; BACILLUS-THURINGIENSIS; MEMBRANE DOMAINS; TRITON X-100; CRYSTAL PROTEINS; AMINOPEPTIDASE-N; PLASMA-MEMBRANE; CRYIA(C) TOXIN; LARVAL MIDGUT; CHOLERA-TOXIN	Lipid rafts are characterized by their insolubility in nonionic detergents such as Triton X-100 at 4 degreesC. They have been studied in mammals, where they play critical roles in protein sorting and signal transduction. To understand the potential role of lipid rafts in lepidopteran insects, we isolated and analyzed the protein and lipid components of these lipid raft microdomains from the midgut epithelial membrane of Heliothis virescens and Manduca sexta. Like their mammalian counterparts, H. virescens and M. sexta lipid rafts are enriched in cholesterol, sphingolipids, and glycosylphosphatidylinositol-anchored proteins. In H. virescens and M. sexta, pretreatment of membranes with the cholesterol-depleting reagent saponin and methyl-g-cyclodextrin differentially disrupted the formation of lipid rafts, indicating an important role for cholesterol in lepidopteran lipid rafts structure. We showed that several putative Bacillus thuringiensis Cry1A receptors, including the 120-and 170-kDa aminopeptidases from H. virescens and the 120-kDa aminopeptidase from M. sexta, were preferentially partitioned into lipid rafts. Additionally, the leucine aminopeptidase activity was enriched approximately 2-3-fold in these rafts compared with brush border membrane vesicles. We also demonstrated that Cry1A toxins were associated with lipid rafts, and that lipid raft integrity was essential for in vitro Cry1Ab pore forming activity. Our study strongly suggests that these microdomains might be involved in Cry1A toxin aggregation and pore formation.	Univ Calif Riverside, Environm Toxicol Grad Program, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; Univ Nacl Autonoma Mexico, Inst Biotecnol, Dept Microbiol, Cuernavaca 62250, Morelos, Mexico	University of California System; University of California Riverside; University of California System; University of California Riverside; Universidad Nacional Autonoma de Mexico	Gill, SS (corresponding author), Univ Calif Riverside, Environm Toxicol Grad Program, 5429 Boyce Hall, Riverside, CA 92521 USA.		Pullikuth, Ashok/AAT-2717-2020; Pullikuth, Ashok K/M-3100-2018; de la Parra, Maria Alejandra Bravo/R-6740-2017	Pullikuth, Ashok K/0000-0002-0041-3310; Bravo, Alejandra/0000-0002-7573-7475				Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Abrami L, 2001, J BIOL CHEM, V276, P30729, DOI 10.1074/jbc.M102039200; Aronson AI, 1999, APPL ENVIRON MICROB, V65, P2503; Aronson AI, 2001, FEMS MICROBIOL LETT, V195, P1, DOI 10.1111/j.1574-6968.2001.tb10489.x; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Banks DJ, 2001, INSECT BIOCHEM MOLEC, V31, P909, DOI 10.1016/S0965-1748(01)00038-8; Barlett G.R., 1959, J BIOL CHEM, V234, P466; BELL RA, 1976, ANN ENTOMOL SOC AM, V69, P365, DOI 10.1093/aesa/69.2.365; Billington SJ, 2000, FEMS MICROBIOL LETT, V182, P197, DOI 10.1016/S0378-1097(99)00536-4; BRAVO A, 1992, J INVERTEBR PATHOL, V60, P247, DOI 10.1016/0022-2011(92)90005-O; BROWN D, 1994, BRAZ J MED BIOL RES, V27, P309; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Coconnier MH, 2000, CELL MICROBIOL, V2, P487, DOI 10.1046/j.1462-5822.2000.00073.x; COWLES EA, 1995, APPL ENVIRON MICROB, V61, P2738, DOI 10.1128/AEM.61.7.2738-2744.1995; de Maagd RA, 2001, TRENDS GENET, V17, P193, DOI 10.1016/S0168-9525(01)02237-5; deMaagd RA, 1996, APPL ENVIRON MICROB, V62, P1537, DOI 10.1128/AEM.62.5.1537-1543.1996; Filippova M, 1998, INSECT MOL BIOL, V7, P223, DOI 10.1111/j.1365-2583.1998.00069.x; FOLCH J, 1956, J BIOL CHEM, V194, P497; Gahan LJ, 2001, SCIENCE, V293, P857, DOI 10.1126/science.1060949; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; GILL SS, 1992, ANNU REV ENTOMOL, V37, P615, DOI 10.1146/annurev.en.37.010192.003151; GILL SS, 1995, J BIOL CHEM, V270, P27277, DOI 10.1074/jbc.270.45.27277; Gomez I, 2001, J BIOL CHEM, V276, P28906, DOI 10.1074/jbc.M103007200; Griffitts JS, 2001, SCIENCE, V293, P860, DOI 10.1126/science.1062441; GUTHER MLS, 1994, ANAL BIOCHEM, V219, P249, DOI 10.1006/abio.1994.1264; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Jacobs T, 1998, MOL MICROBIOL, V28, P1081, DOI 10.1046/j.1365-2958.1998.00858.x; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; KERWIN JL, 1994, J LIPID RES, V35, P1102; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLENK HD, 1969, VIROLOGY, V38, P255, DOI 10.1016/0042-6822(69)90367-5; KNIGHT PJK, 1995, J BIOL CHEM, V270, P17765, DOI 10.1074/jbc.270.30.17765; Kubler E, 1996, J BIOL CHEM, V271, P32975, DOI 10.1074/jbc.271.51.32975; Kurashima K, 1999, J BIOL CHEM, V274, P29843, DOI 10.1074/jbc.274.42.29843; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LECADET MM, 1980, J GEN MICROBIOL, V121, P203; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Lorence A, 1997, FEBS LETT, V414, P303, DOI 10.1016/S0014-5793(97)01014-4; Luo K, 1997, INSECT BIOCHEM MOLEC, V27, P735, DOI 10.1016/S0965-1748(97)00052-0; Nagamatsu Y, 1998, BIOSCI BIOTECH BIOCH, V62, P718, DOI 10.1271/bbb.62.718; Nakai Y, 2000, J NEUROSCI RES, V62, P521, DOI 10.1002/1097-4547(20001115)62:4<521::AID-JNR6>3.0.CO;2-8; Oltean DI, 1999, APPL ENVIRON MICROB, V65, P4760; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Peskan T, 2000, EUR J BIOCHEM, V267, P6989, DOI 10.1046/j.1432-1327.2000.01776.x; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Pullikuth AK, 1999, GENE, V240, P343, DOI 10.1016/S0378-1119(99)00441-2; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10676, DOI 10.1021/bi00499a015; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775, DOI 10.1128/MMBR.62.3.775-806.1998; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Schutz GJ, 2000, EMBO J, V19, P892, DOI 10.1093/emboj/19.5.892; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; VADLAMUDI RK, 1995, J BIOL CHEM, V270, P5490, DOI 10.1074/jbc.270.10.5490; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Van Rie J, 2000, INT J MED MICROBIOL, V290, P463; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Vie V, 2001, J MEMBRANE BIOL, V180, P195, DOI 10.1007/s002320010070; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; WOLFERSBERGER M, 1987, COMP BIOCHEM PHYS A, V86, P301, DOI 10.1016/0300-9629(87)90334-3; Wright JW, 2000, DEV BIOL, V225, P59, DOI 10.1006/dbio.2000.9777; Yaoi K, 1997, EUR J BIOCHEM, V246, P652, DOI 10.1111/j.1432-1033.1997.t01-1-00652.x; Yasuda K, 2000, Tanpakushitsu Kakusan Koso, V45, P1812; Zhang XQ, 1997, BIOCHEM J, V323, P197, DOI 10.1042/bj3230197	69	130	149	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13863	13872		10.1074/jbc.M110057200	http://dx.doi.org/10.1074/jbc.M110057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11836242	hybrid			2022-12-25	WOS:000175096000069
J	Chen, X; Shen, J; Prywes, R				Chen, X; Shen, J; Prywes, R			The luminal domain of ATF6 senses endoplasmic reticulum (ER) stress and causes translocation of ATF6 from the ER to the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLEAVAGE-ACTIVATING PROTEIN; BREFELDIN-A; TRANSMEMBRANE PROTEIN; SECRETORY PROTEINS; PROTEOLYSIS; SREBP; GENE; CELLS; TRANSPORT; PATHWAY	ATF6 is an endoplasmic reticulum. (ER) transmembrane transcription factor that is activated by the ER stress/unfolded protein response by cleavage of its N-terminal half from the membrane. We find that ER stress induces ATF6 to move from the ER to the Golgi, where it is cut in its luminal domain by site I protease. ATF6 contains a single transmembrane domain with 272 amino acids oriented in the lumen of the ER. We found that this luminal domain is required for the translocation of ATF6 to the Golgi and its subsequent cleavage, and we have mapped regions required for these properties. These results suggest that the conserved CD1 region is required for translocation, whereas the CD2 region is required for site I protease cleavage. We also find that ATF6's luminal domain is sufficient to sense ER stress and cause translocation to the Golgi when fused to LZIP, another ER transmembrane protein. These results show that ATF6 has a mechanism to sense ER stress and respond by translocation to the Golgi.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Prywes, R (corresponding author), Columbia Univ, Dept Biol Sci, Fairchild 813B,1212 Amsterdam Ave,MC 2420, New York, NY 10027 USA.			SHEN, JINGSHI/0000-0001-9595-1148	NCI NIH HHS [CA 50329] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050329] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Chen X, 1999, MOL CELL BIOL, V19, P4695; DAI JW, 1995, CELL, V83, P693; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Haze K, 2001, BIOCHEM J, V355, P19, DOI 10.1042/0264-6021:3550019; Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lu R, 2000, J VIROL, V74, P934, DOI 10.1128/JVI.74.2.934-943.2000; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sambrook J., 2002, MOL CLONING LAB MANU; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Urano F, 2000, J CELL SCI, V113, P3697; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Wang Y, 2000, J BIOL CHEM, V275, P27013; Ye J, 2000, P NATL ACAD SCI USA, V97, P5123, DOI 10.1073/pnas.97.10.5123; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957	35	330	348	2	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13045	13052		10.1074/jbc.M110636200	http://dx.doi.org/10.1074/jbc.M110636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821395	hybrid			2022-12-25	WOS:000175036300071
J	Souillac, PO; Uversky, VN; Millett, IS; Khurana, R; Doniach, S; Fink, AL				Souillac, PO; Uversky, VN; Millett, IS; Khurana, R; Doniach, S; Fink, AL			Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENCE-JONES PROTEIN; DIMERIZATION; INTERMEDIATE; ELUCIDATION	Light chain amyloidosis involves the systemic deposition of fibrils in patients overproducing monoclonal immunoglobulin light chains. The kinetics of fibril formation of LEN, a benign light chain variable domain, were investigated at physiological pH in the presence of urea. Despite the lack of in vivo fibril formation, LEN readily forms fibrils in vitro under mildly destabilizing conditions. The effect of low to moderate concentrations of urea on the conformation, association state, stability and kinetics of fibrillation of LEN were investigated. The conformation of LEN was only slightly affected by the addition of up to 4 m urea. The fibrillation kinetics were highly dependent on protein and urea concentrations, becoming faster with decreasing protein concentration and increasing urea concentration. Changes in spectral probes were concomitant to fibril formation throughout the protein and urea concentration ranges' indicating the absence of off-pathway oligomeric species or amorphous aggregates prior to fibril formation. Reducing the amount of dimers initially present in solution by either decreasing the protein concentration or adding urea resulted in faster fibril formation. Thus, increasing concentrations of urea, by triggering dissociation of dimeric LEN, lead to increased rates of fibrillation.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	University of California System; University of California Santa Cruz; Stanford University	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				AZUMA T, 1978, J BIOCHEM-TOKYO, V83, P1485, DOI 10.1093/oxfordjournals.jbchem.a132058; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Huang DB, 1997, MOL IMMUNOL, V34, P1291, DOI 10.1016/S0161-5890(98)00002-9; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; KOLMAR H, 1994, BIOL CHEM H-S, V375, P61; Kratky O, 1982, SMALL ANGLE XRAY SCA, DOI [10.1002/actp.1985.010360520, DOI 10.1002/ACTP.1985.010360520]; Lehrer S S, 1978, Methods Enzymol, V49, P222; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; MAEDA H, 1976, EUR J BIOCHEM, V69, P133, DOI 10.1111/j.1432-1033.1976.tb10866.x; MANNING MC, 1993, ACS SYM SER, V516, P33; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1991, LAB INVEST, V65, P104; NEUMANN N, 1996, PROTEINS FORM FUNCTI, P107; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; Sreerama N, 1999, BIOCHEMISTRY-US, V38, P10814, DOI 10.1021/bi990516z; STEVENS FJ, 1980, P NATL ACAD SCI-BIOL, V77, P1144, DOI 10.1073/pnas.77.2.1144; STEVENS PW, 1995, PROTEIN SCI, V4, P421; STEVENSON GT, 1968, BIOCHEM J, V108, P375, DOI 10.1042/bj1080375; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TIMASHEFF SN, 1992, BIOCHEMISTRY-US, V31, P9857, DOI 10.1021/bi00156a001; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Wall J, 1999, METHOD ENZYMOL, V309, P204; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2	31	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12657	12665		10.1074/jbc.M109230200	http://dx.doi.org/10.1074/jbc.M109230200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815605	hybrid			2022-12-25	WOS:000175036300023
J	Dinculescu, A; McDowell, JH; Amici, SA; Dugger, DR; Richards, N; Hargrave, PA; Smith, WC				Dinculescu, A; McDowell, JH; Amici, SA; Dugger, DR; Richards, N; Hargrave, PA; Smith, WC			Insertional mutagenesis and immunochemical analysis of visual arrestin interaction with rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ROD OUTER SEGMENTS; PHOSPHORYLATED RHODOPSIN; CRYSTAL-STRUCTURE; BOVINE RHODOPSIN; SYNTHETIC PHOSPHOPEPTIDE; METARHODOPSIN-II; 48-KDA PROTEIN; SPLICE VARIANT; BINDING	Visual arrestin inactivates the phototransduction cascade by specifically binding to light-activated phosphorylated rhodopsin. This study describes the combined use of insertional mutagenesis and immunochemical approaches to probe the structural determinants of arrestin function. Recombinant arrestins with insertions of a 10-amino acid c-Myc tag (EQKLISEEDL) were expressed in yeast and characterized. When the tag was placed on the C terminus after amino acid 399, between amino acids 99 and 100 or between residues 162 and 163, binding to rhodopsin was found to be very similar to that of wild-type arrestin. Two stable mutants with Myc insertions in the 68-78 loop were also generated. Binding to rhodopsin was markedly decreased for one (72myc73) and completely abolished for the other (77myc78). Limited proteolysis assays using trypsin in the absence or presence of heparin were performed on all mutants and confirmed their overall conformational integrity. Rhodopsin binding to either 162myc163 or 72myc73 arrestins in solution was completely inhibited in the presence of less than a 2-fold molar excess of anti-Myc antibody relative to arrestin. In contrast, the antibody did not block the interaction of the 399myc or 99myc100 arrestins with rhodopsin. These results indicate that an interactive surface for rhodopsin is located on or near the concave region of the N-domain of arrestin.	Univ Florida, Dept Ophthalmol, Gainesville, FL 32610 USA; Univ Florida, Dept Chem, Gainesville, FL 32610 USA; Univ Florida, Dept Biochem, Gainesville, FL 32610 USA; Univ Florida, Dept Neurosci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Smith, WC (corresponding author), Univ Florida, Dept Ophthalmol, Box 100284 JHMHC, Gainesville, FL 32610 USA.		Smith, W. Clay/AAQ-1589-2021		NEI NIH HHS [EY06225, EY06226, EY08571] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008571, R37EY006226, R01EY006226] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arendt A, 1996, PROTEIN PEPTIDE LETT, V3, P361; Baylor DA, 1998, EYE, V12, P521, DOI 10.1038/eye.1998.140; Bohm SK, 1997, BIOCHEM J, V322, P1; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Granzin J, 1998, NATURE, V391, P918, DOI 10.1038/36147; GrayKeller MP, 1997, BIOCHEMISTRY-US, V36, P7058, DOI 10.1021/bi963110k; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Gurevich VV, 1998, J BIOL CHEM, V273, P15501, DOI 10.1074/jbc.273.25.15501; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; KIESELBACH T, 1994, EUR J BIOCHEM, V226, P87, DOI 10.1111/j.1432-1033.1994.tb20029.x; KRUPNICK JG, 1994, J BIOL CHEM, V269, P3226; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; List K, 1999, J IMMUNOL METHODS, V222, P125, DOI 10.1016/S0022-1759(98)00189-6; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; McDowell JH, 1999, BIOCHEMISTRY-US, V38, P6119, DOI 10.1021/bi990175p; McDowell JH, 2001, INVEST OPHTH VIS SCI, V42, P1439; OHGURO H, 1994, PROTEIN SCI, V3, P2428, DOI 10.1002/pro.5560031226; Ohguro H, 1996, J BIOL CHEM, V271, P5215; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P314; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P18649; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PUIG J, 1995, FEBS LETT, V362, P185, DOI 10.1016/0014-5793(95)00225-X; Pulvermuller A, 2000, J BIOL CHEM, V275, P37679, DOI 10.1074/jbc.M006776200; Pulvermuller A, 1997, BIOCHEMISTRY-US, V36, P9253, DOI 10.1021/bi970772g; Raman D, 1999, BIOCHEMISTRY-US, V38, P5117, DOI 10.1021/bi9824588; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schiweck W, 1997, FEBS LETT, V414, P33, DOI 10.1016/S0014-5793(97)00983-6; SCHLEICHER A, 1989, BIOCHEMISTRY-US, V28, P1770, DOI 10.1021/bi00430a052; Smith AM, 1997, BIOTECHNIQUES, V22, P438, DOI 10.2144/97223bm13; Smith WC, 1999, BIOCHEMISTRY-US, V38, P2752, DOI 10.1021/bi982643l; SMITH WC, 1994, J BIOL CHEM, V269, P15407; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wess J, 1998, PHARMACOL THERAPEUT, V80, P231, DOI 10.1016/S0163-7258(98)00030-8	47	34	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11703	11708		10.1074/jbc.M111833200	http://dx.doi.org/10.1074/jbc.M111833200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809770	hybrid			2022-12-25	WOS:000174846400014
J	Mercer, K; Chiloeches, A; Huser, M; Kiernan, M; Marais, R; Pritchard, C				Mercer, K; Chiloeches, A; Huser, M; Kiernan, M; Marais, R; Pritchard, C			ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf	ONCOGENE			English	Article						A-Raf; knockout; ERK activation; oncogene transformation	PROTEIN-KINASE; B-RAF; EXPRESSION; PROTOONCOGENES; STIMULATE; LETHALITY; MICE	Previous studies have indicated an important role for the Raf family of protein kinases in controlling cellular responses to extracellular stimuli and activated oncogenes, through their ability to activate the MEK/ERKs. To investigate the specific role of A-Raf in this process we generated A-Raf deficient mouse embryonic fibroblasts (MEFs) and embryonic stem (ES) cells by gene targeting and characterized their ability to undergo proliferation, differentiation, apoptosis, ERK activation, and transformation by oncogenic Ras and Src. The A-Raf deficient cells are not disrupted for any of these processes, despite the fact that this protein is normally expressed at high levels in both cell types. This implies either that A-Raf plays no role in MEK/ERK activation, that its function is fully compensated by other Raf proteins or MEK kinases or that its role in MEK/ERK activation is highly tissue-specific. Interestingly, B-Raf and Raf-1 activity towards MEK as measured by the immunoprecipitation kinase cascade assay are both significantly increased in the A-Raf deficient MEFs.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Inst Canc Res, London SW3 6JB, England; Univ Plymouth, Dept Biol Sci, Plymouth PL4 8AA, Devon, England	University of Leicester; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Plymouth	Pritchard, C (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	cap8@le.ac.uk	Chiloeches, Antonio/Z-5993-2019; Dorner, Martin/C-5703-2013	Marais, Richard/0000-0001-7484-4183; Pritchard, Catrin/0000-0003-1859-4487; Antonio, Chiloeches Galvez/0000-0001-7162-330X; Dorner, Martin/0000-0002-8176-797X				BARNIER JV, 1995, J BIOL CHEM, V270, P23381, DOI 10.1074/jbc.270.40.23381; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P26303, DOI 10.1074/jbc.270.44.26303; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; GUBBAY J, 1992, P NATL ACAD SCI USA, V89, P7953, DOI 10.1073/pnas.89.17.7953; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hagemann C, 1997, FEBS LETT, V403, P200, DOI 10.1016/S0014-5793(97)00011-2; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; Luckett JCA, 2000, CELL GROWTH DIFFER, V11, P163; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952; Pritchard CA, 1996, CURR BIOL, V6, P614, DOI 10.1016/S0960-9822(02)00548-1; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; QURESHI SA, 1993, BIOCHEM BIOPH RES CO, V192, P969, DOI 10.1006/bbrc.1993.1510; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SLADEK TL, 1992, ONCOGENE, V7, P1305; STORM SM, 1990, ONCOGENE, V5, P345; Treinies I, 1999, MOL CELL BIOL, V19, P321; Wojnowski L, 2000, MECH DEVELOP, V91, P97, DOI 10.1016/S0925-4773(99)00276-2; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Yuryev A, 2000, MOL CELL BIOL, V20, P4870, DOI 10.1128/MCB.20.13.4870-4878.2000	23	52	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					347	355		10.1038/sj.onc.1205101	http://dx.doi.org/10.1038/sj.onc.1205101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821947				2022-12-25	WOS:000173311200003
J	Asea, A; Rehli, M; Kabingu, E; Boch, JA; Bare, O; Auron, PE; Stevenson, MA; Calderwood, SK				Asea, A; Rehli, M; Kabingu, E; Boch, JA; Bare, O; Auron, PE; Stevenson, MA; Calderwood, SK			Novel signal transduction pathway utilized by extracellular HSP70 - Role of Toll-like receptor (TLR) 2 AND TLR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNATE IMMUNE-RESPONSE; HEAT-SHOCK PROTEINS; BINDING PROTEINS; DROSOPHILA TOLL; FAMILY; MYD88; CELLS; ENDOTOXIN; MICE; HEAT-SHOCK-PROTEIN-70	Recent studies have initiated a paradigm shift in the understanding of the function of heat shock proteins (HSP). It is now clear that HSP can and do exit mammalian cells, interact with cells of the immune system, and exert immunoregulatory effects. We recently demonstrated that exogenously added HSP70 possesses potent cytokine activity, with the ability to bind with high affinity to the plasma membrane, elicit a rapid intracellular Ca2+ flux, activate NF-kappaB, and up-regulate the expression of pro-inflammatory cytokines in human monocytes. Here for the first time, we report that HSP70-induced proinflammatory cytokine production is mediated via the MyD88/IRAK/NF-kappaB signal transduction pathway and that HSP70 utilizes both TLR2 (receptor for Gram-positive bacteria) and TLR4 (receptor for Gram-negative bacteria) to transduce its proinflammatory signal in a CD14-dependent fashion. These studies now pave the way for the development of highly effective pharmacological or molecular tools that will either up-regulate or suppress HSP70-induced functions in conditions where HSP70 effects are desirable (cancer) or disorders where HSP70 effects are undesirable (arthritis and arteriosclerosis).	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA; Univ Regensburg, Hosp Med, Dept Hematol & Oncol, D-93042 Regensburg, Germany; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Regensburg; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; New England Baptist Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Radiat Oncol, 44 Binney St D810, Boston, MA 02115 USA.		Asea, Alexzander/X-6432-2019; Asea, Alexzander A/I-4112-2013; Rehli, Michael/E-9093-2011	Asea, Alexzander A/0000-0003-3592-3481; Rehli, Michael/0000-0003-3992-932X	NCI NIH HHS [CA77465, CA68544, CA50642, CA47404, CA31303] Funding Source: Medline; NIAID NIH HHS [AI44122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA031303, R01CA047404, R01CA068544, R01CA077465, R01CA050642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; ASEA A, 1995, ROLE HISTAMINE REGUL, P1; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Binder RJ, 2000, J IMMUNOL, V165, P2582, DOI 10.4049/jimmunol.165.5.2582; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; DUFF GW, 1982, J IMMUNOL METHODS, V52, P333, DOI 10.1016/0022-1759(82)90005-9; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631; HELDWEIN KA, 2001, MOD ASP IMMUNOBIOL, V1, P249; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; INABA K, 1994, J EXP MED, V180, P1849, DOI 10.1084/jem.180.5.1849; Janeway CA, 1999, CURR BIOL, V9, pR879, DOI 10.1016/S0960-9822(00)80073-1; Jensen LE, 2000, J IMMUNOL, V164, P5277, DOI 10.4049/jimmunol.164.10.5277; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Kanakaraj P, 1999, J EXP MED, V189, P1129, DOI 10.1084/jem.189.7.1129; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Moroi Y, 2000, P NATL ACAD SCI USA, V97, P3485, DOI 10.1073/pnas.070550797; Moseley P, 2000, IMMUNOPHARMACOLOGY, V48, P299, DOI 10.1016/S0162-3109(00)00227-7; Muzio M, 2000, MICROBES INFECT, V2, P251, DOI 10.1016/S1286-4579(00)00303-8; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Suzue K, 1996, J IMMUNOL, V156, P873; Thomassen E, 1998, J INTERF CYTOK RES, V18, P1077, DOI 10.1089/jir.1998.18.1077; Todryk S, 1999, J IMMUNOL, V163, P1398; ULEVITCH RJ, 1994, CURR OPIN IMMUNOL, V6, P125, DOI 10.1016/0952-7915(94)90043-4; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	44	1173	1272	3	84	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15028	15034		10.1074/jbc.M200497200	http://dx.doi.org/10.1074/jbc.M200497200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836257	hybrid			2022-12-25	WOS:000175203000086
J	Chay, KO; Park, SS; Mushinski, JF				Chay, KO; Park, SS; Mushinski, JF			Linkage of caspase-mediated degradation of paxillin to apoptosis in Ba/F3 murine pro-B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE KINASE; LIM DOMAINS; HEMATOPOIETIC-CELLS; PROTEIN BINDS; LD MOTIFS; INTEGRIN; PHOSPHORYLATION; CLEAVAGE; VINCULIN	We have cloned the complete cDNA from mouse paxillin, a 68-kDa adapter protein found in focal adhesions. We found that paxillin was degraded by caspases in Ba/F3 cell apoptosis induced by withdrawal of interleukin-3 (IL-3), a survival factor for this cell, and by ionizing radiation. Also, paxillin was degraded in vitro by incubation with recombinant caspase-3. Western blot analyses of degradation products of overexpressed green fluorescence protein-tagged paxillin and site-specific mutants demonstrated that Asp-102 and Asp-301 were early caspase cleavage sites, and Asp-5, Asp-146, Asp-165, and Asp-222 were late cleavage sites. Overexpression of paxillin delayed apoptosis of Ba/F3 after IL-3 withdrawal. Furthermore, this anti-apoptotic effect of paxillin was augmented by a triple mutation in aspartic acids at caspase cleavage sites. These results suggest that paxillin plays a critical role in cell survival signaling and that the cleavage of paxillin by caspases might be an important event for focal adhesion disassembly during cell apoptosis, contributing to detachment, rounding, and death.	NCI, Genet Lab, NIH, Bethesda, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Mushinski, JF (corresponding author), NCI, Genet Lab, NIH, Bldg 37,Rm 2B23,9000 Rockville Pike, Bethesda, MD 20852 USA.	mushinsj@pop.nci.nih.gov						ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; Brown MC, 1996, J CELL BIOL, V135, P1109, DOI 10.1083/jcb.135.4.1109; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLLINS MKL, 1992, J EXP MED, V176, P1043, DOI 10.1084/jem.176.4.1043; Craig SW, 1996, CURR OPIN CELL BIOL, V8, P74, DOI 10.1016/S0955-0674(96)80051-2; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Fox JEB, 1999, THROMB HAEMOSTASIS, V82, P385; Fujita H, 1998, J BIOL CHEM, V273, P26516, DOI 10.1074/jbc.273.41.26516; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 1996, STRUCTURE, V4, P647, DOI 10.1016/S0969-2126(96)00069-X; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hirsch T, 1998, J IMMUNOL, V161, P35; Johnson Daniel E., 1998, Frontiers in Bioscience, V3, pD313; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; Kisselev AF, 1999, J BIOL CHEM, V274, P3363, DOI 10.1074/jbc.274.6.3363; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kook S, 2000, MOL BIOL CELL, V11, P929, DOI 10.1091/mbc.11.3.929; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Liu SC, 2001, J BIOL CHEM, V276, P37086, DOI 10.1074/jbc.M105114200; Mathieu AL, 2001, J BIOL CHEM, V276, P10935, DOI 10.1074/jbc.M007147200; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Miyamoto S, 1998, ANN NY ACAD SCI, V857, P119, DOI 10.1111/j.1749-6632.1998.tb10112.x; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Orlowski RZ, 1999, CELL DEATH DIFFER, V6, P303, DOI 10.1038/sj.cdd.4400505; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; SALGIA R, 1995, ONCOGENE, V11, P1149; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sattler M, 2000, CRIT REV ONCOGENESIS, V11, P63; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stennicke HR, 1999, CELL DEATH DIFFER, V6, P1054, DOI 10.1038/sj.cdd.4400599; Stennicke HR, 2000, METHOD ENZYMOL, V322, P91; TACHIBANA K, 1995, J EXP MED, V182, P1089, DOI 10.1084/jem.182.4.1089; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Tong X, 1997, J BIOL CHEM, V272, P33373, DOI 10.1074/jbc.272.52.33373; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2000, J CELL SCI, V113, P4139; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; van de Water B, 1999, J BIOL CHEM, V274, P13328, DOI 10.1074/jbc.274.19.13328; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WOOD CK, 1994, J CELL SCI, V107, P709; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	67	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14521	14529		10.1074/jbc.M111639200	http://dx.doi.org/10.1074/jbc.M111639200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11825902	hybrid			2022-12-25	WOS:000175203000024
J	Wilson, MA; Ricci, AR; Deroo, BJ; Archer, TK				Wilson, MA; Ricci, AR; Deroo, BJ; Archer, TK			The histone deacetylase inhibitor trichostatin A blocks progesterone receptor-mediated transactivation of the mouse mammary tumor virus promoter in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; IN-VIVO; TRANSCRIPTION FACTORS; SODIUM-BUTYRATE; GENE-EXPRESSION; NUCLEOSOME STRUCTURE; H4 ACETYLATION; MMTV PROMOTER; CHROMATIN; COMPLEX	Post-translational modifications of histones play an important role in modulating gene transcription within chromatin. We used the mouse mammary tumor virus (MMTV) promoter, which adopts an ordered nucleosomal structure, to investigate the impact of a specific inhibitor of histone deacetylase, trichostatin A (TSA), on progesterone receptor-activated transcription. TSA induced global histone hyperacetylation, and this effect occurred independently of the presence of hormone. Interestingly, chromatin immunoprecipitation analysis revealed no significant change in the level of acetylated histones associated with the MMTV promoter following high TSA treatment. In human breast cancer cells, in which the MMTV promoter adopts a constitutively "open" chromatin structure, treatment with TSA converted the MMTV promoter into a closed structure. Addition of hormone did not overcome this TSA-induced closure of the promoter chromatin. Furthermore, TSA treatment resulted in the eviction of the transcription factor nuclear factor-1 from the promoter and reduced progesterone receptor-induced transcription. Kinetic experiments revealed that a loss of chromatin-remodeling proteins was coincident with the decrease in MMTV transcriptional activity and the imposition of repressed chromatin architecture at the promoter. These results demonstrate that deacetylase inhibitor treatment at levels that induce global histone acetylation may leave specific regulatory regions relatively unaffected and that this treatment may lead to transcriptional inhibition by mechanisms that modify chromatin-remodeling proteins rather than by influencing histone acetylation of the local promoter chromatin structure.	NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Western Ontario, Dept Obstet & Gynaecol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 4L6, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Western University (University of Western Ontario); Western University (University of Western Ontario)	Archer, TK (corresponding author), NIEHS, Chromatin & Gene Express Sect, Reprod & Dev Toxicol Lab, NIH, 111 Alexander Dr,MD E4-06,POB 12233, Res Triangle Pk, NC 27709 USA.		Archer, Trevor K/E-5191-2019	Wilson, Melissa/0000-0002-5391-7838; Archer, Trevor K/0000-0001-7651-3644				Archer TK, 1997, METHODS, V11, P235, DOI 10.1006/meth.1996.0410; Bartsch J, 1996, P NATL ACAD SCI USA, V93, P10741, DOI 10.1073/pnas.93.20.10741; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; CORDINGLEY MG, 1987, CELL, V48, P261, DOI 10.1016/0092-8674(87)90429-6; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Grandjean V, 2001, FEBS LETT, V488, P165, DOI 10.1016/S0014-5793(00)02349-8; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LEFEBVRE P, 1991, MOL CELL BIOL, V11, P2529, DOI 10.1128/MCB.11.5.2529; MCKNIGHT GS, 1980, CELL, V22, P469; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; MYMRYK JS, 1995, MOL CELL BIOL, V15, P26, DOI 10.1128/MCB.15.1.26; MYMRYK JS, 1994, NUCLEIC ACIDS RES, V22, P4344, DOI 10.1093/nar/22.20.4344; NORDEEN SK, 1987, DNA-J MOLEC CELL BIO, V6, P173, DOI 10.1089/dna.1987.6.173; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; ORMANDY CJ, 1992, ENDOCRINOLOGY, V131, P982, DOI 10.1210/en.131.2.982; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; PLESKO MM, 1983, J BIOL CHEM, V258, P3738; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; Sheldon LA, 2001, J BIOL CHEM, V276, P32423, DOI 10.1074/jbc.C100315200; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Takahashi I, 1996, J ANTIBIOT, V49, P453, DOI 10.7164/antibiotics.49.453; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; van Holde K.E., 1988, CHROMATIN; VanLint C, 1996, GENE EXPRESSION, V5, P245; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; WOLFFE AP, 1994, CELL, V77, P13, DOI 10.1016/0092-8674(94)90229-1; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Wolffe AP, 1998, PROG NUCLEIC ACID RE, V61, P379, DOI 10.1016/S0079-6603(08)60832-6; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	44	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15171	15181		10.1074/jbc.M200349200	http://dx.doi.org/10.1074/jbc.M200349200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11821430	hybrid			2022-12-25	WOS:000175203000103
J	Bullard, JM; Williams, JC; Acker, WK; Jacobi, C; Janjic, N; McHenry, CS				Bullard, JM; Williams, JC; Acker, WK; Jacobi, C; Janjic, N; McHenry, CS			DNA polymerase III holoenzyme from Thermus thermophilus identification, expression, purification of components, and use to reconstitute a processive replicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GAMMA-SUBUNIT; BETA-SUBUNIT; INITIATION COMPLEX; ACCESSORY PROTEINS; ALPHA-SUBUNIT; PRIMED DNA; SLIDING CLAMPS; BINDING DOMAIN; TAU	DNA replication in bacteria is performed by a specialized multicomponent replicase, the DNA polymerase III holoenzyme, that consist of three essential components: a polymerase, the beta sliding clamp processivity factor, and the DnaX complex clamp-loader. We report here the assembly of the minimal functional holoenzyme from Thermus thermophilus (Tth), an extreme thermophile. The minimal holoenzyme consists of alpha (pol III catalytic subunit), beta (sliding clamp processivity factor), and the essential DnaX (tau/gamma), delta and delta' components of the DnaX complex. We show with purified recombinant proteins that these five components are required for rapid and processive DNA synthesis on long single-stranded DNA templates. Subunit interactions known to occur in DNA polymerase III holoenzyme from mesophilic bacteria including delta-delta' interaction, deltadelta'-tau/gamma complex formation, and alpha-tau interaction, also occur within the Tth enzyme. As in mesophilic holoenzymes, in the presence of a primed DNA template, these subunits assemble into a stable initiation complex in an ATP-dependent manner. However, in contrast to replicative polymerases from mesophilic bacteria, Tth holoenzyme is efficient only at temperatures above 50 degreesC, both with regard to initiation complex formation and processive DNA synthesis. The minimal Tth DNA polymerase III holoenzyme displays an elongation rate of 350 bp/s at 72 degreesC and a processivity of greater than 8.6 kilobases, the length of the template that is fully replicated after a single association event.	Replidyne Inc, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Gottingen, Inst Microbiol & Genet, D-3400 Gottingen, Germany	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Gottingen	McHenry, CS (corresponding author), Replidyne Inc, Denver, CO 80206 USA.				NIGMS NIH HHS [GM54482] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R44GM054482, R43GM054482] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allawi HT, 1997, BIOCHEMISTRY-US, V36, P10581, DOI 10.1021/bi962590c; Blake RD, 1998, NUCLEIC ACIDS RES, V26, P3323, DOI 10.1093/nar/26.14.3323; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; BULLARD JM, 2001, J BIOL CHEM     0124; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; CARTER JR, 1993, J BACTERIOL, V175, P5604, DOI 10.1128/JB.175.17.5604-5610.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Gao DX, 2001, J BIOL CHEM, V276, P4441, DOI 10.1074/jbc.M009830200; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; JOHANSON KO, 1980, J BIOL CHEM, V255, P984; JOHANSON KO, 1982, J BIOL CHEM, V257, P2310; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Jonczyk P, 1998, J BACTERIOL, V180, P1563, DOI 10.1128/JB.180.6.1563-1566.1998; KALEDIN A S, 1980, Biokhimiya, V45, P644; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim DR, 1996, J BIOL CHEM, V271, P20699, DOI 10.1074/jbc.271.34.20699; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; LAWYER FC, 1989, J BIOL CHEM, V264, P6427; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Lizardi PM, 1998, NAT GENET, V19, P225, DOI 10.1038/898; LOW RL, 1976, J BIOL CHEM, V251, P1311; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; McHenry CS, 1997, J MOL BIOL, V272, P178, DOI 10.1006/jmbi.1997.1238; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; MCHENRY CS, 1987, DNA REPLICATION RECO, P47; MOK M, 1987, J BIOL CHEM, V262, P16644; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; Song MS, 2001, J BIOL CHEM, V276, P48709, DOI 10.1074/jbc.M107936200; Song MS, 2001, J BIOL CHEM, V276, P40668, DOI 10.1074/jbc.M106373200; Song MS, 2001, J BIOL CHEM, V276, P35165, DOI 10.1074/jbc.M100389200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; UYEMURA D, 1976, J BIOL CHEM, V251, P4085; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P3679, DOI 10.1073/pnas.70.12.3679; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yurieva O, 1997, J BIOL CHEM, V272, P27131, DOI 10.1074/jbc.272.43.27131	68	18	24	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13401	13408		10.1074/jbc.M110833200	http://dx.doi.org/10.1074/jbc.M110833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11823461	hybrid, Green Published			2022-12-25	WOS:000175096000009
J	Gross, EA; Callow, MG; Waldbaum, L; Thomas, S; Ruggieri, R				Gross, EA; Callow, MG; Waldbaum, L; Thomas, S; Ruggieri, R			MRK, a mixed lineage kinase-related molecule that plays a role in gamma-radiation-induced cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; HUMAN HOMOLOG; CLONING; YEAST; PATHWAYS; P38; PHOSPHORYLATION; IDENTIFICATION	Mitogen-activated protein (MAP) kinase pathways are three-kinase modules that mediate diverse cellular processes and have been highly conserved among eukaryotes. By using a functional complementation screen in yeast, we have identified a human MAP kinase kinase kinase (MAPKKK) that shares homology with members of the mixed lineage kinase (MLK) family and therefore was called MRK (MLK-related kinase). We report the structure of the MRK gene, from which are generated two splice forms of MRK, MRK-alpha and MRK-beta encoding for proteins of 800 and 456 amino acids, respectively. By using a combination of solid phase protein kinase assays, transient transfections in cells, and analysis of endogenous proteins in stably transfected Madin-Darby canine kidney cells, we found that MRK-beta preferentially activates ERK6/p38gamma via MKK3/MKK6 and JNK through MKK4/MKK7. We also show that expression of wild type MRK increases the cell population in the G(2)/M phase of the cell cycle, whereas dominant negative MRK attenuates the G(2) arrest caused by gamma-radiation. In addition, exposure of cells to gamma-radiation induces MRK activity. These data suggest that MRK may mediate gamma-radiation signaling leading to cell cycle arrest and that MRK activity is necessary for the cell cycle checkpoint regulation in cells.	Picower Inst Med Res, Manhasset, NY 11030 USA; Onyx Pharmaceut, Richmond, CA 94806 USA	Northwell Health	Ruggieri, R (corresponding author), North Shore Long Isl Jewish Res Inst, 350 Community Dr, Manhasset, NY 11030 USA.				NATIONAL CANCER INSTITUTE [R55CA086858] Funding Source: NIH RePORTER; NCI NIH HHS [CA86858-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Deacon K, 1999, J BIOL CHEM, V274, P16604, DOI 10.1074/jbc.274.23.16604; DOROW DS, 1995, EUR J BIOCHEM, V234, P492, DOI 10.1111/j.1432-1033.1995.492_b.x; DOROW DS, 1993, EUR J BIOCHEM, V213, P701, DOI 10.1111/j.1432-1033.1993.tb17810.x; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gotoh I, 2001, J BIOL CHEM, V276, P4276, DOI 10.1074/jbc.M008595200; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Hirai S, 1996, ONCOGENE, V12, P641; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Hutchison M, 1998, J BIOL CHEM, V273, P28625, DOI 10.1074/jbc.273.44.28625; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Jou TS, 2000, MOL BIOL CELL, V11, P287, DOI 10.1091/mbc.11.1.287; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MACARTHUR H, 1984, J VIROL, V52, P483, DOI 10.1128/JVI.52.2.483-491.1984; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Porfiri E, 1996, J BIOL CHEM, V271, P5871, DOI 10.1074/jbc.271.10.5871; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; ROSE MD, 1988, METHODS YEAST GENETI; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; Sherman F., 1982, METHODS YEAST GENETI; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	45	45	48	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13873	13882		10.1074/jbc.M111994200	http://dx.doi.org/10.1074/jbc.M111994200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11836244	hybrid			2022-12-25	WOS:000175096000070
J	Xu, LW; Marians, KJ				Xu, LW; Marians, KJ			A dynamic RecA filament permits DNA polymerase-catalyzed extension of the invading strand in recombination intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAB; REPLICATION FORKS; PROTEIN FILAMENTS; III HOLOENZYME; INITIATION; PRIA; HELICASE; ENZYME; EXCHANGE; BINDING	Recombination-dependent replication is an essential housekeeping function in prokaryotes and eukaryotes, serving, for example, to restart DNA replication after the repair of a double-strand break. Little is known about the interplay between the recombination and replication machinery when recombination intermediates are used as substrates for DNA replication. We show here that recombination intermediates formed between linear duplex and supercoiled plasmid DNAs are substrates for a generalized strand displacement DNA synthesis reaction in which the 3'-OH of the invading strand in the recombination intermediate is used as a primer. DNA synthesis is driven by negative superhelicity and is inhibited if disassembly of the RecA filament is prevented. Thus, assembly and disassembly of RecA filaments in the same direction facilitates filament clearance from the 3'-end of the invading strand, allowing DNA synthesis to occur from recombination intermediates.	Cornell Univ, Weill Coll Med, Grad Sch Med Sci, Grad Program Biochem & Struct Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Marians, KJ (corresponding author), Cornell Univ, Weill Coll Med, Grad Sch Med Sci, Grad Program Biochem & Struct Biol, New York, NY 10021 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, R37 GM034557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson DG, 1997, CELL, V90, P77, DOI 10.1016/S0092-8674(00)80315-3; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; EGELMAN EH, 1989, SCIENCE, V245, P404, DOI 10.1126/science.2667137; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GRIFFITH J, 1985, BIOCHEMISTRY-US, V24, P158, DOI 10.1021/bi00322a022; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P16371; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; ITOH T, 1980, P NATL ACAD SCI-BIOL, V77, P2450, DOI 10.1073/pnas.77.5.2450; IWABUCHI MA, 1983, J BIOL CHEM, V258, P2394; KAGUNI JM, 1984, CELL, V38, P183, DOI 10.1016/0092-8674(84)90539-7; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; Learn BA, 1997, P NATL ACAD SCI USA, V94, P1154, DOI 10.1073/pnas.94.4.1154; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; Marians KJ, 2000, TRENDS BIOCHEM SCI, V25, P185, DOI 10.1016/S0968-0004(00)01565-6; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MENETSKI JP, 1989, BIOCHEMISTRY-US, V28, P5871, DOI 10.1021/bi00440a025; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; MOK M, 1987, J BIOL CHEM, V262, P16644; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; ODONNELL ME, 1985, J BIOL CHEM, V260, P2884; OHTANI T, 1982, NATURE, V299, P86, DOI 10.1038/299086a0; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; ROMAN LJ, 1989, BIOCHEMISTRY-US, V28, P2863, DOI 10.1021/bi00433a018; Rothstein R, 2000, GENE DEV, V14, P1; Sandler SJ, 2000, J BACTERIOL, V182, P9, DOI 10.1128/JB.182.1.9-13.2000; Sandler SJ, 1999, MOL MICROBIOL, V34, P91, DOI 10.1046/j.1365-2958.1999.01576.x; Sandler SJ, 2001, MOL MICROBIOL, V41, P697, DOI 10.1046/j.1365-2958.2001.02547.x; SANDLER SJ, 1996, GENETICS, V145, P5; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921	40	27	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14321	14328		10.1074/jbc.M112418200	http://dx.doi.org/10.1074/jbc.M112418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832493	hybrid			2022-12-25	WOS:000175096000126
J	Zhou, B; Zhang, ZY				Zhou, B; Zhang, ZY			The activity of the extracellular signal-regulated kinase 2 is regulated by differential phosphorylation in the activation loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MAP KINASE; DUAL PHOSPHORYLATION; TYROSINE-PHOSPHATASE; ERK2; MECHANISM; IDENTIFICATION; AUTOPHOSPHORYLATION; RECOGNITION; PATHWAYS	The mitogen-activated protein kinases (MAP kinases) play a central role in signaling pathways initiated by extracellular stimuli such as growth factors, cytokines, and various forms of environmental stress. Full activation of the MAP kinases requires dual phosphorylation of the Thr and Tyr residues in the TXY motif of the activation loop by MAP kinase kinases. Interestingly, down-regulation of MAP kinase activity can be initiated by multiple Ser/Thr phosphatases, Tyr-specific phosphatases, and dual-specificity phosphatases. This would inevitable lead to the formation of monophosphorylated MAP kinases. However, in much of the literature investigating MAP kinase signaling, there has been the implicit assumption that the monophosphorylated forms are inactive. Thus, the significance for the need of multiple phosphatases in regulating MAP kinase activity is not clear, and the biological functions of these monophosphorylated MAP kinases are currently unknown. We have prepared extracellular signal-regulated protein kinase 2 (ERK2) in all phosphorylated forms and kinetically characterized them using two proteins (the myelin basic protein and Elk-1) and ATP as substrates. Our results revealed that a single phosphorylation in the activation loop of ERK2 produces an intermediate activity state. Thus, the catalytic efficiencies of the monophosphorylated ERK2/pY and ERK2/pT (ERK2 phosphorylated on Tyr-185 and Thr-183, respectively) are similar to2-3 orders of magnitude higher than that of the unphosphorylated ERK2 and are only 1-2 orders of magnitude lower than that of the fully active bisphosphorylated ERK2/pTpY. This raises the possibility that the monophosphorylated ERK2s may have distinct biological roles in vivo. Different phosphorylation states in the activation loop could be linked to graded effects on a single ERK2 function. Alter-natively, they could be linked to distinct ERK2 functions. Although less active than the bisphosphorylated species, the monophosphorylated ERK2s may differentially phosphorylate pathway components.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Zhang, ZY (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu			NCI NIH HHS [CA69202] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN NG, 1991, J BIOL CHEM, V266, P4220; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cha HJ, 2001, J CELL BIOL, V153, P1355, DOI 10.1083/jcb.153.7.1355; CHOCK PB, 1980, ANNU REV BIOCHEM, V49, P813, DOI 10.1146/annurev.bi.49.070180.004121; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; Emrick MA, 2001, J BIOL CHEM, V276, P46469, DOI 10.1074/jbc.M107708200; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Killilea SD, 1998, METH MOL B, V93, P23; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; Prowse CN, 2001, J BIOL CHEM, V276, P40817, DOI 10.1074/jbc.M105860200; Prowse CN, 2001, J BIOL CHEM, V276, P99, DOI 10.1074/jbc.M008137200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Robinson MJ, 1996, BIOCHEMISTRY-US, V35, P5641, DOI 10.1021/bi952723e; ROSSOMANDO AJ, 1992, P NATL ACAD SCI USA, V89, P5779, DOI 10.1073/pnas.89.13.5779; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; SERGIENKO EA, 1994, ANAL BIOCHEM, V221, P348, DOI 10.1006/abio.1994.1424; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wilsbacher JL, 2001, METHOD ENZYMOL, V332, P387; Yao Z, 2000, FEBS LETT, V468, P37, DOI 10.1016/S0014-5793(00)01191-1; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200	43	49	53	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13889	13899		10.1074/jbc.M200377200	http://dx.doi.org/10.1074/jbc.M200377200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11839761	hybrid			2022-12-25	WOS:000175096000072
J	Doi, M; Thyboll, J; Kortesmaa, J; Jansson, K; Iivanainen, A; Parvardeh, M; Timpl, R; Hedin, U; Swedenborg, J; Tryggvason, K				Doi, M; Thyboll, J; Kortesmaa, J; Jansson, K; Iivanainen, A; Parvardeh, M; Timpl, R; Hedin, U; Swedenborg, J; Tryggvason, K			Recombinant human laminin-10 (alpha 5,beta 1,gamma 1) - Production, purification, and migration-promoting activity on vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA 1 CHAIN; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; CARCINOMA-CELLS; INTEGRIN ALPHA(V)BETA(3); HUMAN LUNG; ALPHA 1-5; EXPRESSION; ADULT; BINDING	The laminin (LN) family of large heterotrimeric extracellular matrix glycoproteins has multiple functions: LNs take part in the regulation of processes such as cell migration, differentiation, and proliferation, in addition to contributing to the structure of basement membranes. LN-10, composed of alpha5, beta1, and gamma1 chains, is widely distributed in most basement membranes of both epithelia and endothelia. We determined the complete human cDNA sequence for the LN a5 chain and produced recombinant human LN-10 (rLN-10) in HEK293 cells by triple transfection of full-length cDNAs encoding the human LN alpha5, beta1, and gamma1 chains. The rLN-10 was purified using affinity chromatography and had an apparent molecular mass of -800 kDa in SDS-PAGE and a native domain structure in rotary shadowing electron microscopy. By using function-blocking monoclonal antibodies, integrin asp, was found to be a major mediator of adhesion of HT-1080 and human saphenous vein endothelial cells. Human saphenous vein endothelial cells adhered more strongly to rLN-10 than to LN-1 and LN-8 and showed better migration on rLN-10, compared with several other matrices. Considering the cell adhesive and migration-promoting properties of rLN-10 on endothelial cells, this molecule could be useful in improving the biocompatibility and endothelialization of vascular grafts.	Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Biostratum AB, S-17177 Stockholm, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany; Karolinska Hosp, Dept Surg Sci, Div Vasc Surg, S-17176 Stockholm, Sweden	Karolinska Institutet; Max Planck Society; Karolinska Institutet; Karolinska University Hospital	Tryggvason, K (corresponding author), Karolinska Inst, Div Matrix Biol, Dept Med Biochem & Biophys, Scheeles Vag 2,B1,4th Floor, S-17177 Stockholm, Sweden.	Karl.Tryggvason@mbb.ki.se		Hedin, Ulf/0000-0001-9212-3945				Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; Baumgartner R, 1996, J MOL BIOL, V257, P658, DOI 10.1006/jmbi.1996.0192; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; DEJANA E, 1993, KIDNEY INT, V43, P61, DOI 10.1038/ki.1993.11; Dixit P, 2001, J BIOMED MATER RES, V56, P545, DOI 10.1002/1097-4636(20010915)56:4<545::AID-JBM1126>3.0.CO;2-V; DRAKE CJ, 1995, J CELL SCI, V108, P2655; Durbeej M, 1996, MATRIX BIOL, V15, P397, DOI 10.1016/S0945-053X(96)90159-6; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; EKBLOM P, 1996, LAMININS CELL ADHESI, V2, P127; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; ENGVALL E, 1986, J CELL BIOL, V103, P2457, DOI 10.1083/jcb.103.6.2457; Ferletta M, 1999, J CELL SCI, V112, P1; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; *GEN COMP GROUP, 2000, PROGR MAN GCG PACK V; Gu YC, 1999, BLOOD, V93, P2533, DOI 10.1182/blood.V93.8.2533.408k22_2533_2542; HAEGERSTRAND A, 1992, J VASC SURG, V16, P280, DOI 10.1016/0741-5214(92)90119-S; Iivanainen A, 1997, J BIOL CHEM, V272, P27862, DOI 10.1074/jbc.272.44.27862; Jansson K, 1998, EUR J VASC ENDOVASC, V16, P334, DOI 10.1016/S1078-5884(98)80053-1; JARRELL BE, 1986, ANN SURG, V203, P671, DOI 10.1097/00000658-198606000-00012; Kanda S, 1999, EXP CELL RES, V248, P203, DOI 10.1006/excr.1999.4400; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Kortesmaa J, 2000, J BIOL CHEM, V275, P14853, DOI 10.1074/jbc.275.20.14853; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Nielsen PK, 2001, J BIOL CHEM, V276, P10906, DOI 10.1074/jbc.M008743200; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; PEVEC WC, 1992, J VASC SURG, V16, P60, DOI 10.1016/0741-5214(92)90418-8; Pierce RA, 2000, AM J RESP CELL MOL, V23, P742, DOI 10.1165/ajrcmb.23.6.4202; PIKKARAINEN T, 1992, EUR J BIOCHEM, V209, P571, DOI 10.1111/j.1432-1033.1992.tb17322.x; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Pouliot N, 2001, EXP CELL RES, V266, P1, DOI 10.1006/excr.2001.5197; Pouliot N, 2000, EXP CELL RES, V261, P360, DOI 10.1006/excr.2000.5065; RADOMSKI JS, 1989, J SURG RES, V47, P173, DOI 10.1016/0022-4804(89)90084-X; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Shattil SJ, 1997, J CLIN INVEST, V100, pS91; Sixt M, 2001, J BIOL CHEM, V276, P18878, DOI 10.1074/jbc.M010898200; SOROKIN L, 1994, EUR J BIOCHEM, V223, P603, DOI 10.1111/j.1432-1033.1994.tb19031.x; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; Tani T, 1999, EXP CELL RES, V248, P115, DOI 10.1006/excr.1999.4399; THOMSON GJL, 1991, SURGERY, V109, P20; Thyboll J, 2002, MOL CELL BIOL, V22, P1194, DOI 10.1128/MCB.22.4.1194-1202.2002; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; TOKIDA Y, 1990, J BIOL CHEM, V265, P18123; Virtanen I, 1997, AM J PATHOL, V150, P1421; Watelet J, 1997, ANN VASC SURG, V11, P510, DOI 10.1007/s100169900083; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; WILSON YG, 1995, EUR J VASC ENDOVASC, V10, P220, DOI 10.1016/S1078-5884(05)80116-9	58	109	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12741	12748		10.1074/jbc.M111228200	http://dx.doi.org/10.1074/jbc.M111228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821406	hybrid			2022-12-25	WOS:000175036300033
J	Marchand, C; Zhang, XC; Pais, GCG; Cowansage, K; Neamati, N; Burke, TR; Pommier, Y				Marchand, C; Zhang, XC; Pais, GCG; Cowansage, K; Neamati, N; Burke, TR; Pommier, Y			Structural determinants for HIV-1 integrase inhibition by beta-diketo acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND TRANSFER; DNA; COMPLEXES; BINDING; TARGET	Among all the HIV-1 integrase inhibitors, the beta-diketo acids (DKAs) represent a major lead in anti-HIV-1 integrase drug design. These derivatives inhibit the integration reaction in vitro with a strong specificity for the 3'-end joining step. They are also antiviral and inhibit integration in vivo. The aim of the present study has been to investigate the molecular interactions between DKAs and HIV-1 integrase. We have compared 5CITEP with one of the most potent DKAs reported by the Merck group (L-708,906) and found that 5CITEP inhibits 3'-processing at concentrations where L-708,906 is only active on strand transfer. We also report a novel bifunctional DKA derivative that inhibits 3'-processing even more effectively than 5CITEP. The interactions of these inhibitors with the viral DNA donor ends have been studied by performing experiments with oligonucleotides containing defined modifications. We propose that the bifunctional DKA derivative binds to both the acceptor and donor sites of HIV-1 integrase, whereas the monofunctional L-708,906 derivative binds selectively to the acceptor site.	NCI, NIH, Ctr Canc Res, Mol Pharmacol Lab, Bethesda, MD 20892 USA; NCI, Ctr Canc Res, Med Chem Lab, Frederick, MD 21702 USA; Univ So Calif, Coll Pharm, Los Angeles, CA 90089 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Southern California	Pommier, Y (corresponding author), NCI, NIH, Ctr Canc Res, Mol Pharmacol Lab, Bldg 37,Rm 5065, Bethesda, MD 20892 USA.		Burke, Terrence R/N-2601-2014; Marchand, Christophe/D-8559-2016	Burke, Terrence/0000-0001-9925-8586				BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; BROWN PO, 1998, RETROVIRUSES, P161; d'Angelo J, 2001, PATHOL BIOL, V49, P237, DOI 10.1016/S0369-8114(01)00135-3; De Clercq E, 2000, MED RES REV, V20, P323, DOI 10.1002/1098-1128(200009)20:5<323::AID-MED1>3.0.CO;2-A; Espeseth AS, 2000, P NATL ACAD SCI USA, V97, P11244, DOI 10.1073/pnas.200139397; FARNET CM, 1991, J VIROL, V65, P1910, DOI 10.1128/JVI.65.4.1910-1915.1991; Goldgur Y, 1999, P NATL ACAD SCI USA, V96, P13040, DOI 10.1073/pnas.96.23.13040; HAZUDA DJ, 1994, J BIOL CHEM, V269, P3999; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Marchand C, 2001, METHOD ENZYMOL, V340, P624; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Neamati N, 2000, Adv Pharmacol, V49, P147; Pommier Y, 2000, ANTIVIR RES, V47, P139, DOI 10.1016/S0166-3542(00)00112-1; Pommier Y, 1997, ANTIVIR CHEM CHEMOTH, V8, P463, DOI 10.1177/095632029700800601; Richman DD, 2001, NATURE, V410, P995, DOI 10.1038/35073673; SKALKA AM, 1999, RETROVIRAL INTEGRATI, P52	17	116	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12596	12603		10.1074/jbc.M110758200	http://dx.doi.org/10.1074/jbc.M110758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11805103	hybrid			2022-12-25	WOS:000175036300016
J	Pinto, FD; Adamo, HP				Pinto, FD; Adamo, HP			Deletions in the acidic lipid-binding region of the plasma membrane Ca2+ pump - A mutant with high affinity for Ca2+ resembling the acidic lipid-activated enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-PUMP; MONOCLONAL-ANTIBODIES; SARCOPLASMIC-RETICULUM; FUNCTIONAL DOMAINS; PHOSPHOLIPIDS; PROTEOLYSIS; CA2+-ATPASE; EXPRESSION; ATPASE; CELLS	The C-terminal segment of the loop between transmembrane helices 2 and 3 (A(L) region) of the plasma membrane Ca2+ pump (PMCA) is not conserved in other P-ATPases. Part of this region, just upstream from the third transmembrane domain, has been associated with activation of the PMCA by acidic lipids. cDNAs coding for mutants of the Ca2+ pump isoform h4xb with deletions in the A(L) region were constructed, and the proteins were successfully expressed in either COS or Chinese hamster ovary cells. Mutants with deletions in the segment 296-349 had full Ca2+ transport activity, but deletions involving the segment of amino acids 350-356 were inactive suggesting that these residues are required for a functional PMCA. In the absence of calmodulin the V-max of mutant d296-349 was similar to that of the recombinant wild type pump, but its K-0.5 for Ca2+ was about 5-fold lower. The addition of calmodulin increased the V-max and the apparent Ca2+ affinity of both the wild type and d296-349 enzymes indicating that the activating effects of calmodulin were not affected by the deletion. At low concentrations of Ca2+ and in the presence of saturating amounts of calmodulin, the addition of phosphatidic acid increased about 2-fold the activity of the recombinant wild type pump. In contrast, under these conditions phosphatidic acid did not significantly change the activity of mutant d296-349. Taken together these results suggest that (a) deletion of residues 296349 recreates a form of PMCA similar to that resulting from the binding of acidic lipids at the AL region; (b) the A(L) region acts as an acidic lipid-binding inhibitory domain capable of adjusting the Ca2+ affinity of the PMCA to the lipid composition of the membrane; and (c) the function of the A(L) region is independent of the autoinhibition by the C-terminal calmodulin-binding region.	Univ Buenos Aires, IQUIFIB, Fac Farm & Bioquim, RA-1113 Buenos Aires, DF, Argentina	University of Buenos Aires	Adamo, HP (corresponding author), Univ Buenos Aires, IQUIFIB, Fac Farm & Bioquim, Junin 956, RA-1113 Buenos Aires, DF, Argentina.	hpadamo@mail.retina.ar	Adamo, Hugo Pedro/ABB-8338-2021	Adamo, Hugo Pedro/0000-0002-1712-8049				Adamo HP, 2000, BIOCHEMISTRY-US, V39, P14893, DOI 10.1021/bi001222c; ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; ADAMO HP, 1992, BIOCHEM J, V283, P355, DOI 10.1042/bj2830355; Adamo HP, 2000, BBA-BIOMEMBRANES, V1464, P127, DOI 10.1016/S0005-2736(99)00253-9; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; BRODIN P, 1992, EUR J BIOCHEM, V204, P939, DOI 10.1111/j.1432-1033.1992.tb16715.x; CARAFOLI E, 1992, J BIOL CHEM, V267, P2115; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; CHOQUETTE D, 1984, BIOCHEM BIOPH RES CO, V125, P908, DOI 10.1016/0006-291X(84)91369-X; Cornell RB, 2000, TRENDS BIOCHEM SCI, V25, P441, DOI 10.1016/S0968-0004(00)01625-X; Dalton KA, 1998, BIOCHEM J, V329, P637; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1987, J BIOL CHEM, V262, P6425; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FILOTEO AG, 1992, J BIOL CHEM, V267, P11800; HEIM R, 1992, EUR J BIOCHEM, V205, P333, DOI 10.1111/j.1432-1033.1992.tb16784.x; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KEETON TP, 1995, BIOCHEM J, V306, P779, DOI 10.1042/bj3060779; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHOTSKY J, 1992, BIOCHIM BIOPHYS ACTA, V1105, P118, DOI 10.1016/0005-2736(92)90169-M; LUTERBACHER S, 1983, EXPERIENTIA, V39, P311, DOI 10.1007/BF01955322; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; MISSIAEN L, 1989, BIOCHEM J, V263, P687, DOI 10.1042/bj2630687; NIGGLI V, 1981, J BIOL CHEM, V256, P395; PAPP B, 1989, J BIOL CHEM, V264, P4577; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Rosado JA, 2000, J BIOL CHEM, V275, P19529, DOI 10.1074/jbc.M001319200; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; van Voorst F, 2000, BIOCHEM J, V347, P601, DOI 10.1042/bj3470601; vanKlompenburg W, 1997, EMBO J, V16, P4261, DOI 10.1093/emboj/16.14.4261; Wang K K, 1992, Trends Cell Biol, V2, P46, DOI 10.1016/0962-8924(92)90162-G; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZVARITCH E, 1990, BIOCHEMISTRY-US, V29, P8070, DOI 10.1021/bi00487a012	37	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12784	12789		10.1074/jbc.M111055200	http://dx.doi.org/10.1074/jbc.M111055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821403	hybrid			2022-12-25	WOS:000175036300039
J	Suwa, A; Mitsushima, M; Ito, T; Akamatsu, M; Ueda, K; Amachi, T; Kioka, N				Suwa, A; Mitsushima, M; Ito, T; Akamatsu, M; Ueda, K; Amachi, T; Kioka, N			Vinexin beta regulates the anchorage dependence of ERK2 activation stimulated by epidermal growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE ACTIVATION; VINCULIN-BINDING PROTEIN; FOCAL ADHESION KINASE; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; P21-ACTIVATED KINASE; INDEPENDENT GROWTH; TRANSFORMED CELLS; STRESS FIBERS; NUDE MICE	ERK is activated by soluble growth factors in adherent cells. However, activation of ERK is barely detectable and not sufficient for cell proliferation in non-adherent cells. Here, we show that exogenous expression of vinexin beta, a novel focal adhesion protein, allows anchorage-independent ERK2 activation stimulated by epidermal growth factor. In contrast, expression of vinexin beta had no effect on ERK2 activation in adherent cells, suggesting that vinexin beta regulates the anchorage dependence of ERK2 activation. Analyses using deletion mutants demonstrated that a linker region between the second and third SH3 domains of vinexin beta, but not the SH3 domains, is required for this function of vinexin beta. To evaluate the pathway regulating the anchorage dependence of ERK2 activation, we used a dominant-negative mutant of p21-activated kinase (PAK) and a specific inhibitor (1189) of cAMP-dependent protein kinase (PKA) because PAK and PKA are known to regulate the anchorage dependence of ERK2 activation. The dominant-negative mutant of PAK suppressed the anchorage-independent ERK2 activation induced by expression of vinexin beta. The dominant-negative mutant of vinexin beta inhibited the anchorage-independent ERK2 activation induced by the PKA inhibitor. Together, these observations indicate that vinexin beta plays a key role in regulating the anchorage dependence of ERK2 activation through PKA-PAK signaling.	Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Kioka, N (corresponding author), Kyoto Univ, Div Appl Life Sci, Grad Sch Agr, Sakyo Ku, Kyoto 6068502, Japan.	nkioka@kais.kyoto-u.ac.jp		Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X				Akamatsu M, 1999, J BIOL CHEM, V274, P35933, DOI 10.1074/jbc.274.50.35933; Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Aplin AE, 1999, J CELL SCI, V112, P695; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; BENECKE BJ, 1978, CELL, V14, P931, DOI 10.1016/0092-8674(78)90347-1; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cowan CA, 2001, NATURE, V413, P174, DOI 10.1038/35093123; Cybulsky AV, 1997, BIOCHEM BIOPH RES CO, V231, P160, DOI 10.1006/bbrc.1997.6064; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Daniels RH, 1999, J BIOL CHEM, V274, P6047, DOI 10.1074/jbc.274.10.6047; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Harden N, 1996, MOL CELL BIOL, V16, P1896; Howe AK, 2000, NAT CELL BIOL, V2, P593, DOI 10.1038/35023536; Inoue H, 1996, VIROLOGY, V225, P223, DOI 10.1006/viro.1996.0591; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; Kioka N, 1999, J CELL BIOL, V144, P59, DOI 10.1083/jcb.144.1.59; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; SHIN SI, 1975, P NATL ACAD SCI USA, V72, P4435, DOI 10.1073/pnas.72.11.4435; Wang BL, 1997, J BIOL CHEM, V272, P17542, DOI 10.1074/jbc.272.28.17542	43	34	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13053	13058		10.1074/jbc.M108644200	http://dx.doi.org/10.1074/jbc.M108644200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11825889	hybrid			2022-12-25	WOS:000175036300072
J	Ng, DS; Maguire, GF; Wylie, J; Ravandi, A; Xuan, WL; Ahmed, Z; Eskandarian, M; Kuksis, A; Connelly, PW				Ng, DS; Maguire, GF; Wylie, J; Ravandi, A; Xuan, WL; Ahmed, Z; Eskandarian, M; Kuksis, A; Connelly, PW			Oxidative stress is markedly elevated in lecithin : cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR-ACETYLHYDROLASE; LOW-DENSITY-LIPOPROTEIN; SERUM PARAOXONASE; OXIDASE; PLASMA; GENE; PHOSPHOLIPIDS; DISRUPTION; GENERATION; PREVENTS	Complete lecithin:cholesterol acyltransferase (LCAT) deficiency is a rare cause of severe hypoalphalipoproteinemia, but the affected subjects are surprisingly not particularly prone to premature coronary heart disease. We studied oxidative stress in lcat-/- mice and their cross-breed with apolipoprotein-E knockout mice (apoE-/-xlcat-/-) by measuring vascular ring superoxide production and plasma phospholipid (PL)-bound F2-isoprostane levels and their relationship with aortic atherosclerosis. Compared with wild type control (lcat+/+), lcat-/- and lcat+/- mice showed a 4.9- (p = 0.003) and a 2.1-fold (p = 0.04) increase in plasma PL-F2-isoprostane levels, respectively. There was also a 3.6(p < 0.0001) and 2.9-fold (p = 0.003) increase in the area under the curve for the aortic ring superoxide excursion by lucigenin-derived chemiluminescence. A comparison of apoE-/-xlcat+/+ mice with wild type control mice showed a more modest 2.1- (p = 0.04) and 2.2-fold (p < 0.00001) increase in these respective markers. Surprisingly, the apoE-/-xlcat-/- mice showed a paradoxical normalization in both oxidation markers. Furthermore, by fast protein liquid chromatography separation, we observed an associated retention and redistribution of serum paraoxonase activities to the non-high density lipoprotein fractions in both the apoE-/-xlcat-/- and apoE-/-xlcat+/- mice. Aortic atherosclerotic lesions in male apoE-/-xlcat-/- and apoE-/-xlcat+/- mice were reduced by 52 (p = 0.02) and 24% (p = 0.46), respectively. Our data suggest that LCAT-deficient mice are associated with an increased oxidative stress that is paradoxically reversed in a hyperlipidemic background, possibly due to the redistribution of paraoxonase. This modulation of oxidative stress may in part contribute to the reduced atherosclerosis seen in the apoE-/-xlcat-/- mice.	St Michaels Hosp, Dept Med, Toronto, ON M5B 1A6, Canada; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto	Ng, DS (corresponding author), St Michaels Hosp, Dept Med, W Annex,2-015 38 Shuter St, Toronto, ON M5B 1A6, Canada.	ngd@smh.toronto.on.ca	Ravandi, Amir/O-7552-2019; Connelly, Philip W/B-7583-2012	Connelly, Philip W/0000-0001-7244-6843				Aviram M, 1998, ARTERIOSCL THROM VAS, V18, P1617, DOI 10.1161/01.ATV.18.10.1617; Draganov DI, 2000, J BIOL CHEM, V275, P33435, DOI 10.1074/jbc.M004543200; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Elferink RPJO, 1998, J CLIN INVEST, V102, P1749, DOI 10.1172/JCI3597; FIELDING CJ, 1995, J LIPID RES, V36, P211; Forte TM, 1999, J LIPID RES, V40, P1276; GAN KN, 1991, DRUG METAB DISPOS, V19, P100; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guzik TJ, 2000, CIRC RES, V86, pE85, DOI 10.1161/01.RES.86.9.e85; HA YC, 1985, J CHROMATOGR, V341, P154, DOI 10.1016/S0378-4347(00)84020-7; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; James RW, 1998, ATHEROSCLEROSIS, V139, P77, DOI 10.1016/S0021-9150(98)00058-6; Kuivenhoven JA, 1997, J LIPID RES, V38, P191; Lambert G, 2001, J BIOL CHEM, V276, P15090, DOI 10.1074/jbc.M008466200; Mackness MI, 1997, FEBS LETT, V416, P377, DOI 10.1016/S0014-5793(97)01243-X; Navab M, 2000, J LIPID RES, V41, P1495; Ng DS, 1997, J BIOL CHEM, V272, P15777, DOI 10.1074/jbc.272.25.15777; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274, DOI 10.1152/ajpheart.1995.268.6.H2274; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Quarck R, 2001, CIRCULATION, V103, P2495; Ravandi A, 1999, J BIOL CHEM, V274, P16494, DOI 10.1074/jbc.274.23.16494; Reddy ST, 2001, ARTERIOSCL THROM VAS, V21, P542, DOI 10.1161/01.ATV.21.4.542; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Shih DM, 1998, NATURE, V394, P284, DOI 10.1038/28406; Shih DM, 2000, J BIOL CHEM, V275, P17527, DOI 10.1074/jbc.M910376199; Sorenson RC, 1999, ARTERIOSCL THROM VAS, V19, P2214, DOI 10.1161/01.ATV.19.9.2214; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Stafforini DM, 1997, J BIOL CHEM, V272, P17895, DOI 10.1074/jbc.272.29.17895; Subramanian VS, 1999, BBA-MOL CELL BIOL L, V1439, P95, DOI 10.1016/S1388-1981(99)00072-4; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; Tarpey MM, 1999, CIRC RES, V84, P1203, DOI 10.1161/01.RES.84.10.1203; Vohl MC, 1999, BIOCHEMISTRY-US, V38, P5976, DOI 10.1021/bi982258w; WARNICK GR, 1982, CLIN CHEM, V28, P1379; Yokoyama M, 2000, ANN NY ACAD SCI, V902, P241	36	48	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11715	11720		10.1074/jbc.M112320200	http://dx.doi.org/10.1074/jbc.M112320200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809774	hybrid			2022-12-25	WOS:000174846400016
J	Olosz, F; Malek, TR				Olosz, F; Malek, TR			Structural basis for binding multiple ligands by the common cytokine receptor gamma-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; T-LYMPHOCYTE DEVELOPMENT; INTERLEUKIN-2 RECEPTOR; IL-2 RECEPTOR; FUNCTIONAL COMPONENT; COMPLEX; SUPERFAMILY; EXPRESSION; ANTIBODIES; SUBUNIT	The common gamma-chain (gamma(c)) that functions both in ligand binding and signal transduction is a shared subunit of the multichain receptors for interleukin (IL)-2, IL-4, IL-7, IL-9, IL-15, and IL-21. The structural basis by which the ectodomain of gamma(c) contributes to binding six distinct cytokines is only partially defined. In the present study, epitope mapping of antagonistic anti-ye monoclonal antibodies led to the identification of Asn-128 of mouse gamma(c). that represents another potential contact residue that is required for binding IL-2, IL-7, and IL-15 but not IL-4. In addition, Tyr-103, Cys-161, Cys-210, and Cys-211, previously identified to contribute to binding IL-2 and IL-7, were also found to be involved in binding IL-4 and IL-15. Collectively, these data favor a model in which ye utilizes a common mechanism for its interactions with multiple cytokines, and the binding sites are largely overlapping but not identical. Asn-128 and Tyr-103 likely act as contact residues whereas Cys-161, Cys-210, and Gly-211 may stabilize the structure of the proposed ligandinteracting surface formed by the two extracytoplasmic domains.	Univ Miami, Sch Med, Dept Microbiol & Immunol R138, Miami, FL 33101 USA	University of Miami	Malek, TR (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol R138, POB 016960, Miami, FL 33101 USA.				NIAID NIH HHS [AI401114] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asao H, 2001, J IMMUNOL, V167, P1, DOI 10.4049/jimmunol.167.1.1; BAMBOROUGH P, 1994, STRUCTURE, V2, P839, DOI 10.1016/S0969-2126(94)00085-9; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GUSTCHINA A, 1995, PROTEINS, V21, P140, DOI 10.1002/prot.340210208; He YW, 1998, CRIT REV IMMUNOL, V18, P503, DOI 10.1615/CritRevImmunol.v18.i6.20; HE YW, 1995, J IMMUNOL, V154, P1596; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; Kroemer RT, 1996, PROTEIN ENG, V9, P1135, DOI 10.1093/protein/9.12.1135; Kumaki S, 1999, BLOOD, V93, P607, DOI 10.1182/blood.V93.2.607.402k12_607_612; MALEK TR, 1995, J INTERF CYTOK RES, V15, P447, DOI 10.1089/jir.1995.15.447; Malek TR, 1998, J LEUKOCYTE BIOL, V63, P643, DOI 10.1002/jlb.63.6.643; Meissner U, 2001, BLOOD, V97, P183; Middleton SA, 1999, J BIOL CHEM, V274, P14163, DOI 10.1074/jbc.274.20.14163; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; Olosz F, 2000, J BIOL CHEM, V275, P30100, DOI 10.1074/jbc.M004976200; OShea JJ, 1997, IMMUNITY, V7, P1, DOI 10.1016/S1074-7613(00)80505-1; Porter BO, 1999, J IMMUNOL, V163, P5906; Puck JM, 1997, BLOOD, V89, P1968; PUCK JM, 1993, HUM MOL GENET, V2, P1099, DOI 10.1093/hmg/2.8.1099; Puck JM, 1996, IMMUNOL TODAY, V17, P507, DOI 10.1016/0167-5699(96)30062-5; Raskin N, 1998, J IMMUNOL, V161, P3474; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SARAGOVI H, 1987, J IMMUNOL, V139, P1918; SUDO T, 1993, P NATL ACAD SCI USA, V90, P9125, DOI 10.1073/pnas.90.19.9125; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X	34	19	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12047	12052		10.1074/jbc.M110520200	http://dx.doi.org/10.1074/jbc.M110520200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815609	hybrid			2022-12-25	WOS:000174846400059
J	Stenner-Liewen, F; Liewen, H; Zapata, JM; Pawlowski, K; Godzik, A; Reed, JC				Stenner-Liewen, F; Liewen, H; Zapata, JM; Pawlowski, K; Godzik, A; Reed, JC			CADD, a Chlamydia protein that interacts with death receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACHOMATIS INFECTION; APOPTOSIS; CELLS; PSITTACI; SEQUENCE	We report here the identification of a bacterial protein capable of interacting with mammalian death receptors in vitro and in vivo. The protein is encoded in the genome of Chlamydia trachomatis and has homologues in other Chlamydia species. This protein, which we refer to as "Chlamydia protein associating with death domains" (CADD), induces apoptosis in a variety of mammalian cell lines when expressed by transient gene transfection. Apoptosis induction can be blocked by Caspase inhibitors, indicating that CADD triggers cell death by engaging the host apoptotic machinery. CADD interacts with death domains of tumor necrosis factor (TNF) family receptors TNFR1, Fas, DR4, and DR5 but not with the respective downstream adaptors. In infected epithelial cells, CADD is expressed late in the infectious cycle of C. trachomatis and co-localizes with Fas in the proximity of the inclusion body. The results suggest a role for CADD modulating the apoptosis pathways of cells infected, revealing a new mechanism of host-pathogen interaction.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Reed, JC (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org	Godzik, Adam/A-7279-2009; Zapata, Juan M/J-6304-2014; Godzik, Adam/AAW-1467-2020; Pawlowski, Krzysztof/E-3262-2012; Pawłowski, Krzysztof/C-2949-2013	Godzik, Adam/0000-0002-2425-852X; Zapata, Juan M/0000-0002-0110-0009; Godzik, Adam/0000-0002-2425-852X; Pawłowski, Krzysztof/0000-0002-5367-0935; Stenner, Frank/0000-0003-4541-8817; Liewen, Heike/0000-0002-6161-4749	NCI NIH HHS [CA68390] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anttila T, 2001, JAMA-J AM MED ASSOC, V285, P47, DOI 10.1001/jama.285.1.47; CAMPBELL S, 1989, J GEN MICROBIOL, V135, P1153; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Fan T, 1998, J EXP MED, V187, P487, DOI 10.1084/jem.187.4.487; Fischer SF, 2001, INFECT IMMUN, V69, P7121, DOI 10.1128/IAI.69.11.7121-7129.2001; Gerard HC, 1997, MOL GEN GENET, V255, P637, DOI 10.1007/s004380050538; Gibellini D, 1998, ZBL BAKT-INT J MED M, V288, P35, DOI 10.1016/S0934-8840(98)80095-9; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; MEULENBERG JJM, 1990, FEMS MICROBIOL LETT, V71, P337, DOI 10.1016/0378-1097(90)90244-K; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; Ojcius DM, 1998, J BIOL CHEM, V273, P7052, DOI 10.1074/jbc.273.12.7052; Ojcius DM, 1998, J IMMUNOL, V161, P4220; Perfettini JL, 2000, INFECT IMMUN, V68, P2237, DOI 10.1128/IAI.68.4.2237-2244.2000; Roulston A, 1999, ANNU REV MICROBIOL, V53, P577, DOI 10.1146/annurev.micro.53.1.577; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SCHACHTER J, 1982, JAMA-J AM MED ASSOC, V248, P2134, DOI 10.1001/jama.248.17.2134; Schoier J, 2001, MICROB PATHOGENESIS, V31, P173, DOI 10.1006/mpat.2001.0460; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797	18	69	73	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9633	9636		10.1074/jbc.C100693200	http://dx.doi.org/10.1074/jbc.C100693200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11805081	hybrid			2022-12-25	WOS:000174549200004
J	Ramirez de Molina, A; Penalva, V; Lucas, L; Lacal, JC				Ramirez de Molina, A; Penalva, V; Lucas, L; Lacal, JC			Regulation of choline kinase activity by Ras proteins involves Ral-GDS and PI3K	ONCOGENE			English	Article						ras; oncogenes; choline kinase; Ras effectors; Raf; Ral-GDS; PI3K	PHOSPHOLIPASE-D; PHOSPHOINOSITIDE 3-KINASE; STRUCTURAL REQUIREMENTS; NIH 3T3-CELLS; CELL-CYCLE; V-SRC; ACTIVATION; CANCER; TRANSFORMATION; PROLIFERATION	Ras proteins are molecular switches that control signaling pathways critical in the onset of a variety of human cancers. The signaling pathways activated by Ras proteins are those controlled by its direct effectors such as the serine-threonine protein kinase Raf-1, the exchange factor for other GTPases Ral-GDS, and the lipid kinase PI3K. As a consequence of Ras activation, a number of additional enzymes are affected, including several members of the serine-threonine intracellular proteins kinases as well as enzymes related to phospholipid metabolism regulation such as phospholipases A2 and D, and choline kinase. The precise mechanisms by which ras oncogenes impinge into these later molecules and their relevance to the onset of the carcinogenic process is still not fully understood. Here we have investigated the mechanism of regulation of choline kinase by Ras proteins and found no direct link between PLD and choline kinase activation. We provide evidence that Ras proteins regulate the activity of choline kinase through its direct effectors Ral-GDS and PI3K, while the Raf pathways seems to be not relevant in this process. The importance of Ras-dependent activation of choline kinase is discussed.	CSIC, Inst Invest Biomed, Madrid 28049, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Lacal, JC (corresponding author), CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28049, Spain.		Lacal, Juan Carlos/AAL-2235-2020; de Molina, Ana Ramirez/AAA-3848-2019; Lacal, Juan Carlos/N-9064-2015	Lacal, Juan Carlos/0000-0002-1908-2777				Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; Baldassare JJ, 1997, J BIOL CHEM, V272, P4911, DOI 10.1074/jbc.272.8.4911; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARBADELLI A, 1999, ONCOGENE, V18, P1139; BERNHARED EJ, 2000, CANCER RES, V60, P6577; Bhakoo KK, 1996, CANCER RES, V56, P4630; BOS JL, 1989, CANCER RES, V49, P4682; BOS JL, 1997, BIOCHIM BIOPHYS ACTA, V1333, P19; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645; CUADRADO A, 1993, ONCOGENE, V8, P2959; de Molina AR, 2001, BIOCHEM BIOPH RES CO, V285, P873, DOI 10.1006/bbrc.2001.5250; De molina AR, 2001, INT J ONCOL, V19, P5; DECERTAINES JD, 1993, NMR BIOMED, V6, P345, DOI 10.1002/nbm.1940060602; Exton JH, 2000, ANN NY ACAD SCI, V905, P61; FRIEDMAN SL, 1994, J BIOL CHEM, V269, P10551; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; GRATAS C, 1993, ANTICANCER RES, V13, P1239; Guillemain I, 1998, BBA-MOL CELL RES, V1405, P161, DOI 10.1016/S0167-4889(98)00107-4; Hernandez-Alcoceba R, 1999, CANCER RES, V59, P3112; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; HernandezAlcoceba R, 1997, ONCOGENE, V15, P2289, DOI 10.1038/sj.onc.1201414; JIMENEZ B, 1995, J CELL BIOCHEM, V57, P141, DOI 10.1002/jcb.240570114; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Lacal J C, 2001, IDrugs, V4, P419; LACAL JC, 1990, MOL CELL BIOL, V10, P333, DOI 10.1128/MCB.10.1.333; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; Lucas L, 2001, ONCOGENE, V20, P1110, DOI 10.1038/sj.onc.1204216; Lucas L, 2000, ONCOGENE, V19, P431, DOI 10.1038/sj.onc.1203323; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; MACARA IG, 1989, MOL CELL BIOL, V9, P325, DOI 10.1128/MCB.9.1.325; MALUMBRES M, 1999, REV ONCOLOGIA, V1, P66; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Montaner S, 1999, J BIOL CHEM, V274, P8506, DOI 10.1074/jbc.274.13.8506; MOODIE SA, 1995, ONCOGENE, V11, P447; Moore SM, 1998, CANCER RES, V58, P5239; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Muller SM, 2000, BIOCHEM BIOPH RES CO, V270, P892, DOI 10.1006/bbrc.2000.2531; Nakagami K, 1999, JPN J CANCER RES, V90, P419, DOI 10.1111/j.1349-7006.1999.tb00764.x; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RUIZCABELLO J, 1992, NMR BIOMED, V5, P226, DOI 10.1002/nbm.1940050506; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH TAD, 1993, NMR BIOMED, V6, P318, DOI 10.1002/nbm.1940060506; SONG JG, 1991, MOL CELL BIOL, V11, P4903, DOI 10.1128/MCB.11.10.4903; SRIVASTAVA SK, 1989, MOL CELL BIOL, V9, P1779, DOI 10.1128/MCB.9.4.1779; Wang ZL, 1998, STRUCTURE, V6, P1117, DOI 10.1016/S0969-2126(98)00113-0; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	55	95	99	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					937	946		10.1038/sj.onc.1205144	http://dx.doi.org/10.1038/sj.onc.1205144			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840339				2022-12-25	WOS:000173427100009
J	Tang, SH; Bhatia, B; Maldonaldo, CJ; Yang, PY; Newman, RA; Liu, JW; Chandra, D; Traag, J; Klein, RD; Fischer, SM; Chopra, D; Shen, JJ; Zhau, HE; Chung, LWK; Tang, DG				Tang, SH; Bhatia, B; Maldonaldo, CJ; Yang, PY; Newman, RA; Liu, JW; Chandra, D; Traag, J; Klein, RD; Fischer, SM; Chopra, D; Shen, JJ; Zhau, HE; Chung, LWK; Tang, DG			Evidence that arachidonate 15-lipoxygenase 2 is a negative cell cycle regulator in normal prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGODENDROCYTE PRECURSOR CELLS; MESSENGER-RNA; CANCER CELLS; NUDE-MICE; CARCINOMA; EXPRESSION; LINE; ADENOCARCINOMA; LIPOXYGENASES; ESTABLISHMENT	15-Lipoxygenase 2 (15-LOX2) is a recently cloned human lipoxygenase that shows tissue-restricted expression in prostate, lung, skin, and cornea. The protein level and enzymatic activity of 15-LOX2 have been shown to be down-regulated in prostate cancers compared with normal and benign prostate tissues. The biological function of 15-LOX2 and the role of loss of 15-LOX2 expression in prostate tumorigenesis, however, remain unknown. We report the cloning and functional characterization of 15-LOX2 and its three splice variants (termed 15-LOX2sv-a, 15-LOX2sv-b, and 15-LOX2sv-c) from primary prostate epithelial cells. Western blotting with multiple primary prostate cell strains and prostate cancer cell lines reveals that the expression of 15-LOX2 is lost in all prostate cancer cell lines, accompanied by decreased enzymatic activity revealed by liquid chromatography/tandem mass spectrometry analyses. Further experiments show that the loss of 15-LOX2 expression results from transcriptional repression caused by mechanism(s) other than promoter hypermethylation or histone deacetylation. Subsequent functional studies indicate the following: 1) the 15-LOX2 product, 15(S)-hydroxyeicosatetraenoic acid, inhibits prostate cancer cell cycle progression; 2) 15-LOX2 expression in primary prostate epithelial cells is inversely correlated with cell cycle; and 3) restoration of 15-LOX2 expression in prostate cancer cells partially inhibits cell cycle progression. Taken together, these results suggest that 15-LOX2 could be a suppressor of prostate cancer development, which functions by restricting cell cycle progression.	Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Wayne State Univ, Inst Chem Toxicol, Detroit, MI 48226 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA 30322 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Wayne State University; Emory University	Tang, DG (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Pk Rd 1C, Smithville, TX 78957 USA.		Tang, Dean/AAI-3457-2020	Tang, Dean/0000-0001-5029-1174; Chandra, Dhyan/0000-0001-7272-9384	NCI NIH HHS [CA16672, CA-90297, T32 CA09480-16] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, T32CA009480, R01CA090297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Anderson KM, 1998, PROSTATE, V37, P161, DOI 10.1002/(SICI)1097-0045(19981101)37:3<161::AID-PROS5>3.0.CO;2-D; Brash AR, 1997, P NATL ACAD SCI USA, V94, P6148, DOI 10.1073/pnas.94.12.6148; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; BROTHMAN AR, 1991, J UROLOGY, V145, P1088, DOI 10.1016/S0022-5347(17)38540-3; Chopra DP, 1997, CANCER RES, V57, P3688; Chopra DP, 1996, J CELL PHYSIOL, V169, P269, DOI 10.1002/(SICI)1097-4652(199611)169:2<269::AID-JCP6>3.0.CO;2-M; ENDOW SA, 1998, GREEN FLUORESCENT PR, P288; GANN PH, 1994, J NATL CANCER I, V86, P281, DOI 10.1093/jnci/86.4.281; GAO X, 1995, UROLOGY, V46, P227, DOI 10.1016/S0090-4295(99)80198-8; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P1571, DOI 10.1093/jnci/85.19.1571; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; HAN JW, 1991, SCIENCE, V251, P204; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; Jack GS, 2000, HUM PATHOL, V31, P1146, DOI 10.1053/hupa.2000.16670; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kelavkar UP, 2000, CARCINOGENESIS, V21, P1777; Kempen EC, 2001, ANAL BIOCHEM, V297, P183, DOI 10.1006/abio.2001.5325; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kilty I, 1999, EUR J BIOCHEM, V266, P83, DOI 10.1046/j.1432-1327.1999.00818.x; Krieg P, 2001, GENOMICS, V73, P323, DOI 10.1006/geno.2001.6519; Kuhn H, 1999, FEBS LETT, V449, P7, DOI 10.1016/S0014-5793(99)00396-8; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; MAGUAD JP, 1988, J IMMUNOL METHODS, V106, P95; MURAKI J, 1990, UROLOGY, V36, P79, DOI 10.1016/0090-4295(90)80319-I; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Nie DT, 2000, BLOOD, V95, P2304, DOI 10.1182/blood.V95.7.2304.007k23_2304_2311; Ostareck DH, 2001, CELL, V104, P281, DOI 10.1016/S0092-8674(01)00212-4; SCHEFFLER IE, 1999, MITOCHONDRIA, P89; Shappell SB, 1999, AM J PATHOL, V155, P235, DOI 10.1016/S0002-9440(10)65117-6; Shappell SB, 2001, CANCER RES, V61, P497; Spindler SA, 1997, BIOCHEM BIOPH RES CO, V239, P775, DOI 10.1006/bbrc.1997.7471; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tang DG, 1997, ADV EXP MED BIOL, V407, P405; Tang DG, 2000, J CELL BIOL, V148, P971, DOI 10.1083/jcb.148.5.971; TANG DG, 1993, J CELL BIOL, V121, P689, DOI 10.1083/jcb.121.3.689; Tang DG, 1998, CANCER RES, V58, P3466; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; Tang DG, 2001, SCIENCE, V291, P868, DOI 10.1126/science.1056780; TANG DG, 2002, IN PRESS BIOL CHEM, V383; WANG Y, 1995, J NATL CANCER I, V87, P1456, DOI 10.1093/jnci/87.19.1456; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	50	99	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16189	16201		10.1074/jbc.M111936200	http://dx.doi.org/10.1074/jbc.M111936200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839751	hybrid			2022-12-25	WOS:000175510400129
J	Becker, EC; Meyer, RJ				Becker, EC; Meyer, RJ			MobA, the DNA strand transferase of plasmid R1162 - The minimal domain required for DNA processing at the origin of transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGAL TRANSFER; ORIT DNA; PROTEIN; MOBILIZATION; SEQUENCE; GENE; RECOMBINATION; ORGANIZATION; PURIFICATION; TERMINATION	MobA is a DNA strand transferase encoded by the plasmid R1162 and required for plasmid DNA processing during conjugal transfer. The smallest active fragment was identified using phage display and partial enzymatic digestion of the purified protein. This fragment, consisting of approximately the first 184 amino acids, is able to bind and cleave its normal DNA substrate, the origin of transfer (oriT). Smaller fragments having one of these activities were not obtained. An active intermediate consisting of MobA linked to DNA was isolated and used to show that a single molecule of MobA is sufficient to carry out all of the DNA processing steps during transfer. These results, along with those obtained earlier, point to a single large, active site in MobA that makes several different contacts along the oriT DNA strand.	Univ Texas, Sch Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Meyer, RJ (corresponding author), Univ Texas, Sch Biol, Sect Mol Genet & Microbiol, Austin, TX 78712 USA.				NIGMS NIH HHS [GM37462] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037462] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARLETT MM, 1990, NUCLEIC ACIDS RES, V18, P3579, DOI 10.1093/nar/18.12.3579; Becker EC, 2000, J MOL BIOL, V300, P1067, DOI 10.1006/jmbi.2000.3902; BHATTACHARJEE MK, 1991, NUCLEIC ACIDS RES, V19, P1129, DOI 10.1093/nar/19.5.1129; BHATTACHARJEE MK, 1993, NUCLEIC ACIDS RES, V21, P4563, DOI 10.1093/nar/21.19.4563; BRASCH MA, 1986, J BACTERIOL, V167, P703, DOI 10.1128/jb.167.2.703-710.1986; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COURTNEY BC, 1995, GENE, V165, P139, DOI 10.1016/0378-1119(95)00526-C; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; Grandoso G, 2000, J MOL BIOL, V295, P1163, DOI 10.1006/jmbi.1999.3425; Henderson D, 1996, J BACTERIOL, V178, P6888, DOI 10.1128/jb.178.23.6888-6894.1996; KIM K, 1989, J MOL BIOL, V208, P501, DOI 10.1016/0022-2836(89)90513-5; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Meyer R, 2000, J BACTERIOL, V182, P4875, DOI 10.1128/JB.182.17.4875-4881.2000; MEYER R, 1989, J BACTERIOL, V171, P799, DOI 10.1128/jb.171.2.799-806.1989; Miller J. H., 1972, EXPT MOL GENETICS, P433; Perwez T, 1996, J BACTERIOL, V178, P5762, DOI 10.1128/jb.178.19.5762-5767.1996; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SCHERZINGER E, 1993, EUR J BIOCHEM, V217, P929, DOI 10.1111/j.1432-1033.1993.tb18323.x; SCHERZINGER E, 1992, NUCLEIC ACIDS RES, V20, P41, DOI 10.1093/nar/20.1.41; SCHOLZ P, 1989, GENE, V75, P271, DOI 10.1016/0378-1119(89)90273-4; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZHANG SY, 1995, MOL MICROBIOL, V17, P727, DOI 10.1111/j.1365-2958.1995.mmi_17040727.x; ZIEGELIN G, 1989, J BIOL CHEM, V264, P11989	26	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14575	14580		10.1074/jbc.M110759200	http://dx.doi.org/10.1074/jbc.M110759200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839744	hybrid			2022-12-25	WOS:000175203000030
J	Doronin, S; Shumay, E; Wang, HY; Malbon, CC				Doronin, S; Shumay, E; Wang, HY; Malbon, CC			Akt mediates sequestration of the beta(2)-adrenergic receptor in response to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC RECEPTORS; PROTEIN-LINKED RECEPTORS; MASS-SPECTROMETRY; TYROSINE KINASE; POSTTRANSLATIONAL MODIFICATIONS; BETA-2-ADRENERGIC RECEPTOR; SIGNAL-TRANSDUCTION; IN-VIVO; DESENSITIZATION; SUBSTRATE	The counterregulation of catecholamine action by insulin includes insulin-stimulated sequestration of the beta(2)-adrenergic receptor. Herein we examined the signaling downstream of insulin receptor activation, focusing upon the role of 1-phosphatidylinositol 3-kinase and the serine-threonine protein kinase Akt (also known as protein kinase 13) in the internalization of beta(2)-adrenergic receptors. Inhibition of 1-phosphatidylinositol 3-kinase by LY294002 blocks insulin-induced sequestration of the beta(2)-adrenergic receptor, implicating Akt in downstream signaling to the beta(2)-adrenergic receptor. Phosphorylation studies of the C-terminal cytoplasmic domain of the beta(2)-adrenergic receptor by Akt in vitro identified Ser(345) and Ser(346) within a consensus motif for Akt phosphorylation. Double mutation (i.e. S345A/S346A) within this motif abolishes insulin counterregulation of beta-adrenergic stimulation of cyclic AMP accumulation as well as insulin-stimulated sequestration. Furthermore, expression of constitutively activated Akt (T308D/S473D) mimics insulin action on cyclic AMP responses and beta(2)-adrenergic receptor internalization. Expression of the dominant-negative version of Akt (K179A/T308A/S473A), in contrast, abolishes both insulin counterregulation of the cyclic AMP response as well as insulin-stimulated sequestration of the beta(2)-adrenergic receptor. The action of the serine-threonine protein kinase Akt in insulin counterregulation mirrors the central role of protein kinase A in beta-agonist-induced desensitization.	SUNY Stony Brook, Pharmacol HSC, Univ Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Univ Med Ctr, Dept Physiol & Biophys, Diabet & Metab Dis Res Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital	Malbon, CC (corresponding author), SUNY Stony Brook, Pharmacol HSC, Univ Med Ctr, Dept Mol Pharmacol, Stony Brook, NY 11794 USA.		malbon, craig/ABF-3604-2020					Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 2001, BIOCHEM SOC T, V29, P1, DOI 10.1042/bst029a059; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Annan RS, 1997, J PROTEIN CHEM, V16, P391, DOI 10.1023/A:1026384605285; Baltensperger K, 1996, J BIOL CHEM, V271, P1061, DOI 10.1074/jbc.271.2.1061; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Doronin S, 2000, PROTEIN EXPRES PURIF, V20, P451, DOI 10.1006/prep.2000.1322; Fan GF, 2001, J BIOL CHEM, V276, P13240, DOI 10.1074/jbc.M011578200; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Karoor V, 1998, Adv Pharmacol, V42, P425; Karoor V, 1996, PROG NEUROBIOL, V48, P555, DOI 10.1016/0301-0082(96)00004-4; KAROOR V, 1995, J BIOL CHEM, V270, P25305, DOI 10.1074/jbc.270.43.25305; Karoor V, 1996, J BIOL CHEM, V271, P29347, DOI 10.1074/jbc.271.46.29347; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; KASHLES O, 1987, BIOCHEM PHARMACOL, V36, P1531, DOI 10.1016/0006-2952(87)90122-5; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; Lennon JJ, 1999, PROTEIN SCI, V8, P2487; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; MALBON CC, 1980, J BIOL CHEM, V255, P8692; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; McLachlin DT, 2001, CURR OPIN CHEM BIOL, V5, P591, DOI 10.1016/S1367-5931(00)00250-7; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Olefsky JM, 1999, J BIOL CHEM, V274, P1863, DOI 10.1074/jbc.274.4.1863; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Steen H, 2001, J MASS SPECTROM, V36, P782, DOI 10.1002/jms.174; Summers SA, 2000, INT J OBESITY, V24, pS67, DOI 10.1038/sj.ijo.0801509; WANG HY, 1989, BIOCHEM J, V263, P519, DOI 10.1042/bj2630519	29	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15124	15131		10.1074/jbc.M108771200	http://dx.doi.org/10.1074/jbc.M108771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11809767	hybrid			2022-12-25	WOS:000175203000098
J	Liao, YF; Gotwals, PJ; Koteliansky, VE; Sheppard, D; Van de Water, L				Liao, YF; Gotwals, PJ; Koteliansky, VE; Sheppard, D; Van de Water, L			The EIIIA segment of fibronectin is a ligand for integrins alpha(9)beta(1) and alpha(4)beta(1) providing a novel mechanism for regulating cell adhesion by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRA DOMAIN-A; VON-WILLEBRAND-FACTOR; EMBRYONIC FIBRONECTINS; ISOFORM DISTRIBUTION; CRYSTAL-STRUCTURE; III REPEATS; EDA SEGMENT; V-SEGMENT; EXPRESSION; RAT	Alternative splicing of the fibronectin gene transcript gives rise to forms that include the EIIIA (or ED-A) segment. EIIIA-containing fibronectins are prominently expressed during embryogenesis and wound healing and appear to mediate changes in cell adhesion and gene expression. Nonetheless, integrins that bind the EIIIA segment have not been identified. We previously mapped the epitope for two function-blocking monoclonal antibodies to the C-C' loop region of the EIIIA segment (Liao, Y.-F., Wieder, K. G., Classen, J. M., and Van De Water, L. (1999) J. Biol. Chem. 274, 17876-17884). The sequence of this epitope ((39)PEDGIHELFP(48)) resembles the sequence within tenascin-C to which the integrin alpha(9)beta(1) binds. We now report that either integrin alpha(9)beta(1) or alpha(4)beta(1) can mediate cell adhesion to the EIIIA segment. Moreover, this interaction is blocked both by epitope-mapped EIIIA antibodies as well as by the respective anti-integrins. Deletion mutants of the EIIIA segment that include the C-C' loop and flanking sequence bind cells expressing either alpha(9)beta(1) or alpha(4)beta11. Adhesion of alpha(4)beta(1)-containing MOLT-3 cells to the EIIIA segment stimulates phosphorylation of p44/42 MAP kinase. Our observation that two integrins bind the EIIIA segment establishes a novel mechanism by which cell adhesion to fibronectin is regulated by alternative splicing.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA; Harvard Univ, Shriners Burns Hosp, Sch Med, Boston, MA 02114 USA; Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA; Biogen Inc, Cambridge, MA 02142 USA	Albany Medical College; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California San Francisco; Biogen	Van de Water, L (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, Mail Code 165,47 New Scotland Ave, Albany, NY 12208 USA.		Liao, Yung-Feng/A-9761-2011	Van De Water, Livingston/0000-0002-3825-9224	NHLBI NIH HHS [HL47412, HL53949, HL56385, HL/AI33259] Funding Source: Medline; NIGMS NIH HHS [GM56442] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047412, R37HL053949, R01HL033259, P01HL056385, R01HL053949, P50HL056385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056442] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARNES JL, 1994, AM J PATHOL, V145, P585; BARON M, 1992, BIOCHEMISTRY-US, V31, P2068, DOI 10.1021/bi00122a025; Bayless KJ, 1998, J CELL SCI, V111, P1165; BROWN LF, 1993, AM J PATHOL, V142, P793; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; CASTELLANI P, 1994, INT J CANCER, V59, P612, DOI 10.1002/ijc.2910590507; ChiRosso G, 1997, J BIOL CHEM, V272, P31447, DOI 10.1074/jbc.272.50.31447; Coito AJ, 1997, AM J PATHOL, V150, P1757; Copie V, 1998, J MOL BIOL, V277, P663; DUBIN D, 1995, ARTERIOSCL THROM VAS, V15, P1958, DOI 10.1161/01.ATV.15.11.1958; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; GAILIT J, 1993, J INVEST DERMATOL, V100, P323, DOI 10.1111/1523-1747.ep12470011; Gehris AL, 1997, DEV BIOL, V190, P191, DOI 10.1006/dbio.1997.8693; GEORGE EL, 1993, DEVELOPMENT, V119, P1079; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; GUAN JL, 1990, CELL, V60, P53, DOI 10.1016/0092-8674(90)90715-Q; HEDIN U, 1991, AM J PATHOL, V139, P649; Hemler M E, 1995, Curr Opin Hematol, V2, P61; Hynes R. O., 1990, SPRINGERS SERIES MOL, P546; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Isobe T, 1997, J BIOL CHEM, V272, P8447, DOI 10.1074/jbc.272.13.8447; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; KUHN C, 1989, AM REV RESPIR DIS, V140, P1693, DOI 10.1164/ajrccm/140.6.1693; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Liao YF, 1999, J BIOL CHEM, V274, P17876, DOI 10.1074/jbc.274.25.17876; MAIN AL, 1992, CELL, V71, P671, DOI 10.1016/0092-8674(92)90600-H; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; McGilvray ID, 1997, J BIOL CHEM, V272, P10287; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; Moyano JV, 1997, J BIOL CHEM, V272, P24832, DOI 10.1074/jbc.272.40.24832; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; OSBORN L, 1994, J CELL BIOL, V124, P601, DOI 10.1083/jcb.124.4.601; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Peters JH, 2001, ARTHRITIS RHEUM, V44, P2572, DOI 10.1002/1529-0131(200111)44:11<2572::AID-ART438>3.0.CO;2-Y; Peters JH, 1996, CELL ADHES COMMUN, V4, P127, DOI 10.3109/15419069609010767; Peters JH, 1996, CELL ADHES COMMUN, V4, P103, DOI 10.3109/15419069609010766; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Silletti S, 2000, J CELL BIOL, V149, P1485, DOI 10.1083/jcb.149.7.1485; SMITH JW, 1994, J BIOL CHEM, V269, P960; Smith LL, 1996, J BIOL CHEM, V271, P28485, DOI 10.1074/jbc.271.45.28485; Spitzfaden C, 1997, J MOL BIOL, V265, P565, DOI 10.1006/jmbi.1996.0736; Suehiro K, 1996, J BIOL CHEM, V271, P10365, DOI 10.1074/jbc.271.17.10365; Takahashi H, 2000, J BIOL CHEM, V275, P23589, DOI 10.1074/jbc.M003526200; TAKASAKI I, 1992, HYPERTENSION, V20, P20, DOI 10.1161/01.HYP.20.1.20; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; WANG A, 1995, DEV DYNAM, V204, P421, DOI 10.1002/aja.1002040408; Wang A, 1996, AM J RESP CELL MOL, V15, P664, DOI 10.1165/ajrcmb.15.5.8918373; WEINACKER A, 1994, J BIOL CHEM, V269, P6940; XIA P, 1995, EXP CELL RES, V217, P517, DOI 10.1006/excr.1995.1117; XIA P, 1994, EXP CELL RES, V213, P253, DOI 10.1006/excr.1994.1197; Yamada K.M., 1996, MOL CELLULAR BIOL WO, P51; YOKOSAKI Y, 1994, J BIOL CHEM, V269, P26691; Yokosaki Y, 1998, J BIOL CHEM, V273, P11423, DOI 10.1074/jbc.273.19.11423	61	170	186	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14467	14474		10.1074/jbc.M201100200	http://dx.doi.org/10.1074/jbc.M201100200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839764	hybrid			2022-12-25	WOS:000175203000017
J	Saxena, SK; Sirdeshmukh, R; Ardelt, W; Mikulski, SM; Shogen, K; Youle, RJ				Saxena, SK; Sirdeshmukh, R; Ardelt, W; Mikulski, SM; Shogen, K; Youle, RJ			Entry into cells and selective degradation of tRNAs by a cytotoxic member of the RNase A family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-30 PROTEIN; AMPHIBIAN RIBONUCLEASE; INHIBITION; SEQUENCE; EMBRYOS	Onconase (P-30 protein), an enzyme in the ribonuclease A superfamily, exerts cytostatic, cytotoxic, and antiviral activity when added to the medium of growing mammalian cells. We find that onconase enters living mammalian cells and selectively cleaves tRNA with no detectable degradation of rRNA. The RNA specificity of onconase in vitro using reticulocyte lysate and purified RNA substrates indicates that proteins associated with rRNA protect the rRNA from the onconase ribonucleolytic action contributing to the cellular tRNA selectivity of onconase. The onconase-mediated tRNA degradation in cells appears to be accompanied by increased levels of tRNA turnover and induction of tRNA synthesis perhaps in response to the selective toxin-induced loss of tRNA. Degradation products of tRNA(3)(Lys) which acts as a primer for HIV-1 replication, were clearly detected in cells infected with HIV-1 and treated with sublethal concentrations of onconase. However, a new synthesis of tRNA(3)(Lys) also seemed to occur in these cells resulting in plateauing of the steady-state levels of this tRNA, We conclude that the degradation of tRNAs may be a primary factor in the cytotoxic activity of onconase.	NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA; Alfacell Corp, Mol Biol Lab, Bloomfield, NJ 07003 USA; Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB)	Youle, RJ (corresponding author), NINCDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.		Saxena, Shailendra K/ABK-6489-2022; Saxena, Shailendra K/X-4252-2019	Saxena, Shailendra K/0000-0003-2856-4185; Saxena, Shailendra K/0000-0003-2856-4185	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS002859, Z01NS002859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARDELT W, 1991, J BIOL CHEM, V266, P245; D'Alessio Giuseppe, 1993, Trends in Cell Biology, V3, P106, DOI 10.1016/0962-8924(93)90166-X; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; MIKULSKI SM, 1990, J NATL CANCER I, V82, P151, DOI 10.1093/jnci/82.2.151-a; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; RABA M, 1979, EUR J BIOCHEM, V97, P305, DOI 10.1111/j.1432-1033.1979.tb13115.x; ROE BA, 1975, BIOCHEM BIOPH RES CO, V66, P1097, DOI 10.1016/0006-291X(75)90470-2; Sambrook J., 2002, MOL CLONING LAB MANU; Saxena SK, 1996, J BIOL CHEM, V271, P20783, DOI 10.1074/jbc.271.34.20783; Suzuki M, 1999, NAT BIOTECHNOL, V17, P265, DOI 10.1038/7010; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; WU YN, 1994, J CELL BIOL, V125, P743, DOI 10.1083/jcb.125.4.743; YOULE RJ, 1994, P NATL ACAD SCI USA, V91, P6012, DOI 10.1073/pnas.91.13.6012; YOULE RJ, 1993, CRIT REV THER DRUG, V10, P1	18	96	102	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15142	15146		10.1074/jbc.M108115200	http://dx.doi.org/10.1074/jbc.M108115200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839736	hybrid			2022-12-25	WOS:000175203000100
J	van den Bemd, GJCM; Jhamai, M; Staal, A; van Wijnen, AJ; Lian, JB; Stein, GS; Pols, HAP; van Leeuwen, JPTM				van den Bemd, GJCM; Jhamai, M; Staal, A; van Wijnen, AJ; Lian, JB; Stein, GS; Pols, HAP; van Leeuwen, JPTM			A central dinucleotide within vitamin D response elements modulates DNA binding and transactivation by the vitamin D receptor in cellular response to natural and synthetic ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; HUMAN OSTEOCALCIN GENE; 1,25-DIHYDROXYVITAMIN D-3; OSTEOBLASTIC CELLS; IN-VITRO; D ANALOG; ACTIVATION; HORMONE; ALPHA; ACID	There is considerable divergence in the sequences of steroid receptor response elements, including the vitamin D response elements (VDREs). Two major VDRE-containing and thus 1,25-dihydroxyvitamin D-3 (1,25-(OH)(2)D-3)-regulated genes are the two non-collagenous, osteoblast-derived bone matrix proteins osteocalcin and osteopontin. We observed a stronger induction of osteopontin than osteocalcin mRNA expression by 1,25(OH)(2)D-3. Subsequently, we have shown that vitamin D receptor/retinoid X receptor alpha (VDR/RXRalpha) heterodimers bind more tightly to the osteopontin VDRE than to the osteocalcin VDRE. Studies using point mutants revealed that the internal dinucleotide at positions 3 and 4 of the proximal steroid half-element are most important for modulating the strength of receptor binding. In addition, studies with VDRE-driven luciferase reporter gene constructs revealed that the central dinucleotide influences the transactivation potential of VDR/RXRalpha with the same order of magnitude as that observed in the DNA binding studies. The synthetic vitamin D analog KH1060 is a more potent stimulator of transcription and inducer of VDRE binding of VDR/RXR in the presence of nuclear factors isolated from ROS 17/2.8 osteoblast-like cells than the natural ligand 1,25(OH)(2)D-3. Interestingly, however, KH1060 is comparable or even less potent than 1,25-(OH)(2)D-3 in stimulating VDRE binding of in vitro synthesized VDR/RXRalpha. Thus, the extent of 1,25-(OH)(2)D-3- and KH1060-dependent binding of VDR/RXRalpha is specified by a central dinucleotide in the VDRE, and the ligand-induced effects on DNA binding are in part controlled by the cellular context of nuclear proteins.	Erasmus Med Ctr, Dept Internal Med, NL-3015 GD Rotterdam, Netherlands; Univ Massachusetts, Med Ctr, Dept Cell Biol, Worcester, MA 01655 USA	Erasmus University Rotterdam; Erasmus MC; University of Massachusetts System; University of Massachusetts Worcester	van Leeuwen, JPTM (corresponding author), Erasmus Med Ctr, Dept Internal Med, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.		van Leeuwen, Johannes/D-5015-2014; van Wijnen, Andre J./AAG-3578-2019	van Leeuwen, Johannes/0000-0002-2282-4006; van Wijnen, Andre J./0000-0002-4458-0946				Barsony J, 1997, J BIOL CHEM, V272, P5774, DOI 10.1074/jbc.272.9.5774; CANDELIERE GA, 1991, MOL ENDOCRINOL, V5, P1780, DOI 10.1210/mend-5-12-1780; CHESKIS B, 1995, MOL ENDOCRINOL, V9, P1814, DOI 10.1210/me.9.12.1814; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CURTIS SW, 1991, MOL ENDOCRINOL, V5, P959, DOI 10.1210/mend-5-7-959; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; DeLuca H. F., 1997, Vitamin D., P3; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; Dilworth FJ, 1997, ENDOCRINOLOGY, V138, P5485, DOI 10.1210/en.138.12.5485; IMAI Y, 1995, LEUKEMIA RES, V19, P147, DOI 10.1016/0145-2126(94)00127-V; JAASKELAINEN T, 1995, EUR J BIOCHEM, V228, P222; Jin CH, 1996, MOL ENDOCRINOL, V10, P196, DOI 10.1210/me.10.2.196; KERNER SA, 1989, P NATL ACAD SCI USA, V86, P4455, DOI 10.1073/pnas.86.12.4455; Koszewski NJ, 1999, MOL ENDOCRINOL, V13, P455, DOI 10.1210/me.13.3.455; KUNO H, 1994, ENDOCRINOLOGY, V134, P2524, DOI 10.1210/en.134.6.2524; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; Mackey SL, 1996, MOL ENDOCRINOL, V10, P298, DOI 10.1210/me.10.3.298; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; NISHIKAWA J, 1994, NUCLEIC ACIDS RES, V22, P2902, DOI 10.1093/nar/22.15.2902; NODA M, 1990, P NATL ACAD SCI USA, V87, P9995, DOI 10.1073/pnas.87.24.9995; Ozono K, 1998, J STEROID BIOCHEM, V66, P263, DOI 10.1016/S0960-0760(98)00055-7; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; Ryhanen S, 1996, EUR J BIOCHEM, V238, P97, DOI 10.1111/j.1432-1033.1996.0097q.x; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; STAAL A, 1996, ENDOCRINOLOGY, V137, P1991; Thompson PD, 1998, J BIOL CHEM, V273, P8483, DOI 10.1074/jbc.273.14.8483; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; van den Bemd GJCM, 2000, CURR PHARM DESIGN, V6, P717, DOI 10.2174/1381612003400498; VandenBemd GJCM, 1996, P NATL ACAD SCI USA, V93, P10685, DOI 10.1073/pnas.93.20.10685; vandenBemd GJCM, 1995, J STEROID BIOCHEM, V55, P337, DOI 10.1016/0960-0760(95)00218-9; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Zhao XY, 1997, MOL ENDOCRINOL, V11, P366, DOI 10.1210/me.11.3.366	32	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14539	14546		10.1074/jbc.M111224200	http://dx.doi.org/10.1074/jbc.M111224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11834737	hybrid			2022-12-25	WOS:000175203000026
J	Alvarez-Tejado, M; Alfranca, A; Aragones, J; Vara, A; Landazuri, MO; del Peso, L				Alvarez-Tejado, M; Alfranca, A; Aragones, J; Vara, A; Landazuri, MO; del Peso, L			Lack of evidence for the involvement of the phosphoinositide 3-kinase/Akt pathway in the activation of hypoxia-inducible factors by low oxygen tension	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTOR; ENDOTHELIAL GROWTH-FACTOR; INSULIN-RESPONSE SEQUENCE; FACTOR 1-ALPHA; PROTEIN-KINASE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; FACTOR FKHR; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR-SUPPRESSOR	Hypoxia-inducible factors (HIF) belong to an evolutionary conserved family of transcription factors, the activity Of which is tightly regulated by oxygen levels. We have recently demonstrated that hypoxia activates the phosphoinositide 3-kinase (PI3K)/Akt pathway in some cell types, and other works have suggested that this pathway is involved in the activation of HIF. In the present work we studied the role of this pathway in the induction of HIF by hypoxia. Under hypoxic conditions the PI3K/Akt pathway was activated in some (PC 12 and HeLa) but not all cell types (HepG2) tested, whereas the HIF protein was induced by hypoxia in all cases. Kinetics analysis showed that, when observed, the activation of PI3K/Akt occurred after HIF induction. In addition, the chemical inhibition of PI3K had no significant effect on the induction of the HIF protein or its transcriptional activity but prevented Akt activation. Accordingly, transient overexpression of a dominant negative form of the regulatory subunit of PI3K in HEK293T cells did not interfere with the induction of the HIF-alpha protein by hypoxia or affect HIF-mediated transcription in any of the cell types tested. Moreover, forced activation of the PI3K/Akt pathway did not affect the transcriptional activity of HIF under normoxic or hypoxic conditions. Thus, our data suggest that the activation of PI3K/Akt by hypoxia is cell type-specific and, when observed, lies downstream of HIF activation or in a parallel pathway. Furthermore, the activity of the PI3K/Akt is not sufficient for the activation of HIF nor is it essential for its induction by hypoxia.	Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain	Autonomous University of Madrid; Hospital de La Princesa	del Peso, L (corresponding author), Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Diego de Leon 62, Madrid 28006, Spain.		Alfranca, Arantzazu/E-8804-2018; del Peso, Luis/K-9391-2014	del Peso, Luis/0000-0003-4014-5688; Aragones Lopez, Julian/0000-0002-0193-4679				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; Aragones J, 2001, J BIOL CHEM, V276, P10548, DOI 10.1074/jbc.M006180200; Beitner-Johnson D, 2001, CELL SIGNAL, V13, P23, DOI 10.1016/S0898-6568(00)00128-5; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Blancher C, 2001, CANCER RES, V61, P7349; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen EY, 2001, CANCER RES, V61, P2429; Cichy SB, 1998, J BIOL CHEM, V273, P6482, DOI 10.1074/jbc.273.11.6482; Conrad PW, 1999, J BIOL CHEM, V274, P23570, DOI 10.1074/jbc.274.33.23570; Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Haddad JJ, 2001, FEBS LETT, V505, P269, DOI 10.1016/S0014-5793(01)02833-2; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maity A, 2000, CANCER RES, V60, P5879; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Nakae J, 1999, J BIOL CHEM, V274, P15982, DOI 10.1074/jbc.274.23.15982; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Richard DE, 1999, BIOCHEM BIOPH RES CO, V266, P718, DOI 10.1006/bbrc.1999.1889; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Sodhi A, 2000, CANCER RES, V60, P4873; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; Vicente-Manzanares M, 1999, J IMMUNOL, V163, P4001; WANG GL, 1993, BLOOD, V82, P3610; WINDHOLZ M, 1983, MERCK INDEX, P9867; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zundel W, 2000, GENE DEV, V14, P391	56	99	107	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13508	13517		10.1074/jbc.M200017200	http://dx.doi.org/10.1074/jbc.M200017200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11815624	hybrid			2022-12-25	WOS:000175096000024
J	Chen, PW; Lu, CA; Yu, TS; Tseng, TH; Wang, CS; Yu, SM				Chen, PW; Lu, CA; Yu, TS; Tseng, TH; Wang, CS; Yu, SM			Rice a-amylase transcriptional enhancers direct multiple mode regulation of promoters in transgenic rice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE GENE; ALPHA-AMYLASE; CARBOHYDRATE STARVATION; ALEURONE PROTOPLASTS; HORMONAL-REGULATION; BARLEY EMBRYOS; CULTURED-CELLS; ABSCISIC-ACID; EXPRESSION; PLANTS	Expression of alpha-amylase genes in cereals is induced by both gibberellin (GA) and sugar starvation. In a transient expression assay, a 105-bp sugar response sequence (SRS) in the promoter of a sugar starvation highly inducible rice alpha-amylase gene, alphaAmy3, was shown previously to confer sugar response and to enhance the activity of the rice Act1 promoter in rice protoplasts. A 230-bp SRS-like sequence was also found in the promoter of another sugar starvation highly inducible rice alpha-amylase gene, alphaAmy8. The alphaAmy8 SRS contains a GA response sequence and was designated as alphaAmyS SRS/GARS. In the present study, a transgenic approach was employed to characterize the function of the alpha-amylase gene SRSs in rice. We found that the alphaAmy3 SRS significantly enhances the endogenous expression pattern of the Act1 promoter in various rice tissues throughout their developmental stages. By contrast, the alphaAmy8 SRS/GARS significantly enhances Act1 promoter activity only in embryos and endosperms of germinating rice seeds. A minimal promoter fused to the alphaAmy8 SRS/GARS is specifically active in rice embryo and endosperm and is subject to sugar repression and GA induction in rice embryos. This sugar repression was found to override GA induction of alphaAmy8 SRS/GARS activity. Our study demonstrates that the alpha-amylase transcriptional enhancers contain cis-acting elements capable of enhancing endogenous expression patterns or activating sugar-sensitive, hormone-responsive, tissue-specific, and developmental stage-dependent expression of promoters in transgenic rice. These enhancers may facilitate the design of highly active and tightly regulated composite promoters for monocot transformation and gene expression. Our study also reveals the existence of cross-talk between the sugar and GA signaling pathways in cereals and provides a system for analyzing the underlying molecular mechanisms involved.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Taiwan Agr Res Inst, Taichung, Taiwan	Academia Sinica - Taiwan; Agricultural Research Institute of Taiwan	Yu, SM (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.		Yu, Su-May/ABB-6950-2021	Yu, Su-May/0000-0001-8744-9246; Chen, Peng-Wen/0000-0002-3379-7357				CAO J, 1992, PLANT CELL REP, V11, P586, DOI 10.1007/BF00233098; Cercos M, 1999, PLANT J, V19, P107, DOI 10.1046/j.1365-313X.1999.00499.x; CHAN MT, 1994, J BIOL CHEM, V269, P17635; CHRISTENSEN AH, 1992, PLANT MOL BIOL, V18, P675, DOI 10.1007/BF00020010; ELLIS JG, 1987, EMBO J, V6, P3203, DOI 10.1002/j.1460-2075.1987.tb02636.x; Gibson SI, 2000, PLANT PHYSIOL, V124, P1532, DOI 10.1104/pp.124.4.1532; Gomez-Cadenas A, 2001, PLANT CELL, V13, P667, DOI 10.1105/tpc.13.3.667; GUBLER F, 1992, PLANT CELL, V4, P1435; GUBLER F, 1995, PLANT CELL, V7, P1879, DOI 10.1105/tpc.7.11.1879; Gubler F, 1999, PLANT J, V17, P1, DOI 10.1046/j.1365-313X.1999.00346.x; HIEI Y, 1994, PLANT J, V6, P271, DOI 10.1046/j.1365-313X.1994.6020271.x; Ho SL, 2000, PLANT PHYSIOL, V122, P57, DOI 10.1104/pp.122.1.57; HOOD EE, 1986, J BACTERIOL, V168, P1291, DOI 10.1128/jb.168.3.1291-1301.1986; JACOBSEN JV, 1985, NATURE, V316, P275, DOI 10.1038/316275a0; JACOBSEN JV, 1995, PLANT HORMONES PHYSL, P247; LANAHAN MB, 1992, PLANT CELL, V4, P203, DOI 10.1105/tpc.4.2.203; LAST DI, 1991, THEOR APPL GENET, V81, P581, DOI 10.1007/BF00226722; Loreti E, 2000, PLANT MOL BIOL, V44, P85, DOI 10.1023/A:1006496520809; Lu CA, 1998, J BIOL CHEM, V273, P10120, DOI 10.1074/jbc.273.17.10120; LUEHRSEN KR, 1992, METHOD ENZYMOL, V216, P397; MCELROY D, 1994, TRENDS BIOTECHNOL, V12, P62, DOI 10.1016/0167-7799(94)90102-3; MCELROY D, 1990, PLANT MOL BIOL, V15, P257, DOI 10.1007/BF00036912; NAKAGOSHI H, 1990, J BIOL CHEM, V265, P3479; OLIVE MR, 1990, PLANT MOL BIOL, V15, P593, DOI 10.1007/BF00017834; Perata P, 1997, PLANT CELL, V9, P2197, DOI 10.1105/tpc.9.12.2197; SCHLEDZEWSKI K, 1994, TRANSGENIC RES, V3, P249, DOI 10.1007/BF02336778; SEAGULL RW, 1989, CRIT REV PLANT SCI, V8, P131, DOI 10.1080/07352688909382273; Sheen J, 1999, CURR OPIN PLANT BIOL, V2, P410, DOI 10.1016/S1369-5266(99)00014-X; SHEU JJ, 1994, PLANT J, V5, P655, DOI 10.1111/j.1365-313X.1994.00655.x; Sheu JJ, 1996, J BIOL CHEM, V271, P26998, DOI 10.1074/jbc.271.43.26998; Smeekens S, 2000, ANNU REV PLANT PHYS, V51, P49, DOI 10.1146/annurev.arplant.51.1.49; STAIGER CJ, 1987, PROTOPLASMA, V141, P1, DOI 10.1007/BF01276783; THOMAS BR, 1994, PLANT PHYSIOL, V106, P1235, DOI 10.1104/pp.106.4.1235; Toki S, 1997, PLANT MOL BIOL REP, V15, P16, DOI 10.1007/BF02772109; Umemura T, 1998, PLANTA, V204, P420, DOI 10.1007/s004250050275; VERGARA BS, 1980, RICE PRODUCTION UTIL, P75; WILMINK A, 1995, PLANT MOL BIOL, V28, P949, DOI 10.1007/BF00042079; Yu SM, 1999, PLANT PHYSIOL, V121, P687, DOI 10.1104/pp.121.3.687; YU SM, 1992, GENE, V122, P247, DOI 10.1016/0378-1119(92)90212-8; YU SM, 1991, J BIOL CHEM, V266, P21131; Yu SM, 1996, PLANT MOL BIOL, V30, P1277, DOI 10.1007/BF00019558; Yu SM, 1999, MOLECULAR BIOLOGY OF RICE, P161; ZHANG WG, 1991, PLANT CELL, V3, P1155, DOI 10.1105/tpc.3.11.1155; ZWAR JA, 1986, PLANT PHYSIOL, V80, P459, DOI 10.1104/pp.80.2.459	44	55	58	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13641	13649		10.1074/jbc.M109722200	http://dx.doi.org/10.1074/jbc.M109722200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832481	hybrid			2022-12-25	WOS:000175096000041
J	Guo, Y; Srinivasula, SM; Druilhe, A; Fernandes-Alnemri, T; Alnemri, ES				Guo, Y; Srinivasula, SM; Druilhe, A; Fernandes-Alnemri, T; Alnemri, ES			Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; DOMAIN-CONTAINING PROTEIN; PROGRAMMED CELL-DEATH; BCL-2 FAMILY; INTERACTING PROTEIN; SYMPATHETIC NEURONS; MEDIATED APOPTOSIS; ADAPTER MOLECULE; RECEPTOR PATHWAY	Caspase-2 is one of the earliest identified caspases, but the mechanism of caspase-2-induced apoptosis remains unknown. We show here that caspase-2 engages the mitochondria-dependent apoptotie pathway by inducing the release of cytochrome c (Cyt c) and other mitochondrial apoptogenic factors into the cell cytoplasm. In support of these observations we found that Bcl-2 and Bcl-xL can block caspase-2- and CRADD (caspase and RIP adaptor with death domain)-induced cell death. Unlike caspase-8, which can process all known caspase zymogens directly, caspase-2 is completely inactive toward other caspase zymogens. However, like caspase-8, physiological levels of purified caspase-2 can cleave cytosolic Bid protein, which in turn can trigger the release of Cyt c from isolated mitochondria. Interestingly, caspase-2 can also induce directly the release of Cyt c, AIF (apoptosis-inducing factor), and Smac (second mitochondria-derived activator of caspases protein) from isolated mitochondria independent of Bid or other cytosolic factors. The caspase-2-released Cyt c is sufficient to activate the Apaf-caspase-9 apoptosome in vitro. In combination, our data suggest that caspase-2 is a direct effector of the mitochondrial apoptotic pathway.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.		Alnemri, Emad S/B-4526-2010; Druilhe, Anne/O-8684-2016; Druilhe, Anne/T-1296-2019	Druilhe, Anne/0000-0003-3024-5001; Druilhe, Anne/0000-0003-0064-110X	NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chen WP, 1999, J IMMUNOL, V163, P2483; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Droin N, 2001, BLOOD, V97, P1835, DOI 10.1182/blood.V97.6.1835; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Grossmann J, 2001, CELL GROWTH DIFFER, V12, P147; Harvey NL, 1997, J BIOL CHEM, V272, P13134, DOI 10.1074/jbc.272.20.13134; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1995, FEBS LETT, V375, P169, DOI 10.1016/0014-5793(95)01186-I; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIU X, 1996, CELL, V12, P147; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane M, 1997, J BIOL CHEM, V272, P25417, DOI 10.1074/jbc.272.41.25417; Mancini M, 1998, J CELL BIOL, V140, P1485, DOI 10.1083/jcb.140.6.1485; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Skulachev VP, 1996, FEBS LETT, V397, P7, DOI 10.1016/0014-5793(96)00989-1; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Stefanis L, 1998, J NEUROSCI, V18, P9204; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry N A, 1997, Adv Pharmacol, V41, P155, DOI 10.1016/S1054-3589(08)61058-3; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	68	430	442	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13430	13437		10.1074/jbc.M108029200	http://dx.doi.org/10.1074/jbc.M108029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832478	hybrid			2022-12-25	WOS:000175096000013
J	Himmel, KL; Bi, F; Shen, HF; Jenkins, NA; Copeland, NG; Zheng, Y; Largaespada, DA				Himmel, KL; Bi, F; Shen, HF; Jenkins, NA; Copeland, NG; Zheng, Y; Largaespada, DA			Activation of Clg, a novel Dbl family guanine nucleotide exchange factor gene, by proviral insertion at Evi24, a common integration site in B cell and myeloid leukemias	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; RAS TRANSFORMATION; MESSENGER-RNA; RHO-GTPASE; CDC42; APOPTOSIS; RAC1; LYMPHOMAS; TRISTETRAPROLIN; PATHWAYS	Retroviruses induce leukemia in inbred strains of mice by activating cellular proto-oncogenes and/or inactivating tumor suppressors. The proviral integration sites in these leukemias provide powerful genetic tags for disease gene identification. Here we show that Evi24, a common site of retroviral integration in AKXD B cell and BXH-2 myeloid leukemias, contains a novel Db1 family guanine nucleotide exchange factor gene. We have designated this gene Clg (common-site lymphoma/leukemia guanine nucleotide exchange factor). Proviral integrations on chromosome 7 at Evi24 are located 7.6-10.3 kb upstream of Clg and increased Clg expression 2-5-fold compared with leukemias lacking proviral integrations at Evi24. Clg contains Db1/pleckstrin homology domains with substantial sequence homology to many Rho family activators, including the transforming Dbl and Dbs/Ost oncogenes. Nucleotide exchange assays indicated that Clg specifically activated nucleotide exchange on Cdc42, but not RhoA or Rac1, in vitro. NIH 3T3 transfection studies showed that overexpression of full-length and carboxyl-terminally truncated forms of Clg morphologically transformed NIH 3T3 cells. This study and studies showing that the human homolog of EVI24 is located in a region of 19q13 frequently amplified in B cell lymphomas and pancreatic and breast cancers implicate Clg and Cdc42 activation in mouse and human cancers.	Univ Minnesota, Ctr Canc, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA; NCI, Frederick Canc Res & Dev Ctr, Mouse Canc Genet Program, Frederick, MD 21702 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Tennessee System; University of Tennessee Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Largaespada, DA (corresponding author), Univ Minnesota, Ctr Canc, Inst Human Genet, Minneapolis, MN 55455 USA.	larga002@tc.umn.edu	Zheng, Yi/J-7235-2015; Largaespada, David/C-9832-2014	Zheng, Yi/0000-0001-7089-6074; 	NCI NIH HHS [CA81051, CA09138] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081051] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 2000, IMMUNOL RES, V21, P139, DOI 10.1385/IR:21:2-3:139; Borkhardt A, 2000, P NATL ACAD SCI USA, V97, P9168, DOI 10.1073/pnas.150079597; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; Cantrell DA, 2001, J CELL SCI, V114, P1439; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHO BC, 1995, J VIROL, V69, P7138, DOI 10.1128/JVI.69.11.7138-7146.1995; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; Erickson JW, 2001, CURR OPIN CELL BIOL, V13, P153, DOI 10.1016/S0955-0674(00)00192-7; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HAWLEY RG, 1994, GENE THER, V1, P136; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Ingram DA, 2001, J EXP MED, V194, P57, DOI 10.1084/jem.194.1.57; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; JONKERS J, 1996, BIOCHIM BIOPHYS ACTA, V1287, P295; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; Largaespada DA, 2000, LEUKEMIA, V14, P1174, DOI 10.1038/sj.leu.2401852; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Maru Y, 2001, INT J HEMATOL, V73, P308, DOI 10.1007/BF02981955; Michiels F, 1999, BIOCHEM SOC SYMP, V65, P125; Mira JP, 2000, P NATL ACAD SCI USA, V97, P185, DOI 10.1073/pnas.97.1.185; Mitelman F, 1997, NAT GENET, V15, P417, DOI 10.1038/ng0497supp-417; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; O'Brien SP, 2000, P NATL ACAD SCI USA, V97, P12074, DOI 10.1073/pnas.97.22.12074; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1996, J MOL MED-JMM, V74, P563, DOI 10.1007/s001090050060; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; PASTERIS NG, 1994, CELL, V79, P669; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Qu J, 2001, MOL CELL BIOL, V21, P3523, DOI 10.1128/MCB.21.10.3523-3533.2001; Reid T, 1999, J BIOL CHEM, V274, P33587, DOI 10.1074/jbc.274.47.33587; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sawamoto K, 1999, ONCOGENE, V18, P1967, DOI 10.1038/sj.onc.1202522; Seeberger H, 2001, LAB INVEST, V81, P977, DOI 10.1038/labinvest.3780310; SOLOVYEV VV, 1994, NUCLEIC ACIDS RES, V22, P5156, DOI 10.1093/nar/22.24.5156; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Tu S, 2001, J BIOL CHEM, V276, P19656, DOI 10.1074/jbc.M009838200; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wu WJ, 2000, NATURE, V405, P800, DOI 10.1038/35015585; Xerri L, 1998, BRIT J CANCER, V78, P225, DOI 10.1038/bjc.1998.469; ZHENG Y, 1995, METHOD ENZYMOL, V256, P77; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	62	15	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13463	13472		10.1074/jbc.M110981200	http://dx.doi.org/10.1074/jbc.M110981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11839748	hybrid			2022-12-25	WOS:000175096000018
J	Lohi, H; Kujala, M; Makela, S; Lehtonen, E; Kestila, M; Saarialho-Kere, U; Markovich, D; Kere, J				Lohi, H; Kujala, M; Makela, S; Lehtonen, E; Kestila, M; Saarialho-Kere, U; Markovich, D; Kere, J			Functional characterization of three novel tissue-specific anion exchangers SLC26A7,-A8, and-A9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL CHLORIDE DIARRHEA; SULFATE TRANSPORTER; PENDRED SYNDROME; PLASMA-MEMBRANE; GENE ENCODES; DNA-SEQUENCE; PDZ DOMAINS; ADENOMA DRA; PROTEIN; RECOGNITION	A second distinct family of anion exchangers, SLC26, in addition to the classical SLC4 (or anion exchanger) family, has recently been delineated. Particular interest in this gene family is stimulated by the fact that the SLC26A2, SLC26A3, and SLC26A4 genes have been recognized as the disease genes mutated in diastrophic dysplasia, congenital chloride diarrhea, and Pendred syndrome, respectively. We report the expansion of the SLC26 gene family by characterizing three novel tissue-specific members, named SLC26A7, SLC26A8, and SLC26A9, on chromosomes 8, 6, and 1, respectively. The SLC26A7-A9 proteins are structurally very similar at the amino acid level to the previous family members and show tissue-specific expression in kidney, testis, and lung, respectively. More detailed characterization by immunohistochemistry and/or in situ hybridization localized SLC26A7 to distal segments of nephrons, SLC26A8 to developing spermatocytes, and SLC26A9 to the lumenal side of the bronchiolar and alveolar epithelium of lung. Expression of SLC26A7-A9 proteins in Xenopus oocytes demonstrated chloride, sulfate, and oxalate transport activity, suggesting that they encode functional anion exchangers. The functional characterization of the novel tissue-specific members may provide new insights to anion transport physiology in different parts of body.	Karolinska Inst, Dept Biosci Novum, S-14157 Huddinge, Sweden; Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, SF-00014 Helsinki, Finland; Univ Helsinki, Helsinki Univ Cent Hosp, SF-00014 Helsinki, Finland; Univ Helsinki, Dept Pathol, Hartmann Inst, SF-00014 Helsinki, Finland; Helsinki Univ Cent Hosp, Dept Dermatol, SF-00029 Helsinki, Finland; Univ Queensland, Dept Physiol & Pharmacol, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Karolinska Inst, Clin Res Ctr, S-14157 Huddinge, Sweden	Karolinska Institutet; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Queensland; Karolinska Institutet	Kere, J (corresponding author), Karolinska Inst, Dept Biosci Novum, S-14157 Huddinge, Sweden.	juha.kere@bioscik.ki.se	Lehtonen, Eero/AGJ-4027-2022; Kere, Juha/A-9179-2008; Markovich, Daniel/F-7884-2012; Kere, Juha/AAX-9117-2021; Lohi, Hannes/F-4596-2011	Kere, Juha/0000-0003-1974-0271; Kere, Juha/0000-0003-1974-0271; Lohi, Hannes/0000-0003-1087-5532; Lehtonen, Eero/0000-0002-8218-635X				ALPER SL, 1988, J BIOL CHEM, V263, P17092; ALPERN RJ, 1991, KIDNEY INT, V40, pS29; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aravind L, 2000, CURR BIOL, V10, pR53, DOI 10.1016/S0960-9822(00)00335-3; Aroeti B, 1998, BBA-REV BIOMEMBRANES, V1376, P57, DOI 10.1016/S0304-4157(98)00005-7; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Caplan MJ, 1997, AM J PHYSIOL-GASTR L, V272, pG1304, DOI 10.1152/ajpgi.1997.272.6.G1304; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Haila S, 2001, J HISTOCHEM CYTOCHEM, V49, P973, DOI 10.1177/002215540104900805; HASTBACKA J, 1994, CELL, V78, P1073, DOI 10.1016/0092-8674(94)90281-X; Hoglund P, 1996, NAT GENET, V14, P316, DOI 10.1038/ng1196-316; JONES DT, 1994, BIOCHEMISTRY-US, V33, P3038, DOI 10.1021/bi00176a037; Kere J, 1999, AM J PHYSIOL-GASTR L, V276, pG7, DOI 10.1152/ajpgi.1999.276.1.G7; KOPITO RR, 1989, CELL, V59, P927, DOI 10.1016/0092-8674(89)90615-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lohi H, 2000, GENOMICS, V70, P102, DOI 10.1006/geno.2000.6355; Ludwig J, 2001, P NATL ACAD SCI USA, V98, P4178, DOI 10.1073/pnas.071613498; Melvin JE, 1999, J BIOL CHEM, V274, P22855, DOI 10.1074/jbc.274.32.22855; Moseley RH, 1999, AM J PHYSIOL-GASTR L, V276, pG185, DOI 10.1152/ajpgi.1999.276.1.G185; NOONE PG, 1994, ANNU REV MED, V45, P421; Pearson W R, 1994, Methods Mol Biol, V24, P307; PROSSER IW, 1989, AM J PATHOL, V135, P1073; SAARIALHOKERE UK, 1994, J CLIN INVEST, V94, P79, DOI 10.1172/JCI117351; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Satoh H, 1998, J BIOL CHEM, V273, P12307, DOI 10.1074/jbc.273.20.12307; Scott DA, 1999, NAT GENET, V21, P440, DOI 10.1038/7783; Scott DA, 2000, AM J PHYSIOL-CELL PH, V278, pC207, DOI 10.1152/ajpcell.2000.278.1.C207; SFERRA TJ, 1993, ANNU REV MED, V44, P133, DOI 10.1146/annurev.med.44.1.133; SOEIMANI M, 2001, AM J PHYSIOL, V280, pF356; SOLOVYEV VV, 1995, P 2 INT C INT SYST M, V3, P267; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tarran R, 2001, J GEN PHYSIOL, V118, P223, DOI 10.1085/jgp.118.2.223; Toure A, 2001, J BIOL CHEM, V276, P20309, DOI 10.1074/jbc.M011740200; Tsuruoka S, 1999, AM J PHYSIOL-RENAL, V277, pF567, DOI 10.1152/ajprenal.1999.277.4.F567; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; WANG T, 1993, AM J PHYSIOL, V264, pF730, DOI 10.1152/ajprenal.1993.264.4.F730; XU Y, 1994, ISMB, V2, P376; Zhang Z, 1997, J COMPUT BIOL, V4, P339, DOI 10.1089/cmb.1997.4.339; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	43	180	186	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14246	14254		10.1074/jbc.M111802200	http://dx.doi.org/10.1074/jbc.M111802200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834742	hybrid			2022-12-25	WOS:000175096000116
J	Mildner, M; Eckhart, L; Lengauer, B; Tschachler, E				Mildner, M; Eckhart, L; Lengauer, B; Tschachler, E			Hepatocyte growth factor/scatter factor inhibits UVB-induced apoptosis of human keratinocytes but not of keratinocyte-derived cell lines via the phosphatidylinositol 3-kinase/AKT pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASE; GENE-EXPRESSION; TYROSINE KINASE; FACTOR-RECEPTOR; MET RECEPTOR; SKIN-CANCER; SURVIVAL; HGF	Acute irrepairable UV-induced DNA damage leads to apoptosis of epidermal keratinocytes (KC) and the formation of sunburn cells, whereas less severely damaged cells survive but harbor the potential of tumor formation. Here we report that hepatocyte growth factor/scatter factor (HGF/SF) prevents UVB-induced apoptosis in primary KC cultured in vitro. When we analyzed the signaling pathways initiated by the HGF/SF receptor c-met, we found that the phosphatidylinositol (PI) 3-kinase and its downstream-element AKT and the mitogen-activated protein (MAP) kinase were activated. Inhibition of PI 3-kinase led to a complete abrogation of the anti-apoptotic effect of HGF/SF, whereas blockade of the MAP kinase pathway had no effect. In contrast to the observation with primary KC, HGF/SF could not enhance survival after UVB irradiation of HaCaT and A431 cell lines, despite the fact that in these cells the PI 3-kinase and MAP kinase pathways were also activated by HGF/SF. Cell cycle analysis of KC revealed a G(2)/M arrest after UVB irradiation and a complete loss of proliferating cells. Because HGF/SF in the skin is produced by dermal fibroblasts, our findings suggest that the HGF/SF-mediated rescue of KC from apoptosis represents an important paracrine loop by which UVB-damaged KC can be kept alive to maintain the epidermal barrier function but cannot further proliferate, thereby preventing the induction of epithelial skin tumors.	Univ Vienna, Sch Med, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria; Ctr Rech & Invest Epiderm & Sensorielles, F-29521 Neuilly sur Seine, France	University of Vienna	Tschachler, E (corresponding author), Univ Vienna, Sch Med, Dept Dermatol, Div Immunol Allergy & Infect Dis, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Erwin.Tschachler@akh-wien.ac.at		Eckhart, Leopold/0000-0002-5645-2036; Tschachler, Erwin/0000-0002-0248-1798; Mildner, Michael/0000-0002-6892-925X				Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Arakaki N, 1998, BIOCHEM BIOPH RES CO, V245, P211, DOI 10.1006/bbrc.1998.8397; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GOHDA E, 1992, FEBS LETT, V301, P107, DOI 10.1016/0014-5793(92)80220-B; Henseleit U, 1997, J INVEST DERMATOL, V109, P722, DOI 10.1111/1523-1747.ep12340708; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; Kosai K, 1998, BIOCHEM BIOPH RES CO, V244, P683, DOI 10.1006/bbrc.1998.8293; Kraemer KH, 1997, P NATL ACAD SCI USA, V94, P11, DOI 10.1073/pnas.94.1.11; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; KUPPER TS, 1987, J CLIN INVEST, V80, P430, DOI 10.1172/JCI113090; Liu YH, 1999, AM J PHYSIOL-RENAL, V277, pF624, DOI 10.1152/ajprenal.1999.277.4.F624; Liu YH, 1998, BIOCHEM BIOPH RES CO, V246, P821, DOI 10.1006/bbrc.1998.8676; LONGATI P, 1994, ONCOGENE, V9, P49; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Mildner M, 1999, PHOTOCHEM PHOTOBIOL, V70, P674, DOI 10.1562/0031-8655(1999)070<0674:UAURDR>2.3.CO;2; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; PELICCI G, 1995, ONCOGENE, V10, P1631; PLETTENBERG A, 1995, AM J PATHOL, V146, P651; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; REISS M, 1992, ONCOL RES, V4, P349; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SCHWARZ A, 1995, J INVEST DERMATOL, V104, P922, DOI 10.1111/1523-1747.ep12606202; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Tang KQ, 1999, BIOCHEM BIOPH RES CO, V264, P127, DOI 10.1006/bbrc.1999.1496; Webster CRL, 2001, HEPATOLOGY, V33, P608, DOI 10.1053/jhep.2001.22756; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yo Y, 1998, KIDNEY INT, V54, P1128, DOI 10.1046/j.1523-1755.1998.00092.x	45	37	38	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14146	14152		10.1074/jbc.M110687200	http://dx.doi.org/10.1074/jbc.M110687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821397	hybrid			2022-12-25	WOS:000175096000103
J	Millan, C; Lujan, R; Shigemoto, R; Sanchez-Prieto, J				Millan, C; Lujan, R; Shigemoto, R; Sanchez-Prieto, J			The inhibition of glutamate release by metabotropic glutamate receptor 7 affects both [Ca2+](c) and cAMP - Evidence for a strong reduction of Ca2+ entry in single nerve terminals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BETA-ADRENERGIC-RECEPTORS; SYNAPTIC-TRANSMISSION; PRESYNAPTIC LOCALIZATION; CALCIUM-CHANNELS; ADULT-RAT; IMMUNOCYTOCHEMICAL LOCALIZATION; MOLECULAR CHARACTERIZATION; ELECTRON-MICROSCOPE; MGLUR7	Metabotropic glutamate receptors (mGluRs) from group III reduce glutamate release. Because these receptors reduce cAMP levels, we explored whether this signaling pathway contributes to release inhibition caused by mGluRs with low affinity for L-2-amino-4-phosphonobutyrate (L-AP4). In biochemical experiments with the population of cerebrocortical nerve terminals we find that L-AP4 (1 mm) inhibited the Ca2+-dependent-evoked release of glutamate by 25%. This inhibitory effect was largely prevented by the pertussis toxin but was insensitive to inhibitors of protein kinase C bisindolylmaleimide and protein kinase A H-89. Furthermore, this inhibition was associated with reduction in N-type Ca2+ channel activity in the absence of any detectable change in cAMP levels. In the presence of forskolin, however, L-AP4 decreased the levels of cAMP. The activation of this additional signaling pathway was very efficient in counteracting the facilitation of glutamate release induced either by forskolin or the beta-adrenergic receptor agonist isoproterenol. Imaging experiments to measure Ca2+ dynamics in single nerve terminals showed that L-AP4 strongly reduced the Ca2+ response in 28% of the nerve terminals. Moreover, immunochemical experiments showed that 25-35% of the nerve terminals that were immunopositive to synaptophysin were also immunoreactive to the low affinity L-AP4-sensitive mGluR7. Then, mGluR7 mediates the inhibition of glutamate release caused by 1 mM L-AP4, primarily by a strong inhibition of Ca2+ channels, although high cAMP uncovers the receptor ability to decrease cAMP.	Univ Complutense, Fac Vet, Dept Bioquim, Madrid 28040, Spain; Univ Castilla La Mancha, Fac Med, CRIB, Albacete 02071, Spain; Japan Sci & Technol Corp, Div Cerebral Struct, Natl Inst Physiol Sci, Okazaki, Aichi 4448585, Japan	Complutense University of Madrid; Universidad de Castilla-La Mancha; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Sanchez-Prieto, J (corresponding author), Univ Complutense, Fac Vet, Dept Bioquim, Madrid 28040, Spain.	jsprieto@vet.ucm.es	Lujan, Rafael/G-2555-2015; Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444; Sanchez-Prieto, Jose/0000-0002-8513-3501; Lujan Miras, Rafael/0000-0003-2001-9545				BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Bradley SR, 1996, J NEUROSCI, V16, P2044; Cai ZH, 2001, J NEUROCHEM, V78, P756, DOI 10.1046/j.1471-4159.2001.00468.x; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Dev KK, 2000, J NEUROSCI, V20, P7252; DeWaard M, 1997, NATURE, V385, P446, DOI 10.1038/385446a0; DUNKLEY PR, 1986, BRAIN RES, V372, P115, DOI 10.1016/0006-8993(86)91464-2; DUVOISIN RM, 1995, J NEUROSCI, V15, P3075; FORSYTHE ID, 1990, J PHYSIOL-LONDON, V429, P1; GEREAU RW, 1995, J NEUROSCI, V15, P6879; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamid J, 1999, J BIOL CHEM, V274, P6195, DOI 10.1074/jbc.274.10.6195; Herrero I, 1996, EUR J NEUROSCI, V8, P700, DOI 10.1111/j.1460-9568.1996.tb01255.x; Herrero I, 1996, J BIOL CHEM, V271, P30554, DOI 10.1074/jbc.271.48.30554; Hiscock JJ, 2000, J NEUROSCI METH, V95, P1, DOI 10.1016/S0165-0270(99)00163-6; JANE DE, 1995, NEUROPHARMACOLOGY, V34, P851, DOI 10.1016/0028-3908(95)00063-C; Jane DE, 1996, NEUROPHARMACOLOGY, V35, P1029, DOI 10.1016/S0028-3908(96)00048-2; Kinoshita A, 1998, J COMP NEUROL, V393, P332; Kinoshita A, 1996, NEUROSCI LETT, V207, P61, DOI 10.1016/0304-3940(96)12489-7; KINZIE JM, 1995, NEUROSCIENCE, V69, P167, DOI 10.1016/0306-4522(95)00244-D; Li H, 1997, NEUROSCI LETT, V223, P153, DOI 10.1016/S0304-3940(97)13429-2; LLINAS R, 1992, SCIENCE, V256, P677, DOI 10.1126/science.1350109; LUEBKE JI, 1993, NEURON, V11, P895, DOI 10.1016/0896-6273(93)90119-C; Lujan R, 1998, EUR J NEUROSCI, V10, P128; Macek TA, 1998, J NEUROSCI, V18, P6138; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; Nakajima Y, 1999, J BIOL CHEM, V274, P27573, DOI 10.1074/jbc.274.39.27573; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; Nichols RA, 1996, J NEUROCHEM, V67, P581; O'Connor V, 1999, SCIENCE, V286, P1180, DOI 10.1126/science.286.5442.1180; Ohishi H, 1995, NEUROSCI LETT, V202, P85, DOI 10.1016/0304-3940(95)12207-9; OHISHI H, 1995, J COMP NEUROL, V360, P555, DOI 10.1002/cne.903600402; OKAMOTO N, 1994, J BIOL CHEM, V269, P1231; OLIVERA BM, 1985, SCIENCE, V230, P1338, DOI 10.1126/science.4071055; Perroy J, 2000, J NEUROSCI, V20, P7896; Pin JP, 1999, EUR J PHARMACOL, V375, P277, DOI 10.1016/S0014-2999(99)00258-7; Ross FM, 2000, BRIT J PHARMACOL, V131, P453, DOI 10.1038/sj.bjp.0703610; SAHARA Y, 1993, J NEUROSCI, V13, P3041; SAUGSTAD JA, 1994, MOL PHARMACOL, V45, P367; Saugstad JA, 1997, MOL PHARMACOL, V51, P119, DOI 10.1124/mol.51.1.119; SCHOEPP DD, 1993, NEUROCHEM INT, V22, P277, DOI 10.1016/0197-0186(93)90056-B; Shigemoto R, 1997, J NEUROSCI, V17, P7503, DOI 10.1523/jneurosci.17-19-07503.1997; Shigemoto R, 1996, NATURE, V381, P523, DOI 10.1038/381523a0; SWARTZ KJ, 1993, NATURE, V361, P165, DOI 10.1038/361165a0; Takahashi T, 1996, SCIENCE, V274, P594, DOI 10.1126/science.274.5287.594; TANABE Y, 1993, J NEUROSCI, V13, P1372; TIBBS GR, 1989, J NEUROCHEM, V53, P1693, DOI 10.1111/j.1471-4159.1989.tb09232.x; TROMBLEY PQ, 1992, J NEUROSCI, V12, P2043; TURNER TJ, 1995, NEUROPHARMACOLOGY, V34, P1469, DOI 10.1016/0028-3908(95)00133-Q; Vazquez E, 1997, EUR J NEUROSCI, V9, P2009, DOI 10.1111/j.1460-9568.1997.tb01369.x; VAZQUEZ E, 1995, NEUROSCIENCE, V68, P117, DOI 10.1016/0306-4522(95)00121-X; WANAKA A, 1989, BRAIN RES, V485, P125, DOI 10.1016/0006-8993(89)90674-4; WANG JKT, 1989, P NATL ACAD SCI USA, V86, P2253, DOI 10.1073/pnas.86.7.2253; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Zamponi GW, 1997, NATURE, V385, P442, DOI 10.1038/385442a0	56	64	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14092	14101		10.1074/jbc.M109044200	http://dx.doi.org/10.1074/jbc.M109044200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825890	hybrid			2022-12-25	WOS:000175096000097
J	Pearce, LL; Kanai, AJ; Birder, LA; Pitt, BR; Peterson, J				Pearce, LL; Kanai, AJ; Birder, LA; Pitt, BR; Peterson, J			The catabolic fate of nitric oxide - The nitric oxide oxidase and peroxynitrite reductase activities of cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; C-OXIDASE; METMYOGLOBIN REDUCTASE; SKELETAL-MUSCLE; MECHANISM; SUPEROXIDE; OXIDATION; MYOGLOBIN; HEART; SYNTHASE	Stimulation of cardiomyocytes to endogenously evolve nitric oxide is shown by microsensor measurements on single cells to lead to transient nitric oxide concentrations of a few hundred nanomolar. At these submicromolar concentrations, no evidence could be found for the expected reaction between nitric oxide generated and the oxymyoglobin present in the cells: nitric oxide + oxymyoglobin --> nitrate + metmyoglobin. No metmyoglobin formation was detected by electron paramagnetic resonance spectroscopy, and microsensor measurements revealed near quantitative conversion of the nitric oxide to nitrite rather than nitrate ion. Moreover, the rate of nitrite formation is shown to be too rapid to be accounted for by non-enzymatic means. The essentially quantitative and rapid catabolism of nitric oxide to nitrite ion can plausibly be explained on the basis of a cycle of reactions catalyzed by cytochrome c oxidase. It is demonstrated with the purified hemoproteins in vitro that the terminal oxidase can outcompete oxymyoglobin for available nitric oxide. It is proposed that under normal physiological and most pathological (non-inflammatory) conditions, reaction with cytochrome c oxidase is the major route by which NO is removed from mitochondria-rich cells.	Univ Pittsburgh, Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Med, Div Renal, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Pearce, LL (corresponding author), Mellon Inst, 4400 5th Ave, Pittsburgh, PA 15213 USA.			Pearce, Linda/0000-0002-0940-965X; Peterson, James/0000-0002-7300-5887	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061411, R01HL057985] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL57985, HL61411] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BECKMAN JS, 1996, NITRIC OXIDE PRINCIP, P1, DOI DOI 10.1016/B978-012435555-2/50002-4; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; CLAUDIO L, 1989, AM J PATHOL, V135, P1157; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Giuffre A, 2000, BIOCHEMISTRY-US, V39, P15446, DOI 10.1021/bi000447k; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; Granger DL, 1996, METHOD ENZYMOL, V268, P142; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; HAGLER L, 1979, J BIOL CHEM, V254, P6505; Herold S, 2001, BIOCHEMISTRY-US, V40, P3385, DOI 10.1021/bi002407m; Holm DE, 1996, COMP BIOCHEM PHYS B, V114, P345, DOI 10.1016/0305-0491(96)00031-4; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; Kanai AJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1371, DOI 10.1152/ajpcell.1997.273.4.C1371; KANAI AJ, 1995, CIRC RES, V77, P284, DOI 10.1161/01.RES.77.2.284; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Konorev EA, 1996, FEBS LETT, V378, P111, DOI 10.1016/0014-5793(95)01429-2; LIVINGSTON DJ, 1985, J BIOL CHEM, V260, P5699; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; Masuda K, 1999, EUR J APPL PHYSIOL O, V79, P347, DOI 10.1007/s004210050519; PAUL KG, 1953, ACTA CHEM SCAND, V7, P1284, DOI 10.3891/acta.chem.scand.07-1284; Pearce LL, 1999, J BIOL CHEM, V274, P35763, DOI 10.1074/jbc.274.50.35763; Pieper GM, 2000, J CARDIOVASC PHARM, V35, P114, DOI 10.1097/00005344-200001000-00015; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; Poderoso JJ, 1999, J BIOL CHEM, V274, P37709, DOI 10.1074/jbc.274.53.37709; Pollack G.H., 2001, CELLS GELS ENGINES L; RENGASAMY A, 1991, J PHARMACOL EXP THER, V259, P310; SINJORGO KMC, 1987, BIOCHIM BIOPHYS ACTA, V893, P251, DOI 10.1016/0005-2728(87)90046-6; Skinner KA, 1997, ARCH BIOCHEM BIOPHYS, V342, P282, DOI 10.1006/abbi.1997.0114; THOMSON AJ, 1985, J INORG BIOCHEM, V23, P187, DOI 10.1016/0162-0134(85)85025-X; Torres J, 2000, FEBS LETT, V475, P263, DOI 10.1016/S0014-5793(00)01682-3; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; Trimmer BA, 2001, SCIENCE, V292, P2486, DOI 10.1126/science.1059833; VANGELDER BF, 1966, BIOCHIM BIOPHYS ACTA, V118, P36, DOI 10.1016/S0926-6593(66)80142-X; Vaughn MW, 2001, NITRIC OXIDE-BIOL CH, V5, P18, DOI 10.1006/niox.2000.0328; VOET D, 1995, BIOCHEMISTRY-US, P688	44	80	81	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13556	13562		10.1074/jbc.M109838200	http://dx.doi.org/10.1074/jbc.M109838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825895	hybrid			2022-12-25	WOS:000175096000029
J	Sakai, K; Lowman, HB; Clemmons, DR				Sakai, K; Lowman, HB; Clemmons, DR			Increases in free, unbound insulin-like growth factor I enhance insulin responsiveness in human hepatoma G2 cells in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-1; IGF-I; TRANSGENIC MICE; RECEPTORS; HORMONE; HEPATOCYTES; SENSITIVITY; VARIABLES; SECRETION; HYBRIDS	Insulin-like growth factor-binding protein (IGFBP)-1 binds to insulin-like growth factor (IGF)-I and -II with high affinity and has been shown to modulate IGF-I actions in vivo and in vitro. The synthesis of IGFBP-1 is suppressed by insulin, and administration of IGFBP-1 to rats results in impaired glucose metabolism. A synthetic peptide (bp1-01) has been shown to have a high affinity and specificity for human IGFBP-1 and to inhibit IGF-I binding. The current studies were undertaken to determine if, after incubation of bp1-01 with IGF-I-IGFBP-1 complexes, anabolic and insulin-like effects of IGF-I could be detected in human hepatoma (HepG2) cell cultures and to determine the receptor subtype(s) through which these effects were mediated. Incubation of HepG2 cells with bp1-01 (200 nM) increased IGF-I-stimulated protein synthesis by 44% and glycogen synthesis by 170% compared with stimulation by IGF-I alone. Incubation with bp1-01 also enhanced IGF-I-stimulated tyrosine phosphorylation of the IGF-I/insulin hybrid receptor and insulin receptor substrate 1. Exposure of the cells to bp1-01 alone enhanced glycogen synthesis and phosphorylation of IGF-I/insulin hybrid receptors. This was not a direct effect of bp1-01 because it did not bind to the receptor and did not activate tyrosine kinase activity in the presence of an anti-IGF-I receptor antibody. The addition of bp1-01 (200 nM) plus insulin to HepG2 cell culture medium resulted in increased tyrosine phosphorylation of the hybrid receptor, insulin receptor substrate 1, and the glycogen synthesis response compared with the effects of insulin alone. This enhancement of hybrid receptor phosphorylation and glycogen synthesis by bp1-01 peptide was diminished by preincubation with an inhibitory antibody for the a subunit of IGF-I receptor (alphaIR3). bp1-01 stimulated the hybrid receptor phosphorylation response to IGF-I, and this effect was inhibited by prior incubation of the cells with alphaIR3. In conclusion, bp1-01 competes with IGF-I for binding to IGFBP-1, which leads to release of free IGF-I from IGF-I-IGFBP-1 complexes. This released IGF-I stimulates biologic actions that are mediated predominantly through the IGF-I/insulin hybrid receptor.	Univ N Carolina, Dept Med, Sch Med, Div Endocrinol, Chapel Hill, NC 27599 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94124 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Roche Holding; Genentech	Clemmons, DR (corresponding author), Univ N Carolina, Dept Med, Sch Med, Div Endocrinol, Chapel Hill, NC 27599 USA.				NIA NIH HHS [AG-02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG002331, R01AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailyes EM, 1997, BIOCHEM J, V327, P209, DOI 10.1042/bj3270209; BELFORE A, BIOCHEMISTRY, V81, P403; BUSBY WH, 1988, J CLIN ENDOCR METAB, V67, P1225, DOI 10.1210/jcem-67-6-1225; CLEMMONS DR, 1991, J CLIN ENDOCR METAB, V73, P727, DOI 10.1210/jcem-73-4-727; CLEMMONS DR, 1991, J CLIN ENDOCR METAB, V73, P723; CONOVER CA, 1993, ACTA ENDOCRINOL-COP, V128, P140, DOI 10.1530/acta.0.1280140; Crossey PA, 2000, DIABETES, V49, P457, DOI 10.2337/diabetes.49.3.457; DEGERBLAD M, 1989, ACTA ENDOCRINOL-COP, V120, P195, DOI 10.1530/acta.0.1200195; DERCOLE AJ, 1976, GROWTH HORMONE RELAT, P190; Duan CM, 1996, J BIOL CHEM, V271, P4280; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; FERDERICI M, 1996, J CLIN INVEST, V98, P2887; Fernandez AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001; FROST RA, 1994, J CLIN ENDOCR METAB, V78, P1533, DOI 10.1210/jc.78.6.1533; HALL K, 1988, ACTA ENDOCRINOL-COP, V118, P321, DOI 10.1530/acta.0.1180321; HOWELL RJS, 1985, BRIT J OBSTET GYNAEC, V92, P1141, DOI 10.1111/j.1471-0528.1985.tb03026.x; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P446; Jenkins RC, 2000, CLIN ENDOCRINOL, V52, P187, DOI 10.1046/j.1365-2265.2000.00924.x; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; LEE PDK, 1993, METABOLISM, V42, P409, DOI 10.1016/0026-0495(93)90095-6; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LEWITT MS, 1991, ENDOCRINOLOGY, V129, P2254, DOI 10.1210/endo-129-4-2254; Loddick SA, 1998, P NATL ACAD SCI USA, V95, P1894, DOI 10.1073/pnas.95.4.1894; Lowman HB, 1998, BIOCHEMISTRY-US, V37, P8870, DOI 10.1021/bi980426e; Moses AC, 1996, DIABETES, V45, P91, DOI 10.2337/diabetes.45.1.91; PEKONEN F, 1989, FERTIL STERIL, V51, P972; POWELL DR, 1991, J BIOL CHEM, V266, P18868; RAJKUMAR K, 1995, ENDOCRINOLOGY, V136, P4029, DOI 10.1210/en.136.9.4029; RECHLER MM, 1980, ENDOCRINOLOGY, V107, P1451, DOI 10.1210/endo-107-5-1451; RITOVOS O, 1988, ENDOCRINOLOGY, V122, P2150; Sakai K, 2001, DIABETES, V50, P32, DOI 10.2337/diabetes.50.1.32; Sakai K, 2001, J BIOL CHEM, V276, P8740, DOI 10.1074/jbc.M008359200; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419; TARTARE S, 1991, FEBS LETT, V295, P219, DOI 10.1016/0014-5793(91)81422-5; TREADWAY JL, 1992, BIOCHEMISTRY-US, V31, P11801, DOI 10.1021/bi00162a018; USALA AL, 1992, NEW ENGL J MED, V327, P853, DOI 10.1056/NEJM199209173271205; VERSPOHL EJ, 1984, J CLIN INVEST, V74, P1436, DOI 10.1172/JCI111555; VILLAFUERTE BC, 1992, DIABETES, V41, P835, DOI 10.2337/diabetes.41.7.835; Vuguin P, 1999, J CLIN ENDOCR METAB, V84, P2037, DOI 10.1210/jc.84.6.2037; WERNER H, 1991, INSULIN LIKE GROWTH, P263; WIDMER U, 1985, ACTA ENDOCRINOL-COP, V108, P237, DOI 10.1530/acta.0.1080237; ZENOBI PD, 1992, J CLIN INVEST, V90, P2234, DOI 10.1172/JCI116109	43	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13620	13627		10.1074/jbc.M107771200	http://dx.doi.org/10.1074/jbc.M107771200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834727	hybrid			2022-12-25	WOS:000175096000038
J	LeBrun, LA; Hoch, U; de Montellano, PRO				LeBrun, LA; Hoch, U; de Montellano, PRO			Autocatalytic mechanism and consequences of covalent heme attachment in the cytochrome P4504A family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE CYTOCHROME; HUMAN MYELOPEROXIDASE; PROSTHETIC GROUP; BINDING; LACTOPEROXIDASE; PEROXIDASE; CYP4A11; LINKAGE; ESTER; SITE	The prosthetic heme group in the CYP4A family of cytochrome P450 enzymes is covalently attached to an I-helix glutamic acid residue. This glutamic acid is conserved in the CYP4 family but is absent in other P450 families. As shown here, the glutamic acid is linked, presumably via an ester bond, to a hydroxyl group on the heme 5-methyl group. Mutation of the glutamic acid to an alanine in CYP4A1, CYP4A3, and CYP4A11 suppresses covalent heme binding. In wild-type CYP4A3 68% of the heme is covalently bound to the heterologously expressed protein, but in the CYP4A3/E318D mutant, 47% of the heme is unchanged, 47% is present as noncovalently bound 5-hydroxymethylheme, and only 6% is covalently bound to the protein. In the CYP4A3/ E318Q mutant, the majority of the heme is unaltered, and <2% is covalently linked. The proportion of covalently bound heme in the recombinant CYP4A proteins increases with time under turnover conditions. The catalytic activity is sensitive in some, but not all, CYP4A enzymes to the extent of covalent heme binding. Mutations of Glu(318) in CYP4A3 decrease the apparent k(cat) values for lauric acid hydroxylation. The key conclusions are that (a) covalent heme binding occurs via an ester bond to the heme 5-methyl group, (b) covalent binding of the heme is mediated by an autocatalytic process, and (c) fatty acid oxidation is sensitive in some CYP4A enzymes to the presence or absence of the heme covalent link.	Univ Calif San Francisco, Dept Pharmaceut Chem, Sch Pharm, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Sch Pharm, S-926,513 Parnassus Ave, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025515, R37GM025515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 25515] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATOR MA, 1987, J BIOL CHEM, V262, P1542; Barker PD, 1999, STRUCTURE, V7, pR281, DOI 10.1016/S0969-2126(00)88334-3; Chang YT, 1999, PROTEINS, V34, P403, DOI 10.1002/(SICI)1097-0134(19990215)34:3<403::AID-PROT12>3.0.CO;2-D; Colas C, 2002, J BIOL CHEM, V277, P7191, DOI 10.1074/jbc.M109523200; DePillis GD, 1997, J BIOL CHEM, V272, P8857; Dierks EA, 1998, J BIOL CHEM, V273, P23055, DOI 10.1074/jbc.273.36.23055; Dierks EA, 1998, BIOCHEMISTRY-US, V37, P1839, DOI 10.1021/bi972458s; Fayadat L, 1999, J BIOL CHEM, V274, P10533, DOI 10.1074/jbc.274.15.10533; FENNA R, 1995, ARCH BIOCHEM BIOPHYS, V316, P653, DOI 10.1006/abbi.1995.1086; Fiedler TJ, 2000, J BIOL CHEM, V275, P11964, DOI 10.1074/jbc.275.16.11964; Henne KR, 2001, BIOCHEMISTRY-US, V40, P12925, DOI 10.1021/bi011171z; Hoch U, 2000, ARCH BIOCHEM BIOPHYS, V373, P63, DOI 10.1006/abbi.1999.1504; Hoch U, 2001, J BIOL CHEM, V276, P11339, DOI 10.1074/jbc.M009969200; JACQUET A, 1994, BIOCHEM BIOPH RES CO, V202, P73, DOI 10.1006/bbrc.1994.1895; Kooter IM, 1999, J BIOL CHEM, V274, P26794, DOI 10.1074/jbc.274.38.26794; Kooter IM, 1999, EUR J BIOCHEM, V264, P211, DOI 10.1046/j.1432-1327.1999.00606.x; Moore G. R., 1990, CYTOCHROMES C EVOLUT; OMURA T, 1964, J BIOL CHEM, V239, P2370; Orrenius S, 1972, Biochem Soc Symp, V34, P55; Oxvig C, 1999, J BIOL CHEM, V274, P16953, DOI 10.1074/jbc.274.24.16953; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; Rae TD, 1998, J BIOL CHEM, V273, P27968, DOI 10.1074/jbc.273.43.27968; Simpson AECM, 1997, GEN PHARMACOL-VASC S, V28, P351, DOI 10.1016/S0306-3623(96)00246-7; Suriano G, 2001, BIOORG MED CHEM LETT, V11, P2827, DOI 10.1016/S0960-894X(01)00533-9; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; Tomlinson EJ, 2000, J BIOL CHEM, V275, P32530, DOI 10.1074/jbc.M004022200	26	44	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12755	12761		10.1074/jbc.M112155200	http://dx.doi.org/10.1074/jbc.M112155200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821421	hybrid			2022-12-25	WOS:000175036300035
J	Lemke, CT; Howell, PL				Lemke, CT; Howell, PL			Substrate induced conformational changes in argininosuccinate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; VASCULAR SMOOTH-MUSCLE; NITRIC-OXIDE SYNTHESIS; STRUCTURE REFINEMENT; NAD(+) SYNTHETASE; CRYSTAL-STRUCTURE; ACTIVE-SITE; ARGININE; CRYSTALLIZATION; AMINOACYLATION	Argininosuccinate synthetase (AS) is the rate-limiting enzyme of both the urea and arginine-citrulline cycles. In mammals, deficiency of AS leads to citrullinemia, a debilitating and often fatal autosomal recessive urea cycle disorder, whereas its overexpression for sustained nitric oxide production via the arginine-citrulline cycle leads to the potentially fatal hypotension associated with septic and cytokine-induced circulatory shock. The crystal structures of Escherichia coli argininosuccinate synthetase (EAS) in complex with ATP and with ATP and citrulline have been determined at 2.0-Angstrom resolution. These are the first EAS structures to be solved in the presence of a nucleotide substrate and clearly identify the residues that interact with both ATP and citrulline. Two distinct conformations are revealed for ATP, both of which are believed to be catalytically relevant. In addition, comparisons of these EAS structures with those of the apoenzyme and EAS complexed with aspartate and citrulline (Lemke, C. T., and Howell, P. L. (2001) Structure (Lond.) 9, 1153-1164) provide structural evidence of ATP-induced conformational changes in the nucleotide binding domain. Combined, these structures also provide structural explanations of some of the observed kinetic properties of the enzyme and have enabled a detailed enzymatic mechanism of AS catalysis to be proposed.	Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Howell, PL (corresponding author), Hosp Sick Children, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Adams PD, 1999, ACTA CRYSTALLOGR D, V55, P181, DOI 10.1107/S0907444998006635; Akaike T, 2000, IMMUNOLOGY, V101, P300, DOI 10.1046/j.1365-2567.2000.00142.x; Arnez JG, 1997, P NATL ACAD SCI USA, V94, P7144, DOI 10.1073/pnas.94.14.7144; Arnez JG, 1999, J MOL BIOL, V286, P1449, DOI 10.1006/jmbi.1999.2562; BEAUDET AL, 1986, ADV HUM GENET, V15, P161; BELRHALI H, 1995, STRUCTURE, V3, P341, DOI 10.1016/S0969-2126(01)00166-6; Boehlein SK, 1997, J BIOL CHEM, V272, P12384, DOI 10.1074/jbc.272.19.12384; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAVARELLI J, 1994, EMBO J, V13, P327, DOI 10.1002/j.1460-2075.1994.tb06265.x; Desogus G, 2000, BIOCHEMISTRY-US, V39, P8418, DOI 10.1021/bi0006722; Efron D T, 2000, Curr Opin Clin Nutr Metab Care, V3, P197, DOI 10.1097/00075197-200005000-00006; GHOSE C, 1985, BIOCHEMISTRY-US, V24, P5894, DOI 10.1021/bi00342a031; HATTORI Y, 1994, J BIOL CHEM, V269, P9405; Heneka MT, 2001, J NEUROIMMUNOL, V114, P8, DOI 10.1016/S0165-5728(01)00246-6; HILGER F, 1979, EUR J BIOCHEM, V94, P153, DOI 10.1111/j.1432-1033.1979.tb12882.x; Ignarro LJ, 1999, J CARDIOVASC PHARM, V34, P879, DOI 10.1097/00005344-199912000-00016; Karupiah G, 2000, Rev Immunogenet, V2, P387; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Larsen TM, 1999, BIOCHEMISTRY-US, V38, P16146, DOI 10.1021/bi9915768; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemke C, 1999, ACTA CRYSTALLOGR D, V55, P2028, DOI 10.1107/S0907444999011816; Lemke CT, 2001, STRUCTURE, V9, P1153, DOI 10.1016/S0969-2126(01)00683-9; Melino G, 2000, CELL MOL LIFE SCI, V57, P612, DOI 10.1007/PL00000723; MORRIS SM, 1992, ANNU REV NUTR, V12, P81, DOI 10.1146/annurev.nu.12.070192.000501; OBRIEN WE, 1979, BIOCHEMISTRY-US, V18, P5353, DOI 10.1021/bi00591a015; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1998, ACTA CRYSTALLOGR D, V54, P1285, DOI 10.1107/S0907444998004119; RAUSHEL FM, 1983, ARCH BIOCHEM BIOPHYS, V225, P979, DOI 10.1016/0003-9861(83)90114-5; Rizzi M, 1996, EMBO J, V15, P5125, DOI 10.1002/j.1460-2075.1996.tb00896.x; Rizzi M, 1998, STRUCTURE, V6, P1129, DOI 10.1016/S0969-2126(98)00114-2; ROCHOVANSKY O, 1961, J BIOL CHEM, V236, P2254; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; Roussel A, 1991, SILICON GRAPHICS GEO, P81; SAHEKI T, 1975, FEBS LETT, V58, P314, DOI 10.1016/0014-5793(75)80287-0; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; Xie LJ, 1997, J BIOL CHEM, V272, P16624, DOI 10.1074/jbc.272.26.16624; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3; Yaremchuk A, 2001, J MOL BIOL, V309, P989, DOI 10.1006/jmbi.2001.4712	39	17	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13074	13081		10.1074/jbc.M112436200	http://dx.doi.org/10.1074/jbc.M112436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809762	hybrid			2022-12-25	WOS:000175036300075
J	Ni, HP; Capodici, J; Cannon, G; Communi, D; Boeynaems, JM; Kariko, K; Weissman, D				Ni, HP; Capodici, J; Cannon, G; Communi, D; Boeynaems, JM; Kariko, K; Weissman, D			Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOTOXIC T-LYMPHOCYTES; IN-VITRO; P2Y RECEPTORS; MESSENGER-RNA; TNF-ALPHA; MATURATION; ANTIGEN; MECHANISMS; INDUCTION; CANCER	We previously demonstrated that dendritic cell (DC) pulsing with antigen-encoded mRNA resulted in the loading of both major histocompatibility complex class I and 11 antigen presentation pathways and the delivery of an activation signal. Coculture of mRNA-pulsed DC with T cells led to the induction of a potent primary immune response. DC, in addition to recognizing foreign antigens through pattern recognition receptors, also must respond to altered self, transformed, or intracellularly infected cells. This occurs through cell surface receptors that recognize products of inflammation and cell death. In this report, we characterize two signaling pathways utilized by extracellular mRNA to activate DC. In addition, a novel ligand, poly(A), is identified that mediates signaling through a receptor that can be inhibited by pertussis toxin and suramin and can be desensitized by ATP and ADP, suggesting a P2Y type nucleotide receptor. The role of this signaling activity in vaccine design and the potential effect of mRNA released by damaged cells in the induction of immune responsiveness is discussed.	Univ Penn, Div Infect Dis, Philadelphia, PA 19104 USA; Univ Penn, Div Neurosurg, Philadelphia, PA 19104 USA; Free Univ Brussels, Sch Med, Erasme Hosp, Inst Interdisciplinary Res, B-1070 Brussels, Belgium; Free Univ Brussels, Sch Med, Erasme Hosp, Dept Med Chem, B-1070 Brussels, Belgium	University of Pennsylvania; University of Pennsylvania; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Weissman, D (corresponding author), Univ Penn, Div Infect Dis, 522B Johnson Pavil, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [R01-HL-62060-01] Funding Source: Medline; NIAID NIH HHS [R21-AI-45318-01A1] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062060] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Allavena P, 2000, IMMUNOL REV, V177, P141, DOI 10.1034/j.1600-065X.2000.17714.x; Andersson C, 2001, SCAND J IMMUNOL, V54, P117, DOI 10.1046/j.1365-3083.2001.00951.x; Ashley DM, 1997, J EXP MED, V186, P1177, DOI 10.1084/jem.186.7.1177; Berchtold S, 1999, FEBS LETT, V458, P424, DOI 10.1016/S0014-5793(99)01197-7; Boczkowski D, 1996, J EXP MED, V184, P465, DOI 10.1084/jem.184.2.465; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; Communi D, 1996, EUR J PHARMACOL, V317, P383, DOI 10.1016/S0014-2999(96)00740-6; Communi D, 2001, J BIOL CHEM, V276, P41479, DOI 10.1074/jbc.M105912200; Communi D, 1997, J BIOL CHEM, V272, P31969, DOI 10.1074/jbc.272.51.31969; Coutinho-Silva R, 2001, AM J PHYSIOL-CELL PH, V280, pC81, DOI 10.1152/ajpcell.2001.280.1.C81; Delneste Y, 1999, J IMMUNOL, V163, P3071; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; Gilboa E, 1998, CANCER IMMUNOL IMMUN, V46, P82, DOI 10.1007/s002620050465; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Granucci F, 2001, EUR J IMMUNOL, V31, P2539, DOI 10.1002/1521-4141(200109)31:9<2539::AID-IMMU2539>3.0.CO;2-9; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; Imler J L, 2000, Rev Immunogenet, V2, P294; Ito T, 2001, J IMMUNOL, V166, P2961, DOI 10.4049/jimmunol.166.5.2961; Jones KA, 2000, NEUROPSYCHOPHARMACOL, V23, pS41, DOI 10.1016/S0893-133X(00)00145-7; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kariko K, 1998, BBA-BIOMEMBRANES, V1369, P320, DOI 10.1016/S0005-2736(97)00238-1; la Sala A, 2001, J IMMUNOL, V166, P1611, DOI 10.4049/jimmunol.166.3.1611; Lanzavecchia A, 2001, CURR OPIN IMMUNOL, V13, P291, DOI 10.1016/S0952-7915(00)00218-1; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Leitner WW, 1999, VACCINE, V18, P765, DOI 10.1016/S0264-410X(99)00271-6; Liu YJ, 2001, NAT IMMUNOL, V2, P585, DOI 10.1038/89726; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Morse MA, 1998, CANCER RES, V58, P2965; Murphy GP, 1999, PROSTATE, V39, P54, DOI 10.1002/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U; Mutini C, 1999, J IMMUNOL, V163, P1958; Nair SK, 2000, NAT MED, V6, P1011, DOI 10.1038/79519; Nair SK, 1998, NAT BIOTECHNOL, V16, P364, DOI 10.1038/nbt0498-364; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Otero M, 2000, MOL CELL BIOCHEM, V205, P115, DOI 10.1023/A:1007018001735; PINTOR J, 1995, BRIT J PHARMACOL, V115, P895, DOI 10.1111/j.1476-5381.1995.tb15894.x; Pulendran B, 2001, SCIENCE, V293, P253, DOI 10.1126/science.1062060; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; Rieser C, 1997, J EXP MED, V186, P1603, DOI 10.1084/jem.186.9.1603; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Sabala P, 2001, BRIT J PHARMACOL, V132, P393, DOI 10.1038/sj.bjp.0703843; Saenz-Badillos J, 2001, EXP DERMATOL, V10, P143, DOI 10.1034/j.1600-0625.2001.010003143.x; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Santiago-Perez LI, 2001, J CELL PHYSIOL, V187, P196, DOI 10.1002/jcp.1063; Scales D, 2001, J IMMUNOL, V166, P6437, DOI 10.4049/jimmunol.166.10.6437; Schnurr M, 2000, J IMMUNOL, V165, P4704, DOI 10.4049/jimmunol.165.8.4704; Steinbrink K, 2000, ARCH DERMATOL RES, V292, P437, DOI 10.1007/s004030000159; Steinman RM, 1999, J LEUKOCYTE BIOL, V66, P205, DOI 10.1002/jlb.66.2.205; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; Strobel I, 2000, GENE THER, V7, P2028, DOI 10.1038/sj.gt.3301326; Urban BC, 1999, NATURE, V400, P73, DOI 10.1038/21900; Urban BC, 2001, P NATL ACAD SCI USA, V98, P8750, DOI 10.1073/pnas.151028698; Van Tendeloo VFI, 2001, BLOOD, V98, P49, DOI 10.1182/blood.V98.1.49; Vissers JLM, 2001, J LEUKOCYTE BIOL, V69, P785; von Kugelgen I, 2000, N-S ARCH PHARMACOL, V362, P310, DOI 10.1007/s002100000310; Wan YH, 2001, CURR PHARM DESIGN, V7, P977, DOI 10.2174/1381612013397627; Weissman D, 2000, J IMMUNOL, V165, P4710, DOI 10.4049/jimmunol.165.8.4710; Wilkin F, 2001, J IMMUNOL, V166, P7172, DOI 10.4049/jimmunol.166.12.7172; Ying H, 1999, NAT MED, V5, P823, DOI 10.1038/10548; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200; Zhang WP, 1999, HUM GENE THER, V10, P1151, DOI 10.1089/10430349950018148	66	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12689	12696		10.1074/jbc.M110729200	http://dx.doi.org/10.1074/jbc.M110729200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821398	hybrid			2022-12-25	WOS:000175036300026
J	Nicholls, CD; McLure, KG; Shields, MA; Lee, PWK				Nicholls, CD; McLure, KG; Shields, MA; Lee, PWK			Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers - Implications on the dominant negative effect	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; TUMOR-SUPPRESSOR P53; RING-FINGER DOMAIN; GAIN-OF-FUNCTION; MUTANT P53; TETRAMERIZATION DOMAIN; DNA-BINDING; CELL-LINES; BREAST-CANCER; OLIGOMERIZATION DOMAIN	Precisely how mutant p53 exerts a dominant negative effect over wild type p53 has been an enigma. To understand how wild type and mutant p53 form hetero-oligomers, we studied p53 biogenesis in vitro. We show here that p53 dimers are formed cotranslationally (on the polysome), whereas tetramers are formed posttranslationally (by the dimerization of dimers in solution). Coexpression of wild type and mutant p53 therefore results in 50% of the p53 generated being heterotetramers comprised of a single species: wild type dimer/mutant dimer. Using hot spot mutants of p53 and a variety of natural target sites, we show that all wild type/mutant heterotetramers manifest impaired DNA binding activity. This impairment is not due to the mutant dimeric subunit inhibiting association of the complex with DNA but rather due to the lack of significant contribution (positive cooperativity) from the mutant partner. For all heterotetramers, bias in binding is particularly pronounced against those sequences in genes responsible for apoptosis rather than cell growth arrest. These results explain the molecular basis of p53 dominant negative effect and suggest a functional role in the regulation of p53 tetramerization.	Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Hlth Sci Ctr, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba	Lee, PWK (corresponding author), Univ Calgary, Hlth Sci Ctr, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada.							Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; Chene P, 1999, J MOL BIOL, V286, P1269, DOI 10.1006/jmbi.1999.2563; Chene P, 1997, J MOL BIOL, V273, P873, DOI 10.1006/jmbi.1997.1360; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHUMAKOV AM, 1993, ONCOGENE, V8, P3005; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DAVIDOFF AM, 1991, CANCER RES, V51, P2605; Deb D, 1999, INT J ONCOL, V15, P413; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FREBOURG T, 1994, CANCER RES, V54, P878; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Gilmore R, 1996, EMBO J, V15, P2651, DOI 10.1002/j.1460-2075.1996.tb00625.x; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HACHIYA M, 1994, ANTICANCER RES, V14, P1853; Hara T, 2000, EXP CELL RES, V258, P152, DOI 10.1006/excr.2000.4926; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; JEFFREY PD, 1995, SCIENCE, V267, P1498, DOI 10.1126/science.7878469; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Liu YG, 2001, CARCINOGENESIS, V22, P851, DOI 10.1093/carcin/22.6.851; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1993, CANCER GENET CYTOGEN, V66, P83, DOI 10.1016/0165-4608(93)90233-C; Mateu MG, 1999, NAT STRUCT BIOL, V6, P191; MAZARS R, 1992, CANCER RES, V52, P3918; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PARK DJ, 1994, ONCOGENE, V9, P1899; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; ROLLEY N, 1995, ONCOGENE, V11, P763; Sakaguchi K, 1997, J PROTEIN CHEM, V16, P553, DOI 10.1023/A:1026334116189; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; Varley JM, 1997, ONCOGENE, V14, P865, DOI 10.1038/sj.onc.1201041; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WATERMAN JLF, 1995, EMBO J, V14, P512, DOI 10.1002/j.1460-2075.1995.tb07027.x; Waterman MJF, 1996, CANCER RES, V56, P158; Williams KJ, 1996, BRIT J CANCER, V74, P698, DOI 10.1038/bjc.1996.424; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	61	102	104	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12937	12945		10.1074/jbc.M108815200	http://dx.doi.org/10.1074/jbc.M108815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11805092	hybrid			2022-12-25	WOS:000175036300059
J	Vann, LR; Payne, SG; Edsall, LC; Twitty, S; Spiegel, S; Milstien, S				Vann, LR; Payne, SG; Edsall, LC; Twitty, S; Spiegel, S; Milstien, S			Involvement of sphingosine kinase in TNF-alpha-stimulated tetrahydrobiopterin biosynthesis in C6 glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP CYCLOHYDROLASE I; NITRIC-OXIDE SYNTHASE; NECROSIS-FACTOR-ALPHA; SIGNAL-REGULATED KINASE; FUNCTIONAL-CHARACTERIZATION; CELLULAR-RESPONSES; INHIBITS APOPTOSIS; MOLECULAR-CLONING; RECEPTOR EDG-1; EXPRESSION	In C6 glioma cells, the sphingolipid second messenger ceramide potentiates expression of inducible nitric-oxide synthase (iNOS) induced by tumor necrosis factor a (TNF-alpha) without affecting GTP cyclohydrolase I (GT-PCH), the rate-limiting enzyme in the biosynthesis of 6(R)-5,6,7,8-tetrahydrobiopterin (BH4), a cofactor required for iNOS activity. TNF-alpha also stimulates sphingosine kinase, the enzyme that phosphorylates sphingosine to form sphingosine-1-phosphate (SPP), a further metabolite of ceramide. Several clones of C6 cells, expressing widely varying levels of sphingosine kinase, were used to examine the role of SPP in regulation of GTPCH and BH4 biosynthesis. Overexpression of sphingosine kinase, with concomitant increased endogenous SPP levels, potentiated the effect of TNF-alpha on GTPCH expression and activity and BH4 biosynthesis. In contrast, enforced expression of sphingosine kinase had no effect on iNOS expression or NO formation. Furthermore, N,N-dimethylsphingosine, a potent sphingosine kinase inhibitor, completely eliminated the increased GTPCH activity and expression induced by TNF-alpha. Surprisingly, we found that, although C6 cells can secrete SPP, which is enhanced by TNF-alpha, treatment of C6 cells with exogenous SPP or dihydro-SPP had no affect on BH4 biosynthesis. However, both SPP and dihydro-SPP markedly stimulated ERK 1/2 in C6 cells, which express cell surface SPP receptors. Interestingly, although this ERK activation was blocked by PD98059, which also reduced cellular proliferation induced by enforced expression of sphingosine kinase, PD98059 had no effect on GTPCH activity. Collectively, these results suggest that only intracellularly generated SPP plays a role in regulation of GTPCH and BH4 levels.	NIMH, LCMR, NIH, Bethesda, MD 20892 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Georgetown University	Milstien, S (corresponding author), NIMH, LCMR, NIH, Bldg 36,Rm 2A-11, Bethesda, MD 20892 USA.	milstien@codon.nih.gov			NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER; NCI NIH HHS [CA 61774] Funding Source: Medline; NIGMS NIH HHS [GM 43880] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; DSa C, 1996, MOL BRAIN RES, V41, P105, DOI 10.1016/0169-328X(96)00073-3; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Edsall LC, 1999, ANAL BIOCHEM, V272, P80, DOI 10.1006/abio.1999.4157; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hattori Y, 1997, BBA-MOL CELL RES, V1358, P61, DOI 10.1016/S0167-4889(97)00052-9; Hla T, 2001, PROSTAG OTH LIPID M, V64, P135, DOI 10.1016/S0090-6980(01)00109-5; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Kapatos G, 2000, J BIOL CHEM, V275, P5947, DOI 10.1074/jbc.275.8.5947; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; KOSHIMURA K, 1990, J NEUROCHEM, V54, P1391, DOI 10.1111/j.1471-4159.1990.tb01974.x; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Milstien S, 1996, J BIOL CHEM, V271, P19743, DOI 10.1074/jbc.271.33.19743; MILSTIEN S, 1987, UNCONJUGATED PTERINS, P49; Mogi M, 1999, BIOCHEM PHARMACOL, V58, P649, DOI 10.1016/S0006-2952(99)00131-8; MULLER HW, 1995, PHARMACOL THERAPEUT, V65, P1, DOI 10.1016/0163-7258(94)00047-7; Nava VE, 2000, CANCER RES, V60, P4468; Niwa M, 1999, LIFE SCI, V66, P245, DOI 10.1016/S0024-3205(99)00587-1; Olivera A, 1999, FASEB J, V13, P1593, DOI 10.1096/fasebj.13.12.1593; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pebay A, 2001, EUR J NEUROSCI, V13, P2067, DOI 10.1046/j.0953-816x.2001.01585.x; Pitson SM, 2000, J BIOL CHEM, V275, P33945, DOI 10.1074/jbc.M006176200; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; SAKAI N, 1995, J NEUROCHEM, V65, P895; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Sato K, 2000, MOL BRAIN RES, V85, P151, DOI 10.1016/S0169-328X(00)00262-X; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; Singh JK, 1996, BBA-MOL CELL RES, V1310, P201, DOI 10.1016/0167-4889(95)00163-8; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Steinmetz MO, 1998, J MOL BIOL, V279, P189, DOI 10.1006/jmbi.1998.1649; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Thony B, 2000, BIOCHEM J, V347, P1, DOI 10.1042/0264-6021:3470001; Togari A, 1998, FEBS LETT, V428, P212, DOI 10.1016/S0014-5793(98)00531-6; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Vann LR, 2000, J BIOL CHEM, V275, P13275, DOI 10.1074/jbc.275.18.13275; WERNER ER, 1993, P SOC EXP BIOL MED, V203, P1; Werner ER, 1998, P SOC EXP BIOL MED, V219, P171; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533; ZUHERINGDORF DM, 1997, FEBS LETT, V410, P34	52	56	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12649	12656		10.1074/jbc.M109111200	http://dx.doi.org/10.1074/jbc.M109111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815603	hybrid			2022-12-25	WOS:000175036300022
J	Brazzolotto, X; Timmins, P; Dupont, Y; Moulis, JM				Brazzolotto, X; Timmins, P; Dupont, Y; Moulis, JM			Structural changes associated with switching activities of human iron regulatory protein 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT-BINDING; RNA-BINDING; MESSENGER-RNA; NITRIC-OXIDE; CYTOPLASMIC ACONITASE; SOLUTION SCATTERING; OXIDATIVE STRESS; 4FE-4S CLUSTERS; SULFUR CLUSTER; IRE-BP	Metazoan iron regulatory protein 1 is a dual activity protein, being either an aconitase or a regulatory factor binding to messenger RNA involved in iron homeostasis. Sequence comparisons and site-directed mutagenesis experiments have supported a structural relationship between mitochondrial aconitase and iron regulatory protein 1. The structural properties of human recombinant iron regulatory protein 1 have been probed in the present work. Although iron-free iron regulatory protein 1 displays a significantly larger radius of gyration measured by small-angle neutron scattering than calculated for mitochondrial aconitase, binding of either the [4Fe-4S] cluster needed for aconitase activity or of a RNA substrate turns iron regulatory protein I into a more compact molecule. These conformational changes are associated with the gain of secondary structural elements as indicated by circular dichroism studies. They likely involve alpha-helices covering the substrate binding cleft of cytosolic aconitase, and they suggest an induced fit mechanism of iron-responsive element recognition. These studies refine previously proposed models of the "iron-sulfur switch" driving the biological function of human iron regulatory protein 1, and they provide a structural framework to probe the relevance of the numerous cellular molecules proposed to affect its function.	CEA Grenoble, DBMS, MEP, Lab BMC, F-38054 Grenoble 9, France; Inst Max Von Laue Paul Langevin, Large Scale Struct Grp, F-38042 Grenoble, France	CEA; Institut Laue-Langevin (ILL)	Moulis, JM (corresponding author), CEA Grenoble, DBMS, MEP, Lab BMC, 17 Rue Martyrs, F-38054 Grenoble 9, France.		Brazzolotto, Xavier/GXG-3805-2022	Brazzolotto, Xavier/0000-0001-9219-1032; Moulis, Jean-Marc/0000-0001-5615-9852				Addess KJ, 1997, J MOL BIOL, V274, P72, DOI 10.1006/jmbi.1997.1377; [Anonymous], 1996, CIRCULAR DICHROISM C; BASILION JP, 1994, P NATL ACAD SCI USA, V91, P574, DOI 10.1073/pnas.91.2.574; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Bouton C, 1996, J BIOL CHEM, V271, P2300, DOI 10.1074/jbc.271.4.2300; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Butt J, 1996, P NATL ACAD SCI USA, V93, P4345, DOI 10.1073/pnas.93.9.4345; Cairo G, 2000, BIOCHEM J, V352, P241, DOI 10.1042/0264-6021:3520241; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; Draper DE, 1999, J MOL BIOL, V293, P255, DOI 10.1006/jmbi.1999.2991; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; Frishman D, 1996, EUR J BIOCHEM, V239, P197, DOI 10.1111/j.1432-1033.1996.0197u.x; Gdaniec Z, 1998, BIOCHEMISTRY-US, V37, P1505, DOI 10.1021/bi9719814; Gegout V, 1999, J BIOL CHEM, V274, P15052, DOI 10.1074/jbc.274.21.15052; HAILE DJ, 1992, P NATL ACAD SCI USA, V89, P7536, DOI 10.1073/pnas.89.16.7536; Hall KB, 1998, BIOCHEMISTRY-US, V37, P9323, DOI 10.1021/bi9805285; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HENTZE MW, 1991, NUCLEIC ACIDS RES, V19, P1739, DOI 10.1093/nar/19.8.1739; HIRLING H, 1994, EMBO J, V13, P453, DOI 10.1002/j.1460-2075.1994.tb06280.x; JACROT B, 1976, REP PROG PHYS, V39, P911, DOI 10.1088/0034-4885/39/10/001; Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943; Kaldy P, 1999, EMBO J, V18, P6073, DOI 10.1093/emboj/18.21.6073; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; Kohler SA, 1999, J BIOL CHEM, V274, P2401, DOI 10.1074/jbc.274.4.2401; Kyritsis P, 1998, J BIOL CHEM, V273, P15404, DOI 10.1074/jbc.273.25.15404; Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y; Lloyd SJ, 1999, PROTEIN SCI, V8, P2655, DOI 10.1110/ps.8.12.2655; Oliveira L, 2000, P NATL ACAD SCI USA, V97, P6550, DOI 10.1073/pnas.120571797; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; Paraskeva E, 1996, FEBS LETT, V389, P40, DOI 10.1016/0014-5793(96)00574-1; PHILPOTT CC, 1994, P NATL ACAD SCI USA, V91, P7321, DOI 10.1073/pnas.91.15.7321; Rennie A. R., 1998, ILL98GH14T; ROBBINS AH, 1989, PROTEINS, V5, P289, DOI 10.1002/prot.340050406; Rouault TA, 1996, J BIOL INORG CHEM, V1, P494, DOI 10.1007/s007750050083; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; Schalinske KL, 1997, BIOCHEMISTRY-US, V36, P3950, DOI 10.1021/bi9624447; Schalinske KL, 1996, J BIOL CHEM, V271, P7168, DOI 10.1074/jbc.271.12.7168; Schlegl J, 1997, RNA, V3, P1159; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1997, J APPL CRYSTALLOGR, V30, P798, DOI 10.1107/S0021889897001714; Theil EC, 2000, J BIOL CHEM, V275, P40659, DOI 10.1074/jbc.R000019200; Thomson AM, 2000, J BIOL CHEM, V275, P31609, DOI 10.1074/jbc.M002354200; TINOCO I, 1980, ANNU REV BIOPHYS BIO, V9, P107, DOI 10.1146/annurev.bb.09.060180.000543; Wardrop SL, 2000, BIOCHEMISTRY-US, V39, P2748, DOI 10.1021/bi991099t; Williamson JR, 2000, NAT STRUCT BIOL, V7, P834, DOI 10.1038/79575	46	27	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11995	12000		10.1074/jbc.M110938200	http://dx.doi.org/10.1074/jbc.M110938200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812787	hybrid			2022-12-25	WOS:000174846400052
J	Ishido, K; Takagaki, K; Iwafune, M; Yoshihara, S; Sasaki, M; Endo, M				Ishido, K; Takagaki, K; Iwafune, M; Yoshihara, S; Sasaki, M; Endo, M			Enzymatic attachment of glycosaminoglycan chain to peptide using the sugar chain transfer reaction with endo-beta-xylosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGLYCOSYLATION ACTIVITY; CHEMOENZYMATIC SYNTHESIS; N-ACETYLGLUCOSAMINIDASE; DERMATAN SULFATE; OLIGOSACCHARIDES; RECONSTRUCTION; HYALURONIDASE; 2-AMINOPYRIDINE; HEXASACCHARIDE; GALACTOSIDASE	Endo-beta-xylosidase from the mid-gut gland of the molluscus Patinopecten is an endo-type glycosidase that hydrolyzes the xylosyl serine linkage between a core protein and a glycosaminoglycan (GAG) chain, releasing the intact GAG chain from proteoglycan. In this study, we investigated GAG chain transfer activity of this enzyme, in order to develop a method for attaching GAG chains to peptide. Peptidochondroitin sulfate (molecular mass of sugar chain, 30 kDa) from bovine tracheal cartilage as a donor and butyloxycarbonyl-leucyl-seryl-threonyl-arginine-(4-methylcoumaryl-7-amide) as an acceptor were incubated with endo-beta-xylosidase. As a result, a reaction product with the same fluorescence as the acceptor peptide was observed. High pressure liquid chromatography analysis, cellulose acetate membrane electrophoresis, and enzymatic digestion showed that this reaction product had the chondroitin sulfate (ChS) from the donor. Furthermore, the acceptor peptide was released from this reaction product after hydrolysis by endo-beta-xylosidase. Therefore, it was confirmed that the ChS chain released from the donor was transferred to the acceptor peptide by the GAG chain transfer reaction of endo-beta-xylosidase. The optimal pH for hydrolysis by this enzyme was found to be about 4.0, whereas that for this reaction was about 3.0. Not only the ChS but also the dermatan sulfate and the heparan sulfate were transferred to the acceptor peptide by this reaction. By using this reaction, the GAG chain could be attached to the peptide in one step. The GAG chain transfer reaction of endo-beta-xylosidase should be a significant glycotechnological tool for the artificial synthesis of proteoglycan.	Hirosaki Univ, Sch Med, Dept Biochem, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Sch Med, Dept Surg 2, Hirosaki, Aomori 0368562, Japan	Hirosaki University; Hirosaki University	Endo, M (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	endo-m@cc.hirosaki-u.ac.jp						Ajisaka K, 2001, BIOSCI BIOTECH BIOCH, V65, P1240, DOI 10.1271/bbb.65.1240; Ashida H, 2000, ARCH BIOCHEM BIOPHYS, V373, P394, DOI 10.1006/abbi.1999.1565; BARDALES RM, 1989, J BIOL CHEM, V264, P19893; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; DISTLER JJ, 1973, J BIOL CHEM, V248, P6772; Haneda K, 1998, BIOORG MED CHEM LETT, V8, P1303, DOI 10.1016/S0960-894X(98)00209-1; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HASE S, 1984, J BIOCHEM-TOKYO, V95, P197, DOI 10.1093/oxfordjournals.jbchem.a134585; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HIROSE S, 1982, J BIOL CHEM, V257, P6316; HOVINGH P, 1974, CARBOHYD RES, V37, P181, DOI 10.1016/S0008-6215(00)87073-1; Kanayama N, 1997, BIOCHEM BIOPH RES CO, V238, P560, DOI 10.1006/bbrc.1997.7344; KANTOR TG, 1957, J AM CHEM SOC, V79, P152, DOI 10.1021/ja01558a040; KON A, 1991, J BIOCHEM-TOKYO, V110, P132, DOI 10.1093/oxfordjournals.jbchem.a123531; LI YT, 1991, J BIOL CHEM, V266, P10723; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATHEWS MB, 1968, BIOCHIM BIOPHYS ACTA, V156, P419, DOI 10.1016/0304-4165(68)90277-8; Nadanaka S, 1998, J BIOL CHEM, V273, P3296, DOI 10.1074/jbc.273.6.3296; NAKAMURA T, 1990, J BIOL CHEM, V265, P5390; OHNO Y, 1981, J BIOCHEM, V90, P1387, DOI 10.1093/oxfordjournals.jbchem.a133604; OHYA T, 1970, BIOCHIM BIOPHYS ACTA, V198, P607, DOI 10.1016/0005-2744(70)90139-7; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; Silbert JE, 1995, BBA-REV BIOMEMBRANES, V1241, P371, DOI 10.1016/0304-4157(95)00011-9; Simonovic SP, 2000, WATER INT, V25, P1, DOI 10.1080/02508060008686792; Takagaki K, 1999, BIOCHEM BIOPH RES CO, V258, P741, DOI 10.1006/bbrc.1999.0697; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; Takagaki K, 2000, BIOCHEM BIOPH RES CO, V270, P588, DOI 10.1006/bbrc.2000.2452; TAKAGAKI K, 1992, J BIOL CHEM, V267, P18558; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKAGAKI K, 1988, J BIOL CHEM, V263, P7000; Takagaki K, 2000, TRENDS GLYCOSCI GLYC, V12, P295, DOI 10.4052/tigg.12.295; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; Takagaki K, 2000, J BIOCHEM, V127, P695, DOI 10.1093/oxfordjournals.jbchem.a022659; TAKEGAWA K, 1995, J BIOL CHEM, V270, P3094, DOI 10.1074/jbc.270.7.3094; TRIMBLE RB, 1986, J BIOL CHEM, V261, P2000; WEISSMANN B, 1954, J AM CHEM SOC, V76, P1753, DOI 10.1021/ja01636a010; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; Yamamoto K, 1997, CARBOHYD RES, V305, P415, DOI 10.1016/S0008-6215(97)10018-0; Yamamoto K, 1997, TRENDS GLYCOSCI GLYC, V9, P339, DOI 10.4052/tigg.9.339	40	8	9	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11889	11895		10.1074/jbc.M112183200	http://dx.doi.org/10.1074/jbc.M112183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805117	hybrid			2022-12-25	WOS:000174846400038
J	Jo, M; Thomas, KS; Somlyo, AV; Somlyo, AP; Gonias, SL				Jo, M; Thomas, KS; Somlyo, AV; Somlyo, AP; Gonias, SL			Cooperativity between the Ras-ERK and Rho-Rho kinase pathways in urokinase-type plasminogen activator-stimulated cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; FOCAL ADHESION KINASE; RECEPTOR; MOTILITY; CYTOSKELETON; GTPASES; PHOSPHORYLATION; PROLIFERATION; DISSEMINATION; DOWNSTREAM	Binding of the urokinase-type plasminogen activator (uPA) to its receptor activates diverse cell signaling pathways. How these signals are integrated so that cell physiology is altered remains unclear. In this study, we demonstrated that migration of MCF-7 breast cancer cells and HT-1080 fibrosarcoma cells on serum-coated surfaces is stimulated by agents that activate ERK, including uPA, epidermal growth factor, and constitutively active MEK1. The promigratory activity of these agents was entirely blocked not only by the MEK-specific antagonist PD098059, but also by antagonists of the Rho-Rho kinase pathway, including Y-27632 and dominant-negative RhoA (RhoA-N19). uPA did not significantly increase the level of GTP-bound RhoA, suggesting that the constitutive activity of the Rho-Rho kinase pathway may be sufficient to support ERK-stimulated cell migration. Paradoxically, Y-27632 and RhoA-N19 increased ERK phosphorylation in MCF-7 cells, providing further evidence that ERK activation alone does not promote cell migration when Rho kinase is antagonized. When MCF-7 cell migration was stimulated by ERK-independent processes such as expression of the beta(3) integrin subunit or changing the substratum to type I collagen, Y-27632 and RhoA-N19 failed to inhibit the response. This study supports a model in which the Ras-ERK and Rho-Rho kinase pathways cooperate to promote cell migration. Neutralizing either pathway is sufficient to block the response to agents that stimulate cell migration by activating ERK.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, POB 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551, P01HL019242, P01HL048807] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL-19242, R01 HL-60551, P0 HL-48807] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Degryse B, 1999, BLOOD, V94, P649, DOI 10.1182/blood.V94.2.649.414k34_649_662; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Filardo EJ, 1996, J CELL SCI, V109, P1615; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAYMAN EG, 1983, P NATL ACAD SCI-BIOL, V80, P4003, DOI 10.1073/pnas.80.13.4003; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kjoller L, 2001, J CELL BIOL, V152, P1145, DOI 10.1083/jcb.152.6.1145; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; Konakova M, 1998, EUR J BIOCHEM, V253, P421, DOI 10.1046/j.1432-1327.1998.2530421.x; Kusch A, 2000, J BIOL CHEM, V275, P39466, DOI 10.1074/jbc.M003626200; Leng J, 1999, J BIOL CHEM, V274, P37855, DOI 10.1074/jbc.274.53.37855; Lewis JM, 1996, J CELL BIOL, V134, P1323, DOI 10.1083/jcb.134.5.1323; Ma Z, 2001, J CELL SCI, V114, P3387; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1991, J BIOL CHEM, V266, P1926; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Somlyo AV, 2000, BIOCHEM BIOPH RES CO, V269, P652, DOI 10.1006/bbrc.2000.2343; TAKAISHI K, 1994, ONCOGENE, V9, P273; Tang H, 1998, J BIOL CHEM, V273, P18268, DOI 10.1074/jbc.273.29.18268; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146	47	88	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12479	12485		10.1074/jbc.M111147200	http://dx.doi.org/10.1074/jbc.M111147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805108	hybrid			2022-12-25	WOS:000174846400115
J	Kalinichenko, VV; Zhou, Y; Bhattacharyya, D; Kim, W; Shin, B; Bambal, K; Costa, RH				Kalinichenko, VV; Zhou, Y; Bhattacharyya, D; Kim, W; Shin, B; Bambal, K; Costa, RH			Haploinsufficiency of the mouse forkhead box f1 gene causes defects in gall bladder development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WINGED HELIX PROTEINS; LIVER DEVELOPMENT; TRANSCRIPTION FACTORS; EMBRYONIC LIVER; DEFICIENT MICE; GROWTH-FACTOR; DIFFERENTIATION; HEAD; FAMILY; MORPHOGENESIS	The forkhead box f1 (Foxf1) transcription factor is expressed in the visceral (splanchnic) mesoderm, which is involved in mesenchymal-epithelial signaling required for development of organs derived from foregut endoderm such as lung, liver, gall bladder, and pan. creas. Our previous studies demonstrated that haploin-sufficiency of the Foxf1 gene caused pulmonary abnormalities with perinatal lethality from lung hemorrhage in a subset of Foxf1+/- newborn mice. During mouse embryonic development, the liver and biliary primordium emerges from the foregut endoderm, invades the septum transversum mesenchyme, and receives inductive signaling originating from both the septum transversum and cardiac mesenchyme. In this study, we show that Foxf1 is expressed in embryonic septum transversum and gall bladder mesenchyme. Foxf1+/- gall bladders were significantly smaller and had severe structural abnormalities characterized by a deficient external smooth muscle cell layer, reduction in mesenchymal cell number, and in some cases, lack of a discernible biliary epithelial cell layer. This Foxt1+1- phenotype correlates with decreased expression of vascular cell adhesion molecule-1 (VCAM-1), alpha(5) integrin, platelet-derived growth factor receptor alpha (PDGFRalpha) and hepatocyte growth factor (HGF) genes, all of which are critical for cell adhesion, migration, and mesenchymal cell differentiation.	Univ Illinois, Coll Med, Dept Mol Genet MC 669, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Costa, RH (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet MC 669, 900 S Ashland Ave,Rm 2220 Mol Biol Res Bldg, Chicago, IL 60607 USA.		Bhattacharyya, Dibyendu/AAE-9208-2022; Bhattacharyya, Dibyendu/GRS-5261-2022	Bhattacharyya, Dibyendu/0000-0003-3252-7440; Bhattacharyya, Dibyendu/0000-0003-3252-7440	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062446] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043241] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62446] Funding Source: Medline; NIGMS NIH HHS [GM 43241] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyagi M, 1999, HISTOCHEM CELL BIOL, V111, P419, DOI 10.1007/s004180050377; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; Duncan SA, 1997, DEVELOPMENT, V124, P279; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Erlinger S, 1996, J GASTROEN HEPATOL, V11, P575, DOI 10.1111/j.1440-1746.1996.tb01705.x; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; JACOB A, 1994, NUCLEIC ACIDS RES, V22, P2126, DOI 10.1093/nar/22.11.2126; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 2000, GENE DEV, V14, P142; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Karlsson L, 2000, DEVELOPMENT, V127, P3457; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Keng VW, 2000, BIOCHEM BIOPH RES CO, V276, P1155, DOI 10.1006/bbrc.2000.3548; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LIM L, 2002, IN PRESS AM J PHYSL, V282; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Mahlapuu M, 2001, DEVELOPMENT, V128, P2397; Mahlapuu M, 2001, DEVELOPMENT, V128, P155; Mori M, 2000, CELL TISSUE RES, V300, P331, DOI 10.1007/s004410000205; Peterson RS, 1997, MECH DEVELOP, V69, P53, DOI 10.1016/S0925-4773(97)00153-6; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Shiojiri N, 1997, MICROSC RES TECHNIQ, V39, P328, DOI 10.1002/(SICI)1097-0029(19971115)39:4<328::AID-JEMT3>3.0.CO;2-D; Vogt PK, 1997, VIROLOGY, V238, P1, DOI 10.1006/viro.1997.8846; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; YANG JT, 1993, DEVELOPMENT, V119, P1093; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Zaret K, 1999, DEV BIOL, V209, P1, DOI 10.1006/dbio.1999.9228	33	96	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12369	12374		10.1074/jbc.M112162200	http://dx.doi.org/10.1074/jbc.M112162200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809759	hybrid			2022-12-25	WOS:000174846400101
J	Pero, SC; Oligino, L; Daly, RJ; Soden, AL; Liu, C; Roller, PP; Li, P; Krag, DN				Pero, SC; Oligino, L; Daly, RJ; Soden, AL; Liu, C; Roller, PP; Li, P; Krag, DN			Identification of novel non-phosphorylated ligands, which bind selectively to the SH2 domain of Grb7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURE-BASED DESIGN; PHAGE DISPLAY LIBRARIES; GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; SRC HOMOLOGY-2 DOMAIN; HIGH-AFFINITY LIGANDS; PEPTIDE LIBRARIES; GRB2-SH2 DOMAIN; ESOPHAGEAL-CARCINOMA; TYROSINE KINASE	Grb7 is an adapter-type signaling protein, which is recruited via its SH2 domain to a variety of receptor tyrosine kinases (RTKs), including ErbB2 and ErbB3. It is overexpressed in breast, esophageal, and gastric cancers, and may contribute to the invasive potential of cancer cells. Molecular interactions involving Grb7 therefore provide attractive targets for therapeutic intervention. We have utilized phage display random peptide libraries as a source of small peptide ligands to the SH2 domain of Grb7. Screening these libraries against purified Grb7 SH2 resulted in the identification of Grb7-binding peptide phage clones that contained a nonphosphorylated Tyr-X-Asn (YXN) motif. The tyrosine-phosphorylated form of this motif is characteristic of Grb7 SH2 domain binding sites identified in RTKs and other signaling proteins such as Shc. Peptides that are non-phosphorylated have greater potential in the development of therapeutics because of the instability of a phosphate group in vivo. Using a biased library approach with this conserved YXN motif, we identified seven different peptide phage clones, which bind specifically to the SH2 domain of Grb7. These peptides did not bind to the SH2 domain of Grb2 (which also selects for Asn at py(+2)) or Grb14, a closely related family member. The cyclic structure of the peptides was required to bind to the Grb7 SH2 domain. Importantly, the synthetic Grb7-binding peptide G7-18 in cell lysates was able to specifically inhibit the association of Grb7 with the ErbB family of RTKs, in particular ErbB3, in a dose-dependent manner. These peptides will be useful in the development of targeted molecular therapeutics for cancers overexpressing Grb7 and in the development of Grb7-specific inhibitors to gain a complete understanding of the physiological role of Grb7.	Univ Vermont, Sch Med, Dept Surg, Burlington, VT 05405 USA; Univ Vermont, Sch Med, Vermont Canc Ctr, Burlington, VT 05405 USA; St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; NCI, Med Chem Lab, NIH, Frederick, MD 21702 USA	University of Vermont; University of Vermont; Garvan Institute of Medical Research; St Vincents Hospital Sydney; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Krag, DN (corresponding author), Univ Vermont, Sch Med, Dept Surg, Given Med Bldg,Rm E309, Burlington, VT 05405 USA.		Daly, Roger J/C-8179-2009	Daly, Roger/0000-0002-5739-8027	NCI NIH HHS [U01 CA665121, R01 CA087790] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; BARRETT RW, 1992, ANAL BIOCHEM, V204, P357, DOI 10.1016/0003-2697(92)90252-3; Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737; Beaulieu PL, 1999, J MED CHEM, V42, P1757, DOI 10.1021/jm980676t; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; Buchanan JL, 1999, BIOORG MED CHEM LETT, V9, P2353, DOI 10.1016/S0960-894X(99)00388-1; BURKE TR, 1994, BIOCHEMISTRY-US, V33, P6490, DOI 10.1021/bi00187a015; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; Charifson PS, 1997, BIOCHEMISTRY-US, V36, P6283, DOI 10.1021/bi970019n; Cussac D, 1999, FASEB J, V13, P31, DOI 10.1096/fasebj.13.1.31; Cwirla SE, 1997, SCIENCE, V276, P1696, DOI 10.1126/science.276.5319.1696; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Dunican DJ, 2001, BIOPOLYMERS, V60, P45, DOI 10.1002/1097-0282(2001)60:1<45::AID-BIP1003>3.3.CO;2-0; FENDLY BM, 1990, CANCER RES, V50, P1550; Fiddes RJ, 1998, J BIOL CHEM, V273, P7717, DOI 10.1074/jbc.273.13.7717; Furet P, 1999, J MED CHEM, V42, P2358, DOI 10.1021/jm991013u; Furet P, 1998, J MED CHEM, V41, P3442, DOI 10.1021/jm980159a; Garcia-Echeverria C, 1998, J MED CHEM, V41, P1741, DOI 10.1021/jm970856n; GILMER T, 1994, J BIOL CHEM, V269, P31711; Gram H, 1997, EUR J BIOCHEM, V246, P633, DOI 10.1111/j.1432-1033.1997.00633.x; Gullick W J, 1990, Int J Cancer Suppl, V5, P55; Han DC, 2000, J BIOL CHEM, V275, P28911, DOI 10.1074/jbc.M001997200; Han DC, 1999, J BIOL CHEM, V274, P24425, DOI 10.1074/jbc.274.34.24425; Hart CP, 1999, CELL SIGNAL, V11, P453, DOI 10.1016/S0898-6568(99)00017-0; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; Janes PW, 1997, J BIOL CHEM, V272, P8490, DOI 10.1074/jbc.272.13.8490; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Kato D, 1998, FEBS LETT, V427, P203, DOI 10.1016/S0014-5793(98)00426-8; Keegan K, 1996, ONCOGENE, V12, P1537; Kishi T, 1997, BIOCHEM BIOPH RES CO, V232, P5, DOI 10.1006/bbrc.1997.6218; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Llinas-Brunet M, 1999, J MED CHEM, V42, P722, DOI 10.1021/jm980612i; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lung FDT, 1999, LETT PEPT SCI, V6, P45, DOI 10.1023/A:1008815410812; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; MARKLAND W, 1991, GENE, V109, P13, DOI 10.1016/0378-1119(91)90583-W; MARTENS CL, 1995, J BIOL CHEM, V270, P21129, DOI 10.1074/jbc.270.36.21129; Muller K, 1996, J BIOL CHEM, V271, P16500; Nilsson F, 2000, ADV DRUG DELIVER REV, V43, P165, DOI 10.1016/S0169-409X(00)00068-5; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Oligino L, 1997, J BIOL CHEM, V272, P29046, DOI 10.1074/jbc.272.46.29046; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; Pacofsky GJ, 1998, J MED CHEM, V41, P1894, DOI 10.1021/jm970853a; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Park J W, 1997, Adv Pharmacol, V40, P399, DOI 10.1016/S1054-3589(08)60146-5; Park JW, 2001, J CONTROL RELEASE, V74, P95, DOI 10.1016/S0168-3659(01)00315-7; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; Robey F A, 1994, Methods Mol Biol, V35, P73; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Schoepfer J, 1998, BIOORG MED CHEM LETT, V8, P2865, DOI 10.1016/S0960-894X(98)00513-7; Scott Jamie K., 1994, Current Opinion in Biotechnology, V5, P40, DOI 10.1016/S0958-1669(05)80068-0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SESHADRI R, 1993, J CLIN ONCOL, V11, P1936, DOI 10.1200/JCO.1993.11.10.1936; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEIN D, 1994, EMBO J, V13, P1331, DOI 10.1002/j.1460-2075.1994.tb06386.x; Tanaka S, 2000, J CELL PHYSIOL, V183, P411, DOI 10.1002/(SICI)1097-4652(200006)183:3<411::AID-JCP14>3.0.CO;2-Z; Tanaka S, 1997, CANCER RES, V57, P28; Tanaka S, 1998, J CLIN INVEST, V102, P821, DOI 10.1172/JCI2921; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; Valadon P, 1996, J IMMUNOL METHODS, V197, P171, DOI 10.1016/0022-1759(96)00133-0; Vayssiere B, 2000, FEBS LETT, V467, P91, DOI 10.1016/S0014-5793(99)01530-6; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; Yao ZJ, 1999, J MED CHEM, V42, P25, DOI 10.1021/jm980388x; YE B, 1995, J MED CHEM, V38, P4270, DOI 10.1021/jm00021a016; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; Zwick MB, 1998, CURR OPIN BIOTECH, V9, P427, DOI 10.1016/S0958-1669(98)80017-7	73	75	76	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11918	11926		10.1074/jbc.M111816200	http://dx.doi.org/10.1074/jbc.M111816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809769	hybrid			2022-12-25	WOS:000174846400042
J	Rao, H; Sastry, A				Rao, H; Sastry, A			Recognition of specific ubiquitin conjugates is important for the proteolytic functions of the ubiquitin-associated domain proteins Dsk2 and Rad23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIUBIQUITIN-CHAIN-BINDING; SACCHAROMYCES-CEREVISIAE; DNA-REPAIR; PATHWAY; DEGRADATION; MCB1	Ubiquitin (Ub) regulates important cellular processes through covalent attachment to its substrates. The fate of a substrate depends on the number of ubiquitin moieties conjugated, as well as the lysine linkage of Ub-Ub conjugation. The major function of LTh is to regulate the in vivo half-life of its substrates. Once a multi-Ub chain is attached to a substrate, it must be shielded from deubiquitylating enzymes for the 26 S proteasome to recognize it. Molecular mechanisms of the postubiquitylation processes are poorly understood. Here, we have characterized a family of proteins that preferentially binds ubiquitylated substrates and multi-Ub chains through a motif termed the ubiquitin-associated domain (UBA). Our in vivo genetic analysis demonstrates that such interactions require specific lysine residues of LTh that are important for Ub chain formation. We show that Saccharomyces cerevisiae cells lacking two of these UBA proteins, Dsk2 and Rad23, are deficient in protein degradation mediated by the UFD pathway and that the intact UBA motif of Dsk2 is essential for its function in proteolysis. Dsk2 and Rad23 can form a complex(es), suggesting that they cooperate to recognize a subset of multi-Ub chains and deliver the Ub-tagged substrates to the proteasome. Our results suggest a molecular mechanism for differentiation of substrate fates, depending on the precise nature of the mono-Ub or multi-Ub lysine linkage, and provide a foundation to further investigate postubiquitylation events.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Rao, H (corresponding author), CALTECH, Div Biol, 147-75,1200 E Calif Blvd, Pasadena, CA 91125 USA.		Wang, Hongcheng/C-5991-2013	RAO, HAI/0000-0002-4235-2210	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31530] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; Biggins S, 1996, J CELL BIOL, V133, P1331, DOI 10.1083/jcb.133.6.1331; Clarke DJ, 2001, MOL CELL BIOL, V21, P1997, DOI 10.1128/MCB.21.6.1997-2007.2001; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Ghislain M, 1996, EMBO J, V15, P4884, DOI 10.1002/j.1460-2075.1996.tb00869.x; Hicke L, 2001, CELL, V106, P527, DOI 10.1016/S0092-8674(01)00485-8; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lambertson D, 1999, GENETICS, V153, P69; Ortolan TG, 2000, NAT CELL BIOL, V2, P601, DOI 10.1038/35023547; Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Schauber C, 1998, NATURE, V391, P715, DOI 10.1038/35661; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939	20	152	155	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11691	11695		10.1074/jbc.M200245200	http://dx.doi.org/10.1074/jbc.M200245200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805121	Green Accepted, hybrid			2022-12-25	WOS:000174846400012
J	Riese, MJ; Goehring, UM; Ehrmantraut, ME; Moss, J; Barbieri, JT; Aktories, K; Schmidt, G				Riese, MJ; Goehring, UM; Ehrmantraut, ME; Moss, J; Barbieri, JT; Aktories, K; Schmidt, G			Auto-ADP-ribosylation of Pseudomonas aeruginosa ExoS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EXOENZYME-S; TERMINAL DOMAIN; RIBOSYLTRANSFERASE; PROTEIN; RAS; CELLS; HYDROLYSIS; EXPRESSION	Pseudomonas aeruginosa Exoenzyme S (ExoS) is a bifunctional type-III cytotoxin. The N terminus possesses a Rho GTPase-activating protein (GAP) activity, whereas the C terminus comprises an ADP-ribosyltransferase domain. We investigated whether the ADP-ribosyltransferase activity of ExoS influences its GAP activity. Although the ADP-ribosyltransferase activity of ExoS is dependent upon FAS, a 14-3-3 family protein, factor-activating ExoS (FAS) had no influence on the activity of the GAP domain of ExoS (ExoS-GAP). In the presence of NAD and FAS, the GAP activity of full-length ExoS was reduced about 10-fold, whereas NAD and FAS did not affect the activity of the ExoS-GAP fragment. Using [P-32]NAD, ExoS-GAP was identified as a substrate of the ADP-ribosyltransferase activity of ExoS. Site-directed mutagenesis revealed that auto-ADP-ribosylation of Arg-146 of ExoS was crucial for inhibition of GAP activity in vitro. To reveal the auto-ADP-ribosylation of ExoS in intact cells, tetanolysin was used to produce pores in the plasma membrane of Chinese hamster ovary (CHO) cells to allow the intracellular entry of [32p]NAD, the substrate for ADP-ribosylation. After a 3-h infection of CHO cells with Pseudomonas aeruginosa, proteins of 50 and 25 kDa were preferentially ADP-ribosylated. The 50-kDa protein was determined to be auto-ADP-ribosylated ExoS, whereas the 25-kDa protein appeared to represent a group of proteins that included Ras.	Univ Freiburg, Inst Expt, D-79104 Freiburg, Germany; Univ Freiburg, Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Med Coll Wisconsin, Milwaukee, WI 53226 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	University of Freiburg; University of Freiburg; Medical College of Wisconsin; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Aktories, K (corresponding author), Univ Freiburg, Inst Expt, Albertstr 25, D-79104 Freiburg, Germany.	aktories@uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436; Riese, Matthew/0000-0002-2423-0017	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL000659, Z01HL000659] Funding Source: NIH RePORTER; PHS HHS [A1-30162] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHNERTHILGER G, 1992, BIOCHEM J, V284, P321, DOI 10.1042/bj2840321; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; ALAVA MA, 1992, BIOCHEM J, V284, P189, DOI 10.1042/bj2840189; BODEY GP, 1983, REV INFECT DIS, V5, P279; COBURN J, 1989, J BIOL CHEM, V264, P9004; COLLIER RJ, 1990, ADP RIBOSYLATING TOX; CONTI A, 1993, J BIOL CHEM, V268, P783; Frank DW, 1997, MOL MICROBIOL, V26, P621, DOI 10.1046/j.1365-2958.1997.6251991.x; FU H, 1993, P NATL ACAD SCI USA, V90, P2320, DOI 10.1073/pnas.90.6.2320; Ganesan AK, 1999, J BIOL CHEM, V274, P21823, DOI 10.1074/jbc.274.31.21823; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; Ganesan AK, 1999, J BIOL CHEM, V274, P9503, DOI 10.1074/jbc.274.14.9503; Goehring UM, 1999, J BIOL CHEM, V274, P36369, DOI 10.1074/jbc.274.51.36369; Han MK, 1996, BIOCHEM J, V318, P903, DOI 10.1042/bj3180903; KNIGHT DA, 1995, INFECT IMMUN, V63, P3182, DOI 10.1128/IAI.63.8.3182-3186.1995; McGuffie EM, 1998, INFECT IMMUN, V66, P2607, DOI 10.1128/IAI.66.6.2607-2613.1998; Moss J, 2001, INFECT IMMUN, V69, P1185, DOI 10.1128/IAI.69.2.1185-1188.2001; Olson JC, 1997, INFECT IMMUN, V65, P248, DOI 10.1128/IAI.65.1.248-256.1997; Pederson KJ, 1998, MOL MICROBIOL, V30, P751, DOI 10.1046/j.1365-2958.1998.01106.x; Pederson KJ, 1999, MOL MICROBIOL, V32, P393, DOI 10.1046/j.1365-2958.1999.01359.x; Pederson KJ, 2000, MOL MICROBIOL, V37, P287, DOI 10.1046/j.1365-2958.2000.01990.x; Riese MJ, 2001, BIOCHEMISTRY-US, V40, P3289, DOI 10.1021/bi002729q; Stevens LA, 1999, INFECT IMMUN, V67, P259; Sundin C, 2001, CELL MICROBIOL, V3, P237, DOI 10.1046/j.1462-5822.2001.00108.x; Vallis AJ, 1999, INFECT IMMUN, V67, P2040; Wurtele M, 2001, FEBS LETT, V491, P26, DOI 10.1016/S0014-5793(01)02105-6; Wurtele M, 2001, NAT STRUCT BIOL, V8, P23; XU YR, 1995, INFECT IMMUN, V63, P825, DOI 10.1128/IAI.63.3.825-832.1995; YAMADA K, 1994, ARCH BIOCHEM BIOPHYS, V308, P31, DOI 10.1006/abbi.1994.1004; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	31	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12082	12088		10.1074/jbc.M109039200	http://dx.doi.org/10.1074/jbc.M109039200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821389	hybrid			2022-12-25	WOS:000174846400064
J	Sehgal, PB; Guo, GG; Shah, M; Kumar, V; Patel, K				Sehgal, PB; Guo, GG; Shah, M; Kumar, V; Patel, K			Cytokine signaling - STATs in plasma membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; ACTIVATION; COMPONENTS; COMPLEXES; CAVEOLAE; PATHWAY; TRANSCRIPTION; LOCALIZATION; RECEPTOR; CELLS	STAT transcription factors signal from the plasma membrane to the nucleus in response to growth factors and cytokines. We have investigated whether plasma membrane "rafts" are involved in cytokine-activated STAT signaling. Cytokine-free human hepatoma Hep3B cells or cells treated with interleukin-6 (IL-6) or orthovanadate (a general activator of STATs) were fractionated, and plasma membrane raft fractions were obtained by equilibrium sedimentation or flotation through discontinuous sucrose gradients using either non-detergent or detergent-based (saponin or Triton X-100) methods. By Western blotting the plasma membrane raft fractions obtained using either non-detergent or detergent-based methods contained significant amounts of STAT1 and STAT3 (up to -10% of the total cytoplasmic amount) as well as the integral raft proteins caveolin-1 and flotillin-1, the IL-6-receptor signal transducing chain gp130, the interferon-gamma receptor a chain (IFN-gammaRalpha), and the chaperone glucose-regulated protein 58 (GRP58/ER-601ERp57). Upon activation of signaling by IL-6 or orthovanadate the respective Tyr-phosphorylated STAT species were now also observed in the membrane raft fraction but in a form deficient in DNA binding. The data show pre-association of STATs with plasma membrane rafts in flotation fractions, which also contained caveolin-1 and flotillin-1, and suggest that Tyr phosphorylation may not in itself be sufficient to cause the departure of PY-STATs from plasma membrane rafts. Methyl-beta-cyclodextrin, which sequesters cholesterol and disrupts plasma membrane rafts, markedly inhibited IL-6- and IFN-gamma-induced STAT signaling. Signaling through specialized raft microdomains may be a general mechanism operating at the level of the plasma membrane through which cytokines and growth factors activate STAT species (the "raft-STAT signaling hypothesis").	New York Med Coll, Dept Cell Biol & Anat, Valhalla, NY 10595 USA; New York Med Coll, Dept Med, Valhalla, NY 10595 USA	New York Medical College; New York Medical College	Sehgal, PB (corresponding author), New York Med Coll, Dept Cell Biol & Anat, Rm 201,Basic Sci Bldg, Valhalla, NY 10595 USA.	pravin_sehgal@nymc.edu			NCI NIH HHS [CA-82647] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082647] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Greenawalt J W, 1974, Methods Enzymol, V31, P310; GUO GG, 2002, IN PRESS J INTERFERO; Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Ju H, 2000, BIOCHEM J, V351, P257, DOI 10.1042/0264-6021:3510257; Koshelnick Y, 1997, J BIOL CHEM, V272, P28563, DOI 10.1074/jbc.272.45.28563; Lackmann M, 1998, GROWTH FACTORS, V16, P39, DOI 10.3109/08977199809017490; Lafont F, 2001, P NATL ACAD SCI USA, V98, P3180, DOI 10.1073/pnas.051003498; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Marmor MD, 2001, BLOOD, V98, P1489, DOI 10.1182/blood.V98.5.1489; Maziere C, 2001, FEBS LETT, V507, P163, DOI 10.1016/S0014-5793(01)02977-5; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pfeffer L M, 1981, Methods Enzymol, V79, P461; PFEFFER LM, 1981, J INTERFERON RES, V1, P613, DOI 10.1089/jir.1981.1.613; Rayanade RJ, 1998, J IMMUNOL, V161, P325; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Takaoka A, 2000, SCIENCE, V288, P2357, DOI 10.1126/science.288.5475.2357; Yeung YG, 1998, J BIOL CHEM, V273, P17128, DOI 10.1074/jbc.273.27.17128	34	150	155	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12067	12074		10.1074/jbc.M200018200	http://dx.doi.org/10.1074/jbc.M200018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815625	hybrid			2022-12-25	WOS:000174846400062
J	Arthos, J; Cicala, C; Steenbeke, TD; Chun, TW; Cruz, CD; Hanback, DB; Khazanie, P; Nam, D; Schuck, P; Selig, SM; Van Ryk, D; Chaikin, MA; Fauci, AS				Arthos, J; Cicala, C; Steenbeke, TD; Chun, TW; Cruz, CD; Hanback, DB; Khazanie, P; Nam, D; Schuck, P; Selig, SM; Van Ryk, D; Chaikin, MA; Fauci, AS			Biochemical and biological characterization of a dodecameric CD4-Ig fusion protein - Implications for therapeutic and vaccine strategies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECOMBINANT SOLUBLE CD4; T-CELL LINE; CONFORMATIONAL-CHANGES; PEPTIDE INHIBITOR; HIV; BINDING; GP120; INFECTION; NEUTRALIZATION	Drug toxicities associated with HAART lend urgency to the development of new anti-HIV therapies. Inhibition of viral replication at the entry stage of the viral life cycle is an attractive strategy because it prevents de novo infection. Soluble CD4 (sCD4), the first drug in this class, failed to suppress viral replication in vivo. At least three factors contributed to this failure: sCD4 demonstrated poor neutralizing activity against most primary isolates of HIV in vitro; it demonstrated an intrinsic capacity to enhance viral replication at low concentrations; and it exhibited a relatively short half-life in vivo. Many anti-gp120 monoclonal antibodies, including neutralizing monoclonal antibodies also enhance viral replication at suboptimal concentrations. Advances in our understanding of the events leading up to viral entry suggest strategies by which this activity can be diminished. We hypothesized that by constructing a sCD4-based molecule that is large, binds multiple gp120s simultaneously, and is highly avid toward gp120, we could remove its capacity to enhance viral entry. Here we describe the construction of a polymeric CD4-IgG1 fusion protein. The hydrodynamic radius of this molecule is similar to12 nM. It can bind at least 10 gp120 subunits with binding kinetics that suggest a highly avid interaction toward virion-associated envelope. This protein does not enhance viral replication at suboptimal concentrations. These observations may aid in the design of new therapeutics and vaccines.	NIAID, Lab Immunoregulat, Bethesda, MD 20892 USA; Mol Interact Resource Div Bioengn & Phys Sci, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA	Arthos, J (corresponding author), 10 Ctr Dr MSC 1876 Bldg 10 Rm 6A08, Bethesda, MD 20892 USA.		Chun, Tae-Wook/AAC-3101-2020; Schuck, Peter/AAA-6888-2020; Chun, Tae-Wook/W-9187-2019	Schuck, Peter/0000-0002-8859-6966; Chun, Tae-Wook/0000-0001-5153-7340; Khazanie, Prateeti/0000-0001-8959-1609	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000883, ZIAAI000883] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [Z01OD010485] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		ALLAN JS, 1990, SCIENCE, V247, P1084, DOI 10.1126/science.2309120; ARTHOS J, 1989, CELL, V57, P469, DOI 10.1016/0092-8674(89)90922-7; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P7056, DOI 10.1073/pnas.88.16.7056; Berrey MM, 2001, J INFECT DIS, V183, P1466, DOI 10.1086/320189; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CHAIKIN M, 1997, AM AC ALL ASTHM IMM; Chun TW, 1997, J VIROL, V71, P4436, DOI 10.1128/JVI.71.6.4436-4444.1997; CLAPHAM PR, 1992, J VIROL, V66, P3531, DOI 10.1128/JVI.66.6.3531-3537.1992; D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215; DAVIS CB, 1992, DRUG METAB DISPOS, V20, P695; DEEN KC, 1988, NATURE, V331, P82, DOI 10.1038/331082a0; Doranz BJ, 1999, J VIROL, V73, P10346, DOI 10.1128/JVI.73.12.10346-10358.1999; FISHER RA, 1988, NATURE, V331, P76, DOI 10.1038/331076a0; FOLKS T, 1986, SCIENCE, V231, P600, DOI 10.1126/science.3003906; Forster MJ, 2000, J MOL BIOL, V298, P841, DOI 10.1006/jmbi.2000.3715; Gao F, 1996, J VIROL, V70, P1651, DOI 10.1128/JVI.70.3.1651-1667.1996; GELDERBLOM HR, 1987, VIROLOGY, V156, P171, DOI 10.1016/0042-6822(87)90449-1; Jacobson JM, 2000, J INFECT DIS, V182, P326, DOI 10.1086/315698; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Laue T.M., 1992, COMPUTER AIDED INTER; LAYNE SP, 1990, NATURE, V346, P277, DOI 10.1038/346277a0; LIVESEY AK, 1986, J CHEM PHYS, V84, P5102, DOI 10.1063/1.450663; MOORE J, 1995, MICROW OPT TECHN LET, V9, P17, DOI 10.1002/mop.4650090108; MOORE JP, 1992, J VIROL, V66, P235, DOI 10.1128/JVI.66.1.235-243.1992; Myszka DG, 2000, P NATL ACAD SCI USA, V97, P9026, DOI 10.1073/pnas.97.16.9026; ORLOFF SL, 1993, J VIROL, V67, P1461, DOI 10.1128/JVI.67.3.1461-1471.1993; OZEL M, 1988, ARCH VIROL, V100, P255, DOI 10.1007/BF01487688; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; Sambrook J., 2002, MOL CLONING LAB MANU; SCHOOLEY RT, 1990, ANN INTERN MED, V112, P247, DOI 10.7326/0003-4819-112-4-247; Schuck P, 1999, BIOPHYS J, V76, P2288, DOI 10.1016/S0006-3495(99)77384-4; Schuck P, 2002, BIOPHYS J, V82, P1096, DOI 10.1016/S0006-3495(02)75469-6; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; SCHUTTEN M, 1995, SCAND J IMMUNOL, V41, P18, DOI 10.1111/j.1365-3083.1995.tb03528.x; Sorensen V, 1999, J IMMUNOL, V162, P3448; Sullivan N, 1998, J VIROL, V72, P4694, DOI 10.1128/JVI.72.6.4694-4703.1998; SULLIVAN N, 1995, J VIROL, V69, P4413, DOI 10.1128/JVI.69.7.4413-4422.1995; Svedberg T, 1940, THE ULTRACENTRIFUGE; TRAUNECKER A, 1989, NATURE, V339, P68, DOI 10.1038/339068a0; TRKOLA A, 1995, J VIROL, V69, P6609, DOI 10.1128/JVI.69.11.6609-6617.1995; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WERNER A, 1990, J VIROL, V64, P6252, DOI 10.1128/JVI.64.12.6252-6256.1990; Wiersma EJ, 1997, J IMMUNOL, V158, P1719; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILLEY RL, 1994, J VIROL, V68, P1029, DOI 10.1128/JVI.68.2.1029-1039.1994; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Zhang WT, 1999, BIOCHEMISTRY-US, V38, P9405, DOI 10.1021/bi990654o; Zhu P, 2001, J VIROL, V75, P6682, DOI 10.1128/JVI.75.14.6682-6686.2001	51	68	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11456	11464		10.1074/jbc.M111191200	http://dx.doi.org/10.1074/jbc.M111191200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805109	hybrid			2022-12-25	WOS:000174613100090
J	Gu, YS; Parker, A; Wilson, TM; Bai, HB; Chang, DY; Lu, AL				Gu, YS; Parker, A; Wilson, TM; Bai, HB; Chang, DY; Lu, AL			Human MutY homolog, a DNA glycosylase involved in base excision repair, physically and functionally interacts with mismatch repair proteins human MutS homolog 2/human MutS homolog 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SUBCELLULAR-LOCALIZATION; ATPASE ACTIVITY; COUPLED REPAIR; HMYH; EXPRESSION; ENZYME; PCNA; RECOGNITION; CLONING	Adenines mismatched with guanines or 7,8-dihydro-8oxo-deoxyguanines that arise through DNA replication errors can be repaired by either base excision repair or mismatch repair. The human MutY homolog (hMYH), a DNA glycosylase, removes adenines from these mis matches. Human MutS homologs, hMSH2/hMSH6 (bMutSalpha), bind to the mismatches and initiate the repair on the daughter DNA strands. Human MYH is physically associated with hMSH2/bMSH6 via the hMSH6 subunit. The interaction of bMutSa and hMYH is not observed in several mismatch repair-defective cell lines. The hMutSalpha binding site is mapped to amino acid residues 232-254 of hMYH, a region conserved in the MutY family. Moreover, the binding and glycosylase activities of hMYH with an A/7,8-dihydro-S-oxo-deoxyguanine mismatch are enhanced by hMutSa. These results suggest that protein-protein interactions may be a means by which hMYH repair and mismatch repair cooperate in reducing replicative errors caused by oxidized bases.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Dept Radiat Oncol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	aluchang@umaryland.edu	Gu, Jason/AAG-8178-2021; Gu, Yesong/U-9802-2019	Gu, Jason/0000-0001-8278-6227; 	NCI NIH HHS [CA/ES78391] Funding Source: Medline; NIGMS NIH HHS [GM35132] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R56CA078391, R01CA078391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1993, DNA FREE RADICALS, P1; AU KG, 1992, J BIOL CHEM, V267, P12142; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; BOYER JC, 1995, CANCER RES, V55, P6063; Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200; CHENG KC, 1992, J BIOL CHEM, V267, P166; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; Gradia S, 1999, MOL CELL, V3, P255, DOI 10.1016/S1097-2765(00)80316-0; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 1998, EMBO J, V17, P1535, DOI 10.1093/emboj/17.5.1535; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Iaccarino I, 1998, EMBO J, V17, P2677, DOI 10.1093/emboj/17.9.2677; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Kolodner Richard D., 1994, Current Opinion in Biotechnology, V5, P585, DOI 10.1016/0958-1669(94)90079-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leadon SA, 1997, CANCER RES, V57, P3784; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; Lu AL, 2000, METH MOL B, V152, P3; LU AL, 1998, DNA REPAIR HIGHER EU; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; McLennan AG, 1999, INT J MOL MED, V4, P79; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Ni TT, 1999, MOL CELL, V4, P439, DOI 10.1016/S1097-2765(00)80346-9; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Parker A, 2000, NUCLEIC ACIDS RES, V28, P3206, DOI 10.1093/nar/28.17.3206; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; Tomita-Mitchell A, 2000, MUTAT RES-FUND MOL M, V450, P125, DOI 10.1016/S0027-5107(00)00020-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Wang Y, 2000, GENE DEV, V14, P927; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Wilson T, 1999, J BIOL CHEM, V274, P21659, DOI 10.1074/jbc.274.31.21659; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480	67	164	172	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11135	11142		10.1074/jbc.M108618200	http://dx.doi.org/10.1074/jbc.M108618200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801590	hybrid			2022-12-25	WOS:000174613100050
J	Mei, FC; Qiao, JB; Tsygankova, OM; Meinkoth, JL; Quilliam, LA; Cheng, XD				Mei, FC; Qiao, JB; Tsygankova, OM; Meinkoth, JL; Quilliam, LA; Cheng, XD			Differential signaling of cyclic AMP - Opposing effects of exchange protein directly activated by cyclic AMP and cAMP-dependent protein kinase on protein kinase B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY SUBUNIT; LYMPHOID-CELLS; PHOSPHORYLATION; PATHWAY; BINDING; RAP1; INHIBITION; 3-KINASE; CASCADE; FAMILY	The recent discovery of Epac, a novel cAMP receptor protein, opens up a new dimension in studying cAMP-mediated cell signaling. It is conceivable that many of the cAMP functions previously attributed to cAMP-dependent protein kinase (PKA) are in fact also Epac-dependent. The finding of an additional intracellular cAMP receptor provides an opportunity to further dissect the divergent roles that cAMP exerts in different cell types. In this study, we probed cross-talk between cAMP signaling and the phosphatidylinositol 3-kinase/PKB pathways. Specifically, we examined the modulatory effects of cAMP on PKB activity by monitoring the specific roles that Epac and PKA play individually in regulating PKB activity. Our study suggests a complex regulatory scheme in which Epac and PKA mediate the opposing effects of cAMP on PKB regulation. Activation of Epac leads to a phosphatidylinositol 3-kinase-dependent PKB activation, while stimulation of PKA inhibits PKB activity. Furthermore, activation of PKB by Epac requires the proper subcellular targeting of Epac. The opposing effects of Epac and PKA on PKB activation provide a potential mechanism for the cell type-specific differential effects of cAMP. It is proposed that the net outcome of cAMP signaling is dependent upon the dynamic abundance and distribution of intracellular Epac and PKA.	Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sch Med, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Sch Med, Galveston, TX 77555 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Pennsylvania; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis	Cheng, XD (corresponding author), Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Sch Med, 301 Univ Blvd, Galveston, TX 77555 USA.	xcheng@utmb.edu	Cheng, Xiaodong/O-8176-2019; Quilliam, Lawrence/B-6447-2015; Meinkoth, Judy L/G-2900-2010; Quilliam, Lawrence/Q-4987-2019	Cheng, Xiaodong/0000-0002-3479-1694; 	NIEHS NIH HHS [ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ALTSCHULER DL, 1995, J BIOL CHEM, V270, P10373, DOI 10.1074/jbc.270.18.10373; Asha H, 1999, EMBO J, V18, P605, DOI 10.1093/emboj/18.3.605; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; BUBIS J, 1988, J BIOL CHEM, V263, P9668; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Cheng XD, 1998, P NATL ACAD SCI USA, V95, P9849, DOI 10.1073/pnas.95.17.9849; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; David M, 1996, J BIOL CHEM, V271, P4585; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DeBernardi MA, 1996, P NATL ACAD SCI USA, V93, P4577, DOI 10.1073/pnas.93.10.4577; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Filippa N, 1999, MOL CELL BIOL, V19, P4989; FRODIN M, 1994, J BIOL CHEM, V269, P6207; Gao XL, 2001, J BIOL CHEM, V276, P42219, DOI 10.1074/jbc.M105760200; GRAVE LM, 1990, TRENDS ENDOCRIN MET, V7, P43; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Medina DL, 2000, EUR J ENDOCRINOL, V143, P161, DOI 10.1530/eje.0.1430161; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Naderi S, 2000, EUR J IMMUNOL, V30, P1757, DOI 10.1002/1521-4141(200006)30:6<1757::AID-IMMU1757>3.0.CO;2-N; NODA M, 1993, BIOCHIM BIOPHYS ACTA, V1155, P97, DOI 10.1016/0304-419X(93)90024-7; Posternak T, 1974, Methods Enzymol, V38, P399; PRIZON V, 1998, ONCOGENE, V3, P201; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; QUILLIAM LA, 1991, J IMMUNOL, V147, P1628; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rogue PJ, 1998, P NATL ACAD SCI USA, V95, P9178, DOI 10.1073/pnas.95.16.9178; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; SHABB JB, 1992, J BIOL CHEM, V267, P5723; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.bi.59.070190.004543; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Webster CRL, 1999, AM J PHYSIOL-GASTR L, V277, pG1165, DOI 10.1152/ajpgi.1999.277.6.G1165; WITHERS DJ, 1995, J BIOL CHEM, V270, P21411, DOI 10.1074/jbc.270.36.21411; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Zetterqvist O.Z., 1990, PEPTIDES PROTEIN PHO, P171	51	239	243	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11497	11504		10.1074/jbc.M110856200	http://dx.doi.org/10.1074/jbc.M110856200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801596	hybrid			2022-12-25	WOS:000174613100095
J	Wellejus, A; Loft, S				Wellejus, A; Loft, S			Receptor-mediated ethinylestradiol-induced oxidative DNA damage in rat testicular cells	FASEB JOURNAL			English	Article						7,8-dihydro-8-oxo-2 '-deoxyguanosine glutathione; 17 alpha-ethinylestradiol	FUNCTIONAL ESTROGEN-RECEPTOR; HUMAN SPERM MEMBRANE; GERM-CELLS; BREAST-CANCER; FREE-RADICALS; ESCHERICHIA-COLI; P450 AROMATASE; SEA-URCHIN; TESTIS; DIETHYLSTILBESTROL	Estrogenic chemicals are suspected of affecting cancer risk and male reproduction, possibly involving oxidative DNA damage. In this study, formation of 7,8-dihydro-8-oxo-2'-deoxyguanosine (8-oxodG), was measured in testicular cells from rats after 17 alpha-ethinylestradiol (EE) exposure in vivo and in vitro after incubation with EE with or without an antiestrogen. In vivo, preadult (30-35 days) and adult (110-120 days) Wistar rats received 0, 2.8, or 56 mg EE/kg body weight as intraperitoneal injections (n=6). After 1 or 4 h, the 8-oxodG/10(6) dG ratio was measured in the liver, kidneys, and testes. Testes DNA analysis revealed an age-related effect (adult animals had a higher ratio than the young animals) and a concentration effect in preadult rats (increased EE-concentration caused increased ratio), but no time effect. No differences were found in the liver or kidneys. In vitro, testicular cells were isolated and incubated with EE concentrations ranging from 0.1 to 1000 nM. The results indicated an increase in 8-oxodG/10(6) dG from 0 to 10 nM estrogen. At 1000 nM, the level was close to control level. Coincubation of 10 nM EE (maximum damage) with an estrogen antagonist, ICI 182.780, abolished the effect at 10 nM, indicating that the damaging effect is estrogen receptor mediated.	Univ Copenhagen, Inst Publ Hlth, Copenhagen, Denmark	University of Copenhagen	Loft, S (corresponding author), Univ Copenhagen, Panum Inst, Dept Pharmacol, Bldg 18-5,Blegdamsvej 3, DK-2200 Copenhagen, Denmark.	s.loft@pubhealth.ku.dk		Wellejus, Anja/0000-0003-4350-6063; Loft, Steffen/0000-0001-9552-8518				Andersen HR, 1999, ENVIRON HEALTH PERSP, V107, P89, DOI 10.2307/3434476; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BACK DJ, 1980, CONTRACEPTION, V21, P145, DOI 10.1016/0010-7824(80)90126-2; Baldi E, 2000, MOL CELL ENDOCRINOL, V161, P31, DOI 10.1016/S0303-7207(99)00220-8; BARRETT JC, 1983, MUTAT RES, V107, P427; Behl C, 2000, J NEUROCYTOL, V29, P351, DOI 10.1023/A:1007109222673; BELLOMO G, 1992, P NATL ACAD SCI USA, V89, P4412, DOI 10.1073/pnas.89.10.4412; BRADLEY MO, 1985, CELL BIOL TOXICOL, V1, P181, DOI 10.1007/BF00120163; BROKAW CJ, 1984, ANN NY ACAD SCI, V438, P132, DOI 10.1111/j.1749-6632.1984.tb38282.x; BROKAW CJ, 1974, BIOCHEM BIOPH RES CO, V58, P795, DOI 10.1016/S0006-291X(74)80487-0; CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; Chen YM, 2000, CHEM RES TOXICOL, V13, P342, DOI 10.1021/tx990186j; Collins AR, 2000, FREE RADICAL RES, V32, P333, DOI 10.1080/10715760000300331; DREVON C, 1981, MUTAT RES, V89, P83, DOI 10.1016/0165-1218(81)90134-8; Durkee TJ, 1998, AM J OBSTET GYNECOL, V178, P1288, DOI 10.1016/S0002-9378(98)70335-7; EWERTZ M, 1989, INT J CANCER, V43, P27, DOI 10.1002/ijc.2910430107; FACEMIRE CF, 1995, ENVIRON HEALTH PERSP, V103, P79, DOI 10.2307/3432416; Fisher JS, 1997, J ENDOCRINOL, V153, P485, DOI 10.1677/joe.0.1530485; Floreani M, 1997, FREE RADICAL RES, V26, P449, DOI 10.3109/10715769709084481; FORMAN D, 1994, CANCER SURV, V20, P323; FRAGA CG, 1990, P NATL ACAD SCI USA, V87, P4533, DOI 10.1073/pnas.87.12.4533; FREE MJ, 1979, BIOL REPROD, V20, P269, DOI 10.1095/biolreprod20.2.269; GANJAM VK, 1976, ENDOCRINOLOGY, V99, P1618, DOI 10.1210/endo-99-6-1618; GILL WB, 1979, J UROLOGY, V122, P36, DOI 10.1016/S0022-5347(17)56240-0; GLATT HR, 1979, MUTAT RES, V67, P113, DOI 10.1016/0165-1218(79)90122-8; GUENGERICH FP, 1988, MOL PHARMACOL, V33, P500; Guillette LJ, 1999, ARCH ENVIRON CON TOX, V36, P447, DOI 10.1007/PL00006617; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HAN XL, 1994, CANCER RES, V54, P5515; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hudson CE, 1998, CHEM-BIOL INTERACT, V112, P343, DOI 10.1016/S0009-2797(97)00171-3; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; *IARC WORK GROUP, 1999, IARC MON EV CARC RIS, P49; IDAOMAR M, 1989, ARCH ANDROLOGY, V22, P197, DOI 10.3109/01485018908986772; Jorgensen M, 1999, ELECTROPHORESIS, V20, P230, DOI 10.1002/1522-2683(19990201)20:2<230::AID-ELPS230>3.0.CO;2-I; Kacsoh B., 2000, ENDOCRINE PHYSL; Kuczyk MA, 1996, CANCER, V78, P1958, DOI 10.1002/(SICI)1097-0142(19961101)78:9<1958::AID-CNCR17>3.0.CO;2-X; KWON S, 1995, BIOL REPROD, V53, P1259, DOI 10.1095/biolreprod53.6.1259; LANG R, 1979, MUTAT RES, V67, P361, DOI 10.1016/0165-1218(79)90033-8; Liehr J G, 1998, Methods Mol Biol, V108, P425; LIEHR JG, 1990, FREE RADICAL BIO MED, V8, P415, DOI 10.1016/0891-5849(90)90108-U; LOBO RA, 1994, FERTIL STERIL, V61, P592; Loomis AK, 2000, BIOL REPROD, V62, P995, DOI 10.1095/biolreprod62.4.995; Luconi M, 1999, J CLIN ENDOCR METAB, V84, P1670, DOI 10.1210/jc.84.5.1670; Lunec J, 1998, FREE RADICAL RES, V29, P601, DOI 10.1080/10715769800300651; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MALINS DC, 1993, CANCER-AM CANCER SOC, V71, P3036, DOI 10.1002/1097-0142(19930515)71:10<3036::AID-CNCR2820711025>3.0.CO;2-P; McDougal A, 1998, ENVIRON HEALTH PERSP, V106, P203; Nathan L, 1998, SEMIN REPROD ENDOCR, V16, P309, DOI 10.1055/s-2007-1016289; NITTA H, 1993, ENDOCRINOLOGY, V132, P1396, DOI 10.1210/en.132.3.1396; OGAWA T, 1995, CARCINOGENESIS, V16, P831, DOI 10.1093/carcin/16.4.831; Roy D, 1999, MUTAT RES-FUND MOL M, V424, P107, DOI 10.1016/S0027-5107(99)00012-3; ROY D, 1991, CANCER RES, V51, P3882; SAI K, 1992, Journal of Environmental Pathology Toxicology and Oncology, V11, P139; Satoh T, 2000, ANAL BIOCHEM, V286, P179, DOI 10.1006/abio.1999.4775; Saunders PTK, 1998, J ENDOCRINOL, V156, pR13, DOI 10.1677/joe.0.156R013; Seacat AM, 1997, ARCH BIOCHEM BIOPHYS, V347, P45, DOI 10.1006/abbi.1997.0323; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Shen HM, 2000, FREE RADICAL BIO MED, V28, P529, DOI 10.1016/S0891-5849(99)00234-8; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; STAMPFER M, 1994, BRIT MED J, V309, P808, DOI 10.1136/bmj.309.6957.808b; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WANG YJ, 1995, CHEM-BIOL INTERACT, V94, P135, DOI 10.1016/0009-2797(94)03327-5; Westlind A, 2001, BIOCHEM BIOPH RES CO, V281, P1349, DOI 10.1006/bbrc.2001.4505; Yan ZJ, 1995, BIOCHEM MOL BIOL INT, V37, P175	66	34	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					195	201		10.1096/fj.01-0385com	http://dx.doi.org/10.1096/fj.01-0385com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818367				2022-12-25	WOS:000174203700024
J	Bartunek, P; Pajer, P; Karafiat, V; Blendinger, G; Dvorak, M; Zenke, M				Bartunek, P; Pajer, P; Karafiat, V; Blendinger, G; Dvorak, M; Zenke, M			bFGF signaling and v-Myb cooperate in sustained growth of primitive erythroid progenitors	ONCOGENE			English	Article						v-Myb; Myb; FGF; FGF receptor; erythropoiesis; signaling	BLOOD-CELL DIFFERENTIATION; C-MYB; TRANSFORMING GROWTH-FACTOR-BETA-1; TERMINAL DIFFERENTIATION; HEMATOPOIETIC-CELLS; NEURORETINA CELLS; TYROSINE KINASE; SELF-RENEWAL; MIM-1 GENE; RECEPTOR	The development of red blood cells from hematopoietic progenitors requires the interplay of specific extracellular factors and transcriptional regulators. Here we have identified an erythroid progenitor that is critically dependent on bFGF and requires expression of AMV v-Myb for sustained proliferation in vitro, indicating that bFGF and Myb proteins cooperate in these cells. In the presence of bFGF such v-Myb cells are completely blocked in their ability to differentiate and exhibit an exceptionally high proliferative potential and long life-span in vitro. Interestingly, in the absence of bFGF cells effectively differentiate into mature erythrocytes, irrespective of constitutive and elevated levels of v-Myb. We also demonstrate that these cells express high levels of FGF receptor type 1 (FGFR1) and that phospholipase Cgamma (PLC)gamma) is one of the important molecules in FGF receptor signaling. Our studies suggest that bFGF, in cooperation with Myb proteins, represents an important factor for determining erythroid lineage choice. These findings unravel a so far unidentified link between extracellular signaling and Myb in hematopoietic cells.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Acad Sci Czech Republ, Inst Mol Genet, CR-16637 Prague 6, Czech Republic	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences	Zenke, M (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	zenke@mdc-berlin.de	Pajer, Petr/G-5869-2014; Bartunek, Petr/J-3897-2014; Dvořák, Michal/I-9939-2014; Dvorak, Michal/G-5861-2014	Bartunek, Petr/0000-0002-6202-7650; 				Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; ALLOUCHE M, 1995, LEUKEMIA, V9, P937; Bartunek P, 1996, CYTOKINE, V8, P14, DOI 10.1006/cyto.1996.0003; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Bartunek P, 1998, MOL ENDOCRINOL, V12, P1269, DOI 10.1210/mend.12.9.0173; Beug H, 1996, CURR TOP MICROBIOL, V211, P29; BEUG H, 1995, METHOD ENZYMOL, V254, P41; Briegel K, 1996, DEVELOPMENT, V122, P3839; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; BRUNNER G, 1993, BLOOD, V81, P631; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DISELA C, 1991, GENE DEV, V5, P2033, DOI 10.1101/gad.5.11.2033; DOLZNIG H, 1995, CELL GROWTH DIFFER, V6, P1341; Faloon P, 2000, DEVELOPMENT, V127, P1931; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; Ganter B, 1999, ADV CANCER RES, V76, P21, DOI 10.1016/S0065-230X(08)60773-3; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GORDONTHOMSON C, 1994, DEVELOPMENT, V120, P3571; Graf T, 1998, CURR BIOL, V8, pR353, DOI 10.1016/S0960-9822(98)70220-9; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Huber TL, 1998, BLOOD, V92, P4128, DOI 10.1182/blood.V92.11.4128.423k46_4128_4137; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; KLINT P, 1999, FRONT BIOSCI, V4, P165; Koritschoner NP, 1999, ONCOGENE, V18, P5904, DOI 10.1038/sj.onc.1202979; KORNFELD S, 1983, EXP CELL RES, V143, P383, DOI 10.1016/0014-4827(83)90065-4; KRANTZ SB, 1991, BLOOD, V77, P419; KRYSTAL G, 1994, J EXP MED, V180, P851, DOI 10.1084/jem.180.3.851; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; LYON JJ, 1995, DIFFERENTIATION, V59, P171, DOI 10.1046/j.1432-0436.1995.5930171.x; Mead P E, 1998, Curr Opin Hematol, V5, P156; Mink S, 1996, MOL CELL BIOL, V16, P1316; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1994, CURR OPIN GENET DEV, V4, P718, DOI 10.1016/0959-437X(94)90139-T; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; Orkin SH, 2000, NAT MED, V6, P1212, DOI 10.1038/81303; Orkin SH, 1996, CURR OPIN GENET DEV, V6, P597, DOI 10.1016/S0959-437X(96)80089-X; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PECENKA V, 1988, FOLIA BIOL-PRAGUE, V34, P129; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; SCHMIDT JA, 1986, EXP CELL RES, V164, P71, DOI 10.1016/0014-4827(86)90455-6; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; STEINLEIN P, 1995, CURR BIOL, V5, P191, DOI 10.1016/S0960-9822(95)00040-6; Szebenyi G, 1999, INT REV CYTOL, V185, P45; Turque N, 1997, J VIROL, V71, P9778, DOI 10.1128/JVI.71.12.9778-9781.1997; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yuen D, 1998, BLOOD, V91, P3202, DOI 10.1182/blood.V91.9.3202.3202_3202_3209; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	51	19	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					400	410		10.1038/sj/onc/1205103	http://dx.doi.org/10.1038/sj/onc/1205103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821952				2022-12-25	WOS:000173311200008
J	Nam, SY; Amoscato, AA; Lee, YJ				Nam, SY; Amoscato, AA; Lee, YJ			Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway	ONCOGENE			English	Article						akt; apoptosis; FLIP; glucose deprivation; TRAIL	APOPTOSIS-INDUCING LIGAND; ACTIVATED PROTEIN-KINASE; NECROSIS-FACTOR-ALPHA; CYTOCHROME-C RELEASE; HIGH LACTATE LEVELS; DEATH DOMAIN; IONIZING-RADIATION; DECOY RECEPTORS; HUMAN-TUMORS; IN-VIVO	To examine whether the tumor microenvironment alters cytokine-induced cytotoxicity, human prostate adenocarcinoma DU-145 cells were exposed to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and/or glucose deprivation, a common characteristic of the tumor microenvironment. TRAIL alone reduced cell survival in a dose-dependent manner. Glucose deprivation alone induced no cytotoxicity within 4 h. However, the combination of TRAIL (50 ng/ml) and glucose deprivation for 4 h increased cell death and PARP cleavage by promoting activation of caspase-8 and caspase-3, relative to that of TRAIL alone. Similar results were observed in human colorectal carcinoma CX-1 cells. Data from immunoblotting analysis reveal that glucose deprivation-enhanced TRAIL cytotoxicity is inversely related to the intracellular level of FLICE inhibitory protein (FLIP) but not that of death receptor 5 (DR5). Results from mass spectrometry show that glucose deprivation elevates ceramide. The elevation of ceramide may cause dephosphorylation of Akt and maintain dephosphorylation of Akt in the presence of TRAIL and then subsequently down-regulate the expression of FLIP. Taken together, the present studies suggest that glucose deprivation enhances TRAIL-induced cytotoxicity through the ceramide - Akt - FLIP pathway.	Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Sch Med, Inst Canc, Dept Pharmacol, E1056 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.			Amoscato, Andrew/0000-0002-1340-9150	NCI NIH HHS [CA48000] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Burow ME, 1998, CANCER RES, V58, P4940; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chen Q, 2001, BLOOD, V98, P2183, DOI 10.1182/blood.V98.7.2183; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; Gazitt Y, 1999, CYTOKINE, V11, P1010, DOI 10.1006/cyto.1999.0536; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gong BD, 2000, CANCER RES, V60, P5754; Griffith TS, 1998, J IMMUNOL, V161, P2833; GULLINO PM, 1975, CANCER, V3, P327; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; IRMIER M, 1997, NATURE, V388, P190; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; Kuang AA, 2000, J BIOL CHEM, V275, P25065, DOI 10.1074/jbc.C000284200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee YJ, 2001, J CELL SCI, V114, P677; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Leverkus M, 2000, CANCER RES, V60, P553; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu B, 1997, J BIOL CHEM, V272, P16281, DOI 10.1074/jbc.272.26.16281; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MacFarlane DF, 1997, DERMATOL SURG, V23, P848, DOI 10.1111/j.1524-4725.1997.tb00434.x; Mariani SM, 1997, J CELL BIOL, V137, P221, DOI 10.1083/jcb.137.1.221; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; MUELLERKLIESER WF, 1989, PREDICTION TUMOR TRE, P265; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nagane M, 2000, CANCER RES, V60, P847; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813; SARTORELLI A C, 1988, Cancer Research, V48, P775; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; SCHWICKERT G, 1995, CANCER RES, V55, P4757; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Sprenkle AB, 1997, FEBS LETT, V403, P254, DOI 10.1016/S0014-5793(97)00062-8; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Summers SA, 1998, MOL CELL BIOL, V18, P5457, DOI 10.1128/MCB.18.9.5457; Thomas RL, 1999, J BIOL CHEM, V274, P30580, DOI 10.1074/jbc.274.43.30580; VAUPEL P, 1991, CANCER RES, V51, P3316; VAUPEL P, 1989, CANCER RES, V49, P6449; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Walenta S, 1997, AM J PATHOL, V150, P409; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	71	58	59	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					337	346		10.1038/sj.onc.1205068	http://dx.doi.org/10.1038/sj.onc.1205068			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821946				2022-12-25	WOS:000173311200002
J	Okorokov, AL; Rubbi, CP; Metcalfe, S; Milner, J				Okorokov, AL; Rubbi, CP; Metcalfe, S; Milner, J			The interaction of p53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage	ONCOGENE			English	Article						p53; nuclear F-actin; FRET; DNA damage	NORMAL HUMAN-FIBROBLASTS; C-TERMINAL DOMAIN; WILD-TYPE P53; ULTRAVIOLET-LIGHT; NONACTIVATED P53; TRANSCRIPTION; PROTEIN; COMPLEX; BINDING; CELLS	The tumour suppressor protein p53 is localized in the cell nucleus where it serves to initiate cellular responses to a variety of stresses, particularly DNA damage and has the capacity to transactivate stress response genes. An emerging body of evidence indicates that its action is also exerted through direct protein-protein interactions. An approach to understanding p53 function has been to analyse its positioning in relation to nuclear structures and we have shown that p53 can associate with the nuclear matrix. A potential nuclear matrix component for this association is actin. Here we show that p53 interacts with nuclear F-actin and we map the domains involved in this interaction. Using fluorescence resonance energy transfer, we demonstrate that the partition of p53 between F-actin bound and unbound forms is not constant, but is modulated by the presence of DNA damage, which increases binding. Our results indicate that the dynamic interaction of p53 with the nuclear matrix has to be considered for a full understanding of the mechanisms of the p53-mediated cellular response to DNA damage.	Univ York, Dept Biol, Res Grp, York YO10 5DD, N Yorkshire, England; Univ Cambridge, Addenbrookes Hosp, Dept Surg, Cambridge CB2 2QQ, England	University of York - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Milner, J (corresponding author), Univ York, Dept Biol, Res Grp, YCR P53, York YO10 5DD, N Yorkshire, England.			Okorokov, Andrei/0000-0003-2477-3254				Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; Andera L, 1997, MOL MED, V3, P852, DOI 10.1007/BF03401721; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; Bastiaens PIH, 1996, EMBO J, V15, P4246, DOI 10.1002/j.1460-2075.1996.tb00799.x; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; COOK PR, 1991, CELL, V66, P627, DOI 10.1016/0092-8674(91)90109-C; DEPPERT W, 1986, MOL CELL BIOL, V6, P2233, DOI 10.1128/MCB.6.6.2233; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Haugland R., 1996, HDB FLUORESCENT PROB; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; Iborra FJ, 1996, J CELL SCI, V109, P1427; JaresErijman EA, 1996, J MOL BIOL, V257, P597, DOI 10.1006/jmbi.1996.0188; Jiang M, 2001, ONCOGENE, V20, P5449, DOI 10.1038/sj.onc.1204705; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Leveillard T, 1996, EMBO J, V15, P1615, DOI 10.1002/j.1460-2075.1996.tb00506.x; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MCCREADY SJ, 1984, J CELL SCI, V70, P189; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Metcalfe S, 1999, ONCOGENE, V18, P2351, DOI 10.1038/sj.onc.1202559; MULLENDERS LHF, 1988, NUCLEIC ACIDS RES, V16, P10607, DOI 10.1093/nar/16.22.10607; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NAKAYASU H, 1985, EXP CELL RES, V160, P319, DOI 10.1016/0014-4827(85)90179-X; Nguyen E, 1998, MOL REPROD DEV, V50, P263, DOI 10.1002/(SICI)1098-2795(199807)50:3&lt;263::AID-MRD2&gt;3.0.CO;2-H; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Okorokov AL, 1999, MOL CELL BIOL, V19, P7501; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; Rabinovitz I, 1997, J CELL BIOL, V139, P1873, DOI 10.1083/jcb.139.7.1873; Rubbi CP, 2000, ONCOGENE, V19, P85, DOI 10.1038/sj.onc.1203378; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188	40	55	60	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					356	367		10.1038/sj.onc.1205112	http://dx.doi.org/10.1038/sj.onc.1205112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821948				2022-12-25	WOS:000173311200004
J	Yuan, XJ; Whang, YE				Yuan, XJ; Whang, YE			PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway	ONCOGENE			English	Article						PTEN; apoptosis; FADD; death receptors	NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; CYTOCHROME-C RELEASE; PHOSPHATASE-ACTIVITY; PTEN/MMAC1; ACTIVATION; PHOSPHORYLATION; PROTEIN; DOMAIN; MICE	The PTEN tumor suppressor is frequently mutated in human tumors. Loss of PTEN function is associated with constitutive survival signaling through the phosphatidylinositol-3 kinase/Akt pathway. Therefore, we asked if reconstitution of PTEN function would lead to the reversal of resistance to apoptosis in prostate cancer cells. Adenovirus-mediated expression of PTEN completely suppressed constitutive Akt activation in LNCaP prostate cancer cells and enhanced apoptosis induced by a broad range of apoptotic stimuli. PTEN expression sensitized cells to death receptor-mediated apoptosis induced by tumor necrosis factor, anti-Fas antibody, and TRAIL. PTEN also sensitized cells to non-receptor mediated apoptosis induced by a kinase inhibitor staurosporine and chemotherapeutic agents mitoxantrone and etoposide. PTEN-mediated apoptosis was accompanied by caspase-3 and caspase-8 activation and was inhibited by a broad specificity caspase inhibitor Z-VAD-fmk. Bcl-2 overexpression also blocked PTEN-mediated apoptosis. Lipid phosphatase activity of PTEN is required for apoptosis as the PTEN G129E mutant selectively deficient in lipid phosphatase activity was unable to sensitize cells to apoptosis. PTEN-mediated apoptosis involves a FADD-dependent pathway for both death receptor-mediated and drug-induced apoptosis as coexpression of a dominant negative FADD mutant blocked PTEN-mediated apoptosis. Since in death receptor signaling, FADD mediates activation of caspase-8, which in turn cleaves BID, and since caspase-8 is activated in PTEN-mediated apoptosis, we examined BID cleavage in PTEN-mediated apoptosis. PTEN facilitated BID cleavage after treatment with low doses of staurosporine and mitoxantrone. BID cleavage was inhibited by dominant negative FADD. Taken together, these data are consistent with the hypothesis that PTEN promotes drug-induced apoptosis by facilitating caspase-8 activation and BID cleavage through a FADD-dependent pathway.	Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Div Hematol Oncol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Whang, YE (corresponding author), Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA.		Whang, Young/AAK-7435-2021	Whang, Young/0000-0002-1621-6661	NATIONAL CANCER INSTITUTE [K08CA085772] Funding Source: NIH RePORTER; NCI NIH HHS [CA85772] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Choi KB, 1998, J BIOL CHEM, V273, P20185, DOI 10.1074/jbc.273.32.20185; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Davies MA, 1999, CANCER RES, V59, P2551; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hlobilkova A, 2000, EXP CELL RES, V256, P571, DOI 10.1006/excr.2000.4867; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kulik G, 2001, CANCER RES, V61, P2713; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maier D, 1999, CANCER RES, V59, P5479; Marcelli M, 1999, CANCER RES, V59, P382; McMenamin ME, 1999, CANCER RES, V59, P4291; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RAFFO AJ, 1995, CANCER RES, V55, P4438; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RG, 2001, ONCOGENE, V20, P1852, DOI 10.1038/sj.onc.1204264; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Suzuki H, 1998, CANCER RES, V58, P204; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	52	111	114	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					319	327		10.1038/sj/onc/1205054	http://dx.doi.org/10.1038/sj/onc/1205054			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803475				2022-12-25	WOS:000173026200016
J	Zhang, YW; Wang, LM; Jove, R; Vande Woude, GF				Zhang, YW; Wang, LM; Jove, R; Vande Woude, GF			Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis	ONCOGENE			English	Article						HGF/SF; Met; Stat3; Stat3 beta; anchorage independent growth; tumorigenesis	HEPATOCYTE GROWTH-FACTOR; FACTOR SCATTER FACTOR; ANCHORAGE-INDEPENDENT GROWTH; RECEPTOR TYROSINE KINASE; FACTOR/SCATTER FACTOR; SOMATIC MUTATIONS; CELLULAR-TRANSFORMATION; EPITHELIAL-CELLS; SPLICE VARIANT; IN-VIVO	Hepatocyte Growth Factor/Scatter Factor (HGF/SF) mediates a wide variety of cellular responses by acting through the Met tyrosine kinase receptor. Inappropriate expression of HGF/SF and/or Met has been found in most types of solid tumors and is often associated with poor prognosis. Importantly, constitutional and sporadic activating mutations in Met have been discovered in human papillary renal carcinomas and other cancers, while autocrine and paracrine signaling of this receptor/ligand pair has been shown to contribute to tumorigenesis and metastasis. Numerous downstream signaling molecules have been implicated in HGF/SF-Met mediated tumorigenesis and metastasis. Stat3 is a downstream signaling molecule activated by HGF/SF-Met signaling, and is reported to contribute to cell transformation induced by a diverse set of oncoproteins. Stat3 is constitutively activated in many primary tumors and tumor cell lines, suggesting that signaling by this molecule may be important for cell transformation. To address whether Stat3 is required for HGF/SF-Met mediated tumorigenesis and metastasis, we introduced a dominant-negative form of Stat3, Stat3 beta into the human leiomyosarcoma cell line SK-LMS-1. We found that Stat3 beta has no effect on the transformed morphology, proliferation, invasion or branching morphogenesis in vitro. By contrast, expression of Stat3 beta affected HGF/SF-Met mediated anchorage-independent colony formation and prevented tumorigenic growth in athymic nu/nu mice. Thus, Met signaling through Stat3 provides an essential function for tumorigenic growth, which is manifested in vitro by loss of anchorage-independent growth.	Van Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	Van Andel Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Vande Woude, GF (corresponding author), Van Andel Res Inst, Mol Oncol Lab, 333 Bostwick Ave NE, Grand Rapids, MI 49503 USA.							Besser D, 1999, MOL CELL BIOL, V19, P1401; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CORTNER J, 1995, MET HGF SF AUTOCRINE; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Di Renzo MF, 2000, ONCOGENE, V19, P1547, DOI 10.1038/sj.onc.1203455; Faletto D L, 1993, EXS, V65, P107; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1988, J CELL BIOCHEM, V38, P229, DOI 10.1002/jcb.240380402; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Koochekpour S, 1997, CANCER RES, V57, P5391; Lee JH, 2000, ONCOGENE, V19, P4947, DOI 10.1038/sj.onc.1203874; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Matsumoto K, 1993, EXS, V65, P225; Niu GL, 1999, CANCER RES, V59, P5059; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Park WS, 1999, CANCER RES, V59, P307; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodrigues GA, 1997, EMBO J, V16, P2634, DOI 10.1093/emboj/16.10.2634; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STREIT A, 1995, DEVELOPMENT, V121, P813; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	58	152	156	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					217	226		10.1038/sj/onc/1205004	http://dx.doi.org/10.1038/sj/onc/1205004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803465				2022-12-25	WOS:000173026200006
J	Hussain, MA; Miller, CP; Habener, JF				Hussain, MA; Miller, CP; Habener, JF			Brn-4 transcription factor expression targeted to the early developing mouse pancreas induces ectopic glucagon gene expression in insulin-producing beta cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AR42J CELLS; ALPHA-CELLS; ACTIVIN-A; DIFFERENTIATION; PAX6; MICE; ELEMENT; REVEALS; TUMORS; IPF1	The endocrine pancreas is comprised of beta and alpha cells producing the glucostatic hormones insulin and glucagon, respectively, and arises during development by the differentiation of stem/progenitor cells in the foregut programmed by the beta cell lineage-specific homeodomain protein ldx-1. Brain-4 (Brn-4) is expressed in the pancreatic anlaga of the mouse foregut at e10 in the alpha cells and transactivates glucagon gene expression. We expressed Brn-4 in pancreatic precursors or beta cell lineage in transgenic mice by placing it under either Idx-1 or insulin promoter (rat insulin II promoter) control, respectively. Idx-1 expression occurs at developmental day e8.5, and insulin expression occurs at e9.5, respectively. Misexpression of Brn-4 by the Idx-1 promoter results in ectopic expression of the proglucagon gene in insulin-expressing pancreatic beta cells, whereas misexpression by rat insulin II promoter did not. The early developmental expression of Brn-4 appears to be a dominant regulator of the glucagon expressing a cell lineage, even in the context of the beta cell lineage.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Lab Mol Endocrinol, Boston, MA 02114 USA; Wyeth Ayerst Res, Inst Genet, Cambridge, MA 02140 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Howard Hughes Medical Institute; Pfizer	Habener, JF (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Howard Hughes Med Inst,Lab Mol Endocrinol, 55 Fruit St,WEL320, Boston, MA 02114 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030834, R01DK055365] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30834, DK55365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andersen FG, 1999, FEBS LETT, V445, P306, DOI 10.1016/S0014-5793(99)00145-3; Daniel PB, 1998, ENDOCRINOLOGY, V139, P3721, DOI 10.1210/en.139.9.3721; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; GUZ Y, 1995, DEVELOPMENT, V121, P11; Hogan B, 1994, MANIPULATING MOUSE E; Hussain MA, 1997, MOL CELL BIOL, V17, P7186, DOI 10.1128/MCB.17.12.7186; Hussain MA, 1999, J BIOL CHEM, V274, P28950, DOI 10.1074/jbc.274.41.28950; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Josephson R, 1998, DEVELOPMENT, V125, P3087; LEONARD J, 1993, MOL ENDOCRINOL, V7, P1275, DOI 10.1210/me.7.10.1275; Mashima H, 1996, J CLIN INVEST, V97, P1647, DOI 10.1172/JCI118591; MILLER CP, 1994, EMBO J, V13, P1145, DOI 10.1002/j.1460-2075.1994.tb06363.x; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHNISHI H, 1995, J CLIN INVEST, V95, P2304, DOI 10.1172/JCI117922; PHILIPPE J, 1987, J CLIN INVEST, V79, P351, DOI 10.1172/JCI112819; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; Shimazaki T, 1999, EMBO J, V18, P444, DOI 10.1093/emboj/18.2.444; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; StOnge L, 1997, NATURE, V387, P406, DOI 10.1038/387406a0; Sussel L, 1998, DEVELOPMENT, V125, P2213; WAEBER G, 1993, MOL ENDOCRINOL, V7, P1501, DOI 10.1210/mend.7.11.8114764; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Yamaoka T, 2000, DIABETOLOGIA, V43, P332, DOI 10.1007/s001250050051; Zhou J, 1999, DIABETES, V48, P2358, DOI 10.2337/diabetes.48.12.2358	29	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16028	16032		10.1074/jbc.M107124200	http://dx.doi.org/10.1074/jbc.M107124200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11834725	hybrid			2022-12-25	WOS:000175510400108
J	Kozma, E; Brown, E; Ellis, EM; Lapthorn, AJ				Kozma, E; Brown, E; Ellis, EM; Lapthorn, AJ			The crystal structure of rat liver AKR7A1 - A dimeric member of the aldo-keto reductase superfamily	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-1 ALDEHYDE REDUCTASE; DIABETIC COMPLICATIONS; CATALYTIC ACTIVITY; BETA-SUBUNIT; EXPRESSION; PROTEIN; SPECIFICITY; SUBSTRATE; BINDING; CLONING	The structure of the rat liver aflatoxin dialdehyde reductase (AKR7A1) has been solved to 1.38-Angstrom resolution. Although it shares a similar alpha/beta-barrel structure with other members of the aldo-keto reductase superfamily, AKR7A1 is the first dimeric member to be crystallized. The crystal structure also reveals details of the ternary complex as one subunit of the dimer contains NADP(+) and the inhibitor citrate. Although the underlying catalytic mechanism appears similar to other aldo-keto reductases, the substrate-binding pocket contains several charged amino acids (Arg-231 and Arg-327) that distinguish it from previously characterized aldo-keto reductases with respect to size and charge. These differences account for the substrate specificity for 4-carbon acid-aldehydes such as succinic semialdehyde and 2-carboxybenzaldehyde as well as for the idiosyncratic substrate aflatoxin B-1 dialdehyde of this subfamily of enzymes. Structural differences between the AKR7A1 ternary complex and apoenzyme reveal a significant hinged movement of the enzyme involving not only the loops of the structure but also parts of the alpha/beta-barrel most intimately involved in cofactor binding.	Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Strathclyde, Dept Biosci, Glasgow G1 1XW, Lanark, Scotland; Univ Strathclyde, Dept Pharmaceut Sci, Glasgow G1 1XW, Lanark, Scotland	University of Glasgow; University of Strathclyde; University of Strathclyde	Lapthorn, AJ (corresponding author), Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland.			Lapthorn, Adrian/0000-0002-2197-8134				BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Barski OA, 1996, BIOCHEMISTRY-US, V35, P14276, DOI 10.1021/bi9619740; BOHREN KM, 1992, J BIOL CHEM, V267, P20965; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P487, DOI 10.1107/S0907444997011980; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; ELKABBANI O, 1994, ACTA CRYSTALLOGR D, V50, P859, DOI 10.1107/S0907444994005275; Ellis EM, 1996, CANCER RES, V56, P2758; ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350; ELLIS EM, 1995, BIOCHEM J, V312, P535, DOI 10.1042/bj3120535; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; HAYES JD, 1993, CANCER RES, V53, P3887; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; Hur E, 2001, CHEM-BIOL INTERACT, V130, P527, DOI 10.1016/S0009-2797(00)00296-9; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Jin Y, 2001, BIOCHEMISTRY-US, V40, P10161, DOI 10.1021/bi010919a; JUDAH DJ, 1993, BIOCHEM J, V292, P13, DOI 10.1042/bj2920013; Kelly VP, 2000, BIOCHEM J, V348, P389, DOI 10.1042/0264-6021:3480389; Khurana S, 1998, P NATL ACAD SCI USA, V95, P6768, DOI 10.1073/pnas.95.12.6768; Knight LP, 1999, CARCINOGENESIS, V20, P1215, DOI 10.1093/carcin/20.7.1215; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; Ma HC, 1999, P NATL ACAD SCI USA, V96, P11161, DOI 10.1073/pnas.96.20.11161; MAMELAK M, 1989, NEUROSCI BIOBEHAV R, V13, P187, DOI 10.1016/S0149-7634(89)80053-3; MURSHUDOV GN, 1996, MACROMOLECULAR REFIN, P93; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishi N, 2000, ENDOCRINOLOGY, V141, P3194, DOI 10.1210/en.141.9.3194; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Praml C, 1998, CANCER RES, V58, P5014; RONDEAU JM, 1992, NATURE, V355, P469, DOI 10.1038/355469a0; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Singh AP, 1997, P 5 INT C INT SYST M, P284; TILLAKARATNE NJK, 1995, COMP BIOCHEM PHYS A, V112, P247, DOI 10.1016/0300-9629(95)00099-2; WILSON DK, 1995, BIOCHEMISTRY-US, V34, P14323, DOI 10.1021/bi00044a009; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Ye QL, 2000, PROTEINS, V38, P41, DOI 10.1002/(SICI)1097-0134(20000101)38:1<41::AID-PROT5>3.0.CO;2-M	45	49	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16285	16293		10.1074/jbc.M110808200	http://dx.doi.org/10.1074/jbc.M110808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839745	hybrid			2022-12-25	WOS:000175510400139
J	Tombline, G; Fishel, R				Tombline, G; Fishel, R			Biochemical characterization of the human RAD51 protein - I. ATP hydrolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-STRAND EXCHANGE; ESCHERICHIA-COLI RECA; STATE KINETIC-ANALYSIS; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; RECOMBINATION PROTEIN; BINDING; MECHANISM; ABSENCE; DOMAIN	The prototypical bacterial RecA protein promotes recombination/repair by catalyzing strand exchange between homologous DNAs. While the mechanism of strand exchange remains enigmatic, ATP-induced cooperativity between RecA protomers is critical for its function. A human RecA homolog, human RAD51 protein (hRAD51), facilitates eukaryotic recombination/repair, although its ability to hydrolyze ATP and/or promote strand exchange appears distinct from the bacterial RecA. We have quantitatively examined the hRAD51 ATPase. The catalytic efficiency (k(cat)/K-m) of the hRAD51 ATPase was similar to50-fold lower than the RecA ATPase. Altering the ratio of DNA/hRAD51 and including salts that stimulate DNA strand exchange (ammonium sulfate and spermidine) were found to affect the catalytic efficiency of hRAD51. The average site size of hRAD51 was determined to be similar to3 nt (bp) for both single-stranded and double-stranded DNA. Importantly, hRAD51 lacks the magnitude of ATP-induced cooperativity that is a hallmark of RecA. Together, these results suggest that hRAD51 may be unable to coordinate ATP hydrolysis between neighboring protomers.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, BLSB 933,233 S 10th St, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA056542, T32CA009678] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09678, CA56542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADZUMA K, 1991, J BIOL CHEM, V266, P6159; Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Baumann P, 1997, MUTAT RES-DNA REPAIR, V384, P65, DOI 10.1016/S0921-8777(97)00028-1; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bedale WA, 1996, J BIOL CHEM, V271, P5725, DOI 10.1074/jbc.271.10.5725; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Brocchieri L, 1998, J MOL BIOL, V276, P249, DOI 10.1006/jmbi.1997.1527; CANTOR CR, 1980, BIOPHYSICAL CHEM, V3, P920; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; Dahlquist F W, 1978, Methods Enzymol, V48, P270; DICAPUA E, 1990, J STRUCT BIOL, V104, P91, DOI 10.1016/1047-8477(90)90062-H; Dresser ME, 1997, GENETICS, V147, P533; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; KANS JA, 1991, GENE, V105, P139, DOI 10.1016/0378-1119(91)90527-I; KIM JI, 1992, J BIOL CHEM, V267, P16438; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1991, BIOCHIMIE, V73, P289, DOI 10.1016/0300-9084(91)90216-N; KOWALCZYKOWSKI SC, 1995, P NATL ACAD SCI USA, V92, P3478, DOI 10.1073/pnas.92.8.3478; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LAUDER SD, 1991, J BIOL CHEM, V266, P5450; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; Lim DS, 1996, MOL CELL BIOL, V16, P7133; LOVETT ST, 1987, GENETICS, V116, P547; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Mikawa T, 1998, J BIOCHEM-TOKYO, V123, P450; MOREAU PL, 1989, J BIOL CHEM, V264, P2302; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; PUGH BF, 1988, J BIOL CHEM, V263, P76; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REHRAUER WM, 1993, J BIOL CHEM, V268, P1292; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; SEGEL IH, 1976, BIOCH CALCULATIONS, P309; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TATEISHI S, 1992, J MOL BIOL, V223, P115, DOI 10.1016/0022-2836(92)90720-5; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8845; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398; ZLOTNICK A, 1993, J BIOL CHEM, V268, P22525	61	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14417	14425		10.1074/jbc.M109915200	http://dx.doi.org/10.1074/jbc.M109915200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839739	hybrid			2022-12-25	WOS:000175203000011
J	Bond, M; Murphy, G; Bennett, MR; Newby, AC; Baker, AH				Bond, M; Murphy, G; Bennett, MR; Newby, AC; Baker, AH			Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; MEDIATED GENE DELIVERY; CELL-DEATH; IV COLLAGENASE; IN-VITRO; CONVERTING-ENZYME; CD95 FAS/APO-1; CYTOCHROME-C; TIMP-3; BCL-2	Tissue inhibitors of metalloproteinases (TIMPs) are important regulators of matrix metalloproteinase (MMP) and adamalysin metalloproteinase activity. We previously reported that overexpression of TIMP-3 inhibits MMPs and induces apoptotic cell death in a variety of cell types and demonstrated that apoptosis is mediated through the N terminus of TIMP-3, which harbors the MMP inhibitory domain. However, little is known about the mechanisms underlying TIMP-3-induced apoptosis. Here we demonstrate that overexpression of TIMP-3 induced activation of initiator caspase-8 and -9 and promoted caspase-mediated cleavage of the death substrates poly(ADP-ribose) polymerase and focal adhesion kinase. Furthermore, TIMP-3 induced mitochondrial activation as demonstrated by loss of mitochondrial membrane potential and release of cytochrome c. Intervention studies demonstrated that overexpression of Bcl-2, the anti-apoptotic mitochondrial membrane protein, or CrmA, a viral serpin inhibitor of caspase-8, completely inhibited TIMP-3-induced apoptosis. Furthermore, a dominant-negative Fas-associated death domain mutant inhibited TIMP-3-induced death substrate cleavage and apoptotic death. Taken together, these results indicate that TIMP-3 overexpression induces a type II apoptotic pathway initiated via a Fas-associated death domain-dependent mechanism.	Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Glasgow, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	Bristol Royal Infirmary; University of Bristol; University of East Anglia; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Glasgow	Bond, M (corresponding author), Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Level 7, Bristol BS2 8HW, Avon, England.	Mark.bond@bris.ac.uk	Bond, Mark/AAG-9293-2019; Baker, Andy/AAO-5250-2021	Baker, Andy/0000-0003-1441-5576; Bennett, Martin/0000-0002-2565-1825; Bond, Mark/0000-0003-2788-278X				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Ahonen M, 2000, J INVEST DERMATOL, V115, P575; Ahonen M, 1998, CANCER RES, V58, P2310; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; AnandApte B, 1996, BIOCHEM CELL BIOL, V74, P853, DOI 10.1139/o96-090; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; APTE SS, 1994, GENOMICS, V19, P86, DOI 10.1006/geno.1994.1016; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; Bjorkerud S, 1996, AM J PATHOL, V149, P367; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; BOONE TC, 1990, P NATL ACAD SCI USA, V87, P2800, DOI 10.1073/pnas.87.7.2800; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CORCORAN ML, 1995, J BIOL CHEM, V270, P13453, DOI 10.1074/jbc.270.22.13453; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; Fabunmi RP, 1998, CIRC RES, V83, P270, DOI 10.1161/01.RES.83.3.270; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; Gaudin P, 2000, BBA-MOL CELL RES, V1499, P19, DOI 10.1016/S0167-4889(00)00084-7; GENG YJ, 1995, CIRCULATION, V92, P471; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; GOLDBERG GI, 1989, P NATL ACAD SCI USA, V86, P8207, DOI 10.1073/pnas.86.21.8207; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; Greene J, 1996, J BIOL CHEM, V271, P30375, DOI 10.1074/jbc.271.48.30375; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; LECO KJ, 1994, J BIOL CHEM, V269, P9352; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; MAJID M, 2001, IN PRESS BR J OPHTHA; Margolin N, 1997, J BIOL CHEM, V272, P7223, DOI 10.1074/jbc.272.11.7223; Mitsiades N, 1999, J NATL CANCER I, V91, P1678, DOI 10.1093/jnci/91.19.1678; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider P, 1997, IMMUNITY, V7, P831, DOI 10.1016/S1074-7613(00)80401-X; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; SRINIVASULA SM, 1997, CELL, V91, P479; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P17374; STETLERSTEVENSON WG, 1992, FEBS LETT, V296, P231, DOI 10.1016/0014-5793(92)80386-U; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; TAKIGAWA M, 1990, BIOCHEM BIOPH RES CO, V171, P1264, DOI 10.1016/0006-291X(90)90822-5; Tummalapalli CM, 2001, J CELL BIOCHEM, V80, P512, DOI 10.1002/1097-4644(20010315)80:4<512::AID-JCB1005>3.0.CO;2-N; Wajant H, 1998, CURR BIOL, V8, P113, DOI 10.1016/S0960-9822(98)70042-9; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yu WH, 1998, MOL BIOL CELL, V9, p177A	59	120	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13787	13795		10.1074/jbc.M111507200	http://dx.doi.org/10.1074/jbc.M111507200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827969	hybrid			2022-12-25	WOS:000175096000059
J	Degenhardt, K; Sundararajan, R; Lindsten, T; Thompson, C; White, E				Degenhardt, K; Sundararajan, R; Lindsten, T; Thompson, C; White, E			Bax and Bak independently promote cytochrome c release from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY; CELL-DEATH; 19-KILODALTON PROTEIN; CONFORMATIONAL-CHANGE; INDUCE APOPTOSIS; OLIGOMERIZES BAK; P53; COMPLEX; E1A; MEMBERS	Pro-apoptotic Bax and Bak have been implicated in the regulation of p53-dependent apoptosis. We assessed the ability of primary baby mouse kidney (BMK) epithelial cells from bax(-/-), bak(-/-), and bax(-/-) bak(-/-) mice to be transformed by E1A alone or in conjunction with dominant-negative p53 (p53DD). Although E1A alone transformed BMK cells from p53-deficient mice, E1A alone did not transform BMK cells from bax(-/-), bak(-/-), or bax(-/-) bak(-/-) mice. Thus, the loss of both Bax and Bak was not sufficient to relieve p53-dependent suppression of transformation in epithelial cells. To test the requirement for Bax and Bak in other death signaling pathways, stable E1A plus p53DD-transformed BMK cell lines were derived from the bax(-/-), bak(-/-), and bax(-/-) bak(-/-) mice and characterized for their response to tumor necrosis factor-alpha (TNF-alpha)-mediated apoptosis. The loss of both Bax and Bak severely impaired TNF-alpha-mediated apoptosis, but the presence of either Bax or Bak alone was sufficient for cell death. Cytochrome c was released from mitochondria, and caspase-9 was activated in Bax- or Bak-deficient cells in response to TNF-alpha but not in cells deficient in both. Thus, either Bax or Bak is required for death signaling through mitochondria in response to TNF-alpha, but both are dispensable for p53-dependent transformation inhibition.	Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Univ Penn, Dept Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	White, E (corresponding author), Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	ewhite@cabm.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; CUCONATI A, 2002, IN PRESS J VIROL, V76; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; DUERKSENHUGHES PJ, 1991, J VIROL, V65, P1236, DOI 10.1128/JVI.65.3.1236-1244.1991; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1995, CELL, V80, P293; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Pearson AS, 2000, CLIN CANCER RES, V6, P887; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Shindler KS, 1997, J NEUROSCI, V17, P3112; Sundararajan R, 2001, J VIROL, V75, P7506, DOI 10.1128/JVI.75.16.7506-7516.2001; Sundararajan R, 2001, J BIOL CHEM, V276, P45120, DOI 10.1074/jbc.M106386200; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhao RB, 2000, GENE DEV, V14, P981; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	59	159	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14127	14134		10.1074/jbc.M109939200	http://dx.doi.org/10.1074/jbc.M109939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11836241	hybrid			2022-12-25	WOS:000175096000101
J	Graham, DE; Xu, HM; White, RH				Graham, DE; Xu, HM; White, RH			Identification of coenzyme M biosynthetic phosphosulfolactate synthase - A new family of sulfonate-biosynthesizing enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS; CYSTEIC ACID; PATHWAY; ANALOGS; INTERMEDIATE; BIOCHEMISTRY; SPORULATION; BISULFITE; ENOLASE; SULFITE	The hyperthermophilic euryarchaeon Methanococcus jannaschii uses coenzyme M (2-mereaptoethanesulfonic acid) as the terminal methyl carrier in methanogenesis. We describe an enzyme from that organism, (2R)-phospho-3-sulfolactate synthase (ComA), that catalyzes the first step in coenzyme M biosynthesis. ComA catalyzed the stercospecific Michael addition of sulfite to phosphoenolpyruvate over a broad range of temperature and pH conditions. Substrate and product analogs moderately inhibited activity. This enzyme has no significant sequence similarity to previously characterized enzymes; however, its Mg2+-dependent enzyme reaction mechanism may be analogous to one proposed for enolase. A diverse group of microbes and plants have homologs of ComA that could have been recruited for sulfolactate or sulfolipid biosyntheses.	Virginia Polytech Inst & State Univ, Dept Biochem 0308, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	White, RH (corresponding author), Virginia Polytech Inst & State Univ, Dept Biochem 0308, Engel Hall, Blacksburg, VA 24061 USA.	rhwhite@vt.edu	Graham, David E/F-8578-2010	Graham, David E/0000-0001-8968-7344				Allen JR, 1999, P NATL ACAD SCI USA, V96, P8432, DOI 10.1073/pnas.96.15.8432; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON VE, 1984, BIOCHEMISTRY-US, V23, P2779, DOI 10.1021/bi00307a038; Anderson VE, 1998, COMPREHENSIVE BIOL C, V2, P115; Babbitt PC, 1996, BIOCHEMISTRY-US, V35, P16489, DOI 10.1021/bi9616413; BALCH WE, 1979, J BACTERIOL, V137, P256, DOI 10.1128/JB.137.1.256-263.1979; Benning C, 1998, ANNU REV PLANT PHYS, V49, P53, DOI 10.1146/annurev.arplant.49.1.53; BONSEN PPM, 1969, J BACTERIOL, V98, P62, DOI 10.1128/JB.98.1.62-68.1969; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; Cleland W W, 1979, Methods Enzymol, V63, P500; CLELAND WW, 1998, COMPREHENSIVE BIOL C, V2, P1; Cook AM, 1998, FEMS MICROBIOL REV, V22, P399, DOI 10.1111/j.1574-6976.1998.tb00378.x; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FAHEY RC, 1987, METHOD ENZYMOL, V143, P85; FELSTEIN J, 2001, PHYLIP VERSION 3 6A2; Gerlt J.A., 1998, BIOORGANIC CHEM PEPT, P279; Gilbert EE, 1977, SULFONATION RELATED; GILMORE DF, 1989, BIOCHEM BIOPH RES CO, V160, P535, DOI 10.1016/0006-291X(89)92465-0; Grabarse W, 2001, J MOL BIOL, V309, P315, DOI 10.1006/jmbi.2001.4647; Graham DE, 2001, EUR J BIOCHEM, V268, P5176, DOI 10.1046/j.0014-2956.2001.02451.x; GRAHAM DE, 2000, IN PRESS NAT PROD ER, V19; Graupner M, 2000, J BACTERIOL, V182, P3688, DOI 10.1128/JB.182.13.3688-3692.2000; Graupner M, 2000, J BACTERIOL, V182, P4862, DOI 10.1128/JB.182.17.4862-4867.2000; GUNSALUS RP, 1978, BIOCHEMISTRY-US, V17, P2374, DOI 10.1021/bi00605a019; Huxtable RJ, 2000, ADV EXP MED BIOL, V483, P1; IZUMI Y, 1971, B CHEM SOC JPN, V44, P1416, DOI 10.1246/bcsj.44.1416; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; KOSHIKAWA T, 1981, J GEN MICROBIOL, V124, P415; Krum JG, 2001, J BACTERIOL, V183, P2172, DOI 10.1128/JB.183.7.2172-2177.2001; LEHMANN J, 1964, J AM CHEM SOC, V86, P4469, DOI 10.1021/ja01074a045; MCBRIDE BC, 1971, BIOCHEMISTRY-US, V10, P2317; MCFADDEN HG, 1989, AUST J CHEM, V42, P301, DOI 10.1071/CH9890301; Morrison J F, 1979, Methods Enzymol, V63, P257; MORTON M, 1952, J AM CHEM SOC, V74, P3523, DOI 10.1021/ja01134a019; NEUE HU, 1993, BIOSCIENCE, V43, P466, DOI 10.2307/1311906; Poyner RR, 2001, BIOCHEMISTRY-US, V40, P8009, DOI 10.1021/bi0103922; PUGH CE, 1995, BIOCHEM J, V309, P513, DOI 10.1042/bj3090513; Sanda S, 2001, J BIOL CHEM, V276, P3941, DOI 10.1074/jbc.M008200200; SHAW IC, 1987, CANCER TREAT REV, V14, P67, DOI 10.1016/0305-7372(87)90041-7; SOUTHERLAND WM, 1982, J TOXICOL ENV HEALTH, V10, P479, DOI 10.1080/15287398209530270; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Teichmann SA, 2001, J MOL BIOL, V311, P693, DOI 10.1006/jmbi.2001.4912; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOGAWA T, 1992, CHEM PHARM BULL, V40, P3000, DOI 10.1248/cpb.40.3000; TUAZON PT, 1977, BIOCHEMISTRY-US, V16, P1183, DOI 10.1021/bi00625a024; WEDZICHA BL, 1992, FOOD ADDIT CONTAM, V9, P449, DOI 10.1080/02652039209374097; WESTHEAD EW, 1966, METHOD ENZYMOL, V9, P670; WHITE RH, 1986, BIOCHEMISTRY-US, V25, P5304, DOI 10.1021/bi00366a047; WHITE RH, 1985, BIOCHEMISTRY-US, V24, P6487, DOI 10.1021/bi00344a027; WHITE RH, 1987, J LABELLED COMPD RAD, V24, P323, DOI 10.1002/jlcr.2580240313; WHITE RH, 1984, J BACTERIOL, V159, P42, DOI 10.1128/JB.159.1.42-46.1984; WOOD DA, 1971, BIOCHEM J, V123, P601, DOI 10.1042/bj1230601	53	78	80	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13421	13429		10.1074/jbc.M201011200	http://dx.doi.org/10.1074/jbc.M201011200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830598	hybrid			2022-12-25	WOS:000175096000012
J	Kuhn, DM; Sadidi, M; Liu, XL; Kreipke, C; Geddes, T; Borges, C; Watson, JT				Kuhn, DM; Sadidi, M; Liu, XL; Kreipke, C; Geddes, T; Borges, C; Watson, JT			Peroxynitrite-induced nitration of tyrosine hydroxylase - Identification of tyrosines 423, 428, and 432 as sites of modification by matrix-assisted laser desorption ionization time-of-flight mass spectrometry and tyrosine-scanning mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OXIDATIVE DAMAGE; PARKINSONS-DISEASE; NITRIC-OXIDE; PROTEINS; PHENYLALANINE; INACTIVATION; QUANTITATION; SUPEROXIDE; CHEMISTRY	Tyrosine hydroxylase (TH), the initial and rate-limiting enzyme in the biosynthesis of the neurotransmitter dopamine, is inactivated by peroxynitrite. The sites of peroxynitrite-induced tyrosine nitration in TH have been identified by matrix-assisted laser desorption time-of-flight mass spectrometry and tyrosine-scanning mutagenesis. V8 proteolytic fragments of nitrated TH were analyzed by matrix-assisted laser desorption time-of-flight mass spectrometry. A peptide of 3135.4 daltons, corresponding to residues V410-E436 of TH, showed peroxynitrite-induced mass shifts of +45, +90, and +135 daltons, reflecting nitration of one, two, or three tyrosines, respectively. These modifications were not evident in untreated TH. The tyrosine residues (positions 423, 428, and 432) within this peptide were mutated to phenylalanine to confirm the site(s) of nitration and assess the effects of mutation on TH activity. Single mutants expressed wild-type levels of TH catalytic activity and were inactivated by peroxynitrite while showing reduced (30-60%) levels of nitration. The double mutants Y423F,Y428F, Y423F,Y432F, and Y428F,Y432F showed trace amounts of tyrosine nitration (7-30% of control) after exposure to peroxy-nitrite, and the triple mutant Y423F,Y428F,Y432F was not a substrate for nitration, yet peroxynitrite significantly reduced the activity of each. When all tyrosine mutants were probed with PEO-maleimide activated biotin, a thiol-reactive reagent that specifically labels reduced cysteine residues in proteins, it was evident that peroxynitrite resulted in cysteine oxidation. These studies identify residues Tyr(423), Tyr(428), and Tyr(432) as the sites of peroxynitrite-induced nitration in TH. No single tyrosine residue appears to be critical for TH catalytic function, and tyrosine nitration is neither necessary nor sufficient for peroxynitrite-induced inactivation. The loss of TH catalytic activity caused by peroxynitrite is associated instead with oxidation of cysteine residues.	Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; John D Dingell Vet Affairs Med Ctr, Detroit, MI 48201 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Wayne State University; Wayne State University; Michigan State University	Kuhn, DM (corresponding author), Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, 2125 Scott Hall,540 E Canfield, Detroit, MI 48201 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA010756] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 10756] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Almas B, 2000, BIOCHEMISTRY-US, V39, P13676, DOI 10.1021/bi0011983; Alvarez B, 1999, J BIOL CHEM, V274, P842, DOI 10.1074/jbc.274.2.842; Ara J, 1998, P NATL ACAD SCI USA, V95, P7659, DOI 10.1073/pnas.95.13.7659; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Blanchard-Fillion B, 2001, J BIOL CHEM, V276, P46017, DOI 10.1074/jbc.M105564200; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; Crow J P, 1995, Adv Pharmacol, V34, P17; Crow JP, 1996, METHOD ENZYMOL, V269, P185; Daubner SC, 1998, BIOCHEMISTRY-US, V37, P16440, DOI 10.1021/bi981648f; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Erlandsen H, 2000, BIOCHEMISTRY-US, V39, P2208, DOI 10.1021/bi992531+; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Good PF, 1996, AM J PATHOL, V149, P21; Good PF, 1998, J NEUROPATH EXP NEUR, V57, P338, DOI 10.1097/00005072-199804000-00006; Goodwill KE, 1998, BIOCHEMISTRY-US, V37, P13437, DOI 10.1021/bi981462g; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; Groves JT, 1999, CURR OPIN CHEM BIOL, V3, P226, DOI 10.1016/S1367-5931(99)80036-2; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; ISCHIROPOULOS H, 1995, J NEUROCHEM, V65, P2366; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Kuhn DM, 1999, J NEUROCHEM, V73, P1309, DOI 10.1046/j.1471-4159.1999.0731309.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LERNER P, 1978, NEUROCHEM RES, V3, P641, DOI 10.1007/BF00963765; Lymar SV, 1998, CHEM RES TOXICOL, V11, P714, DOI 10.1021/tx980076x; Lyras L, 1998, J NEUROCHEM, V71, P302; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1991, J BIOL CHEM, V266, P4244; Sarver A, 2001, J AM SOC MASS SPECTR, V12, P439, DOI 10.1016/S1044-0305(01)00213-6; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Squadrito GL, 1998, FREE RADICAL BIO MED, V25, P392, DOI 10.1016/S0891-5849(98)00095-1; Torreilles F, 1999, BRAIN RES REV, V30, P153, DOI 10.1016/S0165-0173(99)00014-4; VANIWAARDEN PR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P161, DOI 10.1016/0304-4157(92)90037-B	39	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14336	14342		10.1074/jbc.M200290200	http://dx.doi.org/10.1074/jbc.M200290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834745	hybrid			2022-12-25	WOS:000175096000128
J	Ludewig, U; von Wiren, N; Frommer, WB				Ludewig, U; von Wiren, N; Frommer, WB			Uniport of NH4+ by the root hair plasma membrane ammonium transporter LeAMT1;1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RICE ROOTS; SACCHAROMYCES-CEREVISIAE; UPTAKE SYSTEMS; NET FLUXES; KINETICS; NITRATE; METHYLAMMONIUM; MULTIPLICITY; EXPRESSION; NH3	The transport of ammonium/ammonia is a key process for the acquisition and metabolism of nitrogen. Ammonium transport is mediated by the AMT/MEP/Rh family of membrane proteins which are found in microorganisms, plants, and animals, including the Rhesus blood group antigens in humans. Although ammonium transporters from all kingdoms have been functionally expressed and partially characterized, the transport mechanism, as well as the identity of the true substrate (NH4+ or NH3) remains unclear. Here we describe the functional expression and characterization of LeAMT1:1, a root hair ammonium transporter from tomato (Lycopersicon esculentum) in Xenopus oocytes. Micromolar concentrations of external ammonium were found to induce concentration- and voltage-dependent inward currents in oocytes injected with LeAMT1;1 cRNA, but not in water-injected control oocytes. The NH4+-induced currents were more than 3-fold larger than methylammonium currents and were not subject to inhibition by Na+ or K+. The voltage dependence of the affinity of LeAMT1;1 toward its substrate strongly suggests that charged NH4+, rather than NH3, is the true 4 transport substrate. Furthermore, ammonium transport was independent of the external proton concentration between pH 5.5 and pH 8.5. LeAMT1;1 is concluded to mediate potential-driven NH4+ uptake and retrieval depending on root membrane potential and NH4+ concentration gradient.	Univ Tubingen, Zentrum Mol Biol Pflanzen, D-72076 Tubingen, Germany; Univ Hohenheim, Inst Pflanzenernahrung, D-70599 Stuttgart, Germany	Eberhard Karls University of Tubingen; University Hohenheim	Ludewig, U (corresponding author), Univ Tubingen, Zentrum Mol Biol Pflanzen, Morgenstelle 1, D-72076 Tubingen, Germany.	uwe.ludewig@zmbp.uni-tuebingen.de	Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; von Wiren, Nicolaus/0000-0002-4966-425X				Avent ND, 2000, BLOOD, V95, P375, DOI 10.1182/blood.V95.2.375; Baukrowitz T, 1999, EMBO J, V18, P847, DOI 10.1093/emboj/18.4.847; Britto DT, 2001, PLANT PHYSIOL, V125, P523, DOI 10.1104/pp.125.2.523; Britto DT, 2001, P NATL ACAD SCI USA, V98, P4255, DOI 10.1073/pnas.061034698; Burckhardt BC, 1997, PFLUG ARCH EUR J PHY, V434, P306, DOI 10.1007/s004240050401; Colmer TD, 1998, PLANT CELL ENVIRON, V21, P240, DOI 10.1046/j.1365-3040.1998.00261.x; Cougnon M, 1996, PFLUG ARCH EUR J PHY, V431, P658, DOI 10.1007/BF02191917; DUBOIS E, 1979, MOL GEN GENET, V175, P67, DOI 10.1007/BF00267857; FELLE H, 1980, BIOCHIM BIOPHYS ACTA, V602, P181, DOI 10.1016/0005-2736(80)90300-4; GARBARINO J, 1988, PLANT PHYSIOL, V86, P231, DOI 10.1104/pp.86.1.231; Gazzarrini S, 1999, PLANT CELL, V11, P937, DOI 10.1105/tpc.11.5.937; HENRIKSEN GH, 1992, PLANT PHYSIOL, V99, P734, DOI 10.1104/pp.99.2.734; HIGINBOTHAM N., 1964, PLANT PHYSIOL, V39, P196, DOI 10.1104/pp.39.2.196; KLEINER D, 1981, BIOCHIM BIOPHYS ACTA, V639, P41, DOI 10.1016/0304-4173(81)90004-5; KOSOLA KR, 1994, PLANT PHYSIOL, V105, P435, DOI 10.1104/pp.105.1.435; Lauter FR, 1996, P NATL ACAD SCI USA, V93, P8139, DOI 10.1073/pnas.93.15.8139; Liu Z, 2001, J BIOL CHEM, V276, P1424, DOI 10.1074/jbc.M007528200; Ludewig U, 2001, GENOME BIOL, V2; Madrid R, 1998, J BIOL CHEM, V273, P14838, DOI 10.1074/jbc.273.24.14838; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; Marini AM, 1997, MOL CELL BIOL, V17, P4282, DOI 10.1128/MCB.17.8.4282; Meier-Wagner J, 2001, MICROBIOL-UK, V147, P135, DOI 10.1099/00221287-147-1-135; Moroni A, 1998, J MEMBRANE BIOL, V163, P25, DOI 10.1007/s002329900367; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; SMART DR, 1988, OECOLOGIA, V76, P336, DOI 10.1007/BF00377026; Soupene E, 1998, P NATL ACAD SCI USA, V95, P7030, DOI 10.1073/pnas.95.12.7030; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; ULLRICH WR, 1984, PHYSIOL PLANTARUM, V61, P369, DOI 10.1111/j.1399-3054.1984.tb06342.x; von Wiren N, 2000, PLANT J, V21, P167, DOI 10.1046/j.1365-313x.2000.00665.x; von Wiren N, 2000, CURR OPIN PLANT BIOL, V3, P254, DOI 10.1016/S1369-5266(00)00073-X; WALKER NA, 1979, J MEMBRANE BIOL, V49, P21, DOI 10.1007/BF01871038; WALKER NA, 1979, J MEMBRANE BIOL, V49, P238; WANG MY, 1993, PLANT PHYSIOL, V103, P1249, DOI 10.1104/pp.103.4.1463; WANG MY, 1994, PLANT PHYSIOL, V104, P899, DOI 10.1104/pp.104.3.899; WANG MY, 1993, PLANT PHYSIOL, V103, P1259, DOI 10.1104/pp.103.4.1463; Wells DM, 2000, PLANT SOIL, V221, P103, DOI 10.1023/A:1004767518004	37	201	217	2	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13548	13555		10.1074/jbc.M200739200	http://dx.doi.org/10.1074/jbc.M200739200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821433	hybrid			2022-12-25	WOS:000175096000028
J	Safina, F; Tanaka, S; Inagaki, M; Tsuboi, K; Sugimoto, Y; Ichikawa, A				Safina, F; Tanaka, S; Inagaki, M; Tsuboi, K; Sugimoto, Y; Ichikawa, A			Expression of L-histidine decarboxylase in mouse male germ cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; C-KIT; LOCALIZATION; HISTAMINE; SPERMATOGENESIS; PURIFICATION; SECRETION; TESTIS; FORMS	Histamine synthesis in male reproductive tissues remains largely unknown. The interaction between stem cell factor and its receptor, c-Kit, has been found to be essential for the maturation of male germ cells and peripheral mast cells. Based on this analogy, we investigated the expression of histidine decarboxylase (HDC), the rate-limiting enzyme of histamine synthesis, in mouse male germ cells. Immunohistochemical analyses revealed that HDC is localized in the acrosomes of spermatids and spermatozoa. In the testis, epididymis, and spermatozoa, a significant amount of histamine and HDC activity were detected. W/W-V mice, known to lack most of their germ cells in the seminiferous tubules, were found to lack HDC protein expression as well as HDC activity in the testis. An in vitro acrosome reaction induced by a calcium ionophore, A23187, caused the release of histamine from epididymal spermatozoa. Our observations indicate that histamine is produced in and released from the acrosomes.	Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Chem Phys, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University; Kyoto University	Ichikawa, A (corresponding author), Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Chem Phys, Sakyo Ku, Kyoto 6068501, Japan.	aichikaw@pharm.kyoto-u.ac.jp	BAKRIN, FAIZAH SAFINA/B-8479-2010; TANAKA, Satoshi/B-1624-2011; Sugimoto, Yukihiko/AAV-6470-2021; Tanaka, Satoshi/H-6800-2019	TANAKA, Satoshi/0000-0002-3468-7694; Sugimoto, Yukihiko/0000-0001-6973-932X; Tanaka, Satoshi/0000-0002-3468-7694				ALLISON AC, 1970, J REPROD FERTIL, V21, P501, DOI 10.1530/jrf.0.0210501; Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; BEAVEN MA, 1978, HISTAMINE ITS ROLE P, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREIL JD, 1991, ELEMENTS MAMMALIAN F, V1, P133; CODE CF, 1965, FED PROC, V24, P1311; Dartsch C, 1998, REGUL PEPTIDES, V77, P33, DOI 10.1016/S0167-0115(98)00045-7; Engel N, 1996, BIOCHEM J, V320, P365, DOI 10.1042/bj3200365; Fleming JV, 2000, MOL CELL BIOL, V20, P4932, DOI 10.1128/MCB.20.13.4932-4947.2000; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Loveland KL, 1997, J ENDOCRINOL, V153, P337, DOI 10.1677/joe.0.1530337; Lukacs NW, 1996, BLOOD, V87, P2262, DOI 10.1182/blood.V87.6.2262.bloodjournal8762262; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; OHMORI E, 1990, J BIOCHEM, V107, P834, DOI 10.1093/oxfordjournals.jbchem.a123134; Ohtsu H, 2001, FEBS LETT, V502, P53, DOI 10.1016/S0014-5793(01)02663-1; REITH AD, 1991, GENOME ANAL, V3, P105; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; Sandlow JI, 1997, UROLOGY, V49, P494, DOI 10.1016/S0090-4295(96)00494-3; SCHWARTZ JC, 1980, J NEUROCHEM, V35, P26, DOI 10.1111/j.1471-4159.1980.tb12485.x; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; SUGIMOTO Y, 1994, AM J PHYSIOL, V266, pF823, DOI 10.1152/ajprenal.1994.266.5.F823; TAJIMA Y, 1994, J REPROD FERTIL, V102, P117, DOI 10.1530/jrf.0.1020117; Tanaka S, 1998, J BIOL CHEM, V273, P8177, DOI 10.1074/jbc.273.14.8177; Tanaka S, 1997, FEBS LETT, V417, P203, DOI 10.1016/S0014-5793(97)01281-7; Tanaka S, 2002, GASTROENTEROLOGY, V122, P145, DOI 10.1053/gast.2002.30312; WATABE A, 1992, BIOCHEM PHARMACOL, V43, P587, DOI 10.1016/0006-2952(92)90582-4; WATANABE T, 1983, METHODS BIOGENIC AMI, P6900; WHITTINGHAM DG, 1968, NATURE, V220, P592, DOI 10.1038/220592a0; YAMAMOTO J, 1993, BIOCHIM BIOPHYS ACTA, V1216, P431, DOI 10.1016/0167-4781(93)90011-2; YAMAMOTO J, 1990, FEBS LETT, V276, P214, DOI 10.1016/0014-5793(90)80545-T; Yanagimachi R., 1994, P189; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Zaneveld L. J. D., 1991, A comparative overview of mammalian fertilization., P63	34	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14211	14215		10.1074/jbc.M200702200	http://dx.doi.org/10.1074/jbc.M200702200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827977	hybrid			2022-12-25	WOS:000175096000111
J	Barry, FA; Gibbins, JM				Barry, FA; Gibbins, JM			Protein kinase B is regulated in platelets by the collagen receptor glycoprotein VI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; TYROSINE PHOSPHORYLATION; GAMMA-CHAIN; MOLECULAR-CLONING; THROMBIN RECEPTOR; AKT ACTIVATION; INSULIN; TRANSLOCATION; INHIBITION; 3-KINASE	Phosphoinositide 3-kinase (PI3K) is a critical component of the signaling pathways that control the activation of platelets. Here we have examined the regulation of protein kinase B (PKB), a downstream effector of PI3K, by the platelet collagen receptor glycoprotein (GP) VI and thrombin receptors. Stimulation of platelets with collagen or convulxin (a selective GPVI agonist) resulted in PI3K-dependent, and aggregation independent, Ser(473) and Thr(308) phosphorylation of PKBalpha, which results in PKB activation. This was accompanied by translocation of PKB to cell membranes. The phosphoinositide-dependent kinase PDK1 is known to phosphorylate PKBalpha on Thr(308), although the identity of the kinase responsible for Ser(473) phosphorylation is less clear. One candidate that has been implicated as being responsible for Ser(473) phosphorylation, either directly or indirectly, is the integrin-linked kinase (ELK). In this study we have examined the interactions of PKB, PDK1, and ILK in resting and stimulated platelets. We demonstrate that in platelets PKB is physically associated with PDK1 and ILK. Furthermore, the association of PDK1 and ILK increases upon platelet stimulation. It would therefore appear that formation of a tertiary complex between PDK1, ILK, and PKB may be necessary for phosphorylation of PKB. These observations indicate that PKB participates in cell signaling downstream of the platelet collagen receptor GPVI. The role of PKB in collagen- and thrombin-stimulated platelets remains to be determined.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Gibbins, JM (corresponding author), Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England.	j.m.gibbins@reading.ac.uk		Gibbins, Jonathan/0000-0002-0372-5352				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asselin J, 1997, BLOOD, V89, P1235, DOI 10.1182/blood.V89.4.1235; Banfic H, 1998, J BIOL CHEM, V273, P11630, DOI 10.1074/jbc.273.19.11630; BARRY FA, 2001, THROMB HAEMOSTASIS, V86, pP2645; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1993, ONCOGENE, V8, P745; Bennett JS, 2001, ANN NY ACAD SCI, V936, P340; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; Carver DJ, 2000, BLOOD, V96, P1449, DOI 10.1182/blood.V96.4.1449.h8001449_1449_1456; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; CIEMIL M, 2002, BLOOD, V99, P137; CIEMIL M, 2000, J BIOL CHEM, V275, P27339; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Foran PGP, 1999, J BIOL CHEM, V274, P28087, DOI 10.1074/jbc.274.40.28087; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kahn ML, 1998, NATURE, V394, P690, DOI 10.1038/29325; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Kroner C, 2000, J BIOL CHEM, V275, P27790, DOI 10.1074/jbc.M000540200; Lagrue AH, 1999, FEBS LETT, V448, P95, DOI 10.1016/S0014-5793(99)00340-3; Lynch DK, 1999, ONCOGENE, V18, P8024, DOI 10.1038/sj.onc.1203258; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sambrano GR, 2001, NATURE, V413, P74, DOI 10.1038/35092573; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Tang XW, 2000, J BIOL CHEM, V275, P13142, DOI 10.1074/jbc.275.17.13142; Thomas JM, 2000, BLOOD, V96, p245A; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Wijkander J, 1998, ENDOCRINOLOGY, V139, P219, DOI 10.1210/en.139.1.219; Zhang J, 1996, J BIOL CHEM, V271, P6265, DOI 10.1074/jbc.271.11.6265	47	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12874	12878		10.1074/jbc.M200482200	http://dx.doi.org/10.1074/jbc.M200482200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11825911	hybrid			2022-12-25	WOS:000175036300051
J	Ogretmen, B; Pettus, BJ; Rossi, MJ; Wood, R; Usta, J; Szulc, Z; Bielawska, A; Obeid, LM; Hannun, YA				Ogretmen, B; Pettus, BJ; Rossi, MJ; Wood, R; Usta, J; Szulc, Z; Bielawska, A; Obeid, LM; Hannun, YA			Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide the A549 human lung adenocarcinoma cell line - Role for endogenous ceramide in mediating the action of exogenous ceramide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SPHINGOLIPID BIOSYNTHESIS; NEUTRAL SPHINGOMYELINASE; DOWNSTREAM TARGET; INDUCED APOPTOSIS; CYCLE ARREST; GLUCOSYLCERAMIDE; PURIFICATION; SPHINGOSINE; INHIBITION	Treatment of A549 cells with C-6-ceramide resulted in a significant increase in the endogenous long chain ceramide levels, which was inhibited by fumonisin B1 (FB1), and not by myriocin (MYR). The biochemical mechanisms of generation of endogenous ceramide were investigated using A549 cells treated with selectively labeled C-6-ceramides, [sphingosine-3-H-3]D-erythro-, and N-[N-hexanoyl-1-C-14]D-erythro-C-6-ceramide. The results demonstrated that 311 label was incorporated into newly synthesized long chain ceramides, which was inhibited by FB1 and not by MYR. Interestingly, the C-14 label was not incorporated into long chain ceramides. Taken together, these results show that generation of endogenous ceramide in response to C-6-ceramide is due to recycling of the sphingosine backbone of C-6-ceramide via deacylation/reacylation and not due to the elongation of its fatty acid moiety. Moreover, the generation of endogenous long chain ceramide in response to C-6-ceramide was completely blocked by brefeldin A, which causes Golgi disassembly, suggesting a role for the Golgi in the metabolism of ceramide. In addition, the generation of endogenous ceramide in response to short chain exogenous ceramide was induced by D-erythro- but not L-erythro-C-6-ceramide, demonstrating the stereospecificity of this process. Interestingly, several key downstream biological activities of ceramide, such as growth inhibition, cell cycle arrest, and modulation of telomerase activity were induced by D-erythro-C-6-ceramide, and not L-erythro-C6-ceramide (and inhibited by FB1) in A549 cells, suggesting a role for endogenous long chain ceramide in the regulation of these responses.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA; Amer Univ Beirut, Dept Biochem, Beirut, Lebanon	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; American University of Beirut	Ogretmen, B (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, POB 250779, Charleston, SC 29425 USA.	ogretmen@musc.edu		obeid, lina/0000-0002-0734-0847	NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG012467, R01AG016583, R55AG012467] Funding Source: NIH RePORTER; NCI NIH HHS [CA 87584] Funding Source: Medline; NIA NIH HHS [AG 12467, AG 16583] Funding Source: Medline; NIGMS NIH HHS [GM 48325] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; BERNARDO K, 1995, J BIOL CHEM, V270, P11098, DOI 10.1074/jbc.270.19.11098; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; El Bawab S, 2000, J BIOL CHEM, V275, P21508, DOI 10.1074/jbc.M002522200; El Bawab S, 1999, J BIOL CHEM, V274, P27948, DOI 10.1074/jbc.274.39.27948; El Bawab S, 2001, J BIOL CHEM, V276, P16758, DOI 10.1074/jbc.M009331200; Fukunaga T, 1998, FEBS LETT, V435, P237, DOI 10.3390/cells11060938; Fukunaga T, 2000, J CELL SCI, V113, P3299; Garzotto M, 1998, CANCER RES, V58, P2260; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jenkins GM, 2001, J BIOL CHEM, V276, P8574, DOI 10.1074/jbc.M007425200; KIM MY, 1991, J BIOL CHEM, V266, P484; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KOLESNICK R, 1995, J EXP MED, V181, P1949, DOI 10.1084/jem.181.6.1949; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Mao CG, 2001, J BIOL CHEM, V276, P26577, DOI 10.1074/jbc.M102818200; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Michel C, 1997, J BIOL CHEM, V272, P22432, DOI 10.1074/jbc.272.36.22432; Mizushima N, 1996, FEBS LETT, V395, P267, DOI 10.1016/0014-5793(96)01050-2; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Suzuki A, 1997, EXP CELL RES, V233, P41, DOI 10.1006/excr.1997.3498; Venable ME, 1999, BBA-MOL CELL BIOL L, V1439, P291, DOI 10.1016/S1388-1981(99)00101-8; WANG E, 1991, J BIOL CHEM, V266, P14486; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325	45	169	173	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12960	12969		10.1074/jbc.M110699200	http://dx.doi.org/10.1074/jbc.M110699200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815611	hybrid			2022-12-25	WOS:000175036300062
J	Pace, KE; Lebestky, T; Hummel, T; Arnoux, P; Kwan, K; Baum, LG				Pace, KE; Lebestky, T; Hummel, T; Arnoux, P; Kwan, K; Baum, LG			Characterization of a novel Drosophila melanogaster galectin - Expression in developing immune, neural, and muscle tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTINS; THYMIC EPITHELIAL-CELLS; C-TYPE LECTINS; ENDOGENOUS LECTIN; MAMMALIAN LECTIN; CDNA CLONING; CRYSTAL-STRUCTURE; INSECT IMMUNITY; FAMILY; SEQUENCE	We have cloned and characterized the first galectin to be identified in Drosophila melanogaster. The amino acid sequence of Drosophila galectin showed striking sequence similarity to invertebrate and vertebrate galectins and contained amino acids that are crucial for binding beta-galactoside sugars. Confirming its identity as a galectin family member, the Drosophila galectin bound beta-galactoside sugars. Structurally, the Drosophila galectin was a tandem repeat galectin containing two carbohydrate recognition domains connected by a unique peptide link. This divalent structure suggests that like mammalian galectins, Drosophila galectin may mediate cell-cell communication or facilitate cross-linking of receptors to trigger signal transduction events. The Drosophila galectin was very abundant in embryonic, larval, and adult Drosophila. During embryogenesis, Drosophila galectin had a unique and specific tissue distribution. Drosophila galectin expression was concentrated in somatic and visceral musculature and in the central nervous system. Similar to other insect lectins, Drosophila galectin may function in both embryogenesis and in host defense. Drosophila galectin was expressed by hemocytes, circulating phagocytic cells, suggesting a role for Drosophila galectin in the innate immune system.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of Toronto	Baum, LG (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.	lbaum@mednet.ucla.edu	Arnoux, Pascal/B-3600-2010	ARNOUX, Pascal/0000-0003-4609-4893	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040118] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40118] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; Cooper DNW, 1997, J BIOL CHEM, V272, P1514, DOI 10.1074/jbc.272.3.1514; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DAMICO P, 1995, TISSUE CELL, V27, P23, DOI 10.1016/S0040-8166(95)80005-0; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Dong XZ, 1999, GENE DEV, V13, P954, DOI 10.1101/gad.13.8.954; FOWLIS D, 1995, DEV DYNAM, V203, P241, DOI 10.1002/aja.1002030211; Fradin C, 2000, INFECT IMMUN, V68, P4391, DOI 10.1128/IAI.68.8.4391-4398.2000; Franc NC, 2000, MICROBES INFECT, V2, P243, DOI 10.1016/S1286-4579(00)00304-X; FREDIEU JR, 1994, ACTA ANAT, V149, P89; FRISTROM DK, 1982, DEV BIOL, V92, P418, DOI 10.1016/0012-1606(82)90187-7; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; GEOURJON C, 1994, PROTEIN ENG, V7, P157, DOI 10.1093/protein/7.2.157; GITT MA, 1995, J BIOL CHEM, V270, P5032, DOI 10.1074/jbc.270.10.5032; GU MJ, 1994, J CELL SCI, V107, P175; Hacker U, 1997, DEVELOPMENT, V124, P3565; Hadari YR, 2000, J CELL SCI, V113, P2385; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; Haq S, 1996, J BIOL CHEM, V271, P20213, DOI 10.1074/jbc.271.33.20213; HARRISON FL, 1992, J CELL SCI, V101, P635; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hotta K, 2001, J BIOL CHEM, V276, P34089, DOI 10.1074/jbc.M105097200; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Lagueux M, 2000, P NATL ACAD SCI USA, V97, P11427, DOI 10.1073/pnas.97.21.11427; Leal-Pinto E, 1999, J MEMBRANE BIOL, V169, P13, DOI 10.1007/PL00005897; Leonidas DD, 1995, STRUCTURE, V3, P1379, DOI 10.1016/S0969-2126(01)00275-1; LeshkoLindsay L, 1997, DEVELOPMENT, V124, P169; LEVI G, 1981, J BIOL CHEM, V256, P5735; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; Loukas A, 2000, PARASITOL TODAY, V16, P333, DOI 10.1016/S0169-4758(00)01704-X; MAHANTHAPPA NK, 1994, DEVELOPMENT, V120, P1373; Mann PL, 1998, ACTA ANAT, V161, P153; MARSCHAL P, 1992, J BIOL CHEM, V267, P12942; Mey A, 1996, J IMMUNOL, V156, P1572; Moiseeva EP, 2000, CARDIOVASC RES, V45, P493, DOI 10.1016/S0008-6363(99)00276-X; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MONTELL DJ, 1989, J CELL BIOL, V109, P2441, DOI 10.1083/jcb.109.5.2441; ODA Y, 1993, J BIOL CHEM, V268, P5929; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 1997, TRENDS GLYCOSCI GLYC, V9, P21, DOI 10.4052/tigg.9.21; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; Rechreche H, 1997, EUR J BIOCHEM, V248, P225, DOI 10.1111/j.1432-1033.1997.00225.x; Seppo A, 2000, GLYCOBIOLOGY, V10, P751, DOI 10.1093/glycob/10.8.751; Solis D, 2000, GLYCOBIOLOGY, V10, P1325, DOI 10.1093/glycob/10.12.1325; Tabuchi K, 2000, J NEUROSCI RES, V59, P94, DOI 10.1002/(SICI)1097-4547(20000101)59:1<94::AID-JNR11>3.3.CO;2-H; Theopold U, 1999, BIOCHEM BIOPH RES CO, V261, P923, DOI 10.1006/bbrc.1999.1121; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Tiemeyer M, 1996, DEVELOPMENT, V122, P925; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; Vilmos P, 1998, IMMUNOL LETT, V62, P59, DOI 10.1016/S0165-2478(98)00023-6; Visegrady B, 2001, PROTEIN ENG, V14, P875, DOI 10.1093/protein/14.11.875; Vogel G, 1998, SCIENCE, V281, P1942, DOI 10.1126/science.281.5385.1942; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; Yang RY, 2001, J BIOL CHEM, V276, P20252, DOI 10.1074/jbc.M010914200	69	66	70	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13091	13098		10.1074/jbc.M112105200	http://dx.doi.org/10.1074/jbc.M112105200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809773	hybrid			2022-12-25	WOS:000175036300077
J	Urbanus, ML; Froderberg, L; Drew, D; Bjork, P; de Gier, JWL; Brunner, J; Oudega, B; Luirink, J				Urbanus, ML; Froderberg, L; Drew, D; Bjork, P; de Gier, JWL; Brunner, J; Oudega, B; Luirink, J			Targeting, insertion, and localization of Escherichia coli YidC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; INNER MEMBRANE-PROTEINS; BACTERIAL; TRANSLOCASE; SECA; COMPONENT; SRP; MITOCHONDRIAL; SECRETION; PATHWAYS	YidC was recently shown to play an important role in the assembly of inner membrane proteins (IMPs) both in conjunction with and separate from the Sec-translocon. Little is known about the biogenesis and structural and functional properties of YidC, itself a polytopic IMP. Here we analyze the targeting and membrane integration of YidC using in vivo and in vitro approaches. The combined data indicate that YidC is targeted by the signal recognition particle and inserts at the SecAYEG-YidC translocon early during biogenesis, unlike its mitochondrial homologue Oxa1p. In addition, YidC is shown to be relatively abundant compared with other components involved in IMP assembly and is predominantly localized at the poles of the cell.	Inst Mol Biol Sci, Dept Microbiol, NL-1081 HV Amsterdam, Netherlands; Stockholm Univ, Dept Biochem Biophys & Mol Biol, S-10691 Stockholm, Sweden; Swiss Fed Inst Technol, Inst Biochem, Zurich, Switzerland	Stockholm University; Swiss Federal Institutes of Technology Domain; ETH Zurich	Luirink, J (corresponding author), Inst Mol Biol Sci, Dept Microbiol, De Boelelaan 1087, NL-1081 HV Amsterdam, Netherlands.		Luirink, Joen/AAB-8658-2021; Drew, David/AAY-3455-2020; Drew, David/D-3243-2018	Froderberg Roth, Linda/0000-0002-2684-3650; Drew, David/0000-0001-8866-6349; Luirink, J./0000-0001-8431-0804				Bassilana M, 1996, EMBO J, V15, P5202, DOI 10.1002/j.1460-2075.1996.tb00905.x; Beck K, 2000, EMBO J, V19, P134, DOI 10.1093/emboj/19.1.134; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Bost S, 1997, J BIOL CHEM, V272, P4087, DOI 10.1074/jbc.272.7.4087; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Drew DE, 2001, FEBS LETT, V507, P220, DOI 10.1016/S0014-5793(01)02980-5; DRIESSEN AJM, 1994, J MEMBRANE BIOL, V142, P145; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Herskovits AA, 2000, MOL MICROBIOL, V38, P927, DOI 10.1046/j.1365-2958.2000.02198.x; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; Koch HG, 2000, J CELL BIOL, V150, P689, DOI 10.1083/jcb.150.3.689; Koch HG, 1999, MOL BIOL CELL, V10, P2163, DOI 10.1091/mbc.10.7.2163; LEE HC, 1998, P NATL ACAD SCI USA, V6, P3471; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; NISHIYAMA K, 1994, EMBO J, V13, P3272, DOI 10.1002/j.1460-2075.1994.tb06628.x; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OLIVER DB, 1982, CELL, V30, P311, DOI 10.1016/0092-8674(82)90037-X; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SAMUELSON JC, 2001, J BIOL CHEM, V16, P16; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Urbanus ML, 2001, EMBO REP, V2, P524, DOI 10.1093/embo-reports/kve108; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; vanKlompenburg W, 1995, MOL MEMBR BIOL, V12, P349, DOI 10.3109/09687689509072437	34	73	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12718	12723		10.1074/jbc.M200311200	http://dx.doi.org/10.1074/jbc.M200311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821429	Green Published, hybrid			2022-12-25	WOS:000175036300030
J	Varela, PF; Llera, AS; Mariuzza, RA; Tormo, J				Varela, PF; Llera, AS; Mariuzza, RA; Tormo, J			Crystal structure of imaginal disc growth factor-2 - A member of a new family of growth-promoting glycoproteins from Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINIDASE-H; CHITINASE PROTEIN FAMILY; X-RAY STRUCTURE; INSULIN-RECEPTOR; 1.8-ANGSTROM RESOLUTION; ANGSTROM RESOLUTION; IDENTIFICATION; SEQUENCE; SUBSTRATE; COMPLEX	Imaginal disc growth factor-2 (IDGF-2) is a member of a recently described family of Drosophila melanogaster-soluble polypeptide growth factors that promote cell proliferation in imaginal discs. Although their precise mode of action has not been established, IDGFs cooperate with insulin in stimulating the growth of imaginal disc cells. We report the crystal structure of IDGF-2 at 1.3-Angstrom resolution. The structure shows the classical (betaalpha)(8) barrel-fold of family 18 glycosyl hydrolases, with an insertion of an alpha + beta domain similar to that of Serratia marcescens chitinases A and B. However, amino acid substitutions in the consensus catalytic sequence of chitinases give IDGF-2 a less negatively charged environment in its putative ligand-binding site and preclude the nucleophilic attack mechanism of chitin hydrolysis' Particularly important is the replacement of Glu by Gln at position 132, which has been shown to abolish enzymatic activity in chitinases. Nevertheless, a modest conservation of residues that participate in oligosaccharide recognition suggests that IDGF-2 could bind carbohydrates, assuming several conformational changes to open the partially occluded binding site. Thus, IDGFs may have evolved from chitinases to acquire new functions as growth factors, interacting with cell surface glycoproteins implicated in growth-promoting processes, such as the Drosophila insulin receptor.	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, Rockville, MD 20850 USA; Univ Autonoma Madrid, Ctr Nacl Biotecnol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, WM Keck Lab Struct Biol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@carb.nist.gov	Llera, Andrea S/AAW-8116-2021; Varela, Paloma/AFT-0478-2022	Varela, Paloma/0000-0001-5078-7102; Llera, Andrea/0000-0002-0089-0061	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036900, R37AI036900] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 36900] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryant PJ, 2001, NOVART FDN SYMP, V237, P182, DOI 10.1002/0470846666.ch14; Buhi WC, 1996, BIOL REPROD, V55, P1305, DOI 10.1095/biolreprod55.6.1305; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; DAVIS KT, 1977, SCIENCE, V196, P438, DOI 10.1126/science.403606; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; GAROFALO RS, 1988, MOL CELL BIOL, V8, P1638, DOI 10.1128/MCB.8.4.1638; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HENNIG M, 1992, FEBS LETT, V306, P80, DOI 10.1016/0014-5793(92)80842-5; HENNIG M, 1995, J MOL BIOL, V254, P237, DOI 10.1006/jmbi.1995.0614; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hipfner DR, 1999, BIOESSAYS, V21, P718, DOI 10.1002/(SICI)1521-1878(199909)21:9<718::AID-BIES2>3.0.CO;2-Z; Hollis T, 2000, PROTEIN SCI, V9, P544, DOI 10.1110/ps.9.3.544; Homma K, 1996, J BIOL CHEM, V271, P13770, DOI 10.1074/jbc.271.23.13770; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kawamura K, 1999, DEVELOPMENT, V126, P211; KIRKPATRICK RB, 1995, GENE, V153, P147, DOI 10.1016/0378-1119(94)00756-I; KRAULIS PJ, 1991, SCIENCE, V254, P581, DOI 10.1126/science.1658931; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECONTE I, 1994, J BIOL CHEM, V269, P18062; Lin FP, 1999, IUBMB LIFE, V48, P199, DOI 10.1080/152165499307224; MARINHINCAPIE M, 1995, ENDOCRINOLOGY, V136, P2357, DOI 10.1210/en.136.6.2357; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRISON BW, 1994, ONCOGENE, V9, P3417; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Perrakis A, 1997, FOLD DES, V2, P291, DOI 10.1016/S1359-0278(97)00040-0; RAO VH, 1995, STRUCTURE, V3, P449, DOI 10.1016/S0969-2126(01)00178-2; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; RUAN YM, 1995, J BIOL CHEM, V270, P4236, DOI 10.1074/jbc.270.9.4236; Sawicki MW, 2001, IMMUNOL REV, V181, P52, DOI 10.1034/j.1600-065X.2001.1810104.x; SCHMIDT BF, 1994, ARCH BIOCHEM BIOPHYS, V311, P350, DOI 10.1006/abbi.1994.1247; SHEARN A, 1978, DEV BIOL, V65, P536, DOI 10.1016/0012-1606(78)90049-0; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; STUART DI, 1979, J MOL BIOL, V134, P109, DOI 10.1016/0022-2836(79)90416-9; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANROEY P, 1994, BIOCHEMISTRY-US, V33, P13989, DOI 10.1021/bi00251a005; vanScheltinga ACT, 1996, J MOL BIOL, V262, P243, DOI 10.1006/jmbi.1996.0510; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; WATANABE T, 1993, J BIOL CHEM, V268, P18567; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x	56	66	68	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13229	13236		10.1074/jbc.M110502200	http://dx.doi.org/10.1074/jbc.M110502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821393	hybrid, Green Published			2022-12-25	WOS:000175036300093
J	Alber, BE; Fuchs, G				Alber, BE; Fuchs, G			Propionyl-coenzyme A synthase from Chloroflexus aurantiacus, a key enzyme of the 3-hydroxypropionate cycle for autotrophic CO2 fixation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTOUS BACTERIUM; CARBON FIXATION; PURIFICATION; CARBOXYLASE; GROWTH	The 3-hydroxypropionate cycle has been proposed as a new autotrophic CO2 fixation pathway for the phototrophic green non-sulfur eubacterium Chloroflexus aurantiacus and for some chemotrophic archaebacteria. The cycle requires the reductive conversion of the characteristic intermediate 3-hydroxypropionate to propionyl-CoA. The specific activity of the 3-hydroxypropionate-, CoA-, K+-, and MgATP-dependent oxidation of NADPH in autotrophically grown cells was 0.09 mumol min(-1) mg(-1) protein, which was 2-fold downregulated in heterotrophically grown cells. Unexpectedly, a single enzyme catalyzes the entire reaction sequence: 3-hydroxypropionate + MgATP + CoA + NADPH + H+ --> propionyl-CoA + MgAMP + PPi + NADP(+) + H2O. The enzyme was purified 30-fold to near homogeneity and has a very large native molecular mass between 500 and 800 kDa, with subunits of about 185 kDa as judged by SDS-PAGE, suggesting a homotrimeric or homotetrameric structure. Upon incubation of this new enzyme, termed propionyl-CoA synthase, with the proteinase trypsin, the NADPH oxidation function of the enzyme was lost, whereas the enzyme still activated 3-hydroxypropionate to its CoA-thioester and dehydrated it to acrylyl-CoA. SDS-PAGE revealed that the subunits of propionyl-CoA synthase had been cleaved once and the N-terminal amino acid sequences of the two trypsin digestion products were determined. Two parts of the gene encoding propionyl-CoA synthase (pes) were identified on two contigs of an incomplete genome data base of C. aurantiacus, and the sequence of the pcs gene was completed. Propionyl-CoA synthase is a natural fusion protein of 201 kDa consisting of a CoA ligase, an enoyl-CoA hydratase, and an enoyl-CoA reductase, the reductase domain containing the trypsin cleavage site. Similar polyfunctional. large enzymes are common in secondary metabolism (e.g. polyketide synthases) but rare in primary metabolism (e.g. eukaryotic type I fatty acid synthase). These results lend strong support to the operation of the proposed pathway in autotrophic CO2 fixation.	Univ Freiburg, Inst Biol Mikrobiol 2, D-79104 Freiburg, Germany	University of Freiburg	Alber, BE (corresponding author), Univ Freiburg, Inst Biol Mikrobiol 2, Schanzlestr 1, D-79104 Freiburg, Germany.	alber@uni-freiburg.de						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burton NP, 1999, ARCH MICROBIOL, V172, P349, DOI 10.1007/s002030050771; Chistoserdova LV, 1996, MICROBIOL-UK, V142, P1459, DOI 10.1099/13500872-142-6-1459; EISENREICH W, 1993, EUR J BIOCHEM, V215, P619, DOI 10.1111/j.1432-1033.1993.tb18073.x; Herter S, 2001, J BACTERIOL, V183, P4305, DOI 10.1128/JB.183.14.4305-4316.2001; Hofstein HA, 1999, BIOCHEMISTRY-US, V38, P9508, DOI 10.1021/bi990506y; HOLO H, 1986, ARCH MICROBIOL, V145, P173, DOI 10.1007/BF00446776; HOLO H, 1989, ARCH MICROBIOL, V151, P252, DOI 10.1007/BF00413138; HUGLE RM, 2002, IN PRESS J BACTERIOL; Ishii M, 1996, ARCH MICROBIOL, V166, P368, DOI 10.1007/BF01682981; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Menendez C, 1999, J BACTERIOL, V181, P1088, DOI 10.1128/JB.181.4.1088-1098.1999; PIERSON BK, 1974, ARCH MICROBIOL, V100, P283, DOI 10.1007/BF00446324; PIERSON BK, 1974, ARCH MICROBIOL, V100, P5, DOI 10.1007/BF00446302; SATO K, 1999, J BIOCHEM-TOKYO, V26, P668; SIREVAG R, 1979, ARCH MICROBIOL, V120, P151, DOI 10.1007/BF00409101; STRAUSS G, 1992, EUR J BIOCHEM, V205, P853, DOI 10.1111/j.1432-1033.1992.tb16850.x; STRAUSS G, 1993, EUR J BIOCHEM, V215, P633, DOI 10.1111/j.1432-1033.1993.tb18074.x; van der Meer MTJ, 2000, ENVIRON MICROBIOL, V2, P428, DOI 10.1046/j.1462-2920.2000.00124.x; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; VONKORFF RW, 1953, J BIOL CHEM, V203, P265; WALLACE KK, 1995, EUR J BIOCHEM, V233, P954, DOI 10.1111/j.1432-1033.1995.954_3.x; Xiong J, 2000, SCIENCE, V289, P1724, DOI 10.1126/science.289.5485.1724	25	82	111	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12137	12143		10.1074/jbc.M110802200	http://dx.doi.org/10.1074/jbc.M110802200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821399	hybrid			2022-12-25	WOS:000174846400070
J	Carpentieri, F; De Felice, M; De Falco, M; Rossi, M; Pisani, FM				Carpentieri, F; De Felice, M; De Falco, M; Rossi, M; Pisani, FM			Physical and functional interaction between the mini-chromosome maintenance-like DNA helicase and the single-stranded DNA binding protein from the crenarchaeon Sulfolobus solfataricus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MCM PROTEINS; POLYMERASE-ALPHA; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; REPLICATION; COMPLEX; CHROMATIN; ANTIGEN; CEREVISIAE; INITIATION	Mini-chromosome Maintenance (MCM) proteins play an essential role in both initiation and elongation phases of DNA replication in Eukarya. Genes encoding MGM homologs are present also in the genomic sequence of Archaea and the MCM-like protein from the euryarchaeon Methanobacterium thermoautotrophicum (Mth MCM) was shown to possess a robust ATP-dependent 3'-5' DNA helicase activity in vitro. Herein, we report the first biochemical characterization of a MCM homolog from a crenarchaeon, the thermoacidophile Sulfolobus solfataricus (Sso MCM). Gel filtration and glycerol gradient centrifugation experiments indicate that the Sso MCM forms single hexamers (470 kDa) in solution, whereas the Mth MGM assembles into double hexamers. The Sso MGM has NTPase and DNA helicase activity' which preferentially acts on DNA duplexes containing a 5'-tail and is stimulated by the single-stranded DNA binding protein from S. solfataricus (Sso SSB). In support of this functional interaction, we demonstrated by immunological methods that the Sso MGM and SSB form protein-protein complexes. These findings provide the first in vitro biochemical evidence of a physical/functional interaction between a MCM complex and another replication factor and suggest that the two proteins may function together in vivo in important DNA metabolic pathways.	CNR, Ist Biochim Prot, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biochimica delle Proteine (IBP-CNR)	Pisani, FM (corresponding author), CNR, Ist Biochim Prot, Via P Castellino 111, I-80131 Naples, Italy.		Pisani, Francesca M./AAX-4025-2020					Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Bernander R, 2000, TRENDS MICROBIOL, V8, P278, DOI 10.1016/S0966-842X(00)01760-1; BISWAS EE, 1995, BIOCHEM BIOPH RES CO, V206, P850, DOI 10.1006/bbrc.1995.1121; BISWAS EE, 1993, BIOCHEMISTRY-US, V32, P13393, DOI 10.1021/bi00212a003; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; De Felice M, 1999, J MOL BIOL, V291, P47, DOI 10.1006/jmbi.1999.2939; DODSON M, 1987, SCIENCE, V238, P964, DOI 10.1126/science.2823389; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUHA A, 1997, ANNU REV CELL DEV BI, V13, P293; Fujita M, 1997, J BIOL CHEM, V272, P10928; GEORGAKI A, 1994, NUCLEIC ACIDS RES, V22, P11228; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ishimi Y, 1996, J BIOL CHEM, V271, P24115, DOI 10.1074/jbc.271.39.24115; Ishimi Y, 1997, J BIOL CHEM, V272, P24508, DOI 10.1074/jbc.272.39.24508; ISHIMI Y, 1998, J BIOL CHEM, V273, P8639; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P14783, DOI 10.1073/pnas.96.26.14783; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Labib K, 2000, SCIENCE, V288, P1643, DOI 10.1126/science.288.5471.1643; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lee JK, 2000, J BIOL CHEM, V275, P18871, DOI 10.1074/jbc.M001118200; Lee JK, 2001, P NATL ACAD SCI USA, V98, P54, DOI 10.1073/pnas.98.1.54; MAINE GT, 1984, GENETICS, V106, P365; Matsunaga F, 2001, P NATL ACAD SCI USA, V98, P11152, DOI 10.1073/pnas.191387498; Neuwald AF, 1999, GENOME RES, V9, P27; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pisani FM, 1996, BIOCHEMISTRY-US, V35, P9158, DOI 10.1021/bi960446l; Pisani FM, 2000, J MOL BIOL, V301, P61, DOI 10.1006/jmbi.2000.3964; Poplawski A, 2001, J BIOL CHEM, V276, P49371, DOI 10.1074/jbc.M108519200; SEO YS, 1991, J BIOL CHEM, V266, P13161; SEO YS, 1993, J BIOL CHEM, V268, P10282; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shechter DF, 2000, J BIOL CHEM, V275, P15049, DOI 10.1074/jbc.M000398200; Sherman DA, 1998, NUCLEIC ACIDS RES, V26, P3955, DOI 10.1093/nar/26.17.3955; TAKAHASHI K, 1994, MOL BIOL CELL, V5, P1145, DOI 10.1091/mbc.5.10.1145; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; THOMMES P, 1992, J BIOL CHEM, V267, P6063; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; von Hippel PH, 2001, CELL, V104, P177, DOI 10.1016/S0092-8674(01)00203-3; Wadsworth RIM, 2001, NUCLEIC ACIDS RES, V29, P914, DOI 10.1093/nar/29.4.914; Woese CR, 2000, P NATL ACAD SCI USA, V97, P8392, DOI 10.1073/pnas.97.15.8392; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1987, P NATL ACAD SCI USA, V84, P3643, DOI 10.1073/pnas.84.11.3643; Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636; You ZY, 1999, MOL CELL BIOL, V19, P8003; ZHANG SS, 1992, FEBS LETT, V312, P143, DOI 10.1016/0014-5793(92)80922-4; Zou L, 1998, SCIENCE, V280, P593, DOI 10.1126/science.280.5363.593	53	72	77	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12118	12127		10.1074/jbc.M200091200	http://dx.doi.org/10.1074/jbc.M200091200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821426	hybrid			2022-12-25	WOS:000174846400068
J	Kosowska, K; Reinholdt, J; Rasmussen, LK; Sabat, A; Potempa, J; Kilian, M; Poulsen, K				Kosowska, K; Reinholdt, J; Rasmussen, LK; Sabat, A; Potempa, J; Kilian, M; Poulsen, K			The Clostridium ramosum IgA proteinase represents a novel type of metalloendopeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCI; IMMUNOGLOBULIN A1 PROTEASES; RAY CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; BACILLUS-THURINGIENSIS; ALLOTYPE PARAPROTEINS; MOLECULAR-STRUCTURE; ZINC-ENDOPEPTIDASE; SURFACE-PROTEINS; ALPHA-ANTIGEN	Clostridium ramosum is part of the normal flora in the human intestine. Some strains produce an IgA proteinase that specifically cleaves human IgA1 and the IgA2m(1) allotype. This prolylendopeptidase was purified from a broth culture supernatant, and N-terminal sequences of the native protein and tryptic fragments thereof were determined. A fragment of the iga gene encoding the IgA proteinase was isolated using degenerate primers in PCR, and the complete gene was obtained by inverse PCR. The identity of the iga gene was confirmed by heterologous expression in Escherichia coli. The deduced amino acid sequence indicated a signal peptide of 30 residues and a secreted proteinase of 133,828 Da. A typical Gram-positive cell wall anchor motif was identified in the C terminus. The presence of a putative zinc-binding motif His-Glu-Phe-Gly-His together with inhibition studies indicate that the proteinase belongs to the zinc-dependent metalloproteinases. However, the sequence of the C. ramosum IgA proteinase shows no overall similarity to other proteins except for significant identity around the zinc-binding motif with family M6 of metalloendopeptidases, and the unique sequence of the IgA proteinase in this area presumably establishes a new subfamily. The GC percentage of the iga gene is significantly higher than that for the entire genome of C. ramosum, suggesting that the gene was acquired recently in evolution.	Aarhus Univ, Dept Med Microbiol & Immunol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Oral Biol, DK-8000 Aarhus C, Denmark; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Jagiellonian Univ, Inst Mol Biol & Biotechnol, Dept Microbiol & Immunol, PL-30387 Krakow, Poland	Aarhus University; Aarhus University; Aarhus University; Jagiellonian University	Poulsen, K (corresponding author), Aarhus Univ, Dept Med Microbiol & Immunol, Bartholin Bldg, DK-8000 Aarhus C, Denmark.	kp@microbiology.au.dk		Kilian, Mogens/0000-0002-5861-0472				BARRETT AJ, 1998, HDB PROTEOLYTIC ENZY, P1130; Beck SC, 2000, FEBS LETT, V472, P287, DOI 10.1016/S0014-5793(00)01478-2; BERTHOLD H, 1992, BIOTECHNOL LETT, V14, P245, DOI 10.1007/BF01022318; BEVANGER L, 1983, ACTA PATH MICRO IM B, V91, P75; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Brandtzaeg P., 1999, MUCOSAL IMMUNOLOGY, P439; BROOK I, 1995, J MED MICROBIOL, V42, P78, DOI 10.1099/00222615-42-2-78; BURNE RA, 1987, J BACTERIOL, V169, P4507, DOI 10.1128/jb.169.10.4507-4517.1987; DALHAMMAR G, 1984, EUR J BIOCHEM, V139, P247, DOI 10.1111/j.1432-1033.1984.tb08000.x; FUJIYAMA Y, 1986, MOL IMMUNOL, V23, P147; FUJIYAMA Y, 1985, J IMMUNOL, V134, P573; GENTZ R, 1985, J BACTERIOL, V164, P70, DOI 10.1128/JB.164.1.70-77.1985; GILBERT JV, 1991, INFECT IMMUN, V59, P7, DOI 10.1128/IAI.59.1.7-17.1991; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; GOMISRUTH FX, 1994, J MOL BIOL, V239, P513, DOI 10.1006/jmbi.1994.1392; HASHIM OH, 1991, IMMUNOLOGY, V73, P235; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hellman U, 1997, SPRING LAB MAN, P97; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; JOHNSON JL, 1975, J GEN MICROBIOL, V88, P229, DOI 10.1099/00221287-88-2-229; Kilian M, 1996, APMIS, V104, P321, DOI 10.1111/j.1699-0463.1996.tb00724.x; Kirkeby L, 2000, CLIN DIAGN LAB IMMUN, V7, P31, DOI 10.1128/CDLI.7.1.31-39.2000; LEE SF, 1992, INFECT IMMUN, V60, P4032, DOI 10.1128/IAI.60.10.4032-4039.1992; Lin YD, 1997, IEEE NETWORK, V11, P24, DOI 10.1109/65.567565; LOVGREN A, 1990, MOL MICROBIOL, V4, P2137, DOI 10.1111/j.1365-2958.1990.tb00575.x; MAST AE, 1991, J BIOL CHEM, V266, P15810; Mestecky J., 1999, MUCOSAL IMMUNOLOGY, P133; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Nelson D, 1999, J BIOL CHEM, V274, P12245, DOI 10.1074/jbc.274.18.12245; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; PLAUT AG, 1983, ANNU REV MICROBIOL, V37, P603, DOI 10.1146/annurev.mi.37.100183.003131; Poulsen K, 1998, INFECT IMMUN, V66, P181, DOI 10.1128/IAI.66.1.181-190.1998; Poulsen K, 1996, INFECT IMMUN, V64, P3957, DOI 10.1128/IAI.64.10.3957-3966.1996; REINHOLDT J, 1990, INFECT IMMUN, V58, P1186, DOI 10.1128/IAI.58.5.1186-1194.1990; Reinholdt J, 1996, J IMMUNOL METHODS, V191, P39, DOI 10.1016/0022-1759(95)00286-3; Reinholdt J, 1997, INFECT IMMUN, V65, P4452, DOI 10.1128/IAI.65.11.4452-4459.1997; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SENDA S, 1985, MICROBIOL IMMUNOL, V29, P1019, DOI 10.1111/j.1348-0421.1985.tb00892.x; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; STARK PL, 1982, J PEDIATR-US, V100, P362, DOI 10.1016/S0022-3476(82)80430-7; STOCKER W, 1995, PROTEIN SCI, V4, P823; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; Wani JH, 1996, INFECT IMMUN, V64, P3967, DOI 10.1128/IAI.64.10.3967-3974.1996	47	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11987	11994		10.1074/jbc.M110883200	http://dx.doi.org/10.1074/jbc.M110883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815614	hybrid			2022-12-25	WOS:000174846400051
J	Sotomaru, Y; Katsuzawa, Y; Hatada, I; Obata, Y; Sasaki, H; Kono, T				Sotomaru, Y; Katsuzawa, Y; Hatada, I; Obata, Y; Sasaki, H; Kono, T			Unregulated expression of the imprinted genes H19 and Igf2r in mouse uniparental fetuses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRADER-WILLI-SYNDROME; METHYLATION; OOCYTES; LOCUS; CDNA; MECHANISMS; CANDIDATE; CHROMATIN; DELETION; PROTEIN	The present study shows that the H19 and Igf2r genes, which are imprinted and expressed solely from maternal alleles, are expressed in an unregulatable manner in mouse uniparental, androgenetic, and parthenogenetic fetuses at day 9.5 of gestation. In the androgenetic fetuses, the H19 and Igf2r genes were respectively expressed at 12 and 40% of the levels in biparental fetuses. In addition, the expression of both genes was excessive (1259 and 482%, respectively) in the parthenotes. These expressions of the imprinted genes were not regulated by methylation in the regulatory regions. Moreover, the expression of the antisense Igf2r RNA (Air) was also excessive and was not correlated with Igf2r gene expression in the uniparental fetuses. Taken together, these results indicate that the parental specific expression of imprinted genes is not maintained in particular genes in uniparental embryos, which in turn suggests that both parental genomes are required to establish maternal specific expression of the H19 and Igf2r genes by transacting mechanisms.	Tokyo Univ Agr, Dept Biosci, Setagaya Ku, Tokyo 1568502, Japan; Tokyo Univ Agr, Dept Anim Sci, Kanagawa 2430034, Japan; Gunma Univ, Ctr Gene Res, Gunma 3718511, Japan; Natl Inst Genet, Dept Integrated Genet, Div Human Genet, Shizuoka 4118540, Japan	Tokyo University of Agriculture; Tokyo University of Agriculture; Gunma University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Kono, T (corresponding author), Tokyo Univ Agr, Dept Biosci, Setagaya Ku, 1-1-1 Sakuragaoka, Tokyo 1568502, Japan.	tomohiro@nodai.ac.jp						BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Birger Y, 1999, NATURE, V397, P84, DOI 10.1038/16291; BOSMIKICH A, 1995, MOL REPROD DEV, V41, P84, DOI 10.1002/mrd.1080410113; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Brenton JD, 1999, P NATL ACAD SCI USA, V96, P9242, DOI 10.1073/pnas.96.16.9242; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; Feil R, 1997, AM J HUM GENET, V61, P1213, DOI 10.1086/301655; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hatada I, 2001, J BIOCHEM, V130, P187, DOI 10.1093/oxfordjournals.jbchem.a002971; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; KONO T, 1993, MOL REPROD DEV, V34, P43, DOI 10.1002/mrd.1080340107; Kuroiwa Y, 1996, NAT GENET, V12, P186, DOI 10.1038/ng0296-186; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; Lyle R, 2000, NAT GENET, V25, P19, DOI 10.1038/75546; Miyoshi N, 1998, P NATL ACAD SCI USA, V95, P1102, DOI 10.1073/pnas.95.3.1102; QUINN P, 1982, J REPROD FERTIL, V66, P161; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SADO T, 1993, DEV GROWTH DIFFER, V35, P551; Sasaki H, 1995, DEVELOPMENT, V121, P4195; Sasaki H., 1993, Experientia Supplementum (Basel), V64, P469; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Shemer R, 1996, P NATL ACAD SCI USA, V93, P6371, DOI 10.1073/pnas.93.13.6371; Sleutels F, 2000, CURR OPIN GENET DEV, V10, P229, DOI 10.1016/S0959-437X(00)00062-9; Sotomaru Y, 2001, J BIOL CHEM, V276, P26694, DOI 10.1074/jbc.M101367200; Sotomaru Yusuke, 2001, Journal of Reproduction and Development, V47, P139, DOI 10.1262/jrd.47.139; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; Tremblay KD, 1997, MOL CELL BIOL, V17, P4322, DOI 10.1128/MCB.17.8.4322; WALSH C, 1994, MECH DEVELOP, V46, P55, DOI 10.1016/0925-4773(94)90037-X; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7; Wittwer CT, 1997, BIOTECHNIQUES, V22, P176, DOI 10.2144/97221pf02; Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631; Yang T, 1998, NAT GENET, V19, P25, DOI 10.1038/ng0598-25	39	41	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12474	12478		10.1074/jbc.M109212200	http://dx.doi.org/10.1074/jbc.M109212200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805093	hybrid			2022-12-25	WOS:000174846400114
J	Uversky, VN; Li, J; Souillac, P; Millett, IS; Doniach, S; Jakes, R; Goedert, M; Fink, AL				Uversky, VN; Li, J; Souillac, P; Millett, IS; Doniach, S; Jakes, R; Goedert, M; Fink, AL			Biophysical properties of the synucleins and their propensities to fibrillate - Inhibition of alpha-synuclein assembly by beta- and gamma-synucleins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEWY BODY DEMENTIA; X-RAY-SCATTERING; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; MOLTEN GLOBULE; IN-VITRO; NEURODEGENERATIVE DISORDERS; INFRARED-SPECTROSCOPY; FIBER DIFFRACTION; AMYLOID FIBRILS	The pathological hallmark of Parkinson's disease is the presence of intracellular inclusions, Lewy bodies, and Lewy neurites, in the dopaminergic neurons of the substantia nigra and several other brain regions. Fila. mentous a-synuclein is the major component of these deposits and its aggregation is believed to play an important role in Parkinson's disease and several other neurodegenerative diseases. Two homologous proteins, beta- and gamma-synucleins, are also abundant in the brain. The synucleins are natively unfolded proteins. beta-Synuclein, which lacks 11 central hydrophobic residues compared with its homologs, exhibited the properties of a random coil, whereas alpha- and gamma-synucleins were slightly more compact and structured. gamma-Synuclein, unlike its homologs, formed a soluble oligomer at relatively low concentrations, which appears to be an off-fibrillation pathway species. Here we show that, although they have similar biophysical properties to alpha-synuclein, beta- And gamma-synucleins inhibit a-synuclein fibril formation. Complete inhibition of a-synuclein fibrillation was observed at 4:1 molar excess of beta- and gamma-synucleins. No significant incorporation of beta-synuclein into the fibrils was detected. The lack of fibrils formed by beta-synuclein is most readily explained by the absence of a stretch of hydrophobic residues from the middle region of the protein. A model for the inhibition is proposed.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142292, Moscow Region, Russia; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of California System; University of California Santa Cruz; Russian Academy of Sciences; Stanford University; Stanford University; MRC Laboratory Molecular Biology	Uversky, VN (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.		Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Ackers G K, 1970, Adv Protein Chem, V24, P343, DOI 10.1016/S0065-3233(08)60245-4; Arawaka S, 1998, NEUROLOGY, V51, P887, DOI 10.1212/WNL.51.3.887; Baba M, 1998, AM J PATHOL, V152, P879; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Buchman VL, 1998, J NEUROSCI, V18, P9335; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; CORBETT RJT, 1984, BIOCHEMISTRY-US, V23, P1888, DOI 10.1021/bi00303a047; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; DAMASCHUN G, 1991, BIOCHIM BIOPHYS ACTA, V1078, P289, DOI 10.1016/0167-4838(91)90571-G; Doniach S, 2001, CHEM REV, V101, P1763, DOI 10.1021/cr990071k; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Glatter O., 1982, SMALL ANGLE X RAY SC; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goormaghtigh E, 1999, BBA-REV BIOMEMBRANES, V1422, P105, DOI 10.1016/S0304-4157(99)00004-0; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V237, P611, DOI 10.1006/bbrc.1997.6978; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Iseki E, 1998, NEUROSCI LETT, V258, P81, DOI 10.1016/S0304-3940(98)00856-8; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Ji HJ, 1997, CANCER RES, V57, P759; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lewy F.H., 2017, HDB NEUROLOGIE, V3, P920; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1990, LAB INVEST, V62, P768; Nakajo S, 1996, BRAIN RES, V741, P180, DOI 10.1016/S0006-8993(96)00914-6; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Ninkina NN, 1999, EXP CELL RES, V246, P308, DOI 10.1006/excr.1998.4292; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; OBERG K, 1994, BIOCHEMISTRY-US, V33, P2628, DOI 10.1021/bi00175a035; Oberg KA, 1998, ANAL BIOCHEM, V256, P92, DOI 10.1006/abio.1997.2486; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Takeda A, 1998, AM J PATHOL, V152, P367; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; TOBE T, 1992, J NEUROCHEM, V59, P1624, DOI 10.1111/j.1471-4159.1992.tb10991.x; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Tsuruta H, 1998, J APPL CRYSTALLOGR, V31, P672, DOI 10.1107/S0021889898002702; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; UVERSKY VN, 1994, BIOCHEMISTRY-US, V33, P2782, DOI 10.1021/bi00176a006; Uversky VN, 1998, P NATL ACAD SCI USA, V95, P5480, DOI 10.1073/pnas.95.10.5480; Uversky VN, 1999, PROTEIN SCI, V8, P161; Uversky VN, 1996, J MOL BIOL, V255, P215, DOI 10.1006/jmbi.1996.0018; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Uversky VN, 1994, INT J BIOCHROMATOGR, P103; WAKATSUKI S, 1992, REV SCI INSTRUM, V63, P1736, DOI 10.1063/1.1143332; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	71	364	379	1	58	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11970	11978		10.1074/jbc.M109541200	http://dx.doi.org/10.1074/jbc.M109541200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812782	hybrid			2022-12-25	WOS:000174846400049
J	Wang, S; Hankinson, O				Wang, S; Hankinson, O			Functional involvement of the Brahma/SW12-related gene 1 protein in cytochrome P4501A1 transcription mediated by the aryl hydrocarbon receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN-REMODELING COMPLEX; DNA-BINDING FORM; AH RECEPTOR; HISTONE ACETYLTRANSFERASE; GLUCOCORTICOID RECEPTOR; SWI/SNF COMPLEX; SWI-SNF; ORDERED RECRUITMENT; CELL-CYCLE; IN-VIVO	Chromatin remodeling is a key step in overcoming the nucleosomal repression of active transcription in eukaryotes. The mammalian SWI/SNF ATP-dependent chromatin-remodeling complexes contain multiple subunits. The ATPase activities in these complexes are attributable to either BRG-1 or the related Brahma protein. The aryl hydrocarbon receptor (AHR), after binding xenobiotic ligands such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), associates with the AHR nuclear translocator (ARNT), and the dimer so formed activates transcription of several genes, including the cytochrome P4501A1 (CYP1A1) gene. We show that BRG-1 potentiates AHR/ARNT-mediated reporter gene activity in a TCDD-dependent fashion in Hepa1c1c7 cells. Introduction of BRG-1 into the BRG-1- and hBrm-deficient SW13 and C33A human cell lines also enhances expression from a transiently transfected AHR/ARNT-dependent reporter gene. Replenishment of BRG-1 to SW13 cells also restores endogenous cytochrome P4501A1 (CYP1A1) gene expression, whereas an ATPase-deficient mutant of BRG-1 is unable to do so. Chromatin immuno-precipitation analysis demonstrated that BRG-1 associates with the enhancer region of the mouse CYP1A1 gene in vivo in a TCDD- and ARNT-dependent fashion, suggesting the specific recruitment of BRG-1 by AHR/ ARNT. Finally, we demonstrate that the glutamine-rich subdomain of the transcriptional activation domain of AHR can interact with BRG-1. Together these studies reveal a functional involvement of BRG-1 in activating CYP1A1 gene transcription and implicate the importance of ATP-dependent chromatin remodeling activity on inducible gene expression mediated by AHR/ARNT.	Univ Calif Los Angeles, Dept Pathol & Lab Med, Hlth Sci Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Hankinson, O (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, Hlth Sci Ctr, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA28868, R01 CA028868] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Andreola F, 1997, CANCER RES, V57, P2835; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Carver LA, 1997, J BIOL CHEM, V272, P11452; Chang CY, 1998, MOL CELL BIOL, V18, P525, DOI 10.1128/MCB.18.1.525; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; De la Serna IL, 2000, MOL CELL BIOL, V20, P2839, DOI 10.1128/MCB.20.8.2839-2851.2000; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P31845; Gao L, 2001, ARCH BIOCHEM BIOPHYS, V392, P270, DOI 10.1006/abbi.2001.2440; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1985, J BIOL CHEM, V260, P1790; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; Kumar MB, 1999, GENE EXPRESSION, V8, P273; Kumar MB, 1999, J BIOL CHEM, V274, P22155, DOI 10.1074/jbc.274.32.22155; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Ma Q, 1997, J BIOL CHEM, V272, P8878; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MATSUSHITA N, 1993, J BIOL CHEM, V268, P21002; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; MORGAN JE, 1992, P NATL ACAD SCI USA, V89, P11622, DOI 10.1073/pnas.89.23.11622; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKINO ST, 1995, MOL CELL BIOL, V15, P3714; PERDEW GH, 1988, J BIOL CHEM, V263, P13802; POLLENZ RS, 1994, MOL PHARMACOL, V45, P428; REYES H, 1992, SCIENCE, V256, P1193, DOI 10.1126/science.256.5060.1193; Rowlands JC, 1996, MOL PHARMACOL, V50, P538; Santiago-Josefat B, 2001, MOL CELL BIOL, V21, P1700, DOI 10.1128/MCB.21.5.1700-1709.2001; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Sudarsanam P, 2000, P NATL ACAD SCI USA, V97, P3364, DOI 10.1073/pnas.050407197; Sudarsanam P, 1999, EMBO J, V18, P3101, DOI 10.1093/emboj/18.11.3101; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Whitehouse I, 1999, NATURE, V400, P784, DOI 10.1038/23506; Whitlock JP, 1999, ANNU REV PHARMACOL, V39, P103, DOI 10.1146/annurev.pharmtox.39.1.103; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	52	77	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11821	11827		10.1074/jbc.M110122200	http://dx.doi.org/10.1074/jbc.M110122200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805098	hybrid			2022-12-25	WOS:000174846400029
J	Heegaard, NHH; Roepstorff, P; Melberg, SG; Nissen, MH				Heegaard, NHH; Roepstorff, P; Melberg, SG; Nissen, MH			Cleaved beta(2)-microglobulin partially attains a conformation that has amyloidogenic features	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; DIALYSIS-RELATED AMYLOIDOSIS; MODIFIED BETA-2-MICROGLOBULIN; CAPILLARY-ELECTROPHORESIS; CHRONIC-HEMODIALYSIS; P COMPONENT; CONGO RED; IN-VITRO; PROTEIN; GLYCOSAMINOGLYCAN	beta(2)-Microglobulin, a small protein localized in serum and on cell surfaces, can adopt specific aggregating conformations that generate amyloid in tissues and joints as a complication to long-term hemodialysis. We characterize a proteolytic variant of beta(2)-microglobulin (cleaved after Lys(58)) that as a trimmed form (Lys(58) is removed) can be demonstrated in the circulation in patients with chronic disease. An unexpected electrophoretic heterogeneity of these two cleaved variants was demonstrated by capillary electrophoresis under physiological conditions. Each separated into a fast and a slow component while appearing homogeneous, except for a fraction of oxidized species detected by other techniques. The two components had different binding affinities for heparin and for the amyloid-specific dye Congo red, and the equilibrium between the two forms was dependent on solvent conditions. Together with analysis of the differences in circular dichroism, the results suggest that beta(2)-microglobulin cleaved after Lys(58) readily adopts two equilibrium conformations under native conditions. In the cleaved and trimmed beta(2)-microglobulin that appears in vivo, the less populated conformation is characterized by an increased affinity for Congo red. These observations may help elucidate why beta(2)-microglobulin polymerizes as amyloid in chronic hemodialysis and facilitate the search for means to inhibit this process.	Statens Serum Inst, Dept Autoimmunol, DK-2300 Copenhagen S, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Univ Copenhagen, Inst Med Anat, DK-2200 Copenhagen N, Denmark	Statens Serum Institut; University of Southern Denmark; Novo Nordisk; University of Copenhagen	Heegaard, NHH (corresponding author), Statens Serum Inst, Dept Autoimmunol, Artillerivej 5,Bldg 81,Rm 536, DK-2300 Copenhagen S, Denmark.	nhe@ssi.dk	Nissen, Mogens/B-4825-2008	Nissen, Mogens/0000-0001-7729-8667				BECKER JW, 1985, P NATL ACAD SCI USA, V82, P4225, DOI 10.1073/pnas.82.12.4225; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Blake C, 1996, STRUCTURE, V4, P989, DOI 10.1016/S0969-2126(96)00104-9; Campistol JM, 1996, KIDNEY INT, V50, P1262, DOI 10.1038/ki.1996.436; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Chiti F, 2001, J MOL BIOL, V307, P379, DOI 10.1006/jmbi.2000.4478; CUNNINGHAM BA, 1973, BIOCHEMISTRY-US, V12, P4811, DOI 10.1021/bi00748a001; Drueke TB, 1998, NEPHROL DIAL TRANSPL, V13, P58, DOI 10.1093/ndt/13.suppl_1.58; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GEJYO F, 1986, NEW ENGL J MED, V314, P585; GOREVIC PD, 1986, P NATL ACAD SCI USA, V83, P7908, DOI 10.1073/pnas.83.20.7908; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; Heegaard NHH, 2001, J BIOL CHEM, V276, P32657, DOI 10.1074/jbc.M104452200; Heegaard NHH, 2000, J CHROMATOGR A, V894, P319, DOI 10.1016/S0021-9673(00)00579-3; HEEGAARD NHH, 2001, PROTEIN LIGAND INTER; Jadoul M, 1997, KIDNEY INT, V51, P1928, DOI 10.1038/ki.1997.262; Kelly SM, 1997, BBA-PROTEIN STRUCT M, V1338, P161, DOI 10.1016/S0167-4838(96)00190-2; KISILEVSKY R, 1988, MED HYPOTHESES, V26, P231, DOI 10.1016/0306-9877(88)90125-9; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Kussmann M, 1997, J MASS SPECTROM, V32, P593; LEVEUGLE B, 1994, NEUROREPORT, V5, P1389, DOI 10.1097/00001756-199406000-00025; LINKE RP, 1989, KIDNEY INT, V36, P675, DOI 10.1038/ki.1989.245; LINKE RP, 1986, BIOCHEM BIOPH RES CO, V136, P665, DOI 10.1016/0006-291X(86)90492-4; LYON AW, 1993, J RHEUMATOL, V20, P1108; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Miyata T, 1996, P NATL ACAD SCI USA, V93, P2353, DOI 10.1073/pnas.93.6.2353; MOMOI T, 1995, CLIN CHIM ACTA, V236, P135, DOI 10.1016/0009-8981(95)06039-G; NISSEN MH, 1987, EUR J BIOCHEM, V163, P21, DOI 10.1111/j.1432-1033.1987.tb10731.x; NISSEN MH, 1990, EUR J BIOCHEM, V189, P423, DOI 10.1111/j.1432-1033.1990.tb15505.x; Nissen MH, 1997, J IMMUNOL METHODS, V205, P29; ODANI H, 1990, BIOCHEM BIOPH RES CO, V168, P1223, DOI 10.1016/0006-291X(90)91159-P; Ohashi K, 1997, VIRCHOWS ARCH, V430, P479, DOI 10.1007/s004280050058; OKON M, 1992, BIOCHEMISTRY-US, V31, P8906, DOI 10.1021/bi00152a030; ONO K, 1994, NEPHRON, V66, P404, DOI 10.1159/000187854; OZASA H, 1989, NEPHRON, V53, P87, DOI 10.1159/000185712; PLESNER T, 1979, SCAND J IMMUNOL, V9, P247, DOI 10.1111/j.1365-3083.1979.tb02728.x; SHIMURA K, 1995, ANAL BIOCHEM, V227, P186, DOI 10.1006/abio.1995.1269; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SKINNER M, 1988, METHOD ENZYMOL, V163, P523; SNOW AD, 1987, LAB INVEST, V57, P687; Watson DJ, 1997, J BIOL CHEM, V272, P31617, DOI 10.1074/jbc.272.50.31617; Westermark P, 1999, AMYLOID, V6, P151, DOI 10.3109/13506129909007319	42	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11184	11189		10.1074/jbc.M108837200	http://dx.doi.org/10.1074/jbc.M108837200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801591	hybrid			2022-12-25	WOS:000174613100056
J	Kriajevska, M; Fischer-Larsen, M; Moertz, E; Vorm, O; Tulchinsky, E; Grigorian, M; Ambartsumian, N; Lukanidin, E				Kriajevska, M; Fischer-Larsen, M; Moertz, E; Vorm, O; Tulchinsky, E; Grigorian, M; Ambartsumian, N; Lukanidin, E			Liprin beta 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; HUMAN BREAST-CANCER; NONMUSCLE MYOSIN; HEAVY-CHAIN; CELL-LINE; IN-VITRO; EXPRESSION; GENE; P9KA; RECEPTOR	Metastasis-associated protein S100A4 (Mts1) induces invasiveness of primary tumors and promotes metastasis. S100A4 belongs to the family of small calcium-binding 5100 proteins that are involved in different cellular processes as transducers of calcium signal. S100A4 modulates properties of tumor cells via interaction with its intracellular targets, heavy chain of non-muscle myosin and p53. Here we report identification of a new molecular target of the S100A4 protein, liprin beta1. Liprin beta1 belongs to the family of leukocyte common antigen-related (LAR) transmembrane tyrosine phosphatase-interacting proteins that may regulate LAR protein properties via interaction with another member of the family, liprin alpha1. We showed by the immunoprecipitation analysis that S100A4 interacts specifically with liprin beta1 in vivo. Immunofluorescence staining demonstrated the co-localization of S100A4 and liprin beta1 in the cytoplasm and particularly at the protrusion sites of the plasma membrane. We mapped the S100A4 binding site at the C terminus of the liprin beta1 molecule between amino acid residues 938 and 1005. The S100A4-binding region contains two putative phosphorylation sites by protein kinase C and protein kinase CK2. S100A4-liprin beta1 interaction resulted in the inhibition of liprin beta1 phosphorylation by both kinases in vitro.	Danish Canc Soc, Inst Canc Biol, Dept Mol Canc Biol, DK-2100 Copenhagen O, Denmark; Protana AS, DK-5230 Odense, Denmark	Danish Cancer Society	Kriajevska, M (corresponding author), Danish Canc Soc, Inst Canc Biol, Dept Mol Canc Biol, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark.		Tulchinsky, Eugene/ABD-7070-2021	Mortz, Ejvind/0000-0002-4381-1546				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Behrendt N, 2000, J BIOL CHEM, V275, P1993, DOI 10.1074/jbc.275.3.1993; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies MPA, 1996, ONCOGENE, V13, P1631; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FODSTAD O, 1986, INT J CANCER, V38, P33, DOI 10.1002/ijc.2910380107; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; GRIGORIAN MS, 1993, GENE, V135, P229, DOI 10.1016/0378-1119(93)90070-J; Ke YQ, 1997, INT J CANCER, V71, P832, DOI 10.1002/(SICI)1097-0215(19970529)71:5<832::AID-IJC22>3.0.CO;2-8; Kimura K, 2000, INT J ONCOL, V16, P1125; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; KRIAJEVSKA MV, 1994, J BIOL CHEM, V269, P19679; Krueger NX, 1996, CELL, V84, P611, DOI 10.1016/S0092-8674(00)81036-3; Maelandsmo GM, 1996, CANCER RES, V56, P5490; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; Novitskaya V, 2000, J BIOL CHEM, V275, P41278, DOI 10.1074/jbc.M007058200; O'Grady P, 1998, J CELL BIOL, V141, P1675, DOI 10.1083/jcb.141.7.1675; PEDROCCHI M, 1994, INT J CANCER, V57, P684, DOI 10.1002/ijc.2910570513; Rudland PS, 2000, CANCER RES, V60, P1595; Schaapveld RQJ, 1997, DEV BIOL, V188, P134, DOI 10.1006/dbio.1997.8630; SENIN VM, 1984, VESTNIK USSR ACAD ME, V5, P85; Serra-Pages C, 1998, J BIOL CHEM, V273, P15611, DOI 10.1074/jbc.273.25.15611; SERRAPAGES C, 1995, EMBO J, V14, P2827, DOI 10.1002/j.1460-2075.1995.tb07282.x; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; TAKENAGA K, 1994, J CELL BIOL, V124, P757, DOI 10.1083/jcb.124.5.757; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Tarabykina S, 2000, FEBS LETT, V475, P187, DOI 10.1016/S0014-5793(00)01652-5; Tarabykina S, 2001, J BIOL CHEM, V276, P24212, DOI 10.1074/jbc.M009477200; Terszowski G, 2001, EUR J IMMUNOL, V31, P832, DOI 10.1002/1521-4141(200103)31:3<832::AID-IMMU832>3.0.CO;2-D; Tsujikawa K, 2001, MOL ENDOCRINOL, V15, P271, DOI 10.1210/me.15.2.271; Uozumi M, 2000, CANCER LETT, V149, P135, DOI 10.1016/S0304-3835(99)00352-3; Wang GZ, 2000, J BIOL CHEM, V275, P11141, DOI 10.1074/jbc.275.15.11141; WATANABE Y, 1992, J BIOL CHEM, V267, P17136; Weng LP, 1999, GENES CELLS, V4, P185, DOI 10.1046/j.1365-2443.1999.00251.x; Yang T, 1999, MOL CARCINOGEN, V25, P139, DOI 10.1002/(SICI)1098-2744(199906)25:2<139::AID-MC9>3.3.CO;2-K; Zabolotny JM, 2001, P NATL ACAD SCI USA, V98, P5187, DOI 10.1073/pnas.071050398; Zhen M, 1999, NATURE, V401, P371, DOI 10.1038/43886	47	108	119	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					5229	5235		10.1074/jbc.M110976200	http://dx.doi.org/10.1074/jbc.M110976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11836260	hybrid			2022-12-25	WOS:000173962900088
J	Li, XW; Liu, L; Tupper, JC; Bannerman, DD; Winn, RK; Sebti, SM; Hamilton, AD; Harlan, JM				Li, XW; Liu, L; Tupper, JC; Bannerman, DD; Winn, RK; Sebti, SM; Hamilton, AD; Harlan, JM			Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; CYTOTOXIC NECROTIZING FACTOR-1; SIGNAL-TRANSDUCTION PATHWAY; TUMOR-NECROSIS-FACTOR; RHO-ASSOCIATED KINASE; ACTIN CYTOSKELETON; BCL-2 EXPRESSION; EPITHELIAL-CELLS; GROWTH-FACTOR; KAPPA-B	Geranylgeranylation of RhoA small G-protein is essential for its localization to cell membranes and for its biological functions. Many RhoA effects are mediated by its downstream effector RhoA kinase. The role of protein geranylgeranylation and the RhoA pathway in the regulation of endothelial cell survival has not been elucidated. The hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitor lovastatin depletes cellular pools of geranylgeranyl pyrophosphate and farnesol pyrophosphate and thereby inhibits both geranylgeranylation and farnesylation. Human umbilical vein endothelial cells (HUVECs) were exposed to lovastatin (3 muM-30 muM) for 48 h, and cell death was quantitatively determined by cytoplasmic histone-associated DNA fragments as well as caspase-3 activity. The assays showed that lovastatin caused a dose-dependent endothelial cell death. The addition of geranylgeraniol, which restores geranylgeranylation, rescued HUVEC from apoptosis. The geranylgeranyltransferase inhibitor GGTI-298, but not the farnesyltransferase inhibitor FTI-277, induced apoptosis in HUVEC. Cell death was also induced by a blockade of RhoA function by exoenzyme C3. In addition, treatment of HUVEC with the RhoA kinase inhibitors Y-27632 and HA-1077 caused dose-dependent cell death. Y-27632 did not inhibit other well known survival pathways, such as NF-kappaB, ERK, and phosphatidylinositol 3-kinase/Akt. However, there was an increase in p53 protein level concomitant with Y-27632-induced cell death. Unlike the apoptosis induced by TNF-alpha, which occurs only with inhibition of new protein synthesis, apoptosis induced by inhibitors of HMG-CoA reductase, geranylgeranyltransferase, or RhoA kinase was blocked by cycloheximide. Our data indicate that inhibition of protein geranylgeranylation and RhoA pathways induce apoptosis in HUVEC and that induction of p53 or other proapoptotic proteins is required for this process.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; State University System of Florida; University of South Florida; Yale University	Harlan, JM (corresponding author), Univ Washington, Harborview Med Ctr, Div Hematol, Box 359756, Seattle, WA 98104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 03174, HL 18645] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKTORIES K, 1994, MOL CELL BIOCHEM, V138, P167, DOI 10.1007/BF00928459; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Baichwal V. R., 1997, CURR BIOL, V7, P94; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Boquet P, 1999, ANN NY ACAD SCI, V886, P83, DOI 10.1111/j.1749-6632.1999.tb09403.x; Carbajal JM, 2000, AM J PHYSIOL-CELL PH, V279, pC195; Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425; Cines DB, 1998, BLOOD, V91, P3527; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Esteve P, 1995, ONCOGENE, V11, P2657; FENTON RG, 1992, J CELL BIOL, V117, P347, DOI 10.1083/jcb.117.2.347; Fiorentini C, 1997, BIOCHEM BIOPH RES CO, V241, P341, DOI 10.1006/bbrc.1997.7723; Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057; Fiorentini C, 1998, CELL DEATH DIFFER, V5, P921, DOI 10.1038/sj.cdd.4400422; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GIRY M, 1995, INFECT IMMUN, V63, P4063, DOI 10.1128/IAI.63.10.4063-4071.1995; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; HORI Y, 1991, ONCOGENE, V6, P515; Iwamoto H, 2000, J HEPATOL, V32, P762, DOI 10.1016/S0168-8278(00)80245-7; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JIMENEZ B, 1995, ONCOGENE, V10, P811; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Koch G, 1997, J PHARMACOL EXP THER, V283, P901; Lassus P, 2000, ONCOGENE, V19, P2377, DOI 10.1038/sj.onc.1203553; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, J BIOL CHEM, V274, P33334, DOI 10.1074/jbc.274.47.33334; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; LOWY DR, 1989, NATURE, V341, P384, DOI 10.1038/341384a0; Miquel K, 1997, CANCER RES, V57, P1846; Nagumo H, 2000, AM J PHYSIOL-CELL PH, V278, pC57, DOI 10.1152/ajpcell.2000.278.1.C57; Pena LA, 2000, CANCER RES, V60, P321; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; POHLMAN TH, 1989, CELL IMMUNOL, V119, P41, DOI 10.1016/0008-8749(89)90222-0; Seasholtz TM, 1999, CIRC RES, V84, P1186, DOI 10.1161/01.RES.84.10.1186; Sebbagh M, 2001, NAT CELL BIOL, V3, P346, DOI 10.1038/35070019; Shibata R, 2001, CIRCULATION, V103, P284; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; Sinnett-Smith J, 2001, EXP CELL RES, V266, P292, DOI 10.1006/excr.2001.5219; Stark WW, 1998, AM J PHYSIOL-LUNG C, V275, pL55, DOI 10.1152/ajplung.1998.275.1.L55; Stempien-Otero A, 1999, J BIOL CHEM, V274, P8039, DOI 10.1074/jbc.274.12.8039; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; Sward K, 2000, J PHYSIOL-LONDON, V522, P33, DOI 10.1111/j.1469-7793.2000.0033m.x; Tanaka T, 2000, J NEUROSCI, V20, P2852; Uchida S, 2000, BIOCHEM BIOPH RES CO, V269, P633, DOI 10.1006/bbrc.2000.2315; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vogt A, 1996, ONCOGENE, V13, P1991; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325	59	158	166	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15309	15316		10.1074/jbc.M201253200	http://dx.doi.org/10.1074/jbc.M201253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839765	hybrid			2022-12-25	WOS:000175510400014
J	Song, J; Kwon, O; Chen, SL; Daruwala, R; Eck, P; Park, JB; Levine, M				Song, J; Kwon, O; Chen, SL; Daruwala, R; Eck, P; Park, JB; Levine, M			Flavonoid inhibition of sodium-dependent vitamin C transporter 1 (SVCT1) and glucose transporter isoform 2 (GLUT2), intestinal transporters for vitamin C and glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ASCORBIC-ACID; BRUSH-BORDER MEMBRANE; DEHYDROASCORBIC ACID; DNA-DAMAGE; QUERCETIN; ACCUMULATION; ABSORPTION; FAMILY; SUPPLEMENTATION; METABOLISM	Vitamin C and flavonoids, polyphenols with uncertain function, are abundant in fruits and vegetables. We postulated that flavonoids have a novel regulatory action of delaying or inhibiting absorption of vitamin C and glucose, which are structurally similar. From six structural classes of flavonoids, at least 12 compounds were chosen for studies. We investigated the effects of selected flavonoids on the intestinal vitamin C transporter SVCT1(h) by transfecting and overexpressing SVCT1(h) in Chinese hamster ovary cells. Flavonoids reversibly inhibited vitamin C transport in transfected cells with IC50 values of 10-50 muM, concentrations expected to have physiologic consequences. The most potent inhibitor class was flavonols, of which quercetin is most abundant in foods. Because Chinese hamster ovary cells have endogenous vitamin C transport, we expressed SVCT1(h) in Xenopus laevis oocytes to study the mechanism of transport inhibition. Quercetin was a reversible and non-competitive inhibitor of ascorbate transport; K-i 17.8 muM. Quercetin was a potent non-competitive inhibitor of GLUT2 expressed in Xenopus oocytes; K-i 22.8 muM. When diabetic rats were administered glucose with quercetin, hyperglycemia was significantly decreased compared with administration of glucose alone. Quercetin also significantly decreased ascorbate absorption in normal rats given ascorbate plus quercetin compared with rats given ascorbate alone. Quercetin was a specific transport inhibitor, because it did not inhibit intestinal sugar transporters GLUT5 and SGLT1 that were injected and expressed in Xenopus oocytes. Quercetin inhibited but was not transported by SVCT1(h). Considered together, these data show that flavonoids modulate vitamin C and glucose transport by their respective intestinal transporters and suggest a new function for flavonoids.	NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bethesda, MD 20892 USA; USDA, Phytonutrients Lab, Beltsville Human Nutr Res Ctr, Beltsville, MD 20705 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); United States Department of Agriculture (USDA)	Levine, M (corresponding author), NIDDK, Mol & Clin Nutr Sect, Digest Dis Branch, NIH, Bldg 10,Rm 4D52,MSC 1372, Bethesda, MD 20892 USA.	MarkL@intra.niddk.nih.gov	Chen, Shenglin/B-4049-2010	Eck, Peter/0000-0003-2371-9774				Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Brown JE, 1998, BIOCHEM J, V330, P1173; Brun JF, 2000, DIABETES METAB, V26, P337; BUSH MJ, 1987, RES COMMUN CHEM PATH, V57, P137; Conquer JA, 1998, J NUTR, V128, P593, DOI 10.1093/jn/128.3.593; Correa P, 1998, ALIMENT PHARM THERAP, V12, P73, DOI 10.1111/j.1365-2036.1998.00006.x; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; Doege H, 2000, J BIOL CHEM, V275, P16275, DOI 10.1074/jbc.275.21.16275; Doege H, 2000, BIOCHEM J, V350, P771, DOI 10.1042/0264-6021:3500771; Emancipator K, 1999, AM J CLIN PATHOL, V112, P665; Food and Nutrition Board Institute of Medicine, 2000, DIET REF INT VIT C V, P95, DOI [10.17226/9810, DOI 10.17226/9810]; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GUGLER R, 1975, EUR J CLIN PHARMACOL, V9, P229, DOI 10.1007/BF00614022; Gutierrez M, 1998, J AM COLL NUTR, V17, P595, DOI 10.1080/07315724.1998.10718808; Hecht SS, 1997, P SOC EXP BIOL MED, V216, P181; HEDIGER MA, 1994, PHYSIOL REV, V74, P993, DOI 10.1152/physrev.1994.74.4.993; Helliwell PA, 2000, BIOCHEM J, V350, P163, DOI 10.1042/0264-6021:3500163; Helliwell PA, 2000, BIOCHEM J, V350, P149, DOI 10.1042/0264-6021:3500149; HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267; Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4; Ibberson M, 2000, J BIOL CHEM, V275, P4607, DOI 10.1074/jbc.275.7.4607; ILSI N Amer Tech Comm Food Components, 1999, CRIT REV FOOD SCI, V39, P203; Kellett GL, 2000, BIOCHEM J, V350, P155, DOI 10.1042/0264-6021:3500155; KIMMICH GA, 1978, MEMBRANE BIOCHEM, V1, P221, DOI 10.3109/09687687809063849; Kuo SM, 1997, CANCER LETT, V116, P131, DOI 10.1016/S0304-3835(97)00183-3; Lamson D W, 2000, Altern Med Rev, V5, P196; LEFEVRE PG, 1959, J BIOL CHEM, V234, P3022; Levine M, 1999, METHOD ENZYMOL, V299, P65; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; Lisinski I, 2001, BIOCHEM J, V358, P517, DOI 10.1042/0264-6021:3580517; Long LH, 2000, BIOCHEM BIOPH RES CO, V273, P50, DOI 10.1006/bbrc.2000.2895; Malo C, 2000, J NUTR, V130, P63; MANN GV, 1975, ANN NY ACAD SCI, V258, P243, DOI 10.1111/j.1749-6632.1975.tb29285.x; Mooradian AD, 1999, DRUGS, V57, P19, DOI 10.2165/00003495-199957010-00003; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; Noroozi M, 1998, AM J CLIN NUTR, V67, P1210, DOI 10.1093/ajcn/67.6.1210; Noteborn HPJM, 1997, CANCER LETT, V114, P175, DOI 10.1016/S0304-3835(97)04655-7; Oldreive C, 1998, CHEM RES TOXICOL, V11, P1574, DOI 10.1021/tx980163p; Olthof MR, 2000, J NUTR, V130, P1200, DOI 10.1093/jn/130.5.1200; Park E, 1999, INT J VITAM NUTR RES, V69, P396, DOI 10.1024/0300-9831.69.6.396; Park JB, 2000, J NUTR, V130, P1297, DOI 10.1093/jn/130.5.1297; Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509; Rumsey SC, 1997, J BIOL CHEM, V272, P18982, DOI 10.1074/jbc.272.30.18982; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S; Skaper SD, 1997, FREE RADICAL BIO MED, V22, P669, DOI 10.1016/S0891-5849(96)00383-8; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VERA JC, 1994, BLOOD, V84, P1628; Vera JC, 1996, J BIOL CHEM, V271, P8719, DOI 10.1074/jbc.271.15.8719; VERLANGIERI AJ, 1991, LIFE SCI, V48, P2275, DOI 10.1016/0024-3205(91)90343-A; Vermeer ITM, 1999, MUTAT RES-FUND MOL M, V428, P353, DOI 10.1016/S1383-5742(99)00061-7; Vinson JA, 1998, ADV EXP MED BIOL, V439, P151; Walle T, 2000, J NUTR, V130, P2658, DOI 10.1093/jn/130.11.2658; Wang YX, 2000, BIOCHEM BIOPH RES CO, V267, P488, DOI 10.1006/bbrc.1999.1929; WASHKO P, 1992, J BIOL CHEM, V267, P23568; WASHKO P, 1989, J BIOL CHEM, V264, P18996; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; Zeng LH, 1997, BIOCHEM CELL BIOL, V75, P717, DOI 10.1139/bcb-75-6-717	58	176	182	1	34	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15252	15260		10.1074/jbc.M110496200	http://dx.doi.org/10.1074/jbc.M110496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11834736	hybrid			2022-12-25	WOS:000175510400007
J	Tombline, G; Heinen, CD; Shim, KS; Fishel, R				Tombline, G; Heinen, CD; Shim, KS; Fishel, R			Biochemical characterization of the human RAD51 protein - III. - Modulation of DNA binding by adenosine nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RECA; SINGLE-STRANDED-DNA; C-TERMINAL DOMAIN; HOMOLOGOUS RECOMBINATION; NUCLEOPROTEIN FILAMENT; SUBUNIT INTERFACE; LIGHT-SCATTERING; SELF-ASSOCIATION; MAMMALIAN-CELLS; RESIDUES	Adenosine nucleotides affect the ability of RecA.single-stranded DNA (ssDNA) nucleoprotein filaments to cooperatively assume and maintain an extended structure that facilitates DNA pairing during recombination. Here we have determined that ADP and ATP/ATPgammaS affect the DNA binding and aggregation properties of the human RecA homolog human RAD51 protein (hRAD51). These studies have revealed significant differences between hRAD51 and RecA. In the presence of ATPgammaS, RecA forms a stable complex with ssDNA, while the hRAD51 ssDNA complex is destabilized. Conversely, in the presence of ADP and ATP, the RecA ssDNA complex is unstable, while the hRAD51 ssDNA complex is stabilized. We identified two hRAD51.ssDNA binding forms by gel shift analysis, which were distinct from a well defined RecA.ssDNA binding form. The available evidence suggests that a low molecular weight hRAD51.ssDNA binding form (hRAD51.ssDNA(low)) correlates with active ADP and ATP processing. A high molecular weight hRAD51.ssDNA aggregate (hRAD51.ssDNA(high)) appears to correlate with a form that fails to process ADP and ATP. Our data are consistent with the notion that hRAD51 is unable to appropriately coordinate ssDNA binding with adenosine nucleotide processing. These observations suggest that other factors may assist hRAD51 in order to mirror RecA recombinational function.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, BLSB933,233 S 10th St, Philadelphia, PA 19107 USA.				NCI NIH HHS [5-T32-CA09678, CA56542] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056542, T32CA009678] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aihara H, 1999, J MOL BIOL, V290, P495, DOI 10.1006/jmbi.1999.2904; Aihara H, 1997, J MOL BIOL, V274, P213, DOI 10.1006/jmbi.1997.1403; Baumann P, 1997, MUTAT RES-DNA REPAIR, V384, P65, DOI 10.1016/S0921-8777(97)00028-1; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BENIGHT AS, 1991, BIOCHIMIE, V73, P143, DOI 10.1016/0300-9084(91)90197-9; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BRENNER SL, 1990, J MOL BIOL, V216, P949, DOI 10.1016/S0022-2836(99)80013-8; BRENNER SL, 1988, J MOL BIOL, V204, P959, DOI 10.1016/0022-2836(88)90055-1; Brocchieri L, 1998, J MOL BIOL, V276, P249, DOI 10.1006/jmbi.1997.1527; BRYANT FR, 1985, J BIOL CHEM, V260, P1196; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COTTERILL SM, 1983, BIOCHEMISTRY-US, V22, P3525, DOI 10.1021/bi00283a034; De Zutter SK, 1999, J MOL BIOL, V293, P769, DOI 10.1006/jmbi.1999.3200; Ellouze C, 1997, BIOCHEMISTRY-US, V36, P13524, DOI 10.1021/bi971000n; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; Hortnagel K, 1999, J MOL BIOL, V286, P1097, DOI 10.1006/jmbi.1998.2515; Kelley JA, 1997, J BIOL CHEM, V272, P25778, DOI 10.1074/jbc.272.41.25778; KOBAYASHI N, 1987, BIOCHEMISTRY-US, V26, P6801, DOI 10.1021/bi00395a033; KONOLA JT, 1994, J MOL BIOL, V237, P20, DOI 10.1006/jmbi.1994.1206; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; KURAMITSU S, 1981, J BIOCHEM-TOKYO, V90, P1033, DOI 10.1093/oxfordjournals.jbchem.a133555; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; Masui R, 1998, BIOCHEMISTRY-US, V37, P14788, DOI 10.1021/bi981296c; MCENTEE K, 1981, J BIOL CHEM, V256, P8835; MENETSKI JP, 1985, J MOL BIOL, V181, P281, DOI 10.1016/0022-2836(85)90092-0; MIKAWA T, 1995, J MOL BIOL, V250, P471, DOI 10.1006/jmbi.1995.0391; MORRICAL SW, 1985, BIOCHEMISTRY-US, V24, P760, DOI 10.1021/bi00324a034; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Namsaraev EA, 1998, BIOCHEMISTRY-US, V37, P11932, DOI 10.1021/bi9810297; NGUYEN TT, 1993, J BIOL CHEM, V268, P3107; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; SKIBA MC, 1994, J BIOL CHEM, V269, P3823; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; TAKAHASHI M, 1989, J BIOL CHEM, V264, P288; Thacker J, 1999, BIOCHIMIE, V81, P77, DOI 10.1016/S0300-9084(99)80041-8; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tombline G, 2002, J BIOL CHEM, V277, P14426, DOI 10.1074/jbc.M109916200; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; TSANG SS, 1985, BIOCHEMISTRY-US, V24, P3226, DOI 10.1021/bi00334a023; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8850; Yu X, 2001, P NATL ACAD SCI USA, V98, P8419, DOI 10.1073/pnas.111005398	49	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14434	14442		10.1074/jbc.M109917200	http://dx.doi.org/10.1074/jbc.M109917200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839741	hybrid			2022-12-25	WOS:000175203000013
J	Vorachek-Warren, MK; Carty, SM; Lin, SH; Cotter, RJ; Raetz, CRH				Vorachek-Warren, MK; Carty, SM; Lin, SH; Cotter, RJ; Raetz, CRH			An Escherichia coli mutant lacking the cold shock-induced palmitoleoyltransferase of lipid A biosynthesis - Absence of unsaturated acyl chains and antibiotic hypersensitivity at 12 degrees C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE REQUIREMENT GENE; MEMBRANE-BOUND ENZYME; MULTICOPY SUPPRESSOR; MSBB GENE; PROTEIN; ACYLTRANSFERASE; HTRB; EXPRESSION; ACYLATION; BACTERIAL	An acyltransferase induced by cold shock in Escherichia coli, designated LpxP, incorporates a palmitoleoyl moiety into nascent lipid A in place of the secondary laurate chain normally added by LpxL(HtrB) (Carty, S. M., Sreekumar, K. R., and Raetz, C. R. H. (1999) J. Biol. Chem. 274, 9677-9685). To determine whether the palmitoleoyl residue alters the properties of the outer membrane and imparts physiological benefits at low growth temperatures, we constructed a chromosomal insertion mutation in lpxP, the structural gene for the transferase. Membranes from the lpxP mutant MKV11 grown at 12 degreesC lacked the cold-induced palmitoleoyltransferase present in membranes of cold-shocked wild type cells but retained normal levels of the constitutive lauroyltransferase encoded by lpxL. When examined by mass spectrometry, about two-thirds of the lipid A molecules isolated from wild type E. coli grown at 12 degreesC contained palmitoleate in place of laurate, whereas the lipid A of cold-adapted MKV11 contained only laurate in amounts comparable with those seen in wild type cells grown at 30 degreesC or above. To probe the integrity of the outer membrane, MKV11 and an isogenic wild type strain were grown at 30 or 12 degreesC and then tested for their susceptibility to antibiotics. MKV11 exhibited a 10-fold increase in sensitivity to rifampicin and vancomycin at 12 degreesC compared with wild type cells but showed identical resistance when grown at 30 degreesC. We suggest that the palmitoleoyltransferase may confer a selective advantage upon E. coli cells growing at lower temperatures by making the outer membrane a more effective barrier to harmful chemicals.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu			NIGMS NIH HHS [GM-51310, GM54882-01, GM08558] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, T32GM008558, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Brade H., 1999, ENDOTOXIN HLTH DIS; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; Carty SM, 1999, J BIOL CHEM, V274, P9677, DOI 10.1074/jbc.274.14.9677; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COLEMAN J, 1992, MOL GEN GENET, V232, P295, DOI 10.1007/BF00280009; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; CRONAN JE, 1987, ESCHERICHIA COLI SAL, V1, P474; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; HAMILTON CM, 1989, J BACTERIOL, V171, P4617, DOI 10.1128/jb.171.9.4617-4622.1989; JACKOWSKI S, 1994, J BIOL CHEM, V269, P2921; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; JONES PG, 1994, MOL MICROBIOL, V11, P811, DOI 10.1111/j.1365-2958.1994.tb00359.x; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; Morein S, 1996, J BIOL CHEM, V271, P6801, DOI 10.1074/jbc.271.12.6801; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Rock C O, 1981, Methods Enzymol, V72, P397; ROCK CO, 1982, J BIOL CHEM, V257, P10759; Sambrook J., 1989, MOL CLONING, pA1; SCHEIDELER MA, 1992, METHOD ENZYMOL, V209, P55; SINENSKY M, 1974, P NATL ACAD SCI USA, V71, P522, DOI 10.1073/pnas.71.2.522; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Sorensen PG, 1996, J BIOL CHEM, V271, P25898, DOI 10.1074/jbc.271.42.25898; SPENCER AK, 1978, J BIOL CHEM, V253, P5922; Thieringer HA, 1998, BIOESSAYS, V20, P49; Vaara M, 1999, ANTIMICROB AGENTS CH, V43, P1459, DOI 10.1128/AAC.43.6.1459; Vigh L, 1998, TRENDS BIOCHEM SCI, V23, P369, DOI 10.1016/S0968-0004(98)01279-1; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	48	67	73	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14186	14193		10.1074/jbc.M200408200	http://dx.doi.org/10.1074/jbc.M200408200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830594	hybrid			2022-12-25	WOS:000175096000108
J	Park, KJ; Choi, SH; Lee, SY; Hwang, SB; Lai, MMC				Park, KJ; Choi, SH; Lee, SY; Hwang, SB; Lai, MMC			Nonstructural 5A protein of hepatitis C virus modulates tumor necrosis factor alpha-stimulated nuclear factor kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED APOPTOSIS; CYTOPLASMIC DOMAIN; FACTOR RECEPTOR; TNF RECEPTOR-1; CELL-DEATH; HEPATOCELLULAR-CARCINOMA; RNA-POLYMERASE; NON-A; NS5A; KINASE	The hepatitis C virus nonstructural protein 5A (NS5A) is a multifunctional phosphoprotein that leads to pleiotropic responses, in part by regulating cell growth and cellular signaling pathways. Here we show that overexpression of NS5A inhibits tumor necrosis factor (TNF)a-induced nuclear factor kappaB (NF-kappaB) activation in HEK293 cells, as determined by luciferase reporter gene expression and by electrophoretic mobility shift assay. When overexpressed, NS5A cannot inhibit the recruitment of TNF receptor-associated factor 2 (TRAF2) and IkappaB kinase (IKK)beta into the TNF receptor 1-TNF receptor-associated death domain complex. In contrast, NS5A is a part of the TNF receptor I signaling complex. NF-kappaB activation by TNF receptor-associated death domain and TRAF2 was inhibited by NS5A, whereas MEKK1 and IKKbeta-dependent NF-kappaB activation was not affected, suggesting that NS5A may inhibit NF-kappaB activation signaled by TRAF2. Coimmunoprecipitation and colocalization of NS5A and TRAF2 expressed in vivo provide compelling evidence that NS5A directly interacts with TRAF2. This interaction was mapped to the middle one-third (amino acids 148-301) of NS5A and the TRAIT domain of TRAF2. Our findings suggest a possible molecular mechanism that could explain the ability of NS5A to negatively regulate TNF-alpha-induced NF-kappaB activation.	Hallym Univ, Hallym Acad Sci, Inst Environm & Life Sci, Chunchon 200702, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Univ So Calif, Sch Med, Howard Hughes Med Inst, Dept Mol Microbiol & Immunol, Los Angeles, CA 90033 USA	Hallym University; Ewha Womans University; Ewha Womans University; Howard Hughes Medical Institute; University of Southern California	Hwang, SB (corresponding author), Hallym Univ, Hallym Acad Sci, Inst Environm & Life Sci, 1 Ockcheon Dong, Chunchon 200702, South Korea.		Lai, Michael M. C./I-7001-2012					AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHO YG, 1993, MOL CELLS, V3, P195; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DIBISCEGLIE AM, 1994, J CLIN GASTROENTEROL, V19, P222, DOI 10.1097/00004836-199410000-00011; Domingo E, 1998, EMERG INFECT DIS, V4, P521, DOI 10.3201/eid0404.980402; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hirota M, 1999, VIROLOGY, V257, P130, DOI 10.1006/viro.1999.9658; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; HU HM, 1994, J BIOL CHEM, V269, P30069; Ide Y, 1997, GENE, V201, P151, DOI 10.1016/S0378-1119(97)00440-X; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; Kato N, 1997, J VIROL, V71, P8856, DOI 10.1128/JVI.71.11.8856-8859.1997; Kim BC, 1999, J BIOL CHEM, V274, P24372, DOI 10.1074/jbc.274.34.24372; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; Lee SY, 1996, P NATL ACAD SCI USA, V93, P9699, DOI 10.1073/pnas.93.18.9699; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MANABE S, 1994, VIROLOGY, V198, P636, DOI 10.1006/viro.1994.1075; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Neddermann P, 1997, BIOL CHEM, V378, P469; Nelson DR, 1998, ANTIVIR THER, V3, P25; Park KJ, 2001, VIRUS RES, V74, P89, DOI 10.1016/S0168-1702(00)00251-3; Park YC, 2000, CELL, V101, P777, DOI 10.1016/S0092-8674(00)80889-2; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; SHIMOTOHNO K, 1993, SEMIN VIROL, V4, P305, DOI 10.1006/smvy.1993.1027; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	59	56	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13122	13128		10.1074/jbc.M111599200	http://dx.doi.org/10.1074/jbc.M111599200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821416	hybrid			2022-12-25	WOS:000175036300081
J	Schwartz, JA; Zhong, L; Deighton-Collins, S; Zhao, CQ; Skafar, DF				Schwartz, JA; Zhong, L; Deighton-Collins, S; Zhao, CQ; Skafar, DF			Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; HORMONE-BINDING; AF2 RESIDUES; DOMAIN; LIGAND; PHOSPHORYLATION; TRANSCRIPTION; DETERMINANTS	The human estrogen receptor-alpha, a member of the nuclear receptor superfamily, is a ligand-regulated transcriptional modulator. Because comparatively little is known about the extreme carboxyl-terminal region of the estrogen receptor (F domain), we used secondary structure prediction to design mutations that delete the F domain (S554stop), disrupt a possible turn (G556L/ G557L), and alter a predicted helix (S559A/E562A, Q565P), and we evaluated the effects of these mutations on hormone binding and transcription activation in response to estradiol and the mixed agonist/antagonist 4-hydroxytamoxifen. Mutations that deleted the F domain (S554stop) or targeted the predicted helix (S559A/ E562A, Q565P) greatly reduced or eliminated the agonist activity of 4-hydroxytamoxifen. Deleting the F domain increased the affinity of the receptor for estradiol and decreased the antagonist activity of 4-hydroxytamoxifen. The Q565P mutant exhibited a non-cooperative hormone-binding mechanism, as well as an impaired response to estradiol and increased antagonist activity of 4-hydroxytamoxifen. Our results show that mutations in the F domain alter not only the response to estradiol, the affinity for hormone, and the interaction between receptor subunits but can uncouple the agonist and antagonist activities of 4-hydroxytamoxifen. These results suggest that the F domain modulates the activity of the estrogen receptor-alpha by multiple mechanisms.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA	Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Skafar, DF (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	dskafar@med.wayne.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER; NIDDK NIH HHS [1R01 DK 56934-01A1] Funding Source: Medline; NIEHS NIH HHS [ES 06639] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DELEAGE G, 1987, PROTEIN ENG, V1, P289, DOI 10.1093/protein/1.4.289; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Garnier J, 1996, METHOD ENZYMOL, V266, P540; HARPER ET, 1993, BIOCHEMISTRY-US, V32, P7605, DOI 10.1021/bi00081a001; Hill AV, 1910, J PHYSIOL-LONDON, V40, piv; INCE BA, 1995, ENDOCRINOLOGY, V136, P3194, DOI 10.1210/en.136.8.3194; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Nichols M, 1998, EMBO J, V17, P765, DOI 10.1093/emboj/17.3.765; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; NOTIDES AC, 1981, P NATL ACAD SCI-BIOL, V78, P4926, DOI 10.1073/pnas.78.8.4926; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; Peters GA, 1999, MOL ENDOCRINOL, V13, P286, DOI 10.1210/me.13.2.286; Potthoff SJ, 1996, MOL ENDOCRINOL, V10, P1095, DOI 10.1210/me.10.9.1095; PULLEN K, 1995, PROTEIN SCI, V4, P2478, DOI 10.1002/pro.5560041204; RAJAGOPAL P, 1994, BIOCHEMISTRY-US, V33, P15271, DOI 10.1021/bi00255a008; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwartz JA, 1998, J STEROID BIOCHEM, V67, P223, DOI 10.1016/S0960-0760(98)00117-4; Schwartz JA, 1997, J STEROID BIOCHEM, V62, P173, DOI 10.1016/S0960-0760(97)00028-9; SEALE JW, 1994, PROTEIN SCI, V3, P1741, DOI 10.1002/pro.5560031014; SEIELSTAD DA, 1995, BIOCHEMISTRY-US, V34, P12605, DOI 10.1021/bi00039a016; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Thapar R, 1996, BIOCHEMISTRY-US, V35, P11268, DOI 10.1021/bi960349s; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Weatherman RV, 2001, J BIOL CHEM, V276, P3827, DOI 10.1074/jbc.M005414200; WRENN CK, 1993, J BIOL CHEM, V268, P24089; WYMAN J, 1990, BINDING LINKAGE FUNC, P87; Yudt MR, 1999, BIOCHEMISTRY-US, V38, P14146, DOI 10.1021/bi9911132	35	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13202	13209		10.1074/jbc.M112215200	http://dx.doi.org/10.1074/jbc.M112215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823467	hybrid			2022-12-25	WOS:000175036300090
J	Chang, DY; Lu, AL				Chang, DY; Lu, AL			Functional interaction of MutY homolog with proliferating cell nuclear antigen in fission yeast, Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI MUTY; C-TERMINAL DOMAIN; ADENINE-DNA GLYCOSYLASE; BASE EXCISION-REPAIR; MISMATCH REPAIR; 8-HYDROXYGUANINE 7,8-DIHYDRO-8-OXOGUANINE; SUBSTRATE-SPECIFICITY; MUTAGENIC SUBSTRATE; CATALYTIC DOMAIN; SYNTHESIS PAST	The MutY homolog (MYH) is responsible for removing adenines misincorporated on a template DNA strand containing G or 7,8-dihydro-8-oxoguanine (8-oxoG) and thus preventing G:C to T:A mutations. Human MYH has been shown to interact physically with human proliferating cell nuclear antigen (hPCNA). Here, we report that a similar interaction between SpMYH and SpPCNA occurs in the fission yeast Schizosaccharomyces pombe. Binding of SpMYH to SpPCNA was not observed when phenylalanine 444 in the PCNA binding motif of SpMYH was replaced with alanine. The F444A mutant of SpMYH expressed in yeast cells had normal adenine glycosylase and DNA binding activities. However, expression of this mutant form of SpMYH in a SpMYHDelta cell could not reduce the mutation frequency of the cell to the normal level. Moreover, SpMYH interacted with hPCNA and SpPCNA interacted with hMYH but not with F518A/ F519A mutant hMYH containing mutations in its PCNA binding motif. Although the SpMYHDelta cells expressing hMYH had partially reduced mutation frequency, the F518A/F519A mutant hMYH could not reduce the mutation frequency of SpMYHDelta cells. Thus, the interaction between SpMYH and SpPCNA is important for SpMYH biological function in mutation avoidance.	Univ Maryland, Dept Biochem & Mol Biol, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, Sch Med, 108 N Greene St, Baltimore, MD 21201 USA.				NATIONAL CANCER INSTITUTE [R56CA078391, R01CA078391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035132] Funding Source: NIH RePORTER; NCI NIH HHS [CA/ES78391] Funding Source: Medline; NIGMS NIH HHS [GM35132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Chang DY, 2001, MOL GENET GENOMICS, V266, P336, DOI 10.1007/s004380100567; CHENG KC, 1992, J BIOL CHEM, V267, P166; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gogos A, 1996, BIOCHEMISTRY-US, V35, P16665, DOI 10.1021/bi960843w; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Li XH, 2000, J BIOL CHEM, V275, P8448, DOI 10.1074/jbc.275.12.8448; Li XH, 2000, NUCLEIC ACIDS RES, V28, P4593, DOI 10.1093/nar/28.23.4593; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, GENETICS, V118, P593; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Manuel RC, 1996, J BIOL CHEM, V271, P16218, DOI 10.1074/jbc.271.27.16218; Manuel RC, 1997, BIOCHEMISTRY-US, V36, P11140, DOI 10.1021/bi9709708; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1991, MUTAT RES, V254, P281, DOI 10.1016/0921-8777(91)90067-Y; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647	48	37	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11853	11858		10.1074/jbc.M111739200	http://dx.doi.org/10.1074/jbc.M111739200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805113	hybrid			2022-12-25	WOS:000174846400033
J	Daiber, A; Frein, D; Namgaladze, D; Ullrich, V				Daiber, A; Frein, D; Namgaladze, D; Ullrich, V			Oxidation and nitrosation in the nitrogen monoxide/superoxide system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; TYROSINE NITRATION; REDOX REGULATION; SIMULTANEOUS GENERATION; PEROXYNITRITE OXIDATION; ALCOHOL-DEHYDROGENASE; SUPEROXIDE; ZINC; (NO)-N-CENTER-DOT; NITROSYLATION	Based on the previous report of McCord and co-workers (Crow, J. P., Beckman, J. S., and McCord, J. M. (1995) Biochemistry 34, 3544-3552), the zinc dithiolate active site of alcohol dehydrogenase (ADH) has been studied as a target for cellular oxidants. In the nitrogen monoxide ((NO)-N-.)/superoxide (O-2(.-)) system, an equimolar generation of both radicals under peroxynitrite (PN) formation led to rapid inactivation of ADH activity, whereas hydrogen peroxide and (NO)-N-. alone reacted too slowly to be of physiological significance. 3-Morpholino sydnonimine inactivated the enzyme with an IC50 value of 250 nm; the corresponding values for PN, hydrogen peroxide, and (NO)-N-. were 500 nm, 50 muM, and 200 muM. When superoxide was generated at low fluxes by xanthine oxidase, it was quite effective in ADH inactivation (IC50 (XO) approximate to 1 milli-unit/ml). All inactivations were accompanied by zinc release and disulfide formation, although no strict correlation was observed. From the two zinc thiolate centers, only the zinc CYS(2)His center released the metal by oxidants. The zinc CYS4 center was also oxidized, but no second zinc atom could be found with 4-(2-pyridylazo)resorcinol (PAR) as a chelating agent except under denaturing conditions. Surprisingly, the oxidative actions of PN were abolished by a 2-3-fold excess of (NO)-N-. under generation of a nitrosating species, probably dinitrogen trioxide. We conclude that in cellular systems, low fluxes of (NO)-N-. and O-2(.-) generate peroxynitrite at levels 2 effective for zinc thiolate oxidations, facilitated by the nucleophilic nature of the complexed thiolate group. With an excess of (NO)-N-., the PN actions are blocked, which may explain the antioxidant properties of (NO)-N-. and the mechanism of cellular S-nitrosations.	Univ Konstanz, Fachbereich Biol, Math Naturwissenschaft Sekt, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fachbereich Biol, Math Naturwissenschaft Sekt, LS Ullrich Fach X-910 Sonnenbuhl, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de						Balon TW, 2001, MED SCI SPORT EXER, V33, P382, DOI 10.1097/00005768-200103000-00008; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Caulfield JL, 1998, J BIOL CHEM, V273, P12689, DOI 10.1074/jbc.273.21.12689; Crow JP, 2000, FREE RADICAL BIO MED, V28, P1487, DOI 10.1016/S0891-5849(00)00249-5; CROW JP, 1995, BIOCHEMISTRY-US, V34, P3544, DOI 10.1021/bi00011a008; Daiber A, 2000, EUR J BIOCHEM, V267, P6729, DOI 10.1046/j.1432-1033.2000.01768.x; Daiber A, 2000, J INORG BIOCHEM, V81, P213, DOI 10.1016/S0162-0134(00)00110-0; Daiber A, 1998, NITRIC OXIDE-BIOL CH, V2, P259, DOI 10.1006/niox.1998.0186; DARLEYUSMAR VM, 1992, FREE RADICAL RES COM, V17, P9, DOI 10.3109/10715769209061085; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; FLISS H, 1991, ARCH BIOCHEM BIOPHYS, V287, P175, DOI 10.1016/0003-9861(91)90403-6; FRIDOVICH I, 1970, J BIOL CHEM, V245, P4053; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; Goldstein S, 2000, J BIOL CHEM, V275, P3031, DOI 10.1074/jbc.275.5.3031; Goldstein S, 1999, CHEM RES TOXICOL, V12, P132, DOI 10.1021/tx9802522; Jacob C, 1999, P NATL ACAD SCI USA, V96, P1910, DOI 10.1073/pnas.96.5.1910; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P246; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kelm M, 1997, J BIOL CHEM, V272, P9922; Kissner R, 1997, CHEM RES TOXICOL, V10, P1285, DOI 10.1021/tx970160x; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kuhn DM, 1999, J NEUROSCI, V19, P10289; Lee JB, 1998, J AM CHEM SOC, V120, P6053, DOI 10.1021/ja9801036; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; Nakamura K, 1997, FEBS LETT, V417, P375, DOI 10.1016/S0014-5793(97)01326-4; Naskalski JW, 2001, ADV CLIN CHEM, V35, P161, DOI 10.1016/S0065-2423(01)35017-5; Pfeiffer S, 2000, J BIOL CHEM, V275, P6346, DOI 10.1074/jbc.275.9.6346; Pfeiffer S, 1998, J BIOL CHEM, V273, P27280, DOI 10.1074/jbc.273.42.27280; Pietruszko R, 1975, Adv Exp Med Biol, V56, P1; Pilichowski JF, 1995, CAN J CHEM, V73, P2143, DOI 10.1139/v95-265; Quijano C, 1997, BIOCHEM J, V322, P167, DOI 10.1042/bj3220167; RADI R, 1992, BIOCHIM BIOPHYS ACTA, V1122, P178, DOI 10.1016/0167-4838(92)90321-4; RADI R, 1991, J BIOL CHEM, V266, P4244; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Sawa T, 2000, J BIOL CHEM, V275, P32467, DOI 10.1074/jbc.M910169199; Sen CK, 2001, MED SCI SPORT EXER, V33, P368, DOI 10.1097/00005768-200103000-00005; SHAW CF, 1990, INORG CHEM, V29, P403, DOI 10.1021/ic00328a012; Sies H, 1998, CHEM-BIOL INTERACT, V112, P177, DOI 10.1016/S0009-2797(97)00160-9; SQUADRITO GL, 1995, CHEM-BIOL INTERACT, V96, P203, DOI 10.1016/0009-2797(94)03591-U; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; VANWART HE, 1986, P NATL ACAD SCI USA, V83, P3064; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Zou MH, 1999, BRIT J PHARMACOL, V126, P1283, DOI 10.1038/sj.bjp.0702434; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3	47	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11882	11888		10.1074/jbc.M111988200	http://dx.doi.org/10.1074/jbc.M111988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805115	hybrid			2022-12-25	WOS:000174846400037
J	Kazlauskas, A; Poellinger, L; Pongratz, I				Kazlauskas, A; Poellinger, L; Pongratz, I			Two distinct regions of the immunophilin-like protein XAP2 regulate dioxin receptor function and interaction with hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ARYL-HYDROCARBON RECEPTOR; DNA-BINDING ACTIVITY; HELIX-LOOP-HELIX; AH RECEPTOR; CORE COMPLEX; IN-VIVO; LIGAND; EXPRESSION; ROLES	The dioxin (aryl hydrocarbon) receptor is a ligand inducible transcription factor, which mediates cellular responses to a variety of xenobiotic compounds such as dioxins. In the absence of ligand the receptor is associated with the molecular chaperone hsp90 and the tetratricopeptide repeat (TPR-) containing immunophilin-like protein XAP2. XAP2 has been implicated in regulation of the intracellular localization of the dioxin receptor and protection of the receptor against degradation. In this study a series of XAP2 mutants has been generated in order to identify the structural motif(s) mediating interaction with the dioxin receptor-hsp90 complex and modulation of receptor function. Immunoprecipitation experiments demonstrated that the C-terminal part of XAP2, including the TPR motifs and the region outside the TPR motifs, was required to directly contact hsp90. The N-terminal part of XAP2 was required for the stability of the ternary dioxin receptor-hsp90-XAP2 complex. In addition, the integrity of the N-terminal region of XAP2 was essential for XAP2 to regulate the intracellular localization of the dioxin receptor. In conclusion, these data demonstrate that two distinct regions of XAP2 modulate dioxin receptor function and interaction with hps90, illustrating the complexity in regulation of dioxin receptor signaling by the hsp90 molecular chaperone machinery.	Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Poellinger, L (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden.							ANTONSSON C, 1995, MOL CELL BIOL, V15, P756; Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Bell DR, 2000, J BIOL CHEM, V275, P36407, DOI 10.1074/jbc.M004236200; CARVER LA, 1994, J BIOL CHEM, V269, P30109; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; DENIS M, 1988, ANAL BIOCHEM, V173, P405, DOI 10.1016/0003-2697(88)90207-2; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Heid SE, 2000, MOL PHARMACOL, V57, P82; Huang X, 1991, ADV APPL MATH, V12, P373; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kazlauskas A, 1999, J BIOL CHEM, V274, P13519, DOI 10.1074/jbc.274.19.13519; Kazlauskas A, 2000, J BIOL CHEM, V275, P41317, DOI 10.1074/jbc.M007765200; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; LaPres JJ, 2000, J BIOL CHEM, V275, P6153, DOI 10.1074/jbc.275.9.6153; Ma Q, 1997, J BIOL CHEM, V272, P8878; MCGUIRE J, 1994, MOL CELL BIOL, V14, P2438, DOI 10.1128/MCB.14.4.2438; Meyer BK, 2000, CELL STRESS CHAPERON, V5, P243, DOI 10.1379/1466-1268(2000)005<0243:AHARLA>2.0.CO;2; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Meyer BK, 1999, BIOCHEMISTRY-US, V38, P8907, DOI 10.1021/bi982223w; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PONGRATZ I, 1992, J BIOL CHEM, V267, P13728; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; WHITELAW ML, 1993, EMBO J, V12, P4169, DOI 10.1002/j.1460-2075.1993.tb06101.x; WHITELAW ML, 1995, P NATL ACAD SCI USA, V92, P4437, DOI 10.1073/pnas.92.10.4437; WILHELMSSON A, 1990, EMBO J, V9, P69, DOI 10.1002/j.1460-2075.1990.tb08081.x	29	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11795	11801		10.1074/jbc.M200053200	http://dx.doi.org/10.1074/jbc.M200053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805120	hybrid			2022-12-25	WOS:000174846400026
J	Li, PTX; Scott, DJ; Gollnick, P				Li, PTX; Scott, DJ; Gollnick, P			Creating hetero-11-mers composed of wild-type and mutant subunits to study RNA binding to TRAP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTENUATION PROTEIN TRAP; TRP LEADER RNA; BACILLUS-SUBTILIS BINDS; OPERON; NUCLEOTIDES; TRANSLATION; FEATURES; REPEATS; GAG	TRAP ((t) under bar rp (R) under bar NA-binding (a) under bar ttenuation (p) under bar rotein) is an RNA-binding protein that regulates expression of the tryptophan biosynthetic genes in Bacillus subtilis by binding to RNA targets that contain multiple GAG and UAG repeats. TRAP is composed of 11 identical subunits arranged symmetrically in a ring. The secondary structure of the protein consists entirely of antiparallel,beta-sheets, beta-turns, and loops. We show here that the TRAP 11-mer can be reversibly denatured into unfolded monomers by guanidine hydrochloride. Removing the denaturant allows the protein to spontaneously renature into fully functional 11-mers. Based on this finding, we developed a subunit mixing method to hybridize wild-type and mutant subunits into heteromeric 11-mers by denaturation followed by subunit mixing renaturation. This method allows the study of subunit cooperativity in protein-ligand interaction such as RNA binding. Our data further support and extend the previously proposed two-step model for RNA binding to TRAP by showing that the initiation of binding requires at least one fully active subunit in the protein combined with one fully functional repeat in the RNA. The initiation complex tethers the RNA on the protein, thus allowing cooperative interaction with the remainder of the repeats.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; Univ York, Dept Chem, York Struct Biol Lab, York YO10 5DD, N Yorkshire, England	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of York - UK	Gollnick, P (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.			Scott, David/0000-0002-6726-2078	NIGMS NIH HHS [GM62750] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062750] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adler A J, 1973, Methods Enzymol, V27, P675; Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; ARAKAWA T, 1984, BIOCHEMISTRY-US, V23, P5924, DOI 10.1021/bi00320a005; Babitzke P, 1996, J BACTERIOL, V178, P5159, DOI 10.1128/jb.178.17.5159-5163.1996; BABITZKE P, 1995, P NATL ACAD SCI USA, V92, P7916, DOI 10.1073/pnas.92.17.7916; BABITZKE P, 1995, J BIOL CHEM, V270, P12452, DOI 10.1074/jbc.270.21.12452; BABITZKE P, 1993, P NATL ACAD SCI USA, V90, P133, DOI 10.1073/pnas.90.1.133; Babitzke P, 1997, MOL MICROBIOL, V26, P1, DOI 10.1046/j.1365-2958.1997.5541915.x; Babitzke P, 2001, J BACTERIOL, V183, P5795, DOI 10.1128/JB.183.20.5795-5802.2001; Baumann C, 1996, J BIOL CHEM, V271, P12269, DOI 10.1074/jbc.271.21.12269; Baumann C, 1997, J BIOL CHEM, V272, P19863, DOI 10.1074/jbc.272.32.19863; Chen XP, 1999, J MOL BIOL, V289, P1003, DOI 10.1006/jmbi.1999.2834; Colfen H, 1997, EUR BIOPHYS J BIOPHY, V25, P333, DOI 10.1007/s002490050047; Creighton TE, 1994, MECH PROTEIN FOLDING, P1; Du HS, 1997, J BACTERIOL, V179, P2582, DOI 10.1128/jb.179.8.2582-2586.1997; Du HS, 1998, J BIOL CHEM, V273, P20494, DOI 10.1074/jbc.273.32.20494; Elliott MB, 2001, RNA, V7, P85, DOI 10.1017/S135583820100173X; Elliott MB, 1999, RNA, V5, P1277, DOI 10.1017/S1355838299991057; GOLLNICK P, 1994, MOL MICROBIOL, V11, P991, DOI 10.1111/j.1365-2958.1994.tb00377.x; KURODA MI, 1986, J BACTERIOL, V167, P792, DOI 10.1128/jb.167.3.792-798.1986; Laue T. M., 1991, ANAL ULTRACENTRIFUGA, P90; MERINO E, 1995, J BACTERIOL, V177, P6362, DOI 10.1128/jb.177.22.6362-6370.1995; OTRIDGE J, 1993, P NATL ACAD SCI USA, V90, P128, DOI 10.1073/pnas.90.1.128; Sarsero JP, 2000, J BACTERIOL, V182, P2329, DOI 10.1128/JB.182.8.2329-2331.2000; Tilsta L., 1996, CIRCULAR DICHROISM C, P261; YANG M, 1995, J BACTERIOL, V177, P4272, DOI 10.1128/jb.177.15.4272-4278.1995; Yang M, 1997, J MOL BIOL, V270, P696, DOI 10.1006/jmbi.1997.1149	28	20	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11838	11844		10.1074/jbc.M110860200	http://dx.doi.org/10.1074/jbc.M110860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805104	hybrid			2022-12-25	WOS:000174846400031
J	Ason, B; Reznikoff, WS				Ason, B; Reznikoff, WS			Mutational analysis of the base flipping event found in Tn5 transposition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC COMPLEX; HELIX; DNA	This work identifies novel structure-function relationships between Tn5 transposase (Tnp) and its DNA recognition sequence. The Tn5 Tnp-DNA co-crystal structure revealed the protein-DNA contacts of the post-cleavage complex (Davies, D. R., Goryshin, I. Y., Reznikoff, W. S., and Rayment, I (2000) Science 289, 77-85). One of the most striking features of this complex is the rotation of thymine 2 (T2) away from the DNA helix and into a pocket within the Trip. This interaction appears similar to the "base flipping" phenomenon found in many DNA repair enzymes such as T4 endonuclease V and uracil DNA glycosylase (Roberts, R. J., and Cheng, X (1998) Annu. Rev. Biochem 67, 181-198). To study the biochemical significance of this phenomenon, we mutated the Tnp residues proposed to be involved in stabilizing this interaction and removed the T2 nucleotide to examine which steps in the transposition reaction require T2-Tnp interactions. From this work, we have determined that stacking interactions between T2 and Tnp are critical for efficient transposition in vitro. In addition, our results suggested that T2-Tnp interactions facilitate hairpin formation and hairpin resolution primarily through base stacking and that T2 plays a role in the alignment of the transposon DNA for strand transfer.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.				NIGMS NIH HHS [GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allingham JS, 2001, EMBO J, V20, P2931, DOI 10.1093/emboj/20.11.2931; BERG DE, 1989, MOBILE DNA, P185; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; HANIFORD D, 1994, EMBO J, V13, P3401, DOI 10.1002/j.1460-2075.1994.tb06643.x; Jilk RA, 1996, J BACTERIOL, V178, P1671, DOI 10.1128/jb.178.6.1671-1679.1996; JOHNSON RC, 1983, NATURE, V204, P280; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Naumann TA, 2000, P NATL ACAD SCI USA, V97, P8944, DOI 10.1073/pnas.160107997; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; REZNIKOFF WS, 1993, ANNU REV MICROBIOL, V47, P945, DOI 10.1146/annurev.mi.47.100193.004501; Roberts RJ, 1998, ANNU REV BIOCHEM, V67, P181, DOI 10.1146/annurev.biochem.67.1.181; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; Steiniger-White M, 2000, J BIOL CHEM, V275, P23127, DOI 10.1074/jbc.M003411200; VARANI G, 1995, ANNU REV BIOPH BIOM, V24, P379, DOI 10.1146/annurev.bb.24.060195.002115	16	32	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11284	11291		10.1074/jbc.M111119200	http://dx.doi.org/10.1074/jbc.M111119200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805107	hybrid			2022-12-25	WOS:000174613100068
J	Koch, CA; Huang, SC; Zhuang, ZP; Stolle, C; Azumi, N; Chrousos, GP; Vortmeyer, AO; Pacak, K				Koch, CA; Huang, SC; Zhuang, ZP; Stolle, C; Azumi, N; Chrousos, GP; Vortmeyer, AO; Pacak, K			Somatic VHL gene deletion and point mutation in MEN 2A-associated pheochromocytoma	ONCOGENE			English	Article						RET; MEN 2; VHL; pheochromocytoma; deletion	HIPPEL-LINDAU-DISEASE; TUMOR-SUPPRESSOR GENE; RET PROTOONCOGENE; SPORADIC PHEOCHROMOCYTOMAS; GERMLINE MUTATIONS; SHORT ARM; HETEROZYGOSITY; EVENTS; ALLELE; 1P	Multiple endocrine neoplasia type 2 (MEN 2) is an inherited cancer syndrome that includes pheochromocytoma. Germline mutations in RET are responsible for MEN 2 but the precise pathogenetic mechanisms of tumorigenesis are unknown. We have recently identified possible mechanisms of tumor formation in patients with MEN 2A-related pheochromocytoma. Two of nine tumors investigated, however, did not reveal either of these mechanisms. In the present study, we therefore searched for other possible mechanisms underlying the pathogenesis of MEN 2A-related pheochromocytoma. Hereditary pheochromocytoma also occurs in patients with von Hippel-Lindau (VHL) disease, a syndrome consisting of tumors caused by inactivation of the VHL tumor suppressor gene. A subset of sporadic pheochromocytomas have somatic mutations in RET or VHL, suggesting that both genes contribute to pheochromocytoma pathogenesis in a subset of tumors. It is unknown, however; whether VHL gene alterations would be associated with tumorigenesis in hereditary, MEN 2-related pheochromocytoma. We therefore investigated four pheochromocytomas from patients with MEN 2A and RET germline mutations for the presence of allelic deletion and/or somatic mutation of the VHL gene. LOH analysis using the polymorphic markers D3S1038 and D3S1110 that map to the VHL gene locus 3p25/26, revealed evidence for somatic VHL gene deletion in all four MEN 2A-related pheochromocytomas. Mutation analysis of the VHL gene showed frameshift mutations in two tumors and a splice acceptor mutation in one tumor. The remaining tumor did show LOH but not mutation of the VHL gene. These results suggest that somatic genetic alterations of the VHL gene may play a role in the tumorigenesis of some MEN 2A-related pheochromocytomas.	NICHHD, PREB, NIH, Bethesda, MD 20892 USA; NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Georgetown Univ, Washington, DC USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Pennsylvania; Georgetown University	Koch, CA (corresponding author), NICHHD, PREB, NIH, Bldg 10,Rm 9D42, Bethesda, MD 20892 USA.	kochc@exchange.nih.gov	Koch, Christian A/A-4699-2008	Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002991] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BELDJORD C, 1995, J CLIN ENDOCR METAB, V80, P2063, DOI 10.1210/jc.80.7.2063; Bender BU, 2000, J CLIN ENDOCR METAB, V85, P4568, DOI 10.1210/jc.85.12.4568; Benn DE, 2000, CANCER RES, V60, P7048; Brauch H, 1997, J CLIN ENDOCR METAB, V82, P4101, DOI 10.1210/jc.82.12.4101; CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; CROSSEY PA, 1994, HUM GENET, V93, P53; CROSSEY PA, 1995, J MED GENET, V32, P885, DOI 10.1136/jmg.32.11.885; Dannenberg H, 2000, AM J PATHOL, V157, P353, DOI 10.1016/S0002-9440(10)64547-6; ENG C, 1995, J MED GENET, V32, P934, DOI 10.1136/jmg.32.12.934; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Huang SC, 2000, CANCER RES, V60, P6223; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KHOSLA S, 1991, J CLIN INVEST, V87, P1691, DOI 10.1172/JCI115186; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINDOR NM, 1995, J CLIN ENDOCR METAB, V80, P627, DOI 10.1210/jc.80.2.627; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; MOLEY JF, 1992, CANCER RES, V52, P770; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; Ponder BAJ, 1999, CANCER RES, V59, p1736S; Prowse AH, 1997, AM J HUM GENET, V60, P765; RICCARDI VM, 1991, NEW ENGL J MED, V324, P1283, DOI 10.1056/NEJM199105023241812; Stolle C, 1998, HUM MUTAT, V12, P417, DOI 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K; Vargas MP, 1997, HUM PATHOL, V28, P411, DOI 10.1016/S0046-8177(97)90028-9; Walther MM, 1999, J UROLOGY, V162, P659, DOI 10.1097/00005392-199909010-00004; ZEIGER MA, 1995, GENE CHROMOSOME CANC, V13, P151, DOI 10.1002/gcc.2870130303; Zhuang Z, 1998, Cell Vis, V5, P43	30	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					479	482		10.1038/sj.onc.1205133	http://dx.doi.org/10.1038/sj.onc.1205133			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821960				2022-12-25	WOS:000173311200016
J	Terradillos, O; de la Coste, A; Pollicino, T; Neuveut, C; Sitterlin, D; Lecoeur, H; Gougeon, ML; Kahn, A; Buendia, MA				Terradillos, O; de la Coste, A; Pollicino, T; Neuveut, C; Sitterlin, D; Lecoeur, H; Gougeon, ML; Kahn, A; Buendia, MA			The hepatitis B virus X protein abrogates Bcl-2-mediated protection against Fas apoptosis in the liver	ONCOGENE			English	Article						HBV; apoptosis; liver; mitochondria; cytochrome c; caspase	CYTOCHROME-C RELEASE; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; IN-VIVO; CELL-LINES; BCL-2; GENE; HBX; MITOCHONDRIA; DEATH	The role of the hepatitis B virus protein HBx in liver cell proliferation and apoptosis remains controversial. Using a transgenic mouse model, we have recently shown that HBx stimulates the apoptotic turnover of hepatocytes, independently of p53. In this paper, we tested whether the proapoptotic function of HBx can interfere with Bcl-2 during hepatic apoptosis in vivo. HBx transgenic mice were crossed with PK-hBcl-2 mice that are protected against Fas killing by constitutive overexpression of Bcl-2 in hepatocytes. In a lethal challenge with Fas antibodies, HBx expressed at low levels restored sensitivity to Fas-mediated apoptosis and fulminant hepatic failure in mice overexpressing Bcl-2. Furthermore, cytochrome c release from mitochondria and caspase 3 activation were restored to normal levels in HBx/Bcl-2 mice during transduction of the Fas signal. Thus, the proapoptotic activity of HBx overcomes or bypasses the inhibitory effect of Bcl-2 against Fas cytotoxicity. This effect was not apparently mediated through downregulation of the PK-hBcl-2 transgene or via delocalization of the Bcl-2 protein, and a direct interaction of HBx with Bcl-2, Bcl-X-L or Bax could not be evidenced in yeast two-hybrid assays. We further show that apoptosis induced by ectopic expression of HBx is associated with mitochondrial membrane alterations and caspase 3 activation. Our data indicate that the dominant function of HBx upon Bcl-2-regulated control of apoptosis might play an important role in the pathogenesis of chronic hepatitis B.	Inst Pasteur, Inserm U163, Dept SIDA & Retrovirus, F-75724 Paris, France; Univ Geneva Sci III, Dept Biol Cellulaire, Geneva, Switzerland; Univ Paris 05, Inserm U129, Paris, France; Inst Pasteur, Inserm U163, Unite Recombinaison & Express Genet, F-75724 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Buendia, MA (corresponding author), Inst Pasteur, Inserm U163, Dept SIDA & Retrovirus, 28 Rue Dr Roux, F-75724 Paris, France.	mbuendia@pasteur.fr	Pollicino, Teresa/HDN-3708-2022; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035; Neuveut, Christine/0000-0001-6520-271X				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aillet F, 1998, J VIROL, V72, P9698, DOI 10.1128/JVI.72.12.9698-9705.1998; Amicone L, 1997, EMBO J, V16, P495, DOI 10.1093/emboj/16.3.495; BALSANO C, 1993, ARCH VIROL, P63; BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; BILLET O, 1995, J VIROL, V69, P5912, DOI 10.1128/JVI.69.9.5912-5916.1995; BUENDIA MA, 1992, ADV CANCER RES, V59, P167, DOI 10.1016/S0065-230X(08)60306-1; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Feldmann G, 2000, HEPATOLOGY, V31, P674, DOI 10.1002/hep.510310318; Flajolet M, 2000, GENE, V242, P369, DOI 10.1016/S0378-1119(99)00511-9; GALIBERT F, 1979, NATURE, V281, P646, DOI 10.1038/281646a0; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; GraslKraupp B, 1997, HEPATOLOGY, V25, P906, DOI 10.1002/hep.510250420; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HARPER JW, 1993, CELL, V75, P805; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; Lara-Pezzi E, 1998, EMBO J, V17, P7066, DOI 10.1093/emboj/17.23.7066; Lecoeur H, 1996, J IMMUNOL METHODS, V198, P87, DOI 10.1016/0022-1759(96)00148-2; Lee DK, 2001, GENE DEV, V15, P455, DOI 10.1101/gad.856201; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Macho A, 1996, CYTOMETRY, V25, P333, DOI 10.1002/(SICI)1097-0320(19961201)25:4<333::AID-CYTO4>3.0.CO;2-E; Murphy KM, 1999, ONCOGENE, V18, P5991, DOI 10.1038/sj.onc.1203001; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Pan JB, 2001, J GEN VIROL, V82, P171, DOI 10.1099/0022-1317-82-1-171; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Spengler U, 1996, CYTOKINE, V8, P864, DOI 10.1006/cyto.1996.0115; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TRANSY C, 1995, MOL BIOL REP, V21, P119, DOI 10.1007/BF00986502; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WANG XW, 1995, CANCER RES, V55, P6012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	69	62	69	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					377	386		10.1038/sj.onc.1205110	http://dx.doi.org/10.1038/sj.onc.1205110			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821950				2022-12-25	WOS:000173311200006
J	Comtesse, N; Niedermayer, I; Glass, B; Heckel, D; Maldener, E; Nastainczyk, W; Feiden, W; Meese, E				Comtesse, N; Niedermayer, I; Glass, B; Heckel, D; Maldener, E; Nastainczyk, W; Feiden, W; Meese, E			MGEA6 is tumor-specific overexpressed and frequently recognized by patient-serum antibodies	ONCOGENE			English	Article						tumor antigen; overexpression; central nervous-system neoplasm; meningioma; glioma	CANCER PATIENTS; ANTIGENS; MENINGIOMA; CLONING; PROTEIN	Tumorigenesis of meningioma has been associated with chromosome 22, most notably the NF2 gene, but additional genes have also been implicated in meningioma development. Previously, we have cloned the cDNAs for the meningioma expressed antigen 6 (MGEA6) and its splice variant MGEA11. Here, we show that antibodies against recombinantly expressed MGEA6/11 are found in 41.7% (10/24) of the sera from meningioma patients and in 2/8 sera of glioblastoma patients, whereas no response was seen in 12 sera from healthy persons. Western-blot analyses using generated polyclonal antibodies, revealed overexpression in meningioma and glioma tumor samples compared to normal brain. Immunohistochemical staining of tissue sections confirms reactivity in meningioma tumor cells and tumor cells of glial origin. We found no reactivity to normal astrocytes and only faint reactivity to normal leptomeninges. Sequence analysis predicted membranic localization of MGEA6/11, that was confirmed by cell fractionation. The immune response to MGEA6/11 is frequent in both meningioma and glioma patients and may likely be attributed to overexpression of the MGEA6/11 protein in the tumor cells.	Univ Saarlandes Kliniken, Inst Humangenet, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Abt Neuropathol, D-66421 Homburg, Germany; Univ Saarlandes Kliniken, Inst Med Biochem, D-66421 Homburg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Meese, E (corresponding author), Univ Saarland, Dept Human Genet, Bldg 60, D-66421 Homburg, Germany.		Meese, Eckart Ulrich/ABD-1983-2021					AKAGI K, 1995, INT J CANCER, V60, P178, DOI 10.1002/ijc.2910600208; BARKER CF, 1977, ADV IMMUNOL, V25, P1; BECKER I, 1989, J NEUROIMMUNOL, V25, P161, DOI 10.1016/0165-5728(89)90133-1; BENMAHREZ K, 1990, INT J CANCER, V46, P35, DOI 10.1002/ijc.2910460109; Boon T, 1997, CURR OPIN IMMUNOL, V9, P681, DOI 10.1016/S0952-7915(97)80049-0; Comtesse N, 2001, GENOMICS, V75, P43, DOI 10.1006/geno.2001.6576; Comtesse N, 1999, CLIN CANCER RES, V5, P3560; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; DISIS ML, 1994, CANCER RES, V54, P16; GALLAGER G, 1991, BRIT J CANCER, V61, P35; Harlow E., 1988, ANTIBODIES LAB MANUA; Heckel D, 1997, HUM MOL GENET, V6, P2031, DOI 10.1093/hmg/6.12.2031; Heckel D, 1998, HUM MOL GENET, V7, P1859, DOI 10.1093/hmg/7.12.1859; Kleihues P, 2000, PATHOLOGY GENETICS T; MARCIAS MJ, 1996, NATURE, V382, P646; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; PEES HW, 1979, ACTA NEUROCHIR, V50, P217, DOI 10.1007/BF01808518; PEES HW, 1976, CLIN EXP IMMUNOL, V24, P310; PUPA SM, 1993, CANCER RES, V53, P5864; REAL FX, 1988, P NATL ACAD SCI USA, V85, P3965, DOI 10.1073/pnas.85.11.3965; RUTTLEDGE MH, 1994, NAT GENET, V6, P180, DOI 10.1038/ng0294-180; TABUCHI K, 1979, ACTA NEUROCHI WIEN, V55, P201; Yamamoto A, 1996, INT J CANCER, V69, P283, DOI 10.1002/(SICI)1097-0215(19960822)69:4<283::AID-IJC8>3.3.CO;2-D	23	23	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					239	247		10.1038/sj/onc/1205005	http://dx.doi.org/10.1038/sj/onc/1205005			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803467				2022-12-25	WOS:000173026200008
J	Chen, ZJ; Fitzgerald, RL; Schonfeld, G				Chen, ZJ; Fitzgerald, RL; Schonfeld, G			Hypobetalipoproteinemic mice with a targeted apolipoprotein (Apo) B-27.6-specifying mutation - In vivo evidence for an important role of amino acids 1254-1744 of ApoB in lipid transport and metabolism of the ApoB-containing lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; FAMILIAL HYPOBETALIPOPROTEINEMIA; FATTY LIVER; TRUNCATED APOLIPOPROTEIN; NONSENSE MUTATION; PLASMA-LIPOPROTEINS; MOUSE MODEL; GENE; TRIGLYCERIDE; BUOYANT	Carboxyl-terminal deletion of apoB-100 may impair its triglyceride (TG)-transporting capability and alter its catabolism. Here, we compare our newly generated apoB gene (Apob)-targeted apoB-27.6-bearing mice to our previously reported apoB-38.9 mice to understand further the relationship between the size of a truncated apoB variant and its function/metabolism in vivo. The apoB-27.6-specifying mutation produces a premature stop codon six amino acids (aa) downstream of the last codon of mouse Apob exon 24 (corresponding to aa 1254 of human apoB-100). ApoB-27.6 transcripts were 3- and 5-fold more abundant than apoB wild type and apoB-38.9 transcripts in the liver. Likewise, hepatic secretion rates of apoB-27.6 were 7-fold higher than those of apoB-48 and apoB-38.9. In contrast, apoB-27.6 heterozygotes (Apob(27.6/+)) had lower hepatic TG secretion rates and higher liver TG contents than both apoB-38.9 heterozygotes (Apob(38.9/+)) and apoB wild type mice (Apob(+/+)). ApoB-27.6 was secreted by Apob(27.6/+) hepatocytes as dense high density lipoprotein particles. Moreover, despite its high secretion rates, apoB-27.6 was barely detectable in plasma. Disruption of apoE gene in Apob(38.9/+) and Apob(27.6/+) dramatically increased plasma levels of apoB-38.9 as well as apoB-48 but caused no change in plasma apoB-27.6 concentrations. Finally, the birth rate of apoB-27.6 homozygotes (Apob(27.6/27.6)) from intercrosses of Apob(27.6/+) was 7-fold lower than that of Apob(38.9/38.9) from Apob(38.9/+) intercrosses (1.8% versus 12%). Crossbreeding of APob(27.6/27.6) and Apob(38.9/38.9) produced viable Apib(27.6/38.9) offspring, but Apob(27.6/27.6) intercrosses produced no offspring. Together, these results demonstrate in vivo that the apoB-27.6-apoB-38.9 peptide segment (aa 1254-1744) plays a critical role, not only in supporting hepatic TG-secretion and in modulating catabolism of apoB-containing lipoproteins, but also in normal mouse embryonic development.	Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, St Louis, MO 63110 USA	Washington University (WUSTL)	Chen, ZJ (corresponding author), Washington Univ, Sch Med, Dept Med, Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.	zchen@im.wustl.edu			NCI NIH HHS [1P30CA91842-01] Funding Source: Medline; NCRR NIH HHS [M01RR0036] Funding Source: Medline; NHLBI NIH HHS [R37 HL-424460, R01 HL-59515] Funding Source: Medline; NIDDK NIH HHS [P30DK56341, 5P60DK20579] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P60DK020579] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Castellano G, 1997, J CLIN GASTROENTEROL, V25, P379, DOI 10.1097/00004836-199707000-00021; Chen ZJ, 1999, J CLIN INVEST, V103, P1419, DOI 10.1172/JCI4921; Chen ZJ, 1999, CIRCULATION, V100, P329; Chen ZJ, 2000, J BIOL CHEM, V275, P32807, DOI 10.1074/jbc.M004913200; COLLINS DR, 1988, NUCLEIC ACIDS RES, V16, P8361, DOI 10.1093/nar/16.17.8361; Cooper AD, 1997, J LIPID RES, V38, P2173; Davis RA, 1999, BBA-MOL CELL BIOL L, V1440, P1, DOI 10.1016/S1388-1981(99)00083-9; DIXON JL, 1991, J BIOL CHEM, V266, P5080; FARESE RV, 1995, P NATL ACAD SCI USA, V92, P1774, DOI 10.1073/pnas.92.5.1774; GRAHAM DL, 1991, BIOCHEMISTRY-US, V30, P5616, DOI 10.1021/bi00236a040; GROENEWEGEN WA, 1994, J LIPID RES, V35, P1012; GROENEWEGEN WA, 1994, ARTERIOSCLER THROMB, V14, P1695, DOI 10.1161/01.ATV.14.11.1695; HOMANICS GE, 1993, P NATL ACAD SCI USA, V90, P2389, DOI 10.1073/pnas.90.6.2389; HUANG LS, 1989, J BIOL CHEM, V264, P11394; HUANG LS, 1991, J LIPID RES, V32, P1341; Hug BA, 1996, MOL CELL BIOL, V16, P2906; JIAO S, 1990, J LIPID RES, V31, P467; Kim E, 1998, J BIOL CHEM, V273, P33977, DOI 10.1074/jbc.273.51.33977; Kim E, 1998, J CLIN INVEST, V101, P1468; Kim E, 1998, J LIPID RES, V39, P703; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; Kreuzer J, 1997, J LIPID RES, V38, P324; KRUL ES, 1992, J LIPID RES, V33, P1037; LINTON MF, 1993, J LIPID RES, V34, P521; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK SPA, 1995, BBA-LIPID LIPID MET, V1258, P49, DOI 10.1016/0005-2760(95)00096-U; McLeod RS, 1996, J BIOL CHEM, V271, P18445, DOI 10.1074/jbc.271.31.18445; NemethSlany A, 1997, ATHEROSCLEROSIS, V133, P163, DOI 10.1016/S0021-9150(97)00105-6; Ogata H, 1997, AM J GASTROENTEROL, V92, P339; PARHOFER KG, 1992, J CLIN INVEST, V89, P1931, DOI 10.1172/JCI115799; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; SCHONFELD G, 1995, ANNU REV NUTR, V15, P23, DOI 10.1146/annurev.nu.15.070195.000323; Schonfeld G, 2001, ARTERIOSCL THROM VAS, V21, P656; Segrest JP, 2001, J LIPID RES, V42, P1346; TALMUD PJ, 1994, J LIPID RES, V35, P468; Tarugi P, 1996, GASTROENTEROLOGY, V111, P1125, DOI 10.1016/S0016-5085(96)70082-3; Tarugi P, 2001, J LIPID RES, V42, P1552; VANGREEVENBROEK MMJ, 1995, J LIPID RES, V36, P13; WAGNER RD, 1991, J LIPID RES, V32, P1001; Wu JS, 1999, J LIPID RES, V40, P955; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1990, J CLIN INVEST, V85, P933, DOI 10.1172/JCI114522; Zhu XF, 1997, ARTERIOSCL THROM VAS, V17, P1032, DOI 10.1161/01.ATV.17.6.1032	47	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14135	14145		10.1074/jbc.M200617200	http://dx.doi.org/10.1074/jbc.M200617200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11839763	hybrid			2022-12-25	WOS:000175096000102
J	Hyde, R; Peyrollier, K; Hundal, HS				Hyde, R; Peyrollier, K; Hundal, HS			Insulin promotes the cell surface recruitment of the SAT2/ATA2 system A amino acid transporter from an endosomal compartment in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; TRANS-GOLGI NETWORK; GROWTH-FACTOR-I; GLUCOSE TRANSPORTERS; PLASMA-MEMBRANE; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; ENDOCYTOSIS; ACTIVATION	SAT1-3 comprise members of the recently cloned family of System A transporters that mediate the sodium-coupled uptake of short chain neutral amino acids, and their activity is regulated extensively by stimuli such as insulin, growth factors, and amino acid availability. In skeletal muscle, insulin stimulates System A activity rapidly by a presently ill-defined mechanism. Here we demonstrate that insulin induces an increase in the plasma membrane abundance of SAT2 in a phosphatidylinositol 3-kinase-dependent manner and that this increase is derived from an endosomal compartment that is required for the hormonal activation of System A. Chloroquine, an acidotropic weak base that impairs endosomal recycling of membrane proteins, induced a complete inhibition in the insulin-mediated stimulation of System A, which was associated with a loss in SAT2 recruitment to the plasma membrane. The failure to stimulate System A and recruit SAT2 to the cell surface could not be attributed to a block in insulin signaling, as chloroquine had no effect on the insulin-mediated phosphorylation of protein kinase B or glycogen synthase kinase 3 or upon insulin-stimulated GLUT4 translocation and glucose transport. Our data indicate strongly that insulin increases System A transport in L6 cells by stimulating the exocytosis of SAT2 carriers from a chloroquine-sensitive endosomal compartment.	Univ Dundee, Div Mol Physiol, Inst Med Sci, Wellcome Trust Bioctr Complex, Dundee DD1 5EH, Scotland	University of Dundee	Hundal, HS (corresponding author), Univ Dundee, Div Mol Physiol, Inst Med Sci, Wellcome Trust Bioctr Complex, Dow St, Dundee DD1 5EH, Scotland.	h.s.hundal@dundee.ac.uk	Hundal, Hari/A-8990-2008	Hundal, Hari/0000-0002-7621-4932				Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BILAN PJ, 1992, FEBS LETT, V298, P285, DOI 10.1016/0014-5793(92)80078-U; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Christie GR, 2001, CURR OPIN CLIN NUTR, V4, P425, DOI 10.1097/00075197-200109000-00014; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DOUEN AG, 1991, ENDOCRINOLOGY, V128, P611, DOI 10.1210/endo-128-1-611; Durrbach A, 1996, J CELL SCI, V109, P457; Gazzola RF, 2001, FEBS LETT, V490, P11; GUMA A, 1988, BIOCHEM J, V253, P625, DOI 10.1042/bj2530625; Hajduch E, 2001, FEBS LETT, V492, P199, DOI 10.1016/S0014-5793(01)02242-6; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hatanaka T, 2001, BBA-BIOMEMBRANES, V1510, P10, DOI 10.1016/S0005-2736(00)00390-4; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; HUNDAL HS, 1994, BIOCHEM J, V297, P289, DOI 10.1042/bj2970289; HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Jess TJ, 1996, CELL SIGNAL, V8, P297, DOI 10.1016/0898-6568(96)00054-X; KLIP A, 1987, FEBS LETT, V224, P224, DOI 10.1016/0014-5793(87)80452-0; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Livingstone C, 1996, BIOCHEM J, V315, P487, DOI 10.1042/bj3150487; McDowell HE, 1998, FEBS LETT, V441, P15, DOI 10.1016/S0014-5793(98)01508-7; MCDOWELL HE, 1995, AM J PHYSIOL-CELL PH, V269, pC1287, DOI 10.1152/ajpcell.1995.269.5.C1287; McDowell HE, 1997, EUR J BIOCHEM, V247, P306, DOI 10.1111/j.1432-1033.1997.00306.x; MITSUMOTO Y, 1991, BIOCHEM BIOPH RES CO, V175, P652, DOI 10.1016/0006-291X(91)91615-J; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; OKA Y, 1987, J BIOL CHEM, V262, P17480; Palacin M, 1998, PHYSIOL REV, V78, P969, DOI 10.1152/physrev.1998.78.4.969; Puertollano R, 1999, MOL BIOL CELL, V10, P3435, DOI 10.1091/mbc.10.10.3435; ROMANEK R, 1993, BIOCHEM J, V296, P321, DOI 10.1042/bj2960321; SHEPHERD PR, 1995, BIOCHEM BIOPH RES CO, V211, P535, DOI 10.1006/bbrc.1995.1846; SIBILLE JC, 1989, BIOCHIM BIOPHYS ACTA, V1010, P204, DOI 10.1016/0167-4889(89)90162-6; Sugawara M, 2000, BBA-BIOMEMBRANES, V1509, P7, DOI 10.1016/S0005-2736(00)00349-7; Sugawara M, 2000, J BIOL CHEM, V275, P16473, DOI 10.1074/jbc.C000205200; TRAMACERE M, 1984, EXP CELL RES, V151, P70, DOI 10.1016/0014-4827(84)90356-2; TSAKIRIDIS T, 1995, ENDOCRINOLOGY, V136, P4315, DOI 10.1210/en.136.10.4315; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Yao DD, 2000, J BIOL CHEM, V275, P22790, DOI 10.1074/jbc.M002965200; Zuk PA, 1999, J BIOL CHEM, V274, P22303, DOI 10.1074/jbc.274.32.22303	39	79	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13628	13634		10.1074/jbc.M108609200	http://dx.doi.org/10.1074/jbc.M108609200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834730	hybrid			2022-12-25	WOS:000175096000039
J	Mukai, J; Shoji, S; Kimura, MT; Okubo, S; Sano, H; Suvanto, P; Li, Y; Irie, S; Sato, TA				Mukai, J; Shoji, S; Kimura, MT; Okubo, S; Sano, H; Suvanto, P; Li, Y; Irie, S; Sato, TA			Structure-function analysis of NADE - Identification of regions that mediate nerve growth factor-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P75 NEUROTROPHIN RECEPTOR; NUCLEAR EXPORT SIGNAL; PROGRAMMED CELL-DEATH; ZINC-FINGER PROTEIN; HUMAN NGF RECEPTOR; DOMAIN; LOCALIZATION; INDUCTION; SEQUENCE; P75(NTR)	Nerve growth factor (NGF) can induce apoptosis in neural cells via activation of the low affinity neurotrophin receptor p75NTR. NADE (p75NTR-associated cell death executor) is a p75NTR-associated protein that mediates apoptosis in response to NGF by interacting with the death domain of p75NTR in 293T, PC12, and nnr5 cells (Mukai, J., Hachiya, T., Shoji-Hoshino, S., Kimura, M. T., Nadano, D., Suvanto, P., Hanaoka, T., Li, Y., Irie, S., Greene, L. A., and Sato, T. A. (2000) J. Biol. Chem. 275, 17566-17570). We performed extensive mutational analysis on NADE, to better characterize its structural and functional features. Truncation of a minimal region, including amino acid residues 41-71 of NADE, was found to be sufficient to induce apoptosis. The designated regulatory region includes the C-terminal amino acid residues (72-112) and is essential for NGF-dependent regulation of NADE-induced apoptosis. Furthermore, the mutants with amino acid substitutions in the leucine-rich nuclear export signal (NES) sequence (residues 90100) abolished the export of NADE from the nucleus to the cytoplasm. Mutation of the NES also abolished self-association of NADE, its interaction with p75NTR, and NGF-dependent apoptosis. Expression of a fragment of NADE (amino acid residues 81-124) blocked NGF-induced apoptosis in oligodendrocytes, suggesting that this region has a dominant negative effect on NGF/p75NTR-induced apoptosis. These studies identify distinct regions of NADE that are involved in regulating specific functions involved in p75NTR signal transduction.	Columbia Univ Coll Phys & Surg, Div Mol Oncol, Dept Otolaryngol Head & Neck Surg & Pathol, New York, NY 10032 USA; RIKEN, Inst Phys & Chem Res, Oncol Mol Lab, Tsukuba, Ibaraki 3050074, Japan	Columbia University; RIKEN	Sato, TA (corresponding author), Columbia Univ Coll Phys & Surg, Div Mol Oncol, Dept Otolaryngol Head & Neck Surg & Pathol, 630 W 168th St,P&S 11-451, New York, NY 10032 USA.		Shoji, Shisako/C-3690-2017; Shoji, Shisako/AAJ-2654-2020	Shoji, Shisako/0000-0001-8787-2159; Shoji, Shisako/0000-0001-8787-2159; Mukai, Jun/0000-0003-2065-4784	NIGMS NIH HHS [R01-GM55147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BREDESEN DE, 1997, TRENDS NEUROSCI, V18, P321; Brown AL, 1999, HUM MOL GENET, V8, P611, DOI 10.1093/hmg/8.4.611; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CHAO MV, 1986, SCIENCE, V232, P518, DOI 10.1126/science.3008331; Chittka A, 1999, P NATL ACAD SCI USA, V96, P10705, DOI 10.1073/pnas.96.19.10705; Dechant G, 1997, CURR OPIN NEUROBIOL, V7, P413, DOI 10.1016/S0959-4388(97)80071-2; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Frade JM, 1996, NATURE, V383, P166; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gu CH, 1999, J NEUROSCI, V19, P3043; Irie S, 1999, FEBS LETT, V460, P191, DOI 10.1016/S0014-5793(99)01324-1; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; Khursigara G, 1999, J BIOL CHEM, V274, P2597, DOI 10.1074/jbc.274.5.2597; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Kimura MT, 2001, J BIOL CHEM, V276, P17291, DOI 10.1074/jbc.M005453200; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Lachyankar MB, 1997, EXP NEUROL, V144, P350, DOI 10.1006/exnr.1997.6434; LEVIMONTALCINI R, 1987, EMBO J, V6, P1145, DOI 10.1002/j.1460-2075.1987.tb02347.x; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; MAIDAN M, 1997, J NEUROSCI, V17, P6988; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Miller FD, 1998, CELL DEATH DIFFER, V5, P343, DOI 10.1038/sj.cdd.4400385; Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Park JA, 2000, J NEUROSCI, V20, P9096; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; Salehi AH, 2000, NEURON, V27, P279, DOI 10.1016/S0896-6273(00)00036-2; Seimiya H, 2000, EMBO J, V19, P2652, DOI 10.1093/emboj/19.11.2652; Stegh AH, 1998, EMBO J, V17, P5974, DOI 10.1093/emboj/17.20.5974; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239; VOJEK AB, 1993, CELL, V74, P205; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	49	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13973	13982		10.1074/jbc.M106342200	http://dx.doi.org/10.1074/jbc.M106342200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830582	hybrid			2022-12-25	WOS:000175096000082
J	Rauch, ME; Ferguson, CG; Prestwich, GD; Cafiso, DS				Rauch, ME; Ferguson, CG; Prestwich, GD; Cafiso, DS			Myristoylated alanine-rich C kinase substrate (MARCKS) sequesters spin-labeled phosphatidylinositol 4,5-bisphosphate in lipid bilayers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-BINDING; LATERAL DOMAINS; PHOSPHOLIPASE-C; PEPTIDES; PHOSPHORYLATION; PROTEIN; PIP2; PHOSPHOINOSITIDES; CALMODULIN; DYNAMICS	The myristoylated alanine-rich protein kinase C substrate (MARCKS) may function to sequester phosphoinositides within the plane of the bilayer. To characterize this interaction with phosphatidylinositol 4,5-bisphosphate (PI(4,5)P-2), a novel spin-labeled derivative, proxyl-PIP2, was synthesized and characterized. In the presence of molecules known to bind PI(4,5)P-2 the EPR spectrum of this label exhibits an increase in line width because of a decrease in label dynamics, and titration of this probe with neomycin yields the expected 1:1 stoichiometry. Thus, this probe can be used to quantitate the interactions made by the PI(4,5)P-2 head group within the bilayer. In the presence of a peptide comprising the effector domain of MARCKS the EPR spectrum broadens, but the changes in line shape are modulated by both changes in label correlation time and spin-spin interactions. This result indicates that at least some proxyl-PIP2 are in close proximity when bound to MARCKS and that MARCKS associates with multiple PI(4,5)P-2 molecules. Titration of the proxyl-PIP2 EPR signal by the MARCKS-derived peptide also suggests that multiple PI(4,5)P-2 molecules interact with MARCKS. Site-directed spin labeling of this peptide shows that the position and conformation of this protein segment at the membrane interface are not altered significantly by binding to PI(4,5)P-2. These data are consistent with the hypothesis that MARCKS functions to sequester multiple PI(4,5)P-2 molecules within the plane of the membrane as a result of interactions that are driven by electrostatic forces.	Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; Univ Virginia, Biophys Program, Charlottesville, VA 22904 USA; Univ Utah, Dept Med Chem, Salt Lake City, UT 84112 USA	University of Virginia; University of Virginia; Utah System of Higher Education; University of Utah	Cafiso, DS (corresponding author), Univ Virginia, Dept Chem, McCormick Rd,POB 400319, Charlottesville, VA 22904 USA.		Ferguson, Colin/AAY-2524-2021	Ferguson, Colin/0000-0002-9021-4533	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM058855, R41GM057705, R42GM057705, R01GM062305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029632] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57705, GM58855, GM62305] Funding Source: Medline; NINDS NIH HHS [NS29632] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALTENBACH C, 1994, P NATL ACAD SCI USA, V91, P1667, DOI 10.1073/pnas.91.5.1667; Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; ARCHER SJ, 1991, BIOPHYS J, V60, P389, DOI 10.1016/S0006-3495(91)82064-1; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; Chen J, 1996, J ORG CHEM, V61, P6305, DOI 10.1021/jo960895r; Czech MP, 2000, CELL, V100, P603, DOI 10.1016/S0092-8674(00)80696-0; Denisov G, 1998, BIOPHYS J, V74, P731, DOI 10.1016/S0006-3495(98)73998-0; GABEV E, 1989, BIOCHIM BIOPHYS ACTA, V979, P105, DOI 10.1016/0005-2736(89)90529-4; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; Gross A, 1999, BIOCHEMISTRY-US, V38, P10324, DOI 10.1021/bi990856k; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Martin TFJ, 1997, CURR OPIN NEUROBIOL, V7, P331, DOI 10.1016/S0959-4388(97)80060-8; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MCILROY BK, 1991, J BIOL CHEM, V266, P4959; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Ozaki S, 2000, P NATL ACAD SCI USA, V97, P11286, DOI 10.1073/pnas.210197897; PASTOR RW, 1988, J CHEM PHYS, V89, P1128, DOI 10.1063/1.455219; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Prestwich GD, 1996, ACCOUNTS CHEM RES, V29, P503, DOI 10.1021/ar960136v; Qin ZH, 1996, BIOCHEMISTRY-US, V35, P2917, DOI 10.1021/bi9521452; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Tall E, 1997, BIOCHEMISTRY-US, V36, P7239, DOI 10.1021/bi9702288; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VANPARIDON PA, 1986, BIOCHIM BIOPHYS ACTA, V877, P216, DOI 10.1016/0005-2760(86)90137-2; VERGHESE GM, 1994, J BIOL CHEM, V269, P9361; Victor JE, 1999, GRANA, V38, P12, DOI 10.1080/001731300750044663; Victor K, 1998, BIOCHEMISTRY-US, V37, P3402, DOI 10.1021/bi9721501; Victor KG, 2001, BIOPHYS J, V81, P2241, DOI 10.1016/S0006-3495(01)75871-7; Wang JY, 2001, J BIOL CHEM, V276, P5012, DOI 10.1074/jbc.M008355200	39	82	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14068	14076		10.1074/jbc.M109572200	http://dx.doi.org/10.1074/jbc.M109572200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825894	hybrid			2022-12-25	WOS:000175096000094
J	Rouhier, N; Gelhaye, E; Jacquot, JP				Rouhier, N; Gelhaye, E; Jacquot, JP			Glutaredoxin-dependent peroxiredoxin from poplar - Protein-protein interaction and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL-SPECIFIC ANTIOXIDANT; ONE-CONSERVED CYSTEINE; MAMMALIAN PEROXIREDOXIN; THIOREDOXIN PEROXIDASE; ESCHERICHIA-COLI; FAMILY; EXPRESSION; APOPTOSIS; DISEASE; CLONING	Recently, a poplar phloem peroxiredoxin (Prx) was found to accept both glutaredoxin (Grx) and thioredoxin (Trx) as proton donors. To investigate the catalytic mechanism of the Grx-dependent reduction of hydroperoxides catalyzed by Prx, a series of cysteinic mutants was constructed. Mutation of the most N-terminal conserved cysteine of Prx (Cys-51) demonstrates that it is the catalytic one. The second cysteine (Cys-76) is not essential for peroxiredoxin activity because the C76A mutant retained similar to25% of the wild type Prx activity. Only one cysteine of the Grx active site (Cys-27) is essential for peroxiredoxin catalysis, indicating that Grx can act in this reaction either via a dithiol or a monothiol pathway. The creation of covalent heterodimers between Prx and Grx mutants confirms that Prx Cys-51 and Grx Cys-27 are the two residues involved in the catalytic mechanism. The integration of a third cysteine in position 152 of the Prx, making it similar in sequence to the Trx-dependent human Prx V, resulted in a protein that had no detectable activity with Grx but kept activity with Trx. Based on these experimental results, a catalytic mechanism is proposed to explain the Grx- and Trx-dependent activities of poplar Prx.	Univ Nancy 1, UMR IaM, INRA, F-54506 Vandoeuvre Les Nancy, France	INRAE; Universite de Lorraine	Jacquot, JP (corresponding author), Univ Nancy 1, UMR IaM, INRA, BP 239,Blvd Aiguillettes, F-54506 Vandoeuvre Les Nancy, France.		gelhaye, eric/K-7390-2013; Jacquot, Jean-Pierre/A-1571-2012	gelhaye, eric/0000-0002-0699-9113; Rouhier, Nicolas/0000-0002-2036-7884; Jacquot, Jean-Pierre/0000-0003-4975-8587				Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Behm M, 2000, PLANT PHYSIOL BIOCH, V38, P363, DOI 10.1016/S0981-9428(00)00760-9; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; Choi YO, 1999, BIOCHEM BIOPH RES CO, V258, P768, DOI 10.1006/bbrc.1999.0714; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; Goyer A, 1999, FEBS LETT, V444, P165, DOI 10.1016/S0014-5793(99)00051-4; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; JACQUOT JP, 1994, J MOL BIOL, V235, P1357, DOI 10.1006/jmbi.1994.1091; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kim H, 2000, J BIOL CHEM, V275, P18266, DOI 10.1074/jbc.275.24.18266; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Kong W, 2000, BIOCHEM J, V351, P107, DOI 10.1042/0264-6021:3510107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; Peshenko IV, 2001, FREE RADICAL BIO MED, V31, P292, DOI 10.1016/S0891-5849(01)00579-2; Qin J, 2000, ANTIOXID REDOX SIGN, V2, P827, DOI 10.1089/ars.2000.2.4-827; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; RHEE SG, 1994, ANN NY ACAD SCI, V738, P86; Rouhier N, 2002, FEBS LETT, V511, P145, DOI 10.1016/S0014-5793(01)03302-6; Rouhier N, 2002, PROTEIN EXPRES PURIF, V24, P234, DOI 10.1006/prep.2001.1574; Rouhier N, 2001, PLANT PHYSIOL, V127, P1299, DOI 10.1104/pp.010586; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231	31	140	145	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13609	13614		10.1074/jbc.M111489200	http://dx.doi.org/10.1074/jbc.M111489200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832487	hybrid			2022-12-25	WOS:000175096000036
J	Brinkmann, T; Daumke, O; Herbrand, U; Kuhlmann, D; Stege, P; Ahmadian, MR; Wittinghofer, A				Brinkmann, T; Daumke, O; Herbrand, U; Kuhlmann, D; Stege, P; Ahmadian, MR; Wittinghofer, A			Rap-specific GTPase activating protein follows an alternative mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; CRYSTAL-STRUCTURE; BINDING PROTEIN; EFFECTOR REGION; GAP DOMAIN; COMPLEX; IDENTIFICATION; RESIDUES; SITE; P21	Rap1 is a small GTPase that is involved in signal transduction cascades. It is highly homologous to Ras but it is down-regulated by its own set of GTPase activating proteins (GAPs). To investigate the mechanism of the GTP-hydrolysis reaction catalyzed by Rap1GAP, a catalytically active fragment was expressed in Escherichia coli and characterized by kinetic and mutagenesis studies. The GTPase reaction of Rap1 is stimulated 10(5)-fold by Rap1GAP and has a k(cat) of 6 s(-1) at 25 degreesC. The catalytic effect of GAPs from Ras, Rho, and Rabs depends on a crucial arginine which is inserted into the active site. However, all seven highly conserved arginines of Rap1GAP can be mutated without dramatically reducing V-max of the GTP-hydrolysis reaction. We found instead two lysines whose mutations reduce catalysis 25- and 100-fold, most likely by an affinity effect. Rap1GAP does also not supply the crucial glutamine that is missing in Rap proteins at position 61. The Rap1(G12V) mutant which in Ras reduces catalysis 10(6)-fold is shown to be efficiently down-regulated by Rap1GAP. As an alternative, Rap1(F64A) is shown by kinetic and cell biological studies to be a Rap1GAP-resistant mutant. This study supports the notion of a completely different mechanism of the Rap1GAP-catalyzed GTP-hydrolysis reaction on Rap1.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.	Alfred.Wittinghofer@mpi-dortmund.mpg.de						Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; Ahmadian MR, 1997, NAT STRUCT BIOL, V4, P686, DOI 10.1038/nsb0997-686; Albert S, 1999, EMBO J, V18, P5216, DOI 10.1093/emboj/18.19.5216; Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Cherfils J, 1997, EMBO J, V16, P5582, DOI 10.1093/emboj/16.18.5582; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao QS, 1999, MOL CELL BIOL, V19, P733; Goldberg J, 1999, CELL, V96, P893, DOI 10.1016/S0092-8674(00)80598-X; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Graham DL, 1999, BIOCHEMISTRY-US, V38, P985, DOI 10.1021/bi9821770; Herrmann C, 1996, PROG BIOPHYS MOL BIO, V66, P1, DOI 10.1016/S0079-6107(96)00015-6; Hillig RC, 1999, MOL CELL, V3, P781, DOI 10.1016/S1097-2765(01)80010-1; HOLDEN JL, 1991, J BIOL CHEM, V266, P16992; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; Jordan JD, 1999, J BIOL CHEM, V274, P21507, DOI 10.1074/jbc.274.31.21507; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Kurachi H, 1997, J BIOL CHEM, V272, P28081, DOI 10.1074/jbc.272.44.28081; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; LEUPOLD CM, 1983, EUR J BIOCHEM, V135, P237, DOI 10.1111/j.1432-1033.1983.tb07643.x; Mandiyan V, 1999, EMBO J, V18, P6890, DOI 10.1093/emboj/18.24.6890; MARUTA H, 1991, J BIOL CHEM, V266, P11661; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; Nassar N, 1998, NAT STRUCT BIOL, V5, P1047, DOI 10.1038/4156; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; NICE EC, 1992, J BIOL CHEM, V267, P1546; Nicholas K.B., 1997, EMBNEW NEWS, V4, P14, DOI DOI 10.11118/ACTAUN201361041061; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; Rak A, 2000, EMBO J, V19, P5105, DOI 10.1093/emboj/19.19.5105; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHERER A, 1989, J MOL BIOL, V206, P257, DOI 10.1016/0022-2836(89)90540-8; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; van den Berghe N, 1999, J BIOL CHEM, V274, P11078, DOI 10.1074/jbc.274.16.11078; Vetter IR, 1999, FEBS LETT, V451, P175, DOI 10.1016/S0014-5793(99)00555-4; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	70	65	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12525	12531		10.1074/jbc.M109176200	http://dx.doi.org/10.1074/jbc.M109176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812780	hybrid			2022-12-25	WOS:000175036300008
J	Dai, YS; Cserjesi, P				Dai, YS; Cserjesi, P			The basic helix-loop-helix factor, HAND2, functions as a transcriptional activator by binding to E-boxes as a heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROENDOCRINE CELLS; CARDIAC MORPHOGENESIS; E2A PROTEINS; DNA-BINDING; EXPRESSION; GENE; TWIST; DIFFERENTIATION; DHAND; MOUSE	HAND2 (dHAND) is a basic helix-loop-helix (bHLH) transcription factor expressed in numerous tissues during development including the heart, limbs, and a subset of neural crest derivatives. Functional analysis has shown that HAND2 is involved in development of the branchial arches, heart, limb, vasculature, and nervous system. Although it is essential for development of numerous tissues, little is known about its mode of action. To this end, we have characterized HAND2 transcriptional regulatory mechanisms. Using mammalian one-hybrid analysis we show that HAND2 contains a strong transcriptional activation domain in the amino-terminal third of the protein. Like most tissue-restricted bHLH factors, HAND2 heterodimerizes with the broadly expressed bHLH factors, the E-proteins. We determined the consensus DNA binding site of HAND2 and show that HAND2 binds a subset of E-boxes as a heterodimer with E12. Yeast two-hybrid screening of a neuroblastoma cDNA library for HAND2-interacting proteins selected HAND2 and numerous additional members of the E-protein family. Although HAND2 homodimer formation was confirmed by in vitro analysis, HAND2 fails to homodimerize in a mammalian two-hybrid assay but demonstrates robust HAND2/E12 interaction. We conclude that HAND2 functions as a transcription activator by binding a subset of E-boxes as a heterodimer with E-proteins.	Louisiana State Univ, Ctr Hlth Sci, Dept Cell Biol & Anat, New Orleans, LA 70112 USA; Louisiana State Univ, Ctr Hlth Sci, Mol & Human Genet Ctr, New Orleans, LA 70112 USA; Columbia Univ, Dept Anat & Cell Biol, New York, NY 10032 USA	Louisiana State University System; Louisiana State University System; Columbia University	Cserjesi, P (corresponding author), Louisiana State Univ, Ctr Hlth Sci, Dept Cell Biol & Anat, 1901 Perdido St, New Orleans, LA 70112 USA.		Dai, Yanshan/B-8577-2009	Dai, Yanshan/0000-0001-5048-7417				Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Baum M, 2000, MOL CELL BIOL, V20, P2852, DOI 10.1128/MCB.20.8.2852-2864.2000; BENEZRA R, 1994, CELL, V79, P1057, DOI 10.1016/0092-8674(94)90036-1; BRENNAN TJ, 1990, GENE DEV, V4, P582, DOI 10.1101/gad.4.4.582; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; Charite J, 2000, DEVELOPMENT, V127, P2461; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; CSERJESI P, 1995, DEVELOPMENT, V121, P1099; Fernandez-Teran M, 2000, DEVELOPMENT, V127, P2133; Firulli AB, 1998, NAT GENET, V18, P266, DOI 10.1038/ng0398-266; Firulli BA, 2000, J BIOL CHEM, V275, P33567, DOI 10.1074/jbc.M005888200; FUCHTBAUER EM, 1995, DEV DYNAM, V204, P316; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Harfe BD, 1998, GENE DEV, V12, P2623, DOI 10.1101/gad.12.16.2623; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Howard M, 1999, DEV BIOL, V215, P62, DOI 10.1006/dbio.1999.9450; Huang J, 1998, MOL CELL BIOL, V18, P5478, DOI 10.1128/MCB.18.9.5478; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; Markus M, 1999, J BIOL CHEM, V274, P1040, DOI 10.1074/jbc.274.2.1040; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCormick MB, 1996, MOL CELL BIOL, V16, P5792; Mutoh H, 1997, P NATL ACAD SCI USA, V94, P3560, DOI 10.1073/pnas.94.8.3560; Mutoh H, 1998, GENE DEV, V12, P820, DOI 10.1101/gad.12.6.820; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; NELSEN B, 1992, INT REV CYTOL, V133, P121, DOI 10.1016/S0074-7696(08)61859-8; Okuwaki M, 2001, FEBS LETT, V506, P272, DOI 10.1016/S0014-5793(01)02939-8; Persson P, 2000, BIOCHEM BIOPH RES CO, V274, P22, DOI 10.1006/bbrc.2000.3090; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; Srivastava D, 1997, NAT GENET, V16, P154, DOI 10.1038/ng0697-154; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Wang SM, 1997, GENE, V187, P83, DOI 10.1016/S0378-1119(96)00727-5; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	39	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12604	12612		10.1074/jbc.M200283200	http://dx.doi.org/10.1074/jbc.M200283200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812799	hybrid			2022-12-25	WOS:000175036300017
J	Gennero, I; Fauvel, J; Nieto, M; Cariven, C; Gaits, F; Briand-Mesange, F; Chap, H; Salles, JP				Gennero, I; Fauvel, J; Nieto, M; Cariven, C; Gaits, F; Briand-Mesange, F; Chap, H; Salles, JP			Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED SIGNAL-TRANSDUCTION; PROTEIN-COUPLED RECEPTORS; LYSOPHOSPHATIDIC-ACID; GROWTH-FACTOR; ANGIOTENSIN-II; TYROSINE PHOSPHORYLATION; SPHINGOLIPID METABOLISM; STRESS-RESPONSE; SPHINGOSINE-1-PHOSPHATE; CERAMIDE	The lipid mediator sphingosine 1-phosphate (SIP) may alter the proliferation of mesangial cells during pathophysiological processes. Here, S1P stimulated proliferation of rat mesangial cells and phosphorylation of MAPKs at subconfluent cell density. Both effects were inhibited by pertussis toxin treatment. Mesangial cells expressed several SIP receptors of the endothelial differentiation gene family: EDG-1, -3, -5, and -8. Conversely, S1P induced apoptosis at low cell density (2 X 10(4) cells/cm(2)), which was demonstrated by flow cytometry and Hoechst staining. Apoptosis was observed also in quiescent or growing cells and was not reverted by lysophosphatidic acid or platelet-derived growth factor. SIP enhanced phosphorylation of SAPKs. Incubation with [P-33]S1P, [H-3]S1P, and [H-3]sphingosine demonstrated increased SIP hydrolysis, resulting in enhanced intracellular sphingosine levels and decreased S1P levels. A rise in total ceramide levels was also observed; however, ceramide did not originate from [H-3]sphingosine, and S1P-induced apoptosis was not inhibited by fumonisin B, precluding involvement of de novo ceramide synthesis in apoptosis. Therefore, we suggest that sphingosine accumulation and decreased S1P are primarily responsible for S1P-induced apoptosis. In conclusion, incubation of low-density mesangial cells with S1P results in apoptosis, presumably due to increased S1P hydrolysis.	Hop Purpan, INSERM Unite 326, Inst Claude Preval, Inst Federatif Rech 30, F-31059 Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Salles, JP (corresponding author), Hop Purpan, INSERM Unite 326, Inst Claude Preval, Inst Federatif Rech 30, Pl Dr Baylac, F-31059 Toulouse, France.		SALLES, Jean Pierre/K-2998-2014	Briand Mesange, Fabienne/0000-0002-2524-1762; Gaits-Iacovoni, Frederique/0000-0002-9853-0442				Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Batt DB, 1998, J BIOL CHEM, V273, P3408, DOI 10.1074/jbc.273.6.3408; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brindley DN, 2000, METHOD ENZYMOL, V311, P233; Chen PF, 1998, KIDNEY INT, V54, P1470, DOI 10.1046/j.1523-1755.1998.00162.x; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Cybulsky AV, 2000, CURR OPIN NEPHROL HY, V9, P217, DOI 10.1097/00041552-200005000-00003; Daha MR, 2000, J NEPHROL, V13, pS89; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Edsall LC, 2001, J NEUROCHEM, V76, P1573, DOI 10.1046/j.1471-4159.2001.00164.x; Gaits F, 1997, KIDNEY INT, V51, P1022, DOI 10.1038/ki.1997.143; Gennero I, 2000, ANN NY ACAD SCI, V905, P340; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hung WC, 1996, BIOCHEM BIOPH RES CO, V229, P11, DOI 10.1006/bbrc.1996.1750; HUWILER A, 1995, BIOCHEM J, V305, P777, DOI 10.1042/bj3050777; Igarashi Y, 1998, AM J HEMATOL, V57, P261; Inoue CN, 1999, CLIN SCI, V96, P431, DOI 10.1042/CS19980248; INOUE CN, 1995, CIRC RES, V77, P888, DOI 10.1161/01.RES.77.5.888; Inoue CN, 1997, P SOC EXP BIOL MED, V216, P370; Izevbigie EB, 2000, PEDIATR RES, V47, P614, DOI 10.1203/00006450-200005000-00010; Jasinska R, 1999, BIOCHEM J, V340, P677, DOI 10.1042/0264-6021:3400677; Kagedal K, 2001, BIOCHEM J, V359, P335, DOI 10.1042/0264-6021:3590335; Kitamura M, 1999, KIDNEY INT, V55, P1639, DOI 10.1046/j.1523-1755.1999.00425.x; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Laffargue M, 1999, J BIOL CHEM, V274, P32835, DOI 10.1074/jbc.274.46.32835; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Mandala SM, 2000, P NATL ACAD SCI USA, V97, P7859, DOI 10.1073/pnas.120146897; Mandala SM, 1998, P NATL ACAD SCI USA, V95, P150, DOI 10.1073/pnas.95.1.150; Matsubara S, 2001, J CELL BIOL, V154, P573, DOI 10.1083/jcb.200103097; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moore AN, 1999, NEUROSCIENCE, V94, P405, DOI 10.1016/S0306-4522(99)00288-2; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PREISS J, 1986, J BIOL CHEM, V261, P8597; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Reiser COA, 1998, BIOCHEM J, V330, P1107; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; SALLES JP, 1993, J BIOL CHEM, V268, P12805; Schmelz EM, 2001, CANCER RES, V61, P6723; Schocklmann HO, 1999, KIDNEY INT, V56, P1199, DOI 10.1046/j.1523-1755.1999.00710.x; Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; STRIKER GE, 1985, LAB INVEST, V53, P122; Sweeney EA, 1999, J BIOCHEM, V125, P737, DOI 10.1093/oxfordjournals.jbchem.a022344; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; VAN BT, 1995, NATURE, V376, P781; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Waggoner DW, 1999, BBA-MOL CELL BIOL L, V1439, P299, DOI 10.1016/S1388-1981(99)00102-X; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Wolf G, 2000, KIDNEY INT, V58, pS59, DOI 10.1046/j.1523-1755.2000.07710.x	59	48	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12724	12734		10.1074/jbc.M108933200	http://dx.doi.org/10.1074/jbc.M108933200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821388	hybrid			2022-12-25	WOS:000175036300031
J	Battaile, KP; Molin-Case, J; Paschke, R; Wang, M; Bennett, D; Vockley, J; Kim, JJP				Battaile, KP; Molin-Case, J; Paschke, R; Wang, M; Bennett, D; Vockley, J; Kim, JJP			Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with acetoacetyl-CoA - Comparison with other acyl-CoA dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; LIVER MITOCHONDRIA; BUTYRYL-COA; SUBSTRATE-SPECIFICITY; CARNITINE DEFICIENCY; MEGASPHAERA-ELSDENII; PURIFICATION; ENZYME; GENE; IDENTIFICATION	The acyl-CoA dehydrogenases are a family of flavin adenine dinucleotide-containing enzymes that catalyze the first step in the beta-oxidation of fatty acids and catabolism of some amino acids. They exhibit high sequence identity and yet are quite specific in their substrate binding. Short chain acyl-CoA dehydrogenase has maximal activity toward butyryl-CoA and negligible activity toward substrates longer than octanoyl-CoA. The crystal structure of rat short chain acyl-CoA dehydrogenase complexed with the inhibitor acetoacetyl-CoA has been determined at 2.25 Angstrom resolution. Short chain acyl-CoA dehydrogenase is a homotetramer with a subunit mass of 43 kDa and crystallizes in the space group P321 with a = 143.61 Angstrom and c = 77.46 Angstrom. There are two monomers in the asymmetric unit. The overall structure of short chain acyl-CoA dehydrogenase is very similar to those of medium chain acyl-CoA dehydrogenase, isovaleryl-CoA dehydrogenase, and bacterial short chain acyl-CoA dehydrogenase with a three-domain structure composed of N- and C-terminal alpha-helical domains separated by a beta-sheet domain. Comparison to other acyl-CoA dehydrogenases has provided additional insight into the basis of substrate specificity and the nature of the oxidase activity in this enzyme family. Ten reported pathogenic human mutations and two polymorphisms have been mapped onto the structure of short chain acyl-CoA dehydrogenase. None of the mutations directly affect the binding cavity or intersubunit interactions.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Mayo Clin & Mayo Fdn, Dept Biochem, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Biol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA	Medical College of Wisconsin; Mayo Clinic; Mayo Clinic; Mayo Clinic	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.		Vockley, Jerry/AAF-8523-2020; Vockley, Jerry/B-5210-2016	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457; Battaile, Kevin/0000-0003-0833-3259	NIDDK NIH HHS [DK54936] Funding Source: Medline; NIGMS NIH HHS [GM29076] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054936] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029076] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMENDT BA, 1987, J CLIN INVEST, V79, P1303, DOI 10.1172/JCI112953; ANDRESEN BS, 1993, AM J HUM GENET, V53, P730; Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; Beinert H., 1963, ENZYMES, P447; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COATES PM, 1988, J CLIN INVEST, V81, P171, DOI 10.1172/JCI113290; Corydon MJ, 2001, PEDIATR RES, V49, P18; Corydon TJ, 1998, J BIOL CHEM, V273, P13065, DOI 10.1074/jbc.273.21.13065; CRANE FL, 1956, J BIOL CHEM, V218, P717; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; DuPlessis ER, 1998, BIOCHEMISTRY-US, V37, P10469, DOI 10.1021/bi980767s; ENGEL PC, 1992, CHEM BIOCH FLAVOENZY, P597; FARNSWORTH L, 1990, ANN NEUROL, V28, P717, DOI 10.1002/ana.410280520; FINOCCHIARO G, 1987, J BIOL CHEM, V262, P7982; GHISLA S, 1993, FLAVINS FLAVOPROTEIN, P283; GOODMAN SI, 1992, PROG CLIN BIOL RES, V375, P169; Gregersen N, 1998, HUM MOL GENET, V7, P619, DOI 10.1093/hmg/7.4.619; Hashimoto Takashi, 1992, V375, P19; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1983, J BIOL CHEM, V258, P9477; IKEDA Y, 1985, J BIOL CHEM, V260, P1311; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; JENSEN TG, 1995, HUM MUTAT, V6, P226, DOI 10.1002/humu.1380060305; JOHNSON JK, 1994, BIOCHEMISTRY-US, V33, P4738, DOI 10.1021/bi00181a033; KIM JJ, 1988, P NATL ACAD SCI USA, V84, P6677; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRISTENSEN MJ, 1994, HUM MOL GENET, V3, P1711, DOI 10.1093/hmg/3.9.1711-a; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; LENICH AC, 1986, J BIOL CHEM, V261, P4090; MATSUBARA Y, 1989, J BIOL CHEM, V264, P16321; MCPHERSON A, 1999, CRYSTALLIZATION BIOL, P182; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAITO E, 1990, J CLIN INVEST, V85, P1575, DOI 10.1172/JCI114607; NAITO E, 1989, J CLIN INVEST, V84, P1671, DOI 10.1172/JCI114346; Nandy A, 1996, BIOCHEMISTRY-US, V35, P12402, DOI 10.1021/bi960785e; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; POHL B, 1986, EUR J BIOCHEM, V160, P109, DOI 10.1111/j.1432-1033.1986.tb09946.x; ROUSSEL A, 1993, TURBO FRODO VERSIO 4; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; TURNBULL DM, 1984, NEW ENGL J MED, V311, P1232, DOI 10.1056/NEJM198411083111906; WANG R, 1991, BIOCHEMISTRY-US, V30, P7895, DOI 10.1021/bi00246a004; WILLIAMSON G, 1984, BIOCHEM J, V218, P521, DOI 10.1042/bj2180521	46	67	69	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12200	12207		10.1074/jbc.M111296200	http://dx.doi.org/10.1074/jbc.M111296200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812788	hybrid			2022-12-25	WOS:000174846400078
J	Schreyer, SA; Vick, CM; LeBoeuf, RC				Schreyer, SA; Vick, CM; LeBoeuf, RC			Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; LYMPHOID ORGAN DEVELOPMENT; FACTOR RECEPTOR; TNF RECEPTOR; DEFICIENT MICE; T-CELLS; ACCELERATED ATHEROSCLEROSIS; ADHESION MOLECULE; BETA COMPLEXES; LT-ALPHA	Inflammatory processes are involved with all phases of atherosclerotic lesion growth. Tumor necrosis factor-alpha (TNFalpha) is an inflammatory cytokine that is thought to contribute to lesion development. Lymphotoxin-alpha (LTalpha) is also a proinflammatory cytokine with homology to TNFalpha. However, its presence or function in lesion development has not been investigated. To study the role of these molecules in atherosclerosis, the expression of these cytokines in atherosclerotic lesions was examined. The presence of both cytokines was observed within aortic sinus fatty streak lesions. To deterine the function of these molecules in regulating lesion growth, mice deficient for TNFalpha or LTalpha were examined for induction of atherosclerosis. Surprisingly, loss of TNFalpha did not alter lesion development compared with wild-type mice. This brings doubt to the generally held concept that TNFalpha is a "proatherogenic cytokine." However, LTalpha deficiency resulted in a 62% reduction in lesion size. This demonstrates an unexpected role for LTalpha in promoting lesion growth. The presence of LTalpha was observed in aortic sinus lesions suggesting a direct role of LTalpha in modulating lesion growth. To determine which receptor mediated these responses, diet-induced atherosclerosis in mice deficient for each of the TNF receptors, termed p55 and p75, was examined. Results demonstrated that loss of p55 resulted in increased lesion development, but loss of p75 did not alter lesion size. The disparity in results between ligand- and receptor-deficient mice suggests there are undefined members of the TNF ligand and receptor signaling pathway involved with regulating atherogenesis.	Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Univ Washington, Nutrit Sci Interdisciplinary Program, Seattle, WA 98195 USA; AstraZeneca, Dept Cell Biol & Biochem, S-43183 Molndal, Sweden	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; AstraZeneca	LeBoeuf, RC (corresponding author), Univ Washington, Dept Pathobiol, Rm 305,Raitt Hall,Box 353410, Seattle, WA 98195 USA.				NHLBI NIH HHS [HL52848] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052848] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANKS TA, 1995, J IMMUNOL, V155, P1685; BARATH P, 1990, AM J PATHOL, V137, P503; BARATH P, 1990, AM J CARDIOL, V65, P297, DOI 10.1016/0002-9149(90)90291-8; BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.immunol.7.1.625; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Browning JL, 1997, J IMMUNOL, V159, P3288; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; Browning JL, 1996, J EXP MED, V183, P867, DOI 10.1084/jem.183.3.867; Cuff CA, 1998, J IMMUNOL, V161, P6853; Cuff CA, 1999, J IMMUNOL, V162, P5965; Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642; Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681; De Boer OJ, 1999, J PATHOL, V188, P174, DOI 10.1002/(SICI)1096-9896(199906)188:2<174::AID-PATH333>3.0.CO;2-3; DegliEsposti MA, 1997, J IMMUNOL, V158, P1756; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; Emeson EE, 1996, AM J PATHOL, V149, P675; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; George J, 1999, ARTERIOSCL THROM VAS, V19, P505, DOI 10.1161/01.ATV.19.3.505; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; HANSSON GK, 1989, ARTERIOSCLEROSIS, V9, P567, DOI 10.1161/01.ATV.9.5.567; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; Kaartinen M, 1996, CIRCULATION, V94, P2787, DOI 10.1161/01.CIR.94.11.2787; Kulmburg P, 1998, LEUKEMIA, V12, P493, DOI 10.1038/sj.leu.2400954; Kumaraguru U, 2001, J IMMUNOL, V166, P1066, DOI 10.4049/jimmunol.166.2.1066; Kunjathoor VV, 1996, J CLIN INVEST, V97, P1767, DOI 10.1172/JCI118604; LeBoeuf RC, 1998, TRENDS CARDIOVAS MED, V8, P131, DOI 10.1016/S1050-1738(97)00142-4; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mackay F, 1997, J IMMUNOL, V159, P3299; MACKAY F, 1993, J EXP MED, V177, P1277, DOI 10.1084/jem.177.5.1277; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Neumann B, 1996, J IMMUNOL, V156, P1587; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Paulsson G, 2000, ARTERIOSCL THROM VAS, V20, P10, DOI 10.1161/01.ATV.20.1.10; Peschon JJ, 1998, J IMMUNOL, V160, P943; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; QIAO JH, 1994, ARTERIOSCLER THROMB, V14, P1480, DOI 10.1161/01.ATV.14.9.1480; Reckless J, 1999, CIRCULATION, V99, P2310, DOI 10.1161/01.CIR.99.17.2310; Roselaar SE, 1996, ARTERIOSCL THROM VAS, V16, P1013, DOI 10.1161/01.ATV.16.8.1013; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Schreyer SA, 1996, J BIOL CHEM, V271, P26174, DOI 10.1074/jbc.271.42.26174; Schreyer SA, 1998, ATHEROSCLEROSIS, V136, P17, DOI 10.1016/S0021-9150(97)00165-2; Suen WE, 1997, J EXP MED, V186, P1233, DOI 10.1084/jem.186.8.1233; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; von Wolff M, 1999, MOL HUM REPROD, V5, P146, DOI 10.1093/molehr/5.2.146; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Ware C F, 1995, Curr Top Microbiol Immunol, V198, P175; Ware CF, 1996, J CELL BIOCHEM, V60, P47, DOI 10.1002/(SICI)1097-4644(19960101)60:1<47::AID-JCB8>3.3.CO;2-H; WARNER SJC, 1989, J IMMUNOL, V142, P100; XU QB, 1990, CLIN IMMUNOL IMMUNOP, V56, P344, DOI 10.1016/0090-1229(90)90155-J; Yamakawa T, 1999, ENDOCRINOLOGY, V140, P3562, DOI 10.1210/en.140.8.3562; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zhou X, 1999, SCAND J IMMUNOL, V50, P25	57	128	135	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12364	12368		10.1074/jbc.M111727200	http://dx.doi.org/10.1074/jbc.M111727200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809756	hybrid			2022-12-25	WOS:000174846400100
J	Bieganowski, P; Garrison, PN; Hodawadekar, SC; Faye, G; Barnes, LD; Brenner, C				Bieganowski, P; Garrison, PN; Hodawadekar, SC; Faye, G; Barnes, LD; Brenner, C			Adenosine monophosphoramidase activity of Hint and Hnt1 supports function of Kin28, Ccl1, and Tfb3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CDK-ACTIVATING KINASE; CYCLIN-DEPENDENT KINASE; RNA-POLYMERASE-II; HIT PROTEIN FAMILY; NUCLEOTIDE-BINDING PROTEINS; TRANSCRIPTION FACTOR TFIIH; HISTIDINE TRIAD PROTEINS; RING FINGER PROTEIN; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST	The histidine triad superfamily of nucleotide hydrolases and nucleotide transferases consists of a branch of proteins related to Hint and Aprataxin, a branch of Fhit-related hydrolases, and a branch of galactose-1-phosphate uridylyltransferase (GalT)-related transferases. Although substrates of Fhit and GalT are known and consequences of mutations in Aprataxin, Fhit, and GalT are known, good substrates had not been reported for any member of the Hint branch, and mutational consequences were unknown for Hint orthologs, which are the most ancient and widespread proteins in the Hint branch and in the histidine triad superfamily. Here we show that rabbit and yeast Hint hydrolyze the natural product adenosine-5'-monophosphoramidate (AMPNH(2)) in an active-site-dependent manner at second order rates exceeding 1,000,000 M-1 S-1. Yeast strains constructed with specific loss of the Hntl active site fail to grow on galactose at elevated temperatures. Loss of Hntl enzyme activity also leads to hypersensitivity to mutations in Cell, Tfb3, and Kin28, which constitute the TFIIK kinase subcomplex of general transcription factor TFIIH and to mutations in Cak1, which phosphorylates Kin28. The target of Hnt1 regulation in this pathway was shown to be downstream of Cak1 and not to affect stability of Kin28 monomers. Functional complementation of all Hnt1 phenotypes was provided by rabbit Hint, which is only 22% identical to yeast Hntl but has very similar adenosine monophosphoramidase activity.	Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Inst Curie, UMR 2027, CNRS, F-91405 Orsay, France	Jefferson University; University of Texas System; University of Texas Health San Antonio; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Brenner, C (corresponding author), Kimmel Canc Ctr, Struct Biol & Bioinformat Program, 233 S 10th St,Rm 826, Philadelphia, PA 19107 USA.		Bieganowski, Pawel/ABC-8554-2021; Brenner, Charles/D-6339-2014	Bieganowski, Pawel/0000-0002-1169-4517; Brenner, Charles/0000-0002-4955-3226	NCI NIH HHS [R01 CA075954-05, CA75954, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abend A, 1999, BIOCHEMISTRY-US, V38, P3668, DOI 10.1021/bi981895j; AKOULITCHEV S, 1995, NATURE, V377, P557, DOI 10.1038/377557a0; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Balzarini J, 1996, P NATL ACAD SCI USA, V93, P7295, DOI 10.1073/pnas.93.14.7295; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; Brachmann CB, 1998, YEAST, V14, P115; Brenner C, 1999, J CELL PHYSIOL, V181, P179, DOI 10.1002/(SICI)1097-4652(199911)181:2<179::AID-JCP1>3.0.CO;2-8; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; Bruser T, 2000, J BIOL CHEM, V275, P1691, DOI 10.1074/jbc.275.3.1691; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Cross FR, 1998, MOL CELL BIOL, V18, P2923, DOI 10.1128/MCB.18.5.2923; Date H, 2001, NAT GENET, V29, P184, DOI 10.1038/ng1001-184; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; Enke DA, 1999, J BIOL CHEM, V274, P1949, DOI 10.1074/jbc.274.4.1949; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Espinoza FH, 2000, MOL CELL BIOL, V20, P1898, DOI 10.1128/MCB.20.5.1898-1898.2000; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; FANKHAUSER H, 1981, BIOCHEM BIOPH RES CO, V101, P524, DOI 10.1016/0006-291X(81)91291-2; FANKHAUSER H, 1981, BIOCHEM J, V195, P545, DOI 10.1042/bj1950545; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; Feaver WJ, 1997, J BIOL CHEM, V272, P19319, DOI 10.1074/jbc.272.31.19319; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; Gilmour J, 1997, BIOCHEM J, V326, P471, DOI 10.1042/bj3260471; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; GUMPORT RI, 1971, P NATL ACAD SCI USA, V68, P2559, DOI 10.1073/pnas.68.10.2559; HERREN B, 1993, J RECEPTOR RES, V13, P725, DOI 10.3109/10799899309073689; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Ji L, 1999, CANCER RES, V59, P3333; KAISER C, 1994, METHODS YEAST GENETI, P133; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kimmelman J, 1999, MOL CELL BIOL, V19, P4774; Korsisaari N, 2000, J BIOL CHEM, V275, P34837, DOI 10.1074/jbc.C000505200; KUBA M, 1994, INT J BIOCHEM, V26, P235; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE H, 1971, BIOCHIM BIOPHYS ACTA, V242, P519, DOI 10.1016/0005-2744(71)90144-6; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; Lima CD, 1997, SCIENCE, V278, P286, DOI 10.1126/science.278.5336.286; Moreira MC, 2001, NAT GENET, V29, P189, DOI 10.1038/ng1001-189; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Pekarsky Y, 1998, P NATL ACAD SCI USA, V95, P8744, DOI 10.1073/pnas.95.15.8744; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROSSOMANDO EF, 1986, INT J BIOCHEM, V18, P481, DOI 10.1016/0020-711X(86)90193-X; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; SERIZAWA H, 1995, NATURE, V374, P280, DOI 10.1038/374280a0; SHIEKHATTAR R, 1995, NATURE, V374, P283, DOI 10.1038/374283a0; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; TOMKINSON AE, 1991, P NATL ACAD SCI USA, V88, P400, DOI 10.1073/pnas.88.2.400; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; VALAY JG, 1995, J MOL BIOL, V249, P535, DOI 10.1006/jmbi.1995.0316; Valay JG, 1996, CR ACAD SCI III-VIE, V319, P183; Wedekind JE, 1996, BIOCHEMISTRY-US, V35, P11560, DOI 10.1021/bi9612677	66	97	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10852	10860		10.1074/jbc.M111480200	http://dx.doi.org/10.1074/jbc.M111480200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805111	Green Accepted, hybrid			2022-12-25	WOS:000174613100015
J	Shapiro, DA; Kristiansen, K; Weiner, DM; Kroeze, WK; Roth, BL				Shapiro, DA; Kristiansen, K; Weiner, DM; Kroeze, WK; Roth, BL			Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVELY ACTIVE MUTANTS; SITE-DIRECTED MUTAGENESIS; PROTEIN-COUPLED RECEPTORS; ALPHA(1B)-ADRENERGIC RECEPTOR; CONFORMATIONAL-CHANGES; MUSCARINIC RECEPTOR; INTRACELLULAR LOOP; AMINO-ACIDS; MUTATIONS; BINDING	5-Hydroxytryptamine 2A (5-HT2A) receptors are essential for the actions of serotonin (5-hydroxytryptamine (5-HT)) on physiological processes as diverse as vascular smooth muscle contraction, platelet aggregation, perception, and emotion. In this study, we investigated the molecular mechanism(s) by which 5-HT activates 5-HT2A receptors using a combination of approaches including site-directed mutagenesis, molecular modeling, and pharmacological analysis using the sensitive, cell-based functional assay R-SAT. Alanine-scanning mutagenesis of residues close to the intracellular end of H6 of the 5-HT2A receptor implicated glutamate Glu-318(6.30) in receptor activation, as also predicted by a newly constructed molecular model of the 5-HT2A receptor, which was based on the x-ray structure of bovine rhodopsin. Close examination of the molecular model suggested that Glu-318(6.30) could form a strong ionic interaction with Arg-173(3.50) of the highly conserved "(D/E)RY motif" located at the interface between the third transmembrane segment and the second intracellular loop (i2). A direct prediction of this hypothesis, that disrupting this ionic interaction by an E318(6.30)R mutation would lead to a highly constitutively active receptor with enhanced affinity for agonist, was confirmed using R-SAT. Taken together, these results predict that the disruption of a strong ionic interaction between transmembrane helices 3 and 6 of 5-HT2A receptors is essential for agonist-induced receptor activation and, as recently predicted by ourselves (B. L. Roth and D. A. Shapiro (2001) Expert Opin. Ther. Targets 5, 685-695) and others, that this may represent a general mechanism of activation for many, but not all, G-protein-coupled receptors.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; ACADIA Pharmaceut Inc, San Diego, CA 92121 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA USA; Univ Calif San Diego, Dept Psychiat, La Jolla, CA USA; Univ Tromso, Inst Pharm, Dept Pharmacol, N-9037 Tromso, Norway	Case Western Reserve University; University of California System; University of California San Diego; University of California System; University of California San Diego; UiT The Arctic University of Tromso	Roth, BL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Roth, Bryan L/F-3928-2010; Roth, Bryan/ABE-7032-2020	Roth, Bryan/0000-0002-0561-6520	NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001366, R01MH057635] Funding Source: NIH RePORTER; NIMH NIH HHS [R01MH57635, KO2MH01366] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CHOUDHARY MS, 1993, MOL PHARMACOL, V43, P755; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Egan CT, 1998, J PHARMACOL EXP THER, V286, P85; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HerrickDavis K, 1997, J NEUROCHEM, V69, P1138; Kobilka B K, 1998, Adv Pharmacol, V42, P470; Kristiansen K, 2000, J PHARMACOL EXP THER, V293, P735; Lattion AL, 1999, FEBS LETT, V457, P302, DOI 10.1016/S0014-5793(99)01064-9; MIN KC, 1993, J BIOL CHEM, V268, P9400; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Parnot C, 2000, P NATL ACAD SCI USA, V97, P7615, DOI 10.1073/pnas.110142297; Pauwels PJ, 1999, BIOCHEM J, V343, P435, DOI 10.1042/0264-6021:3430435; Porter JE, 1996, J BIOL CHEM, V271, P28318, DOI 10.1074/jbc.271.45.28318; Porter JE, 1999, J BIOL CHEM, V274, P34535, DOI 10.1074/jbc.274.49.34535; Price RD, 2001, J BIOL CHEM, V276, P44663, DOI 10.1074/jbc.M106745200; ROBINSON PR, 1992, NEURON, V9, P719, DOI 10.1016/0896-6273(92)90034-B; Roth BL, 2000, NEUROSCIENTIST, V6, P252, DOI 10.1177/107385840000600408; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; Roth BL, 1999, NEURON, V23, P629, DOI 10.1016/S0896-6273(02)23443-1; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Roth Bryan L, 2001, Expert Opin Ther Targets, V5, P685; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Shapiro DA, 2000, MOL PHARMACOL, V58, P877, DOI 10.1124/mol.58.5.877; Spalding TA, 1997, BIOCHEMISTRY-US, V36, P10109, DOI 10.1021/bi970565g; Spalding TA, 1998, J BIOL CHEM, V273, P21563, DOI 10.1074/jbc.273.34.21563; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WANG CD, 1993, MOL PHARMACOL, V43, P931; Weiner DM, 2001, J PHARMACOL EXP THER, V299, P268; Wurch T, 1999, BRIT J PHARMACOL, V126, P939, DOI 10.1038/sj.bjp.0702379; ZHOU W, 1994, MOL PHARMACOL, V45, P165	41	147	148	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11441	11449		10.1074/jbc.M111675200	http://dx.doi.org/10.1074/jbc.M111675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801601	hybrid, Green Published			2022-12-25	WOS:000174613100088
J	Kabos, P; Kabosova, A; Neuman, T				Kabos, P; Kabosova, A; Neuman, T			Blocking HES1 expression initiates GABAergic differentiation and induces the expression of p21(CIP1/WAF1) in human neural stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX FACTORS; SIGNALING PATHWAY; NERVOUS-SYSTEM; NOTCH; NEUROGENESIS; GLIOGENESIS; GROWTH; GENES	Mammalian neural stem cells can develop into a variety of neuronal and glial cell types. This involves a highly coordinated process of differentiation in which the Notch signaling pathway and the system of helix-loop-helix (HLH) transcriptional regulators play a key role. By exercising control over proliferation, initiation of differentiation, neurite outgrowth, and synaptogenesis, the network of HLH transcription factors regulates the fate of neural stem cells and progenitors. Here we show that the HLH transcription factor HES1 regulates the proliferation of human neural stem cells and that blocking its expression stimulates the expression of cyclin-dependent kinase inhibitor p21(CIP1/WAF1). Furthermore, we demonstrate that the suppression of HES1 expression initiates differentiation of neural stem cells into neurons, the majority of which develop the GABAergic phenotype. These findings underscore the importance of the HLH network, and HES1 in particular, in guiding the phenotypic development of neural stem cells.	Univ Calif Los Angeles, Sch Med,Cedars Sinai Med Ctr, Maxine Dunitz Neurol Inst, Dept Surg,Burns & Allen Res Inst, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kabos, P (corresponding author), Univ Calif Los Angeles, Sch Med,Cedars Sinai Med Ctr, Maxine Dunitz Neurol Inst, Dept Surg,Burns & Allen Res Inst, 110 George Burns Rd,Davis Rm 2096, Los Angeles, CA 90048 USA.	kabosp@cshs.org						ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Bae SK, 2000, DEVELOPMENT, V127, P2933; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Cai L, 2000, DEVELOPMENT, V127, P3021; Cau E, 2000, DEVELOPMENT, V127, P2323; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; delaPompa J, 1997, DEVELOPMENT, V124, P1139; Gaiano N, 2000, NEURON, V26, P395, DOI 10.1016/S0896-6273(00)81172-1; Gowan K, 2001, NEURON, V31, P219, DOI 10.1016/S0896-6273(01)00367-1; Helms AW, 2001, MOL CELL NEUROSCI, V17, P671, DOI 10.1006/mcne.2000.0969; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Lee SK, 2001, NAT NEUROSCI, V4, P1183, DOI 10.1038/nn750; Morrison SJ, 2000, CELL, V101, P499, DOI 10.1016/S0092-8674(00)80860-0; Nakamura Y, 2000, J NEUROSCI, V20, P283, DOI 10.1523/JNEUROSCI.20-01-00283.2000; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Ohtsuka T, 2001, J BIOL CHEM, V276, P30467, DOI 10.1074/jbc.M102420200; Palm K, 2000, MOL BRAIN RES, V78, P192, DOI 10.1016/S0169-328X(00)00075-9; Panchision DM, 2001, GENE DEV, V15, P2094, DOI 10.1101/gad.894701; Scardigli R, 2001, NEURON, V31, P203, DOI 10.1016/S0896-6273(01)00358-0; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Vetter M, 2001, NEURON, V29, P559, DOI 10.1016/S0896-6273(01)00231-8	26	73	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8763	8766		10.1074/jbc.C100758200	http://dx.doi.org/10.1074/jbc.C100758200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11809764	hybrid			2022-12-25	WOS:000174400600003
J	Polager, S; Kalma, Y; Berkovich, E; Ginsberg, D				Polager, S; Kalma, Y; Berkovich, E; Ginsberg, D			E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis	ONCOGENE			English	Article						E2F; cell cycle; mitosis; DNA replication; DNA repair; DNA microarrays	TRANSCRIPTION FACTOR E2F-1; S-PHASE ENTRY; CELL-CYCLE; PROTEIN; INDUCTION; PROMOTER; BINDING; MICE; SAK; NUCLEAR	The E2F family of transcription factors plays a pivotal role in the regulation of cell proliferation in higher eukaryotes. We used DNA microarrays and cell lines containing either inducible E2F-1 or inducible E2F-3 to identify novel E2F target genes. Our data indicate that E2F up-regulates the expression of genes not previously described as E2F target genes. A number of these E2F-regulated genes are involved in DNA replication, DNA repair and mitosis. These results suggest that E2F affects cell cycle progression both at S phase and during mitosis. Furthermore, our findings indicate that E2F-dependent gene activation may contribute to the cellular response to DNA damage.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Ginsberg, D (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	doron.ginsberg@weizmann.ac.il		ginsberg, doron/0000-0002-1257-4920				Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Davenport JW, 1999, GENOMICS, V55, P113, DOI 10.1006/geno.1998.5629; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FODE C, 1994, P NATL ACAD SCI USA, V91, P6388, DOI 10.1073/pnas.91.14.6388; GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Hofferer M, 1999, NUCLEIC ACIDS RES, V27, P491, DOI 10.1093/nar/27.2.491; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Hudson JW, 2000, GENE, V241, P65, DOI 10.1016/S0378-1119(99)00467-9; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Humbert PO, 2000, GENE DEV, V14, P690; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iwahashi Y, 1998, GENE, V213, P141, DOI 10.1016/S0378-1119(98)00187-5; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kalma Y, 2001, ONCOGENE, V20, P1379, DOI 10.1038/sj.onc.1204230; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; Lavia P, 1999, BIOESSAYS, V21, P221; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Lukas J, 1996, MOL CELL BIOL, V16, P1047; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; O'Connor DJ, 2000, ONCOGENE, V19, P2369, DOI 10.1038/sj.onc.1203540; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Scherer SJ, 1996, HUM GENET, V97, P114; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SOMPAYRAC L, 1994, VIROLOGY, V200, P849, DOI 10.1006/viro.1994.1255; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WALSH MJ, 1995, J BIOL CHEM, V270, P5289, DOI 10.1074/jbc.270.10.5289; Wang A, 2000, J BIOL CHEM, V275, P4532, DOI 10.1074/jbc.275.6.4532; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Wu CL, 1996, MOL CELL BIOL, V16, P3698; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	45	214	217	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					437	446		10.1038/sj.onc.1205102	http://dx.doi.org/10.1038/sj.onc.1205102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821956				2022-12-25	WOS:000173311200012
J	Nimonkar, AV; Boehmer, PE				Nimonkar, AV; Boehmer, PE			In vitro strand exchange promoted by the herpes simplex virus type-1 single strand DNA-binding protein (ICP8) and DNA helicase-primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIELD GEL-ELECTROPHORESIS; VIRAL-A SEQUENCES; HOMOLOGOUS RECOMBINATION; GENETIC-RECOMBINATION; ALKALINE NUCLEASE; ESCHERICHIA-COLI; BRANCH MIGRATION; DIRECT REPEATS; UL8 SUBUNIT; REPLICATION	The genome of herpes simplex virus type-1 undergoes a high frequency of homologous recombination in the absence of a virus-encoded RecA-type protein. We hypothesized that viral homologous recombination is mediated by the combined action of the viral single strand DNA-binding protein (ICP8) and helicase-primase. Our results show that ICP8 catalyzes the formation of recombination intermediates (joint molecules) between circular single-stranded acceptor and linear duplex donor DNA. Joint molecules formed by invasion of a 3'-terminal strand displaces the non-complementary 5'-terminal strand, thereby creating a loading site for the helicase-primase. Helicase-primase acts on these joint molecules to promote ATP-dependent branch migration. Finally, we have reconstituted strand exchange by the synchronous action of ICP8 and helicase-primase. Based on these data, we present a recombination mechanism for a eukaryotic DNA virus in which a single strand DNA-binding protein and helicase cooperate to promote homologous pairing and branch migration.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Boehmer, PE (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, POB 016129, Miami, FL 33101 USA.			Boehmer, Paul/0000-0003-4479-0529	NIGMS NIH HHS [GM62643] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062643] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arana ME, 2001, J BIOL CHEM, V276, P6840, DOI 10.1074/jbc.M007219200; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Boehmer PE, 1998, J BIOL CHEM, V273, P2676, DOI 10.1074/jbc.273.5.2676; BOEHMER PE, 1993, J VIROL, V67, P711, DOI 10.1128/JVI.67.2.711-715.1993; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BORTNER C, 1993, J MOL BIOL, V231, P241, DOI 10.1006/jmbi.1993.1279; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DUTCH RE, 1992, J VIROL, V66, P277, DOI 10.1128/JVI.66.1.277-285.1992; DUTCH RE, 1994, J VIROL, V68, P3733, DOI 10.1128/JVI.68.6.3733-3741.1994; DUTCH RE, 1993, J VIROL, V67, P6945, DOI 10.1128/JVI.67.12.6945-6949.1993; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; EGELMAN EH, 1986, J MOL BIOL, V191, P677, DOI 10.1016/0022-2836(86)90453-5; Falkenberg M, 1997, J BIOL CHEM, V272, P22766, DOI 10.1074/jbc.272.36.22766; FREIDMANN A, 1977, J GEN VIROL, V34, P223; GARBER DA, 1993, VIROLOGY, V197, P459, DOI 10.1006/viro.1993.1612; Gourves AS, 2000, J BIOL CHEM, V275, P10864, DOI 10.1074/jbc.275.15.10864; Hammarsten O, 1997, NUCLEIC ACIDS RES, V25, P1753, DOI 10.1093/nar/25.9.1753; Kong DC, 1997, P NATL ACAD SCI USA, V94, P2987, DOI 10.1073/pnas.94.7.2987; Kong DC, 1996, EMBO J, V15, P2010, DOI 10.1002/j.1460-2075.1996.tb00552.x; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; LeGac NT, 1996, J BIOL CHEM, V271, P21645; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; Marians KJ, 2000, CURR OPIN GENET DEV, V10, P151, DOI 10.1016/S0959-437X(00)00059-9; Martin DW, 1996, J VIROL, V70, P8801, DOI 10.1128/JVI.70.12.8801-8812.1996; Martinez R, 1996, J VIROL, V70, P2075, DOI 10.1128/JVI.70.4.2075-2085.1996; MOCARSKI ES, 1982, P NATL ACAD SCI-BIOL, V79, P5626, DOI 10.1073/pnas.79.18.5626; MOCARSKI ES, 1980, CELL, V22, P243, DOI 10.1016/0092-8674(80)90172-5; Muyrers JPP, 2000, GENE DEV, V14, P1971; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; Sampson DA, 2000, J BIOL CHEM, V275, P2931, DOI 10.1074/jbc.275.4.2931; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARISKY RT, 1994, J VIROL, V68, P34, DOI 10.1128/JVI.68.1.34-47.1994; Seitz EM, 1998, GENE DEV, V12, P1248, DOI 10.1101/gad.12.9.1248; Severini A, 1996, J VIROL, V70, P3169, DOI 10.1128/JVI.70.5.3169-3175.1996; SEVERINI A, 1994, VIROLOGY, V200, P428, DOI 10.1006/viro.1994.1206; Shinohara A, 1999, MUTAT RES-DNA REPAIR, V435, P13, DOI 10.1016/S0921-8777(99)00033-6; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMILEY JR, 1981, VIROLOGY, V113, P345, DOI 10.1016/0042-6822(81)90161-6; THOMAS MS, 1992, J VIROL, V66, P1152, DOI 10.1128/JVI.66.2.1152-1161.1992; Umene K, 1999, REV MED VIROL, V9, P171, DOI 10.1002/(SICI)1099-1654(199907/09)9:3&lt;171::AID-RMV243&gt;3.0.CO;2-A; WEBER PC, 1988, CELL, V54, P369, DOI 10.1016/0092-8674(88)90200-0; WILDY P, 1955, J GEN MICROBIOL, V13, P346, DOI 10.1099/00221287-13-2-346; Yao XD, 1997, J VIROL, V71, P6842, DOI 10.1128/JVI.71.9.6842-6849.1997; Yao XD, 2001, J BIOL CHEM, V276, P2905, DOI 10.1074/jbc.M005627200; YONESAKI T, 1985, EUR J BIOCHEM, V148, P127, DOI 10.1111/j.1432-1033.1985.tb08816.x	48	31	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15182	15189		10.1074/jbc.M109988200	http://dx.doi.org/10.1074/jbc.M109988200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11832483	hybrid			2022-12-25	WOS:000175203000104
J	Schwarze, SR; DePrimo, SE; Grabert, LM; Fu, VX; Brooks, JD; Jarrard, DF				Schwarze, SR; DePrimo, SE; Grabert, LM; Fu, VX; Brooks, JD; Jarrard, DF			Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; GENE-EXPRESSION PATTERNS; HUMAN FIBROBLASTS; BINDING-PROTEINS; CANCER; GROWTH; P53; E7; IMMORTALIZATION; ADENOCARCINOMA	Cellular senescence forms a barrier that inhibits the acquisition of an immortal phenotype, a critical feature in tumorigenesis. The inactivation of multiple pathways that positively regulate senescence are required for immortalization. To identify these pathways in an unbiased manner, we performed DNA microarray analyses to assess the expression of 20,000 genes in human prostate epithelial cells (HPECs) passaged to senescence. These gene expression patterns were then compared with those of HPECs immortalized with the human Papillomavirus 16 E7 oncoprotein. Senescent cells display gene expression patterns that reflect their nonproliferative, differentiated phenotype and express secretory proteases and extracellular matrix components. A comparison of genes transcriptionally up-regulated in senescence to those in which expression is significantly down-regulated in immortalized HPECs identified three genes: the chemokine BRAK, DOC1, and a member of the insulin-like growth factor axis, IGFBP-3. Expression of these genes is found to be uniformly lost in human prostate cancer cell lines and xenografts, and previously, their inactivation was documented in tumor samples. Thus, these genes may function in novel pathways that regulate senescence and are inactivated during immortalization. These changes may be critical not only in allowing cells to bypass senescence in vitro but in the progression of prostate cancer in vivo.	Univ Wisconsin, Sch Med, Dept Surg, Div Urol, Madison, WI 53792 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI 53792 USA; Stanford Univ, Dept Urol, Stanford, CA 94305 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Stanford University	Jarrard, DF (corresponding author), Univ Wisconsin, Sch Med, Dept Surg, Div Urol, K6-530,600 Highland Ave, Madison, WI 53792 USA.	jarrard@surgery.wisc.edu			NCI NIH HHS [CA76184-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA076184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2000, IN VIVO, V14, P183; Campisi J, 1997, J AM GERIATR SOC, V45, P482, DOI 10.1111/j.1532-5415.1997.tb05175.x; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; DeRisi J, 1996, NAT GENET, V14, P457; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; El Gedaily A, 2001, PROSTATE, V46, P184; Ferry RJ, 1999, HORM RES, V51, P53; Frederick MJ, 2000, AM J PATHOL, V156, P1937, DOI 10.1016/S0002-9440(10)65067-5; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; Hampel OZ, 1998, J UROLOGY, V159, P2220, DOI 10.1016/S0022-5347(01)63309-3; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jarrard DF, 1999, CANCER RES, V59, P2957; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Mannhardt B, 2000, MOL CELL BIOL, V20, P6483, DOI 10.1128/MCB.20.17.6483-6495.2000; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Puthenveettil JA, 1996, ONCOGENE, V13, P1123; REZNIKOFF CA, 1987, J CELL PHYSIOL, V131, P285, DOI 10.1002/jcp.1041310302; REZNIKOFF CA, 1994, GENE DEV, V8, P2227, DOI 10.1101/gad.8.18.2227; Reznikoff CA, 1996, CANCER RES, V56, P2886; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; SAITOH S, 1987, ARCH ANDROLOGY, V19, P133, DOI 10.3109/01485018708986809; Sarkar S, 2000, CANCER RES, V60, P3862; SASAKI M, 1994, CANCER RES, V54, P6090; Schwarze SR, 2001, ONCOGENE, V20, P8184, DOI 10.1038/sj.onc.1205049; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Witte JS, 2000, AM J HUM GENET, V67, P92, DOI 10.1086/302960; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Yeager TR, 1998, GENE DEV, V12, P163, DOI 10.1101/gad.12.2.163; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	53	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14877	14883		10.1074/jbc.M200373200	http://dx.doi.org/10.1074/jbc.M200373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836256	hybrid			2022-12-25	WOS:000175203000068
J	Dos Santos, RG; Van Renterghem, C; Martin-Moutot, N; Mansuelle, P; Cordeiro, MN; Diniz, CR; Mori, Y; De Lima, ME; Seagar, M				Dos Santos, RG; Van Renterghem, C; Martin-Moutot, N; Mansuelle, P; Cordeiro, MN; Diniz, CR; Mori, Y; De Lima, ME; Seagar, M			Phoneutria nigriventer omega-phonetoxin IIA blocks the Ca(v)2 family of calcium channels and interacts with omega-conotoxin-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P/Q-TYPE; MULTIPLE TYPES; RAT-BRAIN; P-TYPE; SYNAPTOSOMES; VENOM; ANTAGONIST; EXPRESSION; SUBUNIT; NEURONS	omega-Phonetoxin ILA (omegaPtxIIA), a peptide from spider venom (Phoneutria nigriventer), inhibits high threshold voltage-dependent calcium currents in neurons. To define its pharmacological specificity, we have used patch-clamp methods in cell lines expressing recombinant Ca(v)2.1, Ca(v)2.2, and Ca(v)2.3 channels (P/Q-, N-, and R-type currents, respectively). Calcium currents generated by Ca(v)2.1 and Ca(v)2.2 were blocked almost irreversibly by 3 nM omegaPtxIIA, whereas Ca(v)2.3 showed partial and readily reversible inhibition. Binding assays with mono [I-125]iodo-omegaPtxIILA indicated that membranes expressing recombinant Ca(v)2.1 or Ca(v)2.2 channels showed a single class of sites with similar affinity (K-D similar to 50 pM), whereas low affinity interactions were detectable with Ca(v)2.3. Kinetic, saturation, and displacement assays demonstrated that rat brain synaptosomes displayed multiple classes of binding sites for I-125-omegaPtxIIA. High affinity binding of I-125-omegaPtxIIA was totally displaced by omegaPtxIIA (K-i = 100 pM), but only partially by omega-conotoxin GVIA (25% inhibition) and omega-conotoxin MVIIC (50% inhibition at 0.3 muM). I-125-omegaPtxIIA thus defines a unique high affinity binding site that is predominantly associated with Ca(v)2.1 or Ca(v)2.2 channels.	Univ Mediterranee, Fac Med Secteur N, Inst Jean Roche, INSERM U464, F-13916 Marseille 20, France; Univ Mediterranee, Fac Med Secteur N, Inst Jean Roche, CNRS UMR 6560, F-13916 Marseille, France; Fundacao Ezequiel Dias, BR-30550010 Belo Horizonte, MG, Brazil; Natl Inst Physiol Sci, Dept Informat Physiol, Okazaki, Aichi 4448585, Japan; Ctr Integrat Biosci, Div Mol & Cellular Physiol, Okazaki, Aichi 4448585, Japan; Univ Fed Minas Gerais, Inst Ciencias Biol, Dept Bioquim & Imunol, BR-31270901 Belo Horizonte, MG, Brazil; Ctr Desenvolvimento Tecnol Nucl, Comissao Nacl Energia Nucl, Radiobiol Lab, BR-30123970 Belo Horizonte, MG, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Universidade Federal de Minas Gerais; Centro de Desenvolvimento da Tecnologia Nuclear (CDTN); Comissao Nacional de Energia Nuclear (CNEN)	Seagar, M (corresponding author), Univ Mediterranee, Fac Med Secteur N, Inst Jean Roche, INSERM U464, Blvd Pierre Dramard, F-13916 Marseille 20, France.		Lima, Maria E/P-1707-2017; de Lima, Maria Elena/GQH-4440-2022	Lima, Maria E/0000-0001-6185-4032; mansuelle, pascal/0000-0002-4504-6809				Arsac C, 1996, ANN NEUROL, V40, P695, DOI 10.1002/ana.410400504; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Cassola AC, 1998, PFLUG ARCH EUR J PHY, V436, P545, DOI 10.1007/s004240050670; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Charvin N, 1997, EMBO J, V16, P4591, DOI 10.1093/emboj/16.15.4591; CORDEIRO MD, 1993, TOXICON, V31, P35, DOI 10.1016/0041-0101(93)90354-L; DAYANITHI G, 1988, BIOCHEM BIOPH RES CO, V156, P255, DOI 10.1016/S0006-291X(88)80833-7; ERTEL EA, 1994, BIOCHEMISTRY-US, V33, P5098, DOI 10.1021/bi00183a013; Ertel EA, 2000, NEURON, V25, P533, DOI 10.1016/S0896-6273(00)81057-0; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; MARQUEZE B, 1988, MOL PHARMACOL, V34, P87; MARTINMOUTOT N, 1995, FEBS LETT, V366, P21, DOI 10.1016/0014-5793(95)00467-N; MartinMoutot N, 1996, J BIOL CHEM, V271, P6567, DOI 10.1074/jbc.271.12.6567; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; Miranda DM, 1998, NEUROREPORT, V9, P1371, DOI 10.1097/00001756-199805110-00022; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Motomura M, 1997, J NEUROL SCI, V147, P35, DOI 10.1016/S0022-510X(96)05303-8; Newcomb R, 1998, BIOCHEMISTRY-US, V37, P15353, DOI 10.1021/bi981255g; NIIDOME T, 1994, BIOCHEM BIOPH RES CO, V203, P1821, DOI 10.1006/bbrc.1994.2399; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; RANDALL A, 1995, J NEUROSCI, V15, P2995; REZENDE L, 1991, TOXICON, V29, P1225, DOI 10.1016/0041-0101(91)90195-W; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; WAKAMORI M, 1994, RECEPTOR CHANNEL, V2, P303; Yan LZ, 2000, J BIOL CHEM, V275, P21309, DOI 10.1074/jbc.M000212200	25	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13856	13862		10.1074/jbc.M112348200	http://dx.doi.org/10.1074/jbc.M112348200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827974	hybrid			2022-12-25	WOS:000175096000068
J	Chalfant, CE; Rathman, K; Pinkerman, RL; Wood, RE; Obeid, LM; Ogretmen, B; Hannun, YA				Chalfant, CE; Rathman, K; Pinkerman, RL; Wood, RE; Obeid, LM; Ogretmen, B; Hannun, YA			De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells - Dependence on protein phosphatase-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOTHERAPY-INDUCED APOPTOSIS; INSULIN-INDUCIBLE CHANGES; RECEPTOR MESSENGER-RNA; KINASE C-BETA; SR PROTEINS; SPHINGOLIPID BIOSYNTHESIS; NEUTRAL SPHINGOMYELINASE; SIGNAL-TRANSDUCTION; CELLULAR SENESCENCE; PHOSPHATIDIC-ACID	Previous studies have demonstrated that several splice variants are derived from both the caspase 9 and Bcl-x genes in which the Bcl-x splice variant, Bcl-x(L) and the caspase 9 splice variant, caspase 9b, inhibit apoptosis in contrast to the pro-apoptotic splice variants, Bel-x(s) and caspase 9. In a recent study, we showed that ceramide induces the dephosphorylation of SR proteins, a family of protein factors that regulate alternative splicing. In this study, the regulation of the alternative processing of pre-mRNA of both caspase 9 and Bel-x(L) was examined in response to ceramide. Treatment of A549 lung adenocarcinoma cells with cellpermeable ceramide, D-e-C, ceramide, down-regulated the levels of Bcl-x(L) and caspase 9b mRNA and immunoreactive protein with a concomitant increase in the mRNA and immunoreactive protein levels of Bcl-x(s) and caspase 9 in a dose- and time-dependent manner. Pretreatment with calyculin A (5 nm), an inhibitor of protein phosphatase-1 (PP1) and protein phosphatase 2A (PP2A) blocked ceramide-induced alternative splicing in contrast to okadaic acid (10 nm), a specific inhibitor of PP2A at this concentrations in cells, demonstrating a PP1-mediated mechanism. A role for endogenous ceramide in regulating the alternative splicing of caspase 9 and Bcl-x was demonstrated using the chemotherapeutic agent, gemcitabine. Treatment of A549 cells with gemcitabine (1 muM) increased ceramide levels 3-fold via the de novo sphingolipid pathway as determined by pulse labeling experiments and inhibition studies with myriocin (50 nm), a specific inhibitor of serine palmitoyltransferase (the first step in de novo synthesis of ceramide). Treatment of A549 cells with gemcitabine downregulated the levels of Bcl-x(L) and caspase 9b mRNA with a concomitant increase in the mRNA levels of Bcl-x(s) and caspase 9. Again, inhibitors of ceramide synthesis blocked this effect. We also demonstrate that the change in the alternative splicing of caspase 9 and Bcl-x occurred prior to apoptosis following treatment with gemcitabine. Furthermore, doses of D-e-C-6 ceramide that induce the alternative splicing of both caspase 9 and Bel-x-sensitized A549 cells to daunorubicin. These data demonstrate a role for protein phosphatases 1 (PP1) and endogenous ceramide generated via the de novo pathway in regulating this mechanism. This is the first report on the dynamic regulation of RNA splicing of members of the Bcl-2 and caspase families in response to regulators of apoptosis.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,POB 250509,Rm 501,Basic Sci Bldg, Charleston, SC 29425 USA.			obeid, lina/0000-0002-0734-0847	NCI NIH HHS [CA 87584] Funding Source: Medline; NIGMS NIH HHS [GM 19953-02, GM 43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043825, F32GM019953, R37GM043825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APTE SS, 1995, GENOMICS, V26, P592, DOI 10.1016/0888-7543(95)80180-T; Ballou LR, 1996, BBA-LIPID LIPID MET, V1301, P273, DOI 10.1016/0005-2760(96)00004-5; Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boudrez A, 2000, J BIOL CHEM, V275, P25411, DOI 10.1074/jbc.M001676200; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHALFANT C, 1997, MECH PHYSL SIGNIFICA; CHALFANT CE, 1995, J BIOL CHEM, V270, P13326, DOI 10.1074/jbc.270.22.13326; Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200; Chalfant CE, 1998, J BIOL CHEM, V273, P910, DOI 10.1074/jbc.273.2.910; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chang TC, 1997, FEBS LETT, V415, P11, DOI 10.1016/S0014-5793(97)01083-1; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Du KY, 1997, MOL CELL BIOL, V17, P4096, DOI 10.1128/MCB.17.7.4096; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; GORCZYCA W, 1993, LEUKEMIA, V7, P659; Hannun YA, 1997, BIOCHEM SOC T, V25, P1171, DOI 10.1042/bst0251171; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; HAVRILESKY LJ, 1995, OBSTET GYNECOL, V85, P1007, DOI 10.1016/0029-7844(95)00058-Y; Henkels KM, 1999, CANCER RES, V59, P3077; Hirano K, 1996, FEBS LETT, V389, P191, DOI 10.1016/0014-5793(96)00577-7; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KERR JFR, 1991, APOPTOSIS MOL BASIS, P5; KERR JFR, 1992, INT REV CYTOL, V68, P251; KIM MY, 1991, J BIOL CHEM, V266, P484; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; KISIC A, 1995, J LIPID RES, V36, P787; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; Kren BT, 1996, CELL GROWTH DIFFER, V7, P1633; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LIN CH, 1995, RNA, V1, P234; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Mercatante DR, 2001, J BIOL CHEM, V276, P16411, DOI 10.1074/jbc.M009256200; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; MEYN RE, 1994, CANCER CHEMOTH PHARM, V33, P410, DOI 10.1007/BF00686270; Minn AJ, 1996, J BIOL CHEM, V271, P6306, DOI 10.1074/jbc.271.11.6306; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; MIYASHITA T, 1992, CANCER RES, V52, P5407; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Obeid LM, 1997, J AM GERIATR SOC, V45, P361, DOI 10.1111/j.1532-5415.1997.tb00954.x; Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Priault M, 1999, FEBS LETT, V443, P225, DOI 10.1016/S0014-5793(98)01661-5; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schmitt E, 2000, BIOCHEM BIOPH RES CO, V270, P868, DOI 10.1006/bbrc.2000.2537; SELL SM, 1994, J BIOL CHEM, V269, P30769; Sell SM, 1999, MOL GENET METAB, V66, P189, DOI 10.1006/mgme.1998.2792; Seol DW, 1999, J BIOL CHEM, V274, P2072, DOI 10.1074/jbc.274.4.2072; Shi B, 1999, BIOCHEM BIOPH RES CO, V254, P779, DOI 10.1006/bbrc.1998.0130; Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025; Srinivasula SM, 1999, CANCER RES, V59, P999; SUMANTRAN VN, 1995, CANCER RES, V55, P2507; Taylor JK, 1999, NAT BIOTECHNOL, V17, P1097, DOI 10.1038/15079; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thomas AL, 1999, CELL DEATH DIFFER, V6, P97, DOI 10.1038/sj.cdd.4400474; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WANG E, 1991, J BIOL CHEM, V266, P14486; Wilson GM, 1999, MOL CELL BIOL, V19, P4056; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zahler AM, 1999, METH MOL B, V118, P419; Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325; Zhang P, 1997, J BIOL CHEM, V272, P9609; Zhou M, 1998, J BIOL CHEM, V273, P11930, DOI 10.1074/jbc.273.19.11930	81	269	288	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12587	12595		10.1074/jbc.M112010200	http://dx.doi.org/10.1074/jbc.M112010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11801602	hybrid			2022-12-25	WOS:000175036300015
J	Sun, P; Loh, HH				Sun, P; Loh, HH			Transcriptional regulation of mouse delta-opioid receptor gene - Role of Ikaros in the stimulated transcription of mouse delta-opioid receptor gene in activated T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; HOMEOSTASIS; THYMOCYTES; JURKAT; MYC	delta-Opioid receptors (DOR) present on T cells have been shown to mediate the immunomodulatory effects of endogenous and synthetic DOR agonists on T cells. Considerable evidence indicates that there is stimulated transcription of DOR gene in activated T cells, which is correlated with augmented expression of DOR and enhanced capacity of DOR agonists to affect the T-cell's functions. However, the molecular mechanism underlying the stimulated transcription of the DOR gene in activated T cells is still unclear. In the present study, we analyzed a 1.3-kb DNA fragment immediately upstream of the translation start site (-1300 to +1 bp, with the translation start site designated as +1) of the mouse DOR gene in EL-4 cells, a mouse lymphoma T cell line that exhibits enhanced expression of DOR transcripts when activated by phytohemagglutinin. Through both in vivo and in vitro experiments, we have demonstrated that increased binding activity of Ikaros at the Ikaros-binding site (-378 to -374) in the DOR promoter is required for the stimulated transcription of DOR gene in phytohemagglutinin-activated T cells.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Sun, P (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [K05DA070554, P50DA011806, R01DA001583, R37DA001583] Funding Source: NIH RePORTER; NIDA NIH HHS [K05-DA-70554, DA-01583, DA-00546, DA-11806] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; BLALOCK JE, 1988, PNEI, V1, P9; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; GAVERIAUX C, 1995, FEBS LETT, V369, P272, DOI 10.1016/0014-5793(95)00766-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; JOHNSON DR, 1995, BIOTECHNIQUES, V19, P192; Ko JL, 1997, BIOCHEM BIOPH RES CO, V234, P351, DOI 10.1006/bbrc.1997.6640; Li MD, 1999, J LEUKOCYTE BIOL, V65, P707, DOI 10.1002/jlb.65.5.707; LINNER KM, 1995, J IMMUNOL, V154, P5049; Liu HC, 1999, J BIOL CHEM, V274, P23617, DOI 10.1074/jbc.274.33.23617; Nichogiannopoulou A, 1998, SEMIN IMMUNOL, V10, P119, DOI 10.1006/smim.1998.0113; RALPH P, 1973, J IMMUNOL, V110, P1470; Sedqi M, 1996, J NEUROIMMUNOL, V65, P167, DOI 10.1016/0165-5728(96)00028-8; Shahabi NA, 2000, CELL IMMUNOL, V205, P84, DOI 10.1006/cimm.2000.1717; Sharp BM, 1998, BIOCHEM PHARMACOL, V56, P289, DOI 10.1016/S0006-2952(98)00155-5; Sharp BM, 1998, ANN NY ACAD SCI, V840, P420, DOI 10.1111/j.1749-6632.1998.tb09580.x; Singh VK, 1999, NEUROIMMUNOMODULAT, V6, P355, DOI 10.1159/000026395; WESLEY HJ, 1986, J EXP MED, V163, P1589	21	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12854	12860		10.1074/jbc.M112268200	http://dx.doi.org/10.1074/jbc.M112268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823468	hybrid			2022-12-25	WOS:000175036300048
J	Tanaka, K; Kitagawa, Y; Kadowaki, T				Tanaka, K; Kitagawa, Y; Kadowaki, T			Drosophila segment polarity gene product porcupine stimulates the posttranslational N-glycosylation of wingless in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; PROTEIN; GLYCOPROTEIN; SITE; OLIGOSACCHARYLTRANSFERASE; TRANSPORT; ENDODERM; REVEALS; FAMILY	Wnt is a family of cysteine-rich secreted glycoproteins, which controls the fate and behavior of the cells in multicellular organisms. In the absence of Drosophila segment polarity gene porcupine (pore), which encodes an endoplasmic reticulum (ER) multispanning transmembrane protein, the N-glycosylation of Wingless (Wg), one of Drosophila Wnt family, is impaired. In contrast, the ectopic expression of pore stimulates the N-glycosylation of both endogenously and exogenously expressed Wg. The N-glycosylation of Wg in the ER occurs posttranslationally, while in the presence of dithiothreitol, it efficiently occurs cotranslationally. Thus, the cotranslational disulfide bond formation of Wg competes with the N-glycosylation by an oligosaccharyl transferase complex. Pore binds the N-terminal 24-amino acid domain (residues 83-106) of Wg, which is highly conserved in the Wnt family and stimulates the N-glycosylation at surrounding sites. Pore is also necessary for the processing of Drosophila Wnt-3/5 in both embryos and cultured cells. Thus, Pore binds the N-terminal specific domain of the Wnt family and stimulates its posttranslational N-glycosylation by anchoring them at the ER membrane possibly through acylation.	Nagoya Univ, Grad Sch Bioagr Sci, Grad Program Regulat Biol Signals, Chikusa Ku, Nagoya, Aichi 4648601, Japan	Nagoya University	Kadowaki, T (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Grad Program Regulat Biol Signals, Chikusa Ku, Nagoya, Aichi 4648601, Japan.	emi@nuagr1.agr.nagoya-u.ac.jp						ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BEJSOVEC A, 1995, GENETICS, V139, P309; BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chamoun Z, 2001, SCIENCE, V293, P2080, DOI 10.1126/science.1064437; CHOU TB, 1992, GENETICS, V131, P643; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; Dierick HA, 1998, DEVELOPMENT, V125, P4729; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FRADKIN LG, 1995, DEV BIOL, V168, P202, DOI 10.1006/dbio.1995.1072; GEETHAHABIB M, 1990, J BIOL CHEM, V265, P13655; GERGEN JP, 1986, ROUX ARCH DEV BIOL, V195, P49, DOI 10.1007/BF00444041; Hays R, 1997, DEVELOPMENT, V124, P3727; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; JETHMALANI SM, 1994, J BIOL CHEM, V269, P23603; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; McGinnes LW, 1997, J VIROL, V71, P3083, DOI 10.1128/JVI.71.4.3083-3089.1997; Muller HAJ, 1999, DEVELOPMENT, V126, P577; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; TATU U, 1993, EMBO J, V12, P2151, DOI 10.1002/j.1460-2075.1993.tb05863.x; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886	36	133	145	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12816	12823		10.1074/jbc.M200187200	http://dx.doi.org/10.1074/jbc.M200187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821428	hybrid			2022-12-25	WOS:000175036300043
J	Wang, ZQ; Wei, CC; Stuehr, DJ				Wang, ZQ; Wei, CC; Stuehr, DJ			A conserved tryptophan 457 modulates the kinetics and extent of N-hydroxy-L-Arginine oxidation by inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-TURNOVER CONDITIONS; ELECTRON-TRANSFER; LOW-TEMPERATURE; DIOXYGEN COMPLEX; OXYGENASE DOMAIN; TETRAHYDROBIOPTERIN; CONVERSION; CITRULLINE; MECHANISM; CATALYSIS	In the oxygenase domain of mouse inducible nitricoxide synthase (iNOSoxy), a conserved tryptophan residue, Trp-457, regulates the kinetics and extent Of L-Arg oxidation to N-omega-hydroxy-L-arginine (NOHA) by controlling electron transfer between bound (6R)-tetrahydrobiopterin (H4B) cofactor and the enzyme heme (FeO2)-O-II, intermediate (Wang, Z. Q., Wei, C. C., Ghosh, S., Meade, A L., Hemann, C., Hille, R., and Stuehr, D. J. (2001) Biochemistry 40, 12819-12825). To investigate whether NOHA oxidation to citrulline and nitric oxide (NO) is regulated by a similar mechanism, we performed single turnover reactions with wild type iNOSoxy and mutants W457F and W457A. Ferrous proteins containing NOHA plus HA or NOHA plus 7,8-dihydrobiopterin (11,13), were mixed with O-2-containing buffer, and then heme spectral transitions and product formation were followed versus time. All three proteins formed a (FeO2)-O-II intermediate with identical spectral characteristics. In wild type, H4B increased the disappearance rate of the (FeO2)-O-II intermediate relative to H2B, and its disappearance was coupled to the formation of a (FeNO)-N-II immediate product prior to formation of ferric enzyme. In W457F and W457A, the disappearance rate of the (FeO2)-O-II intermediate was slower than in wild type and took place without detectable build-up of the heme (FeNO)-N-III immediate product. Rates of (FeO2)-O-II disappearance correlated with rates of citrulline formation in all three proteins, and reactions containing HA formed 1.0, 0.54, and 0.38 citrulline/heme in wild type, W457F, and W457A iNOSoxy, respectively. Thus, Trp-457 modulates the kinetics of NOHA oxidation by iNOSoxy, and this is important for determining the extent of citrulline and NO formation. Our findings support a redox role for H4B during NOHA oxidation to NO by iNOSoxy.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.			Wei, Chin-Chuan/0000-0001-6453-9409	NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NCI NIH HHS [CA 53914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P6876, DOI 10.1021/bi010066m; Abu-Soud HM, 2000, J BIOL CHEM, V275, P17349, DOI 10.1074/jbc.M000050200; AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J BIOL CHEM, V276, P23246, DOI 10.1074/jbc.M102509200; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Aoyagi M, 2001, BIOCHEMISTRY-US, V40, P12826, DOI 10.1021/bi011183k; Bec N, 2000, J INORG BIOCHEM, V81, P207, DOI 10.1016/S0162-0134(00)00104-5; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Couture M, 2000, J BIOL CHEM, V275, P3201, DOI 10.1074/jbc.275.5.3201; Crane BR, 2000, BIOCHEMISTRY-US, V39, P4608, DOI 10.1021/bi992409a; Dijols S, 2001, J MED CHEM, V44, P3199, DOI 10.1021/jm0155446; EYER CS, 1992, ARCH BIOCHEM BIOPHYS, V293, P231, DOI 10.1016/0003-9861(92)90390-I; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Fukuto JM, 1996, METHOD ENZYMOL, V268, P365; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Groves JT, 2000, CURR OPIN CHEM BIOL, V4, P687, DOI 10.1016/S1367-5931(00)00146-0; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Huang H, 2001, J AM CHEM SOC, V123, P2674, DOI 10.1021/ja005900u; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Iwanaga T, 1999, BIOCHEMISTRY-US, V38, P16629, DOI 10.1021/bi991277i; KORTH HG, 1994, J BIOL CHEM, V269, P17776; Ledbetter AP, 1999, BIOCHEMISTRY-US, V38, P8014, DOI 10.1021/bi990619h; Li HY, 2001, BIOCHEMISTRY-US, V40, P5399, DOI 10.1021/bi002658v; Li HY, 1999, BBA-MOL CELL BIOL L, V1441, P141, DOI 10.1016/S1388-1981(99)00161-4; Marletta MA, 1998, CURR OPIN CHEM BIOL, V2, P656, DOI 10.1016/S1367-5931(98)80098-7; Marletta MA, 2001, TRENDS BIOCHEM SCI, V26, P519, DOI 10.1016/S0968-0004(01)01937-5; Munro AW, 1996, EUR J BIOCHEM, V239, P403, DOI 10.1111/j.1432-1033.1996.0403u.x; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Renodon-Corniere A, 1999, BIOCHEMISTRY-US, V38, P4663, DOI 10.1021/bi982930p; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Sasaki M, 2000, P NATL ACAD SCI USA, V97, P8617, DOI 10.1073/pnas.97.15.8617; Schmidt PP, 2001, J BIOL INORG CHEM, V6, P151, DOI 10.1007/s007750000185; Stopper H, 1999, TOXICOL LETT, V106, P59, DOI 10.1016/S0378-4274(99)00019-3; Stuehr D, 2001, J BIOL CHEM, V276, P14533, DOI 10.1074/jbc.R100011200; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12830	12837		10.1074/jbc.M111967200	http://dx.doi.org/10.1074/jbc.M111967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823464	hybrid			2022-12-25	WOS:000175036300045
J	Joseloff, E; Cataisson, C; Aamodt, H; Ocheni, H; Blumberg, P; Kraker, AJ; Yuspa, SH				Joseloff, E; Cataisson, C; Aamodt, H; Ocheni, H; Blumberg, P; Kraker, AJ; Yuspa, SH			Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR RECEPTOR; HIGH-AFFINITY RECEPTOR; PKC-DELTA; TRANSEPITHELIAL PERMEABILITY; DIFFERENTIATION MARKERS; EPIDERMAL-KERATINOCYTES; INDUCED APOPTOSIS; EPITHELIAL-CELLS; TUMOR PROMOTION	Protein kinase C delta (PKC delta) is tyrosine-phosphorylated and catalytically inactive in mouse keratinocytes transformed by a ras oncogene. In several other model systems, Src kinases are upstream regulators of PKC delta. To examine this relationship in epidermal carcinogenesis, v-ras transformed mouse keratinocytes were treated with a selective Src kinase inhibitor (PD 173958). PD 173958 decreased autophosphorylation of Src, Fyn, and Lyn kinases and prevented tyrosine phosphorylation of the Src kinase substrate p120. PD 173958 also prevented PKC delta tyrosine phosphorylation and activated PKC delta as detected by membrane translocation. Expression of keratinocyte differentiation markers increased in PD 173958-treated v-ras-keratinocytes, and fluid-filled domes emerged, indicative of tight junction formation. Antisense PKC delta or bryostatin 1 inhibited dome formation, while overexpression of PKC delta in the presence of PD 173958 enhanced the formation of domes. Plasmids encoding phenylalanine mutants of PKC delta tyrosine residues 64 and 565 induced domes in the absence of PD 173958, while phenylalanine mutants of tyrosine residues 52, 155, and 187 were inactive. Thus, Src kinase mediated post-translational modification of PKC delta on specific tyrosine residues in ras-transformed mouse keratinocytes inactivates PKC delta and contributes to alterations in the differentiated phenotype and tight junction formation associated with neoplasia.	NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, Bethesda, MD 20892 USA; Pfizer Global Res & Dev, Canc Pharmacol, Ann Arbor Labs, Ann Arbor, MI 48105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer	Yuspa, SH (corresponding author), NCI, Cellular Carcinogenesis & Tumor Promot Lab, Ctr Canc Res, 37 Convent Dr,MSC-4255,Bldg 37,Rm 3B25, Bethesda, MD 20892 USA.							Alt A, 2001, CANCER RES, V61, P4591; Basu A, 1999, BIOCHEMISTRY-US, V38, P4245, DOI 10.1021/bi982854q; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Cabodi S, 2000, MOL CELL, V6, P1121, DOI 10.1016/S1097-2765(00)00110-6; Cross T, 2000, ONCOGENE, V19, P2331, DOI 10.1038/sj.onc.1203555; Denning MF, 2000, EXP DERMATOL, V9, P192, DOI 10.1034/j.1600-0625.2000.009003192.x; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dorsey JF, 2000, CANCER RES, V60, P3127; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Emoto Y, 1996, BLOOD, V87, P1990; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; GEIGES D, 1995, EXP CELL RES, V219, P299, DOI 10.1006/excr.1995.1231; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kiley SC, 1999, CANCER RES, V59, P3230; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; LEE E, 1992, CARCINOGENESIS, V13, P2367, DOI 10.1093/carcin/13.12.2367; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; LEIBERSPERGER H, 1991, J BIOL CHEM, V266, P14778; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Matsumoto Takashi, 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P421; Moasser MM, 1999, CANCER RES, V59, P6145; Morita K, 1998, J INVEST DERMATOL, V110, P862, DOI 10.1046/j.1523-1747.1998.00209.x; MULLIN JM, 1992, J CELL PHYSIOL, V152, P35, DOI 10.1002/jcp.1041520106; Mullin JM, 1998, AM J PHYSIOL-CELL PH, V275, pC544, DOI 10.1152/ajpcell.1998.275.2.C544; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Reddig PJ, 1999, CANCER RES, V59, P5710; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; ROOP DR, 1986, NATURE, V323, P822, DOI 10.1038/323822a0; Rosson D, 1997, J BIOL CHEM, V272, P14950, DOI 10.1074/jbc.272.23.14950; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Xian WJ, 1997, ONCOGENE, V14, P1435, DOI 10.1038/sj.onc.1200980; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; YUSPA SH, 1994, CANCER RES, V54, P1178; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	53	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12318	12323		10.1074/jbc.M111618200	http://dx.doi.org/10.1074/jbc.M111618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812791	hybrid			2022-12-25	WOS:000174846400094
J	Pozzi, A; LeVine, WF; Gardner, HA				Pozzi, A; LeVine, WF; Gardner, HA			Low plasma levels of matrix metalloproteinase 9 permit increased tumor angiogenesis	ONCOGENE			English	Article						angiostatin; MMP9; doxycycline; angiogenesis	CHEMICALLY-MODIFIED TETRACYCLINES; INTEGRIN ALPHA-1-BETA-1; INHIBITION; DOXYCYCLINE; EXPRESSION; ANGIOSTATIN; ACTIVATION; METASTASIS; CARCINOMA; COLLAGEN	Angiogenesis is essential for tumor growth and blocking this process might be a valid tool for the control of cancer growth. We showed previously that tumor angiogenesis in integrin alpha1-null mice is reduced compared to that of wild type animals and that over-expression of matrix metalloproteinase 9 (MMP-9) in the alpha1-null and consequent generation of angiostatin (an inhibitor of endothetial cell growth) from circulating plasminogen was implicated in the mechanism of tumor inhibition. Our findings suggested that secretion of excess MMPs generates inhibitors of endothelial cell proliferation, including but not necessarily limited to angiostatin, resulting ultimately in auto-inhibition of angiogenesis. Thus MMP inhibitors used as anti-tumor drugs might in fact cause a paradoxical increase in tumor angiogenesis and tumor growth. In order to determine whether MMP-9 expression was directly involved in the regulation of tumor growth, we specifically inhibited or enhanced MMP-9 synthesis in vitro and in vivo, and subsequently analysed primary endothelial cell proliferation and angiostatin synthesis, as well as tumor vascularization and development. We provide evidence that reduction of plasma levels of MMP-9 in either normal or integrin alpha1-null mice leads to decreased synthesis of angiostatin and consequent increased tumor growth and vascularization. In contrast, specifically enhancing MMP-9 expression in vivo caused a reduction in tumor vascularization. These findings are the opposite to other studies suggesting a pro-tumorigenic role for MMP-9, and may account for some of the recently observed failures of anti MMP therapy in tumor treatment.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Pozzi, A (corresponding author), Vanderbilt Univ, Med Ctr N, Dept Med, Div Nephrol & Hypertens, Room B-3109, Nashville, TN 37232 USA.				NIAMS NIH HHS [AR44514] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR044514, R55AR044514, R01AR044514] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Axisa B, 2000, J CHROMATOGR B, V744, P359, DOI 10.1016/S0378-4347(00)00261-9; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Bettany J T, 1998, Adv Dent Res, V12, P136; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; Cornelius LA, 1998, J IMMUNOL, V161, P6845; Curci JA, 2000, J VASC SURG, V31, P325, DOI 10.1016/S0741-5214(00)90163-0; Fife R S, 1998, Adv Dent Res, V12, P94; FIFE RS, 1995, J LAB CLIN MED, V125, P407; Forget MA, 1999, CAN J PHYSIOL PHARM, V77, P465; Gardner H, 1999, J CELL SCI, V112, P263; Hanemaaijer R, 1998, Adv Dent Res, V12, P114; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Jia MC, 2000, ADV EXP MED BIOL, V476, P181; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; Kruger A, 2001, CANCER RES, V61, P1272; Lokeshwar BL, 1999, ANN NY ACAD SCI, V878, P271, DOI 10.1111/j.1749-6632.1999.tb07690.x; Pozzi A, 2000, P NATL ACAD SCI USA, V97, P2202, DOI 10.1073/pnas.040378497; Pozzi M, 1998, J CELL BIOL, V142, P587; RAMOSDESIMONE N, 1993, HYBRIDOMA, V12, P349, DOI 10.1089/hyb.1993.12.349; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; Rivas MJG, 1998, HEPATOLOGY, V28, P986, DOI 10.1002/hep.510280413; Sang Q X, 1998, Cell Res, V8, P171; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Seftor REB, 1998, CLIN EXP METASTAS, V16, P217, DOI 10.1023/A:1006588708131; SIPOS EP, 1994, ANN NY ACAD SCI, V732, P263, DOI 10.1111/j.1749-6632.1994.tb24741.x; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; Sobrin L, 2000, INVEST OPHTH VIS SCI, V41, P1703; Soloway PD, 1996, ONCOGENE, V13, P2307; Sorsa T, 1998, J RHEUMATOL, V25, P975; Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2; VANDENBOGERT C, 1985, LEUKEMIA RES, V9, P617, DOI 10.1016/0145-2126(85)90142-0; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Xiang R, 1998, CANCER RES, V58, P3918	34	122	125	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					272	281		10.1038/sj.onc.1205045	http://dx.doi.org/10.1038/sj.onc.1205045			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803470				2022-12-25	WOS:000173026200011
J	Kong, M; Wang, CS; Donoghue, DJ				Kong, M; Wang, CS; Donoghue, DJ			Interaction of fibroblast growth factor receptor 3 and the adapter protein SH2-B - A role in Stat5 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSPLASIA TYPE-II; INSULIN-RECEPTOR; SKELETAL DYSPLASIA; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; KINASE ACTIVATION; MULTIPLE-MYELOMA; DOMAIN; MUTATIONS; IDENTIFICATION	Fibroblast growth factor receptor 3 (FGFR3) influences a diverse array of biological processes, including cell growth, differentiation, and migration. Activating mutations in FGFR3 are associated with multiple myeloma, cervical carcinoma, and bladder cancer. To identify proteins that interact with FGFR3 and which may mediate FGFR3-dependent signaling, a yeast two-hybrid screen was employed using the cytoplasmic kinase domain of FGFR3 as bait. We identified the adapter protein SH2-B as an FGFR3-interacting protein. Coimmunoprecipitation experiments demonstrate binding of the SH2-Bbeta isoform to FGFR3 in 293T cells. Tyrosine phosphorylation of SH2-Bbeta was observed when coexpressed with activated FGFR3 mutants such as the weakly activated mutant N540K or the strongly activated mutant K650E, both associated with human developmental syndromes. The extent of tyrosine phosphorylation of SH2-Bbeta correlates with receptor activation, suggesting that FGFR3 activation mediates tyrosine phosphorylation of SH2-Bbeta. Furthermore, two tyrosine phosphorylation sites of FGFR3, Tyr-724 and Tyr-760, are required for optimal binding of the Src homology-2 (SH2) domain of SH2-Bbeta We also demonstrate the phosphorylation and nuclear translocation of Stat5 by activated FGFR3, which increases in response to overexpression of SH2-Bbeta. Taken together, our results identify SH2-Bbeta as a novel FGFR,3 binding partner that mediates signal transduction.	Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Donoghue, DJ (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Dept Chem & Biochem, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012581] Funding Source: NIH RePORTER; NIDCR NIH HHS [1R01 DE12581] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bellus GA, 2000, AM J HUM GENET, V67, P1411, DOI 10.1086/316892; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BELLUS GA, 1995, AM J HUM GENET, V56, P368; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Colvin JS, 1996, NAT GENET, V12, P390, DOI 10.1038/ng0496-390; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Hart KC, 2000, ONCOGENE, V19, P3309, DOI 10.1038/sj.onc.1203650; Hart KC, 2001, MOL BIOL CELL, V12, P931, DOI 10.1091/mbc.12.4.931; HATTORI Y, 1992, CANCER RES, V52, P3367; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lin HY, 1998, MOL CELL BIOL, V18, P3762, DOI 10.1128/MCB.18.7.3762; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Nelms K, 1999, MAMM GENOME, V10, P1160, DOI 10.1007/s003359901183; Ong SH, 1997, BIOCHEM BIOPH RES CO, V238, P261, DOI 10.1006/bbrc.1997.7272; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; PARTANEN J, 1993, PHILOS T R SOC B, V340, P297, DOI 10.1098/rstb.1993.0071; PETERS KG, 1992, DEVELOPMENT, V114, P233; Plowright EE, 2000, BLOOD, V95, P992, DOI 10.1182/blood.V95.3.992.003k29_992_998; POLAYES D, 1996, FASEB J, V10, P1124; Popovici C, 1998, P NATL ACAD SCI USA, V95, P5712, DOI 10.1073/pnas.95.10.5712; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; Riedel H, 2000, ONCOGENE, V19, P39, DOI 10.1038/sj.onc.1203253; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; Sehgal PB, 2000, CELL SIGNAL, V12, P525, DOI 10.1016/S0898-6568(00)00098-X; Shoelson SE, 1997, CURR OPIN CHEM BIOL, V1, P227, DOI 10.1016/S1367-5931(97)80014-2; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; Webster MK, 1996, EMBO J, V15, P520, DOI 10.1002/j.1460-2075.1996.tb00384.x; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Webster MK, 1996, MOL CELL BIOL, V16, P4081; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987	59	61	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15962	15970		10.1074/jbc.M102777200	http://dx.doi.org/10.1074/jbc.M102777200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11827956	hybrid			2022-12-25	WOS:000175510400100
J	Yu, F; Finley, RL; Raz, A; Kim, HRC				Yu, F; Finley, RL; Raz, A; Kim, HRC			Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria - A role for synexin in galectin-3 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN GALECTIN-3; CALCIUM-DEPENDENT BINDING; N-TERMINAL DOMAIN; OVEREXPRESSION PROTECTS; ANNEXIN-VII; S-PHASE; EXPRESSION; APOPTOSIS; LECTIN; BCL-2	Galectin-3 is a multifunctional oncogenic protein found in the nucleus and cytoplasm and also the extracellular milieu. Although recent studies demonstrated an anti-apoptotic activity of galectin-3, neither the functional site nor the mechanism of how galectin-3 regulates apoptosis is known. In this study, we examined the subcellular localization of galectin-3 during apoptosis and investigated its anti-apoptotic actions. We report that galectin-3 translocates to the perinuclear membrane following a variety of apoptotic stimuli. Confocal microscopy and biochemical analysis revealed that galectin-3 is enriched in the mitochondria and prevents mitochondrial damage and cytochrome c release. Using a yeast two-hybrid system, we screened for galectin-3-interacting proteins that regulate galectin-3 localization and anti-apoptotic activity. Synexin, a Ca2+- and phospholipid-binding protein, was one of the proteins identified. We confirmed direct interaction between galectin-3 and synexin by glutathione S-transferase pulldown assay in vitro. We showed that galectin-3 failed to translocate to the perinuclear membranes when expression of synexin was down-regulated using an oligodeoxyribonucleotide complementary to the synexin mRNA, suggesting a role for synexin in galectin-3 trafficking. Furthermore, synexin down-regulation abolished anti-apoptotic activity of galectin-3. Taken together, these results suggest that synexin mediates galectin-3 translocation to the perinuclear mitochondrial membranes, where it regulates mitochondrial integrity critical for apoptosis regulation.	Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; Karmanos Canc Inst, Detroit, MI 48201 USA	Wayne State University; Wayne State University; Barbara Ann Karmanos Cancer Institute	Kim, HRC (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, 540 E Canfield, Detroit, MI 48201 USA.			Finley, Russ/0000-0003-1144-6887	NCI NIH HHS [CA64139] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA064139, R01CA064139] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akahani S, 1997, CANCER RES, V57, P5272; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Bresalier RS, 1997, CANCER, V80, P776; Brownawell AM, 1997, J BIOL CHEM, V272, P22182, DOI 10.1074/jbc.272.35.22182; Brownawell AM, 1996, BIOCHEMISTRY-US, V35, P6839, DOI 10.1021/bi952585t; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; CREUTZ CE, 1978, J BIOL CHEM, V253, P2858; CREUTZ CE, 1992, J CELL SCI, V103, P1177; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; Finley RL, 1996, P NATL ACAD SCI USA, V93, P3011, DOI 10.1073/pnas.93.7.3011; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; FINLEY RL, 1995, DNA CLONING EXPRESSI, P169; FINLEY RL, 1996, YEAST 2 HYBRID SYSTE; Gillenwater A, 1996, HEAD NECK-J SCI SPEC, V18, P422, DOI 10.1002/(SICI)1097-0347(199609/10)18:5<422::AID-HED5>3.3.CO;2-S; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Herr C, 2001, MOL CELL BIOL, V21, P4119, DOI 10.1128/MCB.21.13.4119-4128.2001; Honjo Y, 2000, CLIN CANCER RES, V6, P4635; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; Kim HRC, 1999, CANCER RES, V59, P3429; Kim HRC, 1999, CANCER RES, V59, P4148; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Konstantinov KN, 1996, AM J PATHOL, V148, P25; LeMarer N, 1996, J CELL PHYSIOL, V168, P51, DOI 10.1002/(SICI)1097-4652(199607)168:1<51::AID-JCP7>3.0.CO;2-7; Lin HM, 2000, CARCINOGENESIS, V21, P1941, DOI 10.1093/carcin/21.11.1941; LOTAN R, 1994, INT J CANCER, V56, P474, DOI 10.1002/ijc.2910560404; Matarrese P, 2000, INT J CANCER, V85, P545, DOI 10.1002/(SICI)1097-0215(20000215)85:4<545::AID-IJC17>3.0.CO;2-N; Matarrese P, 2000, FEBS LETT, V473, P311, DOI 10.1016/S0014-5793(00)01547-7; Nangia-Makker P, 1998, BREAST CANCER RES TR, V49, P171, DOI 10.1023/A:1005913810250; Pace KE, 1999, J IMMUNOL, V163, P3801; Park JW, 2001, NUCLEIC ACIDS RES, V29, P3595, DOI 10.1093/nar/29.17.3595; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rabinovich GA, 1999, CELL DEATH DIFFER, V6, P711, DOI 10.1038/sj.cdd.4400535; RAZ A, 1989, CANCER RES, V49, P3489; SATO S, 1994, J BIOL CHEM, V269, P4424; SCHOEPPNER HL, 1995, CANCER, V75, P2818, DOI 10.1002/1097-0142(19950615)75:12<2818::AID-CNCR2820751206>3.0.CO;2-#; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Srivastava M, 1999, P NATL ACAD SCI USA, V96, P13783, DOI 10.1073/pnas.96.24.13783; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; van den Brule FA, 2000, INT J CANCER, V89, P361, DOI 10.1002/1097-0215(20000720)89:4<361::AID-IJC8>3.3.CO;2-L; Verzili D, 2000, FEBS LETT, V471, P197, DOI 10.1016/S0014-5793(00)01396-X; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; WANG L, 1995, BIOCHEM BIOPH RES CO, V217, P292, DOI 10.1006/bbrc.1995.2777; XU XC, 1995, AM J PATHOL, V147, P815; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	51	244	256	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15819	15827		10.1074/jbc.M200154200	http://dx.doi.org/10.1074/jbc.M200154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839755	hybrid			2022-12-25	WOS:000175510400082
J	Dunphy, JL; Barcham, GJ; Bischof, RJ; Young, AR; Nash, A; Meeusen, ENT				Dunphy, JL; Barcham, GJ; Bischof, RJ; Young, AR; Nash, A; Meeusen, ENT			Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIC EPITHELIAL-CELLS; EXTRACELLULAR-MATRIX; ENDOGENOUS LECTIN; MOLECULAR-CLONING; GENE-EXPRESSION; BINDING; CHEMOATTRACTANT; ADHESION; ECALECTIN/GALECTIN-9; APOPTOSIS	A novel galectin cDNA (galectin-14) was cloned from ovine eosinophil-rich leukocytes by low stringency reverse transcriptase-PCR and cDNA library screening. Data base searches indicate that this gene encodes a novel prototype galectin that contains one putative carbohydrate recognition domain and exhibits most identity to galectin-9/ecalectin, a potent eosinophil chemoattractant. The sugar binding properties of the recombinant molecule were confirmed by a hemagglutination assay and lactose inhibition. The mRNA and protein of galectin-14 are expressed at high levels in eosinophil-rich cell populations. Flow cytometry and cytospot staining demonstrate that the protein localizes to the cytoplasmic, but not the granular, compartment of eosinophils. In contrast, galectin-14 mRNA and protein were not detected in neutrophils, macrophages, or lymphocytes. Western blot analysis of bronchoalveolar lavage fluid indicates that galectin-14 is released from eosinophils into the lumen of the lungs after challenge with house dust mite allergen. The restricted expression of this novel galectin to eosinophils and its release into the lumen of the lung in a sheep asthma model indicates that it may play an important role in eosinophil function and allergic inflammation.	Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia; AMRAD Operat Pty Ltd, Burnley, Vic 3121, Australia	University of Melbourne	Meeusen, ENT (corresponding author), Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia.	e.meeusen@unimelb.edu.au		Bischof, Robert/0000-0002-6649-9612; Meeusen, Els/0000-0003-1239-6287				ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; Ahmed H, 1996, J BIOCHEM, V120, P1007; Akahani S, 1997, CANCER RES, V57, P5272; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; Bischof RJ, 2002, CLIN EXP ALLERGY, V32, P619, DOI 10.1046/j.0954-7894.2002.01345.x; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung CD, 2000, J IMMUNOL, V165, P3722, DOI 10.4049/jimmunol.165.7.3722; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Cortegano I, 1998, J IMMUNOL, V161, P385; Dabbagh K, 1999, J IMMUNOL, V162, P6233; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Dunphy J, 2001, VET IMMUNOL IMMUNOP, V82, P153, DOI 10.1016/S0165-2427(01)00356-7; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Greenhalgh CJ, 1996, IMMUNOL CELL BIOL, V74, P497, DOI 10.1038/icb.1996.82; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Hadari YR, 2000, J CELL SCI, V113, P2385; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; Hirashima M, 2000, INT ARCH ALLERGY IMM, V122, P6, DOI 10.1159/000053623; KANE JF, 1995, CURR OPIN BIOTECH, V6, P494, DOI 10.1016/0958-1669(95)80082-4; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196, DOI 10.1159/000237545; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LealPinto E, 1997, J BIOL CHEM, V272, P617; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; MCDOWELL GH, 1969, RES VET SCI, V10, P13; Meeusen ENT, 2000, PARASITOL TODAY, V16, P95, DOI 10.1016/S0169-4758(99)01607-5; Mehul B, 1997, J CELL SCI, V110, P1169; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 1999, IMMUNOLOGY, V97, P100; Sano H, 2000, J IMMUNOL, V165, P2156, DOI 10.4049/jimmunol.165.4.2156; Tureci O, 1997, J BIOL CHEM, V272, P6416, DOI 10.1074/jbc.272.10.6416; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; Vespa GNR, 1999, J IMMUNOL, V162, P799; Wada J, 1997, J BIOL CHEM, V272, P6078, DOI 10.1074/jbc.272.9.6078; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; Yoshii T, 2002, J BIOL CHEM, V277, P6852, DOI 10.1074/jbc.M107668200	46	85	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14916	14924		10.1074/jbc.M200214200	http://dx.doi.org/10.1074/jbc.M200214200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839756	hybrid			2022-12-25	WOS:000175203000073
J	Halaban, R; Patton, RS; Cheng, E; Svedine, S; Trombetta, ES; Wahl, ML; Ariyan, S; Hebert, DN				Halaban, R; Patton, RS; Cheng, E; Svedine, S; Trombetta, ES; Wahl, ML; Ariyan, S; Hebert, DN			Abnormal acidification of melanoma cells induces tyrosinase retention in the early secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PINK-EYED DILUTION; GOLGI INTERMEDIATE COMPARTMENT; II OCULOCUTANEOUS ALBINISM; VACUOLAR H+-ATPASE; HUMAN TUMOR-CELLS; ENDOPLASMIC-RETICULUM; INTRACELLULAR PH; DRUG-RESISTANCE; QUALITY-CONTROL; MELANOSOMAL PH	In tyrosinase-positive amelanotic melanoma cells, inactive tyrosinase accumulates in the endoplasmic reticulum. Based on studies described here, we propose that aberrant vacuolar proton ATPase (V-ATPase) -mediated proton transport in melanoma cells disrupts tyrosinase trafficking through the secretory pathway. Amelanotic but not melanotic melanoma cells or normal melanocytes display elevated proton export as observed by the acidification of the extracellular medium and their ability to maintain neutral intracellular pH. Tyrosinase activity and transit through the Golgi were restored by either maintaining the melanoma cells in alkaline medium (pH 7.4-7.7) or by restricting glucose uptake. The translocation of tyrosinase out of the endoplasmic reticulum and the induction of cell pigmentation in the presence of the ionophore monensin or the specific V-ATPase inhibitors concanamycin A and bafilomycin A1 supported a role for V-ATPases in this process. Because it was previously shown that V-ATPase activity is increased in solid tumors in response to an acidified environment, the appearance of hypopigmented cells in tyrosinase-positive melanoma tumors may indicate the onset of enhanced glycolysis and extracellular acidification, conditions known to favor metastatic spread and resistance to weak base chemotherapeutic drugs.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Plast Surg, New Haven, CT 06520 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Mol & Cellular Biol Program, Amherst, MA 01003 USA; Thomas Jefferson Univ, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA	Yale University; Yale University; Yale University; University of Massachusetts System; University of Massachusetts Amherst; Jefferson University	Halaban, R (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059,HRT 610,15 York St, New Haven, CT 06520 USA.	ruth.halaban@yale.edu; dhebert@biochem.umass.edu			NATIONAL CANCER INSTITUTE [R29CA044542, R01CA044542, R01CA079864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039848, P30AR041942] Funding Source: NIH RePORTER; NCI NIH HHS [CA79864, CA44542] Funding Source: Medline; NIAMS NIH HHS [AR39848, AR41942] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altan N, 1998, J EXP MED, V187, P1583, DOI 10.1084/jem.187.10.1583; Ancans J, 2001, J INVEST DERMATOL, V117, P158, DOI 10.1046/j.0022-202x.2001.01397.x; Ancans J, 2001, EXP CELL RES, V268, P26, DOI 10.1006/excr.2001.5251; BERGER W, 1994, INT J CANCER, V59, P717, DOI 10.1002/ijc.2910590522; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; Brilliant MH, 2001, PIGM CELL RES, V14, P86, DOI 10.1034/j.1600-0749.2001.140203.x; Burd R, 2001, CANCER RES, V61, P5630; CHEN YT, 1995, P NATL ACAD SCI USA, V92, P8125, DOI 10.1073/pnas.92.18.8125; Cooksey CJ, 1997, J BIOL CHEM, V272, P26226, DOI 10.1074/jbc.272.42.26226; Cormier JN, 1998, J IMMUNOTHER, V21, P27, DOI 10.1097/00002371-199801000-00003; CUOMO M, 1991, J INVEST DERMATOL, V96, P446, DOI 10.1111/1523-1747.ep12470092; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Drose S, 1997, J EXP BIOL, V200, P1; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; ENGIN K, 1995, INT J HYPERTHER, V11, P211, DOI 10.3109/02656739509022457; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; GARDNER JM, 1992, SCIENCE, V257, P1121, DOI 10.1126/science.257.5073.1121; GILLIES RJ, 1990, P NATL ACAD SCI USA, V87, P7414, DOI 10.1073/pnas.87.19.7414; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HALABAN R, 1977, EXP CELL RES, V108, P119, DOI 10.1016/S0014-4827(77)80017-7; Halaban R, 2001, J BIOL CHEM, V276, P11933, DOI 10.1074/jbc.M008703200; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; KANG XQ, 1995, J IMMUNOL, V155, P1343; Kim JH, 1998, P NATL ACAD SCI USA, V95, P2997, DOI 10.1073/pnas.95.6.2997; LEE ST, 1994, NEW ENGL J MED, V330, P529, DOI 10.1056/NEJM199402243300803; LERNER AB, 1949, J BIOL CHEM, V178, P185; LEVINE EA, 1993, J SURG RES, V54, P621, DOI 10.1006/jsre.1993.1095; Martinez-Zaguilan R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006-2952(99)00022-2; MARTINEZZAGUILAN R, 1992, ANN NY ACAD SCI, V671, P478, DOI 10.1111/j.1749-6632.1992.tb43834.x; MARTINEZZAGUILAN R, 1993, AM J PHYSIOL, V265, pC1015, DOI 10.1152/ajpcell.1993.265.4.C1015; MAXFIELD FR, 1982, J CELL BIOL, V95, P676, DOI 10.1083/jcb.95.2.676; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Mosse CA, 1998, J EXP MED, V187, P37, DOI 10.1084/jem.187.1.37; Naish-Byfield S, 1998, PIGM CELL RES, V11, P127, DOI 10.1111/j.1600-0749.1998.tb00722.x; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; Oetting W S, 1998, Hum Mutat, V12, P434, DOI 10.1002/(SICI)1098-1004(1998)12:6<434::AID-HUMU15>3.0.CO;2-A; Orlow SJ, 1999, EXP EYE RES, V68, P147, DOI 10.1006/exer.1998.0599; Owen CS, 1997, J CELL PHYSIOL, V173, P397, DOI 10.1002/(SICI)1097-4652(199712)173:3<397::AID-JCP12>3.0.CO;2-9; Palokangas H, 1998, MOL BIOL CELL, V9, P3561, DOI 10.1091/mbc.9.12.3561; POMERANTZ SH, 1976, ANAL BIOCHEM, V75, P86, DOI 10.1016/0003-2697(76)90058-0; Potterf SB, 1998, EXP CELL RES, V244, P319, DOI 10.1006/excr.1998.4173; Puri N, 2000, J INVEST DERMATOL, V115, P607, DOI 10.1046/j.1523-1747.2000.00108.x; Raper HS, 1928, PHYSIOL REV, V8, P245, DOI 10.1152/physrev.1928.8.2.245; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Raposo G, 2001, J CELL BIOL, V152, P809, DOI 10.1083/jcb.152.4.809; Riley PA, 1999, CELL MOL BIOL, V45, P951; RILEY PA, 1998, PIGMENTARY SYSTEM PH, P401; RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0; Rinne D, 1998, CANCER, V82, P1664, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2; ROSEMBLAT S, 1994, P NATL ACAD SCI USA, V91, P12071, DOI 10.1073/pnas.91.25.12071; SCHADENDORF D, 1995, AM J PATHOL, V147, P1545; Schindler M, 1996, BIOCHEMISTRY-US, V35, P2811, DOI 10.1021/bi952234e; SCHMIDT WK, 1995, MOL BIOL CELL, V6, P1271, DOI 10.1091/mbc.6.10.1271; SIMON S, 1994, P NATL ACAD SCI USA, V91, P1128, DOI 10.1073/pnas.91.3.1128; Simon SM, 1999, DRUG DISCOV TODAY, V4, P32, DOI 10.1016/S1359-6446(98)01276-8; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; STROUS JAM, 1980, CELL, V22, P709, DOI 10.1016/0092-8674(80)90547-4; Stubbs M, 2000, MOL MED TODAY, V6, P15, DOI 10.1016/S1357-4310(99)01615-9; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TARTAKOFF AM, 1977, J EXP MED, V146, P1332, DOI 10.1084/jem.146.5.1332; Topalian SL, 1996, J EXP MED, V183, P1965, DOI 10.1084/jem.183.5.1965; Toyofuku K, 2001, BIOCHEM J, V355, P259, DOI 10.1042/0264-6021:3550259; Ujvari A, 2001, J BIOL CHEM, V276, P5924, DOI 10.1074/jbc.M009203200; VIJAYASARADHI S, 1995, J CELL BIOL, V130, P807, DOI 10.1083/jcb.130.4.807; Wahl ML, 2000, J CELL PHYSIOL, V183, P373, DOI 10.1002/(SICI)1097-4652(200006)183:3<373::AID-JCP10>3.0.CO;2-S; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wu MM, 2000, METHOD ENZYMOL, V327, P546, DOI 10.1016/S0076-6879(00)27301-1; Wu MM, 2000, CHEM BIOL, V7, P197, DOI 10.1016/S1074-5521(00)00088-0; Yamagata M, 1998, BRIT J CANCER, V77, P1726, DOI 10.1038/bjc.1998.289; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082	75	105	110	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14821	14828		10.1074/jbc.M111497200	http://dx.doi.org/10.1074/jbc.M111497200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11812790	hybrid			2022-12-25	WOS:000175203000061
J	Kiefer, SM; McDill, BW; Yang, J; Rauchman, M				Kiefer, SM; McDill, BW; Yang, J; Rauchman, M			Murine Sall1 represses transcription by recruiting a histone deacetylase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; GENE-COMPLEX; DROSOPHILA; HETEROCHROMATIN; IKAROS; MUTATIONS; INTERACTS; REGION; FATES; DPP	The multi-zinc finger proteins of the Sal family regulate organogenesis. Genetic evidence from Drosophila has shown that spalt (sal) can alter gene expression in a cell autonomous fashion, but Sal proteins have never been directly analyzed for their ability to activate or repress transcription. In this report, we show that a member of the Sal family, mouse Sall1, is a potent transcriptional repressor. When fused to a heterologous DNA-binding domain, Sall1 represses transcription of a luciferase reporter by over 100-fold. Expression of the N terminus alone is sufficient for dose-responsive repression that, as shown by deletion analysis, requires the extreme N-terminal amino acids of the protein. The N terminus of Sall1 can repress at both short and long range relative to the promoter, and treatment with the histone deacetylase (HDAC) inhibitor, trichostatin A, alleviates repression by 3-fold. The same regions of the protein that are required for repression physically interact with components of chromatin remodeling complexes, HDAC1, HDAC2, RbAp46/48, MTA-1, and MTA-2. Finally, we demonstrate that Sall1 is localized to discrete nuclear foci and this localization depends on the N-terminal repression domain. Together, these results suggest that the N terminus of mouse Sall1 can recruit HDAC complexes to mediate transcriptional repression.	Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL)	Rauchman, M (corresponding author), Washington Univ, Sch Med, Div Renal, St Louis, MO 63110 USA.	mrauchma@im.wustl.edu			NIDDK NIH HHS [5T32DK07126] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007126] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Barrio R, 1996, DEV GENES EVOL, V206, P315, DOI 10.1007/s004270050058; Boube M, 2000, MECH DEVELOP, V91, P271, DOI 10.1016/S0925-4773(99)00315-9; Brown KE, 1999, MOL CELL, V3, P207, DOI 10.1016/S1097-2765(00)80311-1; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Buck A, 2000, CYTOGENET CELL GENET, V89, P150, DOI 10.1159/000015598; Cobb BS, 2000, GENE DEV, V14, P2146, DOI 10.1101/gad.816400; Dasen JS, 2001, GENE DEV, V15, P3193, DOI 10.1101/gad.932601; de Celis JF, 2000, MECH DEVELOP, V91, P31, DOI 10.1016/S0925-4773(99)00261-0; deCelis JF, 1996, NATURE, V381, P421, DOI 10.1038/381421a0; Downes M, 2000, P NATL ACAD SCI USA, V97, P10330, DOI 10.1073/pnas.97.19.10330; Elstob PR, 2001, DEVELOPMENT, V128, P723; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hasson P, 2001, EMBO J, V20, P5725, DOI 10.1093/emboj/20.20.5725; Hendzel MJ, 2001, J STEROID BIOCHEM, V76, P9, DOI 10.1016/S0960-0760(00)00153-9; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Kohlhase J, 1999, AM J HUM GENET, V64, P435, DOI 10.1086/302238; Kohlhase J, 1998, NAT GENET, V18, P81, DOI 10.1038/ng0198-81; KUHNLEIN RP, 1994, EMBO J, V13, P168, DOI 10.1002/j.1460-2075.1994.tb06246.x; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; Mollereau B, 2001, NATURE, V412, P911, DOI 10.1038/35091076; Nishinakamura R, 2001, DEVELOPMENT, V128, P3105; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	30	63	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14869	14876		10.1074/jbc.M200052200	http://dx.doi.org/10.1074/jbc.M200052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836251	hybrid			2022-12-25	WOS:000175203000067
J	Mills, DA; Schmidt, B; Hiser, C; Westley, E; Ferguson-Miller, S				Mills, DA; Schmidt, B; Hiser, C; Westley, E; Ferguson-Miller, S			Membrane potential-controlled inhibition of cytochrome c oxidase by zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL REACTION CENTERS; PROTON-TRANSFER; PARACOCCUS-DENITRIFICANS; RHODOBACTER-SPHAEROIDES; ELECTRON-TRANSFER; BINDING-SITES; BC(1) COMPLEX; IONS INHIBIT; ACTIVE-SITE; ZN2+	Like many voltage-sensitive ion pumps, cytochrome c oxidase is inhibited by zinc. Binding of zinc to the outside surface of Rhodobacter sphaeroides cytochrome c oxidase inhibits the enzyme with a K-I, of less than or equal to 5 muM when the enzyme is reconstituted into phospholipid vesicles in the presence of a membrane potential. In the absence of a membrane potential and a pH gradient, millimolar concentrations of zinc are required to inhibit. This differential inhibition causes a dramatic increase in the respiratory control ratio from 6 to 40 for wild-type oxidase. The external zinc inhibition is removed by EDTA and is not competitive with cytochrome c binding but is competitive with protons. Only Cd2+ of the many metals tested (Mg2+, Mn2+, Ca2+, Ba2+, Li2+, Cs2+, Hg2+, Ni2+, Co2+, Cu2+ Tb3+, Tm3+) showed inhibitory effects similar to Zn2+. Proton pumping is slower and less efficient with zinc. The results suggest that zinc inhibits proton movement through a proton exit path, which can allow proton back-leak at high membrane potentials. The physiological and mechanistic significance of proton movement in the exit pathway and its blockage by zinc is discussed in terms of regulation of the efficiency of energy transduction.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University	Mills, DA (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.				NIGMS NIH HHS [R37-GM26196] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aagaard A, 2001, FEBS LETT, V494, P157, DOI 10.1016/S0014-5793(01)02299-2; Alberts IL, 1998, PROTEIN SCI, V7, P1700, DOI 10.1002/pro.5560070805; Axelrod HL, 2000, P NATL ACAD SCI USA, V97, P1542, DOI 10.1073/pnas.97.4.1542; Bender E, 2000, FEBS LETT, V466, P130, DOI 10.1016/S0014-5793(99)01773-1; Berry EA, 2000, BBA-BIOENERGETICS, V1459, P440, DOI 10.1016/S0005-2728(00)00182-1; BRAND MD, 1994, BIOCHEM J, V297, P27, DOI 10.1042/bj2970027; Bratton MR, 1999, BIOCHEMISTRY-US, V38, P16236, DOI 10.1021/bi9914107; Brautigan D L, 1978, Methods Enzymol, V53, P128; BRUNORI M, 1985, EMBO J, V4, P2365, DOI 10.1002/j.1460-2075.1985.tb03940.x; Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819; Cowan J. A., 1997, INORGANIC BIOCH INTR, P1; DeCoursey TE, 2000, BBA-BIOENERGETICS, V1458, P104, DOI 10.1016/S0005-2728(00)00062-1; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Fetter J, 1996, FEBS LETT, V393, P155, DOI 10.1016/0014-5793(96)00874-5; FETTER JR, 1995, P NATL ACAD SCI USA, V92, P1604, DOI 10.1073/pnas.92.5.1604; Florens L, 1999, BIOPHYS J, V76, pA238; FLORENS L, 1999, PHOTOTROPIC PROKARYO, P329; Gerencser L, 2001, BIOCHEMISTRY-US, V40, P1850, DOI 10.1021/bi0021636; Hiser C, 2001, BIOCHEMISTRY-US, V40, P1606, DOI 10.1021/bi0018988; HOSLER JP, 1993, J BIOENERG BIOMEMBR, V25, P121, DOI 10.1007/BF00762854; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kannt A, 2001, FEBS LETT, V503, P142, DOI 10.1016/S0014-5793(01)02719-3; Kannt A, 1998, FEBS LETT, V434, P17, DOI 10.1016/S0014-5793(98)00942-9; Karpefors M, 2000, BIOCHEMISTRY-US, V39, P6850, DOI 10.1021/bi992719t; Karpefors M, 1998, P NATL ACAD SCI USA, V95, P13606, DOI 10.1073/pnas.95.23.13606; KITA K, 1982, J BIOL CHEM, V257, P7933; Kuo CC, 1999, BIOPHYS J, V77, P2552, DOI 10.1016/S0006-3495(99)77090-6; Lee HM, 2000, BIOCHEMISTRY-US, V39, P2989, DOI 10.1021/bi9924821; LINK TA, 1995, J BIOL CHEM, V270, P25001, DOI 10.1074/jbc.270.42.25001; Low CM, 2000, P NATL ACAD SCI USA, V97, P11062, DOI 10.1073/pnas.180307497; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Mills DA, 2000, BBA-BIOENERGETICS, V1458, P180, DOI 10.1016/S0005-2728(00)00067-0; Mills DA, 1998, BBA-BIOENERGETICS, V1365, P46, DOI 10.1016/S0005-2728(98)00040-1; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; Nicholls P., 1988, LIFE SCI ADV BIOCH D, V7, P321; OKAMURA MY, 1992, ANNU REV BIOCHEM, V61, P861; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Paddock ML, 1999, P NATL ACAD SCI USA, V96, P6183, DOI 10.1073/pnas.96.11.6183; Qian J, 1997, BIOCHEMISTRY-US, V36, P2539, DOI 10.1021/bi962721+; Rich PR, 1996, BBA-BIOENERGETICS, V1275, P91, DOI 10.1016/0005-2728(96)00055-2; Riistama S, 1999, BIOCHEMISTRY-US, V38, P10670, DOI 10.1021/bi990885v; SMITH HT, 1977, BIOCHEMISTRY-US, V16, P4971, DOI 10.1021/bi00642a005; THORNSTROM PE, 1988, BIOCHEMISTRY-US, V27, P5441; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; Utschig LM, 1998, BIOCHEMISTRY-US, V37, P8278, DOI 10.1021/bi980395n; VANNESTE WH, 1966, BIOCHEMISTRY-US, V5, P838, DOI 10.1021/bi00867a005; WIKSTROM M, 1994, BBA-BIOENERGETICS, V1187, P106, DOI 10.1016/0005-2728(94)90093-0; Ye B, 2001, P NATL ACAD SCI USA, V98, P2317, DOI 10.1073/pnas.041619198; YOSHIKAWA S, 1988, P NATL ACAD SCI USA, V85, P1354, DOI 10.1073/pnas.85.5.1354; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723; Zhen Y, 1998, PROTEIN EXPRES PURIF, V13, P326, DOI 10.1006/prep.1998.0903; Zhen YJ, 1999, BIOPHYS J, V76, pA237; Zhen YJ, 1999, J BIOL CHEM, V274, P38032, DOI 10.1074/jbc.274.53.38032; Zhen Yuejun, 1999, P157; Zhen Yuejun, 1997, Biophysical Journal, V72, pA93	56	84	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14894	14901		10.1074/jbc.M111922200	http://dx.doi.org/10.1074/jbc.M111922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11832490	hybrid			2022-12-25	WOS:000175203000070
J	Schmidt, A; Hall, A				Schmidt, A; Hall, A			The Rho exchange factor Net1 is regulated by nuclear sequestration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS FIBER FORMATION; BINDING PROTEIN-RHO; DBL ONCOGENE PRODUCT; PLECKSTRIN HOMOLOGY; ACTIN CYTOSKELETON; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; PH DOMAINS; ACTIVATION; GTPASES	Net1 is a guanine nucleotide exchange factor specific for the small GTPase Rho. Oncogenic activation of Net1 occurs by truncation of the N-terminal part of the protein, which functions as a negative regulatory domain. Here, we have investigated the mechanism of Net1 regulation via its N terminus. We find that Net1 localizes to the nucleus, whereas oncogenic Net1 is found in the cytoplasm. Nuclear import of Net1 is mediated by two nuclear localization signals present in the N terminus of the protein, and forced cytoplasmic localization of Net1 is sufficient to activate Rho. In addition, the pleckstrin homology (PH) domain of Net1 acts as a nuclear export signal. Because an amino acid substitution in the PH domain that inhibits guanine nucleotide exchange factor activity does not inhibit nuclear export, we conclude that this PH domain has at least two functions. Together, our results suggest that Net1 can shuttle in and out of the nucleus, and that activation of Rho by Net1 is controlled by changes in its subcellular localization.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, CRC, Oncogene & Signal Transduct Grp, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London; University of London; University College London	Hall, A (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	alan.hall@ucl.ac.uk						Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan AML, 1996, ONCOGENE, V12, P1259; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Engers R, 2000, INT J CANCER, V88, P369, DOI 10.1002/1097-0215(20001101)88:3<369::AID-IJC8>3.0.CO;2-K; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HART MJ, 1994, J BIOL CHEM, V269, P62; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kato J, 2000, BIOCHEM BIOPH RES CO, V268, P141, DOI 10.1006/bbrc.2000.2106; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Koyama Y, 1996, BIOCHEM BIOPH RES CO, V218, P331, DOI 10.1006/bbrc.1996.0058; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Mohamed AJ, 2000, J BIOL CHEM, V275, P40614, DOI 10.1074/jbc.M006952200; Nern A, 2000, J CELL BIOL, V148, P1115, DOI 10.1083/jcb.148.6.1115; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Olson MF, 1997, ONCOGENE, V15, P2827, DOI 10.1038/sj.onc.1201594; PASTERIS NG, 1994, CELL, V79, P669; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; Stam J C, 1999, Prog Mol Subcell Biol, V22, P51; Sweitzer TD, 2000, CURR TOP CELL REGUL, V36, P77; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Tilly BC, 1996, MOL BIOL CELL, V7, P1419, DOI 10.1091/mbc.7.9.1419; TSUKADA S, 1994, P NATL ACAD SCI USA, V91, P11256, DOI 10.1073/pnas.91.23.11256; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; YAKU H, 1994, BIOCHEM BIOPH RES CO, V198, P811, DOI 10.1006/bbrc.1994.1116; ZHANG J, 1993, J BIOL CHEM, V268, P22251; Zhang QH, 1997, MOL BIOL CELL, V8, P1415, DOI 10.1091/mbc.8.8.1415; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	50	56	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14581	14588		10.1074/jbc.M111108200	http://dx.doi.org/10.1074/jbc.M111108200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839749	hybrid			2022-12-25	WOS:000175203000031
J	Baud, C; Karamanou, S; Sianidis, G; Vrontou, E; Politou, AS; Economou, A				Baud, C; Karamanou, S; Sianidis, G; Vrontou, E; Politou, AS; Economou, A			Allosteric communication between signal peptides and the SecA protein DEAD motor ATPase domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; ESCHERICHIA-COLI; PREPROTEIN TRANSLOCATION; CRYSTAL-STRUCTURE; BINDING-PROTEIN; PLASMA-MEMBRANE; CATALYTIC CYCLE; PHOSPHOLIPIDS; MUTATIONS; SEQUENCE	SecA, the preprotein translocase ATPase is built of an amino-terminal DEAD helicase motor domain bound to a regulatory C-domain. SecA recognizes mature and signal peptide preprotein regions. We now demonstrate that the amino-terminal 263 residues of the ATPase subdomain of the DEAD motor are necessary and sufficient for high affinity signal peptide binding. Binding is abrogated by deletion of residues 219-244 that lie within SSD, a novel substrate specificity element of the ATPase subdomain. SSD is essential for protein translocation, is unique to SecA, and is absent from other DEAD proteins. Signal peptide binding to the DEAD motor is controlled in trans by the C-terminal intramolecular regulator of ATPase (IRA1) switch. IRA1 mutations that activate the DEAD motor ATPase also enhance signal peptide affinity. This mechanism coordinates signal peptide binding with ATPase activation. Signal peptide binding causes widespread conformational changes to the ATPase subdomain and inhibits the DEAD motor ATPase. This involves an allosteric mechanism, since binding occurs at sites that are distinct from the catalytic ATPase determinants. Our data reveal the physical determinants and sophisticated intramolecular regulation that allow signal peptides to act as allosteric effectors of the SecA motor.	Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Crete, Greece; Univ Crete, Dept Biol, GR-71110 Iraklion, Crete, Greece; Univ Ioannina, Sch Med, Dept Biol Chem, GR-45110 Ioannina, Greece	Foundation for Research & Technology - Hellas (FORTH); University of Crete; University of Ioannina	Economou, A (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, POB 1527, GR-71110 Iraklion, Crete, Greece.	aeconomo@imbb.forth.gr	Karamanou, Spyridoula/H-7485-2018; Economou, Anastassios/P-8292-2017	Karamanou, Spyridoula/0000-0002-8803-1404; Economou, Anastassios/0000-0002-1770-507X; Baud, Catherine/0000-0002-0816-9092				Ahn T, 1996, J BIOL CHEM, V271, P12372, DOI 10.1074/jbc.271.21.12372; AKITA M, 1990, J BIOL CHEM, V265, P8164; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; denBlaauwen T, 1996, BIOCHEMISTRY-US, V35, P11994, DOI 10.1021/bi9605088; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; Ding HY, 2001, BIOCHEMISTRY-US, V40, P1835, DOI 10.1021/bi002058w; Driessen AJM, 2001, TRENDS MICROBIOL, V9, P193, DOI 10.1016/S0966-842X(01)01980-1; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Duong F, 1997, EMBO J, V16, P4871, DOI 10.1093/emboj/16.16.4871; Economou A, 1995, CELL, V83, P1171, DOI 10.1016/0092-8674(95)90143-4; Economou A, 1998, MOL MICROBIOL, V27, P511, DOI 10.1046/j.1365-2958.1998.00713.x; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Economou A, 2000, FEBS LETT, V476, P18, DOI 10.1016/S0014-5793(00)01662-8; Fekkes P, 1998, MOL MICROBIOL, V29, P1179, DOI 10.1046/j.1365-2958.1998.00997.x; FIKES JD, 1989, J BACTERIOL, V171, P402, DOI 10.1128/jb.171.1.402-409.1989; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HARTL FU, 1990, CELL, V63, P269, DOI 10.1016/0092-8674(90)90160-G; Hirano M, 1996, BIOCHEM BIOPH RES CO, V229, P90, DOI 10.1006/bbrc.1996.1762; HUIE JL, 1995, J BACTERIOL, V177, P3518, DOI 10.1128/jb.177.12.3518-3526.1995; IZARD JW, 1995, BIOCHEMISTRY-US, V34, P9904, DOI 10.1021/bi00031a012; JAROSIK GP, 1991, J BACTERIOL, V173, P860, DOI 10.1128/jb.173.2.860-868.1991; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JOLY JC, 1993, EMBO J, V12, P255, DOI 10.1002/j.1460-2075.1993.tb05651.x; Karamanou S, 1999, MOL MICROBIOL, V34, P1133, DOI 10.1046/j.1365-2958.1999.01686.x; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; KIMURA E, 1991, J BIOL CHEM, V266, P6600; KOONIN EV, 1992, FEBS LETT, V298, P6, DOI 10.1016/0014-5793(92)80009-6; Kourtz L, 2000, MOL MICROBIOL, V37, P1342, DOI 10.1046/j.1365-2958.2000.02078.x; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; MCNICHOLAS P, 1995, J BACTERIOL, V177, P7231, DOI 10.1128/jb.177.24.7231-7237.1995; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Miller A, 1998, J BIOL CHEM, V273, P11409, DOI 10.1074/jbc.273.19.11409; MITCHELL C, 1993, MOL MICROBIOL, V10, P483, DOI 10.1111/j.1365-2958.1993.tb00921.x; Moolenaar GF, 2001, EMBO J, V20, P6140, DOI 10.1093/emboj/20.21.6140; Nishiyama K, 1999, EMBO J, V18, P1049, DOI 10.1093/emboj/18.4.1049; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; Roos T, 2001, J BIOL CHEM, V276, P37909; ROST B, 1995, PROTEINS, V23, P295, DOI 10.1002/prot.340230304; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; Schmidt M, 2000, J BIOL CHEM, V275, P15440, DOI 10.1074/jbc.M000605200; SELIGMAN SJ, 1993, ANAL BIOCHEM, V211, P324, DOI 10.1006/abio.1993.1277; SHINKAI A, 1991, J BIOL CHEM, V266, P5827; Sianidis G, 2001, EMBO J, V20, P961, DOI 10.1093/emboj/20.5.961; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Triplett TL, 2001, J BIOL CHEM, V276, P19648, DOI 10.1074/jbc.M100098200; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; van Voorst F, 2000, FEBS LETT, V486, P57, DOI 10.1016/S0014-5793(00)02209-2; Wang LG, 2000, J BIOL CHEM, V275, P10154, DOI 10.1074/jbc.275.14.10154; Weinkauf S, 2001, ACTA CRYSTALLOGR D, V57, P559, DOI 10.1107/S0907444901001202	54	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13724	13731		10.1074/jbc.M200047200	http://dx.doi.org/10.1074/jbc.M200047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825907	hybrid			2022-12-25	WOS:000175096000051
J	Molotkov, A; Deltour, L; Foglio, MH; Cuenca, AE; Duester, G				Molotkov, A; Deltour, L; Foglio, MH; Cuenca, AE; Duester, G			Distinct retinoid metabolic functions for alcohol dehydrogenase genes Adh1 and Adh4 in protection against vitamin A toxicity or deficiency revealed in double null mutant mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDEHYDE DEHYDROGENASE; ACID SYNTHESIS; MOUSE; OXIDATION; ETHANOL; EXPRESSION; TERATOGENICITY; IDENTIFICATION; TOXICOLOGY; SUBSTRATE	The ability of class I alcohol dehydrogenase (ADHI) and class IV alcohol dehydrogenase (ADH4) to metabolize retinol to retinoic acid is supported by genetic studies in mice carrying Adh1 or Adh4 gene disruptions. To differentiate the physiological roles of ADH1 and ADH4 in retinoid metabolism we report here the generation of an Adh1/4 double null mutant mouse and its comparison to single null mutants. We demonstrate that loss of both ADH1 and ADH4 does not have additive effects, either for production of retinoic acid needed for development or for retinol turnover to minimize toxicity. During gestational vitamin A deficiency Adh4 and Adh1/4 mutants exhibit completely penetrant postnatal lethality by day 15 and day 24, respectively, while 60% of Adh1 mutants survive to adulthood similar to wild-type. Following administration of a 50-mg/kg dose of retinol to examine retinol turnover, Adh1 and Adh1/4 mutants exhibit similar 10-fold decreases in retinoic acid production, whereas Adh4 mutants have only a slight decrease. LD50 studies indicate a large increase in acute retinol toxicity for Adh1 mutants, a small increase for Adh4 mutants, and an intermediate increase for Adh1/4 mutants. Chronic retinol supplementation during gestation resulted in 65% postnatal lethality in Adh1 mutants, whereas only similar to5% for Adh1/4 and Adh4 mutants. These studies indicate that ADH1 provides considerable protection against vitamin A toxicity, whereas ADH4 promotes survival during vitamin A deficiency, thus demonstrating largely non-overlapping functions for these enzymes in retinoid metabolism.	Burnham Inst, Gene Regulat Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, Gene Regulat Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Duester, Gregg/0000-0003-4335-3650	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009731] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA009731-07, AA09731] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Ang HL, 1999, EUR J BIOCHEM, V260, P227, DOI 10.1046/j.1432-1327.1999.00139.x; Armstrong Robert B., 1994, P545; BIESALSKI HK, 1989, TOXICOLOGY, V57, P117, DOI 10.1016/0300-483X(89)90161-3; BOERMAN MHEM, 1995, ARCH BIOCHEM BIOPHYS, V321, P434, DOI 10.1006/abbi.1995.1415; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; Crosas B, 2000, J BIOL CHEM, V275, P25180, DOI 10.1074/jbc.M910040199; Crosas B, 2001, J BIOL CHEM, V276, P19132, DOI 10.1074/jbc.M010478200; Deltour L, 1999, DEV GENET, V25, P1, DOI 10.1002/(SICI)1520-6408(1999)25:1<1::AID-DVG1>3.0.CO;2-W; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; FROLIK CA, 1984, RETINOIDS, V2, P177; GAGNON I, 2002, IN PRESS BIOCH BIOPH; Gamble MV, 1999, J LIPID RES, V40, P2279; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Han CL, 1998, EUR J BIOCHEM, V254, P25, DOI 10.1046/j.1432-1327.1998.2540025.x; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; Haselbeck RJ, 1997, DEV DYNAM, V208, P447, DOI 10.1002/(SICI)1097-0177(199704)208:4<447::AID-AJA1>3.0.CO;2-I; Hogan B, 1994, MANIPULATING MOUSE E; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; Joyner AL, 1993, GENE TARGETING PRACT; KAMM JJ, 1982, J AM ACAD DERMATOL, V6, P652, DOI 10.1016/S0190-9622(82)70054-4; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kono H, 1999, AM J PHYSIOL-GASTR L, V277, pG1259, DOI 10.1152/ajpgi.1999.277.6.G1259; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; MIC FA, 2002, IN PRESS DEVELOPMENT; MOLOTKOV A, 2002, IN PRESS P NATL ACAD; MORTENSEN RM, 1991, P NATL ACAD SCI USA, V88, P7036, DOI 10.1073/pnas.88.16.7036; NELSON M, 1990, BRIT MED J, V301, P1176, DOI 10.1136/bmj.301.6762.1176; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; Szalai G, 2002, EUR J BIOCHEM, V269, P224, DOI 10.1046/j.0014-2956.2001.02642.x; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZHANG K, 1987, GENE, V57, P27, DOI 10.1016/0378-1119(87)90173-9; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	44	77	79	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13804	13811		10.1074/jbc.M112039200	http://dx.doi.org/10.1074/jbc.M112039200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11836246	Green Accepted, hybrid			2022-12-25	WOS:000175096000061
J	Nguyen, VT; Benveniste, EN				Nguyen, VT; Benveniste, EN			Critical role of tumor necrosis factor-alpha and NF-kappa B in interferon-gamma-induced CD40 expression in microglia/macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; IFN-GAMMA; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; ANTIGEN PRESENTATION; MULTIPLE-SCLEROSIS; MICROGLIAL CELLS; TNF-ALPHA; TH1; CYTOKINES		Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Benveniste, EN (corresponding author), Univ Alabama, Dept Cell Biol, 1530 3rd Ave S,MCLM 395, Birmingham, AL 35294 USA.				NIAID NIH HHS [T32AI07493] Funding Source: Medline; NINDS NIH HHS [NS-36765] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036765] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abromson-Leeman S, 2001, EUR J IMMUNOL, V31, P527, DOI 10.1002/1521-4141(200102)31:2<527::AID-IMMU527>3.0.CO;2-D; Aloisi F, 1999, J IMMUNOL, V162, P1384; AUAMER Y, 2001, J CLIN INVEST, V107, P1375; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Becher B, 2000, J NEUROIMMUNOL, V102, P44, DOI 10.1016/S0165-5728(99)00152-6; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Boon L, 2001, J IMMUNOL, V167, P2942, DOI 10.4049/jimmunol.167.5.2942; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746, DOI 10.1128/MCB.17.11.6746; CHUNG IY, 1990, J IMMUNOL, V144, P2999; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Du C, 2001, J NEUROIMMUNOL, V114, P69, DOI 10.1016/S0165-5728(00)00434-3; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; Fuleihan RL, 1998, SEMIN HEMATOL, V35, P321; GALY AHM, 1992, J IMMUNOL, V149, P775; Gerritse K, 1996, P NATL ACAD SCI USA, V93, P2499, DOI 10.1073/pnas.93.6.2499; Goodman RH, 2000, GENE DEV, V14, P1553; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Howard LM, 1999, J CLIN INVEST, V103, P281, DOI 10.1172/JCI5388; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Laman JD, 1997, IMMUNOL TODAY, V18, P272, DOI 10.1016/S0167-5699(97)80022-9; Lee SJ, 1999, GLIA, V25, P21, DOI 10.1002/(SICI)1098-1136(19990101)25:1<21::AID-GLIA3>3.0.CO;2-R; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; MacDonald KPA, 1997, J CLIN INVEST, V100, P2404, DOI 10.1172/JCI119781; McDermott MF, 2001, CELL MOL BIOL, V47, P619; Nguyen VT, 2000, J IMMUNOL, V165, P6235, DOI 10.4049/jimmunol.165.11.6235; Nguyen VT, 2000, J BIOL CHEM, V275, P23674, DOI 10.1074/jbc.M002482200; Nguyen VT, 1998, EUR J IMMUNOL, V28, P2537, DOI 10.1002/(SICI)1521-4141(199808)28:08<2537::AID-IMMU2537>3.0.CO;2-1; OHMORI Y, 1995, J IMMUNOL, V154, P5235; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; RENNO T, 1995, J IMMUNOL, V154, P944; Samoilova EB, 1997, J MOL MED, V75, P603, DOI 10.1007/s001090050145; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Tu Z, 2001, J IMMUNOL, V166, P6839, DOI 10.4049/jimmunol.166.11.6839; Vogel LA, 1998, SEMIN IMMUNOL, V10, P435, DOI 10.1006/smim.1998.0145; Wei RT, 1999, J NEUROIMMUNOL, V95, P8, DOI 10.1016/S0165-5728(98)00248-3	41	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13796	13803		10.1074/jbc.M111906200	http://dx.doi.org/10.1074/jbc.M111906200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830590	hybrid			2022-12-25	WOS:000175096000060
J	Pinakoulaki, E; Pfitzner, U; Ludwig, B; Varotsis, C				Pinakoulaki, E; Pfitzner, U; Ludwig, B; Varotsis, C			The role of the cross-link His-Tyr in the functional properties of the binuclear center in cytochrome c oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTROSCOPY; HEME-COPPER OXIDASES; PARACOCCUS-DENITRIFICANS; ACTIVE-SITE; RHODOBACTER-SPHAEROIDES; INFRARED-SPECTROSCOPY; PROTON TRANSLOCATION; PHOTODISSOCIATED CO; OXYGEN ACTIVATION; BACILLUS-SUBTILIS	Resonance Raman and Fourier transform infrared spectroscopies have been used to study the aa(3)-type cytochrome c oxidase and the Y280H mutant from Paracoccus denitrificans. The stability of the binuclear center in the absence of the Tyr(280)-His(276) cross-link is not compromised since heme a(3) retains the same proximal environment, spin, and coordination state as in the wild type enzyme in both the oxidized and reduced states. We observe two C-O modes in the Y280H mutant at 1966 and 1975 cm(-1). The 1975 cm(-1) mode is assigned to a gamma-form and represents a structure of the active site in which Cu-B exerts a steric effect on the heme a(3)-bound CO. Therefore, the role of the cross-link is to fix Cu-B in a certain configuration and distance from heme a(3), and not to allow histidine ligands to coordinate to Cu-B rather than to heme a(3) rendering the enzyme inactive, as proposed recently (Das, T. K., Pecoraro, C., Tomson, F. L., Gennis, R. B., and Rousseau, D. L. (1998) Biochemistry 37, 14471-14476). The results provide solid evidence that in the Y280H mutant the catalytic site retains its active configuration that allows O-2 binding to heme a(3). Oxygenated intermediates are formed by mixing oxygen with the CO-bound mixed-valence wild type and Y280H enzymes with similar Soret maxima at 438 nm.	Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece; Univ Frankfurt, Biozentrum N200, Inst Biochem, D-60439 Frankfurt, Germany	University of Crete; Goethe University Frankfurt	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Crete, Greece.			Varotsis, Constantinos/0000-0003-2771-8891; Pinakoulaki, Eftychia/0000-0003-3320-6112				ARGADE PV, 1984, SCIENCE, V225, P329, DOI 10.1126/science.6330890; Babcock G. T., 1988, BIOL APPLICATIONS RA, V3, P293; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; CHING YC, 1985, BIOCHEMISTRY-US, V24, P4938, DOI 10.1021/bi00339a032; Das TK, 1998, BIOCHEMISTRY-US, V37, P14471, DOI 10.1021/bi981500w; Das TK, 2001, BIOPHYS J, V80, P2039, DOI 10.1016/S0006-3495(01)76177-2; Das TK, 1999, P NATL ACAD SCI USA, V96, P9591, DOI 10.1073/pnas.96.17.9591; DYER RB, 1989, J AM CHEM SOC, V111, P7657, DOI 10.1021/ja00201a080; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; FergusonMiller S, 1996, CHEM REV, V96, P2889, DOI 10.1021/cr950051s; Gennis RB, 1998, BBA-BIOENERGETICS, V1365, P241, DOI 10.1016/S0005-2728(98)00075-9; HAN SH, 1990, J AM CHEM SOC, V112, P9445, DOI 10.1021/ja00182a001; HEIBEL GE, 1993, BIOCHEMISTRY-US, V32, P10866, DOI 10.1021/bi00091a042; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; HOSLER JP, 1994, J AM CHEM SOC, V116, P5515, DOI 10.1021/ja00091a084; Iwase T, 1999, J AM CHEM SOC, V121, P1415, DOI 10.1021/ja983242w; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; LAURAEUS M, 1992, BIOCHEMISTRY-US, V31, P10054, DOI 10.1021/bi00156a027; LEMON DD, 1993, BIOCHEMISTRY-US, V32, P11953, DOI 10.1021/bi00096a002; Lou BS, 2000, BIOCHEMISTRY-US, V39, P12424, DOI 10.1021/bi001257c; MacMillan F, 1999, BIOCHEMISTRY-US, V38, P9179, DOI 10.1021/bi9911987; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; Michel H, 1999, BIOCHEMISTRY-US, V38, P15129, DOI 10.1021/bi9910934; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P9446, DOI 10.1021/bi960392f; Ostermeier C, 1997, P NATL ACAD SCI USA, V94, P10547, DOI 10.1073/pnas.94.20.10547; Park S, 1996, BIOPHYS J, V71, P1036, DOI 10.1016/S0006-3495(96)79304-9; Pfitzner U, 1998, J BIOENERG BIOMEMBR, V30, P89, DOI 10.1023/A:1020515713103; Proshlyakov DA, 2000, SCIENCE, V290, P1588, DOI 10.1126/science.290.5496.1588; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; PUUSTINEN A, 2000, BIOCHEMISTRY-US, V39, P13195; Rost B, 1999, BIOCHEMISTRY-US, V38, P7565, DOI 10.1021/bi990225q; Schelvis JPM, 1997, J AM CHEM SOC, V119, P8409, DOI 10.1021/ja964133p; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Vamvouka M, 1999, J PHYS CHEM B, V103, P3030, DOI 10.1021/jp984589o; VAROTSIS C, 1995, J PHYS CHEM-US, V99, P16817, DOI 10.1021/j100046a004; Varotsis C, 1998, J PHYS CHEM B, V102, P7670, DOI 10.1021/jp9824095; Varotsis C, 1996, BIOSPECTROSCOPY, V2, P331; VAROTSIS C, 1990, BIOCHEMISTRY-US, V29, P7357, DOI 10.1021/bi00484a001; WANG JL, 1993, J AM CHEM SOC, V115, P3390, DOI 10.1021/ja00061a072; WANG JL, 1995, BIOCHEMISTRY-US, V34, P9819, DOI 10.1021/bi00031a001; WANG JL, 1995, P NATL ACAD SCI USA, V92, P9402, DOI 10.1073/pnas.92.20.9402; WANG JL, 1995, J AM CHEM SOC, V117, P9363, DOI 10.1021/ja00141a033; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859; Yoshikawa S, 1998, SCIENCE, V280, P1723, DOI 10.1126/science.280.5370.1723	47	73	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13563	13568		10.1074/jbc.M112200200	http://dx.doi.org/10.1074/jbc.M112200200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825904	hybrid			2022-12-25	WOS:000175096000030
J	Kaul, S; Blackford, JA; Cho, SY; Simons, SS				Kaul, S; Blackford, JA; Cho, SY; Simons, SS			Ubc9 is a novel modulator of the induction properties of glucocorticoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE AMINOTRANSFERASE GENE; UBIQUITIN-CONJUGATING ENZYME; LIGAND-BINDING DOMAIN; ANDROGEN RECEPTOR; SUMO-1 MODIFICATION; TRANSCRIPTIONAL ACTIVITY; ESTROGEN-RECEPTOR; PROMOTER-CONTEXT; RESPONSE ELEMENT; AGONIST ACTIVITY	The EC50 of agonists and the partial agonist activity of antagonists are crucial parameters for steroid hormone control of gene expression and endocrine therapies. These parameters have been shown to be modulated by a naturally occurring cis-acting element, called the glucocorticoid modulatory element (GME) that binds two proteins, GMEB-1 and -2. We now present evidence that the GMEBs contact Ubc9, which is the mammalian homolog of a yeast E2 ubiquitin-conjugating enzyme. Ubc9 also binds to glucocorticoid receptors (GRs). Ubc9 displays no intrinsic transactivation activity but modifies both the absolute amount of induced gene product and the fold induction by GR. With high concentrations of GR, added Ubc9 also reduces the EC50 of agonists and increases the partial agonist activity of antagonists in a manner that is independent of the ability of Ubc9 to transfer SUMO-1 (small ubiquitin-like modifier-1) to proteins. This new activity of Ubc9 requires only the ligand binding domain of GR and part of the hinge region. Interestingly, Ubc9 modulation of full-length GR transcriptional properties can be seen in the absence of a GME. This, though, is consistent with the GME acting by increasing the local concentration of Ubc9, which then activates a previously unobserved target in the transcriptional machinery. With high concentrations of Ubc9 and GR, Ubc9 binding to GR appears to be sufficient to permit Ubc9 to act independently of the GME.	NIDDK, Steroid Hormones Sect, LCMB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Simons, SS (corresponding author), NIDDK, Steroid Hormones Sect, LCMB, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057800, ZIADK057800] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alen P, 1999, MOL CELL BIOL, V19, P6085; BAN EMH, 1994, IMMUNOL RES, V13, P1, DOI 10.1007/BF02918219; BAULIEU EE, 1989, SCIENCE, V245, P1351, DOI 10.1126/science.2781282; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Bhaskar V, 2000, J BIOL CHEM, V275, P4033, DOI 10.1074/jbc.275.6.4033; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bottomley MJ, 2001, NAT STRUCT BIOL, V8, P626, DOI 10.1038/89675; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Collier CD, 1996, MOL ENDOCRINOL, V10, P463, DOI 10.1210/me.10.5.463; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gottlicher M, 1996, STEROIDS, V61, P257, DOI 10.1016/0039-128X(96)00032-3; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Huggenvik JI, 1998, MOL ENDOCRINOL, V12, P1619, DOI 10.1210/me.12.10.1619; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Jackson DA, 1998, J STEROID BIOCHEM, V66, P79, DOI 10.1016/S0960-0760(98)00048-X; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; JORDAN VC, 1990, ENDOCR REV, V11, P578, DOI 10.1210/edrv-11-4-578; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kaul S, 2000, MOL ENDOCRINOL, V14, P1010, DOI 10.1210/me.14.7.1010; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; LeBoeuf RD, 1998, J BIOL CHEM, V273, P361, DOI 10.1074/jbc.273.1.361; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MERCIER L, 1986, J STEROID BIOCHEM, V25, P11, DOI 10.1016/0022-4731(86)90275-X; OSHIMA H, 1995, J BIOL CHEM, V270, P21893, DOI 10.1074/jbc.270.37.21893; OSHIMA H, 1993, J BIOL CHEM, V268, P26858; OSHIMA H, 1992, MOL ENDOCRINOL, V6, P416, DOI 10.1210/me.6.3.416; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SIMONS S S JR, 1989, Cancer Research, V49, p2244S; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1992, MOL ENDOCRINOL, V6, P995, DOI 10.1210/me.6.7.995; Song LN, 2001, J BIOL CHEM, V276, P24806, DOI 10.1074/jbc.M102610200; Szapary D, 1996, J BIOL CHEM, V271, P30576, DOI 10.1074/jbc.271.48.30576; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1992, ENDOCRINOLOGY, V130, P3492, DOI 10.1210/en.130.6.3492; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; TURCOTTE B, 1990, MOL CELL BIOL, V10, P5002, DOI 10.1128/MCB.10.9.5002; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Wang Q, 2001, J BIOL CHEM, V276, P7493, DOI 10.1074/jbc.M009916200; WASNER G, 1988, MOL ENDOCRINOL, V2, P1009, DOI 10.1210/mend-2-11-1009; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zeng HW, 2000, NUCLEIC ACIDS RES, V28, P1819, DOI 10.1093/nar/28.8.1819; Zeng HW, 2000, MOL CELL ENDOCRINOL, V162, P221, DOI 10.1016/S0303-7207(99)00208-7; Zeng HW, 1998, J BIOL CHEM, V273, P17756, DOI 10.1074/jbc.273.28.17756	62	79	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12541	12549		10.1074/jbc.M112330200	http://dx.doi.org/10.1074/jbc.M112330200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812797	hybrid			2022-12-25	WOS:000175036300010
J	Garnier, C; Lafitte, D; Tsvetkov, PO; Barbier, P; Leclerc-Devin, J; Millot, JM; Briand, C; Makarov, AA; Catelli, MG; Peyrot, V				Garnier, C; Lafitte, D; Tsvetkov, PO; Barbier, P; Leclerc-Devin, J; Millot, JM; Briand, C; Makarov, AA; Catelli, MG; Peyrot, V			Binding of ATP to heat shock protein 90 - Evidence for an ATP-binding site in the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECONDARY STRUCTURE PREDICTION; HSP90 MOLECULAR CHAPERONE; IN-VIVO; CRYSTAL-STRUCTURE; NEURAL NETWORKS; GELDANAMYCIN; DIMERIZATION; INFORMATION; MECHANISM; MAGNESIUM	The presence of a nucleotide binding site on hsp90 was very controversial until x-ray structure of the hsp90 N-terminal domain, showing a nonconventional nucleotide binding site, appeared. A recent study suggested that the hsp90 C-terminal domain also binds ATP (Marcu, M. G., Chadli, A., Bouhouche, L, Catelli, M. G., and Neckers, L. M. (2000) J. Biol. Chem. 275, 3718137186). In this paper, the interactions of ATP with native hsp90 and its recombinant N-terminal (positions 1-221) and C-terminal (positions 446-728) domains were studied by isothermal titration calorimetry, scanning differential calorimetry, and fluorescence spectroscopy. Results clearly demonstrate that hsp90 possesses a second ATP-binding site located on the C-terminal part of the protein. The association constant between this domain of hsp90 and ATP-Mg and a comparison with the binding constant on the full-length protein are reported for the first time. Secondary structure prediction revealed motifs compatible with a Rossmann fold in the C-terminal part of hsp90. It is proposed that this potential Rossmann fold may constitute the C-terminal ATP-binding site. This work also suggests allosteric interaction between N- and C-terminal domains of hsp90.	Fac Pharm Marseille, UMR CNRS 6032, F-13385 Marseille 5, France; ICGM, CNRS, UPR 1524, F-75014 Paris, France; Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow 119991, Russia; Fac Pharm, Lab Spectroscopie Biomol, F-51096 Reims, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Universite de Reims Champagne-Ardenne	Peyrot, V (corresponding author), Fac Pharm Marseille, UMR CNRS 6032, 27 Blvd Jean Moulin, F-13385 Marseille 5, France.		Barbier, Pascale/AAE-1781-2019; peyrot, vincent/B-6365-2015; Makarov, Alexander/P-5279-2016	lafitte, daniel/0000-0001-9921-7522; GARNIER, Cyrille/0000-0002-5715-8218				Barbier P, 1995, BIOCHEMISTRY-US, V34, P16821, DOI 10.1021/bi00051a033; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CALLEBAUT I, 1994, CR ACAD SCI III-VIE, V317, P721; Chadli A, 1999, J BIOL CHEM, V274, P4133, DOI 10.1074/jbc.274.7.4133; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; CSERMELY P, 1993, J BIOL CHEM, V268, P1901; Garnier C, 1998, BIOCHEM BIOPH RES CO, V249, P197, DOI 10.1006/bbrc.1998.9108; Garnier C, 2001, EUR J BIOCHEM, V268, P2402, DOI 10.1046/j.1432-1327.2001.02121.x; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HAALAND DM, 1988, ANAL CHEM, V60, P1193, DOI 10.1021/ac00162a020; KNELLER DG, 1990, J MOL BIOL, V214, P171, DOI 10.1016/0022-2836(90)90154-E; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; MCCLELLAND JL, 1988, EXPLORATIONS PARALLE, V3, P318; Meng X, 1996, J CELL SCI, V109, P1677; MILLOT JM, 1994, ANAL CHIM ACTA, V295, P233, DOI 10.1016/0003-2670(94)80228-9; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; MINTON AP, 1994, MODERN ANAL ULTRACEN, P119; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Nemoto T, 1998, BIOCHEM J, V330, P989, DOI 10.1042/bj3300989; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Ponomarev MA, 2000, BIOCHEMISTRY-US, V39, P4527, DOI 10.1021/bi992420a; Privalov P L, 1986, Methods Enzymol, V131, P4; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Prodromou C, 1997, NAT STRUCT BIOL, V4, P477, DOI 10.1038/nsb0697-477; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; ROST B, 1995, PROTEINS, V23, P295, DOI 10.1002/prot.340230304; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1994, PROTEINS, V20, P216, DOI 10.1002/prot.340200303; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Scheibel T, 1999, MOL MICROBIOL, V34, P701, DOI 10.1046/j.1365-2958.1999.01632.x; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Stafford WF, 1994, MODERN ANAL ULTRACEN, P119; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; YONEZAWA N, 1988, EUR J BIOCHEM, V177, P1, DOI 10.1111/j.1432-1033.1988.tb14337.x; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; [No title captured]	44	130	134	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12208	12214		10.1074/jbc.M111874200	http://dx.doi.org/10.1074/jbc.M111874200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805114	hybrid			2022-12-25	WOS:000174846400079
J	Lova, P; Paganini, S; Sinigaglia, F; Balduini, C; Torti, M				Lova, P; Paganini, S; Sinigaglia, F; Balduini, C; Torti, M			A G(i)-dependent pathway is required for activation of the small GTPase Rap1B in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-DIPHOSPHATE; SHAPE CHANGE; PHOSPHOINOSITIDE 3-KINASE; DEFECTIVE INTERACTION; CALCIUM MOBILIZATION; PHOSPHOLIPASE-C; ADP RECEPTORS; G-PROTEIN; AGGREGATION; THROMBIN	Stimulation of human platelets by cross-linking of the low affinity receptor for immunoglobulin, FcgammaRIIA, caused the rapid activation of the small GTPase Rap1B, as monitored by accumulation of the GTP-bound form of the protein. This process was totally dependent on the action of secreted ADP since it was completely prevented in the presence of either apyrase or creatine phosphate and creatine phosphokinase. Dose-dependent experiments revealed that the inhibitory effect of ADP scavengers was not related to the reduced increase of cytosolic Ca2+ concentration in stimulated platelets. Activation of Rap1B induced by clustering of FcgammaRIIA was totally suppressed by AR-C69931MX, a specific antagonist of the G(i)-coupled ADP receptor P2Y12, but was not affected by blockade of the G(q)-coupled receptor, P2Y1. Similarly, direct stimulation of platelets with ADP induced the rapid activation of Rap1B. Pharmacological blockade of the P2Y1 receptor totally prevented ADP-induced Ca2+ mobilization but did not affect activation of Rap1B. By contrast, prevention of ADP binding to the P2Y12 receptor totally suppressed activation of Rap1B without affecting Ca2+ signaling. In platelets stimulated by cross-linking of FcgammaRIIA, inhibition of Rap1B activation by ADP scavengers could be overcome by the simultaneous recruitment of the Gi-coupled alpha(2A)-adrenergic receptor by epinephrine. By contrast, serotonin, which binds to a Gq-coupled receptor, could not restore activation of Rap1B. When tested alone, epinephrine was found to be able to induce GTP binding to Rap1B, whereas serotonin produced only a slight effect. Finally, activation of Rap1B induced by stimulation of the G(q)-coupled thromboxane A(2) receptor by U46619 was completely inhibited by ADP scavengers under conditions in which intracellular Ca2+ mobilization was unaffected. Inhibition of U46619-induced Rap1B activation was also observed upon blockade of the P2Y12 but not of the P2Y1 receptor for ADP. These results demonstrate that stimulation of a G(i)-dependent signaling pathway by either ADP of epinephrine is necessary and sufficient to activate the small GTPase Rap1B.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy; Univ A Avogadro, Dept Med Sci, I-28100 Novara, Italy	University of Pavia; University of Eastern Piedmont Amedeo Avogadro	Torti, M (corresponding author), Univ Pavia, Dept Biochem, Via Bassi 21, I-27100 Pavia, Italy.							Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; BENCKEMARTI K, 1992, P NATL ACAD SCI USA, V89, P2784; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; CATTANEO M, 1992, BLOOD, V80, P2787; Cattaneo M, 1999, ARTERIOSCL THROM VAS, V19, P2281, DOI 10.1161/01.ATV.19.10.2281; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Daniel JL, 1999, THROMB HAEMOSTASIS, V82, P1322; FISCHER TH, 1990, J BIOL CHEM, V265, P19405; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Franke B, 2000, MOL CELL BIOL, V20, P779, DOI 10.1128/MCB.20.3.779-785.2000; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gratacap MP, 2000, BLOOD, V96, P3439, DOI 10.1182/blood.V96.10.3439.h8003439_3439_3446; Habib A, 1999, J BIOL CHEM, V274, P2645, DOI 10.1074/jbc.274.5.2645; HASLAM RJ, 1978, BIOCHEM J, V176, P83, DOI 10.1042/bj1760083; Hechler B, 1998, BLOOD, V92, P152, DOI 10.1182/blood.V92.1.152.413k27_152_159; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUMPHRIES RG, 1995, TRENDS PHARMACOL SCI, V16, P179, DOI 10.1016/S0165-6147(00)89018-5; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; KLINZ FJ, 1992, EUR J BIOCHEM, V207, P207, DOI 10.1111/j.1432-1033.1992.tb17039.x; Kunapuli SP, 1998, PLATELETS, V9, P343, DOI 10.1080/09537109876401; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; Levy-Toledano S, 1998, THROMB HAEMOSTASIS, V80, P463; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Meng JW, 1999, J BIOL CHEM, V274, P36663, DOI 10.1074/jbc.274.51.36663; NURDEN P, 1995, J CLIN INVEST, V95, P1612, DOI 10.1172/JCI117835; Ohlmann P, 2000, BLOOD, V96, P2134, DOI 10.1182/blood.V96.6.2134.h8002134_2134_2139; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Polgar J, 1998, BLOOD, V91, P549, DOI 10.1182/blood.V91.2.549.549_549_554; POLLOCK WK, 1986, BIOCHEM J, V235, P869, DOI 10.1042/bj2350869; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; SIESS W, 1984, J BIOL CHEM, V259, P8286; STEEN VM, 1988, BIOCHEM J, V253, P581, DOI 10.1042/bj2530581; TORTI M, 1992, BIOCHEM BIOPH RES CO, V186, P440, DOI 10.1016/S0006-291X(05)80827-7; TORTI M, 1992, P NATL ACAD SCI USA, V89, P7796, DOI 10.1073/pnas.89.16.7796; TORTI M, 1994, THROMB HAEMOSTASIS, V71, P533; TORTI M, 1993, P NATL ACAD SCI USA, V90, P7553, DOI 10.1073/pnas.90.16.7553; Trumel C, 1999, BLOOD, V94, P4156, DOI 10.1182/blood.V94.12.4156.424k29_4156_4165; WINEGAR DA, 1991, J BIOL CHEM, V266, P4375; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; Zhang FL, 2001, J BIOL CHEM, V276, P8608, DOI 10.1074/jbc.M009718200	44	99	103	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12009	12015		10.1074/jbc.M111803200	http://dx.doi.org/10.1074/jbc.M111803200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815620	hybrid			2022-12-25	WOS:000174846400054
J	Mateer, SC; McDaniel, AE; Nicolas, V; Habermacher, GM; Lin, MJS; Cromer, DA; King, ME; Bloom, GS				Mateer, SC; McDaniel, AE; Nicolas, V; Habermacher, GM; Lin, MJS; Cromer, DA; King, ME; Bloom, GS			The mechanism for regulation of the F-actin binding activity of IQGAP1 by calcium/calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RASGAP-RELATED PROTEIN; CELL-ADHESION; SMALL GTPASES; BETA-CATENIN; LIGHT-CHAIN; CDC42; CALMODULIN; CYTOKINESIS; IDENTIFICATION; TARGET	IQGAP1 colocalizes with actin filaments in the cell cortex and binds in vitro to F-actin and several signaling proteins, including calmodulin, Cdc42, Rac1, and beta-catenin. It is thought that the F-actin binding activity of IQGAP1 is regulated by its reversible association with these signaling molecules, but the mechanisms have remained obscure. Here we describe the regulatory mechanism for calmodulin. Purified adrenal IQGAP1 was found to consist of two distinct protein pools, one of which bound F-actin and lacked calmodulin, and the other of which did not bind F-actin but was tightly associated with calmodulin. Based on this finding we hypothesized that calmodulin negatively regulates binding of IQGAP1 to F-actin. This hypothesis was tested in vitro using recombinant wild type and mutated IQGAP1s and in live cells that transiently expressed IQGAP1-YFP. In vitro, the affinity of wild type IQGAP1 for F-actin decreased with increasing concentrations of calmodulin, and this effect was dramatically enhanced by Ca2+ and required the IQ domains of IQGAP1. In addition, we found that calmodulin bound wild type IQGAPI much more efficiently in the presence of Ca2+ than EGTA, and all 8 IQ motifs in each IQGAP1 dimer could bind calmodulin simultaneously. In live cells, IQGAP1-YFP localized to the cell cortex, but elevation of intracellular Ca2+ reversibly induced the fluorescent fusion protein to become diffusely distributed. Taken together, these results support a model in which a rise in f ree intracellular Ca2+ promotes binding of calmodulin to IQGAP1, which in turn inhibits IQGAP1 from binding to cortical actin filaments.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA 22903 USA; Cutanix Corp, Oklahoma City, OK 73104 USA; Univ Paris Sud, Fac Pharm, Chatenay Malabry, France; Emory Univ, Sch Med, Atlanta, GA 30322 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Virginia; University of Virginia; UDICE-French Research Universities; Universite Paris Saclay; Emory University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bloom, GS (corresponding author), Univ Virginia, Dept Biol, 229 Gilmer Hall, Charlottesville, VA 22903 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030485] Funding Source: NIH RePORTER; NICHD NIH HHS [HD07528, HD07323] Funding Source: Medline; NINDS NIH HHS [NS30485] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 1997, J CELL BIOL, V137, P891, DOI 10.1083/jcb.137.4.891; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Ben-Ze'ev A, 2000, EXP CELL RES, V261, P75, DOI 10.1006/excr.2000.5045; BLOOM GS, 1993, J CELL BIOL, V120, P467, DOI 10.1083/jcb.120.2.467; Brill S, 1996, MOL CELL BIOL, V16, P4869; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; Epp JA, 1997, CURR BIOL, V7, P921, DOI 10.1016/S0960-9822(06)00411-8; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Faix J, 1996, FEBS LETT, V394, P251, DOI 10.1016/0014-5793(96)00963-5; Fukata M, 1999, J BIOL CHEM, V274, P26044, DOI 10.1074/jbc.274.37.26044; Fukata M, 1997, J BIOL CHEM, V272, P29579, DOI 10.1074/jbc.272.47.29579; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; Ho YD, 1999, J BIOL CHEM, V274, P464, DOI 10.1074/jbc.274.1.464; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; Joyal JL, 1997, J BIOL CHEM, V272, P15419, DOI 10.1074/jbc.272.24.15419; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee S, 1997, DEVELOPMENT, V124, P983; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lippincott J, 1998, J CELL BIOL, V140, P355, DOI 10.1083/jcb.140.2.355; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Osman MA, 1998, J CELL BIOL, V142, P443, DOI 10.1083/jcb.142.2.443; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Venturelli CR, 2000, DEV GENES EVOL, V210, P458, DOI 10.1007/s004270000084; WEIHING RR, 1985, CAN J BIOCHEM CELL B, V63, P397, DOI 10.1139/o85-059; Weissbach L, 1998, BIOCHEM BIOPH RES CO, V251, P269, DOI 10.1006/bbrc.1998.9371; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517	31	96	97	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12324	12333		10.1074/jbc.M109535200	http://dx.doi.org/10.1074/jbc.M109535200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809768	hybrid			2022-12-25	WOS:000174846400095
J	Birbach, A; Gold, P; Binder, BR; Hofer, E; de Martin, R; Schmid, JA				Birbach, A; Gold, P; Binder, BR; Hofer, E; de Martin, R; Schmid, JA			Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPORT SIGNAL; IKK-ALPHA; TRANSCRIPTION FACTORS; ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; CYCLIN D1; ACTIVATION; KINASE; LOCALIZATION; EXPRESSION	We aimed to investigate the dynamics of the NF-kappaB signaling pathway in living cells using GFP variants of p65-NF-kappaB, IkappaBalpha, tumor necrosis factor-receptor associated factor 2 (TRAF2), the NF-kappaB inducing kinase (NIK) and IkappaB kinases (IKK1 and IKK2). Detailed kinetic analysis of constitutive nucleocytoplasmic shuttling processes revealed that IkappaBalpha enters the nucleus faster than p65. Examination of signaling molecules upstream of NF-kappaB and IkappaBalpha revealed a predominant cytoplasmic localization at steady state. However, after addition of leptomycin B, NIK rapidly accumulated in the nucleus, whereas we could not detect any significant effect on TRAF2 or IKK2. Using various truncation mutants of NIK, we identified a functional nuclear export signal within the COOH-terminal region 795-805, which counteracts the inherent NLS at amino acids 143-149. Prolonged incubation in the presence of LMB also leads to nuclear accumulation of IKK1, which was dependent on a lysine residue at position 44, which is also essential for kinase activity. Investigation of endogenous protein levels by immunofluorescence staining and Western blots verified the results obtained with GFP chimeras. We conclude that NF-kappaB(.)IkappaB complexes and the upstream signaling kinases NIK and IKK1 shuttle between cytoplasm and nucleus of nonactivated cells and that this process leads to a basal transcriptional activity of NF-kappaB.	Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria; Competence Ctr Biomol Therapeut, A-1235 Vienna, Austria	University of Vienna	Schmid, JA (corresponding author), Brunnerstr 59, A-1235 Vienna, Austria.		Schmid, Johannes A./C-7659-2009	Schmid, Johannes A./0000-0002-6586-3507				ArenzanaSeisdedos F, 1997, J CELL SCI, V110, P369; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Harhaj EW, 1999, MOL CELL BIOL, V19, P7088; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Huang TT, 2000, P NATL ACAD SCI USA, V97, P1014, DOI 10.1073/pnas.97.3.1014; Huxford T, 1998, CELL, V95, P759, DOI 10.1016/S0092-8674(00)81699-2; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Matsushima A, 2001, J EXP MED, V193, P631, DOI 10.1084/jem.193.5.631; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Renard P, 2000, J BIOL CHEM, V275, P15193, DOI 10.1074/jbc.275.20.15193; Rodriguez MS, 1999, J BIOL CHEM, V274, P9108, DOI 10.1074/jbc.274.13.9108; Sachdev S, 2000, MOL CELL BIOL, V20, P1571, DOI 10.1128/MCB.20.5.1571-1582.2000; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takeuchi M, 1996, J BIOL CHEM, V271, P19935, DOI 10.1074/jbc.271.33.19935; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang JM, 2001, CANCER RES, V61, P4901; Yin L, 2001, SCIENCE, V291, P2162, DOI 10.1126/science.1058453; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697	45	245	258	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10842	10851		10.1074/jbc.M112475200	http://dx.doi.org/10.1074/jbc.M112475200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801607	hybrid			2022-12-25	WOS:000174613100014
J	Krogan, NJ; Dover, J; Khorrami, S; Greenblatt, JF; Schneider, J; Johnston, M; Shilatifard, A				Krogan, NJ; Dover, J; Khorrami, S; Greenblatt, JF; Schneider, J; Johnston, M; Shilatifard, A			COMPASS, a histone H3 (lysine 4) methyltransferase required for telomeric silencing of gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; REPRESS TRANSCRIPTION; DOMAIN PROTEINS; TRITHORAX; CHROMATIN; REGION	The trithorax (Trx) family of proteins is required for maintaining a specific pattern of gene expression in some organisms. Recently we reported the isolation and characterization of COMPASS, a multiprotein complex that includes the Trx-related protein Set1of the yeast Saccharomyces cerevisiae. Here we report that COMPASS catalyzes methylation of the fourth lysine of histone H3 in vitro. Setl and several other components of COMPASS are also required for histone H3 methylation in vivo and for transcriptional silencing of a gene located near a chromosome telomere.	St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Toronto, Banting & Best Dept Med Res, Dept Mol & Med Genet, Toronto, ON M5G 1L6, Canada	Saint Louis University; Washington University (WUSTL); University of Toronto	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NATIONAL CANCER INSTITUTE [R01CA089455] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA089455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger SL, 2001, ONCOGENE, V20, P3007, DOI 10.1038/sj.onc.1204324; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X; Corda Y, 1999, NAT GENET, V21, P204, DOI 10.1038/5991; de la Barre AE, 2000, EMBO J, V19, P379, DOI 10.1093/emboj/19.3.379; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Horita DA, 2001, J MOL BIOL, V307, P861, DOI 10.1006/jmbi.2001.4515; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 1998, CELL MOL LIFE SCI, V54, P80, DOI 10.1007/s000180050127; JONES RS, 1993, MOL CELL BIOL, V13, P6357, DOI 10.1128/MCB.13.10.6357; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; STASSEN MJ, 1995, MECH DEVELOP, V52, P209, DOI 10.1016/0925-4773(95)00402-M; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Thon G, 2000, GENETICS, V155, P551; THON G, 1994, GENETICS, V138, P29; TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	29	316	327	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10753	10755		10.1074/jbc.C200023200	http://dx.doi.org/10.1074/jbc.C200023200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805083	hybrid			2022-12-25	WOS:000174613100002
J	Perlemuter, G; Sabile, A; Letteron, P; Vona, G; Topilco, A; Chretien, Y; Koike, K; Pessayre, D; Chapman, J; Barba, G; Brechot, C				Perlemuter, G; Sabile, A; Letteron, P; Vona, G; Topilco, A; Chretien, Y; Koike, K; Pessayre, D; Chapman, J; Barba, G; Brechot, C			Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis	FASEB JOURNAL			English	Article						HCV; VLDL; MTP	APOLIPOPROTEIN-A-II; NONALCOHOLIC STEATOHEPATITIS; LIPID-PEROXIDATION; TRANSGENIC MICE; LIVER; EXPRESSION; ABETALIPOPROTEINEMIA; HISTOPATHOLOGY; KNOCKOUT; FEATURES	Liver steatosis, which involves accumulation of intracytoplasmic lipid droplets, is characteristic of hepatitis C virus (HCV) infection. By use of an in vivo transgenic murine model, we demonstrate that hepatic overexpression of HCV core protein interferes with the hepatic assembly and secretion of triglyceride-rich very low density lipoproteins (VLDL). Core expression led to reduction in microsomal triglyceride transfer protein (MTP) activity and in the particle size of nascent hepatic VLDL without affecting accumulation of MTP and protein disulfide isomerase. Hepatic human apolipoprotein AII (apo AII) expression in double-core/apo AII transgenic mice diminished intrahepatic core protein accumulation and abrogated its effects on VLDL production. Apo AII and HCV core colocalized in human HCV-infected liver biopsies, thus testifying to the relevance of this interaction in productive HCV infection. Our results lead us to propose a new pathophysiological animal model for induction of viral-related steatosis whereby the core protein of HCV targets microsomal triglyceride transfer protein activity and modifies hepatic VLDL assembly and secretion.	Fac Med Necker Enfants Malad, INSERM, U370, F-75730 Paris 15, France; Hop Beaujon, INSERM, U481, F-92118 Clichy, France; Inst Pasteur, Electron Microscopy Lab, F-75015 Paris, France; Univ Tokyo, Grad Sch Med, Dept Infect Dis, Tokyo, Japan; Hop La Pitie Salpetriere, INSERM, U321, F-75013 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Tokyo; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Brechot, C (corresponding author), Fac Med Necker Enfants Malad, INSERM, U370, 156 Rue Vaugirard, F-75730 Paris 15, France.	brechot@necker.fr		Barba Spaeth, Giovanna/0000-0003-2069-9501				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Aguie GA, 1995, ATHEROSCLEROSIS, V118, P183, DOI 10.1016/0021-9150(95)05605-X; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; ANGERMULLER S, 1982, HISTOCHEM J, V14, P823, DOI 10.1007/BF01033631; Aoyagi K, 1999, J CLIN MICROBIOL, V37, P1802, DOI 10.1128/JCM.37.6.1802-1808.1999; ARBEENY CM, 1992, J LIPID RES, V33, P843; BACH N, 1992, SEMIN LIVER DIS, V12, P205, DOI 10.1055/s-2007-1007392; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; CAMUS MC, 1983, J LIPID RES, V24, P1210; CHAPMAN MJ, 1981, J LIPID RES, V22, P339; Colombo M, 1999, SEMIN LIVER DIS, V19, P263, DOI 10.1055/s-2007-1007116; Czaja AJ, 1998, J HEPATOL, V29, P198, DOI 10.1016/S0168-8278(98)80004-4; Day CP, 1998, HEPATOLOGY, V27, P1463, DOI 10.1002/hep.510270601; Escola-Gil JC, 2000, J LIPID RES, V41, P1328; Fong DG, 2000, HEPATOLOGY, V32, P3, DOI 10.1053/jhep.2000.8978; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; Girotti AW, 1998, J LIPID RES, V39, P1529; GOODMAN ZD, 1995, SEMIN LIVER DIS, V15, P70, DOI 10.1055/s-2007-1007264; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; GRIMBERT S, 1993, HEPATOLOGY, V17, P628, DOI 10.1002/hep.1840170417; Hasty AH, 1999, J LIPID RES, V40, P1529; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Jin FY, 1999, ARTERIOSCL THROM VAS, V19, P1051, DOI 10.1161/01.ATV.19.4.1051; KANTO T, 1994, HEPATOLOGY, V19, P296; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Lai MMC, 2000, CURR TOP MICROBIOL, V242, P117; Large MK, 1999, J IMMUNOL, V162, P931; Lerat H, 1998, HEPATOLOGY, V28, p498A; Letteron P, 1996, J HEPATOL, V24, P200, DOI 10.1016/S0168-8278(96)80030-4; Luyckx FH, 2000, DIABETES METAB, V26, P98; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Navasa M, 1998, J LIPID RES, V39, P1220; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; Paradis V, 1997, J CLIN PATHOL, V50, P401, DOI 10.1136/jcp.50.5.401; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Raabe M, 1998, P NATL ACAD SCI USA, V95, P8686, DOI 10.1073/pnas.95.15.8686; Rubbia-Brandt L, 2000, J HEPATOL, V33, P106, DOI 10.1016/S0168-8278(00)80166-X; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SANTOLINI E, 1994, J VIROL, V68, P3631, DOI 10.1128/JVI.68.6.3631-3641.1994; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SHIMANO H, 1992, J CLIN INVEST, V90, P2084, DOI 10.1172/JCI116091; Shimotohno K, 1995, INTERVIROLOGY, V38, P162, DOI 10.1159/000150427; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4	50	456	472	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					185	194		10.1096/fj.01-0396com	http://dx.doi.org/10.1096/fj.01-0396com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818366				2022-12-25	WOS:000174203700023
J	Kuschak, TI; Kuschak, BC; Taylor, CL; Wright, JA; Wiener, F; Mai, S				Kuschak, TI; Kuschak, BC; Taylor, CL; Wright, JA; Wiener, F; Mai, S			c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene	ONCOGENE			English	Article						c-Myc; genomic instability; amplification; DNA replication; ribonucleotide reductase R2	SYRIAN-HAMSTER CELLS; DIHYDROFOLATE-REDUCTASE; GENOMIC INSTABILITY; METHOTREXATE RESISTANCE; DNA-REPLICATION; CAD GENES; AMPLIFICATION; MOUSE; OVEREXPRESSION; TUMORIGENESIS	The mechanisms through which the oncoprotein c-Myc initiates locus-specific gene amplification are not understood. When analysing the initiation mechanism of c-Myc-dependent amplification of the mouse ribonucleotide reductase R2 (R2) gene, we observe c-Myc-dependent initiation of illegitimate DNA replication of the R2 gene. We demonstrate multiple simultaneous c-Myc-induced R2 replication forks, whereas R2 normally replicates with a single fork. In contrast, cyclin C replicates with only a single replication fork irrespective of c-Myc deregulation. In addition to de novo replication forks, c-Myc also initiates bi-allelic replication of R2, abrogating its normal mono-allelic replication pattern, Moreover, several chromosomal regions also display c-Myc-induced illegitimate replication profiles. Thus, c-Myc can act as an illegitimate replication-licensing factor that promotes de novo replication initiation and illegitimate replication timing that adversely impacts upon genomic stability.	Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag & CancerCare Manitoba, Dept Microbiol, Winnipeg, MB R3E 0V9, Canada; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	CancerCare Manitoba Foundation; University of Manitoba; Karolinska Institutet	Mai, S (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Genom Ctr Canc Res & Diag & CancerCare Manitoba, Dept Microbiol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201				BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; Butler DK, 1996, CELL, V87, P1115, DOI 10.1016/S0092-8674(00)81805-X; CARROLL SM, 1988, MOL CELL BIOL, V8, P1525, DOI 10.1128/MCB.8.4.1525; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; DENIS N, 1991, ONCOGENE, V6, P1453; DIJKWEL PA, 1991, MOL CELL BIOL, V11, P3850, DOI 10.1128/MCB.11.8.3850; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Gandarillas A, 2000, ONCOGENE, V19, P3278, DOI 10.1038/sj.onc.1203630; HAMLIN JL, 1991, PROG NUCLEIC ACID RE, V41, P203; HAMLIN JL, 1990, BIOCHIM BIOPHYS ACTA, V1087, P107, DOI 10.1016/0167-4781(90)90195-8; HENRIKSSON M, 1988, CURR TOP MICROBIOL, V141, P202; JOHNSTON RN, 1983, P NATL ACAD SCI-BIOL, V80, P3711, DOI 10.1073/pnas.80.12.3711; KHAN F, 1994, GENOMICS, V21, P128, DOI 10.1006/geno.1994.1234; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li HM, 1996, GENOMICS, V32, P253, DOI 10.1006/geno.1996.0112; Li Q, 1999, MOL CELL BIOL, V19, P5339; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MA C, 1993, GENE DEV, V7, P605, DOI 10.1101/gad.7.4.605; MAI S, 1994, GENE, V148, P253, DOI 10.1016/0378-1119(94)90696-3; MAI S, 1994, NUCLEIC ACIDS RES, V22, P2264, DOI 10.1093/nar/22.12.2264; Mai S, 1996, ONCOGENE, V12, P277; Mai S, 1996, CHROMOSOME RES, V4, P365, DOI 10.1007/BF02257272; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; MAI S, 1994, CYCLIN D2 TARGET C M, P53; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; MEINKOTH J, 1987, MOL CELL BIOL, V7, P1415, DOI 10.1128/MCB.7.4.1415; MORRIS T, 1993, P NATL ACAD SCI USA, V90, P1392, DOI 10.1073/pnas.90.4.1392; Pipiras E, 1998, EMBO J, V17, P325, DOI 10.1093/emboj/17.1.325; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; RUIZ JC, 1988, MOL CELL BIOL, V8, P4302, DOI 10.1128/MCB.8.10.4302; SCHIMKE RT, 1988, J BIOL CHEM, V263, P5989; Simon I, 1999, NATURE, V401, P929, DOI 10.1038/44866; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; SMITH KA, 1992, P NATL ACAD SCI USA, V89, P5427, DOI 10.1073/pnas.89.12.5427; SMITH KA, 1990, CELL, V63, P1219, DOI 10.1016/0092-8674(90)90417-D; SPRADLING AC, 1981, CELL, V27, P193, DOI 10.1016/0092-8674(81)90373-1; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; THELANDER L, 1986, MOL CELL BIOL, V6, P3433, DOI 10.1128/MCB.6.10.3433; TIsty T.D., 1989, P NATL ACAD SCI USA, V86, P9441; WAHL GM, 1979, J BIOL CHEM, V254, P8679; Wang ST, 1998, MOL CELL BIOL, V18, P39, DOI 10.1128/MCB.18.1.39; Wells J, 1996, MOL CELL BIOL, V16, P634; WIENER F, 2000, TECHNICAL TIPS ONLIN; STATSOFT ELECT STAT	49	29	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					909	920		10.1038/sj.onc.1205145	http://dx.doi.org/10.1038/sj.onc.1205145			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840336				2022-12-25	WOS:000173427100006
J	Furusato, M; Sueyoshi, N; Mitsutake, S; Sakaguchi, K; Kita, K; Okino, N; Ichinose, S; Omori, A; Ito, M				Furusato, M; Sueyoshi, N; Mitsutake, S; Sakaguchi, K; Kita, K; Okino, N; Ichinose, S; Omori, A; Ito, M			Molecular cloning and characterization of sphingolipid ceramide N-deacylase from a marine bacterium, Shewanella alga G8	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE HYDROLYSIS REACTION; BINDING PROTEINS; ACYL LINKAGE; PURIFICATION; SEQUENCE; SPHINGOSYLPHOSPHORYLCHOLINE; ENDOGLYCOCERAMIDASE; GLYCOSPHINGOLIPIDS; LYSOSPHINGOLIPIDS; SPHINGOMYELIN	Recently, lyso-sphingolipids have been identified as ligands for several orphan G protein-coupled receptors, although the molecular mechanism for their generation has yet to toe clarified. Here, we report the molecular cloning of the enzyme, which catalyzes the generation of lyso-sphingolipids from various sphingolipids (sphingolipid ceramide N-deacylase). The 75-kDa enzyme was purified from the marine bacterium, Shewanella alga G8, and its gene was cloned from a G8 genomic library using sequences of the purified enzyme. The cloned enzyme was composed of 992 amino acids, including a signal sequence of 35 residues, and its molecular weight was estimated to be 109,843. Significant sequence similarities were found with an unknown protein of Streptomyces fradiae Y59 and a Lumbricus terrestris lectin but not other known functional proteins. The 106-kDa recombinant enzyme expressed in Escherichia coli hydrolyzed various glycosphingolipids and sphingomyelin, although it seems to be much less active than the native 75-kDa enzyme. In vitro translation using wheat germ extract revealed the activity of a 75-kDa deletion mutant lacking a C terminus to be much stronger than that of the full-length enzyme, suggesting that C-terminal processing is necessary for full activity.	Kyushu Univ, Dept Biosci & Biotechnol, Grad Sch Bioresource & Bioenvironm Sci, Higashi Ku, Fukuoka 8128581, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan	Kyushu University	Ito, M (corresponding author), Kyushu Univ, Dept Biosci & Biotechnol, Grad Sch Bioresource & Bioenvironm Sci, Higashi Ku, 6-10-1 Hakozaki, Fukuoka 8128581, Japan.	makotoi@agr.kyushu-u.ac.jp	Mitsutake, Susumu/A-4082-2012; Okino, Nozomu/AAY-2635-2021; Ito, Makoto/Q-6164-2019	ito, Makoto/0000-0003-3159-7818				ASHIDA H, 1995, BIOSCI BIOTECH BIOCH, V59, P2028, DOI 10.1271/bbb.59.2028; BOS JD, 1994, LANCET, V343, P1338, DOI 10.1016/S0140-6736(94)92473-2; BROSIUS J, 1978, P NATL ACAD SCI USA, V75, P4801, DOI 10.1073/pnas.75.10.4801; Buchanan R.E, 1974, BERGEYS MANUAL DETER, V8th ed., DOI 10.1007/bergeysoutline200405; DAINESE HP, 1997, EUR J BIOCHEM, V264, P336; Fukano Y, 1997, APPL ENVIRON MICROB, V63, P1861, DOI 10.1128/AEM.63.5.1861-1865.1997; GAL AE, 1976, CHEM PHYS LIPIDS, V16, P71, DOI 10.1016/0009-3084(76)90015-3; Hakomori S, 1998, GLYCOBIOLOGY, V8, pXI; HANAI N, 1988, J BIOL CHEM, V263, P10915; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; Higuchi K, 2000, BIOCHEM J, V350, P747, DOI 10.1042/0264-6021:3500747; Hirabayashi J, 1998, J BIOL CHEM, V273, P14450, DOI 10.1074/jbc.273.23.14450; HIRABAYASHI Y, 1988, J BIOCHEM, V103, P1; HIRAISHI A, 1992, LETT APPL MICROBIOL, V15, P210, DOI 10.1111/j.1472-765X.1992.tb00765.x; HOLLERAN WM, 1993, J CLIN INVEST, V91, P1656, DOI 10.1172/JCI116374; Horibata Y, 2000, J BIOL CHEM, V275, P31297, DOI 10.1074/jbc.M003575200; Im DS, 2001, J CELL BIOL, V153, P429, DOI 10.1083/jcb.153.2.429; INUI K, 1990, J NEUROL SCI, V100, P124, DOI 10.1016/0022-510X(90)90022-F; ITO M, 1995, J BIOL CHEM, V270, P24370, DOI 10.1074/jbc.270.41.24370; Izu H, 1997, J BIOL CHEM, V272, P19846, DOI 10.1074/jbc.272.32.19846; Kanazawa T, 2000, J CELL BIOL, V149, P943, DOI 10.1083/jcb.149.4.943; KANFER JN, 1969, METHOD ENZYMOL, V14, P660; Kita K, 2001, EUR J BIOCHEM, V268, P592, DOI 10.1046/j.1432-1327.2001.01907.x; KOBAYASHI T, 1992, J NEUROCHEM, V59, P1452, DOI 10.1111/j.1471-4159.1992.tb08460.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; Maidak BL, 1999, NUCLEIC ACIDS RES, V27, P171, DOI 10.1093/nar/27.1.171; Mano N, 1997, ANAL BIOCHEM, V244, P291, DOI 10.1006/abio.1996.9891; MIYATAKE T, 1972, BIOCHEM BIOPH RES CO, V48, P538, DOI 10.1016/0006-291X(72)90381-6; Nakagawa T, 1999, J BIOCHEM, V126, P604, DOI 10.1093/oxfordjournals.jbchem.a022492; NEURNHOFER S, 1986, BIOL CHEM HOPPESEYLE, V367, P241; OGASAWARA H, 1999, ACTINOMYCETOLOGICA, V13, P82; OHSAWA K, 1983, ANAL BIOCHEM, V135, P409, DOI 10.1016/0003-2697(83)90703-0; Okino N, 1998, J BIOL CHEM, V273, P14368, DOI 10.1074/jbc.273.23.14368; Rodriguez-Lafrasse C, 1999, NEUROCHEM RES, V24, P199, DOI 10.1023/A:1022501702403; SAITO H, 1963, BIOCHIM BIOPHYS ACTA, V72, P619, DOI 10.1016/0926-6550(63)90386-4; Sakaguchi K, 1999, BIOCHEM BIOPH RES CO, V260, P89, DOI 10.1006/bbrc.1999.0855; Sambrook H., 1989, MOL CLONING LAB MANU; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sueyoshi N, 2001, J LIPID RES, V42, P1197; Tani M, 2000, J BIOL CHEM, V275, P3462, DOI 10.1074/jbc.275.5.3462; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uchida Y, 2000, J LIPID RES, V41, P2071; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; YAMADA A, 1988, EUR J BIOCHEM, V175, P213, DOI 10.1111/j.1432-1033.1988.tb14186.x; YAMAGUCHI Y, 1994, J BIOCHEM-TOKYO, V116, P704, DOI 10.1093/oxfordjournals.jbchem.a124584; Zhu K, 2001, J BIOL CHEM, V276, P41325, DOI 10.1074/jbc.M008057200	48	20	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17300	17307		10.1074/jbc.m110688200	http://dx.doi.org/10.1074/jbc.m110688200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11827965	hybrid			2022-12-25	WOS:000175564500125
J	Cota-Gomez, A; Flores, NC; Cruz, C; Casullo, A; Aw, TY; Ichikawa, H; Schaack, J; Scheinman, R; Flores, SC				Cota-Gomez, A; Flores, NC; Cruz, C; Casullo, A; Aw, TY; Ichikawa, H; Schaack, J; Scheinman, R; Flores, SC			The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; LEUKOCYTE ADHESION MOLECULE-1; CARBOXYL-TERMINAL DOMAIN; KAPOSIS-SARCOMA CELLS; RNA-POLYMERASE-II; TRANSCRIPTION FACTOR; HIV-1 TAT; T-CELLS; ALVEOLAR MACROPHAGES; FLK-1/KDR RECEPTOR	Human immunodeficiency virus infection is associated with inflammation and endothelial cell activation that cannot be ascribed to direct infection by the virus or to the presence of opportunistic infections. Factors related to the virus itself, to the host and/or to environmental exposures probably account for these observations. The HIV protein Tat, a viral regulator required for efficient transcription of the viral genome in host cells is secreted from infected cells and taken up by uninfected by-stander cells. Tat can also act as a general transcriptional activator of key inflammatory molecules. We have examined whether Tat contributes to this endothelial cell activation by activating NF-kappaB. Human endothelial cells exposed to Tat in the culture medium activated E-selectin expression with delayed kinetics compared with tumor necrosis factor (TNF). Tat-mediated E-selectin up-regulation required the basic domain of Tat and was inhibited by a Tat antibody. Transfection of human E-selectin promoter-luciferase reporter constructs into Tat-bearing cells or into endothelial cells co-transfected with a Tat expression vector resulted in induction of luciferase expression. Either Tat or TNF activated p65 translocation and binding to an oligonucleotide containing the E-selectin kappaB site 3 sequence. Tat-mediated p65 translocation was also delayed compared with TNF. Neither agent induced new synthesis of p65. A super-repressor adenovirus (AdIkappaBalphaSR) that constitutively sequesters IkappaB in the cytoplasm as well as cycloheximide or actinomycin D inhibited Tat- or TNF-mediated kappaB translocation and E-selectin up-regulation.	Univ Colorado, Hlth Sci Ctr, Sch Pharm, Webb Waring Inst Canc Aging & Antioxidant Res, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Microbiol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA; Louisiana State Univ, Med Ctr, Dept Mol & Cellular Physiol, Shreveport, LA 71130 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Flores, SC (corresponding author), Univ Colorado, Hlth Sci Ctr, Sch Pharm, Webb Waring Inst Canc Aging & Antioxidant Res, Denver, CO 80262 USA.			Cota-Gomez, Adela/0000-0001-7607-6122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058344, R01HL059785] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59785, HL58344] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBINI A, 1995, P NATL ACAD SCI USA, V92, P4838, DOI 10.1073/pnas.92.11.4838; Albini A, 1996, NAT MED, V2, P1371, DOI 10.1038/nm1296-1371; ANDERSON DW, 1988, J AM COLL CARDIOL, V11, P792, DOI 10.1016/0735-1097(88)90213-6; Asimakopoulos G, 2001, J THORAC CARDIOV SUR, V122, P123, DOI 10.1067/mtc.2001.114356; Badou A, 2000, J VIROL, V74, P10551, DOI 10.1128/JVI.74.22.10551-10562.2000; BARILLARI G, 1993, P NATL ACAD SCI USA, V90, P7941, DOI 10.1073/pnas.90.17.7941; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; Blazquez MV, 1999, AIDS RES HUM RETROV, V15, P1209, DOI 10.1089/088922299310304; BRAKE DA, 1990, J CELL BIOL, V111, P1275, DOI 10.1083/jcb.111.3.1275; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Chun RF, 1996, J BIOL CHEM, V271, P27888, DOI 10.1074/jbc.271.44.27888; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; CONALDI PG, 1995, J MED VIROL, V47, P355, DOI 10.1002/jmv.1890470411; Conant K, 1996, J VIROL, V70, P1384, DOI 10.1128/JVI.70.3.1384-1389.1996; COX RA, 1990, AIDS RES HUM RETROV, V6, P431, DOI 10.1089/aid.1990.6.431; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; Demarchi F, 1996, J VIROL, V70, P4427, DOI 10.1128/JVI.70.7.4427-4437.1996; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; DENIS M, 1994, AIDS RES HUM RETROV, V10, P1619, DOI 10.1089/aid.1994.10.1619; Dhawan S, 1997, BLOOD, V90, P1535; DHAWAN S, 1995, J IMMUNOL, V154, P422; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Endo S, 1989, Virus Genes, V3, P99; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; Ganju RK, 1998, J VIROL, V72, P6131, DOI 10.1128/JVI.72.7.6131-6137.1998; Gujuluva C, 2001, MOL MED, V7, P169, DOI 10.1007/BF03401950; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Hofman FM, 1999, J NEUROIMMUNOL, V94, P28, DOI 10.1016/S0165-5728(98)00198-2; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; JEANG KT, 1993, J BIOL CHEM, V268, P24940; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KAUL S, 1991, AM HEART J, V122, P535, DOI 10.1016/0002-8703(91)91013-D; Kelly GD, 1999, VIROLOGY, V263, P128, DOI 10.1006/viro.1999.9966; Kelly GO, 1998, AIDS, V12, P1753, DOI 10.1097/00002030-199814000-00006; Kumar A, 1999, FEBS LETT, V462, P140, DOI 10.1016/S0014-5793(99)01487-8; Lafrenie RM, 1996, J IMMUNOL, V156, P1638; Li-Weber M, 2000, EUR J IMMUNOL, V30, P661, DOI 10.1002/1521-4141(200002)30:2<661::AID-IMMU661>3.3.CO;2-C; LOTZ M, 1994, J CELL BIOL, V124, P365, DOI 10.1083/jcb.124.3.365; Manna SK, 2000, J IMMUNOL, V164, P5156, DOI 10.4049/jimmunol.164.10.5156; McCloskey TW, 1997, J IMMUNOL, V158, P1014; Min W, 1997, J IMMUNOL, V159, P3508; Morton NM, 1999, FEBS LETT, V442, P57, DOI 10.1016/S0014-5793(98)01623-8; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; Nottet HSLM, 1996, J IMMUNOL, V156, P1284; Okamoto H, 1996, P NATL ACAD SCI USA, V93, P11575, DOI 10.1073/pnas.93.21.11575; Ott M, 1998, J IMMUNOL, V160, P2872; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005; POLI G, 1994, ANTIVIR RES, V24, P221, DOI 10.1016/0166-3542(94)90069-8; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; Read MA, 1996, J IMMUNOL, V157, P3472; Read MA, 1997, J BIOL CHEM, V272, P2753, DOI 10.1074/jbc.272.5.2753; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; RUBEN S, 1989, J VIROL, V63, P1; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; Seigneur M, 1997, THROMB HAEMOSTASIS, V77, P646; SFIKAKIS PP, 1995, INFECTION, V23, P207, DOI 10.1007/BF01781198; SHERMAN MY, 1992, EMBO J, V11, P71; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SONG CZ, 1994, P NATL ACAD SCI USA, V91, P9357, DOI 10.1073/pnas.91.20.9357; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Tinkle BT, 1997, J VIROL, V71, P4809, DOI 10.1128/JVI.71.6.4809-4814.1997; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; Xiao H, 2000, P NATL ACAD SCI USA, V97, P11466, DOI 10.1073/pnas.97.21.11466	75	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14390	14399		10.1074/jbc.M108591200	http://dx.doi.org/10.1074/jbc.M108591200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11827962	hybrid			2022-12-25	WOS:000175203000008
J	Kovach, MJ; Tirumalai, R; Landy, A				Kovach, MJ; Tirumalai, R; Landy, A			Site-specific photo-cross-linking between lambda integrase and its DNA recombination target	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; FLP RECOMBINASE; CATALYTIC DOMAIN; GENE-PRODUCT; PROTEIN; PURIFICATION; RECOGNITION; BINDING; FAMILY; INT	The site-specific recombinase (Int) of bacteriophage A is a heterobivalent DNA-binding protein and is composed of three domains as follows: an amino-terminal domain that binds with high affinity to "arm-type" sequences within the recombination target DNA (att sites), a carboxyl-terminal domain that contains all of the catalytic functions, and a central domain that contributes significantly to DNA binding at the "core-type" sequences where DNA cleavage and ligation are executed. We constructed a family of core-type DNA oligonucleotides, each of which contained the photoreactive analog 4-thiodeoxythymidine (4-thioT) at a different position. When tested for their respective abilities to promote covalent cross-links with Int after irradiation with UV light at 366 nm, one oligonucleotide stood out dramatically. The 4-thioT substitution on the DNA strand opposite the site of Int cleavage led to photo-induced cross-linking efficiencies of similar to20%. The efficiency and specificity of Int binding and cleavage at this 4-thioT-substituted core site was shown to be largely uncompromised, and its ability to participate in a full site-specific recombination reaction was reduced only slightly. Identification of the photo-cross-linked residue as Lys-141 in the central domain provides, along with other results, several insights about the nature of core-type DNA recognition by the bivalent recombinases of the lambda Int family.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Celera Genom, Proteom Div, Rockville, MD 20850 USA; So Illinois Univ, Sch Med, Springfield, IL 62794 USA	Brown University; Southern Illinois University System; Southern Illinois University	Landy, A (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Box G-J360, Providence, RI 02912 USA.							ABREMSKI K, 1982, J BIOL CHEM, V257, P9658; ALLEN G, 1989, SEQUENCING PROTEINS, P1; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; Azaro MA., 2002, MOBILE DNA-UK, P118, DOI DOI 10.1128/9781555817954.CH7; Blakely GW, 1996, MOL MICROBIOL, V20, P234, DOI 10.1111/j.1365-2958.1996.tb02505.x; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMPBELL AM, 1962, ADV GENET, V11, P101; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; Chen Y, 2000, MOL CELL, V6, P885, DOI 10.1016/S1097-2765(05)00088-2; Cheng Q, 2000, MOL MICROBIOL, V36, P424, DOI 10.1046/j.1365-2958.2000.01860.x; Dorgai L, 1998, J MOL BIOL, V277, P1059, DOI 10.1006/jmbi.1998.1642; DORGAI L, 1995, J MOL BIOL, V252, P178, DOI 10.1006/jmbi.1995.0486; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; Erskine SG, 1998, J MOL BIOL, V275, P759, DOI 10.1006/jmbi.1997.1517; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Favre A, 1990, BIOORG PHOTOCHEM, V1, P379; FOURREY JL, 1976, TETRAHEDRON LETT, P297; FOURREY JL, 1973, TETRAHEDRON LETT, P3225; FRISCHAUF AM, 1973, BIOCHEM BIOPH RES CO, V53, P1227, DOI 10.1016/0006-291X(73)90596-2; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hallet B, 1997, FEMS MICROBIOL REV, V21, P157, DOI 10.1016/S0168-6445(97)00055-7; HOESS R, 1990, J MOL BIOL, V216, P873, DOI 10.1016/S0022-2836(99)80007-2; KIKUCHI Y, 1978, J BIOL CHEM, V253, P7149; KLEMM P, 1986, EMBO J, V5, P1389, DOI 10.1002/j.1460-2075.1986.tb04372.x; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANGEGUSTAFSON BJ, 1984, J BIOL CHEM, V259, P2724; MacWilliams MP, 1996, GENETICS, V143, P1069; McIlwraith MJ, 1996, J MOL BIOL, V260, P299, DOI 10.1006/jmbi.1996.0400; MEISENHEIMER KM, 2000, CRIT REV BIOCHEM MOL, V32, P101; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; NASH HA, 1981, J BIOL CHEM, V256, P9246; NIKIFOROV TT, 1999, NUCLEIC ACIDS RES, V20, P1209; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1987, CELL, V50, P779, DOI 10.1016/0092-8674(87)90336-9; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; PANIGRAHI GB, 1994, J BIOL CHEM, V269, P10940; PARGELLIS CA, 1988, J BIOL CHEM, V263, P7678; PLEISS M, 1969, BIOCHEM BIOPH RES CO, V34, P70, DOI 10.1016/0006-291X(69)90530-0; PLEISS MG, 1971, BIOCHEMISTRY-US, V10, P3093, DOI 10.1021/bi00792a017; ROSS W, 1983, CELL, V33, P261, DOI 10.1016/0092-8674(83)90355-0; Sarkar D, 2001, EMBO J, V20, P1203, DOI 10.1093/emboj/20.5.1203; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Tirumalai RS, 1997, P NATL ACAD SCI USA, V94, P6104, DOI 10.1073/pnas.94.12.6104; Tirumalai RS, 1998, J MOL BIOL, V279, P513, DOI 10.1006/jmbi.1998.1786; WILLIAMS KR, 1991, METHOD ENZYMOL, V208, P516; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; YIN S, 1985, P NATL ACAD SCI USA, V82, P1040, DOI 10.1073/pnas.82.4.1040	50	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14530	14538		10.1074/jbc.M108197200	http://dx.doi.org/10.1074/jbc.M108197200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11827961	hybrid			2022-12-25	WOS:000175203000025
J	Kwon, HB; Kim, SH; Kim, SE; Jang, IH; Ahn, Y; Lee, WJ; Choi, KY				Kwon, HB; Kim, SH; Kim, SE; Jang, IH; Ahn, Y; Lee, WJ; Choi, KY			Drosophila extracellular signal-regulated kinase involves the insulin-mediated proliferation of Schneider cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; EGF RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; TRANSDUCTION PATHWAYS; RNA INTERFERENCE; EYE DEVELOPMENT; GROWTH; HOMOLOG; SIZE	The Drosophila insulin pathway is involved in the control of the proliferation and size of the cell. The stimulation of Schneider cells with human insulin has been observed to activate Drosophila extracellular signal regulated kinase (DERK). However, the role of DERK in the regulation of proliferation is unknown. In this study, we have identified a role of DERK in the proliferation of Drosophila Schneider cells. The inhibition of DERK activity by the overexpression of DMKP-3, an ERK-specific mitogen-activated protein kinase (MAPK) phosphatase, inhibited G(1) to S phase cell cycle progression as well as bromodeoxyuridine (BrdU) incorporation, which were previously increased by human insulin. However, DMKP-3 overexpression did not significantly reduce cell size that was also enlarged by insulin treatment, which suggests the specificity of the ERK pathway in proliferation but not for cell size. G1 to S phase cell cycle progression and BrdU incorporation were also reduced by catalytically inactive DMKP-3 mutant, and they may be acquired by the trapping of DERK into cytosol. The depletion of DERK or DMKP-3 by inhibitory double-stranded RNA decreased and increased BrdU incorporation, respectively. Thus, we propose that DERK is involved in the proliferation of Schneider cells via the insulin pathway.	Yonsei Univ, Coll Engn, Dept Biotechnol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 120752, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea	Yonsei University; Yonsei University; Yonsei University Health System; Ewha Womans University	Choi, KY (corresponding author), Yonsei Univ, Coll Engn, Dept Biotechnol, 134 Shinchon Dong, Seoul 120752, South Korea.		Kim, Sung-Eun/ABC-8837-2020	Kim, Sung-Eun/0000-0001-8667-3887				BAKER NE, 1992, DEV BIOL, V150, P381, DOI 10.1016/0012-1606(92)90250-K; BAKER NE, 1989, NATURE, V340, P150, DOI 10.1038/340150a0; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DIAZBENJUMEA FJ, 1994, DEVELOPMENT, V120, P569; Duffy JB, 1996, CURR OPIN CELL BIOL, V8, P231, DOI 10.1016/S0955-0674(96)80070-6; Edgar BA, 1999, NAT CELL BIOL, V1, pE191, DOI 10.1038/70217; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Han SJ, 1998, J BIOL CHEM, V273, P369, DOI 10.1074/jbc.273.1.369; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karim FD, 1998, DEVELOPMENT, V125, P1; Kerkhoff E, 1998, ONCOGENE, V17, P1457, DOI 10.1038/sj.onc.1202185; Kim SH, 2002, BIOCHEM J, V361, P143, DOI 10.1042/bj3610143; Lee WJ, 2000, BIOCHEM J, V349, P821, DOI 10.1042/bj3490821; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mattison CP, 2000, GENE DEV, V14, P1229; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Prober DA, 2000, CELL, V100, P435, DOI 10.1016/S0092-8674(00)80679-0; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3	30	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14853	14858		10.1074/jbc.M110366200	http://dx.doi.org/10.1074/jbc.M110366200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11834735	hybrid			2022-12-25	WOS:000175203000065
J	Tombline, G; Shim, KS; Fishel, R				Tombline, G; Shim, KS; Fishel, R			Biochemical characterization of the human RAD51 protein - II. Adenosine nucleotide binding and competition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA STRAND EXCHANGE; ESCHERICHIA-COLI RECA; HEART MITOCHONDRIAL ATPASE; ALLOSTERIC REGULATION; CRYSTAL-STRUCTURE; CATALYTIC SITES; HYDROLYSIS; MECHANISM; RECOMBINATION; 5'-O-(3-THIOTRIPHOSPHATE)	RecA mediated homologous recombination requires cooperative ATP binding and hydrolysis to assume and maintain an active, extended DNA-protein (nucleoprotein) filament. Human RAD51 protein (hRAD51) lacks the magnitude of ATP-induced cooperativity and catalytic efficiency displayed by RecA. Here, we examined hRAD51 binding and ATPase inhibition pattern by ADP and ATP/adenosine 5'-O-(thiotriphosphate) (ATPgammaS). hRAD51 fully saturates with ATP/ATPgammaS regardless of DNA cofactor (K-D approximate to 5 muM; 1 ATP/1 hRAD51). The binding of ADP to hRAD51 appeared bimodal. The first mode was identical to ATP/ATPgammaS binding (K-app1 approximate to 3 muM; 1 ADP/1 hRAD51), while a second mode occurred at elevated ADP concentrations (K-app2 greater than or equal to 125 muM; > 1 ADP/1 hRAD51). We could detect ADP --> ATP exchange in the high affinity ADP binding mode (K-app1) but not the low affinity binding mode (K-app2). At low ATP concentrations (<0.3 mM), ADP and ATP gamma S competitively inhibit the hRAD51 ATPase (K-m(app) > K-m). However, at high ATP (>0.3 mm), the hRAD51 ATPase was stimulated by concentrations of ATPgammaS that were 20-fold above the KD. Ammonium sulfate plus spermidine decreased the affinity of hRAD51 for ADP substantially (similar to10-fold) and ATP modestly (similar to3-fold). Our results suggest that ATP binding is not rate-limiting but that the inability to sustain an active nucleoprotein filament probably restricts the hRAD51 ATPase.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Genet & Mol Biol Program, BLSB933,233 S 10th St,Rm 933, Philadelphia, PA 19107 USA.	rfishel@hendrix.jci.tju.edu			NATIONAL CANCER INSTITUTE [R01CA056542, T32CA009678] Funding Source: NIH RePORTER; NCI NIH HHS [5-T32-CA09678, CA56542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BANKS GR, 1986, BIOCHEMISTRY-US, V25, P5882, DOI 10.1021/bi00368a007; BOMBLINE G, 2002, J BIOL CHEM, V277, P14434; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; COTTERILL SM, 1982, BIOCHEMISTRY-US, V21, P4332, DOI 10.1021/bi00261a023; COX MM, 1994, TRENDS BIOCHEM SCI, V19, P217, DOI 10.1016/0968-0004(94)90025-6; COX MM, 1983, J BIOL CHEM, V258, P2586; CROSS RL, 1982, J BIOL CHEM, V257, P2101; Fishel R, 1998, GENE DEV, V12, P2096, DOI 10.1101/gad.12.14.2096; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; Hortnagel K, 1999, J MOL BIOL, V286, P1097, DOI 10.1006/jmbi.1998.2515; Kelley JA, 1997, J BIOL CHEM, V272, P25778, DOI 10.1074/jbc.272.41.25778; KIM JI, 1992, J BIOL CHEM, V267, P16438; KOWALCZYKOWSKI SC, 1991, ANNU REV BIOPHYS BIO, V20, P539, DOI 10.1146/annurev.bb.20.060191.002543; LEE JW, 1990, BIOCHEMISTRY-US, V29, P7677, DOI 10.1021/bi00485a017; MacFarland KJ, 1997, J BIOL CHEM, V272, P17675, DOI 10.1074/jbc.272.28.17675; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Morrison C, 1999, MOL CELL BIOL, V19, P6891; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Namsaraev EA, 1998, BIOCHEMISTRY-US, V37, P11932, DOI 10.1021/bi9810297; Niedenzu T, 2001, J MOL BIOL, V306, P479, DOI 10.1006/jmbi.2000.4398; Paulus BF, 1997, BIOCHEMISTRY-US, V36, P7832, DOI 10.1021/bi970576+; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; ROSSELLI W, 1991, EMBO J, V10, P4391, DOI 10.1002/j.1460-2075.1991.tb05017.x; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Shan Q, 1997, J BIOL CHEM, V272, P11063; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Stole E, 1997, BIOCHEMISTRY-US, V36, P3483, DOI 10.1021/bi962881l; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Thompson LH, 1999, BIOCHIMIE, V81, P87, DOI 10.1016/S0300-9084(99)80042-X; Tombline G, 2002, J BIOL CHEM, V277, P14417, DOI 10.1074/jbc.M109915200; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Voloshin ON, 2000, J MOL BIOL, V303, P709, DOI 10.1006/jmbi.2000.4163; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8845; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8829; WEINSTOCK GM, 1981, J BIOL CHEM, V256, P8850; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O	45	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14426	14433		10.1074/jbc.M109916200	http://dx.doi.org/10.1074/jbc.M109916200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839740	hybrid			2022-12-25	WOS:000175203000012
J	Tice, DA; Szeto, W; Soloviev, I; Rubinfeld, B; Fong, SE; Dugger, DL; Winer, J; Williams, PM; Wieand, D; Smith, V; Schwall, RH; Pennica, D; Polakis, P				Tice, DA; Szeto, W; Soloviev, I; Rubinfeld, B; Fong, SE; Dugger, DL; Winer, J; Williams, PM; Wieand, D; Smith, V; Schwall, RH; Pennica, D; Polakis, P			Synergistic induction of tumor antigens by Wnt-1 signaling and retinoic acid revealed by gene expression profiling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BETA-CATENIN; SEMAPHORIN-E; C-MYC; IDENTIFICATION; TARGET; EMBRYOGENESIS; CLONING; COMPLEX; GENOME	Novel drug targets can be identified by differential analysis of RNA transcripts isolated from cancer cell lines and tissues. We have extended this approach by analyzing differences in gene expression resulting from the drug treatment of transformed and nontransformed cells. A mouse mammary epithelial cell line (C57MG), which conditionally expresses the Wnt-1 proto-oncogene, was left untreated or treated with retinoic acid in the presence or absence of Wnt-1 expression. The experiment was performed in triplicate, and RNA extracted from the four samples was analyzed by hybridization to over 12,000 unique oligonucleotide probe sets. Reproducible alterations in gene expression that occurred in response to retinoic acid, Wnt-1, or retinoic acid plus Wnt-1 relative to untreated cells were identified. Greater attention was given to genes encoding cell surface antigens that were selectively up-regulated by the combination of Wnt-1 and retinoic acid. These genes included the tumor necrosis factor family 4-1BB ligand, ephrin B1, stra6, autotaxin, and ISLR. Administration of retinoic acid to mice bearing tumors driven by activation of the Wnt-1/beta-catenin pathway resulted in increased expression of stra6 in the tumors but not in normal tissue. In principal, the therapeutic index of antibodies directed against these antigens should be enhanced by co-administration of retinoic acid.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Polakis, P (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way,MS 40, San Francisco, CA 94080 USA.			Rubinfeld, Bonnee/0000-0001-9861-6775				Barker N, 2000, ADV CANCER RES, V77, P1; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Berquin IM, 1999, J LEUKOCYTE BIOL, V66, P609, DOI 10.1002/jlb.66.4.609; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; BOUILLET P, 1995, DEV BIOL, V170, P420, DOI 10.1006/dbio.1995.1226; Clotman F, 1998, NEUROTOXICOL TERATOL, V20, P591, DOI 10.1016/S0892-0362(98)00018-X; Cox RT, 1999, GENETICS, V153, P319; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Dufner-Beattie J, 2001, MOL CARCINOGEN, V30, P181, DOI 10.1002/mc.1028; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; KOJ A, 1993, BIOL CHEM H-S, V374, P193, DOI 10.1515/bchm3.1993.374.1-6.193; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lee CH, 1999, J BIOL CHEM, V274, P31320, DOI 10.1074/jbc.274.44.31320; Martin-Satue M, 1999, J SURG ONCOL, V72, P18; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nagasawa A, 1997, GENOMICS, V44, P273, DOI 10.1006/geno.1997.4889; Nam SW, 2000, ONCOGENE, V19, P241, DOI 10.1038/sj.onc.1203263; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PEARSON D, 1992, J BIOL CHEM, V267, P25364; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 2000, GENE DEV, V14, P1837; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salih HR, 2000, J IMMUNOL, V165, P2903, DOI 10.4049/jimmunol.165.5.2903; Schmucker D, 2001, CELL, V105, P701, DOI 10.1016/S0092-8674(01)00391-9; Szeto W, 2001, CANCER RES, V61, P4197; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tremblay J, 1999, BIOL REPROD, V60, P541, DOI 10.1095/biolreprod60.3.541; Wade DP, 2001, LANCET, V357, P161, DOI 10.1016/S0140-6736(00)03585-6; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yamada T, 1997, P NATL ACAD SCI USA, V94, P14713, DOI 10.1073/pnas.94.26.14713; Zhang LJ, 1998, J BIOL CHEM, V273, P27998, DOI 10.1074/jbc.273.43.27998; Zhang W, 2001, INT J ONCOL, V18, P749; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	42	65	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14329	14335		10.1074/jbc.M200334200	http://dx.doi.org/10.1074/jbc.M200334200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832495	hybrid			2022-12-25	WOS:000175096000127
J	Tintut, Y; Parhami, F; Tsingotjidou, A; Tetradis, S; Territo, M; Demer, LL				Tintut, Y; Parhami, F; Tsingotjidou, A; Tetradis, S; Territo, M; Demer, LL			8-Isoprostaglandin E2 enhances receptor-activated NF kappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNIQUE BIOACTIVE PRODUCTS; ARTERIAL CALCIFICATION; LIPID-PEROXIDATION; BONE-RESORPTION; PROTEIN-KINASE; CELL-FORMATION; IN-VIVO; ISOPROSTANES; DIFFERENTIATION; EP4	Lipid oxidation products promote atherosclerosis and may also affect osteoporosis. We showed previously that oxidized lipids including 8-isoprostaglandin E2 (isoPGE2) inhibit osteoblastic differentiation of preosteoblasts. Since osteoporosis is mediated both by decreased osteoblastic bone formation and by increased osteoclastic bone resorption, we assessed whether oxidized lipids regulate the osteoclastic potential of marrow hematopoietic cells. Treatment of marrow-derived preosteoclasts with isoPGE2 enhanced osteoclastic differentiation as evidenced by increased tartrate-resistant acid phosphatase (TRAP) activity and multinucleation, which were inhibited by calcitonin, and increased numbers of resorption pits. The enhanced osteoclastic differentiation by isoPGE2 was observed whether preosteoclasts were in coculture with stromal cells or in monoculture in the presence of receptor-activated NFkappaB ligand (RANKL) and macrophage colony-stimulating factor. Receptor antagonist studies suggest that isoPGE2 effects were mediated by prostaglandin receptor subtypes EP2/DP on preosteoclasts and subtype EP1 and thromboxane receptors on stromal/osteoblast cells. The enhanced TRAP activity was also inhibited by cAMP-dependent protein kinase inhibitors, and isoPGE2 elevated intracellular cAMP levels of preosteoclast monocultures. Other oxidized lipids also enhanced the TRAP activity of preosteoclast monocultures. These data suggest that isoPGE2 enhances osteoclastic differentiation of marrow preosteoclasts and that this regulation occurs via the cAMP-dependent protein kinase pathway.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol,Ctr Hlth Sci 47 123, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Dent, Dept Oral Radiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Tintut, Y (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol,Ctr Hlth Sci 47 123, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	ytintut@ucla.edu	Tsingotjidou, Anastasia/ABE-3794-2020; Demer, Linda L/I-5770-2013	Tsingotjidou, Anastasia/0000-0002-6610-5847; Demer, Linda L/0000-0002-9618-6895	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568, R01HL069261] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL/AR69261, HL30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano S, 1996, J IMMUNOL, V156, P1931; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Bhattacherjee P, 1999, INVEST OPHTH VIS SCI, V40, P3047; DOWNEY GP, 1988, J APPL PHYSIOL, V64, P728, DOI 10.1152/jappl.1988.64.2.728; Elmhurst JL, 1997, J PHARMACOL EXP THER, V282, P1198; Fiebich BL, 2001, J NEUROCHEM, V79, P950, DOI 10.1046/j.1471-4159.2001.00652.x; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; Kaji H, 1996, J BONE MINER RES, V11, P62; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LACEY DL, 1995, ENDOCRINOLOGY, V136, P2367, DOI 10.1210/en.136.6.2367; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; Liu TZ, 1998, J BIOMED SCI, V5, P415, DOI 10.1159/000025355; Martin TJ, 1998, CRIT REV EUKAR GENE, V8, P107, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.10; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1994, J BIOL CHEM, V269, P4317; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; Ono K, 1998, J ENDOCRINOL, V158, pR1, DOI 10.1677/joe.0.158R001; Parhami F, 1999, J BONE MINER RES, V14, P2067, DOI 10.1359/jbmr.1999.14.12.2067; Parhami F, 1997, CURR OPIN LIPIDOL, V8, P312, DOI 10.1097/00041433-199710000-00010; Parhami F, 1997, ARTERIOSCL THROM VAS, V17, P680, DOI 10.1161/01.ATV.17.4.680; Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182; Parhami F, 2000, ARTERIOSCL THROM VAS, V20, P2346, DOI 10.1161/01.ATV.20.11.2346; Pelletier S, 2001, BRIT J PHARMACOL, V132, P999, DOI 10.1038/sj.bjp.0703886; Pratico D, 1997, J CLIN INVEST, V100, P2028, DOI 10.1172/JCI119735; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Reilly MP, 1998, CIRCULATION, V98, P2822, DOI 10.1161/01.CIR.98.25.2822; Schmitz T, 2001, MOL HUM REPROD, V7, P397, DOI 10.1093/molehr/7.4.397; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Suda T, 1997, METHOD ENZYMOL, V282, P223; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Tomita M, 2002, BONE, V30, P159, DOI 10.1016/S8756-3282(01)00688-3; Unmack MA, 2001, J PHARMACOL EXP THER, V296, P434; Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927; Witztum JL, 1998, CURR OPIN LIPIDOL, V9, P441, DOI 10.1097/00041433-199810000-00008; Yura T, 1999, KIDNEY INT, V56, P471, DOI 10.1046/j.1523-1755.1999.00596.x; ZHANG H, 1991, EUR J PHARMACOL, V195, P27, DOI 10.1016/0014-2999(91)90378-4	37	104	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14221	14226		10.1074/jbc.M111551200	http://dx.doi.org/10.1074/jbc.M111551200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827970	hybrid			2022-12-25	WOS:000175096000113
J	Bibert, S; Jaquinod, M; Concord, E; Ebel, C; Hewat, E; Vanbelle, C; Legrand, P; Weidenhaupt, M; Vernet, T; Gulino-Debrac, D				Bibert, S; Jaquinod, M; Concord, E; Ebel, C; Hewat, E; Vanbelle, C; Legrand, P; Weidenhaupt, M; Vernet, T; Gulino-Debrac, D			Synergy between extracellular modules of vascular endothelial cadherin promotes homotypic hexameric interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; MASS-SPECTROMETRY; CLASSIC CADHERINS; MOLECULAR-WEIGHT; STRUCTURAL BASIS; CALCIUM-BINDING; VE-CADHERIN; N-CADHERIN; IDENTIFICATION; JUNCTIONS	Vascular endothelial (VE) cadherin is an endothelial specific cadherin that plays a major role in remodeling and maturation of vascular vessels. Recently, we presented evidence that the extracellular part of VE cadherin, which consists of five homologous modules, associates as a Ca2+-dependent hexamer in solution (Legrand, P., Bibert, S., Jaquinod, M., Ebel, C., Hewat, E., Vincent, F., Vanbelle, C., Concord, E., Vernet, T., an Gulino, D. (2001) J. Biol. Chem. 276, 3581-3588). In an effort to identify which extracellular modules are involved in the elaboration and stability of this hexameric structure, we expressed various VE cadherin-derived fragments overlapping individual or multiple successive modules as soluble proteins, purified each to homogeneity, and tested their propensity to self-associate. Altogether, the results demonstrate that, as their length increases, VE cadherin recombinant fragments generate increasingly complex self-associating structures; although single module fragments do not oligomerize, some two or three module-containing fragments self. assemble as dimers, and four module-containing fragments associate as hexamers. Our results also suggest that, before elaborating a hexameric structure, molecules of VE cadherin self-assemble as intermediate dimers. A synergy between the extracellular modules of VE cadherin is thus required to build homotypic interactions. Placed in a cellular context, this particular self-association mode may reflect the distinctive biological requirements imposed on VE cadherin at adherens junctions in the vascular endothelium.	Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Ingn Macrom, F-38027 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Biophys Mol, F-38027 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Microscopie, F-38027 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Resonance M, F-38027 Grenoble, France; Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Cristall, F-38027 Grenoble, France; CEA, Lab Chim Prot, Dept Biol Mol & Struct, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA	Gulino-Debrac, D (corresponding author), Univ Grenoble 1, CNRS, CEA, Inst Biol Struct Jean Pierre Ebel,Lab Ingn Macrom, 41 Rue Jules Horowitz, F-38027 Grenoble, France.		LEGRAND, Pierre/G-7709-2011; Vernet, Thierry/G-1118-2012	LEGRAND, Pierre/0000-0003-2431-2255; Bibert, Stephanie/0000-0001-5170-7506; Ebel, Christine/0000-0002-6912-500X				Angst BD, 2001, J CELL SCI, V114, P625; Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; COHEN SL, 1995, PROTEIN SCI, V4, P1088, DOI 10.1002/pro.5560040607; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Geyer H, 1999, GLYCOBIOLOGY, V9, P915, DOI 10.1093/glycob/9.9.915; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HIROKAWA N, 1981, J CELL BIOL, V91, P399, DOI 10.1083/jcb.91.2.399; Hordijk PL, 1999, J CELL SCI, V112, P1915; Johnson-Leger C, 2000, J CELL SCI, V113, P921; JOU TS, 1995, P NATL ACAD SCI USA, V92, P5067, DOI 10.1073/pnas.92.11.5067; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Lambert M, 2000, J CELL SCI, V113, P2207; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Leach L, 1997, MICROSC RES TECHNIQ, V38, P137; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; Legrand P, 2001, J BIOL CHEM, V276, P3581, DOI 10.1074/jbc.M002667200; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Overduin M, 1996, J BIOMOL NMR, V7, P173; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PATEL DJ, 1995, NATURE, V374, P306, DOI 10.1038/374306a0; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shimoyama Y, 2000, BIOCHEM J, V349, P159, DOI 10.1042/0264-6021:3490159; Shimoyama Y, 1998, J BIOL CHEM, V273, P10011, DOI 10.1074/jbc.273.16.10011; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; SUZUKI S, 1991, CELL REGUL, V2, P261, DOI 10.1091/mbc.2.4.261; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; Valiron O, 1996, J CELL SCI, V109, P2141; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wu Q, 2000, P NATL ACAD SCI USA, V97, P3124, DOI 10.1073/pnas.060027397; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0	50	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12790	12801		10.1074/jbc.M111597200	http://dx.doi.org/10.1074/jbc.M111597200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821414	hybrid			2022-12-25	WOS:000175036300040
J	Chiang, SH; Hou, JC; Hwang, J; Pessin, JE; Saltiel, AR				Chiang, SH; Hou, JC; Hwang, J; Pessin, JE; Saltiel, AR			Cloning and functional characterization of related TC10 isoforms, a subfamily of rho proteins involved in insulin-stimulated glucose transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 VESICLE TRAFFICKING; 3T3-L1 ADIPOCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; STORAGE-VESICLES; PLASMA-MEMBRANE; BINDING-PROTEIN; C-CBL; ACTIVATION	Insulin stimulates glucose transport via phosphatidylinositol 3-kinase-dependent and -independent pathways. The phosphatidylinositol 3-kinase-independent pathway involves activation of the G protein TC10. A cDNA encoding the mouse homolog of TC10 was cloned, and its gene was mapped at the distal end of chromosome 17. Additionally, a second gene was discovered with similar to70% sequence identity to TC10. We refer to this gene as TC10beta. Both isoforms of TC10 were activated by insulin upon transfection in 3T3L1 adipocytes. Co-transfection of cells with TC10alpha or beta plus a dominant negative form of the c-cbl-associated protein CAP prevented the activation by insulin, implicating the CAP/Cbl pathway. Interestingly, both forms of TC10 were also localized in lipid raft fractions in transfected adipocytes. However, although overexpression of TC10alpha completely blocked glucose transport, TC10beta only partially inhibited this process. Furthermore, TC10alpha overexpression disrupted adipocyte cortical actin, whereas TC10beta had little if any effect. Thus, there are two isoforms of this key signaling intermediate, both of which are activated by insulin, but they may play different roles in initiating downstream effectors that influence glucose transport.	Univ Michigan, Sch Med, Inst Life Sci, Dept Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Life Sci, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Iowa	Saltiel, AR (corresponding author), Univ Michigan, Sch Med, Inst Life Sci, Dept Med, Ann Arbor, MI 48109 USA.		Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2001, BIOESSAYS, V23, P215, DOI 10.1002/1521-1878(200103)23:3<215::AID-BIES1031>3.0.CO;2-S; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Elmendorf JS, 1998, J BIOL CHEM, V273, P13289, DOI 10.1074/jbc.273.21.13289; Fletcher LM, 1999, BIOCHEM SOC T, V27, P677, DOI 10.1042/bst0270677; Guilherme A, 1998, J BIOL CHEM, V273, P33119, DOI 10.1074/jbc.273.50.33119; ISAKOFF SJ, 1995, P NATL ACAD SCI USA, V92, P10247, DOI 10.1073/pnas.92.22.10247; Jiang T, 1998, J BIOL CHEM, V273, P11017, DOI 10.1074/jbc.273.18.11017; Kanzaki M, 2001, J BIOL CHEM, V276, P49331, DOI 10.1074/jbc.M109657200; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Krook A, 1997, J BIOL CHEM, V272, P30208, DOI 10.1074/jbc.272.48.30208; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Pessin JE, 2000, J CLIN INVEST, V106, P165, DOI 10.1172/JCI10582; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; Ribon V, 1997, BIOCHEM J, V324, P839, DOI 10.1042/bj3240839; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Tanabe K, 2000, J NEUROSCI, V20, P4138; Thurmond DC, 2000, MOL CELL BIOL, V20, P379, DOI 10.1128/MCB.20.1.379-388.2000; Tong P, 2001, J CLIN INVEST, V108, P371, DOI 10.1172/JCI12348; Vignal E, 2000, J BIOL CHEM, V275, P36457, DOI 10.1074/jbc.M003487200; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WIESE RJ, 1995, J BIOL CHEM, V270, P3442, DOI 10.1074/jbc.270.7.3442	26	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13067	13073		10.1074/jbc.M109471200	http://dx.doi.org/10.1074/jbc.M109471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821390	hybrid			2022-12-25	WOS:000175036300074
J	Denhez, F; Wilcox-Adelman, SA; Baciu, PC; Saoncella, S; Lee, S; French, B; Neveu, W; Goetinck, PF				Denhez, F; Wilcox-Adelman, SA; Baciu, PC; Saoncella, S; Lee, S; French, B; Neveu, W; Goetinck, PF			Syndesmos, a syndecan-4 cytoplasmic domain interactor, binds to the focal adhesion adaptor proteins paxillin and Hic-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; TYROSINE PHOSPHORYLATION; PDZ PROTEIN; INTEGRINS; ACTIN; TRANSDUCTION; CASK/LIN-2	Syndecan-4 and integrins are the primary transmembrane receptors of focal adhesions in cells adherent to extracellular matrix molecules. Syndesmos is a cytoplasmic protein that interacts specifically with the cytoplasmic domain of syndecan-4, and it co-localizes with syndecan-4 in focal contacts. In the present study we sought possible interactors with syndesmos. We find that syndesmos interacts with the focal adhesion adaptor protein paxillin. The binding of syndesmos to paxillin is direct, and these interactions are triggered by the activation of protein kinase C. Syndesmos also binds the paxillin homolog, Hic-5. The connection of syndecan-4 with paxillin through syndesmos parallels the connection between paxillin and integrins and may thus reflect the cooperative signaling of these two receptors in the assembly of focal adhesions and actin stress fibers.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Goetinck, PF (corresponding author), MGH E, Cutaneous Biol Res Ctr, Bldg 149,13th St, Charlestown, MA 02129 USA.	paul.goetinck@cbrc2.mgh.harvard.edu			NICHD NIH HHS [HD-37490, F32-HD41235] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037490, F32HD041235] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; BACIU PC, 1995, MOL BIOL CELL, V6, P1503, DOI 10.1091/mbc.6.11.1503; Baciu PC, 2000, J CELL SCI, V113, P315; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Couchman JR, 1999, J CELL SCI, V112, P3415; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Ethell IM, 2000, J CELL BIOL, V151, P53, DOI 10.1083/jcb.151.1.53; Gao YH, 2000, J CELL PHYSIOL, V184, P373, DOI 10.1002/1097-4652(200009)184:3<373::AID-JCP12>3.0.CO;2-I; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Horowitz A, 1999, BIOCHEMISTRY-US, V38, P15871, DOI 10.1021/bi991363i; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Oh ES, 1997, J BIOL CHEM, V272, P11805, DOI 10.1074/jbc.272.18.11805; Oh ES, 1998, J BIOL CHEM, V273, P10624, DOI 10.1074/jbc.273.17.10624; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; SALGIA R, 1995, ONCOGENE, V11, P1149; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Saoncella S, 1999, P NATL ACAD SCI USA, V96, P2805, DOI 10.1073/pnas.96.6.2805; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Subramanian SV, 1997, J BIOL CHEM, V272, P14713, DOI 10.1074/jbc.272.23.14713; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 2000, J CELL SCI, V113, P4139; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183; WOODS A, 1992, J CELL SCI, V101, P277; Zimmermann P, 1999, FASEB J, V13, pS91	32	51	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12270	12274		10.1074/jbc.M110291200	http://dx.doi.org/10.1074/jbc.M110291200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805099	hybrid			2022-12-25	WOS:000174846400087
J	Klein, C; Sunahara, RK; Hudson, TY; Heyduk, T; Howlett, AC				Klein, C; Sunahara, RK; Hudson, TY; Heyduk, T; Howlett, AC			Zinc inhibition of cAMP signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; CATALYTIC MECHANISM; NEURONAL DEATH; ASCORBIC-ACID; NITRIC-OXIDE; BRAIN; BINDING; NEUROTOXICITY; TRANSPORT; DIVERSITY	Zn2+ is required as either a catalytic or structural component for a large number of enzymes and thus contributes to a variety of important biological processes. We report here that low micromolar concentrations of Zn2+ inhibited hormone- or forskolin-stimulated cAMP production in N18TG2 neuroblastoma cells. Similarly, low concentrations inhibited hormone- and forskolin-stimulated adenylyl cyclase (AC) activity in membrane preparations and did so primarily by altering the V-max of the enzyme. Zn2+ also inhibited recombinant isoforms, indicating that this reflects a direct interaction with the enzyme. The IC50 for Zn2+ inhibition was similar to1-2 muM with a Hill coefficient of 1.33. The dose-response curve for Zn2+ inhibition was identical for AC1, AC5, and AC6 as well as for the C441R mutant of AC5 whose defect appears to be in one of the catalytic metal binding sites. However, AC2 displayed a distinct dose-response curve. These data in combination with the findings that Zn2+ inhibition was not competitive with Mg2+ or Mg2+/ATP suggest that the inhibitory Zn2+ binding site is distinct from the metal binding sites involved in catalysis. The prestimulated enzyme was found to be less susceptible to Zn2+ inhibition, suggesting that the ability of Zn2+ to inhibit AC could be significantly influenced by the coincidence timing of the input signals to the enzyme.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Michigan, Dept Pharmacol, Ann Arbor, MI 48109 USA; N Carolina Cent Univ, JL Chambers Res Inst, Neurosci & Drug Abuse Res Program, Durham, NC 27707 USA	Saint Louis University; University of Michigan System; University of Michigan; University of North Carolina; North Carolina Central University	Klein, C (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	kleinc@slu.edu	Sunahara, Roger/AAJ-8667-2020	Howlett, Allyn/0000-0002-2810-0164	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM050514, R01GM034497, R37GM034497, R01GM050514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003690, K05DA000182] Funding Source: NIH RePORTER; NIDA NIH HHS [K05-DA00182, R01 DA003690, DA 03690] Funding Source: Medline; NIGMS NIH HHS [GM34497, GM50514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSTROM CO, 1974, ANAL BIOCHEM, V58, P459, DOI 10.1016/0003-2697(74)90214-0; Choi DW, 1996, COLD SPRING HARB SYM, V61, P385; Colvin RA, 2000, J NUTR, V130, p1484S, DOI 10.1093/jn/130.5.1484S; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; FREDERICKSON CJ, 1989, INT REV NEUROBIOL, V31, P145; Frederickson CJ, 2000, J NUTR, V130, p1471S, DOI 10.1093/jn/130.5.1471S; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; HOWLETT AC, 1982, MOL PHARMACOL, V21, P664; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; KAPLAN J, 1991, J BIOL CHEM, V266, P2997; McVey M, 1999, J BIOL CHEM, V274, P18887, DOI 10.1074/jbc.274.27.18887; MONS N, 1995, TRENDS NEUROSCI, V18, P536, DOI 10.1016/0166-2236(95)98375-9; OKE AF, 1987, ANN NY ACAD SCI, V498, P1, DOI 10.1111/j.1749-6632.1987.tb23747.x; Powell SR, 2000, J NUTR, V130, p1447S, DOI 10.1093/jn/130.5.1447S; ROTH BL, 1984, J NEUROCHEM, V42, P1145, DOI 10.1111/j.1471-4159.1984.tb12723.x; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tao YP, 1998, J PHARMACOL EXP THER, V286, P298; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; Trombley PQ, 2000, BIOCHEMISTRY-MOSCOW+, V65, P807; Truong-Tran AQ, 2000, J NUTR, V130, p1459S, DOI 10.1093/jn/130.5.1459S; TSOU CL, 1988, ADV ENZYMOL RAMB, V61, P381; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; WENSINK J, 1988, J NEUROCHEM, V50, P782, DOI 10.1111/j.1471-4159.1988.tb02982.x; XIE XM, 1991, NATURE, V349, P521, DOI 10.1038/349521a0; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403; Zhang RQ, 2001, BBA-PROTEIN STRUCT M, V1545, P6, DOI 10.1016/S0167-4838(00)00254-5; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	34	59	68	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11859	11865		10.1074/jbc.M108808200	http://dx.doi.org/10.1074/jbc.M108808200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805091	hybrid			2022-12-25	WOS:000174846400034
J	Rosenblum, MEK; Schmidt, K; Freas, J; Mastri, M; Fay, PJ				Rosenblum, MEK; Schmidt, K; Freas, J; Mastri, M; Fay, PJ			Cofactor activities of factor VIIIa and A2 subunit following cleavage of A1 subunit at Arg(336)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; INTRINSIC-FACTOR XASE; LENGTH CROSS-LINKING; PORCINE FACTOR-VIII; FACTOR-IXA; CATALYZED PROTEOLYSIS; FACTOR-X; A1/A3-C1-C2 DIMER; INTERACTIVE SITE; INACTIVATION	Factor VIIIa consists of three subunits designated A1, A2, and A3-C1-C2. The isolated A2 subunit possesses limited cofactor activity in stimulating factor IXa-catalyzed activation of factor X. This activity is markedly enhanced by the A1 subunit (inter-subu-nit K-d = 1.8 mum). The C-terminal region of A1 subunit (residues 337-372) is thought to represent an A2-interactive site. This region appears critical to factor VIIIa, because proteolysis at Arg(336) by activated protein C or factor IXa is inactivating. A truncated A1 (A1(336)) showed similar affinity for A2 subunit (Kd = 0.9 muM) and stimulated its cofactor activity to similar to50% that observed for native A1. However, A1336 was unable to reconstitute factor VIIIa activity in the presence of A2 and A3-C1-C2 subunits. Fluorescence anisotropy of fluorescein (Fl)-FFR-factor IXa was differentially altered by factor VIIIa trimers containing either A1 or A1(336). Fluorescence energy transfer demonstrated that, although Fl-A1(336)/A3-C1-C2 bound acrylodan-A2 with similar affinity as the native dimer, an increased inter-fluorophore separation was observed. These results indicate that the C-terminal region of A1 appears necessary to properly orient A2 subunit relative to factor IXa in the cofactor rather than directly stimulate A2 and elucidate the mechanism for cofactor inactivation following cleavage at this site.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Fay, PJ (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, POB 610,601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30616, HL 38199, HL 07152] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amano K, 1998, THROMB HAEMOSTASIS, V79, P557; CASILLAS G, 1971, COAGULATION, V4, P107; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FAY PJ, 1993, J BIOL CHEM, V268, P17861; Fay PJ, 1998, J BIOL CHEM, V273, P19049, DOI 10.1074/jbc.273.30.19049; FAY PJ, 1994, J BIOL CHEM, V269, P20522; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1991, J BIOL CHEM, V266, P20139; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FAY PJ, 1991, J BIOL CHEM, V266, P8957; Fay PJ, 2001, J BIOL CHEM, V276, P12434, DOI 10.1074/jbc.M009539200; Fay PJ, 1999, J BIOL CHEM, V274, P15401, DOI 10.1074/jbc.274.22.15401; Koszelak ME, 2000, J BIOL CHEM, V275, P27137; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LAMPHEAR BJ, 1992, BLOOD, V80, P3120; Lapan KA, 1997, J BIOL CHEM, V272, P2082; Lapan KA, 1998, THROMB HAEMOSTASIS, V80, P418, DOI 10.1055/s-0037-1615223; Lenting PJ, 1998, BLOOD, V92, P3983, DOI 10.1182/blood.V92.11.3983.423k51_3983_3996; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1991, J BIOL CHEM, V266, P12481; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Lu DS, 1996, BLOOD, V87, P4708, DOI 10.1182/blood.V87.11.4708.bloodjournal87114708; O'Brien LM, 2000, BLOOD, V95, P1714, DOI 10.1182/blood.V95.5.1714.005k40_1714_1720; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OBrien LM, 1997, BLOOD, V90, P3943, DOI 10.1182/blood.V90.10.3943; OBRIEN LM, 1995, J BIOL CHEM, V270, P27087, DOI 10.1074/jbc.270.45.27087; PERSSON E, 1995, BIOCHEMISTRY-US, V34, P12775, DOI 10.1021/bi00039a038; Regan LM, 1996, J BIOL CHEM, V271, P3982; REGAN LM, 1994, J BIOL CHEM, V269, P9445; Sarafanov AG, 2001, J BIOL CHEM, V276, P11970, DOI 10.1074/jbc.M008046200; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; Wakabayashi H, 2001, BIOCHEMISTRY-US, V40, P10293, DOI 10.1021/bi010353q; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	37	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11664	11669		10.1074/jbc.M200037200	http://dx.doi.org/10.1074/jbc.M200037200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11799130	hybrid			2022-12-25	WOS:000174846400008
J	Vucic, D; Deshayes, K; Ackerly, H; Pisabarro, MT; Kadkhodayan, S; Fairbrother, WJ; Dixit, VM				Vucic, D; Deshayes, K; Ackerly, H; Pisabarro, MT; Kadkhodayan, S; Fairbrother, WJ; Dixit, VM			SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-LAP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; PROMOTES APOPTOSIS; CASPASE ACTIVATION; STRUCTURAL BASIS; NMR STRUCTURE; CYTOCHROME-C; IAP; PROTEIN; GENE; XIAP	Inhibitors of apoptosis (IAPs) physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. X-linked IAP (X-IAP) is a prototype UP family member that inhibits several caspases, the effector proteases of apoptosis. The inhibitory activity of X-IAP is regulated by SMAC, a protein that is processed to its active form upon receipt of a death stimulus. Cleaved SMAC binds X-IAP and antagonizes its anti-apoptotic activity. Here we show that melanoma LAP (ML-IAP), a potent anti-cell death protein and caspase inhibitor, physically interacts with SMAC through its BIR (baculovirus IAP repeat) domain. In addition to binding full-length SMAC, MI-IAP BIR associates with SMAC peptides that are derived from the amino terminus of active, processed SMAC. This high affinity interaction is very specific and can be completely abolished by single amino acid mutations either in the amino terminus of active SMAC or in the BIR domain of ML-IAP. In cells expressing ML-IAP and X-IAP, SMAC coexpression or addition of SMAC peptides abrogates the ability of the IAPs to inhibit cell death. These results demonstrate the feasibility of using SMAC peptides as a way to sensitize IAP-expressing cells to pro-apoptotic stimuli such as chemotherapeutic agents.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Dixit, VM (corresponding author), Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA.	dixit@gene.com	Pisabarro, M. Teresa/D-4270-2012; dixit, vishva m/A-4496-2012	dixit, vishva m/0000-0001-6983-0326				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Deveraux QL, 1999, J CLIN IMMUNOL, V19, P388, DOI 10.1023/A:1020502800208; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; FERHAGEN AM, 2002, J BIOL CHEM, V277, P445; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Fraser AG, 1999, CURR BIOL, V9, P292, DOI 10.1016/S0960-9822(99)80137-7; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Kaiser WJ, 1998, FEBS LETT, V440, P243, DOI 10.1016/S0014-5793(98)01465-3; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; MARTINS IM, 2001, J BIOL CHEM, V276, P439; McCarthy JV, 1998, J BIOL CHEM, V273, P24009, DOI 10.1074/jbc.273.37.24009; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uren AG, 1999, P NATL ACAD SCI USA, V96, P10170, DOI 10.1073/pnas.96.18.10170; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 1997, P NATL ACAD SCI USA, V94, P10183, DOI 10.1073/pnas.94.19.10183; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wang SL, 1999, CELL, V98, P453, DOI 10.1016/S0092-8674(00)81974-1; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012	46	122	163	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12275	12279		10.1074/jbc.M112045200	http://dx.doi.org/10.1074/jbc.M112045200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801603	hybrid			2022-12-25	WOS:000174846400088
J	Gentiletti, F; Mancini, F; D'Angelo, M; Sacchi, A; Pontecorvi, A; Jochemsen, AG; Moretti, F				Gentiletti, F; Mancini, F; D'Angelo, M; Sacchi, A; Pontecorvi, A; Jochemsen, AG; Moretti, F			MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts	ONCOGENE			English	Article						MDMX; p53; proteolytic degradation; caspase cleavage	DNA-DAMAGE; TUMOR-SUPPRESSOR; P53 PROTEIN; P53-BINDING PROTEIN; ONCOPROTEIN MDM2; PHOSPHORYLATION; DEGRADATION; CELLS; INHIBITION; APOPTOSIS	MDMX is a p53 binding protein, which shares a high degree of homology with MDM2, a negative regulator of the tumor suppressor p53. MDMX has been shown to counteract MDM2-dependent p53 degradation and to stabilize p53 in its inactive form. In this study: we identify two MDMX proteolytic pathways that control its intracellular levels, and show that MDMX post-translational processing may be regulated by p53. Mouse MDMX is cleaved in vitro and in vivo by caspase activity, between aminoacids 358 and 361, producing a p54 minor form. In addition, MDMX is subjected to proteasome-mediated degradation, which concurs to MDMX proteolysis mainly through degradation of p54. A D361A-MDMX mutant, resistant to caspase cleavage, exhibits prolonged intracellular lifetime in comparison to wild-type protein, indicating that caspase cleavage affects stability of MDMX protein probably by modulating its further degradation. Overexpression of exogenous p53 increases the intracellular levels of p54 product. Similarly, activation of endogenous p53 by adriamycin enhances MDMX cleavage and produces a marked decrease of its intracellular levels, while not affecting the D361A-MDMX mutant. In addition, the D361AMDMX mutant lacks the ability to inhibit p53 transactivation in respect to wild-type MDMX, suggesting that MDMX caspase cleavage play an important functional role. In conclusion, our results demonstrate that, in analogy to MDM2, MDMX may be subjected to proteolytic modifications that regulate its intracellular levels. Moreover, decrease of MDMX protein levels following p53 activation suggests a p53-dependent regulatory feedback of MDMX function.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Catholic Univ, Med Pathol Inst, I-00100 Rome, Italy; Leiden Univ, Ctr Med, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; CNR, Neurobiol & Mol Med Inst, I-00156 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Leiden University; Leiden University - Excl LUMC; Consiglio Nazionale delle Ricerche (CNR)	Moretti, F (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.		Moretti, Fabiola/I-5647-2013; Mancini, Francesca/AAZ-1672-2021; mancini, francesca/K-6062-2016	Moretti, Fabiola/0000-0002-2691-1254; Mancini, Francesca/0000-0002-2459-8815; mancini, francesca/0000-0002-2459-8815				Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Freedman DA, 1999, CANCER RES, V59, P1; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; GRAHAM F, 1991, METHOD MOL BIOL, P3587; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Mayo LD, 1997, CANCER RES, V57, P5013; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moretti F, 1997, ONCOGENE, V14, P729, DOI 10.1038/sj.onc.1200887; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stad R, 2000, J BIOL CHEM, V275, P28039; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	51	35	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					867	877		10.1038/sj.onc.1205137	http://dx.doi.org/10.1038/sj.onc.1205137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840332				2022-12-25	WOS:000173427100002
J	Ackler, S; Ahmad, S; Tobias, C; Johnson, MD; Glazer, RI				Ackler, S; Ahmad, S; Tobias, C; Johnson, MD; Glazer, RI			Delayed mammary gland involution in MMTV-AKT1 transgenic mice	ONCOGENE			English	Article						AKT1; transgenic; mammary gland; cyclin D1	BREAST-CANCER CELLS; AKT/PROTEIN KINASE-B; TRANSCRIPTION FACTOR FKHR; GROWTH-FACTOR PROTECTS; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIN D1; AKT ACTIVATION; INDUCED APOPTOSIS; FACTOR I; KAPPA-B	AKT1/protein kinase B alpha is a protein-serine/threonine kinase that regulates multiple targets involved in cell survival and cell cycle progression in a variety of cell types including breast cancer cells. To explore the role of Akt1 in mammary gland function and tumorigenesis, transgenic mice were generated that express human AKT1 under the control of the MMTV promoter. Virgin transgenic mice did not exhibit a dominant phenotype, but upon cessation of lactation, a notable delay in involution occurred compared to age-matched nontransgenic mice. The delay in involution coincided with increased hyperplasia as evidenced by an increased number of binucleated epithelial cells and a marked elevation in cyclin D1 expression in mammary epithelium. The delayed involution phenotype corresponded to increased phosphorylation of Thr308 in AKT1 and Ser136 in BAD, but not phosphorylation of Ser21 in GSK-3 alpha. There was no evidence of mammary dysplasia or neoplasia during the lifespan of multiparous transgenic mice. These data suggest that AKT1 is involved in cell survival in the lactating and involuting mammary gland, but that overexpression of AKT1 alone is insufficient to induce transformation.	Georgetown Univ, Sch Med, Dept Pharmacol, Washington, DC 20007 USA; Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Georgetown Univ, Sch Med, Dept Oncol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Glazer, RI (corresponding author), Georgetown Univ, Sch Med, Dept Pharmacol, 3970 Reservoir Rd NW,Res Bldg,Room W318, Washington, DC 20007 USA.	glazerr@georgetown.edu			NATIONAL CANCER INSTITUTE [P50CA058185, P30CA051008] Funding Source: NIH RePORTER; NCI NIH HHS [P30-CA51008, P50-CA58185, R01 CA881565] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1999, BIOCHEM PHARMACOL, V58, P425, DOI 10.1016/S0006-2952(99)00125-2; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Andjelkovic M, 1998, EUR J BIOCHEM, V251, P195, DOI 10.1046/j.1432-1327.1998.2510195.x; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Bowers DC, 2000, CANCER RES, V60, P4277; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Cohen P, 1997, FEBS LETT, V410, P3, DOI 10.1016/S0014-5793(97)00490-0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DEL PL, 1997, SCIENCE, V278, P687; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; HAYCOCK JW, 1993, ANAL BIOCHEM, V208, P397, DOI 10.1006/abio.1993.1068; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Krane IM, 1996, ONCOGENE, V12, P1781; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu W, 1999, BIOCHEM BIOPH RES CO, V261, P897, DOI 10.1006/bbrc.1999.1144; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Ma ZQ, 1999, ONCOGENE, V18, P4564, DOI 10.1038/sj.onc.1202809; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761; SANDGREN EP, 1995, CANCER RES, V55, P3915; Schwertfeger KL, 2001, MOL ENDOCRINOL, V15, P867, DOI 10.1210/me.15.6.867; SMITH GH, 1995, AM J PATHOL, V147, P1081; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	47	76	77	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					198	206		10.1038/sj.onc.1205052	http://dx.doi.org/10.1038/sj.onc.1205052			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803463				2022-12-25	WOS:000173026200004
J	Murga, C; Zohar, M; Teramoto, H; Gutkind, JS				Murga, C; Zohar, M; Teramoto, H; Gutkind, JS			Rac1 and RhoG promote cell survival by the activation of PI3K and Akt, independently of their ability to stimulate JNK and NF-kappa B	ONCOGENE			English	Article						RhoG; PI3K; Akt; cell survival	PROTEIN-KINASE B; PHOSPHATIDYLINOSITOL 3-KINASE; PC12 CELLS; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; PATHWAY; APOPTOSIS; RAS; GTPASES; TARGET	Small GTPases of the Rho family play a central role in cellular processes that involve the reorganization of the actin-based cytoskeleton. Rho-related GTPases, which include Rac and Cdc42, can also regulate gene expression often through the activation of kinase cascades leading to enhanced activity of stress activated protein kinases (SAPKs), including JNK and p38 MAP kinases. As SAPKs are implicated in programmed cell death, these observations suggest that Rho GTPases may promote the initiation of the apoptotic process. However, recent reports suggest that Rho GTPases can have either a protective or a proapoptotic role, depending on the particular cellular context. In an effort to explore the molecular mechanisms underlying these divergent biological activities, we asked whether there was indeed a correlation between the ability to induce SAPKs and apoptosis by Rho family members. We found that although constitutively activated (Q61L) mutants of Rac1, Cdc42, and RhoG, a Rac1 related GTPase of unknown function, potently induce JNK in COS 7 cells, none of these GTPases could induce apoptosis, nor enhance uv-induced cell death. In contrast, Rac1 and RhoG efficiently protected cells from uv-induced apoptosis. Furthermore, we provide evidence that Rac1 and RhoG can activate both apoptotic and anti-apoptotic pathways. Whereas the former is mediated through JNK, the latter is independent on the transcriptional activation of NF-KB, a pro-survival pathway, but results from the direct interaction of these GTPases with phosphatidylinositol 3-kinase (PI3K) and the stimulation of Akt. Together, these findings indicate that members of the Rho family of small GTP-binding proteins can provoke the concomitant stimulation of two counteracting signaling pathways, and that their balance ultimately determines the ability of these GTPases to promote cell survival or death.	NIDR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Teramoto, H (corresponding author), NIDR, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Room 211, Bethesda, MD 20892 USA.		Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009; Murga, Cristina/E-1965-2014	Gutkind, J. Silvio/0000-0002-5150-4482; Murga, Cristina/0000-0002-8964-4077	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Blangy A, 2000, J CELL SCI, V113, P729; Bobak D, 1997, ONCOGENE, V15, P2179, DOI 10.1038/sj.onc.1201396; Boehm JE, 1999, J BIOL CHEM, V274, P28632, DOI 10.1074/jbc.274.40.28632; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Brown K, 1997, MOL CELL BIOL, V17, P3021, DOI 10.1128/MCB.17.6.3021; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen YR, 2000, INT J ONCOL, V16, P651; Chiariello M, 2000, MOL CELL BIOL, V20, P1747, DOI 10.1128/MCB.20.5.1747-1758.2000; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gauthier-Rouviere C, 1998, MOL BIOL CELL, V9, P1379, DOI 10.1091/mbc.9.6.1379; Genot EM, 2000, MOL CELL BIOL, V20, P5469, DOI 10.1128/MCB.20.15.5469-5478.2000; Gomez J, 1998, IMMUNOL CELL BIOL, V76, P125, DOI 10.1046/j.1440-1711.1998.00723.x; GUTKIND JS, 1990, MOL CELL BIOL, V10, P3806, DOI 10.1128/MCB.10.7.3806; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lores P, 1997, ONCOGENE, V15, P601, DOI 10.1038/sj.onc.1201378; Madge LA, 2000, J BIOL CHEM, V275, P15458, DOI 10.1074/jbc.M001237200; Minamoto T, 2000, CANCER DETECT PREV, V24, P1; Murga C, 2000, J BIOL CHEM, V275, P12069, DOI 10.1074/jbc.275.16.12069; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang FC, 2000, IMMUNITY, V12, P557, DOI 10.1016/S1074-7613(00)80207-1; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	50	136	139	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					207	216		10.1038/sj.onc.1205036	http://dx.doi.org/10.1038/sj.onc.1205036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803464				2022-12-25	WOS:000173026200005
J	Lane, P; Gross, SS				Lane, P; Gross, SS			Disabling a C-terminal autoinhibitory control element in endothelial nitric-oxide synthase by phosphorylation provides a molecular explanation for activation of vascular NO synthesis by diverse physiological stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME P450 REDUCTASE; ELECTRON FLOW-THROUGH; PROTEIN-KINASE; CALMODULIN; CELLS; AKT; DOMAIN; BINDING; ENZYME; MECHANISM	Calmodulin-dependent activation of endothelial nitric-oxide synthase is generally considered to follow a transient increase in intracellular calcium levels. However, a number of physiological stimuli (e.g. endothelial shear-stress, insulin) are known to activate endothelial nitric oxide (eNOS) via a non-classical, "calcium-independent" pathway. Recent findings demonstrate that such stimuli elicit the phosphorylation of a C-terminal residue in eNOS (Ser(1179) in the bovine isoform), rendering eNOS active at resting levels of intracellular calcium. However, the mechanistic basis for this mode of eNOS activation remains unknown. Protein modeling led us to consider that the C terminus of eNOS may fulfill an autoinhibitory function that can be disrupted by phosphorylation of serine 1179. To test this possibility we contrasted the phenotype of wild type bovine eNOS with that of a mutant lacking C-terminal residues 1179-1205 (CDelta27 eNOS). Despite no observed difference in calmodulin affinity, CDelta27 eNOS exhibited a 5-fold reduction in EC50 for calcium and a 2-4-fold increase in maximal catalytic activities. In these phenotypic properties, CDelta27 accurately mimics phospho-Ser(1179) wild type eNOS. We conclude that the C terminus imposes a significant barrier to the activation of eNOS by calmodulin binding and that this barrier can be functionally disabled by Ser(1179) phosphorylation-elicited enzyme activation.	Cornell Univ, Weill Med Coll, Dept Pharmacol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Program Biochem & Struct Biol, New York, NY 10021 USA	Cornell University; Cornell University	Gross, SS (corresponding author), Cornell Univ, Coll Med, Dept Pharmacol, 1300 York Ave, New York, NY 10021 USA.			Lane, Paul/0000-0003-1595-3237	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL046403, R01HL050656] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50656, HL46403] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ABUSOUD HM, 1994, J BIOL CHEM, V269, P32047; Adak S, 1999, J BIOL CHEM, V274, P26907, DOI 10.1074/jbc.274.38.26907; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BLACK SM, 1995, DNA CELL BIOL, V14, P789, DOI 10.1089/dna.1995.14.789; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; Haynes MP, 2000, CIRC RES, V87, P677, DOI 10.1161/01.RES.87.8.677; Hisamoto K, 2001, J BIOL CHEM, V276, P3459, DOI 10.1074/jbc.M005036200; Igarashi J, 2001, J BIOL CHEM, V276, P12420, DOI 10.1074/jbc.M008375200; Kim JJP, 1996, METHOD ENZYMOL, V272, P368, DOI 10.1016/S0076-6879(96)72042-6; Martasek P, 1996, BIOCHEM BIOPH RES CO, V219, P359, DOI 10.1006/bbrc.1996.0238; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; Persechini A, 1996, J BIOL CHEM, V271, P19279, DOI 10.1074/jbc.271.32.19279; Persechini A, 1996, BIOCHEMISTRY-US, V35, P224, DOI 10.1021/bi952383x; Persechini A, 1999, J BIOL CHEM, V274, P6827, DOI 10.1074/jbc.274.11.6827; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1994, J VASC RES, V31, P131, DOI 10.1159/000159039; Wang M, 1997, P NATL ACAD SCI USA, V94, P8411, DOI 10.1073/pnas.94.16.8411; XIE QW, 1994, J BIOL CHEM, V269, P28500; Zhang J, 2001, J BIOL CHEM, V276, P37506, DOI 10.1074/jbc.M105503200	44	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19087	19094		10.1074/jbc.M200258200	http://dx.doi.org/10.1074/jbc.M200258200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11839759	hybrid			2022-12-25	WOS:000175975800110
J	Robben, J; Hertveldt, K; Bosmans, E; Volckaert, G				Robben, J; Hertveldt, K; Bosmans, E; Volckaert, G			Selection and identification of dense granule antigen GRA3 by Toxoplasma gondii whole genome phage display	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENTOUS PHAGE; IMMUNOGLOBULIN-A; LAMBDA VECTOR; CLONING; PROTEIN; IMMUNIZATION; EXPRESSION; ANTIBODIES; LIBRARIES; SURFACE	Toxoplasma gondii is a ubiquitous, unicellular, eukaryotic parasite with a complex intracellular life cycle capable of invading and chronically infecting a wide variety of vertebrate host species, including man. Although normally opportunistic in healthy adults, it is a lethal pathogen in immunocompromised humans, particularly in AIDS patients. We present the application of a genomic phage display as a tool for the direct identification of antigens with potential value in diagnosis and/or as subunit vaccine components. Using a polycosmid cloning strategy, we constructed a large phagemid display library (>10(9) independent clones) of mixed short genomic restriction fragments (less than or equal to500 bp) of T. gondii genomic DNA (80 Mbp genome size) fused to gene III of the filamentous phage M13. Biopanning of the library with monoclonal Toxoplasma antibodies resulted in the isolation and identification of an epitope of GRA3, an antigen located in the dense granules of T. gondii tachyzoites. The reactivity of the phage displaying the GRA3 epitope with the monoclonal antibody was confirmed by an enzyme-linked immunosorbent assay. These results demonstrate the accessibility of midsized eukaryotic genomes to display technology and the feasibility to screen these whole genome display libraries with antibodies for isolating novel antigenic determinants.	Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; DiaMed Eurogen, B-3980 Tessenderlo, Belgium	KU Leuven	Volckaert, G (corresponding author), Katholieke Univ Leuven, Lab Gene Technol, Kasteelpk Arenberg 21, B-3001 Louvain, Belgium.							Ajioka JW, 1998, GENOME RES, V8, P18, DOI 10.1101/gr.8.1.18; ALTINGMEES MA, 1993, GENE, V137, P93, DOI 10.1016/0378-1119(93)90256-3; BERMUDES D, 1994, MOL BIOCHEM PARASIT, V68, P247, DOI 10.1016/0166-6851(94)90169-4; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; BULOW R, 1991, J IMMUNOL, V147, P3496; BUXTON D, 1995, PARASITOLOGY, V110, pS11, DOI 10.1017/S003118200000144X; Buxton D, 1998, VET RES, V29, P289; FRENKEL JK, 1982, J PARASITOL, V68, P744, DOI 10.2307/3280978; HOGREFE HH, 1993, GENE, V137, P85, DOI 10.1016/0378-1119(93)90255-2; HOHN B, 1983, P NATL ACAD SCI-BIOL, V80, P7456, DOI 10.1073/pnas.80.24.7456; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; JACOBSSON K, 1995, BIOTECHNIQUES, V18, P878; Jespers LS, 1996, GENE, V173, P179, DOI 10.1016/0378-1119(96)00217-X; KIM K, 1994, INFECT IMMUN, V62, P203, DOI 10.1128/IAI.62.1.203-209.1994; KUMOLOSASI E, 1994, MICROSC RES TECHNIQ, V29, P231, DOI 10.1002/jemt.1070290309; Lin JT, 1999, MOL CELL BIOL, V19, P3237; Lunden A, 1997, PARASITOL RES, V83, P6, DOI 10.2307/3284309; LUNDEN A, 1993, INFECT IMMUN, V61, P2639; Martin V, 1998, CLIN DIAGN LAB IMMUN, V5, P627, DOI 10.1128/CDLI.5.5.627-631.1998; MEVELEC MN, 1992, MOL BIOCHEM PARASIT, V56, P227, DOI 10.1016/0166-6851(92)90172-G; Murray Avril, 1993, Applied Parasitology, V34, P235; PARMLEY SF, 1992, J CLIN MICROBIOL, V30, P1127, DOI 10.1128/JCM.30.5.1127-1133.1992; Pellegrini CA, 1997, SURG ENDOSC-ULTRAS, V11, P1, DOI 10.1007/s004649900282; Petersen G, 1995, MOL GEN GENET, V249, P425, DOI 10.1007/BF00287104; SEAH SKK, 1975, CAN J MICROBIOL, V21, P1379, DOI 10.1139/m75-207; SIBLEY LD, 1992, MOL BIOCHEM PARASIT, V51, P291, DOI 10.1016/0166-6851(92)90079-Y; SMITH GP, 1993, METHOD ENZYMOL, V217, P228; TAYLOR DW, 1990, J PROTOZOOL, V37, P540, DOI 10.1111/j.1550-7408.1990.tb01262.x; VANLOON AM, 1980, J CLIN PATHOL, V33, P635, DOI 10.1136/jcp.33.7.635; WANG LF, 1995, J IMMUNOL METHODS, V178, P1, DOI 10.1016/0022-1759(94)00235-O; WONG SY, 1993, AIDS, V7, P299, DOI 10.1097/00002030-199303000-00001	31	13	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17544	17547		10.1074/jbc.M110275200	http://dx.doi.org/10.1074/jbc.M110275200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11825896	Green Published, hybrid			2022-12-25	WOS:000175685100021
J	Edbauer, D; Willem, M; Lammich, S; Steiner, H; Haass, C				Edbauer, D; Willem, M; Lammich, S; Steiner, H; Haass, C			Insulin-degrading enzyme rapidly removes the beta-amyloid precursor protein intracellular domain (AICD)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; TERMINAL FRAGMENT-GAMMA; ALZHEIMERS-DISEASE; EXTRACELLULAR LEVELS; ACTIVE-SITE; SECRETASE; CLEAVAGE; FE65; APP; DEGRADATION	The intramembranous gamma-secretase cleavage of the beta-amyloid precursor protein (APP) is dependent on biologically active presenilins (PS). Notch also undergoes a similar PS-dependent gamma-secretase-like cleavage, resulting in the liberation of the Notch intracellular domain (NICD), which is critically required for developmental signal transduction. gamma-Secretase processing of APP results in the production of a similar fragment called AICD (APP intracellular domain), which may function in nuclear signaling as well. AICD, like NICD, is rapidly removed. By using a battery of protease inhibitors we demonstrate that AICD, in contrast to NICD, is degraded by a cytoplasmic metalloprotease. In vitro degradation of AICD can be reconstituted with cytoplasmic fractions obtained from neuronal and non-neuronal cells. Taking into account the inhibition profile and the cytoplasmic localization, we identified three candidate enzymes (neurolysin, thimet oligopeptidase, and insulin-degrading enzyme (IDE), also known as insulysin), which all are involved in the degradation of bioactive peptides in the brain. When insulin, a well characterized substrate of IDE, was added to the in vitro degradation assay, removal of AICD was efficiently blocked. Moreover, overexpression of IDE resulted in enhanced degradation of AICD, whereas overexpression of the inactive IDE E111Q mutant did not affect AICD degradation. Finally, immunodepletion of IDE significantly reduced the AICD degrading activity. Therefore our data demonstrate that IDE, which is one of the proteases implicated in the removal of extracellular Abeta, also removes the cytoplasmic product of gamma-secretase cleaved APP.	Univ Munich, Adolf Butenandt Inst, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, D-80336 Munich, Germany	University of Munich	Steiner, H (corresponding author), Univ Munich, Adolf Butenandt Inst, Lab Alzheimers & Parkinsons Dis Res, Dept Biochem, Schillerstr 44, D-80336 Munich, Germany.	hsteiner@pbm.med.uni-muenchen.de; chaass@pbm.med	Edbauer, Dieter/M-9906-2019	Edbauer, Dieter/0000-0002-7186-4653				Authier F, 1996, CLIN INVEST MED, V19, P149; BARRETT AJ, 1995, METHOD ENZYMOL, V248, P529; BECKER AB, 1992, P NATL ACAD SCI USA, V89, P3835, DOI 10.1073/pnas.89.9.3835; BECKER AB, 1995, METHOD ENZYMOL, V248, P693; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; McLendon C, 2000, FASEB J, V14, P2383; McLoughlin DM, 1996, FEBS LETT, V397, P197; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; PERLMAN RK, 1993, J BIOL CHEM, V268, P21538; Pinnix I, 2001, J BIOL CHEM, V276, P481, DOI 10.1074/jbc.M005968200; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHII K, 1986, P NATL ACAD SCI USA, V83, P4147, DOI 10.1073/pnas.83.12.4147; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Shrimpton CN, 2000, BIOCHEM J, V345, P351, DOI 10.1042/0264-6021:3450351; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yu CJ, 2001, J BIOL CHEM, V276, P43756, DOI 10.1074/jbc.C100410200; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	43	167	176	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13389	13393		10.1074/jbc.M111571200	http://dx.doi.org/10.1074/jbc.M111571200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11809755	hybrid			2022-12-25	WOS:000175096000007
J	Vorachek-Warren, MK; Ramirez, S; Cotter, RJ; Raetz, CRH				Vorachek-Warren, MK; Ramirez, S; Cotter, RJ; Raetz, CRH			A triple mutant of Escherichia coli lacking secondary acyl chains on lipid A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TEMPERATURE REQUIREMENT GENE; SALMONELLA-TYPHIMURIUM; MULTICOPY SUPPRESSOR; MUTATIONAL ANALYSIS; OUTER-MEMBRANE; NULL MUTATIONS; RHIZOBIUM-ETLI; MSBA GENE; HTRB GENE; BIOSYNTHESIS	All possible combinations of insertion mutations in the three genes encoding the acyl carrier protein-dependent late acyltransferases of lipid A biosynthesis, designated lpxL(htrB), lpxM(msbB), and lpxP, were generated in Escherichia coli K12 W3110. Mutants defective in lpxM synthesize penta-acylated lipid A molecules and grow normally. Strains lacking lpxP fail to incorporate palmitoleate into their lipid A at 12 degreesC but make normal amounts of hexa-acylated lipid A and are viable. Although lpxL mutants and lpxL lpxM double mutants grow slowly on minimal medium at all temperatures, they do not grow on nutrient broth above 32 degreesC. Such mutants retain the ability to synthesize some penta- and hexa-acylated lipid A molecules because of limited induction of lpxP at 30 degreesC but not above 32 degreesC. MKV15, an E. coli lpxL lpxM lpxP triple mutant, likewise grows slowly on minimal medium at all temperatures but not on nutrient broth at any temperature. MKV15 synthesizes a lipid A molecule containing only the four primary (R)-3-hydroxymyristoyl chains. The outer membrane localization and content of lipid A are nearly normal in MKV15, as is the glycerophospholipid and membrane protein composition. However, the rate at which the tetra-acylated lipid A of MKV15 is exported to the outer membrane is reduced compared with wild type. The integrity of the outer membrane of MKV15 is compromised, as judged by antibiotic hypersensitivity, and MKV15 undergoes lysis following centrifugation. MKV15 may prove useful as a host strain for expressing late acyltransferase genes from other Gram-negative bacteria, facilitating the re-engineering of lipid A structure in living cells and the design of novel vaccines.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Lab, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NIGMS NIH HHS [GM-51310, GM08558, GM54882-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054882, T32GM008558, R01GM051310] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROZEK KA, 1987, J BIOL CHEM, V262, P5170; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; Carty SM, 1999, J BIOL CHEM, V274, P9677, DOI 10.1074/jbc.274.14.9677; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; CLEMENTZ T, 1995, FASEB J, V9, pA1311; Doerrler WT, 2001, J BIOL CHEM, V276, P11461, DOI 10.1074/jbc.C100091200; DULBECCO R, 1954, J EXP MED, V99, P167, DOI 10.1084/jem.99.2.167; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1998, J BIOL CHEM, V273, P12457, DOI 10.1074/jbc.273.20.12457; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; JOHNSTON S, 1985, GENE, V34, P137, DOI 10.1016/0378-1119(85)90121-0; KAROW M, 1992, J BACTERIOL, V174, P702, DOI 10.1128/jb.174.3.702-710.1992; KAROW M, 1993, MOL MICROBIOL, V7, P69, DOI 10.1111/j.1365-2958.1993.tb01098.x; KAROW M, 1991, MOL MICROBIOL, V5, P2285, DOI 10.1111/j.1365-2958.1991.tb02159.x; KAROW M, 1991, J BACTERIOL, V173, P741, DOI 10.1128/jb.173.2.741-750.1991; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; Kozak M, 1999, ACTA CRYSTALLOGR D, V55, P1939, DOI 10.1107/S090744499901121X; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205; Murray SR, 2001, J BACTERIOL, V183, P5554, DOI 10.1128/JB.183.19.5554-5561.2001; NISHIJIMA M, 1977, EUR J BIOCHEM, V73, P115, DOI 10.1111/j.1432-1033.1977.tb11297.x; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Osborn M J, 1974, Methods Enzymol, V31, P642; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; Polissi A, 1996, MOL MICROBIOL, V20, P1221, DOI 10.1111/j.1365-2958.1996.tb02642.x; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Rietschel E. T., 1992, BACTERIAL ENDOTOXIC, V1, P3; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; TAKAYAMA K, 1989, INFECT IMMUN, V57, P1336, DOI 10.1128/IAI.57.4.1336-1338.1989; Trent MS, 2001, J BIOL CHEM, V276, P9083, DOI 10.1074/jbc.M010730200; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; Vaara M, 1999, ANTIMICROB AGENTS CH, V43, P1459, DOI 10.1128/AAC.43.6.1459; van der Ley P, 2001, INFECT IMMUN, V69, P5981, DOI 10.1128/IAI.69.10.5981-5990.2001; Vorachek-Warren MK, 2002, J BIOL CHEM, V277, P14186, DOI 10.1074/jbc.M200408200; VUORIO R, 1992, ANTIMICROB AGENTS CH, V37, P354; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	50	97	103	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14194	14205		10.1074/jbc.M200409200	http://dx.doi.org/10.1074/jbc.M200409200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830595	hybrid			2022-12-25	WOS:000175096000109
J	Xie, J; LeBaron, MJ; Nevalainen, MT; Rui, H				Xie, J; LeBaron, MJ; Nevalainen, MT; Rui, H			Role of tyrosine kinase Jak2 in prolactin-induced differentiation and growth of mammary epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CASEIN GENE; C-SRC; RECEPTOR; ACTIVATION; PHOSPHORYLATION; INDUCTION; PROTEINS; STAT5B; STIMULATION; SECRETION	Genetic studies in mice have established a critical role for prolactin receptors and transcription factor Stat5 in mammary gland differentiation. However, the enzymatic coupling between prolactin receptors and Stat5 in this process has not been established. In addition to Jak2, several other tyrosine kinases reportedly also are associated with prolactin receptors and may phosphorylate Stat5. Because Jak2 null mice die in utero, we targeted Jak2 in an ex vivo model of prolactin-induced mammary epithelial cell differentiation to determine the role of Jak2 in regulation of cell differentiation and growth. Two independent targeting strategies were used to suppress Jak2 in immortalized HC11 mouse mammary epithelial cells: 1) stable expression of a specific Jak2 antisense construct and 2) adenoviral delivery of a dominant-negative Jak2 gene. We now demonstrate that Jak2 is essential for prolactin-induced differentiation and activation of Stat5 in normal mouse mammary epithelial cells. Furthermore, suppression of Jak2 in HC11 cells was associated with constitutive activation of oncoprotein Stat3 and a hyperproliferative phenotype characterized by increased mitotic rate, reduced apoptosis, and reduced contact inhibition. Collectively, our data suggest that Jak2 is differentiation-inducing and growth-inhibitory in normal mammary epithelial cells, observations that may shed new light on the role of the Jak2-Stat5 pathway in breast cancer.	Uniformed Serv Univ Hlth Sci, US Mil Canc Inst, Bethesda, MD 20814 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	Uniformed Services University of the Health Sciences - USA; Uniformed Services University of the Health Sciences - USA	Rui, H (corresponding author), Georgetown Univ, Lombardi Canc Ctr, E504A,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	ruih@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA083813] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052013] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA83813] Funding Source: Medline; NIDDK NIH HHS [R01 DK52013] Funding Source: Medline; PHS HHS [R074JW] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; Blatchford DR, 1995, EPITHELIAL CELL BIOL, V4, P8; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Canbay E, 1997, BIOCHEM J, V324, P231, DOI 10.1042/bj3240231; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; DUHE RJ, 1995, GENE, V158, P281, DOI 10.1016/0378-1119(95)00041-4; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Groner B, 2000, BREAST CANCER RES, V2, P149, DOI 10.1186/bcr47; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Humphreys RC, 1997, CELL GROWTH DIFFER, V8, P839; HYNES NE, 1990, MOL CELL BIOL, V10, P4027, DOI 10.1128/MCB.10.8.4027; Kazansky AV, 1999, J BIOL CHEM, V274, P22484, DOI 10.1074/jbc.274.32.22484; Kline JB, 2001, MOL ENDOCRINOL, V15, P832, DOI 10.1210/me.15.5.832; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RUI H, 1992, J BIOL CHEM, V267, P24076; RUI H, 1994, J BIOL CHEM, V269, P5364; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Vara JAF, 2000, BIOCHEM J, V345, P17, DOI 10.1042/0264-6021:3450017; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200	29	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14020	14030		10.1074/jbc.M112399200	http://dx.doi.org/10.1074/jbc.M112399200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821424	hybrid			2022-12-25	WOS:000175096000088
J	Gaitatzis, N; Silakowski, B; Kunze, B; Nordsiek, G; Blocker, H; Hofle, G; Muller, R				Gaitatzis, N; Silakowski, B; Kunze, B; Nordsiek, G; Blocker, H; Hofle, G; Muller, R			The biosynthesis of the aromatic myxobacterial electron transport inhibitor stigmatellin is directed by a novel type of modular polyketide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL PEPTIDE SYNTHETASE; FATTY-ACID SYNTHASE; AURANTIACA SG A15; GENE-CLUSTER; SORANGIUM-CELLULOSUM; GLIDING BACTERIA; IDENTIFICATION; ANTIBIOTICS; POLYPEPTIDE; METABOLITES	Deductions from the molecular analysis of the 65,000-bp stigmatellin biosynthetic gene cluster are reported. The biosynthetic genes (stiA-J) encode an unusual bacterial modular type I polyketide synthase (PKS) responsible for the formation of this aromatic electron transport inhibitor produced by the myxobacterium Stigmatella aurantiaca. Involvement of the PKS gene cluster in stigmatellin biosynthesis is shown using site-directed mutagenesis. One module of the PKS is assumed to be used iteratively during the biosynthetic process, which seems to involve an unusual transacylation of the biosynthetic intermediate from an acyl carrier protein domain back to the preceding ketosynthase domain. Finally, the polyketide chain which is presumably catalyzed by a novel C-terminal domain in StiJ that does not resemble thioesterases, is cyclized and aromatized. The presented results of feeding experiments are in good agreement with the proposed biosynthetic scheme. In contrast to all other PKS type I systems reported to date, each module of StiA-J is encoded on a separate gene. The gene cluster contains a "stand alone" O-methyltransferase and two unusual O-methyltransferase domains embedded in the PKS. In addition, inactivation of a cytochrome P450 monooxygenase-encoding gene involved in post-PKS hydroxylation of the aromatic ring leads to the formation of two novel stigmatellin derivatives.	Gesell Biotechnol Forsch mbH, Abt NBI MX, D-38124 Braunschweig, Germany; TU Braunschweig, Inst Pharmazeut Biol, D-38106 Braunschweig, Germany	Gesellschaft fur Biotechnologische Forschung mbH; Braunschweig University of Technology	Muller, R (corresponding author), Gesell Biotechnol Forsch mbH, Abt NBI MX, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	ROM@GBF.DE	Müller, Rolf/B-1559-2008	Müller, Rolf/0000-0002-1042-5665				August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; Beyer S, 1999, BBA-GENE STRUCT EXPR, V1445, P185, DOI 10.1016/S0167-4781(99)00041-X; BIRCH AJ, 1975, TETRAHEDRON LETT, P4173; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; Cane DE, 1997, CHEM REV, V97, P2463, DOI 10.1021/cr970097g; Chen S, 1999, EUR J BIOCHEM, V261, P98, DOI 10.1046/j.1432-1327.1999.00244.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Fujii I, 2001, CHEM BIOL, V8, P189, DOI 10.1016/S1074-5521(00)90068-1; Gaisser S, 1997, J BACTERIOL, V179, P6271, DOI 10.1128/jb.179.20.6271-6278.1997; Gaitatzis N, 2001, P NATL ACAD SCI USA, V98, P11136, DOI 10.1073/pnas.201167098; Gehring AM, 1998, CHEM BIOL, V5, P573, DOI 10.1016/S1074-5521(98)90115-6; Gokhale RS, 2000, CURR OPIN CHEM BIOL, V4, P22, DOI 10.1016/S1367-5931(99)00046-0; Hardt IH, 2001, J NAT PROD, V64, P847, DOI 10.1021/np000629f; Hendrickson L, 1999, CHEM BIOL, V6, P429, DOI 10.1016/S1074-5521(99)80061-1; HOFLE G, 1984, LIEBIGS ANN CHEM, P1883; Hofle G., 1995, SEKUNDARMETABOLISMUS, P61; Keating TA, 2001, CHEMBIOCHEM, V2, P99, DOI 10.1002/1439-7633(20010202)2:2<99::AID-CBIC99>3.0.CO;2-3; Kennedy J, 1999, SCIENCE, V284, P1368, DOI 10.1126/science.284.5418.1368; Konz D, 1999, CHEM BIOL, V6, pR39, DOI 10.1016/S1074-5521(99)80002-7; KUNZE B, 1984, J ANTIBIOT, V37, P454, DOI 10.7164/antibiotics.37.454; LIGON JM, 1997, Patent No. 5693774; Matsuno-Yagi A, 2001, J BIOL CHEM, V276, P19006, DOI 10.1074/jbc.M101446200; Moore BS, 2001, CHEMBIOCHEM, V2, P35, DOI 10.1002/1439-7633(20010105)2:1<35::AID-CBIC35>3.3.CO;2-T; Muller R, 2000, ARCH MICROBIOL, V173, P303, DOI 10.1007/s002039900131; NEUMANN B, 1992, J BACTERIOL, V174, P6307, DOI 10.1128/JB.174.19.6307-6310.1992; NEUMANN B, 1992, TRENDS GENET, V8, P332, DOI 10.1016/0168-9525(92)90269-A; Nowak-Thompson B, 1997, GENE, V204, P17, DOI 10.1016/S0378-1119(97)00501-5; OETTMEIER W, 1985, BIOCHIM BIOPHYS ACTA, V807, P216, DOI 10.1016/0005-2728(85)90125-2; Rangan VS, 2001, BIOCHEMISTRY-US, V40, P10792, DOI 10.1021/bi015535z; Rawlings BJ, 2001, NAT PROD REP, V18, P231, DOI 10.1039/b100191o; REICHENBACH H, 1993, BIOTECHNOL ADV, V11, P219, DOI 10.1016/0734-9750(93)90042-L; Reichenbach H, 2000, SPR DESKT EDIT CHEM, P149; Reichenbach H, 1993, MYXOBACTERIA, P13; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Shen B, 2000, TOP CURR CHEM, V209, P1; SHIMKETS LJ, 1993, MYXOBACTERIA, V2, P85; Silakowski B, 2000, EUR J BIOCHEM, V267, P6476, DOI 10.1046/j.1432-1327.2000.01740.x; Silakowski B, 2000, ARCH MICROBIOL, V173, P403, DOI 10.1007/s002030000162; Silakowski B, 2001, CHEM BIOL, V8, P59, DOI 10.1016/S1074-5521(00)00056-9; Silakowski B, 1999, J BIOL CHEM, V274, P37391, DOI 10.1074/jbc.274.52.37391; Silakowski B, 2001, GENE, V275, P233, DOI 10.1016/S0378-1119(01)00680-1; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Staunton J, 2001, NAT PROD REP, V18, P380, DOI 10.1039/a909079g; Staunton J, 1998, TOP CURR CHEM, V195, P49; STOESSL A, 1978, CAN J BOT, V56, P2589, DOI 10.1139/b78-311; THIERBACH G, 1984, BIOCHIM BIOPHYS ACTA, V765, P227, DOI 10.1016/0005-2728(84)90017-3; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wilkinson B, 2000, CHEM BIOL, V7, P111, DOI 10.1016/S1074-5521(00)00076-4; Wu N, 2001, J AM CHEM SOC, V123, P6465, DOI 10.1021/ja010219t	50	155	156	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13082	13090		10.1074/jbc.M111738200	http://dx.doi.org/10.1074/jbc.M111738200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809757	hybrid			2022-12-25	WOS:000175036300076
J	Huang, YL; Liu, ZR				Huang, YL; Liu, ZR			The ATPase, RNA unwinding, and RNA binding activities of recombinant p68 RNA helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEAD-BOX PROTEIN; INITIATION-FACTOR 4A; PHOTO-CROSS-LINKING; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; RIBOSOMAL-RNA; TRANSLATION; FAMILY; DOMAIN; IDENTIFICATION	p68 RNA helicase, a nuclear RNA helicase, was identified 2 decades ago. The protein plays very important roles in cell development and organ maturation. However, the biological functions and enzymology of p68 RNA helicase are not well characterized. We report the expression and purification of recombinant p68 RNA helicase in a bacterial system. The recombinant p68 is an ATP-dependent RNA helicase. ATPase assays demonstrated that double-stranded RNA (dsRNA) is much more effective than single-stranded RNA in stimulating ATP hydrolysis by the recombinant protein. Consistently, RNA-binding assays showed that p68 RNA helicase binds single-stranded RNA weakly in an ATP-dependent manner. On the other hand, the recombinant protein has very high affinity for dsRNA. Binding of the protein to dsRNA is ATP-independent. The data indicate that p68 may directly target dsRNA as its natural substrate. Interestingly, the recombinant p68 RNA helicase unwinds dsRNA in both 3' --> 5' and 5' --> 3' directions. This is the second example of a Asp-Glu-Ala-Asp (DEAD) box RNA helicase that unwinds RNA duplexes in a bidirectional manner.	Auburn Univ, Dept Anim & Dairy Sci, Program Cell & Mol Biosci, Auburn, AL 36849 USA	Auburn University System; Auburn University	Liu, ZR (corresponding author), Auburn Univ, Dept Anim & Dairy Sci, Program Cell & Mol Biosci, 210 Upchurch Hall, Auburn, AL 36849 USA.							BARTA I, 1995, EMBO J, V14, P3800, DOI 10.1002/j.1460-2075.1995.tb00049.x; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; Caruthers JM, 2000, P NATL ACAD SCI USA, V97, P13080, DOI 10.1073/pnas.97.24.13080; CHAN KM, 1986, ANAL BIOCHEM, V157, P375, DOI 10.1016/0003-2697(86)90640-8; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; CRAWFORD L, 1982, J VIROL, V42, P612, DOI 10.1128/JVI.42.2.612-620.1982; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; HE F, 1995, GENE DEV, V9, P437, DOI 10.1101/gad.9.4.437; Heinlein UAO, 1998, J PATHOL, V184, P345, DOI 10.1002/(SICI)1096-9896(199804)184:4<345::AID-PATH1243>3.0.CO;2-6; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IGGO RD, 1989, EMBO J, V8, P1827, DOI 10.1002/j.1460-2075.1989.tb03577.x; IGGO RD, 1991, MOL CELL BIOL, V11, P1326, DOI 10.1128/MCB.11.3.1326; Jankowsky E, 2000, NATURE, V403, P447, DOI 10.1038/35000239; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; JARAMILLO M, 1991, MOL CELL BIOL, V11, P5992, DOI 10.1128/MCB.11.12.5992; Johnson ER, 1999, RNA, V5, P1526, DOI 10.1017/S1355838299991410; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; KITAJIMA Y, 1994, BIOCHEM BIOPH RES CO, V199, P748, DOI 10.1006/bbrc.1994.1292; LANE DP, 1980, NATURE, V288, P167, DOI 10.1038/288167a0; Linder P, 2000, NAT STRUCT BIOL, V7, P97, DOI 10.1038/72464; Liu ZR, 1996, RNA, V2, P611; Liu ZR, 1998, MOL CELL BIOL, V18, P6910, DOI 10.1128/MCB.18.12.6910; Liu ZR, 1997, RNA, V3, P1207; Lorkovic ZJ, 1997, MOL CELL BIOL, V17, P2257, DOI 10.1128/MCB.17.4.2257; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2180, DOI 10.1021/bi972430g; Lorsch JR, 1998, BIOCHEMISTRY-US, V37, P2194, DOI 10.1021/bi9724319; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; MAHAL B, 1994, BIOL CHEM H-S, V375, P759, DOI 10.1515/bchm3.1994.375.11.759; Nicol SM, 2000, EXP CELL RES, V257, P272, DOI 10.1006/excr.2000.4886; PAUSE A, 1993, CURR OPIN STRUC BIOL, V3, P953, DOI 10.1016/0959-440X(93)90161-D; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Pugh GE, 1999, J MOL BIOL, V292, P771, DOI 10.1006/jmbi.1999.3112; Raghunathan PL, 1998, CURR BIOL, V8, P847, DOI 10.1016/S0960-9822(07)00345-4; ROSSLEROG, 2001, NUCL ACIDS RES, V29, P2088; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SHUMAN S, 1992, P NATL ACAD SCI USA, V89, P10935, DOI 10.1073/pnas.89.22.10935; Stevenson RJ, 1998, J PATHOL, V184, P351, DOI 10.1002/(SICI)1096-9896(199804)184:4<351::AID-PATH1235>3.0.CO;2-C; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Wang Y, 1998, CURR BIOL, V8, P441, DOI 10.1016/S0960-9822(98)70178-2; WARRENER P, 1995, J VIROL, V69, P1720, DOI 10.1128/JVI.69.3.1720-1726.1995; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	47	78	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12810	12815		10.1074/jbc.M200182200	http://dx.doi.org/10.1074/jbc.M200182200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823473	hybrid			2022-12-25	WOS:000175036300042
J	Laura, RP; Witt, AS; Held, HA; Gerstner, R; Deshayes, K; Koehler, MFT; Kosik, KS; Sidhu, SS; Lasky, LA				Laura, RP; Witt, AS; Held, HA; Gerstner, R; Deshayes, K; Koehler, MFT; Kosik, KS; Sidhu, SS; Lasky, LA			The Erbin PDZ domain binds with high affinity and specificity to the carboxyl termini of delta-catenin and ARVCF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; STRUCTURAL BASIS; PROTEIN; LOCALIZATION; RECOGNITION; INTERACTS; GROWTH; DETERMINANTS; COMPLEXES; JUNCTIONS	Erbin is a recently described member of the LAP (leucine-rich repeat and PDZ domain) protein family. We used a C-terminally displayed phage peptide library to identify optimal ligands for the Erbin PDZ domain. Phage-selected peptides were type 1 PDZ ligands that bound with high affinity and specificity to the Erbin PDZ domain in vitro. These peptides most closely resembled the C-terminal PDZ domain-binding motifs of three p120-related catenins: delta-catenin, ARVCF, and p0071 (DSWV-COOH). Analysis of the interactions of the Erbin PDZ domain with synthetic peptides matching the C termini of ARVCF or delta-catenin also demonstrated specific high affinity binding. We characterized the interactions between the Erbin PDZ domain and both ARVCF and delta-catenin in vitro and in vivo. The Erbin PDZ domain co-localized and coprecipitated with ARVCF or delta-catenin complexed with beta-catenin and E/N-cadherin. Mutagenesis and peptide competition experiments showed that the association of Erbin with the cadherin-catenin complex was mediated by the interaction of its PDZ domain with the C-terminal PDZ domain-binding motifs (DSWV-COOH) of ARVCF and delta-catenin. Finally, we showed that endogenous delta-catenin and Erbin co-localized in and co-immunoprecipitated from neurons. These results suggest that delta-catenin and ARVCF may function to mediate the association of Erbin with the junctional cadherin-catenin complex. They also demonstrate that C-terminal phage-display technology can be used to predict physiologically relevant ligands for PDZ domains.	Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Roche Holding; Genentech; Roche Holding; Genentech; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Lasky, LA (corresponding author), Genentech Inc, Dept Prot Engn, 1 DNA Way, San Francisco, CA 94080 USA.	larsky@earthlink.net		Koehler, Michael/0000-0003-0967-8304				Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Harris BZ, 2001, BIOCHEMISTRY-US, V40, P5921, DOI 10.1021/bi010142l; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Huang YZ, 2001, J BIOL CHEM, V276, P19318, DOI 10.1074/jbc.M100494200; Jaulin-Bastard F, 2001, J BIOL CHEM, V276, P15256, DOI 10.1074/jbc.M010032200; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kaufmann U, 2000, J CELL SCI, V113, P4121; Klapper LN, 2000, ADV CANCER RES, V77, P25; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Mariner DJ, 2000, J CELL SCI, V113, P1481; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; McMahon L, 2001, J CELL SCI, V114, P2265; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; Schaefer G, 1999, J BIOL CHEM, V274, P859, DOI 10.1074/jbc.274.2.859; Selfors LM, 1998, P NATL ACAD SCI USA, V95, P6903, DOI 10.1073/pnas.95.12.6903; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Wodarz A, 2000, CURR BIOL, V10, pR624, DOI 10.1016/S0960-9822(00)00658-8; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199	37	124	131	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12906	12914		10.1074/jbc.M200818200	http://dx.doi.org/10.1074/jbc.M200818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821434	hybrid			2022-12-25	WOS:000175036300055
J	Bao, KK; Skalka, AM; Wong, I				Bao, KK; Skalka, AM; Wong, I			Presteady-state analysis of avian sarcoma virus integrase - II. Reverse-polarity substrates identify preferential processing of the U3-U5 pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA ENDS; FULL-SITE INTEGRATION; RETROVIRUS INTEGRASE; HIV-1 INTEGRASE; CONCERTED INTEGRATION; PROTEIN; SEQUENCE; REPEAT; SELECTION; BINDING	The integrase-catalyzed insertion of the retroviral genome into the host chromosome involves two reactions in vivo: 1) the binding and endonucleolytic removal of the terminal dinucleotides of the viral DNA termini and 2) the recombination of the ends with the host DNA. Kukolj and Skalka (Kukolj, G., and Skalka, A. M. (1995) Genes Dev. 9, 2556-2567) have previously shown that tethering of the termini enhances the endonucleolytic activities of integrase. We have used 5'-5' phosphoramidites to design reverse-polarity tethers that allowed us to examine the reactivity of two viral long terminal repeat-derived sequences when concurrently bound to integrase and, additionally, developed presteady-state assays to analyze the initial exponential phase of the reaction, which is a measure of the amount of productive nucleoprotein complexes formed during preincubation of integrase and DNA. Furthermore, the reversepolarity tether circumvents the integrase-catalyzed splicing reaction (Bao, K., Skalka, A. M., and Wong, 1. (2002) J. BioL Chem. 277, 12089-12098) that obscures accurate analysis of the reactivities of synapsed DNA substrates. Consequently, we were able to establish a lower limit of 0.2 s(-1) for the rate constant of the processing reaction. The analysis showed the physiologically relevant U3/U5 pair of viral ends to be the preferred substrate for integrase with the U3/U3 combination favored over the U5/U5 pair.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Oregon State University; Fox Chase Cancer Center	Wong, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 ALS Bldg, Corvallis, OR 97331 USA.	wongis@onid.orst.edu			NATIONAL CANCER INSTITUTE [P30CA006927, R01CA071515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771] Funding Source: NIH RePORTER; NCI NIH HHS [CA71515, CA06927] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline; NIGMS NIH HHS [GM 58771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Bao KK, 2002, J BIOL CHEM, V277, P12089, DOI 10.1074/jbc.M111315200; Bor YC, 1996, VIROLOGY, V222, P283, DOI 10.1006/viro.1996.0422; BRIN E, 2002, IN PRESS J BIOL CHEM, V277; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Coleman J, 1999, J BIOL CHEM, V274, P32842, DOI 10.1074/jbc.274.46.32842; CRAIGIE R, 1990, CELL, V62, P829, DOI 10.1016/0092-8674(90)90126-Y; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; FITZGERALD ML, 1992, J VIROL, V66, P6257, DOI 10.1128/JVI.66.11.6257-6263.1992; FITZGERALD ML, 1994, J VIROL, V68, P4314, DOI 10.1128/JVI.68.7.4314-4321.1994; FITZGERALD ML, 1991, ANAL BIOCHEM, V196, P19, DOI 10.1016/0003-2697(91)90111-6; GRANDGENETT DP, 1993, J VIROL, V67, P2628, DOI 10.1128/JVI.67.5.2628-2636.1993; HISHINUMA F, 1981, CELL, V23, P155, DOI 10.1016/0092-8674(81)90280-4; JONES KS, 1992, J BIOL CHEM, V267, P16037; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; Scottoline BP, 1997, GENE DEV, V11, P371, DOI 10.1101/gad.11.3.371; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; STARCICH B, 1985, SCIENCE, V227, P538, DOI 10.1126/science.2981438; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VINK C, 1990, J VIROL, V64, P5626, DOI 10.1128/JVI.64.11.5626-5627.1990; Vora A, 2001, J VIROL, V75, P3556, DOI 10.1128/JVI.75.8.3556-3567.2001; VORA AC, 1995, J VIROL, V69, P7483, DOI 10.1128/JVI.69.12.7483-7488.1995; Vora AC, 1997, J BIOL CHEM, V272, P23938, DOI 10.1074/jbc.272.38.23938; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333	39	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12099	12108		10.1074/jbc.M111314200	http://dx.doi.org/10.1074/jbc.M111314200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821408	hybrid			2022-12-25	WOS:000174846400066
J	Luo, S; Ishida, H; Makino, A; Mae, T				Luo, S; Ishida, H; Makino, A; Mae, T			Fe2+-catalyzed site-specific cleavage of the large subunit of ribulose 1,5-bisphosphate carboxylase close to the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER MALIC ENZYME; FE2+-MEDIATED OXIDATIVE CLEAVAGE; METAL-BINDING SITE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE/OXYGENASE; AFFINITY CLEAVAGE; IRON CHELATE; STAPHYLOCOCCAL NUCLEASE; CYSTEINE RESIDUES; RICE LEAVES; OXYGEN	Previous work has demonstrated that the large subunit (rbcL) of ribulose 1,5-bisphosphate carboxylase/oxygenase (RuBisCo) from wheat is cleaved at Gly-329 by the Fe (2+)/ascorbate/H2O2 system (Ishida, H., Makino, A., and Mae, T. (1999) J. Biol Chem. 274, 5222-5226). In this study, we found that the rbcL could also be cleaved into several other fragments by increasing the incubation time or the Fe2+ concentration. By combining immunoblotting with N-terminal amino acid sequencing, cleavage sites were identified at Gly-404, Gly-380, Gly-329, Ala-296, Asp-203, and Gly-122. Conformational analysis demonstrated that five of them are located in the alpha/beta-barrel, whereas Gly-122 is in the N-terminal domain but near the bound metal in the adjacent rbcL. All of these residues are at or very close to the active site and are just around the metal-binding site within a radius of 12 Angstrom. Furthermore, their C H-alpha groups are completely or partially exposed to the bound metal. A radical scavenger, activation of RuBisCo, or binding of a reaction-intermediate analogue to the activated RuBisCo, inhibited the fragmentation. These results strongly suggest that the rbeL is cleaved by reactive oxygen species generated at the metal-binding site and that proximity and favorable orientation are probably the most important parameters in determining the cleavage sites.	Tohoku Univ, Grad Sch Agr Sci, Dept Appl Plant Sci, Sendai, Miyagi 9818555, Japan	Tohoku University	Mae, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Appl Plant Sci, 1-1 Tsutsumidori Amamiyamachi, Sendai, Miyagi 9818555, Japan.	hikomae@biochem.tohoku.ac.jp		Luo, Shen/0000-0002-1912-6741; Ishida, Hiroyuki/0000-0002-8682-4566				Bar Shimon M, 1998, J BIOL CHEM, V273, P34190, DOI 10.1074/jbc.273.51.34190; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BORS W, 1989, PHYTOCHEMISTRY, V28, P1589, DOI 10.1016/S0031-9422(00)97805-1; BROGLIE R, 1983, BIO-TECHNOL, V1, P55, DOI 10.1038/nbt0383-55; BUXTON GV, 1988, J PHYS CHEM REF DATA, V17, P513, DOI 10.1063/1.555805; Cao WG, 1998, J BIOL CHEM, V273, P33002, DOI 10.1074/jbc.273.49.33002; CHOU WY, 1995, J BIOL CHEM, V270, P25935, DOI 10.1074/jbc.270.43.25935; CHRISTELLER JT, 1981, BIOCHEM J, V193, P839, DOI 10.1042/bj1930839; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; Desimone M, 1996, PLANT PHYSIOL, V111, P789, DOI 10.1104/pp.111.3.789; Desimone M, 1998, PLANTA, V205, P459, DOI 10.1007/s004250050344; ECKARDT NA, 1995, PLANT PHYSIOL BIOCH, V33, P273; ERMACORA MR, 1992, P NATL ACAD SCI USA, V89, P6383, DOI 10.1073/pnas.89.14.6383; ERMACORA MR, 1994, BIOCHEMISTRY-US, V33, P13625, DOI 10.1021/bi00250a013; Evans J.R., 1989, PHOTOSYNTHESIS, P183; Gallagher J, 1998, BIOCHEMISTRY-US, V37, P2096, DOI 10.1021/bi971565j; Goldshleger R, 1997, P NATL ACAD SCI USA, V94, P9596, DOI 10.1073/pnas.94.18.9596; HALLIWELL B, 1984, METHOD ENZYMOL, V105, P47; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; Hlavaty JJ, 2000, BIOCHEMISTRY-US, V39, P3097, DOI 10.1021/bi992268c; Hlavaty JJ, 1997, BIOCHEMISTRY-US, V36, P15514, DOI 10.1021/bi970574p; HOYER D, 1990, J AM CHEM SOC, V112, P3249, DOI 10.1021/ja00164a076; Ishida H, 1997, PLANT CELL PHYSIOL, V38, P471, DOI 10.1093/oxfordjournals.pcp.a029191; Ishida H, 1998, PLANTA, V204, P305, DOI 10.1007/s004250050260; Ishida H, 1999, J BIOL CHEM, V274, P5222, DOI 10.1074/jbc.274.8.5222; ISHIDA H, 2002, IN PRESS PLANT CELL; KIM K, 1985, J BIOL CHEM, V260, P5394; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mae T., 1987, Plant senescence: its biochemistry and physiology. Proceedings of the Tenth Annual Symposium in Plant Physiology, 8-10 January, 1987, University of California, Riverside, California, USA., P123; MAKINO A, 1984, PLANT CELL PHYSIOL, V25, P429; MAKINO A, 1985, PLANT PHYSIOL, V79, P57, DOI 10.1104/pp.79.1.57; MIZIORKO HM, 1979, J BIOL CHEM, V254, P270; MIZIORKO HM, 1980, BIOCHEMISTRY-US, V19, P1167, DOI 10.1021/bi00547a020; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PLATIS IE, 1993, BIOCHEMISTRY-US, V32, P12761, DOI 10.1021/bi00210a027; Rana T M, 1994, Adv Inorg Biochem, V10, P177; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RANA TM, 1991, P NATL ACAD SCI USA, V88, P10578, DOI 10.1073/pnas.88.23.10578; RANA TM, 1991, J AM CHEM SOC, V113, P1859, DOI 10.1021/ja00005a076; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SOUNDAR S, 1993, J BIOL CHEM, V268, P5264; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Taylor TC, 1996, NAT STRUCT BIOL, V3, P95, DOI 10.1038/nsb0196-95; Taylor TC, 1997, J MOL BIOL, V265, P432, DOI 10.1006/jmbi.1996.0738; TERACHI T, 1987, JPN J GENET, V62, P375, DOI 10.1266/jjg.62.375; WEI CH, 1994, BIOCHEMISTRY-US, V33, P7931, DOI 10.1021/bi00191a021; WEI CH, 1995, BIOCHEMISTRY-US, V34, P7949, DOI 10.1021/bi00024a020; Zhang ZH, 1997, BIOCHEMISTRY-US, V36, P15999, DOI 10.1021/bi971823c	49	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12382	12387		10.1074/jbc.M111072200	http://dx.doi.org/10.1074/jbc.M111072200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821404	hybrid			2022-12-25	WOS:000174846400103
J	Sukumaran, SK; Prasadarao, NV				Sukumaran, SK; Prasadarao, NV			Regulation of protein kinase C in Escherichia coli K1 invasion of human brain microvascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MYRISTOYL-ELECTROSTATIC SWITCH; BACTERIAL-MENINGITIS; MARCKS; ACTIVATION; IDENTIFICATION; CONTRIBUTES; CALMODULIN; EXPERIENCE; SUBSTRATE	Escherichia coli is one of the most important pathogens involved in the development of neonatal meningitis in many parts of the world. Traversal of E. coli across the blood-brain barrier is a crucial event in the pathogenesis of E. coli meningitis. Our previous studies have shown that outer membrane protein A (OmpA) expression is necessary in E. coli for a mechanism involving actin filaments in its passage through the endothelial cells. Focal adhesion kinase (FAK) and phosphatidylinositol 3-kinase (PI3K) have also been activated in host cells during the process of invasion. In an attempt to elucidate the mechanisms leading to actin filament condensation, we have focused our attention on protein kinase C (PKC), an enzyme central to many signaling events, including actin rearrangement. In the current study, specific PKC inhibitors, bisindolmaleimide and a PKC-inhibitory peptide, inhibited E. coli invasion of human brain microvascular endothelial cells (HBMEC) by more than 75% in a dose-dependent manner, indicating a significant role played by this enzyme in the invasion process. Our results further showed that OmpA+ E. coli induces significant activation of PKC in HBMEC as measured by the PepTag nonradioactive assay. In addition, we identified that the PKC isoform activated in E. coli invasion is a member of the conventional family of PKC, PKC-alpha, which requires calcium for activation. Immunocytochemical studies have indicated that the activated PKC-alpha is associated with actin condensation beneath the bacterial entry site. Overexpression of a dominant negative mutant of PKC-alpha in HBMEC abolished the E. coli invasion without significant changes in FAK phosphorylation or PI3K activity patterns. In contrast, in HBMEC overexpressing the mutant forms of either FAK or PI3K, E. coli-induced PKC activation was significantly blocked. Furthermore, our studies showed that activation of PKC-alpha induces the translocation of myristoylated alanine-rich protein kinase C substrate, an actin cross-linking protein and a substrate for PKC-alpha, from the membrane to cytosol. This is the first report of FAK- and PI3K-dependent PKC-alpha activation in bacterial invasion related to cytoskeletal reorganization.	Univ So Calif, Div Infect Dis, Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; Univ So Calif, Keck Sch Med, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California	Prasadarao, NV (corresponding author), Univ So Calif, Div Infect Dis, Childrens Hosp Los Angeles, MS 51,4650 Sunset Blvd, Los Angeles, CA 90027 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI040567, R01AI040567] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40567] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; ALLEN LAH, 1995, J EXP MED, V182, P829, DOI 10.1084/jem.182.3.829; Arbuzova A, 1997, J BIOL CHEM, V272, P27167, DOI 10.1074/jbc.272.43.27167; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; Bubb MR, 1999, J BIOL CHEM, V274, P36472, DOI 10.1074/jbc.274.51.36472; Crane JK, 1997, INFECT IMMUN, V65, P3277, DOI 10.1128/IAI.65.8.3277-3285.1997; Dehio M, 1998, FEBS LETT, V424, P84, DOI 10.1016/S0014-5793(98)00144-6; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DwyerNield LD, 1996, AM J PHYSIOL-LUNG C, V270, pL526, DOI 10.1152/ajplung.1996.270.4.L526; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; GLADSTONE IM, 1990, PEDIATR INFECT DIS J, V9, P819, DOI 10.1097/00006454-199011000-00009; Glaser M, 1996, J BIOL CHEM, V271, P26187, DOI 10.1074/jbc.271.42.26187; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Koedel U, 1999, INFECT DIS CLIN N AM, V13, P549, DOI 10.1016/S0891-5520(05)70094-5; Laux T, 2000, J CELL BIOL, V149, P1455, DOI 10.1083/jcb.149.7.1455; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Leib SL, 1999, INFECT DIS CLIN N AM, V13, P527, DOI 10.1016/S0891-5520(05)70093-3; MCLAUGHLIN S, 1995, TRENDS BIOCHEM SCI, V20, P272, DOI 10.1016/S0968-0004(00)89042-8; Meyer TF, 1999, CLIN INFECT DIS, V28, P433, DOI 10.1086/515160; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Rosenshine I, 1996, EMBO J, V15, P2613, DOI 10.1002/j.1460-2075.1996.tb00621.x; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Soh JW, 1999, MOL CELL BIOL, V19, P1313; STINS MF, 1994, AM J PATHOL, V145, P1228; UNHANAND M, 1993, J PEDIATR-US, V122, P15, DOI 10.1016/S0022-3476(05)83480-8; Yarmola EG, 2001, J BIOL CHEM, V276, P22351, DOI 10.1074/jbc.M101457200; Zhao Y, 2000, AM J PHYSIOL-CELL PH, V279, pC1611, DOI 10.1152/ajpcell.2000.279.5.C1611	35	47	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12253	12262		10.1074/jbc.M110740200	http://dx.doi.org/10.1074/jbc.M110740200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805101	hybrid			2022-12-25	WOS:000174846400085
J	Walther, T; Olah, L; Harms, C; Maul, B; Bader, M; Hortnagl, H; Schultheiss, HP; Mies, G				Walther, T; Olah, L; Harms, C; Maul, B; Bader, M; Hortnagl, H; Schultheiss, HP; Mies, G			Ischemic injury in experimental stroke depends on angiotensin II	FASEB JOURNAL			English	Article						A II; focal cerebral ischemia; transgenic mice; penumbra; collateral flow	CEREBRAL-ARTERY OCCLUSION; CAPTOPRIL PREVENTION PROJECT; TRANSCRIPTION FACTORS; PROTEIN-SYNTHESIS; BLOOD-PRESSURE; BRAIN EDEMA; RECEPTOR; AT(1); MICE; BLOCKADE	Since pharmacological interactions of the renin-angiotensin system appear to alter the neurological outcome of stroke patients significantly, we examined the effect of elevated levels of angiotensin II and the role of its receptor subtype AT1 in brain infarction in transgenic mice after focal cerebral ischemia. Angiotensinogen-overexpressing and angiotensin receptor AT1 knockout mice underwent 1 h or 24 h permanent middle cerebral artery occlusion (MCAO). The current study revealed a much smaller penumbra size, i.e., brain tissue at risk, in angiotensinogen-overexpressing animals compared with their wild-type subgroup after 1 h MCAO, butanenlarged infarct size after 24 h. In contrast, a smaller lesion area of energy failure and a much larger penumbral area were found in AT1 knockout mice compared with wild-type litter-mates. Lower perfusion thresholds for ATP depletion and protein synthesis inhibition after MCAO in AT1-deficient mice and reduced cell damage in an in vitro model using embryonic neurons of AT1 knockout mice suggest injury mechanisms independent of arterial blood pressure. Our data, therefore, demonstrate a direct correlation between brain angiotensin II and the severity of ischemic injury in experimental stroke.	Free Univ Berlin, Dept Cariol & Pneumol, D-12200 Berlin, Germany; Max Planck Inst Neurol Res, Dept Expt Neurol, Cologne, Germany; Humboldt Univ, Fac Med Charite, Inst Pharmacol & Toxicol, D-1086 Berlin, Germany	Free University of Berlin; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walther, T (corresponding author), Free Univ Berlin, Univ Hosp Benjamin Franklin, Dept Cariol & Pneumol, Hindenburgdamm 30, D-12200 Berlin, Germany.	thomas.walther@ukbf.fu-berlin.de	Bader, Michael/K-2124-2013; Harms, Christoph/AAD-7895-2021; Harms, Christoph/HIK-2989-2022	Harms, Christoph/0000-0002-2063-2860; Bader, Michael/0000-0003-4780-4164				BARRY DI, 1982, J CEREBR BLOOD F MET, V2, P347, DOI 10.1038/jcbfm.1982.35; Blume A, 1998, NEUROSCI LETT, V241, P87, DOI 10.1016/S0304-3940(97)00957-9; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; Catto A, 1996, STROKE, V27, P435, DOI 10.1161/01.STR.27.3.435; Chung O, 1999, AM J HYPERTENS, V12, p150S, DOI 10.1016/S0895-7061(99)00218-6; Dai WJ, 1999, STROKE, V30, P2391, DOI 10.1161/01.STR.30.11.2391; de Gasparo M, 2000, PHARMACOL REV, V52, P415; Diep QN, 1999, HYPERTENSION, V34, P617, DOI 10.1161/01.HYP.34.4.617; Doi Y, 1997, ATHEROSCLEROSIS, V132, P145, DOI 10.1016/S0021-9150(97)00080-4; FERNANDEZ LA, 1994, J CARDIOVASC PHARM, V24, P937, DOI 10.1097/00005344-199424060-00011; FERNANDEZ LA, 1986, STROKE, V17, P82, DOI 10.1161/01.STR.17.1.82; Fournier A, 2000, NEPHROL DIAL TRANSPL, V15, P2, DOI 10.1093/ndt/15.1.2; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; Harms C, 2000, FASEB J, V14, P1814, DOI 10.1096/fj.99-0899com; Hata R, 1998, J CEREBR BLOOD F MET, V18, P367, DOI 10.1097/00004647-199804000-00004; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; Leri A, 1998, J CLIN INVEST, V101, P1326, DOI 10.1172/JCI316; Li DY, 1999, AM J PHYSIOL-HEART C, V276, pH786, DOI 10.1152/ajpheart.1999.276.3.H786; Lorell BH, 1999, AM J CARDIOL, V83, p48H; Maeda K, 1999, J CEREBR BLOOD F MET, V19, P1092, DOI 10.1097/00004647-199910000-00005; Maeda K, 2000, J CEREBR BLOOD F MET, V20, P10, DOI 10.1097/00004647-200001000-00003; Mark KS, 2000, PEPTIDES, V21, P1965, DOI 10.1016/S0196-9781(00)00346-6; MAUL B, 2001, FASEB J, DOI DOI 10.1096/F4.00-0797FJE; MIES G, 1993, NEUROSCI LETT, V155, P65, DOI 10.1016/0304-3940(93)90674-A; MIES G, 1991, J CEREBR BLOOD F MET, V11, P753, DOI 10.1038/jcbfm.1991.132; Nishimura Y, 2000, STROKE, V31, P2478, DOI 10.1161/01.STR.31.10.2478; Saavedra JM, 1999, REGUL PEPTIDES, V85, P31, DOI 10.1016/S0167-0115(99)00081-6; Scheidegger KJ, 1997, J VASC RES, V34, P436, DOI 10.1159/000159254; SPETH RC, 1985, P NATL ACAD SCI USA, V82, P6340, DOI 10.1073/pnas.82.18.6340; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pH667, DOI 10.1152/ajpheart.1991.261.3.H667; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; Yabuuchi F, 1999, FUND CLIN PHARMACOL, V13, P475, DOI 10.1111/j.1472-8206.1999.tb00006.x	37	92	99	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					169	176		10.1096/fj.01-0601com	http://dx.doi.org/10.1096/fj.01-0601com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818364				2022-12-25	WOS:000174203700021
J	Shou, J; Ali-Osman, F; Multani, AS; Pathak, S; Fedi, P; Srivenugopal, KS				Shou, J; Ali-Osman, F; Multani, AS; Pathak, S; Fedi, P; Srivenugopal, KS			Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA	ONCOGENE			English	Article						Wnt antagonist; apoptosis; p53; alkylating agents; brain tumors	MAMMARY EPITHELIAL-CELLS; BETA-CATENIN; DOWN-REGULATION; UP-REGULATION; P53-MEDIATED APOPTOSIS; MEDIATED TRANSCRIPTION; TELOMERASE ACTIVITY; SIGNALING PATHWAY; GLIOMA-CELLS; EXPRESSION	The human Dkk-1 (hDkk-1) gene, a transcriptional target of the p53 tumor suppressor, encodes a powerful inhibitor of the Wnt signaling pathway and regulates the spatial patterning/morphogenesis of the mammalian central nervous system. We investigated the p53-related functions of the hDkk-1 gene by studying its response to DNA damage and its modulation of apoptosis in human glioma cells. Various chemotherapeutic and other agents that induce DNA adducts and compromise its integrity (1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), cisplatin, H2O2 and UV rays) enhanced the expression of hDkk-1 significantly. The damage-induced increase in hDkk-1 mRNA levels occurred in many human tumor cell lines, irrespective of their p53 gene status. The human glioblastorna cell line, U87MG, which had undetectable hDkk-1 expression, was engineered to express moderate levels of the hDkk protein by stable transfection. The engineered cells did not show any morphological changes, but underwent marked apoptosis after ceramide treatment. Further, the DNA cross-linking drugs BCNU and cisplatin, but not the microtubule poison vincristine, induced significant cell death in U87MG/hDkk cells, and this was accompanied by altered Bcl-2/Bax expression and a reduction in the amount of telomere DNA as visualized by fluorescence in situ hybridization. These results show that hDkk-1 is a pro-apoptotic gene and suggest that it may play important roles in linking the oncogenic Wnt and p53 tumor suppressor pathways.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; CUNY Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Srivenugopal, KS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Box 64,1515 Holcombe Blvd, Houston, TX 77030 USA.	ksrivenu@mdanderson.org			NATIONAL CANCER INSTITUTE [R29CA074321, R01CA079644] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74321, CA 79644] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; Barker N, 2000, ADV CANCER RES, V77, P1; Burger AM, 1997, EUR J CANCER, V33, P638, DOI 10.1016/S0959-8049(96)00521-7; Burkhart BA, 1999, EXP CELL RES, V247, P168, DOI 10.1006/excr.1998.4345; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dale TC, 1998, BIOCHEM J, V329, P209; DELANGE T, 1995, TELOMERES, P265; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hayashi S, 1997, P NATL ACAD SCI USA, V94, P242, DOI 10.1073/pnas.94.1.242; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Howe LR, 1999, CANCER RES, V59, P1572; Ishibashi T, 1998, P NATL ACAD SCI USA, V95, P4219, DOI 10.1073/pnas.95.8.4219; Ishii K, 2000, EXP CELL RES, V255, P95, DOI 10.1006/excr.1999.4777; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; Kazanskaya O, 2000, DEVELOPMENT, V127, P4981; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MAO B, 2001, NATURE, V411, P255; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Molenaar M, 1999, INT J DEV BIOL, V43, P675; Moon RT, 1997, CELL, V88, P725, DOI 10.1016/S0092-8674(00)81915-7; Mukhopadhyay T, 1998, ONCOGENE, V17, P901, DOI 10.1038/sj.onc.1202011; Multani AS, 1999, ONCOL RES, V11, P455; Multani AS, 2000, NEOPLASIA, V2, P339, DOI 10.1038/sj.neo.7900105; Nagele RG, 2001, J CELL SCI, V114, P377; Naylor S, 2000, J CELL SCI, V113, P2129; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; PATHAK S, 1976, J REPROD MED, V17, P25; Polakis P, 2000, GENE DEV, V14, P1837; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sanchenkov A, 2001, JNCI-J NATL CANCER I, V93, P347, DOI 10.1093/jnci/93.5.347; Sawada M, 2001, ONCOGENE, V20, P1368, DOI 10.1038/sj.onc.1204207; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; Scotting PJ, 2000, CHILD NERV SYST, V16, P261, DOI 10.1007/s003810050511; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Srivenugopal K. S., 1996, Proceedings of the American Association for Cancer Research Annual Meeting, V37, P5; Srivenugopal KS, 1997, INT J ONCOL, V11, P1251; SRIVENUGOPAL KS, 1990, BIOCHEM PHARMACOL, V40, P473, DOI 10.1016/0006-2952(90)90545-V; TATE G, 1999, J BIOCH MOL BIOL BIO, V3, P239; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Turenne GA, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-12; Ueda Y, 2001, BIOCHEM BIOPH RES CO, V283, P327, DOI 10.1006/bbrc.2001.4788; VAN MEIR EG, 1994, CANCER RES, V54, P649; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wolf V, 1997, FEBS LETT, V417, P385, DOI 10.1016/S0014-5793(97)01324-0; WONG GT, 1994, MOL CELL BIOL, V14, P6278, DOI 10.1128/MCB.14.9.6278; Yoshimura S, 1997, J NEUROCHEM, V69, P713; Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4; Zinda MJ, 2001, BIOCHEM BIOPH RES CO, V280, P1107, DOI 10.1006/bbrc.2000.4248	69	139	148	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					878	889		10.1038/sj.onc.1205138	http://dx.doi.org/10.1038/sj.onc.1205138			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840333				2022-12-25	WOS:000173427100003
J	Wentzensen, N; Ridder, R; Klaes, R; Vinokurova, S; Schaefer, U; Doeberitz, MV				Wentzensen, N; Ridder, R; Klaes, R; Vinokurova, S; Schaefer, U; Doeberitz, MV			Characterization of viral-cellular fusion transcripts in a large series of HPV16 and 18 positive anogenital lesions	ONCOGENE			English	Article						human papillomavirus (HPV); E6-E7 oncogenes; integration; insertional mutagenesis; fusion transcripts	HUMAN-PAPILLOMAVIRUS TYPE-16; GENE-EXPRESSION; CERVICAL-CANCER; FRAGILE SITES; INTEGRATION SITES; SEQUENCES; DNA; E7; E6; ONCOGENES	Persistent high risk type human papillomavirus (HR - HPVs) infections induce dysplasia or cancer of the anogenital tract, most notably of the uterine cervix. The viral genome usually persists and replicates as an episomal molecule in early dysplasia, whereas in advanced dysplasia or cervical cancer HPV genomes are frequently integrated into the chromosomal DNA of the host cell. Previous studies suggested that modification of critical cellular sequences by integration of HPV genomes might significantly contribute to the neoplastic transformation of anogenital epithelia (insertional mutagenesis). This prompted us to characterize the integration loci of high risk HPV genomes in a large set of genital lesions. We amplified E6/E7 oncogene transcripts derived from integrated HPV16 and HPV18 genomes and characterized in detail the co-transcribed cellular sequences! of 64 primary genital lesions and five cervical cancer cell lines. Database analyses of the cellular parts of these fusion transcripts revealed 51 different integration loci, including 26 transcribed genes (14 known genes, 12 EST sequences with unknown gene function). Seventeen sequences showed similarity to repetitive elements, and 26 sequences did not show any database match other than genomic sequence. Chromosomal integration loci were distributed over almost all human chromosomes. Although we found HPV sequences integrated into cancer related genes and close to fragile sites, no preferential site or integration motif could be identified. These data demonstrate that target directed insertional mutagenesis might occur in few HPV-induced anogenital lesions, however, it is rather the exception than the rule.	Heidelberg Univ, Dept Pathol, Div Mol Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Doeberitz, MV (corresponding author), Heidelberg Univ, Dept Pathol, Div Mol Pathol, Im Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	knebel@med.uni-heidelberg.de	Wentzensen, Nicolas/AAG-8522-2019					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; BAKER CC, 1987, J VIROL, V61, P962, DOI 10.1128/JVI.61.4.962-971.1987; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; CANNIZZARO LA, 1988, CANCER GENET CYTOGEN, V33, P93, DOI 10.1016/0165-4608(88)90054-4; Carmody MW, 1996, MOL CELL PROBE, V10, P107, DOI 10.1006/mcpr.1996.0015; Chen M, 1996, NAT GENET, V12, P448, DOI 10.1038/ng0496-448; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DOEBERITZ MV, 1988, CANCER RES, V48, P3780; DOEBERITZ MV, 1991, P NATL ACAD SCI USA, V88, P1411, DOI 10.1073/pnas.88.4.1411; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2001, CANCER RES, V61, P2356; DURST M, 1992, VIROLOGY, V189, P132, DOI 10.1016/0042-6822(92)90688-L; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ELAWADY MK, 1987, VIROLOGY, V159, P389, DOI 10.1016/0042-6822(87)90478-8; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Hopper JL, 2001, BREAST CANCER RES, V3, P154, DOI 10.1186/bcr290; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; Kessis TD, 1996, ONCOGENE, V13, P427; Klaes R, 1999, CANCER RES, V59, P6132; Lazo PA, 1999, BRIT J CANCER, V80, P2008, DOI 10.1038/sj.bjc.6690635; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Luft F, 2001, INT J CANCER, V92, P9, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1144>3.0.CO;2-L; MacDonald JS, 1999, SEMIN ONCOL, V26, P556; MEYER T, 1995, BIOTECHNIQUES, V19, P632; MINCHEVA A, 1987, MED MICROBIOL IMMUN, V176, P245, DOI 10.1007/bf00190531; POPESCU NC, 1987, CYTOGENET CELL GENET, V44, P58, DOI 10.1159/000132342; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Reuter S, 1998, EMBO J, V17, P215, DOI 10.1093/emboj/17.1.215; Scheffner M, 1994, Curr Top Microbiol Immunol, V186, P83; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SHIRASAWA H, 1989, J GEN VIROL, V70, P1913, DOI 10.1099/0022-1317-70-7-1913; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH PP, 1992, GENE CHROMOSOME CANC, V5, P150, DOI 10.1002/gcc.2870050209; STOLER MH, 1992, HUM PATHOL, V23, P117, DOI 10.1016/0046-8177(92)90232-R; Sutherland GR, 1999, AM J HUM GENET, V64, P354, DOI 10.1086/302267; Thorland EC, 2000, CANCER RES, V60, P5916; Tu YZ, 1999, BBA-GENE STRUCT EXPR, V1489, P452, DOI 10.1016/S0167-4781(99)00197-9; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; zur Hausen H, 1999, SEMIN CANCER BIOL, V9, P405, DOI 10.1006/scbi.1999.0144	44	109	122	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					419	426		10.1038/sj.onc.1205104	http://dx.doi.org/10.1038/sj.onc.1205104			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821954				2022-12-25	WOS:000173311200010
J	David, A; Mabjeesh, N; Azar, I; Biton, S; Engel, S; Bernstein, J; Romano, J; Avidor, Y; Waks, T; Eshhar, Z; Langer, SZ; Lifschitz-Mercer, B; Matzkin, H; Rotman, G; Topoirik, A; Savitsky, K; Mintz, L				David, A; Mabjeesh, N; Azar, I; Biton, S; Engel, S; Bernstein, J; Romano, J; Avidor, Y; Waks, T; Eshhar, Z; Langer, SZ; Lifschitz-Mercer, B; Matzkin, H; Rotman, G; Topoirik, A; Savitsky, K; Mintz, L			Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONAL-REGULATION; MOLECULAR-CLONING; MESSENGER-RNA; ANTIGEN; EXPRESSION; TRANSCRIPT; FORM; IDENTIFICATION; DISTINCT; HGK-1	Prostate-specific antigen (PSA) and human kallikrein 2 are closely related products of the human kallikrein genes KLK3 and KLK2, respectively. Both PSA and human kallikrein 2 are produced and secreted in the prostate and have important applications in the diagnosis of prostate cancer. We report here the identification of unusual mRNA splice variants of the KLK2 and KLK3 genes that result from inclusion of intronic sequences adjacent to the first exon. The novel proteins encoded by these transcripts, named PSA-linked molecule (PSA-LM) and hK2-linked molecule (K-LM), share only the signal peptide with the original protein product of the respective gene. The mature proteins are entirely different and bear no similarity to the kallikrein family or to other proteins in the databases. As is the case with PSA, PSA-LM is expressed in the secretory epithelial cells of the prostate and is up-regulated in response to androgenic stimulation. A similar pattern of expression is suggested for K-LM.	Compugen Ltd, IL-69512 Tel Aviv, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Tel Aviv Sourasky Med Ctr, Dept Urol, IL-64239 Tel Aviv, Israel; Tel Aviv Sourasky Med Ctr, Dept Pathol, IL-64239 Tel Aviv, Israel; Compugen Inc, Jamesburg, NJ 08831 USA	Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Rotman, G (corresponding author), Compugen Ltd, 72 Pinchas Rosen St, IL-69512 Tel Aviv, Israel.	galitr@compugen.co.il						Bailleul B, 1997, NUCLEIC ACIDS RES, V25, P2752, DOI 10.1093/nar/25.14.2752; Black DL, 2000, CELL, V103, P367, DOI 10.1016/S0092-8674(00)00128-8; Carroll PR, 2001, UROLOGY, V57, P591, DOI 10.1016/S0090-4295(01)00913-X; Diamandis EP, 2000, CLIN CHEM, V46, P896; Diamandis EP, 1998, TRENDS ENDOCRIN MET, V9, P310, DOI 10.1016/S1043-2760(98)00082-4; Diamandis EP, 2000, TRENDS ENDOCRIN MET, V11, P54, DOI 10.1016/S1043-2760(99)00225-8; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; HENTTU P, 1990, INT J CANCER, V45, P654, DOI 10.1002/ijc.2910450414; Heuze N, 1999, CANCER RES, V59, P2820; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kumar A, 1997, CANCER RES, V57, P3111; LILJA H, 1993, WORLD J UROL, V11, P188; Liu XF, 1999, BIOCHEM BIOPH RES CO, V264, P833, DOI 10.1006/bbrc.1999.1595; Lou H, 1998, J ENDOCRINOL, V156, P401, DOI 10.1677/joe.0.1560401; Lovgren J, 1999, J ANDROL, V20, P348; Lovgren J, 1997, BIOCHEM BIOPH RES CO, V238, P549, DOI 10.1006/bbrc.1997.7333; LUNDWALL A, 1989, BIOCHEM BIOPH RES CO, V161, P1151, DOI 10.1016/0006-291X(89)91362-4; QUI S, 1990, J UROLOGY, V144, P1550; REIGMAN PHJ, 1989, BIOCHEM BIOPH RES CO, V159, P95, DOI 10.1016/0006-291X(89)92409-1; RIEGMAN PHJ, 1991, MOL CELL ENDOCRINOL, V76, P181, DOI 10.1016/0303-7207(91)90272-T; RIEGMAN PHJ, 1988, BIOCHEM BIOPH RES CO, V155, P181, DOI 10.1016/S0006-291X(88)81066-0; Rittenhouse HG, 1998, CRIT REV CL LAB SCI, V35, P275, DOI 10.1080/10408369891234219; *ROCH MOL BIOCH, 1996, NONR IN SIT HYBR APP, P34; Sun ZJ, 1997, NUCLEIC ACIDS RES, V25, P3318, DOI 10.1093/nar/25.16.3318; Tanaka T, 2000, CANCER RES, V60, P56; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; YOUNG CYF, 1992, BIOCHEMISTRY-US, V31, P818, DOI 10.1021/bi00118a026; YOUNG CYF, 1991, CANCER RES, V51, P3748	28	52	60	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18084	18090		10.1074/jbc.M102285200	http://dx.doi.org/10.1074/jbc.M102285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11834722	hybrid			2022-12-25	WOS:000175685100088
J	Chapeaurouge, A; Johansson, JS; Ferreira, ST				Chapeaurouge, A; Johansson, JS; Ferreira, ST			Folding of a de novo designed native-like four-helix bundle protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD DENATURATION; ARC REPRESSOR; PRESSURE; DISSOCIATION; INTERMEDIATE; STABILITY; ASSOCIATION; RECEPTOR; BINDING; MODEL	The folding of a model native-like dimeric four-helix bundle protein, (alpha(2))(2), was investigated using guanidine hydrochloride, hydrostatic pressure, and low temperature. Unfolding by guanidine hydrochloride followed by circular dichroism and intrinsic fluorescence spectroscopy revealed a highly cooperative transition between the native-like and unfolded states, with free energy of unfolding determined from CD data, DeltaG(unf) = 14.3 +/- 0.8 kcal/mol. However, CD and intrinsic fluorescence data were not superimposable, indicating the presence of an intermediate state during the folding transition. To stabilize the folding intermediate, we used hydrostatic pressure and low temperature. In both cases, dissociation of the dimeric native-like (alpha(2))(2) into folded monomers (alpha(2)) was observed, van't Hoff analysis of the low temperature experiments, assuming a two-state dimer 171-monomer transition, yielded a free energy of dissociation of (alpha(2))(2) of DeltaG(diss) = 11.4 +/- 0.4 kcal/mol, in good agreement with the free energy determined from pressure dissociation experiments (DeltaG(diss) = 10.5 +/- 0.1 kcal/mol). Binding of the hydrophobic fluorescent probe 4,4'-dianilino-1,1'-binaphthyl-5,5'-disulfonic acid (bis-ANS) to the pressure- and cold-dissociated states of (alpha(2))(2) indicated the existence of molten-globule monomers. In conclusion, we demonstrate that the folding pathway of (alpha(2))(2) can be described by a three-state transition including a monomeric molten globule-like state.	Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Penn, Johnson Res Fdn, Philadelphia, PA 19104 USA; Univ Penn, Dept Anesthesia, Philadelphia, PA 19104 USA	Universidade Federal do Rio de Janeiro; University of Pennsylvania; University of Pennsylvania	Chapeaurouge, A (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.		Ferreira, Sergio/AAZ-1576-2020	Ferreira, Sergio/0000-0001-7160-9866	NIGMS NIH HHS [GM55876] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chapeaurouge A, 2001, J BIOL CHEM, V276, P14861, DOI 10.1074/jbc.M009622200; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Gibney BR, 1997, J AM CHEM SOC, V119, P2323, DOI 10.1021/ja963561s; Gibney BR, 1997, BIOCHEMISTRY-US, V36, P2798, DOI 10.1021/bi9618225; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; Johansson JS, 1998, BIOCHEMISTRY-US, V37, P1421, DOI 10.1021/bi9721290; KAMTEKAR S, 1995, FASEB J, V9, P1013, DOI 10.1096/fasebj.9.11.7649401; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; PENG XD, 1993, P NATL ACAD SCI USA, V90, P1776, DOI 10.1073/pnas.90.5.1776; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; Ptitsyn Oleg B., 1992, P243; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; Richardson JM, 2000, BIOCHEMISTRY-US, V39, P11154, DOI 10.1021/bi000610b; Rietveld AWM, 1996, BIOCHEMISTRY-US, V35, P7743, DOI 10.1021/bi952118b; Rietveld AWM, 1998, BIOCHEMISTRY-US, V37, P933, DOI 10.1021/bi9721593; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; RUAN K, 1993, BIOCHEMISTRY-US, V32, P6293; RUAN KC, 1988, BIOCHEMISTRY-US, V27, P3295, DOI 10.1021/bi00409a026; Sauder JM, 1998, FOLD DES, V3, P293, DOI 10.1016/S1359-0278(98)00040-6; Sikorski A, 1998, BIOPHYS J, V75, P92, DOI 10.1016/S0006-3495(98)77497-1; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; Vis H, 1998, J AM CHEM SOC, V120, P6427, DOI 10.1021/ja9811187; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; WILSON C, 1994, STRUCTURE, V2, P713, DOI 10.1016/S0969-2126(00)00072-1; YORK SS, 1978, BIOCHEMISTRY-US, V21, P4480	29	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16478	16483		10.1074/jbc.M105232200	http://dx.doi.org/10.1074/jbc.M105232200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11832477	hybrid			2022-12-25	WOS:000175564500020
J	Kahns, S; Lykkobo, S; Jakobsen, LD; Nielsen, MS; Jensen, PH				Kahns, S; Lykkobo, S; Jakobsen, LD; Nielsen, MS; Jensen, PH			Caspase-mediated parkin cleavage in apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; ALZHEIMERS; NEURONS; DISEASE; GENE; ACTIVATION; MUTATIONS; IMMUNOREACTIVITY; IDENTIFICATION; INHIBITION	The parkin protein is important for the survival of the neurons that degenerate in Parkinson's disease as demonstrated by disease-causing lesions in the parkin gene. The Chinese hamster ovary and the SH-SY5Y cell line stably expressing recombinant human parkin combined with epitope-specific parkin antibodies were used to investigate the proteolytic processing of human parkin during apoptosis by immunoblotting. Parkin is cleaved during apoptosis induced by okadaic acid, staurosporine, and camptothecin, thereby generating a 38-kDa C-terminal fragment and a 12-kDa N-terminal fragment. The cleavage was not significantly affected by the disease-causing mutations K161N, G328E, T415N, and G430D and the polymorphism R366W. Parkin and its 38-kDa proteolytic fragment is preferentially associated with vesicles, thereby indicating that cleavage is a membrane-associated event. The proteolysis is sensitive to inhibitors of caspases. The cleavage site was mapped by site-directed mutagenesis of potential aspartic residues and revealed that mutation of Asp-126 alone abrogated the parkin cleavage. The tetrapeptide aldehyde LHTD-CHO, representing the amino acid sequence N-terminal to the putative cleavage site was an efficient inhibitor of parkin cleavage. This suggests that parkin function is compromised in neuropathological states associated with an increased caspase activation, thereby further adding to the cellular stress.	Aarhus Univ, Inst Med Biochem, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Mol & Struct Biol, DK-8000 Aarhus C, Denmark	Aarhus University; Aarhus University	Jensen, PH (corresponding author), Aarhus Univ, Inst Med Biochem, Bldg 170, DK-8000 Aarhus C, Denmark.	phj@biokemi.au.dk	Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Jensen, Poul Henning/0000-0002-4439-9020				Abbas N, 1999, HUM MOL GENET, V8, P567, DOI 10.1093/hmg/8.4.567; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gu WJ, 2000, J NEUROCHEM, V74, P1773, DOI 10.1046/j.1471-4159.2000.0741773.x; Hartmann A, 2000, P NATL ACAD SCI USA, V97, P2875, DOI 10.1073/pnas.040556597; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Horowitz JM, 1999, NEUROREPORT, V10, P3393, DOI 10.1097/00001756-199911080-00025; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; Krebs JF, 2000, BIOCHEMISTRY-US, V39, P16056, DOI 10.1021/bi001007w; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Rohn TT, 2001, AM J PATHOL, V158, P189, DOI 10.1016/S0002-9440(10)63957-0; Schierle GS, 1999, NAT MED, V5, P97, DOI 10.1038/4785; Selznick LA, 1999, J NEUROPATH EXP NEUR, V58, P1020, DOI 10.1097/00005072-199909000-00012; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Stadelmann C, 1999, AM J PATHOL, V155, P1459, DOI 10.1016/S0002-9440(10)65460-0; STEINNICKE HR, 2000, BIOCHIM BIOPHYS ACTA, V1477, P299; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Su JH, 2000, EXP NEUROL, V163, P9, DOI 10.1006/exnr.2000.7340; Su JH, 2001, BRAIN RES, V898, P350, DOI 10.1016/S0006-8993(01)02018-2; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; TSAI Y, 2000, SOC NEUR 30 ANN M ST; Wang M, 1999, ANN NEUROL, V45, P655, DOI 10.1002/1531-8249(199905)45:5<655::AID-ANA15>3.0.CO;2-G; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zarate-Lagunes M, 2001, J COMP NEUROL, V432, P184, DOI 10.1002/cne.1096; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	40	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15303	15308		10.1074/jbc.M111534200	http://dx.doi.org/10.1074/jbc.M111534200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839750	hybrid			2022-12-25	WOS:000175510400013
J	Wong, HC; Liu, GH; Zhang, YM; Rock, CO; Zheng, J				Wong, HC; Liu, GH; Zhang, YM; Rock, CO; Zheng, J			The solution structure of acyl carrier protein from Mycobacterium tuberculosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; FATTY-ACID BIOSYNTHESIS; 3-DIMENSIONAL STRUCTURE; MOLECULAR-GENETICS; DISTANCE GEOMETRY; ESCHERICHIA-COLI; MYCOLIC ACIDS; SYNTHASE; NMR; BACILLUS	Acyl carrier protein (ACP) performs the essential function of shuttling the intermediates between the enzymes that constitute the type II fatty acid synthase system. Mycobacterium tuberculosis is unique in producing extremely long mycolic acids, and tubercular ACP, AcpM, is also unique in possessing a longer carboxyl terminus than other ACPs. We determined the solution structure of AcpM using protein NMR spectroscopy to define the similarities and differences between AcpM and the typical structures. The amino-terminal region of the structure is well defined and consists of four helices arranged in a right-handed bundle held together by interhelical hydrophobic interactions similar to the structures of other bacterial ACPs. The unique carboxyl-terminal extension from helix]IV has a "melted down" feature, and the end of the molecule is a random coil. A comparison of the apo- and holo-forms of AcpM revealed that the 4-phosphopantetheine group oscillates between two states; in one it is bound to a hydrophobic groove on the surface of AcpM, and in another it is solvent-exposed. The similarity between AcpM and other ACPs reveals the conserved structural motif that is recognized by all type II enzymes. However, the function of the coil domain extending from helix IV to the carboxyl terminus remains enigmatic, but its structural characteristics suggest that it may interact with the very long chain intermediates in mycolic acid biosynthesis or control specific protein-protein interactions.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Zheng, J (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale St, Memphis, TN 38105 USA.	jie.zheng@stjude.org		Zheng, Jie/0000-0001-6524-6800	NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI49320] Funding Source: Medline; NIGMS NIH HHS [GM34496, GM61739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI049320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034496, R01GM061739, R01GM034496] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CRONAN JE, 1996, ESCHERICHIA COLI SAL, P616; Crump MP, 1997, BIOCHEMISTRY-US, V36, P6000, DOI 10.1021/bi970006+; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; GRZESIEK S, 1993, J BIOMOL NMR, V3, P185; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HARRIS NL, 1994, J MOL BIOL, V236, P1356, DOI 10.1016/0022-2836(94)90063-9; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; Kremer L, 2001, J BIOL CHEM, V276, P27967, DOI 10.1074/jbc.M103687200; Lukin JA, 1997, J BIOMOL NMR, V9, P151, DOI 10.1023/A:1018602220061; Mumenthaler C, 1997, J BIOMOL NMR, V10, P351, DOI 10.1023/A:1018383106236; OKADA M, 1994, J BACTERIOL, V176, P7456, DOI 10.1128/JB.176.24.7456-7461.1994; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Pellecchia M, 1999, NAT STRUCT BIOL, V6, P336; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Schaeffer ML, 2001, BBA-MOL CELL BIOL L, V1532, P67, DOI 10.1016/S1388-1981(01)00116-0; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; Tsai CJ, 1998, FOLD DES, V3, pR71, DOI 10.1016/S1359-0278(98)00032-7; Tsai CJ, 2001, PROTEINS, V44, P418, DOI 10.1002/prot.1107; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wong HC, 2000, NAT STRUCT BIOL, V7, P1178; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; XIA TH, 1993, XEASY ETH AUTOMATED; Xu GY, 2001, STRUCTURE, V9, P277, DOI 10.1016/S0969-2126(01)00586-X; Yuan Y, 1998, J BIOL CHEM, V273, P21282, DOI 10.1074/jbc.273.33.21282; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	39	104	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15874	15880		10.1074/jbc.M112300200	http://dx.doi.org/10.1074/jbc.M112300200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11825906	hybrid			2022-12-25	WOS:000175510400089
J	Balafanova, Z; Bolli, R; Zhang, J; Zheng, YT; Pass, JM; Bhatnagar, A; Tang, XL; Wang, OL; Cardwell, E; Ping, P				Balafanova, Z; Bolli, R; Zhang, J; Zheng, YT; Pass, JM; Bhatnagar, A; Tang, XL; Wang, OL; Cardwell, E; Ping, P			Nitric oxide (NO) induces nitration of protein kinase C epsilon (PKC epsilon), facilitating PKC epsilon translocation via enhanced PKC epsilon-RACK2 interactions - A novel mechanism of NO-triggered activation of PKC epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; CONSCIOUS RABBITS; INDUCED CARDIOPROTECTION; MYOCARDIAL-ISCHEMIA; SIGNAL-TRANSDUCTION; CARDIAC-FUNCTION; PEROXYNITRITE; PROTECTION; ISOZYMES; HEART	Activation of protein kinase C (PKC) epsilon by nitric oxide (NO) has been implicated in the development of cardio-protection. However, the cellular mechanisms underlying the activation of PKCepsilon by NO remain largely unknown. Nitration of protein tyrosine residues has been shown to alter functions of a variety of proteins, and NO-derived peroxynitrite is known as a strong nitrating agent. In this investigation, we demonstrate that NO donors promote translocation and activation of PKCepsilon in an NO- and peroxynitrite-dependent fashion. NO induces peroxynitrite-mediated tyrosine nitration of PKCepsilon in rabbit cardiomyocytes in vitro, and nitrotyrosine residues were also detected on PKCepsilon in vivo in the rabbit myocardium preconditioned with NO donors. Furthermore, coinununoprecipitation of PKCepsilon and its receptor for activated C kinase, RACK2, illustrated a peroxynitrite-dependent increase in PKCepsilon-RACK2 interactions in NO donor-treated cardiomyocytes. Moreover, using an enzyme-linked immunosorbent assay-based protein-protein interaction assay, PKCepsilon proteins treated with the peroxynitrite donor SIN-1 exhibited enhanced binding to RACK2 in an acellular environment. Our data demonstrate that post-translational modification of PKCepsilon by NO donors, namely nitration of PKCepsilon, facilitates its interaction with RACK2 and promotes translocation and activation of PKCepsilon. These findings offer a plausible novel mechanism by which NO activates the PKC signaling pathway.	Univ Louisville, Dept Physiol & Biophys, Louisville, KY 40202 USA; Dept Med, Div Cardiol, Louisville, KY 40202 USA	University of Louisville	Ping, P (corresponding author), Cardiol Res, 570 S Preston St,Baxter Bldg,Suite 122, Louisville, KY 40202 USA.	ping@ntr.net	Tang, Xian-Liang/L-5703-2015	Ping, Peipei/0000-0003-3583-3881	NHLBI NIH HHS [HL-68088, HL-63901, HL-55757, HL-43151, HL-65431] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068088, R01HL065431, R01HL063901, R37HL063901, R01HL055757, R01HL043151, R37HL055757] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Bolli R, 2001, J MOL CELL CARDIOL, V33, P1897, DOI 10.1006/jmcc.2001.1462; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cohen MV, 2000, ANNU REV PHYSIOL, V62, P79, DOI 10.1146/annurev.physiol.62.1.79; Cohen MV, 1995, CARDIOL REV, V3, P137; Csukai M, 1997, J BIOL CHEM, V272, P29200, DOI 10.1074/jbc.272.46.29200; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Di Stasi AMM, 1999, J NEUROCHEM, V73, P727; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HADDAD J, 1988, AM J PHYSIOL, V255, pC19, DOI 10.1152/ajpcell.1988.255.1.C19; Hellberg CB, 1998, BIOCHEM BIOPH RES CO, V252, P313, DOI 10.1006/bbrc.1998.9581; Ischiropoulos H, 1998, ARCH BIOCHEM BIOPHYS, V356, P1, DOI 10.1006/abbi.1998.0755; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Lane P, 1999, SEMIN NEPHROL, V19, P215; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Li RCX, 2000, AM J PHYSIOL-HEART C, V279, pH1679, DOI 10.1152/ajpheart.2000.279.4.H1679; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Liu HP, 2001, AM J PHYSIOL-HEART C, V281, pH191; Mackay K, 2001, J MOL CELL CARDIOL, V33, P1301, DOI 10.1006/jmcc.2001.1400; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; Nandagopal K, 2001, J PHARMACOL EXP THER, V297, P474; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nishio E, 1997, EUR J PHARMACOL, V339, P245, DOI 10.1016/S0014-2999(97)01368-X; Pass JM, 2001, AM J PHYSIOL-HEART C, V280, pH946, DOI 10.1152/ajpheart.2001.280.3.H946; Ping PP, 1999, CIRC RES, V84, P587, DOI 10.1161/01.RES.84.5.587; Ping PP, 2002, J CLIN INVEST, V109, P499, DOI 10.1172/JCI200213200; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Ping PP, 1999, AM J PHYSIOL-HEART C, V276, pH1468, DOI 10.1152/ajpheart.1999.276.5.H1468; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; Shinmura K, 1999, AM J PHYSIOL-HEART C, V277, pH2495, DOI 10.1152/ajpheart.1999.277.6.H2495; Shizukuda Y, 1999, CIRC RES, V85, P247, DOI 10.1161/01.RES.85.3.247; Souza JM, 1999, ARCH BIOCHEM BIOPHYS, V371, P169, DOI 10.1006/abbi.1999.1480; Takano H, 1998, CIRC RES, V83, P73, DOI 10.1161/01.RES.83.1.73; Tepperman BL, 1999, BRIT J PHARMACOL, V128, P1268, DOI 10.1038/sj.bjp.0702891; Vondriska TM, 2001, CIRC RES, V88, P1306, DOI 10.1161/hh1201.092994; Wooten MW, 2001, MOL CELL BIOL, V21, P8414, DOI 10.1128/MCB.21.24.8414-8427.2001; Xi L, 2000, TOXICOLOGY, V155, P37, DOI 10.1016/S0300-483X(00)00275-4; Yoshida K, 1999, BBA-MOL BASIS DIS, V1453, P230, DOI 10.1016/S0925-4439(98)00105-7; YTREHUS K, 1994, AM J PHYSIOL, V266, pH1145, DOI 10.1152/ajpheart.1994.266.3.H1145; Zhu S, 2000, AM J PHYSIOL-LUNG C, V278, pL1025, DOI 10.1152/ajplung.2000.278.5.L1025	52	138	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15021	15027		10.1074/jbc.M112451200	http://dx.doi.org/10.1074/jbc.M112451200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839754	hybrid			2022-12-25	WOS:000175203000085
J	Nield, J; Balsera, M; De Las Rivas, J; Barber, J				Nield, J; Balsera, M; De Las Rivas, J; Barber, J			Three-dimensional electron cryo-microscopy study of the extrinsic domains of the oxygen-evolving complex of spinach - Assignment of the PsbO protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANGANESE-STABILIZING PROTEIN; SYNECHOCYSTIS SP PCC-6803; PHOTOSYSTEM-II COMPLEXES; 33 KDA PROTEIN; SYNECHOCOCCUS-ELONGATUS; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; ANGULAR RECONSTITUTION; SECONDARY STRUCTURE; CRYSTAL-STRUCTURE	Three independent three-dimensional reconstructions of the spinach photosystem II-light-harvesting complex supercomplex were derived from single particle analyses of non-stained, vitrified samples imaged by electron microscopy. Each reconstruction was found to differ significantly in the composition of the lumenal oxygen-evolving complex extrinsic proteins. From difference mapping, aided by electron microscopy of negatively stained selectively washed samples, regions of density were assigned to the PsbO and PsbP/PsbQ proteins. Interpretation of the density assigned to the PsbO protein was explored using computer-aided structural predictions. PsbO is calculated to be mainly a beta-protein (38% beta) composed of two domains within an overall elongated shape (Pazos, F., Heredia, P., Valencia, A., and De Las Rivas, J. (2001) Proteins Struct. Funct. Genet. 45, 372-381). The positioning and fitting of the proposed structural model for the PsbO protein within the three-dimensional map indicated that there is a single copy per reaction center. Moreover, the structural model derived for PsbO, together with difference mapping, indicates that this protein stretches across the surface of the reaction center with its N- and C-terminal domains located toward the CP47 and CP43 side, respectively. This structural assignment is discussed in terms of the recent x-ray-derived cyanobacterial model of PSII (Zouni A., Witt, H.-T., Kern, J., Fromme, P., Krauss, N., Saenger: W., and Orth, P. (2001) Nature 409, 739-743).	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AY, England; CSIC, Inst Recursos Nat & Agrobiol, Salamanca 37071, Spain	Imperial College London; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Recursos Naturales y Agrobiologia de Sevilla (IRNAS)	Nield, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Wolfson Labs, London SW7 2AY, England.		De Las Rivas, Javier/G-5936-2014; Nield, Jon/C-5892-2013; Balsera, Monica/K-2877-2014	De Las Rivas, Javier/0000-0002-0984-9946; Nield, Jon/0000-0001-9983-0239; Balsera, Monica/0000-0002-5586-6050				AHMED A, 1995, FEBS LETT, V363, P65, DOI 10.1016/0014-5793(95)00282-E; Barber J, 1998, BBA-BIOENERGETICS, V1365, P269, DOI 10.1016/S0005-2728(98)00079-6; Barber J, 1997, PHYSIOL PLANTARUM, V100, P817, DOI 10.1034/j.1399-3054.1997.1000408.x; BOEKEMA EJ, 1995, P NATL ACAD SCI USA, V92, P175, DOI 10.1073/pnas.92.1.175; Boekema EJ, 1998, EUR J BIOCHEM, V252, P268, DOI 10.1046/j.1432-1327.1998.2520268.x; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; Bricker TM, 1998, PHOTOSYNTH RES, V56, P157, DOI 10.1023/A:1006068615220; De Las Rivas J, 1999, PHOTOSYNTH RES, V61, P11, DOI 10.1023/A:1006265816104; DEBUS RJ, 1992, BIOCHIM BIOPHYS ACTA, V1102, P269, DOI 10.1016/0005-2728(92)90133-M; DINER BA, 1996, OXYGENIC PHOTOSYNTHE, P213; Frazao C, 2001, J BIOL INORG CHEM, V6, P324, DOI 10.1007/s007750100208; Hankamer B, 1997, ANNU REV PLANT PHYS, V48, P641, DOI 10.1146/annurev.arplant.48.1.641; Hankamer B, 1999, NAT STRUCT BIOL, V6, P560, DOI 10.1038/9341; Hankamer B, 2001, J STRUCT BIOL, V135, P262, DOI 10.1006/jsbi.2001.4405; HE WZ, 1991, THESIS U LONDON UK; Hutchison RS, 1998, BIOCHEMISTRY-US, V37, P5643, DOI 10.1021/bi9724467; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P404, DOI 10.1021/bi981847z; MAYES SR, 1991, BIOCHIM BIOPHYS ACTA, V1060, P1, DOI 10.1016/S0005-2728(05)80112-4; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; Motoki A, 1998, BBA-BIOENERGETICS, V1365, P492, DOI 10.1016/S0005-2728(98)00102-9; Nield J, 2000, J BIOL CHEM, V275, P27940; Nield J, 2000, NAT STRUCT BIOL, V7, P44; ODOM WR, 1992, BIOCHEMISTRY-US, V31, P5616, DOI 10.1021/bi00139a027; Pazos F, 2001, PROTEINS, V45, P372, DOI 10.1002/prot.10012; PHILBRICK JB, 1991, J BIOL CHEM, V266, P13370; Rhee KH, 1998, NATURE, V396, P283, DOI 10.1038/24421; SCHATZ M, 1995, J STRUCT BIOL, V114, P28, DOI 10.1006/jsbi.1995.1003; SEIBERT M, 1987, J CELL BIOL, V105, P2257, DOI 10.1083/jcb.105.5.2257; SEIDLER A, 1996, BIOCHIM BIOPHYS ACTA, V1277, P33; SHEN JR, 1995, BIOCHEMISTRY-US, V34, P12661, DOI 10.1021/bi00039a023; Shutova T, 1997, BIOCHEMISTRY-US, V36, P6350, DOI 10.1021/bi963115h; Shutova T, 2000, FEBS LETT, V467, P137, DOI 10.1016/S0014-5793(00)01115-7; SIMPSON DJ, 1986, CARLSBERG RES COMMUN, V51, P467, DOI 10.1007/BF02907319; SPETEA C, 2001, P 12 INT C PHOT BRIS; VANHEEL M, 1987, ULTRAMICROSCOPY, V21, P111, DOI 10.1016/0304-3991(87)90078-7; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; XU Q, 1994, BBA-BIOENERGETICS, V1188, P427, DOI 10.1016/0005-2728(94)90065-5; ZHANG HM, 1995, PHOTOSYNTHESIS LIGHT, V2, P447; Zhang LX, 1996, PHOTOSYNTH RES, V48, P379, DOI 10.1007/BF00029470; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589; Zubrzycki IZ, 1998, BIOCHEMISTRY-US, V37, P13553, DOI 10.1021/bi981469y	42	48	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15006	15012		10.1074/jbc.M110549200	http://dx.doi.org/10.1074/jbc.M110549200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11815610	hybrid			2022-12-25	WOS:000175203000083
J	Gradl, D; Konig, A; Wedlich, D				Gradl, D; Konig, A; Wedlich, D			Functional diversity of Xenopus lymphoid enhancer factor/T-cell factor transcription factors relies on combinations of activating and repressing elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCR-ALPHA ENHANCER; NEURAL CREST INDUCTION; BETA-CATENIN-BINDING; AXIS FORMATION; SPEMANNS ORGANIZER; INJECTED XWNT-8; FACTOR XTCF-4; WNT PATHWAYS; FACTOR LEF-1; EMBRYOS	Lymphoid enhancer factor/T-cell factor (LEF/TCF) high mobility group box transcription factors are the nuclear transducers of the Wnt/beta-catenin signaling cascade. In Xenopus, three members of the LEF/TCF family, XLEF-1, XTCF-3, and XTCF-4, with distinct but partially overlapping expression patterns have been identified. The individual Xenopus LEF/TCF family members differ extremely in their properties of target gene regulation. We observed that in contrast to LEF-1, neither XTCF-3 nor XTCF-4 can induce secondary axis formation upon ventral overexpression in Xenopus embryos. To identify functional motifs within the LEF/TCF transcription factors responsible for target gene activation or repression, we created various mutants and a set of XLEF-1/XTCF-3 chimeras. In overexpression studies, we asked whether these constructs can mimic an activated Wnt/beta-catenin pathway and lead to the formation of a secondary body axis. In addition, we examined their capacity to rescue a loss-of-function phenotype given by dominant negative LEF-1 expression. We further analyzed their ability to directly activate target genes in reporter gene assays using the LEF/TCF target promoters, siamois and fibronectin. We found that a region homologous to exon IVa of human TCF-1 is an activating element. This is flanked by two small repressing motifs, LVPQ and SXXSS. Our findings implicate that the motifs identified here play an essential role in determining cell type-specific activity of LEF/TCF transcription factors.	Univ Karlsruhe, Inst Zool 2, D-76128 Karlsruhe, Germany; Univ Ulm, Biochem Abt, D-89081 Ulm, Germany	Helmholtz Association; Karlsruhe Institute of Technology; Ulm University	Gradl, D (corresponding author), Univ Karlsruhe, Inst Zool 2, POB 6980, D-76128 Karlsruhe, Germany.							Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brault V, 2001, DEVELOPMENT, V128, P1253; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Chang CB, 1998, DEV BIOL, V194, P129, DOI 10.1006/dbio.1997.8820; Dorsky RI, 1998, NATURE, V396, P370, DOI 10.1038/24620; Duval A, 2000, CANCER RES, V60, P3872; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Geis K, 1998, DEV GENES EVOL, V207, P471, DOI 10.1007/s004270050138; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Gradl D, 1999, MOL CELL BIOL, V19, P5576; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Itoh K, 1999, GENE DEV, V13, P2328, DOI 10.1101/gad.13.17.2328; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274; Konig A, 2000, MECH DEVELOP, V93, P211, DOI 10.1016/S0925-4773(00)00266-5; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; LaBonne C, 1998, DEVELOPMENT, V125, P2403; LARABELL CA, 1997, J CELL BIOL, V136, P1; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Molenaar M, 1998, MECH DEVELOP, V75, P151, DOI 10.1016/S0925-4773(98)00085-9; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Omer CA, 1999, BIOCHEM BIOPH RES CO, V256, P584, DOI 10.1006/bbrc.1999.0379; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Pukrop T, 2001, J BIOL CHEM, V276, P8968, DOI 10.1074/jbc.M007533200; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; RUPP RAW, 1991, CELL, V65, P927, DOI 10.1016/0092-8674(91)90545-A; SaintJeannet JP, 1997, P NATL ACAD SCI USA, V94, P13713, DOI 10.1073/pnas.94.25.13713; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STEINBEISSER H, 1993, DEVELOPMENT, V118, P499; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867	51	51	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14159	14171		10.1074/jbc.M107055200	http://dx.doi.org/10.1074/jbc.M107055200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821382	hybrid			2022-12-25	WOS:000175096000105
J	Wu, XY; Babnigg, G; Zagranichnaya, T; Villereal, ML				Wu, XY; Babnigg, G; Zagranichnaya, T; Villereal, ML			The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CA2+ ENTRY; STORE-OPERATED CHANNEL; <CA2+>(I) OSCILLATIONS; FUNCTIONAL EXPRESSION; CATION CHANNELS; INTRACELLULAR CA2+; DROSOPHILA TRP; HUMAN HOMOLOG; RECEPTOR; DEPLETION	We utilized 2-aminoethyoxydiphenyl borane, an agent that blocks store-operated Ca2+ entry, as well as an antisense approach to characterize endogenous Ca2+ entry pathways in HEK-293 cells. The thapsigargin- and carbachol-induced, but not the 1-oleolyl-2-acytyl-sn-glycerol (OAG).induced, entry was blocked by 2-aminoethyoxydiphenyl borane. Both reverse transcriptase-PCR and Western blot analyses demonstrated endogenous expression for HTRP1, HTRP3, and HTRP4 and specific suppression of mRNA levels and Trp protein levels in cells stably expressing antisense constructs. Expression of HTRP4 antisense inhibited 35% of the carbachol (CCh)-stimulated Ba2+ entry and 46% of the OAG-stimulated Sr2+ entry but in contrast had no effect on the thapsigargin-stimulated Ba2+ or Sr2+ entry. HTRP3 antisense reduced, while HTRP1 antisense had no effect on, OAG-induced Sr2+ entry. Of greater importance, HTRP4 antisense expression, but not HTRP3 antisense expression, blocked the sustained Ca2+ oscillations produced by low doses of CCh (15 muM), arguing that receptor-stimulated rather than store-operated channels are involved in these sustained oscillations. HTRP4 antisense also inhibited 75% of the arachidonic acid-induced Ca2+ entry. In summary, these data suggest that HTRP4 proteins in HEK-293 cells, differing from HTRP3 and HTRP1 proteins, do not serve as functional subunits of store-operated channels but do function as subunits for CCh- and OAG-stimulated channels. Furthermore, evidence is provided for the first time for the involvement of a Trp isoform (HTRP4) in the formation of the channel responsible for both arachidonic acid-induced Ca2+ entry and the Ca2+ entry needed to sustain long term Ca2+ oscillations induced by low doses of carbachol.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Argonne Natl Lab, Argonne, IL 60439 USA	University of Chicago; United States Department of Energy (DOE); Argonne National Laboratory	Villereal, ML (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Abbott 532,947 E 58th St, Chicago, IL 60637 USA.	mitch@drugs.bsd.uchicago.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054500] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLBRITTON NL, 1993, CELL CALCIUM, V14, P691, DOI 10.1016/0143-4160(93)90095-N; Babnigg G, 2000, CELL CALCIUM, V27, P61, DOI 10.1054/ceca.1999.0093; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; FEICHEL M, 2001, NAT CELL BIOL, V3, P121; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kinoshita M, 2000, CELL CALCIUM, V28, P151, DOI 10.1054/ceca.2000.0143; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; MARTIN SC, 1994, FEBS LETT, V352, P32, DOI 10.1016/0014-5793(94)00913-9; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; McKay RR, 2000, BIOCHEM J, V351, P735, DOI 10.1042/0264-6021:3510735; Mery L, 2001, FEBS LETT, V487, P377, DOI 10.1016/S0014-5793(00)02362-0; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Missiaen L, 2000, CELL CALCIUM, V28, P1, DOI 10.1054/ceca.2000.0131; Mizuno N, 1999, MOL BRAIN RES, V64, P41, DOI 10.1016/S0169-328X(98)00296-4; Montell C, 1998, CURR OPIN NEUROBIOL, V8, P389, DOI 10.1016/S0959-4388(98)80066-4; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Preuss KD, 1997, BIOCHEM BIOPH RES CO, V240, P167, DOI 10.1006/bbrc.1997.7528; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RANGANATHAN R, 1991, NATURE, V354, P230, DOI 10.1038/354230a0; SAGE SO, 1989, J BIOL CHEM, V264, P6; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Schaefer M, 2002, J BIOL CHEM, V277, P3752, DOI 10.1074/jbc.M109850200; Scott K, 1998, CURR OPIN NEUROBIOL, V8, P383, DOI 10.1016/S0959-4388(98)80065-2; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Sinkins WG, 1998, BIOCHEM J, V331, P331, DOI 10.1042/bj3310331; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; THOMAS AP, 1991, CELL CALCIUM, V12, P111, DOI 10.1016/0143-4160(91)90013-5; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Warnat J, 1999, J PHYSIOL-LONDON, V518, P631, DOI 10.1111/j.1469-7793.1999.0631p.x; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	56	81	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13597	13608		10.1074/jbc.M110881200	http://dx.doi.org/10.1074/jbc.M110881200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830588	hybrid			2022-12-25	WOS:000175096000035
J	Cook, KK; Fadool, DA				Cook, KK; Fadool, DA			Two adaptor proteins differentially modulate the phosphorylation and biophysics of Kv1.3 ion channel by Src kinase.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; K+ CHANNELS; TYROSINE KINASE; SH2 DOMAIN; OLFACTORY-BULB; INSULIN; EXPRESSION; FAMILY; BRAIN; TRANSFORMATION	The Shaker family K+ channel protein, Kv1.3, is tyrosine phosphorylated by v-Src kinase at Tyr(137) and Tyr(449) to modulate current magnitude and kinetic properties. Despite two proline rich sequences and these phosphotyrosines contained in the carboxyl and amino terminals of the channel, v-Src kinase fails to co-immunoprecipitate with Kv1.3 as expressed in HEK 293 cells, indicating a lack of direct Src homology 3- or Src homology 2-mediated protein-protein interaction between the channel and the kinase. We show that the adaptor proteins, n-Shc and Grb10, are expressed in the olfactory bulb, a region of the brain where Kv1.3 is highly expressed. In HEK 293 cells, co-expression of Kv1.3 plus v-Src with Grb10 causes a decrease in v-Src-induced Kv1.3 tyrosine phosphorylation and a reversal of v-Src-induced Kv1.3 current suppression, increase in inactivation time constant (tau(inact)), and disruption of cumulative inactivation properties. Co-expression of Kv1.3 plus v-Src with n-Shc did not significantly alter v-Src-induced Kv1.3 current suppression but reversed v-Src induced increased tau(inact) and restored the right-shifted voltage at half-activation (V-1/2) induced by v-Src. The v-Src-induced shift in V and increased tau(inact) was retained when Tyr(220), Tyr(221), and Tyr(304) in the CH domain of n-Shc were mutated to Phe (triple She mutant) but was reversed back to control values when either wildtype She or the family member Sck, which is not a substrate for Src kinase, was substituted for the triple She mutant. Thus the portion of the CH domain that includes Tyr(220), Tyr(221), and Tyr(304) may regulate a shift in Kv1.3 voltage dependence and inactivation kinetics produced by n-Shc in the presence of v-Src. Collectively these data indicate that Grb10 and n-Shc adaptor molecules differentially modulate the degree of Kv1.3 tyrosine phosphorylation, the channel's biophysical properties, and the physical complexes associated with Kv1.3 in the presence of Src kinase.	Florida State Univ, Dept Biol Sci, Program Neurosci & Mol Biophys, Biomed Res Facil 214, Tallahassee, FL 32306 USA	State University System of Florida; Florida State University	Fadool, DA (corresponding author), Florida State Univ, Dept Biol Sci, Program Neurosci & Mol Biophys, Biomed Res Facil 214, Tallahassee, FL 32306 USA.	cook@groton.pfizer.com; dfadool@bio.fsu.edu			NIDCD NIH HHS [R29 DC003387, R01 DC003387, R29 DC003387-05, R29 DC 03387] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003387, R01DC003387] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Arnold DB, 1999, NEURON, V23, P149, DOI 10.1016/S0896-6273(00)80761-8; Balkowiec A, 2000, J NEUROSCI, V20, P7417, DOI 10.1523/jneurosci.20-19-07417.2000; Bence-Hanulec KK, 2000, NEURON, V27, P121, DOI 10.1016/S0896-6273(00)00014-3; Biggin PC, 2000, CURR OPIN STRUC BIOL, V10, P456, DOI 10.1016/S0959-440X(00)00114-7; Bowlby MR, 1997, J GEN PHYSIOL, V110, P601, DOI 10.1085/jgp.110.5.601; Bradshaw JM, 1999, J MOL BIOL, V293, P971, DOI 10.1006/jmbi.1999.3190; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Fadool DA, 1998, J NEUROSCI, V18, P6126; Fadool DA, 1997, J NEUROPHYSIOL, V78, P1563, DOI 10.1152/jn.1997.78.3.1563; Fadool DA, 2000, J NEUROPHYSIOL, V83, P2332, DOI 10.1152/jn.2000.83.4.2332; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hanada T, 1997, J BIOL CHEM, V272, P26899, DOI 10.1074/jbc.272.43.26899; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Ishihara H, 1998, BIOCHEM BIOPH RES CO, V252, P139, DOI 10.1006/bbrc.1998.9621; Ishihara H, 1997, J BIOL CHEM, V272, P9581; Joiner WJ, 2001, J BIOL CHEM, V276, P37980; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KUES WA, 1992, EUR J NEUROSCI, V4, P1296, DOI 10.1111/j.1460-9568.1992.tb00155.x; Langlais P, 2000, ONCOGENE, V19, P2895, DOI 10.1038/sj.onc.1203616; Liao GY, 2000, J NEUROCHEM, V75, P282, DOI 10.1046/j.1471-4159.2000.0750282.x; Magoski NS, 2002, J NEUROSCI, V22, P1; MAROM S, 1994, BIOPHYS J, V67, P579, DOI 10.1016/S0006-3495(94)80517-X; MAROM S, 1993, RECEPTOR CHANNEL, V1, P81; MARONEY AC, 1992, ONCOGENE, V7, P1207; MARSHALL J, 1995, NEURON, V14, P211, DOI 10.1016/0896-6273(95)90279-1; Nakamura T, 1996, ONCOGENE, V13, P1111; Nakamura T, 1998, J BIOL CHEM, V273, P6960, DOI 10.1074/jbc.273.12.6960; Nehring RB, 2000, J NEUROSCI, V20, P156, DOI 10.1523/JNEUROSCI.20-01-00156.2000; Nitabach MN, 2001, P NATL ACAD SCI USA, V98, P705, DOI 10.1073/pnas.031446198; OOI J, 1995, ONCOGENE, V10, P1621; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Sambrook J, 2001, MOL CLONING LAB MANU; Sato K, 1997, BIOCHEM BIOPH RES CO, V240, P399, DOI 10.1006/bbrc.1997.7667; Scannevin RH, 1997, BIOCHEM BIOPH RES CO, V232, P585, DOI 10.1006/bbrc.1997.6333; SENFTEN M, 1995, ONCOGENE, V10, P199; SHI GY, 1994, J BIOL CHEM, V269, P23204; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Tiffany AM, 2000, J CELL BIOL, V148, P147, DOI 10.1083/jcb.148.1.147; Tongiorgi E, 1997, J NEUROSCI, V17, P9492; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; WHITE MF, 1994, J BIOL CHEM, V269, P1; Yi BA, 2000, NEURON, V27, P423, DOI 10.1016/S0896-6273(00)00052-0	50	64	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13268	13280		10.1074/jbc.M108898200	http://dx.doi.org/10.1074/jbc.M108898200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812778	hybrid, Green Accepted			2022-12-25	WOS:000175036300097
J	Garcia-Diaz, M; Bebenek, K; Sabariegos, R; Dominguez, O; Rodriguez, J; Kirchhoff, T; Garcia-Palomero, E; Picher, AJ; Juarez, R; Ruiz, JF; Kunkel, TA; Blanco, L				Garcia-Diaz, M; Bebenek, K; Sabariegos, R; Dominguez, O; Rodriguez, J; Kirchhoff, T; Garcia-Palomero, E; Picher, AJ; Juarez, R; Ruiz, JF; Kunkel, TA; Blanco, L			DNA polymerase lambda, a novel DNA repair enzyme in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CRYSTAL-STRUCTURES; BETA; PROTEIN; IDENTIFICATION; PURIFICATION; MUTAGENESIS; EXPRESSION; FIDELITY; BINDING	DNA polymerase lambda (pol lambda) is a novel family X DNA polymerase that has been suggested to play a role In meiotic recombination and DNA repair. The recent demonstration of an intrinsic 5'-deoxyribose-5-phosphate lyase activity in pol lambda supports a function of this enzyme in base excision repair. However, the biochemical properties of the polymerization activity of this enzyme are still largely unknown. We have cloned and purified human pol lambda to homogeneity in a soluble and active form, and we present here a biochemical description of its polymerization features. In support of a role in DNA repair, pol lambda inserts nucleotides in a DNA template-dependent manner and is processive in small gaps containing a 5'-phosphate group. These properties, together with its nucleotide insertion fidelity parameters and lack of proofreading activity, indicate that pol lambda is a novel beta-like DNA polymerase. However, the high affinity of polk lambda for dNTPs (37-fold over pol beta) is consistent with its possible involvement in DNA, transactions occurring under low cellular levels of dNTPs. This suggests that, despite their similarities, pol beta and pol lambda have nonredundant in vivo functions.	UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain; NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Blanco, L (corresponding author), UAM, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 28049, Spain.	lblanco@cbm.uam.es	Sabariegos, Rosario/K-5169-2014; Dominguez, Orlando/M-7515-2018; Kunkel, Thomas A./D-5088-2019; Ruiz, Jose F./A-1651-2015; Ruiz, Jose F./P-2830-2019; Blanco, Luis/I-1848-2015	Sabariegos, Rosario/0000-0003-3005-7588; Kunkel, Thomas A./0000-0002-9900-1788; Ruiz, Jose F./0000-0002-0039-3524; Ruiz, Jose F./0000-0002-0039-3524; Kirchhoff, Tomas/0000-0002-9055-2364				Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1609, DOI 10.1093/nar/27.7.1609; Beard WA, 2000, MUTAT RES-DNA REPAIR, V460, P231, DOI 10.1016/S0921-8777(00)00029-X; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; Benedict CL, 2000, IMMUNOL REV, V175, P150, DOI 10.1034/j.1600-065X.2000.017518.x; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; Brautigam CA, 1998, CURR OPIN STRUC BIOL, V8, P54, DOI 10.1016/S0959-440X(98)80010-9; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; CORNISHBOWDEN A, 1991, TRENDS BIOCHEM SCI, V16, P281, DOI 10.1016/0968-0004(91)90115-C; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HIROSE F, 1989, EXP CELL RES, V181, P169, DOI 10.1016/0014-4827(89)90191-2; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; ITO J, 1991, NUCLEIC ACIDS RES, V19, P4045, DOI 10.1093/nar/19.15.4045; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; KROLL DJ, 1993, DNA CELL BIOL, V12, P441, DOI 10.1089/dna.1993.12.441; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lavrik OI, 1996, J BIOL CHEM, V271, P21891, DOI 10.1074/jbc.271.36.21891; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Makiniemi M, 2001, J BIOL CHEM, V276, P30399, DOI 10.1074/jbc.M102245200; MILLER MR, 1982, J BIOL CHEM, V257, P204; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Moore DJ, 2000, P NATL ACAD SCI USA, V97, P13649, DOI 10.1073/pnas.250477597; Nagasawa K, 2000, J BIOL CHEM, V275, P31233, DOI 10.1074/jbc.M004263200; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Oliveros M, 1997, J BIOL CHEM, V272, P30899, DOI 10.1074/jbc.272.49.30899; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12778, DOI 10.1021/bi960790i; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PRASAD R, 1993, NUCLEIC ACIDS RES, V21, P5301, DOI 10.1093/nar/21.23.5301; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Steitz TA, 1999, J BIOL CHEM, V274, P17395, DOI 10.1074/jbc.274.25.17395; Wang ZH, 2000, SCIENCE, V289, P774, DOI 10.1126/science.289.5480.774	42	169	176	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13184	13191		10.1074/jbc.M111601200	http://dx.doi.org/10.1074/jbc.M111601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821417	hybrid, Green Published			2022-12-25	WOS:000175036300088
J	Iwai, T; Inaba, N; Naundorf, A; Zhang, Y; Gotoh, M; Iwasaki, H; Kudo, T; Togayachi, A; Ishizuka, Y; Nakanishi, H; Narimatsu, H				Iwai, T; Inaba, N; Naundorf, A; Zhang, Y; Gotoh, M; Iwasaki, H; Kudo, T; Togayachi, A; Ishizuka, Y; Nakanishi, H; Narimatsu, H			Molecular cloning and characterization of a novel UDP-GlcNAc: GalNAc-peptide,beta 1,3-N-acetylglucosaminyltransferase (beta 3Gn-T6), an enzyme synthesizing the core 3 structure of O-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE; ALPHA-D-GALACTOSAMINE; WEIGHT SALIVARY MUCIN; SIALYL LEWIS(X); L-SELECTIN; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; NEUTRAL OLIGOSACCHARIDES; EXPRESSION CLONING; CANCER METASTASIS; GASTRIC MUCIN	The core 3 structure of the O-glycan, GlcNAcbeta1-3Gal-NAcalpha1-serine/threonine, an important precursor in the biosynthesis of mucin-type glycoproteins, is synthesized by UDP-N-acetylglucosamine:GalNAc-peptide beta1,3-N-acetylglucosaminyltransferase (beta3Gn-T; core 3 synthase). The core 3 structure is restricted in its occurrence to mucins from specific tissues such as the stomach, small intestine, and colon. A partial sequence encoding a novel member of the human beta3Gn-T family was found in one of the data bases. We cloned a complementary DNA of this gene and named it beta3Gn-T6. The putative amino acid sequence of beta3Gn-T6 retains the beta3Gn-T motifs and is predicted to comprise a typical type H membrane protein. The soluble form of beta3Gn-T6 expressed in insect cells showed beta3Gn-T activity toward GalNAcalpha-p-nitrophenyl and GalNAcalpha1-serine/threonine. The beta1,3-linkage between GlcNAc and GalNAc of the enzyme reaction product was confirmed by high performance liquid chromatography and NMR analyses. beta3Gn-T6 effectively transferred a GlcNAc to the GalNAc residue on MUC1 mucin, resulting in the synthesis of a core 3 structure. Real time PCR analysis revealed that the beta3Gn-T6 transcript was restricted in its distribution, mainly to the stomach, colon, and small intestine. We concluded that beta3Gn-T6 is the most logical candidate for the core 3 synthase, which plays an important role in the synthesis of mucin-type O-glycans in digestive organs.	Nat Inst AIST, Lab Gene Funct Anal, Inst Mol & Cell Biol, Open Space Lab, Tsukuba, Ibaraki 3058568, Japan; AIST, Biol Informat Res Ctr, Mol Recognit Team, Tsukuba, Ibaraki 3058568, Japan; JGS Japan Genome Solut Inc, Hachioji, Tokyo 1920031, Japan; Mitsui Chem Inc, Chiyoda Ku, Tokyo 1006070, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Mitsui Chemicals	Narimatsu, H (corresponding author), Nat Inst AIST, Lab Gene Funct Anal, Inst Mol & Cell Biol, Open Space Lab, C2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Narimatsu, Hisashi/M-4757-2018; Yang, Fang/AAF-3024-2019; Togayachi, Akira/M-4144-2018	Narimatsu, Hisashi/0000-0002-8402-133X; Togayachi, Akira/0000-0003-3600-9149				Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; BROCKHAUSEN I, 1985, BIOCHEMISTRY-US, V24, P1866, DOI 10.1021/bi00329a010; BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x; Capon C, 2001, BIOCHEM J, V358, P657, DOI 10.1042/bj3580657; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Fukuda M, 1996, CANCER RES, V56, P2237; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kim Young S., 1998, Keio Journal of Medicine, V47, P10; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; MACK DR, 1992, GASTROENTEROLOGY, V102, P1199; Nakamori S, 1997, DIS COLON RECTUM, V40, P420, DOI 10.1007/BF02258386; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; PHILLIPS TE, 1993, PROSTAG LEUKOTR ESS, V48, P423, DOI 10.1016/0952-3278(93)90047-Z; PILLER F, 1988, J BIOL CHEM, V263, P15146; Porchet Nicole, 1999, Journal de la Societe de Biologie, V193, P85; Prakobphol A, 1998, BIOCHEMISTRY-US, V37, P4916, DOI 10.1021/bi972612a; Prakobphol A, 1999, BIOCHEMISTRY-US, V38, P6817, DOI 10.1021/bi990145m; SASAKI K, 1993, J BIOL CHEM, V268, P22782; Schwientek T, 1999, J BIOL CHEM, V274, P4504, DOI 10.1074/jbc.274.8.4504; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SLOMIANY A, 1984, J BIOL CHEM, V259, P4743; SLOMIANY BL, 1984, J BIOL CHEM, V259, P2863; SNYDER JD, 1987, INT ARCH ALLER A IMM, V82, P351, DOI 10.1159/000234225; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; Sreejayan N, 2001, AM J PHYSIOL-GASTR L, V280, pG1043, DOI 10.1152/ajpgi.2001.280.5.G1043; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; VAVASSEUR F, 1995, GLYCOBIOLOGY, V5, P351, DOI 10.1093/glycob/5.3.351; VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x; Wandall HH, 1997, J BIOL CHEM, V272, P23503, DOI 10.1074/jbc.272.38.23503; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156; Williams SJ, 1999, CANCER RES, V59, P4083; YANG JM, 1994, GLYCOBIOLOGY, V4, P873, DOI 10.1093/glycob/4.6.873; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	51	124	133	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12802	12809		10.1074/jbc.M112457200	http://dx.doi.org/10.1074/jbc.M112457200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821425	hybrid			2022-12-25	WOS:000175036300041
J	McCormack, K; Connor, JX; Zhou, L; Ho, LL; Ganetzky, B; Chiu, SY; Messing, A				McCormack, K; Connor, JX; Zhou, L; Ho, LL; Ganetzky, B; Chiu, SY; Messing, A			Genetic analysis of the mammalian K+ channel beta subunit Kv beta 2 (Kcnab2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; POTASSIUM CHANNELS; SCHWANN-CELLS; KV BETA-1; EXPRESSION; ALPHA; INACTIVATION; BRAIN; LOCALIZATION; DETERMINANTS	Kvbeta2 binds to K+ channel alpha subunits from at least two different families (Kv1 and Kv4) and is a member of the aldo-ketoreductase (AKR) superfamily. Proposed functions for this protein in vivo include a chaperone-like role in Kv1 alpha subunit biogenesis and catalytic activity as an AKR oxidoreductase. To investigate the in vivo function of Kvbeta2, Kvbeta2-null and point mutant (Y90F) mice were generated through gene targeting in embryonic stem cells. In Kvbeta2-null mice, Kv1.1 and Kv1.2 localize normally in cerebellar basket cell terminals and the juxtaparanodal region of myelinated nerves. Moreover, normal glycosylation patterns are observed for Kv1.1 and Kv1.2 in whole brain lysates. Thus, loss of the chaperone-like activity does not appear to account for the phenotype of Kvbeta2-null mice, which include reduced life spans, occasional seizures, and cold swim-induced tremors similar to that observed in Kv1.1-null mice. Mice expressing Kvbeta2, mutated at a site (Y90F) that abolishes AKR-like catalytic activity in other family members, have no overt phenotype. We conclude that Kvbeta2 contributes to regulation of excitability in vivo, although not directly through either chaperone-like or typical AKR catalytic activity. Rather, Kvbeta2 relies upon as yet unidentified mechanisms in the regulation of K+ channel and/or oxidoreductive functions.	Univ Wisconsin, Dept Pathobiol Sci, Madison, WI 53705 USA; Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Univ Wisconsin, Genet Lab, Madison, WI 53706 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	McCormack, K (corresponding author), Aurora Biosci Inc, 11010 Torreyana Rd, La Jolla, CA 92121 USA.	mccormack@aurorabio.com			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032375, R01NS015390] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-18420] Funding Source: Medline; NINDS NIH HHS [NS-32375, NS-15390] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Accili EA, 1997, J BIOL CHEM, V272, P28232, DOI 10.1074/jbc.272.45.28232; Accili EA, 1997, J BIOL CHEM, V272, P25824, DOI 10.1074/jbc.272.41.25824; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Arroyo EJ, 1999, J NEUROCYTOL, V28, P333, DOI 10.1023/A:1007009613484; AUTIERI MV, 1995, GENOMICS, V25, P282, DOI 10.1016/0888-7543(95)80137-B; Bahring R, 2001, J BIOL CHEM, V276, P22923, DOI 10.1074/jbc.M100483200; BekeleArcuri Z, 1996, NEUROPHARMACOLOGY, V35, P851, DOI 10.1016/0028-3908(96)00128-1; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Chen ML, 2000, BIOPHYS J, V79, P1358, DOI 10.1016/S0006-3495(00)76388-0; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; FUJII Y, 1990, J BIOL CHEM, V265, P9914; Giese KP, 1998, LEARN MEMORY, V5, P257; Heilstedt HA, 2001, EPILEPSIA, V42, P1103, DOI 10.1046/j.1528-1157.2001.08801.x; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Liu SQ, 2001, J BIOL CHEM, V276, P11812, DOI 10.1074/jbc.M008259200; Manganas LN, 2000, J BIOL CHEM, V275, P29685, DOI 10.1074/jbc.M005010200; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; McCormack T, 1999, J BIOL CHEM, V274, P20123, DOI 10.1074/jbc.274.29.20123; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; McIntosh P, 1997, PFLUG ARCH EUR J PHY, V435, P43, DOI 10.1007/s004240050482; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Penning TM, 1999, J STEROID BIOCHEM, V69, P211, DOI 10.1016/S0960-0760(99)00038-2; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; Perez-Garcia MT, 2000, CIRC RES, V86, P490, DOI 10.1161/01.RES.86.5.490; Peri R, 2001, J BIOL CHEM, V276, P738, DOI 10.1074/jbc.M008445200; Pongs O, 1999, ANN NY ACAD SCI, V868, P344, DOI 10.1111/j.1749-6632.1999.tb11296.x; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rasband MN, 2001, J COMP NEUROL, V429, P166, DOI 10.1002/1096-9861(20000101)429:1<166::AID-CNE13>3.0.CO;2-Y; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Rhodes KJ, 1996, J NEUROSCI, V16, P4846; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P11003, DOI 10.1021/bi980475r; Schultz D, 1996, GENOMICS, V31, P389, DOI 10.1006/geno.1996.0065; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi G, 1999, J MEMBRANE BIOL, V168, P265, DOI 10.1007/s002329900515; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Smart SL, 1998, NEURON, V20, P809, DOI 10.1016/S0896-6273(00)81018-1; Sobko A, 1998, J NEUROSCI, V18, P10398; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Wang XT, 1996, NATURE, V383, P434, DOI 10.1038/383434a0; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728; Yang EK, 2001, J BIOL CHEM, V276, P4839, DOI 10.1074/jbc.M004768200; Yao WD, 1999, J NEUROPHYSIOL, V81, P2472, DOI 10.1152/jn.1999.81.5.2472; Zhou L, 1998, J NEUROSCI, V18, P7200; Zhou L, 1999, J NEUROSCI, V19, P5768, DOI 10.1523/JNEUROSCI.19-14-05768.1999	49	59	62	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13219	13228		10.1074/jbc.M111465200	http://dx.doi.org/10.1074/jbc.M111465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11825900	hybrid			2022-12-25	WOS:000175036300092
J	Wilson, R; Freddi, S; Bateman, JF				Wilson, R; Freddi, S; Bateman, JF			Collagen X chains harboring Shmid metaphyseal chondrodysplasia NC1 domain mutations are selectively retained and degraded in stably transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DISULFIDE-ISOMERASE; CARBOXYL-TERMINAL DOMAIN; IN-VITRO; ENDOCHONDRAL OSSIFICATION; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; ALPHA-1(X) NC1; MESSENGER-RNA; PROCOLLAGEN; CARTILAGE	Collagen X is a short chain, homotrimeric collagen expressed specifically by hypertrophic chondrocytes during endochondral bone formation and growth. Although the exact role of collagen X remains unresolved, mutations in the COL10A1 gene disrupt growth plate function and result in Schmid metaphyseal chondrodysplasia (SMCD). With the exception of two mutations that impair signal peptide cleavage during alpha1(X) chain biosynthesis, SMCD mutations are clustered within the carboxyl-terminal NC1 domain. The formation of stable NC1 domain timers is a critical stage in collagen X assembly, suggesting that mutations within this domain may result in subunit mis-folding or reduce trimer stability. When expressed in transiently transfected cells, alpha1(X) chains containing SMCD mutations were unstable and presumed to be degraded intracellularly. More recently, in vitro studies have shown that certain missense mutations may exert a dominant negative effect on alpha1(X) chain assembly by formation of mutant homotrimers and normal-mutant heterotrimers. In contrast, analysis of cartilage tissue from two SMCD patients revealed that the truncated mutant message was fully degraded, resulting in 50% reduction of functional collagen X within the growth plate. Therefore, in the absence of data that conclusively demonstrates the full cellular response to mutant collagen X chains, the molecular mechanisms underlying SMCD remain controversial. To address this, we closely examined the effect of two NC1 domain mutations, one frameshift mutation (1963del10) and one missense mutation (Y598D), using both semi-permeabilized cell and stable cell transfection expression systems. Although able to assemble to a limited extent in both systems, we show that, in intact cells, collagen X chains harboring both SMCD mutations did not evade quality control mechanisms within the secretory pathway and were degraded intracellularly. Furthermore, co-expression of wild-type and mutant chains in stable transfected cells demonstrated that, although wild-type chains were secreted, mutant chains were largely excluded from hetero-trimer formation. Our data indicate, therefore, that the predominant effect of the NC1 mutations Y598D and 1963del10 is a reduction in the amount of functional collagen X within the growth cartilage extracellular matrix.	Royal Childrens Hosp, Murdoch Childrens Royal Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Paediat, Cell & Matrix Biol Res Unit, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Bateman, JF (corresponding author), Royal Childrens Hosp, Murdoch Childrens Royal Inst, Flemington Rd, Parkville, Vic 3052, Australia.		Wilson, Richard/H-8429-2012	Wilson, Richard/0000-0003-0152-4394; Bateman, John/0000-0001-8542-0730				Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; Chan D, 1996, J BIOL CHEM, V271, P13566, DOI 10.1074/jbc.271.23.13566; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; Chan D, 1998, J CLIN INVEST, V101, P1490, DOI 10.1172/JCI1976; CHESSLER SD, 1992, J BIOL CHEM, V267, P7751; DHARMAVARAM RM, 1994, HUM MOL GENET, V3, P507, DOI 10.1093/hmg/3.3.507; Dublet B, 1999, J BIOL CHEM, V274, P18909, DOI 10.1074/jbc.274.27.18909; GRANT WT, 1987, J BIOL CHEM, V262, P9844; Gregory CA, 2000, J MED GENET, V37, P627, DOI 10.1136/jmg.37.8.627; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Ikegawa S, 1997, HUM MUTAT, V9, P131, DOI 10.1002/(SICI)1098-1004(1997)9:2<131::AID-HUMU5>3.3.CO;2-U; KAO WWY, 1977, J BIOL CHEM, V252, P8391; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; Kwan KM, 1997, J CELL BIOL, V136, P459, DOI 10.1083/jcb.136.2.459; Lamande SR, 1999, SEMIN CELL DEV BIOL, V10, P455, DOI 10.1006/scdb.1999.0317; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; McLaughlin SH, 1998, BIOCHEM J, V331, P793, DOI 10.1042/bj3310793; McLaughlin SH, 1999, J BIOL CHEM, V274, P7570, DOI 10.1074/jbc.274.11.7570; POOLE AR, 1989, J CELL BIOL, V109, P2547, DOI 10.1083/jcb.109.5.2547; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; SCHMID TM, 1985, J CELL BIOL, V100, P598, DOI 10.1083/jcb.100.2.598; SCHMID TM, 1989, CONNECT TISSUE RES, V20, P215, DOI 10.3109/03008208909023890; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; WALLIS GA, 1994, AM J HUM GENET, V54, P169; Wallis GA, 1996, J MED GENET, V33, P450, DOI 10.1136/jmg.33.6.450; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; WARMAN ML, 1993, NAT GENET, V5, P79, DOI 10.1038/ng0993-79; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637; Wilson RR, 2000, METH MOL B, V139, P1	35	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12516	12524		10.1074/jbc.M112044200	http://dx.doi.org/10.1074/jbc.M112044200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11805116	hybrid			2022-12-25	WOS:000175036300007
J	Bao, KK; Skalka, AM; Wong, I				Bao, KK; Skalka, AM; Wong, I			Presteady-state analysis of avian sarcoma virus integrase - I. A splicing activity and structure-function implications for cognate site recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL-DNA ENDS; RETROVIRAL INTEGRATION; V(D)J RECOMBINATION; KINETIC-ANALYSIS; HIV-1 INTEGRASE; PROTEIN; MECHANISM; SEQUENCE; BINDING; ASSAYS	Integrase catalyzes insertion of a retroviral genome into the host chromosome. After reverse transcription, integrase binds specifically to the ends of the duplex retroviral DNA, endonucleolytically cleaves two nucleotides from each 3'-end (the processing activity), and inserts these ends into the host DNA (the joining activity) in a concerted manner. In first-turnover experiments with synapsed DNA substrates, we observed a novel splicing activity that resembles an integrase joining reaction but uses unprocessed ends. This splicing reaction showed an initial exponential phase (k(splicing) 0.02 s(-1)) of product formation and generated products macroscopically indistinguishable from those created by the processing and joining activities, thus bringing into question methods previously used to quantitate these reactions in a time regime where multiple turnovers of the enzyme have occurred. With a presteady-state assay, however, we were able to distinguish between different pathways that led to formation of identical products. Furthermore, the splicing reaction allowed characterization of substrate binding and specificity. Although integrase requires only a 3' hydroxyl with respect to nucleophiles derived from DNA, it specifically favors the cognate sequence CATT as the electrophile. These experimental results support a two-site "switching" model for binding and catalysis of all three integrase activities.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Oregon State University; Fox Chase Cancer Center	Wong, I (corresponding author), Oregon State Univ, Dept Biochem & Biophys, 2011 ALS Bldg, Corvallis, OR 97331 USA.	wongis@cnid.orst.edu	Hu, Ruogu/B-2203-2008		NATIONAL CANCER INSTITUTE [R01CA071515, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058771] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71515] Funding Source: Medline; NIGMS NIH HHS [GM 58771AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Ausubel FM., 1988, CURRENT PROTOCOLS MO; Bao KK, 2002, J BIOL CHEM, V277, P12099, DOI 10.1074/jbc.M111314200; Bor YC, 1996, VIROLOGY, V222, P283, DOI 10.1006/viro.1996.0422; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; CANTOR CR, 1970, BIOPOLYMERS, V9, P1059, DOI 10.1002/bip.1970.360090909; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; Craigie R, 2001, J BIOL CHEM, V276, P23213, DOI 10.1074/jbc.R100027200; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; ELLISON V, 1994, P NATL ACAD SCI USA, V91, P7316, DOI 10.1073/pnas.91.15.7316; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FIERKE CA, 1995, METHOD ENZYMOL, V249, P3; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; JOHNSON KA, 1995, METHOD ENZYMOL, V249, P38; JOHNSON KA, 1992, PHILOS T ROY SOC B, V336, P107, DOI 10.1098/rstb.1992.0050; JONES KS, 1992, J BIOL CHEM, V267, P16037; Katz RA, 1998, J BIOL CHEM, V273, P24190, DOI 10.1074/jbc.273.37.24190; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KATZ RA, 1990, CELL, V63, P87, DOI 10.1016/0092-8674(90)90290-U; Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; KUKOLJ G, 1995, GENE DEV, V9, P2556, DOI 10.1101/gad.9.20.2556; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MULLER B, 1993, P NATL ACAD SCI USA, V90, P11633, DOI 10.1073/pnas.90.24.11633; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; Ramsden DA, 1996, EMBO J, V15, P3197, DOI 10.1002/j.1460-2075.1996.tb00682.x; Reid T.W., 1971, ENZYMES, V4, P373; RICHARDS FM, 1971, ENZYMES, V4, P647; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; SHIH CC, 1988, CELL, V53, P531, DOI 10.1016/0092-8674(88)90569-7; Skinner LM, 2001, J BIOL CHEM, V276, P114, DOI 10.1074/jbc.M007032200; TERRY R, 1988, J VIROL, V62, P2358, DOI 10.1128/JVI.62.7.2358-2365.1988; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; Vora A, 2001, J VIROL, V75, P3556, DOI 10.1128/JVI.75.8.3556-3567.2001; Vora AC, 1997, J BIOL CHEM, V272, P23938, DOI 10.1074/jbc.272.38.23938; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	45	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12089	12098		10.1074/jbc.M111315200	http://dx.doi.org/10.1074/jbc.M111315200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821409	hybrid			2022-12-25	WOS:000174846400065
J	Gong, XQ; Li, L				Gong, XQ; Li, L			Dermo-1, a multifunctional basic helix-loop-helix protein, represses MyoD transactivation via the HLH domain, MEF2 interaction, and chromatin deacetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; BHLH PROTEIN; DNA-BINDING; HISTONE DEACETYLASE; MUSCLE DEVELOPMENT; MADS-BOX; ENHANCER-BINDING; GENE ACTIVATION; MYOGENIC BHLH; FGF-RECEPTOR	Dermo-1 is a multifunctional basic helix-loop-helix (bHLH) transcription factor that has been shown to be a potent negative regulator for gene transcription and apoptosis. To understand the molecular mechanisms that mediate the function of Dermo-1, we generated a series of Dermo-1 mutants and used a MyoD-mediated transcriptional activation model to characterize the roles of its N-terminal, bHLH, and C-terminal structural domains in transcriptional repression. Both the C-terminal and HLH domains of Dermo-1 were essential for its repression of MyoD-mediated transactivation. Dermo-1 repressed, in a dose-dependent fashion, the transactivation activity of myocyte enhancer factor 2 (MEF2), a protein known to cooperate with MyoD in activating E-box-dependent gene expression. Both the N- and C-terminal domains of Dermo-1, but not the bHLH domain, were required for the inhibition of MEF2, suggesting that Dermo-1 inhibits both MyoD- and MEF2-dependent transactivation but through different mechanisms. Dermo-1 interacted directly with MEF2 and selectively repressed the MEF2 transactivation domain. An overall increase of histone acetylation induced by trichostatin A treatment reduced Dermo-1 transcriptional repression activity, suggesting that histone deacetylation is involved in Dermo-1-mediated transcriptional repression. Together, these results suggest that MEF-2 is an important target in Dermo-1-mediated transcriptional repression and provide initial evidence of the involvement of histone acetylation in Dermo-1 transcriptional repression.	Wayne State Univ, Dept Internal Med, Program Mol & Cellular Cardiol, Sch Med, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA	Wayne State University; Wayne State University	Li, L (corresponding author), Wayne State Univ, Dept Internal Med, Program Mol & Cellular Cardiol, Sch Med, 421 E Canfield Ave,1107, Detroit, MI 48201 USA.		gong, xue/GYQ-8649-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058916] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58916-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; BODMER R, 1993, DEVELOPMENT, V118, P719; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Castanon I, 2001, DEVELOPMENT, V128, P3145; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Groisman R, 1996, J BIOL CHEM, V271, P5258; Hamamori Y, 1997, MOL CELL BIOL, V17, P6563, DOI 10.1128/MCB.17.11.6563; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hebrok M, 1997, EXP CELL RES, V232, P295, DOI 10.1006/excr.1997.3541; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; Lee MS, 2000, BONE, V27, P591, DOI 10.1016/S8756-3282(00)00380-X; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LI L, 1995, DEV BIOL, V172, P280, DOI 10.1006/dbio.1995.0023; LILLY B, 1994, P NATL ACAD SCI USA, V91, P5662, DOI 10.1073/pnas.91.12.5662; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Scaal M, 2001, ANAT EMBRYOL, V203, P1, DOI 10.1007/PL00008244; Shishido E, 1997, DEVELOPMENT, V124, P2119; SHISHIDO E, 1993, DEVELOPMENT, V117, P751; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Srivastava D, 2001, ANNU REV PHYSIOL, V63, P451, DOI 10.1146/annurev.physiol.63.1.451; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; Tamura M, 1999, J CELL BIOCHEM, V72, P167, DOI 10.1002/(SICI)1097-4644(19990201)72:2<167::AID-JCB1>3.0.CO;2-3; Wen YD, 2000, P NATL ACAD SCI USA, V97, P7202, DOI 10.1073/pnas.97.13.7202; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Zhang CL, 2001, J BIOL CHEM, V276, P35, DOI 10.1074/jbc.M007364200	52	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12310	12317		10.1074/jbc.M110228200	http://dx.doi.org/10.1074/jbc.M110228200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809751	hybrid			2022-12-25	WOS:000174846400093
J	Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR				Bradshaw, PS; Condie, A; Matutes, E; Catovsky, D; Yuille, MR			Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif	ONCOGENE			English	Article						ATM; rearrangement; somatic hypermutation; T-PLL; T-ALL	ACUTE LYMPHOBLASTIC-LEUKEMIA; ATM GENE; B-CELLS; PROLYMPHOCYTIC LEUKEMIA; MISSENSE MUTATIONS; BCL-6 MUTATIONS; BREAST-CANCER; LYMPHOMA	The mature sporadic T-cell malignancy, T-cell prolymphocytic leukemia (T-PLL) is remarkable for frequently harbouring somatic mutations of the Ataxia Telangiectasia (A-T) gene, ATM. Because some data suggest ATM is frequently rearranged in T-PLL, it was decided to investigate such rearrangements in detail by cloning breakpoints. Among 17 T-PLL tumour samples, three rearrangements were detected by Southern blotting. Two cases harboured a unique type of intragenic duplication in which breakpoints arose at the consensus sequence RGYW/WRCY. The third case harboured a large deletion terminating within the ATM gene. Also, 13 T-cell acute lymphoblastic leukemia (T-ALL) samples were examined and one sample harboured a deletion - insertion with the RGYW motif at the breakpoint in ATM. This is the first known deleterious mutation detected in ATM in T-ALL. Interestingly, the RGYW motif is the signal for a cell-cycle regulated DNA double strand break (DSB) that initiates somatic hypermutation of immunoglobulin and, probably, T-cell receptor genes. The structures of the ATM duplications suggest they may arise from an error in somatic hypermutation. We suggest that aberrant components of somatic hypermutation may contribute to the defective DSB repair characteristic of cancer.	Inst Canc Res, Acad Dept Haematol & Cytogenet, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK	Yuille, MR (corresponding author), HGMP RC, MRC, Cambridge CB2 4AT, England.			Yuille, Martin/0000-0002-4992-5405				Hacia JC, 1998, GENOME RES, V8, P1245, DOI 10.1101/gr.8.12.1245; Haidar MA, 2000, CANCER-AM CANCER SOC, V88, P1057, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6; HECHT F, 1990, CANCER GENET CYTOGEN, V46, P9, DOI 10.1016/0165-4608(90)90003-S; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; Klein U, 1998, IMMUNOL REV, V162, P261; Luo LP, 1998, CANCER RES, V58, P2293; Meyn MS, 1999, CLIN GENET, V55, P289, DOI 10.1034/j.1399-0004.1999.550501.x; Papavasiliou FN, 2000, NATURE, V408, P216, DOI 10.1038/35041599; Pasqualucci L, 2000, CANCER RES, V60, P5644; Pasqualucci L, 1998, P NATL ACAD SCI USA, V95, P11816, DOI 10.1073/pnas.95.20.11816; RAVID Z, 1980, INT J CANCER, V25, P705, DOI 10.1002/ijc.2910250604; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Stankovic T, 2001, BLOOD, V97, P1517, DOI 10.1182/blood.V97.5.1517; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stilgenbauer S, 1997, NAT MED, V3, P1155, DOI 10.1038/nm1097-1155; Stoppa-Lyonnet D, 2000, BLOOD, V96, P374, DOI 10.1182/blood.V96.1.374a.013k56e_374_377; Takeuchi S, 1998, BRIT J HAEMATOL, V103, P536, DOI 10.1046/j.1365-2141.1998.00993.x; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; Vanasse GJ, 1999, BLOOD, V94, P3997, DOI 10.1182/blood.V94.12.3997.424k44_3997_4010; Vorechovsky I, 1997, NAT GENET, V17, P96, DOI 10.1038/ng0997-96; Yuille MAR, 1998, ONCOGENE, V16, P789, DOI 10.1038/sj.onc.1201603; ZHENG B, 1994, NATURE, V372, P556, DOI 10.1038/372556a0	22	4	4	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					483	487		10.1038/sj.onc.1205105	http://dx.doi.org/10.1038/sj.onc.1205105			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821961				2022-12-25	WOS:000173311200017
J	Williams, KJ; Telfer, BA; Airley, RE; Peters, HPW; Sheridan, MR; van der Kogel, AJ; Harris, AL; Stratford, IJ				Williams, KJ; Telfer, BA; Airley, RE; Peters, HPW; Sheridan, MR; van der Kogel, AJ; Harris, AL; Stratford, IJ			A protective role for HIF-1 in response to redox manipulation and glucose deprivation: implications for tumorigenesis	ONCOGENE			English	Article						HIF-1; glucose; redox; tumorigenesis; cyanide; Glut-1	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; GENE-EXPRESSION; OXIDATIVE-PHOSPHORYLATION; FACTOR 1-ALPHA; FACTOR-I; TRANSCRIPTION; CELLS; HIF-1-ALPHA; OVEREXPRESSION; PROLIFERATION	We have investigated the role of HIF-1 in the cellular response to redox modulation via the inhibition of oxidative phosphorylation. We demonstrate that manipulation of redox in air, achieved by inhibiting cytochrome oxidase with cyanide, induces HIF-1 mediated transcription in wild-type CHO and HT1080 human tumour cells but not in CHO cells deficient in the oxygen responsive, HIF-1 alpha sub-unit of HIF-1. Hypoglycaemia attenuates cyanide-mediated transcription in nontransformed HIF-1 wild-type CHO cells but not the human tumour derived cell line. Cells lacking either HIF-1 alpha, or the second composite sub-unit of HIF-1, HIF-1 beta, were markedly more sensitive to the combined stress of perturbed redox and hypoglycaemia than wild-type cells. As such conditions together with hypoxia are prevalent in tumours, these data suggest that HIF-1 may have a protective role in adaptation to the tumour microenvironment. In support of this we demonstrate that HIF-1 alpha deficient cells are less tumorigenic than wild-type cells. They showed a reduced growth rate when grown as xenografts in nude mice. This was not related to vascular parameters that were identical to those found in HIF-1 wild-type tumours. The HIF-1 deficient tumours lacked focal expression of Glut-1 in hypoxic tumour regions. Compromized glucose uptake and metabolic adaptation to the tumour micro-environment may form the basis of the reduced tumorigenecity associated with these cells.	Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England; Christie Hosp NHS Trust, Paterson Inst, Expt Radiat Oncol Grp, Manchester M20 4BX, Lancs, England; Univ Nijmegen, Inst Radiotherapy, Nijmegen, Netherlands; John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DU, England	University of Manchester; Christie NHS Foundation Trust; Christie Hospital; Radboud University Nijmegen; University of Oxford	Williams, KJ (corresponding author), Univ Manchester, Sch Pharm & Pharmaceut Sci, Manchester M13 9PL, Lancs, England.		Harris, Adrian L/ABA-3343-2020; van der Kogel, A.J./L-4441-2015	Harris, Adrian L/0000-0003-1376-8409; stratford, ian/0000-0002-5222-4765; Telfer, Brian/0000-0003-1857-5120	Medical Research Council [G0500366] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Airley R, 2001, CLIN CANCER RES, V7, P928; Behrooz A, 1997, J BIOL CHEM, V272, P5555, DOI 10.1074/jbc.272.9.5555; Birner P, 2000, CANCER RES, V60, P4693; Blancher C, 2000, CANCER RES, V60, P7106; Brown RS, 1996, J NUCL MED, V37, P1042; Bussink J, 1998, BRIT J CANCER, V77, P57, DOI 10.1038/bjc.1998.9; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chung JK, 1999, J NUCL MED, V40, P339; Dachs GU, 1997, NAT MED, V3, P515, DOI 10.1038/nm0597-515; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; GRIFFITHS JR, IN PRESS CANC RES; HODGKISS RJ, 1991, BRIT J CANCER, V63, P119, DOI 10.1038/bjc.1991.24; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 1997, CANCER RES, V57, P5328; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; NECAS E, 1972, AM J PHYSIOL, V222, P1187, DOI 10.1152/ajplegacy.1972.222.5.1187; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Raleigh JA, 1999, RADIAT RES, V151, P580, DOI 10.2307/3580034; Ratcliffe PJ, 1998, J EXP BIOL, V201, P1153; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Stratford IJ, 1999, TUMOR HYPOXIA, P107; TAN CC, 1991, AM J PHYSIOL, V261, pF982, DOI 10.1152/ajprenal.1991.261.6.F982; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Wood SM, 1998, J BIOL CHEM, V273, P8360, DOI 10.1074/jbc.273.14.8360; Wood SM, 1996, J BIOL CHEM, V271, P15117, DOI 10.1074/jbc.271.25.15117; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1998, CANCER RES, V58, P5280; Zhong H, 1999, CANCER RES, V59, P5830	35	65	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					282	290		10.1038/sj.onc.1205047	http://dx.doi.org/10.1038/sj.onc.1205047			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803471				2022-12-25	WOS:000173026200012
J	Umayahara, Y; Kajimoto, Y; Fujitani, Y; Gorogawa, S; Yasuda, T; Kuroda, A; Ohtoshi, K; Yoshida, S; Kawamori, D; Yamasaki, Y; Hori, M				Umayahara, Y; Kajimoto, Y; Fujitani, Y; Gorogawa, S; Yasuda, T; Kuroda, A; Ohtoshi, K; Yoshida, S; Kawamori, D; Yamasaki, Y; Hori, M			Protein kinase C-dependent, CCAAT/enhancer-binding protein beta-mediated expression of insulin-like growth factor I gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROLS TRANSCRIPTIONAL ACTIVATION; CAMP RESPONSE ELEMENT; C/EBP-BETA; IDENTIFICATION; ENHANCER; PHOSPHORYLATION; PATHWAY; IGF; RECEPTOR; FAMILY	The possible involvement of the protein kinase C (PKC) pathway in transcriptional regulation of the human insulin-like growth factor-I (IGF-I) gene has been suggested. In this study, we sought to determine whether a PKC-dependent pathway is implicated in the transcriptional control, and if it is, how this occurs. Treatment with 12-O-tetradecanoylphorbol 13-acetate (TPA) caused an increase in the activity of the human IGF-I gene major promoter in HepG2 cells. A CCAAT/enhancer-binding protein (C/EBP) binding site located at +22 to +30 was bound by C/EBPbeta in a TPA-dependent manner and was solely responsible for the TPA responsiveness. This increase in C/EBPbeta activity occurs through transcriptional and posttranslational regulation, and the latter is mediated by activation of p90 ribosomal S6 kinase (RSK): co-expression of dominant negative RSK abolished the TPA-responsive and C/EBPbeta-dependent transactivation. Also, TPA-responsive activation of GAL4-C/EBPbeta chimera required the Ser residue known as the RSK target. In SK-N-MC cells, which display constitutive, high expression of IGF-I on use of the major promoter, a large amount of C/EBPbeta binding was observed with the C/EBP site in the basal state. Treatment with PKC inhibitors substantially reduced the promoter activity and mRNA amounts of IGF-I, with the binding of C/EBPbeta to the C/EBP site also being reduced. When the C/EBP site was disrupted, the basal promoter activity was reduced, but the reduction by the PKC inhibitor was no longer observed. These observations suggest that the increase of C/EBPbeta binding to the C/EBP site, which is in part mediated via activation of RSK, can primarily explain the TPA responsiveness of the IGF-I gene promoter. The intrinsic PKC activity in SK-N-MC cells should play a major role in the constitutive, high expression of IGF-I and may therefore contribute in part to the maintenance of the tumor phenotype of the cells.	Osaka Univ, Grad Sch mEd, Dept Internal Med & Therapeut A8, Suita, Osaka 5650871, Japan	Osaka University	Kajimoto, Y (corresponding author), Osaka Univ, Grad Sch mEd, Dept Internal Med & Therapeut A8, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kajimoto@medone.med.osaka-u.ac.jp						Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Chen RH, 1996, ONCOGENE, V12, P1493; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Fujitani Y, 1999, MOL CELL BIOL, V19, P8281; Gomez DE, 1999, ONCOL REP, V6, P1363; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HALL LJ, 1992, DNA CELL BIOL, V11, P301, DOI 10.1089/dna.1992.11.301; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; Jaaro H, 1997, P NATL ACAD SCI USA, V94, P3742, DOI 10.1073/pnas.94.8.3742; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAJIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V190, P767, DOI 10.1006/bbrc.1993.1115; KAJIMOTO Y, 1991, J BIOL CHEM, V266, P9724; Kiess W, 1997, REGUL PEPTIDES, V72, P19, DOI 10.1016/S0167-0115(97)01026-4; KIM SW, 1991, MOL ENDOCRINOL, V5, P1964, DOI 10.1210/mend-5-12-1964; Kim-Kaneyama JR, 2000, J BIOL CHEM, V275, P20685, DOI 10.1074/jbc.M908723199; KOIKE M, 1993, MOL CARCINOGEN, V8, P105, DOI 10.1002/mc.2940080207; LEE KAW, 1988, GENE ANAL TECH, V5, P22, DOI 10.1016/0735-0651(88)90023-4; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MEGIDISH T, 1989, NATURE, V342, P807, DOI 10.1038/342807a0; Mittanck DW, 1997, MOL CELL ENDOCRINOL, V126, P153, DOI 10.1016/S0303-7207(96)03979-2; NAGAOKA I, 1990, J CLIN INVEST, V85, P448, DOI 10.1172/JCI114458; NOLTEN LA, 1994, MOL ENDOCRINOL, V8, P1636, DOI 10.1210/me.8.12.1636; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Umayahara Y, 1999, J BIOL CHEM, V274, P10609, DOI 10.1074/jbc.274.15.10609; Umayahara Y, 1997, J BIOL CHEM, V272, P31793, DOI 10.1074/jbc.272.50.31793; UMAYAHARA Y, 1994, J BIOL CHEM, V269, P16433; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959	40	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15261	15270		10.1074/jbc.M110827200	http://dx.doi.org/10.1074/jbc.M110827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11825899	hybrid			2022-12-25	WOS:000175510400008
J	Bonaventura, C; Taboy, CH; Low, PS; Stevens, RD; Lafon, C; Crumbliss, AL				Bonaventura, C; Taboy, CH; Low, PS; Stevens, RD; Lafon, C; Crumbliss, AL			Heme redox properties of S-nitrosated hemoglobin A(0) and hemoglobin S - Implications for interactions of nitric oxide with normal and sickle red blood cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; OXYGEN-BINDING; SPECTROELECTROCHEMICAL METHOD; BIOCHEMICAL-CHARACTERIZATION; BAND-3 PROTEIN; OXIDATION; NITROSOHEMOGLOBIN; REDUCTION; MECHANISM; FRAGMENT	S-Nitrosated hemoglobin is remarkably stable and can be cycled between deoxy, oxygenated, or oxidized forms without significant loss of NO. Here we show that S-nitrosation of adult human hemoglobin (Hb A(0)) or sickle cell Hb (Hb S) results in an increased ease of anaerobic heme oxidation, while anions cause redox shifts in the opposite direction. The negatively charged groups of the cytoplasmic domain of Band 3 protein also produce an allosteric effect on S-nitrosated Hb. Formation and deoxygenation of a SNO-Hb/Band 3 protein assembly does not in itself cause NO release, even in the presence of glutathione; however, this assembly may play a role in the migration of NO from the red blood cells to other targets and may be linked to Heinz body formation. Studies of the anaerobic oxidation of Hb S revealed an altered redox potential relative to Hb A(0) that favors met-Hb formation and may therefore underlie the increased rate of autoxidation of Hb S under aerobic conditions, the increased formation of Heinz bodies in sickle cells, and the decreased lifetime of red cells containing Hb S. A model for the interrelationships between the deoxy, oxy, and met forms of Hb A(0) and Hb S, and their S-nitrosated counterparts, is presented.	Duke Univ, Dept Chem, Durham, NC 27708 USA; Duke Univ, Marine Lab, Nicholas Sch Environm, Beaufort, NC 28516 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA; Duke Univ, Med Ctr, Mass Spectrometry Facil, Durham, NC 27710 USA	Duke University; Duke University; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Duke University	Crumbliss, AL (corresponding author), Duke Univ, Dept Chem, Durham, NC 27708 USA.	alc@chem.duke.edu		Low, Philip/0000-0001-9042-5528	NHLBI NIH HHS [R01 HL-58248, 1R43 HL-6586] Funding Source: Medline; NIEHS NIH HHS [ESO-1908] Funding Source: Medline; NIGMS NIH HHS [GM24417] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058248] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001908, P50ES001908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024417, R37GM024417] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1964, J BIOL CHEM, V239, P907; Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BANERJEE R, 1969, J MOL BIOL, V42, P337, DOI 10.1016/0022-2836(69)90047-3; Bonaventura C, 1999, J BIOL CHEM, V274, P5499, DOI 10.1074/jbc.274.9.5499; Bonaventura C, 1999, J BIOL CHEM, V274, P24742, DOI 10.1074/jbc.274.35.24742; Bonaventura C, 1998, BIOCHEMISTRY-US, V37, P496, DOI 10.1021/bi971574s; BONAVENTURA J, 1974, J MOL BIOL, V82, P499, DOI 10.1016/0022-2836(74)90244-7; BONAVENTURA J, 1975, J BIOL CHEM, V250, P9250; CASSOLY R, 1983, BIOCHIM BIOPHYS ACTA, V745, P134, DOI 10.1016/0167-4838(83)90041-9; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; Deem S, 2001, AM J RESP CRIT CARE, V163, P1164, DOI 10.1164/ajrccm.163.5.2007172; DESBOIS A, 1975, J MOL BIOL, V92, P479, DOI 10.1016/0022-2836(75)90293-4; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; DONG SJ, 1989, BIOELECTROCH BIOENER, V21, P233, DOI 10.1016/0302-4598(89)85003-2; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; Eaton W A, 1990, Adv Protein Chem, V40, P63, DOI 10.1016/S0065-3233(08)60287-9; EATON WA, 1987, BLOOD, V70, P1245; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; FAULKNER KM, 1994, INORG CHIM ACTA, V226, P187, DOI 10.1016/0020-1693(94)04086-9; FAULKNER KM, 1995, J BIOL CHEM, V270, P13604, DOI 10.1074/jbc.270.23.13604; FEELISH M, 1996, METHODS NITRIC OXIDE; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; Ignarro LJ, 1999, ANGEW CHEM INT EDIT, V38, P1882, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1882::AID-ANIE1882>3.0.CO;2-V; Imai K., 1982, ALLOSTERIC EFFECTS H; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P39; KIESE M, 1974, METHEMOGLOBINENIA CO; Knauf P.A, 1979, CURR TOP MEMBR TRANS, V12, P249, DOI 10.1016/S0070-2161(08)60259-2; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; McMahon TJ, 2000, J BIOL CHEM, V275, P16738, DOI 10.1074/jbc.M000532200; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Murad F, 1999, ANGEW CHEM INT EDIT, V38, P1857, DOI 10.1002/(SICI)1521-3773(19990712)38:13/14<1856::AID-ANIE1856>3.0.CO;2-D; Patel RP, 1999, J BIOL CHEM, V274, P15487, DOI 10.1074/jbc.274.22.15487; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; PERUTZ MF, 1990, ANNU REV PHYSIOL, V52, P1; PERUTZ MF, 1969, NATURE, V222, P1240, DOI 10.1038/2221240a0; RIFKIND JM, 1981, MET IONS BIOL SYST, V12, P191; SALHANY JM, 1989, J BIOL CHEM, V264, P1399; SONG SH, 1988, BIOELECTROCH BIOENER, V19, P337, DOI 10.1016/0302-4598(88)80014-X; Spencer NY, 2000, J BIOL CHEM, V275, P36562, DOI 10.1074/jbc.M005347200; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Taboy CH, 1999, BIOELECTROCH BIOENER, V48, P79, DOI 10.1016/S0302-4598(98)00236-0; Taboy CH, 2000, J BIOL CHEM, V275, P39048, DOI 10.1074/jbc.M004547200; TAYLOR JOHN FULLER, 1939, JOUR BIOL CHEM, V131, P649; WALDER JA, 1984, J BIOL CHEM, V259, P238; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; Winterbourn C. C., 1985, CRC HDB METHODS OXYG; WINTERBOURN CC, 1977, BIOCHEM J, V165, P141, DOI 10.1042/bj1650141; Wolzt M, 1999, J BIOL CHEM, V274, P28983, DOI 10.1074/jbc.274.41.28983	49	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14557	14563		10.1074/jbc.M107658200	http://dx.doi.org/10.1074/jbc.M107658200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11834726	hybrid			2022-12-25	WOS:000175203000028
J	Schuttelkopf, AW; Harrison, JA; Boxer, DH; Hunter, WN				Schuttelkopf, AW; Harrison, JA; Boxer, DH; Hunter, WN			Passive acquisition of ligand by the MopII molbindin from Clostridium pasteurianum - Structures of APO and oxyanion-bound forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATOR MODE; MOLYBDATE TRANSPORT OPERON; ESCHERICHIA-COLI; MACROMOLECULAR STRUCTURES; PROTEIN; BINDING; MODABCD; MOLYBDENUM; REFINEMENT; REPRESSOR	MopII from Clostridium pasteurianum is a molbindin family member. These proteins may serve as intracellular storage facilities for molybdate, which they bind with high specificity. High resolution structures of MopII in a number of states, including the first structure of an apo-molbindin, together with calorimetric data, allow us to describe ligand binding and provide support for the proposed storage function of the protein. MopII assembles as a trimer of dimers and binds eight oxyanions at two types of binding sites located at intersubunit interfaces. Two type I sites are on the molecular 3-fold axis and three pairs of type 2 sites occur on the molecular 2-fold axes. The hexamer is largely unaffected by the binding of ligand. Molybdate is admitted to the otherwise inaccessible type 2 binding sites by the movement of the N-terminal residues of each protein chain. This contrasts with the structurally related molybdate-dependent transcriptional regulator ModE, which undergoes extensive conformational rearrangements on ligand binding. Despite similarities between the binding sites of ModE and the type 2 sites of MopII the molbindin has a significantly reduced ligand affinity, due, in part, to the high density of negative charges at the center of the hexamer. In the absence of ligand this effects the movement of an important lysine side chain, thereby partially inactivating the binding sites. The differences are consistent with a biological role in molybdate storage/buffering.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Hunter, WN (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.		Hunter, William/AAE-3947-2019					Anderson LA, 2000, J BACTERIOL, V182, P7035, DOI 10.1128/JB.182.24.7035-7043.2000; Anderson LA, 1997, EUR J BIOCHEM, V246, P119, DOI 10.1111/j.1432-1033.1997.00119.x; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cooper A, 1994, Methods Mol Biol, V22, P137; Delarbre L, 2001, J MOL BIOL, V308, P1063, DOI 10.1006/jmbi.2001.4636; Gourley DG, 2001, J BIOL CHEM, V276, P20641, DOI 10.1074/jbc.M100919200; Grunden AM, 1999, J BIOL CHEM, V274, P24308, DOI 10.1074/jbc.274.34.24308; Grunden AM, 1997, ARCH MICROBIOL, V168, P345, DOI 10.1007/s002030050508; Hall DR, 1999, EMBO J, V18, P1435, DOI 10.1093/emboj/18.6.1435; Harrison JA, 2001, ACTA CRYSTALLOGR D, V57, P1715, DOI 10.1107/S0907444901013798; HINTON SM, 1986, NUCLEIC ACIDS RES, V14, P9371, DOI 10.1093/nar/14.23.9371; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAWSON DM, 1997, J CHEM SOC DA, V21, P3981; McNicholas PM, 1998, J BACTERIOL, V180, P4638, DOI 10.1128/JB.180.17.4638-4643.1998; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAU RN, 1997, IRON RELATED TRANSIT, P217; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RECH S, 1995, J BACTERIOL, V177, P1023, DOI 10.1128/jb.177.4.1023-1029.1995; Self WT, 1999, MICROBIOL-UK, V145, P41, DOI 10.1099/13500872-145-1-41; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wagner UG, 2000, STRUCTURE, V8, P1127, DOI 10.1016/S0969-2126(00)00525-6; Walkenhorst HM, 1995, MICROBIOL RES, V150, P347; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3	33	16	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15013	15020		10.1074/jbc.M201005200	http://dx.doi.org/10.1074/jbc.M201005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836258	hybrid			2022-12-25	WOS:000175203000084
J	Wei, SW; Segura, S; Vendrell, J; Aviles, FX; Lanoue, E; Day, R; Feng, Y; Fricker, LD				Wei, SW; Segura, S; Vendrell, J; Aviles, FX; Lanoue, E; Day, R; Feng, Y; Fricker, LD			Identification and characterization of three members of the human metallocarboxypeptidase gene family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; D DOMAIN-II; 3-DIMENSIONAL STRUCTURE; RAT CARBOXYPEPTIDASE; CRYSTAL-STRUCTURE; MESSENGER-RNAS; EXPRESSION; CLONING; RECOGNITION; INHIBITION	Amino acid homology searches of the human genome revealed three members of the metallocarboxypeptidase (metallo-CP) family that had not been described in the literature in addition to the 14 known genes. One of these three, named CPA5, is present in a gene cluster with CPA1, CPA2, and CPA4 on chromosome 7. The cDNA encoding a mouse homolog of human CPA5 was isolated from a testis library and sequenced. The deduced amino acid sequence of human CPA5 has highest amino acid sequence identity (60%) to CPA1 Modeling analysis shows the overall structure to be very similar to that of other members of the A/B sub-family of metallocarboxypeptidases. The active site of CPA5 is predicted to cleave substrates with C-terminal hydrophobic residues, as do CPA1, -2, and -3. Using Northern blot analysis, CPA5 mRNA is detected in testis but not in kidney, liver, brain, or lung. In situ hybridization analysis shows that CPA5 is localized to testis germ cells. Mouse pro-CPA5 protein expressed in Sf9 cells using the baculovirus system was retained in the particulate fraction of the cells and was not secreted into the media. Pro-CPA5 was not enzymatically active toward standard CPA substrates, but after incubation with prohormone convertase 4 the resulting protein was able to cleave furylacryloyl-Gly-Leu, with 3-4-fold greater activity at pH 7.4 than at 5.6. Two additional members of the human CP gene family were also studied. Modeling analysis indicates that both contain the necessary amino acids required for enzymatic activity. The CP on chromosome 8 is predicted to have a CPA-like specificity for C-terminal hydrophobic residues and was named CPA6. The CP on chromosome 2 is predicted to cleave substrates with C-terminal acidic residues and was named CPO.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Sherbrooke, Inst Pharmacol, Dept Pharmacol, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Sherbrooke, PQ J1H 5N4, Canada	Yeshiva University; Albert Einstein College of Medicine; Autonomous University of Barcelona; Autonomous University of Barcelona; University of Sherbrooke; University of Sherbrooke	Fricker, LD (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		Aviles, Francesc Xavier/F-3482-2019; Avilés, Francesc Xavier/A-2664-2015; Vendrell, Josep/A-6731-2010	Aviles, Francesc Xavier/0000-0002-1399-6789; Avilés, Francesc Xavier/0000-0002-1399-6789; Vendrell, Josep/0000-0002-9378-4742	NCI NIH HHS [CA13330] Funding Source: Medline; NIDA NIH HHS [R01 DA04494, K02 DA00194] Funding Source: Medline; NIDDK NIH HHS [R01 DK51271] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051271] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194, R01DA004494] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aloy P, 2001, J BIOL CHEM, V276, P16177, DOI 10.1074/jbc.M011457200; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Auld D.S., 1998, HDB PROTEOLYTIC ENZY, P1326; AULD DS, 1998, HDB PROTEOLYTIC ENZY, P1321; Aviles F.X., 1998, HDB PROTEOLYTIC ENZY, P1333; Barrett A.J., 1998, HDB PROTEOLYTIC ENZY, P1318; Basak A, 1999, BIOCHEM J, V343, P29, DOI 10.1042/0264-6021:3430029; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; COLL M, 1991, EMBO J, V10, P1; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; Eng FJ, 1998, J BIOL CHEM, V273, P8382, DOI 10.1074/jbc.273.14.8382; Fricker L. D., 1994, PHARM OPIOID PEPTIDE, P87; FRICKER LD, 1993, HDB EXPT PHARM, V104, P529; FRICKER LD, 1998, HDB PROTEOLYTIC ENZY, P1341; FRICKER LD, 1998, HDB PROTEOLYTIC ENZY, P1349; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; Garcia-Saez I, 1997, EMBO J, V16, P6906, DOI 10.1093/emboj/16.23.6906; GARDELL SJ, 1988, J BIOL CHEM, V263, P17828; Gomis-Ruth FX, 1999, EMBO J, V18, P5817, DOI 10.1093/emboj/18.21.5817; GUASCH A, 1992, J MOL BIOL, V224, P141, DOI 10.1016/0022-2836(92)90581-4; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HENDRIKS DF, 1998, HDB PROTEOLYTIC ENZY, P1328; Huang HJ, 1999, CANCER RES, V59, P2981; JUNG YK, 1991, MOL ENDOCRINOL, V5, P1257, DOI 10.1210/mend-5-9-1257; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OLIVA B, 1991, BIOCHEM BIOPH RES CO, V176, P616, DOI 10.1016/S0006-291X(05)80228-1; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819; Robinson SL, 1998, TRENDS IN ORGANIZATIONAL BEHAVIOR, VOL 5, P1; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAFER MKH, 1994, METHOD ENZYMOL, V23, P16; SEIDAH NG, 1998, HDB PROTEOLYTIC ENZY, P345; SEIDAH NG, 1998, HDB PROTEOLYTIC ENZY, P349; SHU-DONG T, 1982, Biology of Reproduction, V27, P755, DOI 10.1095/biolreprod27.3.755; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; Skidgel R.A., 1998, HDB PROTEOLYTIC ENZY, P1347; Skidgel R.A., 1998, HDB PROTEOLYTIC ENZY, P1344; SMYTH DG, 1989, J NEUROCHEM, V53, P489, DOI 10.1111/j.1471-4159.1989.tb07360.x; Song LX, 1997, J BIOL CHEM, V272, P10543; Song LX, 1997, BIOCHEM J, V323, P265, DOI 10.1042/bj3230265; Springman E.B., 1998, HDB PROTEOLYTIC ENZY, P1330; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Gunsteren W. F., 1987, GRONINGEN MOL SIMULA; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; Varlamov O, 2001, J CELL SCI, V114, P311; Xin XN, 1997, DNA CELL BIOL, V16, P897, DOI 10.1089/dna.1997.16.897; Xin XN, 1998, DNA CELL BIOL, V17, P311, DOI 10.1089/dna.1998.17.311; Xin XN, 1998, DNA CELL BIOL, V17, P897, DOI 10.1089/dna.1998.17.897; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	53	66	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14954	14964		10.1074/jbc.M112254200	http://dx.doi.org/10.1074/jbc.M112254200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836249	hybrid			2022-12-25	WOS:000175203000077
J	Chambergo, FS; Bonaccorsi, ED; Ferreira, AJS; Ramos, ASP; Junior, JRF; Abrahao-Neto, J; Farah, JPS; El-Dorry, H				Chambergo, FS; Bonaccorsi, ED; Ferreira, AJS; Ramos, ASP; Junior, JRF; Abrahao-Neto, J; Farah, JPS; El-Dorry, H			Elucidation of the metabolic fate of glucose in the filamentous fungus Trichoderma reesei using expressed sequence tag (EST) analysis and cDNA microarrays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MITOCHONDRIAL; DIMORPHISM; REPRESSION; NUCLEAR	Despite the intense interest in the metabolic regulation and evolution of the ATP-producing pathways, the long standing question of why most multicellular microorganisms metabolize glucose by respiration rather than fermentation remains unanswered. One such microorganism is the cellulolytic fungus Trichoderma reesei (Hypocrea jecorina). Using EST analysis and cDNA microarrays, we find that in T. reesei expression of the genes encoding the enzymes of the tricarboxylic acid cycle and the proteins of the electron transport chain is programmed in a way that favors the oxidation of pyruvate via the tricarboxylic acid cycle rather than its reduction to ethanol by fermentation. Moreover, the results indicate that acetaldehyde may be channeled into acetate rather than ethanol, thus preventing the regeneration of NAD(+), a pivotal product required for anaerobic metabolism. The studies also point out that the regulatory machinery controlled by glucose was most probably the target of evolutionary pressure that directed the flow of metabolites into respiratory metabolism rather than fermentation. This finding has significant implications for the development of metabolically engineered cellulolytic microorganisms for fuel production from cellulose biomass.	Univ Sao Paulo, Dept Biochem, Inst Chem, BR-05508900 Sao Paulo, Brazil; Univ Sao Paulo, Dept Chem, Inst Chem, BR-05508900 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	El-Dorry, H (corresponding author), Univ Sao Paulo, Dept Biochem, Inst Chem, Ave Prof Lineu Prestes 748, BR-05508900 Sao Paulo, Brazil.	dorry@lq.usp.br	Ferreira, Ari J S/C-2266-2015; Farah, Joao P S/C-4481-2012; Chambergo, Felipe S/B-8599-2012; Ramos, Augusto/H-5402-2019; Ferreira-Junior, Jose Ribamar S/B-6951-2012	Ferreira, Ari J S/0000-0002-7526-5543; Farah, Joao P S/0000-0003-2607-8693; Chambergo, Felipe S/0000-0001-7567-0656; Ramos, Augusto/0000-0003-3925-2507; Ferreira-Junior, Jose Ribamar S/0000-0001-5539-5298				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAILEY M, 1993, P 2 TRICEL S, V8, P255; BEGUIN P, 1990, ANNU REV MICROBIOL, V44, P219, DOI 10.1146/annurev.mi.44.100190.001251; Beutler H.O., 1984, METHODS ENZYMATIC AN, VVI, P598; Chet I., 1987, INNOVATIVE APPROACHE, P137; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; ELGOGARY S, 1989, P NATL ACAD SCI USA, V86, P6138, DOI 10.1073/pnas.86.16.6138; Eveleigh D. E., 1985, BIOL IND MICROORGANI, P487; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Flores CL, 2000, FEMS MICROBIOL REV, V24, P507, DOI 10.1111/j.1574-6976.2000.tb00553.x; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GARBER RC, 1983, ANAL BIOCHEM, V135, P416, DOI 10.1016/0003-2697(83)90704-2; GODFREY T, 1996, IND ENZYMOLOGY, P361; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; INDERLIED CB, 1978, J BACTERIOL, V133, P1282, DOI 10.1128/JB.133.3.1282-1286.1978; KELLY JM, 1990, MOL GEN GENET, V222, P323, DOI 10.1007/BF00633836; Kuhn KM, 2001, MOL CELL BIOL, V21, P916, DOI 10.1128/MCB.21.3.916-927.2001; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Margulis L., 1993, SYMBIOSIS CELL EVOLU; MATHEUCCI E, 1995, GENE, V161, P103, DOI 10.1016/0378-1119(95)00283-C; Oksanen J, 1985, P 20 EUR BREW CHEM C, P419; Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079; RAITT DC, 1994, MOL GEN GENET, V242, P17, DOI 10.1007/BF00277343; ROGERS PJ, 1974, J BACTERIOL, V119, P282, DOI 10.1128/JB.119.1.282-293.1974; RONNE H, 1995, TRENDS GENET, V11, P12, DOI 10.1016/S0168-9525(00)88980-5; SCHULZ BE, 1974, J GEN MICROBIOL, V82, P1; ULERY TL, 1994, MOL CELL BIOL, V14, P1160, DOI 10.1128/MCB.14.2.1160; White O, 1996, METHOD ENZYMOL, V266, P27; Zaslavskaia LA, 2001, SCIENCE, V292, P2073, DOI 10.1126/science.160015; Zeeman AM, 2000, YEAST, V16, P611, DOI 10.1002/(SICI)1097-0061(200005)16:7<611::AID-YEA558>3.3.CO;2-Q	34	95	114	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13983	13988		10.1074/jbc.M107651200	http://dx.doi.org/10.1074/jbc.M107651200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825887	hybrid			2022-12-25	WOS:000175096000083
J	Jain, A; Karadag, A; Fohr, B; Fisher, LW; Fedarko, NS				Jain, A; Karadag, A; Fohr, B; Fisher, LW; Fedarko, NS			Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MATRIX ACIDIC PHOSPHOPROTEIN; IMPERFECTA TYPE-II; BONE SIALOPROTEIN; SIALIC-ACID; OSTEOPONTIN; PROTEIN; GENE; SEQUENCE; CLONING; CELLS	Previously we have shown that two members of the newly named SIBLING (small integrin-binding ligand, N-linked glycoproteins) family of proteins, bone sialoprotein, and osteopontin, bound first to a cell surface receptor and then to complement Factor H thereby blocking the lytic activity of the alternative pathway of complement. Another member of this family, dentin matrix protein 1, is shown in this paper to be very similar to osteopontin in that it can bind strongly to Factor H (K similar to 1 nm) and block the lytic activity through either the vitronectin receptor (alpha(V)beta(3) integrin) or CD44. Binding of Factor H to SIBLING localized to the cells surface was demonstrated by fluorescence-activated cell sorting. Extensive overlapping fragment analyses suggests that both dentin matrix protein I and osteopontin interact with cell surface CD44 through their amino termini. Similar fragments of bone sialoprotein, like the intact protein, did not functionally interact with CD44. All three proteins are shown to act in conjunction with Factor 1, a serum protease that, when complexed to appropriate cofactors, stops the lytic pathway by digesting the bound C3b in a series of proteolytic steps. These results show that at least three members of this family confer membrane cofactor protein-like activity (MCP or CD46) upon cells expressing RGD-binding integrins or CD44. The required order of the assembly of the complex suggests that this cofactor activity is limited to short diffusional distances.	Johns Hopkins Univ, Dept Med, Div Geriatr, Baltimore, MD 21224 USA; NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Fedarko, NS (corresponding author), Rm 5A-64 JHAAC,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.			Fedarko, Neal/0000-0001-6055-6279	NCI NIH HHS [CA 87311] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000074] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BECKER TC, 1994, METHOD CELL BIOL, V43, P161; Carroll MC, 1998, ANNU REV IMMUNOL, V16, P545, DOI 10.1146/annurev.immunol.16.1.545; Conrozier T, 1998, ANN RHEUM DIS, V57, P527, DOI 10.1136/ard.57.9.527; CULTY M, 1990, J CELL BIOL, V111, P2765, DOI 10.1083/jcb.111.6.2765; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; FISHER LW, 1990, J BIOL CHEM, V265, P2347; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; GEORGE A, 1993, J BIOL CHEM, V268, P12624; Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945-053X(00)00108-6; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; Gu K, 2000, EUR J ORAL SCI, V108, P35, DOI 10.1034/j.1600-0722.2000.00765.x; Hindmarsh EJ, 1998, J IMMUNOL, V160, P6128; Hirst KL, 1997, GENOMICS, V42, P38, DOI 10.1006/geno.1997.4700; Hirst KL, 1997, J DENT RES, V76, P754, DOI 10.1177/00220345970760030701; INGRAM RT, 1993, J BONE MINER RES, V8, P1019; Kawano Mitsuhiro, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P367; KAZATCHKINE MD, 1979, J IMMUNOL, V122, P75; Kulkarni GV, 2000, ARCH ORAL BIOL, V45, P475, DOI 10.1016/S0003-9969(00)00010-8; Larsson E, 1997, BRIT J RHEUMATOL, V36, P1258; Lohmander LS, 1996, ANN RHEUM DIS, V55, P622, DOI 10.1136/ard.55.9.622; MacDougall M, 1996, CONNECT TISSUE RES, V35, P267, DOI 10.3109/03008209609029200; MacDougall M, 1998, EUR J ORAL SCI, V106, P227, DOI 10.1111/j.1600-0722.1998.tb02180.x; McKee MD, 1996, J BONE MINER RES, V11, P873; McKee MD, 1996, ANAT RECORD, V245, P394, DOI 10.1002/(SICI)1097-0185(199606)245:2<394::AID-AR19>3.0.CO;2-K; MULLEREBERHARD HJ, 1992, BEHRING I MITT, V91, P138; Petersen DN, 2000, J BIOL CHEM, V275, P36172, DOI 10.1074/jbc.M003622200; RIMINUCCI M, 1995, CALCIFIED TISSUE INT, V57, P277, DOI 10.1007/BF00298883; Rowe PSN, 2000, GENOMICS, V67, P54, DOI 10.1006/geno.2000.6235; Shi WX, 1996, J BIOL CHEM, V271, P31526, DOI 10.1074/jbc.271.49.31526; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Volanakis J., 1998, COMPLEMENT ENZYMES H, P49; Volanakis JE, 1998, HUMAN COMPLEMENT SYS, V20, P9, DOI DOI 10.1201/B14212-3; YOUNG MF, 1990, GENOMICS, V7, P491, DOI 10.1016/0888-7543(90)90191-V	36	96	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13700	13708		10.1074/jbc.M110757200	http://dx.doi.org/10.1074/jbc.M110757200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825898	hybrid			2022-12-25	WOS:000175096000048
J	Katsuyama, M; Fan, CY; Yabe-Nishimura, C				Katsuyama, M; Fan, CY; Yabe-Nishimura, C			NADPH oxidase is involved in prostaglandin F-2 alpha-induced hypertrophy of vascular smooth muscle cells - Induction of NOX1 by PGF(2 alpha)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; NAD(P)H OXIDASE; THROMBOXANE A(2); IN-VIVO; EXPRESSION; RIBOZYMES; RECEPTOR; GROWTH	Prostaglandin (PG) F-2alpha, one of the primary prostanoids generated in vascular tissue, is known to cause hypertrophy in vascular smooth muscle cells. To clarify the molecular mechanisms underlying PGF(2alpha)-induced hypertrophy, the involvement of reactive oxygen species was examined in a rat vascular smooth muscle cell line, A7r5. PGF(2alpha) and (+)-fluprostenol, a selective agonist of the PGF receptor, significantly increased intracellular O-2(-) in A7r5. The PGF(2alpha)-induced O-2(-) increase was suppressed by diphenyleneiodonium (DPI), an inhibitor of NADPH oxidase that has been reported to be the major source of 02 in vascular cells. The augmented synthesis of the protein induced by PGF(2alpha) or (+)-fluprostenol was suppressed in the presence of DPI. In PGF(2alpha) or (+)-fluprostenol-treated cells, a dose-dependent increase in the expression of NOX1, a homolog of the catalytic subunit of the phagocyte NADPH oxidase gp91(phox), was demonstrated by Northern blot analysis. Finally, depletion of NOX1 mRNA in the cells transfected with ribozymes targeted for three independent cleavage sites on the mRNA sequence significantly reduced the PGF(2alpha)-induced increase in protein synthesis. Taken together, these results suggest that hypertrophy of vascular smooth muscle cells caused by PGF(2alpha) is mediated by NOX1 induction and the resultant overproduetion of O-2(-) by NADPH oxidase.	Kyoto Prefectural Univ Med, Dept Pharmacol, Kyoto 6028566, Japan	Kyoto Prefectural University of Medicine	Yabe-Nishimura, C (corresponding author), Kyoto Prefectural Univ Med, Dept Pharmacol, Kyoto 6028566, Japan.							Adams JW, 1998, CIRC RES, V83, P167, DOI 10.1161/01.RES.83.2.167; Adams JW, 1996, J BIOL CHEM, V271, P1179, DOI 10.1074/jbc.271.2.1179; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Arnould T, 2001, AM J PATHOL, V159, P345, DOI 10.1016/S0002-9440(10)61701-4; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Banfi B, 2001, J BIOL CHEM, V276, P37594, DOI 10.1074/jbc.M103034200; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cifuentes ME, 2000, AM J PHYSIOL-HEART C, V279, pH2234, DOI 10.1152/ajpheart.2000.279.5.H2234; DORN GW, 1992, J BIOL CHEM, V267, P24897; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guzik TJ, 2000, CIRC RES, V86, pE85, DOI 10.1161/01.RES.86.9.e85; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Koseki S, 1999, J VIROL, V73, P1868, DOI 10.1128/JVI.73.3.1868-1877.1999; Kunapuli P, 1998, J BIOL CHEM, V273, P22442, DOI 10.1074/jbc.273.35.22442; Kuwabara T, 1998, NAT BIOTECHNOL, V16, P961, DOI 10.1038/nbt1098-961; Lai J, 1996, AM J PHYSIOL-HEART C, V271, pH2197, DOI 10.1152/ajpheart.1996.271.6.H2197; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Mark KS, 2001, J PHARMACOL EXP THER, V297, P1051; Morinelli TA, 1997, BIOCHEM PHARMACOL, V53, P1823, DOI 10.1016/S0006-2952(97)00005-1; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; SACHINIDIS A, 1995, HYPERTENSION, V26, P771, DOI 10.1161/01.HYP.26.5.771; SUGIMOTO Y, 1994, J BIOL CHEM, V269, P1356; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317	30	71	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13438	13442		10.1074/jbc.M111634200	http://dx.doi.org/10.1074/jbc.M111634200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832489	hybrid			2022-12-25	WOS:000175096000014
J	Seo, EJ; Lee, C; Yu, MH				Seo, EJ; Lee, C; Yu, MH			Concerted regulation of inhibitory activity of alpha(1)-antitrypsin by the native strain distributed throughout the molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; CENTER LOOP INSERTION; ALPHA-1-PROTEINASE INHIBITOR; CONFORMATIONAL CHANGE; CRYSTAL-STRUCTURE; SERPIN; MECHANISM; METASTABILITY; ASSOCIATION; ALPHA(1)-ANTICHYMOTRYPSIN	The native forms of common globular proteins are in their most stable state but the native forms of plasma serpins (serine protease inhibitors) show high energy state interactions. The high energy state strain of alpha(1)-antitrypsin, a prototype serpin, is distributed throughout the whole molecule, but the strain that regulates the function directly appears to be localized in the region where the reactive site loop is inserted during complex formation with a target protease. To examine the functional role of the strain at other regions of alpha(1)-antitrypsin, we increased the stability of the molecule greatly via combining various stabilizing single amino acid substitutions that did not affect the activity individually. The results showed that a substantial increase of stability, over 13 kcal mol(-1), affected the inhibitory activity with a correlation of 11% activity loss per kcal mol(-1). Addition of an activity affecting single residue substitution in the loop insertion region to these very stable substitutions caused a further activity decrease. The results suggest that the native strain of alpha(1)-antitrypsin distributed throughout the molecule regulates the inhibitory function in a concerted manner.	Korea Inst Sci & Technol, Prot Strain Res Ctr, Natl Creat Res Initiat, Seoul 130650, South Korea	Korea Institute of Science & Technology (KIST)	Yu, MH (corresponding author), Korea Inst Sci & Technol, Prot Strain Res Ctr, Natl Creat Res Initiat, POB 131, Seoul 130650, South Korea.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BEATTY K, 1980, J BIOL CHEM, V255, P3931; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Engh RA, 1995, TRENDS BIOTECHNOL, V13, P503, DOI 10.1016/S0167-7799(00)89013-7; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Im H, 2000, PROTEIN SCI, V9, P934, DOI 10.1110/ps.9.5.934; Kim DY, 1996, BIOCHEM BIOPH RES CO, V226, P378, DOI 10.1006/bbrc.1996.1364; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KWON KS, 1994, J BIOL CHEM, V269, P9627; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; Lee C, 2001, PROTEIN SCI, V10, P1446, DOI 10.1110/ps.840101; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; Orosz A, 1996, MOL CELL BIOL, V16, P7018; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Plotnick MI, 1996, BIOCHEMISTRY-US, V35, P7586, DOI 10.1021/bi960233w; RUBIN H, 1994, BIOCHEMISTRY-US, V33, P7627, DOI 10.1021/bi00190a016; RUBIN H, 1990, J BIOL CHEM, V265, P1199; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; SHORE JD, 1995, J BIOL CHEM, V270, P5395, DOI 10.1074/jbc.270.10.5395; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607	37	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14216	14220		10.1074/jbc.M110272200	http://dx.doi.org/10.1074/jbc.M110272200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834734	hybrid			2022-12-25	WOS:000175096000112
J	Takaki, Y; Seki, N; Kawabata, S; Iwanaga, S; Muta, T				Takaki, Y; Seki, N; Kawabata, S; Iwanaga, S; Muta, T			Duplicated binding sites for (1 -> 3)-beta-D-glucan in the horseshoe crab coagulation factor G - Implications for a molecular basis of the pattern recognition in innate immunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE ZYMOGEN; SELECTIN-CARBOHYDRATE INTERACTIONS; BETA-GLUCAN; CLOSTRIDIUM-THERMOCELLUM; NUCLEOTIDE-SEQUENCE; KINETIC-ANALYSIS; GROWTH-FACTOR; CDNA CLONING; XYLANASE-A; DOMAINS	The horseshoe crab factor G, a heterodimeric serine protease zymogen, is activated by (1-->3)-beta-D-glucan on fungal cell walls. The activation initiates the hemolymph-clotting cascade, a critical reaction for the defense against microorganisms. In the present study, we identified the domain responsible for the glucan recognition by factor G and characterized its interaction with (1-->3)-beta-D-glucan and its derivatives. Among three domains in subunit a of factor G, identified as the glucan-binding domain, was the COOH-terminal xylanase Z-like domain composed of two tandem-repeating units, each of which exhibits sequence similarities to the cellulose-binding domains of bacterial xylanases. Each of the single units bound to the glucan with lower affinities, and the association constant increased two orders with the tandem-repeating structure (K-a = 8.0 x 10(8) m(-1)). In addition to longer glucans, (1-->3)-beta-D-glucan oligosaccharides incapable of activating factor G bound also to factor G and competitively inhibited the zymogen activation. The minimum structure required for the binding was a (1-->3)-beta-D-glucan disaccharide, indicating that conformation-dependent structures are not essential for the recognition. Therefore, increasing avidity by multivalent binding sites with low affinities to simple structures on biologically active polymers may be one of the principles that allows stable and specific recognition of pathogens by pattern recognition receptors in innate immunity.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128581, Japan; Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 8128581, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128581, Japan.							Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Bergner A, 1996, EMBO J, V15, P6789, DOI 10.1002/j.1460-2075.1996.tb01070.x; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; COTE F, 1994, PLANT MOL BIOL, V26, P1379, DOI 10.1007/BF00016481; Fernandes AC, 1999, BIOCHEM J, V342, P105, DOI 10.1042/0264-6021:3420105; Fontes CMGA, 1998, APPL MICROBIOL BIOT, V49, P552, DOI 10.1007/s002530051212; GOSALBES MJ, 1991, J BACTERIOL, V173, P7705, DOI 10.1128/jb.173.23.7705-7710.1991; GREPINET O, 1988, J BACTERIOL, V170, P4582, DOI 10.1128/jb.170.10.4582-4588.1988; Hayashi H, 1999, APPL MICROBIOL BIOT, V51, P348, DOI 10.1007/s002530051401; Iwanaga S, 1998, J BIOCHEM, V123, P1; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KAKINUMA A, 1981, BIOCHEM BIOPH RES CO, V101, P434, DOI 10.1016/0006-291X(81)91278-X; LASKY LA, 1995, ANNU REV BIOCHEM, V64, P113, DOI 10.1146/annurev.bi.64.070195.000553; Linder M, 1996, J BIOL CHEM, V271, P21268, DOI 10.1074/jbc.271.35.21268; Maruyama Y, 2000, BIOSCI BIOTECH BIOCH, V64, P2018, DOI 10.1271/bbb.64.2018; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; MUTA T, 1991, J BIOL CHEM, V266, P6554; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; MUTA T, 1993, J BIOL CHEM, V268, P21384; MUTA T, 1990, J BIOL CHEM, V265, P22426; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; OBAYASHI T, 1995, LANCET, V345, P17, DOI 10.1016/S0140-6736(95)91152-9; Ochiai M, 2000, J BIOL CHEM, V275, P4995, DOI 10.1074/jbc.275.7.4995; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; SAKKA K, 1993, BIOSCI BIOTECH BIOCH, V57, P273, DOI 10.1271/bbb.57.273; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHARP JK, 1984, J BIOL CHEM, V259, P1312; SHINOHARA Y, 1995, J BIOCHEM-TOKYO, V117, P1076; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Sun JL, 1998, J FERMENT BIOENG, V85, P63, DOI 10.1016/S0922-338X(97)80355-8; TANAKA S, 1991, CARBOHYD RES, V218, P167, DOI 10.1016/0008-6215(91)84095-V; Tomme P, 1995, Adv Microb Physiol, V37, P1, DOI 10.1016/S0065-2911(08)60143-5; Umemoto N, 1997, P NATL ACAD SCI USA, V94, P1029, DOI 10.1073/pnas.94.3.1029; WILLIAMS DL, 1978, J RETICULOENDOTH SOC, V23, P479	40	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14281	14287		10.1074/jbc.M200177200	http://dx.doi.org/10.1074/jbc.M200177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830593	hybrid			2022-12-25	WOS:000175096000120
J	Huynh, QK; Kishore, N; Mathialagan, S; Donnelly, AM; Tripp, CS				Huynh, QK; Kishore, N; Mathialagan, S; Donnelly, AM; Tripp, CS			Kinetic mechanisms of I kappa B-related kinases (IKK) inducible IKK and TBK-1 differ from IKK-1/IKK-2 heterodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CATALYTIC SUBUNIT; TYROSINE KINASE; MAP KINASE; COMPLEX; ALPHA; ACTIVATION; BETA; PHOSPHORYLATION; TRANSCRIPTION	Nuclear factor-kappaB activation depends on phosphorylation and degradation of its inhibitor protein, IkappaB. The phosphorylation of IkappaBalpha on Ser(32) and Ser(36) is initiated by an IkappaB kinase (IKK) complex that includes a catalytic heterodimer composed of IkappaB kinase 1 (IKK-1) and IkappaB kinase 2 (IKK-2) as well as a regulatory adaptor subunit, NF-kappaB essential modulator. Recently, two related IkappaB kinases, TBK-1 and IKK-i, have been described. TBK-1 and IKK-i show sequence and structural homology to IKK-1 and IKK-2. TBK-1 and IKK-i phosphorylate Ser(36) of IkappaBalpha. We describe the kinetic mechanisms in terms of substrate and product inhibition of the recombinant human (rh) proteins, rhTBK-1, rhIKK-1, and rhIKK-1/rhIKK-2 heterodimers. The results indicate that although each of these enzymes exhibits a random sequential kinetic mechanism, the effect of the binding of one substrate on the affinity of the other substrate is significantly different. ATP has no effect on the binding of an IkappaBalpha peptide for the rhIKK-1/rhIKK-2 heterodimer (alpha = 0.99), whereas the binding of ATP decreased the affinity of the IkappaBalpha peptide for both rhTBK-1 (alpha = 10.16) and rhIKK-i (alpha = 62.28). Furthermore, the dissociation constants of ATP for rhTBK-1 and rhIKK-i are between the expected values for kinases, whereas the dissociation constants of the IkappaBalpha peptide for each IKK isoforms is unique with rhTBK-1 being the highest (K-IkappaBalpha = 69.87 muM), followed by rhIKK-i (K-IkappaBalpha = 5.47 mum) and rhIKK-1/rhIKK-2 heterodimers (KIkappaBalpha = 0.12 mum). Thus this family of IkappaB kinases has very unique kinetic properties.	Pharmacia Corp, Dept Arthrit & Inflammat Pharmacol, Discovery Res, St Louis, MO 63167 USA	Pfizer	Huynh, QK (corresponding author), Pharmacia Corp, Dept Arthrit & Inflammat Pharmacol, Discovery Res, Mailzone T3M,800 N Lindbergh Blvd, St Louis, MO 63167 USA.							BARRTANA J, 1974, J BIOL CHEM, V249, P1271; BAUMANN P, 1968, BIOCHEMISTRY-US, V7, P3653, DOI 10.1021/bi00850a044; BHATNAGAR D, 1983, BIOCHEMISTRY-US, V22, P6310, DOI 10.1021/bi00295a042; Boerner RJ, 1995, BIOCHEMISTRY-US, V34, P16419, DOI 10.1021/bi00050a024; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burke JR, 1998, J BIOL CHEM, V273, P12041, DOI 10.1074/jbc.273.20.12041; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; Cleland W W, 1979, Methods Enzymol, V63, P103; COLE PA, 1994, J BIOL CHEM, V269, P30880; Connelly MA, 1995, CELL MOL BIOL RES, V41, P537; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; COPELAND RA, 1996, ENZYMES, P263; DEHASE M, 1999, SCIENCE, V284, P309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; GOLD MH, 1974, J BIOL CHEM, V249, P2417; Heilker R, 1999, EUR J BIOCHEM, V259, P253, DOI 10.1046/j.1432-1327.1999.00028.x; Heilker R, 1999, BIOCHEMISTRY-US, V38, P6231, DOI 10.1021/bi990220t; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Huynh QK, 2000, J BIOL CHEM, V275, P25883, DOI 10.1074/jbc.M000296200; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KISHORE N, 2002, IN PRESS J BIOL CHEM, V277; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEATHERBARROW RJ, 1992, GRAFIT VERSION 4 0; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; POSNER I, 1992, J BIOL CHEM, V267, P20638; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Segel I. H., 1975, ENZYME KINETICS, p[107, 132]; SEGEL IH, 1993, ENZYME KINETICS, P623; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; Wisniewski D, 1999, ANAL BIOCHEM, V274, P220, DOI 10.1006/abio.1999.4287; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	48	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12550	12558		10.1074/jbc.M111526200	http://dx.doi.org/10.1074/jbc.M111526200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815618	hybrid			2022-12-25	WOS:000175036300011
J	Jung, BG; Lee, KO; Lee, SS; Chi, YH; Jang, HH; Kang, SS; Lee, K; Lim, D; Yoon, SC; Yun, DJ; Inoue, Y; Cho, MJ; Lee, SY				Jung, BG; Lee, KO; Lee, SS; Chi, YH; Jang, HH; Kang, SS; Lee, K; Lim, D; Yoon, SC; Yun, DJ; Inoue, Y; Cho, MJ; Lee, SY			A Chinese cabbage cDNA with high sequence identity to phospholipid hydroperoxide glutathione peroxidases encodes a novel isoform of thioredoxin-dependent peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MAMMALIAN PEROXIREDOXIN; STRESS; YEAST; PROTEINS; SELENOCYSTEINE; EXPRESSION; REDUCTASE; CLONING; CITRUS	A cDNA, PHCC-TPx, specifying a protein highly homologous to known phospholipid hydroperoxide glutathione peroxidases was isolated from a Chinese cabbage cDNA library. PHCC-TPx encodes a preprotein of 232 amino acids containing a putative N-terminal chloroplast targeting sequence and three conserved Cys residues (Cys(107), Cys(136), and Cys(155)). The mature form of enzyme without the signal peptide was expressed in Escherichia coli, and the recombinant protein was found to utilize thioredoxin (Trx) but not GSH as an electron donor. In the presence of a Trx system, the protein efficiently reduces H2O2 and organic hydroperoxides. Complementation analysis shows that overexpression of the PHCC-TPx restores resistance to oxidative stress in yeast mutants lacking GSH but fails to complement mutant lacking Trx, suggesting that the reducing agent of PHCC-TPx in vivo is not GSH but is Trx. Mutational analysis of the three Cys residues individually replaced with Ser shows that Cys(107) is the primary attacking site by peroxide, and oxidized Cys(107) reacts with Cys(151)-SH to make an intramolecular disulfide bond, which is reduced eventually by Trx. Tryptic peptide analysis by matrix-assisted laser desorption and ionization time of flight mass spectrometry shows that Cys(155) can form a disulfide bond with either Cys(107) or cys(136).	Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci BK21 Program, Chinju 660701, South Korea; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6110011, Japan	Gyeongsang National University; Kyoto University	Lee, SY (corresponding author), Gyeongsang Natl Univ, Plant Mol Biol & Biotechnol Res Ctr, Div Appl Life Sci BK21 Program, Chinju 660701, South Korea.		Cho, Moo Je/F-1649-2010; Yoon, Sung/L-5836-2019	Yun, Dae-Jin/0000-0002-3638-6043; Yoon, Sung Chul/0000-0002-8556-423X				BEEORTZAHAR T, 1995, FEBS LETT, V366, P151, DOI 10.1016/0014-5793(95)00521-A; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Cheong NE, 1999, PLANT MOL BIOL, V40, P825, DOI 10.1023/A:1006271823973; Churin Y, 1999, FEBS LETT, V459, P33, DOI 10.1016/S0014-5793(99)01208-9; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Eshdat Y, 1997, PHYSIOL PLANTARUM, V100, P234, DOI 10.1034/j.1399-3054.1997.1000204.x; ESWORTHY RS, 1993, ARCH BIOCHEM BIOPHYS, V307, P29, DOI 10.1006/abbi.1993.1555; FOYER CH, 1994, PHYSIOL PLANTARUM, V92, P696, DOI 10.1111/j.1399-3054.1994.tb03042.x; HALLIWELL B, 1974, NEW PHYTOL, V73, P1075, DOI 10.1111/j.1469-8137.1974.tb02137.x; HOLLAND D, 1993, PLANT MOL BIOL, V21, P923, DOI 10.1007/BF00027124; IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KARLINNEUMANN GA, 1986, EMBO J, V5, P9, DOI 10.1002/j.1460-2075.1986.tb04170.x; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Lim CO, 1996, PLANT PHYSIOL, V111, P577, DOI 10.1104/pp.111.2.577; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; Mora-Garcia S, 1998, J BIOL CHEM, V273, P16273, DOI 10.1074/jbc.273.26.16273; Mouaheb N, 1998, P NATL ACAD SCI USA, V95, P3312, DOI 10.1073/pnas.95.6.3312; Mullineaux PM, 1998, PLANT J, V13, P375, DOI 10.1046/j.1365-313X.1998.00052.x; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; PERRY ACF, 1992, BIOCHEM J, V285, P863, DOI 10.1042/bj2850863; Schwarz O, 1997, J BIOL CHEM, V272, P16924, DOI 10.1074/jbc.272.27.16924; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; Ullmann P, 1996, EUR J BIOCHEM, V236, P662, DOI 10.1111/j.1432-1033.1996.00662.x; URSINI F, 1995, METHOD ENZYMOL, V252, P38	34	93	105	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12572	12578		10.1074/jbc.M110791200	http://dx.doi.org/10.1074/jbc.M110791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823460	hybrid			2022-12-25	WOS:000175036300013
J	Tompa, P; Mucsi, Z; Orosz, G; Friedrich, P				Tompa, P; Mucsi, Z; Orosz, G; Friedrich, P			Calpastatin subdomains A and C are activators of calpain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CONSERVED REGION; CALMODULIN-LIKE DOMAINS; MU-CALPAIN; PROTEINASE-INHIBITOR; ENDOGENOUS INHIBITOR; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; NEUTRAL PROTEASE; PIG CALPASTATIN; CALCIUM	The inhibitory domains of calpastatin contain three highly conserved regions, A, B, and C, of which A and C bind calpain in a strictly Ca2+-dependent manner but have no inhibitory activity whereas region B inhibits calpain on its own. We synthesized the 19-mer oligopeptides corresponding to regions A and C of human calpastatin domain I and tested their effect on human erythrocyte mu-calpain and rat m-calpain. The two peptides significantly activate both calpains: the Ca2+ concentration required for half-maximal activity is lowered from 4.3 to 2.4 mum for mu-calpain and from 250 to 140 mum for m-calpain. The EC50 concentration of the peptides is 7.5 mum for mu-calpain and 25 mum for m-calpain. It is noteworthy that at low Ca2+ concentrations (1-2 mum for mu-calpain and 70-110 mum for m-calpain) both enzymes are activated about 10-fold by the peptides. Based on these findings, it is suggested that calpastatin fragments may have a role in calpain activation in vivo. Furthermore, these activators open new avenues to cell biological studies of calpain function and eventually may alleviate pathological states caused by calpain malfunction.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Res Grp Peptide Chem, Hungarian Acad Sci, Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Hungarian Academy of Sciences	Tompa, P (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	tompa@enzim.hu	Mucsi, Zoltan/J-9404-2019					Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Baki A, 1996, BIOCHEM J, V318, P897, DOI 10.1042/bj3180897; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Croce K, 1999, J BIOL CHEM, V274, P36321, DOI 10.1074/jbc.274.51.36321; De Tullio R, 2000, FEBS LETT, V475, P17, DOI 10.1016/S0014-5793(00)01613-6; Donkor IO, 2000, CURR MED CHEM, V7, P1171, DOI 10.2174/0929867003374129; ELCE JS, 1995, PROTEIN ENG, V8, P843, DOI 10.1093/protein/8.8.843; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; EMORI Y, 1988, J BIOL CHEM, V263, P2364; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; IMAJOH S, 1985, FEBS LETT, V187, P47, DOI 10.1016/0014-5793(85)81211-4; KAPPRELL HP, 1989, J BIOL CHEM, V264, P17888; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; MA H, 1993, J BIOCHEM, V113, P591, DOI 10.1093/oxfordjournals.jbchem.a124088; MA H, 1994, J BIOL CHEM, V269, P24430; MAKI M, 1987, FEBS LETT, V223, P174, DOI 10.1016/0014-5793(87)80531-8; MAKI M, 1989, J BIOL CHEM, V264, P18866; MAKI M, 1988, J BIOL CHEM, V263, P10254; Mellgren RL, 1997, BIOCHEM BIOPH RES CO, V236, P555, DOI 10.1006/bbrc.1997.7003; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; Melloni E, 1998, BIOCHEM BIOPH RES CO, V249, P583, DOI 10.1006/bbrc.1998.9200; Michetti M, 1996, FEBS LETT, V392, P11, DOI 10.1016/0014-5793(96)00775-2; NISHIMURA T, 1991, J BIOL CHEM, V266, P11842; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; OTSUKA Y, 1987, J BIOL CHEM, V262, P5839; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; Sorimachi H, 2001, J BIOCHEM-TOKYO, V129, P653, DOI 10.1093/oxfordjournals.jbchem.a002903; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; SUZUKI K, 1981, J BIOCHEM-TOKYO, V90, P1787, DOI 10.1093/oxfordjournals.jbchem.a133656; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; Thompson VF, 2000, METH MOL B, V144, P3; Tompa P, 2001, BIOCHEM BIOPH RES CO, V280, P1333, DOI 10.1006/bbrc.2001.4279; TULLIO RD, 1999, BIOCHEM J, V343, P467; Wang K K, 1997, Adv Pharmacol, V37, P117; Wang KKW, 1996, P NATL ACAD SCI USA, V93, P6687, DOI 10.1073/pnas.93.13.6687; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; YANG HQ, 1994, J BIOL CHEM, V269, P18977	44	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					9022	9026		10.1074/jbc.C100700200	http://dx.doi.org/10.1074/jbc.C100700200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11809743	hybrid			2022-12-25	WOS:000174400600039
J	Rivera, R; Murre, C				Rivera, R; Murre, C			The regulation and function of the Id proteins in lymphocyte development	ONCOGENE			English	Review						E-proteins; bHLH; Id	LOOP-HELIX PROTEIN; B-CELL DEVELOPMENT; T-CELL; DNA-BINDING; MAP KINASE; THYMOCYTE MATURATION; SIGNALING PATHWAYS; NEGATIVE REGULATOR; MESSENGER-RNA; E2A ACTIVITY	Helix - loop - helix (HLH) proteins are essential factors for lymphocyte development and function. One class of HLH proteins, the E-proteins, regulate many aspects of lymphocyte maturation, survival, proliferation, and differentiation. E-proteins are negatively regulated by another class of HLH proteins known as the Id proteins. The Id proteins function as dominant negative inhibitors of E-proteins by inhibiting their ability to bind DNA. Here we discuss the function and regulation of the Id proteins in lymphocyte development.	Univ Calif San Diego, Div Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Rivera, R (corresponding author), Univ Calif San Diego, Div Biol, 0366, La Jolla, CA 92093 USA.	r3@biomail.ucsd.edu						ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ARDAVIN C, 1993, NATURE, V362, P761, DOI 10.1038/362761a0; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1997, IMMUNITY, V6, P145, DOI 10.1016/S1074-7613(00)80421-5; Bain G, 1999, J EXP MED, V189, P289, DOI 10.1084/jem.189.2.289; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Barndt R, 1999, J IMMUNOL, V163, P3331; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Brunet A, 1997, ESSAYS BIOCHEM, V32, P1; Carlyle JR, 1997, J EXP MED, V186, P173, DOI 10.1084/jem.186.2.173; CHANTRY D, 1989, EUR J IMMUNOL, V19, P783, DOI 10.1002/eji.1830190433; Chen BB, 1997, NUCLEIC ACIDS RES, V25, P423, DOI 10.1093/nar/25.2.423; CHRISTY BA, 1991, P NATL ACAD SCI USA, V88, P1815, DOI 10.1073/pnas.88.5.1815; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; DEED RW, 1993, ONCOGENE, V8, P599; DESPREZ PY, 1995, MOL CELL BIOL, V15, P3398; DETOGNI P, 1994, SCIENCE, V264, P703, DOI 10.1126/science.8171322; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; Gartner F, 1999, IMMUNITY, V10, P537, DOI 10.1016/S1074-7613(00)80053-9; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heemskerk MHM, 1997, J EXP MED, V186, P1597, DOI 10.1084/jem.186.9.1597; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; Hollnagel A, 1999, J BIOL CHEM, V274, P19838, DOI 10.1074/jbc.274.28.19838; HU JS, 1992, MOL CELL BIOL, V12, P1031, DOI 10.1128/MCB.12.3.1031; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; Ikawa T, 2001, P NATL ACAD SCI USA, V98, P5164, DOI 10.1073/pnas.091537598; JACOBS Y, 1993, MOL CELL BIOL, V13, P7321, DOI 10.1128/MCB.13.12.7321; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; KEE BL, 1995, INT REV CYTOL, V157, P129, DOI 10.1016/S0074-7696(08)62158-0; Kim D, 1999, MOL CELL BIOL, V19, P8240; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kleeff J, 1998, CANCER RES, V58, P3769; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; Koni PA, 1997, IMMUNITY, V6, P491, DOI 10.1016/S1074-7613(00)80292-7; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Leclercq G, 1996, J EXP MED, V184, P325, DOI 10.1084/jem.184.2.325; LEE G, 1989, J IMMUNOL, V142, P3875; Lilja H, 1999, Mol Cell Biol Res Commun, V1, P188, DOI 10.1006/mcbr.1999.0131; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.iy.12.040194.001001; MAKRIS A, 1993, J VIROL, V67, P4283, DOI 10.1128/JVI.67.7.4283-4289.1993; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massy ZA, 1996, SEMIN NEPHROL, V16, P12; MATSUZAKI Y, 1993, J EXP MED, V178, P1283, DOI 10.1084/jem.178.4.1283; Mebius RE, 1997, IMMUNITY, V7, P493, DOI 10.1016/S1074-7613(00)80371-4; Miyazaki T, 1998, J EXP MED, V188, P715, DOI 10.1084/jem.188.4.715; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Pan LH, 1999, MOL CELL BIOL, V19, P5969; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PATRIOTIS C, 1994, P NATL ACAD SCI USA, V91, P9755, DOI 10.1073/pnas.91.21.9755; PATRIOTIS C, 1993, P NATL ACAD SCI USA, V90, P2251, DOI 10.1073/pnas.90.6.2251; PONGUBALA JMR, 1991, MOL CELL BIOL, V11, P1040, DOI 10.1128/MCB.11.2.1040; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Res PCM, 1999, BLOOD, V94, P2647, DOI 10.1182/blood.V94.8.2647.420k06_2647_2657; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; SANCHEZ MJ, 1994, J EXP MED, V180, P569, DOI 10.1084/jem.180.2.569; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; SHOJI W, 1994, J BIOL CHEM, V269, P5078; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Spits H, 2000, J EXP MED, V192, P1775, DOI 10.1084/jem.192.12.1775; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; Tournay O, 1996, MOL CELL BIOL, V16, P2418; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yaswen L, 1996, BLOOD, V87, P1439, DOI 10.1182/blood.V87.4.1439.bloodjournal8741439; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZunigaPflucker JC, 1996, CURR OPIN IMMUNOL, V8, P215, DOI 10.1016/S0952-7915(96)80060-4	105	64	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 20	2001	20	58					8308	8316		10.1038/sj.onc.1205091	http://dx.doi.org/10.1038/sj.onc.1205091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512HT	11840323				2022-12-25	WOS:000173319500004
J	Chang, CF; Chou, HT; Chuang, JL; Chuang, DT; Huang, TH				Chang, CF; Chou, HT; Chuang, JL; Chuang, DT; Huang, TH			Solution structure and dynamics of the lipoic acid-bearing domain of human mitochondrial branched-chain alpha-keto acid dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; DIHYDROLIPOYL ACETYLTRANSFERASE COMPONENT; COLI THIOESTERASE/PROTEASE-I; PANCREATIC TRYPSIN-INHIBITOR; SPECTRAL DENSITY-FUNCTIONS; PRIMARY BILIARY-CIRRHOSIS; MODEL-FREE APPROACH; MULTIENZYME COMPLEX; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE	The lipoyl-bearing domain (LBD) of the transacylase (E2) subunit of the branched-chain alpha-keto acid dehydrogenase complex plays a central role in substrate channeling in this mitochondrial multienzyme complex. We have employed multidimensional heteronuclear NMR techniques to determine the structure and dynamics of the LBD of the human branched-chain alpha-keto acid dehydrogenase complex (hbLBD). Similar to LBD from other members of the alpha-keto acid dehydrogenase family, the solution structure of hbLBD is a flattened beta-barrel formed by two four-stranded antiparallel beta-sheets. The lipoyl Lys(44) residue resides at the tip of a beta-hairpin comprising a sharp type I beta-turn and the two connecting beta-strands 4 and 5. A prominent V-shaped groove formed by a surface loop, L1, connecting beta1- and beta2-strands and the lipoyl lysine beta-hairpin constitutes the functional pocket. We further applied reduced spectral density functions formalism to extract dynamic information of hbLBD from N-15-T-1, N-15-T-2, and (H-1-N-15) nuclear Overhauser effect data obtained at 600 MHz. The results showed that residues surrounding the lipoyl lysine region comprising the L1 loop and the Lys(44) beta-turn are highly flexible, whereas beta-sheet S1 appears to display a slow conformational exchange process.	Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; Natl Taiwan Univ, Dept Phys, Taipei 10673, Taiwan; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	Academia Sinica - Taiwan; National Taiwan University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, TH (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan.			Chang, Chi-Fon/0000-0002-2961-0748	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abragam A., 1961, PRINCIPLES NUCLEAR M, P264; AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; Andrews BK, 1998, STRUCTURE, V6, P587, DOI 10.1016/S0969-2126(98)00060-4; Atreya HS, 2000, J BIOMOL NMR, V17, P125, DOI 10.1023/A:1008315111278; Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BASSENDINE MF, 1997, SEMIN LIVER DIS, V17, P490; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; Berg A, 1996, J MOL BIOL, V261, P432, DOI 10.1006/jmbi.1996.0474; Bracken C, 1999, J MOL BIOL, V285, P2133, DOI 10.1006/jmbi.1998.2429; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chuang D.T., 2001, METABOLIC MOL BASES, P1971; CHUANG DT, 2001, ENCY MOL MED, V1, P393; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; FARROW NA, 1995, J BIOMOL NMR, V6, P153, DOI 10.1007/BF00211779; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Frauenfelder H, 1998, NAT STRUCT BIOL, V5, P757, DOI 10.1038/1784; GERSHWIN ME, 1991, GASTROENTEROLOGY, V100, P822, DOI 10.1016/0016-5085(91)80033-6; Gong XM, 2000, J BIOL CHEM, V275, P13645, DOI 10.1074/jbc.275.18.13645; GREEN JDF, 1995, J MOL BIOL, V248, P328, DOI 10.1006/jmbi.1995.0225; Harris RA, 1997, ADV ENZYME REGUL, V37, P271, DOI 10.1016/S0065-2571(96)00009-X; HIYAMA Y, 1988, J AM CHEM SOC, V110, P2378, DOI 10.1021/ja00216a006; Howard MJ, 1998, GASTROENTEROLOGY, V115, P139, DOI 10.1016/S0016-5085(98)70375-0; Huang YT, 2001, J MOL BIOL, V307, P1075, DOI 10.1006/jmbi.2001.4539; Ishima R, 2000, NAT STRUCT BIOL, V7, P740, DOI 10.1038/78963; ISHIMA R, 1995, J MAGN RESON SER B, V108, P73, DOI 10.1006/jmrb.1995.1104; Jones DD, 2000, BIOCHEMISTRY-US, V39, P8448, DOI 10.1021/bi992978i; Jones DD, 2000, J MOL BIOL, V295, P289, DOI 10.1006/jmbi.1999.3335; Jones DD, 2001, J MOL BIOL, V305, P49, DOI 10.1006/jmbi.2000.4257; KALIA YN, 1993, J MOL BIOL, V230, P323, DOI 10.1006/jmbi.1993.1145; Kay LE, 1998, NAT STRUCT BIOL, V5, P513, DOI 10.1038/755; KAY LE, 1992, J MAGN RESON, V97, P39; KINOSITA K, 1977, BIOPHYS J, V20, P289, DOI 10.1016/S0006-3495(77)85550-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Lin TH, 1998, J BIOMOL NMR, V11, P363, DOI 10.1023/A:1008226515482; Linge JP, 2001, METHOD ENZYMOL, V339, P71, DOI 10.1016/S0076-6879(01)39310-2; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LIU SJ, 1995, J BIOL CHEM, V270, P793, DOI 10.1074/jbc.270.2.793; LONDON RE, 1978, J AM CHEM SOC, V100, P7159, DOI 10.1021/ja00491a006; Lukin JA, 1997, J BIOMOL NMR, V9, P151, DOI 10.1023/A:1018602220061; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; Mande SS, 1996, STRUCTURE, V4, P277, DOI 10.1016/S0969-2126(96)00032-9; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARKLEY JL, 1971, J CHEM PHYS, V55, P3604, DOI 10.1063/1.1676626; MATTEVI A, 1992, SCIENCE, V255, P1544, DOI 10.1126/science.1549782; Miller GP, 1998, CHEM BIOL, V5, pR105, DOI 10.1016/S1074-5521(98)90616-0; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Palmer AG, 1997, CURR OPIN STRUC BIOL, V7, P732, DOI 10.1016/S0959-440X(97)80085-1; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; PENG JW, 1992, J MAGN RESON, V98, P308, DOI 10.1016/0022-2364(92)90135-T; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RADKE GA, 1993, BIOCHEM BIOPH RES CO, V190, P982, DOI 10.1006/bbrc.1993.1146; Ravindran S, 1996, J BIOL CHEM, V271, P653, DOI 10.1074/jbc.271.2.653; Ricaud PM, 1996, J MOL BIOL, V264, P179, DOI 10.1006/jmbi.1996.0632; RICHARZ R, 1980, BIOCHEMISTRY-US, V19, P5189, DOI 10.1021/bi00564a006; ROBIEN MA, 1992, BIOCHEMISTRY-US, V31, P3463, DOI 10.1021/bi00128a021; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; TROPP J, 1980, J CHEM PHYS, V72, P6035, DOI 10.1063/1.439059; Tsai CJ, 1999, PROTEIN SCI, V8, P1181, DOI 10.1110/ps.8.6.1181; Tsou CL, 1998, ANN NY ACAD SCI, V864, P1, DOI 10.1111/j.1749-6632.1998.tb10282.x; WAGNER G, 1993, CURR OPIN STRUC BIOL, V3, P748, DOI 10.1016/0959-440X(93)90059-T; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; Wallis NG, 1996, J MOL BIOL, V263, P463, DOI 10.1006/jmbi.1996.0589; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WOESSNER DE, 1962, J CHEM PHYS, V37, P647, DOI 10.1063/1.1701390; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P125; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZUIDERWEG ERP, 1985, BIOPOLYMERS, V24, P2257, DOI 10.1002/bip.360241208; [No title captured]	80	22	25	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15865	15873		10.1074/jbc.M110952200	http://dx.doi.org/10.1074/jbc.M110952200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839747	hybrid			2022-12-25	WOS:000175510400088
J	Motz, M; Kober, I; Girardot, C; Loeser, E; Bauer, U; Albers, M; Moeckel, G; Minch, E; Voss, H; Kilger, C; Koegl, M				Motz, M; Kober, I; Girardot, C; Loeser, E; Bauer, U; Albers, M; Moeckel, G; Minch, E; Voss, H; Kilger, C; Koegl, M			Elucidation of an archaeal replication protein network to generate enhanced PCR enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; SLIDING CLAMPS; SEQUENCE; ORGANIZATION; FIDELITY; DATABASE; LOADER	Thermostable DNA polymerases are an important tool in molecular biology. To exploit the archaeal repertoire of proteins involved in DNA replication for use in PCR, we elucidated the network of proteins implicated in this process in Archaeoglobus fulgidus. To this end, we performed extensive yeast two-hybrid screens using putative archaeal replication factors as starting points. This approach yielded a protein network involving 30 proteins potentially implicated in archaeal DNA replication including several novel factors. Based on these results, we were able to improve PCR reactions catalyzed by archaeal DNA polymerases by supplementing the reaction with predicted polymerase co-factors. In this approach we concentrated on the archaeal proliferating cell nuclear antigen (PCNA) homologue. This protein is known to encircle DNA as a ring in eukaryotes, tethering other proteins to DNA. Indeed, addition of A. fulgidus PCNA resulted in marked stimulation of PCR product generation. The PCNA-binding domain was determined, and a hybrid DNA polymerase was constructed by grafting this domain onto the classical PCR enzyme from Thermus aquaticus, Taq DNA polymerase. Addition of PCNA to PCR reactions catalyzed by the fusion protein greatly stimulated product generation, most likely by tethering the enzyme to DNA. This sliding clamp-induced increase of PCR performance implies a promising novel micromechanical principle for the development of PCR enzymes with enhanced processivity.	LION Biosci Ktiengesell, Exploratory Res, D-69120 Heidelberg, Germany; LION Biosci Ktiengesell, Life Sci Informat, D-69120 Heidelberg, Germany; LION Biosci Ktiengesell, Prot & Assays, D-69120 Heidelberg, Germany		Koegl, M (corresponding author), LION Biosci AG, Prot & Assays, Neuenheimer Feld 515-519, D-69120 Heidelberg, Germany.	manfred.koegl@lionbioscience.com	Girardot, Charles/AAF-2417-2020	Girardot, Charles/0000-0003-4301-3920				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 2000, NUCLEIC ACIDS RES, V28, P45, DOI 10.1093/nar/28.1.45; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Cann IKO, 1999, J BACTERIOL, V181, P6591, DOI 10.1128/JB.181.21.6591-6599.1999; Cann IKO, 1999, GENETICS, V152, P1249; Cann IKO, 1998, P NATL ACAD SCI USA, V95, P14250, DOI 10.1073/pnas.95.24.14250; Eckert K A, 1991, PCR Methods Appl, V1, P17; Grebe TW, 1999, ADV MICROB PHYSIOL, V41, P139, DOI 10.1016/S0065-2911(08)60167-8; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Hudson JR, 1997, GENOME RES, V7, P1169, DOI 10.1101/gr.7.12.1169; James P, 1996, GENETICS, V144, P1425; Keck JL, 2000, CHEM BIOL, V7, pR63, DOI 10.1016/S1074-5521(00)00094-6; Kelman Z, 2000, J BIOL CHEM, V275, P7327, DOI 10.1074/jbc.275.10.7327; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LUNDBERG KS, 1991, GENE, V108, P1, DOI 10.1016/0378-1119(91)90480-Y; MAKI S, 1988, J BIOL CHEM, V263, P6547; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tsurimoto T, 1998, BBA-GENE STRUCT EXPR, V1443, P23, DOI 10.1016/S0167-4781(98)00204-8; Uemori T, 1997, GENES CELLS, V2, P499, DOI 10.1046/j.1365-2443.1997.1380336.x; UEMORI T, 1999, Patent No. 9900506; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Walhout AJM, 2000, SCIENCE, V287, P116, DOI 10.1126/science.287.5450.116; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Zannis-Hadjopoulos M, 1999, J CELL BIOCHEM, P1	28	43	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16179	16188		10.1074/jbc.M107793200	http://dx.doi.org/10.1074/jbc.M107793200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11805086	hybrid			2022-12-25	WOS:000175510400128
J	Doege, K; Hall, LB; McKinnon, W; Chen, L; Stephens, DT; Garrison, K				Doege, K; Hall, LB; McKinnon, W; Chen, L; Stephens, DT; Garrison, K			A remote upstream element regulates tissue-specific expression of the rat aggrecan gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(II) COLLAGEN GENE; CHONDROCYTE-SPECIFIC ENHANCER; VERTEBRATE LIMB DEVELOPMENT; LARGE AGGREGATING PROTEOGLYCAN; CELL-LINE; SKELETAL DEVELOPMENT; CARTILAGE PROTEOGLYCAN; PATTERN-FORMATION; SONIC HEDGEHOG; RETINOIC ACID	The regulation of chondrogenesis and of the genes expressed as markers of chondrocyte differentiation is poorly understood. The hyaluronan-binding proteoglycan aggrecan is an essential and specific component of cartilage, but the aggrecan proximal promoter is expressed in an unregulated fashion in vitro. DNA comprising the rat aggrecan gene (83 kb including the 30-kb first intron) was surveyed for active elements, which would impart selective expression to the aggrecan promoter in transfection assays in vitro. A 4.7-kb DNA fragment (P3) with cell-specific enhancer activity was discovered similar to12 kb upstream of the transcription start site; this active DNA fragment is position- and orientation-independent, and strongly stimulates aggrecan promoter expression in chondrocytes, while weakly suppressing transcription in fibroblasts. Most of this activity has been localized to P3-7, a 2.3-kb internal fragment of P3. Another enhancer element (A23), which is not tissue-specific, was discovered about 70 kb downstream of the transcription start site. Several lines of transgenic mice were created using combinations of these DNA elements to drive the lacZ reporter gene. Neither a short (900 bp) nor a long (3.7 kb) promoter alone showed detectable expression in 14.5-day embryos, whereas placing the P3 tissue-specific enhancer together with PO gave strong expression restricted to embryonic cartilage of transgenic mice. The A23 downstream enhancer in conjunction with PO did not confer expression. This is the first report of a gene control region which confers authentic tissue-specific regulation of aggrecan in vitro or in vivo and should greatly facilitate understanding the coordinate regulation of chondrocytic genes.	Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida	Doege, K (corresponding author), Univ S Florida, Coll Med, Dept Biochem & Mol Biol, MDC 64,12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.							Bell DM, 1997, NAT GENET, V16, P174, DOI 10.1038/ng0697-174; Bi WM, 2001, P NATL ACAD SCI USA, V98, P6698, DOI 10.1073/pnas.111092198; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Bridgewater LC, 1998, J BIOL CHEM, V273, P14998, DOI 10.1074/jbc.273.24.14998; DOEGE K, 1990, BIOCHEM SOC T, V18, P200, DOI 10.1042/bst0180200; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; DOEGE KJ, 1994, J BIOL CHEM, V269, P29232; DUBOULE D, 1993, ANN GENET-PARIS, V36, P24; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695; Hall BK, 1995, INT J DEV BIOL, V39, P881; HARDINGHAM TE, 1994, EUR J CLIN CHEM CLIN, V32, P249; Hartmann C, 2000, DEVELOPMENT, V127, P3141; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; HORTON WE, 1988, EXP CELL RES, V178, P457, DOI 10.1016/0014-4827(88)90414-4; JOHNSON RL, 1994, BIOCHEM SOC T, V22, P569, DOI 10.1042/bst0220569; Juppner H, 2000, PEDIATR NEPHROL, V14, P606, DOI 10.1007/s004670000343; Kawakami Y, 1999, DEV GROWTH DIFFER, V41, P29; Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925-4773(98)00210-X; Komori T, 2000, BIOCHEM BIOPH RES CO, V276, P813, DOI 10.1006/bbrc.2000.3460; Krebsbach PH, 1996, J BIOL CHEM, V271, P4298, DOI 10.1074/jbc.271.8.4298; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336, DOI 10.1128/MCB.17.4.2336; Li H, 1995, J MOL EVOL, V41, P878; Liu Y, 2000, J BIOL CHEM, V275, P12712, DOI 10.1074/jbc.275.17.12712; Martin GR, 1998, GENE DEV, V12, P1571, DOI 10.1101/gad.12.11.1571; MUKHOPADHYAY K, 1995, J BIOL CHEM, V270, P27711, DOI 10.1074/jbc.270.46.27711; Ng JK, 1999, CURR TOP DEV BIOL, V41, P37; OXFORD JT, 1994, EXP CELL RES, V213, P28, DOI 10.1006/excr.1994.1169; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Pirok EW, 2001, J BIOL CHEM, V276, P16894, DOI 10.1074/jbc.M009944200; SANDELL LJ, 1994, MICROSC RES TECHNIQ, V28, P470, DOI 10.1002/jemt.1070280603; Sekiya I, 2000, J BIOL CHEM, V275, P10738, DOI 10.1074/jbc.275.15.10738; Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; Underhill T M, 2001, Novartis Found Symp, V232, P171; Valhmu WB, 1998, ARCH BIOCHEM BIOPHYS, V353, P29, DOI 10.1006/abbi.1998.0633; VALHMU WB, 1995, BIOCHEM J, V309, P535, DOI 10.1042/bj3090535; Valhmu WB, 1998, J BIOL CHEM, V273, P6196, DOI 10.1074/jbc.273.11.6196; WATANABE H, 1995, BIOCHEM J, V308, P433, DOI 10.1042/bj3080433; WATANABE H, 1994, NAT GENET, V7, P154, DOI 10.1038/ng0694-154; Weed M, 1997, MATRIX BIOL, V16, P53, DOI 10.1016/S0945-053X(97)90072-X; WONG M, 1992, J BIOL CHEM, V267, P5592; Xie WF, 1999, J BONE MINER RES, V14, P757, DOI 10.1359/jbmr.1999.14.5.757; Xu XL, 1999, CELL TISSUE RES, V296, P33, DOI 10.1007/s004410051264; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; ZHOU G, 1995, J CELL SCI, V108, P3677; Zou H, 1997, COLD SPRING HARB SYM, V62, P269	48	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13989	13997		10.1074/jbc.M109627200	http://dx.doi.org/10.1074/jbc.M109627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834732	hybrid			2022-12-25	WOS:000175096000084
J	Razmara, M; Srinivasula, SM; Wang, L; Poyet, JL; Geddes, BJ; DiStefano, PS; Bertin, J; Alnemri, ES				Razmara, M; Srinivasula, SM; Wang, L; Poyet, JL; Geddes, BJ; DiStefano, PS; Bertin, J; Alnemri, ES			CARD-8 protein, a new CARD family member that regulates caspase-1 activation and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; DOMAIN-CONTAINING PROTEIN; GAMMA-INDUCING FACTOR; CELL-DEATH; CYTOCHROME-C; OLIGOMERIZATION; INHIBITOR; INTERACTS; MOLECULE; ICEBERG	Caspase-associated recruitment domains (CARD) are protein-protein interaction modules found extensively in proteins that play important roles in apoptosis, NFkappaB activation, and cytokine regulation. In this study we identified a novel human protein, CARD-8, which contains a C-terminal CARD domain with high similarity to the CARD domain of caspase-1/ICE. We demonstrate that CARD-8 interacts physically with caspase-1 and negatively regulates caspase-1-dependent IL-1beta generation in the THP-1 monocytic cell line. CARD-8 binds also to ICEBERG and pseudo-ICE, two other recently identified proteins, which bind to the CARD domain of caspase-1 and negatively regulate its activity. Reverse transcriptase-PCR analysis revealed that CARD-8 is expressed mainly in monocytes, placenta, lymph nodes, and spleen. This pattern of expression is consistent with caspase-1 expression in the same cells and tissues. CARD-8 was also found to negatively regulate NF-kappaB activation by TNF-alpha stimulation and by ectopically expressed RICK, suggesting that this protein may control cell survival. Consistent with these results, stable expression of CARD-8 in U937 or THP-1 cells sensitizes the cells to differentiation-induced apoptosis. Overexpression of CARD-8 can also induce apoptosis in transfected cells. The results suggest that CARD-8 represents a new signaling molecule involved in the regulation of caspase-1 and NF-kappaB activation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA	Jefferson University; Jefferson University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	bertin@mpi.com; E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010; Poyet, Jean-Luc/G-7114-2017	Poyet, Jean-Luc/0000-0002-3747-255X	NATIONAL CANCER INSTITUTE [R01CA085421] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014357] Funding Source: NIH RePORTER; NCI NIH HHS [CA85421] Funding Source: Medline; NIA NIH HHS [AG14357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahmad M, 1997, CANCER RES, V57, P615; Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bertin J, 2000, J BIOL CHEM, V275, P41082, DOI 10.1074/jbc.C000726200; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S; Druilhe A, 2001, CELL DEATH DIFFER, V8, P649, DOI 10.1038/sj.cdd.4400881; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hida A, 2000, IMMUNOLOGY, V99, P553, DOI 10.1046/j.1365-2567.2000.00985.x; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; Inohara N, 2000, J BIOL CHEM, V275, P27823; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lee RT, 2001, CIRC RES, V88, P262, DOI 10.1161/01.RES.88.3.262; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; O'Reilly M, 1999, SHOCK, V12, P411, DOI 10.1097/00024382-199912000-00001; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Pathan N, 2001, J BIOL CHEM, V276, P32220, DOI 10.1074/jbc.M100433200; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Srinivasula SM, 1999, J BIOL CHEM, V274, P17946, DOI 10.1074/jbc.274.25.17946; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Thomson FS, 1998, IEEE T APPL SUPERCON, V8, P84, DOI 10.1109/77.678446; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; VanCriekinge W, 1996, J BIOL CHEM, V271, P27245, DOI 10.1074/jbc.271.44.27245; Wang L, 2001, J BIOL CHEM, V276, P21405, DOI 10.1074/jbc.M102488200; Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	134	142	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13952	13958		10.1074/jbc.M107811200	http://dx.doi.org/10.1074/jbc.M107811200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821383	hybrid			2022-12-25	WOS:000175096000079
J	Dance, GSC; Sowden, MP; Cartegni, L; Cooper, E; Krainer, AR; Smith, HC				Dance, GSC; Sowden, MP; Cartegni, L; Cooper, E; Krainer, AR; Smith, HC			Two proteins essential for apolipoprotein B mRNA editing are expressed from a single gene through alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; MOLECULAR-CLONING; ENZYME; CYTIDINE; APOBEC-1; BINDING; IDENTIFICATION; DOMAINS; COMPLEX; HEPATOCYTES	Apolipoprotein B (apoB) mRNA editing involves site-specific deamination of cytidine to form uridine, resulting in the production of an in-frame stop codon. Protein translated from edited mRNA is associated with a reduced risk of atherosclerosis, and hence the protein factors that regulate hepatic apoB mRNA editing are of interest. A human protein essential for apoB mRNA editing and an eight-amino acid-longer variant of no known function have been recently cloned. We report that both proteins, henceforth referred to as ACF64 and ACF65, supported APOBEC-1 (the catalytic subunit of the editosome) equivalently in editing of apoB mRNA. They are encoded by a single 82-kb gene on chromosome 10. The transcripts are encoded by 15 exons that are expressed from a tissue-specific promoter minimally contained within the -0.33-kb DNA sequence. ACF64 and ACF65 mRNAs are expressed in both liver and intestinal cells in an approximate 1:4 ratio. Exon 11 is alternatively spliced to include or exclude 24 nucleotides of exon 12, thereby encoding ACF65 and ACF64, respectively. Recognition motifs for the serine/arginine-rich (SR) proteins SC35, SRp40, SRp55, and SF2/ASF involved in alternative RNA splicing were predicted in exon 12. Overexpression of these SR proteins in liver cells demonstrated that alternative splicing of a mini-gene-derived transcript to express ACF65 was enhanced 6-fold by SRp40. The data account for the expression of two editing factors and provide a possible explanation for their different levels of expression.	Univ Rochester, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, Rochester, NY 14642 USA; Univ Rochester, Dept Environm Hlth Sci, Rochester, NY 14642 USA; Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY 14642 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Cold Spring Harbor Laboratory	Smith, HC (corresponding author), Univ Rochester, Dept Biochem & Biophys, 601 Elmwood Ave, Rochester, NY 14642 USA.	harold_smith@urmc.rochester.edu		Smith, Harold/0000-0001-6257-6791; Krainer, Adrian/0000-0001-9024-9501	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043739] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042699, R37GM042699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 43739] Funding Source: Medline; NIGMS NIH HHS [GM 42699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; Blanc V, 2001, J BIOL CHEM, V276, P10272, DOI 10.1074/jbc.M006435200; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; Chester A, 2000, BBA-GENE STRUCT EXPR, V1494, P1, DOI 10.1016/S0167-4781(00)00219-0; Dance GSC, 2001, NUCLEIC ACIDS RES, V29, P1772, DOI 10.1093/nar/29.8.1772; DIAMOND RH, 1993, J BIOL CHEM, V268, P15185; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; FUNAHASHI T, 1995, J LIPID RES, V36, P414; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Ginisty H, 2001, J BIOL CHEM, V276, P14338, DOI 10.1074/jbc.M011120200; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GREEVE J, 1993, J LIPID RES, V34, P1367; Greeve J, 1998, BIOL CHEM, V379, P1063, DOI 10.1515/bchm.1998.379.8-9.1063; HARRIS SG, 1993, J BIOL CHEM, V268, P7382; Hirano H, 1997, J LIPID RES, V38, P847; Lau PP, 1997, J BIOL CHEM, V272, P1452, DOI 10.1074/jbc.272.3.1452; LAU PP, 1990, NUCLEIC ACIDS RES, V18, P5817, DOI 10.1093/nar/18.19.5817; Lellek H, 2000, J BIOL CHEM, V275, P19848, DOI 10.1074/jbc.M001786200; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MACGINNITIE AJ, 1995, J BIOL CHEM, V270, P14768, DOI 10.1074/jbc.270.24.14768; Maquat LE, 2001, CELL, V104, P173, DOI 10.1016/S0092-8674(01)00202-1; McCahill A, 2000, MOL CELL BIOCHEM, V208, P77, DOI 10.1023/A:1007089921674; Mehta A, 2000, MOL CELL BIOL, V20, P1846, DOI 10.1128/MCB.20.5.1846-1854.2000; NAVARATNAM N, 1993, P NATL ACAD SCI USA, V90, P222, DOI 10.1073/pnas.90.1.222; Phung TL, 1996, METABOLISM, V45, P1056, DOI 10.1016/S0026-0495(96)90001-3; Schock D, 1996, P NATL ACAD SCI USA, V93, P1097, DOI 10.1073/pnas.93.3.1097; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Smith HC, 1997, RNA, V3, P1105; Sowden M, 1996, J BIOL CHEM, V271, P3011, DOI 10.1074/jbc.271.6.3011; Sowden M, 1996, RNA, V2, P274; Sowden MP, 2001, BIOCHEM J, V359, P697, DOI 10.1042/0264-6021:3590697; TENG BB, 1994, J BIOL CHEM, V269, P29395; TENG BB, 1993, SCIENCE, V260, P1816, DOI 10.1126/science.8511591; Valasek L, 2001, EMBO J, V20, P891, DOI 10.1093/emboj/20.4.891; Van Mater D, 1998, BIOCHEM BIOPH RES CO, V252, P334, DOI 10.1006/bbrc.1998.9647; von Wronski MA, 1998, METABOLISM, V47, P869, DOI 10.1016/S0026-0495(98)90128-7; Wu Y, 1999, J SURG RES, V85, P148, DOI 10.1006/jsre.1999.5654; Yang Y, 2000, J BIOL CHEM, V275, P22663, DOI 10.1074/jbc.M910406199	40	39	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12703	12709		10.1074/jbc.M111337200	http://dx.doi.org/10.1074/jbc.M111337200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815617	hybrid			2022-12-25	WOS:000175036300028
J	Ma, SG; Hill, KE; Caprioli, RM; Burk, RF				Ma, SG; Hill, KE; Caprioli, RM; Burk, RF			Mass spectrometric characterization of full-length rat selenoprotein P and three isoforms shortened at the C terminus - Evidence that three UGA codons in the mRNA open reading frame have alternative functions of specifying selenocysteine insertion or translation termination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-GEL DIGESTION; SELENIUM; PLASMA; PROTEIN; FORM	Selenoprotein P is an abundant extracellular glycoprotein. Its mRNA contains 10 UGAs in an open reading frame terminated by a UAA. This predicts that full-length selenoprotein P will contain 10 selenocysteine residues. Full-length selenoprotein P and three smaller isoforms that have identical N termini have been demonstrated. Selenoprotein P was purified from rat plasma, and the four isoforms were separated by heparin chromatography and SDS-PAGE. Mass spectrometric peptide analysis of the full-length isoform verified 357 of its 366 predicted amino acid residues, including its C terminus and all 10 selenocysteines. The C termini of the smaller isoforms were characterized by mass spectrometry. The shortened isoforms terminated where the second, third, and seventh selenocysteine residues were predicted to be. This suggests that all isoforms arise from the same mRNA and that the UGAs that specify the second, third, and seventh selenocysteines in full-length selenoprotein P can alternatively serve to terminate translation, producing the shorter isoforms.	Vanderbilt Univ, Sch Med, Med Ctr N, Div Gastroenterol,Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Mass Spectrometry Res Ctr, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Clin Nutr Res Unit, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Burk, RF (corresponding author), Vanderbilt Univ, Sch Med, Med Ctr N, Div Gastroenterol,Dept Med, C2104, Nashville, TN 37232 USA.				NIDDK NIH HHS [DK 26657] Funding Source: Medline; NIEHS NIH HHS [ES 02497] Funding Source: Medline; NIGMS NIH HHS [GM 58008] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002497, R37ES002497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058008] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BURK RF, 1991, AM J PHYSIOL, V261, pE26, DOI 10.1152/ajpendo.1991.261.1.E26; Burk RF, 1997, HISTOCHEM CELL BIOL, V108, P11, DOI 10.1007/s004180050141; BURK RF, 1995, HEPATOLOGY, V21, P561; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; Grundner-Culemann E, 2001, J MOL BIOL, V310, P699, DOI 10.1006/jmbi.2001.4809; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; HILL KE, 1991, J BIOL CHEM, V266, P10050; Himeno S, 1996, J BIOL CHEM, V271, P15769, DOI 10.1074/jbc.271.26.15769; KATO T, 1992, AM J PHYSIOL, V262, pG854, DOI 10.1152/ajpgi.1992.262.5.G854; MCCAUGHAN KK, 1995, P NATL ACAD SCI USA, V92, P5431, DOI 10.1073/pnas.92.12.5431; MOTSENBOCKER MA, 1982, BIOCHIM BIOPHYS ACTA, V719, P147, DOI 10.1016/0304-4165(82)90318-X; Nasim MT, 2000, J BIOL CHEM, V275, P14846, DOI 10.1074/jbc.275.20.14846; READ R, 1990, J BIOL CHEM, V265, P17899; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B	15	73	76	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12749	12754		10.1074/jbc.M111462200	http://dx.doi.org/10.1074/jbc.M111462200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821412	hybrid			2022-12-25	WOS:000175036300034
J	Reed, KA; Hobert, ME; Kolenda, CE; Sands, KA; Rathman, M; O'Connor, M; Lyons, S; Gewirtz, AT; Sansonetti, PJ; Madara, JL				Reed, KA; Hobert, ME; Kolenda, CE; Sands, KA; Rathman, M; O'Connor, M; Lyons, S; Gewirtz, AT; Sansonetti, PJ; Madara, JL			The Salmonella typhimurium flagellar basal body protein FHE is required for flagellin production and to induce a proinflammatory response in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTESTINAL EPITHELIUM; EXPORT APPARATUS; NEUTROPHIL MIGRATION; BACTERIAL FLAGELLIN; VIRULENCE FACTORS; SECRETION; EXPRESSION; CYTOSKELETAL; ACTIVATION	During apical colonization by Salmonella typhimurium, intestinal epithelial cells orchestrate a proinflammatory response that involves secretion of chemoattractants, predominantly interleukin-8, which coordinate neutrophil trans-epithelial migration at the site of infection. This host-pathogen interaction requires several S. typhimurium genes. To identify novel genes that participate in this pathogen-induced proinflammatory response, we created S. typhimurium Tn-10 transposon mutants and identified a single mutant with Tn-10 insertional inactivation within the fliE flagellar locus that was able to adhere to and invade intestinal epithelial cells normally but was unable to induce interleukin-8 secretion in host cells. The fliE-deficient mutant failed to secrete flagellin and lacked any surface assembly of flagellae. Unlike wild-type S. typhimurium, the fliE-deficient mutant did not activate the IkappaBalpha/ NF-kappaB signaling pathway or induce the coordinated trans-epithelial migration of isolated human neutrophils. Transcomplementation of the fliE-deficient mutant with a wild-type fliE-harboring plasmid restored all defects and produced a wild-type S. typhimurium phenotype. Furthermore, functional down-regulation of basolateral TLR5 completely inhibited the monolayers' ability to respond to both wild-type S. typhimurium and purified flagellin but had no affect on tumor necrosis factor alpha-induced responses. We therefore conclude that S. typhimurium fliE is essential for flagellin secretion, flagellar assembly, and S. typhimurium-induced proinflammatory responses through basolateral TLR5 and is consistent with the emerging model of S. typhimurium flagellin-induced inflammation.	Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; Texas A&M Univ, Dept Vet Pathobiol, College Stn, TX 77843 USA; Unite Pathogenie Microbienne Mol, Paris 15, France	Emory University; Texas A&M University System; Texas A&M University College Station	Hobert, ME (corresponding author), Emory Univ, Dept Pathol & Lab Med, 615 Michael St,Rm 125,Whitechurch Res Bldg, Atlanta, GA 30322 USA.	mhobert@emory.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010085, R37DK035932, R01DK035932] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aizawa SI, 1996, MOL MICROBIOL, V19, P1, DOI 10.1046/j.1365-2958.1996.344874.x; ALEXEYEV MF, 1995, GENE, V160, P59, DOI 10.1016/0378-1119(95)00141-R; Blocker A, 1999, J CELL BIOL, V147, P683, DOI 10.1083/jcb.147.3.683; Chen LM, 1996, SCIENCE, V274, P2115, DOI 10.1126/science.274.5295.2115; DAY DW, 1978, HISTOPATHOLOGY, V2, P117, DOI 10.1111/j.1365-2559.1978.tb01700.x; DHARMSATHAPHORN K, 1990, METHOD ENZYMOL, V192, P354; Diamond J M, 1977, Physiologist, V20, P10; Eaves-Pyles T, 2001, J IMMUNOL, V166, P1248, DOI 10.4049/jimmunol.166.2.1248; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; ECKMANN L, 1993, INFECT IMMUN, V61, P4569, DOI 10.1128/IAI.61.11.4569-4574.1993; FINLAY BB, 1991, J CELL SCI, V99, P283; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Gewirtz AT, 2000, J CLIN INVEST, V105, P79, DOI 10.1172/JCI8066; Gewirtz AT, 2001, J CLIN INVEST, V107, P99, DOI 10.1172/JCI10501; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HENSON PM, 1975, J CLIN INVEST, V56, P1053, DOI 10.1172/JCI108152; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; KLECKNER N, 1989, MOBILE DNA; Komoriya K, 1999, MOL MICROBIOL, V34, P767, DOI 10.1046/j.1365-2958.1999.01639.x; KUMAR NB, 1982, AM J SURG PATHOL, V6, P523, DOI 10.1097/00000478-198209000-00004; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Macnab RM, 2000, ASM NEWS, V66, P738; Macnab RM, 1999, J BACTERIOL, V181, P7149, DOI 10.1128/JB.181.23.7149-7153.1999; MADARA JL, 1992, J CLIN INVEST, V89, P1938, DOI 10.1172/JCI115800; MADARA JL, 1993, J CLIN INVEST, V91, P2320, DOI 10.1172/JCI116462; MCCORMICK BA, 1995, J CELL BIOL, V131, P1599, DOI 10.1083/jcb.131.6.1599; MCCORMICK BA, 1995, INFECT IMMUN, V63, P2302, DOI 10.1128/IAI.63.6.2302-2309.1995; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; McCormick BA, 1998, J IMMUNOL, V160, P455; MCGOVERN VJ, 1979, AM J SURG PATHOL, V3, P483, DOI 10.1097/00000478-197912000-00001; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; Minamino T, 1999, J BACTERIOL, V181, P1388, DOI 10.1128/JB.181.5.1388-1394.1999; Minamino T, 2000, MOL MICROBIOL, V35, P1052, DOI 10.1046/j.1365-2958.2000.01771.x; Minamino T, 2000, J BACTERIOL, V182, P3029, DOI 10.1128/JB.182.11.3029-3036.2000; MULLER V, 1992, J BACTERIOL, V174, P2298; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; PARKOS CA, 1992, J CELL BIOL, V117, P757, DOI 10.1083/jcb.117.4.757; PARKOS CA, 1991, J CLIN INVEST, V88, P1605, DOI 10.1172/JCI115473; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; STROHMEIER GR, 1995, J BIOL CHEM, V270, P2387, DOI 10.1074/jbc.270.5.2387; TAKEUCHI A, 1967, AM J PATHOL, V50, P109; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Young GM, 1999, P NATL ACAD SCI USA, V96, P6456, DOI 10.1073/pnas.96.11.6456	48	62	64	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13346	13353		10.1074/jbc.M200149200	http://dx.doi.org/10.1074/jbc.M200149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821427	hybrid, Green Published			2022-12-25	WOS:000175036300106
J	Choi, J; Ko, J; Park, E; Lee, JR; Yoon, J; Lim, S; Kim, E				Choi, J; Ko, J; Park, E; Lee, JR; Yoon, J; Lim, S; Kim, E			Phosphorylation of stargazin by protein kinase A regulates its interaction with PSD-95	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GLUR1 SUBUNIT; AMPA RECEPTOR; POSTSYNAPTIC DENSITY; MOUSE STARGAZER; GAMMA-SUBUNIT; MUTANT MOUSE; PDZ DOMAIN; RAT-BRAIN; CHANNEL; BINDING	Stargazin is the first transmembrane protein known to associate with AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate) glutamate receptors (AMPARs) and regulate their synaptic targeting by two distinct mechanisms, specifically via delivery of AMPARs to the surface membrane and synaptic targeting of these receptors by binding to PSD-95/SAP-90 and related PDZ proteins. However, it is not known whether and how this stargazin-mediated synaptic targeting of AMPs its regulated. Stargazin interacts with the PDZ domains of PSD-95 through the C-terminal PDZ-binding motif. The stargazin C terminus contains a consensus sequence for phosphorylation by cAMP-dependent protein kinase A (PKA). Phosphorylation site-specific stargazin antibodies reveal that the stargazin C terminus is phosphorylated at the Thr-321 residue in heterologous cells and in vivo. Stargazin phosphorylation is enhanced by the catalytic subunit of PKA. Mutations mimicking stargazin phosphorylation (T321E and T321D) lead to elimination of yeast two-hybrid interactions, in vitro coimmunoprecipitation, and coclustering between stargazin and PSD-95. Phosphorylated stargazin shows a selective loss of coimmunoprecipitation with PSD-95 in heterologous cells and limited enrichment in postsynaptic density fractions of rat brain. These results suggest that phosphorylation of the stargazin C terminus by PKA regulates its interaction with PSD-95 and synaptic targeting of AMPARs.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Kim, E (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.		Kim, Eunjoon/C-1566-2011					Banke TG, 2000, J NEUROSCI, V20, P89, DOI 10.1523/JNEUROSCI.20-01-00089.2000; Burgess DL, 2001, GENOMICS, V71, P339, DOI 10.1006/geno.2000.6440; Burgess DL, 1999, GENOME RES, V9, P1204, DOI 10.1101/gr.9.12.1204; CARLIN RK, 1980, J CELL BIOL, V86, P831, DOI 10.1083/jcb.86.3.831; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; Chu PJ, 2001, GENE, V280, P37, DOI 10.1016/S0378-1119(01)00738-7; Cohen NA, 1996, NEURON, V17, P759, DOI 10.1016/S0896-6273(00)80207-X; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Hashimoto K, 1999, J NEUROSCI, V19, P6027, DOI 10.1523/JNEUROSCI.19-14-06027.1999; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Klugbauer N, 2000, FEBS LETT, V470, P189, DOI 10.1016/S0014-5793(00)01306-5; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; MAURER RA, 1989, J BIOL CHEM, V264, P6870; Nakagawa T, 2000, SCIENCE, V290, P2270; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; NOEBELS JL, 1990, EPILEPSY RES, V7, P129, DOI 10.1016/0920-1211(90)90098-G; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Puranam RS, 1998, NAT GENET, V19, P313, DOI 10.1038/1194; Qiao XO, 1996, J NEUROSCI, V16, P640; Qiao XX, 1998, J NEUROSCI, V18, P6990; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Srivastava S, 1998, NEURON, V21, P581, DOI 10.1016/S0896-6273(00)80568-1; Tomita S, 2001, J CELL BIOL, V153, pF19, DOI 10.1083/jcb.153.5.F19; Wyszynski M, 1998, NEUROPHARMACOLOGY, V37, P1335, DOI 10.1016/S0028-3908(98)00120-8	34	100	106	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12359	12363		10.1074/jbc.M200528200	http://dx.doi.org/10.1074/jbc.M200528200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805122	hybrid			2022-12-25	WOS:000174846400099
J	Kanaya, E; Nakajima, N; Okada, K				Kanaya, E; Nakajima, N; Okada, K			Non-sequence-specific DNA binding by the FILAMENTOUS FLOWER protein from Arabidopsis thaliana is reduced by EDTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR; COMPLEX REVEALS; ZINC-FINGER; HMG BOX; GENE; DOMAIN; DETERMINANTS; RECOGNITION; CHROMATIN; ENCODES	The FILAMENTOUS FLOWER protein has a zinc finger domain, hydrophobic region, proline-rich region, and a HMG box-like domain. We have reported that zinc release at the zinc finger is probably facilitated by the non-canonical cysteine residue at position 56, and that EDTA causes the structural change and enhances the self-assembly of the protein (Kanaya, E., Watanabe, K., Nakajima, N., Okada, K., and Shimura, Y. (2001) J. Bio. Chem. 276, 7383-7390). To investigate this aspect further we examined the DNA binding function of the FILAMENTOUS FLOWER protein. Gel retardation experiments showed that the FILAMENTOUS FLOWER protein binds to DNA without sequence specificity. Deletion analyses suggested that the zinc finger domain and the hydrophobic region are not required but the proline-rich region and the HMG box-like domain are indispensable for the DNA binding by the FILAMENTOUS FLOWER protein. The DNA binding by the protein consisting of the zinc finger domain and the rest of the regions was reduced with the addition of EDTA. This result probably suggests that the zinc release, the structural change probably occurring in the zinc finger domain, the intermolecular interaction, and the self-assembly of the protein are related to the dissociation of the FILAMENTOUS FLOWER protein from DNA.	Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyoku 6068502, Japan	Kyoto University	Kanaya, E (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.							Allain FHT, 1999, EMBO J, V18, P2563, DOI 10.1093/emboj/18.9.2563; Bowman JL, 1999, DEVELOPMENT, V126, P2387; Churchill MEA, 1999, METHOD ENZYMOL, V304, P99; Eshed Y, 1999, CELL, V99, P199, DOI 10.1016/S0092-8674(00)81651-7; Fujii Y, 1999, EMBO J, V18, P5028, DOI 10.1093/emboj/18.18.5028; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GE H, 1994, J BIOL CHEM, V269, P17136; Golz JF, 1999, CURR BIOL, V9, pR861, DOI 10.1016/S0960-9822(00)80047-0; INOUE S, 1991, NUCLEIC ACIDS RES, V19, P4091, DOI 10.1093/nar/19.15.4091; JONES DNM, 1994, STRUCTURE, V2, P609, DOI 10.1016/S0969-2126(00)00063-0; Kanaya E, 1999, J BIOL CHEM, V274, P16068, DOI 10.1074/jbc.274.23.16068; Kanaya E, 2001, J BIOL CHEM, V276, P7383, DOI 10.1074/jbc.M009491200; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Miller J. H., 1972, EXPT MOL GENETICS, P433; Murphy FV, 1999, EMBO J, V18, P6610, DOI 10.1093/emboj/18.23.6610; NISHIKAWA J, 1994, NUCLEIC ACIDS RES, V22, P2902, DOI 10.1093/nar/22.15.2902; PAULL TT, 1993, GENE DEV, V7, P1521, DOI 10.1101/gad.7.8.1521; PAULL TT, 1995, J BIOL CHEM, V270, P8744, DOI 10.1074/jbc.270.15.8744; PETTIJOHN DE, 1988, J BIOL CHEM, V263, P12793; PIL PM, 1993, P NATL ACAD SCI USA, V90, P9465, DOI 10.1073/pnas.90.20.9465; Rastinejad F, 2000, EMBO J, V19, P1045, DOI 10.1093/emboj/19.5.1045; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Sawa S, 1999, PLANT CELL, V11, P69, DOI 10.1105/tpc.11.1.69; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; Stros M, 1998, J BIOL CHEM, V273, P10355; SUSSEX I. M., 1955, PHYTOMORPHOLOGY [DELHI], V5, P286; Sussex IM, 1954, NATURE, V174, P351; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; Villanneva JM, 1999, GENE DEV, V13, P3160, DOI 10.1101/gad.13.23.3160; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; Yen YM, 1998, J BIOL CHEM, V273, P4424, DOI 10.1074/jbc.273.8.4424	34	36	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11957	11964		10.1074/jbc.M108889200	http://dx.doi.org/10.1074/jbc.M108889200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812777	hybrid			2022-12-25	WOS:000174846400047
J	Dorsam, G; Goetzl, EJ				Dorsam, G; Goetzl, EJ			Vasoactive intestinal peptide receptor-1 (VPAC-1) is a novel gene target of the hemolymphopoietic transcription factor Ikaros	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; CYCLASE-ACTIVATING POLYPEPTIDE; LYMPHOCYTE DEVELOPMENT; FAMILY; COMPLEXES; EXPRESSION; REPRESSION; ENCODES; VIP	Vasoactive intestinal peptide and its G-protein-coupled receptors, VPAC-1 and VPAC-2, are highly expressed in the immune system and modulate diverse T cell functions. The human VPAC-1 5'-flanking region (1.4 kb) contains four high affinity Ikaros (IK) consensus sequences. Ikaros native protein from T cell nuclear extracts and IK-1 and IK-2 recombinant proteins recognized an IK high affinity binding motif in the VPAC-1 promoter in electrophoretic mobility shift assays by a sequence-specific mechanism, and anti-IK antibodies supershifted this complex. Stable NIH-3T3 clones over-expressing IK-1 or IK-2 isoforms were generated to investigate Ikaros regulation of endogenous VPAC-1 expression as assessed by quantifying VPAC-1 mRNA and protein. By traditional and fluorometric-based kinetic reverse transcription-PCR and I-125-labeled vasoactive intestinal peptide binding, both IK-1 and IK-2 suppressed endogenous VPAC-1 expression in NIH-3T3 clones by a range of 50-93%. When a series of nested deletions of the VPAC-1 luciferase reporter construct were transiently transfected into IK-2 clones there was up to a 41% decrease in transcriptional activity compared with vector control. Two major IK-2 binding domains also were identified at -1076 to -623 bp and at -222 to -35 bp, respectively. As both Ikaros and its novel target VPAC-1 are highly expressed in T cells, this system may be a dominant determinant of the VPAC-1 expression in immune responses.	Univ Calif San Francisco, Med Ctr, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Med Ctr, Dept Microbiol Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Dorsam, G (corresponding author), Univ Calif San Francisco, Med Ctr, Dept Med, UB8B,Box 0711,533 Parnassus Ave & 4th, San Francisco, CA 94143 USA.		Dorsam, Glenn/GYD-8815-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029912, R01AI029912] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK010107] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 29912] Funding Source: Medline; NIDDK NIH HHS [F32DK10107-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avitahl N, 1999, IMMUNITY, V10, P333, DOI 10.1016/S1074-7613(00)80033-3; Bellinger DL, 1996, ADV NEUROIMMUNOL, V6, P5, DOI 10.1016/S0960-5428(96)00008-3; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Cortes M, 1999, CURR OPIN IMMUNOL, V11, P167, DOI 10.1016/S0952-7915(99)80028-4; Couvineau A, 2000, BIOCHEM J, V347, P623, DOI 10.1042/0264-6021:3470623; DANEK A, 1983, J IMMUNOL, V131, P1173; Delgado M, 2000, J IMMUNOL, V165, P114, DOI 10.4049/jimmunol.165.1.114; Dorsam G, 2000, ANN NY ACAD SCI, V921, P79; Dorsam G, 2000, J PHARMACOL EXP THER, V292, P271; Gaudin P, 1998, J BIOL CHEM, V273, P4990, DOI 10.1074/jbc.273.9.4990; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; Georgopoulos K, 1997, ANNU REV IMMUNOL, V15, P155, DOI 10.1146/annurev.immunol.15.1.155; Harmar AJ, 1998, PHARMACOL REV, V50, P265; Jiang XM, 1998, ANN NY ACAD SCI, V865, P397, DOI 10.1111/j.1749-6632.1998.tb11204.x; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Lara-Marquez ML, 2001, J IMMUNOL, V166, P2522, DOI 10.4049/jimmunol.166.4.2522; Madsen B, 2001, MOL CELL ENDOCRINOL, V172, P203, DOI 10.1016/S0303-7207(00)00341-5; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; Molnar A, 1996, J IMMUNOL, V156, P585; Nussdorfer GG, 1998, PEPTIDES, V19, P1443, DOI 10.1016/S0196-9781(98)00102-8; Sabbattini P, 2001, EMBO J, V20, P2812, DOI 10.1093/emboj/20.11.2812; SAID SI, 1972, EUR J BIOCHEM, V28, P199, DOI 10.1111/j.1432-1033.1972.tb01903.x; Shadiack AM, 2001, J NEUROSCI, V21, P363, DOI 10.1523/JNEUROSCI.21-02-00363.2001; SPEEDHARAN SP, 1995, P NATL ACAD SCI USA, V92, P2939; Teresi S, 1996, IMMUNOL LETT, V50, P105, DOI 10.1016/0165-2478(96)02524-2; Trinh LA, 2001, GENE DEV, V15, P1817, DOI 10.1101/gad.905601; Xia MH, 1996, J IMMUNOL, V157, P1132; XIN ZC, 1994, J NEUROIMMUNOL, V54, P59, DOI 10.1016/0165-5728(94)90231-3	30	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13488	13493		10.1074/jbc.M107922200	http://dx.doi.org/10.1074/jbc.M107922200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11812772	hybrid			2022-12-25	WOS:000175096000021
J	Kopperud, R; Christensen, AE; Kjaerland, E; Viste, K; Kleivdal, H; Doskeland, SO				Kopperud, R; Christensen, AE; Kjaerland, E; Viste, K; Kleivdal, H; Doskeland, SO			Formation of inactive cAMP-saturated holoenzyme of cAMP-dependent protein kinase under physiological conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; CYCLIC-AMP; REGULATORY SUBUNITS; GENE-EXPRESSION; ACTIVATION; UBIQUITIN; PHOSPHORYLATION; LOCALIZATION; MECHANISM; POTENCY	The complex of the subunits (RIalpha, Calpha) of cAMP-dependent protein kinase I (cA-PKI) was much more stable (K-d = 0.25 mum) in the presence of excess cAMP than previously thought. The ternary complex of C subunit with cAMP-saturated RIalpha or RIIalpha was devoid of catalytic activity against either peptide or physiological protein substrates. The ternary complex was destabilized by protein kinase substrate. Extrapolation from the in vitro data suggested about one-fourth of the C subunit to be in ternary complex in maximally cAMP-stimulated cells. Cells overexpressing either RIalpha or RIIalpha showed decreased CRE-dependent gene induction in response to maximal cAMP stimulation. This could be explained by enhanced ternary complex formation. Modulation of ternary complex formation by the level of R subunit may represent a novel way of regulating the cAMP kinase activity in maximally cAMP-stimulated cells.	Univ Bergen, Dept Anat & Cell Biol, N-5009 Bergen, Norway	University of Bergen	Doskeland, SO (corresponding author), Univ Bergen, Dept Anat & Cell Biol, Arstadveien 19, N-5009 Bergen, Norway.	doskeland@iac.uib.no		Doskeland, Stein Ove/0000-0002-4009-4756				ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ADAMS SR, 1999, FLUORESCENCE LUMINES, P156; BUILDER SE, 1980, J BIOL CHEM, V255, P3514; BUILDER SE, 1980, COLD SPRING HARB SYM, V8, P33; CHAIN DG, 1995, J NEUROSCI, V15, P7592; Chain DG, 1999, NEURON, V22, P147, DOI 10.1016/S0896-6273(00)80686-8; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Croniger CM, 2001, J BIOL CHEM, V276, P629, DOI 10.1074/jbc.M007576200; DOSKELAND AP, 1992, EUR J BIOCHEM, V206, P161, DOI 10.1111/j.1432-1033.1992.tb16913.x; DOSKELAND SO, 1988, METHOD ENZYMOL, V159, P147; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; EKANGER R, 1989, J BIOL CHEM, V264, P4374; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Francis SH, 1999, CRIT REV CL LAB SCI, V36, P275, DOI 10.1080/10408369991239213; Gangolli EA, 2000, MOL CELL BIOL, V20, P3442, DOI 10.1128/MCB.20.10.3442-3448.2000; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; HAGIWARA M, 1993, MOL CELL BIOL, V13, P4852, DOI 10.1128/MCB.13.8.4852; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HOFMANN F, 1977, J BIOL CHEM, V252, P1441; Honda A, 2001, P NATL ACAD SCI USA, V98, P2437, DOI 10.1073/pnas.051631298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SARASWAT LD, 1986, J BIOL CHEM, V261, P1091; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; SCHULTZ C, 1994, MOL PHARMACOL, V46, P702; SCHULTZ C, 1993, J BIOL CHEM, V268, P6316; WANG YH, 1991, P NATL ACAD SCI USA, V88, P2446, DOI 10.1073/pnas.88.6.2446; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; Zaccolo M, 2000, NAT CELL BIOL, V2, P25, DOI 10.1038/71345	33	54	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13443	13448		10.1074/jbc.M109869200	http://dx.doi.org/10.1074/jbc.M109869200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834733	hybrid			2022-12-25	WOS:000175096000015
J	Kurumizaka, H; Ikawa, S; Nakada, M; Enomoto, R; Kagawa, W; Kinebuchi, T; Yamazoe, M; Yokoyama, S; Shibata, T				Kurumizaka, H; Ikawa, S; Nakada, M; Enomoto, R; Kagawa, W; Kinebuchi, T; Yamazoe, M; Yokoyama, S; Shibata, T			Homologous pairing and ring and filament structure formation activities of the human Xrcc2-Rad51D complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPAIR GENE; SINGLE-STRANDED-DNA; HUMAN RAD52 PROTEIN; COLI RECA PROTEIN; ESCHERICHIA-COLI; RECOMBINATIONAL REPAIR; MOUSE GENES; XRCC2; FAMILY; PROMOTES	The Xrcc2 and Rad51D/Rad51L3 proteins, which belong to the Rad51 paralogs, are required for homologous recombinational repair (HRR) in vertebrates. The Xrcc2 and Rad51D/Rad51L3 genes, whose products interact with each other, have essential roles in ensuring normal embryonic development. In the present study, we coexpressed the human Xrcc2 and Rad51D/Rad51L3 proteins (Xrcc2 and Rad51D, respectively) in Escherichia coli, and purified the Xrcc2-Rad51D complex to homogeneity. The Xrcc2-Rad51D complex catalyzed homologous pairing between single-stranded and double-stranded DNA, similar to the function of the Xrcc3-Rad51C complex, which is another complex of the Rad51 paralogs. An electron microscopic analysis showed that Xrcc2-Rad51D formed a multimeric ring structure in the absence of DNA. In the presence of ssDNA, Xrcc2-Rad51D formed a filamentous structure, which is commonly observed among the human homologous pairing proteins, Rad51, Rad52, and Xrcc3-Rad51C.	RIKEN, Genomic Sci Ctr, Yokohama, Kanagawa 2300045, Japan; RIKEN, Harima Inst, Cellular Signaling Lab, Spring 8, Sayo, Hyogo 6795143, Japan; Japan Sci & Technol Corp, CREST, Chiba 2920812, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 1130033, Japan; Kyoto Univ, Fac Med, Sakyo Ku, Kyoto 6068501, Japan; RIKEN, Cellular & Mol Biol Lab, Wako, Saitama 3510198, Japan	RIKEN; Japan Synchrotron Radiation Research Institute; RIKEN; Japan Science & Technology Agency (JST); University of Tokyo; Kyoto University; RIKEN	Yokoyama, S (corresponding author), RIKEN, Genomic Sci Ctr, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.		Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kurumizaka, Hitoshi/0000-0001-7412-3722; Kagawa, Wataru/0000-0002-8801-6589				Albala JS, 1997, GENOMICS, V46, P476, DOI 10.1006/geno.1997.5062; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Braybrooke JP, 2000, J BIOL CHEM, V275, P29100, DOI 10.1074/jbc.M002075200; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P1653, DOI 10.1093/nar/26.7.1653; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; Deans B, 2000, EMBO J, V19, P6675, DOI 10.1093/emboj/19.24.6675; Dosanjh MK, 1998, NUCLEIC ACIDS RES, V26, P1179, DOI 10.1093/nar/26.5.1179; FLORY J, 1984, P NATL ACAD SCI-BIOL, V81, P7026, DOI 10.1073/pnas.81.22.7026; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Griffin CS, 2000, NAT CELL BIOL, V2, P757, DOI 10.1038/35036399; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JONES NJ, 1995, GENOMICS, V26, P619, DOI 10.1016/0888-7543(95)80187-Q; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Kawabata M, 1999, BIOCHEM BIOPH RES CO, V257, P156, DOI 10.1006/bbrc.1999.0413; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Kurumizaka H, 2001, P NATL ACAD SCI USA, V98, P5538, DOI 10.1073/pnas.091603098; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Masson JY, 2001, GENE DEV, V15, P3296, DOI 10.1101/gad.947001; MCENTEE K, 1979, P NATL ACAD SCI USA, V76, P2615, DOI 10.1073/pnas.76.6.2615; Miller KA, 2002, J BIOL CHEM, V277, P8406, DOI 10.1074/jbc.M108306200; Noirot P, 1998, J BIOL CHEM, V273, P12274, DOI 10.1074/jbc.273.20.12274; O'Regan P, 2001, J BIOL CHEM, V276, P22148, DOI 10.1074/jbc.M102396200; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; Parsons CA, 2000, EMBO J, V19, P4175, DOI 10.1093/emboj/19.15.4175; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Pittman DL, 1998, GENOMICS, V49, P103, DOI 10.1006/geno.1998.5226; Pittman DL, 2000, GENESIS, V26, P167, DOI 10.1002/(SICI)1526-968X(200003)26:3<167::AID-GENE1>3.0.CO;2-M; Rice MC, 1997, P NATL ACAD SCI USA, V94, P7417, DOI 10.1073/pnas.94.14.7417; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; SHIBATA T, 1981, J BIOL CHEM, V256, P7557; SHIBATA T, 1979, P NATL ACAD SCI USA, V76, P1638, DOI 10.1073/pnas.76.4.1638; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; THACKER J, 1995, HUM MOL GENET, V4, P113, DOI 10.1093/hmg/4.1.113; Thacker J, 1999, TRENDS GENET, V15, P166, DOI 10.1016/S0168-9525(99)01733-3	47	65	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14315	14320		10.1074/jbc.M105719200	http://dx.doi.org/10.1074/jbc.M105719200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834724	hybrid			2022-12-25	WOS:000175096000125
J	Ollagnier-de Choudens, S; Sanakis, Y; Hewitson, KS; Roach, P; Munck, E; Fontecave, M				Ollagnier-de Choudens, S; Sanakis, Y; Hewitson, KS; Roach, P; Munck, E; Fontecave, M			Reductive cleavage of S-adenosylmethionine by biotin synthase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTER; PYRUVATE FORMATE-LYASE; ANAEROBIC RIBONUCLEOTIDE REDUCTASE; LYSINE 2,3-AMINOMUTASE; RADICAL MECHANISMS; ACTIVATING ENZYME; PROTEIN; 2FE-2S; QUANTITATION; CONVERSION	Biotin synthase (BioB) catalyzes the insertion of a sulfur atom between the C6 and C9 carbons of dethiobiotin. Reconstituted BioB from Escherichia coli contains a [4Fe-4S](2+/1+) cluster thought to be involved in the reduction and cleavage of S-adenosylmethionine (AdoMet), generating methionine and the reactive 5'-deoxyadenosyl radical responsible for dethiobiotin H-abstraction. Using EPR and Mossbauer spectroscopy as well as methionine quantitation we demonstrate that the reduced S = 1/2 [4Fe-4S](1+) cluster is indeed capable of injecting one electron into AdoMet, generating one equivalent of both methionine and S = 0 [4Fe-4S](2+) cluster. Dethiobiotin is not required for the reaction. Using site-directed mutagenesis we show also that, among the eight cysteines of BioB, only three (Cys-53, Cys-57, Cys-60) are essential for AdoMet reductive cleavage, suggesting that these cysteines are involved in chelation of the [4Fe-4S](2+/1+) cluster.	Univ Grenoble 1, CNRS, CEA,Ctr Redox Biol, Dept Biol Mol Struct & Chim Biol,Lab Chim & Biochi, F-38054 Grenoble 09, France; Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; Oxford Ctr Mol Sci, Dyson Perrins Lab, Oxford OX1 3QY, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Carnegie Mellon University; University of Oxford; University of Southampton	Fontecave, M (corresponding author), Univ Grenoble 1, CNRS, CEA,Ctr Redox Biol, Dept Biol Mol & Struct Chim Biol,Lab Chim & Biochi, 17 Ave des Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr	Roach, Peter/C-6248-2013; Roach, Peter/AAW-7071-2021	Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Roach, Peter/0000-0001-9880-2877	NIGMS NIH HHS [GM22701] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022701] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHTON WT, 1978, J HETEROCYCLIC CHEM, V15, P489, DOI 10.1002/jhet.5570150324; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BIRCH OM, 1995, J BIOL CHEM, V270, P19158, DOI 10.1074/jbc.270.32.19158; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bui BTS, 1998, FEBS LETT, V440, P226, DOI 10.1016/S0014-5793(98)01464-1; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2001, ADV PROTEIN CHEM, V58, P1; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; Guianvarc'h D, 1997, BIOCHEM BIOPH RES CO, V236, P402, DOI 10.1006/bbrc.1997.6952; Henshaw TF, 2000, J AM CHEM SOC, V122, P8331, DOI 10.1021/ja002012q; Hewitson KS, 2000, FEBS LETT, V466, P372, DOI 10.1016/S0014-5793(00)01101-7; Hewitson KS, 2002, J BIOL INORG CHEM, V7, P83, DOI 10.1007/s007750100268; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Lieder KW, 1998, BIOCHEMISTRY-US, V37, P2578, DOI 10.1021/bi972417w; Marquet A, 2001, VITAM HORM, V61, P51; McIver L, 2000, J BIOL CHEM, V275, P13888, DOI 10.1074/jbc.275.18.13888; NOZAKI Y, 1986, ARCH BIOCHEM BIOPHYS, V249, P437, DOI 10.1016/0003-9861(86)90020-2; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ollagnier-de Choudens S, 2000, BIOCHEMISTRY-US, V39, P4165, DOI 10.1021/bi992090u; Padovani D, 2001, BIOCHEMISTRY-US, V40, P6713, DOI 10.1021/bi002936q; PETROVICH RM, 1992, BIOCHEMISTRY-US, V31, P10774, DOI 10.1021/bi00159a019; Ruzicka FJ, 2000, J BACTERIOL, V182, P469, DOI 10.1128/JB.182.2.469-476.2000; SANYAL I, 1994, BIOCHEMISTRY-US, V33, P3625, DOI 10.1021/bi00178a020; Shaw NM, 1998, BIOCHEM J, V330, P1079; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; Tamarit J, 2000, J BIOL CHEM, V275, P15669, DOI 10.1074/jbc.275.21.15669; Ugulava NB, 2000, BIOCHEMISTRY-US, V39, P5206, DOI 10.1021/bi9926227; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8343, DOI 10.1021/bi0104625; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p	35	63	64	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13449	13454		10.1074/jbc.M111324200	http://dx.doi.org/10.1074/jbc.M111324200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834738	hybrid			2022-12-25	WOS:000175096000016
J	Yamasaki, K; Daiho, T; Suzuki, H				Yamasaki, K; Daiho, T; Suzuki, H			Remarkable stability of solubilized and delipidated sarcoplasmic reticulum Ca2+-ATPase with tightly bound fluoride and magnesium against detergent-induced denaturation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ TRANSPORT ATPASE; ADENOSINE-TRIPHOSPHATASE; CONFORMATIONAL CHANGE; CALCIUM ATPASE; HIGH-AFFINITY; THAPSIGARGIN; BINDING; CA-2+-ATPASE; INHIBITION; STABILIZATION	Conditions were developed in the absence of Ca2+ for purification, delipidation, and long term stabilization of octaethylene glycol monododecyl ether (C12E8)-solubilized sarcoplasmic reticulum Ca2+-ATPase with tightly bound Mg2+ and F-, an analog for the phosphoenzyme intermediate without bound Ca2+. The Ca2+-ATPase activity to monitor denaturation was assessed after treatment with 20 mm Ca2+ to release tightly bound Mg2+/F-. The purification and delipidation was successfully achieved with Reactive Red-agarose affinity chromatography. The solubilized Mg2+/F--bound Ca2+-ATPase was very rapidly denatured at pH 8, but was perfectly stabilized at pH 6 against denaturation for over 20 days at 4degreesC even without exogenously added phospholipid and at a high C12E8/enzyme weight ratio (10:1). The activity was not restored unless the enzyme was treated with 20 mm Ca2+, showing that tightly bound Mg2+/F- was not released during the long term incubation. The perfect stability was attained with or without 0.1 mm dithiothreitol, but inactivation occurred with a half-life of 10 days in the presence of 1 mm dithiothreitol, possibly due to reduction of a specific disulfide bond(s). The remarkable stability is likely conferred by intimate gathering of cytoplasmic domains of Ca2+-ATPase molecule induced by tight binding of Mg2+/F-. The present study thus reveals an essential property of the Mg2+/F-/Ca2+-ATPase complex, which will likely provide clues to understanding structure of the Ca2+-released form of phosphoenzyme intermediate at an atomic level.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						BARRABIN H, 1984, BIOCHEMISTRY-US, V23, P1542, DOI 10.1021/bi00302a031; Champeil P, 2001, J BIOL CHEM, V276, P5795, DOI 10.1074/jbc.M006980200; COLL RJ, 1984, J BIOL CHEM, V259, P4249; DAIHO T, 1994, J BIOL CHEM, V269, P11060; DAIHO T, 1993, BIOCHEMISTRY-US, V32, P10021, DOI 10.1021/bi00089a018; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DUPONT Y, 1982, FEBS LETT, V139, P237, DOI 10.1016/0014-5793(82)80860-0; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; GAREWAL HS, 1973, ANAL BIOCHEM, V54, P319, DOI 10.1016/0003-2697(73)90359-X; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; Henao F, 2001, J BIOL CHEM, V276, P24284, DOI 10.1074/jbc.M103905200; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; Hua SM, 1997, BIOCHEMISTRY-US, V36, P11865, DOI 10.1021/bi970105n; INESI G, 1980, J BIOL CHEM, V255, P6040; KOSKKOSICKA D, 1983, BIOCHEMISTRY-US, V22, P2559, DOI 10.1021/bi00279a037; KUBOTA T, 1993, BIOCHIM BIOPHYS ACTA, V1163, P131, DOI 10.1016/0167-4838(93)90174-P; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND S, 1989, J BIOL CHEM, V264, P4907; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCCLARE CWF, 1971, ANAL BIOCHEM, V39, P527, DOI 10.1016/0003-2697(71)90443-X; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; MURPHY AJ, 1992, J BIOL CHEM, V267, P5229; MURPHY AJ, 1992, J BIOL CHEM, V267, P16990; NAKAMURA S, 1994, J BIOL CHEM, V269, P16015; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; PIKULA S, 1988, J BIOL CHEM, V263, P5277; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Seekoe T, 2001, J BIOL CHEM, V276, P46737, DOI 10.1074/jbc.M106320200; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Young HS, 2001, J MOL BIOL, V308, P231, DOI 10.1006/jmbi.2001.4558; Yu MH, 1998, J BIOL CHEM, V273, P3542, DOI 10.1074/jbc.273.6.3542; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994	37	14	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13615	13619		10.1074/jbc.M200625200	http://dx.doi.org/10.1074/jbc.M200625200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830596	Green Submitted, hybrid			2022-12-25	WOS:000175096000037
J	Borra, MT; O'Neill, FJ; Jackson, MD; Marshall, B; Verdin, E; Foltz, KR; Denu, JM				Borra, MT; O'Neill, FJ; Jackson, MD; Marshall, B; Verdin, E; Foltz, KR; Denu, JM			Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD(+)-dependent deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; SACCHAROMYCES-CEREVISIAE; STARFISH OOCYTES; SIR2-LIKE PROTEINS; SIR4 PROTEINS; YEAST; GENE; HETEROCHROMATIN; FERTILIZATION; ACTIVATION	Silent information regulator 2 (Sir2) family of enzymes has been implicated in many cellular processes that include histone deacetylation, gene silencing, chromosomal stability, and aging. Yeast Sir2 and several homologues have been shown to be NAD(+)-dependent histone/protein deacetylases. Previously, it was demonstrated that the yeast enzymes catalyze a unique reaction mechanism in which the cleavage of NAD(+) and the deacetylation of substrate are coupled with the formation of O-acetyl-ADP-ribose, a novel metabolite. We demonstrate that the production of O-acetyl-ADP-ribose is evolutionarily conserved among Sir2-like enzymes from yeast, Drosophila, and human. Also, endogenous yeast Sir2 complex from telomeres was shown to generate O-acetyl-ADP-ribose. By using a quantitative microinjection assay to examine the possible biological function(s) of this newly discovered metabolite, we demonstrate that O-acetyl-ADP-ribose causes a delay/block in oocyte maturation and results in a delay/block in embryo cell division in blastomeres. This effect was mimicked by injection of low nanomolar levels of active enzyme but not with a catalytically impaired mutant, indicating that the enzymatic activity is essential for the observed effects. In cell-free oocyte extracts, we demonstrate the existence of cellular enzymes that can efficiently utilize O-acetyl-ADP-ribose.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA; Univ Calif San Francisco, Inst Immunol & Virol, San Francisco, CA 94141 USA	Oregon Health & Science University; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California San Francisco	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA.		Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; CARROLL DJ, 1997, J CELL BIOL, V138, P1301; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; Ghidelli S, 2001, EMBO J, V20, P4522, DOI 10.1093/emboj/20.16.4522; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Gottschling DE, 2000, CURR BIOL, V10, pR708, DOI 10.1016/S0960-9822(00)00714-4; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gray SG, 2001, EXP CELL RES, V262, P75, DOI 10.1006/excr.2000.5080; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 2001, TRENDS GENET, V17, P391, DOI 10.1016/S0168-9525(01)02339-3; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; HIRAMOTO Y, 1962, EXP CELL RES, V27, P416, DOI 10.1016/0014-4827(62)90006-X; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KIEHART DP, 1982, METHOD CELL BIOL, V25, P13, DOI 10.1016/S0091-679X(08)61418-1; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1991, J BIOL CHEM, V266, P2276; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 1997, P NATL ACAD SCI USA, V94, P2186, DOI 10.1073/pnas.94.6.2186; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; MONROY A, 1986, BIOL BULL, V171, P509, DOI 10.2307/1541620; Muth V, 2001, EMBO J, V20, P1353, DOI 10.1093/emboj/20.6.1353; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; RINE J, 1987, GENETICS, V116, P9; Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81; Russo GL, 1998, SEMIN CELL DEV BIOL, V9, P559, DOI 10.1006/scdb.1998.0250; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; Santella L, 1997, CELL CALCIUM, V22, P11, DOI 10.1016/S0143-4160(97)90085-3; Santella L, 1998, BIOCHEM BIOPH RES CO, V252, P1, DOI 10.1006/bbrc.1998.9583; Sasaki K, 2001, DEV BIOL, V237, P18, DOI 10.1006/dbio.2001.0337; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tachibana K, 2000, P NATL ACAD SCI USA, V97, P14301, DOI 10.1073/pnas.97.26.14301; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; TERASAKI M, 1994, J CELL SCI, V107, P1797; Terasaki M, 2001, MOL BIOL CELL, V12, P503, DOI 10.1091/mbc.12.2.503; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsang AW, 1998, J BIOL CHEM, V273, P31788, DOI 10.1074/jbc.273.48.31788; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wilding M, 1998, AM J PHYSIOL-CELL PH, V275, pC1277, DOI 10.1152/ajpcell.1998.275.5.C1277; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yuce O, 2001, DEV BIOL, V237, P29, DOI 10.1006/dbio.2001.0361	74	134	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12632	12641		10.1074/jbc.M111830200	http://dx.doi.org/10.1074/jbc.M111830200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812793	hybrid			2022-12-25	WOS:000175036300020
J	Kawata, Y; Suzuki, H; Higaki, Y; Denisenko, O; Schullery, D; Abrass, C; Bomsztyk, K				Kawata, Y; Suzuki, H; Higaki, Y; Denisenko, O; Schullery, D; Abrass, C; Bomsztyk, K			bcn-1 element-dependent activation of the laminin gamma 1 chain gene by the cooperative action of transcription factor E3 (TFE3) and Smad proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELIX-LOOP-HELIX; NUCLEAR RIBONUCLEOPROTEIN K; BETA-INDUCED TRANSCRIPTION; LEUCINE-ZIPPER PROTEINS; DNA-BINDING; BASEMENT-MEMBRANES; PROMOTER; EXPRESSION; FUSION; SP1	Laminin is a major component of the extracellular matrix. The laminin gamma1 chain is the least variant component of the laminin heterotrimeric assembly. The laminin gamma1 chain gene (LAMC1) expression is induced by several factors, including transforming growth factor-P (TGF-beta). LAMC1 promoter contains a highly conserved transcriptional element, bcn-1. We screened cDNA libraries with the yeast one-hybrid system to identify transcriptional factors that are recognized by the bcn-1 motif. Using this strategy we isolated the basic helix-loop-helix/leucine zipper (bHLHzip) E-box-binding transcription factor, TFE3. Until now, the E-box was the only element known to recruit the bHLHzip transcription factors. Although the bcn-1 element only remotely resembles the E-box sequence, we show that TFE3 binds and activates the bcn-1 element. TFE3 cooperates with Smad proteins in the activation of the LAMC1 promoter in cells, an effect that is critically dependent not only on the bcn-1 element but also on one of the Smad-binding elements (SBE). The cooperative induction of the LAMC1 promoter and the endogenous LAMC1 gene by TFE3 and Smad3 is augmented by the TGF-beta signaling pathway. Thus, the bcn-1 is a novel TFE3-dependent TGF-beta target element that regulates LAMC1 gene expression.	Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Bomsztyk, K (corresponding author), Univ Washington, Dept Med, Div Nephrol, Box 356521, Seattle, WA 98195 USA.	karolb@u.washington.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045978, R37DK045978] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45978] Funding Source: Medline; NIGMS NIH HHS [GM45134] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMSON DR, 1993, KIDNEY INT, V43, P73, DOI 10.1038/ki.1993.13; ABRASS CK, 1995, KIDNEY INT, V47, P25, DOI 10.1038/ki.1995.3; ADLER S, 1986, J CLIN INVEST, V77, P762, DOI 10.1172/JCI112372; ARTANDI SE, 1994, MOL CELL BIOL, V14, P7704, DOI 10.1128/MCB.14.12.7704; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Carter RS, 1997, MOL CELL BIOL, V17, P18, DOI 10.1128/MCB.17.1.18; Choi ME, 2000, KIDNEY INT, V58, pS53, DOI 10.1046/j.1523-1755.2000.07709.x; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Deutzmann Rainer, 1995, P41; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1992, P NATL ACAD SCI USA, V89, P11779, DOI 10.1073/pnas.89.24.11779; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; GUREVICH VV, 1991, ANAL BIOCHEM, V195, P207, DOI 10.1016/0003-2697(91)90318-N; Hansen K, 1999, PATHOBIOLOGY, V67, P84, DOI 10.1159/000028055; Heimann P, 2001, CANCER RES, V61, P4130; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; Hill CS, 1996, CELL SIGNAL, V8, P533, DOI 10.1016/S0898-6568(96)00122-2; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KALLUNKI T, 1991, J BIOL CHEM, V266, P221; Kedar V, 1997, MOL BRAIN RES, V47, P87, DOI 10.1016/S0169-328X(97)00062-4; Kedar Vishram, 1996, Indian Journal of Experimental Biology, V34, P939; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lietard J, 1997, AM J PATHOL, V151, P1663; Luo X, 1996, MOL CELL BIOL, V16, P1367; Marmillot P, 1998, BBA-GENE STRUCT EXPR, V1395, P228, DOI 10.1016/S0167-4781(97)00153-X; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; OGAWA K, 1988, J BIOL CHEM, V263, P8384; OKAYAMA H, 1987, METHOD ENZYMOL, V154, P3; ONeill BC, 1997, AM J PHYSIOL-RENAL, V273, pF411, DOI 10.1152/ajprenal.1997.273.3.F411; Ostrowski J, 2000, J BIOL CHEM, V275, P3619, DOI 10.1074/jbc.275.5.3619; Parks CL, 1996, J BIOL CHEM, V271, P4417; Phillips SL, 1999, DIABETES, V48, P2083, DOI 10.2337/diabetes.48.10.2083; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; RICHARDSON CA, 1995, AM J PHYSIOL-RENAL, V268, pF273, DOI 10.1152/ajprenal.1995.268.2.F273; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Suzuki H, 1998, AM J PHYSIOL-RENAL, V275, pF518, DOI 10.1152/ajprenal.1998.275.4.F518; Suzuki H, 1996, J BIOL CHEM, V271, P18981, DOI 10.1074/jbc.271.31.18981; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Tunggal P, 2000, MICROSC RES TECHNIQ, V51, P214, DOI 10.1002/1097-0029(20001101)51:3<214::AID-JEMT2>3.0.CO;2-J; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; Weterman MAJ, 1996, P NATL ACAD SCI USA, V93, P15294, DOI 10.1073/pnas.93.26.15294; Weterman MAJ, 2000, ONCOGENE, V19, P69, DOI 10.1038/sj.onc.1203255; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHAO GQ, 1993, MOL CELL BIOL, V13, P4505, DOI 10.1128/MCB.13.8.4505	59	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11375	11384		10.1074/jbc.M111284200	http://dx.doi.org/10.1074/jbc.M111284200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801598	hybrid			2022-12-25	WOS:000174613100080
J	Sheard, MA; Vojtesek, B				Sheard, MA; Vojtesek, B			Simian virus-40 infection inhibits DNA damage-induced enhancement of CD95 expression and function	ONCOGENE			English	Article						CD95/Fas; SV40; p53/Trp53/TP53; apoptosis	LARGE T-ANTIGEN; MURINE RENAL-CANCER; WILD-TYPE P53; CELL-DEATH; MONOCLONAL-ANTIBODIES; GAMMA-IRRADIATION; INDUCED APOPTOSIS; TUMOR-ANTIGEN; UP-REGULATION; FAS RECEPTOR	Many viruses are known to disarm or suppress the cell death machinery of infected cells. Apoptotic cell death can be activated by aggregation of the CD95 cell surface death receptor in sensitive cells, and in most insensitive cells treated with sensitizing agents such as interferon-gamma or inhibitors of protein synthesis. We show that, subsequent to sequestration and inactivation of the p53 tumour suppressor protein, SV40 abrogates p53-dependent, DNA damage-inducible up-regulation of CD95 surface expression. Loss of surface up-regulation of CD95 after sub-lethal mitomycin C treatment resulted in an impaired enhancement of both caspase-8 cleavage and apoptotic cell death following CD95 aggregation. We conclude that infection of human cells with SV40 virus strongly inhibits DNA damage-induced enhancement of CD95-mediated apoptosis.	Masaryk Mem Canc Inst, Lab Apoptosis Res, Brno 65653, Czech Republic; Masaryk Mem Canc Inst, Dept Expt Oncol, Brno 65653, Czech Republic	Masaryk Memorial Cancer Institute; Masaryk Memorial Cancer Institute	Sheard, MA (corresponding author), Masaryk Mem Canc Inst, Lab Apoptosis Res, Zluty Kopec 7, Brno 65653, Czech Republic.	sheard@mou.cz	Sheard, Michael/J-1374-2019	Sheard, Michael/0000-0002-4960-7650				Bouvard V, 2000, ONCOGENE, V19, P649, DOI 10.1038/sj.onc.1203366; Broome HE, 1998, CELL DEATH DIFFER, V5, P200, DOI 10.1038/sj.cdd.4400329; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Conzen SD, 1997, J VIROL, V71, P4536, DOI 10.1128/JVI.71.6.4536-4543.1997; del Arroyo AG, 2000, ONCOGENE, V19, P3647, DOI 10.1038/sj.onc.1203662; Dirks W, 1997, BRIT J HAEMATOL, V96, P584, DOI 10.1046/j.1365-2141.1997.d01-2048.x; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fulda S, 1998, INT J CANCER, V76, P105; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Hashimoto W, 1999, J IMMUNOL, V163, P583; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; JAATTELA M, 1995, ONCOGENE, V10, P2297; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Krammer P H, 1999, Adv Immunol, V71, P163; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee JK, 2000, J IMMUNOL, V164, P231, DOI 10.4049/jimmunol.164.1.231; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Levresse V, 1998, ONCOGENE, V16, P1041, DOI 10.1038/sj.onc.1201627; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Maecker HL, 2000, CANCER RES, V60, P4638; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; METCALF RA, 1992, CANCER RES, V52, P2610; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; MIDGLEY CA, 1992, J CELL SCI, V101, P183; Mor O, 1997, ONCOGENE, V15, P3113, DOI 10.1038/sj.onc.1201549; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nguyen PL, 1996, AM J PATHOL, V148, P847; O'Connor L, 2000, CANCER RES, V60, P1217; Okayasu R, 1999, CANCER RES, V59, P298; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; OWENSCHAUB LB, 1994, CANCER RES, V54, P1580; QUARTIN RS, 1994, J VIROL, V68, P1334, DOI 10.1128/JVI.68.3.1334-1341.1994; Rodier F, 2000, ONCOGENE, V19, P6261, DOI 10.1038/sj.onc.1204015; Rosen D, 2000, J IMMUNOL, V164, P3229, DOI 10.4049/jimmunol.164.6.3229; ROUQUET N, 1995, ONCOGENE, V11, P1061; Sayers TJ, 2000, J LEUKOCYTE BIOL, V68, P81; Sayers TJ, 1998, J IMMUNOL, V161, P3957; Screpanti V, 2001, J IMMUNOL, V167, P2068, DOI 10.4049/jimmunol.167.4.2068; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Topham DJ, 1997, J IMMUNOL, V159, P5197; Tortorella D, 2000, ANNU REV IMMUNOL, V18, P861, DOI 10.1146/annurev.immunol.18.1.861; Tsai SC, 2000, J BIOL CHEM, V275, P3239, DOI 10.1074/jbc.275.5.3239; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wigginton JM, 2001, J CLIN INVEST, V108, P51	58	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					190	197						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803462				2022-12-25	WOS:000173026200003
J	Kao, KI; Henricksen, LA; Liu, Y; Bambara, RA				Kao, KI; Henricksen, LA; Liu, Y; Bambara, RA			Cleavage specificity of Saccharomyces cerevisiae flap endonuclease 1 suggests a double-flap structure as the cellular substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN DNA-REPLICATION; CALF RTH-1 NUCLEASE; OKAZAKI FRAGMENTS; THERMUS-AQUATICUS; CRYSTAL-STRUCTURE; POLYMERASE-I; 5'-NUCLEASE; BINDING; FEN-1; 5'-EXONUCLEASE	Flap endonuclease 1 (FEN1) is a structure-specific nuclease that cleaves substrates containing unannealed 5'-flaps during Okazaki fragment processing. Cleavage removes the flap at or near the point of annealing. The preferred substrate for archaeal FEN 1 or the 5'-nuclease domains of bacterial DNA polymerases is a double-flap structure containing a 3'-tail on the upstream primer adjacent to the 5'-flap. We report that FEN1 in Saccharomyces cerevisiae (Rad27p) exhibits a similar specificity. Cleavage was most efficient when the upstream primer contained a 1-nucleotide 3'-tail as compared with the fully annealed upstream primer traditionally tested. The site of cleavage was exclusively at a position one nucleotide into the annealed region, allowing human DNA ligase I to seal all resulting nicks. In contrast, a portion of the products from traditional flap substrates is not ligated. The 3'-OH of the upstream primer is not critical for double-flap recognition, because Rad27p is tolerant of modifications. However, the positioning of the 3'-nucleotide defines the site of cleavage. We have tested substrates having complementary tails that equilibrate to many structures by branch migration. FEN1 only cleaved those containing a 1-nucleotide 3'-tail. Equilibrating substrates containing 12-ribonucleotides at the end of the 5'-flap simulates the situation in vivo. Rad27p cleaves this substrate in the expected 1-nucleotide 3'-tail configuration. Overall, these results suggest that the double-flap substrate is formed and cleaved during eukaryotic DNA replication in vivo.	Univ Rochester, Sch Med & Dent, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood ave,Box 712, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024441] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24441] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arezi B, 2000, TRENDS BIOCHEM SCI, V25, P572, DOI 10.1016/S0968-0004(00)01680-7; Bae SH, 2001, NATURE, V412, P456, DOI 10.1038/35086609; Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BAMBARA RA, 1995, PROG NUCLEIC ACID RE, V51, P93, DOI 10.1016/S0079-6603(08)60877-6; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Budd ME, 2000, J BIOL CHEM, V275, P16518, DOI 10.1074/jbc.M909511199; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; Formosa T, 1999, GENETICS, V151, P1459; Frank P, 1998, FEBS LETT, V421, P23, DOI 10.1016/S0014-5793(97)01528-7; Garforth SJ, 2001, NUCLEIC ACIDS RES, V29, P2772, DOI 10.1093/nar/29.13.2772; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 1998, LEUKEMIA RES, V22, P1, DOI 10.1016/S0145-2126(97)00113-6; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Huang L, 1996, BIOCHEMISTRY-US, V35, P9266, DOI 10.1021/bi9603074; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Kimura S, 2000, PLANT MOL BIOL, V42, P415, DOI 10.1023/A:1006349511964; KORNBERG A, 1992, DNA REPLICATION, P931; Lyamichev V, 1999, P NATL ACAD SCI USA, V96, P6143, DOI 10.1073/pnas.96.11.6143; Ma WP, 2000, J BIOL CHEM, V275, P24693, DOI 10.1074/jbc.M002268200; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; PONTKINGDON G, 1993, EMBO J, V12, P23, DOI 10.1002/j.1460-2075.1993.tb05628.x; Qiu JZ, 2001, J BIOL CHEM, V276, P4901, DOI 10.1074/jbc.M007825200; Reynaldo LP, 2000, J MOL BIOL, V297, P511, DOI 10.1006/jmbi.2000.3573; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; SIEGAL G, 1992, P NATL ACAD SCI USA, V89, P9377, DOI 10.1073/pnas.89.20.9377; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Xie YL, 2001, MOL CELL BIOL, V21, P4889, DOI 10.1128/MCB.21.15.4889-4899.2001; Xu Y, 2000, J BIOL CHEM, V275, P20949, DOI 10.1074/jbc.M909135199; Xu Y, 2001, J BIOL CHEM, V276, P30167, DOI 10.1074/jbc.M100985200	47	122	132	4	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14379	14389		10.1074/jbc.M110662200	http://dx.doi.org/10.1074/jbc.M110662200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11825897	hybrid			2022-12-25	WOS:000175203000007
J	Paroni, G; Henderson, C; Schneider, C; Brancolini, C				Paroni, G; Henderson, C; Schneider, C; Brancolini, C			Caspase-2 can trigger cytochrome c release and apoptosis from the nucleus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; NUCLEOCYTOPLASMIC TRANSPORT; ACTIVATION; LOCALIZATION; PATHWAYS; DOMAIN; CARD; NUCLEOPORINS; MODULATION; FILAMENTS	The cysteine proteases specific for aspartic residues, known as caspases, are localized in different subcellular compartments and play specific roles during the regulative and the executive phase of the cell death process. Here we investigated the subcellular localization of caspase-2 in healthy cells and during the execution of the apoptotic program. We have found that caspase-2 is a nuclear resident protein and that its import into the nucleus is regulated by two different nuclear localization signals. We have shown that in an early phase of apoptosis caspase-2 can trigger mitochondrial dysfunction from the nucleus without relocalizing into the cytoplasm. Release of cytochrome c occurs in the absence of overt alteration of the nuclear pores and changes of the nuclear/cytoplasmic barrier. Addition of leptomycin B, an inhibitor of nuclear export, did not interfere with the ability of caspase-2 to trigger cytochrome c release. Only during the late phase of the apoptotic process can caspase-2 relocalize in the cytoplasm, as consequence of an increase in the diffusion limits of the nuclear pores. Taken together these data indicate the existence of a nuclear/mitochondrial apoptotic pathway elicited by caspase-2.	Univ Udine, Sez Biol, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Lab Nazl Consorzio Interuniv Biotecnol, I-34142 Trieste, Italy; Univ Udine, MATI Ctr Excellence, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; University of Udine	Brancolini, C (corresponding author), Univ Udine, Sez Biol, Dipartimento Sci & Tecnol Biomed, P Kolbe 4, I-33100 Udine, Italy.	cbrancolini@makek.dstb.uniud.it	Paroni, Gabriela/J-4848-2018	Paroni, Gabriela/0000-0003-0132-0869; BRANCOLINI, Claudio/0000-0002-6597-5373				Ahmad M, 1997, CANCER RES, V57, P615; Allet B, 1996, J CELL BIOL, V135, P479, DOI 10.1083/jcb.135.2.479; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bagley S, 2000, J CELL SCI, V113, P3885; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; BRANCOLINI C, 1994, J CELL BIOL, V124, P743, DOI 10.1083/jcb.124.5.743; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Buendia B, 1999, J CELL SCI, V112, P1743; Choen G. M, 1997, BIOCHEM J, V326, P1, DOI [10.1042/bj3260001, DOI 10.1042/BJ3260001]; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Colussi PA, 1998, J BIOL CHEM, V273, P24535, DOI 10.1074/jbc.273.38.24535; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Doye V, 1997, CURR OPIN CELL BIOL, V9, P401, DOI 10.1016/S0955-0674(97)80014-2; Droin N, 2001, ONCOGENE, V20, P260, DOI 10.1038/sj.onc.1204066; Duan H, 1997, NATURE, V385, P86, DOI 10.1038/385086a0; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Paroni G, 2001, J BIOL CHEM, V276, P21907, DOI 10.1074/jbc.M011565200; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Roy S, 2001, P NATL ACAD SCI USA, V98, P6132, DOI 10.1073/pnas.111085198; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Shikama Y, 2001, EXP CELL RES, V264, P315, DOI 10.1006/excr.2000.5153; Shulga N, 2000, J CELL BIOL, V149, P1027, DOI 10.1083/jcb.149.5.1027; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; STEHNOBITTEL L, 1995, SCIENCE, V270, P1835, DOI 10.1126/science.270.5243.1835; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Talcott B, 1999, TRENDS CELL BIOL, V9, P312, DOI 10.1016/S0962-8924(99)01608-6; Terasaki M, 2001, MOL BIOL CELL, V12, P503, DOI 10.1091/mbc.12.2.503; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 1997, J NEUROSCI, V17, P1911; Troy CM, 2001, J NEUROSCI, V21, P5007, DOI 10.1523/JNEUROSCI.21-14-05007.2001; Troy CM, 2000, J NEUROSCI, V20, P1386; Wang J, 1999, CELL, V98, P47, DOI 10.1016/S0092-8674(00)80605-4; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zheng TS, 2000, NAT MED, V6, P1241, DOI 10.1038/81343; Zhivotovsky B, 1999, CELL DEATH DIFFER, V6, P644, DOI 10.1038/sj.cdd.4400536	56	146	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15147	15161		10.1074/jbc.M112338200	http://dx.doi.org/10.1074/jbc.M112338200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11823470	hybrid			2022-12-25	WOS:000175203000101
J	Clarke, TE; Braun, V; Winkelmann, G; Tari, LW; Vogel, HJ				Clarke, TE; Braun, V; Winkelmann, G; Tari, LW; Vogel, HJ			X-ray crystallographic structures of the Escherichia coli periplasmic protein FhuD bound to hydroxamate-type siderophores and the antibiotic albomycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; OUTER-MEMBRANE; IRON TRANSPORT; SOLUTION CONFORMATION; ACTIVE-TRANSPORT; BINDING; FERRICHROME; SPECIFICITY; RECEPTORS; CHELATORS	Siderophore-binding proteins play an essential role in the uptake of iron in many Gram-positive and Gram-negative bacteria. FhuD is an ATP-binding cassette-type (ABC-type) binding protein involved in the uptake of hydroxamate-type siderophores in Escherichia coli. Structures of FhuD complexed with the antibiotic albomycin, the fungal siderophore coprogen and the drug Desferal have been determined at high resolution by x-ray crystallography. FhuD has an unusual bilobal structure for a periplasmic ligand binding protein, with two mixed beta/alpha domains connected by a long alpha-helix. The binding site for hydroxamate-type ligands is composed of a shallow pocket that lies between these two domains. Recognition of siderophores primarily occurs through interactions between the iron-hydroxamate centers of each siderophore and the side chains of several key residues in the binding pocket. Rearrangements of side chains within the binding pocket accommodate the unique structural features of each siderophore. The backbones of the siderophores are not involved in any direct interactions with the protein, demonstrating how siderophores with considerable chemical and structural diversity can be bound by FhuD. For albomycin, which consists of an antibiotic group attached to a hydroxamate siderophore, electron density for the antibiotic portion was not observed. Therefore, this study provides a basis for the rational design of novel bacteriostatic agents, in the form of siderophore-antibiotic conjugates that can act as "Trojan horses," using the hydroxamate-type siderophore uptake system to actively deliver antibiotics directly into targeted pathogens.	Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, Calgary, AB T2N 1N4, Canada; Univ Tubingen, Dept Microbiol Membranphysiol, D-72076 Tubingen, Germany	University of Calgary; Eberhard Karls University of Tubingen	Tari, LW (corresponding author), Univ Calgary, Dept Biol Sci, Struct Biol Res Grp, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	leslie.tari@syrrx.com; vogel@ucalgary.ca	Clarke, Teresa/ABA-7292-2021	Clarke, Teresa/0000-0001-9718-3226	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NCRR NIH HHS [1P41 RR12408-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ATKIN CL, 1968, BIOCHEMISTRY-US, V7, P3734, DOI 10.1021/bi00850a054; Braun V, 1998, MET IONS BIOL SYST, V35, P67; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRAUN V, 1983, J BACTERIOL, V156, P308, DOI 10.1128/JB.156.1.308-315.1983; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buchanan SK, 1999, NAT STRUCT BIOL, V6, P56; Clarke TE, 2000, NAT STRUCT BIOL, V7, P287; CLARKE TE, 2002, IN PRESS BIOMETALS; Clarke Teresa E., 2001, Current Topics in Medicinal Chemistry, V1, P7, DOI 10.2174/1568026013395623; CONSTANTINE KL, 1990, BIOPOLYMERS, V30, P239, DOI 10.1002/bip.360300303; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, PROTEIN SCI, V9, P956, DOI 10.1110/ps.9.5.956; FOLAJTAR DA, 1982, J AM CHEM SOC, V104, P5775, DOI 10.1021/ja00385a036; HARTMANN A, 1979, EUR J BIOCHEM, V99, P517, DOI 10.1111/j.1432-1033.1979.tb13283.x; HERSHKO C, 1992, MOL ASPECTS MED, V13, P113, DOI 10.1016/0098-2997(92)90013-P; HOSSAIN MB, 1986, ACTA CRYSTALLOGR C, V42, P1305, DOI 10.1107/S0108270186092466; HOSSAIN MB, 1987, J AM CHEM SOC, V109, P4948, DOI 10.1021/ja00250a031; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LLINAS M, 1972, INT J PEPT PROT RES, V4, P157; LLINAS M, 1970, J MOL BIOL, V52, P399, DOI 10.1016/0022-2836(70)90409-2; Locher KP, 1998, CELL, V95, P771, DOI 10.1016/S0092-8674(00)81700-6; MCLACHLAN DRC, 1991, CAN MED ASSOC J, V145, P793; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PUGSLEY AP, 1987, J GEN MICROBIOL, V133, P3505; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; ROHRBACH MR, 1995, J BACTERIOL, V177, P7186, DOI 10.1128/jb.177.24.7186-7193.1995; ROHRBACH MR, 1995, MOL GEN GENET, V248, P33, DOI 10.1007/BF02456611; Roosenberg JM, 2000, CURR MED CHEM, V7, P159, DOI 10.2174/0929867003375353; ROUSSEL A, 1989, TURBO FRODO SILICON; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; VANDERHELM D, 1981, ACTA CRYSTALLOGR B, V37, P323, DOI 10.1107/S056774088100294X	36	106	109	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13966	13972		10.1074/jbc.M109385200	http://dx.doi.org/10.1074/jbc.M109385200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11805094	hybrid			2022-12-25	WOS:000175096000081
J	Liang, XQ; Wisniewski, D; Strife, A; Shivakrupa; Clarkson, B; Resh, MD				Liang, XQ; Wisniewski, D; Strife, A; Shivakrupa; Clarkson, B; Resh, MD			Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-CELL FACTOR; PROTEIN-TYROSINE KINASE; JUXTAMEMBRANE REGION; DOCKING PROTEIN; P62(DOK); RECEPTOR; LYN; ABL; TEC; ONCOGENE	Dok-1 is an adaptor protein that is a substrate for Bcr-Abl and other tyrosine protein kinases. The presence of pleckstrin homology and phosphotyrosine binding domains as well as multiple tyrosine phosphorylation sites suggests that Dok-1 is involved in protein-protein and/or protein-lipid interactions. Here we show that stimulation of Mo7 hematopoietic cells with c-Kit ligand (KL) induces phosphatidylinositol (PI) 3-kinase-dependent tyrosine phosphorylation and membrane recruitment of Dok-1. Addition of the K-Ras membrane-targeting motif to Dok-1 generated a constitutively membrane-bound Dok-1 protein whose tyrosine phosphorylation was independent of PI 3-kinase. Membrane localization of Dok-1 was required for its ability to function as a negative regulator of cell proliferation. Additional experiments revealed that Dok-1 associated with the juxtamembrane region and C-terminal tail of e-Kit. Lyn promoted phosphorylation of c-Kit and association of c-Kit and Dok-1. Both Lyn and Tec were capable of phosphorylating Dok-1. However, the use of primary bone marrow mast cells from normal and Lyn-deficient mice demonstrated that Lyn is required for KL-dependent Dok-1 tyrosine phosphorylation. Taken together, these data indicate that activation of PI 3-kinase by KL promotes binding of the Dok pleckstrin homology domain and Dok-1 recruitment to the plasma membrane where Dok-1 is phosphorylated by Src and/or Tec family kinases.	Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA; NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Basic Res Lab, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Div Basic Sci, Immunobiol Lab, Frederick, MD 21702 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Resh, MD (corresponding author), Sloan Kettering Inst Canc Res, Cell Biol Program, 1275 York Ave,Box 143, New York, NY 10021 USA.	m-resh@ski.mskcc.org		Resh, Marilyn/0000-0001-6118-9466	NCI NIH HHS [P01 CA64593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAND L, 1994, J BIOL CHEM, V269, P16701; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Linnekin D, 1997, J BIOL CHEM, V272, P27450, DOI 10.1074/jbc.272.43.27450; MANO H, 1995, BLOOD, V85, P343; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; O'Laughlin-Bunner B, 2001, BLOOD, V98, P343, DOI 10.1182/blood.V98.2.343; Price DJ, 1999, BIOCHEM BIOPH RES CO, V259, P611, DOI 10.1006/bbrc.1999.0840; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Tamir I, 2000, IMMUNITY, V12, P347, DOI 10.1016/S1074-7613(00)80187-9; TANG B, 1994, MOL CELL BIOL, V14, P8432, DOI 10.1128/MCB.14.12.8432; van Dijk TB, 2000, BLOOD, V96, P3406; van't Hof W, 1999, J CELL BIOL, V145, P377, DOI 10.1083/jcb.145.2.377; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720; Yamanashi Y, 2000, GENE DEV, V14, P11; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607; Yoshida K, 2000, J BIOL CHEM, V275, P24945, DOI 10.1074/jbc.M909012199; Zhao MM, 2001, J EXP MED, V194, P265, DOI 10.1084/jem.194.3.265; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	25	44	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13732	13738		10.1074/jbc.M200277200	http://dx.doi.org/10.1074/jbc.M200277200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825908	hybrid			2022-12-25	WOS:000175096000052
J	Powers, C; Aigner, A; Stoica, GE; McDonnell, K; Wellstein, A				Powers, C; Aigner, A; Stoica, GE; McDonnell, K; Wellstein, A			Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CANCER; CELL-LINES; MULTIFORME; EXPRESSION; PROTEIN; PTEN; AKT; TUMORIGENICITY; ANGIOGENESIS; PHOSPHATASE	Glioblastoma multiforme is the most common highly aggressive human brain cancer, and receptor tyrosine kinases have been implicated in the progression of this malignancy. We have recently identified anaplastic lymphoma kinase (ALK) as a tyrosine kinase receptor for pleiotrophin, a secreted growth factor that is highly expressed during embryonic brain development and in tumors of the central nervous system. Here we report on the contribution of pleiotrophin-ALK signaling to glioblastoma growth. We found ALK overexpressed in human glioblastoma relative to normal brain and detected ALK mRNA in glioblastoma cell lines. We reduced the endogenous ALK in glioblastoma cells by ribozyme targeting and demonstrated that this prevents pleiotrophin-stimulated phosphorylation of the anti-apoptotic protein Akt. Furthermore, this depletion of ALK reduced tumor growth of xenografts in athymic nude mice and prolonged survival of the animals because of increased apoptosis in the tumors. These findings directly implicate ALK signaling as a rate-limiting factor in the growth of glioblastoma multiforme and suggest potential utility of therapeutic targeting of ALK.	Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, Washington, DC 20007 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Dept Oncol, Lombardi Canc Ctr, 3970 Reservoir Rd, Washington, DC 20007 USA.		Powers, Ciaran/E-3890-2011; Aigner, Achim/R-4429-2017	Aigner, Achim/0000-0002-2778-6256; Wellstein, Anton/0000-0002-0570-4950	NCI NIH HHS [CA71585] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Bowers DC, 2000, CANCER RES, V60, P4277; CHAUHAN AK, 1993, P NATL ACAD SCI USA, V90, P679, DOI 10.1073/pnas.90.2.679; Choudhuri R, 1997, CANCER RES, V57, P1814; CZUBAYKO F, 1994, J BIOL CHEM, V269, P21358; Czubayko F, 1997, NAT MED, V3, P1137, DOI 10.1038/nm1097-1137; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; James C. David, 1996, Current Opinion in Oncology, V8, P188; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; NISTER M, 1991, J BIOL CHEM, V266, P16755; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; SCHULTE AM, 1997, TUMOR ANGIOGENESIS, V1, P273; Singer HS, 1999, J NEURO-ONCOL, V45, P1, DOI 10.1023/A:1006323523437; Souttou B, 1997, J BIOL CHEM, V272, P19588, DOI 10.1074/jbc.272.31.19588; Souttou B, 1998, J NATL CANCER I, V90, P1468, DOI 10.1093/jnci/90.19.1468; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Wang SI, 1997, CANCER RES, V57, P4183; WELLSTEIN A, 1989, ANTIANGIOGENIC AGENT, P423; Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798; Yeh HJ, 1998, J NEUROSCI, V18, P3699	31	143	156	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14153	14158		10.1074/jbc.M112354200	http://dx.doi.org/10.1074/jbc.M112354200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11809760	hybrid			2022-12-25	WOS:000175096000104
J	Areschoug, T; Stalhammar-Carlemalm, M; Karlsson, I; Lindahl, G				Areschoug, T; Stalhammar-Carlemalm, M; Karlsson, I; Lindahl, G			Streptococcal beta protein has separate binding sites for human factor H and IgA-Fc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCI; COMPLEMENT FACTOR-H; MOUSE-PROTECTIVE ANTIBODIES; SHORT CONSENSUS REPEAT; CELL-SURFACE PROTEIN; IMMUNOGLOBULIN-A; EXPERIMENTAL-INFECTION; NEISSERIA-GONORRHOEAE; SERUM RESISTANCE; REGULATOR C4BP	The group B streptococcus (GBS) is the most important cause of life-threatening bacterial infections in newborn infants. Protective immunity to GBS infection is elicited by several surface proteins, one of which, the beta protein, is known to bind human IgA-Fc. Here, we show that the beta protein also binds human factor H (FH), a negative regulator of complement activation. Absorption experiments with whole human plasma demonstrated binding of FH to a GBS strain expressing beta protein but not to an isogenic beta-negative mutant. This binding was due to a direct interaction between beta and FH, as shown by experiments with purified proteins. Inhibition tests and studies with P fragments demonstrated that FH and IgA-Fc bind to separate and nonoverlapping regions in beta. Heparin, a known ligand for FH, specifically inhibited the binding between beta and FH, suggesting that FH has overlapping binding sites for beta and heparin. Bacteria-bound FH retained its complement regulatory activity, implying that beta-expressing GBS may use bound FH to evade complement attack. The finding that A protein binds FH adds to a growing list of interactions between human pathogens and complement regulatory proteins, supporting the notion that these interactions are of general importance in bacterial pathogenesis.	Lund Univ, Dept Med Microbiol Dermatol & Infect, SE-22362 Lund, Sweden	Lund University	Areschoug, T (corresponding author), Lund Univ, Dept Med Microbiol Dermatol & Infect, Solvegatan 23, SE-22362 Lund, Sweden.							Accardo P, 1996, J IMMUNOL, V157, P4935; Areschoug T, 1999, INFECT IMMUN, V67, P6350; Baker C., 1995, INFECT DIS FETUS NEW, V4th ed., P980; Berggard K, 1997, INFECT IMMUN, V65, P3638; Berggard K, 2001, MOL MICROBIOL, V42, P539, DOI 10.1046/j.1365-2958.2001.02664.x; Berggard K, 2001, EUR J IMMUNOL, V31, P2771, DOI 10.1002/1521-4141(200109)31:9<2771::AID-IMMU2771>3.0.CO;2-0; BEVANGER L, 1985, ACTA PATH MICRO IM B, V93, P121; BEVANGER L, 1979, ACTA PATH MICRO IM B, V87, P51; Blackmore TK, 1996, J IMMUNOL, V157, P5422; Blackmore TK, 1998, J IMMUNOL, V160, P3342; Blackmore TK, 1998, INFECT IMMUN, V66, P1427, DOI 10.1128/IAI.66.4.1427-1431.1998; Blom AM, 2001, J IMMUNOL, V166, P6764, DOI 10.4049/jimmunol.166.11.6764; BRADY LJ, 1989, INFECT IMMUN, V57, P1573, DOI 10.1128/IAI.57.5.1573-1581.1989; Brodeur BR, 2000, INFECT IMMUN, V68, P5610, DOI 10.1128/IAI.68.10.5610-5618.2000; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; EDWARDS MS, 1980, J EXP MED, V151, P1275, DOI 10.1084/jem.151.5.1275; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; FERRIERI P, 1985, RECENT ADV STREPTOCO, P204; Framson PE, 1997, APPL ENVIRON MICROB, V63, P3539, DOI 10.1128/AEM.63.9.3539-3547.1997; Hammerschmidt S, 1997, MOL MICROBIOL, V25, P1113, DOI 10.1046/j.1365-2958.1997.5391899.x; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; Hellwage J, 2001, J BIOL CHEM, V276, P8427, DOI 10.1074/jbc.M007994200; Holmberg MT, 2001, J IMMUNOL, V167, P935, DOI 10.4049/jimmunol.167.2.935; HORSTMANN RD, 1988, P NATL ACAD SCI USA, V85, P1657, DOI 10.1073/pnas.85.5.1657; HUSMANN LK, 1995, INFECT IMMUN, V63, P345, DOI 10.1128/IAI.63.1.345-348.1995; Janulczyk R, 2000, J BIOL CHEM, V275, P37257, DOI 10.1074/jbc.M004572200; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; Jerlstrom PG, 1996, INFECT IMMUN, V64, P2787; Johnsson E, 1998, J IMMUNOL, V161, P4894; Johnsson E, 1996, J IMMUNOL, V157, P3021; Johnsson E, 1999, J BIOL CHEM, V274, P14521, DOI 10.1074/jbc.274.21.14521; Junnikkala S, 2000, J IMMUNOL, V164, P6075, DOI 10.4049/jimmunol.164.11.6075; Kotarsky H, 2001, MOL MICROBIOL, V41, P817, DOI 10.1046/j.1365-2958.2001.02496.x; Kotarsky H, 1998, J IMMUNOL, V160, P3349; Kraiczy P, 2001, EUR J IMMUNOL, V31, P1674, DOI 10.1002/1521-4141(200106)31:6&lt;1674::AID-IMMU1674&gt;3.0.CO;2-2; KRISTENSEN T, 1986, J IMMUNOL, V136, P3407; LANCEFIELD RC, 1975, J EXP MED, V142, P165, DOI 10.1084/jem.142.1.165; Larsson C, 1999, VACCINE, V17, P454, DOI 10.1016/S0264-410X(98)00218-7; Larsson C, 1996, INFECT IMMUN, V64, P3518, DOI 10.1128/IAI.64.9.3518-3523.1996; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; MADOFF LC, 1994, J CLIN INVEST, V94, P286, DOI 10.1172/JCI117319; MICHEL JL, 1992, P NATL ACAD SCI USA, V89, P10060, DOI 10.1073/pnas.89.21.10060; Morfeldt E, 2001, J IMMUNOL, V167, P3870, DOI 10.4049/jimmunol.167.7.3870; Morgan BP., 1999, COMPLEMENT REGULATOR; Neeleman C, 1999, INFECT IMMUN, V67, P4517, DOI 10.1128/IAI.67.9.4517-4524.1999; PANGBURN MK, 1991, J BIOL CHEM, V266, P16847; PEREZCASAL J, 1993, MOL MICROBIOL, V8, P809, DOI 10.1111/j.1365-2958.1993.tb01628.x; PEREZCASAL J, 1991, J BACTERIOL, V173, P2617, DOI 10.1128/jb.173.8.2617-2624.1991; Pleass RJ, 2001, J BIOL CHEM, V276, P8197, DOI 10.1074/jbc.M009396200; Ram S, 1998, J EXP MED, V187, P743, DOI 10.1084/jem.187.5.743; Ram S, 1998, J EXP MED, V188, P671, DOI 10.1084/jem.188.4.671; Ram S, 2001, J EXP MED, V193, P281, DOI 10.1084/jem.193.3.281; RIPOCHE J, 1988, BIOCHEM J, V249, P593, DOI 10.1042/bj2490593; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; Schuchat A, 1999, LANCET, V353, P51, DOI 10.1016/S0140-6736(98)07128-1; SHIGEOKA AO, 1984, J INFECT DIS, V150, P63, DOI 10.1093/infdis/150.1.63; STALHAMMARCARLEMALM M, 1993, J EXP MED, V177, P1593, DOI 10.1084/jem.177.6.1593; STENBERG L, 1992, MOL MICROBIOL, V6, P1185, DOI 10.1111/j.1365-2958.1992.tb01557.x; THERN A, 1995, J IMMUNOL, V154, P375; Wastfelt M, 1996, J BIOL CHEM, V271, P18892, DOI 10.1074/jbc.271.31.18892; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; Zhang JR, 2000, CELL, V102, P827, DOI 10.1016/S0092-8674(00)00071-4; Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7; Zipfel PF, 1999, IMMUNOPHARMACOLOGY, V42, P53, DOI 10.1016/S0162-3109(99)00015-6	66	77	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12642	12648		10.1074/jbc.M112072200	http://dx.doi.org/10.1074/jbc.M112072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812795	hybrid			2022-12-25	WOS:000175036300021
J	Pontsler, AV; St Hilaire, A; Marathe, GK; Zimmerman, GA; McIntyre, TM				Pontsler, AV; St Hilaire, A; Marathe, GK; Zimmerman, GA; McIntyre, TM			Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; PPAR-GAMMA; ATHEROSCLEROTIC LESIONS; GENE-EXPRESSION; FATTY-ACIDS; TRANSCRIPTIONAL REGULATION; MONONUCLEAR PHAGOCYTES; ENDOTHELIAL-CELLS; CARCINOMA-CELLS; HUMAN PLASMA	Low density lipoprotein (LDL) oxidation and monocyte infiltration of the vessel wall underlie atherogenesis. These cells express cyclooxygenase-2, but the way oxidized LDL stimulates cyclooxygenase-2 transcription is unknown. Oxidized LDL, oxidatively fragmented phospholipids isolated from oxidized LDL, a synthetic oxidized alkylphospholipid (azPC) that is a potent peroxisome proliferator activated receptor (PPAR) gamma agonist, or the PPARgamma agonist rosiglitazone all induced cyclooxygenase-2 expression and enhanced prostaglandin E-2 (PGE(2)) secretion in primary human monocytes. The cyclooxygenase-2 inhibitor NS398 blocked PPARgamma-induced PGE(2) secretion. Phospholipase A(1) and A(2) digestion shows that oxidized alkylphospholipids, and not oxidized fatty acids, were the relevant agonists. The upstream PPAR-responsive element (PPRE) of cyclooxygenase-2 was required for induction of a luciferase reporter by oxidized phospholipids, azPC, and rosiglitazone, and a (COX-2 PPRE)(3)-luciferase reporter was responsive to these PPARgamma agonists. Circulating human monocytes do not contain PPARgamma, but PPARgamma was induced rapidly (<4 h) in monocytes upon ligation of surface ICAM-3, but not P-selectin glycoprotein-1 even though both interactions prime cytokine secretion. Cyclooxygenase-2 induction by oxidized phospholipids only occurred in monocytes containing PPARgamma. Thus PPARgamma was induced rapidly in primary monocytes by appropriate outside-in signaling, sensitizing them to previously undetectable agonists in oxidized LDL. Cyclooxygenase-2 and PGE(2) secretion are induced, not inhibited, by selective PPARy agonists that include oxidatively fragmented phospholipids in oxidized LDL.	Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Human Mol Biol, Salt Lake City, UT 84112 USA; Univ Utah, Genet Program, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	McIntyre, TM (corresponding author), Univ Utah, Dept Pathol, 4130 EIHG,15 N 2030 E, Salt Lake City, UT 84112 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL050153, R37HL044525, R01HL044513, R01HL044525] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 44513, HL 50153, HL 44525] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Babaev VR, 2000, CIRCULATION, V102, P176; Baker CSR, 1999, ARTERIOSCL THROM VAS, V19, P646, DOI 10.1161/01.ATV.19.3.646; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Belton O, 2000, CIRCULATION, V102, P840; BHUYAN BK, 1986, CANCER RES, V46, P1688; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; Burleigh ME, 2000, CIRCULATION, V102, P42; Camp HS, 2000, DIABETES, V49, P539, DOI 10.2337/diabetes.49.4.539; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Cipollone F, 2001, CIRCULATION, V104, P921, DOI 10.1161/hc3401.093152; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIAGNE A, 1984, BIOCHIM BIOPHYS ACTA, V793, P221, DOI 10.1016/0005-2760(84)90324-2; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49; ELSTAD MR, 1988, J IMMUNOL, V140, P1618; FAWCETT J, 1992, NATURE, V360, P481, DOI 10.1038/360481a0; Feldhaus MJ, 1998, J IMMUNOL, V161, P6280; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fyrnys B, 1997, ADV EXP MED BIOL, V407, P93; Ghosh AK, 2000, J PHARMACOL EXP THER, V295, P802; GLAVIND J, 1952, ACTA PATHOL MIC SC, V30, P1; Hayflick JS, 1997, J BIOL CHEM, V272, P22207, DOI 10.1074/jbc.272.35.22207; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; Hong BK, 2000, YONSEI MED J, V41, P82, DOI 10.3349/ymj.2000.41.1.82; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Hunter JG, 2001, J BIOL CHEM, V276, P38297; Ikawa H, 2001, EXP CELL RES, V267, P73, DOI 10.1006/excr.2001.5233; Inoue H, 2000, J BIOL CHEM, V275, P28028; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Jira W, 1998, CHEM PHYS LIPIDS, V91, P1, DOI 10.1016/S0009-3084(97)00095-9; Kessel JM, 1998, J IMMUNOL, V160, P5579; Kim YS, 1998, J BIOL CHEM, V273, P27686, DOI 10.1074/jbc.273.42.27686; Kitamura Y, 1999, BIOCHEM BIOPH RES CO, V254, P582, DOI 10.1006/bbrc.1998.9981; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Ledwith BJ, 1997, J BIOL CHEM, V272, P3707, DOI 10.1074/jbc.272.6.3707; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leininger MT, 1999, BIOCHEM BIOPH RES CO, V263, P749, DOI 10.1006/bbrc.1999.1467; LYNCH SM, 1994, J CLIN INVEST, V93, P998, DOI 10.1172/JCI117107; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Marathe GK, 2001, J LIPID RES, V42, P1430; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Marx N, 1998, AM J PATHOL, V153, P17, DOI 10.1016/S0002-9440(10)65540-X; Maxey KM, 2000, PROSTAG OTH LIPID M, V62, P15, DOI 10.1016/S0090-6980(00)00072-1; McIntyre TM, 1999, J BIOL CHEM, V274, P25189, DOI 10.1074/jbc.274.36.25189; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mummidi S, 2001, J BIOL CHEM, V276, P33196, DOI 10.1074/jbc.M009807200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Paik JH, 2000, J BIOL CHEM, V275, P28173; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; Reis ED, 2000, P NATL ACAD SCI USA, V97, P12764, DOI 10.1073/pnas.210394497; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Rizza C, 1999, LAB INVEST, V79, P1227; Schlame M, 1996, J LIPID RES, V37, P2608; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; Tokumura A, 1996, LIPIDS, V31, P1251, DOI 10.1007/BF02587909; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Tsubouchi Y, 2001, BIOCHEM BIOPH RES CO, V283, P750, DOI 10.1006/bbrc.2001.4847; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; YAGI K, 1984, BIOESSAYS, V1, P58, DOI 10.1002/bies.950010205; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; ZEMBOWICZ A, 1995, J CLIN INVEST, V96, P1688, DOI 10.1172/JCI118211	79	92	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13029	13036		10.1074/jbc.M109546200	http://dx.doi.org/10.1074/jbc.M109546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809750	hybrid			2022-12-25	WOS:000175036300069
J	Scott, CC; Cuellar-Mata, P; Matsuo, T; Davidson, HW; Grinstein, S				Scott, CC; Cuellar-Mata, P; Matsuo, T; Davidson, HW; Grinstein, S			Role of 3-phosphoinositides in the maturation of Salmonella-containing vacuoles within host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL MEMBRANE-GLYCOPROTEINS; TYPHIMURIUM-CONTAINING VACUOLES; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; FILAMENTOUS STRUCTURES; EPITHELIAL-CELLS; PROTEIN; VIRULENCE; DOMAIN; ACTIN; IDENTIFICATION	Salmonella typhimurium invades mammalian cells and replicates within a vacuole that protects it from the host's microbicidal weapons. The Salmonella-containing vacuole (SCV) undergoes a remodelling akin to that of the host cell's endocytic pathway, but SCV progression is arrested prior to fusion with lysosomes. We studied the role of phosphatidylinositol 3-kinase (PI3-K) in SCV maturation within HeLa cells. Phosphatidylinositol 3-phosphate (PI3P), monitored in situ using fluorescent conjugates of FYVE or PX domains, was found to accumulate transiently on the SCV. Wortmannin prevented PI3P accumulation and the recruitment of EEA1 but did not affect the association of Rab5 with the SCV. Importantly, inhibition of P13-K also impaired fusion of the SCV with vesicles containing LAMP-1. Rab7, which is thought to be required for association of LAMP-1 with the SCV, still associated with SCV in wortmannin-treated cells. We have therefore concluded that a 3-phosphoinositide-dependent step exists following recruitment of Rab7 to the SCV. The data also imply that 3-phosphoinositide-dependent effectors of Rab5 are not an absolute requirement for recruitment of Rab7. Despite failure to acquire LAMP-1, the SCV persists and allows effective replication of Salmonella within wortmannin-treated host cells. These findings imply that P13-K is involved in the development of the SCV but is not essential for intracellular survival and proliferation of Salmonella.	Hosp Sick Children, Cell Biol Program, Div Cell Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Harvard Univ, Inst Med, Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA; Univ Cambridge, Addenbrookes Hosp, Wellcome Trust Ctr Mol Mechanisms Dis, Cambridge CB2 2QQ, England	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Harvard University; Beth Israel Deaconess Medical Center; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Grinstein, S (corresponding author), Hosp Sick Children, Cell Biol Program, Div Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	sga@sickkids.ca		Scott, Cameron/0000-0001-5026-3413				Baldeon ME, 2001, CELL MICROBIOL, V3, P473, DOI 10.1046/j.1462-5822.2001.00130.x; Beuzon CR, 2000, EMBO J, V19, P3235, DOI 10.1093/emboj/19.13.3235; Bieber T, 2001, BIOTECHNIQUES, V30, P74, DOI 10.2144/01301st03; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Bragonzi A, 1999, GENE THER, V6, P1995, DOI 10.1038/sj.gt.3301039; BUCCI C, 1995, FEBS LETT, V366, P65, DOI 10.1016/0014-5793(95)00477-Q; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075; Deiwick J, 1999, MOL MICROBIOL, V31, P1759, DOI 10.1046/j.1365-2958.1999.01312.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fu YX, 1998, MOL MICROBIOL, V27, P359, DOI 10.1046/j.1365-2958.1998.00684.x; Garcia-Del Portillo F, 2000, INFECT IMMUN, V68, P2985, DOI 10.1128/IAI.68.5.2985-2991.2000; GARCIADELPORTILLO F, 1993, INFECT AGENT DIS, V2, P227; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hardt WD, 1998, CELL, V93, P815, DOI 10.1016/S0092-8674(00)81442-7; Hashim S, 2000, J BIOL CHEM, V275, P16281, DOI 10.1074/jbc.275.21.16281; Hayward RD, 1999, EMBO J, V18, P4926, DOI 10.1093/emboj/18.18.4926; Hensel M, 2000, MOL MICROBIOL, V36, P1015, DOI 10.1046/j.1365-2958.2000.01935.x; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Lawe DC, 2000, J BIOL CHEM, V275, P3699, DOI 10.1074/jbc.275.5.3699; Mecsas J, 1998, MOL MICROBIOL, V28, P1269, DOI 10.1046/j.1365-2958.1998.00891.x; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; Norris FA, 1998, P NATL ACAD SCI USA, V95, P14057, DOI 10.1073/pnas.95.24.14057; Ochman H, 1996, P NATL ACAD SCI USA, V93, P7800, DOI 10.1073/pnas.93.15.7800; Rathman M, 1996, INFECT IMMUN, V64, P2765, DOI 10.1128/IAI.64.7.2765-2773.1996; Reaves BJ, 1996, J CELL SCI, V109, P749; Row PE, 2001, BIOCHEM J, V353, P655, DOI 10.1042/0264-6021:3530655; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Stein MA, 1996, MOL MICROBIOL, V20, P151, DOI 10.1111/j.1365-2958.1996.tb02497.x; Uchiya K, 1999, EMBO J, V18, P3924, DOI 10.1093/emboj/18.14.3924; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051; Zhou D, 1999, SCIENCE, V283, P2092, DOI 10.1126/science.283.5410.2092	39	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12770	12776		10.1074/jbc.M110399200	http://dx.doi.org/10.1074/jbc.M110399200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821391	hybrid			2022-12-25	WOS:000175036300037
J	Xie, Z; Ho, WT; Spellman, R; Cai, S; Exton, JH				Xie, Z; Ho, WT; Spellman, R; Cai, S; Exton, JH			Mechanisms of regulation of phospholipase D1 and D2 by the heterotrimeric G proteins G(13) and G(q)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; C-TERMINAL DOMAINS; KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE PHOSPHORYLATION; SIGNALING CASCADE; ALPHA-SUBUNIT; RHO-PROTEINS; D ACTIVATION; GENE FAMILY	Our earlier studies of rat brain phospholipase D1 (rPLD1) showed that the enzyme could be activated in cells by alpha subunits of the heterotrimeric G proteins G(13) and G(q). Recently, we showed that rPLD1 is modified by Ser/Thr phosphorylation and palmitoylation. In this study, we first investigated the roles of these post-translational modifications on the activation of rPLD1 by constitutively active Galpha(13)Q226L and Galpha(13)Q209L. Mutations Of Cys(240) and Cys(241) of rPLD1, which abolish both post-translational modifications, did not affect the ability of either Galpha(13)Q226L or Galpha(13)Q209L to activate rPLD1. However, the RhoA-insensitive mutants, rPLD1(K946A,K962A) and rPLD1(K962Q), were not activated by Galpha(13)Q226L, although these mutant enzymes responded to phorbol ester and GalphaQ209L. On the contrary, the PKC-insensitive mutant rPLD1(DeltaN168), which lacks the first 168 amino acids of rPLD1, responded to Galpha(13)Q226L but not to GalphaQ209L. In addition, we found that rPLD2 was strongly activated by GalphaQ209L and phorbol ester. However, surprisingly, the enzymatic activity of rPLD2 was suppressed by Galpha(q)Q209L and constitutively active V14RhoA in COS-7 cells. Abolition of the post-translational modifications of rPLD2 did not alter the effects of Galpha(q)Q209L or Galpha(13)Q226L. The suppressive effect of Galpha(13)Q226L on rPLD2 was reversed by dominant negative N19RhoA and the C3 exoenzyme of Clostridium botulinum, further supporting a role for RhoA. In summary, Galpha(13) activation of rPLD1 in COS-7 cells is mediated by Rho, while Galpha(q) activation requires PKC. rPLD2 is activated by Galpha(q), but is inhibited by Galpha(13). Neither Ser/Thr phosphorylation nor palmitoylation is required for these effects.	Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Physiol & Biophys, Sch Med, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Howard Hughes Med Inst, Sch Med, Nashville, TN 37232 USA.							BUHL AM, 1995, J BIOL CHEM, V270, P14935; Cai SM, 2001, BIOCHEM J, V355, P779, DOI 10.1042/bj3550779; Chung JK, 1997, J BIOL CHEM, V272, P15980, DOI 10.1074/jbc.272.25.15980; Colley WC, 1997, BIOCHEM J, V326, P745, DOI 10.1042/bj3260745; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1994, FEBS LETT, V342, P149, DOI 10.1016/0014-5793(94)80490-7; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Fensome A, 1998, J BIOL CHEM, V273, P13157, DOI 10.1074/jbc.273.21.13157; Fromm C, 1997, P NATL ACAD SCI USA, V94, P10098, DOI 10.1073/pnas.94.19.10098; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hess JA, 1997, J BIOL CHEM, V272, P1615, DOI 10.1074/jbc.272.3.1615; Hooley R, 1996, J BIOL CHEM, V271, P6152, DOI 10.1074/jbc.271.11.6152; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kim JH, 1998, FEBS LETT, V430, P231, DOI 10.1016/S0014-5793(98)00661-9; Kim Y, 2000, J BIOL CHEM, V275, P13621, DOI 10.1074/jbc.275.18.13621; Kim Y, 1999, BIOCHEMISTRY-US, V38, P10344, DOI 10.1021/bi990579h; Kodaki T, 1997, J BIOL CHEM, V272, P11408; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee S, 2001, J BIOL CHEM, V276, P28252, DOI 10.1074/jbc.M008521200; Liscovitch M, 1999, BBA-MOL CELL BIOL L, V1439, P245, DOI 10.1016/S1388-1981(99)00098-0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Liu MY, 2001, J BIOL CHEM, V276, P5556, DOI 10.1074/jbc.M006404200; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Lukowski S, 1996, J BIOL CHEM, V271, P24164, DOI 10.1074/jbc.271.39.24164; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; Morris AJ, 1996, TRENDS PHARMACOL SCI, V17, P182, DOI 10.1016/0165-6147(96)10016-X; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; PARK SK, 1997, J BIOL CHEM, V272, P29268; Plonk SG, 1998, J BIOL CHEM, V273, P4823, DOI 10.1074/jbc.273.9.4823; Ponting CP, 1996, PROTEIN SCI, V5, P914; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sah VP, 2000, ANNU REV PHARMACOL, V40, P459, DOI 10.1146/annurev.pharmtox.40.1.459; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Sciorra VA, 2001, BIOCHEMISTRY-US, V40, P2640, DOI 10.1021/bi002528m; Siddiqi AR, 2000, BBA-MOL CELL RES, V1497, P103, DOI 10.1016/S0167-4889(00)00049-5; Singer WD, 1996, J BIOL CHEM, V271, P4504; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; Slaaby R, 2000, BIOCHEM J, V351, P613, DOI 10.1042/0264-6021:3510613; Sugars JM, 1999, J BIOL CHEM, V274, P30023, DOI 10.1074/jbc.274.42.30023; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Voss M, 1999, J BIOL CHEM, V274, P34691, DOI 10.1074/jbc.274.49.34691; Xie Z, 2000, EUR J BIOCHEM, V267, P7138, DOI 10.1046/j.1432-1327.2000.01816.x; Xie Z, 2001, J BIOL CHEM, V276, P9383, DOI 10.1074/jbc.M009425200; Xie Z, 2000, J BIOL CHEM, V275, P24962, DOI 10.1074/jbc.M909745199; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; XIE Z, 2001, IN PRESS BIOCH BIOPH; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	60	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11979	11986		10.1074/jbc.M109751200	http://dx.doi.org/10.1074/jbc.M109751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812783	hybrid			2022-12-25	WOS:000174846400050
J	Sun, XM; Bratton, SB; Butterworth, M; MacFarlane, M; Cohen, GM				Sun, XM; Bratton, SB; Butterworth, M; MacFarlane, M; Cohen, GM			Bcl-2 and Bcl-x(L) inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CD95 TYPE-I; CASPASE ACTIVATION; STRUCTURAL BASIS; CELL-DEATH; SIGNALS APOPTOSIS; NMR STRUCTURE; XIAP; FAS; IAP	Bcl-2 and Bcl-x(L) are reported to inhibit CD95-mediated apoptosis in "type II" but not in "type I" cells. In the present studies, we found that stimulation of CD95 receptors, with either agonistic antibody or CD95 ligand, resulted in the activation of caspase-8, which in turn processed caspase-3 between its large and small subunits. However, in contrast to control cells, those overexpressing either Bcl-2 or Bcl-x(L) displayed a distinctive pattern of caspase-3 processing. Indeed, the resulting p20/p12 caspase-3 was not active and did not undergo normal autocatalytic processing to form p17/p12 caspase-3, because it was bound to and inhibited by endogenous X-linked inhibitor-of-apoptosis protein (XIAP). Importantly, Bcl-2 and Bcl-x(L) inhibited the release of both cytochrome c and Smac from mitochondria. However, since Smac alone was sufficient to promote caspase-3 activity in vitro by inactivating XIAP, we proposed the existence of a death receptor-induced, Smac-dependent and apoptosome-independent pathway. This type II pathway was subsequently reconstituted in vitro using purified recombinant proteins at endogenous concentrations. Thus, mitochondria and associated Bcl-2 and Bcl-x(L) proteins may play a functional role in death receptor-induced apoptosis by modulating the release of Smac. Our data strongly suggest that the relative ratios of XIAP (and other inhibitor-of-apoptosis proteins) to active caspase-3 and Smac may dictate, in part, whether a cell exhibits a type I or type II phenotype.	Univ Leicester, Med Res Council Toxicol Unit, Leicester LE1 9HN, Leics, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester	Cohen, GM (corresponding author), Univ Leicester, Med Res Council Toxicol Unit, Lancaster Rd POB 138 Hodgkin Bldg Lancaster Rd, Leicester LE1 9HN, Leics, England.	gmc2@le.ac.uk	Cohen, Gerald M/A-1687-2008	Bratton, Shawn/0000-0003-2895-5020				Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Bratton SB, 2001, TRENDS PHARMACOL SCI, V22, P306, DOI 10.1016/S0165-6147(00)01718-1; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cain K, 1999, J BIOL CHEM, V274, P22686, DOI 10.1074/jbc.274.32.22686; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hartmann BL, 1999, ONCOGENE, V18, P713, DOI 10.1038/sj.onc.1202339; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Huang DCS, 2000, CELL DEATH DIFFER, V7, P754, DOI 10.1038/sj.cdd.4400683; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu ZH, 2000, NATURE, V408, P1004, DOI 10.1038/35050006; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Roberts DL, 2001, J CELL BIOL, V153, P221, DOI 10.1083/jcb.153.1.221; Rokhlin OW, 2001, ONCOGENE, V20, P2836, DOI 10.1038/sj.onc.1204410; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Saleh A, 1999, J BIOL CHEM, V274, P17941, DOI 10.1074/jbc.274.25.17941; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schmitz I, 1999, CELL DEATH DIFFER, V6, P821, DOI 10.1038/sj.cdd.4400569; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun CH, 2000, J BIOL CHEM, V275, P33777, DOI 10.1074/jbc.M006226200; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vu CCQ, 2001, J BIOL CHEM, V276, P37602, DOI 10.1074/jbc.M104810200; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zhang XD, 2001, CANCER RES, V61, P7339; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	62	201	204	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11345	11351		10.1074/jbc.M109893200	http://dx.doi.org/10.1074/jbc.M109893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801595	hybrid			2022-12-25	WOS:000174613100076
J	Cao, HM; Courchesne, WE; Mastick, CC				Cao, HM; Courchesne, WE; Mastick, CC			A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14 - Recruitment of C-terminal Src kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; INTEGRIN; FAMILY; MEMBRANE; SITES; CSK; FYN	Caveolin-1 is a substrate for nonreceptor tyrosine kinases including Src, Fyn, and Abl. To investigate the function of caveolin-1 phosphorylation, we modified the Gal4-based yeast two-hybrid system to screen for phosphorylation-dependent protein interactions. A cDNA library was screened using the N terminus of caveolin-1 as bait in a yeast strain expressing the catalytic domain of Abl. We identified two proteins in this screen that interact with caveolin-1 in a phosphorylation-dependent manner: tumor necrosis factor-a receptor-associated factor 2 (TRAF2) and C-terminal Src kinase (Csk). TRAF2 bound to nonphosphorylated caveolin-1, but this association was increased 3-fold by phosphorylation. In contrast, association of Csk with caveolin-1 was completely dependent on phosphorylation of caveolin-1, both for fusion proteins in yeast (>35-fold difference in affinity) and for endogenous proteins in tissue culture cells. Our data suggest that phosphorylation of caveolin-1 leads to Csk translocation into caveolae. This may induce a feedback loop that leads to inactivation of the Src family kinases that are highly enriched in caveolae.	Univ Nevada, Dept Biochem, Reno, NV 89557 USA; Univ Nevada, Dept Microbiol, Reno, NV 89557 USA	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno	Mastick, CC (corresponding author), Univ Nevada, Dept Biochem, Mail Stop 330, Reno, NV 89557 USA.		Mastick, Cynthia/G-9841-2017; Cao, Haiming/P-4634-2016	Mastick, Cynthia/0000-0003-4769-5412; 	NIDDK NIH HHS [DK56197] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056197] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Aoki T, 1999, EXP CELL RES, V253, P629, DOI 10.1006/excr.1999.4652; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Feng X, 2001, J BIOL CHEM, V276, P8341, DOI 10.1074/jbc.M007116200; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; Mastick CC, 2001, EXP CELL RES, V266, P142, DOI 10.1006/excr.2001.5205; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Stahlhut M, 2000, EXP CELL RES, V261, P111, DOI 10.1006/excr.2000.4960; Stearman R, 1998, GENE, V212, P197, DOI 10.1016/S0378-1119(98)00179-6; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; ZHOU SY, 1995, TRENDS BIOCHEM SCI, V20, P470	28	173	177	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8771	8774		10.1074/jbc.C100661200	http://dx.doi.org/10.1074/jbc.C100661200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11805080	hybrid			2022-12-25	WOS:000174400600005
J	van Royen, N; Hoefer, I; Buschmann, I; Heil, M; Kostin, S; Deindl, E; Vogel, S; Korff, T; Augustin, H; Bode, C; Piek, JJ; Schaper, W				van Royen, N; Hoefer, I; Buschmann, I; Heil, M; Kostin, S; Deindl, E; Vogel, S; Korff, T; Augustin, H; Bode, C; Piek, JJ; Schaper, W			Exogenous application of transforming growth factor beta 1 stimulates arteriogenesis in the peripheral circulation	FASEB JOURNAL			English	Article						collateral circulation; angiogenesis; arteries; remodeling; leukocytes	GROWTH-FACTOR-BETA; HUMAN ATHEROSCLEROTIC LESIONS; FEMORAL-ARTERY OCCLUSION; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; CORONARY ANGIOGENESIS; MYOCARDIAL-INFARCTION; ENDOTHELIAL-CELLS; RABBIT HINDLIMB; EXPRESSION	Increased expression of transforming growth factor beta1 (TGF-beta(1)) during collateral artery growth, as well as its numerous effects on monocytes/macrophages and the smooth muscle cell cycle and differentiation, suggest a modulating role for this growth factor during arteriogenesis. We studied the effects of exogenously applied TGF-beta(1) on arteriogenesis as well as its interactions with monocytes, endothelial cells, and smooth muscle cells. In a New Zealand White (NZW) rabbit model of femoral artery ligation, increased expression of active TGF-beta(1) was found around proliferating arteries in NZW rabbits. The exogenous application of TGF-beta(1) led to an increase in both the number of visible collateral arteries as well as the conductance of the collateral circulation (4.0 +/- 0.5 ml/min/100 mmHg vs. 28.9 +/- 3.7 ml/min/100 mmHg, P < 0.05). Fluorescence activated cell sorting analysis showed an increase in the expression of the MAC-1 receptor in both rabbit and human monocytes after treatment with TGF-beta(1) (control: 91.2 +/- 4.2/482 +/- 21.7; TGF-beta(1) 200 ng/ml 193.9 +/- 6.7/675.5 +/- 25.7, P < 0.05 for all differences). TGF-beta(1) treated monocytes showed an increased endothelial adhesion and transmigration in transendothelial migration assays (5.75 +/- 0.63 x 10(5) vs. 10.11 +/- 0.04 x 10(5), P < 0.05). TGF-beta(1) had no direct pro-angiogenic effect on human umbilical vein endothelial cells in a spheroid model of angiogenesis and inhibited the angiogenic effects of vascular endothelial growth factor.	Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Max Planck Inst Physiol & Clin Res, Dept Expt Cardiol, D-6350 Bad Nauheim, Germany; Univ Freiburg, Dept Cardiol & Angiol, Res Grp Expt & Clin Arteriogenesis, Freiburg, Germany; Clin Tumorbiol Angiogenesis Res Ctr, Freiburg, Germany	University of Amsterdam; Academic Medical Center Amsterdam; Max Planck Society; University of Freiburg	van Royen, N (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Cardiol, Room B2-250,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	n.vanroyen@amc.uva.nl	Augustin, Hellmut/AAA-5246-2020; van Royen, Niels/Q-1097-2017; Deindl, Elisabeth/A-2511-2013	Augustin, Hellmut/0000-0002-7173-4242; 				Arras M, 1998, BASIC RES CARDIOL, V93, P97, DOI 10.1007/s003950050069; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BAROLDI G, 1956, CIRC RES, V4, P223, DOI 10.1161/01.RES.4.2.223; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; Blumgart HL, 1940, AM HEART J, V19, P1, DOI 10.1016/S0002-8703(40)90305-2; Bobik A, 1999, CIRCULATION, V99, P2883, DOI 10.1161/01.CIR.99.22.2883; Cai WJ, 2000, J MOL CELL CARDIOL, V32, P997, DOI 10.1006/jmcc.2000.1137; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; CHANTRY D, 1989, J IMMUNOL, V142, P4295; Cucina A, 1998, SURGERY, V123, P212, DOI 10.1016/S0039-6060(98)70260-0; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Epstein SE, 2001, CIRCULATION, V104, P115, DOI 10.1161/01.CIR.104.1.115; FALANGA V, 1991, J INVEST DERMATOL, V97, P634, DOI 10.1111/1523-1747.ep12483126; Fuchs S, 2001, CORONARY ARTERY DIS, V12, P173, DOI 10.1097/00019501-200105000-00003; GENTRY LE, 1988, MOL CELL BIOL, V8, P4162, DOI 10.1128/MCB.8.10.4162; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GRAINGER DJ, 1995, NAT MED, V1, P74, DOI 10.1038/nm0195-74; Grainger DJ, 1998, J CELL SCI, V111, P2977; GRAINGER DJ, 1995, BIOL REV, V70, P571, DOI 10.1111/j.1469-185X.1995.tb01652.x; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Hershey JC, 2001, CARDIOVASC RES, V49, P618, DOI 10.1016/S0008-6363(00)00232-7; Hoefer IE, 2001, CARDIOVASC RES, V49, P609, DOI 10.1016/S0008-6363(00)00243-1; ITO N, 1995, CANCER LETT, V89, P45, DOI 10.1016/0304-3835(94)03651-X; Ito WD, 1997, AM J PHYSIOL-HEART C, V273, pH1255, DOI 10.1152/ajpheart.1997.273.3.H1255; Ito WD, 1997, CIRC RES, V80, P829; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kern MJ, 1999, J INTERV CARDIOL, V12, P313, DOI 10.1111/j.1540-8183.1999.tb00251.x; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Korff T, 1999, J CELL SCI, V112, P3249; Kostin S, 1999, CIRC RES, V85, P154, DOI 10.1161/01.RES.85.2.154; Krupinski J, 1996, STROKE, V27, P852, DOI 10.1161/01.STR.27.5.852; Lazarous DF, 1996, CIRCULATION, V94, P1074, DOI 10.1161/01.CIR.94.5.1074; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; LONGLAND CJ, 1953, ANN ROY COLL SURG, V13, P161; Lutgens E, 2000, P NATL ACAD SCI USA, V97, P7464, DOI 10.1073/pnas.97.13.7464; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; McCaffrey TA, 1995, J CLIN INVEST, V96, P2667, DOI 10.1172/JCI118333; McCartney-Francis N, 1990, GROWTH FACTORS, V4, DOI 10.3109/08977199009011007; NABEL EG, 1993, P NATL ACAD SCI USA, V90, P10759, DOI 10.1073/pnas.90.22.10759; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Panousis CG, 2001, J LIPID RES, V42, P856; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Reckless J, 1997, CIRCULATION, V95, P1542; Rinsch C, 2001, GENE THER, V8, P523, DOI 10.1038/sj.gt.3301436; SAKUDA H, 1992, AM J PATHOL, V141, P1507; SCHAPER J, 1976, VIRCHOWS ARCH A, V370, P193, DOI 10.1007/BF00427580; Schaper W, 1993, COLLATERAL CIRCULATI; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; Simons M, 2000, CIRCULATION, V102, pE73, DOI 10.1161/01.CIR.102.11.e73; Simons M, 2001, AM J PHYSIOL-HEART C, V280, pH1923, DOI 10.1152/ajpheart.2001.280.5.H1923; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Tomanek RJ, 2001, CIRC RES, V88, P1135, DOI 10.1161/hh1101.091191; TURNER M, 1990, Cytokine, V2, P211, DOI 10.1016/1043-4666(90)90018-O; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wang XL, 1997, CARDIOVASC RES, V34, P404, DOI 10.1016/S0008-6363(97)00033-3; WISEMAN DM, 1988, BIOCHEM BIOPH RES CO, V157, P793, DOI 10.1016/S0006-291X(88)80319-X; WUNSCH M, 1991, J MOL CELL CARDIOL, V23, P1051, DOI 10.1016/0022-2828(91)91640-D; Youn TJ, 1999, BASIC RES CARDIOL, V94, P246, DOI 10.1007/s003950050149; Zheng W, 2001, AM J PHYSIOL-HEART C, V280, pH909, DOI 10.1152/ajpheart.2001.280.2.H909; [No title captured]	61	126	129	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					432	+		10.1096/fj.01-0563fje	http://dx.doi.org/10.1096/fj.01-0563fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821255				2022-12-25	WOS:000173656600011
J	van Noort, M; Meeldijk, J; van der Zee, R; Destree, O; Clevers, H				van Noort, M; Meeldijk, J; van der Zee, R; Destree, O; Clevers, H			Wnt signaling controls the phosphorylation status of beta-catenin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTIONAL ACTIVATION; RECEPTOR; AXIN; PROTEINS; XENOPUS; MICE; APC; TRANSDUCTION; GSK3-BETA	At the heart of the canonical Wnt signaling cascade, adenomatous polyposis coli (APC), axin, and GSK3 constitute the so-called destruction complex, which controls the stability of beta-catenin. It is generally believed that four conserved Ser/Thr residues in the N terminus of beta-catenin are the pivotal targets for the constitutively active serine kinase GSK3. In cells that do not receive Wnt signals, glycogen synthase kinase (GSK) is presumed to phosphorylate beta-catenin, thus marking the latter for proteasomal degradation. Wnt signaling inhibits GSK3 activity. As a consequence, beta-catenin would no longer be phosphorylated and accumulate to form nuclear complexes with TCF/LEF factors. Although mutations in or near the N-terminal Ser/Thr residues stabilize beta-catenin in several types of cancer, the hypothesis that Wnt signaling controls phosphorylation of these residues remains unproven. We have generated a monoclonal antibody that recognizes an epitope containing two of the four residues when both are not phosphorylated. The epitope is generated upon Wnt signaling as well as upon pharmacological inhibition of GSK3 by lithium, providing formal proof for the regulated phosphorylation of the Ser/Thr residues of beta-catenin by Wnt signaling. Immunohistochemical analysis of mouse embryos utilizing the antibody visualizes sites that transduce Wnt signals through the canonical Wnt cascade.	Univ Med Ctr Utrecht, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Dept Immunol, NL-3584 CL Utrecht, Netherlands; Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), UMC Utrecht, Dept Immunol, Rm F03-821,POB 85500, NL-3508 GA Utrecht, Netherlands.		van der Zee, Ruurd/O-5256-2015	van der Zee, Ruurd/0000-0002-4331-2755				Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701; Kuhl M, 2001, MECH DEVELOP, V106, P61, DOI 10.1016/S0925-4773(01)00416-6; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	25	400	417	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17901	17905		10.1074/jbc.M111635200	http://dx.doi.org/10.1074/jbc.M111635200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11834740	hybrid			2022-12-25	WOS:000175685100066
J	Sah, JF; Ito, H; Kolli, BK; Peterson, DA; Sassa, S; Chang, KP				Sah, JF; Ito, H; Kolli, BK; Peterson, DA; Sassa, S; Chang, KP			Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINIC-ACID; MEXICANA-AMAZONENSIS; MULTIDRUG-RESISTANCE; IN-VITRO; PROMASTIGOTES; IDENTIFICATION; AMPLIFICATION; DEHYDRATASE; METABOLISM; CRITHIDIA	Leishmania was found deficient in at least five and most likely seven of the eight enzymes in the heme biosynthesis pathway, accounting for their growth requirement for heme compounds. The xenotransfection of this trypanosomatid protozoan led to their expression of the mammalian genes encoding delta-aminolevulinate (ALA) dehydratase and porphobilinogen deaminase, the second and the third enzymes of the pathway, respectively. These transfectants still require hemin or protoporphyrin IX for growth but produce porphyrin when ALA was supplied exogenously. Leishmania is thus deficient in all first three enzymes of the pathway. Uroporphyrin I was produced as the sole intermediate by these transfectants, further indicating that they are also deficient in at least two porphyrinogen-metabolizing enzymes downstream of porphobilinogen deaminase, i.e. uroporphyrinogen III co-synthase and uroporphyrinogen decarboxylase. Pulsing the transfectants with ALA induced their transition from aporphyria to uroporphyria. Uroporphyrin I emerged in these cells initially as diffused throughout the cytosol, rendering them sensitive to UV irradiation. The porphyrin was subsequently sequestered in cytoplasmic vacuoles followed by its release and accumulation in the extracellular milieu, concomitant with a reduced photosensitivity of the cells. These events may represent cellular mechanisms for disposing soluble toxic waste from the cytosol. Monocytic tumor cells were rendered photosensitive by infection with uroporphyric Leishmania, suggestive of their potential application for photodynamic therapy.	Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, N Chicago, IL 60064 USA; Finch Univ Hlth Sci Chicago Med Sch, Dept Neurosci, N Chicago, IL 60064 USA; Rockefeller Univ, New York, NY 10021 USA	Chicago Medical School; Chicago Medical School; Rockefeller University	Chang, KP (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Microbiol & Immunol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	changk@mail.finchcms.edu		Sah, Jerome/0000-0001-9478-7155	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032890] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 20486] Funding Source: Medline; NIDDK NIH HHS [DK32890] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABBAS A, 1993, J BIOL CHEM, V268, P8541; Abels C, 1997, J PHOTOCH PHOTOBIO B, V40, P76, DOI 10.1016/S1011-1344(97)00027-4; Afonso S G, 1990, J Enzyme Inhib, V3, P303, DOI 10.3109/14756369009030379; ANDERSON WL, 1978, ANAL BIOCHEM, V91, P481, DOI 10.1016/0003-2697(78)90534-1; BEAUMONT C, 1989, J BIOL CHEM, V264, P14829; Bermudez R, 1997, MOL BIOCHEM PARASIT, V90, P43, DOI 10.1016/S0166-6851(97)00131-X; CHANG CS, 1985, MOL BIOCHEM PARASIT, V16, P267, DOI 10.1016/0166-6851(85)90069-6; Chang KP, 1999, CLIN DERMATOL, V17, P269, DOI 10.1016/S0738-081X(99)00055-3; CHANG KP, 1983, INT REV CYTOL, P267; CHANG KP, 1975, P NATL ACAD SCI USA, V72, P2979, DOI 10.1073/pnas.72.8.2979; Chen DQ, 2000, INFECT IMMUN, V68, P80, DOI 10.1128/IAI.68.1.80-86.2000; DU YB, 1994, P NATL ACAD SCI USA, V91, P8437, DOI 10.1073/pnas.91.18.8437; ELLENBERGER TE, 1989, J BIOL CHEM, V264, P15094; Essodaigui M, 1999, MOL BIOCHEM PARASIT, V100, P73, DOI 10.1016/S0166-6851(99)00036-5; GALBRAITH RA, 1988, MOL BIOCHEM PARASIT, V29, P47, DOI 10.1016/0166-6851(88)90118-1; Gibson SL, 1999, BRIT J CANCER, V80, P998, DOI 10.1038/sj.bjc.6690454; Glerum DM, 1996, YEAST, V12, P1421; Gueiros FJ, 1995, EXP PARASITOL, V81, P480, DOI 10.1006/expr.1995.1141; GUO GG, 1994, J BIOL CHEM, V269, P12399; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HART DT, 1982, EXP PARASITOL, V54, P397, DOI 10.1016/0014-4894(82)90049-2; Hilf R, 1999, PHOTOCHEM PHOTOBIOL, V70, P334, DOI 10.1111/j.1751-1097.1999.tb08145.x; KAPPAS A, 1995, PEDIATRICS, V95, P468; KAPPAS A, 1969, P NATL ACAD SCI USA, V64, P557, DOI 10.1073/pnas.64.2.557; Kawazu SI, 1997, GENE, V196, P49, DOI 10.1016/S0378-1119(97)00190-X; KURLANDZKA A, 1985, J GEN MICROBIOL, V131, P2909; LIU X, 1992, MOL CELL BIOL, V12, P4112, DOI 10.1128/MCB.12.9.4112; McCaughan JS, 1999, DRUG AGING, V15, P49, DOI 10.2165/00002512-199915010-00005; McGwire BS, 1996, J BIOL CHEM, V271, P7903, DOI 10.1074/jbc.271.14.7903; Sagar R, 1995, MICROBIOL RES, V150, P419, DOI 10.1016/S0944-5013(11)80024-8; SALZMAN TA, 1985, INT J BIOCHEM, V17, P1343, DOI 10.1016/0020-711X(85)90058-8; SALZMAN TA, 1982, COMP BIOCHEM PHYS B, V72, P663, DOI 10.1016/0305-0491(82)90523-5; SANDBERG S, 1982, ACTA DERM-VENEREOL, P75; SANDBERG S, 1982, J CLIN INVEST, V70, P693, DOI 10.1172/JCI110664; SASSA S, 1982, ENZYME, V28, P133, DOI 10.1159/000459097; SASSA S, 1974, P NATL ACAD SCI USA, V71, P732, DOI 10.1073/pnas.71.3.732; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SASSA S, 1995, WILLIAMS HEMATOLOGY, P726; Sengupta S, 1999, J BIOL CHEM, V274, P2758, DOI 10.1074/jbc.274.5.2758; Srivastava P, 1997, MOL CELL BIOCHEM, V171, P65, DOI 10.1023/A:1006830113376; STEIGER RF, 1976, J PARASITOL, V62, P1010, DOI 10.2307/3279200; STUBNICER AC, 1988, NUCLEIC ACIDS RES, V16, P3102, DOI 10.1093/nar/16.7.3102; TAKETANI S, 1984, BIOCHIM BIOPHYS ACTA, V798, P226, DOI 10.1016/0304-4165(84)90308-8; WANG W, 1975, CELL, V6, P75, DOI 10.1016/0092-8674(75)90076-8	44	62	68	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14902	14909		10.1074/jbc.M200107200	http://dx.doi.org/10.1074/jbc.M200107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836252	hybrid			2022-12-25	WOS:000175203000071
J	Zhang, JM; Ye, WJ; Wang, R; Wolfe, MS; Greenberg, BD; Selkoe, DJ				Zhang, JM; Ye, WJ; Wang, R; Wolfe, MS; Greenberg, BD; Selkoe, DJ			Proteolysis of chimeric beta-amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE INHIBITORS; NUCLEAR TRANSLOCATION; PRESENILIN; CLEAVAGE; ENDOPROTEOLYSIS; GENERATION; RELEASE; APP; SPECIFICITY; EXPRESSION	gamma-Secretase is an unusual intramembranous protease that has been reported to cleave the beta-amyloid precursor protein (APP) near the middle of its transmembrane domain (TMD) but cleave Notch near the cytoplasmic end of its TMD. To ascertain whether the TMD sequence of the substrate determines where gamma-secretase cleaves and whether the region just before the TMD participates in recognition by the enzyme, we expressed chimeric human APP molecules containing either the TMD or pre-TMD regions of Notch or other transmembrane proteins. APP chimeras bearing either the Notch or the amyloid precursor-like protein-2 TMD released similar amounts of similar to4-kDa amyloid beta-peptide (Abeta)-like peptides as did intact A-PP. Mass spectrometry revealed that the principal Abeta-like peptide ended at residue 40, indicating cleavage at the middle of the Notch TMD in the chimera. Generation of Abeta-like peptides was significantly decreased when the APP TMD was replaced by those of SREBP-1 or human epithelial growth factor receptor 3. Replacement of the APP pre-TMD region (Abeta 10-28) with that of SREBP-1 increased generation of Abeta-like peptides, while those of human epithelial growth factor receptor 3 or amyloid precursor-like protein-2 decreased it. We conclude that gamma-secretase can cleave near the middle of the Notch TMD, that Abeta-like peptides may arise during Notch processing, and that the pre-TMD sequence of the substrate influences recognition or binding by the enzyme.	Harvard Univ, Inst Med 730, Ctr Neurol Dis, Sch Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; AstraZeneca R&D Boston, Worcester, MA 01605 USA; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; AstraZeneca; Icahn School of Medicine at Mount Sinai	Selkoe, DJ (corresponding author), Harvard Univ, Inst Med 730, Ctr Neurol Dis, Sch Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	selkoe@cnd.bwh.harvard.edu	Wang, Rong/A-8721-2009		NIA NIH HHS [AG15379, AG10491] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG010491, P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Bunnell WL, 1998, J BIOL CHEM, V273, P31947, DOI 10.1074/jbc.273.48.31947; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; CITRON M, 1995, NEURON, V14, P661, DOI 10.1016/0896-6273(95)90323-2; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Hardy J, 1997, P NATL ACAD SCI USA, V94, P2095, DOI 10.1073/pnas.94.6.2095; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Huppert SS, 2000, NATURE, V405, P966, DOI 10.1038/35016111; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Kulic L, 2000, P NATL ACAD SCI USA, V97, P5913, DOI 10.1073/pnas.100049897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; Lichtenthaler SF, 1999, P NATL ACAD SCI USA, V96, P3053, DOI 10.1073/pnas.96.6.3053; LOWERY DE, 1991, J BIOL CHEM, V266, P19842; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; PODLISNY MB, 1991, AM J PATHOL, V138, P1423; Ray WJ, 1999, P NATL ACAD SCI USA, V96, P3263, DOI 10.1073/pnas.96.6.3263; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Ross SL, 1998, J BIOL CHEM, V273, P15309, DOI 10.1074/jbc.273.25.15309; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Tischer E, 1996, J BIOL CHEM, V271, P21914, DOI 10.1074/jbc.271.36.21914; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	43	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15069	15075		10.1074/jbc.M105375200	http://dx.doi.org/10.1074/jbc.M105375200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839734	hybrid			2022-12-25	WOS:000175203000091
J	Bednarek, MA; Tan, C; Hreniuk, DL; Palyha, OC; MacNeill, DJ; Van der Ploeg, LHY; Howard, AD; Feighner, SD				Bednarek, MA; Tan, C; Hreniuk, DL; Palyha, OC; MacNeill, DJ; Van der Ploeg, LHY; Howard, AD; Feighner, SD			Synthesis and biological evaluation in vitro of a selective, high potency peptide agonist of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; MOLECULAR CHARACTERIZATION; BINDING-SITES; HUMAN BRAIN; ALPHA-MSH; MCH; IDENTIFICATION; LIGAND; SLC-1; RAT	Human melanin-concentrating hormone (hMCH) is a nonselective natural ligand for the human melanin-concentrating hormone receptors: hMCH-1R and hMCH-2R. Similarly, the smaller peptide encompassing the disulfide ring and Arg(6) of hMCH, Ac-Arg(6)-cyclo(S-S)(Cys(7)-Met(8)-Leu(9)-Gly(10)-Arg(11)-Val(12)-Tyr(13)-Arg(14)-Pro(15)-Cys(16)).-NH2, Ac-hMCH(6-16)-NH2, binds to and activates equally well both human MCH receptors present in the brain. To separate the physiological functions of hMCH-1R from those of hMCH-2R, new potent and hMCH-1R selective agonists are necessary. In the present study, analogs of Ac-hMCH(6-16)-NH2 were prepared and tested in binding and functional assays on cells expressing the MCH receptors. In these peptides, Arg in position 6 was replaced with various D-amino acids and/or Gly in position 10 was substituted with various L-amino acids. Several of the new compounds turned out to be potent agonists at hMCH-1R with improved selectivity over hMCH-2R. For example, peptide 26 with D-Arg in place of L-Arg in position 6 and Asn in place of Gly in position 10, Ac-DArg(6)-cyclo(S-S)(Cys(7)-Met(8)-Leu(9)-Asn(10)-Arg(11)-Val(12)-Tyr(13)-Arg(14)-Pro(15)-Cys(16))-NH2, was a potent hMCH-1R agonist (IC50 = 0.5 nM, EC50 = 47 nM) with more than 200-fold selectivity with respect to hMCH-2R. Apparently, these structural changes in positions 6 and 10 results in peptide conformations that allow for efficient interactions with hMCH-1R but are unfavorable for molecular recognition at hMCH-2R.	Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Merck Res Labs, Dept Obes & Metab Disorders, Rahway, NJ 07065 USA	Merck & Company; Merck & Company	Bednarek, MA (corresponding author), Merck Res Labs, Dept Med Chem, R50G-141, Rahway, NJ 07065 USA.			MacNeil, Doug/0000-0001-7089-0668				Audinot V, 2001, J BIOL CHEM, V276, P13554, DOI 10.1074/jbc.M010727200; Bachner D, 1999, FEBS LETT, V457, P522, DOI 10.1016/S0014-5793(99)01092-3; Bednarek MA, 2001, BIOCHEMISTRY-US, V40, P9379, DOI 10.1021/bi010867p; Burgaud JL, 1997, BIOCHEM BIOPH RES CO, V241, P622, DOI 10.1006/bbrc.1997.7849; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; Chambers J, 1999, NATURE, V400, P261, DOI 10.1038/22313; DANHO W, 2001, 17 AM PEPT S SAN DIE; Drozdz R, 1995, J Pept Sci, V1, P58, DOI 10.1002/psc.310010108; Gonzalez MI, 1997, PEPTIDES, V18, P387, DOI 10.1016/S0196-9781(96)00337-3; Gonzalez MI, 1996, PEPTIDES, V17, P171, DOI 10.1016/0196-9781(95)02092-6; Hawes BE, 2000, ENDOCRINOLOGY, V141, P4524, DOI 10.1210/en.141.12.4524; Hill J, 2001, J BIOL CHEM, V276, P20125, DOI 10.1074/jbc.M102068200; Hwa JJ, 2001, OBES RES, V9, P69; Lembo PMC, 1999, NAT CELL BIOL, V1, P267, DOI 10.1038/12978; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; Macdonald D, 2000, MOL PHARMACOL, V58, P217, DOI 10.1124/mol.58.1.217; Mori M, 2001, BIOCHEM BIOPH RES CO, V283, P1013, DOI 10.1006/bbrc.2001.4893; MOURI T, 1993, PEPTIDES, V14, P643, DOI 10.1016/0196-9781(93)90158-D; NAHON JL, 1994, CRIT REV NEUROBIOL, V8, P221; PRESSE F, 1990, MOL ENDOCRINOL, V4, P632, DOI 10.1210/mend-4-4-632; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rodriguez M, 2001, MOL PHARMACOL, V60, P632; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Sailer AW, 2001, P NATL ACAD SCI USA, V98, P7564, DOI 10.1073/pnas.121170598; Saito Y, 1999, NATURE, V400, P265, DOI 10.1038/22321; Saito Y, 2000, TRENDS ENDOCRIN MET, V11, P299, DOI 10.1016/S1043-2760(00)00290-3; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Sone M, 2000, PEPTIDES, V21, P245, DOI 10.1016/S0196-9781(99)00206-5; Ungrin MD, 1999, ANAL BIOCHEM, V272, P34, DOI 10.1006/abio.1999.4145; Wang SK, 2001, J BIOL CHEM, V276, P34664, DOI 10.1074/jbc.M102601200	30	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13821	13826		10.1074/jbc.M200563200	http://dx.doi.org/10.1074/jbc.M200563200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11839762	hybrid			2022-12-25	WOS:000175096000063
J	Li, T; Vu, TH; Lee, KO; Yang, YW; Nguyen, CV; Bui, HQ; Zeng, ZL; Nguyen, BT; Hu, JF; Murphy, SK; Jirtle, RL; Hoffman, AR				Li, T; Vu, TH; Lee, KO; Yang, YW; Nguyen, CV; Bui, HQ; Zeng, ZL; Nguyen, BT; Hu, JF; Murphy, SK; Jirtle, RL; Hoffman, AR			An imprinted PEG1/MEST antisense expressed predominantly in human testis and in mature spermatozoa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II GENE; WILMS-TUMOR; METHYLATION IMPRINT; MATERNAL-BEHAVIOR; DNA METHYLATION; GNAS LOCUS; GROWTH; TRANSCRIPT; H19; ESTABLISHMENT	PEG1 (or MESP is an imprinted gene located on human chromosome 7q32 that is expressed predominantly from the paternal allele. In the mouse, Peg1/Mest is associated with embryonic growth and maternal behavior. Human PEG1 is transcribed from two promoters; the transcript from promoter P1 is derived from both parental alleles, and the transcript from P2 is exclusively from the paternal allele. We characterized the P1 and P2 transcripts in various normal and neoplastic tissues. In the normal tissues, PEG1 was transcribed from both promoters P1 and P2, whereas in six of eight neoplastic tissues, PEG1 was transcribed exclusively from promoter P1. Bisulfite sequencing demonstrated high levels of CpG methylation in the P2 region of DNA from a lung tumor. In the region between P1 and P2, we identified a novel transcript, PEG1-AS, in an antisense orientation to PEG1. PEG1-AS is a spliced transcript and was detected as a strong 2.4-kilobase band on a Northern blot. PEG1-AS and PEG1 P2-sense transcript were expressed exclusively from the paternal allele. Fragments of DNA from within the 1.5-kilobase region between PEG1-AS and the P2 exon were ligated to a pGL3 luciferase reporter vector and transfected into NCI H23 cells. This DNA exhibited strong promoter activity in both the sense and antisense directions, indicating that PEG1-AS and P2 exon share a common promoter region. Treatment of the transfected DNA fragments with CpG methylase abolished the promoter activity. Of interest, PEG1-AS was expressed predominantly in testis and in mature motile spermatozoa, indicating a possible role for this transcript in human sperm physiology and fertilization.	Vet Affairs Palo Alto Hlth Care Syst, Med Serv, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Med, Palo Alto, CA 94304 USA; Natl Univ Singapore, Dept Med, Singapore 119074, Singapore; Japan Womens Univ, Dept Food & Nutr, Tokyo 113, Japan; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; National University of Singapore; Japan Womens University; Duke University; Duke University	Vu, TH (corresponding author), Vet Affairs Palo Alto Hlth Care Syst, Med Serv, Bldg 101,Rm B2-125,3801 Miranda Ave, Palo Alto, CA 94304 USA.		Hu, Jifan/Q-3003-2019; Murphy, Susan/R-3903-2019; Lee, Kok-Onn/E-9874-2011	Murphy, Susan/0000-0001-8298-7272; Lee, Kok-Onn/0000-0002-3040-1185; Hoffman, Andrew/0000-0002-0145-1917; Yang, Youwen/0000-0002-6402-8032	NIDDK NIH HHS [DK36054] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036054] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Cuisset L, 1997, ANN GENET-PARIS, V40, P211; Davis TL, 2000, HUM MOL GENET, V9, P2885, DOI 10.1093/hmg/9.19.2885; EKSTROM TJ, 1995, DEVELOPMENT, V121, P309; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; Goodwin LO, 2000, MOL HUM REPROD, V6, P487, DOI 10.1093/molehr/6.6.487; Hayward BE, 2000, HUM MOL GENET, V9, P835, DOI 10.1093/hmg/9.5.835; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; Kelley RL, 2000, CELL, V103, P9, DOI 10.1016/S0092-8674(00)00099-4; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; Kobayashi S, 1997, HUM MOL GENET, V6, P781, DOI 10.1093/hmg/6.5.781; Kosaki K, 2000, AM J HUM GENET, V66, P309, DOI 10.1086/302712; Lee YJ, 2000, FEBS LETT, V472, P230, DOI 10.1016/S0014-5793(00)01461-7; Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464; Lefebvre L, 1997, HUM MOL GENET, V6, P1907, DOI 10.1093/hmg/6.11.1907; Li LL, 1999, SCIENCE, V284, P330, DOI 10.1126/science.284.5412.330; Li T, 2000, GENOMICS, V69, P295, DOI 10.1006/geno.2000.6337; Miller D, 2000, MOL REPROD DEV, V56, P259, DOI 10.1002/(SICI)1098-2795(200006)56:2+<259::AID-MRD10>3.0.CO;2-R; Nishihara S, 2000, INT J ONCOL, V17, P317; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Ohno M, 2001, GENES CELLS, V6, P249, DOI 10.1046/j.1365-2443.2001.00417.x; Okutsu T, 2000, J BIOCHEM-TOKYO, V127, P475, DOI 10.1093/oxfordjournals.jbchem.a022630; Pedersen IS, 1999, CANCER RES, V59, P5449; Riesewijk AM, 1997, GENOMICS, V42, P236, DOI 10.1006/geno.1997.4731; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Vu TH, 2000, GENOMICS, V64, P132, DOI 10.1006/geno.1999.6094; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Vu TH, 1996, J BIOL CHEM, V271, P9014, DOI 10.1074/jbc.271.15.9014; Wroe SF, 2000, P NATL ACAD SCI USA, V97, P3342, DOI 10.1073/pnas.050015397; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yamasaki K, 2000, GENOMICS, V68, P330, DOI 10.1006/geno.2000.6265	31	39	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13518	13527		10.1074/jbc.M200458200	http://dx.doi.org/10.1074/jbc.M200458200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821432	hybrid			2022-12-25	WOS:000175096000025
J	Panigrahi, GB; Cleary, JD; Pearson, CE				Panigrahi, GB; Cleary, JD; Pearson, CE			In vitro (CTG)center dot(CAG) expansions and deletions by human cell extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS-40 DNA-REPLICATION; TRINUCLEOTIDE REPEATS; MISMATCH REPAIR; TRANSGENIC MICE; TRIPLET REPEATS; HUMAN-DISEASE; CTG REPEATS; SOMATIC INSTABILITY; SECONDARY STRUCTURE; MYOTONIC-DYSTROPHY	The mechanism of disease-associated (CTG).(CAG) expansion may involve DNA replication slippage, replication direction, Okazaki fragment processing, recombination, or repair. A length-dependent bias for expansions is observed in humans affected by a trinucleotide repeat-associated disease. We developed an assay to test the effect of replication direction on (CTG).(CAG) instabilities incurred during in vitro (SV40) DNA replication mediated by human cell extracts. This system recapitulates the bias for expansions observed in humans. Replication by HeLa cell extracts generated expansions and deletions that depended upon repeat tract length and the direction of replication. Templates with 79 repeats yielded predominantly expansions (CAG as lagging strand template) or predominantly deletions (CTG as lagging strand template). Templates containing 17 repeats were stable. Thus, replication direction determined the type of mutation. These results provide new insights into the orientation of replication effect upon repeat stability. This system will be useful in determining the contribution of specific human proteins to (CTG).(CAG) expansions.	Hosp Sick Children, Program Genet & Gen Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5A 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Pearson, CE (corresponding author), Hosp Sick Children, Program Genet & Gen Biol, 555 Univ Ave,Elm Wing 11-135, Toronto, ON M5G 1X8, Canada.			Pearson, Christopher/0000-0001-9545-4205				ANDERSON S, 1979, J BIOL CHEM, V254, P1495; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Bill CA, 2001, MUTAT RES-DNA REPAIR, V485, P255, DOI 10.1016/S0921-8777(01)00065-9; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Datta HJ, 2001, J BIOL CHEM, V276, P18018, DOI 10.1074/jbc.M011646200; DEPAMPHILIS ML, 1980, ANNU REV BIOCHEM, V49, P627, DOI 10.1146/annurev.bi.49.070180.003211; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; GACY AM, 1995, CELL, V81, P533; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; Gourdon G, 1997, NAT GENET, V15, P190, DOI 10.1038/ng0297-190; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HAY RT, 1984, J MOL BIOL, V175, P131, DOI 10.1016/0022-2836(84)90471-6; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; JAWORSKI A, 1995, P NATL ACAD SCI USA, V92, P11019, DOI 10.1073/pnas.92.24.11019; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LOPEZ B, 1987, NUCLEIC ACIDS RES, V15, P5643, DOI 10.1093/nar/15.14.5643; Manley K, 1999, NAT GENET, V23, P471, DOI 10.1038/70598; Miret JJ, 1998, P NATL ACAD SCI USA, V95, P12438, DOI 10.1073/pnas.95.21.12438; Monckton DG, 1997, NAT GENET, V15, P193, DOI 10.1038/ng0297-193; Moore H, 1999, P NATL ACAD SCI USA, V96, P1504, DOI 10.1073/pnas.96.4.1504; NAG DK, 1989, NATURE, V340, P318, DOI 10.1038/340318a0; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; Pearse J, 1998, J COMMUNITY APPL SOC, V8, P1; Pearson CE, 1997, HUM MOL GENET, V6, P1117, DOI 10.1093/hmg/6.7.1117; Pearson CE, 1998, BIOCHEMISTRY-US, V37, P2701, DOI 10.1021/bi972546c; Pearson CE, 1996, BIOCHEMISTRY-US, V35, P5041, DOI 10.1021/bi9601013; Richard GF, 2000, EMBO J, V19, P2381, DOI 10.1093/emboj/19.10.2381; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; Samadashwily GM, 1997, NAT GENET, V17, P298, DOI 10.1038/ng1197-298; Schweitzer JK, 1999, GENETICS, V152, P953; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; THOMAS DC, 1994, P NATL ACAD SCI USA, V91, P7752, DOI 10.1073/pnas.91.16.7752; van den Broek WJAA, 2002, HUM MOL GENET, V11, P191, DOI 10.1093/hmg/11.2.191; VASSILEV L, 1988, NUCLEIC ACIDS RES, V16, P7742, DOI 10.1093/nar/16.15.7742; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGE S, 1994, NATURE, V369, P207	43	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13926	13934		10.1074/jbc.M109761200	http://dx.doi.org/10.1074/jbc.M109761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832482	hybrid			2022-12-25	WOS:000175096000076
J	Voisin, MB; Bitard, J; Daburon, S; Moreau, JF; Taupin, JL				Voisin, MB; Bitard, J; Daburon, S; Moreau, JF; Taupin, JL			Separate functions for the two modules of the membrane-proximal cytokine binding domain of glycoprotein 190, the leukemia inhibitory factor low affinity receptor, in ligand binding and receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCER; DISTINCT ROLES; GM-CSF; REVEALS; IL-5; SUBUNIT; REGION; GP190	The receptor for the cytokine leukemia inhibitory factor (LIF) associates the low affinity binding component gp190 and the high affinity converter gp130. Both are members of the hematopoictic receptors family characterized by the cytokine receptor homology (CRH) domain, which consists of two barrel-like modules of around 100 amino acids each. The gp190 is among the very few members of this large family to contain two CRH domains. The membrane-distal one (herein called D1) is followed by an immunoglobulin-like domain, a membrane-proximal CRH domain called D2, and three type III fibronectin-like repeats. A minimal D1IgD2 fragment is required for binding LIF. By using transmembrane forms of deletion mutants in gp190 ectodomain, we demonstrated that removal of D1 led to spontaneous activation of the receptor and that this property was devoted to a peptidic sequence localized within the last 42 amino acids of the carboxyl-terminal module of D2. By using soluble forms of deletion mutants made by progressive truncations from the end of the D1IgD2 fragment, we demonstrated that the carboxyl-terminal module of D2 was dispensable for LIF binding and that the correct conformation of the D1Ig fragment required a full amino-terminal module of D2. Therefore, the two constitutive modules of the membrane-proximal CRH domain D2 of gp190 fulfill two distinct roles in gp190 function, i.e. in stabilizing the conformation of gp190 allowing LIF binding and in activating the receptor.	Univ Bordeaux 2, CNRS, UMR 5540, F-33076 Bordeaux, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Taupin, JL (corresponding author), Univ Bordeaux 2, CNRS, UMR 5540, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	jean-luc.taupin@umr5540.u-bordeaux2.fr		BITARD, Juliette/0000-0001-6626-3522; , Mathieu-Benoit/0000-0003-3001-0894				Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; Bravo G, 2000, CAN J AGING, V19, P1, DOI 10.1017/S0714980800016561; Bravo J, 1998, EMBO J, V17, P1665, DOI 10.1093/emboj/17.6.1665; Carr PD, 2001, CELL, V104, P291, DOI 10.1016/S0092-8674(01)00213-6; DAndrea RJ, 1996, BLOOD, V87, P2641, DOI 10.1182/blood.V87.7.2641.bloodjournal8772641; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Grotzinger J, 1999, BIOL CHEM, V380, P803, DOI 10.1515/BC.1999.100; Hammacher A, 2000, BIOCHEM J, V345, P25, DOI 10.1042/0264-6021:3450025; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; Kurth I, 2000, J IMMUNOL, V164, P273, DOI 10.4049/jimmunol.164.1.273; Pitard V, 1997, J IMMUNOL METHODS, V205, P177, DOI 10.1016/S0022-1759(97)00074-4; Pitard V, 1998, EUR CYTOKINE NETW, V9, P599; Remy I, 1999, SCIENCE, V283, P990, DOI 10.1126/science.283.5404.990; Sabath DF, 1999, BLOOD, V94, P365, DOI 10.1182/blood.V94.1.365.413a46_365_367; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Smith DK, 1998, PROTEIN SCI, V7, P886; Starr R, 1997, J BIOL CHEM, V272, P19982, DOI 10.1074/jbc.272.32.19982; Taupin JL, 1999, J BIOL CHEM, V274, P14482, DOI 10.1074/jbc.274.20.14482; Taupin JL, 2001, J BIOL CHEM, V276, P47975, DOI 10.1074/jbc.M105476200; Taupin JL, 1997, CYTOKINE, V9, P112, DOI 10.1006/cyto.1996.0144; Woodcock JM, 1996, J BIOL CHEM, V271, P25999, DOI 10.1074/jbc.271.42.25999	23	9	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13682	13692		10.1074/jbc.M111624200	http://dx.doi.org/10.1074/jbc.M111624200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834739	hybrid			2022-12-25	WOS:000175096000046
J	Aoukaty, A; Tan, R				Aoukaty, A; Tan, R			Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CUTTING EDGE; RECEPTOR 2B4; T-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; IMMUNOLOGICAL SYNAPSE; CYTOTOXIC LYMPHOCYTES; ENCODING GENE; LIPID RAFTS; PROTEIN	Natural killer (NK) cells express an activating receptor, 2134, that enhances cellular cytotoxicity. Upon NK cell activation by ligation of 2134, the intracellular domain of 2134 associates with the X-linked lymphoproliferative disease (XLP) gene product, signaling lymphocytic activation molecule-associated protein/SR2D1A (SAP/SH2D1A). Defective intracellular association of 2134 with mutated SAP/SH2D1A is likely to underlie the defects in cytotoxicity observed in NK cells from patients with XLP. We report here a role for phosphoinositide 3-kinase (PI3K) in the recruitment and association of SAP/SH2D1A to 2134 in human NK cells. The activation of normal N-K cells by ligation of 2134 leads to the phosphorylation of 2134, recruitment of SAP/SH2D1A, and association of the p85 regulatory subunit of PI3K. The inhibition of PI3K enzymatic activity with either wortmannin or LY294002 prior to 2134 ligation does not alter the association of 2134 with the p85 subunit but prevents the recruitment of SAP/SH2D1A to 2B4. In addition, PI3K inhibitors significantly diminish the cytotoxic function of primary NK cells. This observed inhibition of cytotoxicity, present in normal NK cells, was less apparent or absent in NK cells derived from a patient with XLP. These data indicate that the cytotoxicity of activated N-K cells is mediated by the association of 2134 and SAP/SH2D1A, and that this association is dependent upon the activity of PI3K.	British Columbia Childrens Hosp, Dept Pathol & Lab Med, Vancouver, BC V6H 3V4, Canada; Univ British Columbia, Vancouver, BC V6H 3V4, Canada	BC Childrens Hospital; University of British Columbia; University of British Columbia	Tan, R (corresponding author), British Columbia Childrens Hosp, Dept Pathol & Lab Med, 4480 Oak St,Rm 2G5, Vancouver, BC V6H 3V4, Canada.			Tan, Rusung/0000-0002-2204-2004				Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; Bakker ABH, 2000, HUM IMMUNOL, V61, P18, DOI 10.1016/S0198-8859(99)00160-3; Benoit L, 2000, J IMMUNOL, V165, P3549, DOI 10.4049/jimmunol.165.7.3549; Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; BONNEMA JD, 1994, J EXP MED, V180, P1427, DOI 10.1084/jem.180.4.1427; Bottino C, 2000, EUR J IMMUNOL, V30, P3718; Brown MH, 1998, J EXP MED, V188, P2083, DOI 10.1084/jem.188.11.2083; Chuang SS, 2000, IMMUNOLOGY, V100, P378, DOI 10.1046/j.1365-2567.2000.00031.x; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; Dustin ML, 1999, SCIENCE, V283, P649, DOI 10.1126/science.283.5402.649; Dutz JP, 2001, BLOOD, V97, P95, DOI 10.1182/blood.V97.1.95; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GARNIWAGNER BA, 1993, J IMMUNOL, V151, P60; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Jiang K, 2000, NAT IMMUNOL, V1, P419, DOI 10.1038/80859; Johnson DR, 2000, HUM IMMUNOL, V61, P389, DOI 10.1016/S0198-8859(99)00186-X; KANAKARAJ P, 1994, J EXP MED, V179, P551, DOI 10.1084/jem.179.2.551; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lou ZK, 2000, J EXP MED, V191, P347, DOI 10.1084/jem.191.2.347; MATHEW PA, 1993, J IMMUNOL, V151, P5328; Moran M, 1998, IMMUNITY, V9, P787, DOI 10.1016/S1074-7613(00)80644-5; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; Nakajima H, 2000, HUM IMMUNOL, V61, P39, DOI 10.1016/S0198-8859(99)00170-6; Nakajima H, 1999, EUR J IMMUNOL, V29, P1676, DOI 10.1002/(SICI)1521-4141(199905)29:05<1676::AID-IMMU1676>3.0.CO;2-Y; Nakajima H, 2000, EUR J IMMUNOL, V30, P3309, DOI 10.1002/1521-4141(200011)30:11<3309::AID-IMMU3309>3.0.CO;2-3; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sayos J, 2000, INT IMMUNOL, V12, P1749, DOI 10.1093/intimm/12.12.1749; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schatzle JD, 1999, P NATL ACAD SCI USA, V96, P3870, DOI 10.1073/pnas.96.7.3870; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Stepp SE, 1999, EUR J IMMUNOL, V29, P2392, DOI 10.1002/(SICI)1521-4141(199908)29:08<2392::AID-IMMU2392>3.3.CO;2-I; Sylla BS, 2000, P NATL ACAD SCI USA, V97, P7470, DOI 10.1073/pnas.130193097; Tangye SG, 2000, J IMMUNOL, V165, P2932, DOI 10.4049/jimmunol.165.6.2932; Tangye SG, 1999, J IMMUNOL, V162, P6981; Trinchieri G, 1995, Semin Immunol, V7, P83, DOI 10.1006/smim.1995.0012; VALIANTE NM, 1993, J EXP MED, V178, P1397, DOI 10.1084/jem.178.4.1397; Watzl C, 2000, J IMMUNOL, V165, P3545, DOI 10.4049/jimmunol.165.7.3545; Wei S, 1998, J EXP MED, V187, P1753, DOI 10.1084/jem.187.11.1753; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251	44	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13331	13337		10.1074/jbc.M112029200	http://dx.doi.org/10.1074/jbc.M112029200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815622	hybrid			2022-12-25	WOS:000175036300104
J	Graciet, E; Lebreton, S; Camadro, JM; Gontero, B				Graciet, E; Lebreton, S; Camadro, JM; Gontero, B			Thermodynamic analysis of the emergence of new regulatory properties in a phosphoribulokinase-glyceraldehyde 3-phosphate dehydrogenase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII CHLOROPLASTS; ENZYME REACTION-RATES; MULTIENZYME COMPLEXES; INFORMATION-TRANSFER; SPINACH-CHLOROPLASTS; CALVIN CYCLE; MODULATION; MEMORY; ACTIVATION; BEHAVIOR	Glyceraldehyde 3-phosphate dehydrogenase and phosphoribulokinase exist as stable enzymes and as part of a complex in Chlamydomonas reinhardtii. We show here that phosphoribulokinase exerts an imprinting on glyceraldehyde 3-phosphate dehydrogenase, which affects its catalysis by decreasing the energy barrier of the reactions with NADH or NADPH by 3.8 +/- 0.5 and 1.3 +/- 0.3 kJ.mol(-1). Phosphoribulokinase and glyceraldehyde 3-phosphate dehydrogenase within the complex are regulated by NADP(H) but not by NAD(H). The activities of the metastable phosphoribulokinase and glyceraldehyde 3-phosphate dehydrogenase released from the complex preincubated with NADP(H) are different from those of the metastable enzymes released from the untreated complex. NADP(H) increases phosphoribulokinase and NADPH-glyceraldehyde 3-phosphate dehydrogenase activities with a (K) over tilde (0.5) ((NADP)) of 0.68 +/- 0.16 mm and a (K) over tilde (0.5 (NADPH)) of 2.93 +/- 0.87 mm and decreases NADH-dependent activity. 1 mm NADP increases the energy barrier of the NADH-glyceraldehyde 3-phosphate dehydrogenase-dependent reaction by 1.8 +/- 0.2 kJ.mol(-1) and decreases that of the reactions catalyzed by phosphoribulokinase and NADPH-glyceraldehyde 3-phosphate dehydrogenase by 3 +/- 0.2 and 1.2 +/- 0.3 kJ.mol(-1), respectively. These cofactors have no effect on the independent stable enzymes. Therefore, protein-protein interactions may give rise to new regulatory properties.	Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod, F-75251 Paris 05, France; Univ Paris 07, CNRS, UMR 7592, Inst Jacques Monod, F-75251 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite	Gontero, B (corresponding author), Univ Paris 06, CNRS, UMR 7592, Inst Jacques Monod, 2 Pl Jussieu, F-75251 Paris 05, France.			Graciet, Emmanuelle/0000-0003-3548-8213; Camadro, Jean-Michel/0000-0002-8549-2707; lebreton, Sandrine/0000-0003-4772-9467				ANDERSSON LI, 1995, P NATL ACAD SCI USA, V92, P4788, DOI 10.1073/pnas.92.11.4788; Avilan L, 1997, EUR J BIOCHEM, V246, P78, DOI 10.1111/j.1432-1033.1997.00078.x; Baalmann E, 1996, PLANT MOL BIOL, V32, P505, DOI 10.1007/BF00019102; Baalmann E, 1995, ARCH BIOCHEM BIOPHYS, V324, P201, DOI 10.1006/abbi.1995.0031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FRIEDEN C, 1979, ANNU REV BIOCHEM, V48, P471, DOI 10.1146/annurev.bi.48.070179.002351; GONTERO B, 1993, EUR J BIOCHEM, V217, P1075, DOI 10.1111/j.1432-1033.1993.tb18339.x; GONTERO B, 1988, EUR J BIOCHEM, V173, P437, DOI 10.1111/j.1432-1033.1988.tb14018.x; GONTERO B, 1994, EUR J BIOCHEM, V226, P999, DOI 10.1111/j.1432-1033.1994.00999.x; Gonzalez-Navarro H, 2001, BIOCHEMISTRY-US, V40, P3174, DOI 10.1021/bi002202d; Lebreton S, 1997, EUR J BIOCHEM, V246, P85, DOI 10.1111/j.1432-1033.1997.t01-2-00085.x; Lebreton S, 1997, EUR J BIOCHEM, V250, P286, DOI 10.1111/j.1432-1033.1997.0286a.x; Lebreton S, 1999, J BIOL CHEM, V274, P20879, DOI 10.1074/jbc.274.30.20879; Leegood R.C., 1990, METHODS PLANT BIOCH, P15; MEUNIER JC, 1979, EUR J BIOCHEM, V97, P573, DOI 10.1111/j.1432-1033.1979.tb13146.x; MEUNIER JC, 1974, EUR J BIOCHEM, V49, P209, DOI 10.1111/j.1432-1033.1974.tb03826.x; MULLER B, 1972, Z NATURFORSCH PT B, VB 27, P925, DOI 10.1515/znb-1972-0814; Neet K E, 1980, Methods Enzymol, V64, P192; NICHOLSON S, 1987, EUR J BIOCHEM, V162, P423, DOI 10.1111/j.1432-1033.1987.tb10619.x; OVADI J, 1991, J THEOR BIOL, V152, P135, DOI 10.1016/S0022-5193(05)80528-4; PORTER MA, 1986, ARCH BIOCHEM BIOPHYS, V245, P14, DOI 10.1016/0003-9861(86)90185-2; PRATGAY G, 1991, J BIOL CHEM, V266, P20913; RICARD J, 1988, EUR J BIOCHEM, V176, P103, DOI 10.1111/j.1432-1033.1988.tb14256.x; Ricard J, 1998, CELL MOL LIFE SCI, V54, P1231, DOI 10.1007/s000180050250; RICARD J, 1974, EUR J BIOCHEM, V49, P195, DOI 10.1111/j.1432-1033.1974.tb03825.x; RICARD J, 1977, EUR J BIOCHEM, V80, P581, DOI 10.1111/j.1432-1033.1977.tb11915.x; RICARD J, 1994, EUR J BIOCHEM, V226, P993, DOI 10.1111/j.1432-1033.1994.00993.x; Sambrook J, 1989, MOL CLONING LAB MANU, V3, P18; SOULIE JM, 1988, EUR J BIOCHEM, V176, P111, DOI 10.1111/j.1432-1033.1988.tb14257.x; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; STORER AC, 1977, BIOCHEM J, V165, P61, DOI 10.1042/bj1650061; VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0; Wedel N, 1997, P NATL ACAD SCI USA, V94, P10479, DOI 10.1073/pnas.94.19.10479; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; WOLOSIUK RA, 1976, J BIOL CHEM, V251, P6456	35	15	16	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12697	12702		10.1074/jbc.M111121200	http://dx.doi.org/10.1074/jbc.M111121200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815615	hybrid, Green Accepted			2022-12-25	WOS:000175036300027
J	Yao, Y; Wang, JM; Viroonchatapan, N; Samson, A; Chill, J; Rothe, E; Anglister, J; Wang, ZZ				Yao, Y; Wang, JM; Viroonchatapan, N; Samson, A; Chill, J; Rothe, E; Anglister, J; Wang, ZZ			Yeast expression and NMR analysis of the extracellular domain of muscle nicotinic acetylcholine receptor alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BUNGAROTOXIN BINDING-SITE; HIGH-LEVEL SECRETION; PICHIA-PASTORIS; TORPEDO-CALIFORNICA; LIGAND-BINDING; DELTA-SUBUNIT; SACCHAROMYCES-CEREVISIAE; SENSITIVITY ENHANCEMENT; MONOCLONAL-ANTIBODIES; METHYLOTROPHIC YEAST	The alpha subunit of the nicotinic acetylcholine receptor (AChR) from Torpedo electric organ and mammalian muscle contains high affinity binding sites for a-bungarotoxin and for autoimmune antibodies in sera of patients with myasthenia gravis. To obtain sufficient materials for structural studies of the receptor-ligand complexes, we have expressed part of the mouse muscle alpha subunit as a soluble, secretory protein using the yeast Pichia pastoris. By testing a series of truncated fragments of the receptor protein, we show that alpha211, the entire amino-terminal extracellular domain of AChR alpha subunit (amino acids 1-211), is the minimal segment that could fold properly in yeast. The alpha211 protein was secreted into the culture medium at a concentration of >3 mg/liter. It migrated as a 31-kDa polypeptide with N-linked glycosylation on SDS-polyacrylamide gel. The protein was purified to homogeneity by isoelectric focusing electrophoresis (pI 5.8), and it appeared as a 4.5 S monomer on sucrose gradient at concentrations up to I mm (similar to30 mg/ml). The receptor domain bound monoclonal antibody mAb35, a conformation-specific antibody against the main immunogenic region of the AChR. In addition, it formed a high affinity complex with a-bungarotoxin (k(D) 0.2 nm) but showed relatively low affinity to the small cholinergic ligand acetylcholine. Circular dichroism spectroscopy of alpha211 revealed a composition of secondary structure corresponding to a folded protein. Furthermore, the receptor fragment was efficiently N-15-labeled in A pastoris, and proton cross-peaks were well dispersed in nuclear Overhauser effect and heteronuclear single quantum coherence spectra as measured by NMR spectroscopy. We conclude that the soluble AChR protein is useful for high resolution structural studies.	Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15261 USA; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Weizmann Institute of Science	Wang, ZZ (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurobiol, 3500 Terrace St,E1440 BST, Pittsburgh, PA 15261 USA.	zzwang@pitt.edu	Chill, Jordan/W-5048-2018	Chill, Jordan/0000-0002-9518-824X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038301] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 38301] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexeev T, 1999, EUR J BIOCHEM, V259, P310, DOI 10.1046/j.1432-1327.1999.00041.x; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P1875, DOI 10.1021/bi00577a005; BLOUNT P, 1990, J CELL BIOL, V111, P2613, DOI 10.1083/jcb.111.6.2613; BLOUNT P, 1988, J BIOL CHEM, V263, P1072; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; BRAKE AJ, 1984, P NATL ACAD SCI-BIOL, V81, P4642, DOI 10.1073/pnas.81.15.4642; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CHATRENET B, 1990, P NATL ACAD SCI USA, V87, P3378, DOI 10.1073/pnas.87.9.3378; CHAVEZ RA, 1991, J BIOL CHEM, V266, P15532; Chen YL, 1996, J CHEM TECHNOL BIOT, V67, P143; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CREGG JM, 1993, BIO-TECHNOL, V11, P905, DOI 10.1038/nbt0893-905; CREGG JM, 1985, MOL CELL BIOL, V5, P3376, DOI 10.1128/MCB.5.12.3376; CREGG JM, 1989, MOL CELL BIOL, V9, P1316, DOI 10.1128/MCB.9.3.1316; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; ELLIS SB, 1985, MOL CELL BIOL, V5, P1111, DOI 10.1128/MCB.5.5.1111; FINERMOORE J, 1984, P NATL ACAD SCI-BIOL, V81, P155, DOI 10.1073/pnas.81.1.155; FORSAYETH JR, 1990, J NEUROSCI, V10, P2771; FUJITA N, 1986, SCIENCE, V231, P1284, DOI 10.1126/science.3511531; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GERSHONI JM, 1987, P NATL ACAD SCI USA, V84, P4318, DOI 10.1073/pnas.84.12.4318; Grant MA, 1999, BIOCHEMISTRY-US, V38, P10730, DOI 10.1021/bi983007q; GRINNA LS, 1989, YEAST, V5, P107, DOI 10.1002/yea.320050206; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HAGGERTY JG, 1981, J BIOL CHEM, V256, P8294; ISENBERG KE, 1986, NUCLEIC ACIDS RES, V14, P5111, DOI 10.1093/nar/14.12.5111; JANSEN KU, 1989, J BIOL CHEM, V264, P15022; KARLIN A, 1991, HARVEY LECT, V85, P71; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; KARLIN A, 1983, J BIOL CHEM, V258, P6678; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENTZ TL, 1988, INT REV NEUROBIOL, V29, P117, DOI 10.1016/S0074-7742(08)60085-9; MACHOLD J, 1995, EUR J BIOCHEM, V234, P427, DOI 10.1111/j.1432-1033.1995.427_b.x; MAELICKE A, 1977, J BIOL CHEM, V252, P4811; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MAYNE KM, 1987, MOL BRAIN RES, V2, P191, DOI 10.1016/0169-328X(87)90026-X; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; NEUMANN D, 1986, P NATL ACAD SCI USA, V83, P9250, DOI 10.1073/pnas.83.23.9250; NODA M, 1983, NATURE, V302, P528, DOI 10.1038/302528a0; OHANA B, 1990, BIOCHEMISTRY-US, V29, P6409, DOI 10.1021/bi00479a011; OSWALD RE, 1982, FEBS LETT, V139, P225, DOI 10.1016/0014-5793(82)80857-0; Pervushin KV, 1998, J BIOMOL NMR, V12, P345, DOI 10.1023/A:1008268930690; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; PRIVES J, 1983, J BIOL CHEM, V258, P1775; RATNAM M, 1986, BIOCHEMISTRY-US, V25, P2621, DOI 10.1021/bi00357a051; Samson AO, 2001, BIOCHEMISTRY-US, V40, P5464, DOI 10.1021/bi0022689; Schrattenholz A, 1998, J BIOL CHEM, V273, P32393, DOI 10.1074/jbc.273.49.32393; SINE SM, 1991, J BIOL CHEM, V266, P19369; Sine SM, 1997, J BIOL CHEM, V272, P23521, DOI 10.1074/jbc.272.38.23521; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Spura A, 1999, BIOCHEMISTRY-US, V38, P4912, DOI 10.1021/bi982656z; Tierney ML, 2000, J MOL BIOL, V303, P185, DOI 10.1006/jmbi.2000.4137; TSCHOPP JF, 1987, BIO-TECHNOL, V5, P1305, DOI 10.1038/nbt1287-1305; TZARTOS SJ, 1981, J BIOL CHEM, V256, P8635; Tzartos SJ, 1998, IMMUNOL REV, V163, P89, DOI 10.1111/j.1600-065X.1998.tb01190.x; TZARTOS SJ, 1988, P NATL ACAD SCI USA, V85, P2899, DOI 10.1073/pnas.85.9.2899; TZARTOS SJ, 1984, J BIOL CHEM, V259, P1512; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; Wang ZZ, 1996, J CELL BIOL, V135, P809, DOI 10.1083/jcb.135.3.809; WEILAND GA, 1981, LIFE SCI, V29, P313, DOI 10.1016/0024-3205(81)90324-6; West AP, 1997, J BIOL CHEM, V272, P25468, DOI 10.1074/jbc.272.41.25468; WILSON PT, 1988, MOL PHARMACOL, V34, P643; YELLEN G, 1990, GENE, V86, P145, DOI 10.1016/0378-1119(90)90273-T; Zeng HY, 2001, J BIOL CHEM, V276, P22930, DOI 10.1074/jbc.M102300200; Zhu G, 1999, J BIOMOL NMR, V13, P77, DOI 10.1023/A:1008398227519	71	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12613	12621		10.1074/jbc.M108845200	http://dx.doi.org/10.1074/jbc.M108845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812776	hybrid			2022-12-25	WOS:000175036300018
J	Dennes, A; Madsen, P; Nielsen, MS; Petersen, CM; Pohlmann, R				Dennes, A; Madsen, P; Nielsen, MS; Petersen, CM; Pohlmann, R			The yeast vps10p cytoplasmic tail mediates lysosomal sorting in mammalian cells and interacts with human GGAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; TRANS-GOLGI NETWORK; FACTOR-II RECEPTOR; SACCHAROMYCES-CEREVISIAE; VACUOLAR HYDROLASES; PROTEIN; CLATHRIN; BINDING; ENZYMES; SIGNALS	Yeast Vps10p is a receptor for transport of the soluble vacuolar hydrolase carboxypeptidase Y to the lysosome-like vacuole. Its functional equivalents in mammalian cells are the mannose 6-phosphate receptors that mediate sorting to lysosomes of mannose 6-phosphate-containing lysosomal proteins. A chimeric receptor was constructed by substituting the cytoplasmic domain of M, 300,000 mannose 6-phosphate receptor with the Vps10p cytoplasmic tail. Expression of the chimera in cells lacking endogenous mannose 6-phosphate receptors resulted in a subcellular receptor distribution and an efficiency in sorting of lysosomal enzymes similar to that of the wild type M-r 300,000 mannose 6-phosphate receptor. Moreover, the cytoplasmic tail of the Vps10p was found to interact with GGA1 and GGA2, two mammalian members of a recently discovered family of clathrin-binding cytosolic proteins that participate in trans-Golgi network-endosome trafficking in both mammals and yeast. Our findings suggest a conserved machinery for Golgi-endosome/vacuole sorting and may serve as a model for future studies of yeast proteins.	Univ Munster, Inst Physiol Chem & Pathobiochem, Univ Klinikum Munster, D-48149 Munster, Germany; Aarhus Univ, Dept Med Biochem & Cell Biol, DK-8000 Aarhus C, Denmark	University of Munster; Aarhus University	Pohlmann, R (corresponding author), Univ Munster, Inst Physiol Chem & Pathobiochem, Univ Klinikum Munster, Waldeyerstr 15, D-48149 Munster, Germany.		Nielsen, Morten Schallburg/G-9498-2016	Nielsen, Morten Schallburg/0000-0001-9863-9694; Madsen, Peder Sondergaard/0000-0002-8845-4802				ARTELT P, 1988, GENE, V68, P213, DOI 10.1016/0378-1119(88)90023-6; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; CEREGHINO JL, 1995, MOL BIOL CELL, V6, P1089, DOI 10.1091/mbc.6.9.1089; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CLAIRMONT KB, 1991, J BIOL CHEM, V266, P12131; Conibear E, 1998, BBA-MOL CELL RES, V1404, P211, DOI 10.1016/S0167-4889(98)00058-5; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; Costaguta G, 2001, MOL BIOL CELL, V12, P1885, DOI 10.1091/mbc.12.6.1885; Dell'Angelica EC, 2001, CELL, V106, P395, DOI 10.1016/S0092-8674(01)00470-6; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Deloche O, 2001, MOL BIOL CELL, V12, P475, DOI 10.1091/mbc.12.2.475; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; HILLEREHFELD A, 1995, BBA-REV BIOMEMBRANES, V1241, P177, DOI 10.1016/0304-4157(95)00004-B; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; Kasper D, 1996, J CELL BIOL, V134, P615, DOI 10.1083/jcb.134.3.615; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; KOSTER A, 1994, EUR J BIOCHEM, V224, P685, DOI 10.1111/j.1432-1033.1994.00685.x; LeBorgne R, 1997, J CELL BIOL, V137, P335; LUZIO JP, 1990, BIOCHEM J, V270, P97, DOI 10.1042/bj2700097; Meyer C, 2000, EMBO J, V19, P2193, DOI 10.1093/emboj/19.10.2193; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; POHLMANN R, 1995, J BIOL CHEM, V270, P27311, DOI 10.1074/jbc.270.45.27311; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; ROTHMAN JH, 1989, EMBO J, V8, P2057, DOI 10.1002/j.1460-2075.1989.tb03614.x; ROTHMAN JH, 1986, CELL, V47, P1041, DOI 10.1016/0092-8674(86)90819-6; Sandholzer U, 2000, J BIOL CHEM, V275, P14132, DOI 10.1074/jbc.275.19.14132; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; SEEGER M, 1992, EMBO J, V11, P2811, DOI 10.1002/j.1460-2075.1992.tb05348.x; STEIN M, 1987, BIOL CHEM H-S, V368, P927, DOI 10.1515/bchm3.1987.368.2.927; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Tikkanen R, 2000, TRAFFIC, V1, P631, DOI 10.1034/j.1600-0854.2000.010807.x; VONFIGURA K, 1984, EMBO J, V3, P1281, DOI 10.1002/j.1460-2075.1984.tb01963.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WENDLAND M, 1989, BIOCHEM J, V260, P201, DOI 10.1042/bj2600201; WENK J, 1991, BIOCHEM INT, V23, P723; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	44	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12288	12293		10.1074/jbc.M112295200	http://dx.doi.org/10.1074/jbc.M112295200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801606	hybrid			2022-12-25	WOS:000174846400090
J	Gelman, MS; Kannegaard, ES; Kopito, RR				Gelman, MS; Kannegaard, ES; Kopito, RR			A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; QUALITY-CONTROL; PATHWAY; CFTR; RECEPTOR; SYSTEM; CHAINS	Endoplasmic reticulum-associated degradation of misfolded cystic fibrosis transmembrane conductance regulator (CFTR) protein is known to involve the ubiquitin-proteasome system. In addition, an ATP-independent proteolytic system has been suggested to operate in parallel with this pathway and become up-regulated when proteasomes are inhibited (Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordan, J. R. (1995) Cell 83, 129-135). In this study, we use two independent techniques, pulse-chase labeling and a noninvasive fluorescence cell-based assay, to investigate the proteolytic pathways underlying the degradation of misfolded CFTR. Here we report that only inhibitors of the proteasome have a significant effect on preventing the degradation of CFTR, whereas cell-permeable inhibitors of lysosomal degradation, autophagy, and several classes of protease had no measurable effect on CFTR degradation, when used either alone or in combination with the specific proteasome inhibitor carbobenzoxy-L-leucyl-leucyl-L-leucinal (MG132). Our results suggest that ubiquitin-proteasome-mediated degradation is the dominant pathway for disposal of misfolded CFTR in mammalian cells and provide new mechanistic insight into endoplasmic reticulum-associated degradation.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Kopito, RR (corresponding author), Stanford Univ, Dept Biol Sci, 371 Serra Mall, Stanford, CA 94305 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043994] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK43994] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JAIN N, 1994, ARCH BIOCHEM BIOPHYS, V314, P23, DOI 10.1006/abbi.1994.1407; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnson AE, 2000, CELL, V102, P709, DOI 10.1016/S0092-8674(00)00059-3; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Liao W, 2001, BIOCHEM J, V353, P493, DOI 10.1042/0264-6021:3530493; Loayza D, 1998, MOL CELL BIOL, V18, P779, DOI 10.1128/MCB.18.2.779; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Myung J, 2001, MOL CELL, V7, P411, DOI 10.1016/S1097-2765(01)00188-5; O'Hare T, 1999, J IMMUNOL, V163, P11; Oberdorf J, 2001, BIOCHEMISTRY-US, V40, P13397, DOI 10.1021/bi011322y; Plemper RK, 1999, MOL BIOL REP, V26, P125, DOI 10.1023/A:1006913215484; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sato S, 1998, J BIOL CHEM, V273, P7189, DOI 10.1074/jbc.273.13.7189; Umebayashi K, 2001, J BIOL CHEM, V276, P41444, DOI 10.1074/jbc.M105829200; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wang YH, 1996, AM J PHYSIOL-RENAL, V270, pF1057, DOI 10.1152/ajprenal.1996.270.6.F1057; Wang YH, 2001, AM J PHYSIOL-CELL PH, V281, pC1667, DOI 10.1152/ajpcell.2001.281.5.C1667; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yu H, 1997, J BIOL CHEM, V272, P20800, DOI 10.1074/jbc.272.33.20800; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	32	113	118	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11709	11714		10.1074/jbc.M111958200	http://dx.doi.org/10.1074/jbc.M111958200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812794	hybrid			2022-12-25	WOS:000174846400015
J	Krause, E; Gobel, A; Schulz, I				Krause, E; Gobel, A; Schulz, I			Cell side-specific sensitivities of intracellular Ca2+ stores for inositol 1,4,5-trisphosphate, cyclic ADP-ribose, and nicotinic acid adenine dinucleotide phosphate in permeabilized pancreatic acinar cells from mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; RYANODINE RECEPTORS; EXOCRINE PANCREAS; ZYMOGEN GRANULES; WAVE-PROPAGATION; CALCIUM STORES; RELEASE; TRISPHOSPHATE; OSCILLATIONS; NAADP	In pancreatic acinar cells hormonal stimulation leads to a cytosolic Ca2+ wave that starts in the apical cell pole and subsequently propagates toward the basal cell side. We used permeabilized pancreatic acinar cells from mouse and the mag-fura-2 technique, which allows direct monitoring of changes in [Ca2+] of intracellular stores. We show here that Ca2+ can be released from stores in all cellular regions by inositol 1,4,5-trisphosphate. Stores at the apical cell pole showed a higher affinity to inositol 1,4,5-trisphosphate (EC50 = 89 nM) than those at the basolateral side (EC50 = 256 nM). In contrast, cADP-ribose, a modifier of Ca2+-induced Ca2+ release, and nicotinic acid adenine dinucleotide phosphate (NAADP) were able to release Ca2+ exclusively from intracellular stores located at the basolateral cell side. Our data agree with observations that upon stimulation Ca2+ is released initially at the apical cell side and that this is caused by high affinity inositol 1,4,5-trisphosphate receptors. Moreover, our findings allow the conclusion that in Ca2+ wave propagation from the apical to the basolateral cell side observed in pancreatic acinar cells Ca2+-induced Ca2+ release, modulated by cADP-ribose and/or NAADP, might be involved.	Univ Saarland, Inst Physiol, D-66421 Homburg, Germany	Saarland University	Schulz, I (corresponding author), Univ Saarland, Inst Physiol, Gebaude 58, D-66421 Homburg, Germany.	schulz@med-ph.uni-sb.de		Krause, Elmar/0000-0003-0891-2373				Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Fitzsimmons TJ, 2000, BIOCHEM J, V351, P265, DOI 10.1042/0264-6021:3510265; Fogarty KE, 2000, J PHYSIOL-LONDON, V526, P515, DOI 10.1111/j.1469-7793.2000.t01-1-00515.x; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; Genazzani AA, 1997, TRENDS PHARMACOL SCI, V18, P108, DOI 10.1016/S0165-6147(96)01036-X; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Gobel A, 2001, CELL CALCIUM, V29, P29, DOI 10.1054/ceca.2000.0154; Gonzalez A, 1999, BIOCHEM BIOPH RES CO, V261, P726, DOI 10.1006/bbrc.1999.1106; Gonzalez A, 1998, AM J PHYSIOL-CELL PH, V275, pC810, DOI 10.1152/ajpcell.1998.275.3.C810; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hofer AM, 1996, CELL CALCIUM, V20, P235, DOI 10.1016/S0143-4160(96)90029-9; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; Krause E, 1996, J BIOL CHEM, V271, P32523, DOI 10.1074/jbc.271.51.32523; Lee HC, 2000, J MEMBRANE BIOL, V173, P1, DOI 10.1007/s002320001001; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; Lee Hon Cheung, 1998, Cell Biochemistry and Biophysics, V28, P1, DOI 10.1007/BF02738306; Lee MG, 1997, J BIOL CHEM, V272, P15765, DOI 10.1074/jbc.272.25.15765; Mogami H, 1997, CELL, V88, P49, DOI 10.1016/S0092-8674(00)81857-7; NATHANSON MH, 1992, J BIOL CHEM, V267, P18118; NEWTON CL, 1994, J BIOL CHEM, V269, P28613; Park MK, 2000, EMBO J, V19, P5729, DOI 10.1093/emboj/19.21.5729; Parys JB, 1996, PFLUG ARCH EUR J PHY, V432, P359, DOI 10.1007/s004240050145; PARYS JB, 1995, CELL CALCIUM, V17, P239, DOI 10.1016/0143-4160(95)90070-5; PETERSEN OH, 1992, J PHYSIOL-LONDON, V448, P1; Pfeiffer F, 1998, AM J PHYSIOL-CELL PH, V274, pC663; PUTNEY JW, 1990, PHARMACOL THERAPEUT, V48, P427, DOI 10.1016/0163-7258(90)90059-B; Sabnis RW, 1997, BIOTECH HISTOCHEM, V72, P253, DOI 10.3109/10520299709082249; Straub SV, 2000, J GEN PHYSIOL, V116, P547, DOI 10.1085/jgp.116.4.547; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; THORN P, 1993, CELL CALCIUM, V14, P746, DOI 10.1016/0143-4160(93)90100-K; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; Tojyo Y, 1997, CELL CALCIUM, V22, P455, DOI 10.1016/S0143-4160(97)90073-7; vandePut FHMM, 1996, J BIOL CHEM, V271, P4999; WAKUI M, 1990, CELL, V63, P1025, DOI 10.1016/0092-8674(90)90505-9; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Yule DI, 1997, J BIOL CHEM, V272, P9093	42	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11696	11702		10.1074/jbc.M107794200	http://dx.doi.org/10.1074/jbc.M107794200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809747	hybrid			2022-12-25	WOS:000174846400013
J	Piwien-Pilipuk, G; Ayala, A; Machado, A; Galigniana, MD				Piwien-Pilipuk, G; Ayala, A; Machado, A; Galigniana, MD			Impairment of mineralocorticoid receptor (MR)-dependent biological response by oxidative stress and aging - Correlation with post-translational modification of MR and decreased ADP-ribosylatable level of elongation factor 2 in kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; REQUIRES INTACT CYTOSKELETON; GLUCOCORTICOID RECEPTOR; FACTOR-II; RAT-KIDNEY; CUMENE HYDROPEROXIDE; LIPID-PEROXIDATION; STEROID-BINDING; KINASE-1 PDK1; INHIBITION	Acute and chronic treatments of mice with the glutathione-depleting agent, L-buthionine-(SR)-sulfoximine (BSO), impaired the mineralocorticoid receptor (MR)dependent biological response by inhibiting aldosterone binding. This steroid-binding inhibition was fully reversed when reducing agents were added to kidney cytosol obtained from mice treated for 5 h, but it was only partially reversed in cytosol obtained from mice treated for 10 days. Although the oligomeric structure of the MR-hsp90 heterocomplex was always unaffected, a decreased amount of MR protein was evidenced after the long term treatment. Such a deleterious effect was correlated with a post-translational modification of MR, as demonstrated by an increased level of receptor carbonylation. In addition, a failure at the elongation/termination step was also observed during the receptor translation process in a reticulocyte lysate system. Thus, a high polyribosomes/monomers ratio and both increased proteolysis and decreased ADP-ribosylatable concentration of elongation factor 2 (EF-2) were shown. Importantly, similar observations were also performed in vivo after depletion of glutathione. Notwithstanding the EF-2 functional disruption, not all renal proteins were equally affected as the MR. Interestingly, both EF-2 and AM expressed in old mice were similarly affected as in L-buthionine-(SR)-sulfoximine-treated young mice. We therefore propose that a dramatic depletion of glutathione in kidney cells mimics the cumulative effect of aging which, at the end, may lead to a renal mineralocorticoid dysfunction.	Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina; Univ Sevilla, Fac Farm, Dept Bioquim Bromatol & Toxicol, E-41012 Seville, Spain	University of Buenos Aires; University of Sevilla	Galigniana, MD (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 1301 Med Sci Res Bldg 3, Ann Arbor, MI 48109 USA.		IBIS, ENVEJECIMIENTO/O-9381-2015; Ayala, Antonio/N-7591-2019	Ayala, Antonio/0000-0001-9711-3711; GALIGNIANA, MARIO/0000-0002-9130-8574				ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; Ayala A, 1996, J BIOL CHEM, V271, P23105, DOI 10.1074/jbc.271.38.23105; AYUSOPARRILLA MS, 1976, J BIOL CHEM, V251, P7785; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; BAUD L, 1986, AM J PHYSIOL, V251, pF765, DOI 10.1152/ajprenal.1986.251.5.F765; Bhargava A, 2001, ENDOCRINOLOGY, V142, P1587, DOI 10.1210/en.142.4.1587; BURTON G, 1995, MOL PHARMACOL, V47, P535; CALIGNIANA MD, 2000, CURR TOP STEROID RES, V3, P1; CeballosPicot I, 1996, FREE RADICAL BIO MED, V21, P845, DOI 10.1016/0891-5849(96)00233-X; DASGUPTA A, 1992, NEPHRON, V60, P56, DOI 10.1159/000186705; DAVYDOVA EK, 1993, EUR J BIOCHEM, V215, P291, DOI 10.1111/j.1432-1033.1993.tb18034.x; Dean RT, 1997, BIOCHEM J, V324, P1; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; FALVEY AK, 1970, J MOL BIOL, V53, P21, DOI 10.1016/0022-2836(70)90043-4; Galicka A, 2000, BIOCHEM BIOPH RES CO, V269, P553, DOI 10.1006/bbrc.2000.2322; Galigniana MD, 1998, MOL ENDOCRINOL, V12, P1903, DOI 10.1210/me.12.12.1903; Galigniana MD, 2001, J BIOL CHEM, V276, P14884, DOI 10.1074/jbc.M010809200; Galigniana MD, 1999, J BIOL CHEM, V274, P16222, DOI 10.1074/jbc.274.23.16222; Galigniana MD, 2000, MOL PHARMACOL, V58, P58, DOI 10.1124/mol.58.1.58; Galigniana MD, 1996, LIFE SCI, V59, P511, DOI 10.1016/0024-3205(96)00331-1; Galigniana MD, 1998, BIOCHEM J, V333, P555, DOI 10.1042/bj3330555; Galigniana MD, 1999, BIOCHEM J, V341, P585, DOI 10.1042/0264-6021:3410585; HENSHAW EC, 1973, J BIOL CHEM, V248, P4367; HIMMELFARB J, 1993, J AM SOC NEPHROL, V4, P178; HOERZ W, 1969, P NATL ACAD SCI USA, V63, P1206, DOI 10.1073/pnas.63.4.1206; HOWARD GA, 1970, J BIOL CHEM, V245, P6237; KABAT D, 1969, BIOCHEMISTRY-US, V8, P3743; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; LENZ AG, 1989, ANAL BIOCHEM, V177, P419, DOI 10.1016/0003-2697(89)90077-8; LO YYC, 1996, J BIOL CHEM, V271, P15073; Lupo B, 1998, BIOCHEMISTRY-US, V37, P12153, DOI 10.1021/bi980593e; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; Merker K, 2000, ARCH BIOCHEM BIOPHYS, V375, P50, DOI 10.1006/abbi.1999.1657; NATH KA, 1990, J CLIN INVEST, V86, P1179, DOI 10.1172/JCI114824; Parrado J, 1999, FREE RADICAL BIO MED, V26, P362, DOI 10.1016/S0891-5849(98)00202-0; Pearce D, 2001, TRENDS ENDOCRIN MET, V12, P341, DOI 10.1016/S1043-2760(01)00439-8; Piwien-Pilipuk G, 1998, MOL CELL ENDOCRINOL, V144, P119, DOI 10.1016/S0303-7207(98)00142-7; Piwien-Pilipuk G, 2000, BBA-MOL CELL RES, V1495, P263, DOI 10.1016/S0167-4889(99)00166-4; Prasad N, 2000, BIOCHEMISTRY-US, V39, P6929, DOI 10.1021/bi000387i; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Preville X, 1999, EXP CELL RES, V247, P61, DOI 10.1006/excr.1998.4347; QUIAN MQ, 1996, BIOCHIM BIOPHYS ACTA, V1310, P293; RIIS B, 1989, BIOCHEM BIOPH RES CO, V159, P1141, DOI 10.1016/0006-291X(89)92228-6; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; SCORNIK OA, 1974, J BIOL CHEM, V249, P3876; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SMULSON ME, 1970, J BIOL CHEM, V245, P5350; Souque A, 1996, J STEROID BIOCHEM, V57, P315, DOI 10.1016/0960-0760(95)00278-2; STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616; TAFFE BG, 1987, J BIOL CHEM, V262, P12143; TAMARIT J, 1997, J BIOL CHEM, V271, P3027; Verbeke P, 2001, CELL BIOL INT, V25, P845, DOI 10.1006/cbir.2001.0789; WEISSBACH H, 1976, ANNU REV BIOCHEM, V45, P191, DOI 10.1146/annurev.bi.45.070176.001203; YOSHIOKA T, 1990, KIDNEY INT, V38, P282, DOI 10.1038/ki.1990.197	57	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11896	11903		10.1074/jbc.M109530200	http://dx.doi.org/10.1074/jbc.M109530200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809749	hybrid			2022-12-25	WOS:000174846400039
J	Riccio, A; Mattei, C; Kelsell, RE; Medhurst, AD; Calver, AR; Randall, AD; Davis, JB; Benham, CD; Pangalos, MN				Riccio, A; Mattei, C; Kelsell, RE; Medhurst, AD; Calver, AR; Randall, AD; Davis, JB; Benham, CD; Pangalos, MN			Cloning and functional expression of human short TRP7, a candidate protein for store-operated Ca2+ influx	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; CA2+-PERMEABLE CATION CHANNEL; DROSOPHILA TRP; INTRACELLULAR CALCIUM; MOLECULAR-CLONING; COUPLED RECEPTOR; HTRP3 CHANNELS; HUMAN HOMOLOG; CELLS; DEPLETION	The regulation and control of plasma membrane Ca2+ fluxes is critical for the initiation and maintenance of a variety of signal transduction cascades. Recently, the study of transient receptor potential channels (TRPs) has suggested that these proteins have an important role to play in mediating capacitative calcium entry. In this study, we have isolated a cDNA from human brain that encodes a novel transient receptor potential channel termed human TRP7 (hTRP7). hTRP7 is a member of the short TRP channel family and is 98% homologous to mouse TRP7 (mTRP7). At the mRNA level hTRP7 was widely expressed in tissues of the central nervous system, as well as some peripheral tissues such as pituitary gland and kidney. However, in contrast to mTRP7, which is highly expressed in heart and lung, hTRP7 was undetectable in these tissues. For functional analysis, we heterologously expressed hTRP7 cDNA in an human embryonic kidney cell line. In comparison with untransfected cells depletion of intracellular calcium stores in hTRP7-expressing cells, using either carbachol or thapsigargin, produced a marked increase in the subsequent level of Ca2+ influx. This increased Ca2+ entry was blocked by inhibitors of capacitative calcium entry such as La3+ and Gd3+. Furthermore, transient transfection of an hTRP7 antisense expression construct into cells expressing hTRP7 eliminated the augmented store-operated Ca2+ entry. Our findings suggest that hTRP7 is a store-operated calcium channel, a finding in stark contrast to the mouse orthologue, mTRP7, which is reported to enhance Ca2+ influx independently of store depletion, and suggests that human and mouse TRP7 channels may fulfil different physiological roles.	GlaxoSmithKline, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; GlaxoSmithKline, Genet Res, Harlow CM19 5AW, Essex, England	GlaxoSmithKline; GlaxoSmithKline	Pangalos, MN (corresponding author), GSK Neurol Ctr Excellence Drug Discovery, New Frontiers Sci Pk N,3rd Ave,Rm H17-1-133, Harlow CM19 5AW, Essex, England.	Menelas_N_Pangalos@gsk.com	Mattei, Cesar/K-5286-2015	Mattei, Cesar/0000-0002-2214-2611; Randall, Andrew/0000-0001-8852-3671				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARIKAWA K, 1990, J CELL BIOL, V110, P1993, DOI 10.1083/jcb.110.6.1993; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; CANTIELLO HF, 1995, KIDNEY INT, V48, P970, DOI 10.1038/ki.1995.379; Chambers JK, 2000, J BIOL CHEM, V275, P10767, DOI 10.1074/jbc.275.15.10767; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Davies E, 1993, Semin Cell Biol, V4, P139; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Halaszovich CR, 2000, J BIOL CHEM, V275, P37423, DOI 10.1074/jbc.M007010200; HARTENECK C, 1995, FEBS LETT, V358, P297, DOI 10.1016/0014-5793(94)01455-A; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HU YF, 1995, BIOCHEM J, V305, P605, DOI 10.1042/bj3050605; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Livak KJ, 1999, GENET ANAL-BIOMOL E, V14, P143, DOI 10.1016/S1050-3862(98)00019-9; Medhurst AD, 2000, J NEUROSCI METH, V98, P9, DOI 10.1016/S0165-0270(00)00178-3; MILLS JW, 1994, FASEB J, V8, P1161, DOI 10.1096/fasebj.8.14.7958622; Monk PD, 1996, J NEUROCHEM, V67, P2227; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PETERSEN CCH, 1995, BIOCHEM J, V311, P41, DOI 10.1042/bj3110041; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; Putney JW, 2001, NATURE, V410, P648, DOI 10.1038/35070704; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1997, CELL CALCIUM, V21, P257, DOI 10.1016/S0143-4160(97)90050-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WONG F, 1989, NEURON, V3, P81, DOI 10.1016/0896-6273(89)90117-7; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Xu XZS, 2000, NEURON, V26, P647, DOI 10.1016/S0896-6273(00)81201-5; ZHU X, 1995, FEBS LETT, V373, P193, DOI 10.1016/0014-5793(95)01038-G; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	65	95	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12302	12309		10.1074/jbc.M112313200	http://dx.doi.org/10.1074/jbc.M112313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805119	Green Published, hybrid			2022-12-25	WOS:000174846400092
J	Shimoni, E; Baasov, T; Ravid, U; Shoham, Y				Shimoni, E; Baasov, T; Ravid, U; Shoham, Y			The trans-anethole degradation pathway in an Arthrobacter sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-KETOADIPATE PATHWAY; FERULIC ACID; ACINETOBACTER-CALCOACETICUS; MOLECULAR CHARACTERIZATION; PSEUDOMONAS SP; STRAIN HR199; EUGENOL; METABOLISM; PROTOCATECHUATE; CATABOLISM	A bacterial strain (TA13) capable of utilizing t-anethole as the sole carbon source was isolated from soil. The strain was identified as Arthrobacter aurescens based on its 16 S rRNA gene sequence. Key steps of the degradation pathway of t-anethole were identified by the use of t-anethole-blocked mutants and specific inducible enzymatic activities. In addition to t-anethole, strain TA13 is capable of utilizing anisic acid, anisaldehyde, and anisic alcohol as the sole carbon source. t-Anethole-blocked mutants were obtained following mutagenesis and penicillin enrichment. Some of these blocked mutants, accumulated in the presence of t-anethole quantitative amounts of t-anethole-diol, anisic acid, and 4,6-dicarboxy-2-pyrone and traces of anisic alcohol and anisaldehyde. Enzymatic activities induced by t-anethole included: 4-methoxybenzoate O-demethylase, p-hydroxybenzoate 3-hydroxylase, and protocatechuate-4,5-dioxygenase. These findings indicate that t-anethole is metabolized to protocatechuic acid through t-anethole-diol, anisaldehyde, anisic acid, and p-hydroxybenzoic acid. The protocatechuic acid is then cleaved by protocatechuate-4,5-dioxygenase to yield 2-hydroxy-4-carboxy muconate-semialdehyde. Results from inducible uptake ability and enzymatic assays indicate that at least three regulatory units are involved in the t-anethole degradation pathway. These findings provide new routes for environmental friendly production processes of valuable aromatic chemicals via bioconversion of phenylpropenoids.	Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Catalysis Sci & Technol, IL-32000 Haifa, Israel; Agr Res Org, Newe Yaar Res Ctr, IL-90095 Ramat Yishay, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Shoham, Y (corresponding author), Technion Israel Inst Technol, Dept Food Engn & Biotechnol, IL-32000 Haifa, Israel.		Shoham, Yuval/M-4409-2013; Baasov, Timor/L-5173-2019	Baasov, Timor/0000-0002-1427-2619				Abraham WR, 1988, BIOFLAVOUR 87 ANAL B, P399; ANDREONI V, 1995, APPL MICROBIOL BIOT, V42, P830, DOI 10.1007/BF00191177; Belitz H -D, 1999, FOOD CHEM; BERNHARDT FH, 1977, EUR J BIOCHEM, V72, P107, DOI 10.1111/j.1432-1033.1977.tb11230.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANOVAS JL, 1968, EUR J BIOCHEM, V3, P293, DOI 10.1111/j.1432-1033.1968.tb19529.x; CANOVAS JL, 1967, EUR J BIOCHEM, V1, P289, DOI 10.1111/j.1432-1033.1967.tb00073.x; CRAWFORD RL, 1975, J BACTERIOL, V121, P794, DOI 10.1128/JB.121.3.794-799.1975; DAGLEY S, 1986, BACTERIA; DELNERI D, 1995, BBA-GEN SUBJECTS, V1244, P363, DOI 10.1016/0304-4165(95)00021-3; DOTEN RC, 1987, J BACTERIOL, V169, P3168, DOI 10.1128/jb.169.7.3168-3174.1987; EATON RW, 1982, J BACTERIOL, V151, P48, DOI 10.1128/JB.151.1.48-57.1982; ELSEMORE DA, 1994, J BACTERIOL, V176, P7659, DOI 10.1128/JB.176.24.7659-7666.1994; Fraaije MW, 1997, APPL ENVIRON MICROB, V63, P435, DOI 10.1128/AEM.63.2.435-439.1997; FURUKAWA K, 1982, APPL ENVIRON MICROB, V44, P619, DOI 10.1128/AEM.44.3.619-626.1982; Gasson MJ, 1998, J BIOL CHEM, V273, P4163, DOI 10.1074/jbc.273.7.4163; GERISCHER U, 1993, 93 ANN M AM SOC MICR, P238; GREEN NR, 1978, MUTAT RES, V57, P115, DOI 10.1016/0027-5107(78)90257-9; GURUJEYALAKSHMI G, 1987, CURR MICROBIOL, V16, P69, DOI 10.1007/BF01588174; HAGEDORN C, 1975, CAN J MICROBIOL, V21, P353, DOI 10.1139/m75-050; HAGEDORN SR, 1985, J BACTERIOL, V163, P640, DOI 10.1128/JB.163.2.640-647.1985; Harwood CS, 1996, ANNU REV MICROBIOL, V50, P553, DOI 10.1146/annurev.micro.50.1.553; HAYAISHI O, 1957, J BIOL CHEM, V229, P905; HOSOKAWA K, 1970, J BIOL CHEM, V245, P5304; HOSOKAWA K, 1966, J BIOL CHEM, V241, P2453; JOHNSON BF, 1971, J BACTERIOL, V107, P476, DOI 10.1128/JB.107.2.476-485.1971; Johnson TA, 1999, MICROBIOL RES, V153, P349, DOI 10.1016/S0944-5013(99)80049-4; KARAPINAR M, 1987, INT J FOOD MICROBIOL, V4, P161, DOI 10.1016/0168-1605(87)90023-7; KARAPINAR M, 1990, INT J FOOD MICROBIOL, V10, P193, DOI 10.1016/0168-1605(90)90066-E; Karegoudar TB, 1999, J MICROBIOL, V37, P123; KLAGES U, 1979, FEMS MICROBIOL LETT, V6, P201, DOI 10.1111/j.1574-6968.1979.tb03703.x; KOJIMA Y, 1961, J BIOL CHEM, V236, P2223; Krebs K. G., 1969, THIN LAYER CHROMATOG, P854; LECHNER U, 1988, J BASIC MICROB, V28, P629, DOI 10.1002/jobm.3620280918; MACDONALD DL, 1954, J BIOL CHEM, V210, P809; MARKS TS, 1984, BIOCHEM BIOPH RES CO, V124, P669, DOI 10.1016/0006-291X(84)91607-3; MARUYAMA K, 1979, J BIOCHEM-TOKYO, V86, P1671, DOI 10.1093/oxfordjournals.jbchem.a132687; MARUYAMA K, 1978, J BIOCHEM, V83, P1125, DOI 10.1093/oxfordjournals.jbchem.a132002; *MIDI INC, 1992, MICR ID SYST OP MAN; Mohan RS, 2000, J ORG CHEM, V65, P1407, DOI 10.1021/jo991521b; MULLER R, 1988, BIOL CHEM H-S, V369, P567, DOI 10.1515/bchm3.1988.369.2.567; Nichols NN, 1997, J BACTERIOL, V179, P5056, DOI 10.1128/jb.179.16.5056-5061.1997; ORNSTON LN, 1966, J BIOL CHEM, V241, P3800; ORNSTON LN, 1971, BACTERIOL REV, V35, P87, DOI 10.1128/MMBR.35.2.87-116.1971; Overhage J, 1999, APPL ENVIRON MICROB, V65, P951; Priefert H, 1999, ARCH MICROBIOL, V172, P354, DOI 10.1007/s002030050772; Priefert H, 1997, J BACTERIOL, V179, P2595, DOI 10.1128/JB.179.8.2595-2607.1997; Rabenhorst J, 1996, APPL MICROBIOL BIOT, V46, P470, DOI 10.1007/s002530050846; Rabenhorst J., 1991, Deutsches Patentampt DE, Patent No. [39 20 A1, 3920]; RAHOUTI M, 1989, APPL ENVIRON MICROB, V55, P2391, DOI 10.1128/AEM.55.9.2391-2398.1989; RAVID U, 1983, J NAT PROD, V46, P848, DOI 10.1021/np50030a004; ROSAZZA JPN, 1995, ASM NEWS, V61, P241; STEINBUCHEL A, 1998, Patent No. 0845532; SUTHERLAND JB, 1981, APPL ENVIRON MICROB, V41, P442, DOI 10.1128/AEM.41.2.442-448.1981; SUTHERLAND JB, 1983, CAN J MICROBIOL, V29, P1253, DOI 10.1139/m83-195; SWANSON AB, 1979, MUTAT RES, V60, P143, DOI 10.1016/0027-5107(79)90178-7; TADASA K, 1977, AGR BIOL CHEM TOKYO, V41, P925, DOI 10.1080/00021369.1977.10862621; TADASA K, 1983, AGR BIOL CHEM TOKYO, V47, P2639, DOI 10.1080/00021369.1983.10866004; TRESGUERRES ME, 1970, EUR J BIOCHEM, V14, P445, DOI 10.1111/j.1432-1033.1970.tb00309.x; ZAITSEV GM, 1991, FEMS MICROBIOL LETT, V81, P171	60	31	40	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11866	11872		10.1074/jbc.M109593200	http://dx.doi.org/10.1074/jbc.M109593200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805095	hybrid			2022-12-25	WOS:000174846400035
J	Yokochi, T; Robertson, KD				Yokochi, T; Robertson, KD			Preferential methylation of unmethylated DNA by mammalian de novo DNA methyltransferase Dnmt3a	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEADY-STATE KINETICS; EMBRYONIC STEM-CELLS; DE-NOVO; CYTOSINE-5 METHYLTRANSFERASES; POSTTRANSLATIONAL MODIFICATIONS; INSECT CELLS; MECHANISM; EXPRESSION; SITES; PURIFICATION	DNA methylation is an epigenetic modification of DNA. There are currently three catalytically active mammalian DNA methyltransferases, DNMT1, -3a, and -3b. DNMT1 has been shown to have a preference for hemimethylated DNA and has therefore been termed the maintenance methyltransferase. Although previous studies on DNMT3a and -3b revealed that they act as functional enzymes during development, there is little biochemical evidence about how new methylation patterns are established and maintained. To study this mechanism we have cloned and expressed Dnmt3a using a baculovirus expression system. The substrate specificity of Dnmt3a and molecular mechanism of its methylation reaction were then analyzed using a novel and highly reproducible assay. We report here that Dnmt3a is a true de novo methyltransferase that prefers unmethylated DNA substrates more than 3-fold to hemimethylated DNA. Furthermore, Dnmt3a binds DNA nonspecifically, regardless of the presence of CpG dinucleotides in the DNA substrate. Kinetic analysis supports an Ordered Bi Bi mechanism for Dnmt3a, where DNA binds first, followed by S-adenoSyl-L-methionine.	NCI, Epigenet Gene Regulat & Canc Sect, Lab Receptor Biol & Gene Express, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Robertson, KD (corresponding author), NCI, Epigenet Gene Regulat & Canc Sect, Lab Receptor Biol & Gene Express, NIH, Bldg 41,Rm B602, Bethesda, MD 20892 USA.			Robertson, Keith/0000-0002-7508-3328	NCI NIH HHS [CA84535-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA084535] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Andersen RB, 2001, J BIOL CHEM, V276, P5518, DOI 10.1074/jbc.M007918200; Aoki A, 2001, NUCLEIC ACIDS RES, V29, P3506, DOI 10.1093/nar/29.17.3506; Bacolla A, 1999, J BIOL CHEM, V274, P33011, DOI 10.1074/jbc.274.46.33011; Bacolla A, 2001, J BIOL CHEM, V276, P18605, DOI 10.1074/jbc.M100404200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Berdis AJ, 1998, P NATL ACAD SCI USA, V95, P2874, DOI 10.1073/pnas.95.6.2874; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; Bhattacharya SK, 1999, J BIOL CHEM, V274, P14743, DOI 10.1074/jbc.274.21.14743; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cha KW, 1997, P NATL ACAD SCI USA, V94, P10577, DOI 10.1073/pnas.94.20.10577; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cleland W W, 1977, Adv Enzymol Relat Areas Mol Biol, V45, P273; CLELAND WW, 1989, BIOCHIM BIOPHYS ACTA, P213; Copeland R. A., 2000, ENZYMES, V2nd; Cornish-Bowden A, 2001, FUNDAMENTALS ENZYME; Evdokimov AA, 2002, J BIOL CHEM, V277, P279, DOI 10.1074/jbc.M108864200; Fang NX, 2000, BIOTECHNOL APPL BIOC, V32, P27, DOI 10.1042/BA20000001; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Flynn J, 1996, BIOCHEMISTRY-US, V35, P7308, DOI 10.1021/bi9600512; Flynn J, 1998, BIOCHEMISTRY-US, V37, P15162, DOI 10.1021/bi9810609; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Glickman JF, 1997, J BIOL CHEM, V272, P17851, DOI 10.1074/jbc.272.28.17851; Glickman JF, 1997, BIOCHEM BIOPH RES CO, V230, P280, DOI 10.1006/bbrc.1996.5943; Gowher H, 2000, J MOL BIOL, V303, P93, DOI 10.1006/jmbi.2000.4127; Gowher H, 2001, J MOL BIOL, V309, P1201, DOI 10.1006/jmbi.2001.4710; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; Hsieh PC, 1996, BIOCHEMISTRY-US, V35, P9772, DOI 10.1021/bi9528659; Jeltsch A, 1998, J MOL BIOL, V275, P747, DOI 10.1006/jmbi.1997.1492; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KUMAR S, 1994, NUCLEIC ACIDS RES, V22, P1, DOI 10.1093/nar/22.1.1; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Lindstrom WM, 2000, J BIOL CHEM, V275, P4912, DOI 10.1074/jbc.275.7.4912; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Lyko F, 1999, NAT GENET, V23, P363, DOI 10.1038/15551; Malygin EG, 2000, NUCLEIC ACIDS RES, V28, P4207, DOI 10.1093/nar/28.21.4207; Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172; Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; OReilly D.R., 1992, BACULOVIRUS EXPRESSI; PIWNICAWORMS H, 1990, J VIROL, V64, P61, DOI 10.1128/JVI.64.1.61-68.1990; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 1997, NUCLEIC ACIDS RES, V25, P4666, DOI 10.1093/nar/25.22.4666; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; REICH NO, 1991, NUCLEIC ACIDS RES, V19, P6587, DOI 10.1093/nar/19.23.6587; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Segel I.H, 1993, ENZYME KINETICS; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; SZILAK L, 1993, EUR J BIOCHEM, V218, P727, DOI 10.1111/j.1432-1033.1993.tb18427.x; Vilkaitis G, 2001, J BIOL CHEM, V276, P20924, DOI 10.1074/jbc.M101429200; WU JC, 1987, J BIOL CHEM, V262, P4778; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zinoviev VV, 1998, BIOL CHEM, V379, P481, DOI 10.1515/bchm.1998.379.4-5.481	64	113	128	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11735	11745		10.1074/jbc.M106590200	http://dx.doi.org/10.1074/jbc.M106590200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821381	hybrid			2022-12-25	WOS:000174846400019
J	DeMott, MS; Beyret, E; Wong, D; Bales, BC; Hwang, JT; Greenberg, MM; Demple, B				DeMott, MS; Beyret, E; Wong, D; Bales, BC; Hwang, JT; Greenberg, MM; Demple, B			Covalent trapping of human DNA polymerase beta by the oxidative DNA lesion 2-deoxyribonolactone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; ENDONUCLEASE APE1; STRANDED-DNA; PATHWAY; DAMAGE; 3'-EXO/ENDONUCLEASE; REQUIREMENT; SUBSTRATE; CLEAVAGE; PROTEIN	Oxidized abasic residues in DNA constitute a major class of radiation and oxidative damage. Free radical attack on the nucleotidyl C-1' carbon yields 2-deoxyribonolactone (dL) as a significant lesion. Although dL residues are efficiently incised by the main human abasic endonuclease enzyme Ape1, we show here that subsequent excision by human DNA polymerase beta is impaired at dL compared with unmodified abasic sites. This inhibition is accompanied by accumulation of a protein-DNA cross-link not observed in reactions of polymerase beta with unmodified abasic sites, although a similar form can be trapped by reduction with sodium borohydride. The formation of the stably cross-linked species with dL depends on the polymerase lysine 72 residue, which forms a Schiff base with the C-1 aldehyde during excision of an unmodified abasic site. In the case of a dL residue, attack on the lactone C-1 by lysine 72 proceeds more slowly and evidently produces an amide linkage, which resists further processing. Consequently dL residues may not be readily repaired by "short-patch" base excision repair but instead function as suicide substrates in the formation of protein-DNA crosslinks that may require alternative modes of repair.	Harvard Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA	Harvard University; Harvard T.H. Chan School of Public Health; Colorado State University	Demple, B (corresponding author), Harvard Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA.			BEYRET, ERGIN/0000-0003-1980-532X	NATIONAL CANCER INSTITUTE [T32CA009078, R01CA071993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007155] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER; NCI NIH HHS [CA71993, T32-CA09078] Funding Source: Medline; NIEHS NIH HHS [T32-ES07155] Funding Source: Medline; NIGMS NIH HHS [GM40000, GM54996] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bebenek K, 2001, SCIENCE, V291, P2156, DOI 10.1126/science.1058386; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Chaudhry MA, 1999, BIOCHEM PHARMACOL, V57, P531, DOI 10.1016/S0006-2952(98)00327-X; DeMott MS, 1996, J BIOL CHEM, V271, P30068, DOI 10.1074/jbc.271.47.30068; Demple B, 1997, ENVIRON HEALTH PERSP, V105, P931, DOI 10.2307/3433306; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; GREENBERG MM, 1999, COMPREHENSIVE NATURA, V7, P371; Hashimoto M, 2001, J AM CHEM SOC, V123, P3161, DOI 10.1021/ja003354z; Hwang JT, 1999, NUCLEIC ACIDS RES, V27, P3805, DOI 10.1093/nar/27.19.3805; Hwang JT, 1999, J AM CHEM SOC, V121, P4311, DOI 10.1021/ja990152y; Izumi T, 2000, CARCINOGENESIS, V21, P1329, DOI 10.1093/carcin/21.7.1329; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Xu YJ, 1998, J BIOL CHEM, V273, P28837, DOI 10.1074/jbc.273.44.28837	26	100	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7637	7640		10.1074/jbc.C100577200	http://dx.doi.org/10.1074/jbc.C100577200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11805079	hybrid			2022-12-25	WOS:000174268000003
J	Rosenberger, CM; Finlay, BB				Rosenberger, CM; Finlay, BB			Macrophages inhibit Salmonella typhimurium replication through MEK/ERK kinase and phagocyte NADPH oxidase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; WILD-TYPE; IN-VIVO; PHOSPHATIDYLINOSITOL 3-KINASE; PATHOGENICITY ISLAND-2; ANTIMICROBIAL ACTIONS; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; INTERFERON-GAMMA; ESCHERICHIA-COLI	Host responses during the later stages of Salmonella-macrophage interactions are critical to controlling infection but have not been well characterized. After 24 h of infection, nearly half of interferon-gamma-primed murine RAW 264.7 macrophage-like cells infected by Salmonella enterica serovar Typhimurium contained filamentous bacteria. Bacterial filamentation indicates a defect in completing replication and has been previously observed in bacteria responding to a variety of stresses. To understand whether macrophage gene expression was responsible for this effect on Salmonella Typhimurium replication, we used gene arrays to profile interferon-gamma-primed RAW 264.7 cell gene expression following infection. We observed an increase in MEK1 kinase mRNA at 8 h, an increase in MEK protein at 24 h, and measured phosphorylation of MEK's downstream target kinase, ERK1/2, throughout the 24-h infection period. Treatment of cells with MEK kinase inhibitors significantly reduced numbers of filamentous bacteria observed within macrophages after 24 h and increased the number of intracellular colony-forming units. Phagocyte NADPH oxidase inhibitors and antioxidants also significantly reduced bacterial filamentation. Either MEK kinase or phagocyte oxidase inhibitors could be added 4-8 h after infection and still significantly decrease bacterial filamentation. Oxidase activity appears to mediate bacterial filamentation in parallel to MEK kinase signaling, while inducible nitric-oxide synthase inhibitors had no significant effect on bacterial morphology. In summary, Salmonella Typhimurium infection of interferon-gamma-primed macrophages triggers a MEK kinase cascade at later infection times, and both MEK kinase and phagocyte NADPH oxidase activity impair bacterial replication. These two signaling pathways mediate a host bacteriostatic pathway and may play an important role in innate host defense against intracellular pathogens.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Microbiol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Immunol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Finlay, BB (corresponding author), Univ British Columbia, Biotechnol Lab, Rm 237 Wesbrook Bldg,6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.							Ahn NG, 2001, METHOD ENZYMOL, V332, P417; Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659; BUCHMEIER NA, 1989, INFECT IMMUN, V57, P1; Cano DA, 1998, J BACTERIOL, V180, P5231, DOI 10.1128/JB.180.19.5231-5234.1998; Chan ED, 2001, AM J PHYSIOL-CELL PH, V280, pC441, DOI 10.1152/ajpcell.2001.280.3.C441; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dahlgren C, 1999, J IMMUNOL METHODS, V232, P3, DOI 10.1016/S0022-1759(99)00146-5; Dewas C, 2000, J IMMUNOL, V165, P5238, DOI 10.4049/jimmunol.165.9.5238; Downey GP, 1998, J IMMUNOL, V160, P434; Ehrt S, 2001, J EXP MED, V194, P1123, DOI 10.1084/jem.194.8.1123; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FIELDS PI, 1986, P NATL ACAD SCI USA, V83, P5189, DOI 10.1073/pnas.83.14.5189; GarciadelPortillo F, 1997, INFECT IMMUN, V65, P24, DOI 10.1128/IAI.65.1.24-34.1997; Gulig PA, 1997, INFECT IMMUN, V65, P5191, DOI 10.1128/IAI.65.12.5191-5197.1997; Hancock JT, 1997, BRIT J BIOMED SCI, V54, P38; Hensel M, 2000, MOL MICROBIOL, V36, P1015, DOI 10.1046/j.1365-2958.2000.01935.x; Hill TM, 1997, J BACTERIOL, V179, P1931, DOI 10.1128/jb.179.6.1931-1939.1997; Hu XT, 2000, CELL GROWTH DIFFER, V11, P191; Jesenberger V, 2001, J EXP MED, V193, P353, DOI 10.1084/jem.193.3.353; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Kingsley R A, 2000, Subcell Biochem, V33, P321; Lewis TS, 2000, MOL CELL, V6, P1343, DOI 10.1016/S1097-2765(00)00132-5; Martinez-Lorenzo MJ, 2001, CELL MICROBIOL, V3, P407, DOI 10.1046/j.1462-5822.2001.00123.x; Martinez-Moya M, 1998, RES MICROBIOL, V149, P309, DOI 10.1016/S0923-2508(98)80436-1; Mastroeni P, 2000, J EXP MED, V192, P237, DOI 10.1084/jem.192.2.237; Mulvey MA, 2001, INFECT IMMUN, V69, P4572, DOI 10.1128/IAI.69.7.4572-4579.2001; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Procyk KJ, 1999, INFECT IMMUN, V67, P1011, DOI 10.1128/IAI.67.3.1011-1017.1999; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; RichterDahlfors A, 1997, J EXP MED, V186, P569, DOI 10.1084/jem.186.4.569; Rosenberger CM, 2000, J IMMUNOL, V164, P5894, DOI 10.4049/jimmunol.164.11.5894; Shea JE, 1999, INFECT IMMUN, V67, P213, DOI 10.1128/IAI.67.1.213-219.1999; Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7; Shtrichman R, 2001, CURR OPIN MICROBIOL, V4, P251, DOI 10.1016/S1369-5274(00)00199-5; Steele-Mortimer O, 1999, CELL MICROBIOL, V1, P33, DOI 10.1046/j.1462-5822.1999.00003.x; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Torres M, 1999, ARCH BIOCHEM BIOPHYS, V366, P231, DOI 10.1006/abbi.1999.1225; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Vazquez-Torres A, 2000, SCIENCE, V287, P1655, DOI 10.1126/science.287.5458.1655; Vazquez-Torres A, 2001, TRENDS MICROBIOL, V9, P29, DOI 10.1016/S0966-842X(00)01897-7; Vazquez-Torres A, 2000, J EXP MED, V192, P227, DOI 10.1084/jem.192.2.227; Weiss DS, 1999, J BACTERIOL, V181, P508, DOI 10.1128/JB.181.2.508-520.1999; Wijburg OLC, 2000, EUR J IMMUNOL, V30, P944, DOI 10.1002/1521-4141(200003)30:3<944::AID-IMMU944>3.3.CO;2-T; ZAK O, 1979, REV INFECT DIS, V1, P862	44	85	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18753	18762		10.1074/jbc.M110649200	http://dx.doi.org/10.1074/jbc.M110649200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11821396	hybrid			2022-12-25	WOS:000175975800068
J	Kruger, RP; Winter, HC; Simonson-Leff, N; Stuckey, JA; Goldstein, IJ; Dixon, JE				Kruger, RP; Winter, HC; Simonson-Leff, N; Stuckey, JA; Goldstein, IJ; Dixon, JE			Cloning, expression, and characterization of the Gal alpha 1,3Gal high affinity lectin from the mushroom Marasmius oreades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION; ANTIBODY; PROTEIN; TOXIN; RICIN	The purification and unique carbohydrate binding properties, including blood group B-specific agglutination and preferential binding to Galalpha1,3Gal-containing sugar epitopes, of the Marasmius oreades agglutinin (MOA) are reported in an accompanying paper (Winter, H. C., Mostafapour, K., and Goldstein, 1. J. (2002) J. Biol. Chem. 277, 14996-15001). Here we describe the cloning, characterization, and expression of MOA. MOA was digested with trypsin and endoproteinase Asp-N, and the peptide fragments were purified by high performance liquid chromatography. Amino acid sequence data were obtained for eight peptides. Using oligonucleotides deduced from the peptide sequences for a reverse transcriptase-PCR, a 41-base pair cDNA was obtained. The 41-base pair fragment allowed the generation a full-length cDNA using 5' and 3' rapid amplification of cDNA ends. MOA cDNA encodes a protein of 293 amino acids that contains a ricin domain. These carbohydrate binding domains were first described in subunits of bacterial toxins and are also commonly found in polysaccharidede-grading enzymes. Whereas these proteins are known to display a variety of sugar binding specificities, none to date are known to share MOA's high affinity for Galalpha1,3Gal and Galalpha1,3Galbeta1,4GlcNAc. Recombinantly expressed and purified MOA retains the specificity and affinity observed with the native protein. This study provides the basis for analyzing the underlying cause for the unusual binding specificity of MOA.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Program Neurosci, Ann Arbor, MI 48109 USA; Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Dept Biol Chem, 1301 Catherine St, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM 29470-35] Funding Source: Medline; NIMH NIH HHS [T32 MH14279-24] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH014279] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAENZIGER JU, 1979, J BIOL CHEM, V254, P9795; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GALILI U, 1987, P NATL ACAD SCI USA, V84, P1369, DOI 10.1073/pnas.84.5.1369; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; LARSEN RD, 1990, J BIOL CHEM, V265, P7055; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MURPHY LA, 1979, BIOCHEMISTRY-US, V18, P4999, DOI 10.1021/bi00589a030; OLSNES S, 1973, BIOCHEMISTRY-US, V12, P3121, DOI 10.1021/bi00740a028; Pascal JM, 2001, PROTEINS, V43, P319, DOI 10.1002/prot.1043; SANDRIN MS, 1993, P NATL ACAD SCI USA, V90, P11391, DOI 10.1073/pnas.90.23.11391; Tempel W, 2002, J BIOL CHEM, V277, P6615, DOI 10.1074/jbc.M109919200; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Weis WI, 1996, ANNU REV BIOCHEM, V65, P441, DOI 10.1146/annurev.bi.65.070196.002301; Winter HC, 2002, J BIOL CHEM, V277, P14996, DOI 10.1074/jbc.M200161200; ZENTZ C, 1979, BIOCHIMIE, V61, P1, DOI 10.1016/S0300-9084(79)80307-7	15	36	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15002	15005		10.1074/jbc.M200165200	http://dx.doi.org/10.1074/jbc.M200165200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836254	hybrid			2022-12-25	WOS:000175203000082
J	Lee, JK; Lee, EH; Yun, YP; Kim, K; Kwack, K; Na, DS; Kwon, BS; Lee, CK				Lee, JK; Lee, EH; Yun, YP; Kim, K; Kwack, K; Na, DS; Kwon, BS; Lee, CK			Truncation of NH2-terminal amino acid residues increases agonistic potency of leukotactin-1 on CC chemokine receptors 1 and 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CHEMOATTRACTANT; IDENTIFICATION; PROTEINS; RANTES; LYMPHOCYTES; ANTAGONISTS; CYTOKINE	Leukotactin-1 (Lkn-1) is a human CC chemokine that binds to both CC chemokine receptor 1 (CCR1) and CCR3. Structurally, Lkn-1 is distinct from other human CC chemokines in that it has long amino acid residues preceding the first cysteine at the NH2 terminus, and contains two extra cysteines. NH2-terminal amino acids of Lkn-1 were deleted serially, and the effects of each deletion were investigated. In CCR1-expressing cells, serial deletion up to 20 amino acids (Delta20) did not change the calcium flux-inducing activity significantly. Deletion of 24 amino acids (Delta24), however, increased the agonistic potency similar to100-fold. Deletion of 27 or 28 amino acids also increased the agonistic potency to the same level shown by Delta24. Deletion of 29 amino acids, however, abolished the agonistic activity almost completely showing that at least 3 amino acid residues preceding the first cysteine at the NH2 terminus are essential for the biological activity of Lkn-1. Loss of agonistic activity was due to impaired binding to CCR1. In CCR3-expressing cells, Delta24 was the only form of Lkn-1 mutants that revealed increased agonistic potency. Our results indicate that posttranslational modification is a potential mechanism for the regulation of biological activity of Lkn-1.	Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Chungbuk Natl Univ, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea; Sahm Yook Univ, Coll Pharm, Seoul 139742, South Korea; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Univ Ulsan, Dept Biochem, Seoul 138763, South Korea	Chungbuk National University; Chungbuk National University; Sahmyook University; University of Ulsan; University of Ulsan	Lee, CK (corresponding author), Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea.	cklee@chungbuk.ac.kr						Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BROXMEYER HE, 1990, BLOOD, V76, P1110; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Howard OMZ, 1999, J CLIN IMMUNOL, V19, P280, DOI 10.1023/A:1020587407535; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Proost P, 1998, J IMMUNOL, V160, P4034; Proudfoot AEI, 1996, J BIOL CHEM, V271, P2599, DOI 10.1074/jbc.271.5.2599; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SchulzKnappe P, 1996, J EXP MED, V183, P295, DOI 10.1084/jem.183.1.295; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Tsou CL, 1998, J EXP MED, V188, P603, DOI 10.1084/jem.188.3.603; Wang JM, 1999, J EXP MED, V190, P591, DOI 10.1084/jem.190.5.591; Weber M, 1996, J EXP MED, V183, P681, DOI 10.1084/jem.183.2.681; WOLPE SD, 1988, J EXP MED, V167, P570, DOI 10.1084/jem.167.2.570; Youn BS, 1997, J IMMUNOL, V159, P5201; Zhang SM, 1999, J IMMUNOL, V162, P4938	27	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14757	14763		10.1074/jbc.M109309200	http://dx.doi.org/10.1074/jbc.M109309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11832479	hybrid			2022-12-25	WOS:000175203000053
J	Qiu, ZH; Strickland, DK; Hyman, BT; Rebeck, GW				Qiu, ZH; Strickland, DK; Hyman, BT; Rebeck, GW			alpha 2-macroglobulin exposure reduces calcium responses to N-methyl-D-aspartate via low density lipoprotein receptor-related protein in cultured hippocampal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; TISSUE-PLASMINOGEN ACTIVATOR; APOLIPOPROTEIN-E RECEPTOR; BETA-AMYLOID PEPTIDE; RAT CEREBRAL-CORTEX; ALZHEIMERS-DISEASE; ALPHA(2)-MACROGLOBULIN RECEPTOR; INTRACELLULAR CALCIUM; GLUTAMATE RECEPTORS; CORTICAL-NEURONS	There is increasing evidence that the low-density lipoprotein receptor-related protein (LRP) can function as a signaling link in the central nervous system. To investigate the pathophysiological role of LRP in the central nervous system, we examined the effects of activated alpha(2)-macroglobulin (alpha2M*), a ligand of LRP, on intracellular calcium signaling in cultured rat hippocampal neurons. Neuronal effects of alpha2M* (50 nM) were assessed by a comparison of calcium signals produced in control and alpha2M*-pretreated neurons by N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid. alpha2M* pretreatment significantly decreased the calcium signals to NMDA, whereas little change was observed for the signals to alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid. Native alpha2M, which is not a ligand for LRP, did not affect signals to NMDA. The receptor-associated protein prevented alpha2M*-induced decrease of calcium responses to NMDA, suggesting that alpha2M* exerted its effects through an LRP-mediated pathway. Experiments changing calcium sources demonstrated that alpha2M* pretreatment altered calcium responses to NMDA by primarily changing extracellular calcium influx and subsequently affecting calcium release from intracellular calcium stores. Immunoblot analysis demonstrated that alpha2M* caused a reduction in the levels of the NMDA receptor subunit, NMDAR1. These results suggest that alpha2M* can alter the neuronal response to excitatory neurotransmitters and that alpha2M* pretreatment selectively reduced the calcium responses to NMDA by down-regulating the NMDA receptor.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02129 USA; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; American Red Cross	Qiu, ZH (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, 114 16th St, Boston, MA 02129 USA.		Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X	NIA NIH HHS [AG12406, AG14473] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG012406, R01AG012406, R29AG014473, R01AG014473] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; BATTEY FD, 1994, J BIOL CHEM, V269, P23268; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BU GJ, 1994, J BIOL CHEM, V269, P18521; CHARLES AC, 1993, GLIA, V7, P134, DOI 10.1002/glia.440070203; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Du YS, 1998, J NEUROCHEM, V70, P1182; GIBBONS SJ, 1993, ANN NY ACAD SCI, V679, P22, DOI 10.1111/j.1749-6632.1993.tb18286.x; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hashimoto Y, 2000, J NEUROSCI, V20, P8401, DOI 10.1523/JNEUROSCI.20-22-08401.2000; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLTZMAN DM, 1995, P NATL ACAD SCI USA, V92, P9480, DOI 10.1073/pnas.92.21.9480; Horn G, 1998, TRENDS NEUROSCI, V21, P300, DOI 10.1016/S0166-2236(97)01219-8; Ishii M, 1996, BRAIN RES, V737, P269, DOI 10.1016/0006-8993(96)00741-X; Kanowski S, 1998, J NEURAL TRANSM-SUPP, P195; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Lei SB, 2001, J NEUROSCI, V21, P8464, DOI 10.1523/JNEUROSCI.21-21-08464.2001; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; MATTSON MP, 1993, ANN NY ACAD SCI, V679, P1, DOI 10.1111/j.1749-6632.1993.tb18285.x; Mattson MP, 2000, TRENDS NEUROSCI, V23, P222, DOI 10.1016/S0166-2236(00)01548-4; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723, DOI 10.1152/physrev.1994.74.3.723; MILLER RJ, 1991, PROG NEUROBIOL, V37, P255, DOI 10.1016/0301-0082(91)90028-Y; MINTA A, 1989, J BIOL CHEM, V264, P8171; Misra UK, 1999, ARCH BIOCHEM BIOPHYS, V372, P238, DOI 10.1006/abbi.1999.1521; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Narita M, 1997, J NEUROCHEM, V68, P587; Narita M, 1997, J NEUROCHEM, V69, P1904; Olney JW, 1997, ARCH NEUROL-CHICAGO, V54, P1234, DOI 10.1001/archneur.1997.00550220042012; PRIESTLEY T, 1995, MOL PHARMACOL, V48, P841; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; QIU ZH, 1995, J NEUROSCI, V15, P6688; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Qiu ZH, 1998, J NEUROSCI, V18, P10445; Qiu ZH, 2001, J NEUROPATH EXP NEUR, V60, P430, DOI 10.1093/jnen/60.5.430; REBECK GW, 1995, ANN NEUROL, V37, P211, DOI 10.1002/ana.410370212; REBECK GW, 1993, NEURON, V11, P575; Sheng M, 1997, NATURE, V386, P221, DOI 10.1038/386221a0; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Sze CI, 2001, J NEUROL SCI, V182, P151, DOI 10.1016/S0022-510X(00)00467-6; Thal DR, 1997, BRAIN RES, V777, P223, DOI 10.1016/S0006-8993(97)01021-4; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; Webb DJ, 2000, J CELL SCI, V113, P123; WILLIAMS K, 1993, MOL PHARMACOL, V44, P851; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Yamamoto M, 1998, Brain Tumor Pathol, V15, P23, DOI 10.1007/BF02482097; Yoo JY, 2001, J BIOL CHEM, V276, P26421, DOI 10.1074/jbc.M009935200; ZHENG G, 1994, J HISTOCHEM CYTOCHEM, V42, P531, DOI 10.1177/42.4.7510321; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	57	65	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14458	14466		10.1074/jbc.M112066200	http://dx.doi.org/10.1074/jbc.M112066200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839752	hybrid			2022-12-25	WOS:000175203000016
J	Adachi, K; Zhao, Y; Surrey, S				Adachi, K; Zhao, Y; Surrey, S			Assembly of human hemoglobin (Hb) beta- and gamma-globin chains expressed in a cell-free system with alpha-globin chains to form Hb A and Hb F	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETICS	Rates of in vitro synthesis of radiolabeled gamma and beta chains made in a cell-free transcription/translation system were similar, but expressed globin chains were unstable. The addition of unlabeled beta or gamma chains at the start of chain synthesis generated radiolabeled beta(4) or gamma(2) and gamma(4) chains, respectively. If unlabeled alpha-globin chains were added at the start of chain synthesis, then approximately equal amounts of radiolabeled alphabeta or alphagamma bands were generated. If unlabeled Hb A or Hb F was added to reactions containing radiolabeled alphabeta or alphagamma prior to electrophoresis, then radiolabeled Hb A or Hb F tetramers, respectively, were generated. If alpha chains were added after synthesis of radiolabeled gamma chains made in the presence of unlabeled gamma chains, then little radiolabeled ay formed. In contrast, if alpha chains were added after synthesis of radiolabeled beta chains made in the presence of unlabeled beta chains, then radiolabeled alpha(2)beta(2) formed. These findings suggest that beta and gamma chains associate with alpha chains during or soon after translation. This would prevent the formation of unstable monomers as well as stable gamma(2) dimers and suggests that a chains may bind to nascent non-alpha chains, acting as folding catalysts to promote functional tetrameric hemoglobin formation in vivo.	Childrens Hosp Philadelphia, Div Hematol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Cardeza Fdn Hematol Res, Philadelphia, PA 19107 USA	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; Jefferson University	Adachi, K (corresponding author), Childrens Hosp Philadelphia, Div Hematol, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	adachi@email.chop.edu			NHLBI NIH HHS [HL58879] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058879] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adachi K, 2000, J BIOL CHEM, V275, P12424, DOI 10.1074/jbc.C000137200; ANTONINI E, 1966, J MOL BIOL, V17, P29, DOI 10.1016/S0022-2836(66)80092-X; ASCOLI F, 1981, METHOD ENZYMOL, V232, P292; Benz E J Jr, 1975, Prog Hematol, V9, P107; BUCCI E, 1965, J MOL BIOL, V12, P183, DOI 10.1016/S0022-2836(65)80292-3; BUNN HF, 1983, NATURE, V306, P498, DOI 10.1038/306498a0; BUNN HF, 1969, J CLIN INVEST, V48, P126, DOI 10.1172/JCI105961; BUNN HF, 1987, BLOOD, V69, P1; BUNN HF, 1986, HEMOGLOBIN MOL GENET, P13; FRIEDMAN FK, 1979, ANNU REV BIOCHEM, V48, P217, DOI 10.1146/annurev.bi.48.070179.001245; KAWAMURA Y, 1983, J BIOCHEM-TOKYO, V94, P1851, DOI 10.1093/oxfordjournals.jbchem.a134538; Komar AA, 1997, J BIOL CHEM, V272, P10646; KOMAR AA, 1993, FEBS LETT, V326, P261, DOI 10.1016/0014-5793(93)81803-8; MCDONALD MJ, 1981, J BIOL CHEM, V256, P6487; MCDONALD MJ, 1987, J BIOL CHEM, V262, P5951; MCGOVERN P, 1976, J BIOL CHEM, V251, P7871; MRABET NT, 1986, J BIOL CHEM, V261, P5222; MRABET NT, 1986, J BIOL CHEM, V261, P1111; TASPIS A, 1978, BIOCHEM BIOPH RES CO, V85, P5211; Turner B W, 1981, Methods Enzymol, V76, P596; WILLIAMS RC, 1976, BIOCHEMISTRY-US, V15, P2207, DOI 10.1021/bi00655a028	21	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13415	13420		10.1074/jbc.M200857200	http://dx.doi.org/10.1074/jbc.M200857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827978	hybrid			2022-12-25	WOS:000175096000011
J	Barabe, F; Pare, G; Fernandes, MJG; Bourgoin, SG; Naccache, PH				Barabe, F; Pare, G; Fernandes, MJG; Bourgoin, SG; Naccache, PH			Cholesterol-modulating agents selectively inhibit calcium influx induced by chemoattractants in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; CYCLIC ADP-RIBOSE; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-D; RABBIT NEUTROPHILS; INOSITOL TRISPHOSPHATE; INTRACELLULAR CALCIUM; CHEMOTACTIC FACTOR; SIGNALING COMPLEX; PERTUSSIS-TOXIN	The effects of cholesterol-perturbing agents on the mobilization of calcium induced upon the stimulation of human neutrophils by chemotactic factors were tested. Methyl-beta-cyclodextrin and filipin did not alter the initial peak of calcium mobilization but shortened the duration of the calcium spike that followed the addition of fMet-Leu-Phe. These agents also inhibited the influx of Mn2+ induced by fMet-Leu-Phe or thapsigargin. Methyl-beta-cyclodextrin and filipin completely abrogated the mobilization of calcium induced by 10(-10) m platelet-activating factor, which at this concentration depends to a major extent on an influx of calcium as well as the influx of calcium induced by 10(-7) m platelet-activating factor. On the other hand, methyl-beta-cyclodextrin and filipin enhanced the mobilization of calcium induced by ligation of FcgammaRIIA, an agonist that did not induce a detectable influx of calcium. Finally, methyl-beta-cyclodextrin and filipin enhanced the stimulation of the profile of tyrosine phosphorylation, the activity of phospholipase D (PLD), and the production of superoxide anions induced by fMet-Leu-Phe. These results suggest that the calcium channels utilized by chemotactic factors in human neutrophils are either located in cholesterol-rich regions of the plasma membrane, or that the mechanisms that lead to their opening depend on the integrity of these microdomains.	CHU Laval, Ctr Rech, Ctr Rech Rhumatol & Immunol,Dept Med, Canadian Inst Hlth Res Grp Mol Mech Inflammat, Quebec City, PQ G1V 4G2, Canada; CHU Laval, Canadian Inst Hlth Res Grp Mol Mech Inflammat, Ctr Rech,Ctr Rech Rhumatol & Immunol, Dept Physiol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Naccache, PH (corresponding author), CHU Laval, Ctr Rech, Ctr Rech Rhumatol & Immunol,Dept Med, Canadian Inst Hlth Res Grp Mol Mech Inflammat, 2705 Blvd Laurier,Rm T1-49, Quebec City, PQ G1V 4G2, Canada.			Bourgoin, Sylvain/0000-0001-9779-0368				AlShami A, 1997, J IMMUNOL METHODS, V202, P183, DOI 10.1016/S0022-1759(97)00004-5; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; Berridge MJ, 1996, BIOCHEM J, V314, P1055, DOI 10.1042/bj3141055; BIANCHINI L, 1993, J BIOL CHEM, V268, P3357; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; BOURGOIN S, 1990, J EXP MED, V172, P767, DOI 10.1084/jem.172.3.767; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Czarny M, 2000, FEBS LETT, V467, P326, DOI 10.1016/S0014-5793(00)01174-1; Davies EV, 1998, INT J MOL MED, V1, P485; DEWALD B, 1988, J BIOL CHEM, V263, P16179; EDBERG JC, 1995, J BIOL CHEM, V270, P22301, DOI 10.1074/jbc.270.38.22301; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; FALLMAN M, 1989, J CLIN INVEST, V84, P886, DOI 10.1172/JCI114249; FODER B, 1989, CELL CALCIUM, V10, P77; GAUDRY M, 1993, J CLIN INVEST, V91, P1649, DOI 10.1172/JCI116373; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GYRNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Kim Y, 1999, BBA-MOL CELL BIOL L, V1436, P319, DOI 10.1016/S0005-2760(98)00120-9; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; MARASCO WA, 1984, J BIOL CHEM, V259, P5430; Marcil J, 1999, BIOCHEM J, V337, P185, DOI 10.1042/0264-6021:3370185; MESHULAM T, 1988, BIOCHEM BIOPH RES CO, V150, P532, DOI 10.1016/0006-291X(88)90426-3; Murphy PM, 1997, SEMIN HEMATOL, V34, P311; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; NACCACHE PH, 1986, J LEUKOCYTE BIOL, V40, P533, DOI 10.1002/jlb.40.5.533; NACCACHE PH, 1993, ARTHRITIS RHEUM, V36, P117, DOI 10.1002/art.1780360119; NACCACHE PH, 1990, BLOOD, V76, P2098; NORMAN AW, 1972, J BIOL CHEM, V247, P1918; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Petrie RJ, 2000, J IMMUNOL, V165, P1220, DOI 10.4049/jimmunol.165.3.1220; PETROSKI RJ, 1979, AM J PHYSIOL, V237, pC43, DOI 10.1152/ajpcell.1979.237.1.C43; Prossnitz ER, 1997, PHARMACOL THERAPEUT, V74, P73, DOI 10.1016/S0163-7258(96)00203-3; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 2001, J CELL SCI, V114, P2223; ROBINSON JM, 1984, BIOCHEM BIOPH RES CO, V122, P734, DOI 10.1016/S0006-291X(84)80095-9; SAGE SO, 1990, BIOCHEM J, V265, P915, DOI 10.1042/bj2650915; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V677, P512, DOI 10.1016/0304-4165(81)90267-1; STENDAHL O, 1994, SCIENCE, V265, P1439, DOI 10.1126/science.8073285; WenzelSeifert K, 1996, BIOCHEM J, V314, P679, DOI 10.1042/bj3140679; WHITE JR, 1983, BIOCHEM BIOPH RES CO, V113, P44, DOI 10.1016/0006-291X(83)90429-1; Yamashita T, 2001, J BIOCHEM-TOKYO, V129, P861, DOI 10.1093/oxfordjournals.jbchem.a002930; ZUBIAUR M, 2001, J BIOL CHEM, V31, P31	51	38	40	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13473	13478		10.1074/jbc.M112149200	http://dx.doi.org/10.1074/jbc.M112149200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11839753	hybrid			2022-12-25	WOS:000175096000019
J	Borre, L; Kavanaugh, MP; Kanner, BI				Borre, L; Kavanaugh, MP; Kanner, BI			Dynamic equilibrium between coupled and uncoupled modes of a neuronal glutamate transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN; MEMBRANE-VESICLES; ACID TRANSPORTER; CHLORIDE CHANNEL; GLT-1; EXPRESSION; SUBSTRATE; ACCESSIBILITY; MECHANISM; CLEARANCE	In the brain, the neurotransmitter glutamate is removed from the synaptic cleft by (Na+ + K+)-coupled transporters by an electrogenic process. Moreover, these transporters mediate a sodium- and glutamate-dependent uncoupled chloride conductance. In contrast to the wild type, the uptake of radiolabeled substrate by the I421C mutant is inhibited by the membrane-impermeant [2-(trimethylammonium)ethyl]methanethiosulfortate and also by other sulfhydryl reagents. In the wild-type and the unmodified mutant, substrate-induced currents are inwardly rectifying and reflect the sum of the coupled electrogenic flux and the anion conductance. Remarkably, the I421C mutant modified by sulfhydryl reagents exhibits currents that are nonrectifying and reverse at the equilibrium potential for chloride. Strikingly, almost 10-fold higher concentrations of D-aspartate are required to activate the currents in the modified mutant as compared with untreated I421C. Under conditions in which only the coupled currents are observed, the modified mutant does not exhibit any currents. However, when the uncoupled current is dominant, sulfhydryl reagents cause >4-fold stimulation of this current. Thus, the modification of the cysteine introduced at position 421 impacts the coupled but not the uncoupled fluxes. Although both fluxes are activated by substrate, they behave as independent processes that are in dynamic equilibrium.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Hebrew University of Jerusalem; Oregon Health & Science University	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS016708, R01NS016708] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 16708] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Auger C, 2000, NEURON, V28, P547, DOI 10.1016/S0896-6273(00)00132-X; Bendahan A, 2000, J BIOL CHEM, V275, P37436, DOI 10.1074/jbc.M006536200; Borre L, 2001, J BIOL CHEM, V276, P40396, DOI 10.1074/jbc.M104926200; BREW H, 1987, NATURE, V327, P707, DOI 10.1038/327707a0; Diamond JS, 1997, J NEUROSCI, V17, P4672; Eskandari S, 2000, P NATL ACAD SCI USA, V97, P8641, DOI 10.1073/pnas.97.15.8641; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Grewer C, 2000, P NATL ACAD SCI USA, V97, P9706, DOI 10.1073/pnas.160170397; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1978, BIOCHEMISTRY-US, V17, P3949, DOI 10.1021/bi00612a011; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KANNER BI, 1982, BIOCHEMISTRY-US, V21, P6327, DOI 10.1021/bi00267a044; Kavanaugh MP, 1997, J BIOL CHEM, V272, P1703, DOI 10.1074/jbc.272.3.1703; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Mitrovic AD, 2001, J BIOL CHEM, V276, P26071, DOI 10.1074/jbc.M011318200; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Otis TS, 2000, J NEUROSCI, V20, P2749; Otis TS, 1996, J NEUROSCI, V16, P1634, DOI 10.1523/jneurosci.16-05-01634.1996; PINES G, 1995, J BIOL CHEM, V270, P17093, DOI 10.1074/jbc.270.29.17093; PINES G, 1990, BIOCHEMISTRY-US, V29, P11209, DOI 10.1021/bi00503a008; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Ryan RM, 2002, J BIOL CHEM, V277, P13494, DOI 10.1074/jbc.M109970200; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; Seal RP, 2001, P NATL ACAD SCI USA, V98, P15324, DOI 10.1073/pnas.011400198; Slotboom DJ, 1999, P NATL ACAD SCI USA, V96, P14282, DOI 10.1073/pnas.96.25.14282; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; Wadiche JI, 1998, J NEUROSCI, V18, P7650; WADICHE JI, 1995, NEURON, V15, P721, DOI 10.1016/0896-6273(95)90159-0; Watzke N, 2000, J GEN PHYSIOL, V116, P609, DOI 10.1085/jgp.116.5.609; Zerangue N, 1996, NATURE, V383, P634, DOI 10.1038/383634a0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710; Zhang YM, 1998, P NATL ACAD SCI USA, V95, P751, DOI 10.1073/pnas.95.2.751	43	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13501	13507		10.1074/jbc.M110861200	http://dx.doi.org/10.1074/jbc.M110861200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11823462	hybrid, Green Published			2022-12-25	WOS:000175096000023
J	Denda, K; Shimomura, T; Kawaguchi, T; Miyazawa, K; Kitamura, N				Denda, K; Shimomura, T; Kawaguchi, T; Miyazawa, K; Kitamura, N			Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE-PROTEASE INHIBITOR; MATRIX-DEGRADING PROTEASE; BREAST-CANCER CELLS; PROTEOLYTIC CLEAVAGE; TRYPSIN-INHIBITOR; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; PURIFICATION; EXPRESSION; FORM	Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is a Kunitz-type serine protease inhibitor identified as a strong inhibitor of hepatocyte growth factor (HGF) activator and matriptase. HAI-1 is first produced in a membrane-integrated form with two Kunitz domains in its extracellular region, and subsequent ectodomain shedding releases two major secreted forms, one with a single Kunitz domain and one with two Kunitz domains. To determine the roles of the Kunitz domains in the inhibitory activity of HAI-1 against serine proteases, we constructed various HAI-1 mutant proteins and examined their inhibitory activity against HGF activator and trypsin. The N-terminal Kunitz domain (Kunitz 1) had potent inhibitory activity against both HGF activator and trypsin, whereas the C-terminal Kunitz domain (Kunitz II) had only very weak inhibitory activity against HGF activator, although its potency against trypsin was equivalent to that of Kunitz L These results indicate that Kunitz I is the functional domain of HAI-1 for inhibiting the HGF-converting activity of HGF activator. Furthermore, the presence of two Kunitz domains affected the inhibitory activity of HAI-1 against HGF activator, and it showed a similar, but not additive, level of inhibitory activity against trypsin when compared with that of the individual Kunitz domains. These results suggest that serine protease binding sites of Kunitz I and Kunitz 11 are located close to each other and that proteolytic processing to generate HAI-1 with only one Kunitz domain regulates the activity of HAI-1.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Sci Biol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Mitsubishi Pharma Corp, Res Ctr, Aoba Ku, Yokohama, Kanagawa 2270033, Japan	Tokyo Institute of Technology; Mitsubishi Tanabe Pharma Corporation	Kitamura, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Sci Biol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		MIYAZAWA, KEIJI/I-9713-2014					Benaud C, 2001, EUR J BIOCHEM, V268, P1439, DOI 10.1046/j.1432-1327.2001.02016.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; Itoh H, 2000, AM J PHYSIOL-GASTR L, V278, pG635, DOI 10.1152/ajpgi.2000.278.4.G635; ITOH H, 1994, J BIOL CHEM, V269, P3818; Kataoka H, 1999, J HISTOCHEM CYTOCHEM, V47, P673, DOI 10.1177/002215549904700509; KATSOKA H, 2000, J BIOL CHEM, V275, P40453; Kawaguchi T, 1997, J BIOL CHEM, V272, P27558, DOI 10.1074/jbc.272.44.27558; KIDO H, 1988, J BIOL CHEM, V263, P18104; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1997, J BIOL CHEM, V272, P9147; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIYAZAWA K, 1994, J BIOL CHEM, V269, P8966; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MORISHITA H, 1994, THROMB RES, V73, P193, DOI 10.1016/0049-3848(94)90098-1; NAKA D, 1992, J BIOL CHEM, V267, P20114; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; SHI YE, 1993, CANCER RES, V53, P1409; Shimomura T, 1999, J BIOCHEM-TOKYO, V126, P821, DOI 10.1093/oxfordjournals.jbchem.a022522; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Xu YB, 1998, J MOL BIOL, V276, P955, DOI 10.1006/jmbi.1997.1582	26	56	64	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14053	14059		10.1074/jbc.M112263200	http://dx.doi.org/10.1074/jbc.M112263200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11805118	hybrid			2022-12-25	WOS:000175096000092
J	Guo, Q; Gong, QG; Tong, KL; Vestergaard, B; Costa, A; Desgres, J; Wong, MS; Grosjean, H; Zhu, G; Wong, JTF; Xue, H				Guo, Q; Gong, QG; Tong, KL; Vestergaard, B; Costa, A; Desgres, J; Wong, MS; Grosjean, H; Zhu, G; Wong, JTF; Xue, H			Recognition by tryptophanyl-tRNA synthetases of discriminator base on tRNA(TrP) from three biological domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; TRANSFER RNA(TRP); AMINOACYLATION REACTION; ACCEPTOR STEM; IDENTIFICATION; CONFORMATION; SEQUENCES; STABILITY	To study the recognition by tryptophanyl-tRNA synthetase (TrpRS) of tRNA(Trp) discriminator base, mutations were introduced into the discriminator base of Bacillus subtilis, Archeoglobus fulgidus, and bovine tRNA(Trp), representing the three biological domains. When B. subtilis, A fulgidus, and human TrpRS were used to acylate these tRNA(Trp), two distinct preference profiles regarding the discriminator base of different tRNA(Trp) substrates were found: G>A>U>C for B. subtilis TrpRS, and A>C>U>G for A. fulgidus and human TrpRS. The preference for G73 in tRNA(Trp) by bacterial TrpRS is much stronger than the modest preferences for A73 by the archaeal and eukaryotic TrpRS. Cross-species reactivities between TrpRS and tRNA(Trp) from the three domains were in accordance with the view that the evolutionary position of archaea is intermediate between those of eukarya and bacteria. NMR spectroscopy revealed that mutation of A73 to G73 in bovine tRNA(Trp) elicited a conformational alteration in the G1-C72 base pair. Mutation of G1-C72 to A1-U72 or disruption of the G1-C72 base pair also caused reduction of Trp-tRNA(Trp) formation. These observations identify a tRNA(Trp) structural region near the end of acceptor stem comprising A73 and G1-C72 as a crucial domain required for effective recognition by human TrpRS.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Aarhus Univ, Dept Mol & Struct Biol, DK-8000 Aarhus C, Denmark; Fac Med, Lab Biochim Med, F-21034 Dijon, France; Ctr Hosp Bourgogne, F-21034 Dijon, France; CNRS, UPR, Lab Enzymol & Biochem Struct, F-91198 Gif Sur Yvette, France	Hong Kong University of Science & Technology; Aarhus University; Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Xue, H (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.			Vestergaard, Bente/0000-0001-8011-6414; Wong, J. Tze-Fei/0000-0001-8539-8537; Xue, Hong/0000-0002-8133-9828				Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; Fischer AE, 1999, J BIOL CHEM, V274, P37093, DOI 10.1074/jbc.274.52.37093; FLECKNER J, 1991, P NATL ACAD SCI USA, V88, P11520, DOI 10.1073/pnas.88.24.11520; FOURNIER M, 1978, BIOCHIM BIOPHYS ACTA, V521, P198, DOI 10.1016/0005-2787(78)90262-9; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; Hou YM, 1997, CHEM BIOL, V4, P93, DOI 10.1016/S1074-5521(97)90252-0; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 1999, NUCLEIC ACIDS RES, V27, P3631, DOI 10.1093/nar/27.18.3631; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KWOK Y, 1980, CAN J BIOCHEM CELL B, V58, P213, DOI 10.1139/o80-029; LIMMER S, 1993, P NATL ACAD SCI USA, V90, P6199, DOI 10.1073/pnas.90.13.6199; Madore E, 2000, BIOCHEMISTRY-US, V39, P6791, DOI 10.1021/bi992477x; MATSUGI J, 1992, NUCLEIC ACIDS RES, V20, P3514, DOI 10.1093/nar/20.13.3514; PUGLISI EV, 1994, P NATL ACAD SCI USA, V91, P11467, DOI 10.1073/pnas.91.24.11467; SHI W, 1990, BIOCHEM CELL BIOL, V68, P492, DOI 10.1139/o90-069; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Xu F, 2001, NUCLEIC ACIDS RES, V29, P4125, DOI 10.1093/nar/29.20.4125; XU ZJ, 1989, J BIOL CHEM, V264, P4304; XUE H, 1993, NUCLEIC ACIDS RES, V21, P2479, DOI 10.1093/nar/21.10.2479; XUE H, 1993, J CHROMATOGR-BIOMED, V613, P247, DOI 10.1016/0378-4347(93)80139-U; XUE H, 1993, J BIOL CHEM, V268, P9316; Xue H, 1997, BIOCHEM CELL BIOL, V75, P709, DOI 10.1139/bcb-75-6-709; Yan XZ, 2000, J BIOL CHEM, V275, P6712, DOI 10.1074/jbc.275.10.6712	25	20	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14343	14349		10.1074/jbc.M111745200	http://dx.doi.org/10.1074/jbc.M111745200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834741	hybrid			2022-12-25	WOS:000175096000129
J	Hager, M; Hermann, M; Biehler, A; Krieger-Liszkay, A; Bock, R				Hager, M; Hermann, M; Biehler, A; Krieger-Liszkay, A; Bock, R			Lack of the small plastid-encoded PsbJ polypeptide results in a defective water-splitting apparatus of photosystem II, reduced photosystem I levels, and hypersensitivity to light	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLAMYDOMONAS-REINHARDTII LACKING; READING FRAME REVEALS; TARGETED INACTIVATION; CYTOCHROME B(559); CHLOROPLAST DNA; MESSENGER-RNA; PROTEIN; COMPLEX; GENE; TOBACCO	Photosystem 11 is a large pigment-protein complex catalyzing water oxidation and initiating electron trans. fer processes across the thylakoid membrane. In addition to large protein subunits, many of which bind redox cofactors, photosystem II particles contain a number of low molecular weight polypeptides whose function is only poorly defined. Here we have investigated the function of one of the smallest polypeptides in photosystem 11, PsbJ. Using a reverse genetics approach, we have inactivated the psbJ gene in the tobacco chloroplast genome. We show that, although the PsbJ polypeptide is not principally required for functional photosynthetic electron transport, plants lacking PsbJ are unable to grow photoautotrophically. We provide evidence that this is due to the accumulation of incompletely assembled water-splitting complexes, which in turn causes drastically reduced photosynthetic performance and extreme hypersensitivity to light. Our results suggest a role of PsbJ for the stable assembly of the water-splitting complex of photosystem 11 and, in addition, support a control of photosystem I accumulation through photosystem 11 activity.	Univ Freiburg, Inst Biol 3, D-79104 Freiburg, Germany; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany; Univ Munster, Inst Biochem & Biotechnol Pflanzen, D-48143 Munster, Germany	University of Freiburg; University of Freiburg; University of Munster	Bock, R (corresponding author), Univ Freiburg, Inst Biol 3, Schanzlestr 1, D-79104 Freiburg, Germany.		Bock, Ralph/B-4352-2009	Bock, Ralph/0000-0001-7502-6940; Krieger-Liszkay, Anja/0000-0001-7141-4129				Alexciev K, 1997, PHYSIOL PLANTARUM, V99, P477, DOI 10.1034/j.1399-3054.1997.990317.x; Andersson J, 2001, PLANT CELL, V13, P1193, DOI 10.1105/tpc.13.5.1193; Barber J, 1997, PHYSIOL PLANTARUM, V100, P817, DOI 10.1034/j.1399-3054.1997.1000408.x; Bock R, 1996, EMBO J, V15, P5052, DOI 10.1002/j.1460-2075.1996.tb00885.x; BOCK R, 1994, EMBO J, V13, P4623, DOI 10.1002/j.1460-2075.1994.tb06784.x; BOYNTON JE, 1988, SCIENCE, V240, P1534, DOI 10.1126/science.2897716; Choquet Y, 2000, BIOCHIMIE, V82, P615, DOI 10.1016/S0300-9084(00)00609-X; Coligan JE, 1995, CURRENT PROTOCOLS PR; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; Doyle J.J., 1990, FOCUS, V12, P13, DOI DOI 10.2307/2419362; DUCRUET JM, 1992, PHOTOSYNTH RES, V33, P15, DOI 10.1007/BF00032979; Hager M, 1999, EMBO J, V18, P5834, DOI 10.1093/emboj/18.21.5834; HALEY J, 1990, PLANT CELL, V2, P323, DOI 10.1105/tpc.2.4.323; HARBINSON J, 1993, PLANT PHYSIOL, V103, P649, DOI 10.1104/pp.103.2.649; HOMANN PH, 1986, BIOCHIM BIOPHYS ACTA, V850, P10, DOI 10.1016/0005-2728(86)90003-4; JOHNSON GN, 1994, BBA-BIOENERGETICS, V1184, P85, DOI 10.1016/0005-2728(94)90157-0; KITAMURA K, 1994, FEBS LETT, V354, P113, DOI 10.1016/0014-5793(94)01089-7; Krieger A, 1998, PLANTA, V205, P587, DOI 10.1007/s004250050360; Kudla J, 1999, GENE, V234, P81, DOI 10.1016/S0378-1119(99)00177-8; LIND LK, 1993, J BIOL CHEM, V268, P1575; MACHOLD O, 1979, CARLSBERG RES COMMUN, V44, P235, DOI 10.1007/BF02906158; MIYAO M, 1989, BIOCHIM BIOPHYS ACTA, V977, P315, DOI 10.1016/S0005-2728(89)80086-6; MOR TS, 1995, MOL GEN GENET, V246, P600, DOI 10.1007/BF00298966; Morais F, 1998, J BIOL CHEM, V273, P29315, DOI 10.1074/jbc.273.45.29315; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P493, DOI DOI 10.1111/J.1399-3054.1962.TB08052.X; Nugent JHA, 1996, EUR J BIOCHEM, V237, P519, DOI 10.1111/j.1432-1033.1996.00519.x; Ortega JM, 1999, FEBS LETT, V458, P87, DOI 10.1016/S0014-5793(99)01128-X; PAKRASI HB, 1991, EMBO J, V10, P1619, DOI 10.1002/j.1460-2075.1991.tb07684.x; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pfannschmidt T, 2001, PHYSIOL PLANTARUM, V112, P1, DOI 10.1034/j.1399-3054.2001.1120101.x; Regel RE, 2001, J BIOL CHEM, V276, P41473, DOI 10.1074/jbc.M102007200; Rochaix JD, 1997, TRENDS PLANT SCI, V2, P419, DOI 10.1016/S1360-1385(97)90025-X; Rova EM, 1996, J BIOL CHEM, V271, P28918, DOI 10.1074/jbc.271.46.28918; ROVA M, 1994, PHOTOSYNTH RES, V39, P75, DOI 10.1007/BF00027145; Ruf S, 2000, J CELL BIOL, V149, P369, DOI 10.1083/jcb.149.2.369; Ruf S, 1997, J CELL BIOL, V139, P95, DOI 10.1083/jcb.139.1.95; RUTHERFORD AW, 1982, BIOCHIM BIOPHYS ACTA, V682, P457, DOI 10.1016/0005-2728(82)90061-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SCHREIBER U, 1988, Z NATURFORSCH C, V43, P686; Stewart DH, 1998, BBA-BIOENERGETICS, V1367, P63, DOI 10.1016/S0005-2728(98)00139-X; SVAB Z, 1993, P NATL ACAD SCI USA, V90, P913, DOI 10.1073/pnas.90.3.913; SVAB Z, 1990, P NATL ACAD SCI USA, V87, P8526, DOI 10.1073/pnas.87.21.8526; Takahashi Y, 1998, J PLANT RES, V111, P101, DOI 10.1007/BF02507156; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; Triboush SO, 1998, PLANT MOL BIOL REP, V16, P183, DOI 10.1023/A:1007487806583; VASS I, 1992, PHOTOSYSTEMS STRUCTU, P259; Wakasugi T, 1998, PLANT MOL BIOL REP, V16, P231, DOI 10.1023/A:1007564209282; Wollman FA, 1999, BBA-BIOENERGETICS, V1411, P21, DOI 10.1016/S0005-2728(99)00043-2; Zhang LX, 2000, PLANT CELL, V12, P1769, DOI 10.1105/tpc.12.9.1769; Zheleva D, 1998, J BIOL CHEM, V273, P16122, DOI 10.1074/jbc.273.26.16122; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	53	51	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14031	14039		10.1074/jbc.M112053200	http://dx.doi.org/10.1074/jbc.M112053200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827973	hybrid			2022-12-25	WOS:000175096000089
J	Chakrabarti, SK; James, JC; Mirmira, RG				Chakrabarti, SK; James, JC; Mirmira, RG			Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID POLYPEPTIDE GENE; CELL-SPECIFIC EXPRESSION; INSULIN GENE; DNA-BINDING; BETA-CELLS; HOMEODOMAIN PROTEIN; DROSOPHILA EMBRYOS; HOMEOBOX FACTOR; GLUCAGON GENE; LIVING CELLS	The transcription factor Pdx1 is expressed in the pancreatic beta-cell, where it is believed to regulate several beta-cell-specific genes. Whereas binding by Pdx1 to elements of beta-cell genes has been demonstrated in vitro, almost none of these genes has been demonstrated to be a direct binding target for Pdx1 within cells (where complex chromatin structure exists). To determine which beta-cell promoters are bound by Pdx1 in vivo, we performed chromatin immunoprecipitation assays using Pdx1 antiserum and chromatin from beta-TC3 cells and Pdx1-transfected NIH3T3 cells and subsequently quantitated co-immunoprecipitated promoters using realtime PCR. We compared these in vivo findings to parallel immunoprecipitations in which Pdx1 was allowed to bind to promoter fragments in in vitro reactions. Our results show that in all cells Pdx1 binds strongly to the insulin, islet amyloid polypeptide, glucagon, Pdx1, and Pax4 promoters, whereas it does not bind to either the glucose transporter type 2 or albumin promoters. In addition, no binding by Pdx1 to the glucokinase promoter was observed in beta-cells. In contrast, in in vitro immunoprecipitations, Pdx1 bound all promoters to an extent approximately proportional to the number of Pdx1 binding sites. Our findings suggest a critical role for chromatin structure in directing the promoter binding selectivity of Pdx1 in beta-cells and non-beta-cells.	Univ Virginia, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, Charlottesville, VA 22908 USA	University of Virginia	Mirmira, RG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Med, Div Endocrinol & Metab, 1300 Jefferson Pk Ave,Box 800746, Charlottesville, VA 22908 USA.		Mirmira, Raghavendra G/AAD-7592-2020	Mirmira, Raghavendra G/0000-0002-5013-6075	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002683] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08 DK 02683] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; Anderson JD, 2001, J MOL BIOL, V307, P977, DOI 10.1006/jmbi.2001.4528; Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Carr A, 1999, EMBO J, V18, P1598, DOI 10.1093/emboj/18.6.1598; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; Draganescu A, 1998, J MOL BIOL, V276, P529, DOI 10.1006/jmbi.1997.1567; Dumonteil E, 1998, J BIOL CHEM, V273, P19945, DOI 10.1074/jbc.273.32.19945; Dutta S, 2001, P NATL ACAD SCI USA, V98, P1065, DOI 10.1073/pnas.031561298; EDLUND H, 2001, DIABETES S1, V50, P5; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; Ekawa K, 1997, J MOL ENDOCRINOL, V19, P79, DOI 10.1677/jme.0.0190079; EKKER SC, 1991, EMBO J, V10, P1179, DOI 10.1002/j.1460-2075.1991.tb08058.x; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; GERMAN M, 1995, DIABETES, V44, P1002, DOI 10.2337/diab.44.8.1002; GERMAN MS, 1992, MOL CELL BIOL, V12, P1777, DOI 10.1128/MCB.12.4.1777; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Gerrish K, 2001, J BIOL CHEM, V276, P47775, DOI 10.1074/jbc.M109244200; Glick E, 2000, J BIOL CHEM, V275, P2199, DOI 10.1074/jbc.275.3.2199; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GUZ Y, 1995, DEVELOPMENT, V121, P11; Habener JF, 1998, P ASSOC AM PHYSICIAN, V110, P12; IZBAN MG, 1989, J BIOL CHEM, V264, P9171; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lottmann H, 2001, J MOL MED-JMM, V79, P321, DOI 10.1007/s001090100229; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Macfarlane WM, 2000, J BIOL CHEM, V275, P15330, DOI 10.1074/jbc.M908045199; Madsen OD, 1997, HORM METAB RES, V29, P265, DOI 10.1055/s-2007-979035; MOREL C, 1995, J BIOL CHEM, V270, P3046, DOI 10.1074/jbc.270.7.3039; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Offield MF, 1996, DEVELOPMENT, V122, P983; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; OHLSSON H, 1991, MOL ENDOCRINOL, V5, P897, DOI 10.1210/mend-5-7-897; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Parrizas M, 2001, MOL CELL BIOL, V21, P3234, DOI 10.1128/MCB.21.9.3234-3243.2001; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Peshavaria M, 1997, MOL CELL BIOL, V17, P3987, DOI 10.1128/MCB.17.7.3987; PESHAVARIA M, 1994, MOL ENDOCRINOL, V8, P806, DOI 10.1210/me.8.6.806; Petersen Helle V., 2000, Molecular Cell Biology Research Communications, V3, P249, DOI 10.1006/mcbr.2000.0220; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; PHILIPPE J, 1988, MOL CELL BIOL, V8, P4877, DOI 10.1128/MCB.8.11.4877; POWERS AC, 1990, DIABETES, V39, P406, DOI 10.2337/diabetes.39.4.406; Qiu Y, 2002, MOL CELL BIOL, V22, P412, DOI 10.1128/MCB.22.2.412-420.2002; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sander M, 1997, J MOL MED, V75, P327, DOI 10.1007/s001090050118; Schwitzgebel VM, 2000, DEVELOPMENT, V127, P3533; Serup P, 1996, P NATL ACAD SCI USA, V93, P9015, DOI 10.1073/pnas.93.17.9015; SHELTON KD, 1992, MOL CELL BIOL, V12, P4578, DOI 10.1128/MCB.12.10.4578; Smith SB, 1999, MOL CELL BIOL, V19, P8272; Smith SB, 2000, J BIOL CHEM, V275, P36910, DOI 10.1074/jbc.M005202200; SosaPineda B, 1997, NATURE, V386, P399, DOI 10.1038/386399a0; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Walter J, 1996, P NATL ACAD SCI USA, V93, P2680, DOI 10.1073/pnas.93.7.2680; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 1996, BIOCHEM BIOPH RES CO, V229, P746, DOI 10.1006/bbrc.1996.1875; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217; Xu WZ, 2000, MOL CELL ENDOCRINOL, V170, P79, DOI 10.1016/S0303-7207(00)00329-4	66	257	263	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13286	13293		10.1074/jbc.M111857200	http://dx.doi.org/10.1074/jbc.M111857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11825903	Green Submitted, hybrid			2022-12-25	WOS:000175036300099
J	Lee, KK; Yonehara, S				Lee, KK; Yonehara, S			Phosphorylation and dimerization regulate nucleocytoplasmic shuttling of mammalian STE20-like kinase (MST)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; P21-ACTIVATED PROTEIN-KINASE; CASPASE-MEDIATED ACTIVATION; GERMINAL CENTER KINASE; AMINO-ACID-SEQUENCE; TRANSCRIPTION FACTOR; MAPKAP KINASE-2; APOPTOSIS; STRESS; IDENTIFICATION	Mammalian STE20-like kinase (MST) is a member of the yeast STE20-related kinase family and proteolytically activated by caspase during apoptosis. However, its other cellular functions are not known, including its activation mechanism, substrate(s), and subcellular localization. In this report, using anti-MST monoclonal antibodies, we clearly show that endogenous MST is localized in cytoplasm in a leptomycin B-dependent manner. Analyses with serial deletions and point mutations show that MST has two functional nuclear export signals and, unexpectedly, another localization motif for nuclear import. When cells are treated with leptomycin, monomeric MST is accumulated more rapidly in the nucleus than dimeric MST, indicating that dimerization contributes to the cytoplasmic retention of MST. Okadaic acid, an inhibitor of phosphatase 2A, induces activation of MST and translocation into the nucleus. Using phosphopeptide-specific antibody, we directly show that okadaic acid induces phosphorylation in the activation loop of MST, and, once phosphorylated, MST is rapidly translocated to the nucleus. However, kinase-deficient MST does not enter the nucleus, indicating that phosphorylation and activation is required for okadaic acid-induced nuclear translocation. In apoptotic cells, the activation of MST does not require phosphorylation in the activation loop and occurs through the release of C-terminal regulatory domain by caspase-dependent cleavage. Kinase-deficient MST functions dominant-negatively and represses okadaic acid-induced morphological change indicating that MST plays a role in okadaic acid-induced cellular shrinkage. Our identification of cytoplasmic and nuclear localization motifs and phosphorylation-dependent translocation of MST suggests that regulation of localization is important to the biological function of MST, including its effects on cellular morphology.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Lee, KK (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.							Aurisicchio L, 1998, J BIOL CHEM, V273, P1477, DOI 10.1074/jbc.273.3.1477; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Chen YR, 1999, ONCOGENE, V18, P7370, DOI 10.1038/sj.onc.1203116; Creasy CL, 1996, J BIOL CHEM, V271, P21049, DOI 10.1074/jbc.271.35.21049; CREASY CL, 1995, J BIOL CHEM, V270, P21695, DOI 10.1074/jbc.270.37.21695; Daniels RH, 1999, TRENDS BIOCHEM SCI, V24, P350, DOI 10.1016/S0968-0004(99)01442-5; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; FELDHERR CM, 1994, INT REV CYTOL, V151, P183, DOI 10.1016/S0074-7696(08)62633-9; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lee KK, 2001, J BIOL CHEM, V276, P19276, DOI 10.1074/jbc.M005109200; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McBride KM, 2000, EMBO J, V19, P6196, DOI 10.1093/emboj/19.22.6196; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Reszka AA, 1999, J BIOL CHEM, V274, P34967, DOI 10.1074/jbc.274.49.34967; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 2000, J CELL BIOL, V151, P1449, DOI 10.1083/jcb.151.7.1449; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Taylor LK, 1996, P NATL ACAD SCI USA, V93, P10099, DOI 10.1073/pnas.93.19.10099; Watabe M, 2000, J BIOL CHEM, V275, P8766, DOI 10.1074/jbc.275.12.8766; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	42	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12351	12358		10.1074/jbc.M108138200	http://dx.doi.org/10.1074/jbc.M108138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805089	hybrid			2022-12-25	WOS:000174846400098
J	Wu, YJ; Chen, LW; Zheng, PS; Yang, BB				Wu, YJ; Chen, LW; Zheng, PS; Yang, BB			beta(1)-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-LIKE MOTIFS; ARG-GLY-ASP; SULFATE PROTEOGLYCAN; G1 DOMAIN; G3 DOMAIN; HYALURONIC-ACID; LECTIN DOMAINS; HUMAN VERSICAN; CORE PROTEIN; TENASCIN-R	Integrins are cell-surface glycoproteins that mediate cell activities, including tissue morphogenesis, development, immune response, and cancer, through interaction with extracellular proteins. Here we report a novel means by which integrin signaling and functions are regulated. In pull-down assays and immunoprecipitation, beta(1)-integrin bound to the C-terminal domain of PG-M/versican, an extracellular chondroitin sulfate proteoglycan. This was confirmed by cell-surface binding assays. Binding was calcium- and manganese-dependent. Upon native gel electrophoresis, beta(1)-integrin comigrated with the C-terminal domain of PG-M/versican. The interaction of beta(1)-integrin with the C-terminal domain of PG-M/versican activated focal adhesion kinase, enhanced integrin expression, and promoted cell adhesion. As a result, cells expressing the C-terminal domain of PG-M/versican were resistant to free radical-induced apoptosis. As the PG-M/versican peptide used in this study does not contain the RGD consensus-binding motif for integrins, the mechanism of the observed binding represents an entirely new function.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M4N 3M5, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Yang, BB (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Res Bldg S110,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.							Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Cao L, 1998, MATRIX BIOL, V17, P379, DOI 10.1016/S0945-053X(98)90090-7; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chen LW, 2002, J BIOL CHEM, V277, P2657, DOI 10.1074/jbc.M101153200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Condic ML, 1997, NATURE, V389, P852, DOI 10.1038/39878; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; Domowicz MS, 2000, J BIOL CHEM, V275, P35098, DOI 10.1074/jbc.275.45.35098; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Kiani C, 2002, CELL RES, V12, P19, DOI 10.1038/sj.cr.7290106; Kiani C, 2001, BIOCHEM J, V354, P199, DOI 10.1042/0264-6021:3540199; KIMATA K, 1986, J BIOL CHEM, V261, P3517; KRUSIUS T, 1987, J BIOL CHEM, V262, P13120; LANDOLT RM, 1995, DEVELOPMENT, V121, P2303; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; MARGOLIS RU, 1994, METHOD ENZYMOL, V245, P105; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NASO MF, 1994, J BIOL CHEM, V269, P32999; Olin AI, 2001, J BIOL CHEM, V276, P1253, DOI 10.1074/jbc.M006783200; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; STANLEY P, 1994, EMBO J, V13, P1790, DOI 10.1002/j.1460-2075.1994.tb06447.x; Stigson M, 1997, J BIOL CHEM, V272, P3246, DOI 10.1074/jbc.272.6.3246; Vitale C, 2001, P NATL ACAD SCI USA, V98, P5764, DOI 10.1073/pnas.091097198; Wu YJ, 2001, J BIOL CHEM, V276, P14178, DOI 10.1074/jbc.M100618200; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; Zako M, 1997, J BIOL CHEM, V272, P9325, DOI 10.1074/jbc.272.14.9325; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	49	108	112	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12294	12301		10.1074/jbc.M110748200	http://dx.doi.org/10.1074/jbc.M110748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805102	hybrid			2022-12-25	WOS:000174846400091
J	Zhang, JF; Fu, MG; Zhu, XJ; Xiao, Y; Mou, YS; Zheng, H; Akinbami, MA; Wang, Q; Chen, YE				Zhang, JF; Fu, MG; Zhu, XJ; Xiao, Y; Mou, YS; Zheng, H; Akinbami, MA; Wang, Q; Chen, YE			Peroxisome proliferator-activated receptor delta is up-regulated during vascular lesion formation and promotes post-confluent cell proliferation in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; SIGNALING PATHWAYS; GENE-EXPRESSION; FATTY-ACIDS; PROSTACYCLIN; PHOSPHORYLATION; G(1); INHIBITION; LIGANDS; ALPHA	Although peroxisome proliferator-activated receptor (PPAR) delta is widely expressed in many tissues, the role of PPARdelta is poorly understood. In this study, we report that PPARdelta was up-regulated in vascular smooth muscle cells (VSMC) during vascular lesion formation. By using Northern blot analysis, we demonstrated that PPARdelta was increased by 3-4-fold in VSMC treated with platelet-derived growth factor (PDGF) (20 ng/ml). In addition, PDGF-induced PPARdelta mRNA expression neither needs de novo protein synthesis nor affects the stability of PPARdelta mRNA in VSMC. Preincubation of VSMC with phosphatidylinositol 3-kinase inhibitor (LY294002, 50 mumol/liter) or infection of VSMC with an adenovirus carrying the gene for a dominant negative form of Akt abrogated PDGF-induced PPARdelta mRNA expression, suggesting that phosphatidylinositol 3-kinase/Akt signaling pathway is involved in the regulation of PDGF-induced PPARdelta mRNA expression in VSMC. To explore the role of PPARdelta in VSMC, we generated rat vascular smooth muscle cells (A7r5) stably overexpressing PPARdelta and the control green fluorescent protein. Overexpression of PPARdelta in VSMC increased post-confluent cell proliferation by increasing the cyclin A and CDK2 as well as decreasing p57(kip2). Taken together, the results suggest that PPARdelta plays an important role in the pathology of diseases associated with VSMC proliferation, such as primary atherosclerosis and restenosis.	Morehouse Sch Med, Cardiovasc Res Inst, 720 Westview Dr S W, Atlanta, GA 30310 USA	Morehouse School of Medicine	Chen, YE (corresponding author), Morehouse Sch Med, Cardiovasc Res Inst, 720 Westview Dr S W, Atlanta, GA 30310 USA.	echen@msm.edu			NHLBI NIH HHS [HL03676-02] Funding Source: Medline; NIGMS NIH HHS [S06GM08248] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008248] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams LD, 1999, ARTERIOSCL THROM VAS, V19, P2600, DOI 10.1161/01.ATV.19.11.2600; BAENZIGER NL, 1979, CELL, V16, P967, DOI 10.1016/0092-8674(79)90111-9; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; BROCK TA, 1985, HYPERTENSION, V7, pI105, DOI 10.1161/01.HYP.7.3_Pt_2.I105; Camp HS, 1997, J BIOL CHEM, V272, P10811; CLOWES AW, 1983, LAB INVEST, V49, P208; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Fu MG, 2001, J BIOL CHEM, V276, P45888, DOI 10.1074/jbc.M105490200; Fu MG, 2001, CIRC RES, V89, P1058, DOI 10.1161/hh2301.099642; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Hansen JB, 2001, J BIOL CHEM, V276, P3175, DOI 10.1074/jbc.M005567200; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; HIS LC, 2001, J BIOL CHEM, V276, P34545; INOUE M, 1992, LIFE SCI, V51, P1105, DOI 10.1016/0024-3205(92)90511-M; Jehl-Pietri C, 2000, BIOCHEM J, V350, P93, DOI 10.1042/0264-6021:3500093; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Lemberger T, 1996, ANN NY ACAD SCI, V804, P231, DOI 10.1111/j.1749-6632.1996.tb18619.x; Libby P, 1998, Vasc Med, V3, P225, DOI 10.1177/1358836X9800300309; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; MARCUS AJ, 1978, J BIOL CHEM, V253, P7138; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Skogsberg J, 2000, INT J MOL MED, V6, P73; Sriram V, 2001, CIRCULATION, V103, P2414; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Thommes KB, 1996, EXP CELL RES, V226, P59, DOI 10.1006/excr.1996.0202; Vosper H, 2001, J BIOL CHEM, V276, P44258, DOI 10.1074/jbc.M108482200; Wakino S, 2000, J BIOL CHEM, V275, P22435, DOI 10.1074/jbc.M910452199; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200	45	88	93	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11505	11512		10.1074/jbc.M110580200	http://dx.doi.org/10.1074/jbc.M110580200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11809753	hybrid			2022-12-25	WOS:000174613100096
J	Albert, CJ; Crowley, JR; Hsu, FF; Thukkani, AK; Ford, DA				Albert, CJ; Crowley, JR; Hsu, FF; Thukkani, AK; Ford, DA			Reactive brominating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens - Disparate utilization of sodium halides in the production of alpha-halo fatty aldehydes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; OXIDANT MEMBRANE INJURY; HYDROGEN-PEROXIDE; DIMETHYL-SULFOXIDE; ARACHIDONIC-ACID; ANIMAL-CELLS; PLASMENYLCHOLINE; NEUTROPHILS; PHAGOCYTES; OXIDATION	Plasmalogens are a phospholipid molecular subclass that are enriched in the plasma membrane of many mammalian cells. The present study demonstrates that reactive brominating species produced by myeloperoxidase, as well as activated neutrophils, attack the vinyl ether bond of plasmalogens. Reactive brominating species produced by myeloperoxidase target the vinyl ether bond of plasmalogens, resulting in the production of a neutral lipid and lysophosphatidylcholine. Gas chromatography-mass spectrometry and proton NMR analyses of this neutral lipid demonstrated that it was 2-bromohexadecanal (2-BrHDA). In comparison to myeloperoxidase-generated reactive chlorinating species, reactive brominating species attacked the plasmalogen vinyl ether bond at neutral pH. In the presence of a 20-fold molar excess of NaCl compared with NaBr, myeloperoxidase-derived reactive halogenating species favored the production of 2-BrHDA over that of 2-chlorohexadecanal. Additionally, 2-BrHDA was preferentially produced from plasmalogen treated with hypochlorous acid in the presence of NaBr. The potential physiological significance of this pathway was suggested by the demonstration that both 2-BrHDA and 2-bromooctadecanal were produced by PMA-stimulated neutrophils. Taken together, the present studies demonstrate the targeting of the vinyl ether bond of plasmalogens by the reactive brominating species produced by myeloperoxidase and by activated neutrophils, resulting in the production of novel brominated fatty aldehydes.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL)	Ford, DA (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560; Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042665] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NHLBI NIH HHS [R01 HL 42665-11] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; ARMANI E, 1984, TETRAHEDRON, V40, P2035, DOI 10.1016/S0040-4020(01)88443-X; ARTHUR G, 1986, BIOCHEM J, V236, P475, DOI 10.1042/bj2360475; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr AC, 1996, ARCH BIOCHEM BIOPHYS, V327, P227, DOI 10.1006/abbi.1996.0114; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLARKSON CW, 1983, CIRC RES, V52, P543, DOI 10.1161/01.RES.52.5.543; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; FERRANTE A, 1980, J IMMUNOL METHODS, V36, P109, DOI 10.1016/0022-1759(80)90036-8; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAN XL, 1992, ANAL BIOCHEM, V200, P119, DOI 10.1016/0003-2697(92)90286-G; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Henderson JP, 2001, J BIOL CHEM, V276, P7867, DOI 10.1074/jbc.M005379200; IGARASHI Y, 1990, BIOCHEM BIOPH RES CO, V172, P77, DOI 10.1016/S0006-291X(05)80175-5; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; MANCUSO AJ, 1978, J ORG CHEM, V43, P2480, DOI 10.1021/jo00406a041; MCMASTER CR, 1992, LIPIDS, V27, P945, DOI 10.1007/BF02535569; MORAND OH, 1988, J BIOL CHEM, V263, P11597; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; POST JA, 1988, FEBS LETT, V240, P78, DOI 10.1016/0014-5793(88)80343-0; RIZZO WB, 1991, J CLIN INVEST, V88, P1643, DOI 10.1172/JCI115478; SASAKI Y, 1993, FEBS LETT, V320, P47, DOI 10.1016/0014-5793(93)81655-J; SEDLIS SP, 1983, AM J PHYSIOL, V244, pH32, DOI 10.1152/ajpheart.1983.244.1.H32; SEPE SM, 1985, J IMMUNOL, V134, P1888; SEPE SM, 1985, J IMMUNOL, V134, P1896; TEITZ NW, 1999, TEITZ TXB CLIN CHEM, P2216; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; TINKER JH, 1976, ANESTHESIOLOGY, V44, P194, DOI 10.1097/00000542-197603000-00003; VENABLE ME, 1991, J BIOL CHEM, V266, P18691; Wajon J. E., 1980, WATER CHLORINATION E, V3, P171; WAJON JE, 1982, INORG CHEM, V21, P4258, DOI 10.1021/ic00142a030; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	45	21	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	2002	277	7					4694	4703		10.1074/jbc.M110875200	http://dx.doi.org/10.1074/jbc.M110875200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	523NX	11836259	hybrid			2022-12-25	WOS:000173962900021
J	Deb, D; Scian, M; Roth, KE; Li, W; Keiger, J; Chakraborti, AS; Deb, SP; Deb, S				Deb, D; Scian, M; Roth, KE; Li, W; Keiger, J; Chakraborti, AS; Deb, SP; Deb, S			Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants	ONCOGENE			English	Article						p53; transcriptional activation; repression; oligomerization	WILD-TYPE P53; SUPPRESSOR PROTEIN P53; C-TERMINAL DOMAIN; DNA-BINDING FUNCTION; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; GROWTH SUPPRESSION; KINASE-C; P53-MEDIATED REPRESSION; FUNCTION PHENOTYPE	Tumor-derived p53 mutants activate transcription from promoters of various growth-related genes. We tested whether this transactivation function of the mutant protein is sufficient to induce tumorigenesis ('gain of function'). Tumor-derived mutant p53-281G transactivates. the promoters of human epidermal growth factor receptor (EGFR) and human multiple drug resistance gene (MDR-1). To determine whether the C-terminal domain functions only as an oligomerization domain in mutant p53-mediated transactivation, we have replaced the tetramerization domain of p53 by a heterologous tetramerization domain; although this mutant protein formed tetramers in solution, it failed to transactivate significantly. Therefore, for successful mutant p53-mediated transactivation, sequences near the C-terminus of mutant p53 are required to perform functions in addition to tetramerization. We also demonstrate that co-expression of a deletion mutant of p53 (p53 del 1-293), which retains the p53 oligomerization domain, inhibits this transactivation. p53 del 1-293 co-immunoprecipitates with p53-281G suggesting that hetero-oligomers of p53-281G and p53 del 1-293 are defective in transactivation. We also show that a cell line stably transfected with p53-281G expresses higher levels of endogenous NF-KB and proliferating cell nuclear antigen (PCNA) compared to that transfected with vector alone. On co-expression, p53 del 1-293 lowered the levels of NF-KB and PCNA in p53-281G-expressing cells. However, on co-expression, p53 del 1-293 did not inhibit the tumorigenicity and colony forming ability of p53-281G expressing cells. Our earlier work showed that a deletion of the C-terminal sequences of p53-281G overlapping the oligomerization domain obliterates 'gain of function'. Taken together, the above information suggests that the C-terminal sequences have some critical role in 'gain of function' in addition to transactivation.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Deb, S (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA.	SDEB@HSC.VCU.EDU			NATIONAL CANCER INSTITUTE [R01CA074172, R01CA070712] Funding Source: NIH RePORTER; NCI NIH HHS [CA70712, CA74172] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABARZUA P, 1995, CANCER RES, V55, P3490; Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAUDIER J, 1992, P NATL ACAD SCI USA, V89, P11627, DOI 10.1073/pnas.89.23.11627; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BRAIN R, 1994, ONCOGENE, V9, P1775; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Deb D, 2001, INT J ONCOL, V18, P401; Deb D, 1999, INT J ONCOL, V15, P413; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fourie AM, 1997, J BIOL CHEM, V272, P19471, DOI 10.1074/jbc.272.31.19471; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ishioka C, 1997, BIOCHEM BIOPH RES CO, V232, P54, DOI 10.1006/bbrc.1997.6216; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Johnson MR, 2000, ANAL BIOCHEM, V278, P175, DOI 10.1006/abio.1999.4461; Kelavkar UP, 1999, P NATL ACAD SCI USA, V96, P4378, DOI 10.1073/pnas.96.8.4378; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; Lee KC, 1999, MOL CELL BIOL, V19, P1279; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; LENG P, 1995, ONCOGENE, V10, P1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Prives C, 1999, J PATHOL, V187, P112; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; REED M, 1995, P NATL ACAD SCI USA, V92, P9455, DOI 10.1073/pnas.92.21.9455; Reed Michael, 1993, Gene Expression, V3, P95; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; SANG BC, 1994, ONCOGENE, V9, P853; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SUBLER MA, 1994, ONCOGENE, V9, P1351; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; TAKENAKA I, 1995, J BIOL CHEM, V270, P5405, DOI 10.1074/jbc.270.10.5405; Tanguay RL, 2000, BBA-GENE STRUCT EXPR, V1494, P117, DOI 10.1016/S0167-4781(00)00225-6; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Waterman MJF, 1996, CANCER RES, V56, P158; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Yuan ZM, 1996, J BIOL CHEM, V271, P26457, DOI 10.1074/jbc.271.43.26457; Zhao RB, 2000, GENE DEV, V14, P981; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	91	19	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					176	189		10.1038/sj/onc/1205035	http://dx.doi.org/10.1038/sj/onc/1205035			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803461				2022-12-25	WOS:000173026200002
J	Fratti, RA; Chua, J; Deretic, V				Fratti, RA; Chua, J; Deretic, V			Cellubrevin alterations and Mycobacterium tuberculosis phagosome maturation arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-FUSION; LISTERIA-MONOCYTOGENES; EARLY ENDOSOMES; INTRACELLULAR TRAFFICKING; TETANUS-TOXIN; PHOSPHATIDYLINOSITOL 3-KINASE; INFECTED MACROPHAGES; VESICULAR TRANSPORT; CONTAINING VACUOLES; LYSOSOME FUSION	The intracellular trafficking processes controlling phagosomal maturation remain to be fully delineated. Mycobacterium tuberculosis var. bovis BCG, an organism that causes phagosomal maturation arrest, has emerged as a tool for dissection of critical phagosome biogenesis events. In this work, we report that cellubrevin, a v-SNARE functioning in endosomal recycling and implicated in endosomal interactions with post-Golgi compartments, plays a role in phagosomal maturation and that it is altered on mycobacterial phagosomes. Both mycobacterial phagosomes, which undergo maturation arrest, and model phagosomes containing latex beads, which follow the normal pathway of maturation into phagolysosomes, acquired cellubrevin. However, the mycobacterial and model phagosomes differed, as a discrete proteolytic degradation of this SNARE was detected on mycobacterial phagosomes. The observed cellubrevin alteration on mycobacterial phagosomes was not a passive event secondary to a maturation arrest at another checkpoint of the phagosome maturation pathway, since pharmacological inhibitors of phagosomal/endosomal pathways blocking phagosomal maturation did not cause cellubrevin degradation on model phagosomes. Cellubrevin status on phagosomes had consequences on phagosomal membrane and lumenal content trafficking, involving plasma membrane marker recycling and delivery of lysosomal enzymes. These results suggest that cellubrevin plays a role in phagosomal maturation and that it is a target for modification by mycobacteria or by infection-induced processes in the host cell.	Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA; Univ Michigan, Sch Med, Mol & Cellular Biol Program, Ann Arbor, MI USA; Univ New Mexico, Sch Med, Dept Physiol & Cell Biol, Albuquerque, NM 87131 USA	University of New Mexico; University of Michigan System; University of Michigan; University of New Mexico	Deretic, V (corresponding author), Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, 915 Camino Salud NE, Albuquerque, NM 87131 USA.			Chua, Jennifer/0000-0001-8156-5174; Deretic, Vojo/0000-0002-3624-5208	NIAID NIH HHS [AI45148] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045148] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Alvarez-Dominguez C, 1999, J BIOL CHEM, V274, P11459, DOI 10.1074/jbc.274.17.11459; AlvarezDominguez C, 1996, J BIOL CHEM, V271, P13834, DOI 10.1074/jbc.271.23.13834; AlvarezDominguez C, 1997, J CELL SCI, V110, P731; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Botelho RJ, 2000, J BIOL CHEM, V275, P15717, DOI 10.1074/jbc.M910068199; Bryant NJ, 2001, EMBO J, V20, P3380, DOI 10.1093/emboj/20.13.3380; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; CHAKRABORTY P, 1994, METHOD CELL BIOL, V45, P261; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cossart P, 2001, CURR OPIN IMMUNOL, V13, P96, DOI 10.1016/S0952-7915(00)00188-6; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; Defacque H, 2000, EMBO J, V19, P199, DOI 10.1093/emboj/19.2.199; Deretic V, 1999, MOL MICROBIOL, V31, P1603, DOI 10.1046/j.1365-2958.1999.01279.x; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DHANDAYUTHAPANI S, 1995, MOL MICROBIOL, V17, P901, DOI 10.1111/j.1365-2958.1995.mmi_17050901.x; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Ferrari G, 1999, CELL, V97, P435, DOI 10.1016/S0092-8674(00)80754-0; Fratti RA, 2001, J CELL BIOL, V154, P631, DOI 10.1083/jcb.200106049; Fratti RA, 2000, ELECTROPHORESIS, V21, P3378, DOI 10.1002/1522-2683(20001001)21:16<3378::AID-ELPS3378>3.0.CO;2-B; Fukuda R, 2000, NATURE, V407, P198, DOI 10.1038/35025084; Funato K, 1997, J BIOL CHEM, V272, P16147, DOI 10.1074/jbc.272.26.16147; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gillooly DJ, 2001, J CELL BIOL, V155, P15, DOI 10.1083/jcb.200109001; Hackam DJ, 2001, J BIOL CHEM, V276, P18200, DOI 10.1074/jbc.M102009200; Hackstadt T, 2000, TRAFFIC, V1, P93, DOI 10.1034/j.1600-0854.2000.010201.x; Jahraus A, 1998, J BIOL CHEM, V273, P30379, DOI 10.1074/jbc.273.46.30379; LINK E, 1993, J BIOL CHEM, V268, P18423; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Malik ZA, 2001, J IMMUNOL, V166, P3392, DOI 10.4049/jimmunol.166.5.3392; McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Meresse S, 1999, EMBO J, V18, P4394, DOI 10.1093/emboj/18.16.4394; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; Mukherjee K, 2000, J CELL BIOL, V148, P741, DOI 10.1083/jcb.148.4.741; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Parlati F, 2000, NATURE, V407, P194, DOI 10.1038/35025076; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Predescu SA, 2001, MOL BIOL CELL, V12, P1019, DOI 10.1091/mbc.12.4.1019; RUSSELL DG, 1992, J CELL SCI, V103, P1193; Scidmore MA, 1996, J CELL BIOL, V134, P363, DOI 10.1083/jcb.134.2.363; Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Smith GA, 1997, TRENDS MICROBIOL, V5, P272, DOI 10.1016/S0966-842X(97)01048-2; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; TEYSSEIRE N, 1995, INFECT IMMUN, V63, P366, DOI 10.1128/IAI.63.1.366-374.1995; Ullrich HJ, 2000, J IMMUNOL, V165, P6073, DOI 10.4049/jimmunol.165.11.6073; VANDEURS B, 1995, EUR J CELL BIOL, V66, P309; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Vazquez-Torres A, 2001, P NATL ACAD SCI USA, V98, P2561, DOI 10.1073/pnas.041618998; Via LE, 1998, J CELL SCI, V111, P897; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1998, MOL BIOL CELL, V9, P1549, DOI 10.1091/mbc.9.6.1549; XU SM, 1994, J IMMUNOL, V153, P2568	73	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17320	17326		10.1074/jbc.M200335200	http://dx.doi.org/10.1074/jbc.M200335200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11825909	hybrid			2022-12-25	WOS:000175564500128
J	Linder, JU; Schultz, A; Schultz, JE				Linder, JU; Schultz, A; Schultz, JE			Adenylyl cyclase Rv1264 from Mycobacterium tuberculosis has an autoinhibitory N-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								Mycobacterium tuberculosis contains 15 class III adenylyl cyclase genes. The gene Rv1264 is predicted to be composed of two distinct protein modules. The C terminus seems to code for a catalytic domain belonging to a subfamily of adenylyl. cyclase isozymes mostly found in Gram-positive bacteria. The expressed protein was shown to function as a homodimeric adenylyl cyclase (1 mumol of cAMP.mg(-1).min(-1)). In analogy to the structure of the mammalian adenylyl cyclase catalyst, six amino acids were targeted by point mutations and found to be essential for catalysis. The N-terminal region represents a novel protein domain, the occurrence of which is restricted to several adenylyl cyclases present in Gram-positive bacteria. The purified full-length enzyme was 300-fold less active than the catalytic domain alone. Thus, the N-terminal domain appeared to be autoinhibitory. The N-terminal domain contains three prominent polar amino acid residues (Asp(107), Arg(132), and Arg(191)) that are invariant in all seven sequences of this domain currently available. Mutation of Asp(107) to Ala relaxed the inhibition and resulted in a 6-fold increase in activity of the Rv1264 holoenzyme, thus supporting the role of this domain as a potential novel regulator of adenylyl cyclase activity.	Univ Tubingen, Fak Chem & Pharm, Abt Pharmazeut Biochem, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Linder, JU (corresponding author), Univ Tubingen, Fak Chem & Pharm, Abt Pharmazeut Biochem, Morgenstelle 8, D-72076 Tubingen, Germany.							Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARZU O, 1994, PROG NUCLEIC ACID RE, V49, P241; DANCHIN A, 1993, FEMS MICROBIOL LETT, V114, P145, DOI 10.1016/0378-1097(93)90511-Y; Guo YL, 2001, EMBO J, V20, P3667, DOI 10.1093/emboj/20.14.3667; McCue LA, 2000, GENOME RES, V10, P204, DOI 10.1101/gr.10.2.204; PETERS EP, 1991, MOL MICROBIOL, V5, P1175, DOI 10.1111/j.1365-2958.1991.tb01890.x; Reddy SK, 2001, J BIOL CHEM, V276, P35141, DOI 10.1074/jbc.M104108200; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; TAKAI K, 1974, J BIOL CHEM, V249, P1965; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1999, SCIENCE, V285, P756, DOI 10.1126/science.285.5428.756; Tucker CL, 1998, P NATL ACAD SCI USA, V95, P5993, DOI 10.1073/pnas.95.11.5993; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	16	49	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15271	15276		10.1074/jbc.M200235200	http://dx.doi.org/10.1074/jbc.M200235200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11839758	hybrid			2022-12-25	WOS:000175510400009
J	Pollard, AJ; Krainer, AR; Robson, SC; Europe-Finner, GN				Pollard, AJ; Krainer, AR; Robson, SC; Europe-Finner, GN			Alternative splicing of the adenylyl cyclase stimulatory G-protein G alpha(s) is regulated by SF2/ASF and heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) and involves the use of an unusual TG 3 '-splice site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; SR PROTEINS; IN-VIVO; DOWN-REGULATION; BINDING; ALPHA; EXPRESSION; VARIANTS; EXON; ENHANCERS	The factors involved in regulating alternative splicing of the human adenylyl cyclase stimulatory G-protein Galpha(s) in different cell types remain undefined. We have designed a Galpha(s) minigene that retains the signals required for Galpha(s) alternative splicing in vivo. Employing transient transfection of human myometrial smooth muscle cells and HeLa cells, as well as in vitro splicing assays, we have provided evidence that the antagonistic splicing factors SF2/ASF and hnRNPA1 act as potent regulators of Galpha(s) isoform expression in these cells. Both SF2/ASF and hnRNPA1 control the selection of competing 5'-splice sites and respectively promote inclusion or skipping of the small cassette-type exon 3 of Galpha(s) transcripts, resulting in the generation of Galpha(s)-long and Galpha(s)-short mRNA isoforms. We have also provided evidence that SF2/ASF and hnRNPA1 play a role in T-splice site selection involving the use of a non-canonical TG 3'-splice site preceding exon 4. Using a score-matrix analysis to identify putative exonic enhancer sequences (ESES), we found multiple high score ESE motifs for SF2/ASF, SC35, and SRp40 in exon 3 of Galpha(s). These results suggest that tissue-specific expression of SF2/ASF and hnRNPA1 governs the expression of alternative isoforms of Galpha(s) in these different cells types.	Newcastle Univ, Royal Victoria Infirm, Dept Obstet & Gynaecol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Pollard, AJ (corresponding author), Newcastle Univ, Royal Victoria Infirm, Dept Obstet & Gynaecol, Richardson Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.	A.J.Pollard@ncl.ac.uk.s	europe-finner, Nicholas/F-2569-2010; Robson, Simon C./AAA-8537-2021	Krainer, Adrian/0000-0001-9024-9501				Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; BURGE CB, RNA WORLD, P38; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Chua K, 2001, MOL CELL BIOL, V21, P1509, DOI 10.1128/MCB.21.5.1509-1514.2001; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; EUROPEFINNER GN, 1994, J CLIN ENDOCR METAB, V79, P1835, DOI 10.1210/jc.79.6.1835; EuropeFinner GN, 1996, J CLIN ENDOCR METAB, V81, P1069, DOI 10.1210/jc.81.3.1069; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GRANNEMAN JG, 1991, J NEUROCHEM, V57, P1019, DOI 10.1111/j.1471-4159.1991.tb08252.x; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Hanamura A, 1998, RNA, V4, P430; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; Ichida M, 2000, J BIOL CHEM, V275, P15992, DOI 10.1074/jbc.275.21.15992; KAMMA H, 1995, EXP CELL RES, V221, P187, DOI 10.1006/excr.1995.1366; KILEDJIAN M, 1994, RNA PROTEIN INTERACT, P127; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; MATTERA R, 1989, SCIENCE, V243, P804, DOI 10.1126/science.2536957; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; Mayeda A, 1999, METH MOL B, V118, P315; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Monga M, 1996, BIOL REPROD, V55, P427, DOI 10.1095/biolreprod55.2.427; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; NORTHUP JK, 1980, P NATL ACAD SCI-BIOL, V77, P6516, DOI 10.1073/pnas.77.11.6516; Novotny J, 1998, J MOL ENDOCRINOL, V20, P163, DOI 10.1677/jme.0.0200163; PHANEUF S, 1993, J ENDOCRINOL, V136, P497, DOI 10.1677/joe.0.1360497; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Pollard AJ, 2000, J CLIN ENDOCR METAB, V85, P1928, DOI 10.1210/jc.85.5.1928; PYNE NJ, 1992, BIOCHEM BIOPH RES CO, V186, P1081, DOI 10.1016/0006-291X(92)90857-H; PYNE NJ, 1992, BIOCHEM J, V285, P333, DOI 10.1042/bj2850333; QUAN F, 1990, MOL CELL BIOL, V10, P910, DOI 10.1128/MCB.10.3.910; RAMCHATESINGH J, 1995, MOL CELL BIOL, V15, P4898; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; SCHUBERT B, 1989, SCIENCE, V245, P516, DOI 10.1126/science.2547248; Seeman P, 2000, MOL BRAIN RES, V76, P132, DOI 10.1016/S0169-328X(99)00343-5; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; Stathakis DG, 1999, J NEUROCHEM, V73, P2250, DOI 10.1046/j.1471-4159.1999.0732250.x; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; SUN Q, 1993, GENE DEV, V7, P2598, DOI 10.1101/gad.7.12b.2598; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; Unson CG, 2000, J BIOL CHEM, V275, P21631, DOI 10.1074/jbc.M002093200; WANG J, 1995, RNA, V1, P335; YAGAMI T, 1995, MOL PHARMACOL, V48, P849; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	53	51	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15241	15251		10.1074/jbc.M109046200	http://dx.doi.org/10.1074/jbc.M109046200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11825891	hybrid			2022-12-25	WOS:000175510400006
J	Tell, G; Pines, A; Paron, I; D'Elia, A; Bisca, A; Kelley, MR; Manzini, G; Damante, G				Tell, G; Pines, A; Paron, I; D'Elia, A; Bisca, A; Kelley, MR; Manzini, G; Damante, G			Redox effector factor-1 regulates the activity of thyroid transcription factor 1 by controlling the redox state of the N transcriptional activation domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING ACTIVITY; PROTEIN; REF-1; GENE; THYROTROPIN; EXPRESSION; FRTL-5; PROMOTER; SYSTEM; FOS	Thyroid transcription factor 1 (TTF-1) is a homeodomain-containing transcriptional regulator responsible for the activation of thyroid- and lung-specific genes. It has been demonstrated that its DNA binding activity is redox-regulated in vitro through the formation of dimers and oligomeric species. In this paper, we demonstrate that the redox regulation mainly involves a Cys residue (Cys(87)), which resides out of the DNA binding domain, belonging to the N-transactivation domain. In fact, the oxidized form of a truncated TTF-1 (containing the N-transactivation domain and the DNA-binding domain, here called TTF-1N-HD) looses specific DNA binding activity. Since most of the oxidized TTF-1N-HD is in a monomeric form, these data indicate that the redox state of Cys(87) may control the DNA-binding function of the homeodomain, suggesting that Cys(87) could play an important role in determining the correct folding of the homeodomain. By using gel retardation and transient transfection assays, we demonstrate that the redox effector factor-1 (Ref-1) mediates the redox effects on TTF-1N-HD binding and that it is able to modulate the TTF-1 transcriptional activity. Glutathione S-transferase pull-down experiments demonstrate the occurrence of interaction between Ref-1 and TTF-1N-HD. Having previously demonstrated that Ref-1 is able to modulate the transcriptional activity of another thyroid-specific transcription factor (Pax-8), our data suggest that Ref-1 plays a central role in the regulation of thyroid cells.	Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, I-34127 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA	University of Trieste; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine; Indiana University System; Indiana University-Purdue University Indianapolis	Tell, G (corresponding author), Univ Trieste, Dipartimento Biochim Biofis & Chim Macromol, Via Giorgieri 1, I-34127 Trieste, Italy.	tell@bbcm.univ.trieste.it	P, I/D-8000-2011; Damante, Giuseppe/AAC-5200-2022	Tell, Gianluca/0000-0001-8845-6448; Damante, Giuseppe/0000-0003-2312-4009; Kelley, Mark/0000-0002-6120-9532				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ARNONE MI, 1995, J BIOL CHEM, V270, P12048, DOI 10.1074/jbc.270.20.12048; Asai T, 1997, BIOCHEM BIOPH RES CO, V236, P71, DOI 10.1006/bbrc.1997.6906; BJORKMAN U, 1992, ENDOCRINOLOGY, V130, P393, DOI 10.1210/en.130.1.393; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; Carvalho DP, 1996, ENDOCRINOLOGY, V137, P1007, DOI 10.1210/en.137.3.1007; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; CORVILAIN B, 1991, ENDOCRINOLOGY, V128, P779, DOI 10.1210/endo-128-2-779; DAMANTE G, 1994, NUCLEIC ACIDS RES, V22, P3075, DOI 10.1093/nar/22.15.3075; Damante G, 2001, PROG NUCLEIC ACID RE, V66, P307; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P576, DOI 10.1128/MCB.12.2.576; FRANCISLANG H, 1992, MOL CELL BIOL, V12, P5793, DOI 10.1128/MCB.12.12.5793; Gaiddon C, 1999, EMBO J, V18, P5609, DOI 10.1093/emboj/18.20.5609; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HOFFMAN EK, 1987, MOL CELL BIOL, V7, P2592, DOI 10.1128/MCB.7.7.2592; HUQ I, 1995, MUTAT RES-DNA REPAIR, V337, P191, DOI 10.1016/0921-8777(95)00024-E; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kambe F, 1996, MOL ENDOCRINOL, V10, P801, DOI 10.1210/me.10.7.801; Kimura T, 1997, Am J Physiol, V273, pE639; KIMURA T, 1995, ENDOCRINOLOGY, V136, P116, DOI 10.1210/en.136.1.116; Leseney AM, 1999, BIOCHIMIE, V81, P373, DOI 10.1016/S0300-9084(99)80084-4; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Meira LB, 1997, NAT GENET, V17, P145, DOI 10.1038/ng1097-145; MOLNAR G, 1995, NUCLEIC ACIDS RES, V23, P3318, DOI 10.1093/nar/23.16.3318; Morel Y, 2000, BIOCHEM J, V348, P235, DOI 10.1042/0264-6021:3480235; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; SASSONECORSI P, 1987, NATURE, V326, P507, DOI 10.1038/326507a0; SINCLAIR AJ, 1990, EUR J BIOCHEM, V193, P311, DOI 10.1111/j.1432-1033.1990.tb19339.x; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; Tell G, 2000, NUCLEIC ACIDS RES, V28, P1099, DOI 10.1093/nar/28.5.1099; Tell G, 2000, J MOL ENDOCRINOL, V24, P383, DOI 10.1677/jme.0.0240383; Tell G, 1998, BIOCHEM BIOPH RES CO, V252, P178, DOI 10.1006/bbrc.1998.9548; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; WALKER LJ, 1993, MOL CELL BIOL, V13, P5370, DOI 10.1128/MCB.13.9.5370; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x	39	32	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14564	14574		10.1074/jbc.M200582200	http://dx.doi.org/10.1074/jbc.M200582200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11834746	hybrid			2022-12-25	WOS:000175203000029
J	Dauksaite, V; Akusjarvi, G				Dauksaite, V; Akusjarvi, G			Human splicing factor ASF/SF2 encodes for a repressor domain required for its inhibitory activity on pre-mRNA splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SR PROTEINS; 5-SPLICE-SITE RECOGNITION; PREMESSENGER RNA; COAT PROTEIN; SITE CHOICE; IN-VIVO; BINDING; ENHANCER; FAMILY	The essential splicing factor ASF/SF2 activates or represses splicing depending on where on the pre-mRNA it binds. We have shown previously that ASF/SF2 inhibits adenovirus IIIa pre-mRNA splicing by binding to an intronic repressor element. Here we used MS2-ASF/SF2 fusion proteins to show that the second RNA binding domain (RBD2) is both necessary and sufficient for the splicing repressor function of ASF/SF2. Furthermore, we show that the completely conserved SWQDLKD motif in ASF/SF2-RBD2 is essential for splicing repression. Importantly, this heptapeptide motif is unlikely to be directly involved in RNA binding given its position within the predicted structure of RBD2. The activity of the ASF/SF2-RBD2 domain in splicing was position-dependent. Thus, tethering RBD2 to the IIIa intron resulted in splicing repression, whereas RBD2 binding at the second exon had no effect on IIIa splicing. The splicing repressor activity of RBD2 was not unique to the IIIa pre-mRNA, as binding of RBD2 at an intronic position in the rabbit beta-globin pre-mRNA also resulted in splicing inhibition. Taken together, our results suggest that ASF/SF2 encode distinct domains responsible for its function as a splicing enhancer or splicing repressor protein.	Uppsala Univ, Dept Med Biochem & Microbiol, BMC, S-75123 Uppsala, Sweden	Uppsala University	Akusjarvi, G (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, Box 582, S-75123 Uppsala, Sweden.	goran.akusjarvi@imbim.uu.se						AKUSJARVI G, 1999, RRD VIROLOGY III, V1, P621; Bai YD, 1999, NUCLEIC ACIDS RES, V27, P1126, DOI 10.1093/nar/27.4.1126; BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; CAVALOC Y, 1994, EMBO J, V13, P2639, DOI 10.1002/j.1460-2075.1994.tb06554.x; Chew SL, 1999, P NATL ACAD SCI USA, V96, P10655, DOI 10.1073/pnas.96.19.10655; Cook CR, 1998, VIROLOGY, V242, P211, DOI 10.1006/viro.1997.8983; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Gozani O, 1996, GENE DEV, V10, P233, DOI 10.1101/gad.10.2.233; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Graveley BR, 1998, MOL CELL, V1, P765, DOI 10.1016/S1097-2765(00)80076-3; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kanopka A, 1998, NATURE, V393, P185, DOI 10.1038/30277; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lutzelberger M, 1999, NUCLEIC ACIDS RES, V27, P2618, DOI 10.1093/nar/27.13.2618; Molin M, 2000, J VIROL, V74, P9002, DOI 10.1128/JVI.74.19.9002-9009.2000; Moore DD, 1995, GLOB MOB SURV; MUHLEMANN O, 1999, METH MOLEC MED, V21, P203; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; ROSCIGNO RF, 1995, RNA, V1, P692; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; SenGupta DJ, 1996, P NATL ACAD SCI USA, V93, P8496, DOI 10.1073/pnas.93.16.8496; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; UHLENBECK OC, 1983, J BIOMOL STRUCT DYN, V1, P539, DOI 10.1080/07391102.1983.10507460; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; van Oordt WVH, 2000, NUCLEIC ACIDS RES, V28, P4822, DOI 10.1093/nar/28.24.4822; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; WANG Z, 1995, RNA, V1, P21; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; Yue B G, 2000, Nucleic Acids Res, V28, pE14, DOI 10.1093/nar/28.5.e14; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	43	37	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12579	12586		10.1074/jbc.M107867200	http://dx.doi.org/10.1074/jbc.M107867200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11801589	hybrid			2022-12-25	WOS:000175036300014
J	Tang, DM; Wu, DH; Hirao, AH; Lahti, JM; Liu, LQ; Mazza, B; Kidd, VJ; Mak, TW; Ingram, AJ				Tang, DM; Wu, DH; Hirao, AH; Lahti, JM; Liu, LQ; Mazza, B; Kidd, VJ; Mak, TW; Ingram, AJ			ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; ARF TUMOR-SUPPRESSOR; PROTEIN-KINASE; INDUCED PHOSPHORYLATION; MAP KINASE; RADIOSENSITIZING AGENT; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; SERINE 389; ATM	In response to DNA damage, ataxia-telangiectasia mutant and ataxia-telangiectasia and Rad-3 activate p53, resulting in either cell cycle arrest or apoptosis. We report here that DNA damage stimuli, including etoposide (ETOP), adriamycin (ADR), ionizing irradiation (IR), and ultraviolet irradiation (UV) activate ERK1/2 (ERK) mitogen-activated protein kinase in primary (MEF and IMR90), immortalized (NIH3T3) and transformed (MCF-7) cells. ERR activation in response to ETOP was abolished in ATM-/- fibroblasts (GM05823) and was independent of p53. The MEK1 inhibitor PD98059 prevented ERR activation but not p53 stabilization. Maximal ERR activation in response to DNA damage was not attenuated in MEFP53-1-. However, ERR activation contributes to either cell cycle arrest or apoptosis in response to low or high intensity DNA insults, respectively. Inhibition of ERR activation by PD98059 or U0126 attenuated p21(CIP1) induction, resulting in partial release of the G(2)/M cell cycle arrest induced by ETOP. Furthermore, PD98059 or U0126 also strongly attenuated apoptosis induced by high dose ETOP, ADR, or UV. Conversely, enforced activation of ERR by overexpression of MEK-1/Q56P sensitized cells to DNA damage-induced apoptosis. Taken together, these results indicate that DNA damage activates parallel ERR and p53 pathways in an ATM-dependent manner. These pathways might function cooperatively in cell cycle arrest and apoptosis.	Univ Toronto, Amgen Inst, Toronto, ON M5G 2M9, Canada; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; St Josephs Hosp, Dept Med, Hamilton, ON L8N 1Y2, Canada; St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON L8N 1Y2, Canada; McMaster Univ, Hamilton, ON L8N 1Y2, Canada	University of Toronto; St Jude Children's Research Hospital; McGill University; McMaster University; McGill University; McMaster University; McMaster University	Tang, DM (corresponding author), 708-25 Charlton Ave,E, Hamilton, ON L8N 1Y2, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021	Tang, Damu/0000-0002-3282-9521				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Hall J, 1999, MOL MED TODAY, V5, P157, DOI 10.1016/S1357-4310(99)01435-5; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; HOSHINO R, 2000, J BIOL CHEM, V275, P39435; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lavin MF, 2000, NAT CELL BIOL, V2, pE215, DOI 10.1038/35046628; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lozano G, 2000, NATURE, V404, P24, DOI 10.1038/35003670; MacKeigan JP, 2000, J BIOL CHEM, V275, P38953, DOI 10.1074/jbc.C000684200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; ODWYER PJ, 1985, NEW ENGL J MED, V312, P692, DOI 10.1056/NEJM198503143121106; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; PIPPARD EC, 1988, CANCER RES, V48, P2929; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; SHAFMAN TD, 1995, CANCER RES, V55, P3242; She QB, 2000, J BIOL CHEM, V275, P20444, DOI 10.1074/jbc.M001020200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yang DQ, 2000, NAT CELL BIOL, V2, P893, DOI 10.1038/35046542; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	61	354	372	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12710	12717		10.1074/jbc.M111598200	http://dx.doi.org/10.1074/jbc.M111598200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821415	hybrid			2022-12-25	WOS:000175036300029
J	Haynes, CA; Koder, RL; Miller, AF; Rodgers, DW				Haynes, CA; Koder, RL; Miller, AF; Rodgers, DW			Structures of nitroreductase in three states - Effects of inhibitor binding and reduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI NITROREDUCTASE; MAJOR FLAVIN REDUCTASE; CRYSTAL-STRUCTURE; VIBRIO-FISCHERI; BIOLUMINESCENT BACTERIUM; NAD(P)H-FLAVIN OXIDOREDUCTASE; BIOCHEMICAL-CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; STEADY-STATE; NADH OXIDASE	The crystal structure of the nitroreductase enzyme from Enterobacter cloacae has been determined for the oxidized form in separate complexes with benzoate and acetate inhibitors and for the two-electron reduced form. Nitroreductase is a member of a group of enzymes that reduce a broad range of nitroaromatic compounds and has potential uses in chemotherapy and bioremediation. The monomers of the nitroreductase dimer adopt an alpha+beta fold and together bind two flavin mononucleotide prosthetic groups at the dimer interface. In the oxidized enzyme, the flavin ring system adopts a strongly bent (16degrees) conformation, and the bend increases (25degrees) in the reduced form of the enzyme, roughly the conformation predicted for reduced flavin free in solution. Because free oxidized flavin is planar, the induced bend in the oxidized enzyme may favor reduction, and it may also account for the characteristic inability of the enzyme to stabilize the one electron-reduced semiquinone flavin, which is also planar. Both inhibitors bind over the pyrimidine and central rings of the flavin in partially overlapping sites. Comparison of the two inhibitor complexes shows that a portion of helix H6 can flex to accommodate the differently sized inhibitors suggesting a mechanism for accommodating varied substrates.	Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Ctr Struct Biol, Lexington, KY 40536 USA; Univ Kentucky, Dept Chem, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky; University of Kentucky	Rodgers, DW (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	rodgers@focus.gws.uky.edu	Koder, Ronald L/A-6089-2008; Miller, Anne-Frances/M-7703-2017	Koder, Ronald/0000-0003-0868-4972				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Breinlinger EC, 1998, J AM CHEM SOC, V120, P8606, DOI 10.1021/ja9809556; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYANT C, 1991, J BIOL CHEM, V266, P4119; BRYANT C, 1991, J BIOL CHEM, V266, P4126; BRYANT CP, 1990, THESIS U CALIFORNIA; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cavelier G, 2001, PROTEINS, V43, P420, DOI 10.1002/prot.1055.abs; Chung KT, 1996, ENVIRON MOL MUTAGEN, V27, P67, DOI 10.1002/(SICI)1098-2280(1996)27:1<67::AID-EM9>3.0.CO;2-B; DIXON DA, 1979, BIOCHEMISTRY-US, V18, P5770, DOI 10.1021/bi00593a004; Esteve-Nunez A, 2001, MICROBIOL MOL BIOL R, V65, P335, DOI 10.1128/MMBR.65.3.335-352.2001; FOX KM, 1994, STRUCTURE, V2, P1089, DOI 10.1016/S0969-2126(94)00111-1; Fraaije MW, 2000, TRENDS BIOCHEM SCI, V25, P126, DOI 10.1016/S0968-0004(99)01533-9; FRITCHIE CJ, 1975, ACTA CRYSTALLOGR B, V31, P454, DOI 10.1107/S0567740875003019; GHISLA S, 1989, EUR J BIOCHEM, V181, P1, DOI 10.1111/j.1432-1033.1989.tb14688.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HALL LH, 1987, INT J QUANTUM CHEM, V31, P195, DOI 10.1002/qua.560310203; Hasford JJ, 1997, J ORG CHEM, V62, P5244, DOI 10.1021/jo9703865; HECHT HJ, 1995, NAT STRUCT BIOL, V2, P1109, DOI 10.1038/nsb1295-1109; INOUYE S, 1994, FEBS LETT, V347, P163, DOI 10.1016/0014-5793(94)00528-1; ISAYA G, 1991, J CELL BIOL, V113, P65, DOI 10.1083/jcb.113.1.65; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS PA, 1989, J MOL BIOL, V210, P163, DOI 10.1016/0022-2836(89)90298-2; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KNOX RJ, 1993, CANCER METAST REV, V12, P195, DOI 10.1007/BF00689810; Kobori T, 2001, J BIOL CHEM, V276, P2816, DOI 10.1074/jbc.M002617200; Koder RL, 1998, BBA-PROTEIN STRUCT M, V1387, P395, DOI 10.1016/S0167-4838(98)00151-4; Koder RL, 1998, PROTEIN EXPRES PURIF, V13, P53, DOI 10.1006/prep.1997.0866; KODER RL, 1999, THESIS J HOPKINS U B; Koike H, 1998, J MOL BIOL, V280, P259, DOI 10.1006/jmbi.1998.1871; KUO MC, 1974, ACTA CRYSTALLOGR B, VB 30, P1766, DOI 10.1107/S0567740874005772; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Lennon BW, 1999, PROTEIN SCI, V8, P2366; LI RB, 1995, P NATL ACAD SCI USA, V92, P8846, DOI 10.1073/pnas.92.19.8846; Liochev SI, 1999, P NATL ACAD SCI USA, V96, P3537, DOI 10.1073/pnas.96.7.3537; Lovering AL, 2001, J MOL BIOL, V309, P203, DOI 10.1006/jmbi.2001.4653; Ludwig ML, 1997, BIOCHEMISTRY-US, V36, P1259, DOI 10.1021/bi962180o; MASSEY V, 1969, J BIOL CHEM, V244, P3999; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MCCALLA DR, 1971, BIOCHEM PHARMACOL, V20, P3532, DOI 10.1016/0006-2952(71)90459-X; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Meyer M, 1996, J MOL STRUC-THEOCHEM, V364, P139, DOI 10.1016/0166-1280(96)04491-0; MICHAEL NP, 1994, FEMS MICROBIOL LETT, V124, P195, DOI 10.1111/j.1574-6968.1994.tb07284.x; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4868, DOI 10.1021/bi00316a008; MOONEN CTW, 1984, BIOCHEMISTRY-US, V23, P4859, DOI 10.1021/bi00316a007; MULLER F, 1991, CHEM BIOCH FLAVOENZY, V1, P2; MULLER YA, 1994, J MOL BIOL, V237, P315, DOI 10.1006/jmbi.1994.1233; Murthy YVSN, 1996, J BIOL CHEM, V271, P19915, DOI 10.1074/jbc.271.33.19915; Nakai S, 1999, THEOR CHEM ACC, V103, P109, DOI 10.1007/s002140050521; Niculescu-Duvaz I, 1999, ANTI-CANCER DRUG DES, V14, P517; NISHINO SF, 1993, APPL ENVIRON MICROB, V59, P2520, DOI 10.1128/AEM.59.8.2520-2525.1993; NORRESTAM R, 1972, ACTA CRYSTALL B-STRU, VB 28, P440, DOI 10.1107/S0567740872002547; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAI EF, 1988, BIOCHEMISTRY-US, V27, P4465, DOI 10.1021/bi00412a038; PARK HJ, 1993, EUR J BIOCHEM, V211, P909; PARK HJ, 1992, EUR J BIOCHEM, V205, P881, DOI 10.1111/j.1432-1033.1992.tb16853.x; Parkinson GN, 2000, J MED CHEM, V43, P3624, DOI 10.1021/jm000159m; PLATENKAMP RJ, 1987, EUR BIOPHYS J BIOPHY, V14, P393, DOI 10.1007/BF00254862; PORTER DJT, 1978, ACTA CRYSTALLOGR B, V34, P598, DOI 10.1107/S056774087800360X; PROCHASKA KJ, 1991, OXIDATIVE STRESS OXI, P195; Purohit V, 2000, CHEM RES TOXICOL, V13, P673, DOI 10.1021/tx000002x; Rafii F, 1998, ANTIMICROB AGENTS CH, V42, P1121, DOI 10.1128/AAC.42.5.1121; RICKERT DE, 1987, DRUG METAB REV, V18, P23, DOI 10.3109/03602538708998299; Rodgers DW, 1997, METHOD ENZYMOL, V276, P183, DOI 10.1016/S0076-6879(97)76059-2; Rodgers JD, 2001, WATER RES, V35, P2101, DOI 10.1016/S0043-1354(00)00505-4; Sera N, 1996, MUTAT RES-FUND MOL M, V349, P137, DOI 10.1016/0027-5107(95)00173-5; SPAIN JC, 1995, ANNU REV MICROBIOL, V49, P523, DOI 10.1146/annurev.mi.49.100195.002515; STEWART RC, 1985, J BIOL CHEM, V260, P3639; Tanner JJ, 1996, BIOCHEMISTRY-US, V35, P13531, DOI 10.1021/bi961400v; TEDESCHI G, 1995, J BIOL CHEM, V270, P1198, DOI 10.1074/jbc.270.3.1198; TOKIWA H, 1986, CRIT REV TOXICOL, V17, P23, DOI 10.3109/10408448609037070; Trickey P, 2000, BIOCHEMISTRY-US, V39, P7678, DOI 10.1021/bi9927181; TRUS BL, 1969, ACTA CRYSTALL B-STRU, VB 25, P1911, DOI 10.1107/S0567740869004900; VAZQUEZ SA, 1992, J CHEM SOC P2, V6, P889; WATANABE M, 1990, NUCLEIC ACIDS RES, V18, P1059, DOI 10.1093/nar/18.4.1059; WOUTERS J, 1994, J CHEM CRYSTALLOGR, V24, P607, DOI 10.1007/BF01671675; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994; Zenno S, 1996, J BIOCHEM-TOKYO, V120, P736; Zenno S, 1996, J BACTERIOL, V178, P4508, DOI 10.1128/jb.178.15.4508-4514.1996; Zenno SH, 1996, J BACTERIOL, V178, P4731, DOI 10.1128/jb.178.15.4731-4733.1996; Zheng YJ, 1996, J AM CHEM SOC, V118, P9402, DOI 10.1021/ja9608151	81	112	115	2	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11513	11520		10.1074/jbc.M111334200	http://dx.doi.org/10.1074/jbc.M111334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805110	hybrid			2022-12-25	WOS:000174613100097
J	Yu, XX; Lewin, DA; Forrest, W; Adams, SH				Yu, XX; Lewin, DA; Forrest, W; Adams, SH			Cold elicits the simultaneous induction of fatty acid synthesis and beta-oxidation in murine brown adipose tissue: prediction from differential gene expression and confirmation in vivo	FASEB JOURNAL			English	Article						PPAR; glucose transport; obesity; ACC	COENZYME-A CARBOXYLASE; MITOCHONDRIAL RESPIRATION; PYRUVATE-DEHYDROGENASE; GLYCEROLIPID SYNTHESIS; GLUCOSE-TRANSPORTER; UNCOUPLING PROTEIN; RAT; EXPOSURE; INSULIN; INVIVO	A survey of genes differentially expressed in the brown adipose tissue (BAT) of mice exposed to a range of environmental temperatures was carried out to identify novel genes and pathways associated with the transition of this tissue toward an amplified thermogenic state. The current report focuses on an analysis of the expression patterns of 50 metabolic genes in BAT under control conditions (22degrees C), cold exposure (4degrees C, 1 to 48 h), warm acclimation (33degrees C, 3 wk), or food restriction/meal feeding (animals fed the same amount as warm mice). In general, expression of genes encoding proteins involving glucose uptake and catabolism was significantly elevated in the BAT of cold-exposed mice. The levels of mRNAs encoding proteins critical to de novo lipogenesis were also increased. Gene expression for enzymes associated with procurement and combustion of long chain fatty acids (LCFAs) was increased in the cold. Thus, a model was proposed in which coordinated activation of glucose uptake, fatty acid synthesis, and fatty acid combustion occurs as part of the adaptive thermogenic processes in BAT. Confirmation emerged from in vivo assessments of cold-induced changes in BAT 2-deoxyglucose uptake (increased 2.7-fold), BAT lipogenesis (2.8-fold higher), and incorporation of LCFA carboxyl-carbon into BAT water-soluble metabolites (elevated similar totwofold). It is proposed that temperature-sensitive regulation of distinct intracellular malonyl-CoA pool sizes plays an important role in driving this unique metabolic profile via maintenance of the lipogenic pool but diminution of the carnitine palmitoyltransferase 1 inhibitory pool under cold conditions.	Genentech Inc, Dept Endocrinol, San Francisco, CA 94080 USA; Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA; CuraGen Corp, Dept Collaborat Res, New Haven, CT 06511 USA	Roche Holding; Genentech; Roche Holding; Genentech	Adams, SH (corresponding author), Novartis Pharmaceut Corp, Metab & Cardiovasc Dis Pharmacol Dept, 556 Morris Ave, Summit, NJ 07901 USA.	adams@pharma.novartis.com	ADAMS, SEAN/N-9262-2018	ADAMS, SEAN/0000-0002-9515-2319				Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Adams SH, 2001, BIOCHEM J, V360, P135, DOI 10.1042/bj3600135; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; BUCKLEY MG, 1987, BIOCHEM J, V243, P437, DOI 10.1042/bj2430437; Clarke SD, 2001, J NUTR, V131, P1129, DOI 10.1093/jn/131.4.1129; Daikoku T, 2000, BBA-BIOENERGETICS, V1457, P263, DOI 10.1016/S0005-2728(00)00107-9; DARNLEY AC, 1988, BIOCHEM J, V253, P351, DOI 10.1042/bj2530351; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fukuda H, 1999, J BIOCHEM-TOKYO, V126, P437, DOI 10.1093/oxfordjournals.jbchem.a022469; GRANNEMAN JG, 1992, ENDOCRINOLOGY, V130, P109, DOI 10.1210/en.130.1.109; Guardiola-Diaz HM, 1999, J BIOL CHEM, V274, P23368, DOI 10.1074/jbc.274.33.23368; Guerra C, 1998, J CLIN INVEST, V102, P1724, DOI 10.1172/JCI4532; HIMMSHAGEN J, 1965, CAN J PHYSIOL PHARM, V43, P379, DOI 10.1139/y65-039; HIMMSHAGEN J, 1985, AM J PHYSIOL, V248, pE531, DOI 10.1152/ajpendo.1985.248.5.E531; HIMMSHAGEN J, 1998, HDB OBESITY; HOM FG, 1984, DIABETES, V33, P141, DOI 10.2337/diabetes.33.2.141; Klingenberg M, 1999, J BIOENERG BIOMEMBR, V31, P419, DOI 10.1023/A:1005440221914; KNIGHT BL, 1972, BIOCHEM J, V129, P1175, DOI 10.1042/bj1291175; Mardia K., 1979, MULTIVARIATE ANAL, V15, P518; MARETTE A, 1990, INT J OBESITY, V14, P857; MARETTE A, 1991, BIOCHEM J, V277, P119, DOI 10.1042/bj2770119; MASORO EJ, 1963, FED PROC, V22, P868; MCCORMACK JG, 1977, BIOCHEM J, V166, P627, DOI 10.1042/bj1660627; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MITCHELL JRD, 1991, BIOCHEM J, V277, P665, DOI 10.1042/bj2770665; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Ntambi JM, 1999, J LIPID RES, V40, P1549; OMATSUKANBE M, 1992, FEBS LETT, V314, P246, DOI 10.1016/0014-5793(92)81481-Z; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; RATH EA, 1979, FEBS LETT, V108, P33, DOI 10.1016/0014-5793(79)81172-2; Reszko AE, 2001, ANAL BIOCHEM, V298, P69, DOI 10.1006/abio.2001.5349; REVELLI JP, 1992, BIOCHEM J, V286, P743, DOI 10.1042/bj2860743; Saha AK, 2000, J BIOL CHEM, V275, P24279, DOI 10.1074/jbc.C000291200; SHIMIZU Y, 1993, AM J PHYSIOL, V264, pE890, DOI 10.1152/ajpendo.1993.264.6.E890; SHIMIZU Y, 1991, J BIOCHEM, V110, P688, DOI 10.1093/oxfordjournals.jbchem.a123642; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; STANSBIE D, 1976, BIOCHEM J, V160, P413, DOI 10.1042/bj1600413; STEINER G, 1964, AM J PHYSIOL, V207, P840, DOI 10.1152/ajplegacy.1964.207.4.840; TAKAHASHI A, 1992, JPN J PHYSIOL, V42, P653, DOI 10.2170/jjphysiol.42.653; TRAYHURN P, 1979, FEBS LETT, V104, P13, DOI 10.1016/0014-5793(79)81075-3; VALLERAND AL, 1987, AM J PHYSIOL, V253, pE179, DOI 10.1152/ajpendo.1987.253.2.E179; VALLERAND AL, 1990, AM J PHYSIOL, V259, pR1043, DOI 10.1152/ajpregu.1990.259.5.R1043; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Yu XX, 2001, BIOCHEM J, V353, P369, DOI 10.1042/bj3530369; Yu XX, 2000, AM J PHYSIOL-ENDOC M, V279, pE433, DOI 10.1152/ajpendo.2000.279.2.E433	47	154	156	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					155	168		10.1096/fj.01-0568com	http://dx.doi.org/10.1096/fj.01-0568com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818363				2022-12-25	WOS:000174203700020
J	Levy, E; Stan, S; Delvin, E; Menard, D; Shoulders, C; Garofalo, C; Slight, I; Seidman, E; Mayer, G; Bendayan, M				Levy, E; Stan, S; Delvin, E; Menard, D; Shoulders, C; Garofalo, C; Slight, I; Seidman, E; Mayer, G; Bendayan, M			Localization of microsomal triglyceride transfer protein in the Golgi - Possible role in the assembly of chylomicrons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; B-CONTAINING LIPOPROTEINS; PRIMARY RAT HEPATOCYTES; FATTY-ACID DEFICIENCY; HEP G2 CELLS; APOLIPOPROTEIN-B; ENDOPLASMIC-RETICULUM; APO-B; INTRACELLULAR PHASES; DISULFIDE ISOMERASE	Although a critical role of microsomal transfer protein (MTP) has been recognized in the assembly of nascent apolipoprotein B (apoB) -containing lipoproteins, it remains unclear where and how MTP transfers lipids in the secretory pathway during the maturational process of apoB lipidation. The aims of this study were to determine whether MTP functions in the secretory pathway as well as in the endoplasmic reticulum and whether its large 97-kDa subunit interacts with the small 58-kDa protein disulfide isomerase (PDI) subunit and apoB, particularly in the Golgi apparatus. Using a high resolution immunogold approach combined with specific polyclonal antibodies, the large and small subunits of MTP were observed over the rough endoplasmic reticulum and the Golgi. Double immunocytochemical detection unraveled the colocalization of MTP and PDI as well as MTP and apoB in these same subcellular compartments. To confirm the spatial contact of these proteins, Golgi fractions were isolated, homogenized, and incubated with an anti-MTP large subunit antibody. Immunoprecipitates were applied on SDS-PAGE and then transferred on to nitrocellulose. Immunoblotting the membrane with PDI and apoB antibodies confirmed the colocalization of these proteins with MTP. Furthermore, MTP activity assay disclosed a substantial triglyceride transfer in the Golgi fractions. The occurrence of membrane-associated apoB in the Golgi, coupled with its interaction with active MTP, suggests an important role for the Golgi in the biogenesis of apoB-containing lipoproteins.	Hop St Justine, Dept Nutr, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Dept Biochem, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Dept Pathol, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Dept Cell Biol, Montreal, PQ H3T 1C5, Canada; Univ Montreal, Montreal, PQ H3T 1C5, Canada; Univ Sherbrooke, Fac Med, Canadian Inst Hlth Res, Grp Funct Dev & Physiopathol Digest Tract, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Fac Med, Dept Cellular Biol, Sherbrooke, PQ J1H 5N4, Canada; Hammersmith Hosp, Dept Med, London W12 0NN, England	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Institute for Work & Health; University of Sherbrooke; University of Sherbrooke; Imperial College London	Levy, E (corresponding author), Hop St Justine, Dept Nutr, Montreal, PQ H3T 1C5, Canada.							ALEXANDER CA, 1976, J CELL BIOL, V69, P241, DOI 10.1083/jcb.69.2.241; BAMBERGER MJ, 1990, P NATL ACAD SCI USA, V87, P2390, DOI 10.1073/pnas.87.7.2390; BAMBERGER MJ, 1988, J BIOL CHEM, V263, P11868; BENDAYAN M, 1984, J ELECTRON MICR TECH, V1, P243, DOI 10.1002/jemt.1060010304; BENDAYAN M, 1982, J HISTOCHEM CYTOCHEM, V30, P81, DOI 10.1177/30.1.6172469; BENDAYAN M, 1995, PROG HISTOCHEM CYTOC, V29, P1; Benoist F, 1997, J BIOL CHEM, V272, P20435, DOI 10.1074/jbc.272.33.20435; BLACK DD, 1991, GASTROENTEROLOGY, V101, P520, DOI 10.1016/0016-5085(91)90033-H; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BOSTROM K, 1986, J BIOL CHEM, V261, P3800; Bruneau N, 2000, MICROSC RES TECHNIQ, V49, P329, DOI 10.1002/(SICI)1097-0029(20000515)49:4<329::AID-JEMT2>3.0.CO;2-H; Davidson Nicholas O., 1994, P1909; FAST DG, 1995, BBA-LIPID LIPID MET, V1258, P159, DOI 10.1016/0005-2760(95)00116-T; Gibbons Geoffrey F., 1994, Current Opinion in Lipidology, V5, P191, DOI 10.1097/00041433-199405030-00006; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gordon DA, 1996, J BIOL CHEM, V271, P33047, DOI 10.1074/jbc.271.51.33047; HAMILTON RL, 1991, J LIPID RES, V32, P529; Hebbachi AM, 1999, J LIPID RES, V40, P1758; Hebbachi AM, 1999, BBA-MOL CELL BIOL L, V1441, P36, DOI 10.1016/S1388-1981(99)00138-9; HIGGINS JA, 1988, FEBS LETT, V232, P405, DOI 10.1016/0014-5793(88)80780-4; Hussain MM, 1998, J BIOL CHEM, V273, P25612, DOI 10.1074/jbc.273.40.25612; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; JANERO DR, 1983, J BIOL CHEM, V258, P4496; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LEVY E, 1992, CAN J PHYSIOL PHARM, V70, P413, DOI 10.1139/y92-052; Levy E, 1996, FEBS LETT, V393, P253, DOI 10.1016/0014-5793(96)00896-4; LEVY E, 1987, GASTROENTEROLOGY, V93, P1119, DOI 10.1016/0016-5085(87)90577-4; Levy E, 1996, CLIN INVEST MED, V19, P317; LEVY E, 1990, J LIPID RES, V31, P1937; LEVY E, 1992, AM J PHYSIOL, V262, pG319, DOI 10.1152/ajpgi.1992.262.2.G319; Levy E, 1996, HEPATOLOGY, V23, P848, DOI 10.1002/hep.510230428; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Marks DL, 1999, J BIOL CHEM, V274, P451, DOI 10.1074/jbc.274.1.451; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; OLOFSSON SO, 1987, ATHEROSCLEROSIS, V68, P1, DOI 10.1016/0021-9150(87)90088-8; Patel SB, 1996, J BIOL CHEM, V271, P18686, DOI 10.1074/jbc.271.31.18686; RUSINOL A, 1993, J BIOL CHEM, V268, P3555; RUSTAEUS S, 1995, J BIOL CHEM, V270, P28879, DOI 10.1074/jbc.270.48.28879; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; SWIFT LL, 1995, J LIPID RES, V36, P395; Tso Patrick, 1994, P1867; VERKADE HJ, 1993, J BIOL CHEM, V268, P24980; WANG CN, 1995, J BIOL CHEM, V270, P24924, DOI 10.1074/jbc.270.42.24924; Wang YW, 1997, J BIOL CHEM, V272, P12272, DOI 10.1074/jbc.272.19.12272; WETTERAU JR, 1992, SCIENCE, V258, P999; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P9728, DOI 10.1021/bi00104a023; WETTERAU JR, 1985, CHEM PHYS LIPIDS, V38, P205, DOI 10.1016/0009-3084(85)90068-4; Wetterau JR, 1997, BBA-LIPID LIPID MET, V1345, P136, DOI 10.1016/S0005-2760(96)00168-3; WETTERAU JR, 1991, BIOCHEMISTRY-US, V30, P4406, DOI 10.1021/bi00232a006; Wu JS, 1999, J LIPID RES, V40, P955; Wu XJ, 1996, J BIOL CHEM, V271, P10277, DOI 10.1074/jbc.271.17.10277; Young SG, 1996, METHOD ENZYMOL, V263, P120	59	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16470	16477		10.1074/jbc.M102385200	http://dx.doi.org/10.1074/jbc.M102385200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11830580	hybrid			2022-12-25	WOS:000175564500019
J	Kaminski, PA				Kaminski, PA			Functional cloning, heterologous expression, and purification of two different N-deoxyribosyltransferases from Lactobacillus helveticus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-HIV ACTIVITY; NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE; ENZYMATIC-SYNTHESIS; ESCHERICHIA-COLI; DEOXYNUCLEOSIDE KINASES; SUBSTRATE-SPECIFICITY; KINETIC-ANALYSIS; AMINO-ACID; DEOXYRIBOSYLASE; LEICHMANNII	Lactobacillus helveticus contains two types of N-deoxyribosyltransferases: DRTase I catalyzes the transfer of 2'-deoxyribose between purine bases exclusively whereas DRTase II is able to transfer the 2'-deoxyribose between two pyrimidine or between pyrimidine and purine bases. An Escherichia coli strain, auxotrophic for guanine and unable to use deoxyguanosine as source of guanine, was constructed to clone the corresponding genes. By screening a genomic bank for the production of guanine, the L. helveticus ptd and ntd genes coding for DRTase I and II, respectively, were isolated. Although the two genes have no sequence similarity, the two deduced polypeptides display 25.6% identity, with most of the residues involved in substrate binding and the active site nucleophile Glu-98 being conserved. Overexpression and purification of the two proteins shows that DRTase I is specific for purines with a preference for deoxyinosine (dI) > deoxyadenosine > deoxyguanosine as donor substrates whereas DRTase II has a strong preference for pyrimidines as donor substrates and purines as base acceptors. Purine analogues were substrates as acceptor bases for both enzymes. Comparison of DRTase I and DRTase II activities with dI as donor or hypoxanthine as acceptor and colocalization of the ptd and add genes suggest a specific role for DRTase I in the metabolism of dI.	Inst Pasteur, CNRS, Unite Rech Associee 2128, Unite Chim Organ, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kaminski, PA (corresponding author), Inst Pasteur, CNRS, Unite Rech Associee 2128, Unite Chim Organ, 25-28 Rue Dr Roux, F-75724 Paris 15, France.			Kaminski, Pierre Alexandre/0000-0001-9841-6837				Andersen RB, 2001, J BIOL CHEM, V276, P5518, DOI 10.1074/jbc.M007918200; Armstrong SR, 1996, STRUCTURE, V4, P97, DOI 10.1016/S0969-2126(96)00013-5; BECK W, 1963, J BIOL CHEM, V238, P702; Becker J, 1996, BIOL CHEM H-S, V377, P357, DOI 10.1515/bchm3.1996.377.6.357; BETBEDER D, 1989, NUCLEIC ACIDS RES, V17, P4217, DOI 10.1093/nar/17.11.4217; BETBEDER D, 1990, NUCLEOS NUCLEOT, V9, P569, DOI 10.1080/07328319008045188; CARDINAUD R, 1979, BIOCHIM BIOPHYS ACTA, V568, P339, DOI 10.1016/0005-2744(79)90301-2; CARSON DA, 1988, BIOCHEM BIOPH RES CO, V155, P829, DOI 10.1016/S0006-291X(88)80570-9; CHANG Z, 1991, BIOCHEMISTRY-US, V30, P2273, DOI 10.1021/bi00222a033; Chaveroche MK, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.22.e97; CHAWDHRI RF, 1991, ARCH MICROBIOL, V155, P409, DOI 10.1007/BF00243463; COOK WJ, 1990, J BIOL CHEM, V265, P2682; DANZIN C, 1974, EUR J BIOCHEM, V48, P255, DOI 10.1111/j.1432-1033.1974.tb03763.x; DANZIN C, 1976, EUR J BIOCHEM, V65, P365; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; FREEMAN GA, 1995, BIOORGAN MED CHEM, V3, P447, DOI 10.1016/0968-0896(95)00030-K; HAMMERJESPERSEN K, 1980, MOL GEN GENET, V179, P341, DOI 10.1007/BF00425462; HAMMERJESPERSEN K, 1987, METABOLISM NUCLEOTID, P244; HICKS N, 1992, ANTIVIR CHEM CHEMOTH, V3, P153, DOI 10.1177/095632029200300304; HOLGUIN J, 1975, EUR J BIOCHEM, V54, P505, DOI 10.1111/j.1432-1033.1975.tb04163.x; HUANG MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P133, DOI 10.1016/0003-9861(83)90510-6; HUANG MC, 1981, BIOCHEM PHARMACOL, V30, P2663, DOI 10.1016/0006-2952(81)90535-9; Ives DH, 1998, PROG NUCLEIC ACID RE, V59, P205; LEMEIGNAN B, 1993, J MOL BIOL, V231, P161, DOI 10.1006/jmbi.1993.1269; MACNUTT WS, 1952, BIOCHEM J, V50, P384, DOI 10.1042/bj0500384; Miller J.H., 1972, EXPT MOL GENETICS; Okuyama K, 2000, BIOSCI BIOTECH BIOCH, V64, P2243, DOI 10.1271/bbb.64.2243; POCHET S, 1995, BIOORG MED CHEM LETT, V5, P1679, DOI 10.1016/0960-894X(95)00280-7; PORTER DJT, 1995, J BIOL CHEM, V270, P15557, DOI 10.1074/jbc.270.26.15557; PORTER DJT, 1995, J BIOL CHEM, V270, P15551, DOI 10.1074/jbc.270.26.15551; POWELL JW, 1973, APPL MICROBIOL, V25, P869, DOI 10.1128/AEM.25.6.869-872.1973; RICHAUD C, 1993, J BIOL CHEM, V268, P26827; ROUSH AH, 1958, J BIOL CHEM, V233, P261; SMAR M, 1991, BIOCHEMISTRY-US, V30, P7908, DOI 10.1021/bi00246a006; STEENKAMP DJ, 1992, BIOCHEM J, V287, P125, DOI 10.1042/bj2870125; STEENKAMP DJ, 1991, EUR J BIOCHEM, V197, P431, DOI 10.1111/j.1432-1033.1991.tb15929.x; UHLAND K, 1994, J BACTERIOL, V176, P4565, DOI 10.1128/JB.176.15.4565-4571.1994; VALENTINHANSEN P, 1978, MOL GEN GENET, V159, P191, DOI 10.1007/BF00270893	38	44	51	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14400	14407		10.1074/jbc.M111995200	http://dx.doi.org/10.1074/jbc.M111995200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836245	hybrid			2022-12-25	WOS:000175203000009
J	Papinutto, E; Dundon, WG; Pitulis, N; Battistutta, R; Montecucco, C; Zanotti, G				Papinutto, E; Dundon, WG; Pitulis, N; Battistutta, R; Montecucco, C; Zanotti, G			Structure of two iron-binding proteins from Bacillus anthracis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICOBACTER-PYLORI; TREPONEMA-PALLIDUM; HP-NAP; FERRITIN; SUBTILIS; GENE; DPS	Bacillus anthracis is currently under intense investigation due to its primary importance as a human pathogen. Particularly important is the development of novel anti-anthrax vaccines, devoid of the current side effects. A novel class of immunogenic bacterial proteins consists of dodecamers homologous to the DNA-binding protein of Escherichia coli (Dps). Two Dps homologous genes are present in the B. anthracis genome. The crystal structures of these two proteins (Dlp-1 and Dlp-2) have been determined and are presented here. They are sphere-like proteins with an internal cavity. We also show that they act as ferritins and are thus involved in iron uptake and regulation, a fundamental function during bacterial growth.	Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Padua, CNR, Ctr Biopolimeri, I-35131 Padua, Italy; Univ Padua, CNR, Ctr Biomembrane, I-35121 Padua, Italy; Univ Padua, Dipartimento Sci Biomed, I-35121 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua	Zanotti, G (corresponding author), Univ Padua, Dept Organ Chem, Via Marzolo 1, I-35131 Padua, Italy.	giuseppe.zanotti@unipd.it		Zanotti, Giuseppe/0000-0002-0945-6501; Dundon, William G./0000-0002-2776-169X				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; Antelmann H, 1997, J BACTERIOL, V179, P7251, DOI 10.1128/jb.179.23.7251-7256.1997; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLINI AV, 1991, J BIOTECHNOL, V18, P177, DOI 10.1016/0168-1656(91)90246-R; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; Brentjens RJ, 1996, J BACTERIOL, V178, P808, DOI 10.1128/jb.178.3.808-816.1996; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN ZG, 1995, J NEUROVIROL, V1, P295, DOI 10.3109/13550289509114026; Del Giudice G, 2001, ANNU REV IMMUNOL, V19, P523, DOI 10.1146/annurev.immunol.19.1.523; Dundon WG, 2001, FEMS MICROBIOL LETT, V199, P143, DOI 10.1016/S0378-1097(01)00174-4; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hayes S C, 2000, J R Army Med Corps, V146, P191; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEONG LM, 1992, ANAL BIOCHEM, V207, P317, DOI 10.1016/0003-2697(92)90018-3; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; LUFT BJ, 1989, INFECT IMMUN, V57, P3637, DOI 10.1128/IAI.57.11.3637-3645.1989; *MOL SIM INC, QUANT REL 2000; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NOORDHOEK GT, 1989, MICROB PATHOGENESIS, V6, P29, DOI 10.1016/0882-4010(89)90005-3; REDINBO MR, 1993, ACTA CRYSTALLOGR D, V49, P375, DOI 10.1107/S090744499300294X; Satin B, 2000, J EXP MED, V191, P1467, DOI 10.1084/jem.191.9.1467; Swanson-Biearman B, 2001, J TOXICOL-CLIN TOXIC, V39, P81, DOI 10.1081/CLT-100102885; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483	26	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15093	15098		10.1074/jbc.M112378200	http://dx.doi.org/10.1074/jbc.M112378200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836250	hybrid			2022-12-25	WOS:000175203000094
J	Schoenwaelder, SM; Hughan, SC; Boniface, K; Fernando, S; Holdsworth, M; Thompson, PE; Salem, HH; Jackson, SP				Schoenwaelder, SM; Hughan, SC; Boniface, K; Fernando, S; Holdsworth, M; Thompson, PE; Salem, HH; Jackson, SP			RhoA sustains integrin alpha(IIb)beta(3) adhesion contacts under high shear	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; INDUCED PLATELET-AGGREGATION; NUCLEOTIDE EXCHANGE FACTOR; GLYCOPROTEIN-IIB-IIIA; CELL-ADHESION; SHAPE CHANGE; SIGNAL-TRANSDUCTION; VONWILLEBRAND-FACTOR; RECEPTOR ACTIVATION; FAMILY GTPASES	The small GTPase RhoA modulates the adhesive nature of many cell types; however, despite high levels of expression in platelets, there is currently limited evidence for an important role for this small GTPase in regulating platelet adhesion processes. In this study, we have examined the role of RhoA in regulating the adhesive function of the major platelet integrin, alpha(IIb)beta(3). Our studies demonstrate that activation of RhoA occurs as a general feature of platelet activation in response to soluble agonists (thrombin, ADP, U46619, collagen), immobilized matrices (von Willebrand factor (vWf), fibrinogen) and high shear stress. Blocking the ligand binding function of integrin alpha(IIb)beta(3), by pretreating platelets with c7E3 Fab, demonstrated the existence of integrin alpha(IIb)beta(3)-dependent and -independent mechanisms regulating RhoA activation. Inhibition of RhoA (C3 exoenzyme) or its downstream effector Rho kinase (Y27632) had no effect on integrin alpha(IIb)beta(3) activation induced by soluble agonists or adhesive substrates, however, both inhibitors reduced shear-dependent platelet adhesion on immobilized vWf and shear-induced platelet aggregation in suspension. Detailed analysis of the sequential adhesive steps required for stable platelet adhesion on a vWf matrix under shear conditions revealed that RhoA did not regulate platelet tethering to vWf or the initial formation of integrin alpha(IIb)beta(3) adhesion contacts but played a major role in sustaining stable platelet-matrix interactions. These studies define a critical role for RhoA in regulating the stability of integrin alpha(IIb)beta(3) adhesion contacts under conditions of high shear stress.	Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, Box Hill, Vic 3128, Australia	Box Hill Hospital; Monash University	Schoenwaelder, SM (corresponding author), Monash Univ, Box Hill Hosp, Dept Med, Australian Ctr Blood Dis, 5th Level,Clive Ward Bldg,Arnold St, Box Hill, Vic 3128, Australia.	Simone.Schoenwaelder@med.monash.edu.au	Schoenwaelder, Simone/E-9506-2011	Schoenwaelder, Simone/0000-0003-0465-5840; Jackson, Shaun/0000-0002-4750-1991; Thompson, Philip/0000-0002-5910-7625				Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; Bodie SL, 2001, BIOCHEM BIOPH RES CO, V287, P71, DOI 10.1006/bbrc.2001.5547; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Cichowski K, 1996, J BIOL CHEM, V271, P7544, DOI 10.1074/jbc.271.13.7544; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DILLON ST, 1995, METHOD ENZYMOL, V256, P174; Dopheide SM, 2002, BLOOD, V99, P159, DOI 10.1182/blood.V99.1.159; ECKIY A, 2001, THROMB HAEMOSTASIS, V85, P694; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Grainick H R, 1985, J Clin Invest, V75, P19, DOI 10.1172/JCI111673; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hartwig JH, 1999, THROMB HAEMOSTASIS, V82, P392; HARTWIG JH, 1992, J CELL BIOL, V118, P1421, DOI 10.1083/jcb.118.6.1421; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; JAKOBSEN E, 1973, Thrombosis Research, V3, P145, DOI 10.1016/0049-3848(73)90065-0; Jones KL, 2001, BLOOD, V98, P1456, DOI 10.1182/blood.V98.5.1456; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; LEY K, 1991, BLOOD, V77, P2553; Loh E, 1996, J BIOL CHEM, V271, P30233, DOI 10.1074/jbc.271.47.30233; Missy K, 2001, THROMB HAEMOSTASIS, V85, P514, DOI 10.1055/s-0037-1615614; Mistry N, 2000, BLOOD, V96, P3480; MONTGOMERY RR, 1978, J CLIN INVEST, V61, P1498, DOI 10.1172/JCI109070; MORII N, 1992, J BIOL CHEM, V267, P20921; Nishioka H, 2001, BIOCHEM BIOPH RES CO, V280, P970, DOI 10.1006/bbrc.2001.4237; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; PETERSON DM, 1987, BLOOD, V69, P625; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ruggeri ZM, 1997, J CLIN INVEST, V99, P559, DOI 10.1172/JCI119195; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shattil SJ, 1999, THROMB HAEMOSTASIS, V82, P318; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; Suzuki Y, 1999, BLOOD, V93, P3408, DOI 10.1182/blood.V93.10.3408.410k37_3408_3417; UEHATA M, 2001, Patent No. 4997834; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	62	58	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14738	14746		10.1074/jbc.M200661200	http://dx.doi.org/10.1074/jbc.M200661200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11830597	hybrid			2022-12-25	WOS:000175203000051
J	Cayabyab, FS; Schlichter, LC				Cayabyab, FS; Schlichter, LC			Regulation of an ERG K+ current by Src tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERG POTASSIUM CHANNEL; HUMAN INWARD RECTIFIER; AMINO-TERMINAL DOMAIN; LONG QT SYNDROME; SIGNAL-TRANSDUCTION; CARDIAC-ARRHYTHMIA; RAT MICROGLIA; MESSENGER-RNA; SEIZURE LOCUS; ACTIVATION	The human "ether-a-go-go"-related gene (HERG) K+ channel, and its homologues are present in heart, neuronal tissue, some cancer cells, and the MLS-9 rat microglia cell line (Zhou, W., Cayabyab, F. S., Pennefather, P. S., Schlichter, L. C., and DeCoursey, T. E. (1998) J. Gen. Physiol. 111, 781-794). Despite its importance, there are few studies of ERG modulation. In this first report of regulation by tyrosine phosphorylation we show that MLS-9 cells express transcripts for r-erg1 (rat homologue of HERG) and r-erg2, and an immunoreactive doublet was identified using an anti-HERG antibody. The constitutive tyrosine phosphorylation of the ERG1 protein, detected by co-immunoprecipitation, was reduced by the protein-tyrosine kinase inhibitors, lavendustin A, herbimycin A, or genistein (but not daidzein). The whole cell ERG current was reduced by protein-tyrosine kinase inhibitors or the Src-selective inhibitory peptide, src40-58, but not by a scrambled peptide. Conversely, the current was increased by the Src-activating peptide, srcpY, but not by an inactive analogue. Activating endogenous Src or transfecting constitutively active v-Src altered the voltage dependence and deactivation kinetics to produce more current at negative potentials. Co-immunoprecipitation identified an association between the channel protein and Src. Thus, r-ERG1 and Src tyrosine kinase appear to exist in a signaling complex that is well positioned to modulate this K+ channel and affect its contribution to cellular functions.	Univ Toronto, Hlth Network, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Hosp, MC 9-415,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	schlicht@uhnres.utoronto.ca	DeCoursey, Thomas/A-6820-2009; Cayabyab, Francisco/HHR-8711-2022	DeCoursey, Thomas/0000-0002-4263-180X; 				Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Barros F, 1998, J PHYSIOL-LONDON, V511, P333, DOI 10.1111/j.1469-7793.1998.333bh.x; Bianchi L, 1998, CANCER RES, V58, P815; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CiesielskiTreska J, 1995, EUR J CELL BIOL, V68, P369; Combs CK, 1999, J NEUROSCI, V19, P928; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Fujita A, 2000, BIOCHEM BIOPH RES CO, V269, P1, DOI 10.1006/bbrc.1999.1893; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Illes P, 1996, NEUROCHEM INT, V29, P13; Johnson JP, 1999, J GEN PHYSIOL, V113, P565, DOI 10.1085/jgp.113.4.565; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kiehn J, 1998, J BIOL CHEM, V273, P25285, DOI 10.1074/jbc.273.39.25285; Kiehn J, 1999, AM J PHYSIOL-HEART C, V277, pH199, DOI 10.1152/ajpheart.1999.277.1.H199; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; Kust BM, 1999, GLIA, V25, P120; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; McDonald DR, 1997, J NEUROSCI, V17, P2284; Miyake A, 1999, J BIOL CHEM, V274, P25018, DOI 10.1074/jbc.274.35.25018; NILIUS B, 1994, NEWS PHYSIOL SCI, V9, P105; Pancrazio JJ, 1999, J NEUROBIOL, V38, P466, DOI 10.1002/(SICI)1097-4695(199903)38:4<466::AID-NEU3>3.3.CO;2-#; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pennefather PS, 1998, J GEN PHYSIOL, V111, P795, DOI 10.1085/jgp.111.6.795; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Schafer R, 1999, J PHYSIOL-LONDON, V518, P401, DOI 10.1111/j.1469-7793.1999.0401p.x; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Schwarz JR, 1999, NEWS PHYSIOL SCI, V14, P135; Shi WM, 1997, J NEUROSCI, V17, P9423; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Thomas D, 1999, J BIOL CHEM, V274, P27457, DOI 10.1074/jbc.274.39.27457; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Titus SA, 1997, J NEUROSCI, V17, P875; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang JL, 1998, J GEN PHYSIOL, V112, P637, DOI 10.1085/jgp.112.5.637; Wang JL, 2000, J GEN PHYSIOL, V115, P749, DOI 10.1085/jgp.115.6.749; Wang SM, 1997, J PHYSIOL-LONDON, V502, P45, DOI 10.1111/j.1469-7793.1997.045bl.x; Wang XJ, 1997, J NEUROSCI, V17, P882; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674; Zhou W, 1998, J GEN PHYSIOL, V111, P781, DOI 10.1085/jgp.111.6.781; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	62	61	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13673	13681		10.1074/jbc.M108211200	http://dx.doi.org/10.1074/jbc.M108211200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834728	hybrid			2022-12-25	WOS:000175096000045
J	Feng, ZH; Hu, WW; Komissarova, E; Pao, A; Hung, MC; Adair, GM; Tang, MS				Feng, ZH; Hu, WW; Komissarova, E; Pao, A; Hung, MC; Adair, GM; Tang, MS			Transcription-coupled DNA repair is genomic context-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLOBUTANE PYRIMIDINE DIMERS; NUCLEOTIDE EXCISION-REPAIR; DIPLOID HUMAN FIBROBLASTS; STRAND-SPECIFIC REPAIR; ACTIVE GENES; HPRT GENE; ADENINE PHOSPHORIBOSYLTRANSFERASE; PREFERENTIAL REPAIR; COCKAYNES-SYNDROME; CELL-LINE	DNA damage is preferentially repaired in the transcribed strand of many active genes. Although the concept of DNA repair coupled with transcription has been widely accepted, its mechanisms remain elusive. We recently reported that in Chinese hamster ovary cells while ultraviolet light-induced cyclobutane pyrimidine dimers (CPDs) are preferentially repaired in the transcribed strand of dihydrofolate reductase gene, CPDs are efficiently repaired in both strands of adenine phosphoribosyltransferase (APRT) locus, in either a transcribed or nontranscribed APRT gene (1). These results suggested that the transcription dependence of repair may depend on genomic context. To test this hypothesis, we constructed transfectant cell lines containing a single, actively transcribed APRT gene, integrated at different genomic sites. Mapping of CPD repair in the integrated APRT genes in three transfectant cell lines revealed two distinct repair patterns, either preferential repair of CPDs in the transcribed strand or very poor repair in both strands. Similar kinetics of micrococcal nuclease digestion were seen for all three transfectant APRT gene domains and endogenous APRT locus. Our results suggest that both the efficiency and strand-specificity of repair of an actively transcribed gene are profoundly affected by genomic context but do not reflect changes in first order nucleosomal structure.	NYU, Sch Med, Dept Environm Med Pathol & Med, Tuxedo Pk, NY 10987 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Smithville, TX 78957 USA	New York University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Tang, MS (corresponding author), NYU, Sch Med, Dept Environm Med Pathol & Med, Tuxedo Pk, NY 10987 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Komissarova, Elena V./0000-0001-6848-0635	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124, R01ES008389, P30ES000260] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056165] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 00260, ES 03124, ES 08389, ES 077784] Funding Source: Medline; NIGMS NIH HHS [GM 56165] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAIR GM, 1983, P NATL ACAD SCI-BIOL, V80, P5961, DOI 10.1073/pnas.80.19.5961; ADAIR GM, 1980, MUTAT RES, V72, P187, DOI 10.1016/0027-5107(80)90035-4; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BOHR VA, 1991, CARCINOGENESIS, V12, P1983, DOI 10.1093/carcin/12.11.1983; Bucheli M, 2001, GENETICS, V158, P989; CHEN RH, 1990, P NATL ACAD SCI USA, V87, P8680, DOI 10.1073/pnas.87.21.8680; CHEN RH, 1992, P NATL ACAD SCI USA, V89, P5413, DOI 10.1073/pnas.89.12.5413; Denissenko MF, 1998, ONCOGENE, V16, P1241, DOI 10.1038/sj.onc.1201647; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Gregory SM, 2001, NUCLEIC ACIDS RES, V29, P3080, DOI 10.1093/nar/29.14.3080; Hainaut P, 2001, CARCINOGENESIS, V22, P367, DOI 10.1093/carcin/22.3.367; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; Maxam A M, 1980, Methods Enzymol, V65, P499; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P8232, DOI 10.1073/pnas.88.18.8232; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; Tang Moon-Shong, 1996, P139; Tornaletti Silvia, 1996, P199; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENEMA J, 1992, J BIOL CHEM, V267, P8852; VRIELING H, 1992, MUTAT RES, V274, P147, DOI 10.1016/0921-8777(92)90061-7; Vrieling H, 1998, MUTAT RES-FUND MOL M, V400, P135, DOI 10.1016/S0027-5107(98)00064-5; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; Zheng Y, 2001, J BIOL CHEM, V276, P16786, DOI 10.1074/jbc.M010973200	36	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12777	12783		10.1074/jbc.M112297200	http://dx.doi.org/10.1074/jbc.M112297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821423	hybrid			2022-12-25	WOS:000175036300038
J	Sai, X; Kawamura, Y; Kokame, K; Yamaguchi, H; Shiraishi, H; Suzuki, R; Suzuki, T; Kawaichi, M; Miyata, T; Kitamura, T; De Strooper, B; Yanagisawa, K; Komano, H				Sai, X; Kawamura, Y; Kokame, K; Yamaguchi, H; Shiraishi, H; Suzuki, R; Suzuki, T; Kawaichi, M; Miyata, T; Kitamura, T; De Strooper, B; Yanagisawa, K; Komano, H			Endoplasmic reticulum stress-inducible protein, herp, enhances presenilin-mediated generation of amyloid beta-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE CLEAVAGE; PRECURSOR PROTEIN; INTRAMEMBRANE CLEAVAGE; COGNITIVE IMPAIRMENT; MISSENSE MUTATIONS; AMINO-ACID; GENE; HOMOCYSTEINE; PARKIN	Presenilin (PS) is essential for the gamma-cleavage required for the generation of the C terminus of amyloid beta-protein (Abeta). However, the mechanism underlying PS-mediated gamma-cleavage remains unclear. We have identified Herp cDNA by our newly developed screening method for the isolation of cDNAs that increase the degree of gamma-cleavage. Herp was originally identified as a homocysteine-responsive protein, and its expression is up-regulated by endoplasmic reticulum stress. Herp is an endoplasmic reticulum-localized membrane protein that has a ubiquitin-like domain. Here, we report that a high expression of Herp in cells increases the level of Abeta generation, although not in PS-deficient cells. We found that Herp interacts with both PSI and PS2. Thus, Herp regulates PS-mediated Abeta generation, possibly through its binding to PS. Immunohistochemical analysis of a normal human brain section with an anti-Herp antibody revealed the exclusive staining of neurons and vascular smooth muscle cells. Moreover, the antibody strongly stained activated microglia in senile plaques in the brain of patients with Alzheimer disease. Taken together, Herp could be involved in Abeta accumulation, including the formation of senile plaques and vascular Abeta deposits.	Natl Inst Longev Sci, Dept Dementia Res, Obu, Aichi 4748522, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Natl Cardiovasc Ctr, Res Inst, Osaka 5658565, Japan; Gunma Univ, Sch Hlth Sci, Maebashi, Gumma 3718511, Japan; Hokkaido Univ, Grad Sch Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 63001, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Cellular Therapy, Tokyo 1088639, Japan; Katholieke Univ Leuven, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Japan Science & Technology Agency (JST); National Cerebral & Cardiovascular Center - Japan; Gunma University; Hokkaido University; Nara Institute of Science & Technology; University of Tokyo; KU Leuven	Komano, H (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Obu, Aichi 4748522, Japan.	hkomano@nils.go.jp	Kitamura, Toshio/AAA-2071-2021; De Strooper, Bart/F-6507-2012; Suzuki, Toshiharu/B-5342-2013; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Kokame, Koichi/0000-0002-9654-6299				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Clarke R, 1998, ARCH NEUROL-CHICAGO, V55, P1449, DOI 10.1001/archneur.55.11.1449; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; Gottfries CG, 1998, J NEURAL TRANSM, V105, P773, DOI 10.1007/s007020050094; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; ITAGAKI S, 1989, J NEUROIMMUNOL, V24, P173, DOI 10.1016/0165-5728(89)90115-X; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lehmann M, 1999, DEMENT GERIATR COGN, V10, P12, DOI 10.1159/000017092; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Miller JW, 1999, NUTR REV, V57, P126; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Onishi M, 1996, EXP HEMATOL, V24, P324; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Sudoh S, 1998, J NEUROCHEM, V71, P1535; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Tomita S, 1998, J BIOL CHEM, V273, P19304, DOI 10.1074/jbc.273.30.19304; Weggen S, 2001, NATURE, V414, P212, DOI 10.1038/35102591; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Yamada M, 2000, NEUROPATHOLOGY, V20, P8, DOI 10.1046/j.1440-1789.2000.00268.x; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	41	118	124	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12915	12920		10.1074/jbc.M112372200	http://dx.doi.org/10.1074/jbc.M112372200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11799129	hybrid			2022-12-25	WOS:000175036300056
J	Bergo, M; Wu, GS; Ruge, T; Olivecrona, T				Bergo, M; Wu, GS; Ruge, T; Olivecrona, T			Down-regulation of adipose tissue lipoprotein lipase during fasting requires that a gene, separate from the lipase gene, is switched on	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; EXPRESSION; TRANSLOCATION; GLYCOSYLATION; MATURATION; ADIPOCYTES; INCREASES; GLUCOSE; PROTEIN; LIVER	During short term fasting, lipoprotein lipase (LPL) activity in rat adipose tissue is rapidly down-regulated. This down-regulation occurs on a posttranslational level; it is not accompanied by changes in LPL mRNA or protein levels. The LPL activity can be restored within 4 h by refeeding. Previously, we showed that during fasting there is a shift in the distribution of lipase protein toward an inactive form with low heparin affinity. To study the nature of the regulatory mechanism, we determined the in vivo turnover of LPL activity, protein mass, and mRNA in rat adipose tissue. When protein synthesis was inhibited with cycloheximide, LPL activity and protein mass decreased rapidly and in parallel with half-lives of around 2 h, and the effect of refeeding was blocked. This indicates that maintaining high levels of LPL activity requires continuous synthesis of new enzyme protein. When transcription was inhibited by actinomycin, LPL mRNA decreased with half-lives of 13.3 and 16.8 h in the fed and fasted states, respectively, demonstrating slow turnover of the LPL transcript. Surprisingly, when actinomycin was given to fed rats, LPL activity was not down-regulated during fasting, indicating that actinomycin interferes with the transcription of a gene that blocks the activation of newly synthesized LPL protein. When actinomycin was given to fasted rats, LPL activity increased 4-fold within 6 h, even in the absence of refeeding. The same effect was seen with a-amanitin, another inhibitor of transcription. The response to actinomycin was much less pronounced in aging rats, which are obese and insulin-resistant. These data suggest a default state where LPL protein is synthesized on a relatively stable mRNA and is processed into its active form. During fasting, a gene is switched on whose product prevents the enzyme from becoming active even though synthesis of LPL protein continues unabated.	Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden	Umea University	Olivecrona, T (corresponding author), Umea Univ, Dept Med Biosci, S-90187 Umea, Sweden.		Ruge, Toralph/Q-4289-2017	Ruge, Toralph/0000-0002-1170-5183				AUWERX JH, 1988, BIOCHEMISTRY-US, V27, P2651, DOI 10.1021/bi00408a003; BENZEEV O, 1992, J BIOL CHEM, V267, P6219; Bergo M, 1997, INT J OBESITY, V21, P980, DOI 10.1038/sj.ijo.0800506; Bergo M, 1996, AM J PHYSIOL-ENDOC M, V271, pE1092, DOI 10.1152/ajpendo.1996.271.6.E1092; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BESSESEN DH, 1991, AM J PHYSIOL, V261, pE246, DOI 10.1152/ajpendo.1991.261.2.E246; BRAUN JEA, 1992, BIOCHEM J, V287, P337, DOI 10.1042/bj2870337; Briquet-Laugier V, 1999, J LIPID RES, V40, P2044; CARNEHEIM C, 1988, AM J PHYSIOL, V254, pE155, DOI 10.1152/ajpendo.1988.254.2.E155; CHAJEKSHAUL T, 1988, BIOCHIM BIOPHYS ACTA, V963, P183, DOI 10.1016/0005-2760(88)90279-2; CORNELIUS P, 1988, BIOCHEM J, V249, P765, DOI 10.1042/bj2490765; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; ECKEL RH, 1989, NEW ENGL J MED, V320, P1060; FRAYN KN, 1995, ADV ENZYME REGUL, V35, P163, DOI 10.1016/0065-2571(94)00011-Q; Goldberg IJ, 1996, J LIPID RES, V37, P693; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; MASUNO H, 1990, J BIOL CHEM, V265, P1628; MASUNO H, 1992, J LIPID RES, V33, P1343; MCBRIDE OW, 1963, J LIPID RES, V4, P17; MITCHELL JRD, 1992, AM J PHYSIOL, V263, pE500, DOI 10.1152/ajpendo.1992.263.3.E500; Olivecrona T, 1999, LIPOPROTEINS IN HEALTH AND DISEASE, P223; Olivecrona T., 2000, HDB LIPOPROTEIN TEST, P479; ONG JM, 1989, J CLIN INVEST, V84, P305, DOI 10.1172/JCI114155; PARK JW, 1995, BBA-LIPID LIPID MET, V1254, P45, DOI 10.1016/0005-2760(94)00161-Q; PEINADOONSURBE J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P281, DOI 10.1016/0167-4781(92)90026-V; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; SCHOTZ MC, 1965, BIOCHIM BIOPHYS ACTA, V106, P202, DOI 10.1016/0005-2760(65)90109-8; SEMB H, 1989, J BIOL CHEM, V264, P4195; SIMSOLO RB, 1992, J LIPID RES, V33, P89; VILARO S, 1988, AM J PHYSIOL, V254, pG711, DOI 10.1152/ajpgi.1988.254.5.G711; WING DR, 1968, BIOCHEM J, V106, P667, DOI 10.1042/bj1060667	32	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11927	11932		10.1074/jbc.M200325200	http://dx.doi.org/10.1074/jbc.M200325200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809775	hybrid			2022-12-25	WOS:000174846400043
J	Piccotti, L; Marchetti, C; Migliorati, G; Roberti, R; Corazzi, L				Piccotti, L; Marchetti, C; Migliorati, G; Roberti, R; Corazzi, L			Exogenous phospholipids specifically affect transmembrane potential of brain mitochondria and cytochrome c release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIOLIPIN; LIPOSOMES; APOPTOSIS; BINDING; DEGRADATION; IMPORT; MODEL	Release of cytochrome e, a decrease of membrane potential (Deltapsi(m)), and a reduction of cardiolipin (CL) of rat brain mitochondria occurred upon incubation in the absence of respiratory substrates. Since CL is critical for mitochondrial functioning, CL enrichment of mitochondria was achieved by fusion with CL liposomes. Fusion was triggered by potassium phosphate at concentrations producing mitochondrial permeability transition pore opening but not cytochrome c release, which was observed only at >10 mM. Cyclosporin A inhibited phosphate-induced CL fusion, whereas Pronase pretreatment of mitochondria abolished it, suggesting that mitochondrial permeability transition pore and protein(s) are involved in the fusion process. Phosphate-dependent fusion was enhanced in respiratory state 3 and influenced by phospholipid classes in the order CL > phosphatidylglycerol (PG) > phosphatidylserine. The probe 10-nonylacridine orange indicated that fused CL had migrated to the inner mitochondrial membrane. In state 3, CL enrichment of mitochondria resulted in a pH decrease in the intermembrane space. Cytofluorimetric analysis of mitochondria stained with 3,3'-diexyloxacarbocyanine iodide and 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzymidazolylcarbocyanine iodide showed Deltapsi(m) increase upon fusion with CL or PG. In contrast, phosphatidylserine fusion required Deltapsi(m) consumption, suggesting that Deltapsi(m) is the driving force in mitochondrial phospholipid importation. Moreover, enrichment with CL and PG brought the low energy mitochondrial population to high At m values and prevented phosphate-dependent cytochrome e release.	Univ Perugia, Dept Internal Med, Biochem Lab, I-06122 Perugia, Italy; Univ Perugia, Dept Clin Med Pathol & Pharmacol, I-06122 Perugia, Italy	University of Perugia; University of Perugia	Corazzi, L (corresponding author), Univ Perugia, Dept Internal Med, Biochem Lab, Via Giochetto, I-06122 Perugia, Italy.	corazzi@unipg.it		MIGLIORATI, Graziella/0000-0002-9475-6399; CORAZZI, Lanfranco/0000-0001-5184-6610; ROBERTI, Rita/0000-0003-4131-5933				Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Camici O, 1997, MOL CELL BIOCHEM, V175, P71, DOI 10.1023/A:1006889328983; Cossarizza A, 1996, EXP CELL RES, V222, P84, DOI 10.1006/excr.1996.0011; Crompton M, 1999, BIOCHEM SOC SYMP, V66, P167, DOI 10.1042/bss0660167; Daum G, 1997, PROG LIPID RES, V36, P103, DOI 10.1016/S0163-7827(97)00006-4; FOLCH J, 1957, J BIOL CHEM, V226, P497; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Kroemer G, 1999, BIOCHEM SOC SYMP, V66, P1; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luetjens CM, 2000, J NEUROSCI, V20, P5715; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Monni M, 2000, J MEMBRANE BIOL, V173, P97, DOI 10.1007/s002320001011; NAKAHARA I, 1992, J NEUROSURG, V76, P244, DOI 10.3171/jns.1992.76.2.0244; NAKAHARA I, 1991, J NEUROCHEM, V57, P839, DOI 10.1111/j.1471-4159.1991.tb08227.x; Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Paradies G, 1997, FEBS LETT, V406, P136, DOI 10.1016/S0014-5793(97)00264-0; PISTOLESI R, 1990, MEMBRANE BIOCHEM, V9, P253, DOI 10.3109/09687689009025845; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; ROUSER G, 1967, LIPID CHROMATOGRAPHI, V1, P99; RYTOMAA M, 1995, J BIOL CHEM, V270, P3197, DOI 10.1074/jbc.270.7.3197; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Ushmorov A, 1999, BLOOD, V93, P2342, DOI 10.1182/blood.V93.7.2342.407k09_2342_2352; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	38	35	36	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12075	12081		10.1074/jbc.M200029200	http://dx.doi.org/10.1074/jbc.M200029200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815626	hybrid			2022-12-25	WOS:000174846400063
J	Sakamoto, K; Hirshman, MF; Aschenbach, WG; Goodyear, LJ				Sakamoto, K; Hirshman, MF; Aschenbach, WG; Goodyear, LJ			Contraction regulation of Akt in rat skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; INDUCED GLUCOSE-TRANSPORT; PHOSPHOINOSITIDE 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; POTENTIAL ROLE; MAP KINASE; IN-VITRO; INSULIN; ACTIVATION	The protein serine/threonine kinase Akt/protein kinase B has been recognized as a critical signaling mediator for multiple cell systems. The function of Akt in skeletal muscle is not well understood, and whether contractile activity stimulates Akt activity has been controversial. In the current study, contraction in situ, induced via sciatic nerve stimulation, significantly increased Akt Ser(473) phosphorylation in multiple muscle types including the extensor digitorum longus (13-fold over basal), plantaris (5.8-fold), red gastrocnemius (4.7-fold), white gastrocnemius (3.3-fold), and soleus (1.6-fold). In addition to increasing phosphorylation, contraction in situ significantly increased the activity of all three Akt isoforms (Akt1 > Akt2 > Akt3) with maximal activation occurring at 2.5 min and returning to base line with 15 min of contraction. Akt phosphorylation and activity were also increased when isolated muscles were contracted in vitro in the absence of systemic factors, although to a much lesser extent. The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 fully inhibited contraction-stimulated Akt phosphorylation and activity but did not diminish contraction-stimulated glycogen synthase kinase-3 phosphorylation and glycogen synthase activity. These results demonstrate that contraction increases Akt phosphorylation and activity in skeletal muscle and that this stimulation is rapid, transient, muscle fiber type-specific, and wortmannin- and LY294002-inhibitable. Akt signaling is not necessary for the regulation of glycogen synthase activity in contracting skeletal muscle.	Joslin Diabet Ctr, Metab Sect, Div Res, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yokohama City Univ, Grad Sch Integrated Sci, Kanazawa Ku, Yokohama, Kanagawa 232, Japan	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yokohama City University	Goodyear, LJ (corresponding author), Joslin Diabet Ctr, Metab Sect, Div Res, 1 Joslin Pl, Boston, MA 02215 USA.		sakamoto, kei/C-8806-2019	sakamoto, kei/0000-0001-8839-5980	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042238, R01AR045670, R29AR042238] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK059769] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45670, AR42238] Funding Source: Medline; NIDDK NIH HHS [DK59769] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Aschenbach WG, 2001, J BIOL CHEM, V276, P39959, DOI 10.1074/jbc.M105518200; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Brady MJ, 1998, J BIOL CHEM, V273, P14063, DOI 10.1074/jbc.273.23.14063; Brozinick JT, 1998, J BIOL CHEM, V273, P14679, DOI 10.1074/jbc.273.24.14679; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Cross DAE, 1997, FEBS LETT, V406, P211, DOI 10.1016/S0014-5793(97)00240-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CROSS MJ, 1995, J BIOL CHEM, V270, P25352, DOI 10.1074/jbc.270.43.25352; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fruman DA, 2000, NAT GENET, V26, P379, DOI 10.1038/81715; GOODYEAR LJ, 1995, AM J PHYSIOL-ENDOC M, V268, pE987, DOI 10.1152/ajpendo.1995.268.5.E987; Gorin Y, 2001, FASEB J, V15, P1909, DOI 10.1096/fj..01-0165com; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Hernandez R, 2001, FEBS LETT, V494, P225, DOI 10.1016/S0014-5793(01)02353-5; Hill MM, 2002, METHOD ENZYMOL, V345, P448; Hill MM, 2001, J BIOL CHEM, V276, P25643, DOI 10.1074/jbc.C100174200; Kim YB, 1999, J CLIN INVEST, V104, P733, DOI 10.1172/JCI6928; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; LAUGHLIN MH, 1983, AM J PHYSIOL, V244, pH814, DOI 10.1152/ajpheart.1983.244.6.H814; Lawlor MA, 2001, J CELL SCI, V114, P2903; Lawrence JC, 1997, DIABETES, V46, P541, DOI 10.2337/diabetes.46.4.541; LEE AD, 1995, FEBS LETT, V361, P51, DOI 10.1016/0014-5793(95)00147-2; Lund S, 1998, FEBS LETT, V425, P472, DOI 10.1016/S0014-5793(98)00293-2; LUND S, 1995, P NATL ACAD SCI USA, V92, P5817, DOI 10.1073/pnas.92.13.5817; Markuns JF, 1999, J BIOL CHEM, V274, P24896, DOI 10.1074/jbc.274.35.24896; Nader GA, 2001, J APPL PHYSIOL, V90, P1936, DOI 10.1152/jappl.2001.90.5.1936; Nadler ST, 2001, AM J PHYSIOL-ENDOC M, V281, pE1249, DOI 10.1152/ajpendo.2001.281.6.E1249; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Shaw M, 1997, FEBS LETT, V416, P307, DOI 10.1016/S0014-5793(97)01235-0; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Sherwood DJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE870, DOI 10.1152/ajpendo.1999.276.5.E870; Skurat AV, 2000, DIABETES, V49, P1096, DOI 10.2337/diabetes.49.7.1096; Smith U, 2000, BIOCHEM BIOPH RES CO, V268, P315, DOI 10.1006/bbrc.2000.2145; Song XM, 1999, AM J PHYSIOL-REG I, V277, pR1690, DOI 10.1152/ajpregu.1999.277.6.R1690; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Tanti JF, 1997, ENDOCRINOLOGY, V138, P2005, DOI 10.1210/en.138.5.2005; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Turinsky J, 1999, AM J PHYSIOL-REG I, V276, pR277, DOI 10.1152/ajpregu.1999.276.1.R277; Ueki K, 1998, J BIOL CHEM, V273, P5315, DOI 10.1074/jbc.273.9.5315; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Wojtaszewski JFP, 1999, J CLIN INVEST, V104, P1257, DOI 10.1172/JCI7961; Wojtaszewski JFP, 1996, J APPL PHYSIOL, V81, P1501, DOI 10.1152/jappl.1996.81.4.1501; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zhou Q, 1997, BIOCHEM BIOPH RES CO, V236, P647, DOI 10.1006/bbrc.1997.7028	60	146	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11910	11917		10.1074/jbc.M112410200	http://dx.doi.org/10.1074/jbc.M112410200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809761	hybrid			2022-12-25	WOS:000174846400041
J	Fulton, DC; Edwards, A; Pilling, E; Robinson, HL; Fahy, B; Seale, R; Kato, L; Donald, AM; Geigenberger, P; Martin, C; Smith, AM				Fulton, DC; Edwards, A; Pilling, E; Robinson, HL; Fahy, B; Seale, R; Kato, L; Donald, AM; Geigenberger, P; Martin, C; Smith, AM			Role of granule-bound starch synthase in determination of amylopectin structure and starch granule morphology in potato	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE PYROPHOSPHORYLASE ACTIVITIES; SOLANUM-TUBEROSUM L; PISUM-SATIVUM-L; BRANCHING ENZYME; MAIZE ENDOSPERM; CHLAMYDOMONAS-REINHARDTII; ADP-GLUCOSE; FUNCTIONAL-ANALYSIS; PEA EMBRYOS; RICE-STARCH	Reductions in activity of SSIII, the major isoform of starch synthase responsible for amylopectin synthesis in the potato tuber, result in fissuring of the starch granules. To discover the causes of the fissuring, and thus to shed light on factors that influence starch granule morphology in general, SSIII antisense lines were compared with lines with reductions in the major granule-bound isoform of starch synthase (GBSS) and lines with reductions in activity of both SSIII and GBSS (SSIII/GBSS antisense lines). This revealed that fissuring resulted from the activity of GBSS in the SSIII antisense background. Control (untransformed) lines and GBSS and SSIII/GBSS antisense lines had unfissured granules. Starch analyses showed that granules from SSIII antisense tubers had a greater number of long glucan chains than did granules from the other lines, in the form of larger amylose molecules and a unique fraction of very long amylopectin chains. These are likely to result from increased through GBSS in SSIII antisense tubers, in response to the elevated content of ADP-glucose in these tubers. It is proposed that the long glucan chains disrupt organization of the semi-crystalline parts of the matrix, setting up stresses in the matrix that lead to fissuring.	John Innes Ctr Plant Sci Res, Dept Metab Biol, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Dept Cell & Dev Biol, Norwich NR4 7UH, Norfolk, England; Univ Cambridge, Cavendish Lab, Dept Phys, Cambridge CB3 0HE, England; Max Planck Inst Mol Plant Physiol, D-14476 Golm, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of Cambridge; Max Planck Society	Smith, AM (corresponding author), John Innes Ctr Plant Sci Res, Dept Metab Biol, Colney Lane, Norwich NR4 7UH, Norfolk, England.		Geigenberger, Peter/A-2041-2010	Geigenberger, Peter/0000-0001-9512-349X				Abel GJW, 1996, PLANT J, V10, P981, DOI 10.1046/j.1365-313X.1996.10060981.x; BABA T, 1987, STARCH-STARKE, V39, P52, DOI 10.1002/star.19870390207; Beckles DM, 2001, PLANT PHYSIOL, V125, P818, DOI 10.1104/pp.125.2.818; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; BHATTACHARYYA MK, 1990, CELL, V60, P115, DOI 10.1016/0092-8674(90)90721-P; BOYER CD, 1976, CROP SCI, V16, P298, DOI 10.2135/cropsci1976.0011183X001600020038x; BOYER CD, 1976, STARCH STAERKE, V12, P405; Buleon A, 1997, PLANT PHYSIOL, V115, P949, DOI 10.1104/pp.115.3.949; CAMERON RE, 1992, POLYMER, V33, P2628, DOI 10.1016/0032-3861(92)91147-T; Cao HP, 2000, ARCH BIOCHEM BIOPHYS, V373, P135, DOI 10.1006/abbi.1999.1547; Clarke BR, 1999, PLANTA, V209, P324, DOI 10.1007/s004250050639; COLONNA P, 1984, CARBOHYD RES, V126, P233, DOI 10.1016/0008-6215(84)85381-1; Craig J, 1998, PLANT CELL, V10, P413, DOI 10.1105/tpc.10.3.413; CREECH RG, 1965, GENETICS, V52, P1175; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; Denyer K, 1996, PLANT PHYSIOL, V112, P779, DOI 10.1104/pp.112.2.779; Denyer K, 1996, PLANT J, V10, P1135, DOI 10.1046/j.1365-313X.1996.10061135.x; DRY I, 1992, PLANT J, V2, P193; EDWARDS A, 1995, PLANT J, V8, P283, DOI 10.1046/j.1365-313X.1995.08020283.x; Edwards A, 1999, PLANT J, V17, P251, DOI 10.1046/j.1365-313X.1999.00371.x; Edwards A, 1999, EUR J BIOCHEM, V266, P724, DOI 10.1046/j.1432-1327.1999.00861.x; Geigenberger P, 1997, PLANTA, V201, P502, DOI 10.1007/s004250050095; HEDLEY CL, 1986, ANN BOT-LONDON, V58, P371, DOI 10.1093/oxfordjournals.aob.a087215; HIZUKURI S, 1989, CARBOHYD RES, V189, P227, DOI 10.1016/0008-6215(89)84099-6; JENKINS JPJ, 1993, STARCH-STARKE, V45, P417; Jenkins PJ, 1995, INT J BIOL MACROMOL, V17, P315, DOI 10.1016/0141-8130(96)81838-1; Kim KN, 1998, PLANT MOL BIOL, V38, P945, DOI 10.1023/A:1006057609995; Kossmann J, 1999, PLANTA, V208, P503, DOI 10.1007/s004250050587; KUIPERS AGJ, 1994, PLANT CELL, V6, P43, DOI 10.1105/tpc.6.1.43; Li Z, 1999, THEOR APPL GENET, V98, P1208, DOI 10.1007/s001220051186; Lloyd JR, 1999, BIOCHEM J, V338, P515, DOI 10.1042/0264-6021:3380515; Lloyd JR, 1999, PLANTA, V209, P230, DOI 10.1007/s004250050627; MADDELEIN ML, 1994, J BIOL CHEM, V269, P25150; Marshall J, 1996, PLANT CELL, V8, P1121, DOI 10.1105/tpc.8.7.1121; MERLO L, 1993, J PLANT PHYSIOL, V142, P392, DOI 10.1016/S0176-1617(11)81243-5; REDDY KR, 1993, CARBOHYD POLYM, V22, P267; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; Singletary GW, 1997, PLANT PHYSIOL, V113, P293, DOI 10.1104/pp.113.1.293; SMITH AM, 1988, PLANTA, V175, P270, DOI 10.1007/BF00392437; SMITH AM, 1990, PLANTA, V182, P599, DOI 10.1007/BF02341037; SOWOKINOS JR, 1976, PLANT PHYSIOL, V57, P63, DOI 10.1104/pp.57.1.63; Tatge H, 1999, PLANT CELL ENVIRON, V22, P543, DOI 10.1046/j.1365-3040.1999.00437.x; Tomlinson KL, 1997, PLANT J, V11, P31, DOI 10.1046/j.1365-313X.1997.11010031.x; Umemoto T, 1999, STARCH-STARKE, V51, P58, DOI [10.1002/(SICI)1521-379X(199903)51:2<58::AID-STAR58>3.0.CO;2-J, 10.1002/(SICI)1521-379X(199903)51:2&lt;58::AID-STAR58&gt;3.0.CO;2-J]; van de Wal M, 1998, J BIOL CHEM, V273, P22232, DOI 10.1074/jbc.273.35.22232; VandenKoornhuyse N, 1996, J BIOL CHEM, V271, P16281, DOI 10.1074/jbc.271.27.16281; Visser RGF, 1997, STARCH-STARKE, V49, P438, DOI 10.1002/star.19970491103; WANG YJ, 1993, CEREAL CHEM, V70, P171; YEH JY, 1981, STARKE, V33, P222, DOI 10.1002/star.19810330703	49	61	73	4	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10834	10841		10.1074/jbc.M111579200	http://dx.doi.org/10.1074/jbc.M111579200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801600	hybrid			2022-12-25	WOS:000174613100013
J	Gimenez, I; Isenring, P; Forbush, B				Gimenez, I; Isenring, P; Forbush, B			Spatially distributed alternative splice variants of the renal Na-K-Cl cotransporter exhibit dramatically different affinities for the transported ions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THICK ASCENDING LIMB; MACULA DENSA CELLS; BARTTERS-SYNDROME; HAIR-CELLS; MUTATIONS	Three splice variants of the renal Na-K-Cl cotransporter (NKCC2 F, A, and B) are spatially distributed along the thick ascending limb of the mammalian kidney. To test whether NKCC2 splice variants differ in ion transport characteristics we expressed cDNAs encoding rabbit NKCC2 F, A, and B in Xenopus oocytes and determined the ion dependence of bumetanide-sensitive Rb-86 influx. The three splice variants of NKCC2 showed dramatic differences in their kinetic behavior. The medullary variant F exhibited 3-4-fold lower affinity than variants A and B for Na+ and K+. Chloride affinities also markedly distinguish the three variants (KmF = 111.3, K(m)A = 44.7, and KmB = 8.9 mm Cl-). Thus, the kinetic properties of the NKCC2 splice variants are consistent with the spatial distribution of the variants along the thick ascending limb as they are involved in reabsorbing Na+, K', and Cl- from a progressively diluted fluid in the tubule lumen. Variant B also showed an anomalous inhibition of rubidium influx at high extracellular Na+ concentrations, possibly important in its highly specialized role in the macula densa. The adaptation of the kinetic characteristics of the NKCC2 variants to the luminal concentrations of substrate represents an excellent example of functional specialization and diversity that can be achieved through alternative mRNA splicing.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA	Yale University	Gimenez, I (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	ignacio.gimenez@yale.edu	Giménez, Ignacio/B-6322-2013	Giménez, Ignacio/0000-0002-6043-4869	NIDDK NIH HHS [DK-17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARYSTARKHOVA E, 2002, IN PRESS J BIOL CHEM, V277; BURBAUM JJ, 1989, BIOCHEMISTRY-US, V28, P9293, DOI 10.1021/bi00450a009; BURG MB, 1982, KIDNEY INT, V22, P454, DOI 10.1038/ki.1982.198; Gagnon Edith, 1999, Journal of the American Society of Nephrology, V10, p32A; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gimenez Ignacio, 1999, Journal of the American Society of Nephrology, V10, p32A; Glorioso N, 2001, HYPERTENSION, V38, P204, DOI 10.1161/01.HYP.38.2.204; Greger R, 2000, AM J MED SCI, V319, P51, DOI 10.1097/00000441-200001000-00005; HEBERT SC, 1984, AM J PHYSIOL, V246, pF745, DOI 10.1152/ajprenal.1984.246.6.F745; Herrera VLM, 2001, MOL MED, V7, P125, DOI 10.1007/BF03401946; IGARASHI P, 1995, AM J PHYSIOL-RENAL, V269, pF405, DOI 10.1152/ajprenal.1995.269.3.F405; Isenring P, 1998, P NATL ACAD SCI USA, V95, P7179, DOI 10.1073/pnas.95.12.7179; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Jones EMC, 1999, ANN NY ACAD SCI, V868, P379, DOI 10.1111/j.1749-6632.1999.tb11299.x; Lapointe JY, 1998, KIDNEY INT, V54, pS58, DOI 10.1046/j.1523-1755.1998.06712.x; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; Ramanathan K, 1999, SCIENCE, V283, P215, DOI 10.1126/science.283.5399.215; REEVES WB, 1988, AM J PHYSIOL, V255, pF1145, DOI 10.1152/ajprenal.1988.255.6.F1145; SCHLATTER E, 1989, PFLUG ARCH EUR J PHY, V414, P286, DOI 10.1007/BF00584628; SCHNERMANN J, 1988, AM J PHYSIOL, V274, pR263; Simon DB, 1998, CURR OPIN CELL BIOL, V10, P450, DOI 10.1016/S0955-0674(98)80057-4; Simon DB, 1996, NAT GENET, V13, P183, DOI 10.1038/ng0696-183; SUVITAYAVAT W, 1994, AM J PHYSIOL, V266, pC284, DOI 10.1152/ajpcell.1994.266.1.C284; Takahashi N, 2000, P NATL ACAD SCI USA, V97, P5434, DOI 10.1073/pnas.090091297; Yang TX, 1996, AM J PHYSIOL-RENAL, V271, pF931, DOI 10.1152/ajprenal.1996.271.4.F931	26	83	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8767	8770		10.1074/jbc.C200021200	http://dx.doi.org/10.1074/jbc.C200021200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11815599	hybrid			2022-12-25	WOS:000174400600004
J	O'Neill, T; Giarratani, L; Chen, P; Iyer, L; Lee, CH; Bobiak, M; Kanai, F; Zhou, BB; Chung, JH; Rathbun, GA				O'Neill, T; Giarratani, L; Chen, P; Iyer, L; Lee, CH; Bobiak, M; Kanai, F; Zhou, BB; Chung, JH; Rathbun, GA			Determination of substrate motifs for human Chk1 and hCds1/Chk2 by the oriented peptide library approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA GENE; CELL-CYCLE REGULATION; XENOPUS EGG EXTRACTS; CDK FAMILY MEMBER; PROTEIN-KINASE; S-PHASE; SCHIZOSACCHAROMYCES-POMBE; IONIZING-RADIATION; CRYSTAL-STRUCTURE	Mammalian Chk1 and Chk2 are two Ser/Thr effector kinases that play critical roles in DNA damage-activated cell cycle checkpoint signaling pathways downstream of ataxia telangiectasia-mutated and ataxia telangiectasia-related. Endogenous substrates have been identified for human hCds1/Chk2 and Chk1; however, the sequences surrounding the substrate residues appear unrelated, and consensus substrate motifs for the two Ser/Thr kinases remain unknown. We have utilized peptide library analyses to develop specific, highly preferred substrate motifs for hCds1/Chk2 and Chk1. The optimal motifs are similar for both kinases and most closely resemble the previously identified Chk1 and hCds1/Chk2 substrate target sequences in Cdc25C and Cdc25A, the regulation of which plays an important role in S and G(2)M arrest. Essential residues required for the definition of the optimal motifs were also identified. Utilization of the peptides to assay the substrate specificities and catalytic activities of Chk1 and hCds1/Chk2 revealed substantial differences between the two Ser/Thr kinases. Structural modeling analyses of the peptides into the Chk1 catalytic cleft were consistent with Chk1 kinase assays defining substrate suitability. The library-derived substrate preferences were applied in a genome-wide search program, revealing novel targets that might serve as substrates for hCds1/Chk2 or Chk1 kinase activity.	Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Ctr Blood Res, Boston, MA 02115 USA; Agouron Pharmaceut Inc, San Diego, CA 92121 USA; Harvard Univ, Sch Med, Ctr Res Comp, Boston, MA 02115 USA; NIH, HLBI, Lab Biochem Genet, Bethesda, MD 20892 USA; GlaxoSmithKline, Dept Oncol Res, King Of Prussia, PA 19406 USA; Harvard Univ, Beth Israel Deaconess Hosp, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Pfizer; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; GlaxoSmithKline; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rathbun, GA (corresponding author), Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat,Ctr Blood Res, 200 Longwood Ave,Warren Alpert Bldg,Rm 135, Boston, MA 02115 USA.	grathbun@cbr.med.harvard.edu		Iyer, Lakshmanan/0000-0001-9167-6396				Ahn JY, 2000, CANCER RES, V60, P5934; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; BANGA SS, 1995, MOL GEN GENET, V246, P148, DOI 10.1007/BF00294677; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Besset V, 1998, MOL REPROD DEV, V50, P18, DOI 10.1002/(SICI)1098-2795(199805)50:1&lt;18::AID-MRD3&gt;3.0.CO;2-#; Besset V, 1999, CELL GROWTH DIFFER, V10, P173; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boder E, 1970, Psychiatr Neurol Med Psychol Beih, V13-14, P8; Brondello JM, 1999, MOL CELL BIOL, V19, P4262; Brown AL, 1999, P NATL ACAD SCI USA, V96, P3745, DOI 10.1073/pnas.96.7.3745; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chen MS, 2001, MOL CELL BIOL, V21, P3853, DOI 10.1128/MCB.21.12.3853-3861.2001; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; Esashi F, 1999, MOL CELL, V4, P167, DOI 10.1016/S1097-2765(00)80364-0; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Guo ZJ, 2000, MOL BIOL CELL, V11, P1535, DOI 10.1091/mbc.11.5.1535; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARI KL, 1995, CELL, V82, P815, DOI 10.1016/0092-8674(95)90478-6; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirose T, 1997, EUR J BIOCHEM, V249, P481, DOI 10.1111/j.1432-1033.1997.t01-1-00481.x; Hutchins JRA, 2000, FEBS LETT, V466, P91, DOI 10.1016/S0014-5793(99)01763-9; JIMENEZ G, 1992, P NATL ACAD SCI USA, V89, P4952, DOI 10.1073/pnas.89.11.4952; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; KATO R, 1994, NUCLEIC ACIDS RES, V22, P3104, DOI 10.1093/nar/22.15.3104; Kuljis RO, 1999, BRAIN RES, V842, P351, DOI 10.1016/S0006-8993(99)01813-2; Kumagai A, 2000, MOL CELL, V6, P839, DOI 10.1016/S1097-2765(00)00082-4; Le Boffant F, 1998, EUR J BIOCHEM, V257, P112, DOI 10.1046/j.1432-1327.1998.2570112.x; Le Bouffant F, 2000, MOL CELL NEUROSCI, V16, P388, DOI 10.1006/mcne.2000.0881; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lin PT, 2000, J NEUROSCI, V20, P9152; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu HY, 2002, J BIOL CHEM, V277, P2637, DOI 10.1074/jbc.M109016200; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; Lukas C, 2001, CANCER RES, V61, P4990; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McKinnon PJ, 2001, TRENDS MOL MED, V7, P233, DOI 10.1016/S1471-4914(01)02035-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oishi I, 1998, MECH DEVELOP, V71, P49, DOI 10.1016/S0925-4773(97)00200-1; Oishi I, 2001, MOL CELL BIOL, V21, P1329, DOI 10.1128/MCB.21.4.1329-1335.2001; Oka A, 1998, NEUROSCI LETT, V252, P195, DOI 10.1016/S0304-3940(98)00576-X; OKUDA T, 1992, ONCOGENE, V7, P2249; Rhind N, 2000, J CELL SCI, V113, P3889; Robertson K, 1999, ONCOGENE, V18, P7070, DOI 10.1038/sj.onc.1203194; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; SEATON BL, 1992, GENE, V119, P83, DOI 10.1016/0378-1119(92)90069-2; Shieh SY, 2000, GENE DEV, V14, P289; Sibon OCM, 2000, NAT CELL BIOL, V2, P90, DOI 10.1038/35000041; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Takai H, 2000, GENE DEV, V14, P1439; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Walworth NC, 2000, CURR OPIN CELL BIOL, V12, P697, DOI 10.1016/S0955-0674(00)00154-X; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WEEKES J, 1994, EUR J BIOCHEM, V219, P751, DOI 10.1111/j.1432-1033.1994.tb18554.x; Weinert T, 1998, CURR OPIN GENET DEV, V8, P185, DOI 10.1016/S0959-437X(98)80140-8; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zeng Y, 1999, MOL CELL BIOL, V19, P7410; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	91	125	128	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16102	16115		10.1074/jbc.M111705200	http://dx.doi.org/10.1074/jbc.M111705200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11821419	hybrid			2022-12-25	WOS:000175510400118
J	Uddin, S; Sassano, A; Deb, DK; Verma, A; Majchrzak, B; Rahman, A; Malik, AB; Fish, EN; Platanias, LC				Uddin, S; Sassano, A; Deb, DK; Verma, A; Majchrzak, B; Rahman, A; Malik, AB; Fish, EN; Platanias, LC			Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; IFN-GAMMA; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; DEPENDENT ACTIVATION; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; TUMOR PROMOTION; IRS-PATHWAY; MAP KINASE	It is well established that engagement of the Type I interferon (IFN) receptor results in activation of JAKs (Janus kinases), which in turn regulate tyrosine phosphorylation of STAT proteins. Subsequently, the IFN-dependent tyrosine-phosphorylated/activated STATs translocate to the nucleus to regulate gene transcription. In addition to tyrosine phosphorylation, phosphorylation of Stat1 on serine 727 is essential for induction of its transcriptional activity, but the IFNalpha-dependent serine kinase that regulates such phosphorylation remains unknown. In the present study we provide evidence that PKC-delta, a member of the protein kinase C family of proteins, is activated during engagement of the Type I IFN receptor and associates with Stat1. Such an activation of PKC-delta appears to be critical for phosphorylation of Stat1 on serine 727, as inhibition of PKC-delta activation diminishes the IFNalpha- or IFNbeta-dependent serine phosphorylation of Stat1. In addition, treatment of cells with the PKC-delta inhibitor rottlerin or the expression of a dominant-negative PKC-delta mutant results in inhibition of IFNa- and IFNbeta-dependent gene transcription via ISRE or GAS elements. Interestingly, PKC-delta inhibition also blocks activation of the p38 MAP kinase, the function of which is required for IFNa-dependent transcriptional regulation, suggesting a dual mechanism by which this kinase participates in the generation of IFNalpha responses. Altogether, these findings indicate that PKC-delta functions as a serine kinase for Stat1 and an upstream regulator of the p38 MAP kinase and plays an important role in the induction of Type I IFN-biological responses.	Univ Illinois, Dept Med, Hematol Oncol Sect, Chicago, IL 60607 USA; W Side Vet Adm Med Ctr, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Platanias, LC (corresponding author), Univ Illinois, Dept Med, Hematol Oncol Sect, MBRB,MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.	Lplatani@uic.edu		Malik, Asrar/0000-0002-8205-7128; Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA77816, CA73381] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Alsayed Y, 2000, J IMMUNOL, V164, P1800, DOI 10.4049/jimmunol.164.4.1800; Athie-M V, 2000, EUR J IMMUNOL, V30, P1425, DOI 10.1002/(SICI)1521-4141(200005)30:5<1425::AID-IMMU1425>3.0.CO;2-Q; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Fish EN, 1999, J BIOL CHEM, V274, P571, DOI 10.1074/jbc.274.2.571; Gamero AM, 2000, J BIOL CHEM, V275, P16574, DOI 10.1074/jbc.M910149199; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Matsumoto M, 2001, J BIOL CHEM, V276, P14400, DOI 10.1074/jbc.M011093200; Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nguyen H, 2001, J BIOL CHEM, V276, P33361, DOI 10.1074/jbc.M105070200; Pal S, 2001, J BIOL CHEM, V276, P2395, DOI 10.1074/jbc.M007818200; Patel NA, 2001, J BIOL CHEM, V276, P22648, DOI 10.1074/jbc.M101260200; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Platanias LC, 1996, J BIOL CHEM, V271, P278, DOI 10.1074/jbc.271.1.278; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Reddig PJ, 1999, CANCER RES, V59, P5710; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Schnaper HW, 2000, PEDIATR NEPHROL, V14, P254, DOI 10.1007/s004670050050; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stephens JM, 1998, J BIOL CHEM, V273, P31408, DOI 10.1074/jbc.273.47.31408; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; Su L, 2000, J BIOL CHEM, V275, P12661, DOI 10.1074/jbc.275.17.12661; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tong HY, 2000, CIRC RES, V87, P309, DOI 10.1161/01.RES.87.4.309; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 1997, BLOOD, V90, P2574; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Uddin S, 1997, BIOCHEM BIOPH RES CO, V235, P83, DOI 10.1006/bbrc.1997.6741; Uddin S, 1998, BRIT J HAEMATOL, V101, P446, DOI 10.1046/j.1365-2141.1998.00731.x; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	54	176	182	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14408	14416		10.1074/jbc.M109671200	http://dx.doi.org/10.1074/jbc.M109671200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839738	hybrid			2022-12-25	WOS:000175203000010
J	Rubio, LM; Rangaraj, P; Homer, MJ; Roberts, GP; Ludden, PW				Rubio, LM; Rangaraj, P; Homer, MJ; Roberts, GP; Ludden, PW			Cloning and mutational analysis of the gamma gene from Azotobacter vinelandii defines a new family of proteins capable of metallocluster binding and protein stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-MOLYBDENUM COFACTOR; APO-MOFE PROTEIN; RHODOBACTER-CAPSULATUS; NITROGEN-FIXATION; CRYSTALLOGRAPHIC STRUCTURE; DINITROGENASE REDUCTASE; KLEBSIELLA-PNEUMONIAE; CLUSTER; APODINITROGENASE; BIOSYNTHESIS	Dinitrogenase is a heterotetrameric (alpha(2)beta(2)) enzyme that catalyzes the reduction of dinitrogen to ammonium and contains the iron-molybdenum cofactor (FeMo-co) at its active site. Certain Azotobacter vinelandii mutant strains unable to synthesize FeMo-co accumulate an apo form of dinitrogenase (lacking FeMo-co), with a subunit composition alpha(2)beta(2)gamma(2), which can be activated in vitro by the addition of FeMo-co. The gamma protein is able to bind FeMo-co or apodinitrogenase independently, leading to the suggestion that it facilitates FeMo-co insertion into the apoenzyme. In this work, the non-nif gene encoding they subunit (nafY) has been cloned, sequenced, and found to encode a NifY-like protein. This finding, together with a wealth of knowledge on the biochemistry of proteins involved in FeMo-co and FeV-co biosyntheses, allows us to define a new family of iron and molybdenum (or vanadium) cluster-binding proteins that includes NifY, NifX, VnfX, and now gamma. In vitro FeMo-co insertion experiments presented in this work demonstrate that gamma stabilizes apodinitrogenase in the conformation required to be fully activable by the cofactor. Supporting this conclusion, we show that strains containing mutations in both nafY and nifX are severely affected in diazotrophic growth and extractable dinitrogenase activity when cultured under conditions that are likely to occur in natural environments. This finding reveals the physiological importance of the apodinitrogenase-stabilizing role of which both proteins are capable. The relationship between the metal cluster binding capabilities of this new family of proteins and the ability of some of them to stabilize an apoenzyme is still an open matter.	Univ Wisconsin, Dept Biochem, Coll Agr & Life Sci, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Coll Agr & Life Sci, Madison, WI 53706 USA; Univ Wisconsin, Ctr Study Nitrogen Fixat, Coll Agr & Life Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Wisconsin, Dept Biochem, Coll Agr & Life Sci, 433 Babcock Dr, Madison, WI 53706 USA.	pludden@cals.wisc.edu	Rubio, Luis M./B-5827-2009	Rubio, Luis M./0000-0003-1596-2475	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN RM, 1994, CRIT REV BIOTECHNOL, V14, P225, DOI 10.3109/07388554409079834; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BISHOP PE, 1990, ANNU REV PLANT PHYS, V41, P109; BRANDNER JP, 1989, J BACTERIOL, V171, P360, DOI 10.1128/jb.171.1.360-368.1989; BULEN WA, 1966, P NATL ACAD SCI USA, V56, P979, DOI 10.1073/pnas.56.3.979; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; Christiansen J, 1998, BIOCHEMISTRY-US, V37, P12611, DOI 10.1021/bi981165b; FREY J, 1985, GENE, V36, P143, DOI 10.1016/0378-1119(85)90078-2; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAGEMAN RV, 1978, P NATL ACAD SCI USA, V75, P2699, DOI 10.1073/pnas.75.6.2699; HOMER MJ, 1993, J BACTERIOL, V175, P4907, DOI 10.1128/JB.175.15.4907-4910.1993; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; JACOBSON MR, 1989, J BACTERIOL, V171, P1017, DOI 10.1128/jb.171.2.1017-1027.1989; JACOBSON MR, 1986, J BACTERIOL, V167, P480, DOI 10.1128/jb.167.2.480-486.1986; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JOERGER RD, 1988, J BACTERIOL, V170, P1475, DOI 10.1128/jb.170.4.1475-1487.1988; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; Kumagai H, 1997, BIOCHEMISTRY-US, V36, P5509, DOI 10.1021/bi970014q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MORENOVIVIAN C, 1989, MOL GEN GENET, V216, P353, DOI 10.1007/BF00334376; PAGE WJ, 1979, J BACTERIOL, V139, P1058, DOI 10.1128/JB.139.3.1058-1061.1979; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; Rangaraj P, 2001, J BIOL CHEM, V276, P15968, DOI 10.1074/jbc.M100907200; ROBINSON AC, 1989, J BIOL CHEM, V264, P10088; ROBSON RL, 1986, NATURE, V322, P388, DOI 10.1038/322388a0; Ruttimann-Johnson C, 1999, J BIOL CHEM, V274, P18087, DOI 10.1074/jbc.274.25.18087; SCHMEHL M, 1993, MOL GEN GENET, V241, P602, DOI 10.1007/BF00279903; SHAH VK, 1972, BIOCHIM BIOPHYS ACTA, V256, P498, DOI 10.1016/0005-2728(72)90078-3; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1984, ANNU REV BIOCHEM, V53, P231, DOI 10.1146/annurev.bi.53.070184.001311; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; Smith J.A., 2000, CURRENT PROTOCOLS MO; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WHITE TC, 1992, J BIOL CHEM, V267, P24007	39	48	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14299	14305		10.1074/jbc.M107289200	http://dx.doi.org/10.1074/jbc.M107289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11823455	hybrid			2022-12-25	WOS:000175096000123
J	Santas, AJ; Peterson, JA; Halbleib, JL; Craig, SE; Humphries, MJ; Peters, DMP				Santas, AJ; Peterson, JA; Halbleib, JL; Craig, SE; Humphries, MJ; Peters, DMP			Alternative splicing of the IIICS domain in fibronectin governs the role of the heparin II domain in fibrillogenesis and cell spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METALLOPROTEINASE GENE-EXPRESSION; CHONDROITIN SULFATE PROTEOGLYCAN; HUMAN-PLASMA FIBRONECTIN; FOCAL ADHESION FORMATION; BINDING DOMAIN; V-REGION; ALPHA-4-BETA-1 INTEGRIN; CONNECTING SEGMENT; MELANOMA ADHESION; EDA SEGMENT	The Heparin (Hep) II-binding domain of fibronectin regulates the formation of focal adhesions and actin stress fibers and hence plays an important role in cell spreading, migration, and fibronectin fibrillogenesis. Using human skin fibroblast cultures, we demonstrate that alternative splicing of the neighboring IIICS domain may regulate the activities of the Hep II domain in cell spreading and fibronectin fibrillogenesis. Recombinant Hep II domains, adjacent to either the IIICS domain or the H89 splice variant that contains the amino-terminal sequence of the IIICS domain, blocked fibronectin fibrillogenesis and required sulfated proteoglycans to mediate cell spreading. If the Hep 11 domain was adjacent to either the H0 or H95 splice variants, which both lack the amino terminus of the IIICS domain, fibrillogenesis was not inhibited and cell spreading was independent of a sulfated proteoglycan-mediated mechanism. The effect of the splice variants on the Hep 11 domain could be mimicked using a Hep II domain that contained only 6 amino acids from the 11115 repeat or 10 amino acids from the IIICS domain suggesting that sequences proximal to the 1,1,4 repeat determined the role of the Hep II domain in these processes. We propose that alternative splicing of the IIICS domain modulates interactions between heparan sulfate proteoglycans and the Hep II domain and that this serves as a mechanism to control the biological activities of fibronectin.	Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Manchester	Peters, DMP (corresponding author), Univ Wisconsin, Dept Pathol & Lab Med, Rm 6590 MSC,1300 Univ Ave, Madison, WI 53706 USA.		Santas, Amy/F-5532-2013	Humphries, Martin/0000-0002-4331-6967; Santas, Amy/0000-0001-8342-9969	NEI NIH HHS [EY12515] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012515] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Bloom L, 1999, MOL BIOL CELL, V10, P1521, DOI 10.1091/mbc.10.5.1521; Bultmann H, 1998, J BIOL CHEM, V273, P2601, DOI 10.1074/jbc.273.5.2601; BurtonWurster N, 1997, MATRIX BIOL, V15, P441, DOI 10.1016/S0945-053X(97)90018-4; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; DZAMBA BJ, 1994, J BIOL CHEM, V269, P19646; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; FFRENCHCONSTANT C, 1995, EXP CELL RES, V221, P261, DOI 10.1006/excr.1995.1374; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1988, DEVELOPMENT, V104, P369; FFRENCHCONSTANT C, 1989, DEVELOPMENT, V106, P375; GREENWOOD FC, 1963, BIOCHEM J, V89, P114, DOI 10.1042/bj0890114; HashimotoUoshima M, 1997, J CELL SCI, V110, P2271; HOCKING DC, 1994, J BIOL CHEM, V269, P19183; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; INGHAM KC, 1993, BIOCHEMISTRY-US, V32, P12548, DOI 10.1021/bi00097a035; INGHAM KC, 1990, BIOCHEM J, V272, P605, DOI 10.1042/bj2720605; JARNAGIN WR, 1994, J CELL BIOL, V127, P2037, DOI 10.1083/jcb.127.6.2037; Kapila YL, 1997, J BIOL CHEM, V272, P18932, DOI 10.1074/jbc.272.30.18932; Kapila YL, 1996, MATRIX BIOL, V15, P251, DOI 10.1016/S0945-053X(96)90116-X; Kapila YL, 1999, J BIOL CHEM, V274, P30906, DOI 10.1074/jbc.274.43.30906; Klass CM, 2000, J CELL SCI, V113, P493; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; MacLeod JN, 1996, J BIOL CHEM, V271, P18954, DOI 10.1074/jbc.271.31.18954; Manabe R, 1997, J CELL BIOL, V139, P295, DOI 10.1083/jcb.139.1.295; Manabe R, 1999, J BIOL CHEM, V274, P5919, DOI 10.1074/jbc.274.9.5919; MCCARTHY JB, 1988, BIOCHEMISTRY-US, V27, P1380, DOI 10.1021/bi00404a044; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1984, J CELL BIOL, V98, P22, DOI 10.1083/jcb.98.1.22; MOSHER DF, 1983, J BIOL CHEM, V258, P6595; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; Mosher DF, 1989, FIBRONECTIN; Mostafavi-Pour Z, 2001, MATRIX BIOL, V20, P63, DOI 10.1016/S0945-053X(00)00131-1; MOULD AP, 1994, J BIOL CHEM, V269, P27224; MOULD AP, 1990, J BIOL CHEM, V265, P4020; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; MOULD AP, 1991, J BIOL CHEM, V266, P2579; NOVOKHATNY V, 1992, J MOL BIOL, V227, P1182, DOI 10.1016/0022-2836(92)90530-W; PETERS DMP, 1987, J CELL BIOL, V104, P121, DOI 10.1083/jcb.104.1.121; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Saito S, 1999, J BIOL CHEM, V274, P30756, DOI 10.1074/jbc.274.43.30756; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwarzbauer J., 1990, EXTRACELLULAR MATRIX, P195; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; Sechler JL, 2000, J CELL SCI, V113, P1491; Serini G, 1998, J CELL BIOL, V142, P873, DOI 10.1083/jcb.142.3.873; Sharma A, 1999, EMBO J, V18, P1468, DOI 10.1093/emboj/18.6.1468; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; WOODS A, 1988, EXP CELL RES, V177, P272, DOI 10.1016/0014-4827(88)90461-2; Woods A, 2000, ARCH BIOCHEM BIOPHYS, V374, P66, DOI 10.1006/abbi.1999.1607	56	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13650	13658		10.1074/jbc.M111361200	http://dx.doi.org/10.1074/jbc.M111361200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832485	hybrid			2022-12-25	WOS:000175096000042
J	Soboloff, J; Berger, SA				Soboloff, J; Berger, SA			Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; CALCIUM-IONS; STEEL FACTOR; APOPTOSIS; DEGRANULATION; INTERLEUKIN-3; MITOCHONDRIA; CYTOTOXICITY; CASPASE-12; SECRETION	Depletion of Ca2+ from the endoplasmic reticulum (ER) induces large increases in cytoplasmic Ca2+, mito. chondrial Ca2+ loading, protein synthesis inhibition, and cell death. To clarify the connections among these events, we have evaluated the effect of Ca2+ mobilizing agents thapsigargin (Tg), econazole (Ec), and the growth factor Steel Factor (SLF) on bone marrow-derived mast cells (BMMCs). BMMC Ca2+ stores were found to consist of a Tg-sensitive ER compartment, the Tg-insensitive SIC store, and mitochondrial stores. Low levels of Ec interfered with Tg-stimulated mitochondrial loading while promoting progressive leakage of Ca2+ from the ER. Low levels of Ec completely reversed Tg toxicity while higher levels blocked store-operated influx and induced cell death in a SLF-enhanced manner. Both Ec and Tg inhibited protein synthesis, however, only SLF plus Tg or very high levels of Ec were able to significantly stimulate EIF-2alpha phosphorylation. Cycloheximide only partially protected BMMCs from Tg toxicity yet strongly synergized with Ec to induce cell death. These results therefore indicate that although both Tg and Ec deplete ER Ca2+ levels, Ec-induced cell death results from sustained protein synthesis inhibition while Tg toxicity results primarily from mitochondrial overload and secondarily from ER stress associated with Ca2+ depletion.	Univ Hlth Network, Arthrit & Immune Disorder Res Ctr, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Berger, SA (corresponding author), Univ Hlth Network, Arthrit & Immune Disorder Res Ctr, 620 Univ,Suite 700, Toronto, ON M5G 2M9, Canada.		Soboloff, Jonathan/I-6995-2012	Soboloff, Jonathan/0000-0001-5192-1297				Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; BAUMGARTNER RA, 1994, J IMMUNOL, V153, P2609; BERGER SA, 1994, J EXP MED, V180, P471, DOI 10.1084/jem.180.2.471; Bian XP, 1997, AM J PHYSIOL-CELL PH, V272, pC1241, DOI 10.1152/ajpcell.1997.272.4.C1241; Boitier E, 1999, J CELL BIOL, V145, P795, DOI 10.1083/jcb.145.4.795; Broudy VC, 1997, BLOOD, V90, P1345, DOI 10.1182/blood.V90.4.1345.1345_1345_1364; COLUMBO M, 1994, BIOCHEM PHARMACOL, V47, P2137, DOI 10.1016/0006-2952(94)90248-8; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FRANZIUS D, 1994, PFLUG ARCH EUR J PHY, V428, P433, DOI 10.1007/BF00374562; Gamberucci A, 1998, BIOCHEM BIOPH RES CO, V248, P75, DOI 10.1006/bbrc.1998.8810; Golovina VA, 1997, SCIENCE, V275, P1643, DOI 10.1126/science.275.5306.1643; Gommerman JL, 1998, BLOOD, V91, P1891, DOI 10.1182/blood.V91.6.1891.1891_1891_1900; Gommerman JL, 2000, BLOOD, V96, P3734, DOI 10.1182/blood.V96.12.3734.h8003734_3734_3742; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gunter TE, 2000, CELL CALCIUM, V28, P285, DOI 10.1054/ceca.2000.0168; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Herrington J, 1996, NEURON, V16, P219, DOI 10.1016/S0896-6273(00)80038-0; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Jan CR, 1999, BBA-MOL CELL RES, V1448, P533, DOI 10.1016/S0167-4889(98)00159-1; KANNER BI, 1983, P NATL ACAD SCI-BIOL, V80, P5744, DOI 10.1073/pnas.80.18.5744; Kass GEN, 1999, ENVIRON HEALTH PERSP, V107, P25, DOI 10.2307/3434469; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LAWSON D, 1978, J CELL BIOL, V79, P394, DOI 10.1083/jcb.79.2.394; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; ORRENIUS S, 1992, ANN NEUROL, V32, pS33, DOI 10.1002/ana.410320708; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; Putney JW, 1999, BIOESSAYS, V21, P38; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777	34	83	86	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13812	13820		10.1074/jbc.M112129200	http://dx.doi.org/10.1074/jbc.M112129200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11836247	hybrid			2022-12-25	WOS:000175096000062
J	Genschel, J; Bazemore, LR; Modrich, P				Genschel, J; Bazemore, LR; Modrich, P			Human exonuclease I is required for 5 ' and 3 ' mismatch repair.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; SACCHAROMYCES-CEREVISIAE EXO1; MUTATION AVOIDANCE; TUMOR-CELLS; NUCLEAR EXTRACTS; HMLH1 PROMOTER; COLON-CANCER; GENE; HETERODIMER; IDENTIFICATION	We have partially purified a human activity that restores mismatch-dependent, bi-directional excision to a human nuclear extract fraction depleted for one or more mismatch repair excision activities. Human EXOI copurifies with the excision activity, and the purified activity can be replaced by near homogeneous recombinant hEXOI. Despite the reported 5' to 3' hydrolytic polarity of this activity, hEXOI participates in mismatch-provoked excision directed by a strand break located either 5' or 3' to the mispair. When the strand break that directs repair is located 3' to the mispair, hEXOI- and mismatch-dependent gap formation in excision-depleted extracts requires both hMutSalpha and hMutLalpha. However, excision directed by a 5' strand break requires hMutSa but can occur in absence of hMutLa. In systems comprised of pure components, the 5' to 3' hydrolytic activity of hEXOI is activated by hMutSa in a mismatch-dependent manner. These observations indicate a hydrolytic function for hEXOI in 5'-heteroduplex correction. The involvement of hEXOI in 3'-heteroduplex repair suggests that it has a regulatory/structural role in assembly of the 3'-excision complex or that the protein possesses a cryptic 3' to 5' hydrolytic activity.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Modrich, P (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.			Modrich, Paul/0000-0001-8708-9885	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45190] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Amin NS, 2001, MOL CELL BIOL, V21, P5142, DOI 10.1128/MCB.21.15.5142-5155.2001; Bennett SE, 1997, CANCER RES, V57, P2956; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Dao V, 1998, J BIOL CHEM, V273, P9202, DOI 10.1074/jbc.273.15.9202; Datta A, 2000, MOL CELL, V6, P593, DOI 10.1016/S1097-2765(00)00058-7; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FANG WH, 1993, J BIOL CHEM, V268, P11838; FANG WH, 1993, COLD SPRING HARB SYM, V58, P597, DOI 10.1101/SQB.1993.058.01.066; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jiricny J, 1998, MUTAT RES-DNA REPAIR, V409, P107, DOI 10.1016/S0921-8777(98)00056-1; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Kokoska RJ, 1998, MOL CELL BIOL, V18, P2779, DOI 10.1128/MCB.18.5.2779; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Lin YL, 1998, J BIOL CHEM, V273, P1453, DOI 10.1074/jbc.273.3.1453; Longley MJ, 1997, J BIOL CHEM, V272, P10917; Ma AH, 2000, ONCOGENE, V19, P2249, DOI 10.1038/sj.onc.1203568; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Sokolsky T, 2000, GENETICS, V155, P589; Strathdee G, 1999, ONCOGENE, V18, P2335, DOI 10.1038/sj.onc.1202540; SZANKASI P, 1992, J BIOL CHEM, V267, P3014; SZANKASI P, 1995, SCIENCE, V267, P1166, DOI 10.1126/science.7855597; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tishkoff DX, 1998, CANCER RES, V58, P5027; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Viswanathan M, 2001, J BIOL CHEM, V276, P31053, DOI 10.1074/jbc.M105481200; Wilson DM, 1998, NUCLEIC ACIDS RES, V26, P3762, DOI 10.1093/nar/26.16.3762	51	187	192	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13302	13311		10.1074/jbc.M111854200	http://dx.doi.org/10.1074/jbc.M111854200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809771	hybrid			2022-12-25	WOS:000175036300101
J	Grinberg, M; Sarig, R; Zaltsman, Y; Frumkin, D; Grammatikakis, N; Reuveny, E; Gross, A				Grinberg, M; Sarig, R; Zaltsman, Y; Frumkin, D; Grammatikakis, N; Reuveny, E; Gross, A			tBID homooligomerizes in the mitochondrial membrane to induce apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; CHANNEL ACTIVITY; DEATH; BAX; BCL-2; PROTEIN; BH3	Activation of the tumor necrosis factor R1/Fas receptor results in the cleavage of cytosolic BID to truncated tBID. tBID translocates to the mitochondria to induce the oligomerization of BAX or BAK, resulting in the release of cytochrome c (Cyt c). Here we demonstrate that in tumor necrosis factor alpha-activated FL5.12 cells, tBID becomes part of a 45-kDa cross-linkable mitochondrial complex that does not include BAX or BAK. Using fluorescence resonance energy transfer analysis and co-immunoprecipitation, we demonstrate that tBID-tBID interactions occur in the mitochondria of living cells. Cross-linking experiments using a tBID-GST chimera indicated that tBID forms homotrimers in the mitochondrial membrane. To test the functional consequence of tBID oligomerization, we expressed a chimeric FKBP-tBID molecule. Enforced dimerization of FKBP-tBID by the bivalent ligand FK1012 resulted in Cyt c, release, caspase activation, and apoptosis. Surprisingly, enforced dimerization of tBID did not result in the dimerization of either BAX or BAK. Moreover, a tBID BH3 mutant (G94E), which does not interact with or induce the dimerization of either BAX or BAK, formed the 45kDa complex and induced both Cyt c release and apoptosis. Thus, tBID oligomerization may represent an alternative mechanism for inducing mitochondrial dysfunction and apoptosis.	Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Queens Univ, Dept Microbiol & Immunol, Kingston, ON K7L 3N6, Canada	Weizmann Institute of Science; Weizmann Institute of Science; Queens University - Canada	Gross, A (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, IL-76100 Rehovot, Israel.	atan.gross@weizmann.ac.il	Gross, Atan/ABC-2640-2020					Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahajan NP, 1998, NAT BIOTECHNOL, V16, P547, DOI 10.1038/nbt0698-547; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730	24	133	136	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12237	12245		10.1074/jbc.M104893200	http://dx.doi.org/10.1074/jbc.M104893200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805084	hybrid			2022-12-25	WOS:000174846400083
J	Kilic, G; Fitz, JG				Kilic, G; Fitz, JG			Heterotrimeric G-proteins activate Cl- channels through stimulation of a cyclooxygenase-dependent pathway in a model liver cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); GTP-BINDING PROTEINS; CHLORIDE CHANNELS; RAT HEPATOCYTES; HEPATOMA-CELLS; CA2+ INFLOW; VOLUME REGULATION; ACINAR-CELLS; HTC HEPATOMA; GUINEA-PIG	Circulating hormones produce rapid changes in the Cl- permeability of liver cells through activation of plasma membrane receptors coupled to heterotrimeric G-proteins. The resulting effects on intracellular pH, membrane potential, and Cl- content are important contributors to the overall metabolic response. Consequently, the purpose of these studies was to evaluate the mechanisms responsible for G-protein-mediated changes in membrane Cl- permeability using HTC hepatoma cells as a model. Using patch clamp techniques, intracellular dialysis with 0.3 mM guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) increased membrane conductance from 10 to 260 picosiemens/picofarads due to activation of Ca2+-dependent Cl- currents that were outwardly rectifying and exhibited slow activation at depolarizing potentials. These effects were mimicked by intracellular AIF(4)(-) (0.03 mM) and inhibited by pertussis toxin (PTX), consistent with current activation through Galpha(i). Studies using defined agonists and inhibitors indicate that Cl- channel activation by GTPgammaS occurs through an indomethacin-sensitive pathway involving sequential activation of phospholipase C, mobilization of Ca2+ from inositol 1,4,5-trisphosphate-sensitive stores, and stimulation of phospholipase A, and cyclooxygenase (COX). Accordingly, the conductance responses to GTPgammaS or to intracellular Ca2+ were inhibited by COX inhibitors. These results indicate that PTX-sensitive G-proteins regulate the Cl- permeability of HTC cells through Ca2+-dependent stimulation of COX activity. Thus, receptor-mediated activation of Gai may be essential for hormonal regulation of liver transport and metabolism through COX-dependent opening of a distinct population of plasma membrane Cl- channels.	Univ Colorado, Hlth Sci Ctr, Dept Med, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kilic, G (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, 4200 E 9th Ave,Campus Box B158,Rm 6416, Denver, CO 80262 USA.							Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; BARNARD GF, 1984, J CLIN INVEST, V74, P173, DOI 10.1172/JCI111399; Begenisich T, 1998, J MEMBRANE BIOL, V163, P77, DOI 10.1007/s002329900372; BERVEN LA, 1994, BIOCHEM J, V299, P399, DOI 10.1042/bj2990399; BERVEN LA, 1995, J BIOL CHEM, V270, P25893, DOI 10.1074/jbc.270.43.25893; BERVEN LA, 1994, FEBS LETT, V346, P235, DOI 10.1016/0014-5793(94)00481-1; Bodily K, 1997, HEPATOLOGY, V25, P403; BOYER JL, 1992, ANNU REV PHYSIOL, V54, P415, DOI 10.1146/annurev.ph.54.030192.002215; Brash AR, 2001, J CLIN INVEST, V107, P1339, DOI 10.1172/JCI13210; BREUER W, 1989, BIOCHEM BIOPH RES CO, V163, P398, DOI 10.1016/0006-291X(89)92149-9; CAPIOD T, 1989, PROC R SOC SER B-BIO, V236, P187, DOI 10.1098/rspb.1989.0020; Casado M, 2001, FASEB J, V15, P2016, DOI 10.1096/fj.01-0158fje; DOROSHENKO P, 1992, J PHYSIOL-LONDON, V449, P197, DOI 10.1113/jphysiol.1992.sp019082; DOROSHENKO P, 1991, J PHYSIOL-LONDON, V436, P711, DOI 10.1113/jphysiol.1991.sp018575; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; EVANS MG, 1986, J PHYSIOL-LONDON, V378, P437, DOI 10.1113/jphysiol.1986.sp016229; Farber SA, 1999, J BIOL CHEM, V274, P19338, DOI 10.1074/jbc.274.27.19338; Farber SA, 2001, SCIENCE, V292, P1385, DOI 10.1126/science.1060418; FITZ JG, 1994, AM J PHYSIOL, V266, pG544, DOI 10.1152/ajpgi.1994.266.4.G544; Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241; FRIEDMANN N, 1980, BIOCHIM BIOPHYS ACTA, V596, P180, DOI 10.1016/0005-2736(80)90352-1; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLEESON D, 1990, AM J PHYSIOL, V258, pG299, DOI 10.1152/ajpgi.1990.258.2.G299; Graf J, 1996, J HEPATOL, V24, P53; HADDAD P, 1991, AM J PHYSIOL, V261, pG340, DOI 10.1152/ajpgi.1991.261.2.G340; HEATON JH, 1984, J BIOL CHEM, V259, P2396; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; KAHN RA, 1991, J BIOL CHEM, V266, P15595; Kilic G, 2001, J BIOL CHEM, V276, P26762, DOI 10.1074/jbc.M100992200; Kilic G, 2001, J PHYSIOL-LONDON, V532, P771, DOI 10.1111/j.1469-7793.2001.0771e.x; KRISTENSEN LO, 1986, AM J PHYSIOL, V251, pG575, DOI 10.1152/ajpgi.1986.251.5.G575; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Longo WE, 1998, PROSTAG OTH LIPID M, V56, P325, DOI 10.1016/S0090-6980(98)00058-6; MEIER PJ, 1984, J BIOL CHEM, V259, P614; Mitchell CH, 1997, AM J PHYSIOL-CELL PH, V272, pC212, DOI 10.1152/ajpcell.1997.272.1.C212; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; NUKINA S, 1994, AM J PHYSIOL, V266, pG99, DOI 10.1152/ajpgi.1994.266.1.G99; OGDEN DC, 1990, J PHYSIOL-LONDON, V422, P585, DOI 10.1113/jphysiol.1990.sp018002; PAPPONE PA, 1995, J GEN PHYSIOL, V106, P231, DOI 10.1085/jgp.106.2.231; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; Qu W, 1998, AM J PHYSIOL-GASTR L, V275, pG542, DOI 10.1152/ajpgi.1998.275.3.G542; RANDRIAMAMPITA C, 1988, PFLUG ARCH EUR J PHY, V411, P53, DOI 10.1007/BF00581646; Roman RM, 2001, AM J PHYSIOL-GASTR L, V280, pG344, DOI 10.1152/ajpgi.2001.280.3.G344; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; Sanchez-Margalet V, 1999, CELL MOL LIFE SCI, V55, P142, DOI 10.1007/s000180050279; Sanchez-Margalet V, 1999, DIABETOLOGIA, V42, P317, DOI 10.1007/s001250051157; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; STRANGE K, 1996, AM J PHYSIOL, V270, P711; SUNG CK, 1992, BIOCHEM BIOPH RES CO, V189, P1024, DOI 10.1016/0006-291X(92)92306-I; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; THOMAS CP, 1991, AM J PHYSIOL, V260, pF347, DOI 10.1152/ajprenal.1991.260.3.F347; Tomura H, 1997, J BIOL CHEM, V272, P23130, DOI 10.1074/jbc.272.37.23130; Tong LJ, 1998, MOL CELL BIOCHEM, V189, P55, DOI 10.1023/A:1006804429027; TRANTHI TA, 1987, J HEPATOL, V5, P322, DOI 10.1016/S0168-8278(87)80038-7; Voets T, 1998, J PHYSIOL-LONDON, V506, P341, DOI 10.1111/j.1469-7793.1998.341bw.x; WAKUI M, 1991, J MEMBRANE BIOL, V124, P179, DOI 10.1007/BF01870462; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; YANG LJ, 1991, J BIOL CHEM, V266, P22451	63	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11721	11727		10.1074/jbc.M108631200	http://dx.doi.org/10.1074/jbc.M108631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812774	hybrid			2022-12-25	WOS:000174846400017
J	Xie, Y; Chen, CM; Stevenson, MA; Auron, PE; Calderwood, SK				Xie, Y; Chen, CM; Stevenson, MA; Auron, PE; Calderwood, SK			Heat shock factor 1 represses transcription of IL-1 beta gene through physical interaction with the nuclear factor of interleukin 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; PROINTERLEUKIN 1-BETA GENE; TISSUE-SPECIFIC EXPRESSION; COLONY-STIMULATING FACTOR; C/EBP-RELATED PROTEINS; DNA-BINDING ABILITY; HUMAN-MONOCYTES; ANTIINFLAMMATORY DRUGS; CYTOKINE PRODUCTION	Heat shock factor (HSF) 1 is the major heat shock transcription factor that regulates stress-inducible synthesis of heat shock proteins and is also essential in protection against endotoxic shock. Following our previous study, which demonstrated the transcriptional repression of the IL-1beta gene by HSF1 (Cahill, C. M., Waterman, W. R., Xie, Y., Auron, P. E., and Calderwood, S. K. (1996) J. Biol. Chem. 271, 24874-24879), we have examined the mechanisms of transcriptional repression. Our studies show that HSF1 represses the lipopolyliposaccharide-induced transcription of the IL-1beta promoter through direct interaction with the nuclear factor of interleukin 6 (NF-IL6, also known as CCAAT enhancer binding protein (C/EBP(beta), an essential regulator in IL-1beta transcription. We show for the first time that HSF1 binds directly to NF-IL6 in vivo and antagonizes its activity. The HSF1/NF-IL6 interaction involves a sequence of HSF1 containing the trimerization and regulatory domains and the bZip region of NF-IL6. HSF1 has little effect on IL-1beta promoter activity stimulated by the essential monocytic transcription factor Spi.1 but is strongly inhibitory to transcriptional activation by NF-IL6 and to the synergistic activation by NF-IL6 and Spi.1. Because of its ability to bind to specific C/EBP elements in the promoters of multiple genes and its ability to interact with other transcription factors, NF-IL6 is involved in transcriptional regulation of a wide range of genes. Interaction between HSF1 and NF-IL6 could thus be an important mechanism in HSF1 regulation of general gene transcription during endotoxin stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiat Oncol, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med,Mol & Cell Biol Lab, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Calderwood, SK (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	stuart_calderwood@dfci.harvard.edu			NCI NIH HHS [CA31303, CA47407, CA50642, CA68544] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050642, R01CA047407, P01CA031303, R01CA068544] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; AURON PE, 1994, EUR CYTOKINE NETW, V5, P573; Bassuk AG, 1997, J VIROL, V71, P3563, DOI 10.1128/JVI.71.5.3563-3573.1997; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; Brown IR, 1996, J NEUROSCI RES, V44, P52, DOI 10.1002/(SICI)1097-4547(19960401)44:1<52::AID-JNR7>3.0.CO;2-H; Cahill CM, 1996, J BIOL CHEM, V271, P24874; Chen CM, 1997, J BIOL CHEM, V272, P26803, DOI 10.1074/jbc.272.43.26803; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DINARELLO CA, 1984, REV INFECT DIS, V6, P51, DOI 10.1016/S1359-6101(97)00023-3; DINARELLO CA, 1986, CANCER RES, V46, P6236; Farkas T, 1998, MOL CELL BIOL, V18, P906, DOI 10.1128/MCB.18.2.906; FENTON MJ, 1988, J IMMUNOL, V140, P2267; FENTON MJ, 1987, J IMMUNOL, V138, P3972; FINCATO G, 1991, BLOOD, V77, P579; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; Gewert K, 1999, CELL SIGNAL, V11, P665, DOI 10.1016/S0898-6568(99)00014-5; He HY, 2000, CELL STRESS CHAPERON, V5, P406, DOI 10.1379/1466-1268(2000)005<0406:HAHSFC>2.0.CO;2; Housby JN, 1999, CYTOKINE, V11, P347, DOI 10.1006/cyto.1998.0437; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; KAPPEL M, 1991, IMMUNOLOGY, V73, P304; Kluger MJ, 1996, INFECT DIS CLIN N AM, V10, P1, DOI 10.1016/S0891-5520(05)70282-8; KNUDSEN PJ, 1987, J IMMUNOL, V139, P4129; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; KOMINATO Y, 1995, MOL CELL BIOL, V15, P58; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; McKnight SL, 1992, TRANSCRIPTIONAL REGU, P771; McMillan DR, 1998, J BIOL CHEM, V273, P7523, DOI 10.1074/jbc.273.13.7523; Mink S, 1996, MOL CELL BIOL, V16, P1316; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; NAGULAPALLI S, 1995, J IMMUNOL, V155, P4330; NATSUKA S, 1992, BLOOD, V79, P460; PAHL HL, 1993, J BIOL CHEM, V268, P5014; POLLA BS, 1987, AM J PHYSIOL, V252, pC640, DOI 10.1152/ajpcell.1987.252.6.C640; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SARIBAN E, 1988, J CLIN INVEST, V81, P1506, DOI 10.1172/JCI113482; SCHMIDT JA, 1988, J IMMUNOL, V141, P2027; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Singh IS, 2000, J BIOL CHEM, V275, P9841, DOI 10.1074/jbc.275.13.9841; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Soncin F, 1996, BIOCHEM BIOPH RES CO, V229, P479, DOI 10.1006/bbrc.1996.1829; STEIN B, 1995, MOL CELL BIOL, V15, P4971; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Stevenson MA, 1999, J IMMUNOL, V163, P5608; Swolin-Eide D, 1998, J ENDOCRINOL, V156, P107, DOI 10.1677/joe.0.1560107; Tang D, 2001, BIOCHEM BIOPH RES CO, V280, P280, DOI 10.1006/bbrc.2000.4118; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Teshima S, 1996, BIOCHEM J, V315, P497, DOI 10.1042/bj3150497; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; TSUKADA J, 1994, MOL CELL BIOL, V14, P7285, DOI 10.1128/MCB.14.11.7285; VELASCO S, 1991, J CLIN INVEST, V87, P1674, DOI 10.1172/JCI115184; Voellmy Richard, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P357; WEDEL A, 1995, IMMUNOBIOLOGY, V193, P171, DOI 10.1016/S0171-2985(11)80541-3; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; WU C, 1984, NATURE, V311, P81, DOI 10.1038/311081a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200; Yiangou M, 1998, BBA-GENE STRUCT EXPR, V1396, P191, DOI 10.1016/S0167-4781(97)00188-7; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373; ZHANG Y, 1993, MOL CELL BIOL, V13, P3831, DOI 10.1128/MCB.13.6.3831; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557; [No title captured]	71	128	142	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11802	11810		10.1074/jbc.M109296200	http://dx.doi.org/10.1074/jbc.M109296200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801594	hybrid			2022-12-25	WOS:000174846400027
J	Novac, O; Alvarez, D; Pearson, CE; Price, GB; Zannis-Hadjopoulos, M				Novac, O; Alvarez, D; Pearson, CE; Price, GB; Zannis-Hadjopoulos, M			The human cruciform-binding protein, CBP, is involved in DNA replication and associates in vivo with mammalian replication origins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SIGNALING PATHWAYS; FORMALDEHYDE CROSS-LINKING; ENRICHED ORS FRAGMENTS; MONKEY DNA; NUCLEAR MATRIX; AUTONOMOUS REPLICATION; DELETION ANALYSIS; INVERTED REPEATS; RAF-1 KINASE; CELL-CYCLE	We previously identified and purified from human (HeLa) cells a 66-kDa cruciform-binding protein, CBP,,with binding specificity for cruciform DNA regardless of its sequence. DNA cruciforms have been implicated in the regulation of initiation of DNA replication. CBP is a member of the 14-3-3 family of proteins, which are conserved regulatory molecules expressed in all eukaryotes. Here, the in vivo association of CBP/14-3-3 with mammalian origins of DNA replication was analyzed by studying its association with the monkey replication origins ors8 and ors12, as assayed by a chromatin immunoprecipitation assay and quantitative PCR analysis. The association of the 14-3-3beta, -epsilon, -gamma, and -xi isoforms with these origins was found to be similar to9-fold higher, compared with other portions of the genome, in logarithmically growing cells. In addition, the association of these isoforms with ors8 and ors12 was also analyzed as a function of the cell cycle. Higher binding of 14-3-3beta, -epsilon, -gamma, and -delta isoforms with ors8 and ors12 was found at the G(1)/S border, by comparison with other stages of the cell cycle. The CBP/14-3-3 cruciform. binding activity was also found to be maximal at the G(1)/S boundary. The involvement of 14-3-3 in mammalian DNA replication was analyzed by studying the effect of anti14-3-3beta, -epsilon, -gamma, and -xi antibodies in the in vitro replication of p186, a plasmid containing the minimal replication origin of ors8. Anti-14-3-3epsilon, -gamma, and -xi antibodies alone or in combination inhibited p186 replication by similar to50-80%, while anti-14-3-3beta antibodies had a lesser effect (similar to25-50%). All of the antibodies tested were also able to interfere with CBP binding to cruciform DNA. The results indicate that CBP/14-3-3 is an origin-binding protein, acting at the initiation step of DNA replication by binding to cruciform-containing molecules, and dissociates after origin firing.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Univ Toronto, Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada	McGill University; McGill University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Zannis-Hadjopoulos, M (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	mzannis@med.mcgill.ca		Pearson, Christopher/0000-0001-9545-4205				Abarca D, 1999, FEBS LETT, V462, P377, DOI 10.1016/S0014-5793(99)01560-4; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BOULIKAS T, 1993, J CELL BIOCHEM, V52, P23, DOI 10.1002/jcb.240520105; DAYN A, 1992, NUCLEIC ACIDS RES, V20, P5991, DOI 10.1093/nar/20.22.5991; DIJKWEL PA, 1992, MOL CELL BIOL, V12, P3715, DOI 10.1128/MCB.12.9.3715; DOTT PJ, 1976, BIOCHEMISTRY-US, V15, P4120, DOI 10.1021/bi00663a032; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FRAPPIER L, 1987, P NATL ACAD SCI USA, V84, P6668, DOI 10.1073/pnas.84.19.6668; FRIED M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P143, DOI 10.1016/0167-4781(91)90095-4; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; HAND R, 1978, CELL, V15, P317, DOI 10.1016/0092-8674(78)90001-6; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Homesley L, 2000, GENE DEV, V14, P913; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; Jackson V, 1999, METHODS, V17, P125, DOI 10.1006/meth.1998.0724; KAUFMANN G, 1985, MOL CELL BIOL, V5, P721, DOI 10.1128/MCB.5.4.721; Kriesel JD, 1997, J NEUROVIROL, V3, P441, DOI 10.3109/13550289709031190; LANDRY S, 1991, BIOCHIM BIOPHYS ACTA, V1088, P234, DOI 10.1016/0167-4781(91)90059-U; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Lipps G, 2001, NUCLEIC ACIDS RES, V29, P904, DOI 10.1093/nar/29.4.904; Lobachev KS, 1998, GENETICS, V148, P1507; MAH DCW, 1993, J CELL SCI, V105, P807; Matsunaga S, 2000, IMMUNOL LETT, V75, P47, DOI 10.1016/S0165-2478(00)00273-X; MCMURRAY CT, 1991, P NATL ACAD SCI USA, V88, P666, DOI 10.1073/pnas.88.2.666; MEYER R, 1991, P NATL ACAD SCI USA, V88, P966, DOI 10.1073/pnas.88.3.966; MORRISON D, 1994, SCIENCE, V266, P56, DOI 10.1126/science.7939645; Nickerson JA, 1997, P NATL ACAD SCI USA, V94, P4446, DOI 10.1073/pnas.94.9.4446; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PANAYOTATOS N, 1987, J BIOL CHEM, V262, P11364; PAULSON JR, 1982, J BIOL CHEM, V257, P6064; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; PEARSON CE, 1991, BIOCHIM BIOPHYS ACTA, V1090, P156, DOI 10.1016/0167-4781(91)90096-5; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PEARSON CE, 1994, BIOCHEMISTRY-US, V33, P14185, DOI 10.1021/bi00251a030; Pelletier R, 1999, J CELL BIOCHEM, V74, P562, DOI 10.1002/(SICI)1097-4644(19990915)74:4<562::AID-JCB6>3.3.CO;2-U; Pelletier R, 1997, J CELL BIOCHEM, V66, P87; Pfitzner T, 2000, LEUKEMIA, V14, P754, DOI 10.1038/sj.leu.2401706; RAO BS, 1990, GENE, V87, P233; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Ritzi M, 1998, J BIOL CHEM, V273, P24543, DOI 10.1074/jbc.273.38.24543; ROSENBERG M, 1979, ANNU REV GENET, V13, P319, DOI 10.1146/annurev.ge.13.120179.001535; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SOLOMON MJ, 1985, P NATL ACAD SCI USA, V82, P6470, DOI 10.1073/pnas.82.19.6470; SOLOMON MJ, 1988, CELL, V53, P937, DOI 10.1016/S0092-8674(88)90469-2; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; STEPHENS RE, 1977, J BIOL CHEM, V252, P166; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; TODD A, 1995, J CELL BIOCHEM, V57, P280, DOI 10.1002/jcb.240570212; Treuner K, 1998, J BIOL CHEM, V273, P31744, DOI 10.1074/jbc.273.48.31744; Viswanathan M, 2000, J MOL BIOL, V302, P553, DOI 10.1006/jmbi.2000.4088; Wadkins RM, 2000, CURR MED CHEM, V7, P1; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; Williamson DH, 2001, J MOL BIOL, V306, P159, DOI 10.1006/jmbi.2000.4385; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zannis-Hadjopoulos M, 1998, CRIT REV EUKAR GENE, V8, P81, DOI 10.1615/CritRevEukarGeneExpr.v8.i1.40; Zannis-Hadjopoulos M, 1999, J CELL BIOCHEM, P1; ZANNISHADJOPOUL.M, 1992, DNA REPLICATION REGU, P107; ZANNISHADJOPOULOS M, 1984, J MOL BIOL, V179, P577, DOI 10.1016/0022-2836(84)90156-6; ZANNISHADJOPOULOS M, 1988, EMBO J, V7, P1837, DOI 10.1002/j.1460-2075.1988.tb03016.x; ZANNNISHADJOPOULOS M, 1985, MOL CELL BIOL, V5, P1621, DOI 10.1128/MCB.5.7.1621; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C	75	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11174	11183		10.1074/jbc.M107902200	http://dx.doi.org/10.1074/jbc.M107902200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805087	hybrid			2022-12-25	WOS:000174613100055
J	Deroanne, CF; Bonjean, K; Servotte, S; Devy, L; Colige, A; Clausse, N; Blacher, S; Verdin, E; Foidart, JM; Nusgens, BV; Castronovo, V				Deroanne, CF; Bonjean, K; Servotte, S; Devy, L; Colige, A; Clausse, N; Blacher, S; Verdin, E; Foidart, JM; Nusgens, BV; Castronovo, V			Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling	ONCOGENE			English	Article						angiogenesis; trichostatin A; suberoylanilide hydroxamic acid; VEGF; neuropilin-1; semaphorin III	IN-VITRO; TRICHOSTATIN-A; ANTIANGIOGENIC THERAPY; UP-REGULATION; CANCER CELLS; EXPRESSION; DIFFERENTIATION; RECEPTOR; NEUROPILIN-1; SUPPRESSES	Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin 111, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells., These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors: altering VEGF signaling.	Univ Liege, Lab Connect Tissues Biol, B-4000 Liege, Sart Tilman, Belgium; Univ Liege, Res Ctr Expt Cancerol, B-4000 Liege, Belgium; Univ Liege, Lab Metastasis Res, B-4000 Liege, Belgium; Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Calif San Francisco, San Francisco, CA 94143 USA; Gladstone Inst Virol & Immunol, San Francisco, CA USA	University of Liege; University of Liege; University of Liege; University of Liege; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	Deroanne, CF (corresponding author), Univ Liege, Lab Connect Tissues Biol, B 24-3, B-4000 Liege, Sart Tilman, Belgium.		Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Angelov L, 1999, CANCER RES, V59, P5536; Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Butler LM, 2000, CANCER RES, V60, P5165; Deroanne CF, 1997, CANCER RES, V57, P5590; Deroanne CF, 2001, CARDIOVASC RES, V49, P647, DOI 10.1016/S0008-6363(00)00233-9; Deroanne CF, 1996, EXP CELL RES, V224, P215, DOI 10.1006/excr.1996.0131; FISHER C, 1994, DEV BIOL, V162, P499, DOI 10.1006/dbio.1994.1104; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Glick RD, 1999, CANCER RES, V59, P4392; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Nervi C, 2001, CANCER RES, V61, P1247; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; NICOSIA RF, 1990, LAB INVEST, V63, P115; Niki T, 1999, HEPATOLOGY, V29, P858, DOI 10.1002/hep.510290328; Pepper MS, 1996, CURR TOP MICROBIOL, V213, P31; Ribatti D, 1997, J VASC RES, V34, P455, DOI 10.1159/000159256; Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003; Shaheen RM, 1999, CANCER RES, V59, P5412; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Wang JX, 1999, CANCER RES, V59, P2766; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174	28	350	384	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					427	436		10.1038/sj.onc.1205108	http://dx.doi.org/10.1038/sj.onc.1205108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821955				2022-12-25	WOS:000173311200011
J	Lee, WP; Wen, Y; Varnum, B; Hung, MC				Lee, WP; Wen, Y; Varnum, B; Hung, MC			Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis	ONCOGENE			English	Article						E1A; Axl; Gas 6; Akt; BAD; apoptosis	E1A GENE-PRODUCTS; RECEPTOR TYROSINE KINASE; METASTASIS-SUPPRESSING FUNCTION; OVARIAN-CANCER CELLS; HUMAN TUMOR-CELLS; NF-KAPPA-B; ADENOVIRUS E1A; PHOSPHATIDYLINOSITOL 3-KINASE; SURVIVAL ACTIVITIES; INDUCE APOPTOSIS	Adenovirus type 5 E1A protein (E1A) associates with anti-tumor activities by reversing the transformed phenotype, inhibiting metastasis, and inducing apoptosis. We have previously identified that E1A suppresses the expression of Axl, a transforming tyrosine kinase and that Axl-Gas6 receptor-ligand interaction prevents E1A transfectants from apoptosis induced by serum deprivation. To determine how the Axl-Gas6 interaction prevents E1A-mediated apoptosis, we analysed the expression of anti-apoptotic molecules and found that the activated form of Akt was suppressed in the E1A transfectant ip 1-E1A and that Gas6 was able to activate Akt in ip 1-E1A cells reexpressing Axl (ip 1-E1A-Axl). To determine whether activated Akt is required to prevent E1A-mediated apoptosis, ip 1-E1A-Axl cells were treated with the phosphatidylinositol-3'-OH kinase inhibitor wortmannin or transfected with a dominant negative Akt mutant. In both cases, Gas6 no longer protected the cells from serum deprivation-induced apoptosis. Thus, we conclude that activated Akt is required for Axl-Gas6 signaling to prevent E1A-mediated apoptosis induced by serum deprivation. Downstream molecules of Akt, including NF-kappaB, Fas ligand, and BAD were examined, among which phosphorylation of BAD by Axl-Gas6 signaling is associated with the anti-apoptotic activity of Akt in our study.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Breast Canc Res Program, Houston, TX 77030 USA; Amgen Inc, Thousand Oaks, CA 91320 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Amgen	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Box 108,1515 Holcombe Blvd, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	NATIONAL CANCER INSTITUTE [R01CA058880, R01CA077858, P50CA083639] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA 58880, R01-CA 77858, 1 P50 CA83639] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bellosta P, 1997, ONCOGENE, V15, P2387, DOI 10.1038/sj.onc.1201419; BELLOSTA P, 1995, MOL CELL BIOL, V15, P614; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BYRD PJ, 1988, ONCOGENE, V2, P477; CHINNADURAI G, 1992, ONCOGENE, V7, P1255; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEL PL, 1997, SCIENCE, V278, P687; Deng J, 1998, ONCOGENE, V17, P2167, DOI 10.1038/sj.onc.1202148; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fridell YWC, 1998, J BIOL CHEM, V273, P7123, DOI 10.1074/jbc.273.12.7123; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; FRISCH SM, 1991, P NATL ACAD SCI USA, V88, P9077, DOI 10.1073/pnas.88.20.9077; FRISCH SM, 1995, CANCER RES, V55, P5551; FRISCH SM, 1990, ONCOGENE, V5, P75; Goruppi S, 1999, ONCOGENE, V18, P4224, DOI 10.1038/sj.onc.1202788; Goruppi S, 1997, MOL CELL BIOL, V17, P4442, DOI 10.1128/MCB.17.8.4442; Goruppi S, 1996, ONCOGENE, V12, P471; Hortobagyi GN, 2001, J CLIN ONCOL, V19, P3422, DOI 10.1200/JCO.2001.19.14.3422; LAMBERTI C, 1990, J VIROL, V64, P4997, DOI 10.1128/JVI.64.10.4997-5007.1990; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee WP, 1999, MOL CELL BIOL, V19, P8075; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Mymryk JS, 1996, ONCOGENE, V13, P1581; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Ozes ON, 1999, NATURE, V401, P82; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SHALLOWAY D, 1987, MOL CELL BIOL, V7, P3582, DOI 10.1128/MCB.7.10.3582; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TEODORO JG, 1995, ONCOGENE, V11, P467; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; YAN DH, 1991, ONCOGENE, V6, P343; YU DH, 1993, CANCER RES, V53, P5784; YU DH, 1992, ONCOGENE, V7, P2263; YU DH, 1991, MOL CELL BIOL, V11, P1745, DOI 10.1128/MCB.11.3.1745; YU DH, 1993, CANCER RES, V53, P891; Yu DH, 1998, CANCER METAST REV, V17, P195, DOI 10.1023/A:1006054421970; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499; YU DH, 1995, ONCOGENE, V11, P1383; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	49	66	69	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					329	336		10.1038/sj.onc.1205066	http://dx.doi.org/10.1038/sj.onc.1205066			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821945				2022-12-25	WOS:000173311200001
J	Radetzki, S; Kohne, CH; von Haefen, C; Gillissen, B; Strum, I; Dorken, B; Daniel, PT				Radetzki, S; Kohne, CH; von Haefen, C; Gillissen, B; Strum, I; Dorken, B; Daniel, PT			The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines	ONCOGENE			English	Article						Bak; Nbk; Bik; apoptosis; drug resistance; breast cancer	IN-VIVO; GENE BAX; DNA FRAGMENTATION; COLORECTAL-CANCER; PROTEIN FAMILY; OVARIAN-CANCER; TUMOR-GROWTH; CYTOCHROME-C; DEATH; EXPRESSION	We previously demonstrated that the forced expression of pro-caspase-3 can revert acquired chemoresistance in MT1-Adr breast cancer cells which show a defective activation of the mitochondrial pathway of apoptosis. We now asked whether the manipulation of mitochondrial apoptosis signaling can revert different types of drug resistance, i.e. the resistance due to impaired mitochondrial activation in the MT1-Adr cells and the resistance in MT3-Adr cells which is caused by increased expression of the Mdr-1/p-glycoprotein ABC transporter. Here we show that Bcl-2 overexpression is the underlying cause for the resistant phenotype in the MT1-Adr cells. Overexpression of the apoptosis-promoting Bax homologue Bak or the BH3 only protein Nbk/Bik reverts, as expected, acquired drug resistance in the MT1-Adr cells as recently demonstrated for pro-caspase-3. Moreover, we show that both apoptosis-promoters, Nbk/Bik and Bak, antagonize acquired chemoresistance for epirubicin-mediated apoptosis in MT3-Adr breast cancer cells. Neither drug uptake nor drug efflux were influenced by Bak or Nbk/Bik. Thus, our data show that manipulation of the downstream apoptosis signaling cascade by Bak and Nbk/Bik can overcome not only drug resistance due to mitochondrial apoptosis deficiency (in the MT1-Adr cells) but also classical, i.e. efflux-mediated, resistance for drug-induced cell death in the MT3-Adr cell line. Nbk/Bik and Bak could therefore be target genes to increase chemosensitivity and overcome different types of drug resistance.	Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany	Humboldt University of Berlin	Daniel, PT (corresponding author), Humboldt Univ, Dept Hematol Oncol & Tumor Immunol, Charite Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.			Gillissen, Bernhard/0000-0002-1815-2091				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BARGOU RC, 1995, EUR J IMMUNOL, V25, P770, DOI 10.1002/eji.1830250322; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; BARGOU RC, 1995, INT J CANCER, V60, P854, DOI 10.1002/ijc.2910600622; Blagosklonny MV, 2000, LEUKEMIA, V14, P1502, DOI 10.1038/sj.leu.2401864; BOSANQUET AG, 2001, IN PRESS LEUKEMIA, V15; BOYD JM, 1995, ONCOGENE, V11, P1921; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Daniel PT, 1999, ANAL BIOCHEM, V266, P110, DOI 10.1006/abio.1998.2929; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Daniel PT, 1999, BLOOD, V94, P1100, DOI 10.1182/blood.V94.3.1100.415a16_1100_1107; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Essmann F, 2000, BIOCHEM J, V346, P777, DOI 10.1042/0264-6021:3460777; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Friedrich K, 2001, ONCOGENE, V20, P2749, DOI 10.1038/sj.onc.1204342; Hermann S, 2001, INT J CANCER, V92, P805, DOI 10.1002/ijc.1284; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jones NA, 1998, MOL PHARMACOL, V53, P819; KIEFER MC, 1995, NATURE, V374, P736, DOI 10.1038/374736a0; KNUDSON C, 1995, SCIENCE, V279, P96; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; Krajewski S, 1996, CANCER RES, V56, P2849; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Mandal M, 1998, ONCOGENE, V17, P999, DOI 10.1038/sj.onc.1202020; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; NAUNDORF H, 1992, BREAST CANCER RES TR, V23, P87, DOI 10.1007/BF01831480; Nunez G, 1996, ADV EXP MED BIOL, V406, P75; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Prokop A, 2000, LEUKEMIA, V14, P1606, DOI 10.1038/sj.leu.2401866; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Simonian PL, 1996, J BIOL CHEM, V271, P22764, DOI 10.1074/jbc.271.37.22764; Simonian PL, 1997, ONCOGENE, V15, P1871, DOI 10.1038/sj.onc.1201350; Stein U, 1997, INT J CANCER, V72, P885, DOI 10.1002/(SICI)1097-0215(19970904)72:5<885::AID-IJC28>3.0.CO;2-6; Strobel T, 1998, ONCOGENE, V17, P2419, DOI 10.1038/sj.onc.1202180; Strobel T, 1998, CANCER RES, V58, P4776; Sturm I, 2001, J CLIN ONCOL, V19, P2272, DOI 10.1200/JCO.2001.19.8.2272; Sturm I, 1999, J CLIN ONCOL, V17, P1364, DOI 10.1200/JCO.1999.17.5.1364; Tai YT, 1998, J CLIN ONCOL, V16, P2583, DOI 10.1200/JCO.1998.16.8.2583; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Wagener C, 1996, INT J CANCER, V67, P138, DOI 10.1002/(SICI)1097-0215(19960703)67:1<138::AID-IJC22>3.0.CO;2-9; Wieder T, 2001, BLOOD, V97, P1378, DOI 10.1182/blood.V97.5.1378; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	47	52	54	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					227	238		10.1038/sj/onc/1205010	http://dx.doi.org/10.1038/sj/onc/1205010			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803466				2022-12-25	WOS:000173026200007
J	Nishida, S; Fujimitsu, K; Sekimizu, K; Ohmura, T; Ueda, T; Katayama, T				Nishida, S; Fujimitsu, K; Sekimizu, K; Ohmura, T; Ueda, T; Katayama, T			A nucleotide switch in the Escherichia coli DnaA protein initiates chromosomal replication - EVidence from a mutant DnaA protein defective in regulatory ATP hydrolysis in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORIGIN RECOGNITION COMPLEX; DOUBLE-STRANDED-DNA; IN-VITRO; NEGATIVE CONTROL; POLYMERASE-III; SEQA PROTEIN; BINDING; MINICHROMOSOME; SEQUESTRATION; TRANSCRIPTION	The ATP-bound DnaA protein opens duplex DNA at the Escherichia coli origin of replication, leading to a series of initiation reactions in vitro. When loaded on DNA, the DNA polymerase III sliding clamp stimulates hydrolysis of DnaA-bound ATP in the presence of the IdaB/Hda protein, thereby yielding ADP-DnaA, which is inactive for initiation in vitro. This negative feedback regulation of DnaA activity is proposed to play a crucial role in the replication cycle. We here report that the mutant protein DnaA R334A is inert to hydrolysis of bound ATP, although its affinities for ATP and ADP remain unaffected. The ATP-bound DnaA R334A protein, but not the ADP form, initiates minichromosomal replication in vitro at a level similar to that seen for wild-type DnaA. When expressed at moderate levels in vivo, DnaA R-334A is predominantly in the ATP-bound form, unlike the wild-type and DnaA E204Q proteins, which in vitro hydrolyze ATP in a sliding clamp- and IdaB/Hda-dependent manner. Furthermore, DnaA R334A, but not the wild-type or the DnaA E204Q proteins, promotes overinitiation of chromosomal replication. These in vivo data support a crucial role for bound nucleotides in regulating the activity of DnaA during replication. Based on a homology modeling analysis, we suggest that the Arg-334 residue closely interacts with bound nucleotides.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Microbiol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Immunol, Higashi Ku, Fukuoka 8128582, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Dev Biochem, Bunkyo Ku, Tokyo 1130033, Japan	Kyushu University; Kyushu University; University of Tokyo	Katayama, T (corresponding author), Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Mol Microbiol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	katayama@phar.kyushu-u.ac.jp	Nishida, Satoshi/J-6680-2014	Nishida, Satoshi/0000-0003-0653-7522; Katayama, Tsutomu/0000-0001-9994-1684				ASADA K, 1985, J BACTERIOL, V163, P398, DOI 10.1128/JB.163.1.398-400.1985; ATLUNG T, 1993, J BACTERIOL, V175, P6537, DOI 10.1128/jb.175.20.6537-6545.1993; ATLUNG T, 1987, MOL GEN GENET, V206, P51, DOI 10.1007/BF00326535; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Boye E, 2000, EMBO REP, V1, P479, DOI 10.1093/embo-reports/kvd116; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; CROOKE E, 1995, CELL, V82, P877, DOI 10.1016/0092-8674(95)90020-9; Diffley TFX, 1996, GENE DEV, V10, P2819, DOI 10.1101/gad.10.22.2819; FULLER RS, 1981, P NATL ACAD SCI-BIOL, V78, P7370, DOI 10.1073/pnas.78.12.7370; Guo L, 1999, FEMS MICROBIOL LETT, V176, P357, DOI 10.1016/S0378-1097(99)00261-X; KATAYAMA T, 1994, J BIOL CHEM, V269, P12698; Katayama T, 1997, MOL MICROBIOL, V26, P687, DOI 10.1046/j.1365-2958.1997.5941967.x; Katayama T, 1999, BIOCHIMIE, V81, P835, DOI 10.1016/S0300-9084(99)00213-8; KATAYAMA T, 1994, J BIOL CHEM, V269, P22075; KATAYAMA T, 1995, J BIOL CHEM, V270, P9265, DOI 10.1074/jbc.270.16.9265; Katayama T, 1998, CELL, V94, P61, DOI 10.1016/S0092-8674(00)81222-2; Katayama T, 2001, BIOCHIMIE, V83, P13, DOI 10.1016/S0300-9084(00)01206-2; Katayama T, 2001, MOL MICROBIOL, V41, P9, DOI 10.1046/j.1365-2958.2001.02483.x; Kato J, 2001, EMBO J, V20, P4253, DOI 10.1093/emboj/20.15.4253; KELLENBERGERGUJER G, 1978, MOL GEN GENET, V162, P9, DOI 10.1007/BF00333845; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kitagawa R, 1998, GENE DEV, V12, P3032, DOI 10.1101/gad.12.19.3032; Klemm RD, 2001, P NATL ACAD SCI USA, V98, P8361, DOI 10.1073/pnas.131006898; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; Kornberg A., 1992, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kurokawa K, 1999, EMBO J, V18, P6642, DOI 10.1093/emboj/18.23.6642; Lee DG, 2000, EMBO J, V19, P4774, DOI 10.1093/emboj/19.17.4774; Lee DG, 2000, CURR OPIN CELL BIOL, V12, P280, DOI 10.1016/S0955-0674(00)00089-2; Liu JY, 2000, MOL CELL, V6, P637, DOI 10.1016/S1097-2765(00)00062-9; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; MESSER W, 1996, ESCHERICHIA COLI SAL, V2, P1579; Mizushima T, 1997, EMBO J, V16, P3724, DOI 10.1093/emboj/16.12.3724; Neuwald AF, 1999, GENOME RES, V9, P27; NOZAKI N, 1988, J BIOL CHEM, V263, P14176; Nyborg M, 2000, MOL MICROBIOL, V35, P1202, DOI 10.1046/j.1365-2958.2000.01790.x; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Sakamoto K, 1998, FEMS MICROBIOL LETT, V159, P93; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SEKIMIZU K, 1987, CELL, V50, P259, DOI 10.1016/0092-8674(87)90221-2; SLATER S, 1995, CELL, V82, P927, DOI 10.1016/0092-8674(95)90272-4; SMITH DW, 1985, EMBO J, V4, P1319, DOI 10.1002/j.1460-2075.1985.tb03779.x; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; Speck C, 2001, EMBO J, V20, P1469, DOI 10.1093/emboj/20.6.1469; SULETSUGU M, 2001, MOL MICROBIOL, V40, P376; Takata M, 2000, MOL MICROBIOL, V35, P454, DOI 10.1046/j.1365-2958.2000.01722.x; Wold S, 1998, EMBO J, V17, P4158, DOI 10.1093/emboj/17.14.4158; Yamada K, 2001, P NATL ACAD SCI USA, V98, P1442, DOI 10.1073/pnas.031470598; YOSHIKAWA H, 1991, MOL MICROBIOL, V5, P2589, DOI 10.1111/j.1365-2958.1991.tb01967.x	52	102	102	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14986	14995		10.1074/jbc.M108303200	http://dx.doi.org/10.1074/jbc.M108303200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839737	hybrid			2022-12-25	WOS:000175203000080
J	Tang, S; Zheng, ZM				Tang, S; Zheng, ZM			Kaposi's sarcoma-associated herpesvirus K8 Exon 3 contains three 5 '-splice sites and harbors a K8.1 transcription start site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPSTEIN-BARR-VIRUS; PRIMARY EFFUSION LYMPHOMA; MESSENGER-RNA INVITRO; RIBOSOME ENTRY SITE; GENE-EXPRESSION; BZIP PROTEIN; DNA-SEQUENCES; CELL-LINE; NUCLEAR ANTIGEN; LYTIC CYCLE	Kaposi's sarcoma-associated herpesvirus (KSHV) K8 and K8.1 open reading frames are juxtaposed and span from nucleotide (nt) 74850 to 76695 of the virus genome. A K8 pre-mRNA overlaps the entire K8.1 coding region, and alternative splicing of KSHV K8 and K8.1 pre-mRNAs each produces three isoforms (alpha, beta, and gamma) of the mRNAs. We have mapped the 5' end of the K8.1 RNA in butyrate-induced KSHV-positive JSC-1 cells to nt 75901 in the KSHV genome and have shown that exon 3 of the K8 pre-mRNA in JSC-1 cells covers most part of the intron 3 defined previously and has three 5'-splice sites (ss), respectively, at nt 75838, 76155, and 76338. Selection of the nt 75838 5'-ss dictates the K8 mRNA production and overwhelms the RNA processing. Alternative selection of other two 5'-ss is feasible and leads to production of two additional bicistronic mRNAs, K8/K8.1alpha and -beta. However, the novel bicistronic K8/K8.1 mRNAs translated a little K8 and no detectable K8.1 proteins in 293 cells. Data suggest that production of the K8/K8.1 mRNAs may be an essential way to control K8 mRNAs, especially K8alpha, to a threshold at RNA processing level.	NCI, HIV & AIDS malignancy Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zheng, ZM (corresponding author), NCI, HIV & AIDS malignancy Branch, Ctr Canc Res, NIH, Bldg 10,Rm 10S255,MSC 1868,10 Ctr Dr, Bethesda, MD 20892 USA.	zhengt@exchange.nih.gov	Tang, Shuang/F-9115-2014	Tang, Shuang/0000-0002-3084-0903; Zheng, Zhi-Ming/0000-0001-5547-7912				BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Boshoff C, 1998, ADV CANCER RES, V75, P57, DOI 10.1016/S0065-230X(08)60739-3; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Burysek L, 1999, J HUMAN VIROL, V2, P19; Cannon JS, 2000, J VIROL, V74, P10187, DOI 10.1128/JVI.74.21.10187-10193.2000; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chandran B, 1998, VIROLOGY, V249, P140, DOI 10.1006/viro.1998.9316; Chang J, 2000, J GEN VIROL, V81, P2039, DOI 10.1099/0022-1317-81-8-2039; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen J, 2001, P NATL ACAD SCI USA, V98, P4119, DOI 10.1073/pnas.051004198; Dittmer D, 1998, J VIROL, V72, P8309, DOI 10.1128/JVI.72.10.8309-8315.1998; Du MQ, 2001, BLOOD, V97, P2130, DOI 10.1182/blood.V97.7.2130; Fais F, 1999, LEUKEMIA, V13, P1093, DOI 10.1038/sj.leu.2401436; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; Gradoville L, 2000, J VIROL, V74, P6207, DOI 10.1128/JVI.74.13.6207-6212.2000; Gruffat H, 1999, J GEN VIROL, V80, P557, DOI 10.1099/0022-1317-80-3-557; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; HIMMELSPACH M, 1995, RNA, V1, P794; Hwang S, 2001, J VIROL, V75, P9509, DOI 10.1128/JVI.75.19.9509-9516.2001; Jenner RG, 2001, J VIROL, V75, P891, DOI 10.1128/JVI.75.2.891-902.2001; Katano H, 2001, VIROLOGY, V286, P446, DOI 10.1006/viro.2001.1005; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; KREIVI JP, 1991, NUCLEIC ACIDS RES, V19, P6956, DOI 10.1093/nar/19.24.6956; LANG KM, 1983, SCIENCE, V220, P1351, DOI 10.1126/science.6304877; Lee BS, 2000, J EXP MED, V192, P11, DOI 10.1084/jem.192.1.11; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li MT, 1999, J VIROL, V73, P1341, DOI 10.1128/JVI.73.2.1341-1349.1999; Lin SF, 1999, J VIROL, V73, P1909, DOI 10.1128/JVI.73.3.1909-1917.1999; Liu CN, 1996, J VIROL, V70, P2545, DOI 10.1128/JVI.70.4.2545-2555.1996; Low W, 2001, J VIROL, V75, P2938, DOI 10.1128/JVI.75.6.2938-2945.2001; Lukac DM, 2001, J VIROL, V75, P6786, DOI 10.1128/JVI.75.15.6786-6799.2001; Lukac DM, 1999, J VIROL, V73, P9348, DOI 10.1128/JVI.73.11.9348-9361.1999; Miller G, 1996, NEW ENGL J MED, V334, P1292, DOI 10.1056/NEJM199605163342003; Miller G, 1997, J VIROL, V71, P314, DOI 10.1128/JVI.71.1.314-324.1997; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; Muralidhar S, 1998, J VIROL, V72, P4980, DOI 10.1128/JVI.72.6.4980-4988.1998; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Neipel F, 1997, J VIROL, V71, P4187, DOI 10.1128/JVI.71.6.4187-4192.1997; Park J, 2000, J VIROL, V74, P11977, DOI 10.1128/JVI.74.24.11977-11982.2000; Polson AG, 2001, J VIROL, V75, P3175, DOI 10.1128/JVI.75.7.3175-3184.2001; Portes-Sentis S, 2001, J GEN VIROL, V82, P507, DOI 10.1099/0022-1317-82-3-507; Raab MS, 1998, J VIROL, V72, P6725, DOI 10.1128/JVI.72.8.6725-6731.1998; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1999, J VIROL, V73, P1438, DOI 10.1128/JVI.73.2.1438-1446.1999; Serio TR, 1998, J VIROL, V72, P8338, DOI 10.1128/JVI.72.10.8338-8343.1998; Song B, 1998, J VIROL, V72, P3213, DOI 10.1128/JVI.72.4.3213-3220.1998; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Sterner DA, 1996, P NATL ACAD SCI USA, V93, P15081, DOI 10.1073/pnas.93.26.15081; Sun R, 1998, P NATL ACAD SCI USA, V95, P10866, DOI 10.1073/pnas.95.18.10866; Sun R, 1999, J VIROL, V73, P2232, DOI 10.1128/JVI.73.3.2232-2242.1999; Sun R, 1996, P NATL ACAD SCI USA, V93, P11883, DOI 10.1073/pnas.93.21.11883; SVENSSON C, 1983, J MOL BIOL, V165, P475, DOI 10.1016/S0022-2836(83)80214-9; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; VANSANTEN VL, 1986, NUCLEIC ACIDS RES, V14, P9911, DOI 10.1093/nar/14.24.9911; Wall L, 1996, J BIOL CHEM, V271, P16477, DOI 10.1074/jbc.271.28.16477; Wang FZ, 2001, J VIROL, V75, P7517, DOI 10.1128/JVI.75.16.7517-7527.2001; Wang J, 1998, GENE DEV, V12, P2222, DOI 10.1101/gad.12.14.2222; Wu FY, 2001, J VIROL, V75, P1487, DOI 10.1128/JVI.75.3.1487-1506.2001; YANG XM, 1994, P NATL ACAD SCI USA, V91, P6924, DOI 10.1073/pnas.91.15.6924; Zhang L, 1998, DNA CELL BIOL, V17, P735; Zheng ZM, 2000, J VIROL, V74, P10612, DOI 10.1128/JVI.74.22.10612-10622.2000; Zheng ZM, 2000, J VIROL METHODS, V85, P203, DOI 10.1016/S0166-0934(99)00172-X; Zhong WD, 1997, J VIROL, V71, P1207, DOI 10.1128/JVI.71.2.1207-1212.1997; Zhu FX, 1999, J VIROL, V73, P5556, DOI 10.1128/JVI.73.7.5556-5567.1999; Zhu LJ, 1999, VIROLOGY, V262, P237, DOI 10.1006/viro.1999.9900	71	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14547	14556		10.1074/jbc.M111308200	http://dx.doi.org/10.1074/jbc.M111308200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11832484	hybrid			2022-12-25	WOS:000175203000027
J	Poschet, JF; Skidmore, J; Boucher, JC; Firoved, AM; Van Dyke, RW; Deretic, V				Poschet, JF; Skidmore, J; Boucher, JC; Firoved, AM; Van Dyke, RW; Deretic, V			Hyperacidification of cellubrevin endocytic compartments and defective endosomal recycling in cystic fibrosis respiratory epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PSEUDOMONAS-AERUGINOSA; SODIUM-CHANNELS; NA+ CHANNEL; CFTR; ACIDIFICATION; MEMBRANE; FIBROBLASTS; TRANSFERRIN; ACTIVATION	The cystic fibrosis transmembrane conductance regulator (CFTR), which is aberrant in patients with cystic fibrosis, normally functions both as a chloride channel and as a pleiotropic regulator of other ion transporters. Here we show, by ratiometric imaging with luminally exposed pH-sensitive green fluorescent protein, that CFTR affects the pH of cellubrevin-labeled endosomal organelles resulting in hyperacidification of these compartments in cystic fibrosis lung epithelial cells. The excessive acidification of intracellular organelles was corrected with low concentrations of weak base. Studies with proton ATPase and sodium channel inhibitors showed that the increased acidification was dependent on proton pump activity and sodium transport. These observations implicate sodium efflux in the pH homeostasis of a subset of endocytic organelles and indicate that a dysfunctional CFTR in cystic fibrosis leads to organellar hyperacidification in lung epithelial cells because of a loss of CFTR inhibitory effects on sodium transport. Furthermore, recycling of transferrin receptor was altered in CFTR mutant cells, suggesting a previously unrecognized cellular defect in cystic fibrosis, which may have functional consequences for the receptors on the plasma membrane or within endosomal compartments.	Univ New Mexico, Dept Mol Genet & Microbiol, Ctr Hlth Sci, Sch Med, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Cell Biol & Physiol, Ctr Hlth Sci, Sch Med, Albuquerque, NM 87131 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA	University of New Mexico; University of New Mexico; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Deretic, V (corresponding author), Univ New Mexico, Dept Mol Genet & Microbiol, Ctr Hlth Sci, Sch Med, 915 Camino De Salud NE, Albuquerque, NM 87131 USA.	vderetic@salud.unm.edu		Deretic, Vojo/0000-0002-3624-5208	NIAID NIH HHS [AI31139] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031139] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; BARASCH J, 1993, J CELL SCI, P229; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; Bradbury NA, 1999, PHYSL REV S, V79, P175, DOI DOI 10.1152/physrev.1999.79.1.S175; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Deretic V., 2000, PERSIST BACT INFECT, P305; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; DUNN KW, 1994, J BIOL CHEM, V269, P5336; EGAN M, 1992, NATURE, V358, P581, DOI 10.1038/358581a0; EGAN ME, 1995, AM J PHYSIOL-CELL PH, V268, pC243, DOI 10.1152/ajpcell.1995.268.1.C243; Gibson GA, 2000, AM J PHYSIOL-CELL PH, V279, pC1088, DOI 10.1152/ajpcell.2000.279.4.C1088; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Illek B, 1997, AM J PHYSIOL-LUNG C, V272, pL752, DOI 10.1152/ajplung.1997.272.4.L752; Ismailov II, 1996, J BIOL CHEM, V271, P4725; Kunzelmann K, 1999, J MEMBRANE BIOL, V168, P1, DOI 10.1007/s002329900492; Lee A, 1999, AM J PHYSIOL-LUNG C, V277, pL204, DOI 10.1152/ajplung.1999.277.1.L204; Lee MG, 1999, J BIOL CHEM, V274, P14670, DOI 10.1074/jbc.274.21.14670; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; LI GP, 1993, J BIOL CHEM, V268, P24475; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MARSH EW, 1995, J CELL BIOL, V129, P1509, DOI 10.1083/jcb.129.6.1509; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; OLSEN JC, 1992, HUM GENE THER, V3, P253, DOI 10.1089/hum.1992.3.3-253; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Poschet JF, 2001, P NATL ACAD SCI USA, V98, P13972, DOI 10.1073/pnas.241182598; Presley JF, 1997, J BIOL CHEM, V272, P13929, DOI 10.1074/jbc.272.21.13929; Reddy MM, 1999, NATURE, V402, P301, DOI 10.1038/46297; Rubenstein RC, 2000, AM J PHYSIOL-CELL PH, V278, pC259, DOI 10.1152/ajpcell.2000.278.2.C259; Schreiber R, 1999, P NATL ACAD SCI USA, V96, P5310, DOI 10.1073/pnas.96.9.5310; Schwiebert EM, 1998, P NATL ACAD SCI USA, V95, P3879, DOI 10.1073/pnas.95.7.3879; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SCHWIEBERT EM, 1999, PHYSL REV S, V79, P145; Seksek O, 1996, J BIOL CHEM, V271, P15542, DOI 10.1074/jbc.271.26.15542; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; Teter K, 1998, J BIOL CHEM, V273, P19625, DOI 10.1074/jbc.273.31.19625; Van Dyke R W, 1996, Subcell Biochem, V27, P331; VANWEERT AWM, 1995, J CELL BIOL, V130, P821, DOI 10.1083/jcb.130.4.821; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; YAMASHIRO DJ, 1984, CELL, V37, P789, DOI 10.1016/0092-8674(84)90414-8; ZEITLIN PL, 1991, AM J RESP CELL MOL, V4, P313, DOI 10.1165/ajrcmb/4.4.313; Zeitlin PL, 1999, J CLIN INVEST, V103, P447, DOI 10.1172/JCI6346; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	46	40	41	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13959	13965		10.1074/jbc.M105441200	http://dx.doi.org/10.1074/jbc.M105441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11809765	hybrid			2022-12-25	WOS:000175096000080
J	Liu, QR; Zhang, PW; Zhen, QX; Walther, D; Wang, XB; Uhl, GR				Liu, QR; Zhang, PW; Zhen, QX; Walther, D; Wang, XB; Uhl, GR			KEPI, a PKC-dependent protein phosphatase I inhibitor regulated by morphine.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MU-OPIOID RECEPTOR; KINASE-C PKC; PHOSPHOLIPASE-C; HUMAN NEUROBLASTOMA; DOWN-REGULATION; SMOOTH-MUSCLE; ALPHA-ISOFORM; DARPP-32; PHOSPHORYLATION; EXPRESSION	cDNAs encoding KEPI, a novel protein kinase C (PKC) -potentiated inhibitory protein for type 1 Ser/Thr protein phosphatase (PP1), were identified. They were found among morphine-regulated brain mRNAs identified using subtracted differential display techniques. Full-length rat, mouse, and human cDNA and genomic sequences were elucidated with library screening and data base searching. Rat, mouse, and human KEPI cDNAs encode 164-165 amino acid proteins with calculated isoelectric points of 5.2. Each species' amino acid sequence contains consensus sequences for phosphorylation by PKC ((KVTVK)-V-72), protein kinase A (RKLS154), and casein kinase H ((SSRE)-S-43, (SEEE)-E-120). Multiple KEPI N-terminal myristoylation consensus sites provide potential regions for membrane anchoring. Subcellular fractionation and Western analyses revealed that most KEPI immunoreactivity was associated with P2 and P3 membrane-enriched fractions and little in cytosolic fractions. 2.6-kb KEPI mRNAs were detected in brain, especially in the cerebral cortex and hippocampus, and in heart and skeletal muscle. Brain KEPI mRNA was up-regulated by both acute and chronic morphine treatments. The human KEPI gene contains four exons extending over more than 100 kb of genomic sequence on 6q24-q25, near the mu opiate receptor gene. These sequences displayed sufficient homology with the porcine PP1 inhibitor CPI-17 that we asked whether KEPI could share the ability of CPI-17 to modulate PP1 activity in a PKC-dependent fashion. Recombinant mouse KEPI is phosphorylated by PKC with a K-m of 2.6 mum and a t(1/2), of 20 min. Phospho-KEPI inhibits PP1alpha with an IC50 of 2.7 nM, a potency more than 600-fold greater than that displayed by unphosphorylated KEPI. Neither phosphonor dephospho-KEPI inhibits protein phosphatase 2A. Up-regulation of KEPI expression by morphine, an agonist at PKC-regulating G-protein-coupled mu receptors, provides a novel signaling paradigm in which the half-lives of serine/threonine phosphorylation events can be influenced by activities at G(i)/G(o)-coupled receptors that modulate KEPI expression, KEPI phosphorylation, and KEPI regulation of PP1 activity.	NIDA, Mol Neurobiol Branch, Intramural Res Program, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Uhl, GR (corresponding author), NIDA, Mol Neurobiol Branch, Intramural Res Program, POB 5180,5500 Nathan Shock Dr, Baltimore, MD 21224 USA.		Liu, Qing-Rong/A-3059-2012	Liu, Qing-Rong/0000-0001-8477-6452	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000157, Z01DA000159] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; BEULLENS M, 1993, J BIOL CHEM, V268, P13172; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Caporaso GL, 2000, NEUROPHARMACOLOGY, V39, P1637, DOI 10.1016/S0028-3908(99)00230-0; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Eto M, 1997, FEBS LETT, V410, P356, DOI 10.1016/S0014-5793(97)00657-1; ETO M, 1995, J BIOCHEM, V118, P1104, DOI 10.1093/oxfordjournals.jbchem.a124993; Fienberg AA, 1998, SCIENCE, V281, P838, DOI 10.1126/science.281.5378.838; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Glover CJ, 1997, J BIOL CHEM, V272, P28680, DOI 10.1074/jbc.272.45.28680; Greengard P, 1999, NEURON, V23, P435, DOI 10.1016/S0896-6273(00)80798-9; GUITART X, 1992, J NEUROCHEM, V59, P1164, DOI 10.1111/j.1471-4159.1992.tb08361.x; Hall KU, 1999, J BIOL CHEM, V274, P3485, DOI 10.1074/jbc.274.6.3485; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; Kedra D, 1998, BIOCHEM MOL BIOL INT, V44, P589; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kramer HK, 1999, J NEUROCHEM, V72, P585; Kramer HK, 1999, J NEUROCHEM, V72, P594, DOI 10.1046/j.1471-4159.1999.0720594.x; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Lagercrantz J, 1996, BIOCHEM BIOPH RES CO, V223, P335, DOI 10.1006/bbrc.1996.0895; Lagercrantz J, 1996, GENOMICS, V31, P380, DOI 10.1006/geno.1996.0063; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; LIU QR, 1993, J BIOL CHEM, V268, P2106; LIU QR, 1991, EUR J BIOCHEM, V200, P715, DOI 10.1111/j.1432-1033.1991.tb16236.x; Lou LG, 1999, MOL PHARMACOL, V55, P557; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; NELSON N, 1994, J EXP BIOL, V196, P213; NESTLER EJ, 1992, J NEUROSCI, V12, P2439; NESTLER EJ, 1984, ADV CYCLIC NUCL PROT, V17, P483; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; PARK IK, 1994, J BIOL CHEM, V269, P944; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; SIM ATR, 1994, J NEUROCHEM, V62, P1552; SMART D, 1995, BIOCHEM J, V305, P577, DOI 10.1042/bj3050577; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; Tsao LI, 1997, SYNAPSE, V25, P117; TURNER NA, 1994, BIOCHEM J, V297, P407, DOI 10.1042/bj2970407; Wang XB, 1997, J NEUROSCI, V17, P5993; Wang XB, 1998, MOL BRAIN RES, V53, P344, DOI 10.1016/S0169-328X(97)00333-1	49	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13312	13320		10.1074/jbc.M107558200	http://dx.doi.org/10.1074/jbc.M107558200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812771	hybrid			2022-12-25	WOS:000175036300102
J	Post, PL; Tyska, MJ; O'Connell, CB; Johung, K; Hayward, A; Mooseker, MS				Post, PL; Tyska, MJ; O'Connell, CB; Johung, K; Hayward, A; Mooseker, MS			Myosin-IXb is a single-headed and processive motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; UNCONVENTIONAL MYOSINS; LIGHT-CHAIN; ACTIN; MOVEMENT; KINESIN; BRAIN; RHO; EXPRESSION; MOLECULES	Class IX myosins are unique among the many classes of known actin-based motors in that the tail region of these myosins contains a GTPase-activating protein domain for the small GTP-binding protein, Rho. Previous studies on human myosin-M indicate that this myosin is mechanochemically active and exhibits actin-binding properties similar to the processive motor, myosin-Va. Motility analysis of antibody-tethered myosin-IXb performed using the sliding actin filament assay indicates that this myosin does exhibit properties characteristic of a processive motor. Like myosin-Va, the velocity of myosin-IXb remains constant (38.2 +/- 1.2 nm/s) even at single motor/filament densities. At low motor densities, filaments can be seen passing through and pivoting about single points on the motility surface. Analysis of filament landing rates as a function of motor density also indicates that a single motor is sufficient for filament movement. However, in contrast to myosin-Va, which uses coordinated motion of its two heads to move processively along the filament, hydrodynamic and chemical cross-linking studies indicate that under the conditions tested, myosin-IXb is a single-headed motor consisting of a single heavy chain and associated light chains.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Mooseker, MS (corresponding author), Yale Univ, MCD Biol, KBT 352, POB 208103, New Haven, CT 06520 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK055389, F32DK010113, R37DK025387, R01DK025387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-10113, DK-25387, DK 55389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bahler M, 2000, BBA-MOL CELL RES, V1496, P52, DOI 10.1016/S0167-4889(00)00008-2; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; Chieregatti E, 1998, J CELL SCI, V111, P3597; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; Espindola FS, 2000, CELL MOTIL CYTOSKEL, V47, P269, DOI 10.1002/1097-0169(200012)47:4<269::AID-CM2>3.3.CO;2-7; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Kalhammer G, 1997, FEBS LETT, V414, P599, DOI 10.1016/S0014-5793(97)01076-4; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; Mehta AD, 1999, NATURE, V400, P590, DOI 10.1038/23072; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; Mooseker MS, 1995, ANNU REV CELL DEV BI, V11, P633, DOI 10.1146/annurev.cellbio.11.1.633; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Okada Y, 2000, P NATL ACAD SCI USA, V97, P640, DOI 10.1073/pnas.97.2.640; Post PL, 1998, J CELL SCI, V111, P941; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Reck-Peterson SL, 2001, J CELL BIOL, V153, P1121, DOI 10.1083/jcb.153.5.1121; REINHARD J, 1995, EMBO J, V14, P697, DOI 10.1002/j.1460-2075.1995.tb07048.x; Rief M, 2000, P NATL ACAD SCI USA, V97, P9482, DOI 10.1073/pnas.97.17.9482; Sakakibara H, 1999, NATURE, V400, P586, DOI 10.1038/23066; Sirotkin V, 2000, MOL REPROD DEV, V57, P111, DOI 10.1002/1098-2795(200010)57:2<111::AID-MRD2>3.0.CO;2-T; Stevens RC, 1998, J CELL BIOL, V142, P711, DOI 10.1083/jcb.142.3.711; Tanford C., 1961, PHYSICAL CHEM MACROM, P317; Tauhata SBF, 2001, J BIOL CHEM, V276, P39812, DOI 10.1074/jbc.M102583200; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; Walker ML, 2000, NATURE, V405, P804, DOI 10.1038/35015592; Wirth JA, 1996, J CELL SCI, V109, P653	28	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11679	11683		10.1074/jbc.M111173200	http://dx.doi.org/10.1074/jbc.M111173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11801597	hybrid			2022-12-25	WOS:000174846400010
J	Cerni, C; Skrzypek, B; Popov, N; Sasgary, S; Schmidt, G; Larsson, LG; Luscher, B; Henriksson, M				Cerni, C; Skrzypek, B; Popov, N; Sasgary, S; Schmidt, G; Larsson, LG; Luscher, B; Henriksson, M			Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1	ONCOGENE			English	Article						Mad1ER; Myc; cell cycle; gene repression; telomerase activity; tumor growth	MYC ANTAGONIST MAD1; HISTONE DEACETYLASE ACTIVITY; C-MYC; TRANSCRIPTIONAL REPRESSION; TELOMERASE ACTIVITY; INDUCIBLE EXPRESSION; ESSENTIAL COFACTOR; HTERT GENE; IN-VIVO; N-COR	The Myc/Max/Mad network of transcriptional regulatory proteins plays an essential role in cell proliferation, growth, apoptosis, and differentiation. Whereas, Myc proteins affect cell cycle progression positively,, Mad proteins are negative regulators of cell proliferation. It has been shown in several in vitro systems that Mad proteins antagonize c-Myc functions. In this report we describe the inhibition of tumor cell outgrowth in vivo by Mad1 expression. Transformed cell lines were generated by co-transfection of c-myc, c-H-ras, and a chimeric mad1ER construct into primary rat embryo cells (MRMad1ER cells). Activation of Mad1 by 4-Hydroxy-Tamoxifen (OHT) resulted in abrogation of telomerase activity, reduced cloning efficiency, and decreased proportion of cells in S phase. Injection of MRMad1ER cells into syngenic rats induced aggressively growing tumors after a short latency period. This tumor growth was inhibited by OHT-treatment of animals, with the extent of inhibition correlating with the amount of OHT injected. No effect of OHT on tumor growth was observed with similarly transformed Myc/Ras cell lines which did not express Mad1ER. These data demonstrate that Mad1 is able to suppress Myc/Ras-mediated transformation under in vivo conditions.	Univ Vienna, Inst Canc Res, A-1090 Vienna, Austria; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Swedish Univ Agr Sci, Uppsala Genet Ctr, Dept Plant Biol, SE-75007 Uppsala, Sweden; Rhein Westfal TH Aachen, Inst Biochem, Abt Biochem & Mol Biol, D-52074 Aachen, Germany	University of Vienna; Karolinska Institutet; Swedish University of Agricultural Sciences; RWTH Aachen University	Cerni, C (corresponding author), Univ Vienna, Inst Canc Res, Borschkegasse 8A, A-1090 Vienna, Austria.	Christa.Cerni@univie.ac.at; Marie.Henriksson@mtc.ki.se	Henriksson, Marie Arsenian/F-5010-2015; Larsson, Lars-Gunnar/D-9747-2012; Luscher, Bernhard/A-7330-2011	Arsenian Henriksson, Marie/0000-0001-6376-7792; Luscher, Bernhard/0000-0002-9622-8709				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amati B, 2001, BBA-REV CANCER, V1471, pM135, DOI 10.1016/S0304-419X(01)00020-8; Avilion AA, 1996, CANCER RES, V56, P645; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; Bazarov AV, 2001, CANCER RES, V61, P1178; Bejarano MT, 2000, EXP CELL RES, V260, P61, DOI 10.1006/excr.2000.4996; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Cerni C, 2000, MUTAT RES-REV MUTAT, V462, P31, DOI 10.1016/S1383-5742(99)00091-5; CERNI C, 1995, ONCOGENE, V11, P587; CERNI C, 1990, VIROLOGY, V177, P427, DOI 10.1016/0042-6822(90)90506-M; CHEN J, 1995, NAT MED, V1, P638, DOI 10.1038/nm0795-638; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Cultraro CM, 1997, MOL CELL BIOL, V17, P2353, DOI 10.1128/MCB.17.5.2353; DEPINHO RA, 1991, ADV CANCER RES, V57, P1; Eilers M, 1999, MOL CELLS, V9, P1; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Falchetti ML, 1999, ONCOGENE, V18, P1515, DOI 10.1038/sj.onc.1202438; Foley KP, 1998, EMBO J, V17, P774, DOI 10.1093/emboj/17.3.774; Gehring S, 2000, J BIOL CHEM, V275, P10413, DOI 10.1074/jbc.275.14.10413; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Gunes C, 2000, CANCER RES, V60, P2116; Guo QM, 2000, CANCER RES, V60, P5922; Han S, 2000, CANCER-AM CANCER SOC, V88, P1623, DOI 10.1002/(SICI)1097-0142(20000401)88:7<1623::AID-CNCR17>3.0.CO;2-W; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Hurlin PJ, 1999, EMBO J, V18, P7019, DOI 10.1093/emboj/18.24.7019; HURLIN PJ, 1995, EMBO J, V14, P5646, DOI 10.1002/j.1460-2075.1995.tb00252.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KOSKINEN PJ, 1995, CELL GROWTH DIFFER, V6, P623; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Larcher F, 1996, CANCER RES, V56, P5391; LARSSON LG, 1994, ONCOGENE, V9, P1247; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Luscher B, 1999, ONCOGENE, V18, P2955, DOI 10.1038/sj.onc.1202750; Luscher B, 2001, GENE, V277, P1, DOI 10.1016/S0378-1119(01)00697-7; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Meroni G, 1997, EMBO J, V16, P2892, DOI 10.1093/emboj/16.10.2892; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Prasad GL, 1999, ONCOGENE, V18, P2027, DOI 10.1038/sj.onc.1202264; Pulverer B, 2000, J CELL PHYSIOL, V183, P399, DOI 10.1002/(SICI)1097-4652(200006)183:3<399::AID-JCP13>3.3.CO;2-Z; Queva C, 1999, CELL GROWTH DIFFER, V10, P785; Queva C, 1998, ONCOGENE, V16, P967, DOI 10.1038/sj.onc.1201611; RAK J, 1995, CANCER RES, V55, P4575; Roussel MF, 1996, MOL CELL BIOL, V16, P2796; ROY B, 1995, CELL BIOL INT, V19, P307, DOI 10.1006/cbir.1995.1073; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sommer A, 1997, CURR BIOL, V7, P357, DOI 10.1016/S0960-9822(06)00183-7; Treon SP, 1998, BLOOD, V92, P1749, DOI 10.1182/blood.V92.5.1749.417k38_1749_1757; Ulaner GA, 1998, CANCER RES, V58, P4168; VASTRIK I, 1995, J CELL BIOL, V128, P1197, DOI 10.1083/jcb.128.6.1197; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	72	25	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					447	459		10.1038/sj.onc.1205107	http://dx.doi.org/10.1038/sj.onc.1205107			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821957				2022-12-25	WOS:000173311200013
J	Lawlor, ER; Scheel, C; Irving, J; Sorensen, PHB				Lawlor, ER; Scheel, C; Irving, J; Sorensen, PHB			Anchorage-independent multi-cellular spheroids as an in vitro model of growth signaling in Ewing tumors	ONCOGENE			English	Article						Ewing tumor; spheroids; cyclin D1; PI3K-AKT; ERK	FACTOR-I RECEPTOR; PROTEIN-KINASE-B; GLYCOGEN-SYNTHASE KINASE-3; CYCLIN D1; PHOSPHATIDYLINOSITOL 3-KINASE; CHROMOSOME-TRANSLOCATION; CONSTITUTIVE ACTIVATION; NEUROECTODERMAL TUMOR; TRANSCRIPTION FACTOR; DNA-SYNTHESIS	Little is known about the growth-signaling pathways that govern the proliferation of Ewing tumor (ET) cells either in vitro or in vivo. We have studied signal transduction pathways in ET cell lines and compared kinase expression levels and proliferation rates with primary tumors. Cell lines were studied both as conventional adherent monolayers and as anchorage-independent multi-cellular spheroids. Importantly, we observed significant differences between these in vitro models and found that ET spheroids were more closely related to primary tumors with respect to cell morphology, cell-cell junctions, proliferative index and kinase activation. Monolayer ET cells demonstrated serum-dependent phosphorylation of ERK1/2 and AKT and constitutively high serum-independent cyclin D1 protein expression. However, when ET cells were placed in suspension culture, there was immediate serum-independent activation of ERK1/2 and AKT. In addition, cyclin DI protein expression was completely blocked until stable multicellular spheroids had formed, indicating that cell-cell adhesion is necessary for the proliferation of anchorage independent ET cells. This reduction in cyclin D1 expression was post-transcriptional and could be mimicked in monolayer cells by treatment with phosphatidyl inositol-3 kinase (PI3K) inhibitors. Moreover, PI3K inhibition significantly reduced ET cell proliferation and, in primary ET samples, cyclin DI expression correlated with expression of activated AKT. Thus, the PI3K-AKT pathway appears to be critical for the proliferation of ET cells both in vitro and in vivo and tumor cell growth in vivo may be better represented by the study of anchorage-independent multi-cellular spheroids.	Childrens & Womens Hlth Ctr British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada; Childrens & Womens Hlth Ctr British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 4H4, Canada; Univ British Columbia, Vancouver, BC V5Z 4H4, Canada	BC Women's Hospital & Health Centre; BC Women's Hospital & Health Centre; University of British Columbia	Sorensen, PHB (corresponding author), BC Res Inst Childrens & Womens Hlth, Room 3082-950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	psor@interchange.ubc.ca			NCI NIH HHS [CA88199] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA088199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Assoian RK, 1997, J CELL BIOL, V136, P1, DOI 10.1083/jcb.136.1.1; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; Connell-Crowley L, 1998, CURR BIOL, V8, P65, DOI 10.1016/S0960-9822(98)70021-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de Alava E, 2000, AM J PATHOL, V156, P849, DOI 10.1016/S0002-9440(10)64953-X; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUNN T, 1994, CANCER GENET CYTOGEN, V76, P19, DOI 10.1016/0165-4608(94)90063-9; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Girnita L, 2000, ONCOGENE, V19, P4298, DOI 10.1038/sj.onc.1203755; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Kawamura K, 2000, ANAL QUANT CYTOL, V22, P107; Kopnin BP, 2000, BIOCHEMISTRY-MOSCOW+, V65, P2; Kovar H, 1996, CELL GROWTH DIFFER, V7, P429; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lawlor ER, 1998, CANCER RES, V58, P2469; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Mellin W, 1989, Curr Top Pathol, V80, P115; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; NIGGLI FK, 1994, BRIT J CANCER, V69, P1106, DOI 10.1038/bjc.1994.217; PONTEN J, 1971, SPONTANEOUS VIRUS IN; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V24, P1, DOI 10.1002/(SICI)1098-2744(199901)24:1<1::AID-MC1>3.0.CO;2-E; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Santini MT, 1999, PATHOBIOLOGY, V67, P148, DOI 10.1159/000028065; Scheid MP, 2000, CURR BIOL, V10, pR191, DOI 10.1016/S0960-9822(00)00349-3; SCOTLANDI K, 1995, CANCER, V75, P806, DOI 10.1002/1097-0142(19950201)75:3<806::AID-CNCR2820750310>3.0.CO;2-S; Scotlandi K, 1996, CANCER RES, V56, P4570; Shao JY, 2000, J BIOL CHEM, V275, P22916, DOI 10.1074/jbc.M002235200; Sherr CJ, 2000, CANCER RES, V60, P3689; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Silvany RE, 2000, ONCOGENE, V19, P4523, DOI 10.1038/sj.onc.1203811; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Tanaka K, 1997, J CLIN INVEST, V99, P239, DOI 10.1172/JCI119152; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Toretsky JA, 1999, CANCER RES, V59, P5745; Toretsky JA, 1997, J BIOL CHEM, V272, P30822, DOI 10.1074/jbc.272.49.30822; Treinies I, 1999, MOL CELL BIOL, V19, P321; TRICHE TJ, 1993, PRINCIPLES PRACTICE, V2, P115; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; Vollmer E, 1989, Curr Top Pathol, V80, P91; WHANGPENG J, 1984, NEW ENGL J MED, V311, P584, DOI 10.1056/NEJM198408303110907; Wong CW, 2001, CANCER RES, V61, P333; YEE D, 1990, J CLIN INVEST, V86, P1806, DOI 10.1172/JCI114910; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	53	64	67	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2002	21	2					307	318		10.1038/sj.onc.1205053	http://dx.doi.org/10.1038/sj.onc.1205053			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803474				2022-12-25	WOS:000173026200015
J	Aono, S; Kato, T; Matsuki, M; Nakajima, H; Ohta, T; Uchida, T; Kitagawa, T				Aono, S; Kato, T; Matsuki, M; Nakajima, H; Ohta, T; Uchida, T; Kitagawa, T			Resonance Raman and ligand binding studies of the oxygen-sensing signal transducer protein HemAT from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; CYTOCHROME-C PEROXIDASE; SENSOR FIXL; MYCOBACTERIUM-TUBERCULOSIS; TRANSCRIPTIONAL ACTIVATOR; STRUCTURAL IMPLICATION; RHODOSPIRILLUM-RUBRUM; RHIZOBIUM-MELILOTI; LINKED IONIZATION; CARBON-MONOXIDE	HemAT-Bs is a heme-containing signal transducer protein responsible for aerotaxis of Bacillus subtilis. The recombinant HemAT-Bs expressed in Escherichia coli was purified as the oxy form in which oxygen was bound to the ferrous heme. Oxygen binding and dissociation rate constants were determined to be k(on) = 32 muM(-1) s(-1) and k(off) = 23 s(-1), respectively, revealing that HemAT-Bs has a moderate oxygen affinity similar to that of sperm whale myoglobin (Mb). The rate constant for autoxidation at 37 degreesC was 0.06 h(-1), which is also close to that of Mb. Although the electronic absorption spectra of HemAT-Bs were similar to those of Mb, HemAT-Bs showed some unique characteristics in its resonance Raman spectra. Oxygen-bound HemAT-Bs gave the nu(Fe-O2) band at a noticeably low frequency (560 cm(-1)), which suggests a unique hydrogen bonding between a distal amino acid residue and the proximal atom of the bound oxygen molecule. Deoxy HemAT-Bs gave the nu(Fe-His) band at a higher frequency (225 cm(-1)) than those of ordinary His-coordinated deoxy heme proteins. CO-bound HemAT-Bs gave the nu(Fe-CO) and nu(C-O) bands at 494 and 1964 cm(-1), respectively, which fall on the same nu(C-O) versus nu(Fe-CO) correlation line as that of Mb. Based on these results, the structural and functional properties of HemAT-Bs are discussed.	Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan; Japan Adv Inst Sci & Technol, Sch Mat Sci, Ishikawa 9231292, Japan	National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Japan Advanced Institute of Science & Technology (JAIST)	Aono, S (corresponding author), Okazaki Natl Res Inst, Ctr Integrat Biosci, Okazaki, Aichi 4448585, Japan.		Aono, Shigetoshi/ABD-7618-2020; Uchida, Takeshi/A-6455-2017	Aono, Shigetoshi/0000-0002-2870-3694; Uchida, Takeshi/0000-0001-9270-8329				ABE M, 1978, J CHEM PHYS, V69, P4526, DOI 10.1063/1.436450; Andrew CR, 2001, BIOCHEMISTRY-US, V40, P4115, DOI 10.1021/bi0023652; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 2000, PROG REACT KINET MEC, V25, P65, DOI 10.3184/007967400103165128; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; BRUNNER H, 1974, NATURWISSENSCHAFTEN, V61, P129, DOI 10.1007/BF00606289; CARVER TE, 1992, J BIOL CHEM, V267, P14443; Chan MK, 2001, CURR OPIN CHEM BIOL, V5, P216, DOI 10.1016/S1367-5931(00)00193-9; Chang AL, 2001, BIOCHEMISTRY-US, V40, P3420, DOI 10.1021/bi0100236; CHOI S, 1982, J AM CHEM SOC, V104, P4345, DOI 10.1021/ja00380a006; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Das TK, 2001, P NATL ACAD SCI USA, V98, P479, DOI 10.1073/pnas.98.2.479; Das TK, 2000, BIOCHEMISTRY-US, V39, P14330, DOI 10.1021/bi001681d; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Falke JJ, 2001, TRENDS BIOCHEM SCI, V26, P257, DOI 10.1016/S0968-0004(00)01770-9; Fan BC, 1998, BIOCHEMISTRY-US, V37, P1178, DOI 10.1021/bi971934b; FRANZEN S, 1995, J BIOL CHEM, V270, P1718, DOI 10.1074/jbc.270.4.1718; GARRITY LF, 1995, PHARMACOL THERAPEUT, V68, P87, DOI 10.1016/0163-7258(95)00027-5; GIBSON QH, 1965, PROC R SOC SER B-BIO, V163, P206, DOI 10.1098/rspb.1965.0067; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 2000, BIOCHEMISTRY-US, V39, P3955, DOI 10.1021/bi992346w; HAN S, 1990, P NATL ACAD SCI USA, V87, P2491, DOI 10.1073/pnas.87.7.2491; Hargrove MS, 1997, J MOL BIOL, V266, P1032, DOI 10.1006/jmbi.1996.0833; HASHIMOTO S, 1986, J BIOL CHEM, V261, P1110; Hazelbauer GL, 1992, CURR OPIN STRUC BIOL, V2, P505; HIROTA S, 1994, J PHYS CHEM-US, V98, P6652, DOI 10.1021/j100077a035; Hirota S, 1996, J AM CHEM SOC, V118, P7845, DOI 10.1021/ja9608297; HIROTA S, 1994, J AM CHEM SOC, V116, P10564, DOI 10.1021/ja00102a025; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; Hou SB, 2001, P NATL ACAD SCI USA, V98, P9353, DOI 10.1073/pnas.161185598; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; Kiger L, 1998, BIOPHYS J, V75, P990, DOI 10.1016/S0006-3495(98)77587-3; Kim SY, 1996, J AM CHEM SOC, V118, P8769, DOI 10.1021/ja961411b; KITAGAWA T, 1979, FEBS LETT, V104, P376, DOI 10.1016/0014-5793(79)80856-X; Kitagawa T, 1988, BIOL APPL RAMAN SPEC, V3, P97; MATSUKAWA S, 1985, J AM CHEM SOC, V107, P1108, DOI 10.1021/ja00291a004; Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176; Mukai M, 2000, BIOCHEMISTRY-US, V39, P13810, DOI 10.1021/bi001184x; NAGAI K, 1980, J MOL BIOL, V136, P271, DOI 10.1016/0022-2836(80)90374-5; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; Nakamura H, 1998, BIOCHEM BIOPH RES CO, V247, P427, DOI 10.1006/bbrc.1998.8694; OGURA T, 1990, J AM CHEM SOC, V112, P5630, DOI 10.1021/ja00170a032; Othman S, 1996, BIOCHEMISTRY-US, V35, P9224, DOI 10.1021/bi952818g; OZAKI Y, 1986, J PHYS CHEM-US, V90, P6105, DOI 10.1021/j100281a011; PARKINSON JS, 1993, CELL, V73, P857, DOI 10.1016/0092-8674(93)90267-T; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; Rodgers KR, 1999, J AM CHEM SOC, V121, P11241, DOI 10.1021/ja991916c; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; ROUSSEAU DL, 1988, BIOL APPLICATIONS RA, V3, P133; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SMULEVICH G, 1988, BIOCHEMISTRY-US, V27, P5477, DOI 10.1021/bi00415a014; SPIRO TG, 1990, BIOCHEMISTRY-US, V29, P4497, DOI 10.1021/bi00471a001; Spiro TG, 1988, BIOL APPL RAMAN SPEC, V3, P1; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; TAKAHASHI S, 1994, BIOCHEMISTRY-US, V33, P5531, DOI 10.1021/bi00184a023; TAKAHASHI S, 1995, J AM CHEM SOC, V117, P6002, DOI 10.1021/ja00127a013; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; TERAOKA J, 1981, J BIOL CHEM, V256, P3969; Tomita T, 1997, BIOCHEMISTRY-US, V36, P10155, DOI 10.1021/bi9710131; TSUBAKI M, 1981, P NATL ACAD SCI-BIOL, V78, P3581, DOI 10.1073/pnas.78.6.3581; TSUBAKI M, 1985, BIOCHIM BIOPHYS ACTA, V827, P268, DOI 10.1016/0167-4838(85)90211-0; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; VAROTSIS C, 1989, J AM CHEM SOC, V111, P6439, DOI 10.1021/ja00198a075; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Vogel KM, 1999, J BIOL INORG CHEM, V4, P804, DOI 10.1007/s007750050354; WHITAKER TL, 1995, BIOCHEMISTRY-US, V34, P8221, DOI 10.1021/bi00026a002; WILKS A, 1995, J AM CHEM SOC, V117, P2925, DOI 10.1021/ja00115a027; Yamamoto K, 2001, J BIOL CHEM, V276, P11473, DOI 10.1074/jbc.C100047200; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; YU AE, 1994, J AM CHEM SOC, V116, P4117, DOI 10.1021/ja00088a073; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39; Zhao Y, 1998, BIOCHEMISTRY-US, V37, P4502, DOI 10.1021/bi972686m; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	84	81	86	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13528	13538		10.1074/jbc.M112256200	http://dx.doi.org/10.1074/jbc.M112256200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821422	hybrid			2022-12-25	WOS:000175096000026
J	Bradley, CA; Padovan, JC; Thompson, TL; Benoit, CA; Chait, BT; Rhoads, RE				Bradley, CA; Padovan, JC; Thompson, TL; Benoit, CA; Chait, BT; Rhoads, RE			Mass spectrometric analysis of the N terminus of translational initiation factor eIF4G-1 reveals novel isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR 4G EIF4G; BINDING PROTEIN COMPLEX; AMINO-ACID-SEQUENCE; RIBOSOME ENTRY SITE; MESSENGER-RNA; POLY(A)-BINDING PROTEIN; IN-VITRO; FACTOR EIF-4-GAMMA; HEAT-SHOCK; PROTEOLYTIC CLEAVAGE	In eukaryotes, translation initiation factor 4G (eIF4G) acts as the central binding protein for an unusually large number of proteins involved in mRNA metabolism. Several gene products homologous to eIF4G have been described, the most studied being eIF4G-1. By its association with other initiation factors, eIF4G-1 effects mRNA cap and poly(A) recognition, unwinding of secondary structure, and binding to the 43S initiation complex. Multiple electrophoretic isoforms of eIF4G-1 are observed, and multiple cDNAs have been reported, yet the relationship between the two is not known. We report here a new cDNA for eIF4G-1, present as a previously unidentified human expressed sequence tag, that extends the long open reading frame, provides a new in-frame initiation codon, and predicts a longer form of eIF4G-1 than reported previously. eIF4G isoforms from human K562 cells were cleaved with recombinant Coxsackievirus 2A protease and the N-terminal domains purified by m(7)GTP-Sepharose chromatography and polyacrylamide gel electrophoresis. Proteins were digested with proteolytic enzymes and peptides masses determined by matrix-assisted laser desorption ionization-time of flight mass spectrometry. In selected cases, peptides were sequenced by electrospray-mass spectrometry fragmentation. This identified the N termini of the three most abundant eIF4G-1 isoforms, two of which had not previously been proposed. These proteins appear to have been initiated from three different AUG codons.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Hlth Sci Ctr, Res Core Facil, Shreveport, LA 71130 USA; Rockefeller Univ, Lab Mass Spectrometry & Gaseous Ion Chem, New York, NY 10021 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Rockefeller University	Rhoads, RE (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1501 Kings Highway, Shreveport, LA 71130 USA.	rrhoad@lsuhsc.edu		Bradley, Christopher/0000-0001-9531-996X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000862] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 00862] Funding Source: Medline; NIGMS NIH HHS [GM 20818] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aragon T, 2000, MOL CELL BIOL, V20, P6259, DOI 10.1128/MCB.20.17.6259-6268.2000; BEAVIS RC, 1990, P NATL ACAD SCI USA, V87, P6873, DOI 10.1073/pnas.87.17.6873; Borman AM, 1997, RNA, V3, P186; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Clark BFC, 1996, BIOCHIMIE, V78, P1119, DOI 10.1016/S0300-9084(97)86738-7; Cuesta R, 2000, GENE DEV, V14, P1460; De Gregorio E, 1998, RNA, V4, P828, DOI 10.1017/S1355838298980372; DUNCAN R, 1987, J BIOL CHEM, V262, P380; EDERY I, 1983, J BIOL CHEM, V258, P1398; EHRENFELD E, 1996, TRANSLATIONAL CONTRO, P549; ETCHISON D, 1982, J BIOL CHEM, V257, P4806; Fortes P, 2000, MOL CELL, V6, P191, DOI 10.1016/S1097-2765(00)00020-4; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; Gan WN, 1998, J BIOL CHEM, V273, P5006, DOI 10.1074/jbc.273.9.5006; Gan WN, 1996, J BIOL CHEM, V271, P623, DOI 10.1074/jbc.271.2.623; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; Gradi A, 1998, MOL CELL BIOL, V18, P334, DOI 10.1128/MCB.18.1.334; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayashi S, 2000, BIOCHEM BIOPH RES CO, V277, P117, DOI 10.1006/bbrc.2000.3637; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hershey PEC, 1999, J BIOL CHEM, V274, P21297, DOI 10.1074/jbc.274.30.21297; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Imataka H, 1998, EMBO J, V17, P7480, DOI 10.1093/emboj/17.24.7480; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; JANG SK, 1988, J VIROL, V62, P2636, DOI 10.1128/JVI.62.8.2636-2643.1988; Joachims M, 1999, J VIROL, V73, P718, DOI 10.1128/JVI.73.1.718-727.1999; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; JOSHI B, 1994, J BIOL CHEM, V269, P2048; Kerekatte V, 1999, J VIROL, V73, P709, DOI 10.1128/JVI.73.1.709-717.1999; KIRCHWEGER R, 1994, J VIROL, V68, P5677, DOI 10.1128/JVI.68.9.5677-5684.1994; Kolupaeva VG, 1998, J BIOL CHEM, V273, P18599, DOI 10.1074/jbc.273.29.18599; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; Korneeva NL, 2000, J BIOL CHEM, V275, P41369, DOI 10.1074/jbc.M007525200; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lamphear BJ, 1996, BIOCHEMISTRY-US, V35, P15726, DOI 10.1021/bi961864t; LAMPHEAR BJ, 1993, J BIOL CHEM, V268, P19200; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Le H, 1997, J BIOL CHEM, V272, P16247, DOI 10.1074/jbc.272.26.16247; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; LIEBIG HD, 1993, BIOCHEMISTRY-US, V32, P7581, DOI 10.1021/bi00080a033; MADER S, 1995, MOL CELL BIOL, V15, P4990; McKendrick L, 2001, MOL CELL BIOL, V21, P3632, DOI 10.1128/MCB.21.11.3632-3641.2001; MILBURN SC, 1990, ARCH BIOCHEM BIOPHYS, V276, P6, DOI 10.1016/0003-9861(90)90002-G; OHLMANN T, 1995, NUCLEIC ACIDS RES, V23, P334; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; RAY BK, 1985, J BIOL CHEM, V260, P7651; Rhoads RE, 1999, J BIOL CHEM, V274, P30337, DOI 10.1074/jbc.274.43.30337; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; SOMMERGRUBER W, 1994, VIROLOGY, V198, P741, DOI 10.1006/viro.1994.1089; SOMMERGRUBER W, 1992, J BIOL CHEM, V267, P22639; Tarun SZ, 1996, EMBO J, V15, P7168, DOI 10.1002/j.1460-2075.1996.tb01108.x; URZAINQUI A, 1989, J VIROL, V63, P4729, DOI 10.1128/JVI.63.11.4729-4735.1989; Vilela C, 2000, EMBO J, V19, P4372, DOI 10.1093/emboj/19.16.4372; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; WEBB NR, 1984, BIOCHEMISTRY-US, V23, P177, DOI 10.1021/bi00297a001; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; YAN RQ, 1995, GENOMICS, V26, P394, DOI 10.1016/0888-7543(95)80227-D; YAN RQ, 1992, J BIOL CHEM, V267, P23226; ZHANG WZ, 1994, PROTEIN SCI, V3, P677; ZIEGLER E, 1995, J VIROL, V69, P3465, DOI 10.1128/JVI.69.6.3465-3474.1995	69	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12559	12571		10.1074/jbc.M111134200	http://dx.doi.org/10.1074/jbc.M111134200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821405	Green Published, hybrid			2022-12-25	WOS:000175036300012
J	Irving, JA; Shushanov, SS; Pike, RN; Popova, EY; Bromme, D; Coetzer, THT; Bottomley, SP; Boulynko, IA; Grigoryev, SA; Whisstock, JC				Irving, JA; Shushanov, SS; Pike, RN; Popova, EY; Bromme, D; Coetzer, THT; Bottomley, SP; Boulynko, IA; Grigoryev, SA; Whisstock, JC			Inhibitory activity of a heterochromatin-associated serpin (MENT) against papain-like cysteine proteinases affects chromatin structure and blocks cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; SUSCEPTIBILITY GENE-PRODUCT; CROSS-CLASS INHIBITION; REACTIVE-SITE LOOP; L-TYPE PROTEASE; CATHEPSIN-L; FUNCTIONAL EXPRESSION; CARCINOMA ANTIGEN-1; CRYSTAL-STRUCTURE; CLEAVAGE	MENT (Myeloid and Erythroid Nuclear Termination stage-specific protein) is a developmentally regulated chromosomal serpin that condenses chromatin in terminally differentiated avian blood cells. We show that MENT is an effective inhibitor of the papain-like cysteine proteinases cathepsins L and V. In addition, ectopic expression of MENT in mammalian cells is apparently sufficient to inhibit a nuclear papain-like cysteine proteinase and prevent degradation of the retinoblastoma protein, a major regulator of cell proliferation. MENT also accumulates in the nucleus, causes a strong block in proliferation, and promotes condensation of chromatin. Variants of MENT with mutations or deletions within the M-loop, which contains a nuclear localization signal and an AT-hook motif, reveal that this region mediates nuclear transport and morphological changes associated with chromatin condensation. Non-inhibitory mutants of MENT were constructed to determine whether its inhibitory activity has a role in blocking proliferation. These mutations changed the mode of association with chromatin and relieved the block in proliferation, without preventing transport to the nucleus. We conclude that the repressive effect of MENT on chromatin is mediated by its direct interaction with a nuclear protein that has a papain-like cysteine proteinase active site.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Univ Natal, Sch Mol & Cellular Biosci Biochem, ZA-3209 Scottsville, South Africa; Monash Univ, Victorian Bioinformat Consortium, Clayton, Vic 3800, Australia	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Monash University; Icahn School of Medicine at Mount Sinai; University of Kwazulu Natal; Monash University	Grigoryev, SA (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Biochem & Mol Biol, Hershey, PA 17033 USA.		Shushanov, Sain/R-9622-2019; Irving, James A/I-8467-2015; Coetzer, Theresa/AAE-6207-2019; Coetzer, Theresa/AAM-9193-2021; Irving, James/P-3860-2019	Coetzer, Theresa/0000-0003-0706-3808; Irving, James/0000-0003-3204-6356; Pike, Robert/0000-0002-2083-0269; Whisstock, James/0000-0003-4200-5611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059118] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59118] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Ausubel F. M., 1999, SHORT PROTOCOLS MOL; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; Bjork I, 1998, BIOCHEM J, V335, P701; Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126; Bromme D, 1999, BIOCHEMISTRY-US, V38, P2377, DOI 10.1021/bi982175f; BRUICE PY, 1998, ORGANIC CHEM, P1142; COETZER THT, 1995, COMP BIOCHEM PHYS B, V112, P429, DOI 10.1016/0305-0491(95)00097-6; COETZER THT, 1992, IMMUNOL INVEST, V21, P495, DOI 10.3109/08820139209069386; Dehrmann FM, 1995, ARCH BIOCHEM BIOPHYS, V324, P93, DOI 10.1006/abbi.1995.9924; Dennison C, 2000, ANAL BIOCHEM, V284, P157, DOI 10.1006/abio.2000.4673; Dunstone MA, 2000, PROTEIN SCI, V9, P417; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Fu YHF, 1998, FEBS LETT, V421, P89, DOI 10.1016/S0014-5793(97)01541-X; Grigoryev SA, 1998, J BIOL CHEM, V273, P3082, DOI 10.1074/jbc.273.5.3082; Grigoryev SA, 1999, J BIOL CHEM, V274, P5626, DOI 10.1074/jbc.274.9.5626; Grigoryev SA, 2001, BIOCHEM CELL BIOL, V79, P227, DOI 10.1139/bcb-79-3-227; GRIGORYEV SA, 1993, EXP CELL RES, V206, P335, DOI 10.1006/excr.1993.1154; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HILWIG I, 1972, EXP CELL RES, V75, P122, DOI 10.1016/0014-4827(72)90527-7; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; HOPKINS PCR, 1993, BIOCHEMISTRY-US, V32, P7650, DOI 10.1021/bi00081a008; Huntington JA, 1999, J MOL BIOL, V293, P449, DOI 10.1006/jmbi.1999.3184; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; JONES HB, 1993, J HISTOCHEM CYTOCHEM, V41, P21, DOI 10.1177/41.1.8093255; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; LOMAS DA, 2000, RESP MED SC, V94, P3; Luke C, 2000, BIOCHEMISTRY-US, V39, P7081, DOI 10.1021/bi000050g; Matsumoto K, 1999, BIOPOLYMERS, V51, P99, DOI 10.1002/(SICI)1097-0282(1999)51:1<99::AID-BIP11>3.0.CO;2-R; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Nagaya T, 1998, J BIOL CHEM, V273, P33166, DOI 10.1074/jbc.273.50.33166; Nawata S, 1997, ELECTROPHORESIS, V18, P784, DOI 10.1002/elps.1150180521; Nishinaka T, 1997, BBA-GENE STRUCT EXPR, V1351, P274, DOI 10.1016/S0167-4781(96)00210-2; Nomura Y, 1999, BIOCHEM BIOPH RES CO, V254, P388, DOI 10.1006/bbrc.1998.9941; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROVELLI G, 1992, BIOCHEMISTRY-US, V31, P3542, DOI 10.1021/bi00128a031; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schick C, 1998, P NATL ACAD SCI USA, V95, P13465, DOI 10.1073/pnas.95.23.13465; Schick C, 1998, BIOCHEMISTRY-US, V37, P5258, DOI 10.1021/bi972521d; Scholtz B, 1996, DEV BIOL, V173, P420, DOI 10.1006/dbio.1996.0037; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; Xue YF, 1998, STRUCT FOLD DES, V6, P627, DOI 10.1016/S0969-2126(98)00064-1; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; 2000, PET SYSTEM MANUAL	50	73	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13192	13201		10.1074/jbc.M108460200	http://dx.doi.org/10.1074/jbc.M108460200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821386	hybrid			2022-12-25	WOS:000175036300089
J	Katiyar, S; Suzuki, T; Balgobin, BJ; Lennarz, WJ				Katiyar, S; Suzuki, T; Balgobin, BJ; Lennarz, WJ			Site-directed mutagenesis study of yeast peptide: N-glycanase - Insight into the reaction mechanism of deglycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I HEAVY-CHAINS; QUALITY-CONTROL; ENDOPLASMIC-RETICULUM; 3-DIMENSIONAL STRUCTURE; CYSTEINE PROTEASES; CATALYTIC-ACTIVITY; SERINE PROTEASES; PROTEIN; TRANSGLUTAMINASE; IDENTIFICATION	Yeast peptide:N-glycanase (Png1p; PNGase), a deglycosylation enzyme involved in the proteasome dependent degradation of proteins, has been reported to be a member of the transglutaminase superfamily based on sequence alignment. In this study we have investigated the structure-function relationship of Png1p by site-directed mutagenesis. Cys-191, His-218, and Asp-235 of Png1p are conserved in the sequence of factor XIIIa, where these amino acids constitute a catalytic triad. Point mutations of these residues in Png1p resulted in complete loss in activity, consistent with a role for each in catalyzing deglycosylation of glycoproteins. Other conserved amino acid residues, Trp-220, Trp-231, Arg-210, and Glu-222, were also vitally important for folding and structure stability of the enzyme as revealed by circular dichroism analysis. The potential effects of the mutations were predicted by mapping the conserved amino acids of Png1p within the known three-dimensional structure of factor XIIIa. Our data suggest that the lack in enzyme activity when any of the catalytic triad residues is mutated is either due to the absence of charge relay in the case of the triad or due to the disruption of the native fold of the enzyme. These findings strongly suggest a common evolutionary lineage for the PNGases and transglutaminases.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.cc.sunysb.edu	Suzuki, Tadashi/AAX-5707-2021; Suzuki, Tadashi/I-4536-2014	Suzuki, Tadashi/0000-0003-1030-7631; 	NIGMS NIH HHS [GM 33184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anantharaman V, 2001, HUM MOL GENET, V10, P1627, DOI 10.1093/hmg/10.16.1627; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; Cresswell P, 1997, CURR BIOL, V7, pR552, DOI 10.1016/S0960-9822(06)00279-X; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; FOLK JE, 1966, J BIOL CHEM, V241, P3238; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; HETTASCH JM, 1994, J BIOL CHEM, V269, P28309; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; Makarova KS, 1999, PROTEIN SCI, V8, P1714, DOI 10.1110/ps.8.8.1714; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MICANOVIC R, 1994, J BIOL CHEM, V269, P9190; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Park H, 2001, P NATL ACAD SCI USA, V98, P11163, DOI 10.1073/pnas.201393498; PEDERSEN LC, 1994, PROTEIN SCI, V3, P1131, DOI 10.1002/pro.5560030720; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shamu CE, 1999, J CELL BIOL, V147, P45, DOI 10.1083/jcb.147.1.45; SPRANG S, 1987, SCIENCE, V237, P905, DOI 10.1126/science.3112942; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Story CM, 1999, P NATL ACAD SCI USA, V96, P8516, DOI 10.1073/pnas.96.15.8516; Suzuki T, 2001, J BIOL CHEM, V276, P21601, DOI 10.1074/jbc.M100826200; SUZUKI T, 1994, J BIOL CHEM, V269, P17611; Suzuki T, 1998, J BIOL CHEM, V273, P10083, DOI 10.1074/jbc.273.17.10083; Suzuki T, 1997, P NATL ACAD SCI USA, V94, P6244, DOI 10.1073/pnas.94.12.6244; Suzuki T, 1998, J BIOL CHEM, V273, P21526, DOI 10.1074/jbc.273.34.21526; Suzuki T, 2000, J CELL BIOL, V149, P1039, DOI 10.1083/jcb.149.5.1039; TAKAHASHI N, 1977, BIOCHEM BIOPH RES CO, V76, P1194, DOI 10.1016/0006-291X(77)90982-2; Wiertz EJHJ, 1996, CELL, V84, P769, DOI 10.1016/S0092-8674(00)81054-5; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	36	42	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12953	12959		10.1074/jbc.M111383200	http://dx.doi.org/10.1074/jbc.M111383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812789	hybrid			2022-12-25	WOS:000175036300061
J	Yarwood, JM; McCormick, JK; Paustian, ML; Orwin, PM; Kapur, V; Schlievert, PM				Yarwood, JM; McCormick, JK; Paustian, ML; Orwin, PM; Kapur, V; Schlievert, PM			Characterization and expression analysis of Staphylococcus aureus pathogenicity island 3 - Implications for the evolution of staphylococcal pathogenicity islands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIC-SHOCK-SYNDROME; TUMOR NECROSIS FACTOR; EXOTOXIN TYPE-C; GENETIC-CHARACTERIZATION; DICHELOBACTER-NODOSUS; NUCLEOTIDE-SEQUENCE; BACILLUS-SUBTILIS; CARBON-DIOXIDE; SERUM ANTIBODY; ENTEROTOXIN-B	We describe the complete sequence of the 15.9-kb staphylococcal pathogenicity island 3 encoding staphylococcal enterotoxin serotypes B, K, and Q. The island, which meets the generally accepted definition of pathogenicity islands, contains 24 open reading frames potentially encoding proteins of more than 50 amino acids, including an apparently functional integrase. The element is bordered by two 17-bp direct repeats identical to those found flanking staphylococcal pathogenicity island 1. The island has extensive regions of homology to previously described pathogenicity islands, particularly staphylococcal pathogenicity islands I and bov. The expression of 22 of the 24 open reading frames contained on staphylococcal pathogenicity island 3 was detected either in vitro during growth in a laboratory medium or serum or in vivo in a rabbit model of toxic shock syndrome using DNA microarrays. The effect of oxygen tension on staphylococcal pathogenicity island 3 gene expression was also examined. By comparison with the known staphylococcal pathogenicity islands in the context of gene expression described here, we propose a model of pathogenicity island origin and evolution involving specialized transduction events and addition, deletion, or recombination of pathogenicity island "modules."	Univ Minnesota, Sch Med, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Vet Pathobiol, St Paul, MN 55108 USA; Univ Minnesota, Biomed Genom Ctr, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Schlievert, PM (corresponding author), Univ Minnesota, Sch Med, Dept Microbiol, MMC 196,420 Delaware St SE, Minneapolis, MN 55455 USA.		McCormick, John/E-4232-2015; Kapur, Vivek/F-7610-2013	Schlievert, Patrick/0000-0001-8314-9369; McCormick, John/0000-0003-3742-7289; Kapur, Vivek/0000-0002-9648-0138	NIAID NIH HHS [AI 22159] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022159, R37AI022159] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Attinger A, 2000, J IMMUNOL, V165, P1171, DOI 10.4049/jimmunol.165.3.1171; Bruttin A, 1997, VIROLOGY, V233, P136, DOI 10.1006/viro.1997.8603; Bruttin A, 1996, VIROLOGY, V219, P96, DOI 10.1006/viro.1996.0226; CARROLL D, 1995, MOL MICROBIOL, V16, P877, DOI 10.1111/j.1365-2958.1995.tb02315.x; CHAI SH, 1994, VIROLOGY, V202, P930, DOI 10.1006/viro.1994.1415; CHEETHAM BF, 1995, GENE, V162, P53, DOI 10.1016/0378-1119(95)00315-W; CHEETHAM BF, 1995, MOL MICROBIOL, V18, P201, DOI 10.1111/j.1365-2958.1995.mmi_18020201.x; CHILDS C, 1994, BURNS, V20, P514, DOI 10.1016/0305-4179(94)90011-6; DANIELS DL, 1983, LAMBDA, V2, P473; FAST DJ, 1988, J IMMUNOL, V140, P949; FAST DJ, 1989, INFECT IMMUN, V57, P291, DOI 10.1128/IAI.57.1.291-294.1989; Hacker J, 2000, ANNU REV MICROBIOL, V54, P641, DOI 10.1146/annurev.micro.54.1.641; Hentschel U, 2001, MICROBES INFECT, V3, P545, DOI 10.1016/S1286-4579(01)01410-1; Hofer MF, 1996, P NATL ACAD SCI USA, V93, P5425, DOI 10.1073/pnas.93.11.5425; HOVDE CJ, 1994, MOL MICROBIOL, V13, P897, DOI 10.1111/j.1365-2958.1994.tb00481.x; KASS EH, 1987, J INFECT DIS, V155, P812, DOI 10.1093/infdis/155.4.812; KATZ ME, 1991, J GEN MICROBIOL, V137, P2117, DOI 10.1099/00221287-137-9-2117; KAWABE Y, 1990, J EXP MED, V172, P1065, DOI 10.1084/jem.172.4.1065; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; Kuroda M, 2001, LANCET, V357, P1225, DOI 10.1016/S0140-6736(00)04403-2; Ladero V, 1998, J BACTERIOL, V180, P3474, DOI 10.1128/JB.180.13.3474-3476.1998; LEE PK, 1991, J INFECT DIS, V164, P711, DOI 10.1093/infdis/164.4.711; Lindsay JA, 1998, MOL MICROBIOL, V29, P527, DOI 10.1046/j.1365-2958.1998.00947.x; Loessner MJ, 2000, MOL MICROBIOL, V35, P324, DOI 10.1046/j.1365-2958.2000.01720.x; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; McCormick JK, 2001, ANNU REV MICROBIOL, V55, P77, DOI 10.1146/annurev.micro.55.1.77; MCDONNELL GE, 1994, J BACTERIOL, V176, P5820, DOI 10.1128/JB.176.18.5820-5830.1994; Mishell B, 1980, SELECTED METHODS CEL, p[30, 86]; Moore PCL, 2001, J CLIN MICROBIOL, V39, P2760, DOI 10.1128/JCM.39.8.2760-2767.2001; Narita S, 2001, GENE, V268, P195, DOI 10.1016/S0378-1119(01)00390-0; Novick RP, 2001, MICROBES INFECT, V3, P585, DOI 10.1016/S1286-4579(01)01414-9; Orwin PM, 2001, INFECT IMMUN, V69, P360, DOI 10.1128/IAI.69.1.360-366.2001; POINDEXTER NJ, 1986, J INFECT DIS, V153, P772, DOI 10.1093/infdis/153.4.772; Ross RA, 2000, INFECT IMMUN, V68, P5205, DOI 10.1128/IAI.68.9.5205-5209.2000; Schlievert PM, 1996, J LAB CLIN MED, V127, P13, DOI 10.1016/S0022-2143(96)90161-4; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P236, DOI 10.1093/infdis/147.2.236; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P391, DOI 10.1093/infdis/147.3.391; SCOTT DF, 1983, INFECT IMMUN, V39, P383, DOI 10.1128/IAI.39.1.383-387.1983; STOLZ SJ, 1985, J INFECT DIS, V151, P883, DOI 10.1093/infdis/151.5.883; Tenover FC, 2000, GRAM-POSITIVE PATHOGENS, P414; TODD JK, 1987, J INFECT DIS, V155, P673, DOI 10.1093/infdis/155.4.673; VERGERONT JM, 1983, J INFECT DIS, V148, P692, DOI 10.1093/infdis/148.4.692; WILKINS MR, 1998, 2 D PROTEOME ANAL PR, P531; WONG ACL, 1990, INFECT IMMUN, V58, P1026, DOI 10.1128/IAI.58.4.1026-1029.1990; Yarwood JM, 2000, J CLIN MICROBIOL, V38, P1797, DOI 10.1128/JCM.38.5.1797-1803.2000; Yarwood JM, 2002, J BACTERIOL, V184, P1095, DOI 10.1128/jb.184.4.1095-1101.2002; Yarwood JM, 2001, J BACTERIOL, V183, P1113, DOI 10.1128/JB.183.4.1113-1123.2001; YE ZH, 1993, J BACTERIOL, V175, P1095, DOI 10.1128/JB.175.4.1095-1102.1993; YE ZH, 1990, J BACTERIOL, V172, P2568, DOI 10.1128/jb.172.5.2568-2575.1990; YE ZH, 1989, J BACTERIOL, V171, P4146, DOI 10.1128/JB.171.8.4146-4153.1989	51	116	124	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13138	13147		10.1074/jbc.M111661200	http://dx.doi.org/10.1074/jbc.M111661200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821418	Green Submitted, hybrid			2022-12-25	WOS:000175036300083
J	Yu, Q; He, M; Lee, NH; Liu, ET				Yu, Q; He, M; Lee, NH; Liu, ET			Identification of Myc-mediated death response pathways by microarray analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; C-MYC; DNA-DAMAGE; INDUCED APOPTOSIS; GENE; EXPRESSION; GROWTH; INDUCTION; P53; ACTIVATION	To understand the mechanisms of Myc-mediated apoptosis induced by DNA damage, we have characterized the death kinetics of three Rat-1 fibroblast cell lines that either overexpress Myc or lack Myc and their parental wild-type cells following exposure to the DNA-damaging agent VP-16, and we monitored the changes in gene expression using microarray. We have identified three groups of genes whose expressions are distinctly regulated during this process. One cluster (Cluster A) revealed a VP-16-dependent but Myc-independent induction of a set of genes that is not linked to the apoptotic response. Two other gene clusters, however, were associated with VP-16-induced apoptosis. Cluster 13, which includes p53-responsive genes, was associated with the temporal onset of apoptosis but accounted for only the basal apoptosis. However, Cluster C, which includes c-jun, was highly regulated by Myc and appeared to be critical to mounting the maximal apoptotic response in Myc-expressing cells. Furthermore, the Myc level dropped sharply following VP-16 exposure, which varied inversely with the induction of Cluster C genes, suggesting Myc normally represses their transcription. Thus, we have proposed that removal of Myc-mediated repression of apoptotic signals, combined with Myc-associated acceleration of the p53 responsive pathway, results in complete and rapid cell death following DNA damage.	NCI, Ctr Adv Technol, Canc Res Ctr, NIH, Gaithersburg, MD 20877 USA; Inst Genom Res, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); J. Craig Venter Institute	Liu, ET (corresponding author), Natl Univ Singapore, Genome Inst Singapore, 1 Res Link,IMA Bldg04-01, Singapore 117604, Singapore.	gisliue@nus.edu.sg	Liu, Edison/C-4141-2008	Yu, Qiang/0000-0003-2132-8278				Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Alarcon RM, 1996, CANCER RES, V56, P4315; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Amundson SA, 1998, ONCOGENE, V17, P2149, DOI 10.1038/sj.onc.1202136; Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; ASKEW DS, 1991, ONCOGENE, V6, P1915; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; EBERWINE J, 1992, P NATL ACAD SCI USA, V89, P3010, DOI 10.1073/pnas.89.7.3010; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fan MY, 2001, CANCER RES, V61, P4450; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Guo QM, 2000, CANCER RES, V60, P5922; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HERRLICH P, 1994, ADV ENZYME REGUL, V34, P381, DOI 10.1016/0065-2571(94)90024-8; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; HOANG AT, 1994, P NATL ACAD SCI USA, V91, P6875, DOI 10.1073/pnas.91.15.6875; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Martelli AM, 2000, TRANSFUSION, V40, P169, DOI 10.1046/j.1537-2995.2000.40020169.x; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meng LH, 2001, FEBS LETT, V501, P59, DOI 10.1016/S0014-5793(01)02633-3; Noguchi K, 2000, BIOCHEM BIOPH RES CO, V267, P221, DOI 10.1006/bbrc.1999.1952; Parrinello S, 2001, J BIOL CHEM, V276, P39213, DOI 10.1074/jbc.M104473200; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; ROY B, 1994, MOL CELL BIOL, V14, P7805, DOI 10.1128/MCB.14.12.7805; Rupnow BA, 1998, CANCER LETT, V127, P211, DOI 10.1016/S0304-3835(98)00045-7; Rupnow BA, 1998, CELL DEATH DIFFER, V5, P141, DOI 10.1038/sj.cdd.4400328; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SIEDE W, 1995, MUTAT RES-DNA REPAIR, V337, P73, DOI 10.1016/0921-8777(95)00023-D; Strumberg D, 1999, J BIOL CHEM, V274, P28246, DOI 10.1074/jbc.274.40.28246; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	44	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13059	13066		10.1074/jbc.M111403200	http://dx.doi.org/10.1074/jbc.M111403200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821411	hybrid			2022-12-25	WOS:000175036300073
J	Greenfield, JP; Leung, LW; Cai, DM; Kaasik, K; Gross, RS; Rodriguez-Boulan, E; Greengard, P; Xu, HX				Greenfield, JP; Leung, LW; Cai, DM; Kaasik, K; Gross, RS; Rodriguez-Boulan, E; Greengard, P; Xu, HX			Estrogen lowers Alzheimer beta-amyloid generation by stimulating trans-Golgi network vesicle biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEPATOMA-CELLS; PRECURSOR PROTEIN; REPLACEMENT THERAPY; MEMBRANE TRAFFICKING; DISEASE; PEPTIDES; PITUITARY; IDENTIFICATION; MATURATION; INDUCTION	Estrogen reduces the risk of Alzheimer's disease in post-menopausal women, beta-amyloid (Abeta) burden in animal models of Alzheimer's disease, and secretion of Abeta from neuronal cultures. The biological basis for these effects remains unknown. Here, utilizing cell-free systems derived from both neuroblastoma cells and primary neurons, we demonstrate that 17beta-estradiol (17beta-E2) stimulates formation of vesicles containing the beta-amyloid precursor protein (PAPP) from the transGolgi network (TGN). Accelerated betaAPP trafficking precludes maximal Abeta generation within the TGN. 17beta-E2 appears to modulate TGN phospholipid levels, particularly those of phosphatidylinositol, and to recruit soluble trafficking factors, such as Rab11, to the TGN. Together, these results suggest that estrogen may exert its anti-Abeta effects by regulating betaAPP trafficking within the late secretory pathway. These results suggest a novel mechanism through which 17beta-E2 may act in estrogen-responsive tissues and illustrate how altering the kinetics of the transport of a protein can influence its metabolic fate.	Rockefeller Univ, Fisher Ctr Res Alzheimers Dis, New York, NY 10021 USA; Rockefeller Univ, Lab Mol & Cellular Neurosci, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Inst, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Ophthalmol, New York, NY 10021 USA	Rockefeller University; Rockefeller University; Cornell University; Cornell University	Xu, HX (corresponding author), Rockefeller Univ, Fisher Ctr Res Alzheimers Dis, 1230 York Ave Box 296, New York, NY 10021 USA.		Leung, Lawrence/E-4439-2010; Xu, Huaxi/AAV-7177-2021	Leung, Lawrence/0000-0003-3333-3242; Cai, Dongming/0000-0002-0601-6826; Greenfield, Jeffrey/0000-0003-1904-1040	NIA NIH HHS [P01 AG009464, AG09464] Funding Source: Medline; NIGMS NIH HHS [R01 GM034107] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG009464] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Asthana S, 2001, NEUROLOGY, V57, P605, DOI 10.1212/WNL.57.4.605; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CAPORASO GL, 1994, J NEUROSCI, V14, P3122; Chang D, 1997, ADV EXP MED BIOL, V429, P261; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Chen DH, 1999, MOL ENDOCRINOL, V13, P993, DOI 10.1210/me.13.6.993; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Cockcroft S, 2001, SEMIN CELL DEV BIOL, V12, P183, DOI 10.1006/scdb.2000.0235; DROUVA SV, 1986, ENDOCRINOLOGY, V119, P2611, DOI 10.1210/endo-119-6-2611; DROUVA SV, 1987, ENDOCRINOLOGY, V121, P569, DOI 10.1210/endo-121-2-569; Dumanchin C, 1999, HUM MOL GENET, V8, P1263, DOI 10.1093/hmg/8.7.1263; Greenfield JP, 2000, FRONT BIOSCI, V5, pD72, DOI 10.2741/Greenfield; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; KAIN SR, 1992, J BIOL CHEM, V267, P8128; Manthey D, 2001, EUR J BIOCHEM, V268, P4285, DOI 10.1046/j.1432-1327.2001.02346.x; Mcewen BS, 1999, ENDOCR REV, V20, P279, DOI 10.1210/er.20.3.279; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; NORDSTEDT C, 1993, J BIOL CHEM, V268, P608; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Petanceska SS, 2000, NEUROLOGY, V54, P2212, DOI 10.1212/WNL.54.12.2212; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PLATT EJ, 1991, MOL ENDOCRINOL, V5, P1696, DOI 10.1210/mend-5-11-1696; Robinson LJ, 1998, CURR OPIN CELL BIOL, V10, P483, DOI 10.1016/S0955-0674(98)80063-X; SCAMMELL JG, 1986, ENDOCRINOLOGY, V119, P1543, DOI 10.1210/endo-119-4-1543; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schlierf B, 2000, EXP CELL RES, V259, P257, DOI 10.1006/excr.2000.4947; Schonknecht P, 2001, NEUROSCI LETT, V307, P122, DOI 10.1016/S0304-3940(01)01896-1; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Slooter AJC, 1999, J NEUROL NEUROSUR PS, V67, P779, DOI 10.1136/jnnp.67.6.779; Sollner TH, 1996, CELL STRUCT FUNCT, V21, P407; Soriano S, 1999, J BIOL CHEM, V274, P32295, DOI 10.1074/jbc.274.45.32295; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Waring SC, 1999, NEUROLOGY, V52, P965, DOI 10.1212/WNL.52.5.965; XU HX, 1993, J CELL BIOL, V122, P1169, DOI 10.1083/jcb.122.6.1169; Xu HX, 1998, NAT MED, V4, P447, DOI 10.1038/nm0498-447; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; Zheng H, 2002, J NEUROCHEM, V80, P191, DOI 10.1046/j.0022-3042.2001.00690.x	43	106	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12128	12136		10.1074/jbc.M110009200	http://dx.doi.org/10.1074/jbc.M110009200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11823458	hybrid			2022-12-25	WOS:000174846400069
J	Odaert, B; Landrieu, I; Dijkstra, K; Schuurman-Wolters, G; Casteels, P; Wieruszeski, JM; Inze, D; Scheek, R; Lippens, G				Odaert, B; Landrieu, I; Dijkstra, K; Schuurman-Wolters, G; Casteels, P; Wieruszeski, JM; Inze, D; Scheek, R; Lippens, G			Solution NMR study of the monomeric form of p13(suc1) protein sheds light on the hinge region determining the affinity for a phosphorylated substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-REGULATORY PROTEIN; XENOPUS SUC1/CKS PROTEIN; CELL-CYCLE; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; KINASE; DOMAIN; P13SUC1; MECHANISM; COMPLEX	Cyclin-dependent kinase subunit (CKS) proteins bind to cyclin-dependent kinases and target various proteins to phosphorylation and proteolysis during cell division. Crystal structures showed that CKS can exist both in a closed monomeric conformation when bound to the kinase and in an inactive C-terminal beta-strand-exchanged conformation. With the exception of the hinge loop, however, both crystal structures are identical, and no new protein interface is formed in the dimer. Protein engineering studies have pinpointed the crucial role of the proline 90 residue of the p13(suc1) CKS protein from Schizosaccharomyces pombe in the monomer-dimer equilibrium and have led to the concept of a loaded molecular spring of the beta-hinge motif. Mutation of this hinge proline into an alanine stabilizes the protein and prevents the occurrence of swapping. However, other mutations further away from the hinge as well as ligand binding can equally shift the equilibrium between monomer and dimer. To address the question of differential affinity through relief of the strain, here we compare the ligand binding of the monomeric form of wild-type S. pombe p13(suc1) and its hinge mutant P90A in solution by NMR spectroscopy. We indeed observed a 5-fold difference in affinity with the wild-type protein being the most strongly binding. Our structural study further indicates that both wild-type and the P90A mutant proteins adopt in solution the closed conformation but display different dynamic properties in the C-terminal beta-sheet involved in domain swapping and protein interactions.	Univ Lille 2, CNRS UMR 8525, Inst Pasteur, Inst Biol, F-59019 Lille, France; Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, NL-9747 Groningen, Netherlands; State Univ Ghent VIB, Dept Plant Genet, Genet Lab, B-9000 Ghent, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; University of Groningen; Flanders Institute for Biotechnology (VIB); Ghent University	Lippens, G (corresponding author), Univ Lille 2, CNRS UMR 8525, Inst Pasteur, Inst Biol, F-59019 Lille, France.	guy.lippens@pasteur-lille.fr	Landrieu, Isabelle/AAF-8495-2019; Inzé, Dirk/AAW-6381-2021	Landrieu, Isabelle/0000-0002-4883-2637; Inzé, Dirk/0000-0002-3217-8407; Lippens, Guy/0000-0002-8236-0901				Akke M, 1998, NAT STRUCT BIOL, V5, P55, DOI 10.1038/nsb0198-55; Alonso DOV, 2000, STRUCTURE, V8, P101, DOI 10.1016/S0969-2126(00)00083-6; ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Bergdoll M, 1997, STRUCTURE, V5, P391, DOI 10.1016/S0969-2126(97)00196-2; Birck C, 1996, BIOCHEMISTRY-US, V35, P5577, DOI 10.1021/bi952199b; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; BOURNE Y, 1995, P NATL ACAD SCI USA, V92, P10232, DOI 10.1073/pnas.92.22.10232; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; Burgi R, 2001, J BIOMOL NMR, V19, P305, DOI 10.1023/A:1011295422203; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; ENDICOTT JA, 1995, STRUCTURE, V3, P321, DOI 10.1016/S0969-2126(01)00162-9; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Grzesiek S, 1997, PROTEIN SCI, V6, P1248, DOI 10.1002/pro.5560060613; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Khazanovich N, 1996, STRUCTURE, V4, P299, DOI 10.1016/S0969-2126(96)00034-2; Korchuganov DS, 2001, J AM CHEM SOC, V123, P2068, DOI 10.1021/ja0025447; Landrieu I, 2001, J BIOL CHEM, V276, P1434, DOI 10.1074/jbc.M006420200; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; Lu KP, 1996, NATURE, V380, P544; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pfuhl M, 1999, J BIOMOL NMR, V14, P307, DOI 10.1023/A:1008319917267; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Rousseau F, 1998, J MOL BIOL, V284, P503, DOI 10.1006/jmbi.1998.2173; Schymkowitz JWH, 2001, NAT STRUCT BIOL, V8, P888, DOI 10.1038/nsb1001-888; Schymkowitz JWH, 2000, J MOL BIOL, V301, P199, DOI 10.1006/jmbi.2000.3958; Schymkowitz JWH, 2000, STRUCTURE, V8, P89, DOI 10.1016/S0969-2126(00)00084-8; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957	35	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12375	12381		10.1074/jbc.M111741200	http://dx.doi.org/10.1074/jbc.M111741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812792	Green Published, hybrid			2022-12-25	WOS:000174846400102
J	Speranza, G; Mueller, B; Orlandi, M; Morelli, CF; Manitto, P; Schink, B				Speranza, G; Mueller, B; Orlandi, M; Morelli, CF; Manitto, P; Schink, B			Mechanism of anaerobic ether cleavage - Conversion of 2-phenoxyethanol to phenol and acetaldehyde by Acetobacterium sp.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYETHYLENE-GLYCOL; DIOL DEHYDRATASE; FERMENTATIVE DEGRADATION; PELOBACTER-VENETIANUS; PURE CULTURES; RADICALS; BACTERIA; ACETATE; ENZYME; ACIDS	2-Phenoxyethanol is converted into phenol and acetate by a strictly anaerobic Gram-positive bacterium, Acetobacterium strain LuPhet1. Acetate results from oxidation of acetaldehyde that is the early product of the biodegradation process (Frings, J., and Schink, B. (1994) Arch. Microbiol. 162, 199-204). Feeding experiments with resting cell suspensions and 2-phenoxyethanol bearing two deuterium atoms at either carbon of the glycolic moiety as substrate demonstrated that the carbonyl group of the acetate derives from the alcoholic function and the methyl group derives from the adjacent carbon. A concomitant migration of a deuterium atom from C-1 to C-2 was observed. These findings were confirmed by NMR analysis of the acetate obtained by fermentation of 2-phenoxy-[2-C-13,1-H-2(2)]ethanol, 2-phenoxy-[1-C-13,1-H-2(2)]ethanol, and 2-phenoxy-[1,2-C-13(2),1-H-2(2)] ethanol. During the course of the biotransformation process, the molecular integrity of the glycolic unit was completely retained, no loss of the migrating deuterium occurred by exchange with the medium, and the 1,2-deuterium shift was intramolecular. A diol dehydratase-like mechanism could explain the enzymatic cleavage of the ether bond of 2-phenoxyethanol, provided that an intramolecular H/OC6H5 exchange is assumed, giving rise to the hemiacetal precursor of acetaldehyde. However, an alternative mechanism is proposed that is supported by the well recognized propensity of alpha-hydroxyradical and of its conjugate base (ketyl anion) to eliminate a beta-positioned leaving group.	Univ Milan, Dipartimento Chim Organ & Ind, I-20133 Milan, Italy; CNR, Ctr Studio Sostanze Organ Nat, I-20133 Milan, Italy; Univ Konstanz, Fak Biol, D-78457 Constance, Germany	University of Milan; Consiglio Nazionale delle Ricerche (CNR); University of Konstanz	Speranza, G (corresponding author), Univ Milan, Dipartimento Chim Organ & Ind, Via Venezian 21, I-20133 Milan, Italy.	giovanna.speranza@unimi.it	Morelli, Carlo F./R-2869-2016; Speranza, Giovanna/Q-6280-2016	Morelli, Carlo F./0000-0001-6314-6902; Speranza, Giovanna/0000-0003-4544-1515				Arigoni D., 1979, VITAMIN B12, P389; Buckel W, 1996, FEBS LETT, V389, P20, DOI 10.1016/0014-5793(96)00530-3; Buckel W, 1998, FEMS MICROBIOL REV, V22, P523, DOI 10.1016/S0168-6445(98)00038-2; CIOMMER B, 1983, J ORGANOMET CHEM, V244, P319, DOI 10.1016/0022-328X(83)80040-0; Cox D P, 1978, Adv Appl Microbiol, V23, P173, DOI 10.1016/S0065-2164(08)70068-6; DUPUIS J, 1984, ANGEW CHEM INT EDIT, V23, P896, DOI 10.1002/anie.198408961; DWYER DF, 1983, APPL ENVIRON MICROB, V46, P185, DOI 10.1128/AEM.46.1.185-190.1983; EGGER KW, 1973, HELV CHIM ACTA, V56, P1516, DOI 10.1002/hlca.19730560509; FINKE RG, 1984, COORDIN CHEM REV, V54, P1, DOI 10.1016/0010-8545(84)85016-X; FINKE RG, 1983, J AM CHEM SOC, V105, P7592, DOI 10.1021/ja00364a022; FINKE RG, 1990, MOLECULAR MECHANISMS IN BIOORGANIC PROCESSES, P244; FREY PA, 1990, CHEM REV, V90, P1343, DOI 10.1021/cr00105a014; Frey PA, 2000, ARCH BIOCHEM BIOPHYS, V382, P6, DOI 10.1006/abbi.2000.2010; FRINGS J, 1992, APPL ENVIRON MICROB, V58, P2164, DOI 10.1128/AEM.58.7.2164-2167.1992; FRINGS J, 1994, ARCH MICROBIOL, V162, P199, DOI 10.1007/s002030050125; Golding B. T., 1997, COMPREHENSIVE BIOL C, P239; Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v; GRANT MA, 1983, BIOTECHNOL BIOENG, V25, P627, DOI 10.1002/bit.260250229; GRAY GA, 1969, J MAGN RESON, V1, P41; HAMMERSCHMIDT F, 1988, LIEBIGS ANN CHEM, P537; Hansen P. E., 1984, ANNU REP NMR SPECTRO, V15, P105, DOI [10.1016/S0066-4103(08)60208-2, DOI 10.1016/S0066-4103(08)60208-2]; HOMMELTOFT SI, 1985, J AM CHEM SOC, V107, P2548, DOI 10.1021/ja00294a056; KALINOSWSKI HO, 1988, CARBON 13 NMR SPECTR, P47; KAWAI F, 1987, CRC CR REV BIOTECHN, V6, P273, DOI 10.3109/07388558709089384; MATTA MS, 1987, J AM CHEM SOC, V109, P4916, DOI 10.1021/ja00250a026; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; OBRADORS N, 1991, APPL ENVIRON MICROB, V57, P2383, DOI 10.1128/AEM.57.8.2383-2388.1991; OGAWA T, 1994, J CHEM SOC PERK T 1, P3473, DOI 10.1039/p19940003473; PEARCE BA, 1980, J GEN MICROBIOL, V118, P21; RAGSDALE SW, 1985, J BIOL CHEM, V260, P3970; RETEY J, 1982, STEREOSPECIFICITY OR, P185; SCHINK B, 1983, APPL ENVIRON MICROB, V45, P1905, DOI 10.1128/AEM.45.6.1905-1913.1983; Schramm E, 1991, Biodegradation, V2, P71, DOI 10.1007/BF00114597; Smith DM, 2001, J AM CHEM SOC, V123, P1664, DOI 10.1021/ja001454z; Solladie G, 1998, TETRAHEDRON-ASYMMETR, V9, P3081, DOI 10.1016/S0957-4166(98)00301-2; STRASS A, 1986, APPL MICROBIOL BIOT, V25, P37; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TAKEUCHI Y, 1992, MAGN RESON CHEM, V30, P58, DOI 10.1002/mrc.1260300111; THELU J, 1980, FEMS MICROBIOL LETT, V8, P187, DOI 10.1016/0378-1097(80)90046-4; TORAYA T, 1994, MET IONS BIOL SYST, V30, P217; Toraya T, 2000, CELL MOL LIFE SCI, V57, P106, DOI 10.1007/s000180050502; VEDERAS JC, 1987, NAT PROD REP, V4, P277, DOI 10.1039/np9870400277; WAGENER S, 1988, APPL ENVIRON MICROB, V54, P561, DOI 10.1128/AEM.54.2.561-565.1988; White GF, 1996, MICROBIOL REV, V60, P216, DOI 10.1128/MMBR.60.1.216-232.1996; WIDDEL F, 1981, ARCH MICROBIOL, V129, P395, DOI 10.1007/BF00406470	45	14	14	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11684	11690		10.1074/jbc.M111059200	http://dx.doi.org/10.1074/jbc.M111059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805106	hybrid, Green Published			2022-12-25	WOS:000174846400011
J	Wu, DC; Ingram, A; Lahti, JH; Mazza, B; Grenet, J; Kapoor, A; Liu, LQ; Kidd, VJ; Tang, DM				Wu, DC; Ingram, A; Lahti, JH; Mazza, B; Grenet, J; Kapoor, A; Liu, LQ; Kidd, VJ; Tang, DM			Apoptotic release of histories from nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASPASE-ACTIVATED DNASE; CHROMATIN CONDENSATION; MORPHOLOGICAL-CHANGES; ENDONUCLEASE-G; CELL-DEATH; HISTONE H3; PHOSPHORYLATION; FRAGMENTATION; CLEAVAGE; INHIBITORS	Chromatin structure is influenced by histone modification, and this may help direct chromatin behavior to facilitate transcription, DNA replication, and DNA repair. Chromatin condensation and DNA fragmentation are the classic nuclear features but remain poorly characterized. It is highly probable that nucleosomal structure must be altered to allow these features to become apparent, but data to support this construct are lacking. We report here that in response to apoptotic signals from a death receptor (CD95 and tumor necrosis factor-alpha) ormitochondrial (staurosporine) apoptotic stimulus, the core nucleosomal histones H2A, H2B, H3, and H4 become separated from DNA during apoptosis in Jurkat and HeLa cells and are consequently detectable in the cell lysate prepared using a non-ionic detergent. The timing of this histone release from DNA correlates well with the progression of apoptosis. We also show expression of a caspase cleavage-resistant form of ICAD (ICAD-DM) in Jurkat and HeLa cells abolished DNA fragmentation and also dramatically reduced histone release in apoptotic cells. However, we demonstrate that apoptotic histone release is not an inevitable consequence of CAD/DFF-40-mediated DNA destruction as DNA fragmentation but not histone release occurs efficiently in tumor necrosis factor-alpha- and etoposide-treated NlH3T3 cells. Furthermore, in an in vitro apoptotic assay, incubation of apoptotic Jurkat cellular extract with non-apoptotic Jurkat nuclei led to nuclear DNA fragmentation without obvious histone release. Taken together, these data demonstrate that CAD/DFF-40 functions indirectly in mediating nucleosomal destruction during apoptosis.	McMaster Univ, Dept Med, Hamilton, ON L8N 1Y2, Canada; McMaster Univ, Dept Surg, Hamilton, ON L8N 1Y2, Canada; St Josephs Hosp, Father Sean O Sullivan Res Inst, Hamilton, ON L8N 1Y2, Canada; St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA	McMaster University; McMaster University; McGill University; McMaster University; St Jude Children's Research Hospital	Tang, DM (corresponding author), 708-25 Charlton Ave E, Hamilton, ON L8N 1Y2, Canada.	damut@mcmaster.ca	Tang, Damu/AAQ-1786-2021; Kapoor, Anil/AAQ-7184-2021	Tang, Damu/0000-0002-3282-9521; Kapoor, Anil/0000-0001-9180-8029	NATIONAL CANCER INSTITUTE [R56CA067938, R01CA067938] Funding Source: NIH RePORTER; NCI NIH HHS [CA67938] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Green DR, 2000, NATURE, V405, P28, DOI 10.1038/35011175; Green GR, 2001, BIOCHEM CELL BIOL, V79, P275, DOI 10.1139/bcb-79-3-275; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; Hengartner MO, 2001, NATURE, V412, P27, DOI 10.1038/35083663; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kratzmeier M, 2000, J BIOL CHEM, V275, P30478, DOI 10.1074/jbc.M003956200; Lee E, 1999, IUBMB LIFE, V48, P79, DOI 10.1080/152165499307459; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1999, J BIOL CHEM, V274, P13836, DOI 10.1074/jbc.274.20.13836; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; MARUSHIGE Y, 1995, ANTICANCER RES, V15, P267; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Tang D, 2001, J BIOL CHEM, V276, P30461, DOI 10.1074/jbc.M102045200; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Waring P, 1997, J BIOL CHEM, V272, P17929, DOI 10.1074/jbc.272.29.17929; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; Zhou P, 2001, P NATL ACAD SCI USA, V98, P6051, DOI 10.1073/pnas.111145098	34	93	100	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12001	12008		10.1074/jbc.M109219200	http://dx.doi.org/10.1074/jbc.M109219200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812781	hybrid			2022-12-25	WOS:000174846400053
J	Nolan, T; Bower, TM; Brown, AE; Crisanti, A; Catteruccia, F				Nolan, T; Bower, TM; Brown, AE; Crisanti, A; Catteruccia, F			piggyBac-mediated germline transformation of the malaria mosquito Anopheles stephensi using the red fluorescent protein dsRED as a selectable marker	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TRANSFER; TRANSPOSABLE ELEMENT; DROSOPHILA-MELANOGASTER; LINE TRANSFORMATION; PRECISE EXCISION; MINOS; VECTOR	It is estimated that every year malaria infects similar to300 million people and accounts for the death of 2 million individuals. The Plasmodium parasites that cause malaria in humans are transmitted exclusively by mosquito species belonging to the Anopheles genus. The recent development of a gene transfer technology for Anopheles stephensi mosquitoes, using the Minos transposable element marked with the enhanced green fluorescent protein EGFP (Catteruccia, F., Nolan, T., Loukeris, T. G., Blass, C., Savakis, C., Kafatos, F. C., and Crisanti, A. (2000) Nature 405, 959-962), provides now a powerful tool to investigate the role of mosquito molecules involved in the interaction with the malaria parasite. Such technology, when further developed with additional markers and transposable elements, will be invaluable for analyzing the biology of the vector and for developing malaria-resistant mosquitoes to be used as a tool to control malaria transmission in the field. We report here the germline transformation of A. stephensi mosquitoes using a piggyBac-based transposon to drive integration of the gene encoding for the red fluorescent protein dsRED. A. stephensi embryos were injected with transformation vector pPBRED containing the dsRED marker cloned within the arms of piggyBac. Microscopic analysis of G, larvae revealed the presence of seven fluorescent phenotypes whose different molecular origins were confirmed by Southern blotting analysis. Sequencing of the insertion sites in two lines demonstrated that integrations had occurred at TTAA nucleotides in accordance with piggyBac-mediated transpositions.	Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England	Imperial College London	Catteruccia, F (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.	f.catteruccia@ic.ac.uk	Nolan, Tony/I-4925-2012	Nolan, Tony/0000-0002-2982-8333; Brown, Anthony/0000-0002-1271-310X; Catteruccia, Flaminia/0000-0003-3295-6683; Crisanti, Andrea/0000-0002-2406-4426				Allen ML, 2001, J MED ENTOMOL, V38, P701, DOI 10.1603/0022-2585-38.5.701; Arca B, 2000, GENETICA, V108, P263, DOI 10.1023/A:1004185024017; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Finley KR, 2001, BIOTECHNIQUES, V31, P66, DOI 10.2144/01311st02; FRANZ G, 1994, P NATL ACAD SCI USA, V91, P4746, DOI 10.1073/pnas.91.11.4746; Fraser MJ, 1996, INSECT MOL BIOL, V5, P141, DOI 10.1111/j.1365-2583.1996.tb00048.x; Grossman GL, 2001, INSECT MOL BIOL, V10, P597, DOI 10.1046/j.0962-1075.2001.00299.x; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Handler AM, 2001, BIOTECHNIQUES, V31, P820; Handler AM, 2000, INSECT MOL BIOL, V9, P605, DOI 10.1046/j.1365-2583.2000.00227.x; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; Klinakis AG, 2000, INSECT MOL BIOL, V9, P269, DOI 10.1046/j.1365-2583.2000.00183.x; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Pinkerton AC, 2000, INSECT MOL BIOL, V9, P1, DOI 10.1046/j.1365-2583.2000.00133.x; Rodrigues F, 2001, J BACTERIOL, V183, P3791, DOI 10.1128/JB.183.12.3791-3794.2001; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sarkar A, 1997, GENETICA, V99, P15, DOI 10.1023/A:1018349803656; Thibault ST, 1999, INSECT MOL BIOL, V8, P119, DOI 10.1046/j.1365-2583.1999.810119.x; Warren WD, 1996, GENETICA, V98, P249, DOI 10.1007/BF00057589; Zhang GH, 1996, BIOCHEM BIOPH RES CO, V227, P707, DOI 10.1006/bbrc.1996.1573	23	63	70	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	2002	277	11					8759	8762		10.1074/jbc.C100766200	http://dx.doi.org/10.1074/jbc.C100766200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	531DK	11805082	hybrid			2022-12-25	WOS:000174400600002
J	Rudiger, JJ; Roth, M; Bihl, MP; Cornelius, BC; Johnson, M; Ziesche, R; Block, LH				Rudiger, JJ; Roth, M; Bihl, MP; Cornelius, BC; Johnson, M; Ziesche, R; Block, LH			Interaction of C/EBP alpha and the glucocorticoid receptor in vivo and in nontransformed human cells	FASEB JOURNAL			English	Article; Proceedings Paper	39th Annual Meeting of the American-Society-for-Cell-Biology	DEC, 1999	WASHINGTON, D.C.	Amer Soc Cell Biol		glucocorticoids; CCAAT/enhancer binding protein alpha; cell proliferation; protein complex	AIRWAY SMOOTH-MUSCLE; RAT HEPATOMA-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR; NUCLEAR FACTOR; CHRONIC ASTHMA; HUMAN LUNG; BINDING; PROLIFERATION; PROTEIN	Belonging to the family of steroid hormones, glucocorticoids are essential for development and survival of vertebrates. The cellular response to glucocorticoids is attributed to the glucocorticoid receptor, which functions as a transcription factor. However, the majority of glucocorticoid-modulated genes lack a DNA binding site for the glucocorticoid receptor, raising the question of which mechanism mediates the responses to glucocorticoids. It has been suggested that besides direct DNA binding of the glucocorticoid receptor, interaction with members of other transcription factor families modulates the effect of the glucocorticoid receptor. However, the significance of such transcription factor interaction is not clear. In cultured human mesenchymal cells and peripheral blood leukocytes of human volunteers treated with glucocorticoids, we detected the formation of a complex between the GR and the CCAAT/enhancer binding protein alpha. In in vitro experiments, this interaction turned out to be responsible for the inhibitory action of glucocorticoids on lymphocytic and mesenchymal cell proliferation. Our results suggest that complex formation of the GR with C/EBPalpha accounts for a novel pathway of glucocorticoid action.	Univ Hosp Vienna, AKH, Dept Internal Med 4, A-1090 Vienna, Austria; Univ Basel, Dept Forsch, CH-4031 Basel, Switzerland; Univ Sydney, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Pharmacol, Camperdown, NSW 2050, Australia; GlaxoSmithKline, Res & Dev, Dept Resp Commercial Strategy, Stockley Pk UB11 1BU, Middx, England	University Hospital Vienna; University of Basel; University of Sydney; University of Sydney; GlaxoSmithKline	Block, LH (corresponding author), Univ Hosp Vienna, AKH, Dept Internal Med 4, Wahringer Gurtel 18-22, A-1090 Vienna, Austria.	lutz-henning.block@akh-wien.ac.at	Roth, Michael/H-8657-2019	Roth, Michael/0000-0002-8139-2821				ADCOCK IM, 1994, LIFE SCI, V55, P1147, DOI 10.1016/0024-3205(94)00243-6; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANTONSON P, 1995, BIOCHEM BIOPH RES CO, V215, P106, DOI 10.1006/bbrc.1995.2439; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Beurton F, 1999, BIOCHEM J, V343, P687, DOI 10.1042/0264-6021:3430687; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998; CHESTERMAN CN, 1983, BIOCHEM BIOPH RES CO, V116, P809, DOI 10.1016/S0006-291X(83)80214-9; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016, DOI 10.1164/ajrccm/144.5.1016; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214, DOI 10.1164/ajrccm.150.1.7912988; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Gelfand EW, 1998, ALLERGY ASTHMA PROC, V19, P365, DOI 10.2500/108854198778612744; GRUNFELD C, 1981, ENDOCRINOLOGY, V109, P1723, DOI 10.1210/endo-109-5-1723; HACZKU A, 1994, J ALLERGY CLIN IMMUN, V93, P510, DOI 10.1016/0091-6749(94)90361-1; Hirst SJ, 1998, AM J RESP CRIT CARE, V158, pS201, DOI 10.1164/ajrccm.158.supplement_2.13tac190; HOLZ O, 1991, CARCINOGENESIS, V12, P2181, DOI 10.1093/carcin/12.11.2181; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; PINKSTON P, 1987, J IMMUNOL, V139, P755; POZNANSKY MC, 1985, CLIN EXP IMMUNOL, V61, P135; Ramos RA, 1999, FASEB J, V13, P169, DOI 10.1096/fasebj.13.1.169; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Roth M, 1996, P NATL ACAD SCI USA, V93, P5478, DOI 10.1073/pnas.93.11.5478; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219, DOI 10.1111/j.1476-5381.1995.tb15127.x; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Timchenko NA, 1996, GENE DEV, V10, P804, DOI 10.1101/gad.10.7.804; Timchenko NA, 1997, MOL CELL BIOL, V17, P7353, DOI 10.1128/MCB.17.12.7353; van der Velden VHJ, 1998, MEDIAT INFLAMM, V7, P229, DOI 10.1080/09629359890910; VANMAARSSEVEEN T, 1991, J IMMUNOL METHODS, V143, P95, DOI 10.1016/0022-1759(91)90277-M; Zhang ZX, 1997, J BIOL CHEM, V272, P30607, DOI 10.1074/jbc.272.49.30607; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	40	57	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2					177	184		10.1096/fj.01-0226com	http://dx.doi.org/10.1096/fj.01-0226com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818365				2022-12-25	WOS:000174203700022
J	Konduri, SD; Osman, FA; Rao, CN; Srinivas, H; Yanamandra, N; Tasiou, A; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Kouraklis, G; Rao, JS				Konduri, SD; Osman, FA; Rao, CN; Srinivas, H; Yanamandra, N; Tasiou, A; Dinh, DH; Olivero, WC; Gujrati, M; Foster, DC; Kisiel, W; Kouraklis, G; Rao, JS			Minimal and inducible regulation of tissue factor pathway inhibitor-2 in human gliomas	ONCOGENE			English	Article						promoter; transcriptional regulation; TFPI-2; gliomas	SERINE PROTEINASE-INHIBITORS; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; COAGULATION INHIBITOR; PLASMINOGEN-ACTIVATOR; LESS PROMOTER; MESSENGER-RNA; GENE; EXPRESSION; IDENTIFICATION	Tissue factor pathway inhibitor-2 (TFPI-2), a serine protease inhibitor abundant in the extra cellular matrix, is highly expressed in non-invasive cells but undetectable levels in highly invasive human glioma cells. The mechanisms responsible for its transcriptional regulation are not well elucidated. In this study, we made several deletion constructs from a 3.6 kb genomic fragment from Hs683 cells containing the 5'-flanking region of the TFPI-2 gene, transiently transfected with these constructs into non-invasive (Hs683) and highly invasive (SNB19) human glioma cells, and assessed their expression by using a luciferase reporter gene. Three constructs showed high promoter activity (pTF5, -670 to +1; pTF6, -312 to +1; pTF2, -1511 to +1). Another construct, pTF8 (-81 to +1), showed no activity. PTF9, a variant of pTF5 in which a further 231 bp fragment (-312 to -81) was deleted, from the [-670 to +1] pTF5 region, also showed no promoter activity. Hence, (-312 to -81) this region is essential for the transcription of TFPI-2 in glioma cells. Sequencing of this promoter region revealed that it has a high G+C content, contains potential SP1 and AP1 binding motifs, and lacks canonical TATA and CAAT boxes immediately upstream of the major transcriptional initiation site, although CAAT boxes were found about -3000 bp upstream of the transcription start site. We also found a strong repressor in the region between -927 to -1181, upstream of the major transcriptional initiation site, followed by positive elements or enhancers between -1511 to -1181. These positive elements masked the silencer effect. Finally TFPI-2 was induced in Hs683 cells transfected with the pTF6 construct (-312 to + 1) and stimulated with phorbol-12-myristate-13-acetate (PMA). We conclude that the -312 to +1 region is critical for the minimal and inducible regulation of TFPI-2 in non-invasive (Hs683) and highly invasive (SNB19) human glioma cell lines.	Univ Illinois, Sch Med, Dept Biomed & Therapeut Sci, Div Canc Biol, Peoria, IL 61656 USA; Univ Illinois, Dept Neurosurg, Peoria, IL 61656 USA; Univ Illinois, Dept Neuropathol, Peoria, IL 61656 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Ctr Prostate Dis Res, Rockville, MD USA; Zymogenet Inc, Seattle, WA 98105 USA; Univ New Mexico, Ctr Hlth Sci, Albuquerque, NM 87131 USA; Univ Athens, Sch Med, Dept Propedeut Surg, GR-11527 Athens, Greece	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Zymogenet Inc.; University of New Mexico; Athens Medical School; National & Kapodistrian University of Athens	Rao, JS (corresponding author), Univ Illinois, Sch Med, Dept Biomed & Therapeut Sci, Div Canc Biol, 1 Illini Dr, Peoria, IL 61656 USA.	jsrao@uic.edu		Tasiou, Anastasia/0000-0002-8853-540X	NATIONAL CANCER INSTITUTE [R01CA075557, R01CA076350] Funding Source: NIH RePORTER; NCI NIH HHS [CA-75557, CA-76350, CA-75692] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAJAJ MS, 1990, P NATL ACAD SCI USA, V87, P8869, DOI 10.1073/pnas.87.22.8869; Baker DL, 1996, J BIOL CHEM, V271, P5921, DOI 10.1074/jbc.271.10.5921; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; BUTZOW R, 1988, BIOCHEM BIOPH RES CO, V150, P483, DOI 10.1016/0006-291X(88)90546-3; Chabannes E, 2001, CELL SIGNAL, V13, P585, DOI 10.1016/S0898-6568(01)00184-X; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; CHEN L, 1992, J BIOL CHEM, V267, P12380; ENJYOJI K, 1993, GENOMICS, V17, P423, DOI 10.1006/geno.1993.1342; GIRARD TJ, 1991, J BIOL CHEM, V266, P5036; Gomez DE, 1997, EUR J CELL BIOL, V74, P111; HASCALL VC, 1991, CELL BIOL EXTRA CELL; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; Iino M, 1998, ARTERIOSCL THROM VAS, V18, P40, DOI 10.1161/01.ATV.18.1.40; Kamei S, 2001, BBA-GENE STRUCT EXPR, V1517, P430, DOI 10.1016/S0167-4781(00)00298-0; Kazama Y, 2000, THROMB HAEMOSTASIS, V83, P141; Kim MS, 2001, CANCER LETT, V171, P79, DOI 10.1016/S0304-3835(01)00505-5; Konduri SD, 2001, INT J ONCOL, V18, P127; Konduri SD, 2000, CLIN EXP METASTAS, V18, P303, DOI 10.1023/A:1011085820250; Konduri SD, 2001, ONCOGENE, V20, P6938, DOI 10.1038/sj.onc.1204847; KORNER G, 1993, J CELL PHYSIOL, V154, P456, DOI 10.1002/jcp.1041540303; Lakka SS, 2000, CLIN EXP METASTAS, V18, P239, DOI 10.1023/A:1006755223357; LANS MS, 1994, J BIOL CHEM, V269, P14170; LEE JK, 1992, J BIOL CHEM, V267, P4638; MCGUIRE PG, 1989, J CELL BIOCHEM, V40, P215, DOI 10.1002/jcb.240400210; MIMURO J, 1987, BLOOD, V70, P721; MIYAGI Y, 1994, J BIOCHEM-TOKYO, V116, P939, DOI 10.1093/oxfordjournals.jbchem.a124648; Miyagi Y, 1996, GENOMICS, V35, P267, DOI 10.1006/geno.1996.0353; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Petersen LC, 1996, BIOCHEMISTRY-US, V35, P266, DOI 10.1021/bi951501d; Petersen LC, 1996, EUR J BIOCHEM, V235, P310, DOI 10.1111/j.1432-1033.1996.0310f.x; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V317, P311, DOI 10.1006/abbi.1995.1168; RAO CN, 1995, ARCH BIOCHEM BIOPHYS, V319, P55, DOI 10.1006/abbi.1995.1266; Rao CN, 1998, INT J CANCER, V76, P749, DOI 10.1002/(SICI)1097-0215(19980529)76:5<749::AID-IJC21>3.0.CO;2-Y; RAO CN, 1995, J INVEST DERMATOL, V104, P379, DOI 10.1111/1523-1747.ep12665851; Rao CN, 2001, CLIN CANCER RES, V7, P570; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPRECHER CA, 1994, P NATL ACAD SCI USA, V91, P3353, DOI 10.1073/pnas.91.8.3353; Udagawa K, 1998, PLACENTA, V19, P217, DOI 10.1016/S0143-4004(98)90011-X; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; WERLING RW, 1993, THROMB HAEMOSTASIS, V69, P366	41	14	19	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2002	21	6					921	928		10.1038/sj.onc.1204983	http://dx.doi.org/10.1038/sj.onc.1204983			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840337				2022-12-25	WOS:000173427100007
J	Li, M; Song, SM; Lippman, SM; Zhang, XK; Liu, XM; Lotan, R; Xu, XC				Li, M; Song, SM; Lippman, SM; Zhang, XK; Liu, XM; Lotan, R; Xu, XC			Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells	ONCOGENE			English	Article						retinoids; retinoic acid receptor-beta; cyclooxygenase-2; esophageal cancer	ACTIVATOR PROTEIN-1 ACTIVITY; UP-REGULATION; SELECTIVE-INHIBITION; EPITHELIAL-CELLS; APOPTOSIS; GROWTH; TRANSCRIPTION; ASPIRIN; N-(4-HYDROXYPHENYL)RETINAMIDE; DIFFERENTIATION	Since retinoic acid receptor (RAR)-beta mRNA is frequently lost during esophageal carcinogenesis and esophageal cancer cells that do not express RAR-beta are resistant to retinoic acid (RA), we stably transfected RAR-beta expression vector into an esophageal cancer cell line TE-8 and an antisense RAR-beta into TE-3 cells. Transfection of RAR-beta decreased cell growth and colony formation and induced apoptosis in TE-8 cells. Antisense RAR-beta-transfected TE-3 cells had a shorter doubling time and became resistant to RA. Induction of RAR-beta decreased COX-2 expression in RAR-beta transfected TE-8 cells, whereas antisense RAR-beta transfected TE-3 cells increased COX-2 expression. The inhibitory effect of RAR-beta on COX-2 expression was further enhanced in the presence of RA, which was blocked by an RAR antagonist. The synthetic retinoid N-(4-hydroxyphenyl)-retinamide, which does not bind effectively to RAR-beta, had no effect on COX-2 suppression. Furthermore, RA blocked bile acid-induced COX-2 expression and prostaglandin E-2 production only in the RAR-beta positive cells. Our data demonstrated that anticancer effect of RAR-beta may be related to its ability to suppress COX-2 expression and support that the loss of RAR-beta expression may contribute to esophageal carcinogenesis.	Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Sanford Burnham Prebys Medical Discovery Institute	Xu, XC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, 1515 Holcombe Blvd,Box 236, Houston, TX 77030 USA.	xxu@mdanderson.org						Berard J, 1996, FASEB J, V10, P1091, DOI 10.1096/fasebj.10.9.8801172; Carey M, 2000, TRANSCRIPTIONAL REGU; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Clifford JL, 1999, CANCER RES, V59, P14; DE LUCA LM, 1991, FASEB J, V5, P2924; Dmitrovsky E, 1997, J NATL CANCER I, V89, P1179, DOI 10.1093/jnci/89.16.1179; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; FUNKHOUSER EM, 1995, CANCER-AM CANCER SOC, V76, P1116, DOI 10.1002/1097-0142(19951001)76:7<1116::AID-CNCR2820760703>3.0.CO;2-I; GEBERT JF, 1991, ONCOGENE, V6, P1859; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GOLDSTEIN SM, 1984, CANCER RES, V44, P120; GUDAS LJ, 1992, CELL GROWTH DIFFER, V3, P655; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; HU L, 1991, CANCER RES, V51, P3972; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Li M, 2000, CANCER EPIDEM BIOMAR, V9, P545; Li M, 2001, INT J CANCER, V93, P218, DOI 10.1002/ijc.1322; Lin F, 2000, CANCER RES, V60, P3271; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; MARNETT LJ, 1992, CANC RES, V52; Mestre JR, 1997, CANCER RES, V57, P2890; Mestre JR, 1997, ANN NY ACAD SCI, V833, P173, DOI 10.1111/j.1749-6632.1997.tb48605.x; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pfahl M, 1996, ANNU REV NUTR, V16, P257, DOI 10.1146/annurev.nu.16.070196.001353; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Song SM, 2001, BIOCHEM BIOPH RES CO, V281, P872, DOI 10.1006/bbrc.2001.4433; Souza RF, 2000, CANCER RES, V60, P5767; Sporn M.B., 1994, RETINOIDS BIOL CHEM; Subbaramaiah K, 2001, J BIOL CHEM, V276, P12440, DOI 10.1074/jbc.M007237200; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; Taketo MM, 1998, JNCI-J NATL CANCER I, V90, P1609, DOI 10.1093/jnci/90.21.1609; Taketo MM, 1998, J NATL CANCER I, V90, P1529, DOI 10.1093/jnci/90.20.1529; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Xu X.-C., 1999, HANDB EXP PHARM, P323; Xu XC, 1999, CANCER RES, V59, P2477; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zimmermann KC, 1999, CANCER RES, V59, P198	49	50	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					411	418		10.1038/sj.onc.1205106	http://dx.doi.org/10.1038/sj.onc.1205106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821953	Bronze			2022-12-25	WOS:000173311200009
J	Ashrafi, GH; Tsirimonaki, E; Marchetti, B; O'Brien, PM; Sibbet, GJ; Andrew, L; Campo, MS				Ashrafi, GH; Tsirimonaki, E; Marchetti, B; O'Brien, PM; Sibbet, GJ; Andrew, L; Campo, MS			Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins	ONCOGENE			English	Article						papillomavirus; E5; MHC class I; Golgi apparatus; cell transformation	GROWTH-FACTOR RECEPTOR; COMPLEX CLASS-I; CERVICAL CARCINOMAS; INTERCELLULAR COMMUNICATION; TRANSFORMING FUNCTIONS; CELL-TRANSFORMATION; E7 ONCOPROTEINS; KINASE-ACTIVITY; E8 PROTEIN; TYPE-4 E8	The papillomavirus E5 protein is localized in the endoplasmic reticulum (ER) and Golgi apparatus (GA) of the host cell. Transformed bovine fibroblasts expressing bovine papillomavirus (BPV) E5 are highly vacuolated and have a much enlarged, distorted and fragmented GA. Major histocompatibility complex class I (MHC I) is processed and transported to the cell surface through the GA. Given the cellular localization of E5 in the GA and the morphologically abnormal GA, we investigated the expression of MHC I in cells transformed by E5 from BPV-1 and BPV-4. Two cell lines were used: bovine cells that also express E6, E7 and activated ras, and NIH3T3 cells that express only E5. In addition, PalF cells acutely infected with a recombinant retrovirus expressing E5 were also examined. In contrast to non-transformed normal cells, or transformed cells expressing other papillomavirus proteins, cells expressing E5 do not express MHC I on their surface, but retain it intracellularly, independently of the presence of other viral or cellular oncogenes, or of whether the cells are long-term transformants or acutely infected. We conclude that expression of E5 prevents expression of MHC I to the cell surface and causes its retention within the cell. In addition, lower amounts of total MHC I heavy chain and of heavy chain RNA are detected in E5-transformed cells than in control cells. As surface expression of another glycosylated membrane protein, the transferrin receptor, is not affected, it appears that E5 targets MHC I with at least a degree of specificity. In papillomavirus lesions this effect would have important implications for antigen presentation by, and immunosurveillance of, virally infected cells.	Univ Glasgow, Dept Vet Pathol, Inst Comparat Med, Papillomavirus Res Grp, Glasgow G61 1QH, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, LRF Virus Ctr, Glasgow G61 1QH, Lanark, Scotland	University of Glasgow; University of Glasgow	Campo, MS (corresponding author), Beatson Inst Canc Res, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.			Ashrafi, G. Hossein/0000-0002-4516-5111				Anderson RA, 1997, VET J, V154, P69, DOI 10.1016/S1090-0233(05)80010-3; Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Ashby ADM, 2001, J GEN VIROL, V82, P2353, DOI 10.1099/0022-1317-82-10-2353; Ashrafi GH, 2000, J GEN VIROL, V81, P689, DOI 10.1099/0022-1317-81-3-689; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; BELL SC, 1981, J REPROD IMMUNOL, V3, P3, DOI 10.1016/0165-0378(81)90024-3; BENSAID A, 1989, ANIM GENET, V20, P241; Bontkes HJ, 1998, LANCET, V351, P187, DOI 10.1016/S0140-6736(05)78209-X; Brady CS, 2000, TISSUE ANTIGENS, V55, P401, DOI 10.1034/j.1399-0039.2000.550502.x; Briggs MW, 2001, VIROLOGY, V280, P169, DOI 10.1006/viro.2000.0783; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; BURNETT S, 1992, P NATL ACAD SCI USA, V89, P5665, DOI 10.1073/pnas.89.12.5665; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; CROMME FV, 1993, ONCOGENE, V8, P2969; CROMME FV, 1994, J EXP MED, V179, P335, DOI 10.1084/jem.179.1.335; Crusius K, 1999, ONCOGENE, V18, P6714, DOI 10.1038/sj.onc.1203075; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; Erickson JW, 1996, J BIOL CHEM, V271, P26850, DOI 10.1074/jbc.271.43.26850; Faccini AM, 1996, J VIROL, V70, P9041, DOI 10.1128/JVI.70.12.9041-9045.1996; FIMBOW ME, 1991, MOL CARCINOG, V4, P441; FRANCHINI G, 1993, J VIROL, V67, P7701, DOI 10.1128/JVI.67.12.7701-7704.1993; Frazer IH, 1999, IMMUNOL REV, V168, P131, DOI 10.1111/j.1600-065X.1999.tb01288.x; FRAZER JH, 1996, PAPILLOMAVIRUS REV, P151; Georgopoulos NT, 2000, ONCOGENE, V19, P4930, DOI 10.1038/sj.onc.1203860; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; Greenberg ME, 1998, EMBO J, V17, P2777, DOI 10.1093/emboj/17.10.2777; GU ZM, 1995, J VIROL, V69, P8051, DOI 10.1128/JVI.69.12.8051-8056.1995; JACKSON ME, 1991, MOL CARCINOGEN, V4, P382, DOI 10.1002/mc.2940040510; Johnson JM, 2001, J VIROL, V75, P6086, DOI 10.1128/JVI.75.13.6086-6094.2001; KEATING PJ, 1995, BRIT J CANCER, V72, P405, DOI 10.1038/bjc.1995.346; Kubbutat MHG, 1996, SEMIN VIROL, V7, P295, DOI 10.1006/smvy.1996.0037; KUNHE C, 1999, PAPILLOMAVIRUS REPOR, V10, P139; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Morgan IM, 2000, PAPILLOMAVIRUS REP, V11, P127; Naessens J, 1996, VET IMMUNOL IMMUNOP, V52, P257, DOI 10.1016/0165-2427(96)05572-9; Noguchi Y, 1998, J BIOL CHEM, V273, P3649, DOI 10.1074/jbc.273.6.3649; O'Brien V, 1999, VIROLOGY, V255, P385, DOI 10.1006/viro.1998.9563; O'Brien V, 1998, ONCOGENE, V17, P293, DOI 10.1038/sj.onc.1201937; OELZE I, 1995, J VIROL, V69, P4489, DOI 10.1128/JVI.69.7.4489-4494.1995; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PENNIE WD, 1993, VIROLOGY, V193, P614, DOI 10.1006/viro.1993.1169; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; Reich Z, 1997, P NATL ACAD SCI USA, V94, P2495, DOI 10.1073/pnas.94.6.2495; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; SAWHNEY SMS, 1995, IMMUNOGENETICS, V41, P246, DOI 10.1007/BF00172066; Schapiro F, 2000, J CELL BIOL, V148, P305, DOI 10.1083/jcb.148.2.305; Seliger B, 1997, IMMUNOL TODAY, V18, P292, DOI 10.1016/S0167-5699(97)01052-9; Sibbet G, 2000, J GEN VIROL, V81, P327, DOI 10.1099/0022-1317-81-2-327; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Suprynowicz FA, 2000, J BIOL CHEM, V275, P5111, DOI 10.1074/jbc.275.7.5111; Thomsen P, 2000, ONCOGENE, V19, P6023, DOI 10.1038/sj.onc.1204010; TOYE PG, 1990, IMMUNOLOGY, V70, P20; Vambutas A, 2000, CLIN DIAGN LAB IMMUN, V7, P79, DOI 10.1128/CDLI.7.1.79-85.2000; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Yewdell JW, 1999, ANNU REV CELL DEV BI, V15, P579, DOI 10.1146/annurev.cellbio.15.1.579	63	81	86	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					248	259						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803468				2022-12-25	WOS:000173026200009
J	Shariat-Madar, Z; Mahdi, F; Schmaier, AH				Shariat-Madar, Z; Mahdi, F; Schmaier, AH			Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; RENIN-ANGIOTENSIN SYSTEM; BINDING-PROTEIN; FACTOR-XII; RECEPTOR; CYTOKERATIN-1; EXPRESSION; BRADYKININ; IDENTITY; THROMBIN	Our recent investigations have postulated a human umbilical vein endothelial cell (HUVEC) -associated prekallikrein activator (PKA). When prekallikrein (PK) assembles on high molecular weight kininogen on HUVEC, PK is activated to kallikrein. PKA was found in the 15,800 X g pellet of HUVEC lysates using an assay that measures PK activation only when bound to high molecular weight kininogen linked to microtiter plates. Sequential DEAE, wheat germ lectin affinity, and hydroxyapatite chromatography resulted in four protein bands on SDS-PAGE. One protein in the 73-kDa band was identified by amino acid sequencing as prolylcarboxypeptidase (PRCP). On gel filtration, PKA activity was a single homogenous peak identical in migration to the 73-kDa immunoblot of PRCP. Anti-PRCP inhibits PKA activity and PK activation on HUVEC. Purified PKA was blocked by diisopropyl fluorophosphate (1 mm), phenylmethylsulfonyl fluoride (3 mm), leupeptin (100 mum), antipain (IC50 = 2 mum), HgCl2 (IC50 = 500 mum), Z-Pro-Pro-aldehydedimethyl acetate (IC50 = 1 mum), and corn trypsin inhibitor (IC50 = 40 nm). PKA did not correct the coagulant defect in factor XII deficient plasma, was purified from HUVEC cultured in factor XII-deficient serum, was not detected by antibody to factor XII, did not activate FXI, and was not inhibited by a neutralizing antibody to FXII. Angiotensin II (IC50 = 2 mum) or bradykinin (IC50 = 100 mum), but not angiotensin II-(1-7) or bradykinin(1-5), and the prolyl oligopeptidase inhibitor Fmoc-Ala-Pyr-CN (IC50 = 50 nm) also blocked purified PKA activation of PK. The K-m of PK activation by PRCP is 6.7 nm. PRCP antigen is present on the membrane of fixed but not permeabilized HUVEC. PRCP appears to be a HUVEC-associated PK activator.	Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Div Hematol & Oncol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Schmaier, AH (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol & Oncol, 5301 MSRB 3,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Schmaier, Alvin/AAM-1063-2020	Schmaier, Alvin/0000-0002-3884-6234	NHLBI NIH HHS [HL52779] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052779] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; Biederbick A, 1999, J CELL SCI, V112, P2473; Brown N J, 2000, Adv Intern Med, V45, P419; Brown NJ, 1999, HYPERTENSION, V33, P1431, DOI 10.1161/01.HYP.33.6.1431; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ferrario CM, 1998, REGUL PEPTIDES, V78, P13, DOI 10.1016/S0167-0115(98)00134-7; Feterik K, 2000, BRAIN RES, V873, P75, DOI 10.1016/S0006-8993(00)02482-3; FUJIKAWA K, 1981, METHOD ENZYMOL, V80, P198; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Herwald H, 1996, J BIOL CHEM, V271, P13040, DOI 10.1074/jbc.271.22.13040; HONG SL, 1980, THROMB RES, V18, P787, DOI 10.1016/0049-3848(80)90201-7; Joseph K, 1996, P NATL ACAD SCI USA, V93, P8552, DOI 10.1073/pnas.93.16.8552; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Li JR, 1996, J NEUROCHEM, V66, P2105; Lin YZ, 1997, BLOOD, V90, P690, DOI 10.1182/blood.V90.2.690.690_690_697; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MELONI FJ, 1991, J BIOL CHEM, V266, P6786; Motta G., 1995, Blood, V86, p374A; Motta G, 1998, BLOOD, V91, P516, DOI 10.1182/blood.V91.2.516.516_516_528; ODYA CE, 1978, J BIOL CHEM, V253, P5927; Oliveira MA, 1999, PEPTIDES, V20, P1195; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Reudelhuber TL, 1998, ADV EXP MED BIOL, V436, P229; Rojkjaer R, 1999, P ASSOC AM PHYSICIAN, V111, P220, DOI 10.1046/j.1525-1381.1999.99232.x; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74, DOI 10.1055/s-0037-1615142; SANTOS RAS, 1992, HYPERTENSION, V19, P56; SCHMAIER AH, 1988, J LAB CLIN MED, V112, P182; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; Skidgel RA, 1998, IMMUNOL REV, V161, P129, DOI 10.1111/j.1600-065X.1998.tb01577.x; TAN FL, 1993, J BIOL CHEM, V268, P16631; VAUGHAN DE, 1995, J CLIN INVEST, V95, P995, DOI 10.1172/JCI117809; YANG HYT, 1968, NATURE, V218, P1224, DOI 10.1038/2181224a0; [No title captured]	37	220	229	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17962	17969		10.1074/jbc.M106101200	http://dx.doi.org/10.1074/jbc.M106101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11830581	hybrid			2022-12-25	WOS:000175685100073
J	Kim, BT; Kitagawa, H; Tamura, J; Kusche-Gullberg, M; Lindahl, U; Sugahara, K				Kim, BT; Kitagawa, H; Tamura, J; Kusche-Gullberg, M; Lindahl, U; Sugahara, K			Demonstration of a novel gene DEXT3 of Drosophila melanogaster as the essential N-acetylglucosamine transferase in the heparan sulfate biosynthesis - Chain initiation and elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE-REGION; CHONDROITIN SULFATE; CAENORHABDITIS-ELEGANS; TOUT-VELU; STRUCTURAL-ANALYSIS; TUMOR SUPPRESSORS; IDENTIFICATION; FAMILY; GLUCURONOSYLTRANSFERASE; GLYCOSAMINOGLYCANS	Hereditary multiple exostoses gene (EXT) family members encode glycosyltransferases required for heparan sulfate (HS) biosynthesis in humans as well as in Drosophila. In the present study, we identified a novel Drosophila EXT protein with a type 11 transmembrane topology and demonstrated its glycosyltransferase activities. The truncated soluble form of this new homolog designated DEXT3 transferred N-acetylglucosamine (GlcNAc) through an alpha1,4-linkage not only to N-acetylheparosan oligosaccharides that represent growing HS chains (alpha-GlcNAc transferase II activity) but also to GlcUAbeta1-3Galbeta1-O-C(2)H(4)NHCbz, a synthetic substrate for alpha-GlcNAc transferase I that determines and initiates HS biosynthesis. The results suggest that DEXT3 is the ortholog of human EXTL3 and Caenorhabditis elegans rib-2. Semiquantitative reverse transcriptase-PCR analysis revealed ubiquitous expression of the DEXT3 mRNA. Based on the findings of the present study and those of a recent study where a fly mutant, deficient in the botv gene identical to DEXT3, affected HS proteoglycan-mediated developmental signalings, it is suggested that DEXT3 with the revealed glycosyltransferase activities is critically involved in HS formation in Drosophila. These results suggest the essential roles of DEXT3, its human ortholog EXTL3, and the C. elegans ortholog rib-2 in the biosynthesis of heparan sulfate and heparin, if present, in the respective organisms.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; Tottori Univ, Dept Environm Sci, Fac Educ & Reg Sci, Tottori 6808551, Japan; Uppsala Univ, Dept Med Biochem & Microbiol, Biomed Ctr, S-75123 Uppsala, Sweden	Kobe Pharmaceutical University; Tottori University; Uppsala University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020; Kusche-Gullberg, Marion/P-4466-2016	Kitagawa, Hiroshi/0000-0002-9307-7079; Kusche-Gullberg, Marion/0000-0002-5636-1695				AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Clines GA, 1997, GENOME RES, V7, P359, DOI 10.1101/gr.7.4.359; FRITZ TA, 1994, J BIOL CHEM, V269, P28809; HAN C, 2001, ANN DROS RES C WASH; Hartmann U, 2001, MATRIX BIOL, V20, P23, DOI 10.1016/S0945-053X(00)00137-2; HECHT JT, 1995, AM J HUM GENET, V56, P1125; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; KIM BT, 2001, GLYCOCONJ J, V18, P119; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kitagawa H, 1999, GLYCOBIOLOGY, V9, P697, DOI 10.1093/glycob/9.7.697; LIDHOLT K, 1992, P NATL ACAD SCI USA, V89, P2267, DOI 10.1073/pnas.89.6.2267; LIND T, 1993, J BIOL CHEM, V268, P20705; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Nadanaka S, 1999, BIOCHEM J, V340, P353, DOI 10.1042/0264-6021:3400353; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; RASKIND WH, 1995, AM J HUM GENET, V56, P1132; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Saito T, 1998, BIOCHEM BIOPH RES CO, V243, P61, DOI 10.1006/bbrc.1997.8062; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; SOLOMON L, 1964, AM J HUM GENET, V16, P351; Stickens D, 1996, NAT GENET, V14, P25, DOI 10.1038/ng0996-25; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Tamura J, 1996, LIEBIGS ANN, P1239; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; Van Hul W, 1998, GENOMICS, V47, P230, DOI 10.1006/geno.1997.5101; Wise CA, 1997, GENOME RES, V7, P10, DOI 10.1101/gr.7.1.10; Wuyts W, 1997, EUR J HUM GENET, V5, P382, DOI 10.1159/000484796; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	39	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13659	13665		10.1074/jbc.M111630200	http://dx.doi.org/10.1074/jbc.M111630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832488	hybrid			2022-12-25	WOS:000175096000043
J	O'Callaghan, DW; Ivings, L; Weiss, JL; Ashby, MC; Tepikin, AV; Burgoyne, RD				O'Callaghan, DW; Ivings, L; Weiss, JL; Ashby, MC; Tepikin, AV; Burgoyne, RD			Differential use of myristoyl groups on neuronal calcium sensor proteins as a determinant of spatio-temporal aspects of Ca2+ signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT MEMBRANE ASSOCIATION; CENTRAL-NERVOUS-SYSTEM; BINDING PROTEIN; CONFORMATIONAL-CHANGES; GUANYLYL CYCLASE; ESCHERICHIA-COLI; RAT-BRAIN; EXPRESSION; FREQUENIN; CELLS	The localizations of three members of the neuronal calcium sensor (NCS) family were studied in HeLa cells. Using hippocalcin-EYFP and NCS-1-ECFP, it was found that their localization differed dramatically in resting cells. NCS-1 had a distinct predominantly perinuclear localization (similar to trans-Golgi markers), whereas hippocalcin was present diffusely throughout the cell. Upon the elevation of intracellular Ca2+, hippocalcin rapidly translocated to the same perinuclear compartment as NCS-1. Another member of the family, neurocalcin 5, also translocated to this region after a rise in Ca2+ concentration. Permeabilization of transfected cells using digitonin caused loss of hippocalcin and neurocalcin 6 in the absence of calcium, but in the presence of 10 muM Ca2+, both proteins translocated to and were retained in the perinuclear region. NCS-1 localization was unchanged in permeabilized cells regardless of calcium concentration. The localization of NCS-1 was unaffected by mutations in all functional EF hands, indicating that its localization was independent of Ca2+. A minimal myristoylation motif (hippocalcin-(1-14)) fused to EGFP resulted in similar perinuclear targeting, showing that localization of these proteins is because of the exposure of the myristoyl group. This was confirmed by mutation of the myristoyl motif of NCS-1 and hippocalcin that resulted in both proteins remaining cytosolic, even at elevated Ca2+ concentration. Dual imaging of hippocalcin-EYFP and cytosolic Ca2+ concentration in Fura Red-loaded cells demonstrated the kinetics of the Ca2+/myristoyl switch in living cells and showed that hippocalcin rapidly translocated with a half-time of similar to12 s after a short lag period when Ca2+ was elevated. These results demonstrate that closely related Ca2+ sensor proteins use their myristoyl groups in distinct ways in vivo in a manner that will determine the time course of Ca2+ signal transduction.	Univ Liverpool, Physiol Lab, Liverpool L69 3BX, Merseyside, England	University of Liverpool	Burgoyne, RD (corresponding author), Univ Liverpool, Physiol Lab, Crown St, Liverpool L69 3BX, Merseyside, England.		Weiss, Jamie/HHS-2536-2022; Burgoyne, Robert D/P-6641-2019; Burgoyne, Robert/C-6706-2008	Burgoyne, Robert D/0000-0002-9219-0387; Burgoyne, Robert/0000-0002-9219-0387; Weiss, Jamie L/0000-0001-6784-5831; Ashby, Michael/0000-0002-8593-8473; Tepikin, Alexei/0000-0002-8172-7513				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bootman MD, 2001, J CELL SCI, V114, P2213; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Burgoyne RD, 2001, BIOCHEM J, V353, P1; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; COX JA, 1994, J BIOL CHEM, V269, P32807; Craske H, 1999, P NATL ACAD SCI USA, V96, P4426, DOI 10.1073/pnas.96.8.4426; Deisseroth K, 1998, NATURE, V392, P198, DOI 10.1038/32448; DIZHOOR AM, 1995, J BIOL CHEM, V270, P25200, DOI 10.1074/jbc.270.42.25200; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Ermilov AN, 2001, J BIOL CHEM, V276, P48143, DOI 10.1074/jbc.M107539200; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; Gomez M, 2001, NEURON, V30, P241, DOI 10.1016/S0896-6273(01)00276-8; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Hwang JY, 2001, FEBS LETT, V508, P355, DOI 10.1016/S0014-5793(01)03094-0; KOBAYASHI M, 1992, BIOCHEM BIOPH RES CO, V189, P511, DOI 10.1016/0006-291X(92)91587-G; KOBAYASHI M, 1993, J BIOL CHEM, V268, P18898; LADANT D, 1995, J BIOL CHEM, V270, P3179; Martone ME, 1999, CELL TISSUE RES, V295, P395, DOI 10.1007/s004410051246; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; McCabe JB, 2001, MOL BIOL CELL, V12, P3601, DOI 10.1091/mbc.12.11.3601; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; NEF S, 1995, J RECEPT SIGNAL TR R, V15, P365, DOI 10.3109/10799899509045227; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; OKAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P147, DOI 10.1016/S0006-291X(05)80968-4; Oleshevskaya EV, 1997, J BIOL CHEM, V272, P14327; Paterlini M, 2000, NEUROSCIENCE, V99, P205, DOI 10.1016/S0306-4522(00)00201-3; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RAY S, 1992, P NATL ACAD SCI USA, V89, P5705, DOI 10.1073/pnas.89.13.5705; SAITOH S, 1994, DEV BRAIN RES, V80, P199, DOI 10.1016/0165-3806(94)90105-8; Sokal I, 1999, J BIOL CHEM, V274, P19829, DOI 10.1074/jbc.274.28.19829; Spilker C, 2000, NEUROSCIENCE, V96, P121, DOI 10.1016/S0306-4522(99)00536-9; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Teruel MN, 2000, CURR BIOL, V10, P86, DOI 10.1016/S0960-9822(00)00295-5; Weiss JL, 2001, J BIOL CHEM, V276, P44804, DOI 10.1074/jbc.M103262200; Weiss JL, 2000, J BIOL CHEM, V275, P40082, DOI 10.1074/jbc.M008603200; Weisz OA, 2000, J BIOL CHEM, V275, P24341, DOI 10.1074/jbc.M000671200; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200; ZOZULYA S, 1992, P NATL ACAD SCI USA, V89, P11569, DOI 10.1073/pnas.89.23.11569	45	120	125	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14227	14237		10.1074/jbc.M111750200	http://dx.doi.org/10.1074/jbc.M111750200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11836243	hybrid			2022-12-25	WOS:000175096000114
J	Zingman, LV; Hodgson, DM; Bienengraeber, M; Karger, AB; Kathmann, EC; Alekseev, AE; Terzic, A				Zingman, LV; Hodgson, DM; Bienengraeber, M; Karger, AB; Kathmann, EC; Alekseev, AE; Terzic, A			Tandem function of nucleotide binding domains confers competence to sulfonylurea receptor in gating ATP-sensitive K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; POTASSIUM CHANNELS; INSULIN-SECRETION; ABC TRANSPORTERS; SUR1; DIAZOXIDE; SUBUNIT; SITES; ADP; REGULATOR	Fundamental to the metabolic sensor function of ATP-sensitive K+ (K-ATP) channels is the sulfonylurea receptor. This ATP-binding cassette protein, which contains nucleotide binding domains (NBD1 and NBD2) with conserved Walker motifs, regulates the ATP sensitivity of the pore-forming Kir6.2 subunit. Although NBD2 hydrolyzes ATP, a property essential in K-ATP channel gating, the role of NBD1, which has limited catalytic activity, if at all, remains less understood. Here, we provide functional evidence that cooperative interaction, rather than the independent contribution of each NBD, is critical for K-ATP channel regulation. Gating of cardiac K-ATP channels by distinct conformations in the NBD2 ATPase cycle, induced by gamma-phosphate analogs, was disrupted by point mutation not only of the Walker motif in NBD2 but also in NBD1. Cooling membrane patches to decelerate the intrinsic ATPase activity counteracted ATP-induced K-ATP channel inhibition, an effect that mimicked stabilization of the MgADP-bound posthydrolytic state at NBD2 by the gamma-phosphate analog orthovanadate. Temperature-induced channel activation was abolished by mutations that either prevent stabilization of MgADP at NBD2 or ATP at NBD1. These findings provide a paradigm of K-ATP channel gating based on integration of both NBDs into a functional unit within the multimeric channel complex.	Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Expt Therapeut, Div Cardiovasc Dis, Rochester, MN 55905 USA; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142290, Russia	Mayo Clinic; Mayo Clinic; Mayo Clinic; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics	Terzic, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Div Cardiovasc Dis, 200 1St St Sw, Rochester, MN 55905 USA.	terzic.andre@mayo.edu	Zingman, Leonid V/GXG-0136-2022; Alekseev, Alexey/I-5346-2013	Zingman, Leonid V/0000-0002-7566-4616; Karger, Amy/0000-0002-2781-3824	NHLBI NIH HHS [HL-68422, HL-07111] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL068422] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham MR, 1999, FASEB J, V13, P1901; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Alekseev AE, 1998, J GEN PHYSIOL, V111, P381, DOI 10.1085/jgp.111.2.381; Azzam NA, 2000, NATURE, V407, P317, DOI 10.1038/35030294; Babenko AP, 2000, J BIOL CHEM, V275, P717, DOI 10.1074/jbc.275.2.717; Banfi B, 2000, SCIENCE, V287, P138, DOI 10.1126/science.287.5450.138; Beaudet L, 1998, BIOCHEMISTRY-US, V37, P9073, DOI 10.1021/bi972656j; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Bryan J, 1999, BBA-BIOMEMBRANES, V1461, P285, DOI 10.1016/S0005-2736(99)00164-9; Carrasco AJ, 2001, P NATL ACAD SCI USA, V98, P7623, DOI 10.1073/pnas.121038198; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; D'hahan N, 1999, P NATL ACAD SCI USA, V96, P12162, DOI 10.1073/pnas.96.21.12162; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Dzeja PP, 1998, FASEB J, V12, P523, DOI 10.1096/fasebj.12.7.523; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Ganim RB, 1998, COMP BIOCHEM PHYS A, V119, P395, DOI 10.1016/S1095-6433(97)00443-1; GOLDSTEIN G, 1964, ANAL CHEM, V36, P243, DOI 10.1021/ac60207a074; Gribble FM, 2000, MOL PHARMACOL, V57, P1256; Gribble FM, 1997, EMBO J, V16, P1145, DOI 10.1093/emboj/16.6.1145; Hopfner KP, 2001, CELL, V105, P473, DOI 10.1016/S0092-8674(01)00335-X; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; John SA, 2001, J GEN PHYSIOL, V118, P391, DOI 10.1085/jgp.118.4.391; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; Kevelaitis E, 1999, CIRCULATION, V99, P3079, DOI 10.1161/01.CIR.99.23.3079; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; Matsuoka T, 2000, CIRC RES, V87, P873, DOI 10.1161/01.RES.87.10.873; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Pucar D, 2001, J BIOL CHEM, V276, P44812, DOI 10.1074/jbc.M104425200; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sankaran B, 1997, BIOCHEMISTRY-US, V36, P6847, DOI 10.1021/bi970034s; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Senior AE, 1997, SEMIN CANCER BIOL, V8, P143, DOI 10.1006/scbi.1997.0065; Shyng SL, 1997, J GEN PHYSIOL, V110, P643, DOI 10.1085/jgp.110.6.643; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; WEISS JN, 1987, SCIENCE, V238, P67, DOI 10.1126/science.2443972; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	50	68	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14206	14210		10.1074/jbc.M109452200	http://dx.doi.org/10.1074/jbc.M109452200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11825892	hybrid			2022-12-25	WOS:000175096000110
J	Bullard, JM; Pritchard, AE; Song, MS; Glover, BP; Wieczorek, A; Chen, J; Janjic, N; McHenry, CS				Bullard, JM; Pritchard, AE; Song, MS; Glover, BP; Wieczorek, A; Chen, J; Janjic, N; McHenry, CS			A three-domain structure for the delta subunit of the DNA polymerase III holoenzyme delta domain III binds delta ' and assembles into the DnaX complex.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION FORK; LAGGING-STRAND; INITIATION COMPLEX; TAU; GAMMA; PSI; PURIFICATION; ALIGNMENT; SSB	Using psi-BLAST, we have developed a method for identifying the poorly conserved delta subunit of the DNA polymerase III holoenzyme from all sequenced bacteria. This approach, starting with Escherichia coli delta, leads not only to the identification of delta but also to the DnaX and delta' subunits of the DnaX complex and other AAA(+)-class ATPases. This suggests that, although not an ATPase, delta is related structurally to the other subunits of the DnaX complex that loads the beta sliding clamp processivity factor onto DNA. To test this prediction, we aligned delta sequences with those of delta' and, using the start of delta' Domain III established from its x-ray crystal structure, predicted the juncture between Domains II and III of delta. This putative delta Domain III could be expressed to high levels, consistent with the prediction that it folds independently. delta Domain III, like Domain III of DnaX and delta', assembles by itself into a complex with the other DnaX complex components. Cross-linking studies indicated a contact of delta with the DnaX subunits. These observations are consistent with a model where two T subunits and one each of the gamma, delta', and delta subunits mutually interact to form a pentameric functional core for the DnaX complex.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Replidyne Inc, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.	charles.mchenrt@uchsc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35695] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; CARTER JR, 1992, J BACTERIOL, V174, P7013, DOI 10.1128/JB.174.21.7013-7025.1992; Clover BP, 2001, CELL, V105, P925, DOI 10.1016/S0092-8674(01)00400-7; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; Gao DX, 2001, J BIOL CHEM, V276, P4447, DOI 10.1074/jbc.M009827200; Gao DX, 2001, J BIOL CHEM, V276, P4441, DOI 10.1074/jbc.M009830200; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 2001, J BIOL CHEM, V276, P35842, DOI 10.1074/jbc.M103719200; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GLOVER BP, 2002, IN PRESS J BACTERIOL; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KUNAU WH, 1993, BIOCHIMIE, V75, P209, DOI 10.1016/0300-9084(93)90079-8; Li XJ, 2000, J BIOL CHEM, V275, P34757, DOI 10.1074/jbc.M006556200; MAKI S, 1988, J BIOL CHEM, V263, P6555; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1987, DNA REPLICATION RECO, P47; MCHENRY CS, 1984, PROTEINS INVOLVED DN, P315; Neuwald AF, 1999, GENOME RES, V9, P27; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Song MS, 2001, J BIOL CHEM, V276, P48709, DOI 10.1074/jbc.M107936200; Song MS, 2001, J BIOL CHEM, V276, P40668, DOI 10.1074/jbc.M106373200; Song MS, 2001, J BIOL CHEM, V276, P35165, DOI 10.1074/jbc.M100389200; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Walker JR, 2000, J BACTERIOL, V182, P6106, DOI 10.1128/JB.182.21.6106-6113.2000	37	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13246	13256		10.1074/jbc.M108708200	http://dx.doi.org/10.1074/jbc.M108708200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809766	hybrid			2022-12-25	WOS:000175036300095
J	Chen, XQ; Tan, I; Ng, CH; Hall, C; Lim, L; Leung, T				Chen, XQ; Tan, I; Ng, CH; Hall, C; Lim, L; Leung, T			Characterization of RhoA-binding kinase ROK alpha implication of the pleckstrin homology domain in ROK alpha function using region-specific antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; CYTOSKELETAL REORGANIZATION; ACTIN CYTOSKELETON; CATALYTIC-ACTIVITY; FOCAL ADHESIONS; CITRON KINASE; STRESS FIBERS; EFFECTOR; GTPASES; TARGET	Rho-binding kinase alpha (ROKalpha) is a serine/threonine kinase with multiple functional domains involved in actomyosin assembly. It has previously been documented that the C terminus part of ROKalpha interacts with the N-terminal kinase domain and thereby regulates its catalytic activity. Here we used antibodies against different domains of ROKalpha and were able to reveal some structural aspects that are essential for the specific functions of ROKalpha. Antibodies against the kinase domain revealed that this part of the protein is highly complex and inaccessible. Further experiments confirmed that this domain could undergo inter. and intramolecular interactions in a complex manner, which regulates the kinase catalytic activity. Other antibodies that raised against the coiled-coil domain, Rho binding domain, and the pleckstrin homology (PH) domain were all effective in recognizing the native proteins in an immunoprecipitation assay. Only the anti-Rho binding domain antibodies could activate the kinase independent of RhoA. The PH antibodies had no apparent effects on the catalytic activity but were effective in blocking actomyosin assembly and cell contractility. Likewise, mutations of the PH domains can abrogate its dominant negative effects on actin morphology. The subsequent disruption of endogenous ROK localization to the actomyosin network by overexpressing the PH domain is supportive of a role of the PH domain of ROK in targeting the kinase to these structures.	Glaxo IMCB Grp, Inst Mol & Cell Biol, Singapore 117609, Singapore; UCL, Neurol Inst, London WC1N 1PJ, England	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); GlaxoSmithKline; University of London; University College London	Leung, T (corresponding author), Glaxo IMCB Grp, Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbthom1@imcb.nus.edu.sg	Hall, Christine/C-8390-2009	Ng, Chong Han/0000-0003-2926-9831				Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Amano M, 1999, J BIOL CHEM, V274, P32418, DOI 10.1074/jbc.274.45.32418; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bush EW, 2000, BIOCHEMISTRY-US, V39, P8480, DOI 10.1021/bi992142f; Di Cunto F, 2000, NEURON, V28, P115, DOI 10.1016/S0896-6273(00)00090-8; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Jin S, 2000, CELL MOTIL CYTOSKEL, V45, P133, DOI 10.1002/(SICI)1097-0169(200002)45:2<133::AID-CM5>3.0.CO;2-S; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Leung T, 1996, MOL CELL BIOL, V16, P5313; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; Leung T, 1998, MOL CELL BIOL, V18, P130, DOI 10.1128/MCB.18.1.130; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Maesaki R, 1999, MOL CELL, V4, P793, DOI 10.1016/S1097-2765(00)80389-5; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Tan I, 2001, MOL CELL BIOL, V21, P2767, DOI 10.1128/MCB.21.8.2767-2778.2001; TOUHARA K, 1995, J BIOL CHEM, V270, P17000, DOI 10.1074/jbc.270.28.17000; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056	28	89	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12680	12688		10.1074/jbc.M109839200	http://dx.doi.org/10.1074/jbc.M109839200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815607	hybrid			2022-12-25	WOS:000175036300025
J	Menguy, T; Corre, F; Juul, B; Bouneau, L; Lafitte, D; Derrick, PJ; Sharma, PS; Falson, P; Levine, BA; Moller, JV; le Maire, M				Menguy, T; Corre, F; Juul, B; Bouneau, L; Lafitte, D; Derrick, PJ; Sharma, PS; Falson, P; Levine, BA; Moller, JV; le Maire, M			Involvement of the cytoplasmic loop L6-7 in the entry mechanism for transport of Ca2+ through the sarcoplasmic reticulum Ca2+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CALCIUM-PUMP; SACCHAROMYCES-CEREVISIAE; ADENOSINE-TRIPHOSPHATASE; TRANSMEMBRANE SEGMENT-6; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; CHARGED RESIDUES; CATION OCCLUSION; BINDING	We previously found that mutants of conserved aspartate residues of sarcoplasmic reticulum Ca2+-ATPase in the cytosolic loop, connecting transmembrane segments M6 and M7 (L6-7 loop), exhibit a strongly reduced sensitivity toward Ca2+ activation of the transport process. In this study, yeast membranes, expressing wild type and mutant Ca2+-ATPases, were reacted with Cr(.)ATP and tested for their ability to occlude 45 Ca2+ by HPLC analysis, after cation resin and Cl,E, treatment. We found that the D813A/D818A mutant that displays markedly low calcium affinity was capable of occluding Ca2+ to the same extent as wild type ATPase. Using NMR and mass spectrometry we have analyzed the conformational properties of the synthetic L6-7 loop and demonstrated the formation of specific 1:1 cation complexes of the peptide with calcium and lanthanum. All three aspartate Asp(813)/Asp(815)/Asp(818) were required to coordinate the trivalent lanthanide ion. Overall these observations suggest a dual function of the loop: in addition to mediating contact between the intramembranous Ca2+-binding sites and the cytosolic phosphorylation site (Zhang, Z., Lewis, D., Sumbilla, C., Inesi G., and Toyoshima, C. (2001) J. Biol. Chem. 276, 15232-15239), the L6-7 loop, in a preceding step, participates in the formation of an entrance port, before subsequent high affinity binding of Ca2+ inside the membrane.	Ctr Etud Saclay, SBFM, DBJC, CEA, F-91191 Gif Sur Yvette, France; Univ Paris 11, Ctr Etud Saclay, CNRS, URA 2096, F-91191 Gif Sur Yvette, France; Univ Paris 11, Ctr Etud Saclay, LRA17V, F-91191 Gif Sur Yvette, France; Aarhus Univ, Danish Biomembrane Res Ctr, Dept Biophys, DK-8000 Aarhus C, Denmark; Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England; Univ Warwick, Inst Mass Spectrometry, Coventry CV4 7AL, W Midlands, England; Univ Birmingham, Sch Biosci, Birmingham B15 2TT, W Midlands, England	CEA; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; Aarhus University; University of Warwick; University of Warwick; University of Birmingham	le Maire, M (corresponding author), Ctr Etud Saclay, SBFM, DBJC, CEA, Bat 528, F-91191 Gif Sur Yvette, France.	lemairem@dsvidf.cea.fr		lafitte, daniel/0000-0001-9921-7522; Falson, Pierre/0000-0002-9760-4577				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; Andersen JP, 1998, TRENDS CARDIOVAS MED, V8, P41, DOI 10.1016/S1050-1738(97)00121-7; Asahi M, 2001, P NATL ACAD SCI USA, V98, P10061, DOI 10.1073/pnas.181348298; Beaulieu H, 1999, BIOCHEM J, V340, P813, DOI 10.1042/0264-6021:3400813; BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; CENTENO F, 1994, FEBS LETT, V354, P117, DOI 10.1016/0014-5793(94)01104-4; CHAMPEIL P, 1980, P NATL ACAD SCI-BIOL, V77, P2405, DOI 10.1073/pnas.77.5.2405; CHAVANIEU A, 1994, EUR J BIOCHEM, V224, P115, DOI 10.1111/j.1432-1033.1994.tb20002.x; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; Dwek RA., 1973, NUCL MAGNETIC RESONA; Falson P, 1997, J BIOL CHEM, V272, P17258, DOI 10.1074/jbc.272.28.17258; GARIEPY J, 1983, BIOCHEMISTRY-US, V22, P1765, DOI 10.1021/bi00277a004; GARRIGOS M, 1991, ANAL BIOCHEM, V194, P82, DOI 10.1016/0003-2697(91)90154-L; Groves JD, 1996, P NATL ACAD SCI USA, V93, P12245, DOI 10.1073/pnas.93.22.12245; Hamilton TG, 1999, MOL CELL BIOL, V19, P5298; Hill TJ, 2000, BIOCHEMISTRY-US, V39, P7284, DOI 10.1021/bi000139m; INESI G, 1987, J BIOL CHEM, V262, P16338; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; JUUL B, 1995, J BIOL CHEM, V270, P20123, DOI 10.1074/jbc.270.34.20123; Lavanant H, 1998, ANAL BIOCHEM, V255, P74, DOI 10.1006/abio.1997.2441; Lee AG, 2001, BIOCHEM J, V356, P665, DOI 10.1042/0264-6021:3560665; LEE L, 1979, FEBS LETT, V98, P169, DOI 10.1016/0014-5793(79)80176-3; LENOIR G, 2002, IN PRESS BIOCH BIOPH; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; Menguy T, 1998, J BIOL CHEM, V273, P20134, DOI 10.1074/jbc.273.32.20134; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; OR E, 1993, J BIOL CHEM, V268, P16929; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P5553, DOI 10.1021/bi00415a025; Poch E, 1998, AM J PHYSIOL-CELL PH, V275, pC1449, DOI 10.1152/ajpcell.1998.275.6.C1449; Pompon D, 1996, METHOD ENZYMOL, V272, P51, DOI 10.1016/S0076-6879(96)72008-6; SERPERSU EH, 1982, EUR J BIOCHEM, V122, P347, DOI 10.1111/j.1432-1033.1982.tb05887.x; SHAINSKAYA A, 1994, J BIOL CHEM, V269, P10780; Shainskaya A, 2000, J BIOL CHEM, V275, P2019, DOI 10.1074/jbc.275.3.2019; SILLEN LG, 1964, SPECIAL PUBLICATION, V17, P426; SKERJANC IS, 1993, J BIOL CHEM, V268, P15944; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soulie S, 1996, ANAL BIOCHEM, V236, P363, DOI 10.1006/abio.1996.0183; Soulie S, 1999, BIOCHEMISTRY-US, V38, P5813, DOI 10.1021/bi983039d; Soulie S, 1998, EUR J BIOCHEM, V257, P216, DOI 10.1046/j.1432-1327.1998.2570216.x; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; TAKISAWA H, 1981, NATURE, V290, P271, DOI 10.1038/290271a0; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1992, FEBS LETT, V306, P247, DOI 10.1016/0014-5793(92)81010-J; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; VILSEN B, 1995, ACTA PHYSIOL SCAND, V154, P1; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959; Zhang ZS, 2000, BIOCHEMISTRY-US, V39, P8758, DOI 10.1021/bi000185m; Zhang ZS, 2001, J BIOL CHEM, V276, P15232, DOI 10.1074/jbc.M010813200	62	21	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13016	13028		10.1074/jbc.M108899200	http://dx.doi.org/10.1074/jbc.M108899200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11801592	hybrid			2022-12-25	WOS:000175036300068
J	Moroz, C; Traub, L; Maymon, R; Zahalka, MA				Moroz, C; Traub, L; Maymon, R; Zahalka, MA			PLIF, a novel human ferritin subunit from placenta with immunosuppressive activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; ISOFERRITIN; P43; LYMPHOCYTES; CLONING; PROTEIN; DOMAIN	Ferritin is a ubiquitous iron storage protein existing in multiple isoforms composed of 24 heavy and light chain subunits. We describe here a third ferritin-related subunit cloned from human placenta cDNA library and named PLIF (placental immunomodulatory ferritin). The PLIF coding region is composed of ferritin heavy chain (FTH) sequence lacking the 65 C-terminal amino acids, which are substituted with a novel 48 amino acid domain (C48). In contrast to FTH, PLIF mRNA does not include the iron response element in the 5'-untranslated region, suggesting that PLIF synthesis is not regulated by iron. The linkage between the FTH and C48 domains created a restriction site for EcoRI. PLIF protein was found to localize in syncytiotrophoblasts of placentas (8 weeks of gestation) at the fetal-maternal interface. Increased levels of PLIF transcript and protein were also detected in the breast carcinoma cell lines T47D and MCF-7 but not in the benign corresponding cell line HBL-100. In vitro, PLIF was shown to down-modulate mixed lymphocyte reactions and to inhibit the proliferation of peripheral blood mononuclear cells stimulated with OKT3. The accumulated data indicate that PLIF is an embryonic immune factor involved in down-modulating the maternal immune recognition of the embryo toward anergy. This mechanism may have been adapted by breast cancer cells over expressing PLIF.	Tel Aviv Univ, Lab Mol Immunol, Felsenstein Med Res Ctr, Sackler Sch Med,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Moroz, C (corresponding author), Tel Aviv Univ, Lab Mol Immunol, Felsenstein Med Res Ctr, Sackler Sch Med,Rabin Med Ctr, IL-49100 Petah Tiqwa, Israel.	hmoroz@post.tau.ac.il						Bentwich Z, 1996, CLIN EXP IMMUNOL, V103, P239, DOI 10.1046/j.1365-2249.1996.d01-612.x; BOYD D, 1985, J BIOL CHEM, V260, P1755; Constanzo F, 1986, NUCLEIC ACIDS RES, V14, P721; COSTANZO F, 1984, EMBO J, V3, P23, DOI 10.1002/j.1460-2075.1984.tb01756.x; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; HAZARD JT, 1977, NATURE, V265, P755, DOI 10.1038/265755a0; Holdorf AD, 1999, J EXP MED, V190, P375, DOI 10.1084/jem.190.3.375; Jauniaux E, 2000, PLACENTA, V21, P408, DOI 10.1053/plac.1999.0491; MARCUS DM, 1974, ARCH BIOCHEM BIOPHYS, V162, P493, DOI 10.1016/0003-9861(74)90209-4; MATZNER Y, 1985, BRIT J HAEMATOL, V59, P443, DOI 10.1111/j.1365-2141.1985.tb07331.x; Maymon R, 2000, AM J OBSTET GYNECOL, V182, P670, DOI 10.1067/mob.2000.104145; Maymon R, 1996, BRIT J OBSTET GYNAEC, V103, P301, DOI 10.1111/j.1471-0528.1996.tb09732.x; MOROZ C, 1987, EXP HEMATOL, V15, P258; MOROZ C, 1977, NEW ENGL J MED, V296, P1172; MOROZ C, 1985, CLIN CHIM ACTA, V148, P111, DOI 10.1016/0009-8981(85)90220-7; MOROZ C, 1989, IRON IMMUNITY CANCER, P283; MUNRO H, 1993, NUTR REV, V51, P65, DOI 10.1111/j.1753-4887.1993.tb03072.x; Rosen HR, 1998, CANCER LETT, V127, P129, DOI 10.1016/S0304-3835(98)00017-2; ROUAULT TA, 1990, P NATL ACAD SCI USA, V87, P7958, DOI 10.1073/pnas.87.20.7958; SIROTA L, 1989, CLIN EXP IMMUNOL, V77, P257; STRUMOWICZ M, 1996, J TUMOR MARKER ONCOL, V11, P1; Swingler S, 1997, J VIROL, V71, P4372, DOI 10.1128/JVI.71.6.4372-4377.1997	22	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12901	12905		10.1074/jbc.M200956200	http://dx.doi.org/10.1074/jbc.M200956200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821435	hybrid			2022-12-25	WOS:000175036300054
J	Neves-Ferreira, AGC; Perales, J; Fox, JW; Shannon, JD; Makino, DL; Garratt, RC; Domont, GB				Neves-Ferreira, AGC; Perales, J; Fox, JW; Shannon, JD; Makino, DL; Garratt, RC; Domont, GB			Structural and functional analyses of DM43, a snake venom metalloproteinase inhibitor from Didelphis marsupialis serum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTHROPS-JARARACA VENOM; IMMUNOGLOBULIN SUPERGENE FAMILY; MHC CLASS-I; CRYSTAL-STRUCTURE; ANTIHEMORRHAGIC FACTOR; AGKISTRODON-ACUTUS; GROWTH-HORMONE; GENE FAMILY; PROTEIN; RECEPTOR	DM43, an opossum serum protein inhibitor of snake venom metalloproteinases, has been completely sequenced, and its disulfide bond pattern has been experimentally determined. It shows homology to human alpha(I)B-glycoprotein, a plasma protein of unknown function and a member of the immunoglobulin supergene family. Size exclusion and dynamic laser light scattering data indicated that two monomers of DM43, each composed of three immunoglobulin-like domains, associated to form a homodimer in solution. Analysis of its glycan moiety showed the presence of N-acetylglucosamine, mannose, galactose, and sialic acid, most probably forming four biantennary N-linked chains. DM43 inhibited the fibrinogenolytic activities of bothrolysin and jararhagin and formed 1:1 stoichiometric stable complexes with both metalloproteinases. DM43 was ineffective against atrolysin C or A. No complex formation was detected between DM43 and jararhagin C, indicating the essential role of the metalloproteinase domain for interaction. Homology modeling based on the crystal structure of a killer cell inhibitory receptor suggested the existence of an I-type Ig fold, a hydrophobic dimerization surface and six surface loops potentially forming the metalloproteinase-binding surface on DM43.	Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, BR-21949900 Rio De Janeiro, Brazil; Fiocruz MS, Inst Oswaldo Cruz, Dept Fisiol & Farmacodinam, BR-21045900 Rio De Janeiro, Brazil; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Sao Paulo, Inst Fis Sao Carlos, Dept Fis & Informat, BR-13566590 Sao Paulo, Brazil	Universidade Federal do Rio de Janeiro; Fundacao Oswaldo Cruz; University of Virginia; Universidade de Sao Paulo	Domont, GB (corresponding author), Univ Fed Rio de Janeiro, Inst Quim, Dept Bioquim, BR-21949900 Rio De Janeiro, Brazil.		garratt, richard c/F-6921-2011; Neves-Ferreira, Ana Gisele C./N-3596-2013	Neves-Ferreira, Ana Gisele C./0000-0002-7863-9512; garratt, richard/0000-0002-2016-3179	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R21GM057908] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 57908] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN G, 1989, SEQUENCING PROTEINS, P95; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; BARTON GJ, 1987, J MOL BIOL, V198, P327, DOI 10.1016/0022-2836(87)90316-0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BJARNASON JB, 1995, METHOD ENZYMOL, V248, P345; BJARNASON JB, 1994, PHARMACOL THERAPEUT, V62, P325, DOI 10.1016/0163-7258(94)90049-3; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CATANESE JJ, 1992, BIOCHEMISTRY-US, V31, P410, DOI 10.1021/bi00117a015; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DOMONT GB, 1991, TOXICON, V29, P1183, DOI 10.1016/0041-0101(91)90191-S; Dunn RD, 2001, BBA-MOL CELL BIOL L, V1533, P29, DOI 10.1016/S1388-1981(01)00138-X; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Fox Jay W., 1998, P151; Fox Jay W., 1998, P599; FOX JW, 1995, METHOD ENZYMOL, V248, P368; GOMISRUTH FX, 1993, EMBO J, V12, P4151, DOI 10.1002/j.1460-2075.1993.tb06099.x; Gong WM, 1998, J MOL BIOL, V283, P657, DOI 10.1006/jmbi.1998.2110; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; HITE LA, 1994, ARCH BIOCHEM BIOPHYS, V308, P182, DOI 10.1006/abbi.1994.1026; HOOD L, 1985, CELL, V40, P225, DOI 10.1016/0092-8674(85)90133-3; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; ISHIOKA N, 1986, P NATL ACAD SCI USA, V83, P2363, DOI 10.1073/pnas.83.8.2363; Jones S, 1997, J MOL BIOL, V272, P133, DOI 10.1006/jmbi.1997.1233; Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7; Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200; KRUTZSCH HC, 1993, ANAL BIOCHEM, V209, P109, DOI 10.1006/abio.1993.1089; Kumasaka T, 1996, J BIOCHEM, V119, P49, DOI 10.1093/oxfordjournals.jbchem.a021215; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Loechel F, 2000, BIOCHEM BIOPH RES CO, V278, P511, DOI 10.1006/bbrc.2000.3835; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; Maenaka K, 1999, STRUCTURE, V7, P391, DOI 10.1016/S0969-2126(99)80052-5; Markland FS, 1998, TOXICON, V36, P1749, DOI 10.1016/S0041-0101(98)00126-3; Matsui T, 2000, BBA-PROTEIN STRUCT M, V1477, P146, DOI 10.1016/S0167-4838(99)00268-X; Mebs Dietrich, 1998, P1; MELO PA, 1988, TOXICON, V26, P87, DOI 10.1016/0041-0101(88)90140-7; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; MOUSSATCHE H, 1989, MEM I OSWALDO CRUZ, V84, P391, DOI 10.1590/S0074-02761989000800070; Neves-Ferreira AGC, 2000, BBA-GEN SUBJECTS, V1474, P309, DOI 10.1016/S0304-4165(00)00022-2; NevesFerreira AGC, 1997, TOXICON, V35, P849, DOI 10.1016/S0041-0101(96)00195-X; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; PERALES J, 1992, AGENTS ACTIONS, V37, P250, DOI 10.1007/BF02028117; PERALES J, 1994, TOXICON, V32, P1237, DOI 10.1016/0041-0101(94)90353-0; PERALES J, 2001, IN PRESS PERSPECTIVE; Perez JC, 1999, TOXICON, V37, P703, DOI 10.1016/S0041-0101(98)00205-0; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; QI ZQ, 1994, TOXICON, V32, P1459, DOI 10.1016/0041-0101(94)90417-0; QI ZQ, 1995, TOXICON, V33, P241, DOI 10.1016/0041-0101(94)00146-Y; RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Snyder GA, 1999, P NATL ACAD SCI USA, V96, P3864, DOI 10.1073/pnas.96.7.3864; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STOCKER W, 1995, PROTEIN SCI, V4, P823; Takeya Hiroyuki, 1998, P11; Thwin MM, 1998, TOXICON, V36, P1471, DOI 10.1016/S0041-0101(98)00137-8; USAMI Y, 1994, BIOCHEM BIOPH RES CO, V201, P331, DOI 10.1006/bbrc.1994.1706; Valente RH, 2001, EUR J BIOCHEM, V268, P3042, DOI 10.1046/j.1432-1327.2001.02199.x; Valiante NM, 1997, IMMUNOL REV, V155, P155, DOI 10.1111/j.1600-065X.1997.tb00948.x; VRIEND G, 1993, J APPL CRYSTALLOGR, V26, P47, DOI 10.1107/S0021889892008240; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; YAMAKAWA Y, 1992, J BIOCHEM-TOKYO, V112, P583, DOI 10.1093/oxfordjournals.jbchem.a123944; ZHANG DC, 1994, P NATL ACAD SCI USA, V91, P8447, DOI 10.1073/pnas.91.18.8447; Zhu XY, 1999, ACTA CRYSTALLOGR D, V55, P1834, DOI 10.1107/S0907444999010306	70	54	59	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13129	13137		10.1074/jbc.M200589200	http://dx.doi.org/10.1074/jbc.M200589200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815628	hybrid			2022-12-25	WOS:000175036300082
J	Kasirer-Friede, A; Ware, J; Leng, LJ; Marchese, P; Ruggeri, ZM; Stattil, SJ				Kasirer-Friede, A; Ware, J; Leng, LJ; Marchese, P; Ruggeri, ZM; Stattil, SJ			Lateral clustering of platelet GP Ib-IX complexes leads to up-regulation of the adhesive function of integrin alpha(IIb)beta(3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; MEMBRANE GLYCOPROTEIN-IB; VONWILLEBRAND-FACTOR BINDING; PROTEIN-TYROSINE KINASE; CYTOPLASMIC DOMAIN; FIBRINOGEN BINDING; V-IX; THROMBIN RESPONSIVENESS; RECEPTOR INTERACTIONS; SIGNAL-TRANSDUCTION	Binding of von Willebrand factor (VWF) to GP Ib-IX mediates initial platelet adhesion and increases the subsequent adhesive function of alpha(IIb)beta(3). Because these responses are promoted most effectively by large VWF multimers, we hypothesized that receptor clustering modulates GP Ib-IX function. To test this, GP IX was fused at its cytoplasmic tail to tandem repeats of FKBP, and GP Ib-IX(FKBP)(2) and alpha(IIb)beta(3) were expressed in Chinese hamster ovary cells. Under flow conditions at wall shear rates of up to 2000 s(-1), GP Ib-IX(FKBP)(2) mediated cell tethering to immobilized VWF, just as in platelets. Conditional oligoinerization of GP Ib-IX(FKBP)(2) by AP20187, a cell-permeable FKBP dimerizer, caused a decrease in cell translocation velocities on VWF (p < 0.001). Moreover, clustering of GP Ib-IX(FKBP)(2) by AP20187 led to an increase in alpha(IIb)beta(3) function, manifested under static conditions by increased cell adhesion to fibrinogen (p < 0.01) and under flow by increased stable cell adhesion to VWF (p < 0.04). Clustering of GP Ib-IX(FKBP)(2) also stimulated rapid tyrosine phosphorylation of ectopically expressed Syk, a putative downstream effector of GP Ib-IX in platelets. These studies establish that GP Ib-IX oligomerization, per se, affects the interaction of this receptor with VWF and its ability to influence the adhesive function of alpha(IIb)beta(3). By extrapolation, GP Ib-IX clustering in platelets may promote thrombus formation.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Stattil, SJ (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd,VB-5, La Jolla, CA 92037 USA.	shattil@scripps.edu		Kasirer-Friede, Ana/0000-0001-5970-828X	NHLBI NIH HHS [HL 56595, HL 42846] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056595, R01HL042846, R37HL042846] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AAKHUS AM, 1991, BIOCHEM PHARMACOL, V42, P805, DOI 10.1016/0006-2952(91)90040-C; Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Bennett JS, 1999, J BIOL CHEM, V274, P25301, DOI 10.1074/jbc.274.36.25301; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; BERTOLINO G, 1995, THROMB HAEMOSTASIS, V73, P689; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; Canobbio I, 2001, J BIOL CHEM, V276, P26022, DOI 10.1074/jbc.M102639200; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; COLLER BS, 1981, BLOOD, V57, P846; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; DEMARCO L, 1985, P NATL ACAD SCI USA, V82, P7424; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; DU XP, 1987, BLOOD, V69, P1524; Englund GD, 2001, J BIOL CHEM, V276, P16952, DOI 10.1074/jbc.M008048200; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; Fredrickson BJ, 1998, BLOOD, V92, P3684, DOI 10.1182/blood.V92.10.3684.422k39_3684_3693; Freiberg RA, 1996, J BIOL CHEM, V271, P31666, DOI 10.1074/jbc.271.49.31666; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Gu MY, 1998, J BIOL CHEM, V273, P33465, DOI 10.1074/jbc.273.50.33465; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; Hato T, 1998, J CELL BIOL, V141, P1685, DOI 10.1083/jcb.141.7.1685; HICKEY MJ, 1993, P NATL ACAD SCI USA, V90, P8327, DOI 10.1073/pnas.90.18.8327; HONDA S, 1995, J BIOL CHEM, V270, P11947, DOI 10.1074/jbc.270.20.11947; HUANG MM, 1993, J CELL BIOL, V122, P473, DOI 10.1083/jcb.122.2.473; IKEDA Y, 1993, THROMB HAEMOSTASIS, V69, P496; JACKSON SP, 1994, J BIOL CHEM, V269, P27093; Kahn ML, 1999, BLOOD, V94, P4112, DOI 10.1182/blood.V94.12.4112.424k40_4112_4121; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LI CQ, 1995, J BIOL CHEM, V270, P16302, DOI 10.1074/jbc.270.27.16302; Longhurst CM, 1999, EUR J BIOCHEM, V263, P104, DOI 10.1046/j.1432-1327.1999.00467.x; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Marchese P, 1999, P NATL ACAD SCI USA, V96, P7837, DOI 10.1073/pnas.96.14.7837; Mazzucato M, 1996, THROMB HAEMOSTASIS, V75, P655; Meyer SC, 1997, J BIOL CHEM, V272, P2914, DOI 10.1074/jbc.272.5.2914; Mistry N, 2000, BLOOD, V96, P3480; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; Miyata S, 1999, J BIOL CHEM, V274, P6586, DOI 10.1074/jbc.274.10.6586; MOAKE JL, 1982, NEW ENGL J MED, V307, P1432, DOI 10.1056/NEJM198212023072306; MOHRI H, 1989, J BIOL CHEM, V264, P17361; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; OTOOLE TE, 1994, J CELL BIOL, V124, P1047, DOI 10.1083/jcb.124.6.1047; Ramachandran V, 2001, P NATL ACAD SCI USA, V98, P10166, DOI 10.1073/pnas.171248098; Ramakrishnan V, 1999, P NATL ACAD SCI USA, V96, P13336, DOI 10.1073/pnas.96.23.13336; RAZDAN K, 1994, BIOCHEM J, V302, P681, DOI 10.1042/bj3020681; Ruggeri Z. M., 1999, MOL BASIS CARDIOVASC, P566; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; RUGGERI ZM, 1998, VONWILLEBRAND FACTOR, P79; Sadler JE, 2000, THROMB HAEMOSTASIS, V84, P160; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; SCOTT JP, 1991, J BIOL CHEM, V266, P8149; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHRIMPTON CN, 2001, THROMB HAEMOSTASIS, V86, pP2640; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Stockwell BR, 1998, CURR BIOL, V8, P761, DOI 10.1016/S0960-9822(98)70299-4; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; Sun B, 1999, BIOCHEM BIOPH RES CO, V266, P24, DOI 10.1006/bbrc.1999.1761; VICENTE V, 1990, J BIOL CHEM, V265, P274; Wagner CL, 1996, BLOOD, V88, P907; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; Watson SP, 1998, IMMUNOL TODAY, V19, P260, DOI 10.1016/S0167-5699(98)01267-5; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Yanabu M, 1997, BLOOD, V89, P1590, DOI 10.1182/blood.V89.5.1590.1590_1590_1598; Yap CL, 2000, J BIOL CHEM, V275, P41377, DOI 10.1074/jbc.M005590200; Yuan YP, 1999, J BIOL CHEM, V274, P36241, DOI 10.1074/jbc.274.51.36241; Zaffran Y, 2000, J BIOL CHEM, V275, P16779, DOI 10.1074/jbc.275.22.16779	84	59	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11949	11956		10.1074/jbc.M108727200	http://dx.doi.org/10.1074/jbc.M108727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812775	hybrid			2022-12-25	WOS:000174846400046
J	Yoo, J; Jeong, MJ; Kwon, BM; Hur, MW; Park, YM; Han, MY				Yoo, J; Jeong, MJ; Kwon, BM; Hur, MW; Park, YM; Han, MY			Activation of dynamin I gene expression by Sp1 and Sp3 is required for neuronal differentiation of N1E-115 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE FORMATION; NEUROBLASTOMA-CELLS; BINDING-PROTEIN; RAT-TISSUES; IDENTIFICATION; DOMAINS; BRAIN; MOUSE; ENDOCYTOSIS; INDUCTION	Dynamin I is a key molecule required for the recycling of synaptic vesicles in neurons, and it has been known that dynamin I gene expression is induced during neuronal differentiation. Our previous studies established that neuronal restriction of dynamin I gene expression is controlled by Sp1 and nuclear factor-kappaB-like element-1. Here, using a series of deletion constructs and site-directed mutation, we found that transcription of dynamin I gene during neuronal differentiation of N1E-115 cells is controlled primarily by the Sp1 element located between -13 to -4 bp of the dynamin I promoter. Gel shift analysis demonstrated that in addition to Sp1, Sp3 could interact with this Sp1 element. The requirement for Sp family transcription factors in dynamin I gene expression was confirmed by using mithramycin, an inhibitor of Sp1/Sp3 binding. Mithramycin repressed dynamin I gene expression and resulted in blocking of neuronal differentiation of N1E-115 cells. The localization of the dynamin I protein was also restricted in the peripheral region of the nucleus by the mithramycin treatment. Thus, all of our results suggest that induction of dynamin I gene expression during NlE-115 cell differentiation is modulated by Sp1/Sp3 interactions with the dynamin I promoter, and its expression is important for neuronal differentiation of the NlE-115 cells.	Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305600, South Korea; Yonsei Univ, Sch Med, Inst Genet Sci, Project Med Sci BK 21,Dept Biochem & Mol Biol, Seoul 120752, South Korea; Inchon Univ, Coll Nat Sci, Dept Biol, Inchon 402749, South Korea; Green Cross Inst Med Genet, Seoul 135260, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University	Han, MY (corresponding author), Korea Res Inst Biosci & Biotechnol, Cell Biol Lab, Taejon 305600, South Korea.	myhan@mail.gcrl.co.kr		Hur, Man-Wook/0000-0002-3416-1334				ALTANKOV G, 1993, J CELL BIOL, V120, P1449, DOI 10.1083/jcb.120.6.1449; AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; Cook T, 1996, J NEUROCHEM, V67, P927; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; FAIRE K, 1992, P NATL ACAD SCI USA, V89, P8376, DOI 10.1073/pnas.89.17.8376; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; Lee TH, 2000, ONCOGENE, V19, P3766, DOI 10.1038/sj.onc.1203715; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Merilainen J, 1997, J BIOL CHEM, V272, P23278, DOI 10.1074/jbc.272.37.23278; Ochoa GC, 2000, J CELL BIOL, V150, P377, DOI 10.1083/jcb.150.2.377; PRASAD KN, 1975, BIOL REV, V50, P129, DOI 10.1111/j.1469-185X.1975.tb01055.x; Qualmann B, 1999, MOL BIOL CELL, V10, P501, DOI 10.1091/mbc.10.2.501; Ritter B, 1999, FEBS LETT, V454, P356, DOI 10.1016/S0014-5793(99)00830-3; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Sever S, 2000, TRAFFIC, V1, P385, DOI 10.1034/j.1600-0854.2000.010503.x; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; Simpson F, 1999, NAT CELL BIOL, V1, P119, DOI 10.1038/10091; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; TORRE E, 1994, J BIOL CHEM, V269, P32411; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967; Xiao HY, 2000, J BIOL CHEM, V275, P1371, DOI 10.1074/jbc.275.2.1371; Xu Q, 2000, J BIOL CHEM, V275, P24583, DOI 10.1074/jbc.M003894200; Yoo J, 2001, BIOCHEM BIOPH RES CO, V283, P340, DOI 10.1006/bbrc.2001.4784; Yoo JY, 2001, BIOCHEM BIOPH RES CO, V283, P928, DOI 10.1006/bbrc.2001.4857; Yoo JY, 2000, BIOCHEM J, V351, P661, DOI 10.1042/0264-6021:3510661	41	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11904	11909		10.1074/jbc.M111788200	http://dx.doi.org/10.1074/jbc.M111788200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11809758	hybrid			2022-12-25	WOS:000174846400040
J	Hellberg, CB; Burden-Gulley, SM; Pietz, GE; Brady-Kalnay, SM				Hellberg, CB; Burden-Gulley, SM; Pietz, GE; Brady-Kalnay, SM			Expression of the receptor protein-tyrosine phosphatase, PTP mu, restores E-cadherin-dependent adhesion in human prostate carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; HOMOPHILIC BINDING; CYTOPLASMIC DOMAIN; BETA-SUBUNIT; CATENINS; RACK1; HOMOLOG; CLONING	Normal prostate expresses the receptor protein-tyrosine phosphatase, PTPmu, whereas LNCaP prostate carcinoma cells do not. PTPmu has been shown previously to interact with the E-cadherin complex. LNCaP cells express normal levels of E-cadherin and catenins but do not mediate either PTPmu- or E-cadherin-dependent adhesion. Re-expression of PTPmu restored cell adhesion to PTPmu and to E-cadherin. A mutant form of PTPmu that is catalytically inactive was re-expressed, and it also restored adhesion to PTPmu and to E-cadherin. Expression of PTPmu-extra (which lacks most of the cytoplasmic domain) induced adhesion to PTPmu but not to E-cadherin, demonstrating a requirement for the presence of the intracellular domains of PTPmu to restore E-cadherin-mediated adhesion. We previously observed a direct interaction between the intracellular domain of PTPmu and RACK1, a receptor for activated protein kinase C (PKC). We demonstrate that RACK1 binds to both the catalytically active and inactive mutant form of PTPmu. In addition, we determined that RACK1 binds to the PKCS isoform in LNCaP cells. We tested whether PKC could be playing a role in the ability of PTPmu to restore E-cadherin-dependent adhesion. Activation of PKC reversed the adhesion of PTPmuWT-expressing cells to E-cadherin, whereas treatment of parental LNCaP cells with a PKCdelta-specific inhibitor induced adhesion to E-cadherin. Together, these studies suggest that PTPmu regulates the PKC pathway to restore E-cadherin-dependent adhesion via its interaction with RACK1.	Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA	Case Western Reserve University	Brady-Kalnay, SM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	smb4@po.cwru.edu		Burden-Gulley, Susan/0000-0001-7419-9073				Aono S, 1999, J CELL BIOL, V145, P551, DOI 10.1083/jcb.145.3.551; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1993, J CELL BIOL, V122, P961, DOI 10.1083/jcb.122.4.961; BRADYKALNAY SM, 1994, J BIOL CHEM, V269, P28472; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; BRADYKALNAY SM, 2001, CELL ADHESION FRONTI, V39, P217; Burden-Gulley SM, 1999, J CELL BIOL, V144, P1323, DOI 10.1083/jcb.144.6.1323; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; GEBBINK MFBG, 1993, BIOCHEMISTRY-US, V32, P13516, DOI 10.1021/bi00212a017; GEBBINK MFBG, 1993, J BIOL CHEM, V268, P16101; GEBBINK MFBG, 1991, FEBS LETT, V290, P123, DOI 10.1016/0014-5793(91)81241-Y; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hiscox S, 1998, INT J ONCOL, V13, P1077; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEWIS JE, 1994, J CELL SCI, V107, P3615; Llosas MD, 1996, BIOCHEM J, V315, P1049; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ohkubo T, 1999, J BIOL CHEM, V274, P21409, DOI 10.1074/jbc.274.30.21409; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; SKOUDY A, 1995, FEBS LETT, V374, P415, DOI 10.1016/0014-5793(95)01167-D; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TONKS NK, 1992, COLD SPRING HARB SYM, V57, P87, DOI 10.1101/SQB.1992.057.01.012; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; ZONDAG GCM, 1995, J BIOL CHEM, V270, P14247, DOI 10.1074/jbc.270.24.14247	32	67	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11165	11173		10.1074/jbc.M112157200	http://dx.doi.org/10.1074/jbc.M112157200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801604	hybrid			2022-12-25	WOS:000174613100054
J	Shirota, Y; Luo, H; Qin, WP; Kaneko, S; Yamashita, T; Kobayashi, K; Murakami, S				Shirota, Y; Luo, H; Qin, WP; Kaneko, S; Yamashita, T; Kobayashi, K; Murakami, S			Hepatitis C virus (HCV) NS5A binds RNA-dependent RNA polymerase (RdRP) NS5B and modulates RNA-dependent RNA polymerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NON-B-HEPATITIS; X-PROTEIN; NON-A; HEPATOCELLULAR-CARCINOMA; NONSTRUCTURAL PROTEINS; JAPANESE PATIENTS; TERMINAL REGION; P-PROTEIN; IN-VITRO; GENOME	Hepatitis C virus (HCV) NS5B is RNA-dependent RNA polymerase (RdRP), the essential catalytic enzyme for HCV replication. Recently, NS5A has been reported to be important for the establishment of HCV replication in vitro by the adaptive mutations, although its role in viral replication remains uncertain. Here we report that purified bacterial recombinant NS5A and NS5B directly interact with each other in vitro, detected by glutathione S-transferase (GST) pull-down assay. Furthermore, complex formation of these proteins transiently coexpressed in mammalian cells was detected by coprecipitation. Using terminally and internally truncated NS5A, two discontinuous regions of NS5A (amino acids 105-162 and 277-334) outside of the adaptive mutations were identified to be independently essential for the binding both in vivo and in vitro (Yamashita, T., Kaneko, S., Shirota, Y., Qin, W., Nomura, T., Kobayashi, K., and Mliyrakami, S. (1998) J. Biol. Chem. 273, 15479-15486). We previously examined the effect of His-NS5A on RdRP activity of the soluble recombinant NS5Bt in vitro (see Yamashita et al. above). Wild NS5A weakly stimulated at first (when less than 0.1 molar ratio to NS5B) and then inhibited the NS5Bt RdRP activity in a dose-dependent manner. The internal deletion mutants defective in NS5B binding exhibited no inhibitory effect, indicating that the NS5B binding is necessary for the inhibition. Taken together, our results support the idea that NS5A modulates HCV replication as a component of replication complex.	Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, Kanazawa, Ishikawa 9200934, Japan; Kanazawa Univ, Canc Res Inst, Dept Internal Med 1, Kanazawa, Ishikawa 9200934, Japan; Sichuan Univ, W China Hosp, Inst Infect Dis, Chengdu, Sichuan, Peoples R China	Kanazawa University; Kanazawa University; Sichuan University	Murakami, S (corresponding author), Kanazawa Univ, Canc Res Inst, Dept Mol Oncol, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.			Shirota, Yukihiro/0000-0001-6561-4626				ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Asabe SI, 1997, J VIROL, V71, P790, DOI 10.1128/JVI.71.1.790-796.1997; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BOUFFARD P, 1995, VIROLOGY, V209, P52, DOI 10.1006/viro.1995.1229; Canter DM, 1996, VIROLOGY, V219, P376, DOI 10.1006/viro.1996.0263; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Dorjsuren D, 1998, MOL CELL BIOL, V18, P7546, DOI 10.1128/MCB.18.12.7546; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; FAILLA C, 1994, J VIROL, V68, P3753, DOI 10.1128/JVI.68.6.3753-3760.1994; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1993, J VIROL, V67, P4665, DOI 10.1128/JVI.67.8.4665-4675.1993; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; HONDA M, 1993, ARCH VIROL, V128, P163, DOI 10.1007/BF01309797; Ishido S, 1998, BIOCHEM BIOPH RES CO, V244, P35, DOI 10.1006/bbrc.1998.8202; JEFFERS LJ, 1992, HEPATOLOGY, V15, P187, DOI 10.1002/hep.1840150204; KANEKO T, 1994, BIOCHEM BIOPH RES CO, V205, P320, DOI 10.1006/bbrc.1994.2667; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lin C, 1997, J VIROL, V71, P6465, DOI 10.1128/JVI.71.9.6465-6471.1997; Lin Y, 1998, J BIOL CHEM, V273, P27097, DOI 10.1074/jbc.273.42.27097; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Reed KE, 1997, J VIROL, V71, P7187, DOI 10.1128/JVI.71.10.7187-7197.1997; REED KE, 1995, J VIROL, V69, P4127, DOI 10.1128/JVI.69.7.4127-4136.1995; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SMALLWOOD S, 1994, VIROLOGY, V202, P154, DOI 10.1006/viro.1994.1331; SUZICH JA, 1993, J VIROL, V67, P6152, DOI 10.1128/JVI.67.10.6152-6158.1993; Tai CL, 1996, J VIROL, V70, P8477, DOI 10.1128/JVI.70.12.8477-8484.1996; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; TANJI Y, 1995, J VIROL, V69, P3980, DOI 10.1128/JVI.69.7.3980-3986.1995; TOMEI L, 1993, J VIROL, V67, P4017, DOI 10.1128/JVI.67.7.4017-4026.1993; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479	42	181	189	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11149	11155		10.1074/jbc.M111392200	http://dx.doi.org/10.1074/jbc.M111392200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801599	hybrid, Green Submitted			2022-12-25	WOS:000174613100052
J	Bryan, PM; Potter, LR				Bryan, PM; Potter, LR			The atrial natriuretic peptide receptor (NPR-A/GC-A) is dephosphorylated by distinct microcystin-sensitive and magnesium-dependent protein phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLYL CYCLASE-A; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; CYCLIC-GMP; KINASE-C; DESENSITIZATION; BINDING; MUTANT; DOMAIN; FAMILY	Natriuretic peptide receptor (NPR)-A is the primary signaling receptor for atrial natriuretic peptide and brain natriuretic peptide. Ligand binding to NPR-A rapidly activates its guanylyl cyclase domain, but its rate of cGMP synthesis declines with time. This waning of activity is called homologous desensitization and is mediated in part by receptor dephosphorylation. Here, we characterize two distinct NPR-A phosphatase activities. The serine/threonine protein phosphatase inhibitor, microcystin, inhibited the desensitization of NPR-A in membrane guanylyl cyclase assays in the absence of magnesium. EDTA also inhibited the desensitization, whereas MgCl2 stimulated the desensitization. Because the effects of microcystin and EDTA were additive, and microcystin did not block the magnesium-dependent desensitization, the targets for these agents appear to be distinct. Incubation of membranes at 37 degreesC stimulated the dephosphorylation of NPR-A, and microcystin blocked the temperature-dependent dephosphorylation. The addition of MgCl2 or MnCl2, but not CaCl2, further stimulated the dephosphorylation of NPR-A, and microcystin failed to inhibit this process. The desensitization required changes in the phosphorylation state of NPR-A because the guanylyl cyclase activity of a receptor variant containing glutamate substitutions at all six phosphorylation sites was unaffected by MgCl2, EDTA or microcystin. Together, these data indicate that NPR-A is regulated by two distinct phosphatases, possibly including a member of the protein phosphatase 2C family. Finally, we observed that the desensitization of NPR-A in membranes from mouse kidneys and NIH3T3 cells was increased by prior exposure to atrial natriuretic peptide, suggesting that hormone binding enhances receptor dephosphorylation.	Univ Minnesota, Dept Biochem Mol Biol & Biophys, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities	Potter, LR (corresponding author), Univ Minnesota, Dept Biochem Mol Biol & Biophys, 1479 Gortner Ave, St Paul, MN 55108 USA.				NHLBI NIH HHS [R01 HL066397] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066397] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANANDSRIVASTAVA MB, 1993, PHARMACOL REV, V45, P455; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; CAHILL PA, 1990, J BIOL CHEM, V265, P21896; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Foster DC, 1998, J BIOL CHEM, V273, P16311, DOI 10.1074/jbc.273.26.16311; Guthridge MA, 1997, MOL CELL BIOL, V17, P5485, DOI 10.1128/MCB.17.9.5485; HANEDA M, 1991, KIDNEY INT, V40, P188, DOI 10.1038/ki.1991.199; Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173; Huang XZ, 1998, J BIOL CHEM, V273, P1462, DOI 10.1074/jbc.273.3.1462; Huo XW, 1999, BIOCHEMISTRY-US, V38, P16941, DOI 10.1021/bi9919448; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; Ishida A, 1998, J BIOL CHEM, V273, P1904, DOI 10.1074/jbc.273.4.1904; JAISWAL RK, 1992, BIOCHEM BIOPH RES CO, V182, P395, DOI 10.1016/S0006-291X(05)80158-5; Joubert S, 2001, BIOCHEMISTRY-US, V40, P11096, DOI 10.1021/bi010580s; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; KOLLER KJ, 1993, J BIOL CHEM, V268, P5997; Labrecque J, 1999, J BIOL CHEM, V274, P9752, DOI 10.1074/jbc.274.14.9752; Levin ER, 1998, NEW ENGL J MED, V339, P321; Lopez MJ, 1997, J BIOL CHEM, V272, P23064, DOI 10.1074/jbc.272.37.23064; LOWE DG, 1992, BIOCHEMISTRY-US, V31, P10421, DOI 10.1021/bi00158a001; Lucas KA, 2000, PHARMACOL REV, V52, P375; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; Misono KS, 1999, BIOCHEMISTRY-US, V38, P516, DOI 10.1021/bi982127v; Murthy KS, 2000, AM J PHYSIOL-GASTR L, V278, pG974, DOI 10.1152/ajpgi.2000.278.6.G974; Pagano M, 2001, J BIOL CHEM, V276, P22064, DOI 10.1074/jbc.M101587200; POTTER LR, 1992, J BIOL CHEM, V267, P14531; POTTER LR, 1994, J BIOL CHEM, V269, P14636; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; Schulz S, 1999, VITAM HORM, V57, P123; Sheppeck JE, 1997, BIOORGAN MED CHEM, V5, P1739, DOI 10.1016/S0968-0896(97)00146-6; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tong Y, 1998, J BIOL CHEM, V273, P35282, DOI 10.1074/jbc.273.52.35282; Trachte GJ, 2000, J PHARMACOL EXP THER, V294, P210; Wedel BJ, 2001, ANNU REV PHYSIOL, V63, P215, DOI 10.1146/annurev.physiol.63.1.215; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; WOODS M, 1991, BIOCHEM PHARMACOL, V41, P385, DOI 10.1016/0006-2952(91)90535-D; YASUNARI K, 1992, HYPERTENSION, V19, P314, DOI 10.1161/01.HYP.19.4.314	44	37	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16041	16047		10.1074/jbc.M110626200	http://dx.doi.org/10.1074/jbc.M110626200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11821394	hybrid			2022-12-25	WOS:000175510400110
J	Motoki, A; Usui, M; Shimazu, T; Hirano, M; Katoh, S				Motoki, A; Usui, M; Shimazu, T; Hirano, M; Katoh, S			A domain of the manganese-stabilizing protein from Synechococcus elongatus involved in functional binding to photosystem II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							33-KDA EXTRINSIC PROTEIN; OXYGEN-EVOLUTION SYSTEM; 33 KDA PROTEIN; SECONDARY STRUCTURE; THERMOPHILIC CYANOBACTERIUM; RECONSTITUTION EXPERIMENTS; DIRECTED MUTAGENESIS; CYANIDIUM-CALDARIUM; CIRCULAR-DICHROISM; EVOLVING COMPLEX	Site-directed mutagenesis was performed to investigate whether the two protease-sensitive sequences Phe(156)-Gly(163) and Arg(184)-Ser(191). of the manganese-stabilizing protein (MSP) from a thermophilic cyanobacterium, Synechococcus elongatus (Motoki, A., Shimazu, T., Hirano, M., and Katoh, S. (1998) Biochim. Biophys. Acta 1365, 492-502), are involved in functional interaction with photosystem II (PSII). The ability of MSP to bind to its functional site on the PSII complex and to reactivate oxygen evolution was dramatically reduced by the substitution of Axg(152), Asp(158), Lys(160), or Axg(162) with uncharged residues, by insertion of a single residue between Phe(156) and Leu(157), or by deletion of Leu(157). Substitution of each of the four charged residues with an identically charged residue showed that the charges at Asp(158), and possibly Lys(160), are important for the electrostatic interaction with PSII The reactivating ability was also strongly affected by the alteration of Phe(156) to Leu. Replacement of Lys(188), the only strictly conserved charged residue in the Arg(184)-Ser(191) sequence, by Gln had only a marginal effect on the function of MSP. High affinity binding of MSP to PSII was also affected significantly by mutation at Axg(152), which is located in a region (Val(148)-Arg(152)) strictly conserved among the 14 sequences so far reported. These results imply that the Val(148)-Gly(163) sequence, which is well conserved among MSPs from cyanobacteria to higher plants, is a domain of MSP for functional interaction with PSII.	Toray Res Ctr Ltd, Dept Biol Sci, Kamakura, Kanagawa 2488555, Japan; Toho Univ, Fac Sci, Dept Biol, Funabashi, Chiba 2748510, Japan	Toray Research Center, Inc.; Toho University	Motoki, A (corresponding author), Toray Res Ctr Ltd, Dept Biol Sci, Kamakura, Kanagawa 2488555, Japan.							BRICKER TM, 1988, FEBS LETT, V231, P111, DOI 10.1016/0014-5793(88)80713-0; Bricker TM, 1998, PHOTOSYNTH RES, V56, P157, DOI 10.1023/A:1006068615220; BURNAP RL, 1994, BIOCHEMISTRY-US, V33, P13712, DOI 10.1021/bi00250a023; EATONRYE JJ, 1989, BIOCHIM BIOPHYS ACTA, V977, P219, DOI 10.1016/S0005-2728(89)80075-1; ENAMI I, 1991, BIOCHIM BIOPHYS ACTA, V1060, P224, DOI 10.1016/S0005-2728(09)91010-6; ENAMI I, 1987, FEBS LETT, V226, P161, DOI 10.1016/0014-5793(87)80571-9; Enami I, 1998, BIOCHEMISTRY-US, V37, P2787, DOI 10.1021/bi9724624; ENAMI I, 1994, BBA-BIOENERGETICS, V1186, P52, DOI 10.1016/0005-2728(94)90134-1; Enami I, 2000, PLANT CELL PHYSIOL, V41, P1354, DOI 10.1093/pcp/pcd069; ENAMI I, 1994, BBA-BIOENERGETICS, V1185, P75, DOI 10.1016/0005-2728(94)90195-3; ENAMI I, 1992, PLANT CELL PHYSIOL, V33, P291, DOI 10.1093/oxfordjournals.pcp.a078253; Enami I, 1995, BBA-BIOENERGETICS, V1232, P208, DOI 10.1016/0005-2728(95)00122-0; Frankel LK, 1999, BIOCHEMISTRY-US, V38, P14271, DOI 10.1021/bi991366v; FRANKEL LK, 1995, BIOCHEMISTRY-US, V34, P7492, DOI 10.1021/bi00022a024; ICHIMURA T, 1992, PLANT CELL PHYSIOL, V33, P299, DOI 10.1093/oxfordjournals.pcp.a078254; ISOGAI Y, 1987, PLANT CELL PHYSIOL, V28, P1493; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KUWABARA T, 1985, BIOCHIM BIOPHYS ACTA, V806, P283, DOI 10.1016/0005-2728(85)90107-0; Lydakis-Simantiris N, 1999, BIOCHEMISTRY-US, V38, P404, DOI 10.1021/bi981847z; MANAVALAN P, 1987, ANAL BIOCHEM, V167, P76, DOI 10.1016/0003-2697(87)90135-7; MEI R, 1989, BIOCHEMISTRY-US, V28, P5560, DOI 10.1021/bi00439a033; Miura T, 1997, J BIOL CHEM, V272, P3788, DOI 10.1074/jbc.272.6.3788; MIYAO M, 1984, FEBS LETT, V170, P350, DOI 10.1016/0014-5793(84)81342-3; Motoki A, 1998, BBA-BIOENERGETICS, V1365, P492, DOI 10.1016/S0005-2728(98)00102-9; MOTOKI A, 1995, PHOTOSYNTHESIS LIGHT, V2, P487; MURATA N, 1985, TRENDS BIOCHEM SCI, V10, P122, DOI 10.1016/0968-0004(85)90272-5; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; ODOM WR, 1992, BIOCHEMISTRY-US, V31, P5616, DOI 10.1021/bi00139a027; ONO T, 1986, BIOCHIM BIOPHYS ACTA, V850, P380, DOI 10.1016/0005-2728(86)90194-5; ONO T, 1984, FEBS LETT, V166, P381, DOI 10.1016/0014-5793(84)80117-9; Qian M, 1997, BIOCHEMISTRY-US, V36, P15244, DOI 10.1021/bi9713198; QUEIROLA CB, 1992, THESIS LOUISIANA STA; SAYERS JR, 1992, BIOTECHNIQUES, V13, P592; Seidler A, 1996, EUR J BIOCHEM, V242, P485, DOI 10.1111/j.1432-1033.1996.0485r.x; Seidler A, 1996, PLANT MOL BIOL, V31, P183, DOI 10.1007/BF00020619; Seidler A, 1996, BBA-BIOENERGETICS, V1277, P35, DOI 10.1016/S0005-2728(96)00102-8; SEIDLER A, 1995, PHOTOSYNTHESIS LIGHT, V2, P259; SEIDLER A, 1992, RES PHOTOSYNTHESIS, V2, P409; SHEN JR, 1992, FEBS LETT, V301, P145, DOI 10.1016/0014-5793(92)81235-E; SHEN JR, 1993, BIOCHEMISTRY-US, V32, P1825, DOI 10.1021/bi00058a017; Shutova T, 1997, BIOCHEMISTRY-US, V36, P6350, DOI 10.1021/bi963115h; Sonoyama M, 1996, BBA-PROTEIN STRUCT M, V1297, P167, DOI 10.1016/S0167-4838(96)00099-4; STRICKLAND EH, 1976, CRC HDB BIOCH MOL BI, V3, P141; TANAKA S, 1988, PHOTOSYNTH RES, V17, P255, DOI 10.1007/BF00035452; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; XU Q, 1994, BBA-BIOENERGETICS, V1188, P427, DOI 10.1016/0005-2728(94)90065-5	46	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14747	14756		10.1074/jbc.M100766200	http://dx.doi.org/10.1074/jbc.M100766200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11809745	hybrid			2022-12-25	WOS:000175203000052
J	Qi, JH; Ebrahem, Q; Yeow, K; Edwards, DR; Fox, PL; Anand-Apte, B				Qi, JH; Ebrahem, Q; Yeow, K; Edwards, DR; Fox, PL; Anand-Apte, B			Expression of sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOROIDAL ENDOTHELIAL-CELLS; TISSUE INHIBITOR; IN-VITRO; BRUCHS MEMBRANE; MELANOMA-CELLS; NEOVASCULARIZATION; TIMP-3; INVASION; OVEREXPRESSION; APOPTOSIS	Sorsby's fundus dystrophy (SFD) is an autosomal dominant degenerative disease of the macula caused by mutations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) gene. Choroidal neovascularization is a hallmark of this disease, which closely resembles the exudative form of age-related macular degeneration. However, the mechanism by which TIMP-3 mutations induce the disease phenotype in SFD remains unknown. To address this question we established human retinal pigment epithelial cell lines expressing wild type or S156C (Ser(156) changed to cysteine) mutant TIMP-3. S156C TIMP-3 had reduced matrix metalloproteinase (MMP) inhibitory activity in retinal pigment epithelial cells and resulted in increased secretion and activation of gelatinase A and B. The conditioned medium from these cells induced angiogenesis in "in vivo" chick chorioallantoic membrane assays that could be reversed with recombinant wild type TIMP-3. Our data indicate that the choroidal neovascularization in SFD may be a result of increased MMP activity, which could lead to the stimulation of angiogenesis. These results also suggest the potential therapeutic use of TIMP-3 or synthetic MMP inhibitors in this disease.	Cleveland Clin Fdn, Dept Ophthalm Res, Cole Dye Inst I131, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of East Anglia	Anand-Apte, B (corresponding author), Cleveland Clin Fdn, Dept Ophthalm Res, Cole Dye Inst I131, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Edwards, Dylan R/B-4734-2009	Edwards, Dylan R/0000-0002-3292-2064	NATIONAL CANCER INSTITUTE [R01CA106415] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R29EY012109, R01EY016490] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106415] Funding Source: Medline; NEI NIH HHS [R29 EY012109, 1 R29 EY12109-01, R01 EY016490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahonen M, 1998, CANCER RES, V58, P2310; Ahonen M, 1998, ADV EXP MED BIOL, V451, P69; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3; Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200; Brooks PC, 1996, CANCER METAST REV, V15, P187, DOI 10.1007/BF00437471; Campochiaro P.A., 1999, MOL VIS, V5, P24; Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H; CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329; Fariss RN, 1997, AM J PATHOL, V150, P323; Fata JE, 2001, J CLIN INVEST, V108, P831, DOI 10.1172/JCI13171; George SJ, 2000, CIRCULATION, V101, P296, DOI 10.1161/01.CIR.101.3.296; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HOLZ FG, 1994, RETINA-J RET VIT DIS, V14, P329, DOI 10.1097/00006982-199414040-00006; Itoh T, 1998, CANCER RES, V58, P1048; JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27; KALMUS H, 1976, J MED GENET, V13, P271, DOI 10.1136/jmg.13.4.271; Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367; KORTE GE, 1986, ACTA ANAT, V127, P171; Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778; Langton KP, 2000, J BIOL CHEM, V275, P27027; Leco KJ, 2001, J CLIN INVEST, V108, P817, DOI 10.1172/JCI12067; MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; PAVLOFF N, 1992, J BIOL CHEM, V267, P17321; POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763; SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039; SAKAMOTO T, 1995, CURR EYE RES, V14, P621, DOI 10.3109/02713689508998488; SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67; Stetler-Stevenson W G, 2001, Surg Oncol Clin N Am, V10, P383; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/PL00008707; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Werb Z, 1999, APMIS, V107, P11, DOI 10.1111/j.1699-0463.1999.tb01521.x; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Xu JS, 2001, J CELL BIOL, V154, P1069, DOI 10.1083/jcb.200103111; Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9; YU M, 1995, CANCER RES, V55, P3272; Yu WH, 2000, J BIOL CHEM, V275, P31226, DOI 10.1074/jbc.M000907200	46	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13394	13400		10.1074/jbc.M110870200	http://dx.doi.org/10.1074/jbc.M110870200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11821400	hybrid			2022-12-25	WOS:000175096000008
J	Shi, HK; Asher, C; Chigaev, A; Yung, Y; Reuveny, E; Seger, R; Garty, H				Shi, HK; Asher, C; Chigaev, A; Yung, Y; Reuveny, E; Seger, R; Garty, H			Interactions of beta and gamma ENaC with Nedd4 can be facilitated by an ERK-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; ACTIVATED PROTEIN-KINASE; SODIUM-CHANNEL; WW DOMAINS; SURFACE EXPRESSION; COLLECTING DUCT; LIDDLE SYNDROME; ALPHA-SUBUNIT; TGF-BETA; ALDOSTERONE	Phosphorylation of the epithelial Na+ channel (ENaC) has been suggested to play a role in its regulation. Here we demonstrate that phosphorylating the carboxyl termini of the beta and gamma subunits facilitates their interactions with the ubiquitin ligase Nedd4 and inhibits channel activity. Three protein kinases, which phosphorylate the carboxyl termini of beta and gammaENaC, have been identified by an in vitro assay. One of these phosphorylates betaThr-613 and gammaThr-623, well-conserved C-tail threonines in the immediate vicinity of the PY motifs. Phosphorylation of gammaThr-623 has also been demonstrated in vivo in channels expressed in Xenopus oocytes, and mutating betaThr-613 and gammaThr-623 into alanine increased the channel activity by 3.5-fold. Effects of the above phosphorylations on interactions between ENaC and Nedd4 have been studied using surface plasmon resonance. Peptides having phospho-threonine at positions beta613 or gamma623 bind the WW domains of Nedd4 two to three times better than the non-phosphorylated analogues, due to higher association rate constants. Using a number of different approaches it was demonstrated that the protein kinase acting on betaThr-613 and gammaThr-623 is the extracellular regulated kinase (ERK). It is suggested that an ERK-mediated phosphorylation of betaThr-613 and gammaThr-623 down-regulates the channel by facilitating its interaction with Nedd4.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Garty, H (corresponding author), Weizmann Inst Sci, Dept Biol Chem, POB 26, IL-76100 Rehovot, Israel.		Chigaev, Alexandre/A-3103-2010	Chigaev, Alexandre/0000-0002-7726-638X				AHN NG, 1990, J BIOL CHEM, V265, P11487; Al-Baldawi NF, 2000, AM J PHYSIOL-CELL PH, V279, pC429, DOI 10.1152/ajpcell.2000.279.2.C429; Asher C, 2001, BIOCHEM BIOPH RES CO, V286, P1228, DOI 10.1006/bbrc.2001.5508; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Chigaev A, 2001, AM J PHYSIOL-RENAL, V280, pF1030, DOI 10.1152/ajprenal.2001.280.6.F1030; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Farr TJ, 2000, BIOCHEM J, V345, P503, DOI 10.1042/0264-6021:3450503; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Harvey KF, 1999, J BIOL CHEM, V274, P12525, DOI 10.1074/jbc.274.18.12525; Horisberger JD, 1998, CURR OPIN CELL BIOL, V10, P443, DOI 10.1016/S0955-0674(98)80056-2; Husted RF, 2000, AM J PHYSIOL-RENAL, V278, pF425, DOI 10.1152/ajprenal.2000.278.3.F425; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; Ji HL, 1998, AM J PHYSIOL-CELL PH, V275, pC1182; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; Kanelis V, 2001, NAT STRUCT BIOL, V8, P407, DOI 10.1038/87562; Lin HH, 1999, J BIOL CHEM, V274, P21544, DOI 10.1074/jbc.274.31.21544; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Mastroberardino L, 1998, MOL BIOL CELL, V9, P3417, DOI 10.1091/mbc.9.12.3417; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PALMER LG, 2000, KIDNEY PHYSL PATHOPH, P251; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; RUBINFELD H, 1998, CURRENT PROTOCOLS CE; Schild L, 1996, EMBO J, V15, P2381, DOI 10.1002/j.1460-2075.1996.tb00594.x; SEGER R, 1995, J BIOL CHEM, V270, P28325; Shigaev A, 2000, AM J PHYSIOL-RENAL, V278, pF613, DOI 10.1152/ajprenal.2000.278.4.F613; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Snyder PM, 2002, J BIOL CHEM, V277, P5, DOI 10.1074/jbc.C100623200; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Staub O, 1997, EMBO J, V16, P6325, DOI 10.1093/emboj/16.21.6325; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Tian W, 2000, AM J PHYSIOL-RENAL, V279, pF593, DOI 10.1152/ajprenal.2000.279.4.F593; Zentner MD, 1998, J BIOL CHEM, V273, P30770, DOI 10.1074/jbc.273.46.30770	40	104	104	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13539	13547		10.1074/jbc.M111717200	http://dx.doi.org/10.1074/jbc.M111717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11805112	hybrid			2022-12-25	WOS:000175096000027
J	Antinozzi, PA; Ishihara, H; Newgard, CB; Wollheim, CB				Antinozzi, PA; Ishihara, H; Newgard, CB; Wollheim, CB			Mitochondrial metabolism sets the maximal limit of fuel-stimulated insulin secretion in a model pancreatic beta cell - A survey of four fuel secretagogues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH SHUTTLE SYSTEM; UNCOUPLING PROTEIN-2; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; GLYCERALDEHYDE PHOSPHATE; ISLET METABOLISM; GLYCEROL KINASE; CYTOSOLIC CA2+; RAT ISLETS; GLUCOSE; RELEASE	The precise metabolic steps that couple glucose catabolism to insulin secretion in the pancreatic beta cell are incompletely understood. ATP generated from glycolytic metabolism in the cytosol, from mitochondrial metabolism, and/or from the hydrogen shuttles operating between cytosolic and mitochondrial compartments has been implicated as an important coupling factor. To identify the importance of each of these metabolic pathways, we have compared the fates of four fuel secretagogues (glucose, pyruvate, dihydroxyacetone, and glycerol) in the V;SI-E beta cell line. Two of these fuels, dihydroxyacetone and glycerol, are normally ineffective as secretagogues but are enabled by adenovirus-mediated expression of glycerol kinase. Comparison of these two particular fuels allows the effect of redox state on insulin secretion to be evaluated since the phosphorylated products dihydroxyacetone phosphate and glycerol phosphate lie on opposite sides of the NADH-consuming glycerophosphate dehydrogenase reaction. Based upon measurements of glycolytic metabolites, mitochondrial oxidation, mitochondrial matrix calcium, and mitochondrial membrane potential, we find that insulin secretion most tightly correlates with mitochondrial metabolism for each of the four fuels. In the case of glucose stimulation, the high control strength of glucose phosphorylation sets the pace of glucose metabolism and thus the rate of insulin secretion. However, bypassing this reaction with pyruvate, dihydroxyacetone, or glycerol uncovers constraints imposed by mitochondrial metabolism, each of which attains a similar maximal limit of insulin secretion. More specifically, we found that the hyperpolarization of the mitochondrial membrane, related to the proton export from the mito. chondrial matrix, correlates well with insulin secretion. Based on these findings, we propose that fuel-stimulated secretion is in fact limited by the inherent thermodynamic constraints of proton gradient formation.	Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem & Expt Diabetol, CH-1211 Geneva 4, Switzerland; Univ Texas, SW Med Ctr, Dept Biochem, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Touchstone Ctr Diabet Res, Dallas, TX 75390 USA	University of Geneva; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Antinozzi, PA (corresponding author), Univ Geneva, Med Ctr, Dept Internal Med, Div Clin Biochem & Expt Diabetol, CH-1211 Geneva 4, Switzerland.	Peter.Antinozzi@clocs.com						ALCAZAR O, 1995, BIOCHEM J, V310, P215, DOI 10.1042/bj3100215; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; ARKHAMMAR P, 1986, BIOSCIENCE REP, V6, P355, DOI 10.1007/BF01116422; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; ASHCROFT SJ, 1973, BIOCHEM J, V132, P223, DOI 10.1042/bj1320223; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; Bergmeyer HU, 1974, METHODS ENZYMATIC AN; Berman HK, 1998, BIOCHEMISTRY-US, V37, P4543, DOI 10.1021/bi9726133; Brun T, 1996, DIABETES, V45, P190, DOI 10.2337/diabetes.45.2.190; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; Detimary P, 1996, J BIOL CHEM, V271, P20559, DOI 10.1074/jbc.271.34.20559; ELLIOTT AC, 1993, EUR J BIOCHEM, V213, P359, DOI 10.1111/j.1432-1033.1993.tb17769.x; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Eto K, 1999, J BIOL CHEM, V274, P25386, DOI 10.1074/jbc.274.36.25386; GARRIB A, 1986, J BIOL CHEM, V261, P8042; GIROIX MH, 1992, ENDOCRINOLOGY, V130, P2634, DOI 10.1210/en.130.5.2634; HAYASHI SI, 1967, J BIOL CHEM, V242, P1030; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Janjic D, 1999, BIOCHEM PHARMACOL, V57, P639, DOI 10.1016/S0006-2952(98)00346-3; JIJKALI H, 1996, ARCH BIOCHEM BIOPHYS, V355, P245; JUNTTIBERGGREN L, 1992, BIOCHEM J, V287, P59, DOI 10.1042/bj2870059; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; KUNZ WS, 1991, ARCH BIOCHEM BIOPHYS, V284, P40, DOI 10.1016/0003-9861(91)90260-P; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Lembert N, 2001, BIOCHEM J, V354, P345, DOI 10.1042/0264-6021:3540345; MACDONALD MJ, 1992, HORM METAB RES, V24, P158, DOI 10.1055/s-2007-1003284; MACDONALD MJ, 1990, ARCH BIOCHEM BIOPHYS, V279, P104, DOI 10.1016/0003-9861(90)90468-E; MACDONALD MJ, 1989, ARCH BIOCHEM BIOPHYS, V270, P15, DOI 10.1016/0003-9861(89)90002-7; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; Maechler P, 2000, IUBMB LIFE, V50, P27, DOI 10.1080/15216540050176557; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MALAISSE WJ, 1979, DIABETOLOGIA, V16, P331, DOI 10.1007/BF01223623; MALAISSE WJ, 1976, MOL CELL ENDOCRINOL, V4, P1, DOI 10.1016/0303-7207(76)90002-2; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MATSCHINSKY FM, 1986, J BIOL CHEM, V261, P14057; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; MCGINNIS JF, 1974, BIOCHIM BIOPHYS ACTA, V364, P17, DOI 10.1016/0005-2744(74)90128-4; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; Noel RJ, 1997, J BIOL CHEM, V272, P18621, DOI 10.1074/jbc.272.30.18621; PANTEN U, 1988, N-S ARCH PHARMACOL, V338, P459; Rotig A, 1996, DIABETES METAB, V22, P291; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; SENER A, 1978, BIOCHEM J, V176, P217, DOI 10.1042/bj1760217; SENER A, 1992, J BIOL CHEM, V267, P13251; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Skelly RH, 2001, DIABETES, V50, P1791, DOI 10.2337/diabetes.50.8.1791; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Stein DT, 1997, J CLIN INVEST, V100, P398, DOI 10.1172/JCI119546; VIRJI MAG, 1978, ENDOCRINOLOGY, V102, P706, DOI 10.1210/endo-102-3-706; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; WIELAND O, 1957, BIOCHEM Z, V329, P320; Zawalich WS, 1997, J BIOL CHEM, V272, P3527, DOI 10.1074/jbc.272.6.3527; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zhao C, 2001, DIABETES, V50, P361, DOI 10.2337/diabetes.50.2.361	68	90	93	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11746	11755		10.1074/jbc.M108462200	http://dx.doi.org/10.1074/jbc.M108462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821387	Green Published, hybrid			2022-12-25	WOS:000174846400020
J	Chiapperino, D; Kroth, H; Kramarczuk, IH; Sayer, JM; Masutani, C; Hanaoka, F; Jerina, DM; Cheh, AM				Chiapperino, D; Kroth, H; Kramarczuk, IH; Sayer, JM; Masutani, C; Hanaoka, F; Jerina, DM; Cheh, AM			Preferential misincorporation of purine nucleotides by human DNA polymerase eta opposite benzo[a]pyrene 7,8-diol 9,10-epoxide deoxyguanosine adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE PHOSPHORIBOSYLTRANSFERASE GENE; TEMPLATE-PRIMER JUNCTION; PRONE LESION BYPASS; XERODERMA-PIGMENTOSUM; SOLUTION CONFORMATION; NUCLEOSIDE ADDUCTS; THYMINE DIMER; V-79 CELLS; MUTATIONS; REPLICATION	Human DNA polymerase eta was used to copy four stereoisomeric deoxyguanosine (dG) adducts derived from benzo[a]pyrene 7,8-diol 9,10-epoxide (diastereomer with the 7-hydroxyl group and epoxide oxygen trans (BaP DE-2)). The adducts, formed by either cis or trans epoxide ring opening of each enantiomer of BaP DE-2 by N-2 of dG, were placed at the fourth nucleotide from the 5'-end in two 16-mer sequence contexts, 5'similar toCG*Asimilar to and 5'similar toGG*T. poleta was remarkably error prone at all four diol epoxide adducts, preferring to misincorporate G and A at frequencies 3- to more than 50-fold greater than the frequencies for T or the correct C, although the highest rates were 60-fold below the rate of incorporation of C opposite a non-adducted G. Anti to syn rotation of the adducted base, consistent with previous NMR data for a BaP DE-2 dG adduct placed just beyond a primer terminus, provides a rationale for preferring purine misincorporation. Extension of purine misincorporations occurred preferentially, but extension beyond the adduct site was weak with V-max/K-m values generally 10-fold less than for misincorporation. Mostly A was incorporated opposite (+)-BaP DE-2 dG adducts, which correlates with published observations that G --> T is the most common type of mutation that (+)-BaP DE-2 induces in mammalian cells.	NIDDK, Lab Bioorgan Chem, Bethesda, MD 20892 USA; American Univ, Dept Chem, Washington, DC 20016 USA; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Wako, Saitama 3510198, Japan; RIKEN, Wako, Saitama 3510198, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); American University; Japan Science & Technology Agency (JST); RIKEN; Osaka University	Cheh, AM (corresponding author), NIDDK, Lab Bioorgan Chem, Bethesda, MD 20892 USA.	acheh@american.edu	Masutani, Chikahide/I-6160-2014	Masutani, Chikahide/0000-0002-8600-8227; Kroth, Heiko/0000-0002-6936-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1985, BIOACTIVATION FOREIG; Baynton K, 2000, TRENDS BIOCHEM SCI, V25, P74, DOI 10.1016/S0968-0004(99)01524-8; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P15334, DOI 10.1021/bi00046a043; Cosman M, 1996, BIOCHEMISTRY-US, V35, P9850, DOI 10.1021/bi9605346; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P4145, DOI 10.1021/bi00067a001; COSMAN M, 1992, P NATL ACAD SCI USA, V89, P1914, DOI 10.1073/pnas.89.5.1914; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Dipple A., 1984, ACS MONOGR SER, V182, P41, DOI DOI 10.1074/JBC.M409155200; Efrati E, 1999, J BIOL CHEM, V274, P15920, DOI 10.1074/jbc.274.22.15920; Feng BB, 1997, BIOCHEMISTRY-US, V36, P13769, DOI 10.1021/bi970069s; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; Jerina D M, 1991, Adv Exp Med Biol, V283, P533; Jerina D M, 1986, Adv Exp Med Biol, V197, P11; Jerina D.M., 1977, ORIGINS HUMAN CANCER, P639; JERINA DM, 1984, FOREIGN COMPOUND MET, P257; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; Johnson RE, 2001, MOL CELL BIOL, V21, P3558, DOI 10.1128/MCB.21.10.3558-3563.2001; KOUCHAKDJIAN M, 1991, BIOCHEMISTRY-US, V30, P1403, DOI 10.1021/bi00219a034; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; Livneh Z, 2001, J BIOL CHEM, V276, P25639, DOI 10.1074/jbc.R100019200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; OHANDLEY SF, 1993, BIOCHEMISTRY-US, V32, P2481, DOI 10.1021/bi00061a005; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Page JE, 1998, BIOCHEMISTRY-US, V37, P9127, DOI 10.1021/bi980273v; Perlow RA, 2001, J MOL BIOL, V309, P519, DOI 10.1006/jmbi.2001.4674; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Schiltz M, 1999, CARCINOGENESIS, V20, P2279, DOI 10.1093/carcin/20.12.2279; Shibutani S, 2001, BIOCHEMISTRY-US, V40, P3717, DOI 10.1021/bi0027581; THAKKER DR, 1977, CHEM-BIOL INTERACT, V16, P281, DOI 10.1016/0009-2797(77)90108-9; THAKKER DR, 1988, STEREOCHEMICAL ASPEC, P271; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Vaisman A, 2000, BIOCHEMISTRY-US, V39, P4575, DOI 10.1021/bi000130k; WEI SJC, 1993, CANCER RES, V53, P3294; WEI SJC, 1994, CARCINOGENESIS, V15, P1729, DOI 10.1093/carcin/15.8.1729; Wei SJC, 1999, CARCINOGENESIS, V20, P1689, DOI 10.1093/carcin/20.9.1689; Wood RD, 1999, NATURE, V399, P639, DOI 10.1038/21323; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; YA NQ, 1994, STRUCTURAL BIOLOGY: THE STATE OF THE ART, VOL 2, P349; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4717, DOI 10.1093/nar/28.23.4717; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	57	77	79	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11765	11771		10.1074/jbc.M112139200	http://dx.doi.org/10.1074/jbc.M112139200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821420	hybrid			2022-12-25	WOS:000174846400022
J	Ma, YM; Lieber, MR				Ma, YM; Lieber, MR			Binding of inositol hexakisphosphate (IP6) to Ku but not to DNA-PKcs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; STRAND BREAK REPAIR; V(D)J RECOMBINATION; LIGASE-IV; COMPLEX; PATHWAY; ROLES; ENDS	The nonhomologous DNA end joining (NHEJ) pathway is responsible for repairing a major fraction of double strand DNA breaks in somatic cells of all multicellular eukaryotes. As an indispensable protein in the NHEJ pathway, Ku has been hypothesized to be the first protein to bind at the DNA ends generated at a double strand break being repaired by this pathway. When bound to a DNA end, Ku improves the affinity of another DNA end-binding protein, DNA-PKcs, to that end. The Ku-DNA-PKcs complex is often termed the DNA-PK holoenzyme. It was recently shown that myo-inositol hexakisphosphate (IP6) stimulates the joining of complementary DNA ends in a cell free system. Moreover, the binding data suggested that IP6, bound to DNA-PUcs (not to Ku). Here we clearly show that, in fact, IP6 associates not with DNA-PKcs but rather with Ku. Furthermore, the binding of DNA ends and IP6 to Ku are independent of each other. The possible relationship between inositol phosphate metabolism and DNA repair is discussed in light of these findings.	Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Pathol Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Sci Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Lieber, MR (corresponding author), Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Dept Pathol Biochem & Mol Biol, Los Angeles, CA 90089 USA.	lieber@usc.edu		Lieber, Michael/0000-0003-3700-6345				Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1996, MOL ANAL DNA REARRAN, P91; Barnes DE, 1998, CURR BIOL, V8, P1395, DOI 10.1016/S0960-9822(98)00021-9; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chen L, 2000, J BIOL CHEM, V275, P26196, DOI 10.1074/jbc.M000491200; Cooper MP, 2000, GENE DEV, V14, P907; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; Grawunder U, 1997, NUCLEIC ACIDS RES, V25, P1375, DOI 10.1093/nar/25.7.1375; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kanaar Roland, 1997, Genes and Function, V1, P165; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Karanjawala ZE, 1999, CURR BIOL, V9, P1501, DOI 10.1016/S0960-9822(00)80123-2; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Lieber MR, 1998, AM J PATHOL, V153, P1323, DOI 10.1016/S0002-9440(10)65716-1; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Ma YM, 2001, BIOCHEMISTRY-US, V40, P9638, DOI 10.1021/bi010932v; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Schar P, 1997, GENE DEV, V11, P1912, DOI 10.1101/gad.11.15.1912; Smider V, 1998, MOL CELL BIOL, V18, P6853, DOI 10.1128/MCB.18.11.6853; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; West RB, 1998, MOL CELL BIOL, V18, P5908, DOI 10.1128/MCB.18.10.5908; Wilson TE, 1997, NATURE, V388, P495, DOI 10.1038/41365; Yaneva M, 1997, EMBO J, V16, P5098, DOI 10.1093/emboj/16.16.5098; York JD, 1999, SCIENCE, V285, P96, DOI 10.1126/science.285.5424.96	32	66	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					10756	10759		10.1074/jbc.C200030200	http://dx.doi.org/10.1074/jbc.C200030200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11821378	hybrid			2022-12-25	WOS:000174613100003
J	Watanabe, K; Nair, P; Labeit, D; Kellermayer, MSZ; Greaser, M; Labeit, S; Granzier, H				Watanabe, K; Nair, P; Labeit, D; Kellermayer, MSZ; Greaser, M; Labeit, S; Granzier, H			Molecular mechanics of cardiac titin's PEVK and N2B spring elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; ENTROPIC ELASTICITY; STIFFNESS DIVERSITY; PASSIVE TENSION; CONTOUR-LENGTH; LASER TWEEZERS; MUSCLE; PROTEIN; EXTENSIBILITY; IMMUNOGLOBULIN	Titin is a giant elastic protein that is responsible for the majority of passive force generated by the myocardium. Titin's force is derived from its extensible I-band region, which, in the cardiac isoform, comprises three main extensible elements: tandem Ig segments, the PEVK domain, and the N2B unique sequence (N2B-Us). Using atomic force microscopy, we characterized the single molecule force-extension curves of the PEVK and N2B-Us spring elements, which together are responsible for physiological levels of passive force in moderately to highly stretched myocardium. Stretch-release force-extension curves of both the PEVK domain and N2B-Us displayed little hysteresis: the stretch and release data nearly overlapped. The force-extension curves closely followed worm-like chain behavior. Histograms of persistence length (measure of chain bending rigidity) indicated that the single molecule persistence lengths are similar to1.4 and similar to0.65 nm for the PEVK domain and N2B-Us, respectively. Using these mechanical characteristics and those determined earlier for the tandem Ig segment (assuming folded Ig domains), we modeled the cardiac titin extensible region in the sarcomere and calculated the extension of the various spring elements and the forces generated by titin, both as a function of sarcomere length. In the physiological sarcomere length range, predicted values and those obtained experimentally were indistinguishable.	Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA; Univ Hosp Mannheim, Dept Anesthesiol & Intens Operat Med, D-68135 Mannheim, Germany; Univ Pecs, Sch Med, Dept Biophys, H-7624 Pecs, Hungary; Univ Wisconsin, Muscle Biol Lab, Madison, WI 53706 USA	Washington State University; Ruprecht Karls University Heidelberg; University of Pecs; University of Wisconsin System; University of Wisconsin Madison	Granzier, H (corresponding author), Washington State Univ, Dept Vet & Comparat Anat Pharmacol & Physiol, Pullman, WA 99164 USA.	granzier@wsunix.wsu.edu		Kellermayer, Miklos/0000-0002-5553-6553	NHLBI NIH HHS [HL62466, HL61497, HL62881] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061497, R01HL062881, R01HL062466] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bang ML, 2001, CIRC RES, V89, P1065, DOI 10.1161/hh2301.100981; BELL GI, 1978, SCIENCE, V200, P618, DOI 10.1126/science.347575; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; Carrion-Vazquez M, 2000, PROG BIOPHYS MOL BIO, V74, P63, DOI 10.1016/S0079-6107(00)00017-1; Cazorla O, 2000, CIRC RES, V86, P59, DOI 10.1161/01.RES.86.1.59; Cazorla O, 2001, CIRC RES, V88, P1028, DOI 10.1161/hh1001.090876; Daughdrill GW, 1997, NAT STRUCT BIOL, V4, P285, DOI 10.1038/nsb0497-285; Freiburg A, 2000, CIRC RES, V86, P1114; GRANZIER H, 2002, IN PRESS J PHYSL LON; GRANZIER HL, 1995, BIOPHYS J, V68, P1027, DOI 10.1016/S0006-3495(95)80278-X; Gutierrez-Cruz G, 2001, J BIOL CHEM, V276, P7442, DOI 10.1074/jbc.M008851200; Helmes M, 1999, CIRC RES, V84, P1339, DOI 10.1161/01.RES.84.11.1339; Improta S, 1996, STRUCTURE, V4, P323, DOI 10.1016/S0969-2126(96)00036-6; Irving TC, 2000, AM J PHYSIOL-HEART C, V279, pH2568, DOI 10.1152/ajpheart.2000.279.5.H2568; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kellermayer MSZ, 2000, ADV EXP MED BIOL, V481, P111; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Li HB, 2000, P NATL ACAD SCI USA, V97, P6527, DOI 10.1073/pnas.120048697; Li HB, 2000, NAT STRUCT BIOL, V7, P1117; Li HB, 2001, P NATL ACAD SCI USA, V98, P10682, DOI 10.1073/pnas.191189098; Linke WA, 1999, J CELL BIOL, V146, P631, DOI 10.1083/jcb.146.3.631; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Liversage AD, 2001, J MOL BIOL, V305, P401, DOI 10.1006/jmbi.2000.4279; Ma K, 2001, BIOCHEMISTRY-US, V40, P3427, DOI 10.1021/bi0022792; Millman BM, 1998, PHYSIOL REV, V78, P359, DOI 10.1152/physrev.1998.78.2.359; Minajeva A, 2001, BIOPHYS J, V80, P1442, DOI 10.1016/S0006-3495(01)76116-4; Namba K, 2001, GENES CELLS, V6, P1, DOI 10.1046/j.1365-2443.2001.00384.x; Oberhauser AF, 2001, P NATL ACAD SCI USA, V98, P468, DOI 10.1073/pnas.021321798; Pascual J, 1997, J MOL BIOL, V273, P740, DOI 10.1006/jmbi.1997.1344; Plaxco KW, 1997, NATURE, V386, P657, DOI 10.1038/386657a0; RABANAL F, 1993, BIOPOLYMERS, V33, P1019, DOI 10.1002/bip.360330704; Rief M, 1998, BIOPHYS J, V75, P3008, DOI 10.1016/S0006-3495(98)77741-0; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3; Trombitas K, 1999, BIOPHYS J, V77, P3189, DOI 10.1016/S0006-3495(99)77149-3; Trombitas K, 2000, BIOPHYS J, V79, P3226, DOI 10.1016/S0006-3495(00)76555-6; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; TROMBITAS K, 1995, CIRC RES, V77, P856, DOI 10.1161/01.RES.77.4.856; Tskhovrebova L, 2001, J MOL BIOL, V310, P755, DOI 10.1006/jmbi.2001.4700; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Wu YM, 2000, J MOL CELL CARDIOL, V32, P2151, DOI 10.1006/jmcc.2000.1281; Yamasaki R, 2001, BIOPHYS J, V81, P2297, DOI 10.1016/S0006-3495(01)75876-6	42	107	109	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11549	11558		10.1074/jbc.M200356200	http://dx.doi.org/10.1074/jbc.M200356200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11799131	hybrid			2022-12-25	WOS:000174613100102
J	Pastier, D; Lacorte, JM; Chambaz, J; Cardot, P; Ribeiro, A				Pastier, D; Lacorte, JM; Chambaz, J; Cardot, P; Ribeiro, A			Two initiator-like elements are required for the combined activation of the human apolipoprotein C-III promoter by upstream stimulatory factor and hepatic nuclear factor-4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR USF; CREB-BINDING PROTEIN; HUMAN APOCIII GENE; PROXIMAL PROMOTERS; VISCERAL ENDODERM; TRANSGENIC MICE; MAMMALIAN-CELLS; BOX-BINDING; A-I; EXPRESSION	Human apoC-III (similar to890/+24) promoter activity is strongly activated by hepatic nuclear factor (HNF)-4 through its binding to the proximal (-87/-72) element B. This site overlaps the binding site for an activity that we identified as the ubiquitously expressed upstream stimulatory factor (USF) (Ribeiro, A., Pastier, D., Kardassis, D., Chambaz, J., and Cardot, P. (1999) J. Biol. Chem. 274,1216-1225). In the present study, we characterized the relationship between USF and HNF-4 in the activation of human apoC-III transcription. Although USF and HNF-4 binding to element B is mutually exclusive, co-transfection experiments in HepG2 cells surprisingly showed a combined effect of USF and HNF-4 in the transactivation of the (-890/+24) apoC-III promoter. This effect only requires the proximal region (-99/+24) of the apoC-III promoter and depends neither on USF binding to its cognate site in element B nor on a USF-dependent facilitation of HNF-4 binding to its site. By contrast, we found by electrophoretic mobility shift assay and footprinting analysis two USF low affinity binding sites, located within the proximal promoter at positions -58/-31 (element 11) and -19/-4 (element 1), which are homologous to initiator-like element sequence. Co-transfection experiments in HepG2 cells show that a mutation in element 11 reduces 2-fold the USF transactivation effect on the proximal promoter of apoC-Ill and that a mutation in element I inhibits the combined effect of USF and HNF-4. In conclusion, these initiator-like elements are directly involved in the transactivation of the apoC-III promoter by USF and are necessary to the combined effect between USF and HNF-4 for the apoC-III transcription.	Univ Paris 06, Inst Cordeliers, INSERM, U505, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Ribeiro, A (corresponding author), Univ Paris 06, Inst Cordeliers, INSERM, U505, 15 Rue Ecole Med, F-75006 Paris, France.		Ribeiro, Agnès/Q-9702-2017	Ribeiro, Agnès/0000-0003-2063-6084				BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BISAHA JG, 1995, J BIOL CHEM, V270, P19979, DOI 10.1074/jbc.270.34.19979; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Breen GAM, 1999, BBA-GEN SUBJECTS, V1428, P169, DOI 10.1016/S0304-4165(99)00061-6; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARTHEW RW, 1987, GENE DEV, V1, P973, DOI 10.1101/gad.1.9.973; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHARTIER FL, 1994, GENE, V147, P269, DOI 10.1016/0378-1119(94)90079-5; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; DESBOIS C, 1992, TRENDS GENET, V8, P300, DOI 10.1016/0168-9525(92)90260-B; DESILVA HV, 1994, J BIOL CHEM, V269, P2324; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Duncan SA, 1997, DEVELOPMENT, V124, P279; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; HATA S, 1995, BBA-GENE STRUCT EXPR, V1260, P55, DOI 10.1016/0167-4781(94)00177-5; HENRION AA, 1995, GENOMICS, V25, P36, DOI 10.1016/0888-7543(95)80107-W; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; Kardassis D, 1997, ARTERIOSCL THROM VAS, V17, P222, DOI 10.1161/01.ATV.17.1.222; Kardassis D, 1996, HYPERTENSION, V27, P980, DOI 10.1161/01.HYP.27.4.980; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kingsley-Kallesen ML, 1999, J BIOL CHEM, V274, P34020, DOI 10.1074/jbc.274.48.34020; Lacorte JM, 1996, BIOCHEM J, V318, P681, DOI 10.1042/bj3180681; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Le Beyec J, 1998, TRANSGENICS, V2, P211; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OGAMI K, 1991, J BIOL CHEM, V266, P9640; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Ribeiro A, 1999, J BIOL CHEM, V274, P1216, DOI 10.1074/jbc.274.3.1216; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAWADOGO M, 1988, J BIOL CHEM, V263, P11994; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHIH HM, 1995, J BIOL CHEM, V270, P21991, DOI 10.1074/jbc.270.37.21991; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; SLADEK FM, 1994, LIVER GENE EXPRESSIO, V11, P207; TALIANIDIS I, 1995, BIOCHEMISTRY-US, V34, P10298, DOI 10.1021/bi00032a025; TIMCHENKO N, 1995, MOL CELL BIOL, V15, P1192; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Viollet B, 1996, J BIOL CHEM, V271, P1405, DOI 10.1074/jbc.271.3.1405; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	51	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15199	15206		10.1074/jbc.M200227200	http://dx.doi.org/10.1074/jbc.M200227200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11839757	hybrid			2022-12-25	WOS:000175203000106
J	Sijwali, PS; Shenai, BR; Rosenthal, PJ				Sijwali, PS; Shenai, BR; Rosenthal, PJ			Folding of the Plasmodium falciparum cysteine protease falcipain-2 is mediated by a chaperone-like peptide and not the prodomain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR CHAPERONE; MALARIA PARASITE; PRO-REGION; RECOMBINANT FALCIPAIN-2; EXPRESSION; PROTEINASE; ERYTHROCYTE; INHIBITION; PROPEPTIDE; SUBTILISIN	Papain-family cysteine proteases of the malaria parasite Plasmodium falciparum, known as falcipains, are hemoglobinases and potential drug targets. Available data suggest that papain-family proteases require prodomains for correct folding into functional conformations. However, in prior studies of falcipain-2, an Escherichia coli-expressed construct containing only a small portion of the prodomain refolded efficiently, suggesting that this enzyme differs in this regard from other papain-family enzymes. To better characterize the determinants of folding for falcipain-2, we expressed multiple pro- and mature constructs of the enzyme in E. coli and assessed their abilities to refold. Mature falcipain-2 refolded into active protease with very similar properties to those of proteins resulting from the refolding of proenzyme constructs. Deletion of a 17-amino acid amino-terminal segment of the mature protease yielded a construct incapable of correct folding, but inclusion of this segment in trans allowed folding to active falcipain-2. The prodomain was a potent, competitive, and reversible inhibitor of mature falcipain-2 (K-i 10(-10) M). Our results identify a chaperone-like function of an amino-terminal segment of mature falcipain-2 and suggest that protease inhibition, but not the mediation of folding, is a principal function of the falcipain-2 prodomain.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94143 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Rosenthal, PJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Box 0811, San Francisco, CA 94143 USA.	rosnthl@itsa.ucsf.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035800, R29AI035800, R56AI035800] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01081] Funding Source: Medline; NIAID NIH HHS [AI35800] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BERTI PJ, 1995, J MOL BIOL, V246, P273, DOI 10.1006/jmbi.1994.0083; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Dua M, 2001, MOL BIOCHEM PARASIT, V116, P95, DOI 10.1016/S0166-6851(01)00306-1; FORTENBERRY SC, 1995, J BIOL CHEM, V270, P9778, DOI 10.1074/jbc.270.17.9778; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Guay J, 2000, EUR J BIOCHEM, V267, P6311, DOI 10.1046/j.1432-1327.2000.01730.x; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KARRER KM, 1993, P NATL ACAD SCI USA, V90, P3063, DOI 10.1073/pnas.90.7.3063; Kreusch S, 2000, EUR J BIOCHEM, V267, P2965; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Ma BY, 2000, PROTEIN ENG, V13, P617, DOI 10.1093/protein/13.9.617; Olliaro PL, 1999, PHARMACOL THERAPEUT, V81, P91, DOI 10.1016/S0163-7258(98)00036-9; Raphael P, 2000, MOL BIOCHEM PARASIT, V110, P259, DOI 10.1016/S0166-6851(00)00283-8; ROSENTHAL PJ, 1988, J CLIN INVEST, V82, P1560, DOI 10.1172/JCI113766; Rosenthal PJ, 2001, INFEC DIS S, P1; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; SALVESEN G, 1989, PROTEOLYTIC ENZYMES, P87; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Shinde U, 2000, SEMIN CELL DEV BIOL, V11, P35, DOI 10.1006/scdb.1999.0349; Shinde UP, 1997, NATURE, V389, P520, DOI 10.1038/39097; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Sijwali PS, 2001, PROTEIN EXPRES PURIF, V22, P128, DOI 10.1006/prep.2001.1416; SILEN JL, 1989, J BACTERIOL, V171, P1320, DOI 10.1128/jb.171.3.1320-1325.1989; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; SLOMIANNY C, 1990, BLOOD CELLS, V16, P369; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TAYLOR MAJ, 1995, PROTEIN ENG, V8, P59, DOI 10.1093/protein/8.1.59; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Venekei I, 1996, FEBS LETT, V379, P139, DOI 10.1016/0014-5793(95)01483-7; Yamamoto Y, 1999, ARCH INSECT BIOCHEM, V42, P167, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;167::AID-ARCH1&gt;3.0.CO;2-Z; ZHU XL, 1989, NATURE, V339, P483, DOI 10.1038/339483a0	38	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14910	14915		10.1074/jbc.M109680200	http://dx.doi.org/10.1074/jbc.M109680200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11827964	hybrid			2022-12-25	WOS:000175203000072
J	D'Souza, CA; Mak, B; Moscarello, MA				D'Souza, CA; Mak, B; Moscarello, MA			The up-regulation of stromelysin-1 (MMP-3) in a spontaneously demyelinating transgenic mouse precedes onset of disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; MATRIX-METALLOPROTEINASE 3; MURINE TISSUE INHIBITOR; MULTIPLE-SCLEROSIS; INFLAMMATORY DEMYELINATION; GELATINASE B; SERUM-LEVELS; EXPRESSION; PROTEIN; TIMP-1	The matrix metalloproteinases (MMPs) are a family of endoproteinases that degrade various components of the extracellular matrix and have been implicated in the pathogenesis of multiple sclerosis. To determine whether up-regulation of MMP-3, or stromelysin-1, was a causative factor during the development of demyelination, we have examined the expression of MMP-3 mRNA and protein in brain tissue of a spontaneously demyelinating mouse model overexpressing DM20 (ND4 line) prior to and during the progression of disease. Stromelysin-1, but not other MIAP mRNA was elevated similar to 10-fold in transgenic mice between 5 days and 1 month of age, more than 2 months before the onset of disease, and was coordinately expressed with the DM20 transgene. Stromelysin-1 protein levels were also up-regulated as was tissue inhibitor of metalloproteinase-1 (TIMP-1), an in vivo regulator of stromelysin-1 mRNA. When we crossed our ND4 mice with a line of transgenic mice overexpressing TIMP-1 in brain, clinical signs in these mice were attenuated, and the level of stromelysin-1 protein was reduced. Thus, in this transgenic model of demyelinating disease up-regulation of DM20, MMP-3, and TIMP-1 represent important changes in the chemical pathogenesis in brain, which precede the onset of disease.	Hosp Sick Children, Dept Struct Biol & Biochem, Toronto, ON M5G 1X8, Canada; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Washington; University of Washington Seattle	Moscarello, MA (corresponding author), Hosp Sick Children, Dept Struct Biol & Biochem, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	mam@sickkids.ca						Arumugam S, 1998, BIOCHEMISTRY-US, V37, P9650, DOI 10.1021/bi980128h; Barrese N, 1998, J NEUROSCI RES, V53, P143, DOI 10.1002/(SICI)1097-4547(19980715)53:2<143::AID-JNR3>3.0.CO;2-7; Betmouni S, 1999, CURR BIOL, V9, pR677, DOI 10.1016/S0960-9822(99)80437-0; Bode W, 1999, CELL MOL LIFE SCI, V55, P639, DOI 10.1007/s000180050320; CAMPBELL CE, 1991, J BIOL CHEM, V266, P7199; Chandler S, 1995, NEUROSCI LETT, V201, P223, DOI 10.1016/0304-3940(95)12173-0; Cheung NT, 2000, J RHEUMATOL, V27, P882; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clements JM, 1997, J NEUROIMMUNOL, V74, P85, DOI 10.1016/S0165-5728(96)00210-X; Conlon P, 1999, NEUROBIOL DIS, V6, P149, DOI 10.1006/nbdi.1999.0239; Cuzner ML, 1996, J NEUROPATH EXP NEUR, V55, P1194, DOI 10.1097/00005072-199612000-00002; Cuzner ML, 1999, J NEUROIMMUNOL, V94, P1, DOI 10.1016/S0165-5728(98)00241-0; DAVISON AN, 1966, BRIT MED BULL, V22, P40, DOI 10.1093/oxfordjournals.bmb.a070434; Derrigo M, 2000, INT J MOL MED, V5, P111; Edwards DR, 2000, CANC DRUG DISC DEV, P67; EDWARDS DR, 1986, NUCLEIC ACIDS RES, V14, P8863, DOI 10.1093/nar/14.22.8863; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FOSANG AJ, 1991, J BIOL CHEM, V266, P15579; GIJBELS K, 1992, J NEUROIMMUNOL, V41, P29, DOI 10.1016/0165-5728(92)90192-N; Haro H, 2000, J CLIN INVEST, V105, P133, DOI 10.1172/JCI7090; HENRIET P, 1992, FEBS LETT, V310, P175, DOI 10.1016/0014-5793(92)81323-E; Huang W, 1997, J BIOL CHEM, V272, P22086, DOI 10.1074/jbc.272.35.22086; IKENAKA K, 1992, J NEUROCHEM, V58, P2248, DOI 10.1111/j.1471-4159.1992.tb10970.x; ITO A, 1990, FEBS LETT, V269, P93, DOI 10.1016/0014-5793(90)81127-A; Kieseier BC, 1998, BRAIN, V121, P159, DOI 10.1093/brain/121.1.159; Kieseier BC, 1999, NEUROLOGY, V53, P20, DOI 10.1212/WNL.53.1.20; KNAUPER V, 1993, BIOCHEM J, V295, P581; Kouwenhoven M, 2001, J AUTOIMMUN, V16, P463, DOI 10.1006/jaut.2001.0505; Kruger A, 1998, ONCOGENE, V16, P2419, DOI 10.1038/sj.onc.1201774; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leco KJ, 1997, FEBS LETT, V401, P213, DOI 10.1016/S0014-5793(96)01474-3; Lee MA, 1999, BRAIN, V122, P191, DOI 10.1093/brain/122.2.191; Leppert D, 1998, BRAIN, V121, P2327, DOI 10.1093/brain/121.12.2327; Leppert D, 1996, ANN NEUROL, V40, P846, DOI 10.1002/ana.410400606; Maeda A, 1996, J NEUROPATH EXP NEUR, V55, P300, DOI 10.1097/00005072-199603000-00005; Mastronardi FG, 1996, J NEUROSCI RES, V44, P301, DOI 10.1002/(SICI)1097-4547(19960515)44:4<301::AID-JNR1>3.0.CO;2-G; MASTRONARDI FG, 1993, J NEUROSCI RES, V36, P315, DOI 10.1002/jnr.490360309; Matsuzawa K, 1996, J NEUROPATH EXP NEUR, V55, P88, DOI 10.1097/00005072-199601000-00009; MILNER RJ, 1985, CELL, V42, P931, DOI 10.1016/0092-8674(85)90289-2; MIYAZAKI K, 1992, BIOCHEM BIOPH RES CO, V185, P852, DOI 10.1016/0006-291X(92)91705-U; MOHANAM S, 1995, CLIN EXP METASTAS, V13, P57, DOI 10.1007/BF00144019; MOSCARELLO MA, 1994, J CLIN INVEST, V94, P146, DOI 10.1172/JCI117300; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; Nagase H, 1997, BIOCHEM J, V325, P163, DOI 10.1042/bj3250163; NAVE KA, 1987, P NATL ACAD SCI USA, V84, P5665, DOI 10.1073/pnas.84.16.5665; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; OGATA Y, 1992, J BIOL CHEM, V267, P3581; Ozenci V, 1999, J AUTOIMMUN, V12, P297, DOI 10.1006/jaut.1999.0285; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; Ribbens C, 2000, J RHEUMATOL, V27, P888; SANZ L, 1994, J BIOL CHEM, V269, P10044; SANZ L, 1995, MOL CELL BIOL, V15, P3164; SCHORPP M, 1995, BIOCHEM J, V308, P211, DOI 10.1042/bj3080211; SIMONSJOHNSON R, 1995, J NEUROCHEM, V64, P967; Sternlicht MD, 2000, CANC DRUG DISC DEV, P1; Stuve O, 1996, ANN NEUROL, V40, P853, DOI 10.1002/ana.410400607; TANAKA H, 1993, BIOCHEM BIOPH RES CO, V190, P732, DOI 10.1006/bbrc.1993.1110; TISMIT SG, 1992, J NEUROCHEM, V58, P1172; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Uhm JH, 1999, ANN NEUROL, V46, P319, DOI 10.1002/1531-8249(199909)46:3<319::AID-ANA7>3.0.CO;2-N; Uhm JH, 1998, GLIA, V22, P53, DOI 10.1002/(SICI)1098-1136(199801)22:1<53::AID-GLIA5>3.0.CO;2-9; Vaillant C, 1999, J NEUROSCI, V19, P4994; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Woessner J.F., 2000, PROTEIN PROFILE SER; Wood DD, 1996, ANN NEUROL, V40, P18, DOI 10.1002/ana.410400106; Yamanaka H, 2000, ARTHRITIS RHEUM, V43, P852, DOI 10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, NEUROLOGY, V51, P682	70	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13589	13596		10.1074/jbc.M108817200	http://dx.doi.org/10.1074/jbc.M108817200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830584	hybrid			2022-12-25	WOS:000175096000034
J	Hunton, DL; Lucchesi, PA; Pang, Y; Cheng, XG; Dell'Italia, LJ; Marchase, RB				Hunton, DL; Lucchesi, PA; Pang, Y; Cheng, XG; Dell'Italia, LJ; Marchase, RB			Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; HUMAN ADENOVIRUS TYPE-5; NA+-H+ EXCHANGE; ANGIOTENSIN-II; CARDIAC-HYPERTROPHY; INTRACELLULAR CA2+; HYDROGEN-PEROXIDE; CATION CHANNELS; CALCINEURIN; HEART	In nonexcitable cells, depletion of endoplasmic reticulum Ca2+ stores leads to activation of plasma membrane Ca2+ channels, a process termed capacitative Ca2+ entry. Here, we demonstrate that this pathway functions in cells that also contain voltage-gated Ca2+ channels, neonatal rat ventricular myocytes. The depletion of sarcoplasmic reticulum Ca2+ stores elicited a prolonged increase in cytoplasmic Ca2+ dependent on extracellular Ca2+. Inhibitors of store-operated channels but not L-type channels diminished this response. The importance of this pathway to cardiac hypertrophy, which often is dependent on Ca2+/calmodulin-dependent transcription factors, was also assessed in this model. Hypertrophy and atrial natriuretic factor expression induced by angiotensin II or phenylephrine was more effectively attenuated by inhibitors of capacitative entry than of L-type channels. Additionally, cardiomyocytes were transfected with a construct encoding a fluorescent nuclear factor of activated T-cells chimeric protein to follow nuclear localization in response to thapsigargin, angiotensin II, and phenylephrine. This translocation was completely prevented by inhibitors of capacitative Ca2+ entry and only partially abrogated by inhibitors of L-type channels. In contrast, a hypertrophic response induced by overexpression of the transcription factor MEK1 was unaffected by inhibitors of capacitative entry. Together, these data suggest a role for CCE in cardiomyocyte physiology and, in particular, in Ca2+-mediated cardiac hypertrophy.	Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Marchase, RB (corresponding author), Univ Alabama, Dept Cell Biol, 1530 3rd Ave S,MCLM 690, Birmingham, AL 35294 USA.		Lucchesi, Pamela A/E-3558-2011		NHLBI NIH HHS [T32 HL07918, HL 60707] Funding Source: Medline; NIDDK NIH HHS [DK 55647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007918, R01HL060707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antoine S, 1998, J MOL CELL CARDIOL, V30, P2623, DOI 10.1006/jmcc.1998.0818; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Bueno OF, 2000, EMBO J, V19, P6341, DOI 10.1093/emboj/19.23.6341; Chien KR, 2000, J CLIN INVEST, V105, P1339, DOI 10.1172/JCI10079; Chien KR, 1999, CELL, V98, P555, DOI 10.1016/S0092-8674(00)80043-4; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Darbha S, 1996, CELL CALCIUM, V20, P361, DOI 10.1016/S0143-4160(96)90042-1; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; DEJONGE HW, 1995, CELL CALCIUM, V18, P515, DOI 10.1016/0143-4160(95)90014-4; DellItalia LJ, 1997, AM J PHYSIOL-HEART C, V273, pH961, DOI 10.1152/ajpheart.1997.273.2.H961; Dipla K, 1999, CIRC RES, V84, P435, DOI 10.1161/01.RES.84.4.435; DUNNMON PM, 1990, J MOL CELL CARDIOL, V22, P901, DOI 10.1016/0022-2828(90)90121-H; Felzen B, 1998, CIRC RES, V82, P438, DOI 10.1161/01.RES.82.4.438; Fujita S, 1999, N-S ARCH PHARMACOL, V360, P575, DOI 10.1007/s002109900123; Garcia RL, 1997, BIOCHEM BIOPH RES CO, V239, P279, DOI 10.1006/bbrc.1997.7458; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hitt M M, 1997, Adv Pharmacol, V40, P137, DOI 10.1016/S1054-3589(08)60140-4; Ichida M, 2001, J BIOL CHEM, V276, P3524, DOI 10.1074/jbc.M004275200; IKENOUCHI H, 1994, J PHYSIOL-LONDON, V480, P203, DOI 10.1113/jphysiol.1994.sp020353; KASS RS, 1981, J MOL CELL CARDIOL, V13, P797, DOI 10.1016/0022-2828(81)90237-6; KIM DH, 1993, J MEMBRANE BIOL, V135, P27; Kurebayashi N, 2001, J PHYSIOL-LONDON, V533, P185, DOI 10.1111/j.1469-7793.2001.0185b.x; Lamont C, 1996, PFLUG ARCH EUR J PHY, V432, P961, DOI 10.1007/s004240050223; LEVY D, 1990, NEW ENGL J MED, V322, P1561, DOI 10.1056/NEJM199005313222203; Liang QR, 2001, J BIOL CHEM, V276, P30245, DOI 10.1074/jbc.M102174200; Liang QR, 2001, MOL CELL BIOL, V21, P7460, DOI 10.1128/MCB.21.21.7460-7469.2001; Liu SJ, 1998, AM J PHYSIOL-HEART C, V274, pH2203, DOI 10.1152/ajpheart.1998.274.6.H2203; LUKUTA A, 1994, J CARDIOVASC ELECTR, V5, P50; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Merle PL, 1997, J MOL CELL CARDIOL, V29, P2687, DOI 10.1006/jmcc.1997.0500; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NIEDERGERKE R, 1963, J PHYSIOL-LONDON, V167, P515, DOI 10.1113/jphysiol.1963.sp007166; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Paradis P, 2000, P NATL ACAD SCI USA, V97, P931, DOI 10.1073/pnas.97.2.931; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Petroff MGV, 2000, J PHYSIOL-LONDON, V529, P189, DOI 10.1111/j.1469-7793.2000.00189.x; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Sabri A, 1998, CIRC RES, V82, P1053, DOI 10.1161/01.RES.82.10.1053; Schroder F, 1998, CIRCULATION, V98, P969, DOI 10.1161/01.CIR.98.10.969; Shao QM, 1998, BIOCHEM PHARMACOL, V55, P1413, DOI 10.1016/S0006-2952(97)00653-9; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; SIGURDSON W, 1992, AM J PHYSIOL, V262, pH1110, DOI 10.1152/ajpheart.1992.262.4.H1110; SLAUGHTER RS, 1988, BIOCHEMISTRY-US, V27, P2403, DOI 10.1021/bi00407a023; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; TOMINAGA M, 1993, J CLIN INVEST, V91, P1231, DOI 10.1172/JCI116285; Touyz RM, 1996, HYPERTENSION, V28, P797, DOI 10.1161/01.HYP.28.5.797; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; WANG SY, 1995, J MOL CELL CARDIOL, V27, P211, DOI 10.1016/S0022-2828(08)80020-X	55	137	141	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14266	14273		10.1074/jbc.M107167200	http://dx.doi.org/10.1074/jbc.M107167200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827959	hybrid			2022-12-25	WOS:000175096000118
J	Kaczmarczyk, A; Thuveson, M; Fries, E				Kaczmarczyk, A; Thuveson, M; Fries, E			Intracellular coupling of the heavy chain of pre-alpha-inhibitor to chondroitin sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY CROSS-LINKS; TRYPSIN-INHIBITOR; RAT HEPATOCYTES; SERUM-ALBUMIN; BIKUNIN; CELLS; LIVER; TRANSCRIPTION; BIOSYNTHESIS; HYALURONAN	Pre-alpha-inhibitor is a serum protein consisting of two polypeptides, the heavy chain and bikunin, covalently linked through an ester bond between the chondroitin sulfate chain of bikunin and the a-carboxyl group of the carboxyl-terminal residue of the heavy chain. The heavy chain is synthesized with a carboxyl-terminal extension, which is cleaved off just before the link to bikunin is formed. Our earlier studies indicate that this extension mediates the cleavage, and we have now found that a short segment on the amino-terminal side of the cleavage site is also required for the reaction. Furthermore, we previously showed that coexpression of the heavy chain precursor and bikunin in COS-1 cells leads to linkage, and we have now used this system to identify a His residue in the carboxyl-terminal extension that is specifically required for the intracellular coupling of the two proteins. In addition, we have shown that another chondroitin sulfate-containing protein, decorin, will also form a complex with the heavy chain, as will free chondroitin sulfate chains. These results suggest that in vivo there might be other, as yet unknown, chondroitin sulfate-containing polypeptides linked to the heavy chain.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden	Uppsala University	Kaczmarczyk, A (corresponding author), Box 582, S-75123 Uppsala, Sweden.							BLOM A, 1995, J BIOL CHEM, V270, P9698, DOI 10.1074/jbc.270.17.9698; Blom AM, 1997, BIOCHEM J, V328, P185; BRATT T, 1993, BIOCHIM BIOPHYS ACTA, V1157, P147, DOI 10.1016/0304-4165(93)90058-G; CHAN P, 1995, BIOCHEM J, V306, P505, DOI 10.1042/bj3060505; Daveau M, 1998, ARCH BIOCHEM BIOPHYS, V350, P315, DOI 10.1006/abbi.1997.0515; ENGHILD JJ, 1991, J BIOL CHEM, V266, P747; FOSANG AJ, 1996, EXTRACELLULAR MATRIX, V2, P200; Fries E, 2000, INT J BIOCHEM CELL B, V32, P125, DOI 10.1016/S1357-2725(99)00125-9; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; HUANG L, 1993, J BIOL CHEM, V268, P26725; HUTADILOK N, 1988, ANN RHEUM DIS, V47, P377, DOI 10.1136/ard.47.5.377; LINDQVIST A, 1992, BIOCHIM BIOPHYS ACTA, V1130, P63, DOI 10.1016/0167-4781(92)90462-9; Martin-Vandelet N, 1999, EUR J BIOCHEM, V259, P476, DOI 10.1046/j.1432-1327.1999.00067.x; MORELLE W, 1994, EUR J BIOCHEM, V221, P881, DOI 10.1111/j.1432-1033.1994.tb18803.x; PETERS T, 1982, J BIOL CHEM, V257, P8847; SALIER JP, 1993, BIOCHEM J, V296, P85, DOI 10.1042/bj2960085; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SIMKIN PA, 1992, J RHEUMATOL, V19, P1017; SJOBERG EM, 1992, ARCH BIOCHEM BIOPHYS, V295, P217, DOI 10.1016/0003-9861(92)90509-U; SJOBERG EM, 1990, BIOCHEM J, V272, P113; Sugio S, 1999, PROTEIN ENG, V12, P439, DOI 10.1093/protein/12.6.439; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Thuveson M, 2000, J BIOL CHEM, V275, P30996, DOI 10.1074/jbc.M002399200; Thuveson M, 1999, J BIOL CHEM, V274, P6741, DOI 10.1074/jbc.274.10.6741; VETR H, 1990, BIOL CHEM H-S, V371, P1185, DOI 10.1515/bchm3.1990.371.2.1185; Wisniewski HG, 1996, J IMMUNOL, V156, P1609; ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657; Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200	28	15	15	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13578	13582		10.1074/jbc.M200288200	http://dx.doi.org/10.1074/jbc.M200288200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827976	hybrid			2022-12-25	WOS:000175096000032
J	Pediaditakis, P; Monga, SPS; Mars, WM; Michalopoulos, GK				Pediaditakis, P; Monga, SPS; Mars, WM; Michalopoulos, GK			Differential mitogenic effects of single chain hepatocyte growth factor (HGF)/scatter factor and HGF/NK1 following cleavage by factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; C-MET RECEPTOR; HEPARIN-BINDING; CRYSTAL-STRUCTURE; NK1 FRAGMENT; IDENTIFICATION; ANTAGONIST; ACTIVATION; EXPRESSION; VARIANT	Hepatocyte growth factor/scatter factor (HGF/SF) is a multifunctional cytokine that is involved in many normal as well as pathological conditions. HGF/NK1, a splice variant of HGF/SF, has been reported to have either antagonistic or agonistic effects with regard to c-Met signaling depending on the cell type. In these experiments, we have determined that HGF/NK1 is a potent mitogen for rat hepatocytes in culture. Furthermore, we have found that coagulation factor Xa (fXa) is capable of cleaving HGF/NK1 and single chain HGF/SF (scHGF/SF). The products resulting from cleavage of HGF/NK1 or scHGF/SF by fXa appear as single bands under non-reducing conditions. The reaction products from the digestion of HGF/NK1 by fXa were separated under reducing conditions, and the cleavage site, as determined by N-terminal sequencing, was located C-terminal to arginine 134. Previous work established that the heparin-binding domain for HGF/SF is located in the N domain of HGF/SF. Additionally, the dimerization of the HGF/SF receptor (c-Met) by the ligand HGF/NK1 is facilitated by heparin and related sulfonated sugars on the cell surface, whereas heparin is not required for HGF/SF-mediated dimerization. Cleavage of single chain HGF/SF or HGF/NK1 by factor Xa does not alter the affinity of the respective molecules for heparin, but it did variably affect the associated mitogenic activity of these factors. The associated mitogenic activity of HGF/NK1 was reduced by more than 90%, whereas the mitogenic activity of scHGF/SF was unaffected. This suggests mandatory maintenance of a steric interaction of the N domain and the first kringle domain for HGF/NK1 to act as an agonist for rat hepatocyte growth but is not required by full-length HGF/SF.	Univ Pittsburgh, Dept Pathol, Sch Med, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Michalopoulos, GK (corresponding author), Univ Pittsburgh, Dept Pathol, Sch Med, 200 Desoto St, Pittsburgh, PA 15261 USA.	michalopoulosgk@MSX.UPMC.EDU		Monga, Satdarshan/0000-0002-8437-3378	NATIONAL CANCER INSTITUTE [R37CA030241, R01CA035373, R01CA030241] Funding Source: NIH RePORTER; NCI NIH HHS [CA30241, CA35373, R01 CA035373] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; Chirgadze DY, 1999, NAT STRUCT BIOL, V6, P72; Cioce V, 1996, J BIOL CHEM, V271, P13110, DOI 10.1074/jbc.271.22.13110; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; GALIMI F, 1993, STEM CELLS, V11, P22; Gherardi E, 1993, EXS, V65, P31; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; JIRTLE RL, 1981, CANCER RES, V41, P3512; Kinosaki M, 1998, BBA-PROTEIN STRUCT M, V1384, P93, DOI 10.1016/S0167-4838(98)00002-8; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; Mars WM, 1996, CANCER RES, V56, P2837; MARS WM, 1993, AM J PATHOL, V143, P949; Matsumoto K, 1996, CANCER CHEMOTH PHARM, V38, pS42, DOI 10.1007/s002800051037; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P195; Natali PG, 1996, INT J CANCER, V69, P212, DOI 10.1002/(SICI)1097-0215(19960621)69:3<212::AID-IJC11>3.0.CO;2-9; NATALI PG, 1993, BRIT J CANCER, V68, P746, DOI 10.1038/bjc.1993.422; Olivero M, 1996, BRIT J CANCER, V74, P1862, DOI 10.1038/bjc.1996.646; Ozhogina OA, 2001, PROTEIN SCI, V10, P2114, DOI 10.1110/ps.15801; PRAT M, 1991, INT J CANCER, V49, P323, DOI 10.1002/ijc.2910490302; RONG S, 1993, CANCER RES, V53, P5355; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Sakata H, 1997, J BIOL CHEM, V272, P9457; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schwall RH, 1996, J CELL BIOL, V133, P709, DOI 10.1083/jcb.133.3.709; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; Sonnenberg E, 1993, EXS, V65, P381; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; Stevens RC, 2000, STRUCTURE, V8, pR177, DOI 10.1016/S0969-2126(00)00193-3; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tuck AB, 1996, AM J PATHOL, V148, P225; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; WALZ DA, 1977, P NATL ACAD SCI USA, V74, P1969, DOI 10.1073/pnas.74.5.1969; Yang J, 2001, GENE THER, V8, P1470, DOI 10.1038/sj.gt.3301545; ZARNEGAR R, 1989, CANCER RES, V49, P3314; Zhou HJ, 1999, BIOCHEMISTRY-US, V38, P14793, DOI 10.1021/bi9908641	48	17	17	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14109	14115		10.1074/jbc.M112196200	http://dx.doi.org/10.1074/jbc.M112196200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832492	Green Accepted, hybrid			2022-12-25	WOS:000175096000099
J	Seo, SB; Macfarlan, T; McNamara, P; Hong, R; Mukai, Y; Heo, S; Chakravarti, D				Seo, SB; Macfarlan, T; McNamara, P; Hong, R; Mukai, Y; Heo, S; Chakravarti, D			Regulation of histone acetylation and transcription by nuclear protein pp32, a subunit of the INHAT complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOVIRAL ONCOPROTEIN E1A; ACTIVATING FACTOR-I; ACETYLTRANSFERASE ACTIVITY; CHROMATIN STRUCTURE; PHOSPHORYLATION; IDENTIFICATION; BINDING; P300; RICH; CBP	Histone acetylation by p300/CBP and PCAF coactivators is considered to be a key mechanism of chromatin modification and transcriptional regulation. A multiprotein cellular complex, INHAT (inhibitor of acetyltransferases), containing the Set/TAF-Ibeta oncoprotein and pp32 strongly inhibits the HAT activity of p300/CBP and PCAF by histone masking. Here we report that the INHAT complex and its subunits have overlapping but distinct RAT inhibitory and histone binding characteristics. We provide evidence suggesting that the histone binding and INHAT activity of pp32 can be regulated by its physical association with other INHAT subunits. In vivo colocalization and transfection studies show that pp32 INHAT domains are responsible for histone binding, HAT inhibitory activity, and repression of transcription. We propose that INHAT and its subunits may function by modulating histone acetyltransferases through a histone-masking mechanism and may play important regulatory roles in the establishment and maintenance of the newly proposed "histone code" of chromatin.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Chakravarti, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Macfarlan, Todd/S-3750-2017	Macfarlan, Todd/0000-0003-2495-9809; Chakravarti, Debabrata/0000-0001-8446-8599	NIDDK NIH HHS [R01-DK57079, R01 DK057079, P30-DK50306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050306, R01DK057079] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Bjorklund S, 1999, CELL, V96, P759, DOI 10.1016/S0092-8674(00)80586-3; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brody JR, 1999, J BIOL CHEM, V274, P20053, DOI 10.1074/jbc.274.29.20053; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen TH, 1996, MOL BIOL CELL, V7, P2045, DOI 10.1091/mbc.7.12.2045; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Fyodorov DV, 2001, CELL, V106, P523, DOI 10.1016/S0092-8674(01)00478-0; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Hassan AH, 2001, FRONT BIOSCI, V6, pD1054, DOI 10.2741/Hassan; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; MALEK SN, 1990, J BIOL CHEM, V265, P13400; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; Matsumoto K, 1999, FEBS LETT, V463, P285, DOI 10.1016/S0014-5793(99)01632-4; MATSUOKA K, 1994, P NATL ACAD SCI USA, V91, P9670, DOI 10.1073/pnas.91.21.9670; Mencinger M, 1998, BBA-GENE STRUCT EXPR, V1395, P176, DOI 10.1016/S0167-4781(97)00165-6; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Struhl K, 1999, CELL, V98, P1, DOI 10.1016/S0092-8674(00)80599-1; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Ulitzur N, 1997, P NATL ACAD SCI USA, V94, P5084, DOI 10.1073/pnas.94.10.5084; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	41	111	114	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14005	14010		10.1074/jbc.M112455200	http://dx.doi.org/10.1074/jbc.M112455200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830591	hybrid			2022-12-25	WOS:000175096000086
J	Dhar, J; Pande, AH; Sundram, V; Nanda, JS; Mande, SC; Sahni, G				Dhar, J; Pande, AH; Sundram, V; Nanda, JS; Mande, SC; Sahni, G			Involvement of a nine-residue loop of streptokinase in the generation of macromolecular substrate specificity by the activator complex through interaction with substrate kringle domains.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMINOGEN; BIOMOLECULAR INTERACTIONS; CIRCULAR-DICHROISM; CRYSTAL-STRUCTURE; RESONANT MIRROR; SITE; BINDING; AFFINITY; POLYMERASE; EXPRESSION	The selective deletion of a discrete surface-exposed epitope (residues 254-262; 250-loop) in the beta domain of streptokinase (SK) significantly decreased the rates of substrate human plasminogen (HPG) activation by the mutant (SKdel254-262). A kinetic analysis of SKdel254-262 revealed that its low HPG activator activity arose from a 5-6-fold increase in K-m, for HPG as substrate, with little alteration in k(cat) rates. This increase in the K-m for the macromolecular substrate was proportional to a similar decrease in the binding affinity for substrate HPG as observed in a new resonant mirror-based assay for the real-time kinetic analysis of the docking of substrate HPG onto preformed binary complex. In contrast, studies on the interaction of the two proteins with microplasminogen showed no difference between the rates of activation of microplasminogen under conditions where HPG was activated differentially by nSK and SKdel254-262. The involvement of kringles was further indicated by a hypersusceptibility of the SKdel254-262. plasmin activator complex to epsilon-aminocaproic acid-mediated inhibition of substrate HPG activation in comparison with that of the nSK.plasmin activator complex. Further, ternary binding experiments on the resonant mirror showed that the binding affinity of kringles 1-5 of HPG to SKdel214-262.HPG was reduced by about 3-fold in comparison with that of nSK.HPG. Overall, these observations identify the 250 loop in the 13 domain of SK as an important structural determinant of the inordinately stringent substrate specificity of the SK.HPG activator complex and demonstrate that it promotes the binding of substrate HPG to the activator via the kringle(s) during the HPG activation process.	Inst Microbial Technol, Chandigarh 160036, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Institute of Microbial Technology (IMTECH)	Sahni, G (corresponding author), Inst Microbial Technol, Sector 39-A, Chandigarh 160036, India.	sahni@imtech.res.in	Mande, Shekhar/C-2136-2012; Nanda, Jagpreet/F-9833-2011; SUNDRAM, VASUDHA/D-8000-2012	Nanda, Jagpreet/0000-0002-6629-4641				Boxrud PD, 2000, J BIOL CHEM, V275, P14579, DOI 10.1074/jbc.275.19.14579; Boxrud PD, 2001, J BIOL CHEM, V276, P26084, DOI 10.1074/jbc.M101966200; BUCKLE PE, 1993, BIOSENS BIOELECTRON, V8, P355, DOI 10.1016/0956-5663(93)80074-Y; CASTELLINO FJ, 1981, CHEM REV, V81, P431, DOI 10.1021/cr00045a001; CHASE T, 1969, BIOCHEMISTRY-US, V8, P2212, DOI 10.1021/bi00833a063; Chaudhary A, 1999, PROTEIN SCI, V8, P2791; Conejero-Lara F, 1998, PROTEIN SCI, V7, P2190, DOI 10.1002/pro.5560071017; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; DAWSON KM, 1994, BIOCHEMISTRY-US, V33, P12042, DOI 10.1021/bi00206a005; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Esmon CT, 1998, NAT STRUCT BIOL, V5, P933, DOI 10.1038/2906; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNT D, 1992, LANCET, V339, P753; Lin LF, 1996, BIOCHEMISTRY-US, V35, P16879, DOI 10.1021/bi961531w; Lin LF, 2000, BIOCHEMISTRY-US, V39, P4740, DOI 10.1021/bi992028x; Loy JA, 2001, BIOCHEMISTRY-US, V40, P14686, DOI 10.1021/bi011309d; MARKUS G, 1964, J BIOL CHEM, V239, P2637; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; MORTON TA, 1995, ANAL BIOCHEM, V227, P176, DOI 10.1006/abio.1995.1268; Myszka DG, 1997, CURR OPIN BIOTECH, V8, P50, DOI 10.1016/S0958-1669(97)80157-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nihalani D, 1997, PROTEIN SCI, V6, P1284, DOI 10.1002/pro.5560060616; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Parrado J, 1996, PROTEIN SCI, V5, P693; Parry MAA, 2000, TRENDS BIOCHEM SCI, V25, P53, DOI 10.1016/S0968-0004(99)01521-2; Parry MAA, 1998, NAT STRUCT BIOL, V5, P917, DOI 10.1038/2359; RADEK JT, 1989, J BIOL CHEM, V264, P9915; ROBBINS KC, 1981, METHOD ENZYMOL, V80, P379; SHI GY, 1988, J BIOL CHEM, V263, P17071; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Wang SG, 1999, BIOCHEMISTRY-US, V38, P5232, DOI 10.1021/bi981915h; Wang XQ, 1998, SCIENCE, V281, P1662, DOI 10.1126/science.281.5383.1662; Wang XQ, 1999, FEBS LETT, V459, P85, DOI 10.1016/S0014-5793(99)01214-4; WOHL RC, 1980, J BIOL CHEM, V255, P2005; WOHL RC, 1977, J BIOL CHEM, V252, P1141; WOHL RC, 1984, BIOCHEMISTRY-US, V23, P3799, DOI 10.1021/bi00312a002; WU HL, 1990, J BIOL CHEM, V265, P19658; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110	40	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13257	13267		10.1074/jbc.M108422200	http://dx.doi.org/10.1074/jbc.M108422200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821385	hybrid			2022-12-25	WOS:000175036300096
J	Domgall, I; Venzke, D; Luttge, U; Ratajczak, R; Bottcher, B				Domgall, I; Venzke, D; Luttge, U; Ratajczak, R; Bottcher, B			Three-dimensional map of a plant V-ATPase based on electron microscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; PROTON-TRANSLOCATING ATPASE; KALANCHOE-DAIGREMONTIANA; 3-DIMENSIONAL STRUCTURE; CONFORMATIONAL-CHANGES; SUBUNIT INTERACTIONS; STATOR STRUCTURE; CDNA SEQUENCE; PROTEINS; SYNTHASE	V-ATPases pump protons into the interior of various subcellular compartments at the expense of ATP. Previous studies have shown that these pumps comprise a membrane-integrated, proton-translocating (V-0), and a soluble catalytic (V-1) subcomplex connected to one another by a thin stalk region. We present two three-dimensional maps derived from electron microscopic images of the complete V-ATPase complex from the plant Kalanchoe daigremontiana at a resolution of 2.2 nm. In the presence of a non-hydrolyzable ATP analogue, the details of the stalk region between V-0 and V-1 were revealed for the first time in their three-dimensional organization. A central stalk was surrounded by three peripheral stalks of different sizes and shapes. In the absence of the ATP analogue, the tilt of V-0 changed with respect to V-1, and the stalk region was less clearly defined, perhaps due to increased flexibility and partial detachment of some of the peripheral stalks. These structural changes corresponded to decreased stability of the complex and might be the initial step in a controlled disassembly.	EMBL, Struct & Computat Biol Program, D-69117 Heidelberg, Germany; TH Darmstadt, Inst Bot, D-64287 Darmstadt, Germany	European Molecular Biology Laboratory (EMBL); Technical University of Darmstadt	Bottcher, B (corresponding author), EMBL, Struct & Computat Biol Program, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Bottcher, Bettina/E-9397-2010	Bottcher, Bettina/0000-0002-7962-4849; Venzke, David/0000-0001-8180-9562				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ADACHI I, 1990, J BIOL CHEM, V265, P967; ARAI H, 1988, J BIOL CHEM, V263, P8796; Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; Bauerle C, 1998, PLANT PHYSIOL, V117, P859, DOI 10.1104/pp.117.3.859; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Boekema EJ, 1999, NATURE, V401, P37, DOI 10.1038/43369; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Bottcher B, 2000, J MOL BIOL, V296, P449, DOI 10.1006/jmbi.1999.3435; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; BOWMAN EJ, 1995, BBA-BIOMEMBRANES, V1237, P95, DOI 10.1016/0005-2736(95)00108-F; CARAZO JM, 1989, BIOPHYS J, V55, P465, DOI 10.1016/S0006-3495(89)82840-1; Charsky CMH, 2000, J BIOL CHEM, V275, P37232, DOI 10.1074/jbc.M006640200; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Drose S, 1997, J EXP BIOL, V200, P1; FischerSchliebs E, 1997, BIOL CHEM, V378, P1131, DOI 10.1515/bchm.1997.378.10.1131; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; Grabe M, 2000, BIOPHYS J, V78, P2798, DOI 10.1016/S0006-3495(00)76823-8; Graham LA, 2000, J EXP BIOL, V203, P61; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Gruber G, 2001, J EXP BIOL, V204, P2597; Gruber G, 2000, BIOCHEMISTRY-US, V39, P8609, DOI 10.1021/bi000103u; GUO XW, 1992, BIOPHYS J, V63, P418, DOI 10.1016/S0006-3495(92)81627-2; KANE PM, 1995, J BIOL CHEM, V270, P17025; Kane PM, 2000, J EXP BIOL, V203, P81; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; KUHLBRANDT W, 1982, ULTRAMICROSCOPY, V7, P221, DOI 10.1016/0304-3991(82)90169-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landolt-Marticorena C, 1999, J BIOL CHEM, V274, P26057, DOI 10.1074/jbc.274.37.26057; Lange BMH, 1996, J STRUCT BIOL, V117, P222, DOI 10.1006/jsbi.1996.0086; Leng XH, 1996, J BIOL CHEM, V271, P22487, DOI 10.1074/jbc.271.37.22487; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; LIN TI, 1977, ANAL BIOCHEM, V77, P10, DOI 10.1016/0003-2697(77)90284-6; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; MANDEL M, 1988, P NATL ACAD SCI USA, V85, P5521, DOI 10.1073/pnas.85.15.5521; Miura K, 2001, J BIOL CHEM, V276, P46276, DOI 10.1074/jbc.M102387200; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; NELSON H, 1995, P NATL ACAD SCI USA, V92, P497, DOI 10.1073/pnas.92.2.497; NELSON H, 1989, J BIOL CHEM, V264, P1775; Parra KJ, 1998, MOL CELL BIOL, V18, P7064, DOI 10.1128/MCB.18.12.7064; POPOV N, 1975, ACTA BIOL MED GER, V34, P1441; Powell B, 2000, J BIOL CHEM, V275, P23654, DOI 10.1074/jbc.M004440200; PUOPOLO K, 1992, J BIOL CHEM, V267, P5171; RACHEL R, 1986, ULTRAMICROSCOPY, V20, P305, DOI 10.1016/0304-3991(86)90194-4; Radermacher M, 2001, J STRUCT BIOL, V135, P26, DOI 10.1006/jsbi.2001.4395; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; RATAJCZAK R, 1994, PLANTA, V195, P226, DOI 10.1007/BF00199683; RATAJCZAK R, 2002, IN PRESS BIOL PLANTA; Sagermann M, 2001, P NATL ACAD SCI USA, V98, P7134, DOI 10.1073/pnas.131192798; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Supekova L, 1996, J EXP BIOL, V199, P1147; Svergun DI, 1998, BIOCHEMISTRY-US, V37, P17659, DOI 10.1021/bi982367a; Sze H, 1999, PLANT CELL, V11, P677, DOI 10.1105/tpc.11.4.677; TAIZ L, 1992, J EXP BIOL, V172, P113; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Ubbink-Kok T, 2000, J MOL BIOL, V296, P311, DOI 10.1006/jmbi.1999.3459; UNWIN PNT, 1975, J MOL BIOL, V94, P425, DOI 10.1016/0022-2836(75)90212-0; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; WARREN M, 1992, BIOCHIM BIOPHYS ACTA, V1106, P117, DOI 10.1016/0005-2736(92)90229-F; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Wilkens S, 2001, J BIOL CHEM, V276, P44064, DOI 10.1074/jbc.M106579200; WRIGLEY NG, 1968, J ULTRA MOL STRUCT R, V24, P454, DOI 10.1016/S0022-5320(68)80048-6; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909; Xu T, 2000, J BIOL CHEM, V275, P22075, DOI 10.1074/jbc.M002983200; ZIMNIAK L, 1988, J BIOL CHEM, V263, P9102	70	64	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13115	13121		10.1074/jbc.M112011200	http://dx.doi.org/10.1074/jbc.M112011200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815621	hybrid			2022-12-25	WOS:000175036300080
J	Mettenburg, JM; Webb, DJ; Gonias, SL				Mettenburg, JM; Webb, DJ; Gonias, SL			Distinct binding sites in the structure of alpha(2)-macroglobulin mediate the interaction with beta-amyloid peptide and growth factors.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; ALZHEIMERS-DISEASE; HUMAN ALPHA-2-MACROGLOBULIN; PRECURSOR PROTEIN; TRANSFORMING GROWTH-FACTOR-BETA-1; GENETIC ASSOCIATION; TRANSGENIC MOUSE; FAST FORMS; FACTOR-BB; A-BETA	alpha2-Macroglobulin (alpha2M) and its receptor, low density lipoprotein receptor-related protein (LRP), function together to facilitate the cellular uptake and degradation of beta-amyloid peptide (Abeta). In this study, we demonstrate that Abeta binds selectively to alpha(2)M that has been induced to undergo conformational change by reaction with methylamine. Denatured alpha(2)M subunits, which were immobilized on polyvinylidene difluoride membranes, bound Abeta, suggesting that alpha(2)M tertiary and quaternary structure are not necessary. To determine whether a specific sequence in a,M is responsible for Abeta binding, we prepared and analyzed defined a2M fragments and glutathione S-transferase-alpha(2)M peptide fusion proteins. A single sequence, centered at amino acids (aa) 1314-1365, was identified as the only major Abeta-binding site. Importantly, Abeta did not bind to the previously characterized growth factor-binding site (aa 718-734). Although the Abeta binding sequence is adjacent to the binding site for LRP, the results of experiments with mutated fusion proteins indicate that the two sites are distinct. Furthermore, a saturating concentration of Abeta did not inhibit LRP-mediated clearance of alpha(2)M-MA in mice. Using various methods, we determined that the K-D for the interaction of A,6 with its binding site in the individual alpha(2)M subunit is 0.7-2.4 gm. The capacity of alpha(2)M to bind Abeta and deliver it to LRP may be greater than that predicted by the KD, because each alpha(2)M subunit may bind Abeta and the bound Abeta may multimerize. These studies suggest a model in which alpha(2)M has three protein interaction sites with distinct specificities, mediating the interaction with Abeta, growth factors, and LRP.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu			NCI NIH HHS [CA-53462] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053462] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARRETT AJ, 1979, BIOCHEM J, V181, P401, DOI 10.1042/bj1810401; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; Chen GQ, 2000, NATURE, V408, P975, DOI 10.1038/35050103; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DESTROOPER B, 1992, FEBS LETT, V308, P50, DOI 10.1016/0014-5793(92)81048-Q; Dodel RC, 2000, NEUROLOGY, V54, P438, DOI 10.1212/WNL.54.2.438; Du YS, 1997, J NEUROCHEM, V69, P299; Fabrizi C, 1999, EXP NEUROL, V155, P252, DOI 10.1006/exnr.1998.6978; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Gibson AM, 2000, NEUROLOGY, V54, P433, DOI 10.1212/WNL.54.2.433; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; GONIAS SL, 1982, BIOCHIM BIOPHYS ACTA, V705, P306, DOI 10.1016/0167-4838(82)90252-7; Gonias SL, 2000, J BIOL CHEM, V275, P5826, DOI 10.1074/jbc.275.8.5826; HALL SW, 1991, J BIOL CHEM, V266, P12329; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; HARPEL PC, 1979, J BIOL CHEM, V254, P8669; HERZ J, 1991, J BIOL CHEM, V266, P21232; Howard GC, 1996, J BIOL CHEM, V271, P14105, DOI 10.1074/jbc.271.24.14105; Huang W, 2000, J BIOL CHEM, V275, P1089, DOI 10.1074/jbc.275.2.1089; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; HUSSAINI IM, 1990, BIOCHEM J, V270, P291, DOI 10.1042/bj2700291; Hyman BT, 2000, ARCH NEUROL-CHICAGO, V57, P646, DOI 10.1001/archneur.57.5.646; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Jenner L, 1998, STRUCTURE, V6, P595, DOI 10.1016/S0969-2126(98)00061-6; Jhoo JH, 2001, J NEUROL SCI, V184, P21, DOI 10.1016/S0022-510X(00)00494-9; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kim ES, 1998, MOL BRAIN RES, V62, P122, DOI 10.1016/S0169-328X(98)00217-4; Koster MN, 2000, NEUROLOGY, V55, P678, DOI 10.1212/WNL.55.5.678; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Liao A, 1998, HUM MOL GENET, V7, P1953, DOI 10.1093/hmg/7.12.1953; LYSIAK JJ, 1995, J BIOL CHEM, V270, P21919, DOI 10.1074/jbc.270.37.21919; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Myllykangas L, 1999, ANN NEUROL, V46, P382; Narita M, 1997, J NEUROCHEM, V69, P1904; Nielsen KL, 1996, J BIOL CHEM, V271, P12909, DOI 10.1074/jbc.271.22.12909; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIZZO SV, 1984, RECEPTORS, V1, P177; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Shibata M, 2000, J CLIN INVEST, V106, P1489, DOI 10.1172/JCI10498; SISODIA SS, 1995, FASEB J, V9, P366, DOI 10.1096/fasebj.9.5.7896005; Sottrup-Jensen L, 1987, PLASMA PROTEINS STRU, V5, P192; SOTTRUPJENSEN L, 1980, FEBS LETT, V121, P275, DOI 10.1016/0014-5793(80)80361-9; SOTTRUPJENSEN L, 1989, J BIOL CHEM, V264, P15781; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; SWENSON RP, 1980, J BIOL CHEM, V255, P8087; Terai K, 2001, BRAIN RES, V900, P48, DOI 10.1016/S0006-8993(01)02202-8; Tucker HM, 2000, J NEUROSCI, V20, P3937; Ulery PG, 2000, J CLIN INVEST, V106, P1077, DOI 10.1172/JCI11455; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; VANGOOL D, 1993, NEUROBIOL AGING, V14, P233, DOI 10.1016/0197-4580(93)90006-W; VANLEUVEN F, 1981, J BIOL CHEM, V256, P9016; Weaver AM, 1995, J BIOL CHEM, V270, P30741, DOI 10.1074/jbc.270.51.30741; Webb DJ, 2000, PROTEIN SCI, V9, P1986, DOI 10.1110/ps.9.10.1986; Webb DJ, 1998, J BIOL CHEM, V273, P13339, DOI 10.1074/jbc.273.21.13339; WOLF BB, 1994, BIOCHEMISTRY-US, V33, P11270, DOI 10.1021/bi00203a024; WYSECORAY T, 2001, NAT MED, V7, P612	65	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13338	13345		10.1074/jbc.M106792200	http://dx.doi.org/10.1074/jbc.M106792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823454	hybrid			2022-12-25	WOS:000175036300105
J	Perry, K; Mondragon, A				Perry, K; Mondragon, A			Biochemical characterization of an invariant histidine involved in Escherichia coli DNA topoisomerase I catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; CLEAVAGE; MUTAGENESIS; AFFINITY; RESIDUES; FRAGMENT; MG(II)	An invariant histidine residue, His-365 in Escherichia coli DNA topoisomerase I, is located at the active site of type IA DNA topoisomerases and near the active site tyrosine. Its ability to participate in the multistep catalytic process of DNA relaxation was investigated. His-365 was mutated to alanine, arginine, asparagine, aspartate, glutamate, and glutamine to study its ability to participate in general acid/base catalysis and bind DNA. The mutants were examined for pH-dependent DNA relaxation and cleavage, salt-dependent DNA relaxation, and salt-dependent DNA binding affinity. The mutants relax DNA in a pH-dependent manner and at low salt concentrations. The pH dependence of all mutants is different from the wild type, suggesting that His-365 is responsible for the pH dependence of the enzyme. Additionally, whereas the wild type enzyme shows pH-dependent oligonuelcotide cleavage, cleavage by both H365Q and H365A is pH-independent. H365Q cleaves DNA with rates similar to the wild type enzyme, whereas H365A has a slower rate of DNA cleavage than the wild type but can cleave more substrate overall. H365A also has a lower DNA binding affinity than the wild type enzyme. The binding affinity was determined at different salt concentrations, showing that the alanine mutant displaces half a charge less upon binding DNA than an inactive form of topoisomerase I. These observations indicate that His-365 participates in DNA binding and is responsible for optimal catalysis at physiological pH.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.			Perry, Kay/0000-0002-4046-1704	NIGMS NIH HHS [GM 51350, R01 GM051350] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051350] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahumada A, 1998, BIOCHEM BIOPH RES CO, V251, P509, DOI 10.1006/bbrc.1998.9500; BENSON N, 1997, FOC FLUOR S IND APPL; BERANSTEED RK, 1989, PROTEINS, V6, P249, DOI 10.1002/prot.340060307; BLOOMFIELD VA, 2000, NUCL ACIDS STRUCTURE, P488; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Changela A, 2001, NATURE, V411, P1077, DOI 10.1038/35082615; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; DOMANICO PL, 1988, BIOCHEMISTRY-US, V27, P6365, DOI 10.1021/bi00417a026; Feinberg H, 1999, NAT STRUCT BIOL, V6, P961; GODSON GN, 1967, BIOCHIM BIOPHYS ACTA, V149, P476, DOI 10.1016/0005-2787(67)90175-X; Grishin NV, 2000, J MOL BIOL, V299, P1165, DOI 10.1006/jmbi.2000.3841; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; LIMA CD, 1993, J MOL BIOL, V232, P1213, DOI 10.1006/jmbi.1993.1474; MANNING GS, 1978, Q REV BIOPHYS, V11, P179, DOI 10.1017/S0033583500002031; MASCOTTI DP, 1990, P NATL ACAD SCI USA, V87, P3142, DOI 10.1073/pnas.87.8.3142; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; Record M T Jr, 1985, Adv Biophys, V20, P109; Roche CJ, 2001, INT J BIOL MACROMOL, V29, P175, DOI 10.1016/S0141-8130(01)00165-9; SAMBROOK J, 1989, MOL CLONONG LAB MANU; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P327, DOI 10.1021/bi00167a043; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tse-Dinh Y C, 1994, Adv Pharmacol, V29A, P21; TSEDINH YC, 1983, NUCLEIC ACIDS RES, V11, P8691, DOI 10.1093/nar/11.24.8691; TSEDINH YC, 1986, J BIOL CHEM, V261, P931; TSEDINH YC, 1986, J MOL BIOL, V191, P321, DOI 10.1016/0022-2836(86)90129-4; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; YU LP, 1995, BIOCHEMISTRY-US, V34, P7622, DOI 10.1021/bi00023a008; Zhang HL, 1996, J BIOL CHEM, V271, P9039, DOI 10.1074/jbc.271.15.9039; Zhu CX, 1997, J BIOL CHEM, V272, P16206, DOI 10.1074/jbc.272.26.16206; Zhu CX, 2000, J BIOL CHEM, V275, P5318, DOI 10.1074/jbc.275.8.5318; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783; ZUMSTEIN L, 1986, J MOL BIOL, V191, P333, DOI 10.1016/0022-2836(86)90130-0	35	24	24	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13237	13245		10.1074/jbc.M112019200	http://dx.doi.org/10.1074/jbc.M112019200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809772	hybrid			2022-12-25	WOS:000175036300094
J	Suzuki, T; Ueno, H; Mitome, N; Suzuki, J; Yoshida, M				Suzuki, T; Ueno, H; Mitome, N; Suzuki, J; Yoshida, M			F-0 of ATP synthase is a rotary proton channel. Obligatory coupling of proton translocation with rotation of c-subunit ring.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; THERMOPHILIC BACTERIUM; ADENOSINE-TRIPHOSPHATASE; CROSS-LINKING; GAMMA-SUBUNIT; MECHANISM; MOTOR; PURIFICATION; MUTAGENESIS; F0F1-ATPASE	Coupling of proton flow and rotation in the F-0 motor of ATP synthase was investigated using the thermophilic Bacillus PS3 enzyme expressed functionally in Escherichia coli cells. Cysteine residues introduced into the N-terminal regions of subunits b and c of ATP synthase (bL2C/cS2C) were readily oxidized by treating the expressing cells with CuCl2 to form predominantly a b-c cross-link with b-b and c-c cross-links being minor products. The oxidized ATP synthases, either in the inverted membrane vesicles or in the reconstituted proteoliposomes, showed drastically decreased proton pumping and ATPase activities compared with the reduced ones. Also, the oxidized F-0, either in the F-1-stripped inverted vesicles or in the reconstituted F-0-proteoliposomes, hardly mediated passive proton translocation through F-0. Careful analysis using single mutants (bL2C or cS2C) as controls indicated that the b-c cross-link was responsible for these defects. Thus, rotation of the c-oligomer ring relative to subunit b is obligatory for proton translocation; if there is no rotation of the c-ring there is no proton flow through F-0.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, ERATO, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Nagatsuta 4259, Yokohama, Kanagawa 2268503, Japan.							Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Cross RL, 2000, BBA-BIOENERGETICS, V1458, P270, DOI 10.1016/S0005-2728(00)00079-7; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, EMBO J, V17, P5887, DOI 10.1093/emboj/17.20.5887; Kaim G, 1998, FEBS LETT, V434, P57, DOI 10.1016/S0014-5793(98)00969-7; Ko YH, 1999, J BIOL CHEM, V274, P28853, DOI 10.1074/jbc.274.41.28853; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; OHTA S, 1988, BIOCHIM BIOPHYS ACTA, V933, P141, DOI 10.1016/0005-2728(88)90064-3; OKAMOTO H, 1977, J BIOL CHEM, V252, P6125; Ren HM, 2000, BBA-BIOENERGETICS, V1458, P221, DOI 10.1016/S0005-2728(00)00075-X; Sambrook J., 2002, MOL CLONING LAB MANU; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Seelert H, 2000, NATURE, V405, P418, DOI 10.1038/35013148; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; SONE N, 1975, J BIOL CHEM, V250, P7917; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P898, DOI 10.1073/pnas.031564198; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509; YOSHIDA M, 1975, J BIOL CHEM, V250, P7910	35	71	74	3	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13281	13285		10.1074/jbc.M111210200	http://dx.doi.org/10.1074/jbc.M111210200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815616	hybrid			2022-12-25	WOS:000175036300098
J	Ahn, BH; Rhim, H; Kim, SY; Sung, YM; Lee, MY; Choi, JY; Wolozin, B; Chang, JS; Lee, YH; Kwon, TK; Chung, KC; Yoon, SH; Hahn, SJ; Kim, MS; Jo, YH; Min, DS				Ahn, BH; Rhim, H; Kim, SY; Sung, YM; Lee, MY; Choi, JY; Wolozin, B; Chang, JS; Lee, YH; Kwon, TK; Chung, KC; Yoon, SH; Hahn, SJ; Kim, MS; Jo, YH; Min, DS			A-synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; TYROSINE-PHOSPHORYLATION; PARKINSONS-DISEASE; LEWY BODIES; BINDING; FAMILY; INCLUSIONS	alpha-Synuclein has been implicated in the pathogenesis of many neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease. Although the function of alpha-synuclein remains largely unknown, recent studies have demonstrated that this protein can interact with phospholipids. To address the role of alpha-synuclein in neurodegenerative disease, we have investigated whether it binds phospholipase D (PLD) and affects PLD activity in human embryonic kidney (HEK)-293 cells overexpressing wild type -synuclein or the mutant forms of alpha-synuclein (A53T, A30P) associated with Parkinson's disease. Tyrosine phosphorylation of alpha-synuclein appears to play a modulatory role in the inhibition of PLD, because mutation of Tyr(125) to Phe slightly increases inhibitory effect of alpha-synuclein on PLD activity. Treatment with pervanadate or phorbol myristate acetate inhibits PLD more in HEK 293 cells overexpressing alpha-synuclein than in control cells. Binding of alpha-synuclein to PLD requires phox and pleckstrin homology domain of PLD and the amphipathic repeat region and non-Abeta component of alpha-synuclein. Although biologically important, co-transfection studies indicate that the interaction of alpha-synuclein with PLD does not influence the tendency of alpha-synuclein to form pathological inclusions. These results suggest that the association of alpha-synuclein with PLD, and modulation of PLD activity, is biologically important, but PLD does not appear to play an essential role in the pathophysiology of alpha-synuclein.	Catholic Univ, Coll Med, Dept Physiol, Seoul 137701, South Korea; Catholic Univ, Coll Med, Res Inst Mol Genet, Seoul 137701, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea; Loyola Univ, Med Ctr, Dept Pharmacol, Maywood, IL 60153 USA; Daejin Univ, Dept Life Sci, Kyeongggido 487800, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Keimyung Univ, Sch Med, Dept Immunol, Taegu 700712, South Korea; Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea	Catholic University of Korea; Catholic University of Korea; Korea University; Loyola University Chicago; Daejin University; Yeungnam University; Keimyung University; Yonsei University; Yonsei University Health System	Min, DS (corresponding author), Catholic Univ, Coll Med, Dept Physiol, Seoul 137701, South Korea.	dsmin@cmc.cuk.ac.kr						Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; DAVID LS, 1998, CELLS LAB MANUAL; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; de Silva HA, 2000, CURR OPIN GENET DEV, V10, P292; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Dickson DW, 2001, CURR OPIN NEUROL, V14, P423, DOI 10.1097/00019052-200108000-00001; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Ghee M, 2000, J NEUROCHEM, V75, P2221, DOI 10.1046/j.1471-4159.2000.0752221.x; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gurd JW, 1997, NEUROCHEM INT, V31, P635, DOI 10.1016/S0197-0186(97)00022-3; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Kanfer JN, 1996, J LIPID MEDIAT CELL, V14, P361, DOI 10.1016/0929-7855(96)00545-7; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; KLEIN J, 1995, J NEUROCHEM, V65, P1445; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Le Stunff H, 2000, J PHARMACOL EXP THER, V292, P629; Lee C, 2000, J BIOL CHEM, V275, P18751, DOI 10.1074/jbc.M001695200; Lee MY, 2000, BRAIN RES, V864, P52, DOI 10.1016/S0006-8993(00)02134-X; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Min DS, 1998, J BIOL CHEM, V273, P7044, DOI 10.1074/jbc.273.12.7044; Min DS, 2001, NEUROPHARMACOLOGY, V41, P384, DOI 10.1016/S0028-3908(01)00070-3; Min DS, 1998, J BIOL CHEM, V273, P29986, DOI 10.1074/jbc.273.45.29986; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rumenapp U, 1998, BIOCHEM J, V334, P625; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Vitale N, 2001, EMBO J, V20, P2424, DOI 10.1093/emboj/20.10.2424; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513	49	106	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12334	12342		10.1074/jbc.M110414200	http://dx.doi.org/10.1074/jbc.M110414200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821392	hybrid, Green Published			2022-12-25	WOS:000174846400096
J	Piatelli, MJ; Doughty, C; Chiles, TC				Piatelli, MJ; Doughty, C; Chiles, TC			Requirement for a hsp90 chaperone-dependent MEK1/2-ERK pathway for B cell antigen receptor-induced cyclin D2 expression in mature B lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; RETINOBLASTOMA PROTEIN; TYROSINE KINASES; ACTIVATION; INDUCTION; D1; RAF-1; DESTABILIZATION; PHOSPHORYLATION; PROLIFERATION	A requirement for cyclin D2 in G(1)-to-S phase progression has been definitively established in mature B cells stimulated via the B cell antigen receptor (BCR). However, the identity of constituents of the BCR signaling cascade that leads to cyclin D2 accumulation remains incomplete. We report that inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1/2 blocked BCR-induced activation of extracellular signal-regulated kinase (ERK). Inhibition of the MEK1/2-ERK pathway was sufficient to abrogate BCR-induced cyclin D2 expression at the mRNA and protein levels. Disruption of endogenous heat shock protein 90 (hsp90) function with geldanamycin abrogated BCR-induced cyclin D2 expression and proliferation. Geldanamycin effects were attributed to a selective depletion of cellular Raf-1 that interrupted BCR-coupled activation of MEK1/2 and ERK. By contrast, signaling through the phosphatidylinositol 3-kinase and protein kinase C pathways was not affected, suggesting that disruption of hsp90 function did not cause a general impairment of BCR signaling. These results suggest that the MEK1/2-ERK pathway is essential for BCR signaling to cyclin D2 accumulation in ex vivo splenic B lymphocytes. Furthermore, these findings imply that hsp90 function is required for BCR signaling through the Raf1-MEK1/2-ERK pathway but not through the phosphatidylinositol 3-kinase- or protein kinase C-dependent pathways.	Boston Coll, Dept Biol, Chestnut Hill, MA 02467 USA	Boston College	Chiles, TC (corresponding author), Boston Coll, Dept Biol, 414 Higgins Hall, Chestnut Hill, MA 02467 USA.	ChilesT@bc.edu			NIAID NIH HHS [AI34586, AI49994] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034586, R01AI049994, R29AI034586, R21AI049994] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Banerji L, 2001, ONCOGENE, V20, P7352, DOI 10.1038/sj.onc.1204951; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boylan JF, 1999, EXP CELL RES, V248, P110, DOI 10.1006/excr.1999.4389; Brorson K, 1997, J IMMUNOL, V159, P135; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; Chavany C, 1996, J BIOL CHEM, V271, P4974; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Dey A, 2000, MOL BIOL CELL, V11, P3835, DOI 10.1091/mbc.11.11.3835; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Forssell J, 1999, SCAND J IMMUNOL, V49, P155; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Gold MR, 1999, J IMMUNOL, V163, P1894; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HUO L, 1995, J IMMUNOL, V154, P3300; Jiang A, 1998, J EXP MED, V188, P1297, DOI 10.1084/jem.188.7.1297; Jun DY, 1997, MOL CELLS, V7, P537; Lee H, 1995, Curr Top Microbiol Immunol, V194, P247; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Reid S, 1996, MOL IMMUNOL, V33, P1139, DOI 10.1016/S0161-5890(96)00065-X; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Richards JD, 2001, J IMMUNOL, V166, P3855, DOI 10.4049/jimmunol.166.6.3855; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SEFTON BM, 1994, CURR OPIN IMMUNOL, V6, P372, DOI 10.1016/0952-7915(94)90115-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Solvason N, 2000, INT IMMUNOL, V12, P631, DOI 10.1093/intimm/12.5.631; Solvason N, 1996, J EXP MED, V184, P407, DOI 10.1084/jem.184.2.407; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Sutherland CL, 1996, J IMMUNOL, V157, P3381; Tan JEL, 2001, J BIOL CHEM, V276, P20055, DOI 10.1074/jbc.M010800200; Tanguay DA, 1996, J IMMUNOL, V156, P539; Tanguay DA, 1999, J EXP MED, V189, P1685, DOI 10.1084/jem.189.11.1685; Tomlinson M G, 2001, BMC Immunol, V2, P4, DOI 10.1186/1471-2172-2-4; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wu HJ, 2001, J IMMUNOL, V167, P1263, DOI 10.4049/jimmunol.167.3.1263; XIE HJ, 1995, J IMMUNOL, V154, P1717; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	54	59	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12144	12150		10.1074/jbc.M200102200	http://dx.doi.org/10.1074/jbc.M200102200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11823472	hybrid			2022-12-25	WOS:000174846400071
J	Schirmer, J; Just, I; Aktories, K				Schirmer, J; Just, I; Aktories, K			The ADP-ribosylating mosquitocidal toxin from Bacillus sphaericus - Proteolytic activation, enzyme activity, and cytotoxic effects	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NAD-BINDING-SITE; AERUGINOSA EXOENZYME S; DIPHTHERIA-TOXIN; CATALYTIC SITE; RIBOSYLTRANSFERASE; IDENTIFICATION; RESIDUE; PROTEIN; MECHANISMS; CLONING	The mosquitocidal toxin (MTX) from Bacillus sphaericus SSII-1 is a similar to97-kDa protein sharing sequence homology within the N terminus with the catalytic domains of various bacterial ADP-ribosyltransferases. Here we studied the proteolytic activation of the ADP-ribosyltransferase activity of MTX. Chymotrypsin treatment of the 97-kDa AM holotoxin (MTX30-870) results in a 70-kDa putative binding component (MTX265-870) and a 27-kDa enzyme component (MTX30-264), possessing ADP-ribosyltransferase activity. Chymotryptic cleavage of an N-terminal 32-kDa fragment of MTX (MTV30-308) also yields MTX30-264, but the resulting ADP-ribosyltransferase activity is much greater than that of the processed MTX30-870. Kinetic studies revealed a K-m NAD value of 45 mum for the processed 32-kDa MTX fragment, and a K-m NAD value of 1300 mum for the processed holotoxin. Moreover, the k(cat) value for the activated MTX30-308 fragment was about 10-fold higher than that for the activated holotoxin (MTX30-870). Precipitation analysis showed that the 70-kDa proteolytic fragment of MTX remains noncovalently bound to the N-terminal 27-kDa fragment, thereby inhibiting ADP-ribosyltransferase and NAD glycohydrolase activities. Glu(197) of MTX30-264 was identified as the "catalytic" glutamate that is conserved in all ADP-ribosyltransferases. Whereas mutated MTX(30-264)E197Q has neither ADP-ribosyltransferase nor NAD glycohydrolase activity, mutated MTX(30-264)E195Q possesses glycohydrolase activity but not transferase activity. Transfection of HeLa cells with a vector encoding a fusion protein of MTX30-264 with a green fluorescent protein led to cytotoxic effects characterized by cell rounding and formation of filopodia-like protrusions. These cytotoxic effects were not observed with the catalytically inactive MTX(30-264)E197Q mutant, indicating that the MTX enzyme activity is essential for the cytotoxicity in mammalian cells.	Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany	University of Freiburg	Aktories, K (corresponding author), Univ Freiburg, Inst Expt & Klin Pharmakol & Toxikol, Albertstr 25, D-79104 Freiburg, Germany.	aktories@uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022	Aktories, Klaus/0000-0002-5397-0436				AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; BLANKE SR, 1994, BIOCHEMISTRY-US, V33, P5155, DOI 10.1021/bi00183a019; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CARROLL SF, 1984, P NATL ACAD SCI-BIOL, V81, P3307, DOI 10.1073/pnas.81.11.3307; COBURN J, 1989, J BIOL CHEM, V264, P9004; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; DOMENIGHINI M, 1994, MOL MICROBIOL, V14, P41, DOI 10.1111/j.1365-2958.1994.tb01265.x; DOMENIGHINI M, 1995, BACTERIAL TOXINS VIR, P59; Ganesan AK, 1998, J BIOL CHEM, V273, P7332, DOI 10.1074/jbc.273.13.7332; JUNG M, 1993, J BIOL CHEM, V268, P23215; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu SY, 1996, BIOCHEMISTRY-US, V35, P2754, DOI 10.1021/bi952340g; LOCHT C, 1997, BACTERIAL TOXINS TOO, P33; MASIGNANI V, 2000, BACTERIAL PROTEIN TO; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; Radke J, 1999, INFECT IMMUN, V67, P1508, DOI 10.1128/IAI.67.3.1508-1510.1999; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TAKADA T, 1995, J BIOL CHEM, V270, P541, DOI 10.1074/jbc.270.2.541; THANABALU T, 1993, J BACTERIOL, V175, P2314, DOI 10.1128/JB.175.8.2314-2320.1993; THANABALU T, 1991, J BACTERIOL, V173, P2776, DOI 10.1128/JB.173.9.2776-2785.1991; THANABALU T, 1992, J BACTERIOL, V174, P5051, DOI 10.1128/JB.174.15.5051-5056.1992; Van den Akker F, 2000, HANDB EXP PHARM, V145, P109; Watanabe M, 1999, P NATL ACAD SCI USA, V96, P10608, DOI 10.1073/pnas.96.19.10608	27	31	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11941	11948	PII 10.1074/jbc.M108463200	10.1074/jbc.M108463200	http://dx.doi.org/10.1074/jbc.M108463200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812773	hybrid			2022-12-25	WOS:000174846400045
J	Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Gao, SJ				Wang, XP; Zhang, YJ; Deng, JH; Pan, HY; Zhou, FC; Gao, SJ			Transcriptional regulation of Kaposi's sarcoma-associated herpesvirus-encoded oncogene viral interferon regulatory factor by a novel transcriptional silencer, Tis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICENTRIC CASTLEMANS DISEASE; CAVITY-BASED LYMPHOMA; DNA-SEQUENCES; GENE-TRANSCRIPTION; NUCLEOTIDE-SEQUENCE; NEGATIVE REGULATION; REPRESSION; ELEMENTS; IRF-1; KSHV	Viral interferon regulatory factor (vIRF) encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) has been shown to transform NIH3T3 and Rat-1 cells, inhibit interferon signal transduction, and regulate the expression of KSHV genes. We had previously characterized the vIRF core promoter and defined a 12-O-tetradecanoylphorbol-13-acetate (TPA)-responsive region in the upstream regulatory sequence of vIRF gene. Here, we have further identified a novel transcriptional silencer, named Tis in this region. Tis represses the promoter activities of vIRF and heterologous herpes simplex virus thymidine kinase genes in both position- and orientation-independent manners. Deletion analysis has identified a cis-element of 23 nucleotides that is essential for the negative regulation. Two Tis-binding protein complexes, named vR1 and vR2, were observed by electrophoretic mobility shift assays using nuclear extracts from both KSHV-negative and -positive cell lines. A sequence fragment GAGTTAATAGGTAGAG in the cis-element was shown to be required for the DNA-protein interactions as well as the repression of vIRF promoter activity. Point-mutation analysis identified TTAAT and GTTAATAG as the core sequence motifs for the binding of vR1 and vR2, respectively. These results define the function of a novel transcriptional silencer in the regulation of vIRF gene expression.	Univ Texas, Hlth Sci Ctr, Dept Pediat, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Gao, SJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.		Gao, Shou-Jiang/B-8641-2012	Gao, Shou-Jiang/0000-0001-6194-1742	NHLBI NIH HHS [HL60604-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060604] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antalis TM, 1996, BLOOD, V88, P3686, DOI 10.1182/blood.V88.10.3686.bloodjournal88103686; Avisar N, 1999, J BIOL CHEM, V274, P11399, DOI 10.1074/jbc.274.16.11399; Beier F, 1997, J CELL BIOCHEM, V66, P210, DOI 10.1002/(SICI)1097-4644(19970801)66:2<210::AID-JCB8>3.0.CO;2-T; BOSHOFF C, 1995, LANCET, V345, P1043; Brabletz T, 1999, INT IMMUNOL, V11, P1701, DOI 10.1093/intimm/11.10.1701; Burysek L, 1999, J VIROL, V73, P7334; Carbone A, 1996, BRIT J HAEMATOL, V94, P533, DOI 10.1046/j.1365-2141.1996.d01-1826.x; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHADBURN A, 1996, LAB INVEST, V74, pA109; Chang MS, 1999, BIOCHEM J, V339, P335, DOI 10.1042/0264-6021:3390335; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; Chen JG, 2000, J VIROL, V74, P8623, DOI 10.1128/JVI.74.18.8623-8634.2000; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; Gao SJ, 1997, ONCOGENE, V15, P1979, DOI 10.1038/sj.onc.1201571; Gessain A, 1996, BLOOD, V87, P414; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; Inagi R, 1999, J HUMAN VIROL, V2, P63; KARCHER DS, 1995, NEW ENGL J MED, V333, P797; Kieff E, 1998, SEMIN VIROL, V8, P471, DOI 10.1006/smvy.1998.0151; LATCHMAN DS, 1999, TRANSCRIPTION FR 201, V201; LATCHMAN DS, 1998, EUKARYOTIC TRANSCRIP; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li MT, 1998, J VIROL, V72, P5433, DOI 10.1128/JVI.72.7.5433-5440.1998; Liu B, 1996, J BIOL CHEM, V271, P26281, DOI 10.1074/jbc.271.42.26281; Lupo A, 1997, J BIOL CHEM, V272, P31641, DOI 10.1074/jbc.272.50.31641; Moffat GJ, 1996, J BIOL CHEM, V271, P20740, DOI 10.1074/jbc.271.34.20740; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; NADOR RG, 1995, NEW ENGL J MED, V333, P943, DOI 10.1056/NEJM199510053331417; Nakamura H, 2001, J VIROL, V75, P7572, DOI 10.1128/JVI.75.16.7572-7582.2001; NGUYEN H, 1995, ONCOGENE, V11, P537; Ogbourne S, 1998, BIOCHEM J, V331, P1; PASTORE C, 1995, BRIT J HAEMATOL, V91, P918, DOI 10.1111/j.1365-2141.1995.tb05410.x; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; Roan F, 1999, J GEN VIROL, V80, P2205, DOI 10.1099/0022-1317-80-8-2205; Russo JJ, 1996, P NATL ACAD SCI USA, V93, P14862, DOI 10.1073/pnas.93.25.14862; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; SCHALLING M, 1995, NAT MED, V1, P707, DOI 10.1038/nm0795-707; Seo T, 2000, BIOCHEM BIOPH RES CO, V270, P23, DOI 10.1006/bbrc.2000.2393; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; TANIGUCHI T, 1995, INDIAN J BIOCHEM BIO, V32, P235; Taniguchi T, 1998, EUR CYTOKINE NETW, V9, P43; Wang XP, 2001, ONCOGENE, V20, P523, DOI 10.1038/sj.onc.1204115; Zimring JC, 1998, J VIROL, V72, P701, DOI 10.1128/JVI.72.1.701-707.1998	54	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12023	12031		10.1074/jbc.M108026200	http://dx.doi.org/10.1074/jbc.M108026200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821384	hybrid			2022-12-25	WOS:000174846400056
J	Haigis, MC; Kurten, EL; Abel, RL; Raines, RT				Haigis, MC; Kurten, EL; Abel, RL; Raines, RT			KFERQ sequence in ribonuclease A-mediated cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ACTIVITY; P-30 PROTEIN; CONFORMATIONAL STABILITY; MOLECULAR DETERMINANTS; AMPHIBIAN RIBONUCLEASE; WILD-TYPE; INHIBITOR; BINDING; ANGIOGENIN; ENZYME	Onconase(R) (ONC) is an amphibian ribonuelease that is in clinical trials as a cancer chemotherapeutic agent. ONC is a homolog of ribonuclease A (RNase A). RNase A can be made toxic to cancer cells by replacing Gly(88) with an arginine residue, thereby enabling the enzyme to evade the endogenous cytosolic ribonuclease inhibitor protein (RI). Unlike ONC, RNase A contains a KFERQ sequence (residues 7-11), which signals for lysosomal degradation. Here, substitution of Arg(10) of the KFERQ sequence has no effect on either the cytotoxicity of G88R RNase A or its affinity for RI In contrast, K7A/G88R RNase A is nearly 10-fold more cytotoxic than G88R RNase A and has more than 10-fold less affinity for RI. Up-regulation of the KFERQ-mediated lysosomal degradation pathway has no effect on the cytotoxicity of these ribonucleases. Thus, KFERQ-mediated degradation does not limit the cytotoxicity of RNase A variants. Moreover, only two amino acid substitutions (K7A and G88R) are shown to endow RNase A with cytotoxic activity that is nearly equal to that of ONC.	Univ Wisconsin, Dept Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Raines, RT (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53705 USA.		Raines, Ronald T./A-5009-2013	Raines, Ronald T./0000-0001-7164-1719	NATIONAL CANCER INSTITUTE [R01CA073808] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008293] Funding Source: NIH RePORTER; NCI NIH HHS [CA73808] Funding Source: Medline; NIGMS NIH HHS [T32 GM08293] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agarraberes FA, 1997, J CELL BIOL, V137, P825, DOI 10.1083/jcb.137.4.825; ARDELT W, 1991, J BIOL CHEM, V266, P245; BLACKBURN P, 1977, J BIOL CHEM, V252, P5904; BOIX E, 1994, J BIOL CHEM, V269, P2529; Boix E, 1996, J MOL BIOL, V257, P992, DOI 10.1006/jmbi.1996.0218; Bretscher LE, 2000, J BIOL CHEM, V275, P9893, DOI 10.1074/jbc.275.14.9893; Cuervo AM, 1998, J MOL MED-JMM, V76, P6, DOI 10.1007/s109-1998-8099-y; DARZYNKIEWICZ Z, 1988, CELL TISSUE KINET, V21, P169, DOI 10.1111/j.1365-2184.1988.tb00855.x; DELCARDAYRE SB, 1995, ANAL BIOCHEM, V225, P176, DOI 10.1006/abio.1995.1132; DELCARDAYRE SB, 1995, PROTEIN ENG, V8, P261, DOI 10.1093/protein/8.3.261; DICE JF, 1990, TRENDS BIOCHEM SCI, V15, P305, DOI 10.1016/0968-0004(90)90019-8; DICE JF, 1988, J PROTEIN CHEM, V7, P115, DOI 10.1007/BF01025241; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; DICE JF, 1986, J BIOL CHEM, V261, P6853; DUNN BM, 1975, J MOL BIOL, V95, P497, DOI 10.1016/0022-2836(75)90313-7; Eberhardt ES, 1996, PROTEIN SCI, V5, P1697, DOI 10.1002/pro.5560050823; Fisher BM, 1998, BIOCHEMISTRY-US, V37, P12121, DOI 10.1021/bi980743l; Irie M, 1998, CELL MOL LIFE SCI, V54, P775, DOI 10.1007/s000180050206; Kelemen BR, 1999, NUCLEIC ACIDS RES, V27, P3696, DOI 10.1093/nar/27.18.3696; KIM JS, 1995, BIOCHEM J, V308, P547, DOI 10.1042/bj3080547; Klink TA, 2001, PROTEIN EXPRES PURIF, V22, P174, DOI 10.1006/prep.2001.1422; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; Kothandaraman S, 1998, VIROLOGY, V251, P264, DOI 10.1006/viro.1998.9434; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE FS, 1989, BIOCHEMISTRY-US, V28, P225, DOI 10.1021/bi00427a031; LEE FS, 1989, BIOCHEMISTRY-US, V28, P3556, DOI 10.1021/bi00434a061; Leland PA, 1998, P NATL ACAD SCI USA, V95, P10407, DOI 10.1073/pnas.95.18.10407; Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8; Leland PA, 2000, FEBS LETT, V477, P203, DOI 10.1016/S0014-5793(00)01804-4; Matousek J, 2001, COMP BIOCHEM PHYS C, V129, P175, DOI 10.1016/S1532-0456(01)90202-9; MCELLIGOTT MA, 1985, J BIOL CHEM, V260, P1986; MESSMORE JM, 1995, J AM CHEM SOC, V117, P8057, DOI 10.1021/ja00136a001; MIKULSKI SM, 1995, INT J ONCOL, V6, P889; MIKULSKI SM, 1993, INT J ONCOL, V3, P57; Mikulski SM, 1998, INT J ONCOL, V13, P633; MOSIMANN SC, 1994, J MOL BIOL, V236, P1141, DOI 10.1016/0022-2836(94)90017-5; NEUMANN U, 1994, PROTEIN SCI, V3, P248; NOGUES MV, 1995, BBA-PROTEIN STRUCT M, V1253, P16, DOI 10.1016/0167-4838(95)00138-K; Quirk DJ, 1998, BIOCHEMISTRY-US, V37, P17958, DOI 10.1021/bi981688j; Rybak SM, 1999, EXP CELL RES, V253, P325, DOI 10.1006/excr.1999.4718; SAXENA SK, 1991, J BIOL CHEM, V266, P21208; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SCOFFONE E, 1967, J AM CHEM SOC, V89, P5450, DOI 10.1021/ja00997a028; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; Shapiro R, 2000, J MOL BIOL, V302, P497, DOI 10.1006/jmbi.2000.4075; Vasandani VM, 1996, CANCER RES, V56, P4180; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WU YN, 1995, J BIOL CHEM, V270, P17476, DOI 10.1074/jbc.270.29.17476; WU YN, 1993, J BIOL CHEM, V268, P10686; Youle R. J., 1997, RIBONUCLEASES STRUCT, P491	51	34	39	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11576	11581		10.1074/jbc.M112227200	http://dx.doi.org/10.1074/jbc.M112227200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11801605	hybrid			2022-12-25	WOS:000174613100105
J	Ma, HP; Saxena, S; Warnock, DG				Ma, HP; Saxena, S; Warnock, DG			Anionic phospholipids regulate native and expressed epithelial sodium channel (ENaC)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNELS; POTASSIUM CHANNELS; PIP2; ALDOSTERONE; SENSITIVITY; MECHANISMS; TRANSPORT; SUBUNITS; CLONING; CELLS	Using patch clamp techniques, we found that the epithelial sodium channel (ENaC) activity in the apical membrane of A6 distal nephron cells showed a sudden rundown beginning at 4 min after forming the inside-out configuration. This sudden rundown was prevented by addition of anionic phospholipids such as phosphatidylinositol 4,5-bisphosphate (PIP2), phosphatidylinositol 3,4,5-trisphosphate (PIP3), and phosphatidylserine (PS) to the "cytoplasmic" bath. Conversely, chelation of endogenous PIP2 with anti-PIP2 antibody, hydrolysis of PIP2 with either exogenous phospholipase C (PLC) or activation of endogenous PLC by extracellular ATP, or application of the positively charged molecule, poly-L-lysine, accelerated channel rundown. However, neutral phosphatidylcholine had no effect on ENaC activity. By two-electrode voltage clamp recordings, we demonstrated that PIP2 and PIP3 significantly increased amiloride-sensitive current in Xenopus oocytes injected with cRNAs of rat alpha-, beta-, and gamma-ENaC. However, PIP2 and PIP3 did not affect surface expression of ENaC, indicating that PIP2 and PIP3 regulate ENaC at the level of the inner plasma membrane through a mechanism that is independent of ENaC trafficking. These data suggest that anionic phospholipids may mediate the regulation of ENaC by PLC- or phosphoinositide 3-kinase-coupled receptors.	Univ Alabama, Dept Med, Div Nephrol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Ma, HP (corresponding author), Univ Alabama, Dept Med, Div Nephrol, 1530 3rd Ave S,Sparks Bldg 865, Birmingham, AL 35294 USA.							Ashcroft FM, 1998, SCIENCE, V282, P1059, DOI 10.1126/science.282.5391.1059; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Baukrowitz T, 1998, SCIENCE, V282, P1141, DOI 10.1126/science.282.5391.1141; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; Chalfant ML, 1999, J BIOL CHEM, V274, P32889, DOI 10.1074/jbc.274.46.32889; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Firsov D, 1996, P NATL ACAD SCI USA, V93, P15370, DOI 10.1073/pnas.93.26.15370; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Koster JC, 1999, J GEN PHYSIOL, V114, P203, DOI 10.1085/jgp.114.2.203; Lehrmann H, 2002, J AM SOC NEPHROL, V13, P10, DOI 10.1681/ASN.V13110; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Ma HP, 1996, AM J PHYSIOL-RENAL, V270, pF798, DOI 10.1152/ajprenal.1996.270.5.F798; Ma HP, 2002, AM J PHYSIOL-RENAL, V282, pF501, DOI 10.1152/ajprenal.00147.2001; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Pearce D, 2000, KIDNEY INT, V57, P1283, DOI 10.1046/j.1523-1755.2000.00963.x; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Saxena S, 1999, J BIOL CHEM, V274, P20812, DOI 10.1074/jbc.274.30.20812; Shyng SL, 1998, SCIENCE, V282, P1138, DOI 10.1126/science.282.5391.1138; Tucker JK, 1998, AM J PHYSIOL-CELL PH, V274, pC1081, DOI 10.1152/ajpcell.1998.274.4.C1081; Verrey F, 2000, KIDNEY INT, V57, P1277, DOI 10.1046/j.1523-1755.2000.00962.x; Waldegger S, 1997, P NATL ACAD SCI USA, V94, P4440, DOI 10.1073/pnas.94.9.4440; Yue G, 2000, FASEB J, V14, pA340; Zambon AC, 2000, AM J PHYSIOL-RENAL, V279, pF1045, DOI 10.1152/ajprenal.2000.279.6.F1045	27	135	136	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 8	2002	277	10					7641	7644		10.1074/jbc.C100737200	http://dx.doi.org/10.1074/jbc.C100737200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	528WR	11809744	hybrid			2022-12-25	WOS:000174268000004
J	Saintigny, Y; Lopez, BS				Saintigny, Y; Lopez, BS			Homologous recombination induced by replication inhibition, is stimulated by expression of mutant p53	ONCOGENE			English	Article						homologous recombination; replication inhibition; p53; RAD51	HUMAN RAD51 PROTEIN; CELL-CYCLE CHECKPOINT; G1 CHECKPOINT; BREAK REPAIR; MICE; DISSOCIATION; CHROMOSOMES; MECHANISMS; DEFICIENT; SEQUENCES	Cell cycle control, faithful DNA replication, repair and recombination are associated in a network of pathways controlling genome maintenance. In mammalian cells, inhibition of replication produces DNA breaks and induces RAD51-dependent recombination, in a late step. Here we examine whether the status of p53 affects this process in mouse L-cells containing a recombination substrate. We show that expression of the mutant (His175)p53 strongly stimulates recombination induced by aphidicolin, in a late step (kinetically related to the RAD51 step). Mutant p53 stimulates recombination induced by the replication elongation inhibitors (aphidicolin, hydroxyurea and Ara-C) but is without effect on recombination induced by the initiation inhibitors (mimosine and ciclopirox olamine). We compared the impact of several p53 mutations showing different effects on the G1 checkpoint and on recombination. We show that the mutant 1,273 p53 protein, which does not alter the G1 checkpoint, strongly stimulates recombination induced by elongation inhibitors. These results show that p53 can act on recombination induced by replication arrest independently of its role in the G1 checkpoint. An action of p53 via the RAD51 pathway is discussed.	CEA, UMR217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, F-92265 Fontenay Aux Roses, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, UMR217 CNRS, Direct Sci Vivant, Dept Radiobiol & Radiopathol, 60-68 Ave Gen Leclerc, F-92265 Fontenay Aux Roses, France.		Lopez, Bernard S/O-7308-2017; Saintigny, Yannick/C-2697-2008	Lopez, Bernard S/0000-0001-5088-0155; Saintigny, Yannick/0000-0002-3839-3562				Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bertrand P, 1997, ONCOGENE, V14, P1117, DOI 10.1038/sj.onc.1200931; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Buchhop S, 1997, NUCLEIC ACIDS RES, V25, P3868, DOI 10.1093/nar/25.19.3868; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Dudenhoffer C, 1999, ONCOGENE, V18, P5773, DOI 10.1038/sj.onc.1202964; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hyrien O, 2000, BIOCHIMIE, V82, P5, DOI 10.1016/S0300-9084(00)00344-8; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LISKAY RM, 1984, COLD SPRING HARB SYM, V49, P183, DOI 10.1101/SQB.1984.049.01.021; Maacke H, 2000, ONCOGENE, V19, P2791, DOI 10.1038/sj.onc.1203578; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; ONNO M, 1992, ONCOGENE, V7, P2519; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Rothstein R, 2000, GENE DEV, V14, P1; Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809; Wiesmuller L, 1996, J VIROL, V70, P737; Willers H, 2000, ONCOGENE, V19, P632, DOI 10.1038/sj.onc.1203142	33	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					488	492		10.1038/sj.onc.1205040	http://dx.doi.org/10.1038/sj.onc.1205040			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821962	Green Published			2022-12-25	WOS:000173311200018
J	Hanai, J; Dhanabal, M; Karumanchi, SA; Albanese, C; Waterman, M; Chan, B; Ramchandran, R; Pestell, R; Sukhatme, VP				Hanai, J; Dhanabal, M; Karumanchi, SA; Albanese, C; Waterman, M; Chan, B; Ramchandran, R; Pestell, R; Sukhatme, VP			Endostatin causes G(1) arrest of endothelial cells through inhibition of cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER-CELLS; TUMOR-GROWTH; EXPRESSION; ANTISENSE; ANGIOGENESIS; APOPTOSIS; MYC; TUMORIGENICITY; IDENTIFICATION; CARCINOMA	Endostatin, a type XVIII collagen fragment, is a potent antiangiogenic molecule that inhibits endothelial cell migration, promotes apoptosis, and induces cell cycle arrest in vitro. We have investigated the mechanism by which endostatin causes G, arrest in endothelial cells. Endostatin decreased the hyperphosphorylated retinoblastoma gene product and down-regulated cyclin D1 mRNA and protein. Importantly, endostatin was unable to arrest cyclin D1 overexpressing endothelial cells, suggesting that cyclin D1 is a critical target for endostatin action. Next, we analyzed cyclin D1 promoter activity in endothelial cells and found that endostatin down-regulated the cyclin D1 promoter. Using a series of deletion and mutant promoter constructs, we identified the LEF1 site in the cyclin D1 promoter as essential for the inhibitory effect of endostatin. Finally, we showed that endostatin can repress cyclin D1 promoter activity in cells over-expressing beta-catenin but not in cells over-expressing a transcriptional activator that functions through the LEF1 site and is insensitive to beta-catenin. Collectively, our data pointed to a role for cyclin D1, and in particular, transcription through the LEF1 site as critical for endostatin action in vitro and suggest that beta-catenin is a target for endostatin.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Nephrol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Ctr Study Tumor Microenvironm, Boston, MA 02215 USA; Albert Einstein Coll Med, Dept Dev & Mol Biol & Med, Bronx, NY 10462 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Sukhatme, VP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Nephrol, 330 Brookline Ave,RW 563, Boston, MA 02215 USA.		Sukhatme, Vikas/W-2776-2019; Karumanchi, Subbian Ananth/AAI-1694-2021					Arber N, 1997, CANCER RES, V57, P1569; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kornmann M, 1999, CANCER RES, V59, P3505; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lang S, 2000, J AM SOC NEPHROL, V11, P1398, DOI 10.1681/ASN.V1181398; Nagata D, 2001, J BIOL CHEM, V276, P662, DOI 10.1074/jbc.M005522200; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Saikawa Y, 2001, JPN J CANCER RES, V92, P1102, DOI 10.1111/j.1349-7006.2001.tb01065.x; Sasaki T, 1999, EMBO J, V18, P6240, DOI 10.1093/emboj/18.22.6240; Sauter ER, 1999, CANCER RES, V59, P4876; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; STEINER P, 1995, EMBO J, V14, P4814, DOI 10.1002/j.1460-2075.1995.tb00163.x; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; Vonica A, 2000, DEV BIOL, V217, P230, DOI 10.1006/dbio.1999.9551; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; ZHOU P, 1995, ONCOGENE, V11, P571	29	182	222	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16464	16469		10.1074/jbc.M112274200	http://dx.doi.org/10.1074/jbc.M112274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11815623	hybrid			2022-12-25	WOS:000175564500018
J	Blumer, JB; Chandler, LJ; Lanier, SM				Blumer, JB; Chandler, LJ; Lanier, SM			Expression analysis and subcellular distribution of the two G-protein regulators AGS3 and LGN indicate distinct functionality - Localization of LGN to the midbody during cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; ASYMMETRIC CELL-DIVISION; G-ALPHA SUBUNITS; DISSOCIATION INHIBITOR; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; BINDING; ACTIVATION; SURVIVIN	Activator of G-protein signaling 3 (AGS3) and LGN have a similar domain structure and contain four G-protein regulatory motifs that serve as anchors for the binding of the GDP-bound conformation of specific G-protein a subunits. As an initial approach to define further the different functional roles of AGS3 and LGN, we determined their expression profile and subcellular distribution. AGS3- and LGN-specific antisera indicated a widespread tissue distribution of LGN, whereas AGS3 is primarily enriched in brain. Brain punch biopsies of 13 discrete brain regions indicated that both AGS3 and LGN are expressed in all areas tested but are differentially regulated during development. LGN is expressed in neuronal, astroglial, and microglial cultures, whereas AGS3 expression is restricted to neurons. In primary neuronal cultures as well as in dividing cultures of PC12 cells, immunocytochemistry indicated distinct subcellular locations of AGS3 and LGN. The subcellular locations of the two proteins were differentially regulated by external stimuli and the cell cycle. In PC12 and COS7 cells, LGN moves from the nucleus to the midbody structure separating daughter cells during the later stages of mitosis, suggesting a role for G-proteins in cytokinesis. Thus, although AGS3 and LGN share a similar overall motif structure and both bind G-proteins, nature has endowed these proteins with different regulatory elements that allow functional diversity by virtue of tissue-specific expression and subcellular positioning.	Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Medical University of South Carolina	Lanier, SM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol, 1901 Perdido St, New Orleans, LA 70112 USA.	slanie@lsuhsc.edu	Chandler, Lawrence/N-8569-2017	Chandler, Lawrence/0000-0002-1468-7320; Blumer, Joe/0000-0002-0020-3815; Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH065092] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024821, R29NS024821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010983, R29AA010983] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA10983] Funding Source: Medline; NIMH NIH HHS [MH90531, F32 MH065092] Funding Source: Medline; NINDS NIH HHS [NS24821] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams RR, 2000, CURR BIOL, V10, P1075, DOI 10.1016/S0960-9822(00)00673-4; Bellaiche Y, 2001, CELL, V106, P355, DOI 10.1016/S0092-8674(01)00444-5; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; Chandler LJ, 1997, MOL PHARMACOL, V51, P733, DOI 10.1124/mol.51.5.733; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Cismowski MJ, 2000, J BIOL CHEM, V275, P23421, DOI 10.1074/jbc.C000322200; Cismowski MJ, 1999, NAT BIOTECHNOL, V17, P878, DOI 10.1038/12867; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; Du QS, 2001, NAT CELL BIOL, V3, P1069, DOI 10.1038/ncb1201-1069; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; DUZIC E, 1992, J BIOL CHEM, V267, P24045; Glotzer M, 2001, ANNU REV CELL DEV BI, V17, P351, DOI 10.1146/annurev.cellbio.17.1.351; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Kroslak T, 2001, J BIOL CHEM, V276, P39772, DOI 10.1074/jbc.M106991200; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Mackay AM, 1998, J CELL BIOL, V140, P991, DOI 10.1083/jcb.140.5.991; MARTINEAU SN, 1995, J CELL BIOL, V131, P191, DOI 10.1083/jcb.131.1.191; Martineau-Thuillier S, 1998, CHROMOSOMA, V107, P461, DOI 10.1007/s004120050330; Mochizuki N, 1996, GENE, V181, P39, DOI 10.1016/S0378-1119(96)00456-8; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Parmentier ML, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-14-j0003.2000; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Pizzinat N, 2001, J BIOL CHEM, V276, P16601, DOI 10.1074/jbc.M007573200; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saha C, 1998, J BIOL CHEM, V273, P21629, DOI 10.1074/jbc.273.34.21629; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Sato M, 1996, J BIOL CHEM, V271, P30052, DOI 10.1074/jbc.271.47.30052; SATO M, 1995, J BIOL CHEM, V270, P15269, DOI 10.1074/jbc.270.25.15269; Schaefer M, 2000, CURR BIOL, V10, P353, DOI 10.1016/S0960-9822(00)00401-2; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; STRITTMATTER SM, 1991, J BIOL CHEM, V266, P22465; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Wodarz A, 2001, CURR BIOL, V11, pR975, DOI 10.1016/S0960-9822(01)00578-4; Yu FW, 2000, CELL, V100, P399, DOI 10.1016/S0092-8674(00)80676-5; Zhang JH, 2001, J BIOL CHEM, V276, P10284, DOI 10.1074/jbc.M009247200	45	93	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15897	15903		10.1074/jbc.M112185200	http://dx.doi.org/10.1074/jbc.M112185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11832491	hybrid			2022-12-25	WOS:000175510400092
J	Reuben, PM; Brogley, MA; Sun, Y; Cheung, HS				Reuben, PM; Brogley, MA; Sun, Y; Cheung, HS			Molecular mechanism of the induction of metalloproteinases 1 and 3 in human fibroblasts by basic calcium phosphate crystals - Role of calcium-dependent protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; SMOOTH-MUSCLE CELLS; ANGIOTENSIN-II; OLIGODENDROCYTE PROGENITORS; ARTICULAR CHONDROCYTES; TYROSINE KINASE; PHOSPHOCITRATE; COLLAGENASE; ACTIVATION; INHIBITION	Synovial fluid basic calcium phosphate (BCP) crystals are common in osteoarthritis and are often associated with destructive arthropathies involving cartilage degeneration. These crystals are mitogenic and induce oncogene expression and matrix metalloproteinase (MMP) synthesis and secretion in human fibroblasts. To date, BCP crystal-elicited signal transduction pathways have not been completely studied. Because protein kinase C (PKC) is known to play an important role in signal transduction, we investigated the participation of this pathway in the BCP crystal induction of MMP-1 and MMP-3 mRNA and protein expressions in human fibroblasts. Using reverse transcription/polymerase chain reaction (RT-PCR) and Northern and Western blotting techniques, we show here that BCP crystal stimulation of MMP-1 and MMP-3 mRNA and protein expressions in human fibroblasts is dependent upon the calcium-dependent PKC signal transduction pathway and that the PKCalpha isozyme is specifically involved in the pathway. We have previously shown that BCP crystal induction of MMP-1 and MMP-3 is also dependent on the p44/42 mitogen-activated protein kinase (p44/42 MAPK) signal transduction pathway. We now show that these two pathways operate independently and seem to complement each other. This leads to our hypothesis that the two pathways initially function independently, ultimately leading to an increase in mitogenesis and MMP synthesis, and may converge downstream of PKC and p44/42 MAPK to mediate BCP crystal-induced cellular responses.	Vet Adm Med Ctr, Res Serv, Miami, FL 33125 USA; Univ Miami, Sch Med, Dept Med, Miami, FL 33101 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Miami, FL 33125 USA; Univ Miami, Dept Biomed Engn, Coral Gables, FL 33146 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami	Cheung, HS (corresponding author), Vet Adm Med Ctr, Res Serv, 1201 NW 16th St, Miami, FL 33125 USA.				NIAMS NIH HHS [AR-38421-13] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038421] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bai G, 2001, OSTEOARTHR CARTILAGE, V9, P416, DOI 10.1053/joca.2000.0407; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P59; Berts A, 1999, MOL PHARMACOL, V55, P296, DOI 10.1124/mol.55.2.296; Brogley MA, 1999, J CELL PHYSIOL, V180, P215, DOI 10.1002/(SICI)1097-4652(199908)180:2<215::AID-JCP9>3.0.CO;2-J; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Cheung, 1980, J TISS CULT METHODS, V6, P39, DOI 10.1007/BF01665905; Cheung H S, 1999, Curr Rheumatol Rep, V1, P128, DOI 10.1007/s11926-999-0009-1; Cheung HS, 1996, BBA-MOL BASIS DIS, V1315, P105, DOI 10.1016/0925-4439(95)00106-9; CHEUNG HS, 1989, CANCER RES, V49, P134; CHEUNG HS, 1986, J CELL PHYSIOL, V128, P143, DOI 10.1002/jcp.1041280202; Cheung HS, 1996, J BIOL CHEM, V271, P28082, DOI 10.1074/jbc.271.45.28082; CHEUNG HS, 1993, JOINT CARTILAGE DEGR, P209; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; Cohen RI, 1996, MOL BRAIN RES, V43, P193, DOI 10.1016/S0169-328X(96)00176-3; CRESPO P, 1994, J BIOL CHEM, V269, P21103; DAVIS PD, 1992, J MED CHEM, V35, P177, DOI 10.1021/jm00079a024; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Eguchi S, 1996, J BIOL CHEM, V271, P14169, DOI 10.1074/jbc.271.24.14169; EVANS RW, 1984, CALCIFIED TISSUE INT, V36, P645, DOI 10.1007/BF02405384; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; Gu H, 1996, CANCER LETT, V106, P199, DOI 10.1016/0304-3835(96)04314-5; Halverson PB, 1998, OSTEOARTHR CARTILAGE, V6, P324, DOI 10.1053/joca.1998.0131; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kimura A, 1999, ENDOCRINOLOGY, V140, P722, DOI 10.1210/en.140.2.722; KOEMTIANI P, 1988, J BIOL CHEM, V273, P15249; KRUG HE, 1993, ARTHRITIS RHEUM, V36, P1603, DOI 10.1002/art.1780361116; Ku WC, 1997, BIOCHEM BIOPH RES CO, V241, P730, DOI 10.1006/bbrc.1997.7874; Larocca JN, 1997, J NEUROSCI RES, V50, P743, DOI 10.1002/(SICI)1097-4547(19971201)50:5<743::AID-JNR11>3.0.CO;2-2; LI SL, 1994, J MOL ENDOCRINOL, V13, P303, DOI 10.1677/jme.0.0130303; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McCarthy GM, 1998, J BIOL CHEM, V273, P35161, DOI 10.1074/jbc.273.52.35161; MCCARTHY GM, 1991, ARTHRITIS RHEUM-US, V34, P1021, DOI 10.1002/art.1780340812; MCCARTHY GM, 1992, J CELL PHYSIOL, V153, P140, DOI 10.1002/jcp.1041530118; McCarthy GM, 2001, ANN RHEUM DIS, V60, P399, DOI 10.1136/ard.60.4.399; MCCARTY DJ, 1981, ARTHRITIS RHEUM, V24, P464, DOI 10.1002/art.1780240303; MITCHELL PG, 1989, J BIOL CHEM, V264, P14071; MITCHELL PG, 1992, ARTHRITIS RHEUM, V35, P343, DOI 10.1002/art.1780350314; Murasawa S, 1998, HYPERTENSION, V32, P668, DOI 10.1161/01.HYP.32.4.668; Nair D, 1997, J BIOL CHEM, V272, P18920, DOI 10.1074/jbc.272.30.18920; NISHIZUKA Y, 1988, NATURE, V351, P662; PANKOWSKI AH, 1994, TETRAHEDRON LETT, V35, P927, DOI 10.1016/S0040-4039(00)76002-3; Reuben PM, 2001, CONNECT TISSUE RES, V42, P1, DOI 10.3109/03008200109014244; ROTHENBERG RJ, 1987, ARTHRITIS RHEUM, V30, P266, DOI 10.1002/art.1780300304; ROTHENBERG RJ, 1988, AM J PHYSIOL-CELL PH, V23, pC554; Ryan LM, 1999, RHEUM DIS CLIN N AM, V25, P257, DOI 10.1016/S0889-857X(05)70066-1; SAUS J, 1988, J BIOL CHEM, V263, P6742; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Sun YB, 2002, J BIOL CHEM, V277, P1544, DOI 10.1074/jbc.M100567200; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; Todisco A, 1997, AM J PHYSIOL-GASTR L, V273, pG891, DOI 10.1152/ajpgi.1997.273.4.G891; Zhu DM, 1999, CLIN CANCER RES, V5, P355	54	56	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15190	15198		10.1074/jbc.M200278200	http://dx.doi.org/10.1074/jbc.M200278200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836255	hybrid			2022-12-25	WOS:000175203000105
J	Vickers, C; Hales, P; Kaushik, V; Dick, L; Gavin, J; Tang, J; Godbout, K; Parsons, T; Baronas, E; Hsieh, F; Acton, S; Patane, M; Nichols, A; Tummino, P				Vickers, C; Hales, P; Kaushik, V; Dick, L; Gavin, J; Tang, J; Godbout, K; Parsons, T; Baronas, E; Hsieh, F; Acton, S; Patane, M; Nichols, A; Tummino, P			Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APJ; NEUROTENSIN; LIGAND; BRADYKININ; DEPENDENCE; ACTIVATION; DYNORPHIN; MECHANISM; CHLORIDE; RECEPTOR	Human angiotensin-converting enzyme-related carboxypeptidase (ACE2) is a zinc metalloprotease whose closest homolog is angiotensin I-converting enzyme. To begin to elucidate the physiological role of ACE2, ACE2 was purified, and its catalytic activity was characterized. ACE2 proteolytic activity has a pH optimum of 6.5 and is enhanced by monovalent anions, which is consistent with the activity of ACE. ACE2 activity is increased similar to10-fold by Cl- and F- but is unaffected by Br-. ACE2 was screened for hydrolytic activity against a panel of 126 biological peptides, using liquid chromatography-mass spectrometry detection. Eleven of the peptides were hydrolyzed by ACE2, and in each case, the proteolytic activity resulted in removal of the C-terminal residue only. ACE2 hydrolyzes three of the peptides with high catalytic efficiency: angiotensin II (1-8) (k(cat)/K-m = 1.9 x 10(6) m(-1) s(-1)), apelin-13 (k(cat)/K-m = 2.1 x 10(6) M-1 s(-1)), and dynorphin A 1-13 (k(cat)/K-m = 3.1 x 10(6) M-1 s(-1)). The ACE2 catalytic efficiency is 400-fold higher with angiotensin 11 (1-8) as a substrate than with angiotensin I (1-10). ACE2 also efficiently hydrolyzes des-Are-bradykinin (k(cat)/K-m = 1.3 x 10(5) m(-1) s(-1)), but it does not hydrolyze bradykinin. An alignment of the ACE2 peptide substrates reveals a consensus sequence of: Pro-X(1-3 residues)-Pro-Hydrophobic, where hydrolysis occurs between proline and the hydrophobic amino acid.	Millennium Pharmaceut Inc, Dept Metab Dis, Cambridge, MA 02139 USA; Millennium Pharmaceut Inc, Dept Lead Discovery, Cambridge, MA 02139 USA; Millennium Pharmaceut Inc, Dept Prot Sci, Cambridge, MA 02139 USA; Millennium Pharmaceut Inc, Dept Technol Platform, Cambridge, MA 02139 USA; Millennium Pharmaceut Inc, Dept Cardiovasc Biol, Cambridge, MA 02139 USA; Millennium Pharmaceut Inc, Dept Med Chem, Cambridge, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Tummino, P (corresponding author), Millennium Pharmaceut Inc, Dept Metab Dis, 270 Albany St, Cambridge, MA 02139 USA.	tummino@mpi.com	Dick, Lawrence/ABA-8831-2021	Dick, Larry/0000-0002-6880-0405				Blais C, 2000, PEPTIDES, V21, P1903, DOI 10.1016/S0196-9781(00)00348-X; BUNNING P, 1983, BIOCHEMISTRY-US, V22, P110, DOI 10.1021/bi00270a016; Caudle RM, 2000, PAIN, V87, P235, DOI 10.1016/S0304-3959(00)00360-2; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; Donoghue M, 2000, CIRC RES, V87, pE1, DOI 10.1161/01.res.87.5.e1; EHLERS MRW, 1989, BIOCHEMISTRY-US, V28, P5311, DOI 10.1021/bi00439a001; EHLERS MRW, 1988, BIOCHEMISTRY-US, V27, P5538, DOI 10.1021/bi00415a023; Fernandez M, 2001, J BIOL CHEM, V276, P4998, DOI 10.1074/jbc.M009009200; Ferrario CM, 1998, J AM SOC NEPHROL, V9, P1716; Ferrario CM, 1997, HYPERTENSION, V30, P535, DOI 10.1161/01.HYP.30.3.535; Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; Francis GS, 2000, NEW ENGL J MED, V342, P201, DOI 10.1056/NEJM200001203420309; Griendling KK, 1997, HYPERTENSION, V29, P366, DOI 10.1161/01.HYP.29.1.366; Hermans E, 1998, PHARMACOL THERAPEUT, V79, P89, DOI 10.1016/S0163-7258(98)00009-6; Hosoya M, 2000, J BIOL CHEM, V275, P21061, DOI 10.1074/jbc.M908417199; JASPARD E, 1993, J BIOL CHEM, V268, P9496; Katugampola SD, 2001, BRIT J PHARMACOL, V132, P1255, DOI 10.1038/sj.bjp.0703939; Lee DK, 2000, J NEUROCHEM, V74, P34, DOI 10.1046/j.1471-4159.2000.0740034.x; Liu XF, 2001, J BIOL CHEM, V276, P33518, DOI 10.1074/jbc.M101495200; Rovere C, 1996, J BIOL CHEM, V271, P11368, DOI 10.1074/jbc.271.19.11368; SHAPIRO R, 1983, BIOCHEMISTRY-US, V22, P3850, DOI 10.1021/bi00285a021; SKEGGS LT, 1956, J EXP MED, V103, P295, DOI 10.1084/jem.103.3.295; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Tipnis SR, 2000, J BIOL CHEM, V275, P33238, DOI 10.1074/jbc.M002615200; Vincent JP, 1999, TRENDS PHARMACOL SCI, V20, P302, DOI 10.1016/S0165-6147(99)01357-7	25	1030	1151	3	73	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14838	14843		10.1074/jbc.M200581200	http://dx.doi.org/10.1074/jbc.M200581200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11815627	hybrid			2022-12-25	WOS:000175203000063
J	Winter, HC; Mostafapour, K; Goldstein, IJ				Winter, HC; Mostafapour, K; Goldstein, IJ			The mushroom Marasmius oreades lectin is a blood group type B agglutinin that recognizes the Gal alpha 1,3Gal and Gal alpha 1,3Gal beta 1,4G1cNAc porcine xenotransplantation epitopes with high affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSYL; TUMOR-CELLS; BINDING; RESIDUES; PURIFICATION	A blood group B-specific lectin from the mushroom Marasmius oreades (MOA) was investigated with respect to its molecular structure and carbohydrate binding properties. SDS-PAGE mass spectrometric analysis showed it to consist of an intact (H; 33 kDa) and truncated (L; 23 kDa) subunit in addition to a small polypeptide (P; 10 kDa). Isolation in the presence of EDTA produced only the H subunits, indicating that the latter two are formed by metalloprotease cleavage of the intact H subunit. Tryptic digestion of the H, L, and P polypeptide chains followed by mass spectral analysis supports this view. The lectin strongly precipitated blood group type B substance, was nonreactive with type A substance, and reacted weakly with type H substance. Carbohydrate binding studies reveal a high affinity for Galalpha1,3Ga1 (but not for the isomeric alpha1,2-, alpha1,4-, and alpha1,6-disaccharides); Galalpha1,3Galbeta1,4GlcNAc; and the type B branched trisaccharide. MOA also reacts strongly with murine laminin from the Engelbreth-Holm-Swarm sarcoma and bovine thyroglobulin, both of which contain multiple Galalpha1,3Galbeta1,4GlcNAc end groups. This linear B trisaccharide is a component of porcine tissues and organs, preventing their transplantation into humans. MOA also shares carbohydrate recognition of this trisaccharide with toxin A elaborated by Clostridium difficile.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Nat Sci, Dearborn, MI 48128 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldstein, IJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, 1301 Catherine St, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM29470-35] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bird G., 1951, CURRENT SCIENCE, V20, P298; BOYD WC, 1954, SCIENCE, V119, P419, DOI 10.1126/science.119.3091.419; BOYD WC, 1949, J IMMUNOL, V62, P333; ECKHARDT AE, 1983, BIOCHEMISTRY-US, V22, P5290, DOI 10.1021/bi00292a007; ELO J, 1951, ANN MED EXP BIOL FEN, V29, P297; ELO J, 1952, ANN MED EXP BIOL FEN, V30, P165; ENTLICHE.G, 1970, BIOCHIM BIOPHYS ACTA, V221, P272, DOI 10.1016/0005-2795(70)90267-9; ETZLER ME, 1970, BIOCHEMISTRY-US, V9, P869, DOI 10.1021/bi00806a022; GALILI U, 1988, J BIOL CHEM, V263, P17755; HOREJSI V, 1978, BIOCHIM BIOPHYS ACTA, V538, P299, DOI 10.1016/0304-4165(78)90358-6; JONSSON B, 1944, ACTA PATH MICROBIO S, V54, P456; Kirkeby S, 2001, IMMUNOL CELL BIOL, V79, P121, DOI 10.1046/j.1440-1711.2001.00992.x; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; Kruger RP, 2002, J BIOL CHEM, V277, P15002, DOI 10.1074/jbc.M200165200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mo HQ, 2000, J BIOL CHEM, V275, P10623, DOI 10.1074/jbc.275.14.10623; Mo HQ, 1999, J BIOL CHEM, V274, P33300, DOI 10.1074/jbc.274.47.33300; Mo HQ, 2001, EUR J BIOCHEM, V268, P2609, DOI 10.1046/j.1432-1327.2001.02148.x; MURPHY LA, 1979, BIOCHEMISTRY-US, V18, P4999, DOI 10.1021/bi00589a030; OKADA Y, 1980, J BIOL CHEM, V255, P4739; PEMBERTON RT, 1994, MYCOL RES, V98, P277, DOI 10.1016/S0953-7562(09)80455-3; PETERS BP, 1979, EXP CELL RES, V120, P321, DOI 10.1016/0014-4827(79)90392-6; Ramasamy R, 1997, BBA-MOL BASIS DIS, V1360, P241, DOI 10.1016/S0925-4439(97)00005-7; ROTH J, 1995, GLYCOCONJUGATE J, V12, P142, DOI 10.1007/BF00731358; SHIBATA S, 1982, FEBS LETT, V142, P194, DOI 10.1016/0014-5793(82)80132-4; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; STANLEY WS, 1979, P NATL ACAD SCI USA, V76, P304; SUGISHITA S, 1935, J JUZEN MED SOC, V40, P1938; Takahashi N, 2001, J BIOL CHEM, V276, P23230, DOI 10.1074/jbc.M101380200; Tempel W, 2002, J BIOL CHEM, V277, P6615, DOI 10.1074/jbc.M109919200; Teneberg S, 1996, GLYCOBIOLOGY, V6, P599, DOI 10.1093/glycob/6.6.599; Wang HX, 1998, MYCOL RES, V102, P897, DOI 10.1017/S0953756298006200; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V981, P1; Yagi Fumio, 2000, Mycoscience, V41, P323, DOI 10.1007/BF02463945	35	57	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14996	15001		10.1074/jbc.M200161200	http://dx.doi.org/10.1074/jbc.M200161200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11836253	hybrid			2022-12-25	WOS:000175203000081
J	Liu, L; Eby, MT; Rathore, N; Sinha, SK; Kumar, A; Chaudhary, PM				Liu, L; Eby, MT; Rathore, N; Sinha, SK; Kumar, A; Chaudhary, PM			The human herpes virus 8-encoded viral FLICE inhibitory protein physically associates with and persistently activates the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOMA-ASSOCIATED HERPESVIRUS; DOMAIN-CONTAINING PROTEIN; DNA-SEQUENCES; COUPLED RECEPTOR; IKK-ALPHA; CELL-LINE; BETA; HUMAN-HERPESVIRUS-8; APOPTOSIS; PHOSPHORYLATION	The human herpesvirus 8 (HHVS, also called Kaposi's sarcoma-associated herpesvirus) has been linked to Kaposi's sarcoma and primary effusion lymphoma (PEL) in immunocompromised individuals. We demonstrate that PEL cell lines have a constitutively active NF-kappaB pathway, which is associated with persistent phosphorylation of IkappaBalpha. To elucidate the mechanism of NF-kappaB activation in PEL cell lines, we have investigated the role of viral FLICE inhibitory protein (vFLIP) in this process. We report that stable expression of HHV8 vFLIP in a variety of cell lines is associated with persistent NF-kappaB activation caused by constitutive phosphorylation of IkappaBalpha. HHV8 vFLIP gets recruited to a similar to700-kDa IkappaB kinase (IKK) complex and physically associates with IKKalpha, IKKbeta, NEMO/IKKgamma, and RIP. HHV8 vFLIP is incapable of activating NF-kappaB in cells deficient in NEMO/IKK-gamma, thereby suggesting an essential role of an intact IKK complex in this process. Our results suggest that HHV8 vFLIP might contribute to the persistent NF-kappaB activation observed in PEL cells by associating with and stimulating the activity of the cellular IRK complex.	Univ Utrecht, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Utrecht, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	preet.chaudhary@utsouthwestern.edu	Kumar, Arvind/B-6094-2009; Chaudhary, Preet/E-1970-2018	Kumar, Arvind/0000-0003-2879-3826				Alexander L, 2000, J VIROL, V74, P3388, DOI 10.1128/JVI.74.7.3388-3398.2000; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Belanger C, 2001, J HUMAN VIROL, V4, P62; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gessain A, 1996, BLOOD, V87, P414; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Han DKM, 1997, P NATL ACAD SCI USA, V94, P11333, DOI 10.1073/pnas.94.21.11333; HAWLEY RG, 1994, GENE THER, V1, P136; Hu SM, 1997, J BIOL CHEM, V272, P9621; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Keller SA, 2000, BLOOD, V96, P2537; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luppi M, 1996, BLOOD, V87, P3903, DOI 10.1182/blood.V87.9.3903.bloodjournal8793903; Luque I, 1997, SEMIN CANCER BIOL, V8, P103, DOI 10.1006/scbi.1997.0061; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 2000, METH MOL B, V99, P109; Montaner S, 2001, CANCER RES, V61, P2641; Mosialos G, 1997, SEMIN CANCER BIOL, V8, P121, DOI 10.1006/scbi.1997.0063; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Samaniego F, 2001, J Natl Cancer Inst Monogr, P15; Sarid R, 1998, J VIROL, V72, P1005, DOI 10.1128/JVI.72.2.1005-1012.1998; Schulz TF, 1998, J GEN VIROL, V79, P1573, DOI 10.1099/0022-1317-79-7-1573; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Searles RP, 1999, J VIROL, V73, P3040, DOI 10.1128/JVI.73.4.3040-3053.1999; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; THORNE M, 1997, NATURE, V386, P517; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Wang GH, 1997, J VIROL, V71, P8928, DOI 10.1128/JVI.71.11.8928-8932.1997; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	65	175	180	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13745	13751		10.1074/jbc.M110480200	http://dx.doi.org/10.1074/jbc.M110480200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11830587	hybrid			2022-12-25	WOS:000175096000054
J	Pyrzynska, B; Serrano, M; Martinez-A, C; Kaminska, B				Pyrzynska, B; Serrano, M; Martinez-A, C; Kaminska, B			Tumor suppressor p53 mediates apoptotic cell death triggered by cyclosporin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AP-1 TRANSCRIPTION FACTOR; PHOSPHORYLATED IN-VITRO; WILD-TYPE P53; GLIOMA-CELLS; BAX GENE; NUCLEAR FACTOR; DNA-DAMAGE; PROTEIN; PATHWAY; KINASE	The tumor suppressor p53 can induce growth arrest and cell death via apoptosis in response to a number of cellular stresses. We have shown previously that the immunosuppressant cyclosporin A (CsA) induces programmed cell death with typical features of apoptosis in rat glioma cells. We report that CsA treatment results in increased level of the p53 tumor suppressor, its nuclear accumulation, and transcriptional activation of p53-dependent genes. The increase of p53 correlates with the elevation of p21(Waf1) and Bax protein expression. The increased level of Bax protein was accompanied with changes in its subcellular localization and association with mitochondria. Importantly, we demonstrate that glioma cells stably transfected with a mutant p53 (p53Val135) fail to increase p21 and Bax protein levels and are less sensitive to CsA-induced apoptosis. Furthermore, primary fibroblasts from p53-/- knockout mice are significantly more resistant to CsA-induced apoptosis compared with their corresponding counterparts containing functional p53. Together, our results suggest that the apoptotic program activated by CsA can be mediated by activation of p53 tumor suppressor and potentiation of its ability to initiate apoptosis.	M Nencki Inst Expt Biol, Lab Transcript Regulat, Dept Cellular Biochem, PL-02093 Warsaw, Poland; Natl Ctr Biotechnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Kaminska, B (corresponding author), M Nencki Inst Expt Biol, Lab Transcript Regulat, Dept Cellular Biochem, Pasteur 3 Str, PL-02093 Warsaw, Poland.		Kaminska, Bozena/B-2915-2014; Serrano, Manuel/H-2634-2015; Pyrzyńska, Beata/T-2187-2018; Kaminska, Bozena/H-4592-2011	Serrano, Manuel/0000-0001-7177-9312; Pyrzyńska, Beata/0000-0002-0490-618X; Kaminska, Bozena/0000-0002-2642-4616				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; ASAI A, 1994, J NEURO-ONCOL, V19, P259, DOI 10.1007/BF01053280; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BOGLER O, 1995, GLIA, V15, P308, DOI 10.1002/glia.440150311; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Claveria C, 1998, EMBO J, V17, P7199, DOI 10.1093/emboj/17.24.7199; Cregan SP, 1999, J NEUROSCI, V19, P7860; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Ding HF, 1998, CRIT REV ONCOGENESIS, V9, P83, DOI 10.1615/CritRevOncog.v9.i1.60; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FRITSCHE M, 1993, ONCOGENE, V8, P307; GomezManzano C, 1996, CANCER RES, V56, P694; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; HAFFNER R, 1995, CURR OPIN GENE DEV, V5, P94; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HERRMANN CPE, 1991, ONCOGENE, V6, P877; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Ikeda J, 2001, INT J CANCER, V94, P35, DOI 10.1002/ijc.1431; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kagawa S, 2000, CANCER RES, V60, P1157; KASTAN MB, 1991, CANCER RES, V51, P6304; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li HW, 1999, CLIN CANCER RES, V5, P637; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Michel G, 1996, BIOCHEM PHARMACOL, V51, P1315, DOI 10.1016/0006-2952(96)00039-1; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Mosieniak G, 1997, J NEUROCHEM, V68, P1142; Mosieniak G, 1998, J NEUROCHEM, V71, P134; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Prives C, 1999, J PATHOL, V187, P112; Pyrzynska B, 2000, J NEUROCHEM, V74, P42, DOI 10.1046/j.1471-4159.2000.0740042.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Robles AI, 2001, CANCER RES, V61, P6660; Sawada M, 2000, ONCOGENE, V19, P3508, DOI 10.1038/sj.onc.1203699; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shinoura N, 2000, CANCER GENE THER, V7, P732, DOI 10.1038/sj.cgt.7700160; Shinoura N, 2001, NEUROSURGERY, V49, P177, DOI 10.1097/00006123-200107000-00027; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Vogelbaum MA, 1999, J NEUROSURG, V91, P483, DOI 10.3171/jns.1999.91.3.0483; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang H, 1998, J NEUROSCI, V18, P1363; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhao RB, 2000, GENE DEV, V14, P981	63	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14102	14108		10.1074/jbc.M104443200	http://dx.doi.org/10.1074/jbc.M104443200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827957	hybrid			2022-12-25	WOS:000175096000098
J	Silva-Neto, MAC; Atella, GC; Shahabuddin, M				Silva-Neto, MAC; Atella, GC; Shahabuddin, M			Inhibition of Ca2+/calmodulin-dependent protein kinase blocks morphological differentiation of Plasmodium gallinaceum zygotes to ookinetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALARIA PARASITE; TRYPANOSOMA-CRUZI; CA2+ CALMODULIN; CALCIUM; FALCIPARUM; CYTOSKELETON; MEMBRANE; PHOSPHORYLATION; CELLS; TRANSFORMATION	Once ingested by mosquitoes, malaria parasites undergo complex cellular changes. These include zygote formation, transformation of zygote to ookinete, and differentiation from ookinete to oocyst. Within the oocyst, the parasite multiplies into numerous sporozoites. Modulators of intracellular calcium homeostasis A23187, MAPTAM, and TMB-8 blocked ookinete development as did the calmodulin (CaM) antagonists W-7 and calmidazolium. Ca2+/CaM-dependent protein kinase inhibitor KN-93 also blocked zygote elongation, while its ineffective analog KN-92 did not have such effect. In vitro both zygote and ookinete extracts efficiently phosphorylated autocamtide-2, a classic CaM kinase substrate, which could be blocked by calmodulin antagonists W-7 and calmidazolium and CaM kinase inhibitor KN-93. These results demonstrated the presence of calmodulin-dependent CaM kinase activity in the parasite. KN-93-treated parasites, however, expressed the ookinete-specific enzyme chitinase and the ookinete surface antigen Pgs28 normally, suggesting that the morphologically untransformed parasites are biochemically mature ookinetes. In mosquitoes, KN-93-treated parasites did not develop as oocysts, while KN-92-treated parasites produced similar numbers of oocysts as controls. These data suggested that in Plasmodium gallinaceum morphological development of zygote to ookinete, but not its biochemical maturation, relies on Ca2+/CaM-dependent protein kinase activity and demonstrated that the morphological differentiation is essential for the further development of the parasite in infected blood-fed mosquitoes.	NIAID, Lab Malaria & Vector Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Shahabuddin, M (corresponding author), NIAID, Lab Malaria & Vector Res, NIH, 4 Ctr Dr,Rm 4-B2-37, Bethesda, MD 20892 USA.	mshahabudd@niaid.nih.gov	Silva-Neto, Mario A C/C-1211-2013; Atella, Georgia/AAK-7897-2020	Silva-Neto, Mario A C/0000-0003-2273-194X; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000811] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Acuto O, 2000, ANNU REV IMMUNOL, V18, P165, DOI 10.1146/annurev.immunol.18.1.165; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BLOCKMANS D, 1995, BLOOD REV, V9, P143, DOI 10.1016/0268-960X(95)90020-9; Carbajal ME, 1996, EXP PARASITOL, V82, P11, DOI 10.1006/expr.1996.0002; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; Desai SA, 1996, AM J TROP MED HYG, V54, P464, DOI 10.4269/ajtmh.1996.54.464; Dorin D, 1999, J BIOL CHEM, V274, P29912, DOI 10.1074/jbc.274.42.29912; Dorin D, 2001, EUR J BIOCHEM, V268, P2600, DOI 10.1046/j.1432-1327.2001.02151.x; DUNBAR AJ, 1994, FEMS MICROBIOL LETT, V115, P113; Garcia CRS, 1998, EUR J CELL BIOL, V76, P133, DOI 10.1016/S0171-9335(98)80026-5; Garcia CRS, 1999, PARASITOL TODAY, V15, P488, DOI 10.1016/S0169-4758(99)01571-9; GROTENDORST CA, 1984, INFECT IMMUN, V45, P775, DOI 10.1128/IAI.45.3.775-777.1984; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HIRANOOHNISHI J, 1989, J BIOCHEM, V105, P858, DOI 10.1093/oxfordjournals.jbchem.a122766; Hook SS, 2001, ANNU REV PHARMACOL, V41, P471, DOI 10.1146/annurev.pharmtox.41.1.471; Hotta CT, 2000, NAT CELL BIOL, V2, P466, DOI 10.1038/35017112; HUBER M, 1991, P NATL ACAD SCI USA, V88, P2807, DOI 10.1073/pnas.88.7.2807; ISHIDA A, 1995, BIOCHEM BIOPH RES CO, V212, P806, DOI 10.1006/bbrc.1995.2040; Kappes B, 1999, PARASITOL TODAY, V15, P449, DOI 10.1016/S0169-4758(99)01527-6; KAUSHAL DC, 1983, J IMMUNOL, V131, P2557; KAWAMOTO F, 1990, MOL BIOCHEM PARASIT, V42, P101, DOI 10.1016/0166-6851(90)90117-5; KAWAMOTO F, 1993, EUR J CELL BIOL, V60, P101; Kieschnick H, 2001, J BIOL CHEM, V276, P12369, DOI 10.1074/jbc.M011045200; KUMAR N, 1985, MOL BIOCHEM PARASIT, V14, P127, DOI 10.1016/0166-6851(85)90032-5; Kurasawa Y, 1996, J BIOCHEM-TOKYO, V119, P791; le Gouvello S, 1998, J IMMUNOL, V161, P1113; Li JL, 2000, MOL BIOCHEM PARASIT, V109, P157, DOI 10.1016/S0166-6851(00)00242-5; LONERGAN TA, 1988, J CELL SCI, V89, P365; MARTIN SK, 1994, J PARASITOL, V80, P371, DOI 10.2307/3283406; MATSUMOTO Y, 1987, EUR J CELL BIOL, V45, P36; MCCALLUMDEIGHTON N, 1992, MOL BIOCHEM PARASIT, V50, P317, DOI 10.1016/0166-6851(92)90229-D; Means AR, 2000, MOL ENDOCRINOL, V14, P4, DOI 10.1210/me.14.1.4; Newell PC, 1995, BIOSCIENCE REP, V15, P445, DOI 10.1007/BF01204348; Oberstar JV, 1997, J NEUROBIOL, V33, P161, DOI 10.1002/(SICI)1097-4695(199708)33:2<161::AID-NEU5>3.0.CO;2-0; Ogueta S, 1996, MOL BIOCHEM PARASIT, V78, P171, DOI 10.1016/S0166-6851(96)02622-9; Ogueta SB, 1998, J EUKARYOT MICROBIOL, V45, P392, DOI 10.1111/j.1550-7408.1998.tb05089.x; Pettit EJ, 1998, PHYSIOL REV, V78, P949, DOI 10.1152/physrev.1998.78.4.949; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; SCHEIBEL LW, 1992, INT REV CYTOL, V134, P165, DOI 10.1016/S0074-7696(08)62029-X; Shahabuddin M, 1998, PARASITOLOGY, V116, pS83, DOI 10.1017/S0031182000084973; Soderling TR, 2000, CURR OPIN NEUROBIOL, V10, P375, DOI 10.1016/S0959-4388(00)00090-8; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; van Weert AWM, 2000, EUR J CELL BIOL, V79, P394, DOI 10.1078/0171-9335-00062; Yamauchi T, 1998, BRAIN RES PROTOC, V2, P250, DOI 10.1016/S1385-299X(98)00002-6; YIN HL, 1988, J CELL SCI, P169; ZHAO Y, 1994, MOL BIOCHEM PARASIT, V66, P329, DOI 10.1016/0166-6851(94)90159-7	47	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14085	14091		10.1074/jbc.M107903200	http://dx.doi.org/10.1074/jbc.M107903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827960	hybrid			2022-12-25	WOS:000175096000096
J	Watanabe, H; Davis, JB; Smart, D; Jerman, JC; Smith, GD; Hayes, P; Vriens, J; Cairns, W; Wissenbach, U; Prenen, J; Flockerzi, V; Droogmans, G; Benham, CD; Nilius, B				Watanabe, H; Davis, JB; Smart, D; Jerman, JC; Smith, GD; Hayes, P; Vriens, J; Cairns, W; Wissenbach, U; Prenen, J; Flockerzi, V; Droogmans, G; Benham, CD; Nilius, B			Activation of TRPV4 channels (hVRL-2/mTRP12) by phorbol derivatives	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR IONIC-STRENGTH; VANILLOID RECEPTOR; ENDOTHELIAL-CELLS; CATION CHANNEL; RUTHENIUM RED; INDEPENDENT INHIBITION; CAPSAICIN-RECEPTOR; CALCIUM-CHANNEL; PROTEIN; CURRENTS	We have studied activation by phorbol derivatives of TRPV4 channels, the human VRL-2, and murine TRP12 channels, which are highly homologous to the human VR-OAC, and the human and murine OTRPC4 channel. 4alpha-Phorbol 12,13-didecanoate (4alpha-PDD) induced an increase in intracellular Ca2+ concentration, [Ca2+](i), in 1321N1 cells stably transfected with human VRL-2 (hVRL-2.1321N1) or HEK-293 cells transiently transfected with murine TRP12, but not in nontransfected or mock-transfected cells. Concomitantly with the increase in [Ca2+](i), 4alpha-PDD activated an outwardly rectifying cation channel with an Eisenman IV permeation sequence for monovalent cations that is Ca2+-permeable with P-Ca/PNa = 5.8. Phorbol 12-myristate 13-acetate also induced an increase in [Ca2+](i) but was similar to50 times less effective than 4alpha-PDD. EC50 for Ca2+ increase and current activation was nearly identical (pEC(50) similar to 6.7). Similar effects were observed in freshly isolated mouse aorta endothelial cells which express TRP12 endogenously. By using 4alpha-PDD as a tool to stimulate TRP12, we showed that activation of this channel is modulated by [Ca2+](i); an increase in [Ca2+](i) inhibits the channel with an IC50 of 406 nM. Ruthenium Red at a concentration of 1 muM completely blocks inward currents at -80 mV but has a smaller effect on outward currents likely indicating a voltage dependent channel block. We concluded that the phorbol derivatives activate TRPV4 (VR-OAC, VRL-2, OTRPC4, TRP12) independently from protein kinase C, in a manner consistent with direct agonist gating of the channel.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; GlaxoSmithKline, Neurol CEDD & Discovery Res, Harlow CM19 5AW, Essex, England; Univ Saarland, Inst Pharmakol & Toxikol, D-66427 Homburg, Germany	KU Leuven; GlaxoSmithKline; Saarland University	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	bernd.nilius@med.kuleuven.ac.be	Vriens, Joris/G-9966-2018	Vriens, Joris/0000-0002-2502-0409				Asai T, 1996, AM J PHYSIOL-HEART C, V270, pH620, DOI 10.1152/ajpheart.1996.270.2.H620; BLUMBERG PM, 1984, BIOCHEM PHARMACOL, V33, P933, DOI 10.1016/0006-2952(84)90448-9; CARDOSO CM, 1993, BIOCHEM J, V296, P49, DOI 10.1042/bj2960049; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cibulsky SM, 1999, J PHARMACOL EXP THER, V289, P1447; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Colbert HA, 1997, J NEUROSCI, V17, P8259; DOERNER D, 1990, J NEUROSCI, V10, P1699; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Garcia-Martinez C, 2000, J BIOL CHEM, V275, P32552, DOI 10.1074/jbc.M002391200; Haburcak M, 1997, CELL CALCIUM, V21, P291, DOI 10.1016/S0143-4160(97)90117-2; HOCKBERGER P, 1989, NATURE, V338, P340, DOI 10.1038/338340a0; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Jerman JC, 2000, BRIT J PHARMACOL, V130, P916, DOI 10.1038/sj.bjp.0703390; Kannurpatti SS, 2000, NEUROCHEM RES, V25, P1527, DOI 10.1023/A:1026602100160; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; Lukyanenko V, 2000, BIOPHYS J, V79, P1273, DOI 10.1016/S0006-3495(00)76381-8; Nakamura J, 2001, CELL SIGNAL, V13, P199, DOI 10.1016/S0898-6568(01)00136-X; Nilius B, 1998, J PHYSIOL-LONDON, V506, P353, DOI 10.1111/j.1469-7793.1998.353bw.x; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Nilius B, 2001, J BIOL CHEM, V276, P1020, DOI 10.1074/jbc.M006184200; OIKE M, 1994, P NATL ACAD SCI USA, V91, P2940, DOI 10.1073/pnas.91.8.2940; Pottosin II, 1999, BIOPHYS J, V77, P1973, DOI 10.1016/S0006-3495(99)77038-4; REEVE HL, 1995, PFLUG ARCH EUR J PHY, V429, P729, DOI 10.1007/BF00373996; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Stoyanovsky DA, 1998, FREE RADICAL BIO MED, V24, P745, DOI 10.1016/S0891-5849(97)00328-6; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suga S, 2001, BMC Pharmacol, V1, P3, DOI 10.1186/1471-2210-1-3; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Szallasi A, 1999, PHARMACOL REV, V51, P159; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Viana F, 1998, CELL CALCIUM, V24, P117, DOI 10.1016/S0143-4160(98)90079-3; Voelker D, 1996, BIOPHYS J, V70, P818, DOI 10.1016/S0006-3495(96)79621-2; Voets T, 1999, P NATL ACAD SCI USA, V96, P5298, DOI 10.1073/pnas.96.9.5298; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596	43	456	482	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13569	13577		10.1074/jbc.M200062200	http://dx.doi.org/10.1074/jbc.M200062200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827975	hybrid			2022-12-25	WOS:000175096000031
J	Haemmerle, G; Zimmermann, R; Strauss, JG; Kratky, D; Riederer, M; Knipping, G; Zechner, R				Haemmerle, G; Zimmermann, R; Strauss, JG; Kratky, D; Riederer, M; Knipping, G; Zechner, R			Hormone-sensitive lipase deficiency in mice changes the plasma lipid profile by affecting the tissue-specific expression pattern of lipoprotein lipase in adipose tissue and muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; BINDING CASSETTE TRANSPORTER-1; TANGIER-DISEASE; TRANSGENIC MICE; SKELETAL-MUSCLE; MESSENGER-RNA; TRIGLYCERIDE; METABOLISM; ADIPOCYTES	Hormone-sensitive lipase (HSL) is believed to play an important role in the mobilization of fatty acids from triglycerides (TG), diglycerides, and cholesteryl esters in various tissues. Because HSL-mediated lipolysis of TG in adipose tissue (AT) directly feeds non-esterified fatty acids (NEFA) into the vascular system, the enzyme is expected to affect many metabolic processes including the metabolism of plasma lipids and lipoproteins. In the present study we examined these metabolic changes in induced mutant mouse lines that lack HSL expression (HSL-ko mice). During fasting, when HSL is normally strongly induced in AT, HSL-ko animals exhibited markedly decreased plasma concentrations of NEFA (-40%) and TG (-63%), whereas total cholesterol and HDL cholesterol levels were increased (+34%). Except for the increased HDL cholesterol concentrations, these differences were not observed in fed animals, in which HSL activity is generally low. Decreased plasma TG levels in fasted HSL-ko mice were mainly caused by decreased hepatic very low density lipid lipoprotein (VLDL) synthesis as a result of decreased NEFA transport from the periphery to the liver. Reduced NEFA transport was also indicated by a depletion of hepatic TG stores (-99%) and strongly decreased ketone body concentrations in plasma (-80%). Decreased plasma NEFA and TG levels in fasted HSL-ko mice were associated with increased fractional catabolic rates of VLDL-TG and an induction of the tissue-specific lipoprotein lipase (LPL) activity in cardiac muscle, skeletal muscle, and white AT. In brown AT, LPL activity was decreased. Both increased VLDL fractional catabolic rates and increased LPL activity in muscle were unable to provide the heart with sufficient NEFA, which led to decreased tissue TG levels in cardiac muscle. Our results demonstrate that HSL deficiency markedly affects the metabolism of TG-rich lipoproteins by the coordinate down-regulation of VLDL synthesis and up-regulation of LPL in muscle and white adipose tissue. These changes result in an "anti-atherogenic" lipoprotein profile.	Graz Univ, Inst Mol Biol Biochem & Microbiol, A-8010 Graz, Austria; Graz Univ, Inst Med Biochem & Mol Biol, A-8010 Graz, Austria	University of Graz; University of Graz	Zechner, R (corresponding author), Graz Univ, Inst Mol Biol Biochem & Microbiol, Heinrichstr 31A, A-8010 Graz, Austria.		Riederer, Markus/B-5540-2008; Kratky, Dagmar/ABF-5699-2021	Riederer, Markus/0000-0001-7081-1456; Zimmermann, Robert/0000-0002-7354-870X; Zechner, Rudolf/0000-0001-5483-1182; Haemmerle, Guenter/0000-0001-9900-5896; Bogner-Strauss, Juliane/0000-0003-2459-0124; Kratky, Dagmar/0000-0003-1357-7573				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; Barrans A, 1996, BBA-LIPID LIPID MET, V1300, P73, DOI 10.1016/0005-2760(95)00236-7; BELFRAGE P, 1977, FEBS LETT, V75, P259, DOI 10.1016/0014-5793(77)80099-9; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Bulow J, 1999, J LIPID RES, V40, P2034; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; CONTRERAS JA, 1994, ISRAEL J MED SCI, V30, P778; ELKS ML, 1985, ENDOCRINOLOGY, V116, P2119, DOI 10.1210/endo-116-5-2119; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Ewart HS, 1999, BIOCHEM J, V340, P485, DOI 10.1042/0264-6021:3400485; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRAYN KN, 1995, ADV ENZYME REGUL, V35, P163, DOI 10.1016/0065-2571(94)00011-Q; FRAYN KN, 1995, P NUTR SOC, V54, P177, DOI 10.1079/PNS19950047; Frayn KN, 1994, AM J PHYSIOL-ENDOC M, V266, P308; GAW A, 1992, LIPOPROTEIN ANAL PRA, P139; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; GOLDBERG DI, 1985, J BIOL CHEM, V260, P5879; GOLDBERG I, 1996, CURR OPIN LIPIDOL, V7, P184; Gordon DA, 1997, CURR OPIN LIPIDOL, V8, P131, DOI 10.1097/00041433-199706000-00002; Haemmerle G, 2002, J BIOL CHEM, V277, P4806, DOI 10.1074/jbc.M110355200; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; KHOO JC, 1993, J LIPID RES, V34, P1969; Kratky D, 2001, BIOCHEM J, V355, P647, DOI 10.1042/bj3550647; Kuipers F, 1997, J CLIN INVEST, V100, P2915, DOI 10.1172/JCI119841; Langfort J, 1998, ADV EXP MED BIOL, V441, P219; Levak-Frank S, 1999, P NATL ACAD SCI USA, V96, P3165, DOI 10.1073/pnas.96.6.3165; LEVAKFRANK S, 1995, J CLIN INVEST, V96, P976, DOI 10.1172/JCI118145; Lewis GF, 1997, CURR OPIN LIPIDOL, V8, P146, DOI 10.1097/00041433-199706000-00004; MATHEWS CH, PHYS MED BIOL, V2, P36; McKnight GS, 1998, RECENT PROG HORM RES, V53, P139; Mulder H, 1999, DIABETES, V48, P228, DOI 10.2337/diabetes.48.1.228; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; OSCAI LB, 1981, J APPL PHYSIOL, V50, P250, DOI 10.1152/jappl.1981.50.2.250; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Raclot T, 1998, BIOCHEM BIOPH RES CO, V245, P510, DOI 10.1006/bbrc.1998.8469; Roduit R, 2001, DIABETES, V50, P1970, DOI 10.2337/diabetes.50.9.1970; ROMEIS B, 1989, MIKROSKOPISCHE TECHN, P378; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SADDIK M, 1991, J BIOL CHEM, V266, P8162; Santamarina-Fojo S, 2000, CURR OPIN LIPIDOL, V11, P267, DOI 10.1097/00041433-200006000-00007; SHEPHERD RE, 1981, J APPL PHYSIOL, V50, P143, DOI 10.1152/jappl.1981.50.1.143; Speake BK, 1998, PROG LIPID RES, V37, P1, DOI 10.1016/S0163-7827(97)00012-X; Syu LJ, 1999, MOL CELL, V4, P109, DOI 10.1016/S1097-2765(00)80192-6; SZTALRYD C, 1994, AM J PHYSIOL, V266, P179; Wang SP, 2001, OBES RES, V9, P119, DOI 10.1038/oby.2001.15; Wei SH, 1997, J BIOL CHEM, V272, P14159, DOI 10.1074/jbc.272.22.14159; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Winzell MS, 2001, DIABETES, V50, P2225, DOI 10.2337/diabetes.50.10.2225; YEAMAN SJ, 1990, BIOCHIM BIOPHYS ACTA, V1052, P128, DOI 10.1016/0167-4889(90)90067-N; Yip RGC, 1999, ENDOCRINOLOGY, V140, P1219, DOI 10.1210/en.140.3.1219	53	120	132	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12946	12952		10.1074/jbc.M108640200	http://dx.doi.org/10.1074/jbc.M108640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11809748	hybrid			2022-12-25	WOS:000175036300060
J	Kira, M; Sano, S; Takagi, S; Yoshikawa, K; Takeda, J; Itami, S				Kira, M; Sano, S; Takagi, S; Yoshikawa, K; Takeda, J; Itami, S			STAT3 deficiency in keratinocytes leads to compromised cell migration through hyperphosphorylation of p130(cas)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TYROSINE-PHOSPHATASE SHP-2; ARP2/3 COMPLEX; DIRECT BINDING; V-SRC; PROTEIN; PHOSPHORYLATION; SUBSTRATE; CRK; ACTIVATION	We previously reported that STAT3 plays a crucial role in transducing a signal for migration of keratinocytes (Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., Yoshikawa, K., Akira, S., and Takeda, J. (1999) EMBO J. 18, 4657-4668). To clarify the role of STAT3 in signaling the migration, we studied the intracellular signaling pathway through an integrin receptor in STAT3-deficient keratinocytes. STAT3-deficient keratinocytes demonstrated increased adhesiveness and fast spreading on a collagen matrix. Staining with anti-phosphotyrosine antibody revealed that STAT3-deficient keratinocytes had an increased number of tyrosyl-hyperphosphorylated focal adhesions. Analyses with immunoprecipitation revealed that p130(cas) was constitutively hyperphosphorylated on tyrosine residues, while other focal adhesion molecules such as focal adhesion kinase and paxillin were not. Transfection of STAT3-deficient keratinocytes with an adenoviral vector encoding the wild-type Stat3 gene reversed not only impaired migration but also the increased tyrosine phosphorylation of p130(cas). These results strongly suggest that STAT3 in keratinocytes plays a critical role in turnover of tyrosine phosphorylation of p130(cas), modulating cell adhesiveness to the substratum leading to growth factor-dependent cell migration.	Osaka Univ, Dept Dermatol, Course Mol Med, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Social & Environm Med, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Itami, S (corresponding author), Osaka Univ, Dept Dermatol, Course Mol Med, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.							Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; BENNETT NT, 1993, AM J SURG, V165, P728, DOI 10.1016/S0002-9610(05)80797-4; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; ILIE D, 1995, NATURE, V377, P539; Inagaki K, 2000, ONCOGENE, V19, P75, DOI 10.1038/sj.onc.1203204; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Manie SN, 1997, J BIOL CHEM, V272, P15636, DOI 10.1074/jbc.272.25.15636; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Ryu H, 2000, J IMMUNOL, V165, P2116, DOI 10.4049/jimmunol.165.4.2116; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tashiro F, 1999, HUM GENE THER, V10, P1845, DOI 10.1089/10430349950017527; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Welch MD, 1999, TRENDS CELL BIOL, V9, P423, DOI 10.1016/S0962-8924(99)01651-7; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	41	50	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12931	12936		10.1074/jbc.M110795200	http://dx.doi.org/10.1074/jbc.M110795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812786	hybrid			2022-12-25	WOS:000175036300058
J	Koteish, A; Yang, SQ; Lin, HZ; Huang, XW; Diehl, AM				Koteish, A; Yang, SQ; Lin, HZ; Huang, XW; Diehl, AM			Chronic ethanol exposure potentiates lipopolysaccharide liver injury despite inhibiting Jun N-terminal kinase and caspase 3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; NITRIC-OXIDE SYNTHASE; MITOCHONDRIAL PERMEABILITY TRANSITION; ACUTE ALCOHOLIC HEPATITIS; FACTOR-INDUCED APOPTOSIS; KAPPA-B; FACTOR-ALPHA; HEPATOCYTE APOPTOSIS; ENERGY-METABOLISM; INTERFERON-GAMMA	Although ethanol is known to sensitize hepatocytes to tumor necrosis factor (TNF) lethality, the mechanisms involved remain controversial. Recently, others have shown that adding TNFalpha to cultures of ethanol-pretreated hepatocytes provokes the mitochondrial permeability transition, cytochrome c release, procaspase 3 activation, and apoptosis. Although this demonstrates that ethanol can sensitize hepatocytes to TNF-mediated apoptosis, the hepatic inflammation and ballooning hepatocyte degeneration that typify alcohol-induced liver injury suggest that other mechanisms might predominate in vivo. To evaluate this possibility, acute responses to lipopolysaccharide (LPS), a potent inducer of TNFa, were compared in mice that had been fed either an ethanol-containing or control diet for 5 weeks. Despite enhanced induction of cytokines such as interleukin (IL)-10, IL-15, and IL-6 that protect hepatocytes from apoptosis, ethanol-fed mice exhibited a 4-5-fold increase in serum alanine amino transferase after LPS, confirming increased liver injury. Six h post-LPS histology also differed notably in the two groups, with control livers demonstrating only scattered apoptotic hepatocytes, whereas ethanol-exposed livers had large foci of ballooned hepatocytes, inflammation, and scattered hemorrhage. No caspase 3 activity was noted during the initial 6 h after LPS in ethanol-fed mice, but this tripled by 1.5 h after LPS in controls. Procaspase 8 cleavage and activity of the apoptosis-associated kinase, Jun N-terminal kinase, were also greater in controls. In contrast, ethanol exposure did not inhibit activation of cytoprotective mitogen-activated protein kinases and AKT or attenuate induction of the anti-apoptotic factors NF-kappaB and inducible nitric oxide synthase. Consistent with these responses, neither cytochrome c release, an early apoptotic response, nor hepatic oligonucleosomal DNA fragmentation, the ultimate consequence of apoptosis, was increased by ethanol. Thus, ethanol exacerbates TNF-related hepatotoxicity in vivo without enhancing caspase 3-dependent apoptosis.	Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA	Johns Hopkins University	Diehl, AM (corresponding author), Johns Hopkins Univ, Dept Med, 912 Ross Bldg,720 Rutland St, Baltimore, MD 21205 USA.	amdiehl@welch.jhu.edu	Mordwinkin, Nicholas M/A-4347-2010					Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Bader A, 1999, EXP CELL RES, V246, P221, DOI 10.1006/excr.1998.4295; Bailey SM, 1999, FREE RADICAL BIO MED, V27, P891, DOI 10.1016/S0891-5849(99)00138-0; Baker SJ, 1996, ONCOGENE, V12, P1; BARONI GS, 1994, J HEPATOL, V20, P508, DOI 10.1016/S0168-8278(05)80498-2; BERRY MN, 1992, LIFE SCI, V51, P1, DOI 10.1016/0024-3205(92)90212-8; Bohlinger I, 1995, HEPATOLOGY, V22, P1829, DOI 10.1016/0270-9139(95)90212-0; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Capuano F, 1997, J BIOENERG BIOMEMBR, V29, P379, DOI 10.1023/A:1022402915431; Cheng HL, 2001, J NEUROCHEM, V76, P935, DOI 10.1046/j.1471-4159.2001.00110.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colell A, 1998, GASTROENTEROLOGY, V115, P1541, DOI 10.1016/S0016-5085(98)70034-4; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; CUNNINGHAM CC, 1990, ALCOHOL ALCOHOLISM, V25, P127, DOI 10.1093/oxfordjournals.alcalc.a044987; Day CP, 1998, GASTROENTEROLOGY, V114, P842, DOI 10.1016/S0016-5085(98)70599-2; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; DIEHL AM, 1994, AM J PHYSIOL-GASTR L, V267, pG552, DOI 10.1152/ajpgi.1994.267.4.G552; Eguchi Y, 1997, CANCER RES, V57, P1835; FRNANDEZCHECA JC, 1997, AM J PHYSIOL, V273, pG7; Galle PR, 1997, J HEPATOL, V27, P405, DOI 10.1016/S0168-8278(97)80189-4; GAO WS, 1995, TRANSPLANTATION, V59, P674, DOI 10.1097/00007890-199503150-00005; GOLDIN RD, 1993, J PATHOL, V171, P73, DOI 10.1002/path.1711710115; Goldring CEP, 1996, NUCLEIC ACIDS RES, V24, P1682, DOI 10.1093/nar/24.9.1682; Higuchi M, 1997, J CLIN INVEST, V99, P1751, DOI 10.1172/JCI119339; HOEK JB, 1994, CURR TOP BIOENERG, V17, P197; HONCHEL R, 1992, ALCOHOL CLIN EXP RES, V16, P665, DOI 10.1111/j.1530-0277.1992.tb00656.x; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Israel Y, 1984, Recent Dev Alcohol, V2, P119; Jaeschke H, 1998, J IMMUNOL, V160, P3480; JOHNSON RD, 1985, ALCOHOL ALCOHOLISM, V20, P137; Kim YM, 1997, BIOCHEM BIOPH RES CO, V236, P655, DOI 10.1006/bbrc.1997.7031; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAD PJ, 1982, ALCOHOL CLIN EXP RES, V6, P72, DOI 10.1111/j.1530-0277.1982.tb05383.x; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LAVERY DJ, 1993, GENE DEV, V7, P1871, DOI 10.1101/gad.7.10.1871; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEIST M, 1994, J IMMUNOL, V153, P1778; Lelbach W K, 1976, Prog Liver Dis, V5, P494; Lemasters JJ, 1999, J BIOENERG BIOMEMBR, V31, P305, DOI 10.1023/A:1005419617371; Levresse V, 2000, J NEUROSCI RES, V62, P799; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin HZ, 2000, NAT MED, V6, P998, DOI 10.1038/79697; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOWENSTEIN CJ, 1994, METHOD ENZYMOL, V233, P264; MACSWEEN RNM, 1986, SEMIN LIVER DIS, V6, P221, DOI 10.1055/s-2008-1040605; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Marsano LS, 1998, HEPATO-GASTROENTEROL, V45, P331; Mayeux PR, 1997, J TOXICOL ENV HEALTH, V51, P415, DOI 10.1080/00984109708984034; NAGAKAWA J, 1990, GASTROENTEROLOGY, V99, P758, DOI 10.1016/0016-5085(90)90965-4; OSYPIW JC, 1994, BIOCHEM J, V304, P617, DOI 10.1042/bj3040617; Park HS, 2001, EMBO J, V20, P446, DOI 10.1093/emboj/20.3.446; Pastorino JG, 2000, HEPATOLOGY, V31, P1141, DOI 10.1053/he.2000.7013; Pastorino JG, 1996, J BIOL CHEM, V271, P29792, DOI 10.1074/jbc.271.47.29792; PEQUIGNOT G, 1978, INT J EPIDEMIOL, V7, P113, DOI 10.1093/ije/7.2.113; Richard M, 1999, BLOOD, V93, P4318, DOI 10.1182/blood.V93.12.4318.412k09_4318_4327; ROTHSCHILD MA, 1993, SEMIN LIVER DIS, V13; SEEFF LB, 1986, ANN INTERN MED, V104, P399, DOI 10.7326/0003-4819-104-3-399; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Serfaty L, 1997, HEPATOLOGY, V26, P776, DOI 10.1002/hep.510260334; SHERON N, 1993, HEPATOLOGY, V18, P41, DOI 10.1002/hep.1840180108; SHIRATORI Y, 1995, J GASTROEN HEPATOL, V10, pS97, DOI 10.1111/j.1440-1746.1995.tb01811.x; SUMNER IG, 1983, EUR J BIOCHEM, V134, P539, DOI 10.1111/j.1432-1033.1983.tb07600.x; Takada E, 2001, J IMMUNOL, V166, P1641, DOI 10.4049/jimmunol.166.3.1641; THURMAN RG, 1984, FUND APPL TOXICOL, V4, P125, DOI 10.1016/0272-0590(84)90112-X; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; Waldmann TA, 2001, IMMUNITY, V14, P105, DOI 10.1016/S1074-7613(01)00093-0; Weisz A, 1996, BIOCHEM J, V316, P209, DOI 10.1042/bj3160209; WESTWICK JK, 1995, J CLIN INVEST, V95, P803, DOI 10.1172/JCI117730; WILLIAMS AJK, 1987, GUT, V28, P1157, DOI 10.1136/gut.28.9.1157; YACOUB LK, 1995, ALCOHOL CLIN EXP RES, V19, P854, DOI 10.1111/j.1530-0277.1995.tb00958.x; YAN MH, 1994, NATURE, V372, P798; Yang SQ, 1998, AM J PHYSIOL-GASTR L, V275, pG696, DOI 10.1152/ajpgi.1998.275.4.G696; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9; Zeldin G, 1996, ALCOHOL CLIN EXP RES, V20, P1639, DOI 10.1111/j.1530-0277.1996.tb01710.x; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZIEGLERHEITBROCK HWL, 1994, J BIOL CHEM, V269, P17001	83	75	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13037	13044		10.1074/jbc.M101632200	http://dx.doi.org/10.1074/jbc.M101632200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812769	hybrid			2022-12-25	WOS:000175036300070
J	Lee, SY; Wang, Z; Lin, CK; Contag, CH; Olds, LC; Cooper, AD; Sibley, E				Lee, SY; Wang, Z; Lin, CK; Contag, CH; Olds, LC; Cooper, AD; Sibley, E			Regulation of intestine-specific spatiotemporal expression by the rat lactase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN GENE; PHLORHIZIN HYDROLASE GENE; CIS-ACTING ELEMENTS; TRANSGENIC MICE; MESSENGER-RNA; ENZYMATIC-ACTIVITY; GUT EPITHELIUM; LIVING MAMMALS; FUSION GENES; DIFFERENTIATION	Lactase gene transcription is spatially restricted to the proximal and middle small intestine of the developing mouse. To identify regions of the lactase gene involved in mediating the spatiotemporal expression pattern, transgenic mice harboring 0.8-, 1.3-, and 2.0-kb fragments of the 5'-flanking region cloned upstream of a firefly-luciferase reporter were generated. Transgene expression was assessed noninvasively in living mice using a sensitive low light imaging system. Two independent, 1.3- and 2.0-kb, lactase promoter-reporter transgenic lines expressed appropriate high levels of luciferase activity in the small intestine (300-3,000 relative light units/mug) with maximal expression in the middle segments. Post-weaned 30-day transgenic offspring also demonstrated an appropriate 4-fold maturational decline in luciferase expression in the small intestine. The pattern of the 2.0-kb promoter transgene mRNA abundance most closely mimicked that of the endogenous lactase gene with respect to spatiotemporal restriction. In contrast, a 0.8-kb promoter-reporter construct expressed low level luciferase activity (<25 relative light units/mug) in multiple organs and throughout the gastrointestinal tract in transgenic mice. Thus, a distinct 5'-region of the lactase promoter directs intestine-specific expression in the small intestine of transgenic mice, and regulatory sequences have been localized to a 1.2-kb region upstream of the lactase transcription start site. In addition, we have demonstrated that in vivo bioluminescence imaging can be utilized for assessment of intestinal expression patterns of a luciferase reporter gene driven by lactase promoter regions in transgenic mice.	Stanford Univ, Med Ctr, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Med Ctr, Dept Pediat, Palo Alto, CA 94304 USA	Stanford University; Stanford University	Sibley, E (corresponding author), Stanford Univ, Sch Med, Dept Pediat, 750 Welch Rd,Ste116, Palo Alto, CA 94304 USA.			Contag, Christopher/0000-0002-1011-8278	NIDDK NIH HHS [DK-02552] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002552] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; Colnot S, 1998, J BIOL CHEM, V273, P31939, DOI 10.1074/jbc.273.48.31939; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Contag CH, 1995, MOL MICROBIOL, V18, P593, DOI 10.1111/j.1365-2958.1995.mmi_18040593.x; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; DULUC I, 1991, GENE, V103, P275, DOI 10.1016/0378-1119(91)90286-K; Dusing MR, 2000, AM J PHYSIOL-GASTR L, V279, pG1080, DOI 10.1152/ajpgi.2000.279.5.G1080; Fang RX, 2001, AM J PHYSIOL-GASTR L, V280, pG58, DOI 10.1152/ajpgi.2001.280.1.G58; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Fitzgerald K, 1998, AM J PHYSIOL-GASTR L, V274, pG314, DOI 10.1152/ajpgi.1998.274.2.G314; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; FREUND JN, 1990, CELL MOL BIOL, V36, P729; HAUFT SM, 1989, J BIOL CHEM, V264, P8419; Hecht A, 1997, GASTROENTEROLOGY, V112, P803, DOI 10.1053/gast.1997.v112.pm9041242; HENNING S, 1992, PHYSL GASTROINTESTIN, P571; Hocker M, 2001, GASTROENTEROLOGY, V121, P43, DOI 10.1053/gast.2001.25526; KELLER P, 1992, FEBS LETT, V313, P265, DOI 10.1016/0014-5793(92)81206-2; Krasinski SD, 1997, GASTROENTEROLOGY, V113, P844, DOI 10.1016/S0016-5085(97)70179-3; KRASINSKI SD, 1994, AM J PHYSIOL-GASTR L, V267, pG584, DOI 10.1152/ajpgi.1994.267.4.G584; LACEY SW, 1994, BIOCHEM J, V302, P929, DOI 10.1042/bj3020929; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; NUDELL DM, 1993, AM J PHYSIOL, V265, pG1108, DOI 10.1152/ajpgi.1993.265.6.G1108; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; RINGS EHHM, 1992, GASTROENTEROLOGY, V103, P1154, DOI 10.1016/0016-5085(92)91498-S; Romagnolo B, 1996, J BIOL CHEM, V271, P16820, DOI 10.1074/jbc.271.28.16820; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SIMON TC, 1995, P NATL ACAD SCI USA, V92, P8685, DOI 10.1073/pnas.92.19.8685; SOTO U, 1993, EXP CELL RES, V205, P66, DOI 10.1006/excr.1993.1059; Spodsberg N, 1999, GASTROENTEROLOGY, V116, P842, DOI 10.1016/S0016-5085(99)70067-3; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; TROELSEN JT, 1992, J BIOL CHEM, V267, P20407; Troelsen JT, 1997, BIOCHEM J, V322, P833, DOI 10.1042/bj3220833; TROELSEN JT, 1994, FEBS LETT, V342, P291, DOI 10.1016/0014-5793(94)80519-9; Tung J, 1997, AM J PHYSIOL-GASTR L, V273, pG83, DOI 10.1152/ajpgi.1997.273.1.G83; VERHAVE M, 1995, BIOCHEM BIOPH RES CO, V209, P989, DOI 10.1006/bbrc.1995.1595	38	35	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13099	13105		10.1074/jbc.M112152200	http://dx.doi.org/10.1074/jbc.M112152200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812796	hybrid			2022-12-25	WOS:000175036300078
J	Lim, YM; Han, I; Kwon, HJ; Oh, ES				Lim, YM; Han, I; Kwon, HJ; Oh, ES			Trichostatin A-induced detransformation correlates with decreased focal adhesion kinase phosphorylation at tyrosine 861 in ras-transformed fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; HISTONE DEACETYLASE; MORPHOLOGICAL TRANSFORMATION; GELSOLIN EXPRESSION; SIGNAL-TRANSDUCTION; CELL-MIGRATION; CARCINOMA CELL; NIH3T3 CELLS; INTEGRIN; SRC	To elucidate the role of focal adhesion kinase (pp125FAK) in transformation, its phosphorylation in transformed fibroblasts was compared with that of detransformed fibroblasts induced by a histone deacetylase inhibitor, trichostatin A (TSA). Inhibition of histone deacetylase activity in two different ras-transformed fibroblast lines by TSA induced a morphological change into a flattened and more spread morphology, implying detransformation. These morphological changes included increased spreading ability of transformed NIH 3T3 cells on fibronectin. Of the six tyrosine phosphorylation sites in pp125FAK, phosphorylation at position 861 (Tyr-861) was clearly decreased during detransformation by TSA. It resulted from decreased activity of Src family tyrosine kinase and/or decreased amount of Sre kinase interacting with pp125FAK. Furthermore, phosphorylation of Tyr-861 was reduced substantially by the Sre family kinase inhibitor, PP1, while overexpression of Sre kinase increased its phosphorylation, implying that Sre kinase regulates phosphorylation of pp125FAK at Tyr-861. All of these findings suggest that increased phosphorylation of pp125FAK at Tyr-861 correlates with Ras-induced transformation of fibroblasts, and TSA is able to detransform them through regulation of pp125FAK phosphorylation at Tyr-861 by an Src family kinase.	Ewha Womans Univ, Ctr Cell Signaling Res, Seodaemoon Gu, Seoul 120750, South Korea; Ewha Womans Univ, Dept Life Sci, Seodaemoon Gu, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seodaemoon Gu, Seoul 120750, South Korea; Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Seoul 143747, South Korea	Ewha Womans University; Ewha Womans University; Ewha Womans University; Sejong University	Oh, ES (corresponding author), Ewha Womans Univ, Ctr Cell Signaling Res, Seodaemoon Gu, Seoul 120750, South Korea.	OhES@mm.ewha.ac.kr	권, 호정/AAS-3642-2021					Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Aplin AE, 1999, J CELL SCI, V112, P695; Brenner KA, 2000, ONCOGENE, V19, P3156, DOI 10.1038/sj.onc.1203626; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calalb MB, 1996, BIOCHEM BIOPH RES CO, V228, P662, DOI 10.1006/bbrc.1996.1714; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; FUTAMURA M, 1995, ONCOGENE, V10, P1119; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Hildebrand JD, 1996, MOL CELL BIOL, V16, P3169; Hocking DC, 1999, J BIOL CHEM, V274, P27257, DOI 10.1074/jbc.274.38.27257; Hocking DC, 2000, J BIOL CHEM, V275, P10673, DOI 10.1074/jbc.275.14.10673; HOSHIKAWA Y, 1994, EXP CELL RES, V214, P189, DOI 10.1006/excr.1994.1248; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Ilic D, 1997, J CELL SCI, V110, P401; Kapur R, 1998, EXP CELL RES, V244, P275, DOI 10.1006/excr.1998.4156; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Kwon HJ, 1997, ONCOGENE, V15, P2625, DOI 10.1038/sj.onc.1201443; Nakayama S, 2001, INT J CANCER, V93, P667, DOI 10.1002/ijc.1386; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208; Spencer VA, 2000, J CELL BIOCHEM, P27; SUGITA K, 1992, CANCER RES, V52, P168; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; TANAKA M, 1995, CANCER RES, V55, P3228; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Wharton W, 2000, J BIOL CHEM, V275, P33981, DOI 10.1074/jbc.M005600200; WOODS A, 1993, MOL BIOL CELL, V4, P605, DOI 10.1091/mbc.4.6.605; Zhong Y, 2001, CLIN CANCER RES, V7, P1683	41	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12735	12740		10.1074/jbc.M111011200	http://dx.doi.org/10.1074/jbc.M111011200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821402	hybrid			2022-12-25	WOS:000175036300032
J	Nargang, FE; Preuss, M; Neupert, W; Herrmann, JM				Nargang, FE; Preuss, M; Neupert, W; Herrmann, JM			The oxal protein forms a homooligomeric complex and is an essential part of the mitochondrial export translocase in Neurospora crassa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR GENE; COILED COILS; N-TERMINI; C-TERMINI; MEMBRANE; IMPORT; YEAST; COMPLEMENTATION; TRANSFORMATION	The Oxa1 protein is a ubiquitous constituent of the inner membrane of mitochondria. Oxa1 was identified in yeast as a crucial component of the protein export machinery known as the OXA translocase, which facilitates the integration of proteins from the mitochondrial matrix into the inner membrane. We have identified the Neurospora crassa Oxa1 protein which shows a sequence identity of 22% to the yeast homologue. Despite the low level of identity, the function of the homologues is conserved as the N. crassa gene fully complemented a yeast null mutant. Genetic analysis revealed that Oxa1 is essential for viability in N. crassa. Cells propagated under conditions that severely reduce Oxa1 levels grew extremely slowly and were deficient in subunits of complex I and complex IV. Isolation of the Oxa1 complex from N. crassa mitochondria revealed a 170-180-kDa complex that contained exclusively Oxa1. Since the Oxa1 monomer has a molecular weight of 43,000, our data suggest that the OXA translocase consists of a homooligomer most likely containing four Oxa1 subunits.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Univ Munich, Adolf Butenandt Inst Physiol Chem, D-81377 Munich, Germany	University of Alberta; University of Munich	Nargang, FE (corresponding author), Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada.		Nargang, Frank/A-2669-2014	Nargang, Frank/0000-0002-1383-4720				AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; [Anonymous], [No title captured]; AUSTIN B, 1990, GENE, V93, P157, DOI 10.1016/0378-1119(90)90152-H; AUSUBEL RA, 1992, CURRENT PROTOCOLS MO; BAUER M, 1994, MOL GEN GENET, V245, P272, DOI 10.1007/BF00290106; BONNEFOY N, 1994, P NATL ACAD SCI USA, V91, P11978, DOI 10.1073/pnas.91.25.11978; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; Bonnefoy N, 2000, MOL MICROBIOL, V35, P1135, DOI 10.1046/j.1365-2958.2000.01781.x; Burkhard P, 2001, TRENDS CELL BIOL, V11, P82, DOI 10.1016/S0962-8924(00)01898-5; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; GESSERT SF, 1994, J BIOL CHEM, V269, P8189; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glick BS, 1996, PROTEIN SCI, V5, P2651, DOI 10.1002/pro.5560051229; GOOD AG, 1989, PLANT PHYSIOL, V90, P1305, DOI 10.1104/pp.90.4.1305; HARKNESS TAA, 1994, GENETICS, V136, P107; He SC, 1997, MOL BIOL CELL, V8, P1449, DOI 10.1091/mbc.8.8.1449; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; Herrmann JM, 1997, EMBO J, V16, P2217, DOI 10.1093/emboj/16.9.2217; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P611, DOI 10.1006/bbrc.1999.1703; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; METZENBERG RL, 1992, FUNGAL GENET NEWSLET, V39, P50; METZENBERG RL, 1984, NEUROSPORA NEWSL, V31, P35; MOLLER JV, 1993, J BIOL CHEM, V268, P18659; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Preuss M, 2001, J CELL BIOL, V153, P1085, DOI 10.1083/jcb.153.5.1085; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SCHWEIZER M, 1981, P NATL ACAD SCI-BIOL, V78, P5086, DOI 10.1073/pnas.78.8.5086; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHARROCKS AD, 1994, GENE, V138, P105, DOI 10.1016/0378-1119(94)90789-7; Sirrenberg C, 1997, J BIOL CHEM, V272, P29963, DOI 10.1074/jbc.272.47.29963; Staben C, 1989, FUNGAL GENET NEWSL, V36, P79, DOI DOI 10.4148/1941-4765.1519; van der Laan M, 2001, EMBO REP, V2, P519, DOI 10.1093/embo-reports/kve106; WACHTER E, 1973, FEBS LETT, V35, P97, DOI 10.1016/0014-5793(73)80585-X	44	75	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12846	12853		10.1074/jbc.M112099200	http://dx.doi.org/10.1074/jbc.M112099200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11823466	hybrid			2022-12-25	WOS:000175036300047
J	Oh, MK; Rohlin, L; Kao, KC; Liao, JC				Oh, MK; Rohlin, L; Kao, KC; Liao, JC			Global expression profiling of acetate-grown Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; MICROARRAY ANALYSIS; STARVATION GENE; ACID; METABOLISM; IDENTIFICATION; INACTIVATION; INDUCTION; TRANSPORT; RESPONSES	This study characterized the transcript profile of Escherichia coli in acetate cultures using DNA microarray on glass slides. Glucose-grown cultures were used as a reference. At the 95% confidence level, 354 genes were up-regulated in acetate, while 370 genes were down-regulated compared with the glucose-grown culture. Generally, more metabolic genes were up-regulated in acetate than other gene groups, while genes involved in cell replication, transcription, and translation machinery tended to be down-regulated. It appears that E. coli commits more resources to metabolism at the expense of growth when cultured in the poor carbon source. The expression profile confirms many known features in acetate metabolism such as the induction of the glyoxylate pathway, tricarboxylic acid cycle, and gluconeogenic genes. It also provided many previously unknown features, including induction of malic enzymes, ppsA, and the glycolate pathway and repression of glycolytic and glucose phosphotransferase genes in acetate. The carbon flux delivered from the malic enzymes and PpsA in acetate was further confirmed by deletion mutations. In general, the gene expression profiles qualitatively agree with the metabolic flux changes and may serve as a predictor for gene function and metabolic flux distribution.	Univ Calif Los Angeles, Dept Chem Engn, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Liao, JC (corresponding author), Univ Calif Los Angeles, Dept Chem Engn, 5531 Boelter Hall, Los Angeles, CA 90095 USA.	liaoj@ucla.edu	Oh, Min-Kyu/F-6933-2013	Oh, Min-Kyu/0000-0001-6406-3930; Kao, Katy/0000-0002-1184-276X; Liao, James/0000-0002-4580-7276				[Anonymous], 1996, ESCHERICHIA COLI SAL, P1325; Arfin SM, 2000, J BIOL CHEM, V275, P29672, DOI 10.1074/jbc.M002247200; Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Cozzone AJ, 1998, ANNU REV MICROBIOL, V52, P127, DOI 10.1146/annurev.micro.52.1.127; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P206; Cusa E, 1999, J BACTERIOL, V181, P7479, DOI 10.1128/JB.181.24.7479-7484.1999; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Davies SJ, 1999, J BACTERIOL, V181, P5624, DOI 10.1128/JB.181.18.5624-5635.1999; DeLisa MP, 2001, J BACTERIOL, V183, P5239, DOI 10.1128/JB.183.18.5239-5247.2001; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DiRusso CC, 1999, MOL CELL BIOCHEM, V192, P41, DOI 10.1023/A:1006823831984; Eisen MB, 1999, METHOD ENZYMOL, V303, P179; Fraley CD, 1998, J BACTERIOL, V180, P4287, DOI 10.1128/JB.180.16.4287-4290.1998; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; Gong F, 2001, J BIOL CHEM, V276, P1974, DOI 10.1074/jbc.M008892200; Holms H, 1996, FEMS MICROBIOL REV, V19, P85, DOI 10.1111/j.1574-6976.1996.tb00255.x; KAKUDA H, 1994, J BIOCHEM-TOKYO, V116, P916, DOI 10.1093/oxfordjournals.jbchem.a124616; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Keener J, 1996, ESCHERICHIA COLI SAL, V2, P1417; Khodursky AB, 2000, P NATL ACAD SCI USA, V97, P12170, DOI 10.1073/pnas.220414297; Kumari S, 2000, J BACTERIOL, V182, P4173, DOI 10.1128/JB.182.15.4173-4179.2000; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; LULI GW, 1990, APPL ENVIRON MICROB, V56, P1004, DOI 10.1128/AEM.56.4.1004-1011.1990; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MURAI T, 1971, BIOCHEM BIOPH RES CO, V43, P875, DOI 10.1016/0006-291X(71)90698-X; Oh MK, 2000, METAB ENG, V2, P201, DOI 10.1006/mben.2000.0149; Oh MK, 2000, BIOTECHNOL PROGR, V16, P278, DOI 10.1021/bp000002n; Pellicer MT, 1999, J BIOL CHEM, V274, P1745, DOI 10.1074/jbc.274.3.1745; Plumbridge J, 1999, MOL MICROBIOL, V33, P260, DOI 10.1046/j.1365-2958.1999.01462.x; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Postma P.W., 1996, ESCHERICHIA COLI SAL, P1149; Pruss BM, 2001, FEMS MICROBIOL LETT, V197, P91; REIZER LJ, 1996, ESCHERICHIA COLI SAL, P391; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Robison K, 1998, J MOL BIOL, V284, P241, DOI 10.1006/jmbi.1998.2160; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHULTZ JE, 1991, J MOL BIOL, V218, P129, DOI 10.1016/0022-2836(91)90879-B; Stols L, 1997, APPL ENVIRON MICROB, V63, P2695, DOI 10.1128/AEM.63.7.2695-2701.1997; Tao H, 1999, J BACTERIOL, V181, P6425, DOI 10.1128/JB.181.20.6425-6440.1999; Tao H, 2001, J BACTERIOL, V183, P2979, DOI 10.1128/JB.183.10.2979-2988.2001; Thomson GJ, 1998, BIOCHEM J, V331, P437, DOI 10.1042/bj3310437; Tseng GC, 2001, NUCLEIC ACIDS RES, V29, P2549, DOI 10.1093/nar/29.12.2549; Umbarger H. E., 1996, ESCHERICHIA COLI SAL, P442; van der Rest ME, 2000, J BACTERIOL, V182, P6892, DOI 10.1128/JB.182.24.6892-6899.2000; VANDERWI.E, 1968, EUR J BIOCHEM, V5, P81, DOI 10.1111/j.1432-1033.1968.tb00340.x; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001; Zimmer DP, 2000, P NATL ACAD SCI USA, V97, P14674, DOI 10.1073/pnas.97.26.14674	50	230	257	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					13175	13183		10.1074/jbc.M110809200	http://dx.doi.org/10.1074/jbc.M110809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815613	hybrid, Green Published			2022-12-25	WOS:000175036300087
J	Souillac, PO; Uversky, VN; Millett, IS; Khurana, R; Doniach, S; Fink, AL				Souillac, PO; Uversky, VN; Millett, IS; Khurana, R; Doniach, S; Fink, AL			Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation - Evidence for an off-pathway oligomer at acidic pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPECTRAL PARAMETERS; DEPOSITION DISEASE; PROTEIN; INTERMEDIATE; FLUORESCENCE; STATES; SPECTROSCOPY; AGGREGATION; FIBRILS; MODEL	Light chain amyloidosis involves the systemic pathologic deposition of monoclonal light chain variable domains of immunoglobulins as insoluble fibrils. The variable domain LEN was obtained from a patient who had no overt amyloidosis; however, LEN forms fibrils in vitro, under mildly destabilizing conditions. The in vitro kinetics of fibrillation were investigated using a wide variety of probes. The rate of fibril formation was highly dependent on the initial protein concentration. In contrast to most amyloid systems, the kinetics became slower with increasing LEN concentrations. At high protein concentrations a significant lag in time was observed between the conformational changes and the formation of fibrils, consistent with the formation of soluble off-pathway oligomeric species and a branched pathway. The presence of off-pathway species was confirmed by small angle x-ray scattering. At low protein concentrations the structural rearrangements were concurrent with fibril formation, indicating the absence of formation of the off-pathway species. The data are consistent with a model for fibrillation in which a dimeric form of LEN (at high protein concentration) inhibits fibril formation by interaction with an intermediate on the fibrillation pathway and leads to formation of the off-pathway intermediate.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA	University of California System; University of California Santa Cruz; Stanford University	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				AZUMA T, 1978, J BIOCHEM-TOKYO, V83, P1485, DOI 10.1093/oxfordjournals.jbchem.a132058; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BUXBAUM J, 1992, HEMATOL ONCOL CLIN N, V6, P323, DOI 10.1016/S0889-8588(18)30347-2; CHIRGADZE YN, 1974, BIOPOLYMERS, V13, P1701, DOI 10.1002/bip.1974.360130902; EFTINK MR, 1982, BIOCHEMISTRY-US, V21, P117, DOI 10.1021/bi00530a021; ELIEZER D, 1993, BIOPHYS J, V65, P912, DOI 10.1016/S0006-3495(93)81124-X; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; Goormaghtigh E, 1994, Subcell Biochem, V23, P329; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Helms LR, 1996, J MOL BIOL, V257, P77, DOI 10.1006/jmbi.1996.0148; Huang DB, 1997, MOL IMMUNOL, V34, P1291, DOI 10.1016/S0161-5890(98)00002-9; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; KHURANA R, 2002, IN PRESS BIOCHEMISTR; Kisilevsky R, 2000, J STRUCT BIOL, V130, P99, DOI 10.1006/jsbi.2000.4222; Kratky O, 1982, SMALL ANGLE XRAY SCA, DOI [10.1002/actp.1985.010360520, DOI 10.1002/ACTP.1985.010360520]; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lehrer S S, 1978, Methods Enzymol, V49, P222; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; MANNING MC, 1993, ACS SYM SER, V516, P33; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; MIDDAUGH CR, 1978, BIOCHIM BIOPHYS ACTA, V535, P33; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; NAIKI H, 1991, LAB INVEST, V65, P104; NEUMANN N, 1996, PROTEINS FORM FUNCTI, P107; Oberg KA, 1998, ANAL BIOCHEM, V256, P92, DOI 10.1006/abio.1997.2486; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Raffen R, 1999, PROTEIN SCI, V8, P509; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Semisotnov GV, 1996, J MOL BIOL, V262, P559, DOI 10.1006/jmbi.1996.0535; Seshadri S, 1999, METHOD ENZYMOL, V309, P559; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SOLOMON A, 1986, SEMIN ONCOL, V13, P341; SOLOMON A, 1985, METHOD ENZYMOL, V116, P101; Sreerama N, 1999, BIOCHEMISTRY-US, V38, P10814, DOI 10.1021/bi990516z; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; STRYER L, 1968, SCIENCE, V162, P526, DOI 10.1126/science.162.3853.526; Uversky V.N., 1999, MED SCI MONITOR, V5, P1238; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; UVERSKY VN, 1991, MED SCI MONITOR, V5, P1001; VENYAMINOV SY, 1990, BIOPOLYMERS, V30, P1243, DOI 10.1002/bip.360301309; VIRCHOW R, 1851, VIRCHOWS ARCH, V6, P415; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Woody R.W., 1996, CIRCULAR DICHROISM C, P25, DOI DOI 10.1007/978-1-4757-2508-7_2	45	97	99	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12666	12679		10.1074/jbc.M109229200	http://dx.doi.org/10.1074/jbc.M109229200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11815604	hybrid			2022-12-25	WOS:000175036300024
J	Sung, YK; Moon, C; Yoo, JY; Moon, C; Pearse, D; Pevsner, J; Ronnett, GV				Sung, YK; Moon, C; Yoo, JY; Moon, C; Pearse, D; Pevsner, J; Ronnett, GV			Plunc, a member of the secretory gland protein family, is up-regulated in nasal respiratory epithelium after olfactory bulbectomy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY-INCREASING PROTEIN; GRAM-NEGATIVE BACTERIA; DIFFERENTIAL DISPLAY; MOLECULAR-CLONING; BINDING PROTEINS; ODORANT-BINDING; SENSORY NEURONS; MESSENGER-RNA; HOST-DEFENSE; NEUROGENESIS	Subtraction suppression hybridization was used with high throughput screening to identify transcripts of genes that are differentially expressed in nasal epithelium following lesioning of the olfactory bulb, termed bulbectomy. We isolated the rat homologue of plunc, a murine gene highly expressed in lung and nasopharyngeal regions, by this method. Rat plunc encodes a 270-amino acid protein containing a putative signal peptide. plunc up-regulation in respiratory epithelium was confirmed by Northern blot and in situ hybridization. plunc mRNA was expressed in nasal epithelium, heart, lung, thymus, and salivary gland in adult rodent. plunc was expressed in nasal epithelium, thymus, and salivary gland during embryogenesis. Antibodies against Plunc detected a 31-kDa protein in lung, heart, and spleen. Rat nasal epithelium displayed robust immunoreactivity that was highly localized to the microvilli layer of respiratory epithelium. The expression of plunc was upregulated after bulbectomy in respiratory epithelium. We also detected secreted plunc in rat and human mucus. Sequence and homology analyses suggest that Plume is a member of the secretory gland protein family with putative bactericidal/bacteriostatic function. This is the first protein found in respiratory epithelium whose expression is regulated by olfactory neuronal injury and may provide protection against infection subsequent to injury.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Mol, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Eulji Univ, Sch Med, Dept Internal Med, Div Cardiol, Seoul 139711, South Korea	Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Kennedy Krieger Institute; Eulji University	Ronnett, GV (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Howard Hughes Med Inst, PCTB 1006B,725 N Wolfe St, Baltimore, MD 21205 USA.			Moon, Cheil/0000-0002-9741-7229	NIDCD NIH HHS [DC-2979] Funding Source: Medline; NINDS NIH HHS [NS-39657] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002979] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Buck LB, 1996, ANNU REV NEUROSCI, V19, P517, DOI 10.1146/annurev.ne.19.030196.002505; Calof AL, 1996, J NEUROBIOL, V30, P67; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONSTANZO RM, 1983, J COMP NEUROL, V215, P370; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEAR TN, 1991, BIOCHEMISTRY-US, V30, P10376, DOI 10.1021/bi00107a003; DEAR TN, 1991, EMBO J, V10, P2813, DOI 10.1002/j.1460-2075.1991.tb07830.x; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; ELSBACH P, 1993, IMMUNOBIOLOGY, V187, P417, DOI 10.1016/S0171-2985(11)80354-2; GRAZIADEI PPC, 1979, J NEUROCYTOL, V8, P1, DOI 10.1007/BF01206454; GRAZIADEI PPC, 1980, BRAIN RES, V186, P289, DOI 10.1016/0006-8993(80)90976-2; Graziadei PPC, 1978, NEURONAL PLASTICITY, P131; HOLCOMB JD, 1995, DEV BIOL, V172, P307, DOI 10.1006/dbio.1995.0025; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Iwao K, 2001, INT J CANCER, V91, P433, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1059>3.0.CO;2-B; Kanthan R, 1999, AM J FOREN MED PATH, V20, P57, DOI 10.1097/00000433-199903000-00014; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; Lim JH, 1999, J NEUROBIOL, V39, P207, DOI 10.1002/(SICI)1097-4695(199905)39:2<207::AID-NEU5>3.0.CO;2-C; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; MADSEN HO, 1985, NUCLEIC ACIDS RES, V13, P1, DOI 10.1093/nar/13.1.1; Mirels L, 1998, BIOCHEM J, V330, P437, DOI 10.1042/bj3300437; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; PEVSNER J, 1986, P NATL ACAD SCI USA, V83, P4942, DOI 10.1073/pnas.83.13.4942; Rajan GH, 1996, ANIM GENET, V27, P407, DOI 10.1111/j.1365-2052.1996.tb00507.x; ROSKAMS AJ, 1994, NEURON, V13, P289; Roskams AJI, 1996, J NEUROSCI, V16, P1294; SCHER KS, 1982, J TRAUMA, V22, P407, DOI 10.1097/00005373-198205000-00010; vonStein OD, 1997, NUCLEIC ACIDS RES, V25, P2598, DOI 10.1093/nar/25.13.2598; Weston WM, 1999, J BIOL CHEM, V274, P13698, DOI 10.1074/jbc.274.19.13698; [No title captured]	33	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12762	12769		10.1074/jbc.M106208200	http://dx.doi.org/10.1074/jbc.M106208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11821380	hybrid			2022-12-25	WOS:000175036300036
J	Waas, WF; Dalby, KN				Waas, WF; Dalby, KN			Transient protein-protein interactions and a random-ordered kinetic mechanism for the phosphorylation of a transcription factor by extracellular-regulated protein kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN BASIC-PROTEIN; RATE-DETERMINING STEP; RIBOSOMAL S6 KINASE; MAP KINASE; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; DOCKING SITE; DOMAIN; IDENTIFICATION; PATHWAY	No thorough mechanistic study of extracellular signal-regulated protein kinase 2 (ERK2) has appeared in the literature. A recombinant protein termed EtsDelta138, which comprises of residues 1-138 of the transcription factor Ets-1 is an excellent substrate of ERK2 (Waas W. F., and Dalby, K. N. (2001) Protein Exp. Purif 23, 191-197). The kinetic mechanism of ERK2 was examined, with excess magnesium, by initial velocity measurements, both in the absence and presence of products at 27 degreesC, pH 7.5, and ionic strength 0.1 m (KCl). The velocity data are consistent with a steady-state random-ordered ternary complex mechanism, where both substrates have unhindered access to binding sites on the enzyme. The mechanism and magnitude of product inhibition by monophosphorylated EtsDelta138 is consistent with, but does not prove, the notion that ERK2 forms a discrete interaction with EtsDelta138 in the absence of active site interactions, and that this "docking complex" facilitates intramolecular phosphorylation of the substrate. The approximation of the steady-state data to a rapid equilibrium model strongly suggests that the formation of ERK2(.)Ets138 complexes are transient in nature with dissociation constants of greater magnitude than the catalytic constant, of k(cat) = 17 s(-1).	Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Texas, Grad Programs Biochem & Mol Biol, Austin, TX 78712 USA; Univ Texas, Ctr Mol & Cellular Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Dalby, KN (corresponding author), Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.	Dalby@mail.utexas.edu	Dalby, Kevin N/A-1905-2013	Dalby, Kevin N/0000-0001-9272-5129	NIEHS NIH HHS [P30 ES 07784] Funding Source: Medline; NIGMS NIH HHS [GM 59802] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059802] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JA, 2001, CHEM REV, V101, P2271, DOI 10.1021/cr000230w; Allison R D, 1979, Methods Enzymol, V63, P3; Beniac DR, 1997, J BIOL CHEM, V272, P4261, DOI 10.1074/jbc.272.7.4261; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; BOEMER RJ, 1995, BIOCHEMISTRY-US, V34, P16419; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; CORNISHBOWDEN A, 1989, CURR TOP CELL REGUL, V30, P143; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fox T, 1999, FEBS LETT, V461, P323, DOI 10.1016/S0014-5793(99)01488-X; Fromm H J, 1979, Methods Enzymol, V63, P42; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GULBINSKY JS, 1968, BIOCHEMISTRY-US, V7, P566, DOI 10.1021/bi00842a009; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; Hoofnagle AN, 2001, P NATL ACAD SCI USA, V98, P956, DOI 10.1073/pnas.98.3.956; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; Lew J, 1997, BIOCHEMISTRY-US, V36, P6717, DOI 10.1021/bi963164u; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Mansour SJ, 1996, BIOCHEMISTRY-US, V35, P15529, DOI 10.1021/bi961854s; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; Myers JK, 2001, BIOCHEMISTRY-US, V40, P8479, DOI 10.1021/bi0027884; Parast CV, 1998, BIOCHEMISTRY-US, V37, P16788, DOI 10.1021/bi981291f; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prowse CN, 2000, BIOCHEMISTRY-US, V39, P6258, DOI 10.1021/bi000277b; RAUSHEL FM, 1977, BIOCHEMISTRY-US, V16, P2176, DOI 10.1021/bi00629a021; Rudolph F B, 1979, Methods Enzymol, V63, P411; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Shaffer J, 1999, BIOCHEMISTRY-US, V38, P5572, DOI 10.1021/bi982768q; Shaffer J, 1999, BIOCHEMISTRY-US, V38, P12072, DOI 10.1021/bi991109q; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Smith CM, 1999, PROG BIOPHYS MOL BIO, V71, P313, DOI 10.1016/S0079-6107(98)00059-5; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Smith JK, 2000, J BIOL CHEM, V275, P31588, DOI 10.1074/jbc.M005892200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Waas WF, 2001, PROTEIN EXPRES PURIF, V23, P191, DOI 10.1006/prep.2001.1491; Waas WF, 2001, J BIOL CHEM, V276, P5676, DOI 10.1074/jbc.M008787200; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zand R, 1998, BIOCHEMISTRY-US, V37, P2441, DOI 10.1021/bi972347t; ZHANG FM, 1993, J MOL BIOL, V233, P550, DOI 10.1006/jmbi.1993.1532; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou J, 1997, BIOCHEMISTRY-US, V36, P15733, DOI 10.1021/bi971438n	56	39	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12532	12540		10.1074/jbc.M110523200	http://dx.doi.org/10.1074/jbc.M110523200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812784	hybrid			2022-12-25	WOS:000175036300009
J	Wang, Z; Tseng, CP; Pong, RC; Chen, H; McConnell, JD; Navone, N; Hsieh, JT				Wang, Z; Tseng, CP; Pong, RC; Chen, H; McConnell, JD; Navone, N; Hsieh, JT			The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer - Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; RAS; KINASE; CELL; GENE; PHOSPHORYLATION; CARCINOMA; CLONING	DOC-2/DAB2 is a member of the disable gene family with tumor-inhibitory activity. Its down-regulation is associated with several neoplasms, and serine phosphorylation of its N terminus modulates DOC-2/DAB2's inhibitory effect on AP-1 transcriptional activity. We describe the cloning of DIP1/2, a novel gene that interacts with the N-terminal domain of DOC-2/DAB2. DIP1/2 is a novel GTPase-activating protein containing a Ras GTPase-activating protein homology domain (N terminus) and two other unique domains (i.e. 10 proline repeats and leucine zipper). Interaction between DOC-2/DAB2 and DIP1/2 is detected in normal tissues such as the brain and prostate. Altered expression of these two proteins is often detected in prostate cancer cells. Indeed, the presence of DIP1/2 effectively blocks mitogen-induced gene expression and inhibits the growth of prostate cancer. Thus, DOC-2/DAB2 and DIP1/2 appear to represent a unique negative regulatory complex that maintains cell homeostasis.	Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX 75390 USA; Univ Texas, MD Anderson Canc Ctr, Dept GU Med Oncol, Houston, TX 77030 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; UTMD Anderson Cancer Center	Hsieh, JT (corresponding author), Univ Texas, SW Med Ctr, Dept Urol, 5232 Harry Hines Blvd, Dallas, TX 75390 USA.	JT.Hsieh@UTSouthwestern.edu		TSENG, CHING-PING/0000-0002-2587-210X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047657] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-47657] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abate C, 1990, Semin Cancer Biol, V1, P19; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Denhardt DT, 1996, BIOCHEM J, V318, P729, DOI 10.1042/bj3180729; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fulop V, 1998, ONCOGENE, V17, P419, DOI 10.1038/sj.onc.1201955; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILLIES RJ, 1986, ANAL BIOCHEM, V159, P109, DOI 10.1016/0003-2697(86)90314-3; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; HATA A, 1993, J BIOL CHEM, V268, P9122; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; MOK SC, 1994, GYNECOL ONCOL, V52, P247, DOI 10.1006/gyno.1994.1040; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; Navone NM, 1997, CLIN CANCER RES, V3, P2493; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; PERGOLIZZI RG, 1993, CANCER INVEST, V11, P25, DOI 10.3109/07357909309020257; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Schwahn DJ, 1998, ONCOGENE, V17, P1173, DOI 10.1038/sj.onc.1202038; SOZERI O, 1992, ONCOGENE, V7, P2259; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; Tseng CP, 1999, J BIOL CHEM, V274, P31981, DOI 10.1074/jbc.274.45.31981; Tseng CP, 1998, ENDOCRINOLOGY, V139, P3542, DOI 10.1210/en.139.8.3542; WEIJERMAN PC, 1994, CANCER RES, V54, P5579; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184; Xu XX, 1998, ONCOGENE, V16, P1561, DOI 10.1038/sj.onc.1201678; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686; Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200	36	118	128	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12622	12631		10.1074/jbc.M110568200	http://dx.doi.org/10.1074/jbc.M110568200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11812785	hybrid			2022-12-25	WOS:000175036300019
J	Gillotte-Taylor, K; Nickel, M; Johnson, WJ; Francone, OL; Holvoet, P; Lund-Katz, S; Rothblatt, GH; Phillips, MC				Gillotte-Taylor, K; Nickel, M; Johnson, WJ; Francone, OL; Holvoet, P; Lund-Katz, S; Rothblatt, GH; Phillips, MC			Effects of enrichment of fibroblasts with unesterified cholesterol on the efflux of cellular lipids to apolipoprotein A-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; PLASMA-MEMBRANE MICROSOLUBILIZATION; MESSENGER-RNA LEVELS; PHOSPHOLIPID EFFLUX; UP-REGULATION; CELLS; HDL; TRANSPORT; RECEPTOR; DISEASE	This study elucidates the factors underlying the enhancement in efflux of human fibroblast unesterified cholesterol and phospholipid (PL) by lipid-free apolipoprotein (apo) A-I that is induced by cholesterol enrichment of the cells. Doubling the unesterified cholesterol content of the plasma membrane by incubation for 24 h with low density lipoprotein and lipid/cholesterol dispersions increases the pools of PL and cholesterol available for removal by apoA-I from about 0.8-5%; the initial rates of mass release of cholesterol and PL are both increased about 6-fold. Expression of the ATP binding cassette transporter A1 (ABCA1) is critical for this increased efflux of lipids, and cholesterol loading of the fibroblasts over 24 h increases ABCA1 mRNA about 12-fold. The presence of more ABCA1 and cholesterol in the plasma membrane results in a 2-fold increase in the level of specific binding of apoA-I to the cells with no change in binding affinity. Characterization of the species released from either control or cholesterol-enriched cells indicates that the plasma membrane domains from which lipids are removed are cholesterol-enriched with respect to the average plasma membrane composition. Cholesterol enrichment of fibroblasts also affects PL synthesis, and this leads to enhanced release of phosphatidylcholine (PC) relative to sphingomyelin (SM); the ratios of PC to SM solubilized from control and cholesterol-enriched fibroblasts are similar to2/1 and 5/1, respectively. Biosynthesis of PC is critical for this preferential release of PC and the enhanced cholesterol efflux because inhibition of PC synthesis by choline depletion reduces cholesterol efflux from cholesterol-enriched cells. Overall, it is clear that enrichment of fibroblasts with unesterified cholesterol enhances efflux of cholesterol and PL to apoA-I because of three effects, 1) increased PC biosynthesis, 2) increased PC transport via ABCA1, and 3) increased cholesterol in the plas membrane.	Univ Penn, Sch Med, Abramson Res Ctr, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19129 USA; Pfizer Inc, Div Cent Res, Groton, CT 06340 USA; Katholieke Univ Leuven, Ctr Expt Surg & Anesthesiol, B-3000 Louvain, Belgium	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Drexel University; Pfizer; KU Leuven	Phillips, MC (corresponding author), Univ Penn, Sch Med, Abramson Res Ctr, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.	phillipsmi@email.chop.edu	HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Arakawa R, 2000, J LIPID RES, V41, P1952; Barter PJ, 1996, ATHEROSCLEROSIS, V121, P1, DOI 10.1016/0021-9150(95)05675-0; Barter PJ, 1996, CURR OPIN LIPIDOL, V7, P82, DOI 10.1097/00041433-199604000-00006; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Christian AE, 1997, J LIPID RES, V38, P2264; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte KL, 1996, J BIOL CHEM, V271, P23792, DOI 10.1074/jbc.271.39.23792; Ito J, 2000, J LIPID RES, V41, P894; JOHNSON WJ, 1986, J BIOL CHEM, V261, P5766; JOHNSON WJ, 1988, J BIOL CHEM, V263, P14099; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; Kellner-Weibel G, 1998, ARTERIOSCL THROM VAS, V18, P423, DOI 10.1161/01.ATV.18.3.423; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Leppimaki P, 2000, EUR J BIOCHEM, V267, P6385, DOI 10.1046/j.1432-1327.2000.01726.x; Leppimaki P, 1998, BIOCHEM J, V335, P285, DOI 10.1042/bj3350285; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Mendez AJ, 1997, J LIPID RES, V38, P1807; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1996, J LIPID RES, V37, P2473; Oram JF, 2001, J LIPID RES, V42, P1173; Phillips MC, 1998, ATHEROSCLEROSIS, V137, pS13, DOI 10.1016/S0021-9150(97)00312-2; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Remaley AT, 1998, J LIPID RES, V39, P1231; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rothblat GH, 1999, J LIPID RES, V40, P781; Saito H, 1997, J LIPID RES, V38, P287; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; Schmitz G, 2001, CURR OPIN LIPIDOL, V12, P129, DOI 10.1097/00041433-200104000-00006; SCOTT RE, 1979, J CELL SCI, V35, P229; SCOTT RE, 1979, J CELL SCI, V35, P245; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Tabas I, 1996, J BIOL CHEM, V271, P22773, DOI 10.1074/jbc.271.37.22773; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Van Bambeke F, 2000, BIOCHEM PHARMACOL, V60, P457, DOI 10.1016/S0006-2952(00)00291-4; Venkateswaran A, 2000, P NATL ACAD SCI USA, V97, P12097, DOI 10.1073/pnas.200367697; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Yokoyama S, 1998, BBA-LIPID LIPID MET, V1392, P1, DOI 10.1016/S0005-2760(98)00032-0; Zhang WW, 1998, J LIPID RES, V39, P1601	55	44	44	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11811	11820		10.1074/jbc.M108268200	http://dx.doi.org/10.1074/jbc.M108268200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805090	hybrid			2022-12-25	WOS:000174846400028
J	Gregory, RI; O'Neill, LP; Randall, TE; Fournier, C; Khosla, S; Turner, BM; Feil, R				Gregory, RI; O'Neill, LP; Randall, TE; Fournier, C; Khosla, S; Turner, BM; Feil, R			Inhibition of histone deacetylases alters allelic chromatin conformation at the imprinted U2af1-rs1 locus in mouse embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; TRICHOSTATIN-A; SNRPN GENE; ACETYLATION; EXPRESSION; HETEROCHROMATIN; COMPLEX; REGIONS; GENOME; DOMAIN	Most loci that are regulated by genomic imprinting have differentially methylated regions (DMRs). Previously, we showed that the DMRs of the mouse Snrpn and U2af1-rs1 genes have paternal allele-specific patterns of acetylation on histones H3 and H4. To investigate the maintenance of acetylation at these DMRs, we performed chromatin immunoprecipitation on trichostatin-A (TSA)-treated and control cells. In embryonic stem (ES) cells and fibroblasts, brief (6-h) TSA treatment induces global hyperacetylation of H3 and H4. In ES cells only, TSA led to a selective increase in maternal acetylation at U2af1-rs1, at lysine 5 of H4 and at lysine 14 of H3. TSA treatment of ES cells did not affect DNA methylation or expression of U2af1-rs1, but was sufficient to increase DNase I sensitivity along the maternal allele to a level comparable with that of the paternal allele. In fibroblasts, TSA did not alter U2af1-rs1 acetylation, and the parental alleles retained their differential DNase I sensitivity. At Snrpn, no changes in acetylation were observed in the TSA-treated cells. Our data suggest that the mechanisms regulating histone acetylation at DMRs are locus and developmental stage-specific and are distinct from those effecting global levels of acetylation. Furthermore, it seems that the allelic U2af1-rs1 acetylation determines DNase I sensitivity/chromatin conformation.	IFR 24, CNRS UMR 5535, Inst Mol Genet, F-34293 Montpellier 5, France; Babraham Inst, Cambridge CB2 4AT, England; Univ Birmingham, Chromatin & Gene Express Grp, Sch Med, Birmingham B15 2TT, W Midlands, England	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of Birmingham	Feil, R (corresponding author), IFR 24, CNRS UMR 5535, Inst Mol Genet, F-34293 Montpellier 5, France.		Feil, Robert P/D-2087-2013	Feil, Robert P/0000-0002-5671-5860				Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Barlow AL, 2001, EXP CELL RES, V265, P90, DOI 10.1006/excr.2001.5162; Bielinska B, 2000, NAT GENET, V25, P74, DOI 10.1038/75629; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Carmen AA, 1999, P NATL ACAD SCI USA, V96, P12356, DOI 10.1073/pnas.96.22.12356; Carmen AA, 1996, J BIOL CHEM, V271, P15837, DOI 10.1074/jbc.271.26.15837; CATTANACH BM, 1985, NATURE, V315, P496, DOI 10.1038/315496a0; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Constancia M, 1998, GENOME RES, V8, P881, DOI 10.1101/gr.8.9.881; Dean W, 1998, DEVELOPMENT, V125, P2273; El Kharroubi A, 2001, J BIOL CHEM, V276, P8674, DOI 10.1074/jbc.M009392200; Feil R, 1999, TRENDS GENET, V15, P431, DOI 10.1016/S0168-9525(99)01822-3; Feil R, 1997, J BIOL CHEM, V272, P20893, DOI 10.1074/jbc.272.33.20893; Glenn CC, 1996, AM J HUM GENET, V58, P335; Grandjean V, 2001, FEBS LETT, V488, P165, DOI 10.1016/S0014-5793(00)02349-8; Greally JM, 1999, P NATL ACAD SCI USA, V96, P14430, DOI 10.1073/pnas.96.25.14430; Gregory RI, 2001, MOL CELL BIOL, V21, P5426, DOI 10.1128/MCB.21.16.5426-5436.2001; GREGORY RI, 1999, NUCLEIC ACIDS RES, V27, pR1; Haaf T, 2001, CHROMOSOME RES, V9, P263, DOI 10.1023/A:1016686312142; HATADA I, 1993, NUCLEIC ACIDS RES, V21, P5577, DOI 10.1093/nar/21.24.5577; HAYASHIZAKI Y, 1994, NAT GENET, V6, P33, DOI 10.1038/ng0194-33; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hu JF, 2000, ENDOCRINOLOGY, V141, P4428, DOI 10.1210/en.141.12.4428; Keohane AM, 1998, DEV GENET, V22, P65, DOI 10.1002/(SICI)1520-6408(1998)22:1&lt;65::AID-DVG7&gt;3.0.CO;2-5; Leuba SH, 1998, BIOPHYS J, V74, P2823, DOI 10.1016/S0006-3495(98)77989-5; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Pedone PV, 1999, FEBS LETT, V458, P45, DOI 10.1016/S0014-5793(99)01124-2; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Saitoh S, 2000, AM J HUM GENET, V66, P1958, DOI 10.1086/302917; Shemer R, 2000, NAT GENET, V26, P440, DOI 10.1038/82571; Shemer R, 1997, P NATL ACAD SCI USA, V94, P10267, DOI 10.1073/pnas.94.19.10267; Surani MA, 1998, CELL, V93, P309, DOI 10.1016/S0092-8674(00)81156-3; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; White DA, 1999, METHODS, V19, P417, DOI 10.1006/meth.1999.0878; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	41	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11728	11734		10.1074/jbc.M105775200	http://dx.doi.org/10.1074/jbc.M105775200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821379	Green Published, hybrid			2022-12-25	WOS:000174846400018
J	Hong, SK; Cha, MK; Choi, YS; Kim, WC; Kim, IH				Hong, SK; Cha, MK; Choi, YS; Kim, WC; Kim, IH			Msn2p/Msn4p act as a key transcriptional activator of yeast cytoplasmic thiol peroxidase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; ANTIOXIDANT PROTEIN; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; MAMMALIAN PEROXIREDOXIN; NUCLEAR-LOCALIZATION; PROTECTOR PROTEIN; CAMP LEVELS; CYCLIC-AMP; PURIFICATION	We observed that the transcription of Saccharomyces cerevisiae cytoplasmic thiol peroxidase type II (cTPx II) (YDR453C) is regulated in response to various stresses (e.g. oxidative stress, carbon starvation, and heatshock). It has been suggested that both transcriptionactivating proteins, Yap1p and Skn7p, regulate the transcription of cTPx II upon exposure to oxidative stress. However, a dramatic loss of transcriptional response to various stresses in yeast mutant strains lacking both Msn2p and Msn4p suggests that the transcription factors act as a principal transcriptional activator. In addition to two Yap1p response elements (YREs), TTACTAA and TTAGTAA, the presence of two stress response elements (STREs) (CCCCT) in the upstream sequence of cTPx II also suggests that Msn2p/Msn4p could control stress-induced expression of cTPx II. Analysis of the transcriptional activity of site-directed mutagenesis of the putative STREs (STRE1 and STRE2) and YREs (TRE1 and YRE2) in terms of the activity of a lacZ reporter gene under control of the cTPx II promoter indicates that STRE2 acts as a principal binding element essential for transactivation of the cTPx II promoter. The transcriptional activity of the cTPx Il promoter was exponentially increased after postdiauxic growth. The transcriptional activity of the cTPx II promoter is greatly increased by rapamycin. Deletion of Tor1, Tor2, Ras1, and Ras2 resulted in a considerable induction when compared with their parent strains, suggesting that the transcription of cTPx II is under negative control of the Ras/cAMP and target of rapamycin signaling pathways. Taken together, these results suggest that cTPx II is a target of Msn2p/Msn4p transcription factors under negative control of the Ras-protein kinase A and target of rapamycin signaling pathways. Furthermore, the accumulation of cTPx II upon exposure to oxidative stress and during the postdiauxic shift suggests an important antioxidant role in stationary phase yeast cells.	Paichai Univ, Dept Biochem, Seo Gu, Taejon 302735, South Korea	Pai Chai University	Kim, IH (corresponding author), Paichai Univ, Dept Biochem, Seo Gu, 439-6 Doma 2 Dong, Taejon 302735, South Korea.	ihkim@mail.pcu.ac.kr	Kim, Il-Han/W-1401-2019					Adams A, 1997, METHODS YEAST GENETI; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; BARONI MD, 1992, EXP CELL RES, V201, P299, DOI 10.1016/0014-4827(92)90277-F; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; BOUCHERIE H, 1985, J BACTERIOL, V161, P385, DOI 10.1128/JB.161.1.385-392.1985; Boy-Marcotte E, 1998, J BACTERIOL, V180, P1044, DOI 10.1128/JB.180.5.1044-1052.1998; BoyMarcotte E, 1996, MICROBIOL-UK, V142, P459, DOI 10.1099/13500872-142-3-459; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; Cha MK, 1998, J BIOCHEM MOL BIOL, V31, P409; Cha MK, 1996, J BIOCHEM MOL BIOL, V29, P236; Cha MK, 2000, BIOCHEMISTRY-US, V39, P6944, DOI 10.1021/bi000034j; Cha MK, 1996, J BACTERIOL, V178, P5610, DOI 10.1128/jb.178.19.5610-5614.1996; CHA MK, 1995, J BIOL CHEM, V270, P28635, DOI 10.1074/jbc.270.48.28635; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; ENGELBERG D, 1994, CELL, V77, P381, DOI 10.1016/0092-8674(94)90153-8; Estruch F, 2000, FEMS MICROBIOL REV, V24, P469, DOI 10.1016/S0168-6445(00)00035-8; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GOUNALAKI N, 1994, EMBO J, V13, P4036, DOI 10.1002/j.1460-2075.1994.tb06720.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; Halliwell B, 1999, FREE RADICAL BIO MED, P105, DOI DOI 10.1093/ACPR0F:0S0/9780198717478.003.0005; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; Jeong W, 2000, J BIOCHEM MOL BIOL, V33, P234; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; Knoops B, 1999, J BIOL CHEM, V274, P30451, DOI 10.1074/jbc.274.43.30451; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; LIM YS, 1994, GENE, V140, P279, DOI 10.1016/0378-1119(94)90558-4; LIM YS, 1994, BIOCHEM BIOPH RES CO, V199, P199, DOI 10.1006/bbrc.1994.1214; MartinezPastor MT, 1996, EMBO J, V15, P2227, DOI 10.1002/j.1460-2075.1996.tb00576.x; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; Park SG, 2000, J BIOL CHEM, V275, P5723, DOI 10.1074/jbc.275.8.5723; ROSE M, 1983, METHOD ENZYMOL, V101, P167; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; Schmitt AP, 1996, P NATL ACAD SCI USA, V93, P5777, DOI 10.1073/pnas.93.12.5777; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	60	16	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12109	12117		10.1074/jbc.M111341200	http://dx.doi.org/10.1074/jbc.M111341200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821410	hybrid			2022-12-25	WOS:000174846400067
J	Olry, A; Boschi-Muller, S; Marraud, M; Sanglier-Cianferani, S; Van Dorsselear, A; Branlant, G				Olry, A; Boschi-Muller, S; Marraud, M; Sanglier-Cianferani, S; Van Dorsselear, A; Branlant, G			Characterization of the methionine sulfoxide reductase activities of PILB, a probable virulence factor from Neisseria meningitidis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; PROTEINS; MSRA; IDENTIFICATION; DETERMINANT; CONTRIBUTES; EXPRESSION; MECHANISM	PILB has been described as being involved in the virulence of bacteria of Neisseria genus. The PILB protein is composed of three subdomains. In the present study, the central subdomain (PILB-MsrA), the C terminus subdomain (PILB-MsrB), and the fused subdomain (PILB-MsrA/MsrB) of N. meningitidis were produced as folded entities. The central subdomain shows a methionine sulfoxide reductase A (MsrA) activity, whereas PILB-MsrB displays a methionine sulfoxide reductase B (MsrB) activity. The catalytic mechanism of PILB-MsrB can be divided into two steps: 1) an attack of the Cys-494 on the sulfur atom of the sulfoxide substrate, leading to formation of a sulfenic acid intermediate and release of 1 mol of methionine/mol of enzyme and 2) a regeneration of Cys-494 via formation of an intradisulfide bond with Cys-439 followed by reduction with thioredoxin. The study also shows that 1) MsrA and MsrB display opposite stereoselectivities toward the sulfoxide function; 2) the active sites of both Msrs, particularly MsrB, are rather adapted for binding protein-bound MetSO more efficiently than free MetSO; 3) the carbon Calpha is not a determining factor for efficient binding to both Msrs; and 4) the presence of the sulfoxide function is a prerequisite for binding to Msrs. The fact that the two Msrs exhibit opposite stereoselectivities argues for a structure of the active site of MsrBs different from that of MsrAs. This is further supported by the absence of sequence homology between the two Msrs in particular around the cysteine that is involved in formation of the sulfenic acid derivative. The fact that the catalytic mechanism takes place through formation of a sulfenic acid intermediate for both Msrs supports the idea that sulfenic acid chemistry is a general feature in the reduction of sulfoxides by thiols.	UHP, CNRS, UMR Maturat ARN & Enzymol Mol 7567, Fac Sci, F-54506 Vandoeuvre Les Nancy, France; INPL, CNRS, UMR 7568, Lab Chim Phys Macromol,Grp ENSIC, F-54001 Nancy, France; Univ Strasbourg, CNRS, ULP,Lab Spectrometrie Mass Bioorgan, UMR 7509, F-67087 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Branlant, G (corresponding author), UHP, CNRS, UMR Maturat ARN & Enzymol Mol 7567, Fac Sci, Blvd Aiguillettes,BP 239, F-54506 Vandoeuvre Les Nancy, France.	guy.branlant@maem.uhp-nancy.fr		Boschi, Sandrine/0000-0001-8962-4749; Cianferani, Sarah/0000-0003-4013-4129				BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, P103; Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Boschi-Muller S, 2001, PROTEIN SCI, V10, P2272, DOI 10.1110/ps.10701; BOSE AK, 1960, ORG SYNTH, V40, P82; Dhandayuthapani S, 2001, J BACTERIOL, V183, P5645, DOI 10.1128/JB.183.19.5645-5650.2001; El Hassouni M, 1999, P NATL ACAD SCI USA, V96, P887, DOI 10.1073/pnas.96.3.887; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Hayes CS, 1998, J BACTERIOL, V180, P2694, DOI 10.1128/JB.180.10.2694-2700.1998; Holland HL, 1999, TETRAHEDRON-ASYMMETR, V10, P2833, DOI 10.1016/S0957-4166(99)00271-2; Jeong W, 2000, J BIOL CHEM, V275, P2924, DOI 10.1074/jbc.275.4.2924; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; Mossner E, 1998, PROTEIN SCI, V7, P1233; Mulrooney SB, 1997, PROTEIN EXPRES PURIF, V9, P372, DOI 10.1006/prep.1996.0698; Pedrajas JR, 2000, J BIOL CHEM, V275, P16296, DOI 10.1074/jbc.275.21.16296; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Silver M, 1979, Methods Enzymol, V62, P135, DOI 10.1016/0076-6879(79)62208-5; Singh VK, 2001, MICROBIOL-SGM, V147, P3037, DOI 10.1099/00221287-147-11-3037; TAHA MK, 1991, MOL MICROBIOL, V5, P137, DOI 10.1111/j.1365-2958.1991.tb01834.x; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; WALLACE TJ, 1965, J ORG CHEM, V30, P1502, DOI 10.1021/jo01016a039; Wizemann TM, 1996, P NATL ACAD SCI USA, V93, P7985, DOI 10.1073/pnas.93.15.7985	25	101	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12016	12022		10.1074/jbc.M112350200	http://dx.doi.org/10.1074/jbc.M112350200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812798	Green Published, hybrid			2022-12-25	WOS:000174846400055
J	Sun, W; Qureshi, HY; Cafferty, PW; Sobue, K; Agarwal-Mawal, A; Neufield, KD; Paudel, HK				Sun, W; Qureshi, HY; Cafferty, PW; Sobue, K; Agarwal-Mawal, A; Neufield, KD; Paudel, HK			Glycogen synthase kinase-3,beta is complexed with tau protein in brain microtubules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISEASE-LIKE PHOSPHORYLATION; BETA-CATENIN; KINASE-I; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; CROSS-LINKING; SITES; LOCALIZATION; 3-BETA; FETAL; STATE	In Alzheimer's disease, microtubule-associated protein tau is hyperphosphorylated by an unknown mechanism and is aggregated into paired helical filaments. Hyperphosphorylation causes loss of tau function, microtubule instability, and neurodegeneration. Glycogen synthase kinase-3beta (GSK3beta) has been implicated in the phosphorylation of tau in normal and Alzheimer's disease brain. The molecular mechanism of GSK3beta-tau interaction has not been clarified. In this study, we find that when microtubules are disassembled, microtubule-associated GSK3beta dissociates from microtubules. From a gel filtration column, the dissociated GSK3beta elutes as an similar to400-kDa complex. When fractions containing the similar to400-kDa complex are chromatographed through an anti-GSK3beta immunoaffinity column, tau co-elutes with GSK3beta. From fractions containing the similar to400-kDa complex, both tau and GSK3beta co-immunoprecipitate with each other. GSK3beta binds to nonphosphorylated tau, and the GSK3beta-binding region is located within the N-terminal projection domain of tau. In vitro, GSK3beta associates with microtubules only in the presence of tau. From brain extract, similar to6-fold more GSK3beta co-immunoprecipitates with tau than GSK3alpha. These data indicate that, in brain, GSK3beta is bound to tau within a similar to400-kDa microtubule-associated complex, and GSK3beta associates with microtubules via tau.	Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University; McGill University	Paudel, HK (corresponding author), Lady Davis Inst Med Res, Bloomfield Ctr Res Aging, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	hemant.paudel@mcgill.ca		Cafferty, Patrick/0000-0001-5563-1158				Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371; BOYLE WJ, 1990, CELL, V29, P7617; BueeScherrer V, 1996, MOL BRAIN RES, V39, P79, DOI 10.1016/0169-328X(96)00003-4; BUTNER KA, 1991, J CELL BIOL, V115, P717, DOI 10.1083/jcb.115.3.717; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Evans DB, 2000, J BIOL CHEM, V275, P24977, DOI 10.1074/jbc.M000808200; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GOEDERT M, 1991, TRENDS NEUROSCI, V14, P193, DOI 10.1016/0166-2236(91)90105-4; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; HEMMINGS BA, 1982, EUR J BIOCHEM, V127, P473; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; ISHIGURO K, 1992, NEUROSCI LETT, V148, P202, DOI 10.1016/0304-3940(92)90839-Y; ISHIGURO K, 1992, J BIOL CHEM, V267, P10897; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Liao H, 1998, J BIOL CHEM, V273, P21901, DOI 10.1074/jbc.273.34.21901; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lovestone S, 1996, NEUROSCIENCE, V73, P1145, DOI 10.1016/0306-4522(96)00126-1; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MORISHIMAKAWASHIMA M, 1995, J BIOL CHEM, V270, P823, DOI 10.1074/jbc.270.2.823; MunozMontano JR, 1997, FEBS LETT, V411, P183, DOI 10.1016/S0014-5793(97)00688-1; Paudel HK, 1999, J BIOL CHEM, V274, P8029, DOI 10.1074/jbc.274.12.8029; Paudel HK, 1997, J BIOL CHEM, V272, P28328, DOI 10.1074/jbc.272.45.28328; PAUDEL HK, 1993, J BIOL CHEM, V268, P23512; PLYLE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; SEUBERT P, 1995, J BIOL CHEM, V270, P18917, DOI 10.1074/jbc.270.32.18917; Sobue K, 2000, J BIOL CHEM, V275, P16673, DOI 10.1074/jbc.M000784200; Spittaels K, 2000, J BIOL CHEM, V275, P41340, DOI 10.1074/jbc.M006219200; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; Wagner U, 1996, J CELL SCI, V109, P1537; WANG JZ, 1995, J BIOL CHEM, V270, P4854, DOI 10.1074/jbc.270.9.4854; WATANABE A, 1993, J BIOL CHEM, V268, P25712; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; YANG SD, 1992, J PROTEIN CHEM, V11, P539, DOI 10.1007/BF01025031	49	95	102	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11933	11940		10.1074/jbc.M107182200	http://dx.doi.org/10.1074/jbc.M107182200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812770	hybrid			2022-12-25	WOS:000174846400044
J	Yi, JZ; Cheng, H; Andrake, MD; Dunbrack, RL; Roder, H; Skalka, AM				Yi, JZ; Cheng, H; Andrake, MD; Dunbrack, RL; Roder, H; Skalka, AM			Mapping the epitope of an inhibitory monoclonal antibody to the C-terminal DNA-binding domain of HIV-1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 INTEGRASE; ACTIVE-SITE; DIVALENT-CATIONS; CATALYTIC DOMAIN; IN-VITRO; PROTEIN; CORE; ZINC; MULTIMERIZATION; IDENTIFICATION	Integrase (IN) catalyzes the insertion of retroviral DNA into chromosomal DNA of a host cell and is one of three virus-encoded enzymes that are required for replication. A library of monoclonal antibodies against human immunodeficiency virus type 1 (HIV-1) IN was raised and characterized in our laboratory. Among them, monoclonal antibody (mAb) 33 and mAb32 compete for binding to the C-terminal domain of the HIV-1 IN protein. Here, we show that mAb33 is a strong inhibitor of IN catalytic activity, whereas mAb32 is only weakly inhibitory. Furthermore, as the Fab fragment of mAb32 had no effect on IN activity, inhibition by this mAb may result solely from its bivalency. In contrast, Fab33 did inhibit IN catalytic activity, although bivalent binding by mAb33 may enhance the inhibition. Interaction with Fab33 also prevented DNA binding to the isolated C-terminal domain of IN. Results from size-exclusion chromatography, gel electrophoresis, and matrixassisted laser desorption ionization time-of-flight mass spectrometric analyses revealed that multiple Fab33-IN C-terminal domain complexes exist in solution. Studies using heteronuclear NAIR showed a steep decrease in H-1-N-15 cross-peak intensity for 8 residues in the isolated C-terminal domain upon binding of Fab33, indicating that these residues become immobilized in the complex. Among them, Ala(239) and Ile(251) are buried in the interior of the domain, whereas the remaining residues Phe(213), Arg(224), Tyr(226), Lys(244), Ile(267), and Ile(268)) form a contiguous, solvent-accessible patch on the surface of the protein likely including the epitope of Fab33. Molecular modeling of Fab33 followed by computer-assisted docking with the IN C-terminal domain suggested a structure for the antibody-antigen complex that is consistent with our experimental data and suggested a potential target for anti-AIDS drug design.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Roder, H (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.		Roder, Heinrich/B-3455-2009; Dunbrack, Roland/ABG-7141-2020	Roder, Heinrich/0000-0003-1860-2491; Dunbrack, Roland/0000-0001-7674-6667	NATIONAL CANCER INSTITUTE [R01CA071515, P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040385] Funding Source: NIH RePORTER; NCI NIH HHS [CA06927, CA71515] Funding Source: Medline; NIAID NIH HHS [AI40385] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andrake MD, 1996, J BIOL CHEM, V271, P19633, DOI 10.1074/jbc.271.33.19633; Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; AsanteAppiah E, 1997, J BIOL CHEM, V272, P16196, DOI 10.1074/jbc.272.26.16196; BIZUBBENDER D, 1994, AIDS RES HUM RETROV, V10, P1105, DOI 10.1089/aid.1994.10.1105; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; Cai ML, 1997, NAT STRUCT BIOL, V4, P567, DOI 10.1038/nsb0797-567; CHEETHAM JC, 1991, P NATL ACAD SCI USA, V88, P7968, DOI 10.1073/pnas.88.18.7968; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Eijkelenboom APAM, 1997, CURR BIOL, V7, P739, DOI 10.1016/S0960-9822(06)00332-0; Eijkelenboom APAM, 1999, PROTEINS, V36, P556, DOI 10.1002/(SICI)1097-0134(19990901)36:4<556::AID-PROT18>3.0.CO;2-6; EIJKELENBOOM APAM, 1995, NAT STRUCT BIOL, V2, P807, DOI 10.1038/nsb0995-807; Fraczkiewicz R, 1998, J COMPUT CHEM, V19, P319, DOI 10.1002/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Heuer TS, 1998, BIOCHEMISTRY-US, V37, P6667, DOI 10.1021/bi972949c; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; Huang XL, 1998, J MOL BIOL, V281, P61, DOI 10.1006/jmbi.1998.1930; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee SP, 1996, BIOCHEMISTRY-US, V35, P3837, DOI 10.1021/bi952056p; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LevyMintz P, 1996, J VIROL, V70, P8821, DOI 10.1128/JVI.70.12.8821-8832.1996; LODI PJ, 1995, BIOCHEMISTRY-US, V34, P9826, DOI 10.1021/bi00031a002; Maignan S, 1998, J MOL BIOL, V282, P359, DOI 10.1006/jmbi.1998.2002; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; PURASLUTZKE RA, 1998, J VIROL, V72, P4841; PURASLUTZKE RA, 1994, NUCLEIC ACIDS RES, V22, P4125; Ritchie DW, 2000, PROTEINS, V39, P178, DOI 10.1002/(SICI)1097-0134(20000501)39:2<178::AID-PROT8>3.3.CO;2-Y; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; Visintin M, 1999, P NATL ACAD SCI USA, V96, P11723, DOI 10.1073/pnas.96.21.11723; WOERNER AM, 1992, AIDS RES HUM RETROV, V8, P297, DOI 10.1089/aid.1992.8.297; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Yi JZ, 2000, BIOPOLYMERS, V55, P308; Yi JZ, 2000, J BIOL CHEM, V275, P38739, DOI 10.1074/jbc.M005499200; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	39	23	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12164	12174		10.1074/jbc.M105072200	http://dx.doi.org/10.1074/jbc.M105072200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11805085	hybrid			2022-12-25	WOS:000174846400074
J	Yue, G; Malik, B; Yue, G; Eaton, DC				Yue, G; Malik, B; Yue, G; Eaton, DC			Phosphatidylinositol 4,5-bisphosphate (PIP2) stimulates epithelial sodium channel activity in A6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NA+ CHANNEL; POTASSIUM CHANNELS; CATION-CHANNEL; BETA-GAMMA; SUBUNIT; ALDOSTERONE; INHIBITION; ACTIVATION; TRANSPORT	Phosphatidylinositol 4,5-bisphosphate (PIP2) is a membrane lipid found in all eukaryotic cells, which regulates many important cellular processes, including ion channel activity. In this study, we used inside-out patch clamp technique, immunoprecipitation, and Western blot analysis to investigate the effect Of PIP2 on epithelial sodium channel activity in A6 cells. A6 cells were cultured in media supplemented with 1.5 mum aldosterone. Single sodium channel activity in excised, inside-out patches was increased by perfusion of the bath solution with 30 mum PIP2 Plus 100 mum GTP (NPo = 1.34 +/- 0.14) compared with the paired control (NPo = 0.09 +/- 0.02). However, neither 30 mum PIP2 (NPo = 0.11 +/- 0.02) nor 100 mum GTP (NPo = 0.10 +/- 0.02) alone stimulated the sodium channels. The PIP2-stimulated channel activity was abolished by application of 10 nm G protein betagamma subunits (NPo = 0.14 +/- 0.05). However, 10 nm Galpha(i-3) + 30 mum PIP2 increased both NP. and P.. The stimulating effect of 10 nm Galpha(i-3) + 30 muM PIP2 is similar to that of 30 muM PIP2 plus 100 muM GTP. Immunoprecipitation and Western blot analysis show that both Gi(alpha-3) and PIP2 bind beta and gamma epithelial Na+ channels (ENaC), but not a ENaC. These results indicate that PIP2 increases ENaC activity by direct interaction with beta or gamma xENaC in the presence of Galpha(i-3).	Emory Univ, Sch Med, Ctr Cell & Mol Signaling, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Physiol, Atlanta, GA 30322 USA	Emory University; Emory University	Eaton, DC (corresponding author), Emory Univ, Sch Med, Ctr Cell & Mol Signaling, 1648 Pierce Dr, Atlanta, GA 30322 USA.			Eaton, Douglas/0000-0002-2686-6692	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037963, R37DK037963] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37963] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSIELLO DA, 1992, J BIOL CHEM, V267, P4759; Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; EATON DC, 1995, KIDNEY INT, V48, P941, DOI 10.1038/ki.1995.375; Edinger RS, 1999, AM J PHYSIOL-RENAL, V277, pF575, DOI 10.1152/ajprenal.1999.277.4.F575; Fan Z, 1999, J GEN PHYSIOL, V114, P251, DOI 10.1085/jgp.114.2.251; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Kleyman TR, 2001, AM J PHYSIOL-RENAL, V281, pF213, DOI 10.1152/ajprenal.2001.281.2.F213; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; LING BN, 1992, J CLIN INVEST, V90, P1328, DOI 10.1172/JCI115998; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Middleton P, 1998, FASEB J, V12, pA982; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; Paunescu TG, 2000, AM J PHYSIOL-CELL PH, V279, pC236, DOI 10.1152/ajpcell.2000.279.1.C236; Record RD, 1998, AM J PHYSIOL-ENDOC M, V274, pE611, DOI 10.1152/ajpendo.1998.274.4.E611; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; Rokaw MD, 1996, J BIOL CHEM, V271, P4491; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Sui JL, 1998, P NATL ACAD SCI USA, V95, P1307, DOI 10.1073/pnas.95.3.1307; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; YU FX, 1992, J BIOL CHEM, V267, P14616; Zhainazarov AB, 1999, J NEUROSCI, V19, P2929; Zhang XL, 1998, SEMIN CELL DEV BIOL, V9, P153, DOI 10.1006/scdb.1997.0220	28	135	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11965	11969		10.1074/jbc.M108951200	http://dx.doi.org/10.1074/jbc.M108951200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11812779	hybrid			2022-12-25	WOS:000174846400048
J	Nagano, F; Kawabe, H; Nakanishi, H; Shinohara, M; Deguchi-Tawarada, M; Takeuchi, M; Sasaki, T; Takai, Y				Nagano, F; Kawabe, H; Nakanishi, H; Shinohara, M; Deguchi-Tawarada, M; Takeuchi, M; Sasaki, T; Takai, Y			Rabconnectin-3, a novel protein that binds both GDP/GTP exchange protein and GTPase-activating protein for Rab3 small G protein family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT EXOCYTOSIS; SUBCELLULAR-DISTRIBUTION; SYNAPTIC VESICLE; RAT-BRAIN; LOCALIZATION; SUBFAMILY; GENE	Rab3A, a member of the Rab3 small G protein family, regulates Ca2+-dependent exocytosis of neurotransmitter. The cyclical activation and inactivation of Rab3A are essential for the Rab3A action in exocytosis. GDP-Rab3A is activated to GTP-Rab3A by Rab3 GDP/GTP exchange protein (Rab3 GEP), and GTP-Rab3A is inactivated to GDP-Rab3A by Rab3 GTPase-activating protein (Rab3 GAP). It remains unknown how or in which step of the multiple exocytosis steps these regulators are activated and inactivated. We isolated here a novel protein that was co-immunoprecipitated with Rab3 GEP and GAP by their respective antibodies from the crude synaptic vesicle fraction of rat brain. The protein, named rabconnectin-3, bound both Rab3 GEP and GAP. The cDNA of rabconnectin-3 was cloned from a human cDNA library and its primary structure was determined. Human rabconnectin-3 consisted of 3,036 amino acids and showed a calculated M-r of 339,753. It had 12 WD domains. Tissue and subcellular distribution analyses in rat indicated that rabconnectin-3 was abundantly expressed in the brain where it was enriched in the synaptic vesicle fraction. Immunofluorescence and immunoelectron microscopy revealed that rabconnectin-3 was concentrated on synaptic vesicles at synapses. These results indicate that rabconnectin-3 serves as a scaffold molecule for both Rab3 GEP and GAP on synaptic vesicles.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan; KAN Res Inst Inc, Shimogyo Ku, Kyoto 6008815, Japan; Univ Tokushima, Sch Med, Dept Biochem, Tokushima 7708503, Japan	Osaka University; KAN Research Institute; Tokushima University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018	Kawabe, Hiroshi/0000-0001-5650-8696; Nakanishi, Hiroyuki/0000-0002-9765-0266				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Darchen F, 2000, BIOCHIMIE, V82, P375, DOI 10.1016/S0300-9084(00)00219-4; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; IMAZUMI K, 1994, BIOCHEM BIOPH RES CO, V205, P1409, DOI 10.1006/bbrc.1994.2822; Kawabe H, 1999, J BIOL CHEM, V274, P30914, DOI 10.1074/jbc.274.43.30914; Kraemer C, 2000, GENOMICS, V64, P97, DOI 10.1006/geno.1999.6050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luan P, 1999, J BIOL CHEM, V274, P14806, DOI 10.1074/jbc.274.21.14806; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MIZOGUCHI A, 1994, BIOCHEM BIOPH RES CO, V202, P1235, DOI 10.1006/bbrc.1994.2063; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; Nagano F, 1998, J BIOL CHEM, V273, P24781, DOI 10.1074/jbc.273.38.24781; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Oishi H, 1998, J BIOL CHEM, V273, P34580, DOI 10.1074/jbc.273.51.34580; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takai Y, 1996, GENES CELLS, V1, P615, DOI 10.1046/j.1365-2443.1996.00257.x; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875	22	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 22	2002	277	12					9629	9632		10.1074/jbc.C100730200	http://dx.doi.org/10.1074/jbc.C100730200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	533UR	11809763	hybrid			2022-12-25	WOS:000174549200003
J	Liu, Y; Emilion, G; Mungall, AJ; Dunham, I; Beck, S; Le Meuth-Metzinger, VG; Shelling, AN; Charnock, FML; Ganesan, TS				Liu, Y; Emilion, G; Mungall, AJ; Dunham, I; Beck, S; Le Meuth-Metzinger, VG; Shelling, AN; Charnock, FML; Ganesan, TS			Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovarian cancer chromosome 6q27	SELF-INCOMPATIBILITY GENE; PROTEIN-COUPLED RECEPTOR; DISTINCT REGIONS; NICOTIANA-ALATA; HUMAN DNA; LONG ARM; TUMORS; DELETION; RIBONUCLEASES; CLONING	We have previously shown a high frequency of allele loss at D6S193 (62%) on chromosomal arm 6q27 in ovarian tumours and mapped the minimal region of allele loss between D6S297 and D6S264 (3 cM). We isolated and mapped a single non-chimaeric YAC (17IA12, 260 - 280 kb) containing D6S193 and D6S297. A further extended bacterial contig (between D6S264 and D6S149) has been established using PACs and BACs and a transcript map has been established. We have mapped six new markers to the YAC; three of them are ESTs (WI-15078, WI-8751, and TCP10). We have isolated three cDNA clones of EST WI-15078 and one clone contains a complete open reading frame. The sequence shows homology to a new member of the ribonuclease family. The other two clones are splice variants of this new gene. The gene is expressed ubiquitously in normal tissues. It is expressed in 4/8 ovarian cancer cell lines by Northern analysis. The gene encodes for a 40 kDa protein. Direct sequencing of the gene in all the eight ovarian cancer cell lines did not identify any mutations. Clonogenic assays were performed by transfecting the full-length gene in to ovarian cancer cell lines and no suppression of growth was observed.	John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England; Sanger Ctr, Cambridge CB10 1SA, England; INRA, UMR Genet Anim, F-35042 Rennes, France; Natl Womens Hosp, Dept Obstet & Gynaecol, Res Ctr Reprod Med, Auckland, New Zealand	University of Oxford; Wellcome Trust Sanger Institute; INRAE	Ganesan, TS (corresponding author), John Radcliffe Hosp, Imperial Canc Res Fund, Mol Oncol Labs, Oxford OX3 9DS, England.	ganesan@icrf.icnet.uk	GANESAN, Trivadi Sundaram/AAU-1499-2020; Meuth, Valérie Metzinger-Le/H-6338-2016; Mungall, Andrew J./U-7067-2018; Shelling, Andrew/E-7496-2010	GANESAN, Trivadi Sundaram/0000-0002-4671-8099; Meuth, Valérie Metzinger-Le/0000-0003-1718-5083; Mungall, Andrew J./0000-0002-0905-2742; Shelling, Andrew/0000-0002-5300-1934; Liu, Ying/0000-0003-3703-2498; Dunham, Ian/0000-0003-2525-5598				Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANAND R, 1990, NUCLEIC ACIDS RES, V18, P1951, DOI 10.1093/nar/18.8.1951; ANDERSON MA, 1989, PLANT CELL, V1, P483, DOI 10.1105/tpc.1.5.483; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BLANCHE H, 1992, GENOMICS, V12, P826, DOI 10.1016/0888-7543(92)90317-L; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; FRANCESCONI M, 1984, CANCER, V53, P1927, DOI 10.1002/1097-0142(19840501)53:9<1927::AID-CNCR2820530920>3.0.CO;2-#; GAIDANO G, 1992, BLOOD, V80, P1781, DOI 10.1182/blood.V80.7.1781.bloodjournal8071781; Greaves DR, 1997, J EXP MED, V186, P837, DOI 10.1084/jem.186.6.837; HIME G, 1995, GENE, V158, P203, DOI 10.1016/0378-1119(94)00896-Z; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; ISLAM SD, 1993, HUM MOL GENET, V2, P2075, DOI 10.1093/hmg/2.12.2075; Katso RMT, 1997, CANCER METAST REV, V16, P81, DOI 10.1023/A:1005796307286; Kurihara H, 1996, J MOL BIOL, V255, P310, DOI 10.1006/jmbi.1996.0025; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936; Liao F, 1997, GENOMICS, V40, P175, DOI 10.1006/geno.1996.4544; LIU Y, 2001, IN PRESS RE REPROD; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; Mungall AJ, 1997, DNA SEQUENCE, V8, P151, DOI 10.3109/10425179709034066; Obata K, 1998, CANCER RES, V58, P2095; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; SAHA V, 1995, GENE CHROMOSOME CANC, V14, P220, DOI 10.1002/gcc.2870140311; SAITO S, 1992, CANCER RES, V52, P5815; Saito S, 1996, CANCER RES, V56, P5586; Sassa H, 1996, MOL GEN GENET, V252, P222, DOI 10.1007/BF02173225; Schein CH, 1997, NAT BIOTECHNOL, V15, P529, DOI 10.1038/nbt0697-529; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; Walter MH, 1996, EUR J BIOCHEM, V239, P281, DOI 10.1111/j.1432-1033.1996.0281u.x; WAN MH, 1994, INT J ONCOL, V5, P1043; Ye ZH, 1996, PLANT MOL BIOL, V30, P697, DOI 10.1007/BF00019005; Zingoni A, 1997, GENOMICS, V42, P519, DOI 10.1006/geno.1997.4754; [No title captured]	46	24	32	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 17	2002	21	3					387	399		10.1038/sj.onc.1205067	http://dx.doi.org/10.1038/sj.onc.1205067			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821951				2022-12-25	WOS:000173311200007
J	Ueda, C; Akasaka, T; Kurata, M; Maesako, Y; Nishikori, M; Ichinohasama, R; Imada, K; Uchiyama, T; Ohno, H				Ueda, C; Akasaka, T; Kurata, M; Maesako, Y; Nishikori, M; Ichinohasama, R; Imada, K; Uchiyama, T; Ohno, H			The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma	ONCOGENE			English	Article						BCL6 gene; non-immunoglobulin gene; t(3;16)(q27;p11) translocation; interleukin-21 receptor gene; diffuse large B-cell lymphoma	GERMINAL-CENTER FORMATION; NON-HODGKINS-LYMPHOMA; FINGER ENCODING GENE; POZ DOMAIN; BETA-CHAIN; TRANSCRIPTIONAL REPRESSION; LAZ3/BCL6 ONCOPROTEIN; TRANSLOCATION; PROTEIN; DIFFERENTIATION	BCL6 translocation affecting the chromosomal band 3q27 can involve a number of non-immunoglobulin (non-IG) gene loci as partners. We report here that the gene for interleukin-21 receptor (IL-21R) is the partner of BCL6 in t(3;16)(q27;p11) translocation. The two breakpoints on 16p11 of a lymphoma cell line YM and case no. 1012 with diffuse large B-cell lymphoma, both of which carried t(3;16), were localized within the similar to27-kb intron I of IL-21R. As a result of t(3;16), the promoter region of IL-21R was substituted for the regulatory sequences of BCL6 in the same transcriptional orientation. Reverse transcriptase-mediated polymerase chain reaction revealed chimeric mRNA consisting of two noncoding exons 1a/1b of IL-21R and coding exons of BCL6 in both lymphoma cells. Fluorescence in situ chromosomal hybridization of YM metaphase cells revealed fusion signals that contained both the BCL6 and IL-21R sequences on the der(3)t(3;16) chromosome. IL-21R was actively transcribed in YM cells, while BCL6 that was under the control of the IL-21R promoter was only moderately expressed at the mRNA and protein level. We constructed expression plasmid of BCL6 that followed the promoter sequences of IL-21R. COS-7 cells transiently transfected with the plasmid expressed high level Bcl-6 protein and displayed nuclear staining with a characteristic punctate pattern by immunofluorescence, indicating that expression of BCL6 can be enhanced by t(3;16). This study added to the list of non-IG partners of BCL6 translocations a new class of gene, i.e. cytokine receptor gene, the expression of which is closely associated with lymphoid cells.	Kyoto Univ, Fac Med, Dept Internal Med, Sakyo Ku, Kyoto 6068507, Japan; Tohoku Univ, Sch Dent, Dept Oral Pathol, Aoba Ku, Sendai, Miyagi 9808575, Japan	Kyoto University; Tohoku University	Ohno, H (corresponding author), Kyoto Univ, Fac Med, Dept Internal Med, Sakyo Ku, Div 1,54 Shogoin Kawaramachi, Kyoto 6068507, Japan.			Imada, Kazunori/0000-0002-0945-0513				Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 1997, CANCER RES, V57, P7; Albagli O, 1996, BIOCHEM BIOPH RES CO, V220, P911, DOI 10.1006/bbrc.1996.0505; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BASTARD C, 1994, BLOOD, V83, P2423; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; DALLERY E, 1995, ONCOGENE, V10, P2171; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dhordain P, 1998, NUCLEIC ACIDS RES, V26, P4645, DOI 10.1093/nar/26.20.4645; Dhordain P, 1995, ONCOGENE, V11, P2689; Fukuda T, 1997, J EXP MED, V186, P439, DOI 10.1084/jem.186.3.439; Galiegue-Zouitina S, 1999, GENE CHROMOSOME CANC, V26, P97, DOI 10.1002/(SICI)1098-2264(199910)26:2<97::AID-GCC1>3.0.CO;2-9; Galieque-Zouitina S, 1996, LEUKEMIA, V10, P579; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; Hosokawa Y, 2000, BLOOD, V95, P2719; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ichinohasama R, 1998, CANCER GENET CYTOGEN, V103, P133, DOI 10.1016/S0165-4608(97)00390-7; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kuppers R, 1999, NEW ENGL J MED, V341, P1520; Lin JX, 1997, MOL CELL BIOL, V17, P3714, DOI 10.1128/MCB.17.7.3714; MIKI T, 1994, BLOOD, V83, P26; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Ohno H, 1997, LEUKEMIA LYMPHOMA, V27, P53, DOI 10.3109/10428199709068271; ONIZUKA T, 1995, BLOOD, V86, P28, DOI 10.1182/blood.V86.1.28.bloodjournal86128; Ozaki K, 2000, P NATL ACAD SCI USA, V97, P11439, DOI 10.1073/pnas.200360997; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Xu WS, 2000, GENE CHROMOSOME CANC, V27, P69, DOI 10.1002/(SICI)1098-2264(200001)27:1<69::AID-GCC9>3.0.CO;2-5; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yonetani N, 1998, ONCOGENE, V17, P971, DOI 10.1038/sj.onc.1202027; Yoshida S, 1999, ONCOGENE, V18, P7994, DOI 10.1038/sj.onc.1203293; ZOLA H, 1991, IMMUNOLOGY, V72, P167	38	31	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2002	21	3					368	376		10.1038/sj.onc.1205099	http://dx.doi.org/10.1038/sj.onc.1205099			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	512FV	11821949	Green Submitted			2022-12-25	WOS:000173311200005
J	Richie, ER; Schumacher, A; Angel, JM; Holloway, M; Rinchik, EM; Magnuson, T				Richie, ER; Schumacher, A; Angel, JM; Holloway, M; Rinchik, EM; Magnuson, T			The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas	ONCOGENE			English	Article						lymphomagenesis; Polycom-group gene; eed; thymocyte differentiation	EXTRA SEX COMBS; METHYL-N-NITROSOUREA; MURINE THYMIC LYMPHOMAS; MOUSE CHROMOSOME-7; EVOLUTIONARY CONSERVATION; RAPID DEVELOPMENT; MICE; DROSOPHILA; PROTEIN; EXPRESSION	The mouse Polycomb-group gene, embryonic ectoderm development (eed), appears to regulate cellular growth and differentiation in a developmental and tissue specific manner. During embryogenesis, eed regulates axial patterning, whereas in the adult eed represses proliferation of myeloid and B cell precursors. The present report demonstrates two novel functional activities of eed:alteration of thymocyte maturation and suppression of thymic lymphoma development. Mice that inherit the viable hypomorphic 17Rn5(1989SB) eed allele sustain a partial developmental block at or before the CD4(-)CD8(-)CD44(-) CD25(+) stage of thymocyte differentiation. Furthermore, mice that are homozygous or heterozygous for the hypomorphic eed allele have an increased incidence and decreased latency of N-methyl-N-nitrosourea-induced thymic lymphoma compared to wild-type littermates. These findings support the notion that Polycomb-group genes exert pleiotrophic effects dictated by developmental stage and cellular context.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of North Carolina; University of North Carolina Chapel Hill	Richie, ER (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, POB 389, Smithville, TX 78957 USA.			Richie, Ellen/0000-0003-0786-973X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024462, R37HD024462] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NHGRI NIH HHS [HG00370] Funding Source: Medline; NICHD NIH HHS [HD24462] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ANGEL JM, 1989, J NATL CANCER I, V81, P1652, DOI 10.1093/jnci/81.21.1652; ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; FAUST C, 1995, DEVELOPMENT, V121, P273; Faust C, 1998, DEVELOPMENT, V125, P4495; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FREI JV, 1974, CHEM-BIOL INTERACT, V9, P65, DOI 10.1016/0009-2797(74)90068-4; FREI JV, 1980, CARCINOGENESIS, V1, P721, DOI 10.1093/carcin/1.8.721; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Gomez G, 2000, INT IMMUNOL, V12, P263, DOI 10.1093/intimm/12.3.263; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kung AL, 2000, GENE DEV, V14, P272; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; NEWCOMB EW, 1988, CANCER RES, V48, P5514; Ng J, 1997, MOL CELL BIOL, V17, P6663, DOI 10.1128/MCB.17.11.6663; RICHIE ER, 1988, LEUKEMIA RES, V12, P233, DOI 10.1016/0145-2126(88)90141-5; RICHIE ER, 1996, PROGR CLIN BIOL RES, P23; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; ROMACH E, 1994, CARCINOGENESIS, V15, P2275, DOI 10.1093/carcin/15.10.2275; SATHE SS, 1995, MECH DEVELOP, V52, P77, DOI 10.1016/0925-4773(95)00392-E; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schumacher A, 1998, GENOMICS, V54, P79, DOI 10.1006/geno.1998.5509; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STETTNER SL, 1991, CANCER RES, V51, P737; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047	45	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					299	306		10.1038/sj.onc.1205051	http://dx.doi.org/10.1038/sj.onc.1205051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803473				2022-12-25	WOS:000173026200014
J	Spalding, AC; Jotte, RM; Scheinman, RI; Geraci, MW; Clarke, P; Tyler, KL; Johnson, GL				Spalding, AC; Jotte, RM; Scheinman, RI; Geraci, MW; Clarke, P; Tyler, KL; Johnson, GL			TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappa B-dependent, genotoxin-induced apoptosis of cancer cells	ONCOGENE			English	Article						TRAIL; IAP; NF-kappa B; apoptosis; chemotherapy	PACLITAXEL-INDUCED APOPTOSIS; INTESTINAL TREFOIL FACTOR; NECROSIS-FACTOR-ALPHA; ZINC FINGER PROTEIN; CYTOCHROME-C; TRANSCRIPTIONAL ACTIVATION; FORKHEAD PROTEINS; DECOY RECEPTORS; DEATH RECEPTORS; EXPRESSION	Opposing pro- and anti-apoptotic actions of TRAIL and the inhibitors of apoptosis (IAPs) contribute to the cell's decision to survive or die. We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Inhibition of NF-kappaB activation in H157 cells in response to genotoxin resulted in loss of cell surface expression of TRAIL and DR5, aggressive growth and chemotherapy resistance of tumors in nude mice. Similar to the paracrine TRAIL response in H157 cells, the sensitivity of normal lung and breast epithelium and carcinomas to undergo genotoxin-induced apoptosis correlates strongly with cell surface expression of TRAIL. Suppression of TRAIL signaling by expression of the TRAIL decoy receptor, DeR1, confers chemo-resistance to cancer cells. These findings demonstrate that TRAIL signaling via its death receptors is a significant contributor to genotoxin-induced apoptosis in human epithelial carcinomas.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, SOM,Canc Ctr, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Dept Neurol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Sch Pharm, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Johnson, GL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, SOM,Canc Ctr, C236,Room 2809,4200 E 9th Ave, Denver, CO 80262 USA.		Tyler, Kenneth L./J-2420-2019	Tyler, Kenneth L./0000-0003-3294-5888				Altucci L, 2001, NAT MED, V7, P680, DOI 10.1038/89050; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Basu S, 1998, BIOCHEM BIOPH RES CO, V247, P79, DOI 10.1006/bbrc.1998.8741; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chaudhary PM, 1997, IMMUNITY, V7, P821, DOI 10.1016/S1074-7613(00)80400-8; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Clarke P, 2000, J VIROL, V74, P8135, DOI 10.1128/JVI.74.17.8135-8139.2000; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Fisher MJ, 2001, CLIN CANCER RES, V7, P1688; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; HAN JY, 2001, P ASCO, V20; Hellqvist M, 1996, J BIOL CHEM, V271, P4482; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee SH, 1999, CANCER RES, V59, P5683; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mahlapuu M, 1998, DEV BIOL, V202, P183, DOI 10.1006/dbio.1998.9010; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakamura M, 2000, ACTA NEUROPATHOL, V99, P1, DOI 10.1007/PL00007399; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Ozoren N, 2000, INT J ONCOL, V16, P917; Pai SI, 1998, CANCER RES, V58, P3513; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Sakai T, 2001, NAT MED, V7, P324, DOI 10.1038/85471; Schneider P, 1997, FEBS LETT, V416, P329, DOI 10.1016/S0014-5793(97)01231-3; Sedger LM, 1999, J IMMUNOL, V163, P920; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Strobel T, 1996, P NATL ACAD SCI USA, V93, P14094, DOI 10.1073/pnas.93.24.14094; SUEMORI S, 1991, P NATL ACAD SCI USA, V88, P11017, DOI 10.1073/pnas.88.24.11017; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; THIM L, 1989, FEBS LETT, V250, P85, DOI 10.1016/0014-5793(89)80690-8; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang SW, 1999, ANN CLIN LAB SCI, V29, P192; Wu WG, 2000, ANTICANCER RES, V20, P4525; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					260	271		10.1038/sj.onc.1205048	http://dx.doi.org/10.1038/sj.onc.1205048			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803469				2022-12-25	WOS:000173026200010
J	Khan, KMF; Laurie, GW; McCaffrey, TA; Falcone, DJ				Khan, KMF; Laurie, GW; McCaffrey, TA; Falcone, DJ			Exposure of cryptic domains in the alpha 1-chain of laminin-1 by elastase stimulates macrophages urokinase and matrix metalloproteinase-9 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; CELL-ADHESION; HEPARIN-BINDING; DIFFERENTIAL EXPRESSION; PLASMINOGEN-ACTIVATOR; GLOBULAR DOMAIN; TISSUE; SITES; IDENTIFICATION; LOCALIZATION	Degradation of the extracellular matrix leads to the release of fragments, which elicit biological responses distinct from intact molecules. We have reported that alpha1:Ser(2091)-Arg(2108), a peptide derived from the alpha1-chain of laminin-1, triggers protein kinase C-dependent activation of MAPK(erk1/2), leading to the up-regulation of macrophage urokinase type plasminogen activator and matrix metalloproteinase (MMP)-9 expression. Since intact laminin-1 failed to trigger these events, we hypothesized that alpha1:Ser(2091)-Arg(2108) is cryptic or assumes a conformation not recognized by macrophages. Here we demonstrate that elastase cleavage of laminin-1 generates fragments, which stimulate proteinase expression by RAW264.7 macrophages and peritoneal macrophages. In contrast, fragments generated by MMP-2, MMP-7, or plasmin had no effect on macrophage proteinase expression. Elastase-generated laminin-1 fragments were fractionated by heparin-Sepharose chromatography. Heparin-binding fragments stimulated macrophages' proteinase expression severalfold greater than nonbinding fragments. The heparin binding fragments reacted with antibodies directed against regions of the alpha1-chain including alpha1:Ser(2091)-Arg(2108) and the globular domain. A peptide from the first loop of the globular domain (alpha1:Ser(2179)-Ser(2198)) triggered the phosphorylation of MAPK(erk1/2) and stimulated the expression of macrophage urokinase type plasminogen activator and MMP-9. Moreover, a heparin-binding fraction isolated from an aortic aneurysm contained fragments of alpha1-chain and stimulated macrophages' proteinase expression. Based on these data, we conclude that cryptic domains in the COOH-terminal portion of the alpha1-chain of laminin are exposed by proteolysis and stimulate macrophages' proteinase expression.	Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Univ Virginia, Dept Cell Biol, Charlottesville, VA USA; George Washington Univ, Med Ctr, Washington, DC 20037 USA; Cornell Univ, Weill Med Coll, Vasc Biol Ctr, New York, NY 10021 USA	Cornell University; Cornell University; University of Virginia; George Washington University; Cornell University	Falcone, DJ (corresponding author), Cornell Univ, Weill Med Coll, Dept Pathol, Rm A678,1300 York Ave,Joan & Sanford 1, New York, NY 10021 USA.		Laurie, Gordon W/A-5244-2008	Laurie, Gordon W/0000-0002-5311-2650	NEI NIH HHS [R01-EY09747, R01 EY009747-08] Funding Source: Medline; NHLBI NIH HHS [R01-HL40819] Funding Source: Medline; NIA NIH HHS [R01-AG12712] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009747] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012712] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Andresen JL, 1996, DIABETES, V45, pS91, DOI 10.2337/diab.45.3.S91; AUMAILLEY M, 1987, J BIOL CHEM, V262, P11532; AUMAILLEY M, 1990, EXP CELL RES, V188, P55, DOI 10.1016/0014-4827(90)90277-H; BECK K, 1990, FASEB J, V4, P148, DOI 10.1096/fasebj.4.2.2404817; CAMPBELL EJ, 1991, J IMMUNOL, V146, P1286; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, J CLIN INVEST, V99, P200, DOI 10.1172/JCI119148; Chen LL, 1997, AM J PHYSIOL-LUNG C, V272, pL494, DOI 10.1152/ajplung.1997.272.3.L494; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; CORCORAN ML, 1995, J BIOL CHEM, V270, P10365, DOI 10.1074/jbc.270.18.10365; DALFERES ER, 1985, ARTERY, V13, P41; Davis GE, 2000, AM J PATHOL, V156, P1489, DOI 10.1016/S0002-9440(10)65020-1; DEUTZMANN R, 1990, EUR J BIOCHEM, V191, P513, DOI 10.1111/j.1432-1033.1990.tb19151.x; Dogic D, 1999, MATRIX BIOL, V18, P433, DOI 10.1016/S0945-053X(99)00046-3; EDELSON PJ, 1976, PURIFICATION CULTIVA, P333; FALCONE DJ, 1988, J CELL PHYSIOL, V135, P387, DOI 10.1002/jcp.1041350305; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; FALCONE DJ, 1991, J BIOL CHEM, V266, P22726; FREESTONE T, 1995, ARTERIOSCL THROM VAS, V15, P1145, DOI 10.1161/01.ATV.15.8.1145; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; GLUKHOVA M, 1993, DEV BIOL, V157, P437, DOI 10.1006/dbio.1993.1147; Haruno A, 1999, SCAND J CLIN LAB INV, V59, P395, DOI 10.1080/00365519950185418; HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186; KANEMOTO T, 1990, P NATL ACAD SCI USA, V87, P2279, DOI 10.1073/pnas.87.6.2279; Khan KMF, 1997, J BIOL CHEM, V272, P8270, DOI 10.1074/jbc.272.13.8270; Khan KMF, 2000, J BIOL CHEM, V275, P4492, DOI 10.1074/jbc.275.6.4492; KIBBEY MC, 1994, J CELL PHYSIOL, V160, P185, DOI 10.1002/jcp.1041600121; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; LASSILA R, 1993, EUR HEART J, V14, P94; LIOTTA LA, 1981, THROMB RES, V21, P663, DOI 10.1016/0049-3848(81)90268-1; MASURE S, 1993, EUR J BIOCHEM, V218, P129, DOI 10.1111/j.1432-1033.1993.tb18359.x; MATTER ML, 1994, J CELL BIOL, V124, P1083, DOI 10.1083/jcb.124.6.1083; Miner JH, 1999, KIDNEY INT, V56, P2016, DOI 10.1046/j.1523-1755.1999.00785.x; MOSER TL, 1993, J BIOL CHEM, V268, P18917; Nag S, 1996, J NEUROPATH EXP NEUR, V55, P381, DOI 10.1097/00005072-199603000-00014; Nakahara H, 1996, J BIOL CHEM, V271, P27221, DOI 10.1074/jbc.271.44.27221; NOMIZU M, 1995, J BIOL CHEM, V270, P20583, DOI 10.1074/jbc.270.35.20583; ODEKON LE, 1991, IMMUNOLOGY, V74, P114; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; OTT U, 1982, EUR J BIOCHEM, V123, P63, DOI 10.1111/j.1432-1033.1982.tb06499.x; Peutz-Kootstra CJ, 2000, J PATHOL, V192, P404, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH707>3.0.CO;2-L; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; Ramos-DeSimone N, 1999, J BIOL CHEM, V274, P13066, DOI 10.1074/jbc.274.19.13066; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; SCHITTNY JC, 1990, J CELL BIOL, V110, P825, DOI 10.1083/jcb.110.3.825; SENIOR RM, 1980, J CLIN INVEST, V66, P859, DOI 10.1172/JCI109926; SEPHEL GC, 1989, BIOCHEM BIOPH RES CO, V162, P821, DOI 10.1016/0006-291X(89)92384-X; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Shipley JM, 1996, P NATL ACAD SCI USA, V93, P3942, DOI 10.1073/pnas.93.9.3942; SKUBITZ APN, 1988, J BIOL CHEM, V263, P4861; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; Sung U, 1997, EUR J BIOCHEM, V250, P138, DOI 10.1111/j.1432-1033.1997.00138.x; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; WERB Z, 1980, J EXP MED, V152, P1537, DOI 10.1084/jem.152.6.1537; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; YURCHENCO PD, 1993, J BIOL CHEM, V268, P8356	59	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13778	13786		10.1074/jbc.M111290200	http://dx.doi.org/10.1074/jbc.M111290200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827968	hybrid			2022-12-25	WOS:000175096000058
J	Lakaye, B; Makarchikov, AF; Antunes, AF; Zorzi, W; Coumans, B; De Pauw, E; Wins, P; Grisar, T; Bettendorff, L				Lakaye, B; Makarchikov, AF; Antunes, AF; Zorzi, W; Coumans, B; De Pauw, E; Wins, P; Grisar, T; Bettendorff, L			Molecular characterization of a specific thiamine triphosphatase widely expressed in mammalian tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTRANSFERASE ACTIVITY; NEUROBLASTOMA-CELLS; EXCITABLE TISSUES; ELECTRIC ORGAN; RAT-BRAIN; PURIFICATION; DERIVATIVES; ENZYME; ATP; COMPARTMENTATION	Thiamine triphosphate (ThTP) is found at low concentrations in most animal tissues, and recent data suggest that it may act as a phosphate donor for the phosphorylation of some proteins. In the mammalian brain, ThTP synthesis is rapid, but its steady-state concentration remains low, presumably because of rapid hydrolysis. In this report we purified a soluble thiamine triphosphatase (ThTPase; EC 3.6.1.28) from calf brain. The bovine ThTPase is a 24-kDa monomer, hydrolyzing ThTP with virtually absolute specificity. Partial sequence data obtained from the purified bovine enzyme by tandem mass spectrometry were used to search the GenBank(TM) data base. A significant identity was found with only one human sequence, the hypothetical 230-amino acid protein MGC2652. The coding regions from human and bovine brain mRNA were amplified by reverse transcription-PCR, cloned in Escherichia coli, and sequenced. The human open reading frame was expressed in E. coli as a GST fusion protein. Transformed bacteria had a high isopropyl-beta-D-thiogalactopyranoside-inducible ThTPase activity. The recombinant ThTPase had properties similar to those of human brain ThTPase, and it was specific for ThTP. The mRNA was expressed in most human tissues but at relatively low levels. This is the first report of a molecular characterization of a specific ThTPase.	Univ Liege, Ctr Cellular & Mol Neurobiol, B-4020 Liege, Belgium; Univ Liege, Dept Human Histol, B-4020 Liege, Belgium; Univ Liege, Dept Phys Chem, B-4000 Liege, Belgium; Natl Acad Sci Belarus, Inst Biochem, Enzymol Lab, Grodno 230009, BELARUS	University of Liege; University of Liege; University of Liege; National Academy of Sciences of Belarus (NASB); Institute of Biochemistry of Biologically Active Compounds of the National Academy of Sciences of Belarus	Bettendorff, L (corresponding author), Univ Liege, Ctr Cellular & Mol Neurobiol, 17 Pl Delcour, B-4020 Liege, Belgium.	L.Bettendorff@ulg.ac.be		De Pauw, Edwin/0000-0003-3475-1315				BARCHI RL, 1972, J BIOL CHEM, V247, P7668; BETTENDORFF L, 1993, J MEMBRANE BIOL, V136, P281; BETTENDORFF L, 1994, BBA-MOL CELL RES, V1222, P1, DOI 10.1016/0167-4889(94)90018-3; BETTENDORFF L, 1990, BIOCHEM PHARMACOL, V40, P2557, DOI 10.1016/0006-2952(90)90099-7; BETTENDORFF L, 1991, ANAL BIOCHEM, V198, P52, DOI 10.1016/0003-2697(91)90505-N; BETTENDORFF L, 1995, J NEUROCHEM, V64, P2013; BETTENDORFF L, 1989, J NEUROCHEM, V53, P738, DOI 10.1111/j.1471-4159.1989.tb11767.x; BETTENDORFF L, 1994, BBA-MOL CELL RES, V1222, P7, DOI 10.1016/0167-4889(94)90019-1; Bettendorff L, 1996, J NEUROCHEM, V66, P250; BETTENDORFF L, 1994, J BIOL CHEM, V269, P14379; BETTENDORFF L, 1994, METAB BRAIN DIS, V9, P183, DOI 10.1007/BF01991194; BETTENDORFF L, 1987, J NEUROCHEM, V49, P495, DOI 10.1111/j.1471-4159.1987.tb02891.x; BETTENDORFF L, 1993, J NEUROCHEM, V60, P423, DOI 10.1111/j.1471-4159.1993.tb03168.x; Bettendorff L., 1999, RRD NEUROCHEMISTRY 1, P37; CHERNIKEVICH I P, 1984, Biokhimiya, V49, P899; COOPER JR, 1979, NEUROCHEM RES, V4, P223, DOI 10.1007/BF00964146; Fleming JC, 1999, NAT GENET, V22, P305, DOI 10.1038/10379; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; HAAS RH, 1988, ANNU REV NUTR, V8, P483, DOI 10.1146/annurev.nu.08.070188.002411; HARATA N, 1993, METAB BRAIN DIS, V8, P45, DOI 10.1007/BF01000529; HASHITANI Y, 1972, J BIOL CHEM, V247, P2117; Hazell AS, 2001, J NEUROCHEM, V78, P560, DOI 10.1046/j.1471-4159.2001.00436.x; HILL M, 1988, FEBS LETT, V230, P47, DOI 10.1016/0014-5793(88)80639-2; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; MAKARCHIKOV AF, 1992, BIOCHIM BIOPHYS ACTA, V1117, P326, DOI 10.1016/0304-4165(92)90032-P; MAKARCHIKOV AF, 2001, J BIOCH MOL BIOL BIO, V5, P75; MATAGNE A, 1991, BIOCHEM J, V280, P553, DOI 10.1042/bj2800553; MIYOSHI K, 1990, J BIOCHEM-TOKYO, V108, P267, DOI 10.1093/oxfordjournals.jbchem.a123192; Nghiem HO, 2000, FASEB J, V14, P543, DOI 10.1096/fasebj.14.3.543; NISHIMUNE T, 1987, J NUTR SCI VITAMINOL, V33, P113; NISHINO K, 1983, J BIOL CHEM, V258, P1871; Nosaka K, 1999, J BIOL CHEM, V274, P34129, DOI 10.1074/jbc.274.48.34129; PENTTINEN HK, 1981, MED BIOL, V59, P177; Shevchenko A, 2000, METH MOL B, V146, P1, DOI 10.1385/1-59259-045-4:1; Shin RK, 2000, ARCH NEUROL-CHICAGO, V57, P405, DOI 10.1001/archneur.57.3.405; VOSKOBOYEV AI, 1980, VOP MED KHIM, V26, P564; Zimatkina TI, 2000, ALCOHOL CLIN EXP RES, V24, P1620	39	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13771	13777		10.1074/jbc.M111241200	http://dx.doi.org/10.1074/jbc.M111241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827967	hybrid			2022-12-25	WOS:000175096000057
J	Mucke, M; Pingoud, V; Grelle, G; Kraft, R; Kruger, DH; Reuter, M				Mucke, M; Pingoud, V; Grelle, G; Kraft, R; Kruger, DH; Reuter, M			Asymmetric photocross-linking pattern of restriction endonuclease EcoRII to the DNA recognition sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKING; BINDING SITES; TARGET RECOGNITION; SUBSTITUTED RNA; INT-FAMILY; IDENTIFICATION; CLEAVAGE; COMPLEX; PROTEIN; BASE	The EcoRII homodimer engages two of its recognition sequences (5'-CCWGG) simultaneously and is therefore a type IIE restriction endonuclease. To identify the amino acids of EcoRII that interact specifically with the recognition sequence, we photocross-linked EeoRII with oligonucleotide substrates that contained only one recognition sequence for EcoRII. In this recognition sequence, we substituted either 5-iododeoxycytidine for each C or 5-iododeoxyuridine for A, G, or T. These iodopyrimidine bases were excited using a UV laser to result in covalent cross-linking products. The yield of EcoRII photocross-linked to the 5'-C of the 5'-CCAGG strand of the recognition sequence was 45%. However, we could not photocross-link EcoRII to the 5'-C of the 5'-CCTGG strand. Thus, the contact of EcoRII to the bases of the recognition sequence appears to be asymmetric, unlike that expected for most type II restriction endonucleases. Tryptic digestion of free and of cross-linked EcoRII, followed by high performance liquid chromatography (HPLC) separation of the individual peptides and Edman degradation, identified amino acids 25-49 of EcoRII as the cross-linking peptide. Mutational analysis of the electron-rich amino acids His(36) and Tyr(41) of this peptide indicates that Tyr(41) is the amino acid involved in the cross-link and that it therefore contributes to specific DNA recognition by EcoRII.	Humboldt Univ, Fak Med, Inst Virol, Charite, D-10098 Berlin, Germany; Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Justus Liebig University Giessen; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Reuter, M (corresponding author), Humboldt Univ, Fak Med, Inst Virol, Charite, D-10098 Berlin, Germany.	monika.reuter@charite.de						BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; BLATTER EE, 1992, NATURE, V359, P650, DOI 10.1038/359650a0; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Holz B, 1999, J BIOL CHEM, V274, P15066, DOI 10.1074/jbc.274.21.15066; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; Huai Q, 2001, NAT STRUCT BIOL, V8, P665, DOI 10.1038/90366; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; JO K, 1995, SCIENCE, V267, P1817, DOI 10.1126/science.7892605; Karpova EA, 1999, IUBMB LIFE, V48, P91, DOI 10.1080/713803460; KARYAGINA AS, 1990, GENE, V87, P113, DOI 10.1016/0378-1119(90)90501-H; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; Kubareva EA, 2000, NUCLEIC ACIDS RES, V28, P1085, DOI 10.1093/nar/28.5.1085; Lukacs CM, 2000, NAT STRUCT BIOL, V7, P134; Malkov VA, 1997, J BIOL CHEM, V272, P23811, DOI 10.1074/jbc.272.38.23811; Meisenheimer KM, 1996, NUCLEIC ACIDS RES, V24, P981, DOI 10.1093/nar/24.5.981; Mucke M, 2001, J MOL BIOL, V312, P687, DOI 10.1006/jmbi.2001.4998; Mucke M, 2000, J BIOL CHEM, V275, P30631, DOI 10.1074/jbc.M003904200; NEWMAN M, 1994, NATURE, V368, P660, DOI 10.1038/368660a0; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud V, 1999, J BIOL CHEM, V274, P10235, DOI 10.1074/jbc.274.15.10235; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Reuter M, 1999, J BIOL CHEM, V274, P5213, DOI 10.1074/jbc.274.8.5213; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; Wang Y, 1996, BIOCHEMISTRY-US, V35, P3563, DOI 10.1021/bi952438v; WESTERMEIER R, 1990, ELEKTROPHORESE PRAKT, P225; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; Wong DL, 1998, NUCLEIC ACIDS RES, V26, P645, DOI 10.1093/nar/26.2.645; Wong DL, 2000, BIOCHEMISTRY-US, V39, P15410, DOI 10.1021/bi001164v; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YOLOV AA, 1984, FEBS LETT, V167, P147, DOI 10.1016/0014-5793(84)80850-9	36	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14288	14293		10.1074/jbc.M109311200	http://dx.doi.org/10.1074/jbc.M109311200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11832480	hybrid			2022-12-25	WOS:000175096000121
J	Naiki, T; Nagaki, M; Shidoji, Y; Kojima, H; Imose, M; Kato, T; Ohishi, N; Yagi, K; Moriwaki, H				Naiki, T; Nagaki, M; Shidoji, Y; Kojima, H; Imose, M; Kato, T; Ohishi, N; Yagi, K; Moriwaki, H			Analysis of gene expression profile induced by hepatocyte nuclear factor 4 alpha in hepatoma cells using an oligonucleotide microarray	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; ENRICHED TRANSCRIPTIONAL ACTIVATOR; FACTOR HNF-4; BINDING; PROTEIN; TISSUE; ZINC; IDENTIFICATION; ATHEROGENESIS; ADENOVIRUS	Hepatocyte nuclear factor 4alpha (HNF-4alpha), a liver-specific transcription factor, plays a significant role in many liver-specific functions, including lipid, glucose, drug, and ammonia metabolism, and also in embryonal liver development. However, its functions and regulation are not yet clearly understood. In this study, we constructed an adenovirus vector carrying rat HNF-4alpha cDNA and transfected the adenovirus to human hepatoma cells, HuH-7, to enforce expression of the exogenous HNF-4alpha gene. We analyzed HNF-4alpha-induced genes using cDNA microarray technology, which included over 9000 genes. As a result, 62 genes showed a greater than 2.0-fold change in expression level after the viral transfection. Fifty-six genes were consistently induced by HNF-4alpha overexpression, and six genes were repressed. To assess HNF-4alpha function, we attempted to classify the genes, which had been classified by their encoding protein functions in a previous report. We could classify 45 genes. The rest of the HNF-4alpha-sensitive genes were unclassified (4 genes) or not identified (13 genes). Among the classified genes, almost half of the induced genes (26 of 40) were related to metabolism genes and particularly to lipid metabolism-related genes. This cDNA microarray analysis showed that HNF-4alpha is one of the central liver metabolism regulators.	Gifu Univ, Sch Med, Dept Internal Med 1, Gifu 5008705, Japan; Gifu Univ, Sch Med, Dept Neurol & Psychiat, Gifu 5008705, Japan; Siebold Univ Nagasaki, Dept Nutr & Hlth Sci, Lab Cellular Biochem, Nagasaki 8512195, Japan; Inst Appl Biochem, Gifu 5050116, Japan	Gifu University; Gifu University	Nagaki, M (corresponding author), Gifu Univ, Sch Med, Dept Internal Med 1, 40 Tsukasa Machi, Gifu 5008705, Japan.	mnagaki@cc.gifu-u.ac.jp						ADAMS MD, 1995, NATURE, V377, P3; BOISJOYEUX B, 1994, BIOCHEM J, V301, P49, DOI 10.1042/bj3010049; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; CASTELLI WP, 1992, AM J CARDIOL, V70, pH3, DOI 10.1016/0002-9149(92)91083-G; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Chausmer AB, 1998, J AM COLL NUTR, V17, P109, DOI 10.1080/07315724.1998.10718735; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; COGNET M, 1991, J BIOL CHEM, V266, P7368; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DiSilvestro RA, 2000, J NUTR, V130, p1509S, DOI 10.1093/jn/130.5.1509S; DUNCAN SA, 1994, P NATL ACAD SCI USA, V91, P7598, DOI 10.1073/pnas.91.16.7598; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; Fraser JD, 1997, J BIOL CHEM, V272, P13892, DOI 10.1074/jbc.272.21.13892; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; HEMPE JM, 1991, P NATL ACAD SCI USA, V88, P9671, DOI 10.1073/pnas.88.21.9671; HERBST RS, 1991, NEW BIOL, V3, P289; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; Li JX, 2000, GENE DEV, V14, P464; MasucciMagoulas L, 1997, SCIENCE, V275, P391, DOI 10.1126/science.275.5298.391; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAGAKI M, 1995, BIOCHEM BIOPH RES CO, V210, P38, DOI 10.1006/bbrc.1995.1624; Neve BP, 2000, BIOCHEM PHARMACOL, V60, P1245, DOI 10.1016/S0006-2952(00)00430-5; NISHIWAKI R, 1994, CANCER LETT, V83, P283, DOI 10.1016/0304-3835(94)90331-X; Rajas F, 2000, DIABETES, V49, P1165, DOI 10.2337/diabetes.49.7.1165; RAYMONDJEAN M, 1991, NUCLEIC ACIDS RES, V19, P6145, DOI 10.1093/nar/19.22.6145; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHONFELD G, 1979, METABOLISM, V28, P1001, DOI 10.1016/0026-0495(79)90004-0; Shih DQ, 2000, DIABETES, V49, P832, DOI 10.2337/diabetes.49.5.832; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Smoot LM, 2001, P NATL ACAD SCI USA, V98, P10416, DOI 10.1073/pnas.191267598; Spath GF, 1997, MOL CELL BIOL, V17, P1913; Spath GF, 1998, J CELL BIOL, V140, P935, DOI 10.1083/jcb.140.4.935; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Vergnes L, 1997, BBA-LIPID LIPID MET, V1348, P299, DOI 10.1016/S0005-2760(97)00071-4; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; YANUKAKASHLES O, 1994, MOL CELL BIOL, V14, P7124, DOI 10.1128/MCB.14.11.7124; Yue HB, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.8.e41	47	67	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14011	14019		10.1074/jbc.M105403200	http://dx.doi.org/10.1074/jbc.M105403200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834723	hybrid			2022-12-25	WOS:000175096000087
J	Pingoud, V; Kubareva, E; Stengel, G; Friedhoff, P; Bujnicki, JM; Urbanke, C; Sudina, A; Pingoud, A				Pingoud, V; Kubareva, E; Stengel, G; Friedhoff, P; Bujnicki, JM; Urbanke, C; Sudina, A; Pingoud, A			Evolutionary relationship between different subgroups of restriction endonucleases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 RECOGNITION SITES; CRYSTAL-STRUCTURE; DNA RECOGNITION; REFRACTORY DNA; OLIGONUCLEOTIDE DUPLEXES; MODIFICATION SYSTEM; TARGET RECOGNITION; STIMULATE CLEAVAGE; SEQUENCE; ECORII	The type II restriction endonuclease SsoII shows sequence similarity with 10 other restriction endonucleases, among them the type HE restriction endonuclease EcoRII, which requires binding to an effector site for efficient DNA cleavage, and the type IIF restriction endonuclease NgoMIV, which is active as a homotetramer and cleaves DNA with two recognition sites in a concerted reaction. We show here that SsoII is an orthodox type II enzyme, which is active as a homodimer and does not require activation by binding to an effector site. Nevertheless, it shares with EcoRII and NgoMIV a very similar DNA-binding site and catalytic center as shown here by a mutational analysis, indicative of an evolutionary relationship between these three enzymes. We suggest that a similar relationship exists between other orthodox type II, type IIE, and type IIF restriction endonucleases. This may explain why similarities may be more pronounced between members of different subtypes of restriction enzymes than among the members of a given subtype.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Moscow MV Lomonosov State Univ, Physicochem Biol & Chem Dept, AN Belozersky Inst, Moscow 119899, Russia; Int Inst Mol & Cell Biol, Bioinformat Lab, PL-02109 Warsaw, Poland; Hannover Med Sch, D-30623 Hannover, Germany	Justus Liebig University Giessen; Lomonosov Moscow State University; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Hannover Medical School	Pingoud, V (corresponding author), Univ Giessen, Inst Biochem, Heinrich Buff Ring 58, D-35392 Giessen, Germany.	vera.pingoud@chemie.bio.uni-giessen.de	Kubareva, Elena A/I-3184-2012; Friedhoff, Peter/G-7905-2012; Sudina, Anna/I-5753-2014	Friedhoff, Peter/0000-0003-1946-1117				ANDERSON JE, 1993, CURR OPIN STRUC BIOL, V3, P24, DOI 10.1016/0959-440X(93)90197-S; Aravind L, 2000, NUCLEIC ACIDS RES, V28, P3417, DOI 10.1093/nar/28.18.3417; BHAGWAT AS, 1990, J BIOL CHEM, V265, P767; BIGGER CH, 1973, NATURE-NEW BIOL, V244, P7, DOI 10.1038/newbio244007a0; Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; Bujnicki Janusz M., 2001, Acta Microbiologica Polonica, V50, P219; Bujnicki JM, 2001, BIOINFORMATICS, V17, P750, DOI 10.1093/bioinformatics/17.8.750; Bujnicki JM, 2001, TRENDS BIOCHEM SCI, V26, P9, DOI 10.1016/S0968-0004(00)01690-X; Bujnicki JM, 2001, J MOL MICROB BIOTECH, V3, P69; Bujnicki JM, 2001, GENE, V267, P183, DOI 10.1016/S0378-1119(01)00405-X; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Den'mukhametov M. M., 1997, Molekulyarnaya Biologiya (Moscow), V31, P831; Denjmukhametov MM, 1998, FEBS LETT, V433, P233, DOI 10.1016/S0014-5793(98)00921-1; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Embleton ML, 2001, J MOL BIOL, V311, P503, DOI 10.1006/jmbi.2001.4892; Friedhoff P, 2001, J BIOL CHEM, V276, P23581, DOI 10.1074/jbc.M101694200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Heitman J, 1993, Genet Eng (N Y), V15, P57; Huai Q, 2000, EMBO J, V19, P3110, DOI 10.1093/emboj/19.12.3110; Huai Q, 2001, NAT STRUCT BIOL, V8, P665, DOI 10.1038/90366; JELTSCH A, 1995, GENE, V160, P7, DOI 10.1016/0378-1119(95)00181-5; KARYAGINA AS, 1993, GENE, V124, P13, DOI 10.1016/0378-1119(93)90756-S; Kirsch RD, 1998, NUCLEIC ACIDS RES, V26, P1848, DOI 10.1093/nar/26.7.1848; KOSSYKH V, 1989, BIOCHIM BIOPHYS ACTA, V1009, P290, DOI 10.1016/0167-4781(89)90117-6; Kovall RA, 1999, CURR OPIN CHEM BIOL, V3, P578, DOI 10.1016/S1367-5931(99)00012-5; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; Kubareva EA, 2000, NUCLEIC ACIDS RES, V28, P1085, DOI 10.1093/nar/28.5.1085; KUBAREVA EA, 1992, NUCLEIC ACIDS RES, V20, P4533, DOI 10.1093/nar/20.17.4533; Kunz A, 1998, BIOL CHEM, V379, P617; Lundstrom J, 2001, PROTEIN SCI, V10, P2354, DOI 10.1110/ps.08501; Miyahara M, 1997, BIOL PHARM BULL, V20, P201; Morgan R, 1998, APPL ENVIRON MICROB, V64, P3669; Mucke M, 2000, J BIOL CHEM, V275, P30631, DOI 10.1074/jbc.M003904200; NIKOLSKAYA II, 1983, MOL GENET MIKROBIOL, V12, P5; NOBBS TJ, 1995, J MOL BIOL, V252, P399, DOI 10.1006/jmbi.1995.0506; PEIN CD, 1989, FEBS LETT, V245, P141, DOI 10.1016/0014-5793(89)80208-X; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PETRAUSKENE OV, 1992, EUR J BIOCHEM, V208, P617, DOI 10.1111/j.1432-1033.1992.tb17226.x; PETRAUSKENE OV, 1995, NUCLEIC ACIDS RES, V23, P2192, DOI 10.1093/nar/23.12.2192; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; Reuter M, 1999, J BIOL CHEM, V274, P5213, DOI 10.1074/jbc.274.8.5213; Roberts RJ, 2001, NUCLEIC ACIDS RES, V29, P268, DOI 10.1093/nar/29.1.268; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Sapranauskas R, 2000, J BIOL CHEM, V275, P30878, DOI 10.1074/jbc.M003350200; Scott WRP, 1999, J PHYS CHEM A, V103, P3596, DOI 10.1021/jp984217f; Sheflyan GY, 1996, FEBS LETT, V390, P307, DOI 10.1016/0014-5793(96)00645-X; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Skirgaila R, 1998, J MOL BIOL, V279, P473, DOI 10.1006/jmbi.1998.1803; Stahl F, 1998, BIOL CHEM, V379, P467, DOI 10.1515/bchm.1998.379.4-5.467; THIELKING V, 1991, BIOCHEMISTRY-US, V30, P6416, DOI 10.1021/bi00240a011; Twomey DP, 1997, MICROBIOL-SGM, V143, P2277, DOI 10.1099/00221287-143-7-2277; VENCLOVAS C, 1994, PROTEINS, V20, P279, DOI 10.1002/prot.340200308; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; WENTZELL LM, 1995, J MOL BIOL, V248, P581, DOI 10.1006/jmbi.1995.0244; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; Winkler F. K., 1992, CURR OPIN STRUC BIOL, V2, P93; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019	64	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14306	14314		10.1074/jbc.M111625200	http://dx.doi.org/10.1074/jbc.M111625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11827971	hybrid			2022-12-25	WOS:000175096000124
J	Yang, E; Henriksen, MA; Schaefer, O; Zakharova, N; Darnell, JE				Yang, E; Henriksen, MA; Schaefer, O; Zakharova, N; Darnell, JE			Dissociation time from DNA determines transcriptional function in a STAT1 linker mutant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; DOMAIN; FORMALDEHYDE; ACTIVATION; KINETICS; RECEPTOR; SITES; BETA	The STAT1 transcription factor is organized into several highly conserved domains, each of which has been assigned a function with the exception of the linker domain. We previously characterized a mutant in the linker domain of STAT1 that gave normal DNA binding using a standard probe in an electrophoretic mobility assay but failed to activate transcription in response to interferon gamma. We now report the mechanistic basis for the inactivity of this STAT1(K544A/E545A) mutant. Rather than failing to attract transcriptional coactivators, the STAT1(K544A/E545A) mutant has a subtle biophysical defect, which prevents accumulation of the activated protein on chromatin in vivo: the mutant has comparable K-d with greatly increased k(off) for DNA binding. The increase in both on-rate and off-rate of DNA binding results in a substantially reduced residence time of STAT1(K544A/E545A) on STAT binding sites. We find a similar correlation between off-rate and transcriptional potency for STAT1(N460A), which bears a mutation in the DNA binding domain. These results yield insight into the rate of complex assembly involving STAT1 that leads to transcriptional stimulation.	Rockefeller Univ, Lab Mol Cell Biol, New York, NY 10021 USA	Rockefeller University	Darnell, JE (corresponding author), Rockefeller Univ, Lab Mol Cell Biol, 1230 York Ave,Box 235, New York, NY 10021 USA.	darnell@mail.rockefeller.edu	Yang, Edward/Q-8175-2019		NCI NIH HHS [CA09673] Funding Source: Medline; NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034420, R01AI032489, R01AI034420] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Besser D, 1999, MOL CELL BIOL, V19, P1401; BURATWOSKI S, 1987, CURRENT PROTOCOLS MO, V2; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Kim J, 1997, MOL CELL BIOL, V17, P3173, DOI 10.1128/MCB.17.6.3173; MCGHEE JD, 1975, BIOCHEMISTRY-US, V14, P1281, DOI 10.1021/bi00677a029; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Richieri GV, 1999, BIOCHEMISTRY-US, V38, P5888, DOI 10.1021/bi982703n; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Yang E, 1999, MOL CELL BIOL, V19, P5106	22	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13455	13462		10.1074/jbc.M112038200	http://dx.doi.org/10.1074/jbc.M112038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11834743	hybrid			2022-12-25	WOS:000175096000017
J	Amaar, YG; Thompson, GR; Linkhart, TA; Chen, ST; Baylink, DJ; Mohan, S				Amaar, YG; Thompson, GR; Linkhart, TA; Chen, ST; Baylink, DJ; Mohan, S			Insulin-like growth factor-binding protein 5 (IGFBP-5) interacts with a four and a half LIM protein 2 (FHL2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; NORMAL HUMAN BONE; DOMAIN PROTEIN; ONLY PROTEIN; IGF-I; SYSTEM; SERUM; BETA; ROLES; IDENTIFICATION	Recent studies using insulin-like growth factor I (IGF-1) knockout mice demonstrate that IGF-binding protein (IGFBP)-5, an important bone formation regulator, itself is a growth factor with cellular effects not dependent on IGFs. Because IGFBP-5 contains a nuclear localization sequence that mediates transport of IGFBP-5 into the nucleus, we propose that IGFBP-5 interacts with nuclear proteins to affect transcription of genes involved in bone formation. We therefore undertook studies to identify proteins that bind to IGFBP-5 using IGFBP-5 as bait in a yeast two-hybrid screen of a U2 human osteosarcoma cDNA library. Five related clones that interacted strongly with the bait corresponded to the FHL2 gene, which contains four and a half LIM domains. Co-immunoprecipitation studies with lysates from U2 cells overexpressing FHL2 and IGFBP-5 confirmed that interaction between IGFBP-5 and FHL2 occurs in whole cells. In vitro interaction studies revealed that purified FHL2 interacted with IGFBP-5 but not with IGFBP-3, -4, or -6. Northern blot analysis showed that FHL2 was strongly expressed in human osteoblasts. Nuclear localization of both FHL2 and IGFBP-5 was evident from Western immunoblot analysis and immunofluorescence. The role of FHL2 as an intracellular mediator of the effects of IGFBP-5 and other osteoregulatory agents in osteoblasts will need to be verified in future studies.	Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr 151, Loma Linda, CA 92357 USA; Loma Linda Univ, Dept Biochem, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Pediat, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Med, Loma Linda, CA 92350 USA; Loma Linda Univ, Dept Physiol, Loma Linda, CA 92350 USA	Loma Linda University; Loma Linda University; Loma Linda University; Loma Linda University	Mohan, S (corresponding author), Jerry L Pettis Mem Vet Adm Med Ctr, Musculoskeletal Dis Ctr 151, 11201 Benton St, Loma Linda, CA 92357 USA.	mohans@lom.med.va.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007543, R01AR031062] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR07543, AR31062] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDRESS DL, 1993, BIOCHEM BIOPH RES CO, V195, P25, DOI 10.1006/bbrc.1993.2004; Andress DL, 1998, AM J PHYSIOL-ENDOC M, V274, pE744, DOI 10.1152/ajpendo.1998.274.4.E744; Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; Boden SD, 1998, ENDOCRINOLOGY, V139, P5125, DOI 10.1210/en.139.12.5125; Boonen S, 1999, J BONE MINER RES, V14, P2150, DOI 10.1359/jbmr.1999.14.12.2150; Butt AJ, 1999, IMMUNOL CELL BIOL, V77, P256, DOI 10.1046/j.1440-1711.1999.00822.x; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; Chevalley T, 1996, EUR J ENDOCRINOL, V134, P591, DOI 10.1530/eje.0.1340591; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Clemmons DR, 1998, MOL CELL ENDOCRINOL, V140, P19, DOI 10.1016/S0303-7207(98)00024-0; Collett-Solberg PF, 2000, ENDOCRINE, V12, P121, DOI 10.1385/ENDO:12:2:121; Dailly YP, 2001, BBA-GENE STRUCT EXPR, V1518, P145, DOI 10.1016/S0167-4781(01)00192-0; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; FARLEY JR, 1991, METABOLISM, V40, P664, DOI 10.1016/0026-0495(91)90081-7; Ferry RJ, 1999, HORM METAB RES, V31, P192, DOI 10.1055/s-2007-978719; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Gasmi M, 1999, J VIROL, V73, P1828, DOI 10.1128/JVI.73.3.1828-1834.1999; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; HARLOW E, 1998, USING ANTIBODIES LAB, P269; KLING L, 1996, J BONE MINER RES S, V11, P153; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Li X, 2000, BBA-GEN SUBJECTS, V1524, P102, DOI 10.1016/S0304-4165(00)00118-5; LINKHART TA, 1991, J BONE MINER RES, V6, P1285; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Malpe R, 1997, J BONE MINER RES, V12, P423, DOI 10.1359/jbmr.1997.12.3.423; Miyakoshi N, 2001, J CLIN INVEST, V107, P73, DOI 10.1172/JCI10459; MOHAN S, 1988, BIOCHIM BIOPHYS ACTA, V966, P44, DOI 10.1016/0304-4165(88)90127-4; Mohan S, 1996, J CLIN ENDOCR METAB, V81, P3817, DOI 10.1210/jc.81.11.3817; MOHAN S, 1995, J BIOL CHEM, V270, P20424, DOI 10.1074/jbc.270.35.20424; Mohan S, 1996, HORM RES, V45, P59, DOI 10.1159/000184833; Mohan S, 1997, ENDOCRINE, V7, P87, DOI 10.1007/BF02778070; MOHAN S, 1999, IGF SYSTEM MOL BIOL, P457; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; NICOLAS V, 1995, CALCIFIED TISSUE INT, V57, P206, DOI 10.1007/BF00310260; OH YM, 1993, J BIOL CHEM, V268, P14964; Peng HR, 2001, MOL THER, V4, P95, DOI 10.1006/mthe.2001.0423; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; Richman C, 1999, ENDOCRINOLOGY, V140, P4699, DOI 10.1210/en.140.10.4699; Rosen CJ, 1998, P SOC EXP BIOL MED, V219, P1; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Shi ZD, 2000, J BIOL CHEM, V275, P18574, DOI 10.1074/jbc.M002172200; Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200	54	111	115	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12053	12060		10.1074/jbc.M110872200	http://dx.doi.org/10.1074/jbc.M110872200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821401	hybrid			2022-12-25	WOS:000174846400060
J	del Pino, MMS; Perez-Mato, I; Sanz, JM; Mato, JM; Corrales, FJ				del Pino, MMS; Perez-Mato, I; Sanz, JM; Mato, JM; Corrales, FJ			Folding of dimeric methionine adenosyltransferase III - Identification of two folding intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE SYNTHETASE; RAT-LIVER; BACTERIAL LUCIFERASE; CRYSTAL-STRUCTURE; PROTEIN; PURIFICATION; ENZYME; FRACTIONATION; DIMERIZATION; EQUILIBRIUM	Methionine adenosyl transferase (MAT) is an essential enzyme that synthesizes AdoMet. The liver-specific MAT isoform, MAT III, is a homodimer of a 43.7-kDa subunit that organizes in three nonsequential alpha-beta domains. Although MAT III structure has been recently resolved, little is known about its folding mechanism. Equilibrium unfolding and refolding of MAT III, and the monomeric mutant R265H, have been monitored using different physical parameters. Tryptophanyl fluorescence showed a three-state folding mechanism. The first unfolding step was a folding/association process as indicated by its dependence on protein concentration. e monomeric folding intermediate produced was the predominant species between 1.5 and 3 m urea. It had a relatively compact conformation with tryptophan residues and hydrophobic surfaces occluded from the solvent, although its N-terminal region may be very unstructured. The second unfolding step monitored the denaturation of the intermediate. Refolding of the intermediate showed first order kinetics, indicating the presence of a kinetic intermediate within the folding(association transition. Its presence was confirmed by measuring the 1,8-anilinonaphtalene-8-sulfonic acid binding in the presence of tripolyphosphate. We propose that the folding rate-limiting step is the formation of an intermediate, probably a structured monomer with exposed hydrophobic surfaces, that rapidly associates to form dimeric MAT III.	Univ Navarra, Div Hepatol & Gene Therapy, Pamplona 31008, Navarra, Spain; Univ Miguel Hernandez, Ctr Biol Mol & Celular, Elche 03202, Alicante, Spain	University of Navarra; Universidad Miguel Hernandez de Elche	Corrales, FJ (corresponding author), Univ Navarra, Div Hepatol & Gene Therapy, Irunlarrea 1, Pamplona 31008, Navarra, Spain.	mspino@unav.es; fjcorrales@unav.es	Sanz, Jesus M/B-2244-2008; MATO, JOSE/A-5187-2011; del Pino, Manuel M. Sánchez/I-3977-2015	Sanz, Jesus M/0000-0002-4421-9376; MATO, JOSE/0000-0003-1264-3153; del Pino, Manuel M. Sánchez/0000-0001-9696-7600; Corrales, Fernando/0000-0002-0231-5159				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; CABRERO C, 1987, EUR J BIOCHEM, V170, P299, DOI 10.1111/j.1432-1033.1987.tb13699.x; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CANTONI GL, 1953, J BIOL CHEM, V204, P403; CLARK AC, 1993, J BIOL CHEM, V268, P10773; CREIGHTON TE, 1990, BIOCHEM J, V270, P1; del Pino MMS, 2000, J BIOL CHEM, V275, P23476, DOI 10.1074/jbc.M002730200; Doyle SM, 2000, BIOCHEMISTRY-US, V39, P11667, DOI 10.1021/bi000299y; FINKELSTEIN JD, 1990, J NUTR BIOCHEM, V1, P228, DOI 10.1016/0955-2863(90)90070-2; FU Z, 1996, J BIOMOL STRUCT; GOLDENBERG DP, 1981, J MOL BIOL, V145, P633, DOI 10.1016/0022-2836(81)90307-7; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; HaasePettingell C, 1997, J MOL BIOL, V267, P88, DOI 10.1006/jmbi.1996.0841; HOFFMAN JL, 1983, METHOD ENZYMOL, V94, P223; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; JAENICKE R, 1991, BIOCHEMISTRY-US, V30, P3147, DOI 10.1021/bi00227a001; JAENICKE R, 1989, PROTEIN STRUCTURE PR; KOTB M, 1985, J BIOL CHEM, V260, P3923; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Mato IP, 2001, J BIOL CHEM, V276, P13803, DOI 10.1074/jbc.M009017200; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Mingorance J, 1996, BIOCHEM J, V315, P761, DOI 10.1042/bj3150761; MITSUI KI, 1988, J BIOL CHEM, V263, P11211; MUDD SH, 1980, METABOLISM, V29, P707, DOI 10.1016/0026-0495(80)90192-4; NEET KE, 1994, PROTEIN SCI, V3, P2167, DOI 10.1002/pro.5560031202; OKADA G, 1981, BIOCHEMISTRY-US, V20, P934, DOI 10.1021/bi00507a045; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Ptitsyn Oleg B., 1992, P243; Schonbrunn E, 2000, P NATL ACAD SCI USA, V97, P6345, DOI 10.1073/pnas.120120397; SERRANO L, 1992, J MOL BIOL, V224, P783, DOI 10.1016/0022-2836(92)90562-X; SULLIVAN DM, 1983, BIOCHEMISTRY-US, V22, P1636, DOI 10.1021/bi00276a017; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Takusagawa F, 1996, BIOCHEMISTRY-US, V35, P2586, DOI 10.1021/bi952604z; WADDLE JJ, 1987, BIOCHEMISTRY-US, V26, P4917, DOI 10.1021/bi00390a004; ZIEGLER MM, 1993, J BIOL CHEM, V268, P10760	39	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					12061	12066		10.1074/jbc.M111546200	http://dx.doi.org/10.1074/jbc.M111546200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11815619	hybrid			2022-12-25	WOS:000174846400061
J	Odersky, A; Panyutin, IV; Panyutin, IG; Schunck, C; Feldmann, E; Goedecke, W; Neumann, RD; Obe, G; Pfeiffer, P				Odersky, A; Panyutin, IV; Panyutin, IG; Schunck, C; Feldmann, E; Goedecke, W; Neumann, RD; Obe, G; Pfeiffer, P			Repair of sequence-specific I-125-induced double-strand breaks by nonhomologous DNA end joining in mammalian cell-free extracts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL-ABERRATIONS; RESTRICTION ENDONUCLEASES; ENZYMATIC RESTRICTION; XENOPUS-LAEVIS; RECOMBINATION; MECHANISMS; I-125; TRIPLEX; OLIGONUCLEOTIDES; POLYMERASES	In mammalian cells, nonhomologous DNA end joining (NHEJ) is considered the major pathway of double-strand break (DSB) repair. Rejoining of DSB produced by decay of I-125 positioned against a specific target site in plasmid DNA via a triplex-forming oligonucleotide (TFO) was investigated in cell-free extracts from Chinese hamster ovary cells. The efficiency and quality of NHEJ of the "complex" DSB induced by the I-125-TFO was compared with that of "simple" DSB induced by restriction enzymes. We demonstrate that the extracts are indeed able to rejoin I-125-TFO-induced DSB, although at approximately 10-fold decreased efficiency compared with restriction enzyme-induced DSB. The resulting spectrum of junctions is highly heterogeneous exhibiting deletions (1-30 bp), base pair substitutions, and insertions and reflects the heterogeneity of DSB induced by the I-125-TFO within its target site. We show that NHEJ of I-125-TFO-induced DSB is not a random process that solely depends on the position of the DSB but is driven by the availability of microhomology patches in the target sequence. The similarity of the junctions obtained with the ones found in vivo after I-125-TFO-mediated radiodamage indicates that our in vitro system may be a useful tool to elucidate the mechanisms of ionizing radiation-induced mutagenesis and repair.	Univ Essen Gesamthsch, Inst Genet, FB9, D-45117 Essen, Germany; NIH, Warren G Magnuson Clin Ctr, Dept Nucl Med, Bethesda, MD 20854 USA	University of Duisburg Essen; National Institutes of Health (NIH) - USA	Pfeiffer, P (corresponding author), Univ Essen Gesamthsch, Inst Genet, FB9, S05 T04 B26,Univ St 5, D-45117 Essen, Germany.				CLINICAL CENTER [Z01CL060001, ZIACL060001] Funding Source: NIH RePORTER	CLINICAL CENTER		Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Bennett RAO, 1996, INT J RADIAT BIOL, V70, P623; BEYERT N, 1994, NUCLEIC ACIDS RES, V22, P1643, DOI 10.1093/nar/22.9.1643; BRYANT PE, 1984, INT J RADIAT BIOL, V46, P57, DOI 10.1080/09553008414551061; BRYANT PE, 1985, INT J RADIAT BIOL, V48, P55, DOI 10.1080/09553008514551061; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; DAZA P, 1996, BIOL CHEM HOPPESEYLE, V377, P75; Featherstone C, 1999, CURR BIOL, V9, pR759, DOI 10.1016/S0960-9822(00)80005-6; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Gu XY, 1996, J BIOL CHEM, V271, P19660, DOI 10.1074/jbc.271.33.19660; Haber JE, 1999, TRENDS BIOCHEM SCI, V24, P271, DOI 10.1016/S0968-0004(99)01413-9; Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9; Haber JE, 2000, CURR OPIN CELL BIOL, V12, P286, DOI 10.1016/S0955-0674(00)00090-9; KING JS, 1993, NUCLEIC ACIDS RES, V21, P1055, DOI 10.1093/nar/21.5.1055; KING JS, 1994, J BIOL CHEM, V269, P13061; King JS, 1996, J BIOL CHEM, V271, P20450, DOI 10.1074/jbc.271.34.20450; Labhart P, 1999, EUR J BIOCHEM, V265, P849, DOI 10.1046/j.1432-1327.1999.00805.x; Lin YF, 2001, GENETICS, V158, P1665; LUTZE LH, 1993, MUTAT RES, V299, P225, DOI 10.1016/0165-1218(93)90099-Y; Mezhevaya K, 1999, NUCLEIC ACIDS RES, V27, P4282, DOI 10.1093/nar/27.21.4282; NATARAJAN AT, 1984, CHROMOSOMA, V90, P120, DOI 10.1007/BF00292448; NICOLAS AL, 1995, NUCLEIC ACIDS RES, V23, P1036, DOI 10.1093/nar/23.6.1036; Nikjoo H, 2000, INT J RADIAT BIOL, V76, P1607, DOI 10.1080/09553000050201091; NORTH P, 1990, NUCLEIC ACIDS RES, V18, P6205, DOI 10.1093/nar/18.21.6205; OBE G, 1985, MUTAT RES, V150, P359; PANYUTIN IG, 1994, NUCLEIC ACIDS RES, V22, P4979, DOI 10.1093/nar/22.23.4979; Panyutin IG, 1997, NUCLEIC ACIDS RES, V25, P883, DOI 10.1093/nar/25.4.883; Panyutin IG, 1996, ACTA ONCOL, V35, P817, DOI 10.3109/02841869609104032; Panyutin IG, 2000, Q J NUCL MED, V44, P256; Panyutin IV, 2001, RADIAT RES, V156, P158, DOI 10.1667/0033-7587(2001)156[0158:SBIWPD]2.0.CO;2; PFEIFFER P, 1988, NUCLEIC ACIDS RES, V16, P907, DOI 10.1093/nar/16.3.907; PFEIFFER P, 1994, MOL CELL BIOL, V14, P888, DOI 10.1128/MCB.14.2.888; Pfeiffer P, 1998, TOXICOL LETT, V96-7, P119, DOI 10.1016/S0378-4274(98)00058-7; PFEIFFER P, 1994, MUTAGENESIS, V9, P527, DOI 10.1093/mutage/9.6.527; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; Reichenberger S, 1998, EUR J BIOCHEM, V251, P81, DOI 10.1046/j.1432-1327.1998.2510081.x; ROTH DB, 1991, NUCLEIC ACIDS RES, V19, P7201, DOI 10.1093/nar/19.25.7201; ROTH DB, 1989, MOL CELL BIOL, V9, P3049, DOI 10.1128/MCB.9.7.3049; ROTH DB, 1985, P NATL ACAD SCI USA, V82, P3355, DOI 10.1073/pnas.82.10.3355; ROTH DB, 1985, MOL CELL BIOL, V5, P2599, DOI 10.1128/MCB.5.10.2599; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; Sedelnikova OA, 2001, INT J RADIAT ONCOL, V49, P391, DOI 10.1016/S0360-3016(00)01486-3; Sedelnikova OA, 2000, ANTISENSE NUCLEIC A, V10, P443, DOI 10.1089/oli.1.2000.10.443; THODE S, 1990, CELL, V60, P921, DOI 10.1016/0092-8674(90)90340-K; Tijssen P., 1993, LAB TECHNIQUES BIOCH	50	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11756	11764		10.1074/jbc.M111304200	http://dx.doi.org/10.1074/jbc.M111304200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11821407	hybrid			2022-12-25	WOS:000174846400021
J	McCain, DF; Catrina, IE; Hengge, AC; Zhang, ZY				McCain, DF; Catrina, IE; Hengge, AC; Zhang, ZY			The catalytic mechanism of Cdc25A phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; LOW-MOLECULAR-WEIGHT; TRANSITION-STATE STRUCTURES; SUBSTRATE-TRAPPING MUTANTS; LEAVING GROUP DEPENDENCE; P-NITROPHENYL PHOSPHATE; CRYSTAL-STRUCTURE; CELL-CYCLE; BOVINE HEART; KINASE PHOSPHATASE-3	Cdc25 phosphatases are dual specificity phosphatases that dephosphorylate and activate cyclin-dependent kinases (CDKs), thereby effecting the progression from one phase of the cell cycle to the next. Despite its central role in the cell cycle, relatively little is known about the catalytic mechanism of Cdc25. In order to provide insights into the catalytic mechanism of Cdc25, we have performed a detailed mechanistic analysis of the catalytic domain of human Cdc25A. Our kinetic isotope effect results, Bronsted analysis, and pH dependence studies employing a range of aryl phosphates clearly indicate a dissociative transition state for the Cdc25A reaction that does not involve a general acid for the hydrolysis of substrates with low leaving group p, values (5.45-8.05). Interestingly, our Bronsted analyis and pH dependence studies reveal that Cdc25A employs a different mechanism for the hydrolysis of substrates with high leaving group pK(alpha), values (8.68-9.99) that appears to require the protonation of glutamic acid 431. Mutation of glutamic acid 431 into glutamine leads to a dramatic drop in the hydrolysis rate for the high leaving group pK(alpha) substrates and the disappearance of the basic limb of the pH rate profile for the substrate with a leaving group pK(alpha) of 8.05, indicating that glutamic acid 431 is essential for the efficient hydrolysis of substrates with high leaving group pK(alpha). We suggest that hydrolysis of the high leaving group pK(alpha) substrates proceeds through an unfavored but more catalytically active form of Cdc25A, and we propose several models illustrating this. Since the activity of Cdc25A toward small molecule substrates is several orders of magnitude lower than toward the physiological substrate, cyclin-CDK, we suggest that the cyclin-CDK is able to preferentially induce this more catalytically active form of Cdc25A for efficient phosphothreonine and phosphotyrosine dephosphorylation.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Utah State Univ, Dept Chem & Biochem, Logan, UT 84322 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Utah System of Higher Education; Utah State University	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu	Hengge, Alvan C/C-8667-2011	Hengge, Alvan C/0000-0002-5696-2087; Catrina, Irina/0000-0001-5976-4548	NATIONAL CANCER INSTITUTE [R01CA069202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047297, R01GM047297] Funding Source: NIH RePORTER; NCI NIH HHS [CA69202] Funding Source: Medline; NIGMS NIH HHS [R01 GM047297, GM47297] Funding Source: Medline; OHS HRSA HHS [ST32GM07260] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); OHS HRSA HHS		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BIGELEISEN J, 1958, ADV CHEM PHYS, V1, P15; BLACK MJ, 1983, ANAL BIOCHEM, V135, P233, DOI 10.1016/0003-2697(83)90756-X; Broggini M, 2000, ANTICANCER RES, V20, P4835; CALDWELL SR, 1991, BIOCHEMISTRY-US, V30, P7444, DOI 10.1021/bi00244a011; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Chen L, 1996, BIOCHEMISTRY-US, V35, P9349, DOI 10.1021/bi960700+; Chen W, 2000, BIOCHEMISTRY-US, V39, P10781, DOI 10.1021/bi000909u; CHO HJ, 1992, J AM CHEM SOC, V114, P7296, DOI 10.1021/ja00044a052; CIRRI P, 1993, EUR J BIOCHEM, V214, P647, DOI 10.1111/j.1432-1033.1993.tb17965.x; Cleland WW, 1995, FASEB J, V9, P1585, DOI 10.1096/fasebj.9.15.8529838; COLEMAN TR, 1994, CURR OPIN CELL BIOL, V6, P877, DOI 10.1016/0955-0674(94)90060-4; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Denu JM, 1996, P NATL ACAD SCI USA, V93, P2493, DOI 10.1073/pnas.93.6.2493; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Eckstein JW, 1996, PROTEIN SCI, V5, P5; Fauman EB, 1998, CELL, V93, P617, DOI 10.1016/S0092-8674(00)81190-3; Fjeld CC, 2000, J BIOL CHEM, V275, P6749, DOI 10.1074/jbc.275.10.6749; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gottlin EB, 1996, J BIOL CHEM, V271, P27445, DOI 10.1074/jbc.271.44.27445; GUAN KL, 1991, J BIOL CHEM, V266, P17026; HALL AD, 1986, BIOCHEMISTRY-US, V25, P4784, DOI 10.1021/bi00365a010; HENGGE AC, 1995, BIOCHEMISTRY-US, V34, P13982, DOI 10.1021/bi00043a003; Hengge AC, 1996, BIOCHEMISTRY-US, V35, P7084, DOI 10.1021/bi960255i; HENGGE AC, 1994, J AM CHEM SOC, V116, P5045, DOI 10.1021/ja00091a003; Hengge AC, 1997, BIOCHEMISTRY-US, V36, P7928, DOI 10.1021/bi970364c; Hernandez S, 2000, INT J CANCER, V89, P148, DOI 10.1002/(SICI)1097-0215(20000320)89:2<148::AID-IJC8>3.0.CO;2-R; Hernandez S, 2001, LAB INVEST, V81, P465, DOI 10.1038/labinvest.3780254; Hoff RH, 1999, J AM CHEM SOC, V121, P9514, DOI 10.1021/ja992361o; HOFFMANN I, 1994, J CELL SCI, P75; Hofmann K, 1998, J MOL BIOL, V282, P195, DOI 10.1006/jmbi.1998.1998; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; KIRBY AJ, 1967, J AM CHEM SOC, V89, P415, DOI 10.1021/ja00978a044; Lohse DL, 1997, BIOCHEMISTRY-US, V36, P4568, DOI 10.1021/bi963094r; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Northrop D. B., 1977, ISOTOPE EFFECTS ENZY, P122; OLEARY MH, 1979, J AM CHEM SOC, V101, P3300, DOI 10.1021/ja00506a027; Peng HR, 2001, J MED CHEM, V44, P834, DOI 10.1021/jm0004401; Reynolds RA, 1999, J MOL BIOL, V293, P559, DOI 10.1006/jmbi.1999.3168; Rigas JD, 2001, BIOCHEMISTRY-US, V40, P4398, DOI 10.1021/bi002951v; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SU XD, 1994, NATURE, V370, P575, DOI 10.1038/370575a0; TADDEI N, 1994, FEBS LETT, V350, P328, DOI 10.1016/0014-5793(94)00805-1; Takahashi M, 2000, BIOORG MED CHEM LETT, V10, P2571, DOI 10.1016/S0960-894X(00)00527-8; Tamura K, 1999, ONCOGENE, V18, P6989, DOI 10.1038/sj.onc.1203179; Wang SS, 2000, BIOCHEMISTRY-US, V39, P1903, DOI 10.1021/bi991348d; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Wu FYH, 1999, EUR J CANCER, V35, P1388, DOI 10.1016/S0959-8049(99)00156-2; Wu L, 1996, BIOCHEMISTRY-US, V35, P5426, DOI 10.1021/bi952885a; Xu X, 1996, J BIOL CHEM, V271, P5118; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHANG M, 1994, BIOCHEMISTRY-US, V33, P11097, DOI 10.1021/bi00203a006; Zhang YL, 2000, J BIOL CHEM, V275, P34205, DOI 10.1074/jbc.M004490200; Zhang YL, 1999, BIOCHEMISTRY-US, V38, P12111, DOI 10.1021/bi990836i; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16389, DOI 10.1021/bi00050a020; ZHANG ZY, 1993, BIOCHEMISTRY-US, V32, P9340, DOI 10.1021/bi00087a012; ZHANG ZY, 1991, BIOCHEMISTRY-US, V30, P8954, DOI 10.1021/bi00101a006; Zhang ZY, 1995, BIOCHEMISTRY-US, V34, P16088, DOI 10.1021/bi00049a024; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHANG ZY, 1995, J BIOL CHEM, V270, P11199, DOI 10.1074/jbc.270.19.11199; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; Zhao Y, 1996, BIOCHEMISTRY-US, V35, P11797, DOI 10.1021/bi960471r; Zhao Y, 1998, J BIOL CHEM, V273, P5484, DOI 10.1074/jbc.273.10.5484; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200; Zhou B, 2001, J BIOL CHEM, V276, P6506, DOI 10.1074/jbc.M009753200; Zhou B, 1999, J BIOL CHEM, V274, P35526, DOI 10.1074/jbc.274.50.35526	79	43	43	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 29	2002	277	13					11190	11200		10.1074/jbc.M109636200	http://dx.doi.org/10.1074/jbc.M109636200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	534WQ	11805096	hybrid			2022-12-25	WOS:000174613100057
J	Devy, L; Blacher, S; Grignet-Debrus, C; Bajou, K; Masson, R; Gerard, RD; Gils, A; Carmeliet, G; Carmeliet, P; Declerck, PJ; Noel, A; Foidart, JM				Devy, L; Blacher, S; Grignet-Debrus, C; Bajou, K; Masson, R; Gerard, RD; Gils, A; Carmeliet, G; Carmeliet, P; Declerck, PJ; Noel, A; Foidart, JM			The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent	FASEB JOURNAL			English	Article						angiogenesis; cell migration; proteolysis; serine protease; PAI-1	ENDOTHELIAL-CELLS; UROKINASE RECEPTOR; ANGIOGENESIS INVITRO; BREAST-CANCER; GROWTH-FACTOR; MOUSE MODEL; MICE; PAI-1; GENE; METASTASIS	Plasminogen activator inhibitor 1 (PAI-1) is believed to control proteolytic activity and cell migration during angiogenesis. We previously demonstrated in vivo that this inhibitor is necessary for optimal tumor invasion and vascularization. We also showed that PAI-1 angiogenic activity is associated with its control of plasminogen activation but not with the regulation of cell-matrix interaction. To dissect the role of the various components of the plasminogen activation system during angiogenesis, we have adapted the aortic ring assay to use vessels from gene-inactivated mice. The single deficiency of tPA, uPA, or uPAR, as well as combined deficiencies of uPA and tPA, did not dramatically affect microvessel formation. Deficiency of plasminogen delayed microvessel outgrowth. Lack of PAI-1 completely abolished angiogenesis, demonstrating its importance in the control of plasmin-mediated proteolysis. Microvessel outgrowth from PAI-1(-/-) aortic rings could be restored by adding exogenous PAI-1 (wild-type serum or purified recombinant PAI-1). Addition of recombinant PAI-1 led to a bell-shaped angiogenic response clearly showing that PAI-1 is proangiogenic at physiological concentrations and antiangiogenic at higher levels. Using specific PAI-1 mutants, we could demonstrate that PAI-1 promotes angiogenesis at physiological (nanomolar) concentrations through its antiproteolytic activity rather than by interacting with vitronectin.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX USA; Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX USA; Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Lab Expt Med & Endocrinol LEGENDO, B-3000 Louvain, Belgium; Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium	University of Liege; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; KU Leuven; KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Tour Pathol B23,Sart Tilman, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be	Declerck, Paul J/A-2330-2017; Carmeliet, Peter/AAQ-5140-2020	Declerck, Paul J/0000-0003-1259-9105; Carmeliet, Peter/0000-0001-7961-1821; Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BEHRINGER RR, 1993, DEVELOPMENT, V117, P823; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Carmeliet P, 1998, THROMB RES, V91, P255, DOI 10.1016/S0049-3848(98)00122-4; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1999, CURR TOP MICROBIOL, V237, P133; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; COLMAN RW, 1969, BIOCHEM BIOPH RES CO, V35, P273, DOI 10.1016/0006-291X(69)90278-2; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Eitzman DT, 1996, BLOOD, V87, P4718; Foekens JA, 2000, CANCER RES, V60, P636; GERARD RD, 1995, DNA CLONING PRACTICA, P285; Gils A, 1996, BIOCHEMISTRY-US, V35, P7474, DOI 10.1021/bi960079d; Gutierrez LS, 2000, CANCER RES, V60, P5839; Harbeck N, 2000, INT J BIOL MARKER, V15, P79, DOI 10.1177/172460080001500115; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; MILES LA, 1983, THROMB RES, V29, P407, DOI 10.1016/0049-3848(83)90244-X; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; NICOSIA RF, 1990, LAB INVEST, V63, P115; NICOSIA RF, 1982, IN VITRO CELL DEV B, V18, P538; PEPPER MS, 1992, J CELL PHYSIOL, V153, P129, DOI 10.1002/jcp.1041530117; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; SHUBEITA HE, 1990, J BIOL CHEM, V265, P18379; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; TSUBOI R, 1990, INT J CANCER, V46, P56, DOI 10.1002/ijc.2910460112; Tsuchiya H, 1997, ANTICANCER RES, V17, P313; Vleugels N, 2000, BBA-PROTEIN STRUCT M, V1476, P20, DOI 10.1016/S0167-4838(99)00224-1; VOYTA JC, 1984, J CELL BIOL, V99, P2034, DOI 10.1083/jcb.99.6.2034; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521	38	236	244	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2002	16	2							UNSP 0892-6638/02/0016-0147	10.1096/fj.01-0552com	http://dx.doi.org/10.1096/fj.01-0552com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818362				2022-12-25	WOS:000174203700019
J	Ojcius, DM; Delarbre, C; Kourilsky, P; Gachelin, G				Ojcius, DM; Delarbre, C; Kourilsky, P; Gachelin, G			MHC and MHC-related proteins as pleiotropic signal molecules	FASEB JOURNAL			English	Article						signal transduction; homeostasis; protein-protein interaction; MHC class I	CLASS-I MHC; CRYSTAL-STRUCTURE; NKG2D RECEPTOR; T-CELLS; EXPRESSION; LIGANDS; CNS	Class I molecules of the major histocompatibility complex (MHC) have been studied primarily for their role in presenting peptide antigens to conventional T lymphocytes. An increasing body of evidence suggests that MHC and newly characterized MHC-related molecules have a much more varied function in the body. Many of these molecules are involved in pleiotropic interactions with other proteins, which initiate signal transduction cascades and contribute to cellular and tissue homeostasis.	Inst Pasteur, INSERM, U277, F-75724 Paris 15, France; Univ Paris 07, Inst Pasteur, Unite Biol Mol Gene, F-75724 Paris 15, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	Gachelin, G (corresponding author), Inst Pasteur, Unite Biol Mol Gene, 25 Rue Dr Roux, F-75015 Paris, France.	ggachel@pasteur.fr						Cerwenka A, 2000, IMMUNITY, V12, P721, DOI 10.1016/S1074-7613(00)80222-8; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Cosman D, 2001, IMMUNITY, V14, P123, DOI 10.1016/S1074-7613(09)00098-3; Crowley MP, 2000, SCIENCE, V287, P314, DOI 10.1126/science.287.5451.314; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Diefenbach A, 2000, NAT IMMUNOL, V1, P119, DOI 10.1038/77793; Diefenbach A, 2001, NATURE, V413, P165, DOI 10.1038/35093109; Groh V, 2001, NAT IMMUNOL, V2, P255, DOI 10.1038/85321; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Lauvau G, 2001, J EXP MED, V193, pF35, DOI 10.1084/jem.193.10.F35; Li PW, 1999, IMMUNITY, V10, P577, DOI 10.1016/S1074-7613(00)80057-6; Park SH, 2001, J EXP MED, V193, P893, DOI 10.1084/jem.193.8.893; Ronet C, 2001, J IMMUNOL, V166, P1755, DOI 10.4049/jimmunol.166.3.1755; Sanchez LM, 1999, SCIENCE, V283, P1914, DOI 10.1126/science.283.5409.1914; Ugolini S, 2001, NAT IMMUNOL, V2, P198, DOI 10.1038/85246; Wingren C, 2000, SCIENCE, V287, P310, DOI 10.1126/science.287.5451.310	17	13	14	1	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2002	16	2					202	206		10.1096/fj.01-0758com	http://dx.doi.org/10.1096/fj.01-0758com			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	527TM	11818368				2022-12-25	WOS:000174203700025
J	Jones, AK; Bentley, GN; Parra, WGO; Agnew, A				Jones, AK; Bentley, GN; Parra, WGO; Agnew, A			Molecular characterization of an acetylcholinesterase implicated in the regulation of glucose scavenging by the parasite Schistosoma	FASEB JOURNAL			English	Article						GPI-anchor; glucose transport; acetylcholine receptor	NONNEURONAL SECRETED ACETYLCHOLINESTERASE; IN-VITRO EXPRESSION; ENCODING ACETYLCHOLINESTERASE; SUBSTRATE-SPECIFICITY; TORPEDO-CALIFORNICA; BINDING; CLONING; SITE; IDENTIFICATION; SEQUENCE	Acetylcholinesterase (AChE) present on the surface of the trematode blood fluke Schistosoma has been implicated in the regulation of glucose scavenging from the host blood. Determination of the molecular structure and functional characteristics of this molecule is a crucial first step in understanding the novel function for AChE and in evaluating the potential of schistosome AChE as a target of new parasite control methods. We have determined the primary structure of acetylcholinesterase from Schistosoma haematobium. Immunolocalization studies confirmed that the enzyme was present on the parasite surface as well as in the muscle. The derived amino acid sequence possesses features common to acetylcholinesterases: the catalytic triad, six cysteines that form three intramolecular disulphide bonds, and aromatic residues lining the catalytic gorge. An unusual feature is that the fully processed native enzyme exists as a glycoinositol phospholipid (GPI)-anchored dimer, but the sequence of the C-terminus does not conform to the current consensus for GPI modification. The enzyme expressed in Xenopus oocytes showed conventional substrate specificity and sensitivity to established inhibitors of AChE, although it is relatively insensitive to the peripheral site inhibitor propidium iodide. Distinctions between host and parasite AChEs will allow the rational design of schistosome-specific drugs and vaccines.	Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Agnew, A (corresponding author), Univ Leeds, Sch Biol, Leeds LS2 9JT, W Yorkshire, England.	a.m.agnew@leeds.ac.uk		Jones, Andrew/0000-0002-7835-0890				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; BARAK D, 1995, BIOCHEMISTRY-US, V34, P15444, DOI 10.1021/bi00047a008; Bucht C, 1996, BBA-PROTEIN STRUCT M, V1292, P223, DOI 10.1016/0167-4838(95)00205-7; CAMACHO M, 1994, PARASITOLOGY, V108, P153, DOI 10.1017/S0031182000068244; Camacho M, 1996, PARASITOLOGY, V112, P199, DOI 10.1017/S0031182000084766; Camacho M, 1995, EXP PARASITOL, V81, P584, DOI 10.1006/expr.1995.1152; CAMACHO M, 1995, MOL BIOCHEM PARASIT, V71, P127, DOI 10.1016/0166-6851(94)00039-P; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Combes D, 2000, J MOL BIOL, V300, P727, DOI 10.1006/jmbi.2000.3917; Cousin X, 1996, J BIOL CHEM, V271, P15099, DOI 10.1074/jbc.271.25.15099; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; ESPINOZA B, 1991, EUR J BIOCHEM, V195, P863, DOI 10.1111/j.1432-1033.1991.tb15776.x; FOURNIER D, 1989, J MOL BIOL, V210, P15, DOI 10.1016/0022-2836(89)90287-8; Fujii T, 1995, NEUROSCI LETT, V201, P207, DOI 10.1016/0304-3940(95)12180-3; FUNKEL Y, 1980, AM J TROP MED HYG, V29, P426; GILSON MK, 1994, SCIENCE, V263, P1276, DOI 10.1126/science.8122110; HAAS R, 1988, BIOCHEMISTRY-US, V27, P6453, DOI 10.1021/bi00417a038; Hussein AS, 1999, J BIOL CHEM, V274, P9312, DOI 10.1074/jbc.274.14.9312; Hussein AS, 2000, EUR J BIOCHEM, V267, P2276, DOI 10.1046/j.1432-1327.2000.01232.x; KAWASHIMA K, 1993, BIOGENIC AMINES, V9, P251; Kohler P, 2001, INT J PARASITOL, V31, P336, DOI 10.1016/S0020-7519(01)00131-X; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; Massoulie J, 1998, J PHYSIOLOGY-PARIS, V92, P183, DOI 10.1016/S0928-4257(98)80007-7; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; McClellan JS, 1998, EUR J BIOCHEM, V258, P419, DOI 10.1046/j.1432-1327.1998.2580419.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; PAX RA, 1984, EXP PARASITOL, V58, P314, DOI 10.1016/0014-4894(84)90048-1; SASTRY BVR, 1978, PHARMACOL REV, V30, P65; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; Simon S, 1999, J BIOL CHEM, V274, P27740, DOI 10.1074/jbc.274.39.27740; Soreq H, 2001, NAT REV NEUROSCI, V2, P294, DOI 10.1038/35067589; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; SWICK AG, 1992, P NATL ACAD SCI USA, V89, P1812, DOI 10.1073/pnas.89.5.1812; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Talesa V, 1999, J NEUROCHEM, V72, P1250, DOI 10.1046/j.1471-4159.1999.0721250.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003	42	30	32	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					441	+		10.1096/fj.01-0683fje	http://dx.doi.org/10.1096/fj.01-0683fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821256				2022-12-25	WOS:000173656600012
J	Joussen, AM; Poulaki, V; Mitsiades, N; Kirchhof, B; Koizumi, K; Dohmen, S; Adamis, AP				Joussen, AM; Poulaki, V; Mitsiades, N; Kirchhof, B; Koizumi, K; Dohmen, S; Adamis, AP			Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression	FASEB JOURNAL			English	Article						cyclooxygenase; nitric oxide; NF-kappa B; Erk kinase	NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; CELL-ADHESION MOLECULE-1; BLOOD-RETINAL BARRIER; SMOOTH-MUSCLE-CELLS; RHEUMATOID-ARTHRITIS; ICAM-1 EXPRESSION; GENE-EXPRESSION; IN-VIVO	Leukocyte adhesion to the diabetic retinal vasculature results in blood-retinal barrier breakdown, capillary nonperfusion, and endothelial cell injury and death. Intercellular adhesion molecule-1 (ICAM-1) and the leukocyte integrin CD18 are required for these processes. Diabetes was induced in Long Evans rats, resulting in a two- to threefold increase in retinal leukocyte adhesion. Following one week of diabetes, neutrophil CD11a, CD11b, and CD18 expression was increased significantly, as were retinal ICAM-1 levels. Animals were treated with aspirin, a cyclooxygenase 2 (COX-2) inhibitor (meloxicam), or a soluble tumor necrosis factor alpha (TNF-alpha) receptor/Fc construct (TNFR-Fc, etanercept). High-dose aspirin, etanercept, and high-dose meloxicam each reduced leukocyte adhesion and suppressed blood-retinal barrier breakdown. High-dose aspirin also reduced the expression of CD11a, CD11b, and CD18, whereas meloxicam and etanercept did not. High-dose aspirin, etanercept, and high-dose meloxicam each reduced retinal ICAM-1 expression. Aspirin and meloxicam both lowered retinal TNF-alpha levels. Notably, aspirin, meloxicam, and etanercept did not change retinal vascular endothelial growth factor levels. High-dose aspirin, etanercept and high-dose meloxicam, each suppressed the retinal expression of eNOS and the DNA-binding capacity of retinal nuclear factor-kappaB. High-dose aspirin also suppressed Erk kinase activity, which is involved in CD18 up-regulation. Taken together, these data identify COX-2 and TNF-alpha as operative in the early signature pathologies of diabetic retinopathy, a newly recognized inflammatory disease.	Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, Boston, MA 02114 USA; Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, D-50931 Cologne, Germany; Univ Cologne, Ctr Mol Med ZMMK, D-50931 Cologne, Germany; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary; University of Cologne; University of Cologne; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Adamis, AP (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Res Lab, 324 Cambridge St, Boston, MA 02114 USA.	tony_adamis@meei.harvard.edu	Joussen, Antonia/AAA-6901-2022					ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; Amore Alessandro, 2000, Journal of the American Society of Nephrology, V11, p634A; Amrani Y, 1999, J IMMUNOL, V163, P2128; [Anonymous], 1991, OPHTHALMOLOGY, V98, P741; ARIASNEGRETE S, 1995, BIOCHEM BIOPH RES CO, V208, P582, DOI 10.1006/bbrc.1995.1378; AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; Barner A, 1996, SCAND J RHEUMATOL, P29, DOI 10.3109/03009749609097228; Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153; BELLAS RE, 1995, J CLIN INVEST, V96, P2521, DOI 10.1172/JCI118313; Carmo A, 2000, NITRIC OXIDE-BIOL CH, V4, P590, DOI 10.1006/niox.2000.0312; Carteron NL, 2000, MOL MED TODAY, V6, P315, DOI 10.1016/S1357-4310(00)01757-3; Chen TT, 1999, MAR BIOTECHNOL, V1, P1; CHEW EY, 1995, ARCH OPHTHALMOL-CHIC, V113, P52, DOI 10.1001/archopht.1995.01100010054020; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; COLLINS T, 1993, LAB INVEST, V68, P499; DAMAD GD, 1982, DIABETES METAB, V8, P307; DiRosa M, 1996, PROSTAG LEUKOTR ESS, V54, P229, DOI 10.1016/S0952-3278(96)90053-8; Dumont I, 1999, J PHARMACOL EXP THER, V291, P627; FERRIS FL, 1992, JAMA-J AM MED ASSOC, V268, P1292; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Hawrami K, 1996, HUM IMMUNOL, V46, P49, DOI 10.1016/0198-8859(95)00177-8; Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1; JOUSSEN AM, 2002, IN PRESS AM J PATHOL; Kacimi R, 1998, CIRC RES, V82, P576, DOI 10.1161/01.RES.82.5.576; KHOSLA PK, 1982, DIABETOLOGIA, V23, P104, DOI 10.1007/BF01271169; Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEE SE, 2001, J BIOL CHEM, V23; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Limb GA, 1996, BRIT J OPHTHALMOL, V80, P168, DOI 10.1136/bjo.80.2.168; Limb GA, 1999, CLIN EXP IMMUNOL, V118, P213; Limb GA, 1999, CLIN EXP IMMUNOL, V115, P409; Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330; Lu M, 1999, INVEST OPHTH VIS SCI, V40, P1808; Luong BT, 2000, ANN PHARMACOTHER, V34, P743; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; McCormack K, 1998, J RHEUMATOL, V25, P2279; MCLEOD DS, 1995, AM J PATHOL, V147, P642; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4; Mohamed AK, 1999, BIOFACTORS, V10, P157, DOI 10.1002/biof.5520100211; Moreland LW, 2000, J RHEUMATOL, V27, P601; Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003-4819-130-6-199903160-00004; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Murata T, 1996, LAB INVEST, V74, P819; Najarian T, 2000, CIRC RES, V87, P1149, DOI 10.1161/01.RES.87.12.1149; Niederberger E, 2001, FASEB J, V15, P1622, DOI 10.1096/fj.00-0716fje; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Pierce JW, 1996, J IMMUNOL, V156, P3961; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; POWELL EDU, 1964, LANCET, V2, P17; Qaum T, 2001, INVEST OPHTH VIS SCI, V42, P2408; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Safieh-Garabedian B, 2000, NEUROPHARMACOLOGY, V39, P1653, DOI 10.1016/S0028-3908(99)00247-6; SCHRODER S, 1991, AM J PATHOL, V139, P81; Shi XL, 1999, MOL CELL BIOCHEM, V199, P93, DOI 10.1023/A:1006934612368; SPRANGER J, 1995, MED KLIN, V90, P134; Tummala PE, 2000, J MOL CELL CARDIOL, V32, P1499, DOI 10.1006/jmcc.2000.1183; Valen G, 2000, CARDIOVASC RES, V47, P49, DOI 10.1016/S0008-6363(00)00071-7; Van Assche G, 2000, EXPERT OPIN INV DRUG, V9, P103; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wang WH, 2000, J BIOL CHEM, V275, P16899, DOI 10.1074/jbc.M000301200; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WILLIAMS B, 1993, J CLIN INVEST, V92, P2889, DOI 10.1172/JCI116911; Wright PS, 1999, J CELL PHYSIOL, V180, P381, DOI 10.1002/(SICI)1097-4652(199909)180:3<381::AID-JCP9>3.0.CO;2-F; Xu QW, 2001, INVEST OPHTH VIS SCI, V42, P789; Yerneni KKV, 1999, DIABETES, V48, P855, DOI 10.2337/diabetes.48.4.855; Zouki C, 2001, FASEB J, V15, P25	72	437	480	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					438	+		10.1096/fj.01-0707fje	http://dx.doi.org/10.1096/fj.01-0707fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	11821258				2022-12-25	WOS:000173656600014
